PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Boyd, M; Wilson, N				Boyd, Matt; Wilson, Nick			Just ask Siri? A pilot study comparing smartphone digital assistants and laptop Google searches for smoking cessation advice	PLOS ONE			English	Article								Objective To compare voice-activated internet searches by smartphone (two digital assistants) with laptop ones for information and advice related to smoking cessation. Design Responses to 80 questions on a range of topics related to smoking cessation (including the FAQ from a NHS website), compared for quality. Setting Smartphone and internet searches as performed in New Zealand. Main outcome measures Ranked responses to the questions. Results Google laptop internet searches came first (or first equal) for best quality smoking cessation advice for 83% (66/80) of the responses. Voiced questions to Google Assistant ("OK Google") came first/first equal 76% of the time vs Siri (Apple) at 28%. Google and Google Assistant were statistically significantly better than Siri searches (odds ratio 12.4 and 8.5 respectively, p<0.0001 in each comparison). When asked FAQs from the National Health Service website, or to find information the Centers for Disease Control has made videos on, the best search results used expert sources 59% (31/52) of the time, "some expertise" (eg, Wikipedia) 18% of the time, but also magazines and other low quality sources 19% of the time. Using all three methods failed to find relevant information 8% (6/80) of the time, with Siri having the most failed responses (53% of the time). Conclusion Google Internet searches and Google Assistant were found to be significantly superior to the Siri digital assistant for smoking cessation information. While expert content was returned over half the time, there is still substantial room for improvement in how these software systems deliver smoking cessation advice.	[Boyd, Matt] Adapt Res Ltd, Reefton, New Zealand; [Wilson, Nick] Univ Otago, Dept Publ Hlth, Wellington, New Zealand	University of Otago	Boyd, M (corresponding author), Adapt Res Ltd, Reefton, New Zealand.	matt@adaptresearchwriting.com		Boyd, Matt/0000-0002-1387-5047				Centers for Disease Control and Prevention, TIPS FORM SMOK VID; Domegan C., 2011, LIT REV HLTH INFORM; Dunn J., 2016, BUSINESS INSIDER; Gibbs S, 2015, GUARDIAN; Hachman M., 2016, PCWORLD; Miner AS, 2016, JAMA INTERN MED, V176, P619, DOI 10.1001/jamainternmed.2016.0400; National health Service, SMOK NHS FREQ ASK QU; Ofcom, 2020, AD MED US ATT; Stevens L, 2017, DIGITAL HLTH	9	26	26	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2018	13	3							e0194811	10.1371/journal.pone.0194811	http://dx.doi.org/10.1371/journal.pone.0194811			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8PV	29590168	Green Published, Green Submitted, gold			2023-01-03	WOS:000428603100074
J	Akogou, FUG; den Besten, HMW; Kayode, APP; Fogliano, V; Linnemann, AR				Akogou, Folachode U. G.; den Besten, Heidy M. W.; Kayode, A. P. Polycarpe; Fogliano, Vincenzo; Linnemann, Anita R.			Antimicrobial evaluation of red, phytoalexin-rich sorghum food biocolorant	PLOS ONE			English	Article							AFRICAN SOFT CHEESE; CALOTROPIS-PROCERA; EXTRACTION METHODS; DRINKING-WATER; DYE SORGHUM; ANTIOXIDANT; GROWTH; 3-DEOXYANTHOCYANIDINS; APIGENINIDIN; COLOR	Sorghum (Sorghum bicolor) extract is traditionally used as red biocolorant in West Africa to colour foods, among which wagashi, a soft cheese. This biocolorant is a source of the phytoalexin apigeninidin and phenolic acids, and users claim that it has preservative effects next to its colouring properties. If such a claim can be scientifically substantiated, it adds a valuable functional property to this natural red colorant, thereby increasing its potential applications in the food industry. Hence, the present study evaluated the antimicrobial properties of dye sorghum extracts using challenge tests in broth and wagashi as a model of a popular food application. The alkaline extract and hot aqueous extract were used for dyeing wagashi by 87.7% and 12.3% of the traders, respectively. The dyeing procedure is perceived as a preservation strategy, and is also a means to maximise the revenues. However, results demonstrated that the application of sorghum biocolorant on wagashi had no inhibitory effect on the growth of fungi (Penicillium chrysogenum, Cladosporium macrocarpum) and Escherichia coli 0157:H7. Furthermore, sorghum biocolorant in broth had no effect on growth of Listeria monocytogenes and Escherichia coli 0157:H7. Consequently, the commonly used extracts for colouring soft West-African cheese did not show a preservative effect. In addition, dyeing did not affect the physico-chemical properties of wagashi. Still, the red colour hampered visual detection of microbial growth, thus clarifying the preservative effect reported by users.	[Akogou, Folachode U. G.; Kayode, A. P. Polycarpe] Univ AbomeyCalavi, DNSA FSA, Lab Valorizat & Qual Management Food Bioingredien, Cotonou, Benin; [Akogou, Folachode U. G.; Fogliano, Vincenzo; Linnemann, Anita R.] Wageningen Univ, Food Qual & Design, Wageningen, Netherlands; [Akogou, Folachode U. G.; den Besten, Heidy M. W.] Wageningen Univ, Lab Food Microbiol, Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Linnemann, AR (corresponding author), Wageningen Univ, Food Qual & Design, Wageningen, Netherlands.	anita.linnemann@wur.nl	fogliano, vincenzo/W-6885-2019; fogliano, vincenzo/A-1419-2009; Fogliano, Vincenzo/M-8166-2019	fogliano, vincenzo/0000-0001-8786-9355; fogliano, vincenzo/0000-0001-8786-9355; Akogou, Folachode/0000-0001-7500-5226	Netherlands Organization for International Cooperation in Higher Education [CF8188/2012]	Netherlands Organization for International Cooperation in Higher Education	This research is funded by Netherlands Organization for International Cooperation in Higher Education (http://www.nuffic.nl/en) (Grant award CF8188/2012). The grant is awarded to FUG Akogou. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adetunji VO, 2008, AFR J MICROBIOL RES, V2, P272; Adetunji VO, 2011, PAK J NUTR; Adeyeye SAO, 2017, BRIT FOOD J, V119, P322, DOI [10.1108/bfj-05-2016-0218, 10.1108/BFJ-05-2016-0218]; Aissi V. M., 2009, AUST J BASIC APPL SC, V3, P2397; Akogou FUG, 2018, LWT-FOOD SCI TECHNOL, V90, P592, DOI 10.1016/j.lwt.2017.12.071; Akogou FUG, 2018, J SCI FOOD AGR, V98, P361, DOI 10.1002/jsfa.8479; Alalade O.A., 2006, INT J DAIRY SCI, V1, P126; Ameyapoh Y, 2008, BIORESOURCE TECHNOL, V99, P5798, DOI 10.1016/j.biortech.2007.10.035; Assogbadjo AE, 2005, BELG J BOT, V138, P47; AWORH OC, 1985, J DAIRY RES, V52, P189, DOI 10.1017/S0022029900024018; Boto-Ordonez M, 2014, FOOD FUNCT, V5, P1932, DOI [10.1039/c4fo00029c, 10.1039/C4FO00029C]; Brul S, 1999, INT J FOOD MICROBIOL, V50, P1, DOI 10.1016/S0168-1605(99)00072-0; Bup DN, 2012, FOOD BIOPROCESS TECH, V5, P108, DOI 10.1007/s11947-009-0274-z; Butkhup L, 2010, S AFR J ENOL VITIC, V31, P89; Cadmus S. I. B., 2013, British Microbiology Research Journal, V3, P218; CLYDESDALE FM, 1993, CRIT REV FOOD SCI, V33, P83, DOI 10.1080/10408399309527614; Cruz-Romero MC, 2013, FOOD CONTROL, V34, P393, DOI 10.1016/j.foodcont.2013.04.042; Dekker DM, 2015, INT J ENV RES PUB HE, V12, P3535, DOI 10.3390/ijerph120403535; Dubey VK, 2003, PHYTOCHEMISTRY, V62, P1057, DOI 10.1016/S0031-9422(02)00676-3; FDA, 2016, FOOD ADD STAT LIST; Gadgil A, 1998, ANNU REV ENERG ENV, V23, P253, DOI 10.1146/annurev.energy.23.1.253; Gallego CG, 2016, APPL FOOD BIOTECHNOL, V3, P72; Han J, 2011, FOOD RES INT, V44, P494, DOI 10.1016/j.foodres.2010.10.026; Hasegawa M, 2014, MOLECULES, V19, P11404, DOI 10.3390/molecules190811404; Hidalgo M, 2012, J AGR FOOD CHEM, V60, P3882, DOI 10.1021/jf3002153; Jeandet P, 2015, MOLECULES, V20, P2770, DOI 10.3390/molecules20022770; Johnson R. C., 2014, Journal of Environmental Protection, V5, P1277, DOI 10.4236/jep.2014.512121; Kayode APP, 2011, J AGR FOOD CHEM, V59, P1178, DOI 10.1021/jf103963t; Kil HY, 2009, FOOD CHEM, V115, P1234, DOI 10.1016/j.foodchem.2009.01.032; Klancnik A, 2009, J FOOD PROTECT, V72, P1744, DOI 10.4315/0362-028X-72.8.1744; Koch C, 2003, J PSYCHOL, V137, P233, DOI 10.1080/00223980309600611; Kumar H, 2015, CURR OPIN BIOTECH, V32, P99, DOI 10.1016/j.copbio.2014.11.021; Kumar Y, 2015, COMPR REV FOOD SCI F, V14, P796, DOI 10.1111/1541-4337.12156; Ling MP, 2015, J AGR FOOD CHEM, V63, P2074, DOI 10.1021/jf503987y; Martins N, 2016, TRENDS FOOD SCI TECH, V52, P1, DOI 10.1016/j.tifs.2016.03.009; McCann D, 2007, LANCET, V370, P1560, DOI 10.1016/S0140-6736(07)61306-3; NazarowecWhite M, 1997, LETT APPL MICROBIOL, V24, P9, DOI 10.1046/j.1472-765X.1997.00328.x; Nostro A, 2000, LETT APPL MICROBIOL, V30, P379, DOI 10.1046/j.1472-765x.2000.00731.x; Obuotor, 2014, AM J FOOD NUTR, V2, P59, DOI [10.12691/ajfn-2-4-2, DOI 10.12691/AJFN-2-4-2]; Petti C, 2014, J AGR FOOD CHEM, V62, P1227, DOI 10.1021/jf405324j; Poloni A, 2014, MOLECULES, V19, P9114, DOI 10.3390/molecules19079114; Raheem D, 2007, INT J FOOD SCI TECH, V42, P220, DOI 10.1111/j.1365-2621.2006.01244.x; Ramos MV, 2013, INT J BIOL MACROMOL, V58, P211, DOI 10.1016/j.ijbiomac.2013.04.001; Resurreccion AVA, 2004, MEAT SCI, V66, P11, DOI 10.1016/S0309-1740(03)00021-4; Saliu BK, 2014, J MICROB BIOTEC FOOD, V3, P337; Sanzani SM, 2014, MOLECULES, V19, P12500, DOI 10.3390/molecules190812500; SCHUTT C, 1991, J CHEM ECOL, V17, P2261, DOI 10.1007/BF00988006; Shih CH, 2007, J AGR FOOD CHEM, V55, P254, DOI 10.1021/jf062516t; Singh AN, 2011, APPL BIOCHEM BIOTECH, V164, P573, DOI 10.1007/s12010-011-9158-6; Sousa A, 2016, FOOD CHEM, V192, P142, DOI 10.1016/j.foodchem.2015.06.108; Stevens LJ, 2014, CLIN PEDIATR, V53, P133, DOI 10.1177/0009922813502849; Stojkovic D, 2013, J SCI FOOD AGR, V93, P3205, DOI 10.1002/jsfa.6156; STONECIPHER LL, 1993, J CHEM ECOL, V19, P1021, DOI 10.1007/BF00992535; Vegara S, 2013, LWT-FOOD SCI TECHNOL, V54, P592, DOI 10.1016/j.lwt.2013.06.022; Wrolstad RE, 2012, ANNU REV FOOD SCI T, V3, P59, DOI 10.1146/annurev-food-022811-101118; Yang LY, 2009, J AGR FOOD CHEM, V57, P1797, DOI 10.1021/jf8035066	56	11	11	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2018	13	3							e0194657	10.1371/journal.pone.0194657	http://dx.doi.org/10.1371/journal.pone.0194657			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ9LE	29561885	Green Published, gold, Green Submitted			2023-01-03	WOS:000427931600067
J	Carns, J; Kawaza, K; Quinn, MK; Miao, YS; Guerra, R; Molyneux, E; Oden, M; Richards-Kortum, R				Carns, Jennifer; Kawaza, Kondwani; Quinn, M. K.; Miao, Yinsen; Guerra, Rudy; Molyneux, Elizabeth; Oden, Maria; Richards-Kortum, Rebecca			Impact of hypothermia on implementation of CPAP for neonatal respiratory distress syndrome in a low-resource setting	PLOS ONE			English	Article							DELIVERY ROOM MANAGEMENT; BIRTH-WEIGHT INFANTS; ADMISSION TEMPERATURE; RANDOMIZED-TRIAL; HEAT-LOSS; NEWBORN; MORTALITY; BABIES; RISK; WRAP	Background Neonatal hypothermia is widely associated with increased risks of morbidity and mortality, but remains a pervasive global problem. No studies have examined the impact of hypothermia on outcomes for preterm infants treated with CPAP for respiratory distress syndrome (RDS). Methods This retrospective analysis assessed the impact of hypothermia on outcomes of 65 neonates diagnosed with RDS and treated with either nasal oxygen (N = 17) or CPAP (N = 48) in a low-resource setting. A classification tree approach was used to develop a model predicting survival for subjects diagnosed with RDS. Findings Survival to discharge was accurately predicted based on three variables: mean temperature, treatment modality, and mean respiratory rate. None of the 23 neonates with a mean temperature during treatment below 35.8 degrees C survived to discharge, regardless of treatment modality. Among neonates with a mean temperature exceeding 35.8 degrees C, the survival rate was 100% for the 31 neonates treated with CPAP and 36.4% for the 11 neonates treated with nasal oxygen (p<0.001). For neonates treated with CPAP, outcomes were poor if more than 50% of measured temperatures indicated hypothermia (5.6% survival). In contrast, all 30 neonates treated with CPAP and with more than 50% of temperature measurements above 35.8 degrees C survived to discharge, regardless of initial temperature. Conclusion The results of our study suggest that successful implementation of CPAP to treat RDS in low-resource settings will require aggressive action to prevent persistent hypothermia.	[Carns, Jennifer; Quinn, M. K.; Oden, Maria; Richards-Kortum, Rebecca] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Kawaza, Kondwani; Molyneux, Elizabeth] Queen Elizabeth Cent Hosp, Coll Med, Dept Pediat, Blantyre, Malawi; [Miao, Yinsen; Guerra, Rudy] Rice Univ, Dept Stat, Houston, TX 77251 USA	Rice University; University of Malawi; Rice University	Carns, J (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.	jcarns@rice.edu			United States Agency for International Development (USAID); Government of Norway; Bill & Melinda Gates Foundation; Grand Challenges Canada; UKAID;  [AID-OAA-A-13-00014]	United States Agency for International Development (USAID)(United States Agency for International Development (USAID)CGIAR); Government of Norway; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Grand Challenges Canada(CGIAR); UKAID(CGIAR); 	This manuscript is made possible through the generous support of the Saving Lives at Birth partners: the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the UKAID. It was prepared by Rice University and does not necessarily reflect the views of the Saving Lives at Birth partners. Grant Number: AID-OAA-A-13-00014; URL: https://savinglivesatbirth.net/.	ADAMSONS K, 1965, ANESTHESIOLOGY, V26, P531, DOI 10.1097/00000542-196507000-00017; Baumgart S., 2005, NEONATOLOGY PATHOPHY, P446; Belsches TC, 2013, PEDIATRICS, V132, pE656, DOI 10.1542/peds.2013-0172; BERTEROTTIERE D, 1990, J DEV PHYSIOL, V13, P303; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Boo NY, 2013, J TROP PEDIATRICS, V59, P447, DOI 10.1093/tropej/fmt051; BRIEND A, 1981, LANCET, V1, P846; Brown J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053622; Byaruhanga R, 2005, J TROP PEDIATRICS, V51, P212, DOI 10.1093/tropej/fmh098; Chang HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131976; Christidis Iris, 2003, Gynaekologisch-Geburtshilfliche Rundschau, V43, P31, DOI 10.1159/000067168; Clair CS, 2008, AM J PERINAT, V25, P473, DOI 10.1055/s-0028-1085066; Costeloe KL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7976; DAHM LS, 1972, PEDIATRICS, V49, P504; DeMauro SB, 2013, PEDIATRICS, V132, pE1018, DOI 10.1542/peds.2013-0686; Hamid SAAE, 2012, J EGYPT PUBLIC HEAL, V87, P104, DOI 10.1097/01.EPX.0000421565.24496.d9; Kambarami R, 2003, Cent Afr J Med, V49, P103; Kawaza K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086327; Kumar V, 2009, J PERINATOL, V29, P401, DOI 10.1038/jp.2008.233; Laptook AR, 2007, PEDIATRICS, V119, pE643, DOI 10.1542/peds.2006-0943; Lee HC, 2014, PEDIATRICS, V134, pE1378, DOI 10.1542/peds.2014-0863; Lenhardt Rainer, 2003, Best Pract Res Clin Anaesthesiol, V17, P569, DOI 10.1016/S1521-6896(03)00048-X; Lunze K, 2012, J PERINATOL, V32, P317, DOI 10.1038/jp.2012.11; Lunze K, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-24; Manani Madhu, 2013, Perm J, V17, P8, DOI 10.7812/TPP/12-130; Mathur N. B., 2005, EVALUATION WHO CLASS, P341; MCCALL EM, 2010, COCHRANE DB SYST REV, V3, P1; McGrory L., J PEDIAT; Meyer MP, 2015, J PEDIATR-US, V166, P245, DOI 10.1016/j.jpeds.2014.09.049; MORLEY DC, 1960, LANCET, V2, P1170; Mullany LC, 2010, SEMIN PERINATOL, V34, P426, DOI 10.1053/j.semperi.2010.09.007; Mullany LC, 2010, ARCH PEDIAT ADOL MED, V164, P650, DOI 10.1001/archpediatrics.2010.103; Mullany LC, 2010, ARCH PEDIAT ADOL MED, V164, P71, DOI 10.1001/archpediatrics.2009.239; Muula A, 2015, MALAWI MED J, V27, P75, DOI 10.4314/mmj.v27i2.10; Neighbour R., 2016, ANAESTHESIA, V31, P63; Nye H., 2014, RT MAG, P14; Ogunlesi TA, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-40; Onalo R, 2013, NIGER J CLIN PRACT, V16, P129, DOI 10.4103/1119-3077.110120; R-Core-Team, 2016, LANG ENV STAT COMP; Reilly MC, 2015, J PEDIATR-US, V166, P262, DOI 10.1016/j.jpeds.2014.09.068; Shah S., 2012, BR MED J OPEN, V2, P1; Singh A, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-33; SMALES ORC, 1978, ARCH DIS CHILD, V53, P58, DOI 10.1136/adc.53.1.58; Therneau T., 2015, PACKAGE RPART; WHO, 2010, ESS NEWB CAR TRAIN C; World Health Organization. Maternal and Newborn Health/Safe Motherhood, 1997, THERM PROT NEWB PRAC; Zanelli S, 2011, J PERINATOL, V31, P377, DOI 10.1038/jp.2010.146	47	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2018	13	3							e0194144	10.1371/journal.pone.0194144	http://dx.doi.org/10.1371/journal.pone.0194144			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ3GA	29543861	Green Published, gold, Green Submitted			2023-01-03	WOS:000427473500050
J	Boussiotis, VA; Charest, A				Boussiotis, Vassiliki A.; Charest, Alain			Immunotherapies for malignant glioma	ONCOGENE			English	Review							CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; CANCER STEM-CELLS; NEWLY-DIAGNOSED GLIOBLASTOMA; CHIMERIC ANTIGEN RECEPTOR; BLOOD-BRAIN-BARRIER; TUMOR-ASSOCIATED MACROPHAGES; IMMUNE CHECKPOINT BLOCKADE; GROWTH-FACTOR RECEPTOR; MICROGLIAL CELLS	Glioblastoma multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient's immune system to recognize and eliminate GBM. Here, we discuss the unique properties of GBM's tumor microenvironment, the effects of GBM standard on care therapy on tumor-associated immune cells, and review several approaches aimed at therapeutically targeting the immune system for GBM treatment. We believe that a comprehensive understanding of the intricate micro-environmental landscape of GBM will abound into the development of novel immunotherapy strategies for GBM patients.	[Boussiotis, Vassiliki A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA; [Boussiotis, Vassiliki A.; Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; [Boussiotis, Vassiliki A.; Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA; [Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Genet, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.; Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA.; Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Genet, Boston, MA 02115 USA.	acharest@bidmc.harvard.edu; vboussio@bidmc.harvard.edu			NIH/NCI [CA183605, CA183605S1, CA212605, CA185137, CA179563, CA069246]; DoD [PC140571]; NATIONAL CANCER INSTITUTE [R01CA212605, R01CA183605, R01CA185137, P01CA069246, U19CA179563] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI grants CA183605, CA183605S1, and CA212605 and the DoD grant PC140571 (to V.A.B.) and NIH/NCI grants CA185137, CA179563, and CA069246 (to A.C.)	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Alexiou GA, 2013, ACTA NEUROL BELG, V113, P7, DOI 10.1007/s13760-012-0097-y; Alizadeh D, 2010, CLIN CANCER RES, V16, P3399, DOI 10.1158/1078-0432.CCR-09-3087; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Ardon H, 2010, J NEURO-ONCOL, V99, P261, DOI 10.1007/s11060-010-0131-y; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Badie B, 2000, NEUROSURGERY, V46, P957, DOI 10.1097/00006123-200004000-00035; Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1; Bardella C, 2016, CANCER CELL, V30, P578, DOI 10.1016/j.ccell.2016.08.017; Bauer M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039956; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Belcaid Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101764; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brown CE, 2009, CANCER RES, V69, P8886, DOI 10.1158/0008-5472.CAN-09-2687; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Campanella M, 2014, PEERJ, V2, DOI 10.7717/peerj.497; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; da Fonseca ACC, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/264124; Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Charles N, 2010, CELL CYCLE, V9, P3012, DOI 10.4161/cc.9.15.12710; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen WL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0487-0; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Curtin JF, 2009, PLOS MED, V6, P83, DOI 10.1371/journal.pmed.1000010; Danaila L., 1993, Romanian Journal of Neurology and Psychiatry, V31, P195; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Di Tomaso T, 2010, CLIN CANCER RES, V16, P800, DOI 10.1158/1078-0432.CCR-09-2730; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Ellsworth S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27357; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Fadul CE, 2011, J IMMUNOTHER, V34, P382, DOI 10.1097/CJI.0b013e318215e300; Fadul CE, 2011, NEURO-ONCOLOGY, V13, P393, DOI 10.1093/neuonc/noq204; Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773; Fleurence J, 2016, ONCOTARGET, V7, P41172, DOI 10.18632/oncotarget.9226; FORD AL, 1995, J IMMUNOL, V154, P4309; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Galarneau H, 2007, CANCER RES, V67, P8874, DOI 10.1158/0008-5472.CAN-07-0177; Geranmayeh F, 2007, NEUROSURGERY, V60, P159, DOI 10.1227/01.NEU.0000249192.30786.67; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Gielen PR, 2015, J NEUROPATH EXP NEUR, V74, P390, DOI 10.1097/NEN.0000000000000183; Gieryng A, 2017, LAB INVEST, V97, P498, DOI 10.1038/labinvest.2017.19; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Heimberger AB, 2008, CLIN CANCER RES, V14, P5166, DOI 10.1158/1078-0432.CCR-08-0320; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hodges TR, 2017, NEURO-ONCOLOGY, V19, P1047, DOI 10.1093/neuonc/nox026; Hou Y, 2016, BLOOD, V127, P1587, DOI 10.1182/blood-2015-10-674531; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Huang JY, 2010, J IMMUNOL, V185, P1450, DOI 10.4049/jimmunol.0901352; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Hussain SF, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-15; Jacobs JFM, 2010, J NEUROIMMUNOL, V225, P195, DOI 10.1016/j.jneuroim.2010.05.020; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Jhaveri N, 2016, CANCER LETT, V380, P545, DOI 10.1016/j.canlet.2014.12.028; Johanns TM, 2016, CANCER DISCOV, V6, P1230, DOI 10.1158/2159-8290.CD-16-0575; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Jun HJ, 2012, ONCOGENE, V31, P3039, DOI 10.1038/onc.2011.474; Kabba JA, 2017, CELL MOL NEUROBIOL, V22; Kakarla S, 2014, CANCER J, V20, P151, DOI 10.1097/PPO.0000000000000032; Kaminska B, 2016, BBA-MOL BASIS DIS, V1862, P339, DOI 10.1016/j.bbadis.2015.10.026; Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim JE, 2017, CLIN CANCER RES, V23, P124, DOI 10.1158/1078-0432.CCR-15-1535; Kim TG, 2010, CLIN VACCINE IMMUNOL, V17, P143, DOI 10.1128/CVI.00292-09; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; LAFFERTY KJ, 1978, BLOOD CELLS, V4, P395; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; LeBlanc AK, 2016, NEURO-ONCOLOGY, V18, P1209, DOI 10.1093/neuonc/now051; Leung W, 2014, CLIN CANCER RES, V20, P3390, DOI 10.1158/1078-0432.CCR-13-1766; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Ling Y, 2007, EUR J HAEMATOL, V79, P310, DOI 10.1111/j.1600-0609.2007.00917.x; Litterman AJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26294; Llaguno SRA, 2015, CANCER CELL, V28, P429, DOI 10.1016/j.ccell.2015.09.007; Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557; Louis DN, 2016, HO CLASSIFICATION TU, V1; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; LOWE J, 1989, J PATHOL, V159, P143, DOI 10.1002/path.1711590209; Maes W, 2011, CANCER IMMUNOL IMMUN, V60, P153, DOI 10.1007/s00262-010-0946-6; Marko AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015425; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mathios D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2942; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; Maxwell R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0754-x; Mendez JS, 2016, J NEURO-ONCOL, V127, P329, DOI 10.1007/s11060-015-2037-1; Mieczkowski J, 2015, ONCOTARGET, V6, P33077, DOI 10.18632/oncotarget.5310; Mineo JF, 2004, BRIT J CANCER, V91, P1195, DOI 10.1038/sj.bjc.6602089; Molofsky AV, 2015, GLIA, V63, P1320, DOI 10.1002/glia.22836; MORRIS CS, 1991, J NEUROL SCI, V101, P47, DOI 10.1016/0022-510X(91)90017-2; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Nagai T, 2009, CANCER IMMUNOL IMMUN, V58, P1577, DOI 10.1007/s00262-009-0667-x; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Oh T, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-107; Olson JJ, 2014, J NEURO-ONCOL, V118, P557, DOI 10.1007/s11060-013-1339-4; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Paff M, 2014, HUM VACC IMMUNOTHER, V10, P3322, DOI 10.4161/21645515.2014.983002; Pallud J, 2015, NEURO-ONCOLOGY, V17, P1609, DOI 10.1093/neuonc/nov126; Parada LF, 2005, COLD SH Q B, V70, P173, DOI 10.1101/sqb.2005.70.025; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Patsoukis N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00330; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Perng P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00153; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pitter KL, 2016, BRAIN, V139, P1458, DOI 10.1093/brain/aww046; Placone AL, 2016, TUMOR BIOL, V37, P61, DOI 10.1007/s13277-015-4242-0; Poli A, 2013, ONCOTARGET, V4, P1527, DOI 10.18632/oncotarget.1291; Prados MD, 2015, NEURO-ONCOLOGY, V17, P1051, DOI 10.1093/neuonc/nov031; Priceman SJ, 2015, CURR OPIN ONCOL, V27, P466, DOI 10.1097/CCO.0000000000000232; Prins RM, 2011, CLIN CANCER RES, V17, P1603, DOI 10.1158/1078-0432.CCR-10-2563; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reardon DA, 2017, SEMIN IMMUNOPATHOL, V39, P225, DOI 10.1007/s00281-016-0616-7; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Ridolfi L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-135; Roth P, 2015, NEURO-ONCOL PRACT, V2, P6, DOI 10.1093/nop/npu029; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Sampson JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031046; Sampson JH, 2011, NEURO-ONCOLOGY, V13, P324, DOI 10.1093/neuonc/noq157; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schultze SM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002109; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; Varga G, 2008, J LEUKOCYTE BIOL, V84, P644, DOI 10.1189/jlb.1107768; Vauleon E, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-41; Vecht CJ, 2014, ONCOLOGIST, V19, P751, DOI 10.1634/theoncologist.2014-0060; Venkatesh HS, 2015, CELL, V161, P803, DOI 10.1016/j.cell.2015.04.012; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wainwright DA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00116; Wainwright DA, 2011, NEURO-ONCOLOGY, V13, P1308, DOI 10.1093/neuonc/nor134; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Ward-Kavanagh LK, 2016, IMMUNITY, V44, P1005, DOI 10.1016/j.immuni.2016.04.019; Wei J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016195, 10.1371/journal.pone.0017868]; Wei J, 2010, MOL CANCER THER, V9, P67, DOI 10.1158/1535-7163.MCT-09-0734; Weiss T, 2016, EXPERT REV ANTICANC, V16, P1087, DOI 10.1080/14737140.2016.1229600; Wheeler CJ, 2004, CLIN CANCER RES, V10, P5316, DOI 10.1158/1078-0432.CCR-04-0497; Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772; Wierzba-Bobrowicz T, 1994, Folia Neuropathol, V32, P251; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wintterle S, 2003, CANCER RES, V63, P7462; Wong ET, 2015, BRIT J CANCER, V113, P232, DOI 10.1038/bjc.2015.238; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xia M, 1999, CELL MOL LIFE SCI, V55, P1649, DOI 10.1007/s000180050403; Xing KL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0103-2; Yan D, 2017, ONCOGENE, V36, P6049, DOI 10.1038/onc.2017.261; Yeo AT, 2017, J CELL BIOCHEM, V118, P2516, DOI 10.1002/jcb.25948; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117; Zhang CF, 2016, J SENSORS, V2016, DOI 10.1155/2016/9307560; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004	202	77	81	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1121	1141		10.1038/s41388-017-0024-z	http://dx.doi.org/10.1038/s41388-017-0024-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242608	Green Accepted, Green Submitted			2023-01-03	WOS:000426505400001
J	di Martino, S; Amoreo, CA; Nuvoli, B; Galati, R; Strano, S; Facciolo, F; Alessandrini, G; Pass, HI; Ciliberto, G; Blandino, G; De Maria, R; Cioce, M				di Martino, Simona; Amoreo, Carla Azzurra; Nuvoli, Barbara; Galati, Rossella; Strano, Sabrina; Facciolo, Francesco; Alessandrini, Gabriele; Pass, Harvey I.; Ciliberto, Gennaro; Blandino, Giovanni; De Maria, Ruggero; Cioce, Mario			HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome	ONCOGENE			English	Article							MALIGNANT PLEURAL MESOTHELIOMA; CELL LUNG-CANCER; POTENT ANTITUMOR-ACTIVITY; ADVANCED SOLID TUMORS; IN-VITRO; SENESCENT CELLS; STEM-CELLS; INTRATUMORAL HETEROGENEITY; ACQUIRED-RESISTANCE; DRUG-RESISTANCE	Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP). Thus, administration of a clinical trial grade, HSP90, inhibitor blunted the release of several cytokines by the chemotherapy-treated MPM cells, including interleukin (IL)-8. Reduction of IL-8 levels hampered the FAK-AKT signaling and inhibited 3D growth and migration. This correlated with downregulation of key EMT and chemoresistance genes and affected the survival of chemoresistant ALDH(bright) cell subpopulations. Altogether, inhibition of HSP90 provoked a switch from a pro-tumorigenic SASP to a pro-apoptotic senescence status, thus resulting in chemosensitizing effects. In mouse xenografts treated with firstline agents, inhibiting HSP90 blunted FAK activation and reduced the expression of ALDH1A3 and the levels of circulating human IL-8, these latter strongly correlating with the effect on tumor growth. We validated the above findings in primary mesothelioma cultures, a more clinically relevant model. We unveiled here a key contribution of the chaperone HSP90 at assisting the secretory stress in chemotherapy-treated cells, which may warrant further investigation in combinatorial therapeutic settings.	[di Martino, Simona; Blandino, Giovanni; Cioce, Mario] Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy; [Amoreo, Carla Azzurra] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Nuvoli, Barbara; Galati, Rossella] Regina Elena Inst Canc Res, Preclin Models & New Therapeut Agents Unit, Rome, Italy; [Strano, Sabrina] Regina Elena Inst Canc Res, Mol Chemoprevent Unit, Rome, Italy; [Facciolo, Francesco; Alessandrini, Gabriele] Regina Elena Inst Canc Res, Dept Thorac Surg, Rome, Italy; [Pass, Harvey I.] NYU, Sch Med, Dept Cardiothorac Surg, New York, NY USA; [Ciliberto, Gennaro; De Maria, Ruggero] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy; [De Maria, Ruggero] Catholic Univ, Inst Gen Pathol, Rome, Italy; [De Maria, Ruggero] Gemelli Polyclin, Rome, Italy; [Strano, Sabrina; Blandino, Giovanni] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; New York University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; McMaster University	Cioce, M (corresponding author), Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy.; De Maria, R (corresponding author), Regina Elena Inst Canc Res, Sci Direct, Rome, Italy.; De Maria, R (corresponding author), Catholic Univ, Inst Gen Pathol, Rome, Italy.; De Maria, R (corresponding author), Gemelli Polyclin, Rome, Italy.	demariaruggero@gmail.com; mariocioce@gmail.com	Cioce, Mario/R-9734-2017; Galati, Rossella/ABH-6437-2020; Ciliberto, Gennaro/J-4131-2017; Galati, Rossella Maria/H-8867-2017; De Maria, Ruggero/S-6385-2019; Strano, Sabrina/K-9654-2016; di Martino, Simona SdM/K-9304-2016; AMOREO, CARLA AZZURRA/K-5375-2018	Cioce, Mario/0000-0001-8129-6664; Galati, Rossella/0000-0003-2646-8384; Ciliberto, Gennaro/0000-0003-2851-8605; Galati, Rossella Maria/0000-0003-2646-8384; De Maria, Ruggero/0000-0003-2255-0583; di Martino, Simona SdM/0000-0003-4533-3776; AMOREO, CARLA AZZURRA/0000-0003-3817-1967; Facciolo, Francesco/0000-0002-7137-8946; Pass, Harvey/0000-0003-3222-3471; strano, sabrina/0000-0002-6341-4230; Alessandrini, Gabriele/0000-0002-4380-7627	Fundacio' La Marato' de TV3 [432/C/2013]; AIRC; Marie Curie Actions-People-COFUND fellowship; Italian Ministry of Health (Progetto Nazionale Amianto)	Fundacio' La Marato' de TV3; AIRC(Fondazione AIRC per la ricerca sul cancro); Marie Curie Actions-People-COFUND fellowship; Italian Ministry of Health (Progetto Nazionale Amianto)	The funding for this study was provided by the Fundacio' La Marato' de TV3 (grant 432/C/2013) to RDM. M.C. was supported by an AIRC and Marie Curie Actions-People-COFUND fellowship. We thankfully acknowledge the support of the Italian Ministry of Health (Progetto Nazionale Amianto) to R.D.M. We thankfully acknowledge the helpful advice of Dr. Paola Nistico, Dr. Maria Lucia Dell' Anna, and Dr. Valeria Catena (Regina Elena National Cancer Institute, Rome, Italy).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aird Katherine M, 2013, Methods Mol Biol, V965, P185, DOI 10.1007/978-1-62703-239-1_12; Alimbetov D, 2016, BIOGERONTOLOGY, V17, P305, DOI 10.1007/s10522-015-9610-z; Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Basu D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052188; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Busacca S, 2016, ONCOGENE, V35, P1483, DOI 10.1038/onc.2015.213; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Campisi J, 2011, SEMIN CANCER BIOL, V21, P354, DOI 10.1016/j.semcancer.2011.09.001; Canino C, 2012, ONCOGENE, V31, P3148, DOI 10.1038/onc.2011.485; Canino C, 2016, METHODS MOL BIOL, V1379, P139, DOI 10.1007/978-1-4939-3191-0_13; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Chatterjee S, 2017, MOL CANCER THER, V16, P793, DOI 10.1158/1535-7163.MCT-16-0677; Chernova T, 2016, CELL DEATH DIFFER, V23, P1152, DOI 10.1038/cdd.2015.165; Cioce M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.136; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corpet A, 2014, CHROMOSOMA, V123, P423, DOI 10.1007/s00412-014-0469-6; Cortes-Dericks L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-304; Cortes-Dericks L, 2010, INT J ONCOL, V37, P437, DOI 10.3892/ijo_00000692; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69; Galffy G, 1999, CANCER RES, V59, P367; Galffy G, 1999, ONCOL RES, V11, P187; Garon EB, 2013, MOL CANCER THER, V12, P890, DOI 10.1158/1535-7163.MCT-12-0998; Genovese G, 2017, NATURE, V542, P362, DOI 10.1038/nature21064; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gomez-Casal R, 2015, CANCERS, V7, P876, DOI 10.3390/cancers7020814; He SQ, 2014, INVEST NEW DRUG, V32, P577, DOI 10.1007/s10637-014-0095-4; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Jones SF, 2015, INVEST NEW DRUG, V33, P1100, DOI 10.1007/s10637-015-0282-y; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Kim KL, 2005, AM J RESP CELL MOL, V33, P541, DOI 10.1165/rcmb.2004-0355OC; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lai CH, 2014, ONCOGENE, V33, P4867, DOI 10.1038/onc.2013.439; Liu X, 2016, ANTI-CANCER DRUG, V27, P417, DOI 10.1097/CAD.0000000000000347; Lundgren K, 2009, MOL CANCER THER, V8, P921, DOI 10.1158/1535-7163.MCT-08-0758; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Mathias RA, 2009, J PROTEOME RES, V8, P2827, DOI 10.1021/pr8010974; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Ohkubo S, 2015, MOL CANCER THER, V14, P14, DOI 10.1158/1535-7163.MCT-14-0219; Park SY, 2014, EUR J CANCER, V50, P341, DOI 10.1016/j.ejca.2013.09.021; Patel S, 2014, ADV EXP MED BIOL, V806, P409, DOI 10.1007/978-3-319-06068-2_20; Piper PW, 2011, PHARMACEUTICALS, V4, P1400, DOI 10.3390/ph4111400; Pribluda A, 2015, CLIN CANCER RES, V21, P2916, DOI 10.1158/1078-0432.CCR-14-1213; Sarker D, 2015, CLIN CANCER RES, V21, P77, DOI 10.1158/1078-0432.CCR-14-0947; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Shapiro IM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008639; Shimamura T, 2012, CLIN CANCER RES, V18, P4973, DOI 10.1158/1078-0432.CCR-11-2967; Shimizu T, 2016, CANCER CHEMOTH PHARM, V77, P997, DOI 10.1007/s00280-016-3010-1; Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436; Socinski MA, 2013, CLIN CANCER RES, V19, P3068, DOI 10.1158/1078-0432.CCR-12-3381; Taipale M, 2012, CELL, V150, P987, DOI 10.1016/j.cell.2012.06.047; Thakur MK, 2016, INVEST NEW DRUG, V34, P112, DOI 10.1007/s10637-015-0307-6; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wang Y, 2011, CYTOKINE, V56, P365, DOI 10.1016/j.cyto.2011.06.005; Ying WW, 2012, MOL CANCER THER, V11, P475, DOI 10.1158/1535-7163.MCT-11-0755	65	16	17	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1369	1385		10.1038/s41388-017-0044-8	http://dx.doi.org/10.1038/s41388-017-0044-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29311642				2023-01-03	WOS:000427279300008
J	Sears, CL; Pardoll, DM				Sears, Cynthia L.; Pardoll, Drew M.			The intestinal microbiome influences checkpoint blockade	NATURE MEDICINE			English	Editorial Material							MELANOMA; EFFICACY; THERAPY	Studies in metastatic melanoma, non-small-cell lung carcinoma and renal cell carcinoma indicate certain bacteria within the gut microbiota enhance clinical responses to checkpoint blockade.	[Sears, Cynthia L.; Pardoll, Drew M.] Johns Hopkins Univ, Sch Med, Bloomberg Kimmel Inst Immunotherapy, Balitmore, MD 21218 USA	Johns Hopkins University	Sears, CL (corresponding author), Johns Hopkins Univ, Sch Med, Bloomberg Kimmel Inst Immunotherapy, Balitmore, MD 21218 USA.	csears@jhmi.edu	Sears, Cynthia L/AAJ-6704-2020	Sears, Cynthia L/0000-0003-4059-1661	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK089502] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK089502] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389	11	32	34	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2018	24	3					254	255		10.1038/nm.4511	http://dx.doi.org/10.1038/nm.4511			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	FY3EN	29509750	Green Accepted			2023-01-03	WOS:000426700900004
J	Bucholc, M; O'Kane, M; Ashe, S; Wong-Lin, K				Bucholc, Magda; O'Kane, Maurice; Ashe, Siobhan; Wong-Lin, KongFatt			Prescriptive variability of drugs by general practitioners	PLOS ONE			English	Article							PRESCRIBING RATES; DEPRIVATION; POPULATIONS; OUTCOMES; QUALITY; COSTS; CARE	Prescription drug spending is growing faster than any other sector of healthcare. However, very little is known about patterns of prescribing and cost of prescribing between general practices. In this study, we examined variation in prescription rates and prescription costs through time for 55 GP surgeries in Northern Ireland Western Health and Social Care Trust. Temporal changes in variability of prescribing rates and costs were assessed using the Mann-Kendall test. Outlier practices contributing to between practice variation in prescribing rates were identified with the interquartile range outlier detection method. The relationship between rates and cost of prescribing was explored with Spearman's statistics. The differences in variability and mean number of prescribing rates associated with the practice setting and socioeconomic deprivation were tested using t-test and F-test respectively. The largest between-practice difference in prescribing rates was observed for Apr-Jun 2015, with the number of prescriptions ranging from 3.34 to 8.36 per patient. We showed that practices with outlier prescribing rates greatly contributed to between-practice variability. The largest difference in prescribing costs was reported for Apr-Jun 2014, with the prescription cost per patient ranging from 26.4 pound to 64.5 pound. In addition, the temporal changes in variability of prescribing rates and costs were shown to undergo an upward trend. We demonstrated that practice setting and socio-economic deprivation accounted for some of the between-practice variation in prescribing. Rural practices had higher between practice variability than urban practices at all time points. Practices situated in more deprived areas had higher prescribing rates but lower variability than those located in less deprived areas. Further analysis is recommended to assess if variation in prescribing can be explained by demographic characteristics of patient population and practice features. Identification of other factors contributing to prescribing variability can help us better address potential inappropriateness of prescribing.	[Bucholc, Magda; Wong-Lin, KongFatt] Univ Ulster, Intelligent Syst Res Ctr, Magee Campus, Londonderry, North Ireland; [O'Kane, Maurice; Ashe, Siobhan] Altnagelvin Hosp, Western Hlth & Social Care Trust, Glenshane Rd, Londonderry, North Ireland	Ulster University	Bucholc, M (corresponding author), Univ Ulster, Intelligent Syst Res Ctr, Magee Campus, Londonderry, North Ireland.	bucholc-m@email.ulster.ac.uk	Bucholc, Magda/ABF-9272-2020	Bucholc, Magda/0000-0002-8417-1602; Wong-Lin, KongFatt/0000-0001-8724-4398	Invest NI through Northern Ireland Science Park (Catalyst Inc)	Invest NI through Northern Ireland Science Park (Catalyst Inc)	This work was performed under the Northern Ireland International Health Analytics Centre (IHAC) collaborative network project funded by Invest NI through Northern Ireland Science Park (Catalyst Inc). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alderwick H, 2015, BETTER VALUE NHS ROL; [Anonymous], [No title captured]; [Anonymous], 2016, PRESCR DISP COMM STA; [Anonymous], 2016, PRESCR COSTS HOSP CO; [Anonymous], 2013, PAYING PRIC PRESCR C; Ashworth M, 2007, J PUBLIC HEALTH-UK, V29, P40, DOI 10.1093/pubmed/fdl068; Backer C., 2016, MED STAT GP PRESCRIB; Baker K., 2016, MED STAT GP PRESCRIB; Burton JH, 2016, WEST J EMERG MED, V17, P258, DOI 10.5811/westjem.2016.3.29692; Cahir C, 2010, BRIT J CLIN PHARMACO, V69, P543, DOI 10.1111/j.1365-2125.2010.03628.x; Covvey JR, 2014, J ANTIMICROB CHEMOTH, V69, P835, DOI 10.1093/jac/dkt439; Duerden M, 2011, QUALITY GP PRESCRIBI; Favato G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000592; Fischer SH, 2013, J GEN INTERN MED, V28, P513, DOI 10.1007/s11606-012-2271-6; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; Haastrup PF, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0460-9; Hallsworth M, 2016, LANCET, V387, P1743, DOI 10.1016/S0140-6736(16)00215-4; Hann M, 2004, J CLIN PHARM THER, V29, P537, DOI 10.1111/j.1365-2710.2004.00604.x; Holm M, 1988, Scand J Prim Health Care, V6, P169, DOI 10.3109/02813438809009311; HSC Business Services Organisation, PRESCR GP PRACT; Hull SA, 2005, FAM PRACT, V22, P37, DOI 10.1093/fampra/cmh712; Kvam PH, 2007, NONPARAMETRIC STATISTICS WITH APPLICATIONS TO SCIENCE AND ENGINEERING, P1, DOI 10.1002/9780470168707; LASH S, 1995, J MANAGE CARE PHARM, V1, P193; Mackenzie IF, 1999, BRIT J GEN PRACT, V49, P884; Majeed A, 1998, BRIT MED J, V316, P748, DOI 10.1136/bmj.316.7133.748; MCLEOD AI, 1991, ENVIRONMETRICS, V2, P169, DOI 10.1002/env.3770020205; Meals DW, 2011, TECH NOTES US EPA; Moon JC, 2010, BMJ-BRIT MED J, P341; Morrison J, 2009, BRIT J GEN PRACT, V59, P88, DOI 10.3399/bjgp09X395076; Northern Ireland Statistics and Research Agency, 2015, REV STAT CLASS DEL S; Northern Ireland Statistics and Research Agency, 2010, NO IR MULT DEPR MEAS; OFORIASENSO R, 2016, PHARMACY, V4, P61295, DOI [DOI 10.3390/pharmacy4040035, DOI 10.3390/PHARMACY4040035]; PECK R, 2015, INTRO STAT DATA ANAL; PHAROAH PDP, 1995, BRIT J GEN PRACT, V45, P595; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102; Srivastava, 2012, REGRESSION ANAL THEO; Szczepura A, 2005, POSTGRAD MED J, V81, P141, DOI 10.1136/pgmj.2004.026237; Thompson J, 2015, PRIMARY CARE PRESCRI; Thompson M, 2016, LANCET, V387, P2270, DOI 10.1016/S0140-6736(16)00743-1; Ventola C Lee, 2015, P T, V40, P277; Wagner Andrew C., 2010, Pharmacy Pract (Granada), V8, P193; Wise J., 2005, BMJ-BRIT MED J, P351; Wu JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067611	44	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2018	13	2							e0189599	10.1371/journal.pone.0189599	http://dx.doi.org/10.1371/journal.pone.0189599			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW8CI	29462143	gold, Green Submitted, Green Published			2023-01-03	WOS:000425554200002
J	Amstad, E				Amstad, Esther			Capsules made from prefabricated thin films	SCIENCE			English	Editorial Material							MICROCAPSULES; RELEASE		[Amstad, Esther] Ecole Polytech Fed Lausanne, Inst Mat, Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Amstad, E (corresponding author), Ecole Polytech Fed Lausanne, Inst Mat, Lausanne, Switzerland.							Abbaspourrad A, 2013, LANGMUIR, V29, P12697, DOI 10.1021/la403064f; Amstad E, 2017, ACS MACRO LETT, V6, P841, DOI 10.1021/acsmacrolett.7b00472; Datta SS, 2014, ADV MATER, V26, P2205, DOI 10.1002/adma.201305119; De Cock LJ, 2010, ANGEW CHEM INT EDIT, V49, P6954, DOI 10.1002/anie.200906266; Gaitzsch J, 2016, CHEM REV, V116, P1053, DOI 10.1021/acs.chemrev.5b00241; Hitchcock JP, 2015, ACS APPL MATER INTER, V7, P14808, DOI 10.1021/acsami.5b03116; Kumar D, 2018, SCIENCE, V359, P775, DOI 10.1126/science.aao1290; Mora-Huertas CE, 2010, INT J PHARMACEUT, V385, P113, DOI 10.1016/j.ijpharm.2009.10.018; Shchukin DG, 2004, ADV MATER, V16, P671, DOI 10.1002/adma.200306466; Skorb EV, 2013, ADV MATER, V25, P5029, DOI 10.1002/adma.201302142; Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164; Zhang J, 2012, SCIENCE, V335, P690, DOI 10.1126/science.1215416; Zoldesi CI, 2005, ADV MATER, V17, P924, DOI 10.1002/adma.200401183	13	5	5	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	2018	359	6377					743	743	aar4027	10.1126/science.aar4027	http://dx.doi.org/10.1126/science.aar4027			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FW2ET	29449478				2023-01-03	WOS:000425116200027
J	Mellouk, N; Rame, C; Marchand, M; Staub, C; Touze, JL; Venturi, E; Mercerand, F; Travel, A; Chartrin, P; Lecompte, F; Ma, LL; Froment, P; Dupont, J				Mellouk, Namya; Rame, Christelle; Marchand, Maxime; Staub, Christophe; Touze, Jean-Luc; Venturi, Eric; Mercerand, Frederic; Travel, Angelique; Chartrin, Pascal; Lecompte, Francois; Ma, Linlin; Froment, Pascal; Dupont, Joelle			Effect of different levels of feed restriction and fish oil fatty acid supplementation on fat deposition by using different techniques, plasma levels and mRNA expression of several adipokines in broiler breeder hens	PLOS ONE			English	Article							DIET-INDUCED OBESITY; EICOSAPENTAENOIC ACID; BODY-COMPOSITION; N-3 ENRICHMENT; CHICKEN MEAT; DOCOSAHEXAENOIC ACID; METABOLIC HORMONES; FOOD-DEPRIVATION; COUNTRY CHICKENS; ADIPONECTIN GENE	Background Reproductive hens are subjected to a restricted diet to limit the decline in fertility associated with change in body mass. However, endocrine and tissue responses to diet restriction need to be documented. Objective We evaluated the effect of different levels of feed restriction, with or without fish oil supplementation, on metabolic parameters and adipokine levels in plasma and metabolic tissues of reproductive hens. Methods We designed an in vivo protocol involving 4 groups of hens; RNS: restricted (Rt) unsupplemented, ANS: ad libitum (Ad, receiving an amount of feed 1.7 times greater than animals on the restricted diet) unsupplemented, RS: Rt supplemented, and AS: Ad supplemented. The fish oil supplement was used at 1% of the total diet composition. Results Hens fed with the Rt diet had a significantly (P < 0.0001) lower growth than Ad hens, while the fish oil supplementation had no effect on these parameters. Furthermore, the bioelectrical impedance analysis (BIA) and the fat ultrasonographic examinations produced similar results to the other methods that required animals to be killed (carcass analysis and weight of adipose tissue). In addition, the Rt diet significantly (P < 0.05) decreased plasma levels of triglycerides, phospholipids, glucose and ADIPOQ, and fish oil supplementation decreased plasma levels of RARRES2. We also showed a positive correlation between insulin values and ADIPOQ or NAMPT or RARRES2 values, and a negative correlation of fat percentage to RARRES2 values. Moreover, the effects of the Rt diet and fish oil supplementation on the mRNA expression depended on the factors tested and the hen age. Conclusions Rt diet and fish oil supplementation are able to modulate metabolic parameters and the expression of adipokines and their receptors in metabolic tissue.	[Mellouk, Namya; Rame, Christelle; Lecompte, Francois; Ma, Linlin; Froment, Pascal; Dupont, Joelle] INRA UMR85 Physiol Reprod & Comportements, Nouzilly, France; [Mellouk, Namya; Rame, Christelle; Lecompte, Francois; Ma, Linlin; Froment, Pascal; Dupont, Joelle] CNRS, UMR7247 Physiol Reprod & Comportements, Nouzilly, France; [Mellouk, Namya; Rame, Christelle; Lecompte, Francois; Ma, Linlin; Froment, Pascal; Dupont, Joelle] Univ Francois Rabelais Tours, Tours, France; [Mellouk, Namya; Rame, Christelle; Lecompte, Francois; Ma, Linlin; Froment, Pascal; Dupont, Joelle] IFCE Nouzilly, Nouzilly, France; [Marchand, Maxime; Mercerand, Frederic] INRA, UEPEAT, Nouzilly, France; [Staub, Christophe; Touze, Jean-Luc; Venturi, Eric] INRA, UEPAO 1297, Nouzilly, France; [Travel, Angelique] Ctr INRA Ctr Val Loire, ITAVI, Nouzilly, France; [Chartrin, Pascal] INRA, URA, Nouzilly, France	INRAE; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; INRAE; INRAE; INRAE	Dupont, J (corresponding author), INRA UMR85 Physiol Reprod & Comportements, Nouzilly, France.; Dupont, J (corresponding author), CNRS, UMR7247 Physiol Reprod & Comportements, Nouzilly, France.; Dupont, J (corresponding author), Univ Francois Rabelais Tours, Tours, France.; Dupont, J (corresponding author), IFCE Nouzilly, Nouzilly, France.	jdupont@tours.fr	Mellouk, Namya/AAL-7583-2021		Region Centre Val de Loire grant "Adipofertikines" [32000407]; MENRT	Region Centre Val de Loire grant "Adipofertikines"; MENRT	This work has been supported by Region Centre Val de Loire grant "Adipofertikines" No 32000407. Namya Mellouk is a PhD student supported by the MENRT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bozaoglu K, 2007, ENDOCRINOLOGY, V148, P4687, DOI 10.1210/en.2007-0175; Broiler M J. A., 2002, WORLDS POULTRY SCI J, V58, P23; Bruggeman V, 1999, POULTRY SCI, V78, P1424, DOI 10.1093/ps/78.10.1424; Buyse J, 2000, BRIT POULTRY SCI, V41, P107, DOI 10.1080/00071660086493; Cachaldora P, 2006, BRIT POULTRY SCI, V47, P43, DOI 10.1080/00071660500475541; Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x; Carre B, 2013, ANIMAL, V7, P1246, DOI 10.1017/S1751731113000359; Chabrolle C, 2007, DOMEST ANIM ENDOCRIN, V33, P480, DOI 10.1016/j.domaniend.2006.08.002; Chapkin RS, 2009, PROSTAG LEUKOTR ESS, V81, P187, DOI 10.1016/j.plefa.2009.05.010; Chen LR, 2007, ANIM REPROD SCI, V100, P172, DOI 10.1016/j.anireprosci.2006.07.005; Cheshmehkani A, 2015, INFLAMM RES, V64, P809, DOI 10.1007/s00011-015-0864-3; Cornall LM, 2011, CELL PHYSIOL BIOCHEM, V28, P949, DOI 10.1159/000335820; de Jong IC, 2002, BRIT POULTRY SCI, V43, P157, DOI 10.1080/00071660120121355; DECUYPERE E, 1988, Acta Physiologica Polonica, V39, P380; Diot M, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0081-5; Flachs P, 2006, DIABETOLOGIA, V49, P394, DOI 10.1007/s00125-005-0053-y; FOLCH J, 1957, J BIOL CHEM, V226, P497; Friedman-Einat M, 1999, GEN COMP ENDOCR, V115, P354, DOI 10.1006/gcen.1999.7322; Geier MS, 2009, POULTRY SCI, V88, P2399, DOI 10.3382/ps.2009-00126; Ghazanfari S, 2011, ASIAN J ANIM VET ADV, V6, P429, DOI 10.3923/ajava.2011.429.439; Hendricks GL, 2009, ENDOCRINOLOGY, V150, P3092, DOI 10.1210/en.2008-1558; Hocking PM, 1996, BRIT POULTRY SCI, V37, P263, DOI 10.1080/00071669608417858; Joseph NS, 2000, POULTRY SCI, V79, P1790, DOI 10.1093/ps/79.12.1790; Kita K, 2002, J NUTR, V132, P145, DOI 10.1093/jn/132.2.145; Koppenol A, 2014, POULTRY SCI, V93, P564, DOI 10.3382/ps.2013-03320; Krzysik-Walker SM, 2008, ENDOCRINOLOGY, V149, P1543, DOI 10.1210/en.2007-1301; Li J, 2012, POULTRY SCI, V91, P2885, DOI 10.3382/ps.2012-02315; Lopez-Ferrer S, 1999, POULTRY SCI, V78, P356, DOI 10.1093/ps/78.3.356; Lopez-Ferrer S, 2001, POULTRY SCI, V80, P741, DOI 10.1093/ps/80.6.741; Lopez-Ferrer S, 2001, POULTRY SCI, V80, P753, DOI 10.1093/ps/80.6.753; Lorente-Cebrian S, 2009, CLIN SCI, V117, P243, DOI 10.1042/CS20090020; Maddineni S, 2005, ENDOCRINOLOGY, V146, P4250, DOI 10.1210/en.2005-0254; Mori TA, 1999, AM J CLIN NUTR, V70, P817; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Oster RT, 2010, APPL PHYSIOL NUTR ME, V35, P783, DOI 10.1139/H10-076; Pan YE, 2014, ANIM REPROD SCI, V151, P229, DOI 10.1016/j.anireprosci.2014.10.003; PEARCE J, 1977, J ENDOCRINOL, V75, P343, DOI 10.1677/joe.0.0750343; Poniedzialek-Czajkowska E, 2014, CURR PHARM BIOTECHNO, V15, P84, DOI 10.2174/1389201015666140330195614; Ramachandran R, 2013, GEN COMP ENDOCR, V190, P88, DOI 10.1016/j.ygcen.2013.05.004; Resnyk CW, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-557; Richards MP, 2007, POULTRY SCI, V86, P1478, DOI 10.1093/ps/86.7.1478; ROBBINS KR, 1986, POULTRY SCI, V65, P2226, DOI 10.3382/ps.0652226; Ruzickova J, 2004, LIPIDS, V39, P1177, DOI 10.1007/s11745-004-1345-9; Schreiner M, 2005, J SCI FOOD AGR, V85, P219, DOI 10.1002/jsfa.1948; Sell H, 2010, J CLIN ENDOCR METAB, V95, P2892, DOI 10.1210/jc.2009-2374; Seroussi E, 2016, ENDOCRINOLOGY, V157, P737, DOI 10.1210/en.2015-1634; Shils M. E., 2006, MODERN NUTR HLTH DIS, V10th, P92; Sledzinski T, 2013, J ENDOCRINOL INVEST, V36, P428, DOI 10.3275/8770; Sun JM, 2006, POULTRY SCI, V85, P1173, DOI 10.1093/ps/85.7.1173; Tahmoorespur M, 2010, POULTRY SCI, V89, P2092, DOI 10.3382/ps.2010-00772; Tishinsky JM, 2011, OBESITY, V19, P262, DOI 10.1038/oby.2010.186; van Krimpen MM, 2014, WORLD POULTRY SCI J, V70, P139, DOI 10.1017/S0043933914000129; Vu JP, 2015, J MOL NEUROSCI, V56, P377, DOI 10.1007/s12031-015-0556-z; Yan J, 2013, MOL BIOL REP, V40, P7017, DOI 10.1007/s11033-013-2821-y; Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077716	55	17	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2018	13	1							e0191121	10.1371/journal.pone.0191121	http://dx.doi.org/10.1371/journal.pone.0191121			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT8OQ	29364913	Green Published, gold, Green Submitted			2023-01-03	WOS:000423412500036
J	Kitagawa, T; Oda, N; Mizukawa, M; Hidaka, T; Naka, M; Nakayama, S; Kihara, Y				Kitagawa, Toshiro; Oda, Noboru; Mizukawa, Mariko; Hidaka, Takayuki; Naka, Makiko; Nakayama, Susumu; Kihara, Yasuki			Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels	PLOS ONE			English	Article							HEART-FAILURE; CLINICAL CHARACTERISTICS; MANAGEMENT; REGISTRY	Background Patients with heart failure (HF) are reportedly at high risk for 'all-cause' re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanese patients detected by an elevated serum NT-proBNP, and also evaluated the effects of institutional team approaches for HF on their all-cause hospitalizations. Methods We retrospectively extracted all adult patients with serum NT-proBNP >= 400 pg/ml measured between January and March 2012 in Hiroshima University Hospital as pHF-positive patients. We studied their all-cause hospitalization records during the past 3-year period. We also extracted all pHF-negative patients with NT-proBNP < 400 pg/ml and studied as well. In the pHF-positive patients followed for 3 years after starting interprofessional team approaches to prevent the onset and exacerbation of HF in the hospital, we compared the hospitalization and medical cost between the 3-year periods before and after the start of the team approaches. Results We enrolled 432 pHF-positive and 485 pHF-negative patients with one or more hospitalization records. Compared to the pHF-negative patients, the pHF-positive patients had longer total hospitalization days (median [interquartile range], 30 [13 +/- 58] versus. 18 [8 +/- 39], p < 0.0001) and higher total medical cost for hospitalizations (2.42 [1.07 +/- 5.08] versus. 1.80 [0.79 +/- 3.65] million yen, p < 0.0001). A subset of 303 pHF-positive patients was followed for 3 years after starting the team approaches, and we found that both total hospitalization days (30 [13 +/- 57] to 8 [0 +/- 31]) and medical cost for hospitalizations (2.59 [1.37 +/- 5.05] to 0.76 [0 +/- 2.38] million yen) showed marked reduction in them. Conclusions Patients with an elevated serum NT-proBNP have longer hospitalizations and higher costs for all-cause hospitalizations than those without. Institutional team approaches for HF may reduce them.	[Kitagawa, Toshiro; Hidaka, Takayuki; Kihara, Yasuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima, Japan; [Kitagawa, Toshiro; Mizukawa, Mariko; Hidaka, Takayuki; Naka, Makiko; Nakayama, Susumu; Kihara, Yasuki] Hiroshima Univ Hosp, Heart Failure Ctr, Hiroshima, Japan; [Oda, Noboru] Hiroshima City Asa Hosp, Dept Cardiol, Hiroshima, Japan	Hiroshima University; Hiroshima University	Kitagawa, T (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima, Japan.; Kitagawa, T (corresponding author), Hiroshima Univ Hosp, Heart Failure Ctr, Hiroshima, Japan.	toshirok@hiroshima-u.ac.jp		Kitagawa, Toshiro/0000-0002-5433-2428	local medical program of the Hiroshima Prefecture Government in Japan (Hiroshima Heart Health Promotion Project); Grants-in-Aid for Scientific Research [15K09084] Funding Source: KAKEN	local medical program of the Hiroshima Prefecture Government in Japan (Hiroshima Heart Health Promotion Project); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This survey is supported by a local medical program of the Hiroshima Prefecture Government in Japan (Hiroshima Heart Health Promotion Project). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Fukuta H, 2008, CIRC J, V72, P212, DOI 10.1253/circj.72.212; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Ishii Masami, 2012, Japan Med Assoc J, V55, P279; Kawashiro N, 2008, CIRC J, V72, P2015, DOI 10.1253/circj.CJ-08-0323; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; Palazzuoli A, 2014, HEART FAIL REV, V19, P267, DOI 10.1007/s10741-013-9391-x; Scrutinio D, 2014, CIRC J, V78, P2439, DOI 10.1253/circj.CJ-14-0405; Shiba N, 2004, CIRC J, V68, P427, DOI 10.1253/circj.68.427; Starling RC, 1998, CLEV CLIN J MED, V65, P351; Stromberg A, 2003, EUR HEART J, V24, P1014, DOI 10.1016/S0195-668X(03)00112-X; Takabayashi K, 2017, CIRC J, V81, P69, DOI 10.1253/circj.CJ-16-0914; Tsutsui H, 2006, CIRC J, V70, P1617, DOI 10.1253/circj.70.1617; Wang GJ, 2010, AM J MANAG CARE, V16, P769; Yancy CW, 2013, CIRCULATION, V128, P1810, DOI 10.1161/CIR.0b013e31829e8807	16	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2018	13	1							e0190979	10.1371/journal.pone.0190979	http://dx.doi.org/10.1371/journal.pone.0190979			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR9OU	29304158	gold, Green Submitted, Green Published			2023-01-03	WOS:000419403800142
J	Routy, B; Le Chatelier, E; Derosa, L; Duong, CPM; Alou, MT; Daillere, R; Fluckiger, A; Messaoudene, M; Rauber, C; Roberti, MP; Fidelle, M; Flament, C; Poirier-Colame, V; Opolon, P; Klein, C; Iribarren, K; Mondragon, L; Jacquelot, N; Qu, B; Ferrere, G; Clemenson, C; Mezquita, L; Masip, JR; Naltet, C; Brosseau, S; Kaderbhai, C; Richard, C; Rizvi, H; Levenez, F; Galleron, N; Quinquis, B; Pons, N; Ryffel, B; Minard-Colin, V; Gonin, P; Soria, JC; Deutsch, E; Loriot, Y; Ghiringhelli, F; Zalcman, G; Goldwasser, F; Escudier, B; Hellmann, MD; Eggermont, A; Raoult, D; Albiges, L; Kroemer, G; Zitvogel, L				Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa; Duong, Connie P. M.; Alou, Maryam Tidjani; Daillere, Romain; Fluckiger, Aurelie; Messaoudene, Meriem; Rauber, Conrad; Roberti, Maria P.; Fidelle, Marine; Flament, Caroline; Poirier-Colame, Vichnou; Opolon, Paule; Klein, Christophe; Iribarren, Kristina; Mondragon, Laura; Jacquelot, Nicolas; Qu, Bo; Ferrere, Gladys; Clemenson, Celine; Mezquita, Laura; Masip, Jordi Remon; Naltet, Charles; Brosseau, Solenn; Kaderbhai, Coureche; Richard, Corentin; Rizvi, Hira; Levenez, Florence; Galleron, Nathalie; Quinquis, Benoit; Pons, Nicolas; Ryffel, Bernhard; Minard-Colin, Veronique; Gonin, Patrick; Soria, Jean-Charles; Deutsch, Eric; Loriot, Yohann; Ghiringhelli, Francois; Zalcman, Gerard; Goldwasser, Francois; Escudier, Bernard; Hellmann, Matthew D.; Eggermont, Alexander; Raoult, Didier; Albiges, Laurence; Kroemer, Guido; Zitvogel, Laurence			Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors	SCIENCE			English	Article							CELL LUNG-CANCER; INTESTINAL MICROBIOTA; PD-1 BLOCKADE; ANTITUMOR IMMUNITY; NIVOLUMAB; MELANOMA; CYCLOPHOSPHAMIDE; MICROENVIRONMENT; RESISTANCE; GENES	Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlations between clinical responses to ICIs and the relative abundance of Akkermansia muciniphila. Oral supplementation with A. muciniphila after FMT with nonresponder feces restored the efficacy of PD-1 blockade in an interleukin-12-dependent manner by increasing the recruitment of CCR9(+)CXCR3(+)CD4(+) T lymphocytes into mouse tumor beds.	[Routy, Bertrand; Derosa, Lisa; Duong, Connie P. M.; Alou, Maryam Tidjani; Daillere, Romain; Fluckiger, Aurelie; Messaoudene, Meriem; Rauber, Conrad; Roberti, Maria P.; Fidelle, Marine; Flament, Caroline; Poirier-Colame, Vichnou; Jacquelot, Nicolas; Qu, Bo; Ferrere, Gladys; Clemenson, Celine; Mezquita, Laura; Masip, Jordi Remon; Minard-Colin, Veronique; Gonin, Patrick; Soria, Jean-Charles; Deutsch, Eric; Loriot, Yohann; Escudier, Bernard; Eggermont, Alexander; Albiges, Laurence; Zitvogel, Laurence] GRCC, Villejuif, France; [Routy, Bertrand; Derosa, Lisa; Duong, Connie P. M.; Alou, Maryam Tidjani; Daillere, Romain; Fluckiger, Aurelie; Messaoudene, Meriem; Rauber, Conrad; Roberti, Maria P.; Flament, Caroline; Poirier-Colame, Vichnou; Jacquelot, Nicolas; Qu, Bo; Ferrere, Gladys; Eggermont, Alexander; Zitvogel, Laurence] INSERM, U1015, Villejuif, France; [Routy, Bertrand; Derosa, Lisa; Duong, Connie P. M.; Alou, Maryam Tidjani; Daillere, Romain; Fluckiger, Aurelie; Messaoudene, Meriem; Rauber, Conrad; Roberti, Maria P.; Flament, Caroline; Poirier-Colame, Vichnou; Jacquelot, Nicolas; Qu, Bo; Ferrere, Gladys; Eggermont, Alexander; Zitvogel, Laurence] Equipe Labellisee Ligue Natl Canc, Villejuif, France; [Routy, Bertrand; Derosa, Lisa; Alou, Maryam Tidjani; Daillere, Romain; Rauber, Conrad; Fidelle, Marine; Jacquelot, Nicolas; Qu, Bo; Ferrere, Gladys; Loriot, Yohann; Albiges, Laurence; Zitvogel, Laurence] Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, Villejuif, France; [Le Chatelier, Emmanuelle; Levenez, Florence; Galleron, Nathalie; Quinquis, Benoit; Pons, Nicolas] Univ Paris Saclay, INRA, MGP MetaGenoPolis, Jouy En Josas, France; [Duong, Connie P. M.; Fluckiger, Aurelie; Roberti, Maria P.; Fidelle, Marine; Flament, Caroline; Poirier-Colame, Vichnou; Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France; [Opolon, Paule] Gustave Roussy, Lab Pathol Expt, F-94800 Villejuif, France; [Klein, Christophe] Univ Paris 06, Univ Pierre & Marie Curie, Univ Paris Descartes,Sorbonne Univ, Ctr Rech Cordeliers,INSERM,Sorbonne Paris Cite,UM, Paris, France; [Iribarren, Kristina; Mondragon, Laura; Kroemer, Guido] GRCC, Metabol & Cell Biol Platforms, Villejuif, France; [Iribarren, Kristina; Mondragon, Laura; Goldwasser, Francois; Kroemer, Guido] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France; [Iribarren, Kristina; Mondragon, Laura; Kroemer, Guido] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France; [Iribarren, Kristina; Mondragon, Laura; Kroemer, Guido] INSERM, U1138, Paris, France; [Iribarren, Kristina; Mondragon, Laura; Kroemer, Guido] Univ Paris 06, Paris, France; [Clemenson, Celine; Deutsch, Eric] Univ Paris Saclay, Gustave Roussy, Dept Radiat Oncol, INSERM,U1030, F-94805 Villejuif, France; [Clemenson, Celine; Deutsch, Eric] Univ Paris Saclay, Gustave Roussy, Mol Radiotherapy, F-94805 Villejuif, France; [Mezquita, Laura; Masip, Jordi Remon; Soria, Jean-Charles; Loriot, Yohann; Escudier, Bernard; Eggermont, Alexander; Albiges, Laurence] Gustave Roussy, Dept Med Oncol, Villejuif, France; [Naltet, Charles; Brosseau, Solenn; Zalcman, Gerard] Univ Paris Diderot, Hosp Bichat Claude Bernard, AP HP, Thorac Oncol Dept,CIC1425 CLIP2 Paris Nord, Paris, France; [Kaderbhai, Coureche; Richard, Corentin; Ghiringhelli, Francois] Ctr GF Leclerc, Dept Med Oncol, Dijon, France; [Rizvi, Hira] Mem Sloan Kettering Canc Ctr, Druckenmiller Ctr Lung Canc Res, 1275 York Ave, New York, NY 10021 USA; [Ryffel, Bernhard] Univ Orleans, Mol Immunol & Embryol, UMR 7355, CNRS, Orleans, France; [Minard-Colin, Veronique] GRCC, Dept Pediat Oncol, Villejuif, France; [Gonin, Patrick] GRCC, Preclin Res Platform, Villejuif, France; [Goldwasser, Francois] Cochin Hosp, AP HP, Dept Med Oncol, Paris, France; [Goldwasser, Francois] Immunomodulatory Therapies Multidisciplinary Stud, Paris, France; [Escudier, Bernard] GRCC, INSERM, U981, Villejuif, France; [Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA; [Hellmann, Matthew D.] Weill Cornell Med Coll, Dept Med, New York, NY USA; [Raoult, Didier] Aix Marseille Univ, URMITE, CNRS, UM63 7278,IRD 198,INSERM 1095,IHU Mediterranee In, F-13005 Marseille, France; [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Kroemer, Guido] Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; INRAE; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Georges-Francois Leclerc; Memorial Sloan Kettering Cancer Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Orleans; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Memorial Sloan Kettering Cancer Center; Cornell University; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche pour le Developpement (IRD); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital	Zitvogel, L (corresponding author), GRCC, Villejuif, France.; Zitvogel, L (corresponding author), INSERM, U1015, Villejuif, France.; Zitvogel, L (corresponding author), Equipe Labellisee Ligue Natl Canc, Villejuif, France.; Zitvogel, L (corresponding author), Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, Villejuif, France.; Zitvogel, L (corresponding author), Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France.; Kroemer, G (corresponding author), GRCC, Metabol & Cell Biol Platforms, Villejuif, France.; Kroemer, G (corresponding author), Paris Descartes Univ, Sorbonne Paris Cite, Paris, France.; Kroemer, G (corresponding author), Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France.; Kroemer, G (corresponding author), INSERM, U1138, Paris, France.; Kroemer, G (corresponding author), Univ Paris 06, Paris, France.; Kroemer, G (corresponding author), Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.; Kroemer, G (corresponding author), Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden.	kroemer@orange.fr; laurence.zitvogel@gustaveroussy.fr	DEROSA, LISA/E-6814-2015; Qu, Bo/V-6675-2019; Soria, Jean-Charles/F-3619-2014; Martinez, Laura Mondragon/P-1670-2018; Rauber, Conrad/ABA-8389-2021; ZALCMAN, Gerard/M-8113-2019; CLEMENSON, Celine/AAR-4208-2021; KROEMER, Guido/B-4263-2013; RAOULT, Didier/A-8434-2008; Loriot, Yohann/W-5572-2019; Kroemer, Guido/AAY-9859-2020; Jacquelot, Nicolas/AAY-6937-2020; Martinez, Laura Mondragon/X-1577-2019; GONIN, Patrick/R-1920-2019; MEZQUITA, LAURA/AAH-8859-2020; LE CHATELIER, Emmanuelle/O-1243-2017	Martinez, Laura Mondragon/0000-0002-3257-045X; CLEMENSON, Celine/0000-0002-3700-481X; KROEMER, Guido/0000-0002-9334-4405; RAOULT, Didier/0000-0002-0633-5974; Martinez, Laura Mondragon/0000-0002-3257-045X; GONIN, Patrick/0000-0001-6151-4580; MEZQUITA, LAURA/0000-0003-0936-7338; LE CHATELIER, Emmanuelle/0000-0002-2724-0536; Fidelle, Marine/0000-0002-5589-9688; ZITVOGEL, laurence/0000-0003-1596-0998; klein, christophe/0000-0001-8015-287X; Duong, Connie/0000-0002-9067-8557; Tidjani Alou, Maryam/0000-0002-0167-6235; Derosa, Lisa/0000-0003-0527-2964; deutsch, eric/0000-0002-8223-3697; ghiringhelli, francois/0000-0002-5465-8305; Jacquelot, Nicolas/0000-0003-0282-1892	Gustave Roussy Course of Excellence in Oncology-Fondation Philanthropia; McGill University Townsend hematology research fellowship award; Ligue contre le Cancer (equipe labelisee); Agence Nationale de la Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2 (ERA-Net for Research on Rare Diseases); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LeDucq Foundation; LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); philanthropia; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Gustave Roussy Course of Excellence in Oncology-Fondation Philanthropia; McGill University Townsend hematology research fellowship award; Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence Nationale de la Recherche (ANR)-Projets blancs(French National Research Agency (ANR)); ANR under the frame of E-Rare-2 (ERA-Net for Research on Rare Diseases)(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)); LeDucq Foundation(Leducq Foundation); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); philanthropia; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the animal facility team and V. Rouffiac from the imaging platform of Gustave Roussy, as well as S. Jabs for technical help. The data reported in this manuscript are tabulated in the main paper and the supplementary materials. The metagenomic shotgun sequencing data are available from the European Nucleotide Archive (EMBL-EBI) under accession number PRJEB22863. B.R. was supported by Gustave Roussy Course of Excellence in Oncology-Fondation Philanthropia and a McGill University Townsend hematology research fellowship award. L.Z. and G.K. were supported by the Ligue contre le Cancer (equipe labelisee), Agence Nationale de la Recherche (ANR)-Projets blancs, ANR under the frame of E-Rare-2 (ERA-Net for Research on Rare Diseases), Association pour la recherche sur le cancer (ARC), Canceropole Ile-de-France, Institut National du Cancer (INCa), Institut Universitaire de France, Fondation pour la Recherche Medicale (FRM), the European Commission (ArtForce), the European Research Council (ERC), the LeDucq Foundation, LabEx Immuno-Oncology, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE), SIRIC Cancer Research and Personalized Medicine (CARPEM), the Paris Alliance of Cancer Research Institutes (PACRI), and philanthropia (E. Badinter and N. Meyer). L.Z., E.L.C., and B.R. are inventors on patent EP17305206 and European license 16306779.6 held by Institut Gustave Roussy that covers use of microbial modulators for PD1/PD-L1/PD-L2 mAb-based treatments. L.Z. and G.K. are cofounders of EverImmune, a biotech company focused on the use of commensal bacteria for cancer treatment.	Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Blaser MJ, 2016, SCIENCE, V352, P544, DOI 10.1126/science.aad9358; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Collado MC, 2007, APPL ENVIRON MICROB, V73, P7767, DOI 10.1128/AEM.01477-07; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Jackson MA, 2016, GUT, V65, P749, DOI 10.1136/gutjnl-2015-310861; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Pardoll D, 2015, SEMIN ONCOL, V42, P523, DOI 10.1053/j.seminoncol.2015.05.003; Peled JU, 2017, J CLIN ONCOL, V35, P1650, DOI 10.1200/JCO.2016.70.3348; Restifo NP, 2012, NAT REV IMMUNOL, V12, P269, DOI 10.1038/nri3191; Riaz N, 2016, NAT GENET, V48, P1327, DOI 10.1038/ng.3677; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Suau A, 1999, APPL ENVIRON MICROB, V65, P4799; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Wang XH, 2017, CANCER RES, V77, P839, DOI 10.1158/0008-5472.CAN-15-3142	30	2412	2560	111	1270	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2018	359	6371					91	+		10.1126/science.aan3706	http://dx.doi.org/10.1126/science.aan3706			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR8KW	29097494				2023-01-03	WOS:000419324700074
J	Garcia, J; Garg, A; Song, YM; Fotios, A; Andersen, C; Garg, S				Garcia, Jowell; Garg, Alka; Song, Yunmei; Fotios, Ambados; Andersen, Chad; Garg, Sanjay			Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion	PLOS ONE			English	Article							PATENT DUCTUS-ARTERIOSUS; PHARMACOPEIAL STANDARDS; PRETERM INFANTS; PARACETAMOL; STABILITY; MANAGEMENT; ADMIXTURES	There is increasing interest to administer ibuprofen as a continuous infusion instead of a traditional bolus for treating Patent Ductus Arteriosus (PDA). However, its compatibility data with commonly used drugs in the neonatal period, including parenteral nutrition (PN) and lipids is unavailable. The aim is to determine the compatibility of intravenous ibuprofen lysine with various ANZNN parenteral nutrition consensus group standard neonatal PN formulations and lipids. The PN and lipid solutions used in a tertiary neonatal unit were obtained. These included a Starter, Standard Preterm and low carbohydrate PN, and IV SMOF lipid admixture (SMOFLipid 20% 15 mL; Vitalipid N infant 4 mL, Soluvit N 1 mL) plus vitamin mixtures. 10% glucose was used as a control. 1: 1 mixtures of different concentrations (1.25 to 5mg/mL) of ibuprofen lysine and each of the PN/glucose/lipid formulations were made. Samples were taken at hourly intervals for a total of 4 hours and tested for both physical (visual assessment, pH and microscopy) and chemical compatibility (High Performance Liquid Chromatography analysis). Zeta potential and particle diameter were measured for SMOF lipid admixture and ibuprofen combination to assess emulsion stability. 24 hour stability of ibuprofen dilution in 5 mL BD Luer-lok polypropylene syringes at 25 degrees C was also assessed. Most PN formed opaque solutions when mixed with ibuprofen 2.5 and 5mg/mL solutions. However, ibuprofen dilution of 1.25mg/mL produced clear, colourless solutions with no microscopic particles when mixed with all PN/glucose/lipid formulations tested. Ibuprofen was chemically stable with all PN and SMOF lipid admixture, for a period of 4 hours. The zeta potential and particle diameter were within acceptable limits. Ibuprofen lysine was stable over 24 hours in Luer-lok polypropylene syringes. Ibuprofen 1.25mg/mL is physically and chemically compatible with 10% glucose, starter PN, standard preterm and low carbohydrate PN, and SMOF lipid admixture plus vitamins for a period of four hours, which is the maximum time they could be in an admixture during a continuous infusion.	[Garcia, Jowell; Song, Yunmei; Garg, Sanjay] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia; [Garg, Alka; Fotios, Ambados] SA Pharm, Womens & Childrens Hosp, Adelaide, SA, Australia; [Andersen, Chad] Womens & Childrens Hosp, Dept Neonatal Med, Adelaide, SA, Australia	University of South Australia; Womens & Childrens Hospital Australia	Garg, S (corresponding author), Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia.	sanjay.garg@unisa.edu.au	Garg, Sanjay/B-2516-2012	Garg, Sanjay/0000-0001-7253-2629				Driscoll DF, 2010, JPEN-PARENTER ENTER, V34, P305, DOI 10.1177/0148607109338215; Driscoll DF, 2005, CURR OPIN CLIN NUTR, V8, P297, DOI 10.1097/01.mco.0000165009.24202.64; Gallegos C, 2012, AM J HEALTH-SYST PH, V69, P1332, DOI 10.2146/ajhp110520; Holt Robert J, 2008, J Pediatr Pharmacol Ther, V13, P156, DOI 10.5863/1551-6776-13.3.156; KOORENHOF MJC, 1992, PHARM WEEKBLAD, V14, P50, DOI 10.1007/BF01980482; Lago P, 2014, NEONATOLOGY, V105, P46, DOI 10.1159/000355679; Mercanti I, 2012, CURR PHARM DESIGN, V18, P3007, DOI 10.2174/1381612811209023007; Moore GP, 2012, PAED CHILD HEALT-CAN, V17, pE26, DOI 10.1093/pch/17.4.e26; Ohlsson A, 2013, COCHRANE DATABASE SY; Oncel MY, 2014, J PEDIATR-US, V164, P510, DOI 10.1016/j.jpeds.2013.11.008; Oncel MY, 2013, NEONATOLOGY, V103, P166, DOI 10.1159/000345337; Staven V, 2016, NUTR J, V15, DOI 10.1186/s12937-016-0149-x; Terrin G, 2016, ARCH DIS CHILD-FETAL, V101, pF127, DOI 10.1136/archdischild-2014-307312; Volonte MG, 2005, AM J HEALTH-SYST PH, V62, P630, DOI 10.1093/ajhp/62.6.630	14	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2018	13	1							e0190577	10.1371/journal.pone.0190577	http://dx.doi.org/10.1371/journal.pone.0190577			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR6OK	29298359	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000419185200055
J	Alfaro-Viquez, E; Roling, BF; Krueger, CG; Rainey, CJ; Reed, JD; Ricketts, ML				Alfaro-Viquez, Emilia; Roling, Brent F.; Krueger, Christian G.; Rainey, Charlene J.; Reed, Jess D.; Ricketts, Marie-Louise			An extract from date palm fruit (&ITPhoenix dactylifera&IT) acts as a co-agonist ligand for the nuclear receptor FXR and differentially modulates FXR target-gene expression&IT in vitro &IT	PLOS ONE			English	Article							FARNESOID-X-RECEPTOR; FLIGHT MASS-SPECTROMETRY; FIBROBLAST-GROWTH-FACTOR; BILE-ACID TRANSPORTER; ORGANIC SOLUTE TRANSPORTER; LOWER TRIGLYCERIDE LEVELS; CORONARY-HEART-DISEASE; PHOENIX-DACTYLIFERA; METABOLIC SYNDROME; BINDING-PROTEIN	Date palm fruit (Phoenix dactylifera) consumption reduces serum triglyceride levels in human subjects. The objective of this study was to prepare an extract from dates and determine whether it acts as a ligand for the farnesoid x receptor (FXR), a nuclear receptor important for maintaining triglyceride and cholesterol homeostasis. Freeze-dried extracts were isolated from California-grown dates (Deglet Noor and Medjool) from the 2014 and 2015 harvests, by means of liquid extraction and solid phase separation. Each date palm extract (DPE) was characterized via HPLC and MALDI-TOF mass spectrometry, and the procyanidin content was qualitatively determined. Extracts were tested to determine their ability to modulate nuclear receptor-mediated transactivation using transient transfection. The effect of DPE on FXR-target genes regulating bile acid absorption and transport was then assessed in vitro, in Caco-2 cells. Characterization reveals that DPE is a rich source of polyphenols including hydroxycinnamic acids, proanthocyanidins, and lipohilic polyphenols, and comprises 13% proanthocyanidins. Transactivation results show that DPE acts as a co-agonist ligand for both mouse and human FXR, wherein it activates bile acid-bound FXR greater than that seen with bile acid alone. Additionally, DPE alone activated a peroxisome proliferator activated receptor alpha (PPAR alpha) chimera in a dose-dependent manner. Consistent with DPE as a co-agonist ligand for FXR, studies in Caco-2 cells reveal that co-incubation with bile acid, dose-dependently enhances the expression of fibroblast growth factor 19 (FGF19), compared to treatment with bile acid alone. In contrast, DPE inhibited bile acid-induced expression of ileal bile acid binding protein (IBABP). Our results demonstrate that DPE acts as a potent co-agonist ligand for FXR, and that it differentially regulates FXR-target gene expression in vitro in human intestinal cells. This study provides novel insight into a potential mechanism by which dates may exert a hypotriglyceridemic effect via FXR and modulation of bile acid homeostasis.	[Alfaro-Viquez, Emilia; Krueger, Christian G.; Reed, Jess D.] Univ Wisconsin, Dept Anim Sci, Reed Res Grp, Madison, WI USA; [Roling, Brent F.; Ricketts, Marie-Louise] Univ Nevada, Dept Agr Nutr & Vet Sci, Reno, NV 89557 USA; [Krueger, Christian G.; Reed, Jess D.] Complete Phytochem Solut, Cambridge, WI USA; [Rainey, Charlene J.] Date Res Inst, San Juan Capistrano, CA USA	University of Wisconsin System; University of Wisconsin Madison; Nevada System of Higher Education (NSHE); University of Nevada Reno	Ricketts, ML (corresponding author), Univ Nevada, Dept Agr Nutr & Vet Sci, Reno, NV 89557 USA.	marielouise.ricketts@gmail.com		Alfaro-Viquez, Emilia/0000-0002-8320-6017; Ricketts, Marie-Louise/0000-0002-8306-7563	California Date Commission [1321-153-07BN, 1321-153-07BB]	California Date Commission	Funding was provided by the California Date Commission, Project numbers: 1321-153-07BN and 1321-153-07BB, to Dr. Marie-Louise Ricketts. Christian G. Krueger and Jess D. Reed have ownership interests in Complete Phytochemical Solutions LLC, and in full disclosure, their affiliation with this company is acknowledged in the author affiliation. The funder provided support for research only and did not provide support in the form of salaries, and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the "author contributions" section.	Al-Farsi M, 2005, J AGR FOOD CHEM, V53, P7592, DOI 10.1021/jf050579q; Al-Farsi M, 2005, J AGR FOOD CHEM, V53, P7586, DOI 10.1021/jf050578y; Al-Farsi MA, 2008, CRIT REV FOOD SCI, V48, P877, DOI 10.1080/10408390701724264; Al-Shahib W, 2003, INT J FOOD SCI NUTR, V54, P247, DOI [10.1080/09637480120091982, 10.1080/096374803766666120]; Alkaabi JM, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-59; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Atkinson FS, 2008, DIABETES CARE, V31, P2281, DOI 10.2337/dc08-1239; Auger C, 2004, J AGR FOOD CHEM, V52, P5297, DOI 10.1021/jf040125d; Beltran-Sanchez H, 2013, J AM COLL CARDIOL, V62, P697, DOI 10.1016/j.jacc.2013.05.064; Berglund L, 2012, J CLIN ENDOCR METAB, V97, P2969, DOI 10.1210/jc.2011-3213; Braga FC, 2007, FITOTERAPIA, V78, P353, DOI [10.1016/j.fitote.2007.02.007, 10.1016/J.fitote.2007.02.007]; Caimari A, 2012, INT J OBESITY; Caiozzi G, 2012, CELL BIOCHEM FUNCT, V30, P531, DOI 10.1002/cbf.2842; Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Dasgupta S, 2014, ANNU REV MED, V65, P279, DOI 10.1146/annurev-med-051812-145316; Dawson PA, 2005, J BIOL CHEM, V280, P6960, DOI 10.1074/jbc.M412752200; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; Del Bas JM, 2008, MOL NUTR FOOD RES, V52, P1172, DOI 10.1002/mnfr.200800054; del Rio JC, 2004, RAPID COMMUN MASS SP, V18, P2691, DOI 10.1002/rcm.1677; Domitrovic R, 2008, BIOL TRACE ELEM RES, V126, P176, DOI 10.1007/s12011-008-8181-0; Downing LE, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600347; Downing LE, 2017, CELL BIOCHEM FUNCT, V35, P12, DOI 10.1002/cbf.3247; Downing LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140267; Dussault I, 2003, J BIOL CHEM, V278, P7027, DOI 10.1074/jbc.M209863200; Edwards PA, 2002, J LIPID RES, V43, P2; Eid NMS, 2013, J AGR FOOD CHEM, V61, P2453, DOI 10.1021/jf303951e; Feliciano RP, 2012, FOOD CHEM, V135, P1485, DOI 10.1016/j.foodchem.2012.05.102; Feliciano RP, 2012, J AGR FOOD CHEM, V60, P4578, DOI 10.1021/jf3007213; Galassi A, 2006, AM J MED, V119, P812, DOI 10.1016/j.amjmed.2006.02.031; Gonzalez FJ, 2012, COMPR PHYSIOL, V2, P2811, DOI 10.1002/cphy.c120007; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hansen MK, 2008, CURR OPIN INVEST DR, V9, P247; Heidker RM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154305; Heidker RM, 2016, MOL NUTR FOOD RES, V60, P727, DOI 10.1002/mnfr.201500795; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Hong C, 2014, NAT REV DRUG DISCOV, V13, P433, DOI 10.1038/nrd4280; Hong YJ, 2006, J AGR FOOD CHEM, V54, P2405, DOI 10.1021/jf0581776; Houten SM, 2007, MOL ENDOCRINOL, V21, P1312, DOI 10.1210/me.2007-0113; Hwang ST, 2002, GASTROENTEROLOGY, V122, P1483, DOI 10.1053/gast.2002.32982; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Ipatova O. M., 2003, Biomeditsinskaya Khimiya, V49, P165; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158; Karonen M, 2004, ANAL CHIM ACTA, V522, P105, DOI 10.1016/j.aca.2004.06.041; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Kim I, 2007, J LIPID RES, V48, P2664, DOI 10.1194/jlr.M700330-JLR200; Kok T, 2003, J BIOL CHEM, V278, P41930, DOI 10.1074/jbc.M306309200; Krueger CG, 2003, J AGR FOOD CHEM, V51, P538, DOI 10.1021/jf020746b; Krueger CG, 2000, J AGR FOOD CHEM, V48, P1663, DOI 10.1021/jf990534n; Krueger CG, 2004, ACS S SERIES; Landrier JF, 2006, AM J PHYSIOL-GASTR L, V290, pG476, DOI 10.1152/ajpgi.00430.2005; Li GD, 2012, TOXICOL APPL PHARM, V258, P268, DOI 10.1016/j.taap.2011.11.006; Li H, 2005, AM J PHYSIOL-GASTR L, V288, pG60, DOI 10.1152/ajpgi.00170.2004; Li YL, 2009, J NUTR, V139, P898, DOI 10.3945/jn.108.103572; Lo Sasso G, 2010, CELL METAB, V12, P187, DOI 10.1016/j.cmet.2010.07.002; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mansouri A, 2005, FOOD CHEM, V89, P411, DOI 10.1016/j.foodchem.2004.02.051; Del Bas JM, 2009, MOL NUTR FOOD RES, V53, P805, DOI 10.1002/mnfr.200800364; Matsubara T, 2013, MOL CELL ENDOCRINOL, V368, P17, DOI 10.1016/j.mce.2012.05.004; Mattila P, 2006, J AGR FOOD CHEM, V54, P7193, DOI 10.1021/jf0615247; Neimark E, 2004, HEPATOLOGY, V40, P149, DOI 10.1002/hep.20295; Osakabe N, 2013, J CLIN BIOCHEM NUTR, V52, P186, DOI 10.3164/jcbn.12-130; Oszmianski J, 2009, LWT-FOOD SCI TECHNOL, V42, P581, DOI 10.1016/j.lwt.2008.07.009; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Porter ML, 2001, J SCI FOOD AGR, V81, P1306, DOI 10.1002/jsfa.940; Praslickova D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050810; Rasmussen SE, 2005, MOL NUTR FOOD RES, V49, P159, DOI 10.1002/mnfr.200400082; Reed JD, 2005, PHYTOCHEMISTRY, V66, P2248, DOI 10.1016/j.phytochem.2005.05.015; REED JD, 1982, J SCI FOOD AGR, V33, P213, DOI 10.1002/jsfa.2740330302; Ricketts ML, 2007, MOL ENDOCRINOL, V21, P1603, DOI 10.1210/me.2007-0133; Ricketts ML, 2005, J NUTR BIOCHEM, V16, P321, DOI 10.1016/j.jnutbio.2004.11.008; Rock W, 2009, J AGR FOOD CHEM, V57, P8010, DOI 10.1021/jf901559a; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schiller C, 2005, ALIMENT PHARM THER, V22, P971, DOI 10.1111/j.1365-2036.2005.02683.x; Song KH, 2009, HEPATOLOGY, V49, P297, DOI 10.1002/hep.22627; Srinivasan M, 2005, FUND CLIN PHARMACOL, V19, P491, DOI 10.1111/j.1472-8206.2005.00332.x; Stroeve JHM, 2010, LAB INVEST, V90, P1457, DOI 10.1038/labinvest.2010.107; Tang ZX, 2013, J SCI FOOD AGR, V93, P2351, DOI 10.1002/jsfa.6154; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; Vayalil PK, 2012, CRIT REV FOOD SCI, V52, P249, DOI 10.1080/10408398.2010.499824; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zern TL, 2005, J NUTR, V135, P1911, DOI 10.1093/jn/135.8.1911; Zhang YQ, 2008, FEBS LETT, V582, P10, DOI 10.1016/j.febslet.2007.11.015; Zheng QS, 2005, BIOMED ENVIRON SCI, V18, P65	94	11	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2018	13	1							e0190210	10.1371/journal.pone.0190210	http://dx.doi.org/10.1371/journal.pone.0190210			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR5JA	29293579	Green Published, gold, Green Submitted			2023-01-03	WOS:000419101600077
J	Lo, WY; Yang, SH				Lo, Wan-Yu; Yang, Shu-Hua			Metastatic spinal cord compression (MSCC) treated with palliative decompression: Surgical timing and survival rate	PLOS ONE			English	Article							LUNG-CANCER PATIENTS; PROGNOSTIC-FACTORS; SCORING SYSTEM; POSTERIOR DECOMPRESSION; PREOPERATIVE EVALUATION; SURGERY; STABILIZATION; RECOVERY; COHORT; TUMOR	Background Metastatic spinal cord compression (MSCC) treatment depends on life expectancies. Data regarding palliative decompression outcomes is scarce. We demonstrate that surgical timing has a significant impact on survival in MSCC patients treated with palliative decompression. Methods Eighty-nine consecutive MSCC patients at a tertiary referral medical center were enrolled between January 2012 and February 2016. Wide laminectomy was performed for tumors invading the vertebral body. Debulking surgery was done for tumors damaging the posterior column of the spine. Patient records were retrospectively analyzed. Results Better survival was observed in patients with preoperative intact motor function (Group A, n = 37) than in those with motor deficit (Group B, n = 52, p = 0.0031). In Group B, survival was better in those who underwent surgery within 7 days of motor deficit onset than in those who underwent surgery 7 days after onset (p = 0.0444) and in postoperative ambulant patients than in nonambulant patients (p = 0.0120). In Group B, Frankel grade improved in patients who underwent surgery within 48 h than in those who underwent surgery after 48 h (p = 0.0992). Group A patients had a shorter hospital stay and higher revised Tokuhashi score than Group B patients. Overall survival was better in patients with a lower Tomita score (<= 5, p = 0.0012), higher revised Tokuhashi score (>= 9, p = 0.0009), better preoperative Frankel grade (p < 0.0001), and younger age (<= 55 years, p = 0.0179). There were no significant differences in age, sex, tumor type, involved vertebrae level, Tomita score, intraoperative blood loss, operation time, incidence of infection, and postoperative complications between groups. Conclusion We can improve the survival of MSCC patients with palliative decompression before motor deficits occur. After motor deficit onset, survival can still be improved with surgery within 7 days. Overall survival was better in patients aged <= 55 years.	[Lo, Wan-Yu; Yang, Shu-Hua] Natl Taiwan Univ Hosp, Dept Orthoped, Taipei, Taiwan; [Lo, Wan-Yu] Natl Taiwan Univ, Inst Toxicol, Coll Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Lo, WY; Yang, SH (corresponding author), Natl Taiwan Univ Hosp, Dept Orthoped, Taipei, Taiwan.; Lo, WY (corresponding author), Natl Taiwan Univ, Inst Toxicol, Coll Med, Taipei, Taiwan.	aeromouse007@gmail.com; shuhuayang@ntu.edu.tw	Yang, Shu-Hua/AAT-1243-2020	YANG, SHU-HUA/0000-0002-9879-0164; Lo, Wan-Yu/0000-0003-0931-4674				Bauer H, 1976, SPINE, V27, P1124; Chaichana KL, 2008, NEUROSURGERY, V62, P683, DOI 10.1227/01.neu.0000317317.33365.15; Chong S, 2012, SPINE J, V12, P1083, DOI 10.1016/j.spinee.2012.10.015; Crnalic S, 2013, ACTA ONCOL, V52, P809, DOI 10.3109/0284186X.2012.705437; Frankel H L, 1969, Paraplegia, V7, P179; Furstenberg CH, 2009, J BONE JOINT SURG BR, V91B, P240, DOI 10.1302/0301-620X.91B2.20894; Helweg-Larsen S, 2000, INT J RADIAT ONCOL, V46, P1163, DOI 10.1016/S0360-3016(99)00333-8; Kim JM, 2012, SPINE, V37, P78, DOI 10.1097/BRS.0b013e318223b9b6; Lee CH, 2014, SPINE, V39, pE587, DOI 10.1097/BRS.0000000000000258; Lei M, 2016, EJSO-EUR J SURG ONC, V42, P728, DOI 10.1016/j.ejso.2016.01.018; Lei MX, 2016, EUR SPINE J, V25, P3971, DOI 10.1007/s00586-015-4290-6; Lei MX, 2016, SPINE, V41, P1469, DOI 10.1097/BRS.0000000000001538; Mattana JL, 2015, REV BRAS ORTOP, V46, P424; Moon KY, 2011, J KOREAN NEUROSURG S, V50, P216, DOI 10.3340/jkns.2011.50.3.216; Morgen SS, 2014, J CANCER RES CLIN, V140, P2059, DOI 10.1007/s00432-014-1776-2; Murakami H, 2010, ORTHOPEDICS, P165; Nemelc RM, 2014, EUR SPINE J, V23, P2272, DOI 10.1007/s00586-014-3268-0; Park JH, 2013, SPINE, V38, pE798, DOI 10.1097/BRS.0b013e3182927559; Park JH, 2011, J KOREAN NEUROSURG S, V50, P434, DOI 10.3340/jkns.2011.50.5.434; Park SJ, 2016, SPINE J, V16, P322, DOI 10.1016/j.spinee.2015.11.005; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Putz C, 2014, ONCOLOGY-BASEL, V86, P177, DOI 10.1159/000358597; Putz C, 2010, J CRANIOVERTEBRAL JU, V1, P67, DOI 10.4103/0974-8237.77670; Quraishi NA, 2013, EUR SPINE J, V22, P1383, DOI 10.1007/s00586-012-2635-y; Quraishi NA, 2013, EUR SPINE J, V22, pS21, DOI 10.1007/s00586-012-2649-5; Schmidt Meic H, 2005, J Natl Compr Canc Netw, V3, P711; Tabouret E, 2015, SPINE J, V15, P944, DOI 10.1016/j.spinee.2013.06.036; Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5; Tokuhashi Y, 2009, SPINE, V34, P69, DOI 10.1097/BRS.0b013e3181913f19	29	20	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2017	12	12							e0190342	10.1371/journal.pone.0190342	http://dx.doi.org/10.1371/journal.pone.0190342			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR5HD	29287117	Green Submitted, Green Published, gold			2023-01-03	WOS:000419096600046
J	Araujo, SA; Soares, AMD; Silva, CR; Almeida, EB; Rocha, CAUQ; Ferreira, ATD; Perales, J; Costa, LM				Araujo, Sandra Alves; dos Santos Soares, Alexandra Martins; Silva, Carolina Rocha; Almeida Junior, Eduardo Bezerra; Rocha, Claudia Quintino; da Silva Ferreira, Andre Teixeira; Perales, Jonas; Costa-Junior, Livio M.			In vitro anthelmintic effects of Spigelia anthelmia protein fractions against Haemonchus contortus	PLOS ONE			English	Article							TANNIFEROUS PLANT-EXTRACTS; GASTROINTESTINAL NEMATODES; PARASITIC NEMATODES; NEMATOPHAGOUS FUNGI; RESISTANCE; LECTINS; SHEEP; EXSHEATHMENT; HELMINTHS; LIVESTOCK	Gastrointestinal nematodes are a significant concern for animal health and well-being, and anthelmintic treatment is mainly performed through the use of chemical products. However, bioactive compounds produced by plants have shown promise for development as novel anthelmintics. The aim of this study is to assess the anthelmintic activity of protein fractions from Spigelia anthelmia on the gastrointestinal nematode Haemonchus contortus. Plant parts were separated into leaves, stems and roots, washed with distilled water, freeze-dried and ground into a fine powder. Protein extraction was performed with sodium phosphate buffer (75 mM, pH 7.0). The extract was fractionated using ammonium sulfate (0 +/- 90%) and extensively dialyzed. The resulting fractions were named LPF (leaf protein fraction), SPF (stem protein fraction) and RPF (root protein fraction), and the protein contents and activities of the fractions were analyzed. H. contortus egg hatching (EHA), larval exsheathment inhibition (LEIA) and larval migration inhibition (LMIA) assays were performed. Proteomic analysis was conducted, and high-performance liquid chromatography (HPLC) chromatographic profiles of the fractions were established to identify proteins and possible secondary metabolites. S. anthelmia fractions inhibited H. contortus egg hatching, with LPF having the most potent effects (EC50 0.17 mg mL(-1)). During LEIA, SPF presented greater efficiency than the other fractions (EC50 0.25 mg mL(-1)). According to LMIA, the fractions from roots, stems and leaves also reduced the number of larvae, with EC50 values of 0.11, 0.14 and 0.21 mg mL(-1), respectively. Protein analysis indicated the presence of plant defense proteins in the S. anthelmia fractions, including protease, protease inhibitor, chitinase and others. Conversely, secondary metabolites were absent in the S. anthemia fractions. These results suggest that S. anthelmia proteins are promising for the control of the gastrointestinal nematode H. contortus.	[Araujo, Sandra Alves; dos Santos Soares, Alexandra Martins] Univ Fed Maranhao, Ctr Exact Sci & Technol, Lab Plant Biochem, Chem Engn Course, Sao Luis, MA, Brazil; [Silva, Carolina Rocha; Costa-Junior, Livio M.] Univ Fed Maranhao, Dept Pathol, Ctr Biol & Hlth Sci, Lab Parasite Control, Sao Luis, MA, Brazil; [Almeida Junior, Eduardo Bezerra] Univ Fed Maranhao, Dept Biol, Ctr Biol & Hlth Sci, Lab Bot Studies, Sao Luis, MA, Brazil; [Rocha, Claudia Quintino] Univ Fed Maranhao, Dept Chem, Ctr Exact Sci & Technol, Lab Adv Studies Phytomed, Sao Luis, MA, Brazil; [da Silva Ferreira, Andre Teixeira; Perales, Jonas] Fundacao Oswaldo Cruz, Lab Toxinol, Rio De Janeiro, RJ, Brazil	Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Universidade Federal do Maranhao; Fundacao Oswaldo Cruz	Soares, AMD (corresponding author), Univ Fed Maranhao, Ctr Exact Sci & Technol, Lab Plant Biochem, Chem Engn Course, Sao Luis, MA, Brazil.; Costa, LM (corresponding author), Univ Fed Maranhao, Dept Pathol, Ctr Biol & Hlth Sci, Lab Parasite Control, Sao Luis, MA, Brazil.	alexandra.ufma@gmail.com; livio.martins@ufma.br	Rocha, Cláudia Quintino da/C-2320-2013; Costa-Junior, Livio M/H-7530-2012	Rocha, Cláudia Quintino da/0000-0002-3578-1869; Costa-Junior, Livio M/0000-0002-1475-049X; Rocha e Silva, Carolina/0000-0001-8667-1064; Alves de Araujo, Sandra/0000-0001-6398-9686	CNPq (The Brazilian National Council for Scientific and Technological Development); CAPES (the Brazilian Federal Agency for support and evaluation of graduate education); CNPq (The Brazilian National Council for Scientific and Technological Development) [447877/2014-3]; FAPEMA (Maranhao State Research Foundation) [PRONEM-01773/14]	CNPq (The Brazilian National Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES (the Brazilian Federal Agency for support and evaluation of graduate education)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq (The Brazilian National Council for Scientific and Technological Development)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPEMA (Maranhao State Research Foundation)	The work was supported by the following: CNPq (The Brazilian National Council for Scientific and Technological Development), grant number 447877/2014-3; and FAPEMA (Maranhao State Research Foundation), grant number PRONEM-01773/14.; The authors wish to thank the CNPq (The Brazilian National Council for Scientific and Technological Development) for awarding a fellowship to L.M. Costa-Junior and J. Perales, and CAPES (the Brazilian Federal Agency for support and evaluation of graduate education) for their scholarships to C.R. Silva and S.A. Araujo. We also thank Technology Platform Network from FIOCRUZ, Brazil for facilities support.	ABE M, 1992, EUR J BIOCHEM, V209, P933, DOI 10.1111/j.1432-1033.1992.tb17365.x; Ademola IO, 2007, PARASITOL RES, V101, P63, DOI 10.1007/s00436-006-0444-0; Assis LM, 2003, VET PARASITOL, V117, P43, DOI 10.1016/j.vetpar.2003.07.021; Bahuaud D, 2006, PARASITOLOGY, V132, P545, DOI 10.1017/S0031182005009509; Benchabane M, 2010, BIOCHIMIE, V92, P1657, DOI 10.1016/j.biochi.2010.06.006; de Oliveira LMB, 2011, REV BRAS PARASITOL V, V20, P155, DOI 10.1590/S1984-29612011000200011; Boller T, 1992, MOL PLANT PATHOL, P23; Boss EA, 2004, CHEM ENG PROCESS, V43, P1475, DOI 10.1016/j.cep.2004.01.005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga FR, 2014, RES VET SCI, V97, P527, DOI 10.1016/j.rvsc.2014.09.005; COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; Soares AMD, 2015, REV BRAS PARASITOL V, V24, P396, DOI 10.1590/S1984-29612015072; Elandalousi RB, 2013, VET PARASITOL, V197, P374, DOI 10.1016/j.vetpar.2013.05.016; FETTERER RH, 1993, VET PARASITOL, V46, P103, DOI 10.1016/0304-4017(93)90051-N; Filipenko E., 2013, RUSSIAN J GENETICS A, V3, P474, DOI 10.1134/S2079059713060026; Galiana E, 1997, PLANT PHYSIOL, V115, P1557, DOI 10.1104/pp.115.4.1557; Graphpad Software Inc., 2007, PRISM DAT AN SOFTW V; He MZ, 2015, ECOL EVOL, V5, P1494, DOI 10.1002/ece3.1441; Heim C, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1032-x; Irum S, 2015, VET PARASITOL, V212, P451, DOI 10.1016/j.vetpar.2015.06.028; Jackson F, 2010, IN VITRO SCREENING OF PLANT RESOURCES FOR EXTRA-NUTRITIONAL ATTRIBUTES IN RUMINANTS: NUCLEAR AND RELATED METHODOLOGIES, P25, DOI 10.1007/978-90-481-3297-3_3; Liang LM, 2010, FASEB J, V24, P1391, DOI 10.1096/fj.09-136408; Ma B, 2003, RAPID COMMUN MASS SP, V17, P2337, DOI 10.1002/rcm.1196; Makkar HPS, 2003, SMALL RUMINANT RES, V49, P241, DOI 10.1016/S0921-4488(03)00142-1; MANSFIELD LS, 1992, COMP BIOCHEM PHYS B, V103, P681, DOI 10.1016/0305-0491(92)90390-D; MARBANMENDOZA N, 1987, J NEMATOL, V19, P331; Marie-Magdeleine C, 2010, RES VET SCI, V89, P88, DOI 10.1016/j.rvsc.2010.01.002; Martinez-Ortiz-de-Montellano C, 2013, EXP PARASITOL, V133, P281, DOI 10.1016/j.exppara.2012.11.024; Moore BD, 2004, TRENDS PLANT SCI, V9, P221, DOI 10.1016/j.tplants.2004.03.005; Nurit Kiriaki, 2005, Acta Bot. Bras., V19, P407, DOI 10.1590/S0102-33062005000200024; Rios-de Alvarez L, 2012, VET PARASITOL, V186, P390, DOI 10.1016/j.vetpar.2011.11.004; Rocha RO, 2015, J AGR FOOD CHEM, V63, P5335, DOI 10.1021/acs.jafc.5b01109; Roditakis E, 2005, PEST MANAG SCI, V61, P577, DOI 10.1002/ps.1029; ROGERS W. P., 1966, Biology of parasites. Emphasis on veterinary parasites., P33; ROGERS WP, 1965, COMP BIOCHEM PHYSIOL, V14, P311, DOI 10.1016/0010-406X(65)90207-0; ROGERS WP, 1977, INT J PARASITOL, V7, P61, DOI 10.1016/0020-7519(77)90026-1; Rogers WP, 1962, NATURE PARASITISM; Rose Hannah, 2014, International Journal for Parasitology Parasites and Wildlife, V3, P209, DOI 10.1016/j.ijppaw.2014.01.001; Salgado JA, 2016, REV BRAS PARASITOL V, V25, P3, DOI 10.1590/S1984-29612016008; Sandoval-Castro CA, 2012, ANIM FEED SCI TECH, V176, P192, DOI 10.1016/j.anifeedsci.2012.07.023; Scopes R. K, 1994, PROTEIN PURIFICATION, V3rd, DOI 10.1007/978-1-4757-2333-5; Sharma N., 2011, Asian Journal of Biochemistry, V6, P29, DOI 10.3923/ajb.2011.29.37; Shih MC, 2011, INT J MOL SCI, V12, P6077, DOI 10.3390/ijms12096077; Simpraga M, 2015, BERL MUNCH TIERARZTL, V128, P257, DOI 10.2376/0005-9366-128-257; Wang JW, 2013, FEMS MICROBIOL LETT, V344, P53, DOI 10.1111/1574-6968.12154; XAVIERFILHO J, 1989, J AGR FOOD CHEM, V37, P1139, DOI 10.1021/jf00088a071	47	9	9	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2017	12	12							e0189803	10.1371/journal.pone.0189803	http://dx.doi.org/10.1371/journal.pone.0189803			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ2KG	29244856	Green Published, Green Submitted, gold			2023-01-03	WOS:000418184700067
J	Germano, G; Lamba, S; Rospo, G; Barault, L; Magri, A; Maione, F; Russo, M; Crisafulli, G; Bartolini, A; Lerda, G; Siravegna, G; Mussolin, B; Frapolli, R; Montone, M; Morano, F; de Braud, F; Amirouchene-Angelozzi, N; Marsoni, S; D'Incalci, M; Orlandi, A; Giraudo, E; Sartore-Bianchi, A; Siena, S; Pietrantonio, F; Di Nicolantonio, F; Bardelli, A				Germano, Giovanni; Lamba, Simona; Rospo, Giuseppe; Barault, Ludovic; Magri, Alessandro; Maione, Federica; Russo, Mariangela; Crisafulli, Giovanni; Bartolini, Alice; Lerda, Giulia; Siravegna, Giulia; Mussolin, Benedetta; Frapolli, Roberta; Montone, Monica; Morano, Federica; de Braud, Filippo; Amirouchene-Angelozzi, Nabil; Marsoni, Silvia; D'Incalci, Maurizio; Orlandi, Armando; Giraudo, Enrico; Sartore-Bianchi, Andrea; Siena, Salvatore; Pietrantonio, Filippo; Di Nicolantonio, Federica; Bardelli, Alberto			Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth	NATURE			English	Article							METASTATIC COLORECTAL-CANCER; MISMATCH-REPAIR; PD-1 BLOCKADE; MUTATIONS; TEMOZOLOMIDE; BLOOD; GLIOBLASTOMAS; SENSITIVITY; PROGRESSION; RESISTANCE	Molecular alterations in genes involved in DNA mismatch repair (MMR) promote cancer initiation and foster tumour progression(1). Cancers deficient in MMR frequently show favourable prognosis and indolent progression(2). The functional basis of the clinical outcome of patients with tumours that are deficient in MMR is not clear. Here we genetically inactivate MutL homologue 1 (MLH1) in colorectal, breast and pancreatic mouse cancer cells. The growth of MMR-deficient cells was comparable to their proficient counterparts in vitro and on transplantation in immunocompromised mice. By contrast, MMR-deficient cancer cells grew poorly when transplanted in syngeneic mice. The inactivation of MMR increased the mutational burden and led to dynamic mutational profiles, which resulted in the persistent renewal of neoantigens in vitro and in vivo, whereas MMR-proficient cells exhibited stable mutational load and neoantigen profiles over time. Immune surveillance improved when cancer cells, in which MLH1 had been inactivated, accumulated neoantigens for several generations. When restricted to a clonal population, the dynamic generation of neoantigens driven by MMR further increased immune surveillance. Inactivation of MMR, driven by acquired resistance to the clinical agent temozolomide, increased mutational load, promoted continuous renewal of neoantigens in human colorectal cancers and triggered immune surveillance in mouse models. These results suggest that targeting DNA repair processes can increase the burden of neoantigens in tumour cells; this has the potential to be exploited in therapeutic approaches.	[Germano, Giovanni; Lamba, Simona; Rospo, Giuseppe; Barault, Ludovic; Magri, Alessandro; Maione, Federica; Russo, Mariangela; Crisafulli, Giovanni; Bartolini, Alice; Lerda, Giulia; Siravegna, Giulia; Mussolin, Benedetta; Montone, Monica; Amirouchene-Angelozzi, Nabil; Marsoni, Silvia; Giraudo, Enrico; Di Nicolantonio, Federica; Bardelli, Alberto] IRCCS, Candiolo Canc Inst FPO, I-10060 Turin, Italy; [Germano, Giovanni; Barault, Ludovic; Magri, Alessandro; Russo, Mariangela; Crisafulli, Giovanni; Lerda, Giulia; Siravegna, Giulia; Di Nicolantonio, Federica; Bardelli, Alberto] Univ Turin, Dept Oncol, I-10060 Turin, Italy; [Frapolli, Roberta; D'Incalci, Maurizio] IRCCS Ist Ric Farmacol Mario Negri, I-20156 Milan, Italy; [Morano, Federica; de Braud, Filippo; Pietrantonio, Filippo] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, I-20133 Milan, Italy; [de Braud, Filippo; Siena, Salvatore] Univ Milan, Dept Oncol & Hemat Oncol, I-20122 Milan, Italy; [Amirouchene-Angelozzi, Nabil] FIRC Inst Mol Oncol IFOM, I-20139 Milan, Italy; [Orlandi, Armando] Policlin Univ A Gemelli, I-00168 Rome, Italy; [Giraudo, Enrico] Univ Torino, Dept Sci & Drug Technol, I-10125 Turin, Italy; [Sartore-Bianchi, Andrea; Siena, Salvatore] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, I-20142 Milan, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; IFOM - FIRC Institute of Molecular Oncology; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Turin	Bardelli, A (corresponding author), IRCCS, Candiolo Canc Inst FPO, I-10060 Turin, Italy.; Bardelli, A (corresponding author), Univ Turin, Dept Oncol, I-10060 Turin, Italy.	alberto.bardelli@unito.it	Giraudo, Enrico/K-3192-2016; D'Incalci, Maurizio/AAA-9021-2020; Orlandi, Armando/A-1517-2015; Barault, Ludovic/J-2472-2016; Giraudo, Enrico/K-6441-2019; SIENA, SALVATORE/AAC-5806-2019; Frapolli, Roberta/AAA-6729-2020; Pietrantonio, Filippo/C-2180-2017; Russo, Mariangela/K-1900-2018; Crisafulli, Giovanni/AAB-6256-2019; Morano, Federica/B-7910-2018; Sartore-Bianchi, Andrea/AAB-9848-2019; Rospo, Giuseppe/AAC-4523-2020; Maione, Federica/K-6679-2016; Germano, Giovanni/AAB-6672-2020; Di Nicolantonio, Federica/A-2503-2011; Siravegna, Giulia/Z-2826-2019; BARDELLI, Alberto/J-9721-2018; BARTOLINI, ALICE/K-2534-2018; de Braud, Filippo Guglielmo Maria/B-9997-2017	Giraudo, Enrico/0000-0003-4128-4786; D'Incalci, Maurizio/0000-0001-8784-1360; Orlandi, Armando/0000-0001-5253-4678; Barault, Ludovic/0000-0001-5227-5047; Giraudo, Enrico/0000-0003-4128-4786; SIENA, SALVATORE/0000-0002-2681-2846; Frapolli, Roberta/0000-0003-2907-273X; Pietrantonio, Filippo/0000-0002-8530-8420; Russo, Mariangela/0000-0003-4625-1449; Crisafulli, Giovanni/0000-0002-5511-1555; Morano, Federica/0000-0002-5306-3596; Sartore-Bianchi, Andrea/0000-0003-0780-0409; Rospo, Giuseppe/0000-0002-1757-9085; Maione, Federica/0000-0003-2789-799X; Germano, Giovanni/0000-0003-1688-8684; Di Nicolantonio, Federica/0000-0001-9618-2010; Siravegna, Giulia/0000-0002-7132-6484; BARDELLI, Alberto/0000-0003-1647-5070; BARTOLINI, ALICE/0000-0003-3492-0772; MUSSOLIN, BENEDETTA/0000-0001-5723-5685; Lamba, Simona Elena/0000-0003-3207-1594; Marsoni, Silvia/0000-0002-5361-7122; MONTONE, MONICA/0000-0001-7907-4333; de Braud, Filippo Guglielmo Maria/0000-0003-0103-730X	European Community's Seventh Framework Programme [602901 MErCuRIC, 635342-2 MoTriColor]; IMI contract [115749 CANCER-ID]; AIRC Special Program Molecular Clinical Oncology 5 per mille [9970]; AIRC IG [16788, 17707]; Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille Ministero della Salute; AIRC-IG Grant [15645]; Swiss National Science Foundation SNSF), Sinergia Grant [CRSII3 160742/1]; AIRC; EU under a Marie Curie COFUND; AIRC 3-year fellowship; grant Terapia Molecolare Tumori by Fondazione Oncologia Niguarda Onlus; Merck grant for Oncology Innovation -GOI-	European Community's Seventh Framework Programme(European Commission); IMI contract; AIRC Special Program Molecular Clinical Oncology 5 per mille; AIRC IG(Fondazione AIRC per la ricerca sul cancro); Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille Ministero della Salute; AIRC-IG Grant(Fondazione AIRC per la ricerca sul cancro); Swiss National Science Foundation SNSF), Sinergia Grant(Swiss National Science Foundation (SNSF)); AIRC; EU under a Marie Curie COFUND; AIRC 3-year fellowship; grant Terapia Molecolare Tumori by Fondazione Oncologia Niguarda Onlus; Merck grant for Oncology Innovation -GOI-	We thank B. Van Emburgh, A. Sogari, C. Falcomata, V. Amodio and C. Cancelliere for assistance with in vitro experiments; F. Sassi and S. Giove for help with the immunohistochemistry; M. Buscarino for suggestions on MSI analysis; D. Cantarella for performing RNA-seq; G. Corti and L. Novara for bioinformatic analysis and comments; D. Sangiolo and M. Rescigno for discussion; D. Hananhan and K. Shchors for providing the PDAC cell model; and C. Torrance and J. Roix for scientific support, suggestions and critically reading the manuscript. This study was supported by European Community's Seventh Framework Programme under grant agreement no. 602901 MErCuRIC (A. Bard. and G. G.); no. 635342-2 MoTriColor (A. Bard. and S. S.); IMI contract no. 115749 CANCER-ID (A. Bard.); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, Project no. 9970 (A. Bard. and S. S.); AIRC IG no. 16788 (A. Bard.); AIRC IG no. 17707 (F.D.N.); Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (A. Bard. and F.D.N.); AIRC-IG Grant no. 15645 and Swiss National Science Foundation SNSF), Sinergia Grant (CRSII3 160742/1) (E.G.); AIRC and the EU under a Marie Curie COFUND (G.G.); AIRC 3-year fellowship (G.S.); grant Terapia Molecolare Tumori by Fondazione Oncologia Niguarda Onlus (A.S.-B. and S.S.); and Merck grant for Oncology Innovation -GOI- 2016 (A. Bard.).	Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cahill DP, 2007, CLIN CANCER RES, V13, P2038, DOI 10.1158/1078-0432.CCR-06-2149; Cahill Daniel P, 2008, Clin Neurosurg, V55, P165; Calegari MA, 2017, BRIT J CANCER, V116, P1279, DOI 10.1038/bjc.2017.109; Castle JC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-190; Chen LX, 2017, SCIENCE, V355, P752, DOI 10.1126/science.aai8690; Chew WL, 2016, NAT METHODS, V13, P868, DOI 10.1038/nmeth.3993; CORBETT TH, 1975, CANCER RES, V35, P2434; Fink D, 1998, CLIN CANCER RES, V4, P1; Gaide O, 2015, NAT MED, V21, P647, DOI 10.1038/nm.3860; Gilles ME, 2016, CANCER RES, V76, P7181, DOI 10.1158/0008-5472.CAN-16-0300; Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Jiricny J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012633; Juneja VR, 2017, J EXP MED, V214, P895, DOI 10.1084/jem.20160801; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee SY, 2016, GENES DIS, V3, P198, DOI 10.1016/j.gendis.2016.04.007; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Maione F, 2012, J CLIN INVEST, V122, P1832, DOI 10.1172/JCI58976; Maletzki C, 2013, EUR J CANCER, V49, P2587, DOI 10.1016/j.ejca.2013.02.035; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; NANNI P, 1983, CLIN EXP METASTAS, V1, P373, DOI 10.1007/BF00121199; Orthwein A, 2015, NATURE, V528, P422, DOI 10.1038/nature16142; Ponti G, 2015, CLIN GENET, V87, P507, DOI 10.1111/cge.12529; Rayner E, 2016, NAT REV CANCER, V16, P71, DOI 10.1038/nrc.2015.12; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sartore-Bianchi A, 2017, EUR J CANCER, V71, P43, DOI 10.1016/j.ejca.2016.10.032; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq622; Woerner SM, 2015, MOL CARCINOGEN, V54, P1376, DOI 10.1002/mc.22213; Yip S, 2009, CLIN CANCER RES, V15, P4622, DOI 10.1158/1078-0432.CCR-08-3012	44	326	332	9	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2017	552	7683					116	+		10.1038/nature24673	http://dx.doi.org/10.1038/nature24673			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP4BA	29186113				2023-01-03	WOS:000417560500054
J	Essex, H; Parrott, S; Atkin, K; Ballard, K; Bland, M; Eldred, J; Hewitt, C; Hopton, A; Keding, A; Lansdown, H; Richmond, S; Tilbrook, H; Torgerson, D; Watt, I; Wenham, A; Woodman, J; MacPherson, H				Essex, Holly; Parrott, Steve; Atkin, Karl; Ballard, Kathleen; Bland, Martin; Eldred, Janet; Hewitt, Catherine; Hopton, Ann; Keding, Ada; Lansdown, Harriet; Richmond, Stewart; Tilbrook, Helen; Torgerson, David; Watt, Ian; Wenham, Aniela; Woodman, Julia; MacPherson, Hugh			An economic evaluation of Alexander Technique lessons or acupuncture sessions for patients with chronic neck pain: A randomized trial (ATLAS)	PLOS ONE			English	Article							TRADITIONAL ACUPUNCTURE; COST-EFFECTIVENESS; LIFE; PRACTITIONERS; COORDINATION; EUROQOL; ADVICE; CARE	Objectives To assess the cost-effectiveness of acupuncture and usual care, and Alexander Technique lessons and usual care, compared with usual GP care alone for chronic neck pain patients. Methods An economic evaluation was undertaken alongside the ATLAS trial, taking both NHS and wider societal viewpoints. Participants were offered up to twelve acupuncture sessions or twenty Alexander lessons (equivalent overall contact time). Costs were in pounds sterling. Effectiveness was measured using the generic EQ-5D to calculate quality adjusted life years (QALYs), as well as using a specific neck pain measure-the Northwick Park Neck Pain Questionnaire (NPQ). Results In the base case analysis, incremental QALY gains were 0.032 and 0.025 in the acupuncture and Alexander groups, respectively, in comparison to usual GP care, indicating moderate health benefits for both interventions. Incremental costs were 451 pound for acupuncture and 667 pound for Alexander, mainly driven by intervention costs. Acupuncture was likely to be cost-effective (ICER = 18,767 pound/QALY bootstrapped 95% CI 4,426 pound to 74,562) pound and was robust to most sensitivity analyses. Alexander lessons were not cost-effective at the lower NICE threshold of 20,000 pound/QALY (25,101 pound/QALY bootstrapped 95% CI -150,208 pound to 248,697) pound but may be at 30,000 pound/QALY, however, there was considerable statistical uncertainty in all tested scenarios. Conclusions In comparison with usual care, acupuncture is likely to be cost-effective for chronic neck pain, whereas, largely due to higher intervention costs, Alexander lessons are unlikely to be cost-effective. However, there were high levels of missing data and further research is needed to assess the long-term cost-effectiveness of these interventions.	[Essex, Holly; Parrott, Steve; Atkin, Karl; Bland, Martin; Eldred, Janet; Hewitt, Catherine; Hopton, Ann; Keding, Ada; Lansdown, Harriet; Tilbrook, Helen; Torgerson, David; Watt, Ian; Wenham, Aniela; Woodman, Julia; MacPherson, Hugh] Univ York, Dept Hlth Sci, York, N Yorkshire, England; [Ballard, Kathleen; Woodman, Julia] Soc Teachers Alexander Tech, London, England; [Lansdown, Harriet] British Acupuncture Council, London, England; [Richmond, Stewart] Sydera Res Associates, York, N Yorkshire, England; [Watt, Ian] Univ York, Hull York Med Sch, York, N Yorkshire, England	University of York - UK; University of Hull; University of York - UK	Essex, H (corresponding author), Univ York, Dept Hlth Sci, York, N Yorkshire, England.	holly.essex@york.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Parrott, Steven James/0000-0002-0165-1150; Hewitt, Catherine Elizabeth/0000-0002-0415-3536	Arthritis Research UK [19702]; Versus Arthritis [19702] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); Versus Arthritis(Versus Arthritis)	This work was supported by Arthritis Research UK (clinical studies grant number 19702 to HM, http://www.arthritisresearchuk.org/).	Ambrosio EMM, 2012, COMPLEMENT THER MED, V20, P364, DOI 10.1016/j.ctim.2012.05.002; Barnes PM, 2008, NATL HLTH STAT REPOR, P1; Cacciatore TW, 2011, HUM MOVEMENT SCI, V30, P74, DOI 10.1016/j.humov.2010.10.002; Cacciatore TW, 2014, J NEUROPHYSIOL, V112, P719, DOI 10.1152/jn.00617.2013; Cacciatore TW, 2011, GAIT POSTURE, V34, P496, DOI 10.1016/j.gaitpost.2011.06.026; Cacciatore TW, 2005, PHYS THER, V85, P565; Coyle D, 1998, INT J TECHNOL ASSESS, V14, P135, DOI 10.1017/S0266462300010588; Curtis L, 2013, UNIT COSTS HLTH SOC; Department of Health, 2013, NHS REF COSTS 2012 2; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Driessen MT, 2012, EUR SPINE J, V21, P1441, DOI 10.1007/s00586-012-2272-5; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Drummond MF., 2005, METHODS EC EVALUATIO, P55; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Evans M, 2011, J ALTERN COMPLEM MED, V17, P519, DOI 10.1089/acm.2010.0749; Health and Social Care Information Centre, 2015, PRESCR COST AN ENGL; Hill C, 2014, HLTH RESOURCE USE ME; Hollinghurst Sandra, 2008, BMJ, V337, pa2656, DOI 10.1136/bmj.a2656; Hoy D, 2014, ANN RHEUM DIS, V73, P1309, DOI 10.1136/annrheumdis-2013-204431; Jull G., 2008, WHIPLASH HEADACHE NE; LEAK AM, 1994, BRIT J RHEUMATOL, V33, P469; Little P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a884; MacPherscon H, 2008, COMPLEMENT THER MED, V16, P101, DOI 10.1016/j.ctim.2008.02.010; MacPherson H, 2015, ANN INTERN MED, V163, P653, DOI 10.7326/M15-0667; MacPherson H, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-209; Miller J, 2010, MANUAL THER, V15, P334, DOI 10.1016/j.math.2010.02.007; National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR; National Institute for Health and Care Excellence (NICE, 2009, LOW BACK PAIN EARL M; National Institute for Health and Clinical Excellence, 2012, NICE GUIDELINE MAN; Petrou S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1548; Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C; Richardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901; Robinson N, 2012, J ETHNOPHARMACOL, V140, P604, DOI 10.1016/j.jep.2012.01.052; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; Torgerson D, 1999, BMJ-BRIT MED J, V318, P1413, DOI 10.1136/bmj.318.7195.1413; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Willich SN, 2006, PAIN, V125, P107, DOI 10.1016/j.pain.2006.06.006; Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013; Woodman JP, 2012, INT J CLIN PRACT, V66, P98, DOI 10.1111/j.1742-1241.2011.02817.x	41	8	8	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 6	2017	12	12							e0178918	10.1371/journal.pone.0178918	http://dx.doi.org/10.1371/journal.pone.0178918			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FO9MS	29211741	gold, Green Accepted, Green Published			2023-01-03	WOS:000417212200002
J	Lara, B; Enberg, L; Ortega, M; Leon, P; Kripper, C; Aguilera, P; Kattan, E; Castro, R; Bakker, J; Hernandez, G				Lara, Barbara; Enberg, Luis; Ortega, Marcos; Leon, Paula; Kripper, Cristobal; Aguilera, Pablo; Kattan, Eduardo; Castro, Ricardo; Bakker, Jan; Hernandez, Glenn			Capillary refill time during fluid resuscitation in patients with sepsis-related hyperlactatemia at the emergency department is related to mortality	PLOS ONE			English	Article							INDUCED TISSUE HYPOPERFUSION; PERIPHERAL PERFUSION; SEPTIC SHOCK; CONSENSUS; SEVERITY; LACTATE	Introduction Acute circulatory dysfunction in patients with sepsis can evolve rapidly into a progressive stage associated with high mortality. Early recognition and adequate resuscitation could improve outcome. However, since the spectrum of clinical presentation is quite variable, signs of hypoperfusion are frequently unrecognized in patients just admitted to the emergency department (ED). Hyperlactatemia is considered a key parameter to disclose tissue hypoxia but it is not universally available and getting timely results can be challenging in low resource settings. In addition, non-hypoxic sources can be involved in hyperlactatemia, and a misinterpretation could lead to over-resuscitation in an unknown number of cases. Capillary refill time (CRT) is a marker of peripheral perfusion that worsens during circulatory failure. An abnormal CRT in septic shock patients after ICU-based resuscitation has been associated with poor outcome. The aim of this study was to determine the prevalence of abnormal CRT in patients with sepsis-related hyperlactatemia in the early phase after ED admission, and its relationship with outcome. Methods We performed a prospective observational study. Septic patients with hyperlactemia at ED admission subjected to an initial fluid resuscitation (FR) were included. CRT and other parameters were assessed before and after FR. CRT-normal or CRT-abnormal subgroups were defined according to the status of CRT following initial FR, and major outcomes were registered. Results Ninety-five hyperlactatemic septic patients were included. Thirty-one percent had abnormal CRT at ED arrival. After FR, 87 patients exhibited normal CRT, and 8 an abnormal one. Patients with abnormal CRT had an increased risk of adverse outcomes (88% vs. 20% p<0.001; RR 4.4 [2.7-7.4]), and hospital mortality (63% vs. 9% p<0.001; RR 6.7 [2.9-16]) as compared to those with normal CRT after FR. Specifically, CRT-normal patients required less frequently mechanical ventilation, renal replacement therapy, and ICU admission, and exhibited a lower hospital mortality. Conclusions Hyperlactatemic sepsis patients with abnormal CRT after initial fluid resuscitation exhibit higher mortality and worse clinical outcomes than patients with normal CRT.	[Lara, Barbara; Enberg, Luis; Kripper, Cristobal; Aguilera, Pablo] Pontificia Univ Catolica Chile, Fac Med, Programa Med Urgencia, Santiago, Chile; [Ortega, Marcos; Leon, Paula; Kattan, Eduardo; Castro, Ricardo; Bakker, Jan; Hernandez, Glenn] Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Santiago, Chile; [Bakker, Jan] Erasmus MC Univ, Med Ctr, Dept Intens Care Adults, Rotterdam, CA, Netherlands; [Bakker, Jan] Columbia Univ, Dept Med, Med Ctr, Div Pulm Allergy & Crit Care Med, New York, NY USA; [Bakker, Jan] New York Univ Langone, Div Pulm & Crit Care Med, New York, NY USA	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Erasmus University Rotterdam; Erasmus MC; Columbia University; New York University	Hernandez, G (corresponding author), Pontificia Univ Catolica Chile, Fac Med, Dept Med Intens, Santiago, Chile.	glennguru@gmail.com	Lara, Barbara/GWZ-9082-2022; Kattan, Eduardo/GSJ-4141-2022; Bakker, Jan/A-4011-2009	Kattan, Eduardo/0000-0002-1997-6893; Bakker, Jan/0000-0003-2236-7391; Gomez Rodriguez, Diego Manuel/0000-0003-2128-9854; Lara, Barbara/0000-0002-0265-808X				Ait-Oufella H, 2014, INTENS CARE MED, V40, P958, DOI 10.1007/s00134-014-3326-4; Ait-Oufella H, 2011, INTENS CARE MED, V37, P801, DOI 10.1007/s00134-011-2163-y; Alsma J, 2017, CHEST, V151, P1106, DOI 10.1016/j.chest.2016.11.035; BAILEY JM, 1990, CRIT CARE MED, V18, P1353, DOI 10.1097/00003246-199012000-00008; Bakker J, 2015, CRIT CARE MED, V43, P705, DOI 10.1097/CCM.0000000000000870; Brabrand M, 2011, EUR J EMERG MED, V18, P46, DOI 10.1097/MEJ.0b013e32833b4fba; Casserly B, 2015, CRIT CARE MED, V43, P567, DOI 10.1097/CCM.0000000000000742; Cecconi M, 2014, INTENS CARE MED, V40, P1795, DOI 10.1007/s00134-014-3525-z; CHAMPION HR, 1980, CRIT CARE MED, V8, P201, DOI 10.1097/00003246-198004000-00001; Coudroy R, 2015, INTENS CARE MED, V41, P452, DOI 10.1007/s00134-014-3600-5; Dellinger R. P., 2013, INTENS CARE MED, V41, P580, DOI [DOI 10.1007/s00134-012-2769-8, 10.1007/s00134-012-2769-8]; Dunser MW, 2013, CRIT CARE, V17, DOI 10.1186/cc12727; Espinoza Emilio Daniel Valenzuela, 2014, Rev Bras Ter Intensiva, V26, P269; Garcia-Alvarez M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0503-3; Gu WJ, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0570-5; Hernandez G, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0030-z; Hernandez G, 2012, J CRIT CARE, V27, P283, DOI 10.1016/j.jcrc.2011.05.024; Hernandez G, 2012, CURR OPIN CRIT CARE, V18, P280, DOI 10.1097/MCC.0b013e3283532c08; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lima A, 2005, INTENS CARE MED, V31, P1316, DOI 10.1007/s00134-005-2790-2; Lima A, 2015, CURR OPIN CRIT CARE, V21, P226, DOI 10.1097/MCC.0000000000000194; Lima A, 2009, CRIT CARE MED, V37, P934, DOI 10.1097/CCM.0b013e31819869db; Otieno H, 2004, ARCH DIS CHILD, V89, P977, DOI 10.1136/adc.2003.043901; Peake SL, 2014, NEW ENGL J MED, V371, P1496, DOI 10.1056/NEJMoa1404380; Roland D, 2010, J PAEDIATR CHILD H, V46, P103, DOI 10.1111/j.1440-1754.2009.01646.x; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; van Genderen ME, 2015, AM J RESP CRIT CARE, V191, P477, DOI 10.1164/rccm.201408-1575LE; van Genderen ME, 2014, CRIT CARE, V18, DOI 10.1186/cc13905; Vincent JL, 2012, CRIT CARE, V16, DOI 10.1186/cc11510; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602	31	50	53	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2017	12	11							e0188548	10.1371/Journal.pone.0188548	http://dx.doi.org/10.1371/Journal.pone.0188548			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN8QZ	29176794	Green Published, gold, Green Submitted			2023-01-03	WOS:000416291900095
J	Espelt, A; Bosque-Prous, M; Folch, C; Sarasa-Renedo, A; Majo, X; Casabona, J; Brugal, MT				Espelt, Albert; Bosque-Prous, Marina; Folch, Cinta; Sarasa-Renedo, Ana; Majo, Xavier; Casabona, Jordi; Teresa Brugal, M.		REDAN Grp	Is systematic training in opioid overdose prevention effective?	PLOS ONE			English	Article							TAKE-HOME NALOXONE; NONFATAL HEROIN OVERDOSE; INJECTION-DRUG USERS; OPIATE USERS; RISK-FACTORS; KNOWLEDGE; PROGRAMS; DEATH; METAANALYSIS; REGRESSION	The objectives were to analyze the knowledge about overdose prevention, the use of naloxone, and the number of fatal overdoses after the implementation of Systematic Training in Overdose Prevention (STOOP) program. We conducted a quasi-experimental study, and held face-to-face interviews before (n = 725) and after (n = 722) implementation of systematic training in two different samples of people who injected opioids attending harm reduction centers. We asked participants to list the main causes of overdose and the main actions that should be taken when witnessing an overdose. We created two dependent variables, the number of (a) correct and (b) incorrect answers. The main independent variable was Study Group: Intervention Group (IG), Comparison Group (CG), Pre-Intervention Group With Sporadic Training in Overdose Prevention (PREIGS), or Pre-Intervention Group Without Training in Overdose Prevention (PREIGW). The relationship between the dependent and independent variables was assessed using a multivariate Poisson regression analysis. Finally, we conducted an interrupted time series analysis of monthly fatal overdoses before and after the implementation of systematic program during the period 2006 +/- 2015. Knowledge of overdose prevention increased after implementing systematic training program. Compared to the PREIGW, the IG gave more correct answers (IRR = 1.40; 95% CI: 1.33-1.47), and fewer incorrect answers (IRR = 0.33; 95% CI: 0.25-0.44). Forty percent of people who injected opioids who received a naloxone kit had used the kit in response to an overdose they witnessed. These courses increase knowledge of overdose prevention in people who use opioids, give them the necessary skills to use naloxone, and slightly diminish the number of fatal opioid overdoses in the city of Barcelona.	[Espelt, Albert; Bosque-Prous, Marina; Sarasa-Renedo, Ana; Teresa Brugal, M.] Agencia Salut Publ Barcelona, Barcelona, Spain; [Espelt, Albert] Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Calle Melchor Fernandez Almagro, Madrid, Spain; [Espelt, Albert] UVicUCC, Fac Ciencies Salut Manresa, Ave Univ, Manresa, Spain; [Espelt, Albert] Univ Autonoma Barcelona, Dept Psicobiol Metodol Ciencies Salut, Campus UAB, Bellaterra, Spain; [Folch, Cinta] Generalitat Catalunya, Ctr Estudis Epidemiol Infecc Transmissio Sexual &, ASPC, Carretera Canyet S-N, Badalona, Spain; [Sarasa-Renedo, Ana] Inst Salud Carlos III, PEAC, Calle Sinesio Delgado, Madrid, Spain; [Majo, Xavier; Casabona, Jordi] Generalitat Catalunya, Dept Salut, Subdireccio Gen Drogodependencies, Carrer Roc Boronat, Barcelona, Spain	Public Health Agency of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); Autonomous University of Barcelona; Instituto de Salud Carlos III	Espelt, A (corresponding author), Agencia Salut Publ Barcelona, Barcelona, Spain.; Espelt, A (corresponding author), Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Calle Melchor Fernandez Almagro, Madrid, Spain.; Espelt, A (corresponding author), UVicUCC, Fac Ciencies Salut Manresa, Ave Univ, Manresa, Spain.; Espelt, A (corresponding author), Univ Autonoma Barcelona, Dept Psicobiol Metodol Ciencies Salut, Campus UAB, Bellaterra, Spain.	aespelt@umanresa.cat	Brugal, M. Teresa/K-5190-2012; Bosque-Prous, Marina/AAE-1562-2020; Espelt, Albert/G-2281-2014	Brugal, M. Teresa/0000-0003-0580-676X; Bosque-Prous, Marina/0000-0002-8830-8880; Folch, Cinta/0000-0001-8400-2668; Espelt, Albert/0000-0002-8625-4356; Colom Farran, Joan/0000-0001-6861-7865	Spanish Network on Addictive Disorders [RD06/0001/1018, RD12/0028/0018]	Spanish Network on Addictive Disorders	This work was supported by the Spanish Network on Addictive Disorders [grant numbers RD06/0001/1018, and RD12/0028/0018] (http:// www.eng.isciii.es/ISCIII/es/cortenidos/fd-investigacion/fd-ejecucion/fd-centros-participados/centros-participados-redes-retics.shmtl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arribas-Ibar E, 2014, HARM REDUCT J, V11, DOI 10.1186/1477-7517-11-33; Bhaskaran K, 2013, INT J EPIDEMIOL, V42, P1187, DOI 10.1093/ije/dyt092; Binswanger IA, 2016, ADDICTION, V111, P499, DOI 10.1111/add.13200; Bird SM, 2016, ADDICTION, V111, P883, DOI 10.1111/add.13265; Brugal MT, 2002, ADDICTION, V97, P319, DOI 10.1046/j.1360-0443.2002.00058.x; CEESCAT. SIVES, 2012, SIVES 2012 INT SURV; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Darke S, 1996, ADDICTION, V91, P413, DOI 10.1046/j.1360-0443.1996.91341310.x; Darke S, 2003, ADDICTION, V98, P1169, DOI 10.1046/j.1360-0443.2003.00474.x; de la Fuente de Hoz Luis, 2005, Rev Esp Salud Publica, V79, P475, DOI 10.1590/S1135-57272005000400005; EMCDDA, 2013, PREV OV DEATHS EUR; EMCDDA, 2016, 2016 ANN REP STAT DR; Espelt A, NALOXON UBERLEBENSHI; Espelt A, 2015, EUR ADDICT RES, V21, P300, DOI 10.1159/000377626; Frisher M., 2012, PREVENTING OPIOID OV; Galea S, 2006, ADDICT BEHAV, V31, P907, DOI 10.1016/j.addbeh.2005.07.020; Gaston RL, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-26; Gossop M, 1996, BRIT MED J, V313, P402; Green TC, 2008, ADDICTION, V103, P979, DOI 10.1111/j.1360-0443.2008.02182.x; Hilbe J.M., 2014, MODELING COUNT DATA; Hoef JMV, 2007, ECOLOGY, V88, P2766, DOI 10.1890/07-0043.1; Lopez Ma Jose, 2011, Gac Sanit, V25 Suppl 1, P9, DOI 10.1016/S0213-9111(11)70003-6; Majo A X, 2009, ADRECAT GEN CATALUNY; Maldjian L, 2016, SUBST ABUS, V37, P459, DOI 10.1080/08897077.2015.1135850; McAuley A, 2015, INT J DRUG POLICY, V26, P1183, DOI 10.1016/j.drugpo.2015.09.011; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Neale J, 2003, ADDICTION, V98, P1171, DOI 10.1046/j.1360-0443.2003.00476.x; Neira-Leon M, 2006, J URBAN HEALTH, V83, P477, DOI 10.1007/s11524-006-9054-5; Neira-Leon M, 2011, INT J DRUG POLICY, V22, P16, DOI 10.1016/j.drugpo.2010.06.003; Rossi C., 1999, INT J DRUG POLICY, V10, P131; Sarasa-Renedo A, 2014, GAC SANIT, V28, P146, DOI 10.1016/j.gaceta.2013.10.012; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Sherman SG, 2009, INT J DRUG POLICY, V20, P137, DOI 10.1016/j.drugpo.2008.02.004; Strang J, 2008, ADDICTION, V103, P1648, DOI 10.1111/j.1360-0443.2008.02314.x; Strang J, 2015, ADDICTION, V110, P27, DOI 10.1111/add.12904; Tobin KE, 2009, INT J DRUG POLICY, V20, P131, DOI 10.1016/j.drugpo.2008.03.002; Wagner KD, 2010, INT J DRUG POLICY, V21, P186, DOI 10.1016/j.drugpo.2009.01.003; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; WHO, 1994, MULT STUD INJ RISK H; Williams AV, 2013, DRUG ALCOHOL DEPEN, V132, P383, DOI 10.1016/j.drugalcdep.2013.02.007	42	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0186833	10.1371/journal.pone.0186833	http://dx.doi.org/10.1371/journal.pone.0186833			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL2ZD	29088247	Green Published, gold, Green Submitted			2023-01-03	WOS:000414088900024
J	Grothey, A; Sobrero, AF; Shields, AF; Yoshino, T; Paul, J; Taieb, J; Souglakos, J; Shi, Q; Kerr, R; Labianca, R; Meyerhardt, JA; Vernerey, D; Yamanaka, T; Boukovinas, I; Meyers, JP; Renfro, LA; Niedzwiecki, D; Watanabe, T; Torri, V; Saunders, M; Sargent, DJ; Andre, T; Iveson, T				Grothey, A.; Sobrero, A. F.; Shields, A. F.; Yoshino, T.; Paul, J.; Taieb, J.; Souglakos, J.; Shi, Q.; Kerr, R.; Labianca, R.; Meyerhardt, J. A.; Vernerey, D.; Yamanaka, T.; Boukovinas, I.; Meyers, J. P.; Renfro, L. A.; Niedzwiecki, D.; Watanabe, T.; Torri, V.; Saunders, M.; Sargent, D. J.; Andre, T.; Iveson, T.			Duration of Adjuvant Chemotherapy for Stage III Colon Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; SURVIVAL; BEVACIZUMAB	BACKGROUND Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. METHODS We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority of adjuvant therapy with either FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin) administered for 3 months, as compared with 6 months. The primary end point was the rate of disease-free survival at 3 years. Noninferiority of 3 months versus 6 months of therapy could be claimed if the upper limit of the two-sided 95% confidence interval of the hazard ratio did not exceed 1.12. RESULTS After 3263 events of disease recurrence or death had been reported in 12,834 patients, the noninferiority of 3 months of treatment versus 6 months was not confirmed in the overall study population (hazard ratio, 1.07; 95% confidence interval [CI], 1.00 to 1.15). Noninferiority of the shorter regimen was seen for CAPOX (hazard ratio, 0.95; 95% CI, 0.85 to 1.06) but not for FOLFOX (hazard ratio, 1.16; 95% CI, 1.06 to 1.26). In an exploratory analysis of the combined regimens, among the patients with T1, T2, or T3 and N1 cancers, 3 months of therapy was noninferior to 6 months, with a 3-year rate of disease-free survival of 83.1% and 83.3%, respectively (hazard ratio, 1.01; 95% CI, 0.90 to 1.12). Among patients with cancers that were classified as T4, N2, or both, the disease-free survival rate for a 6-month duration of therapy was superior to that for a 3-month duration (64.4% vs. 62.7%) for the combined treatments (hazard ratio, 1.12; 95% CI, 1.03 to 1.23; P = 0.01 for superiority). CONCLUSIONS Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population. However, in patients treated with CAPOX, 3 months of therapy was as effective as 6 months, particularly in the lower-risk subgroup. (Funded by the National Cancer Institute and others.)	[Grothey, A.] Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA; [Shi, Q.; Meyers, J. P.; Renfro, L. A.; Sargent, D. J.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Sobrero, A. F.] Ist Ricovero & Cura Carattere Sci IRCCS San Marti, Genoa, Italy; [Labianca, R.] Osped Papa Giovanni XXIII, Bergamo, Italy; [Torri, V.] IRCCS, Mario Negri Inst Pharmacol Res, Milan, Italy; [Shields, A. F.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA; [Yoshino, T.] Natl Canc Ctr Hosp East, Chiba, Japan; [Yamanaka, T.] Yokohama City Univ, Sch Med, Yokohama, Kanagawa, Japan; [Watanabe, T.] Univ Tokyo, Tokyo, Japan; [Paul, J.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Kerr, R.] Univ Oxford, Oxford, England; [Saunders, M.] Christie Hosp, Manchester, Lancs, England; [Iveson, T.] Univ Hosp Southampton, Southampton, Hants, England; [Taieb, J.] Paris Descartes Univ, Sorbonne Paris Cite, Hop Europeen Georges Pompidou, Paris, France; [Vernerey, D.] INSERM, Unite 1098, Methodol & Qual Life Unit, Besancon, France; [Souglakos, J.] Univ Crete, Fac Med, Univ Hosp Heraklion, Dept Med Oncol, Iraklion, Greece; [Boukovinas, I.] Bioclin Thessaloniki, Thessaloniki, Greece; [Meyerhardt, J. A.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Niedzwiecki, D.] Duke Canc Inst, Durham, NC USA	Mayo Clinic; Mayo Clinic; ASST Papa Giovanni XXIII; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Barbara Ann Karmanos Cancer Institute; Wayne State University; National Cancer Center - Japan; Yokohama City University; University of Tokyo; University of Glasgow; University of Oxford; Christie NHS Foundation Trust; Christie Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; University Hospital of Heraklion; University of Crete; Harvard University; Dana-Farber Cancer Institute; Duke University	Grothey, A (corresponding author), Mayo Clin, Div Med Oncol, 200 First St SW, Rochester, MN 55905 USA.	grothey.axel@mayo.edu	Torri, Valter/H-7550-2015; Sobrero, Alberto/AAF-9742-2019; André, Thierry P/N-8830-2017; Shi, Qian/AAW-8907-2020	Torri, Valter/0000-0001-9541-9354; Sobrero, Alberto/0000-0001-7764-673X; André, Thierry P/0000-0002-5103-7095; Shi, Qian/0000-0002-4640-8832; Kerr, Rachel/0000-0002-7240-3269; Iveson, Timothy/0000-0002-4681-2712; Niedzwiecki, Donna/0000-0002-3566-0450	National Cancer Institute; NATIONAL CANCER INSTITUTE [U10CA180819, U10CA180835, U10CA180888, U10CA180821, U10CA180882] Funding Source: NIH RePORTER; MRC [G0601705] Funding Source: UKRI	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funded by the National Cancer Institute and others.	Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385; Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238; Andre T, 2013, CURR COLORECT CANC R, V9, P261, DOI 10.1007/s11888-013-0181-6; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Chau I, 2005, ANN ONCOL, V16, P549, DOI 10.1093/annonc/mdi116; de Gramont A, 2012, LANCET ONCOL, V13, P1225, DOI 10.1016/S1470-2045(12)70509-0; Grothey A, 2003, SEMIN ONCOL, V30, P5, DOI 10.1016/S0093-7754(03)00399-3; Haller DG, 2008, J CLIN ONCOL, V26, P2118, DOI 10.1200/JCO.2007.15.2090; Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297; Haller DG, 2005, J CLIN ONCOL, V23, P8671, DOI 10.1200/JCO.2004.00.5686; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; Sargent DJ, 2005, J CLIN ONCOL, V23, P8664, DOI 10.1200/JCO.2005.01.6071; Therneau TM., 2000, MODELING SURVIVAL DA; Twelves C, 2005, NEW ENGL J MED, V352, P2696, DOI 10.1056/NEJMoa043116	16	459	480	4	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2018	378	13					1177	1188		10.1056/NEJMoa1713709	http://dx.doi.org/10.1056/NEJMoa1713709			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA8HN	29590544	Green Accepted, Bronze			2023-01-03	WOS:000428580500004
J	Lyons, S				Lyons, Sophie			WHAT YOUR PATIENT IS THINKING Be brave	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												sophie.lyons12@gmail.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2018	360								k1299	10.1136/bmj.k1299	http://dx.doi.org/10.1136/bmj.k1299			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB5NC	29592901	Bronze, Green Published			2023-01-03	WOS:000429110700004
J	Harris, RA; Haberer, JE; Musinguzi, N; Chang, KM; Schechter, CB; Doubeni, CA; Gross, R				Harris, Rebecca Arden; Haberer, Jessica E.; Musinguzi, Nicholas; Chang, Kyong-Mi; Schechter, Clyde B.; Doubeni, Chyke A.; Gross, Robert			Predicting short-term interruptions of antiretroviral therapy from summary adherence data: Development and test of a probability model	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; RURAL UGANDA; SUPPRESSION; RESISTANCE; FAILURE; KAMPALA; COHORT; BIAS; RNA; ERA	Antiretroviral therapy (ART) for HIV is vulnerable to unplanned treatment interruptions consecutively missed doses over a series of days which can result in virologic rebound. Yet clinicians lack a simple, valid method for estimating the risk of interruptions. If the likelihood of ART interruption could be derived from a convenient-to-gather summary measure of medication adherence, it might be a valuable tool for both clinical decision-making and research. We constructed an a priori probability model of ART interruption based on average adherence and tested its predictions using data collected on 185 HIV-infected, treatment-naive individuals over the first 90 days of ART in a prospective cohort study in Mbarara, Uganda. The outcome of interest was the presence or absence of a treatment gap, defined as >72 hours without a dose. Using the pre-determined value of 0.50 probability as the cut point for predicting an interruption, the classification accuracy of the model was 73% (95% CI = 66%-79%), the specificity was 87% (95% CI = 79%-93%), and the sensitivity was 59% (95% CI = 48%-69%). Overall model performance was satisfactory, with an area under the receiver operator characteristic curve (AUROC) of 0.85 (95% CI = 0.80-0.91) and Brier score of 0.20. The study serves as proof-of-concept that the probability model can accurately differentiate patients on the continuum of risk for short-term ART interruptions using a summary measure of adherence. The model may also aid in the design of targeted interventions.	[Harris, Rebecca Arden; Chang, Kyong-Mi; Doubeni, Chyke A.; Gross, Robert] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Haberer, Jessica E.] Harvard Med Sch, Boston, MA USA; [Haberer, Jessica E.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Musinguzi, Nicholas] Mbarara Univ Sci & Technol, Mbarara, Uganda; [Chang, Kyong-Mi] Philadelphia VA Med Ctr, Philadelphia, PA USA; [Schechter, Clyde B.] Albert Einstein Coll Med, Bronx, NY 10467 USA	University of Pennsylvania; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Mbarara University of Science & Technology; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Yeshiva University; Albert Einstein College of Medicine	Harris, RA (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.	Rebecca.Harris@uphs.upenn.edu	Haberer, Jessica/AAH-7976-2019	Haberer, Jessica/0000-0001-5845-3190; Harris, Rebecca Arden/0000-0001-6058-0463	University of Pennsylvania Center for AIDS Research; NIH [P30-AI045008]	University of Pennsylvania Center for AIDS Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	University of Pennsylvania Center for AIDS Research, an NIH-funded program (grant P30-AI045008 to R.G.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adakun SA, 2013, JAIDS-J ACQ IMM DEF, V62, P317, DOI 10.1097/QAI.0b013e3182800daf; Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526; Bangsberg DR, 2013, JAMA INTERN MED, V173, P306, DOI 10.1001/jamainternmed.2013.2858; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Chen LF, 2015, INFECT CONT HOSP EP, V36, P1444, DOI 10.1017/ice.2015.216; Derogatis L., 2010, CORSINI ENCY PSYCHOL, P1, DOI [DOI 10.1002/9780470479216.CORPSY0970, 10.1002/9780470479216.corpsy0970]; Ewald B, 2006, J CLIN EPIDEMIOL, V59, P798, DOI 10.1016/j.jclinepi.2005.11.025; Feller W., 1968, INTRO PROBABILITY TH, V1; Genberg BL, 2012, AIDS, V26, P1415, DOI 10.1097/QAD.0b013e328354bed6; Geng EH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014098; Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680; Grossberg R, 2004, J CLIN EPIDEMIOL, V57, P1107, DOI 10.1016/j.jclinepi.2004.04.002; Haberer JE, 2017, AIDS, V31, P169, DOI 10.1097/QAD.0000000000001310; Haberer JE, 2015, JAIDS-J ACQ IMM DEF, V70, P386, DOI 10.1097/QAI.0000000000000737; Hastie T, 2013, ELEMENTS STAT LEARNI; Hoel PG., 1984, INTRO MATH STAT; Hosmer D. J., 2013, APPL LOGISTIC REGRES, DOI DOI 10.1002/9781118548387; Imaz A, 2013, ANTIVIR THER, V18, P125, DOI 10.3851/IMP2249; Knafl GJ, 2010, AIDS BEHAV, V14, P755, DOI 10.1007/s10461-008-9512-z; Kranzer K, 2011, TROP MED INT HEALTH, V16, P1297, DOI 10.1111/j.1365-3156.2011.02828.x; Leeflang MMG, 2008, CLIN CHEM, V54, P729, DOI 10.1373/clinchem.2007.096032; Li XH, 2005, JAIDS-J ACQ IMM DEF, V38, P320; Lyimo RA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-92; Marzel A, 2016, CLIN INFECT DIS, V62, P115, DOI 10.1093/cid/civ732; MAYHEW BH, 1984, J MATH SOCIOL, V9, P259, DOI 10.1080/0022250X.1984.9989948; Medecins Sans Frontieres Access Campaign, 2016, UNT WEB ANT PRIC RED; Mood AM, 1940, ANN MATH STAT, V11, P367, DOI 10.1214/aoms/1177731825; Moriarty K, 2018, J ASSOC NURSE AIDS C, V29, P231, DOI 10.1016/j.jana.2017.09.014; Moye L. A., 2000, DIFFERENCE EQUATIONS; Munene E, 2016, AIDS CARE, V28, P1110, DOI 10.1080/09540121.2016.1140890; Musinguzi N, 2017, AIDS BEHAV, V21, P1735, DOI 10.1007/s10461-016-1447-1; Oyugi JH, 2007, AIDS, V21, P965, DOI 10.1097/QAD.0b013e32802e6bfa; Parienti JJ, 2004, CLIN INFECT DIS, V38, P1311, DOI 10.1086/383572; Rodger AJ, 2013, AIDS, V27, P973, DOI 10.1097/QAD.0b013e32835cae9c; Sauceda JA, 2016, AIDS BEHAV, V20, P2624, DOI 10.1007/s10461-015-1283-8; Sax PE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031591; Seidu B, 2016, J AIDS HIV RES, V8, P44; Seneta E, 2013, BERNOULLI, V19, P1088, DOI 10.3150/12-BEJSP12; Smith GCS, 2014, AM J EPIDEMIOL, V180, P318, DOI 10.1093/aje/kwu140; Spacek LA, 2006, CLIN INFECT DIS, V42, P252, DOI 10.1086/499044; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Tuller DM, 2010, AIDS BEHAV, V14, P778, DOI 10.1007/s10461-009-9533-2; VanderWeele TJ, 2015, EXPLANATION CAUSAL I; Viswanathan S, 2015, JAIDS-J ACQ IMM DEF, V69, P493, DOI 10.1097/QAI.0000000000000643; Williams AB, 2013, AIDS BEHAV, V17, P284, DOI 10.1007/s10461-012-0172-7; World Health Organization, 2016, CONS GUID US ANT DRU	47	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194713	10.1371/journal.pone.0194713	http://dx.doi.org/10.1371/journal.pone.0194713			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA1RF	29566096	Green Published, Green Submitted, gold			2023-01-03	WOS:000428093900096
J	Chen, CQ; Long, L; Zhang, FS; Chen, Q; Chen, C; Yu, XR; Liu, QY; Bao, JK; Long, ZF				Chen, Ciqiong; Long, Li; Zhang, Fusheng; Chen, Qin; Chen, Cheng; Yu, Xiaorui; Liu, Qingya; Bao, Jinku; Long, Zhangfu			Antifungal activity, main active components and mechanism of Curcuma longa extract against Fusarium graminearum	PLOS ONE			English	Article							L. ESSENTIAL OIL; PROTEOMIC ANALYSIS; HEXANE EXTRACT; LIQUID; ANTIOXIDANT; PHAEOCAULIS; COMBINATION; PLANTS; FUNGI; WOOD	Curcuma longa possesses powerful antifungal activity, as demonstrated in many studies. In this study, the antifungal spectrum of Curcuma longa alcohol extract was determined, and the resulting EC50 values (mg/mL) of its extract on eleven fungi, including Fusarium graminearum, Fusarium chlamydosporum, Alternaria alternate, Fusarium tricinctum, Sclerotinia sclerotiorum, Botrytis cinerea, Fusarium culmorum, Rhizopus oryzae, Cladosporium cladosporioides, Fusarium oxysporum and Colletotrichum higginsianum, were 0.1088, 0.1742, 0.1888, 0.2547, 0.3135, 0.3825, 0.4229, 1.2086, 4.5176, 3.8833 and 5.0183, respectively. Among them, F. graminearum was selected to determine the inhibitory effects of the compounds (including curdione, isocurcumenol, curcumenol, curzerene, (3-elemene, curcumin, germacrone and curcumol) derived from Curcuma longa. In addition, the antifungal activities of curdione, curcumenol, curzerene, curcumol and isocurcumenol and the synergies of the complexes of curdione and seven other chemicals were investigated. Differential proteomics of F. graminearum was also compared, and at least 2021 reproducible protein spots were identified. Among these spots, 46 were classified as differentially expressed proteins, and these proteins are involved in energy metabolism, tRNA synthesis and glucose metabolism. Furthermore, several fungal physiological differences were also analysed. The antifungal effect included fungal cell membrane disruption and inhibition of ergosterol synthesis, respiration, succinate dehydrogenase (SDH) and NADH oxidase.	[Chen, Ciqiong; Long, Li; Zhang, Fusheng; Chen, Qin; Chen, Cheng; Yu, Xiaorui; Liu, Qingya; Bao, Jinku; Long, Zhangfu] Sichuan Univ, Coll Life Sci, Minist Educ, Key Lab Bioresources & Ecoenvironm, Chengdu, Sichuan, Peoples R China	Sichuan University	Long, ZF (corresponding author), Sichuan Univ, Coll Life Sci, Minist Educ, Key Lab Bioresources & Ecoenvironm, Chengdu, Sichuan, Peoples R China.	Lzf0028@163.com	Liu, Qing/GWC-9222-2022; liu, qingqing/HHD-0360-2022	Long, Zhangfu/0000-0003-1289-3400	National Key Research and Development Program of China [2017YFD020201105]; Sichuan Province Scientific Support Program [2016KZ0006, 2012ZZ0001]; Chengdu Scientific Research Plan [2015-NY02-00100-NC]	National Key Research and Development Program of China; Sichuan Province Scientific Support Program; Chengdu Scientific Research Plan	This work was supported by National Key Research and Development Program of China (2017YFD020201105), the Sichuan Province Scientific Support Program (2016KZ0006, 2012ZZ0001) and the Chengdu Scientific Research Plan (2015-NY02-00100-NC). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amalraj Augustine, 2017, J Tradit Complement Med, V7, P205, DOI 10.1016/j.jtcme.2016.05.005; Aqueveque P, 2017, FOOD CHEM TOXICOL, V109, P1048, DOI 10.1016/j.fct.2017.05.036; Avanco GB, 2017, FOOD CONTROL, V73, P806, DOI 10.1016/j.foodcont.2016.09.032; Bautista-Banos S, 2013, CROP PROT, V49, P8, DOI 10.1016/j.cropro.2013.02.011; Bentz BJ, 2009, ANN ENTOMOLOGICAL SO, V99, P189; Boradia VM, 2014, BIOCHEM SOC T, V42, P1796, DOI 10.1042/BST20140220; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cespedes CL, 2014, ENVIRON RES, V132, P391, DOI 10.1016/j.envres.2014.04.003; Changtam C, 2010, EUR J MED CHEM, V45, P941, DOI 10.1016/j.ejmech.2009.11.035; Chen IN, 2008, PLANT FOOD HUM NUTR, V63, P15, DOI 10.1007/s11130-007-0063-7; [陈琴 Chen Qin], 2017, [四川大学学报. 自然科学版, Journal of Sichuan University. Natural Science Edition], V54, P209; Chen YF, 1994, FOOD FERMENTATION IN, P26; Chen ZZ, 2013, ASIAN J CHEM, V25, P6597, DOI 10.14233/ajchem.2013.14379; Dao TT, 2012, FOOD CHEM, V134, P21, DOI 10.1016/j.foodchem.2012.02.015; Dohnal V., 2007, Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis, V55, P9; Felipe FL, 2001, INT DAIRY J, V11, P37; Ferreira FD, 2013, SCI WORLD J, DOI 10.1155/2013/343804; GEORGOPAPADAKOU NH, 1994, SCIENCE, V264, P371, DOI 10.1126/science.8153622; Ghannoum MA, 1999, CLIN MICROBIOL REV, V12, P501, DOI 10.1128/CMR.12.4.501; Goswami RS, 2004, MOL PLANT PATHOL, V5, P515, DOI [10.1111/j.1364-3703.2004.00252.x, 10.1111/J.1364-3703.2004.00252.X]; Gupta Ankur, 2015, Biotechnol Rep (Amst), V6, P51, DOI 10.1016/j.btre.2015.02.001; Hamdi OAA, 2010, ACTA CRYSTALLOGR E, V66, pO2844, DOI 10.1107/S1600536810040559; Higuchi M, 2000, J BIOSCI BIOENG, V90, P484, DOI 10.1016/S1389-1723(01)80028-1; Hou XL, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep229; [胡梁斌 Hu Liangbin], 2010, [微生物学通报, Microbiology], V37, P251; Hu YC, 2017, FOOD CHEM, V220, P1, DOI 10.1016/j.foodchem.2016.09.179; Itokawa H., 2008, CHIN MED, V3, P1; Kong Q, 2013, CELL J, V15, P160; Kumar KN, 2016, LWT-FOOD SCI TECHNOL, V69, P522, DOI 10.1016/j.lwt.2016.02.005; Lakshmi S, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/253962; Li Hui-Fen, 2011, Sichuan Daxue Xuebao (Ziran Kexueban), V48, P191, DOI 10.3969/j.issn.0490-6756.2011.01.034; Li S.Y., 2011, PHARM CROPS, V2, P28, DOI [10.2174/2210290601102010028, DOI 10.2174/2210290601102010028]; Liu Hai-Hua, 2008, Sichuan Daxue Xuebao (Ziran Kexueban), V45, P1235; Long ZF, 2007, ACTIVE CONSTITUENT C; Madden L.V., 2007, STUDY PLANT DIS EPID; Martinez-Correa HA, 2017, J SUPERCRIT FLUID, V119, P122, DOI 10.1016/j.supflu.2016.08.017; Maxfield FR, 2005, NATURE, V438, P612, DOI 10.1038/nature04399; Meng S., 2006, STUDIES ANTIFUNGAL A; Moghadamtousi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/186864; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nguyen VN, 2009, BIOCONTROL, V54, P697, DOI 10.1007/s10526-009-9220-2; Niemenmaa O, 2008, INT BIODETER BIODEGR, V62, P125, DOI 10.1016/j.ibiod.2007.12.009; Nugroho A, 2015, ANAL CURCUMIN ETHANO, V9, P188; Piasecka M, 2001, ANDROLOGIA, V33, P1, DOI 10.1046/j.1439-0272.2001.00369.x; Pitt JI, 2009, FUNGI FOOD SPOILAGE, P519; Priya R., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS695; Radwan MM, 2014, FITOTERAPIA, V99, P341, DOI 10.1016/j.fitote.2014.08.021; Rodrigues AMS, 2010, J NAT PROD, V73, P1706, DOI 10.1021/np1001412; Rodriguez-Celma J, 2010, J PROTEOMICS, V73, P1694, DOI 10.1016/j.jprot.2010.05.001; Sanit S., 2016, Journal of Medicinal Plants Research, V10, P248; Singh G, 2002, PROG CRYST GROWTH CH, V45, P75, DOI 10.1016/S0960-8974(02)00030-X; Su X, 2008, J ZHEJIANG FORESTRY, V25, P405; Taniguchi S, 2014, J PLANT PHYSIOL, V171, P625, DOI 10.1016/j.jplph.2014.01.007; Wang JY, 2016, NAT PROD COMMUN, V11, P825; WONG DT, 1971, J BACTERIOL, V106, P168, DOI 10.1128/JB.106.1.168-173.1971; Wu LQ, 2013, PLANT MOL BIOL REP, V31, P485, DOI 10.1007/s11105-012-0515-6; XIE Y, 2001, CHINESE TRADITIONAL, V32, P600; Yang FQ, 2006, J CHROMATOGR A, V1134, P226, DOI 10.1016/j.chroma.2006.09.048; YON JM, 1990, BIOCHIMIE, V72, P417, DOI 10.1016/0300-9084(90)90066-P	59	55	60	3	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2018	13	3							e0194284	10.1371/journal.pone.0194284	http://dx.doi.org/10.1371/journal.pone.0194284			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ3GA	29543859	Green Published, gold, Green Submitted			2023-01-03	WOS:000427473500062
J	Mayr, U; Karsten, E; Lahmer, T; Rasch, S; Thies, P; Henschel, B; Fischer, G; Schmid, RM; Huber, W				Mayr, Ulrich; Karsten, Eugen; Lahmer, Tobias; Rasch, Sebastian; Thies, Philipp; Henschel, Benedikt; Fischer, Gerrit; Schmid, Roland M.; Huber, Wolfgang			Impact of large volume paracentesis on respiratory parameters including transpulmonary pressure and on transpulmonary thermodilution derived hemodynamics: A prospective study	PLOS ONE			English	Article							CENTRAL VENOUS-PRESSURE; ACUTE LUNG INJURY; ABDOMINAL COMPARTMENT SYNDROME; MECHANICAL VENTILATION; DISTRESS-SYNDROME; INTRAABDOMINAL HYPERTENSION; ESOPHAGEAL PRESSURE; CIRRHOTIC-PATIENTS; TENSE ASCITES; INTERNATIONAL-CONFERENCE	Introduction Appropriate mechanical ventilation and prevention of alveolar collaps is mainly dependent on transpulmonary pressure TPP. TPP is assessed by measurement of esophageal pressure EP, largely influenced by pleural and intraabdominal pressure IAP. Consecutively, TPP-guided ventilation might be particularly useful in patients with high IAP. This study investigates the impact of large volume paracentesis LVP on TPP, EP, IAP as well as on hemodynamic and respiratory function in patients with liver cirrhosis and tense ascites. Material and methods We analysed 23 LVP-procedures in 11 cirrhotic patients ventilated with the AVEA Viasys respirator (CareFusion, USA) which is capable to measure EP via an esophageal tube. Results LVP of a mean volume of 4826 +/- 1276 mL of ascites resulted in marked increases in inspiratory (17.9 +/- 8.9 vs. 5.4 +/- 13.3 cmH(2)O; p<0.001) as well as expiratory TPP (-3.0 +/- 4.7 vs. -15.9 +/- 10.9 cmH(2)O; p<0.001; primary endpoint). In parallel, the inspiratory (2.4 +/- 8.7 vs. 14.1 +/- 14.5 cmH(2)O; p<0.001) and expiratory EP (12.4 +/- 6.0 vs. 24.9 +/- 11.3 cmH(2)O; p<0.001) significantly decreased. The effects were most pronounced for the release of the first 500 mL of ascites. LVP evoked substantial decreases in IAP and central venous pressure CVP. By contrast, mean arterial pressure, cardiac index, global end-diastolic volume index, extravascular lung water index and systemic vascular resistance index did not change. Among the respiratory parameters we observed an increase in paO(2)/FiO2 (247.7 +/- 60.9 vs. 208.3 +/- 46.8 mmHg; p<0.001) and a decrease in Oxygenation Index OI (4.8 +/- 2.0 vs. 5.8 +/- 3.1 cmH(2)O/mmHg; p = 0.002). Tidal volume (510 +/- 100 vs. 452 +/- 113 mL; p = 0.008) and dynamic respiratory system compliance Cdyn (46.8 +/- 15.9 vs. 35.1 +/- 14.6 mL/cmH(2)O; p<0.001) increased, whereas paCO(2) (47.3 +/- 10.7 vs. 51.2 +/- 12.3mmHg; p = 0.046) and the respiratory rate decreased (17.1 +/- 7.3 vs. 19.6 +/- 7.8 min(-1); p = 0.010). Conclusions In mechanically ventilated patients with decompensated cirrhosis, intraabdominal hypertension resulted in a substantially decreased TPP despite PEEP-setting according to the ARDSNet. In these patients LVP markedly increased TPP and improved respiratory function in parallel with a decline of EP. Furthermore, LVP induced a decrease in IAP and CVP, while other hemodynamic parameters did not change.	[Mayr, Ulrich; Karsten, Eugen; Lahmer, Tobias; Rasch, Sebastian; Thies, Philipp; Henschel, Benedikt; Fischer, Gerrit; Schmid, Roland M.; Huber, Wolfgang] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Innere Med 2, Ismaninger Str 22, Munich, Germany	Technical University of Munich	Huber, W (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Innere Med 2, Ismaninger Str 22, Munich, Germany.	wolfgang.huber@tum.de	Lahmer, Tobias/AAD-3838-2021	Rasch, Sebastian/0000-0002-7917-8017				Akoumianaki E, 2014, AM J RESP CRIT CARE, V189, P520, DOI 10.1164/rccm.201312-2193CI; ANGUEIRA CE, 1994, HEPATOLOGY, V20, P825, DOI 10.1002/hep.1840200409; Balzer F, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0272-4; BARNES GE, 1985, AM J PHYSIOL, V248, pR208, DOI 10.1152/ajpregu.1985.248.2.R208; Bein T, 2016, INTENS CARE MED, V42, P699, DOI 10.1007/s00134-016-4325-4; Bernardi M, 2015, J HEPATOL, V63, P1272, DOI 10.1016/j.jhep.2015.07.004; BONE RC, 1989, CHEST, V96, P849, DOI 10.1378/chest.96.4.849; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Byrd RP, 1996, SOUTHERN MED J, V89, P689, DOI 10.1097/00007611-199607000-00008; Cabrera J, 2001, GUT, V48, P384, DOI 10.1136/gut.48.3.384; CHAO Y, 1994, J HEPATOL, V20, P101, DOI 10.1016/S0168-8278(05)80474-X; Cheatham ML, 2007, INTENS CARE MED, V33, P951, DOI 10.1007/s00134-007-0592-4; Cheatham ML, 2009, WORLD J SURG, V33, P1116, DOI 10.1007/s00268-009-0003-9; Chieveley-Williams S, 2002, CHEST, V121, P533, DOI 10.1378/chest.121.2.533; Costa ELV, 2013, CRIT CARE, V17, DOI 10.1186/cc12556; Eskesen TG, 2016, INTENS CARE MED, V42, P324, DOI 10.1007/s00134-015-4168-4; Fumagalli J, 2017, CRIT CARE MED, V45, P1374, DOI 10.1097/CCM.0000000000002460; Fusco MA, 2001, J TRAUMA, V50, P297, DOI 10.1097/00005373-200102000-00016; Gacouin A, 2016, SHOCK, V45, P16, DOI 10.1097/SHK.0000000000000487; Gines A, 1996, GASTROENTEROLOGY, V111, P1002, DOI 10.1016/S0016-5085(96)70068-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; Gines P, 2004, NEW ENGL J MED, V350, P1646, DOI 10.1056/NEJMra035021; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; Gupta D, 2000, Trop Gastroenterol, V21, P68; Hedenstierna G, 2012, MINERVA ANESTESIOL, V78, P959; Hess DR, 2014, RESP CARE, V59, P1773, DOI 10.4187/respcare.03410; Huber W, 2008, CRIT CARE MED, V36, P2348, DOI 10.1097/CCM.0b013e3181809928; Kao HC, 2013, THESCIENTIFICWORLDJO, V2013; Levesque E, 2014, J HEPATOL, V60, P570, DOI 10.1016/j.jhep.2013.11.012; Levesque E, 2011, J CRIT CARE, V26, P257, DOI 10.1016/j.jcrc.2010.08.020; Lucangelo Umberto, 2005, Respir Care, V50, P55; Magder S, 2015, CURR OPIN CRIT CARE, V21, P369, DOI 10.1097/MCC.0000000000000238; Malbrain MLNG, 2006, INTENS CARE MED, V32, P1722, DOI 10.1007/s00134-006-0349-5; Malbrain MLNG, 2005, CRIT CARE MED, V33, P315, DOI 10.1097/01.CCM.0000153408.09806.1B; Malbrain MLNG, 2004, INTENS CARE MED, V30, P357, DOI 10.1007/s00134-003-2107-2; Malbrain MLNG, 1999, INTENS CARE MED, V25, P1453, DOI 10.1007/s001340051098; Marik PE, 2008, CHEST, V134, P172, DOI 10.1378/chest.07-2331; Mietto C, 2015, ANAESTH INTENSIVE TH, V47, pS27, DOI 10.5603/AIT.a2015.0065; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; Moore KP, 2006, GUT, V55, P1, DOI 10.1136/gut.2006.099580; Nasr G, 2010, J Cardiovasc Dis Res, V1, P136, DOI 10.4103/0975-3583.70914; Pedersen JS, 2015, THER ADV CHRONIC DIS, V6, P124, DOI 10.1177/2040622315580069; Peltekian KM, 1997, AM J GASTROENTEROL, V92, P394; Phillip V, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-18; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rouby JJ, 2004, ANESTHESIOLOGY, V101, P228, DOI 10.1097/00000542-200407000-00033; RuizdelArbol L, 1997, GASTROENTEROLOGY, V113, P579, DOI 10.1053/gast.1997.v113.pm9247479; Saugel B, 2013, J CRIT CARE, V28, P196, DOI 10.1016/j.jcrc.2012.05.002; Seeley E, 2008, THORAX, V63, P994, DOI 10.1136/thx.2007.093658; Shawcross DL, 2012, J HEPATOL, V56, P1054, DOI 10.1016/j.jhep.2011.12.014; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; Talmor D, 2006, CRIT CARE MED, V34, P1389, DOI 10.1097/01.CCM.0000215515.49001.A2; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Umgelter A, 2008, CRIT CARE, V12, DOI 10.1186/cc6765; von Delius S, 2007, ENDOSCOPY, V39, P962, DOI 10.1055/s-2007-966973; Wauters J, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/763181	56	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2018	13	3							e0193654	10.1371/journal.pone.0193654	http://dx.doi.org/10.1371/journal.pone.0193654			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ2XG	29538440	Green Published, gold			2023-01-03	WOS:000427446400044
J	Miller, FG; Appelbaum, PS				Miller, Franklin G.; Appelbaum, Paul S.			Physician-Assisted Death for Psychiatric Patients - Misguided Public Policy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DISORDERS		[Miller, Franklin G.] Weill Cornell Med Coll, New York, NY 10065 USA; [Appelbaum, Paul S.] Columbia Univ, Coll Phys & Surg, New York, NY USA	Cornell University; Columbia University	Miller, FG (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.		Appelbaum, Paul/AFU-3908-2022	Appelbaum, Paul/0000-0002-1940-0042				Appelbaum PS, 2017, PSYCHIAT SERV, V68, P315, DOI 10.1176/appi.ps.201700013; Aviv R, 2015, NEW YORKER; Kim SYH, 2016, JAMA PSYCHIAT, V73, P362, DOI 10.1001/jamapsychiatry.2015.2887; Li M, 2017, NEW ENGL J MED, V376, P2082, DOI 10.1056/NEJMms1700606; Schuklenk U, 2015, J MED ETHICS, V41, P577, DOI 10.1136/medethics-2014-102458	5	25	25	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2018	378	10					883	885		10.1056/NEJMp1709024	http://dx.doi.org/10.1056/NEJMp1709024			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FY4CY	29514026				2023-01-03	WOS:000426770200002
J	Rahimi-Levene, N; Ziv-Baran, T; Peer, V; Golik, A; Kornberg, A; Zeidenstein, R; Koren-Michowitz, M				Rahimi-Levene, Naomi; Ziv-Baran, Tomer; Peer, Victoria; Golik, Ahuva; Kornberg, Abraham; Zeidenstein, Ronit; Koren-Michowitz, Maya			Hemoglobin transfusion trigger in an internal medicine department - A "real world" six year experience	PLOS ONE			English	Article							BLOOD-CELL TRANSFUSION; REQUIREMENTS; SURGERY; TRENDS; TRIAL	Background Transfusion guidelines advocate restrictive rather than liberal use of red blood cells (RBC) and are based mostly on randomized trials in intensive care and surgical departments. We aimed to study RBC transfusion practice in the medical patients' population. Methods The data in this study were collected from patients over the age of 18 years admitted to an Internal Medicine department between 2009 and 2014 who received at least one unit of packed red blood cells (RBC). In addition, data on demographics, patients' diagnoses, laboratory tests and number of transfused RBC units were extracted from the electronic health records. Results One thousand three hundred and twenty eight patients were included, having mean age of 75 +/- 14 years. The median hemoglobin (Hb) trigger for RBC transfusion was 8.0 g/dl (IQR 7.3-8.7g/dl), and most patients received either one (43.4%) or two (33.4%) RBC units. There was no significant difference in Hb trigger between males and females (Hb 8.0 g/dl and 7.9 g/dl, respectively, p = 0.098), and a weak correlation with age (r = 0.108 p = 0.001). Patients with cardiovascular and lung diseases had a statistically significant higher Hb trigger compared to patients without those diagnoses, however the median difference between them was 0.5 g/dl or less. Conclusions These "real world" data we collected show a Hb trigger compliant with the upper limit of published guidelines and influenced by medical patients' common diagnoses. Prospective trials addressing patients hospitalized in internal medicine departments could further contribute to transfusion decision algorithms.	[Rahimi-Levene, Naomi; Peer, Victoria] Assaf Harofeh Med Ctr, Blood Bank, Zerifin, Israel; [Rahimi-Levene, Naomi; Kornberg, Abraham; Koren-Michowitz, Maya] Assaf Harofeh Med Ctr, Hematol Inst, Zerifin, Israel; [Rahimi-Levene, Naomi; Golik, Ahuva; Kornberg, Abraham; Zeidenstein, Ronit; Koren-Michowitz, Maya] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Ziv-Baran, Tomer] Tel Aviv Univ, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Sackler Fac Med, Tel Aviv, Israel; [Golik, Ahuva; Zeidenstein, Ronit] Assaf Harofeh Med Ctr, Internal Med Dept A, Zerifin, Israel	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf Harofeh); Tel Aviv University	Rahimi-Levene, N (corresponding author), Assaf Harofeh Med Ctr, Blood Bank, Zerifin, Israel.; Rahimi-Levene, N; Koren-Michowitz, M (corresponding author), Assaf Harofeh Med Ctr, Hematol Inst, Zerifin, Israel.; Rahimi-Levene, N; Koren-Michowitz, M (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	nrlevene@asaf.health.gov.il; korenm@asaf.health.gov.il	Ziv-Baran, Tomer/AAA-8408-2022	Koren-Michowitz, Maya/0000-0002-7223-328X				Avdic A, 2016, TRANSFUSION, V56, P2346, DOI 10.1111/trf.13708; Callum JL, 2014, TRANSFUSION, V54, P2344, DOI 10.1111/trf.12802; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 2002, TRANSFUS MED REV, V16, P187, DOI 10.1053/tmrv.2002.33461; Frank SM, 2013, TRANSFUSION, V53, P3052, DOI 10.1111/trf.12227; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; James P, 2011, GETTING STARTED PATI; Kass G.V., 1980, J R STAT SOC C, V29, P119, DOI 10.2307/2986296; Roubinian NH, 2014, TRANSFUSION, V54, P2678, DOI 10.1111/trf.12825; Salpeter SR, 2014, AM J MED, V127, P124, DOI 10.1016/j.amjmed.2013.09.017; Shehata N, 2014, TRANSFUSION, V54, P2631, DOI 10.1111/trf.12644; Surial B, 2015, SWISS MED WEEKLY, P1; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801	16	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0193873	10.1371/journal.pone.0193873	http://dx.doi.org/10.1371/journal.pone.0193873			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513750	Green Published, Green Submitted, gold			2023-01-03	WOS:000426896800085
J	Kim, DH; Cho, S; Jo, K; Shin, E; Hong, CS; Han, Y; Suh, TS; Lim, DH; Choi, DH				Kim, Dae-Hyun; Cho, Sungkoo; Jo, Kwanghyun; Shin, EunHyuk; Hong, Chae-Seon; Han, Youngyih; Suh, Tae-Suk; Lim, Do Hoon; Choi, Doo Ho			Proton range verification in inhomogeneous tissue: Treatment planning system vs. measurement vs. Monte Carlo simulation	PLOS ONE			English	Article							PENCIL BEAM ALGORITHM; RADIATION-THERAPY; DOSE CALCULATION; STOPPING POWER; BRAGG PEAK; UNCERTAINTIES; GEANT4; NOZZLE	In particle radiotherapy, range uncertainty is an important issue that needs to be overcome. Because high-dose conformality can be achieved using a particle beam, a small uncertainty can affect tumor control or cause normal-tissue complications. From this perspective, the treatment planning system (TPS) must be accurate. However, there is a well-known inaccuracy regarding dose computation in heterogeneous media. This means that verifying the uncertainty level is one of the prerequisites for TPS commissioning. We evaluated the range accuracy of the dose computation algorithm implemented in a commercial TPS, and Monte Carlo (MC) simulation against measurement using a CT calibration phantom. A treatment plan was produced for eight different materials plugged into a phantom, and two-dimensional doses were measured using a chamber array. The measurement setup and beam delivery were simulated by MC code. For an infinite solid water phantom, the gamma passing rate between the measurement and TPS was 97.7%, and that between the measurement and MC was 96.5%. However, gamma passing rates between the measurement and TPS were 49.4% for the lung and 67.8% for bone, and between the measurement and MC were 85.6% for the lung and 100.0% for bone tissue. For adipose, breast, brain, liver, and bone mineral, the gamma passing rates computed by TPS were 91.7%, 90.6%, 81.7%, 85.6%, and 85.6%, respectively. The gamma passing rates for MC for adipose, breast, brain, liver, and bone mineral were 100.0%, 97.2%, 95.0%, 98.9%, and 97.8%, respectively. In conclusion, the described procedure successfully evaluated the allowable range uncertainty for TPS commissioning. The TPS dose calculation is inefficient in heterogeneous media with large differences in density, such as lung or bone tissue. Therefore, the limitations of TPS in heterogeneous media should be understood and applied in clinical practice.	[Kim, Dae-Hyun; Cho, Sungkoo; Jo, Kwanghyun; Shin, EunHyuk; Hong, Chae-Seon; Han, Youngyih; Lim, Do Hoon; Choi, Doo Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea; [Kim, Dae-Hyun; Suh, Tae-Suk] Catholic Univ Korea, Dept Biomed Engn, Coll Med, Seoul, South Korea; [Kim, Dae-Hyun; Suh, Tae-Suk] Catholic Univ Korea, Res Inst Biomed Engn, Coll Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Catholic University of Korea; Catholic University of Korea	Han, Y (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea.; Suh, TS (corresponding author), Catholic Univ Korea, Dept Biomed Engn, Coll Med, Seoul, South Korea.; Suh, TS (corresponding author), Catholic Univ Korea, Res Inst Biomed Engn, Coll Med, Seoul, South Korea.	youngyih@skku.edu; suhsanta@catholic.ac.kr		Hong, Chae-Seon/0000-0001-9120-6132	National Research Foundation - Ministry of Science, ICT and Future Planning, Republic of Korea [2013M2A2A7043507, 2012M3A9B6055201, 2016R1C1B2009258]	National Research Foundation - Ministry of Science, ICT and Future Planning, Republic of Korea	This study was supported by a grant (2013M2A2A7043507, 2012M3A9B6055201, 2016R1C1B2009258) of the National Research Foundation funded by the Ministry of Science, ICT and Future Planning, Republic of Korea.	Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8; Andreo P, 2009, PHYS MED BIOL, V54, pN205, DOI 10.1088/0031-9155/54/11/N01; Besemer A, 2013, PHYS MED BIOL, V58, P887, DOI 10.1088/0031-9155/58/4/887; Brada M, 2007, J CLIN ONCOL, V25, P965, DOI 10.1200/JCO.2006.10.0131; Carlsson AK, 1997, PHYS MED BIOL, V42, P1033, DOI 10.1088/0031-9155/42/6/004; Chung K, 2015, RADIAT ONCOL J, V33, P337, DOI 10.3857/roj.2015.33.4.337; Egashira Y, 2013, PHYS MED BIOL, V58, P1169, DOI 10.1088/0031-9155/58/4/1169; Fippel M, 2004, MED PHYS, V31, P2263, DOI 10.1118/1.1769631; GOITEIN M, 1978, RADIAT RES, V74, P217, DOI 10.2307/3574883; Hall EJ, 2006, INT J RADIAT ONCOL, V65, P1, DOI 10.1016/j.ijrobp.2006.01.027; Hong L, 1996, PHYS MED BIOL, V41, P1305, DOI 10.1088/0031-9155/41/8/005; ICRU, 46 ICRU; ICRU, 1993, 49 ICRU; International Commission on Radiation Units and Measurements (ICRU), 44 ICRU; Jiang H, 2004, MED PHYS, V31, P2811, DOI 10.1118/1.1796952; Kim DH, 2012, J KOREAN PHYS SOC, V61, P1125, DOI 10.3938/jkps.61.1125; Kimura A, 2004, IEEE NUCL SCI CONF R, P2124; Low DA, 2003, MED PHYS, V30, P2455, DOI 10.1118/1.1598711; Paganetti H, 2004, MED PHYS, V31, P2107, DOI 10.1118/1.1762792; Paganetti H, 2008, PHYS MED BIOL, V53, P4825, DOI 10.1088/0031-9155/53/17/023; Paganetti H, 2012, PHYS MED BIOL, V57, pR99, DOI 10.1088/0031-9155/57/11/R99; PETTI PL, 1992, MED PHYS, V19, P137, DOI 10.1118/1.596887; Sawakuchi GO, 2008, PHYS MED BIOL, V53, P4605, DOI 10.1088/0031-9155/53/17/010; Schneider U, 2005, MED PHYS, V32, P195, DOI 10.1118/1.1833041; Schuemann J, 2014, PHYS MED BIOL, V59, P4007, DOI 10.1088/0031-9155/59/15/4007; Schulz-Ertner D, 2007, J CLIN ONCOL, V25, P953, DOI 10.1200/JCO.2006.09.7816; Stankovskiy A, 2009, PHYS MED BIOL, V54, P2377, DOI 10.1088/0031-9155/54/8/008; Szymanowski H, 2002, PHYS MED BIOL, V47, P3313, DOI 10.1088/0031-9155/47/18/304; Szymanowski H, 2001, MED PHYS, V28, P975, DOI 10.1118/1.1376445; URIE M, 1986, PHYS MED BIOL, V31, P1, DOI 10.1088/0031-9155/31/1/001; Warren DR, 2015, PHYS MED BIOL, V60, P4243, DOI 10.1088/0031-9155/60/11/4243; Yamashita T, 2012, PHYS MED BIOL, V57, P7673, DOI 10.1088/0031-9155/57/22/7673	32	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2018	13	3							e0193904	10.1371/journal.pone.0193904	http://dx.doi.org/10.1371/journal.pone.0193904			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY1CC	29505589	Green Submitted, Green Published, gold			2023-01-03	WOS:000426548200041
J	Lembke, A; Papac, J; Humphreys, K				Lembke, Anna; Papac, Jennifer; Humphreys, Keith			Our Other Prescription Drug Problem	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lembke, Anna; Papac, Jennifer; Humphreys, Keith] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA; [Humphreys, Keith] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Lembke, A (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.							[Anonymous], 2016, PRESCR DRUG MON PROG; Bachhuber MA, 2016, AM J PUBLIC HEALTH, V106, P686, DOI 10.2105/AJPH.2016.303061; Dowell D, 2016, HEALTH AFFAIR, V35, P1876, DOI 10.1377/hlthaff.2016.0448; Gorevski E, 2012, ANN PHARMACOTHER, V46, P503, DOI 10.1345/aph.1Q618; Sun EC, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j760	5	81	81	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 22	2018	378	8					693	695		10.1056/NEJMp1715050	http://dx.doi.org/10.1056/NEJMp1715050			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FW8VA	29466163				2023-01-03	WOS:000425613900005
J	Williams, JG; Bachman, MW; Lyons, MD; Currie, BB; Brown, LH; Jones, AW; Cabanas, JG; Kronhaus, AK; Myers, JB				Williams, J. G.; Bachman, M. W.; Lyons, M. D.; Currie, B. B.; Brown, L. H.; Jones, A. W.; Cabanas, J. G.; Kronhaus, A. K.; Myers, J. B.			Transport to the Emergency Department for Assisted Living Residents Who Fall	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													jones, wayne/Q-9508-2019						0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2018	168	3					I26	I26		10.7326/P17-9051	http://dx.doi.org/10.7326/P17-9051			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV0CU	29230471				2023-01-03	WOS:000424224300003
J	Bucci, M				Bucci, Mirella			A path of DSF destruction	NATURE CHEMICAL BIOLOGY			English	Editorial Material														Bucci, Mirella/0000-0003-1654-3758					0	3	3	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2018	14	2					107	107		10.1038/nchembio.2562	http://dx.doi.org/10.1038/nchembio.2562			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HH4IE	29337964				2023-01-03	WOS:000455684900003
J	Castro-Codesal, ML; Dehaan, K; Bedi, PK; Bendiak, GN; Schmalz, L; Katz, SL; MacLean, JE				Castro-Codesal, Maria L.; Dehaan, Kristie; Bedi, Prabhjot K.; Bendiak, Glenda N.; Schmalz, Leah; Katz, Sherri L.; MacLean, Joanna E.			Longitudinal changes in clinical characteristics and outcomes for children using long-term non-invasive ventilation	PLOS ONE			English	Article							HOME MECHANICAL VENTILATION; POSITIVE AIRWAY PRESSURE; MEDICAL COMPLEXITY; SLEEP-APNEA; SUPPORT	Objectives To describe longitudinal trends in long-term non-invasive ventilation (NIV) use in children including changes in clinical characteristics, NIV technology, and outcomes. Methods This was a multicenter retrospective cohort of all children started on long-term NIV from 2005 to 2014. All children 0 to 18 years who used NIV continuously for at least 3 months were included. Measures and main outcomes were: 1) Number of children starting NIV; 2) primary medical condition; 3) medical complexity defined by number of comorbidities, surgeries and additional technologies; 4) severity of sleep disordered breathing measured by diagnostic polysomnography; 5) NIV technology and use; 6) reasons for NIV discontinuation including mortality. Data were divided into equal time periods for analysis. Results A total of 622 children were included in the study. Median age at NIV initiation was 7.8 years (range 0-18 years). NIV incidence and prevalence increased five and three-fold over the 10-year period. More children with neurological and cardio-respiratory conditions started NIV overtime, from 13% (95%CI, 8%-20%) and 6% (95%CI, 3%-10%) respectively in 2005-2008 to 23% (95%CI, 18%-28%) and 9% (95%CI, 6%-14%, p = 0.008) in 2011-2014. Medical complexity and severity of the sleep-disordered breathing did not change over time. Overall, survival was 95%; mortality rates, however, rose from 3.4 cases (95% CI, 0.5-24.3) to 142.1 (95% CI 80.7-250.3, p<0.001) per 1000 children-years between 2005-2008 and 2011-2014. Mortality rates differed by diagnostic category, with higher rates in children with neurological and cardio-respiratory conditions. Conclusions As demonstrated in other centers, there was a significant increase in NIV prevalence and incidence rate. There was no increase in medical complexity or severity of the breathing abnormalities of children receiving long-term NIV over time. The mortality rate increased over time, maybe attributable to increased use of NIV for children with neurological and cardio-respiratory conditions.	[Castro-Codesal, Maria L.; Dehaan, Kristie; Bedi, Prabhjot K.; MacLean, Joanna E.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Castro-Codesal, Maria L.; MacLean, Joanna E.] Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB, Canada; [Castro-Codesal, Maria L.; MacLean, Joanna E.] Stollery Childrens Hosp, Edmonton, AB, Canada; [Bendiak, Glenda N.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Bendiak, Glenda N.; Schmalz, Leah] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Katz, Sherri L.] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada; [Katz, Sherri L.] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada	University of Alberta; University of Alberta; Stollery Children's Hospital; University of Calgary; Alberta Childrens Hospital; University of Calgary; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	Castro-Codesal, ML (corresponding author), Univ Alberta, Dept Pediat, Edmonton, AB, Canada.; Castro-Codesal, ML (corresponding author), Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB, Canada.; Castro-Codesal, ML (corresponding author), Stollery Childrens Hosp, Edmonton, AB, Canada.	castroco@ualberta.ca	Codesal, Maria L Castro/D-2327-2015	Codesal, Maria L Castro/0000-0002-1079-2502; Bedi, Prabhjot/0000-0003-4663-6760; MacLean, Joanna/0000-0001-7994-9910	Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute at the University of Alberta; Alberta Health Services through the Respiratory Health Strategic Clinical Network; Women and Children's Health Research Institute	Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute at the University of Alberta; Alberta Health Services through the Respiratory Health Strategic Clinical Network; Women and Children's Health Research Institute	Salary for a research fellowship has been funded by the generous support of the Stollery Children's Hospital Foundation through the Women and Children's Health Research Institute at the University of Alberta. Funding support for data collection has been received from Alberta Health Services through the Respiratory Health Strategic Clinical Network and from the Women and Children's Health Research Institute. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin R, 2014, PEDIATR PULM, V49, P816, DOI 10.1002/ppul.22868; Castro-Codesal ML, 2017, SLEEP MED REV; Chan T, 2016, J PEDIATR-US, V177, P197, DOI 10.1016/j.jpeds.2016.06.035; Chatwin M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125839; Cohen E, 2011, PEDIATRICS, V127, P529, DOI 10.1542/peds.2010-0910; Edwards EA, 2005, J PAEDIATR CHILD H, V41, P652, DOI 10.1111/j.1440-1754.2005.00753.x; ELLIS ER, 1987, AM REV RESPIR DIS, V136, P188, DOI 10.1164/ajrccm/136.1.188; Fauroux B, 2003, PEDIATR PULM, V35, P119, DOI 10.1002/ppul.10237; Gold JM, 2016, J HOSP MED, V11, P750, DOI 10.1002/jhm.2633; Cortes RG, 2013, AN PEDIATR, V78, P227, DOI 10.1016/j.anpedi.2012.06.011; Goodwin S, 2011, EUR J PEDIATR, V170, P1187, DOI 10.1007/s00431-011-1430-9; GUILLEMINAULT C, 1986, PEDIATRICS, V78, P797; Guttmann A., 2009, PAED CHILD HEALT-CAN, V14, P310, DOI [10.1093/pch/14.5.310, DOI 10.1093/PCH/14.5.310]; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Ishikawa Y, 2011, NEUROMUSCULAR DISORD, V21, P47, DOI 10.1016/j.nmd.2010.09.006; Kamm M, 2001, SWISS MED WKLY, V131, P261; Keilty K, 2015, J PEDIATR REHAB MED, V8, P113, DOI 10.3233/PRM-150325; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Kuo DZ, 2015, MATERN CHILD HLTH J, V19, P40, DOI 10.1007/s10995-014-1493-0; McDougall CM, 2013, ARCH DIS CHILD, V98, P660, DOI 10.1136/archdischild-2012-303062; Nathan AM, 2017, PEDIATR PULM, V52, P500, DOI 10.1002/ppul.23569; Prado F, 2011, REV CHIL PEDIATR-CHI, V82, P289; Racca F, 2011, MINERVA ANESTESIOL, V77, P892; Ramirez A, 2012, INTENS CARE MED, V38, P655, DOI 10.1007/s00134-012-2516-1; SCHMIDTNOWARA WW, 1984, AM J DIS CHILD, V138, P82, DOI 10.1001/archpedi.1984.02140390070021; Simonds AK, 2016, ANN AM THORAC SOC, V13, P2035, DOI 10.1513/AnnalsATS.201606-454FR; Sovtic A, 2012, PEDIATR INT, V54, P676, DOI 10.1111/j.1442-200X.2012.03634.x; Srivastava R, 2016, J PAEDIATR CHILD H, V52, P566, DOI 10.1111/jpc.13152; Thomson J, 2016, J PEDIATR-US, V172, P187, DOI 10.1016/j.jpeds.2016.01.049; Tkachenko N, 2016, PEDIATR NEUROL, V57, P39, DOI 10.1016/j.pediatrneurol.2015.12.020; Wallis C, 2011, ARCH DIS CHILD, V96, P998, DOI 10.1136/adc.2010.192864; Zullig LL, 2016, J GEN INTERN MED, V31, P329, DOI 10.1007/s11606-015-3512-2	32	24	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2018	13	1							e0192111	10.1371/journal.pone.0192111	http://dx.doi.org/10.1371/journal.pone.0192111			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU1NX	29381756	Green Submitted, gold, Green Published			2023-01-03	WOS:000423617800057
J	Mounier, R; Lobo, D; Voulgaropoulos, J; Martin, M; Ait-Mamar, B; Bitot, V; Jost, PH; Birnbaum, R; Nebbad, B; Cook, F; Dhonneur, G				Mounier, Roman; Lobo, David; Voulgaropoulos, Julia; Martin, Mathieu; Ait-Mamar, Bouziane; Bitot, Valerie; Jost, Paul-Henri; Birnbaum, Ron; Nebbad, Biba; Cook, Fabrice; Dhonneur, Gilles			The multistep road to ventilator-associated lung abscess: A retrospective study of S-aureus ventilator-associated pneumonia	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PANTON-VALENTINE LEUKOCIDIN; INFECTIONS; MANAGEMENT; PATHOPHYSIOLOGY; ASPIRATION; INJURIES; PROGRESS; ADULTS; DAMAGE	Object We observed some cases of lung abscess (LA) in ICU patients suffering S. aureus ventilator-associated pneumonia (S. aureus-VAP). We aimed to assess which of the host and/or bacteria-related features are associated with LA. Methods We conducted a retrospective study from January 2009 to July 2013 in a trauma surgical ICU within a teaching hospital. All adult patients presenting with S. aureus-VAP were included. We compared two groups of patients according to the formation or not of LA concomitantly to S. aureus-VAP. Results Seventy-nine S. aureus-VAP patients, predominantly males (85%) of rather young age (mean [SD]: 35yr [21-64]) with severe trauma (initial Simplified Acute Score II = 42 [32-52]) related-ICU admission, were included. Among them, 10 (14%) developed LA. Patient's characteristics significantly associated with LA development were: a younger age (p = 0.003), road traffic accidents admission (p = 0.017), head injury (p = 0.002), lower Glasgow Coma Scale (p = 0.009), blunt chest trauma (p = 0.01) pneumothorax (p = 0.01) and lung contusions (p = 0.002). No microbiological factors were significantly associated with LA formation. Abscesses were mostly bilateral, >= 5 cm of diameter and with a posterior location. Conclusions Our results do not favor a specific virulence of S. aureus, but rather highlight the role of multiple insults to the lung, promoting LA formation. Despite a similar severity score, patients with LA had more serious trauma, combining severe both chest and head insults.	[Mounier, Roman; Lobo, David; Martin, Mathieu; Ait-Mamar, Bouziane; Bitot, Valerie; Jost, Paul-Henri; Birnbaum, Ron; Cook, Fabrice; Dhonneur, Gilles] Henri Mondor Univ Hosp Paris, Paris Sch Med 12, Dept Anesthesia & Surg Intens Care, Creteil, France; [Voulgaropoulos, Julia] Bichat Claude Bernard Univ Hosp Paris, Paris Sch Med 12, Dept Anesthesia & Surg Intens Care, Paris, France; [Nebbad, Biba] Henri Mondor Univ Hosp Paris, Paris Sch Med 12, Dept Microbiol, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Mounier, R (corresponding author), Henri Mondor Univ Hosp Paris, Paris Sch Med 12, Dept Anesthesia & Surg Intens Care, Creteil, France.	roman.mounier@laposte.net		Bitot, Valerie/0000-0002-8447-2296				Beitler JR, 2014, CHEST, V146, P1102, DOI 10.1378/chest.14-0555; Casadevall A, 2003, NAT REV MICROBIOL, V1, P17, DOI 10.1038/nrmicro732; Chambers HF, 2009, NAT REV MICROBIOL, V7, P629, DOI 10.1038/nrmicro2200; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; DiBardino DM, 2015, J CRIT CARE, V30, P40, DOI 10.1016/j.jcrc.2014.07.011; Ganie Farooq Ahmad, 2013, Bull Emerg Trauma, V1, P7; Gattinoni L, 2001, AM J RESP CRIT CARE, V164, P1701, DOI 10.1164/ajrccm.164.9.2103121; Gavelli G, 2002, EUR RADIOL, V12, P1273, DOI 10.1007/s00330-002-1439-6; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Gleeson K, 1997, CHEST, V111, P1266, DOI 10.1378/chest.111.5.1266; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hoth JJ, 2009, J TRAUMA, V67, P14, DOI 10.1097/TA.0b013e31819ea600; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI [10.1056/NEJMoa1500245, 10.1056/NEJMc1511751]; Kuhajda I, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.07.08; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Matthes G, 2007, ZBL CHIR, V132, P142, DOI 10.1055/s-2007-960646; Niemann S, 2012, J INFECT DIS, V206, P1138, DOI 10.1093/infdis/jis468; Patradoon-Ho P, 2007, PAEDIATR RESPIR REV, V8, P77, DOI 10.1016/j.prrv.2006.10.002; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; Raghavendran K, 2009, SHOCK, V32, P122, DOI 10.1097/SHK.0b013e31819c385c; Shallcross LJ, 2013, LANCET INFECT DIS, V13, P43, DOI 10.1016/S1473-3099(12)70238-4; Stock CT, 2013, SURG INFECT, V14, P335, DOI 10.1089/sur.2012.060; Tong SYC, 2015, CLIN MICROBIOL REV, V28, P603, DOI 10.1128/CMR.00134-14; Valour F, 2013, REV PNEUMOL CLIN, V69, P368, DOI 10.1016/j.pneumo.2013.08.004; Wunderink RG, 2004, INFECT DIS CLIN N AM, V18, P743, DOI 10.1016/j.idc.2004.07.004	26	4	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2017	12	12							e0189249	10.1371/journal.pone.0189249	http://dx.doi.org/10.1371/journal.pone.0189249			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7SY	29261721	gold, Green Submitted, Green Published			2023-01-03	WOS:000418564200035
J	Palmer, AC; Sorger, PK				Palmer, Adam C.; Sorger, Peter K.			Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy	CELL			English	Article							PHASE-III TRIAL; METASTATIC BREAST-CANCER; RECURRENT EPITHELIAL OVARIAN; 1ST-LINE TREATMENT; PRIMARY PERITONEAL; COLORECTAL-CANCER; ACUTE LEUKEMIA; SINGLE-AGENT; CHEMOTHERAPY; BEVACIZUMAB	Combination cancer therapies aim to improve the probability and magnitude of therapeutic responses and reduce the likelihood of acquired resistance in an individual patient. However, drugs are tested in clinical trials on genetically diverse patient populations. We show here that patient-to-patient variability and independent drug action are sufficient to explain the superiority of many FDA-approved drug combinations in the absence of drug synergy or additivity. This is also true for combinations tested in patient-derived tumor xenografts. In a combination exhibiting independent drug action, each patient benefits solely from the drug to which his or her tumor is most sensitive, with no added benefit from other drugs. Even when drug combinations exhibit additivity or synergy in pre-clinical models, patient-to-patient variability and low cross-resistance make independent action the dominant mechanism in clinical populations. This insight represents a different way to interpret trial data and a different way to design combination therapies.	[Palmer, Adam C.; Sorger, Peter K.] Harvard Med Sch, Lab Syst Pharmacol, Program Therapeut Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sorger, PK (corresponding author), Harvard Med Sch, Lab Syst Pharmacol, Program Therapeut Sci, Boston, MA 02115 USA.	peter_sorger@hms.harvard.edu	Palmer, Adam/N-5495-2019; Palmer, Adam C/J-3589-2012	Palmer, Adam/0000-0001-5028-7028; Palmer, Adam C/0000-0001-5028-7028; Sorger, Peter/0000-0002-3364-1838	NHMRC [1072965]; NIH [GM107618]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM107618] Funding Source: NIH RePORTER	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Hafner, S. Goel, M. Cokol, S. Chopra, E. Sober, T. Mitchison, and B. Chabner for discussions. This work was supported by NHMRC Early Career Fellowship 1072965 (to A.C.P.) and NIH grant GM107618.	Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505; Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057; Bookman MA, 2009, J CLIN ONCOL, V27, P1419, DOI 10.1200/JCO.2008.19.1684; Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747; Brugarolas J, 2003, LANCET, V361, P1758, DOI 10.1016/S0140-6736(03)13446-0; Burger RA, 2007, J CLIN ONCOL, V25, P5165, DOI 10.1200/JCO.2007.11.5345; Cardoso F, 2009, JNCI-J NATL CANCER I, V101, P1174, DOI 10.1093/jnci/djp235; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Ducreux M, 2004, ANN ONCOL, V15, P467, DOI 10.1093/annonc/mdh098; Eder J.P., 2010, HOLLAND FREI CANC ME, V8; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; FREI E, 1985, CANCER RES, V45, P6523; FREI E, 1965, BLOOD-J HEMATOL, V26, P642, DOI 10.1182/blood.V26.5.642.642; FREIREICH EJ, 1963, BLOOD, V21, P699; Fuentes G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2888; Gaddum J.H., 1940, PHARMACOLOGY, V1st; Gandhi L, 2013, J THORAC ONCOL, V8, pE3, DOI 10.1097/JTO.0b013e3182762d20; Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/nmeth.3853, 10.1038/NMETH.3853]; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Jonas O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010564; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966; Klinghoffer RA, 2015, SCI TRANSL MED, V7; Kummar S, 2010, NAT REV DRUG DISCOV, V9, P843, DOI 10.1038/nrd3216; LAW LW, 1952, CANCER RES, V12, P871; Liu JF, 2014, LANCET ONCOL, V15, P1207, DOI 10.1016/S1470-2045(14)70391-2; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Malaney P, 2014, CANCER LETT, V344, P1, DOI 10.1016/j.canlet.2013.10.010; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Oza AM, 2015, LANCET ONCOL, V16, P87, DOI 10.1016/S1470-2045(14)71135-0; Perez EA, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw207; Polyzos A, 2000, CLIN DRUG INVEST, V19, P349, DOI 10.2165/00044011-200019050-00005; Pritchard JR, 2013, P NATL ACAD SCI USA, V110, pE170, DOI 10.1073/pnas.1210419110; Renouf DJ, 2014, EUR J CANCER, V50, P1909, DOI 10.1016/j.ejca.2014.04.008; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sledge GW, 2003, J CLIN ONCOL, V21, P588, DOI 10.1200/JCO.2003.08.013; STEEL G. G., 1967, EUR J CANCER, V3, P381, DOI 10.1016/0014-2964(67)90022-9; Swain SM, 2015, NEW ENGL J MED, V372, P724, DOI 10.1056/NEJMoa1413513; TUBIANA M, 1989, ACTA ONCOL, V28, P113, DOI 10.3109/02841868909111193; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719	48	306	309	4	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 14	2017	171	7					1678	+		10.1016/j.cell.2017.11.009	http://dx.doi.org/10.1016/j.cell.2017.11.009			27	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FQ0KF	29245013	Green Accepted, Bronze			2023-01-03	WOS:000418044000022
J	Yin, N; Fang, L; Shi, XH; Huang, HQ; Zhang, L				Yin, Ning; Fang, Lei; Shi, Xiaohua; Huang, Hongqiang; Zhang, Li			A comprehensive scoring system in correlation with perioperative airway management for neonatal Pierre Robin Sequence	PLOS ONE			English	Article							LARYNGEAL MASK AIRWAY; TRACHEAL INTUBATION	Purpose To evaluate a comprehensive scoring system which combines clinical manifestations of Pierre Robin Sequence (PRS) including severity of breathing difficulties, body weight and preoperative Cormack-Lehane grade, for its correlation with perioperative PRS airway management decision. Design Forty PRS children were retrospectively recruited after surgery. Specialists examined all subjects and scored for clinical manifestations (1' - 4'), weight gain (1' - 4'), dyspnea scores (1' - 4'), and Cormack- Lehane grade (1' - 4'). The correlation of the integrated scores and the necessity of endotracheal intubation or laryngeal mask application were analyzed. In addition, the score correlation with postoperative dyspnea and/or low pulse oxygen saturation (SPO2) levels after extubation was determined. Findings In our study every individual patient had a score from 0' to 16', while the higher in the numbers represented higher risk of breathing difficulty. All patients with comprehensive scores < 10 points underwent endotracheal intubation successfully. Patients scoring 10-12 points had an intubation success rate of 47%, whereas all patients scored > 13 points required a laryngeal mask assisted airway management and were considered to have difficult airways. Dyspnea after extubation and postoperative low SPO2 occurred among patients who scored over 10 points. Conclusion In PRS patients, preoperative weight gaining status and severity of dyspnea in combination with Cormack-Lehane classification provide a scoring system that could help to optimize airway management decisions such as endotracheal intubation or laryngeal mask airway placement and has the potential to predict postoperative dyspnea or low SPO2 levels.	[Yin, Ning] Nanjing Med Univ, Sir Run Run Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China; [Yin, Ning; Fang, Lei] Southeast Univ, Zhongda Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China; [Yin, Ning; Fang, Lei] Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China; [Shi, Xiaohua; Huang, Hongqiang; Zhang, Li] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Southeast University - China; Southeast University - China; Nanjing Medical University	Yin, N (corresponding author), Nanjing Med Univ, Sir Run Run Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.; Yin, N (corresponding author), Southeast Univ, Zhongda Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.; Yin, N (corresponding author), Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China.	yinning882000@126.com						BARAKA A, 1995, ANESTHESIOLOGY, V83, P645; CAOUETTELABERGE L, 1994, PLAST RECONSTR SURG, V93, P934, DOI 10.1097/00006534-199404001-00006; Cladis F, 2014, ANESTH ANALG, V119, P400, DOI 10.1213/ANE.0000000000000301; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Dinwiddie Robert, 2004, Paediatr Respir Rev, V5, P17, DOI 10.1016/j.prrv.2003.10.001; Gandini D, 2003, PAEDIATR ANAESTH, V13, P181, DOI 10.1046/j.1460-9592.2003.01019_4.x; Gangopadhyay Noopur, 2012, Semin Plast Surg, V26, P76, DOI 10.1055/s-0032-1320065; HANSEN TG, 1995, ACTA ANAESTH SCAND, V39, P129, DOI 10.1111/j.1399-6576.1995.tb05604.x; Hong Paul, 2015, Ear Nose Throat J, V94, pE25; Mackay DR, 2011, J CRANIOFAC SURG, V22, P415, DOI 10.1097/SCS.0b013e3182074799; MARKAKIS DA, 1992, ANESTH ANALG, V75, P823; Marston AP, 2012, LARYNGOSCOPE, V122, P1401, DOI 10.1002/lary.23260; Ryan G, 2016, SEMIN FETAL NEONAT M, V21, P230, DOI 10.1016/j.siny.2016.03.002; Smith MC, 2006, INT J PEDIATR OTORHI, V70, P319, DOI 10.1016/j.ijporl.2005.07.003; St-Hilaire H, 2000, OTOLARYNG CLIN N AM, V33, P1241, DOI 10.1016/S0030-6665(05)70279-6; Xiong X, 2007, MATERN CHILD HLTH J, V11, P57, DOI 10.1007/s10995-006-0140-9	16	7	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2017	12	12							e0189052	10.1371/journal.pone.0189052	http://dx.doi.org/10.1371/journal.pone.0189052			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP0ZD	29216230	Green Published, Green Submitted, gold			2023-01-03	WOS:000417337800061
J	McDermott, M; Ferrucci, L; Tian, L; Guralnik, JM; Lloyd-Jones, D; Kibbe, MR; Polonsky, TS; Domanchuk, K; Stein, JH; Zhao, LH; Taylor, D; Skelly, C; Pearce, W; Perlman, H; McCarthy, W; Li, LY; Gao, Y; Sufit, R; Bloomfield, CL; Criqui, MH				McDermott, Marym.; Ferrucci, Luigi; Tian, Lu; Guralnik, Jack M.; Lloyd-Jones, Donald; Kibbe, Melina R.; Polonsky, Tamar S.; Domanchuk, Kathryn; Stein, James H.; Zhao, Lihui; Taylor, Doris; Skelly, Christopher; Pearce, William; Perlman, Harris; McCarthy, Walter; Li, Lingyu; Gao, Ying; Sufit, Robert; Bloomfield, Christina L.; Criqui, Michael H.			Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease The PROPEL Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENDOTHELIAL PROGENITOR CELLS; ANKLE-BRACHIAL INDEX; TREADMILL TESTS; MOBILIZATION; ANGIOGENESIS; CLAUDICATION; ASSOCIATION; ISCHEMIA	IMPORTANCE Benefits of granulocyte-macrophage colony-stimulating factor(GM-CSF) for improving walking ability in people with lower extremity peripheral artery disease (PAD) are unclear. Walking exercise may augment the effects of GM-CSF in PAD, since exercise-induced ischemia enhances progenitor cell release and may promote progenitor cell homing to ischemic calf muscle. OBJECTIVES To determine whether GM-CSF combined with supervised treadmill exercise improves 6-minute walk distance, compared with exercise alone and compared with GM-CSF alone; to determine whether GM-CSF alone improves 6-minute walk more than placebo and whether exercise improves 6-minute walk more than an attention control intervention. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial with 2 x 2 factorial design. Participants were identified from the Chicago metropolitan area and randomized between January 6, 2012, and December 22, 2016, to 1 of 4 groups: supervised exercise + GM-CSF (exercise + GM-CSF) (n = 53), supervised exercise + placebo (exercise alone) (n = 53), attention control + GM-CSF (GM-CSF alone) (n = 53), attention control + placebo (n = 51). The final follow-up visit was on August 15, 2017. INTERVENTIONS Supervised exercise consisted of treadmill exercise 3 times weekly for 6 months. The attention control consisted of weekly educational lectures by clinicians for 6 months. GM-CSF (250 mu g/m(2)/d) or placebo were administered subcutaneously (double-blinded) 3 times/wk for the first 2 weeks of the intervention. MAIN OUTCOMES AND MEASURES The primary outcome was change in 6-minute walk distance at 12-week follow-up (minimum clinically important difference, 20 m). P values were adjusted based on the Hochberg step-up method. RESULTS Of 827 persons evaluated, 210 participants with PAD were randomized (mean age, 67.0 [SD, 8.6] years; 141 [67%] black, 82 [39%] women). One hundred ninety-five (93%) completed 12-week follow-up. At 12-week follow-up, exercise + GM-CSF did not significantly improve 6-minute walk distance more than exercise alone (mean difference, -6.3m[95% CI, -30.2 to + 17.6]; P =.61) or more than GM-CSF alone (mean difference, + 28.7m[95% CI, + 5.1 to + 52.3]; Hochberg-adjusted P =.052). GM-CSF alone did not improve 6-minutewalk more than attention control + placebo (mean difference, -1.4m[95% CI, -25.2 to + 22.4]; P =.91). Exercise alone improved 6-minutewalk compared with attention control + placebo (mean difference, + 33.6m [95% CI, + 9.4 to + 57.7]; Hochberg-adjusted P =.02). CONCLUSIONS AND RELEVANCE Among patients with PAD, supervised treadmill exercise significantly improved 6-minute walk distance compared with attention control + placebo, whereas GM-CSF did not significantly improve walking performance, either when used alone or when combined with supervised treadmill exercise. These results confirm the benefits of exercise but do not support using GM-CSF to treat walking impairment in patients with PAD.	[McDermott, Marym.; Lloyd-Jones, Donald; Domanchuk, Kathryn; Perlman, Harris; Li, Lingyu; Gao, Ying; Bloomfield, Christina L.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [McDermott, Marym.; Lloyd-Jones, Donald; Zhao, Lihui] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Ferrucci, Luigi] NIA, Div Intramural Res, Baltimore, MD 21224 USA; [Tian, Lu] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Guralnik, Jack M.] Univ Maryland, Dept Epidemiol, Baltimore, MD 21201 USA; [Kibbe, Melina R.] Univ N Carolina, Dept Surg, Chapel Hill, NC USA; [Polonsky, Tamar S.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Stein, James H.] Univ Wisconsin, Dept Med, Madison, WI USA; [Taylor, Doris] Texas Heart Inst, Houston, TX 77025 USA; [Skelly, Christopher] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Pearce, William] Northwestern Univ, Dept Surg, Chicago, IL 60611 USA; [Pearce, William] Jesse Brown VA Med Ctr, Chicago, IL USA; [McCarthy, Walter; Sufit, Robert] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Stanford University; University System of Maryland; University of Maryland Baltimore; University of North Carolina; University of North Carolina Chapel Hill; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Texas Heart Institute; University of Chicago; Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Northwestern University; Feinberg School of Medicine; University of California System; University of California San Diego	McDermott, M (corresponding author), Northwestern Univ, Div Gen Internal Med & Geriatr, Feinberg Sch Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.	mdm608@northwestern.edu	Skelly, Christopher/ABD-6187-2020	Lloyd-Jones, Donald/0000-0003-0847-6110; Stein, James/0000-0002-2770-8223; tian, lu/0000-0002-5893-0169	National Heart, Lung, and Blood Institute (NHLBI) [R01-HL107510]; National Institute on Aging; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107510] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by the National Heart, Lung, and Blood Institute (NHLBI) (R01-HL107510) and the National Institute on Aging. The material reported in this article is in part the result of work supported with resources and the use of facilities at the Jesse Brown VA Medical Center in Chicago, Illinois.	Aboyans V, 2012, CIRCULATION, V126, P2890, DOI 10.1161/CIR.0b013e318276fbcb; Amirhamzeh MMR, 1997, EUR J VASC ENDOVASC, V13, P301, DOI 10.1016/S1078-5884(97)80102-5; Arai M, 2006, CIRC J, V70, P1093, DOI 10.1253/circj.70.1093; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Criqui M H, 1996, Vasc Med, V1, P65; Domanchuk K, 2013, CONTEMP CLIN TRIALS, V36, P502, DOI 10.1016/j.cct.2013.09.011; Fadini GP, 2005, J AM COLL CARDIOL, V45, P1449, DOI 10.1016/j.jacc.2004.11.067; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Harel O, 2007, STAT MED, V26, P3057, DOI 10.1002/sim.2787; Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Laufs U, 2004, CIRCULATION, V109, P220, DOI 10.1161/01.CIR.0000109141.48980.37; McDermott MM, 2014, CIRCULATION, V130, P61, DOI 10.1161/CIRCULATIONAHA.114.007002; McDermott MM, 2013, JAMA-J AM MED ASSOC, V310, P57, DOI 10.1001/jama.2013.7231; McDermott MM, 2009, JAMA-J AM MED ASSOC, V301, P165, DOI 10.1001/jama.2008.962; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Poole J, 2013, JAMA-J AM MED ASSOC, V310, P2631, DOI 10.1001/jama.2013.282540; Raghunathan TE, 2004, ANNU REV PUBL HEALTH, V25, P99, DOI 10.1146/annurev.publhealth.25.102802.124410; Saber R, 2015, VASC MED, V20, P534, DOI 10.1177/1358863X15600255; Sandri M, 2005, CIRCULATION, V111, P3391, DOI 10.1161/CIRCULATIONAHA.104.527135; Subramaniyam V, 2009, AM HEART J, V158, P53, DOI 10.1016/j.ahj.2009.04.014; Thijssen DHJ, 2009, FRONT BIOSCI-LANDMRK, V14, P4685, DOI 10.2741/3560; van Royen N, 2005, CIRCULATION, V112, P1040, DOI 10.1161/CIRCULATIONAHA.104.529552	27	42	42	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2017	318	21					2089	2098		10.1001/jama.2017.17437	http://dx.doi.org/10.1001/jama.2017.17437			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FO7XT	29141087	Bronze, Green Published			2023-01-03	WOS:000417093500014
J	Daniels, JP				Daniels, Joe Parkin			Frontline: caring for soldiers after the peace deal in Colombia	LANCET			English	Editorial Material																			0	2	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	2017	390	10106					1939	1939		10.1016/S0140-6736(17)32736-8	http://dx.doi.org/10.1016/S0140-6736(17)32736-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FK9HW	29115220				2023-01-03	WOS:000413823200019
J	Gaeta, JM; Racine, M				Gaeta, Jessie M.; Racine, Melanie			New Strategies Are Needed to Stop Overdose Fatalities: The Case for Supervised Injection Facilities	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Gaeta, Jessie M.; Racine, Melanie] Boston Hlth Care Homeless Program, Inst Res Qual & Policy Homeless Hlth Care, 780 Albany St, Boston, MA 02118 USA; [Gaeta, Jessie M.] Boston Med Ctr, Sect Gen Internal Med, Boston, MA 02118 USA	Boston Medical Center	Gaeta, JM (corresponding author), Boston Hlth Care Homeless Program, Inst Res Qual & Policy Homeless Hlth Care, 780 Albany St, Boston, MA 02118 USA.	jgaeta@bhchp.org	Racine, Melanie/GNH-3956-2022					*AMER MED ASS, 2017, AMA WANTS NEW APPR C; DeBeck K, 2011, DRUG ALCOHOL DEPEN, V113, P172, DOI 10.1016/j.drugalcdep.2010.07.023; Kerr T, 2006, BRIT MED J, V332, P220, DOI 10.1136/bmj.332.7535.220; Kral AH, 2017, AM J PREV MED, V53, P919, DOI 10.1016/j.amepre.2017.06.010; LEON C, 2017, SUBSTANCE ABUSEL, P1; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; *MASS MED SOC, 2017, EST PIL MED SUP INJ; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Takach, 2016, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20160831.056280/full/, DOI 10.1377/HBLOG20160831.056280/FULL]; WOOD, 2006, N ENGL 4 7ED, V354, P2512	10	2	2	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	2018	168	9					664	666		10.7326/M18-0258	http://dx.doi.org/10.7326/M18-0258			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GI3BZ	29404601				2023-01-03	WOS:000434247300024
J	Vandenberghe, J				Vandenberghe, Joris			Physician-Assisted Suicide and Psychiatric Illness	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NETHERLANDS		[Vandenberghe, Joris] Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium; [Vandenberghe, Joris] Katholieke Univ Leuven, Univ Psychiat Ctr, Leuven, Belgium	KU Leuven; KU Leuven	Vandenberghe, J (corresponding author), Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium.; Vandenberghe, J (corresponding author), Katholieke Univ Leuven, Univ Psychiat Ctr, Leuven, Belgium.							Doernberg SN, 2016, PSYCHOSOMATICS, V57, P556, DOI 10.1016/j.psym.2016.06.005; Kim SYH, 2016, JAMA PSYCHIAT, V73, P362, DOI 10.1001/jamapsychiatry.2015.2887; Tholen AJ, 2009, PHYS ASSISTED SUICID; Vandenberghe J, 2017, VLAAMSE VERENIGING P; Vandenberghe Joris., 2017, EUTHANASIA ASSISTED, P150	5	24	24	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2018	378	10					885	887		10.1056/NEJMp1714496	http://dx.doi.org/10.1056/NEJMp1714496			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FY4CY	29514019				2023-01-03	WOS:000426770200003
J	Davis, MI; Crittenden, JR; Feng, AY; Kupferschmidt, DA; Naydenov, A; Stella, N; Graybiel, AM; Lovinger, DM				Davis, Margaret I.; Crittenden, Jill R.; Feng, Austin Y.; Kupferschmidt, David A.; Naydenov, Alipi; Stella, Nephi; Graybiel, Ann M.; Lovinger, David M.			The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra	PLOS ONE			English	Article							MU-OPIOID RECEPTOR; MEDIUM SPINY NEURONS; MATRIX COMPARTMENTS; CB1 RECEPTOR; RAT-BRAIN; BASAL GANGLIA; DOPAMINE-D2 RECEPTORS; TYPE-1 RECEPTORS; GENE-EXPRESSION; MOUSE STRIATUM	Presynaptic cannabinoid-1 receptors (CB1-R) bind endogenous and exogenous cannabinoids to modulate neurotransmitter release. CB1-Rs are expressed throughout the basal ganglia, including striatum and substantia nigra, where they play a role in learning and control of motivated actions. However, the pattern of CB1-R expression across different striatal compartments, microcircuits and efferent targets, and the contribution of different CB1-R-expressing neurons to this pattern, are unclear. We use a combination of conventional techniques and novel genetic models to evaluate CB1-R expression in striosome (patch) and matrix compartments of the striatum, and in nigral targets of striatal medium spiny projection neurons (MSNs). CB1-R protein and mRNA follow a descending dorsolateral-to-ventromedial intensity gradient in the caudal striatum, with elevated expression in striosomes relative to the surrounding matrix. The lateral predominance of striosome CB1-Rs contrasts with that of the classical striosomal marker, the mu opioid receptor (MOR), which is expressed most prominently in rostromedial striosomes. The dorsolateral-to-ventromedial CB1-R gradient is similar to Drd2 dopamine receptor immunoreactivity and opposite to Substance P. This topology of CB1-R expression is maintained downstream in the globus pallidus and substantia nigra. Dense CB1-R-expressing striatonigral fibers extend dorsally within the substantia nigra pars reticulata, and colocalize with bundles of ventrally extending, striosome-targeted, dendrites of dopamine-containing neurons in the substantia nigra pars compacta (striosome- dendron bouquets). Within striatum, CB1-Rs colocalize with fluorescently labeled MSN collaterals within the striosomes. Cre recombinase-mediated deletion of CB1-Rs from cortical projection neurons or MSNs, and MSN-selective reintroduction of CB1-Rs in knockout mice, demonstrate that the principal source of CB1-Rs in dorsolateral striosomes is local MSN collaterals. These data suggest a role for CB1-Rs in caudal dorsolateral striosome collaterals and striosome-dendron bouquet projections to lateral substantia nigra, where they are anatomically poised to mediate presynaptic disinhibition of both striosomal MSNs and midbrain dopamine neurons in response to endocannabinoids and cannabinomimetics.	[Davis, Margaret I.; Feng, Austin Y.; Kupferschmidt, David A.; Lovinger, David M.] NIAAA, Lab Integrat Neurosci, NIH, Bethesda, MD 20892 USA; [Crittenden, Jill R.; Graybiel, Ann M.] MIT, McGovern Inst Brain Res, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Naydenov, Alipi; Stella, Nephi] Univ Washington, Sch Med, Lab Brain Immunol, Seattle, WA USA; [Feng, Austin Y.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Massachusetts Institute of Technology (MIT); University of Washington; University of Washington Seattle; Stanford University	Davis, MI (corresponding author), NIAAA, Lab Integrat Neurosci, NIH, Bethesda, MD 20892 USA.	midavis@mail.nih.gov	Crittenden, Jill/V-5490-2019	Crittenden, Jill/0000-0002-1981-1917; Graybiel, Ann/0000-0002-4326-7720; Davis, Margaret/0000-0002-0489-8351	Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health; CHDI Foundation [A5552]; Saks-Kavanaugh Foundation; National Institute of Mental Health [R01 MH060379]; William N. and Bernice E. Bumpus Foundation Innovation Award [2017.1.1]; Rapid Response Discovery Award RRDA Pilot [2013.1]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000407] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [U42OD012210] Funding Source: NIH RePORTER	Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health; CHDI Foundation; Saks-Kavanaugh Foundation; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); William N. and Bernice E. Bumpus Foundation Innovation Award; Rapid Response Discovery Award RRDA Pilot; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health; CHDI Foundation Grant #A5552 http://chdifoundation.org/; Saks-Kavanaugh Foundation; National Institute of Mental Health R01 MH060379 Dr. Ann M. Graybiel; William N. and Bernice E. Bumpus Foundation Innovation Award 2017.1.1 Dr. Jill R. Crittenden; William N. and Bernice E. Bumpus Foundation Innovation Award 2017.1.1 Dr. Ann M. Graybiel; Rapid Response Discovery Award RRDA Pilot:2013.1 Dr. Ann M. Graybiel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ade KK, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00032; Adermark L, 2009, EUR J NEUROSCI, V29, P32, DOI 10.1111/j.1460-9568.2008.06551.x; Amemori KI, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00047; Balleine BW, 2010, NEUROPSYCHOPHARMACOL, V35, P48, DOI 10.1038/npp.2009.131; Banghart MR, 2015, NEURON, V88, P1227, DOI 10.1016/j.neuron.2015.11.010; Biezonski DK, 2015, J COMP NEUROL, V523, P1175, DOI 10.1002/cne.23730; Blume LC, 2013, J NEUROCHEM, V124, P808, DOI 10.1111/jnc.12139; Brimblecombe KR, 2015, J NEUROSCI, V35, P9017, DOI 10.1523/JNEUROSCI.0870-15.2015; Bubser M, 2002, EUR J NEUROSCI, V15, P713, DOI 10.1046/j.1460-9568.2002.01903.x; Canales JJ, 2000, ANN NEUROL, V47, pS53; Cazorla M, 2014, NEURON, V81, P153, DOI 10.1016/j.neuron.2013.10.041; CHARUCHINDA C, 1987, J NEUROSCI, V7, P1352; Corbille AG, 2007, J NEUROSCI, V27, P6937, DOI 10.1523/JNEUROSCI.3936-06.2007; Covey DP, 2017, NEUROPHARMACOLOGY, V124, P52, DOI 10.1016/j.neuropharm.2017.04.033; Crittenden JR, 2016, P NATL ACAD SCI USA, V113, P11318, DOI 10.1073/pnas.1613337113; Crittenden JR, 2017, HDB BASAL GANGLIA ST, P783; Cui YJ, 2014, NAT NEUROSCI, V17, P254, DOI 10.1038/nn.3622; Dang MT, 2006, P NATL ACAD SCI USA, V103, P15254, DOI 10.1073/pnas.0601758103; Davis MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027434; EBLEN F, 1995, J NEUROSCI, V15, P5999; Friedman A, 2017, CELL, V171, P1191, DOI 10.1016/j.cell.2017.10.017; Friedman A, 2015, CELL, V161, P1320, DOI 10.1016/j.cell.2015.04.049; Fujiyama F, 2011, EUR J NEUROSCI, V33, P668, DOI 10.1111/j.1460-9568.2010.07564.x; Gangarossa G, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00124; Gangarossa G, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00022; GERFEN CR, 1985, J COMP NEUROL, V236, P454, DOI 10.1002/cne.902360404; GERFEN CR, 1984, NATURE, V311, P461, DOI 10.1038/311461a0; Gokce O, 2016, CELL REP, V16, P1126, DOI 10.1016/j.celrep.2016.06.059; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; Gong SC, 2007, J NEUROSCI, V27, P9817, DOI 10.1523/JNEUROSCI.2707-07.2007; Gonzalez B, 2009, J PHARMACOL EXP THER, V328, P822, DOI 10.1124/jpet.108.145425; Gorski JA, 2002, J NEUROSCI, V22, P6309; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Graybiel AM, 2008, ANNU REV NEUROSCI, V31, P359, DOI 10.1146/annurev.neuro.29.051605.112851; Gremel CM, 2016, NEURON, V90, P1312, DOI 10.1016/j.neuron.2016.04.043; Grimsey NL, 2008, J NEUROSCI METH, V171, P78, DOI 10.1016/j.jneumeth.2008.02.014; Gutierrez-Rodriguez A, 2017, J COMP NEUROL, V525, P302, DOI 10.1002/cne.24066; HABER SN, 1985, J COMP NEUROL, V235, P322, DOI 10.1002/cne.902350304; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Hilario MRF, 2007, FRONT INTEGR NEUROSC, V1, DOI [10.3389/neuro.07/006.2007, 10.3389/neuro.07.006.2007]; Hoffman A.F., 2013, COLD SPRING HARB PER, V3, DOI [10.1101/cshperspect.a012237, DOI 10.1101/CSHPERSPECT.A012237]; Hohmann AG, 2000, SYNAPSE, V37, P71, DOI 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K; Horne EA, 2013, EUR J NEUROSCI, V37, P429, DOI 10.1111/ejn.12045; Houchi H, 2005, NEUROPSYCHOPHARMACOL, V30, P339, DOI 10.1038/sj.npp.1300568; Hu SSJ, 2015, HANDB EXP PHARMACOL, V231, P59, DOI 10.1007/978-3-319-20825-1_3; Jedynak JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034227; Julian MD, 2003, NEUROSCIENCE, V119, P309, DOI 10.1016/S0306-4522(03)00070-8; Kearn CS, 2005, MOL PHARMACOL, V67, P1697, DOI 10.1124/mol.104.006882; KENNEDY RT, 1992, J NEUROCHEM, V59, P449, DOI 10.1111/j.1471-4159.1992.tb09391.x; Kincaid AE, 1996, J COMP NEUROL, V374, P578; Kupferschmidt DA, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00006; Lalchandani RR, 2013, J NEUROSCI, V33, P14075, DOI 10.1523/JNEUROSCI.0692-13.2013; LANGER LF, 1989, BRAIN RES, V498, P344, DOI 10.1016/0006-8993(89)91114-1; Lee CR, 2009, J NEURAL TRANSM-SUPP, P71, DOI 10.1007/978-3-211-92660-4_6; LEVEY AI, 1993, P NATL ACAD SCI USA, V90, P8861, DOI 10.1073/pnas.90.19.8861; Lovinger DM, 2010, HBK BEHAV NEUROSCI, V20, P167; Madisen L, 2012, NAT NEUROSCI, V15, P793, DOI 10.1038/nn.3078; MAILLEUX P, 1992, NEUROSCIENCE, V48, P655, DOI 10.1016/0306-4522(92)90409-U; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Martin AB, 2008, NEUROPSYCHOPHARMACOL, V33, P1667, DOI 10.1038/sj.npp.1301558; Mateo Y, 2017, NEURON, V95, P1; Matsuda W, 2009, J NEUROSCI, V29, P444, DOI 10.1523/JNEUROSCI.4029-08.2009; Matyas F, 2006, NEUROSCIENCE, V137, P337, DOI 10.1016/j.neuroscience.2005.09.005; Miura M, 2008, MOL NEUROBIOL, V37, P104, DOI 10.1007/s12035-008-8023-2; Morozov YM, 2013, EUR J NEUROSCI, V38, P2341, DOI 10.1111/ejn.12237; Mulder J, 2008, P NATL ACAD SCI USA, V105, P8760, DOI 10.1073/pnas.0803545105; Munoz-Arenas G, 2015, SYNAPSE, V69, P103, DOI 10.1002/syn.21796; Murray RC, 2014, BRAIN STRUCT FUNCT, V219, P1213, DOI 10.1007/s00429-013-0559-x; Naydenov AV, 2014, NEUROBIOL DIS, V71, P140, DOI 10.1016/j.nbd.2014.08.009; Ophuis RJAO, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00014; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Prensa L, 2001, J NEUROSCI, V21, P7247, DOI 10.1523/JNEUROSCI.21-18-07247.2001; Saka E, 2004, J NEUROSCI, V24, P7557, DOI 10.1523/JNEUROSCI.1072-04.2004; Sales-Carbonell C, 2013, P NATL ACAD SCI USA, V110, P719, DOI 10.1073/pnas.1217144110; Salinas AG, 2016, NEUROPHARMACOLOGY, V108, P275, DOI 10.1016/j.neuropharm.2016.03.049; Sgobio C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05598-1; Smith JB, 2016, NEURON, V91, P1069, DOI 10.1016/j.neuron.2016.07.046; Tajima K, 2013, NEUROSCIENCE, V241, P215, DOI 10.1016/j.neuroscience.2013.03.012; Taverna S, 2008, J NEUROSCI, V28, P5504, DOI 10.1523/JNEUROSCI.5493-07.2008; Thanos PK, 2011, ALCOHOL CLIN EXP RES, V35, P19, DOI 10.1111/j.1530-0277.2010.01318.x; Thorn CA, 2010, NEURON, V66, P781, DOI 10.1016/j.neuron.2010.04.036; Valjent E, 2001, EUR J NEUROSCI, V14, P342, DOI 10.1046/j.0953-816x.2001.01652.x; Van Waes V, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00021; VANDERWEIDE J, 1987, NEUROSCI LETT, V83, P259, DOI 10.1016/0304-3940(87)90096-6; Watabe-Uchida M, 2012, NEURON, V74, P858, DOI 10.1016/j.neuron.2012.03.017; Winters BD, 2012, P NATL ACAD SCI USA, V109, pE2717, DOI 10.1073/pnas.1206303109; Wouterlood FG, 2012, J COMP NEUROL, V520, P2123, DOI 10.1002/cne.23031; Wu CS, 2010, EUR J NEUROSCI, V32, P693, DOI 10.1111/j.1460-9568.2010.07337.x; Yin HH, 2004, EUR J NEUROSCI, V19, P181, DOI 10.1111/j.1460-9568.2004.03095.x	89	41	41	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2018	13	2							e0191436	10.1371/journal.pone.0191436	http://dx.doi.org/10.1371/journal.pone.0191436			33	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW8RO	29466446	Green Submitted, gold, Green Published			2023-01-03	WOS:000425604300010
J	Gardner, CD; Trepanowski, JF; Del Gobbo, LC; Hauser, ME; Rigdon, J; Ioannidis, JPA; Desai, M; King, AC				Gardner, Christopher D.; Trepanowski, John F.; Del Gobbo, Liana C.; Hauser, Michelle E.; Rigdon, Joseph; Ioannidis, John P. A.; Desai, Manisha; King, Abby C.			Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion The DIETFITS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL GLUCOSE-TOLERANCE; LOW-GLYCEMIC LOAD; BODY-COMPOSITION; RESISTANCE; STRATEGIES; SENSITIVITY; OBESITY; SIZE	IMPORTANCE Dietary modification remains key to successful weight loss. Yet, no one dietary strategy is consistently superior to others for the general population. Previous research suggests genotype or insulin-glucose dynamics may modify the effects of diets. OBJECTIVE To determine the effect of a healthy low-fat (HLF) diet vs a healthy low-carbohydrate (HLC) diet on weight change and if genotype pattern or insulin secretion are related to the dietary effects on weight loss. DESIGN, SETTING, AND PARTICIPANTS The Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) randomized clinical trial included 609 adults aged 18 to 50 years without diabetes with a body mass index between 28 and 40. The trial enrollment was from January 29, 2013, through April 14, 2015; the date of final follow-up was May 16, 2016. Participants were randomized to the 12-month HLF or HLC diet. The study also tested whether 3 single-nucleotide polymorphism multilocus genotype responsiveness patterns or insulin secretion (INS-30; blood concentration of insulin 30 minutes after a glucose challenge) were associated with weight loss. INTERVENTIONS Health educators delivered the behavior modification intervention to HLF (n = 305) and HLC (n = 304) participants via 22 diet-specific small group sessions administered over 12 months. The sessions focused on ways to achieve the lowest fat or carbohydrate intake that could be maintained long-term and emphasized diet quality. MAIN OUTCOMES AND MEASURES Primary outcome was 12-month weight change and determination of whether there were significant interactions among diet type and genotype pattern, diet and insulin secretion, and diet and weight loss. RESULTS Among 609 participants randomized (mean age, 40 [SD, 7] years; 57% women; mean body mass index, 33 [SD, 3]; 244 [40%] had a low-fat genotype; 180 [30%] had a low-carbohydrate genotype; mean baseline INS-30, 93 mu IU/mL), 481 (79%) completed the trial. In the HLF vs HLC diets, respectively, the mean 12-month macronutrient distributions were 48% vs 30% for carbohydrates, 29% vs 45% for fat, and 21% vs 23% for protein. Weight change at 12 months was -5.3 kg for the HLF diet vs -6.0 kg for the HLC diet (mean between-group difference, 0.7 kg [95% CI, -0.2 to 1.6 kg]). There was no significant diet-genotype pattern interaction (P = .20) or diet-insulin secretion (INS-30) interaction (P = .47) with 12-month weight loss. There were 18 adverse events or serious adverse events that were evenly distributed across the 2 diet groups. CONCLUSIONS AND RELEVANCE In this 12-month weight loss diet study, there was no significant difference in weight change between a healthy low-fat diet vs a healthy low-carbohydrate diet, and neither genotype pattern nor baseline insulin secretion was associated with the dietary effects on weight loss. In the context of these 2 common weight loss diet approaches, neither of the 2 hypothesized predisposing factors was helpful in identifying which diet was better for whom.	[Gardner, Christopher D.; Trepanowski, John F.; Del Gobbo, Liana C.; Hauser, Michelle E.; Ioannidis, John P. A.; King, Abby C.] Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, 1265 Welch Rd, Stanford, CA 94305 USA; [Rigdon, Joseph; Desai, Manisha] Stanford Univ, Sch Med, Quantitat Sci Unit, Stanford, CA 94305 USA; [Ioannidis, John P. A.; Desai, Manisha; King, Abby C.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Ioannidis, John P. A.; Desai, Manisha] Stanford Univ, Sch Humanities & Sci, Dept Stat, Stanford, CA 94305 USA; [Ioannidis, John P. A.; Desai, Manisha] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Gardner, CD (corresponding author), Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, 1265 Welch Rd, Stanford, CA 94305 USA.	cgardner@stanford.edu	King, Abby/AAD-5257-2021; Rigdon, Joseph/W-3919-2019; Ioannidis, John P. A./G-9836-2011; Hauser, Michelle/J-9023-2017	Rigdon, Joseph/0000-0001-6265-0752; Hauser, Michelle/0000-0002-0983-7347; Ioannidis, John P./0000-0003-3118-6859; King, Abby/0000-0002-7949-8811	National Institute of Diabetes and Digestive and Kidney Diseases [1R01DK091831]; Nutrition Science Initiative [T32HL007034]; National Heart, Lung, and Blood Institute [1K12GM088033]; Stanford Clinical and Translational Science Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK116074, R01DK091831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM088033] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Nutrition Science Initiative; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Stanford Clinical and Translational Science Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grant 1R01DK091831 from the National Institute of Diabetes and Digestive and Kidney Diseases, grant T32HL007034 from the Nutrition Science Initiative, grant 1K12GM088033 from the National Heart, Lung, and Blood Institute, and the Stanford Clinical and Translational Science Award.	Bandura A., 1997, SELF EFFICACY EXERCI; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Batterham MJ, 2013, NUTRITION, V29, P1024, DOI 10.1016/j.nut.2013.01.017; Bray MS, 2016, OBESITY, V24, P14, DOI 10.1002/oby.21381; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; Chaput JP, 2008, AM J CLIN NUTR, V87, P303, DOI 10.1093/ajcn/87.2.303; Chiu KC, 2002, METABOLISM, V51, P115, DOI 10.1053/meta.2002.29027; Cornier MA, 2005, OBES RES, V13, P703, DOI 10.1038/oby.2005.79; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; Dopler Nelson M, 2010, JOINT C 50 CARD DIS; Ebbeling CB, 2007, JAMA-J AM MED ASSOC, V297, P2092, DOI 10.1001/jama.297.19.2092; FESKANICH D, 1989, COMPUT METH PROG BIO, V30, P47, DOI 10.1016/0169-2607(89)90122-3; Field AE, 2013, JAMA-J AM MED ASSOC, V310, P2147, DOI 10.1001/jama.2013.281501; Flegal KM, 2016, JAMA-J AM MED ASSOC, V315, P2284, DOI 10.1001/jama.2016.6458; Foreyt J P, 1994, Am J Health Promot, V8, P466; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Gardner CD, 2016, OBESITY, V24, P79, DOI 10.1002/oby.21331; Goni L, 2016, J NUTR, V146, p905S, DOI 10.3945/jn.115.218354; Grau K, 2010, AM J CLIN NUTR, V91, P472, DOI 10.3945/ajcn.2009.27947; Heianza Y, 2016, DIABETES CARE, V39, P1909, DOI 10.2337/dc16-1111; Hron BM, 2015, OBESITY, V23, P2216, DOI 10.1002/oby.21213; Johnston BC, 2014, JAMA-J AM MED ASSOC, V312, P923, DOI 10.1001/jama.2014.10397; KING AC, 1989, ARCH INTERN MED, V149, P2741, DOI 10.1001/archinte.149.12.2741; Kuznetsova A., 2016, LMERTEST TESTS LINEA; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; McClain AD, 2013, DIABETES OBES METAB, V15, P87, DOI 10.1111/j.1463-1326.2012.01668.x; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID AM; Pittas AG, 2005, DIABETES CARE, V28, P2939, DOI 10.2337/diacare.28.12.2939; Pittas AG, 2006, NUTR REV, V64, P435, DOI 10.1111/j.1753-4887.2006.tb00174.x; Qi QB, 2012, AM J CLIN NUTR, V95, P506, DOI 10.3945/ajcn.111.025270; Qi QB, 2011, CIRCULATION, V124, P563, DOI 10.1161/CIRCULATIONAHA.111.025767; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Stanton MV, 2017, CONTEMP CLIN TRIALS, V53, P151, DOI 10.1016/j.cct.2016.12.021; Sun X, 2014, JAMA-J AM MED ASSOC, V311, P405, DOI 10.1001/jama.2013.285063; Wallach JD, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5826; Zylke JW, 2016, JAMA-J AM MED ASSOC, V315, P2277, DOI 10.1001/jama.2016.6190	39	287	296	11	139	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2018	319	7					667	679		10.1001/jama.2018.0245	http://dx.doi.org/10.1001/jama.2018.0245			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW7MQ	29466592	Green Published, Bronze			2023-01-03	WOS:000425508400017
J	Bridoux, F; Carron, PL; Pegourie, B; Alamartine, E; Augeul-Meunier, K; Karras, A; Joly, B; Peraldi, MN; Arnulf, B; Vigneau, C; Lamy, T; Wynckel, A; Kolb, B; Royer, B; Rabot, N; Benboubker, L; Combe, C; Jaccard, A; Moulin, B; Knebelmann, B; Chevret, S; Fermand, JP				Bridoux, Frank; Carron, Pierre-Louis; Pegourie, Brigitte; Alamartine, Eric; Augeul-Meunier, Karine; Karras, Alexandre; Joly, Bertrand; Peraldi, Marie-Noelle; Arnulf, Bertrand; Vigneau, Cecile; Lamy, Thierry; Wynckel, Alain; Kolb, Brigitte; Royer, Bruno; Rabot, Nolwenn; Benboubker, Lotfi; Combe, Christian; Jaccard, Arnaud; Moulin, Bruno; Knebelmann, Bertrand; Chevret, Sylvie; Fermand, Jean-Paul		MYRE Study Group	Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FREE LIGHT-CHAINS; ACUTE-RENAL-FAILURE; ACUTE KIDNEY INJURY; DIAGNOSED MULTIPLE-MYELOMA; BORTEZOMIB-BASED REGIMENS; PLASMA-EXCHANGE; IMPAIRMENT; RECOVERY; SERUM; CHEMOTHERAPY	IMPORTANCE Cast nephropathy is the main cause of acute kidney injury in multiple myeloma and persistent reduction in kidney function strongly affects prognosis. Strategies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents have not been evaluated prospectively. OBJECTIVE To compare the hemodialysis independence rate among patients newly diagnosed with myeloma cast nephropathy treated with hemodialysis using a high-cutoff dialyzer (with very large membrane pores and high permeability to immunoglobulin light chains) or a conventional high-flux dialyzer (with small pores and lower permeability). DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial involving 98 patients with biopsy-proven myeloma cast nephropathy requiring hemodialysis treated at 48 French centers between July 2011 and June 2016; the final date of follow-up was June 29, 2016. INTERVENTIONS Intensive hemodialysis (eight 5-hour sessions over 10 days) with either a high-cutoff dialyzer (46 patients) or a conventional high-flux dialyzer (48 patients). All patients received the same chemotherapy regimen of bortezomib and dexamethasone. MAIN OUTCOMES AND MEASURES Primary end point was hemodialysis independence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12 months, hemodialysis- and chemotherapy-related adverse events, and death. RESULTS Among 98 randomized patients, 94 (96%) (median age, 68.8 years [interquartile range, 61.2-75.3 years]; 45% women) were included in the modified intent-to-treat analysis. The hemodialysis independence rate at 3 months was 41.3%(n = 19) in the high-cutoff hemodialysis group vs 33.3%(n = 16) in the conventional hemodialysis group (between-group difference, 8.0%[95% CI, -12.0% to 27.9%], P =.42); at 6 months, the rate was 56.5%(n = 26) vs 35.4%(n = 17), respectively (between-group difference, 21.1% [95% CI, 0.9% to 41.3%], P =.04); and at 12 months, the rate was 60.9%(n = 28) vs 37.5%(n = 18) (between-group difference, 23.4%[95% CI, 3.2% to 43.5%], P =.02). The incidence of hemodialysis-related adverse events was 43% in the high-cutoff hemodialysis group vs 39% in the conventional hemodialysis group; chemotherapy-related serious adverse events, 39% vs 37%, respectively; and at 12 months, 9 patients vs 10 patients died. CONCLUSIONS AND RELEVANCE Among patients with myeloma cast nephropathy treated with a bortezomib-based chemotherapy regimen, the use of high-cutoff hemodialysis compared with conventional hemodialysis did not result in a statistically significant difference in hemodialysis independence at 3 months. However, the study may have been underpowered to identify an early clinically important difference.	[Bridoux, Frank] Ctr Hosp Univ, Ctr Invest Clin 1402, Inst Natl Sante & Rech Med, Dept Nephrol, Poitiers, France; [Bridoux, Frank; Jaccard, Arnaud] Ctr Reference Malad Rares, Poitiers, France; [Bridoux, Frank; Jaccard, Arnaud] Univ Limoges, Unite Mixte Rech 7276, Ctr Natl Rech Sci, Limoges, France; [Carron, Pierre-Louis] Ctr Hosp Univ, Dept Nephrol, Grenoble, France; [Pegourie, Brigitte] Ctr Hosp Univ, Dept Hematol, Grenoble, France; [Alamartine, Eric] Ctr Hosp Univ, Dept Nephrol, St Etienne, France; [Augeul-Meunier, Karine] Ctr Hosp Univ, Dept Hematol, St Etienne, France; [Karras, Alexandre] Hop Europeen Georges Pompidou, AP HP, Dept Nephrol, Paris, France; [Joly, Bertrand] Ctr Hosp Sud Francilien, Dept Hematol, Corbeil Essonnes, France; [Peraldi, Marie-Noelle] Hop St Louis, AP HP, Dept Nephrol, Paris, France; [Arnulf, Bertrand; Fermand, Jean-Paul] Hop St Louis, AP HP, Dept Hematol & Immunol, Inst Natl Sante & Rech Med,Unite Mixte Rech 1126, Paris, France; [Vigneau, Cecile] Ctr Hosp Univ, Dept Nephrol, Rennes, France; [Lamy, Thierry] Ctr Hosp Univ, Dept Hematol, Rennes, France; [Wynckel, Alain] Ctr Hosp Univ, Dept Nephrol, Reims, France; [Kolb, Brigitte] Ctr Hosp Univ, Dept Hematol, Reims, France; [Royer, Bruno] Ctr Hosp Univ, Dept Hematol, Amiens, France; [Rabot, Nolwenn] Ctr Hosp Univ, Dept Nephrol, Tours, France; [Benboubker, Lotfi] Ctr Hosp Univ, Dept Hematol, Tours, France; [Combe, Christian] Ctr Hosp Univ, Dept Nephrol, Bordeaux, France; [Jaccard, Arnaud] Ctr Hosp Univ, Dept Hematol, Limoges, France; [Moulin, Bruno] Ctr Hosp Univ, Dept Nephrol, Strasbourg, France; [Knebelmann, Bertrand] Hop Necker Enfants Malad, AP HP, Dept Nephrol, Paris, France; [Chevret, Sylvie] Paris Diderot Univ, Hop St Louis, AP HP,Unite Mixte Rech ECSTRA Team 1153, Dept Biostat & Med Informat,Inst Natl Sante & Rec, Paris, France	CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Limoges; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU de St Etienne; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Sud Francilien; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; CHU Rennes; CHU de Reims; CHU de Reims; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU Tours; CHU Tours; CHU Bordeaux; CHU Limoges; CHU Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Bridoux, F (corresponding author), Ctr Hosp Univ, Dept Nephrol, 2 Rue Miletrie, F-86021 Poitiers, France.	f.bridoux@chu-poitiers.fr	DECONINCK, ERIC/AAF-3647-2021; vigneau, cecile/I-3178-2015; Herbrecht, Raoul/AAT-1763-2021; Combe, Christian/N-3726-2015	DECONINCK, ERIC/0000-0002-6006-8088; Herbrecht, Raoul/0000-0002-9381-4876; Bridoux, Frank/0000-0002-2005-8424; Maillard, Nicolas/0000-0002-3073-7252; MOULIN, Bruno/0000-0001-6772-7165; Combe, Christian/0000-0002-0360-573X; Delmer, Alain/0000-0002-1430-2574; Alamartine, Eric/0000-0001-7720-8297; burtey, stephane/0000-0003-1813-7884	Programme Hospitalier de Recherche Clinique-Cancer 2009 grant from the French Ministry of Health, French National Hospital Program for Clinical Research Cancer	Programme Hospitalier de Recherche Clinique-Cancer 2009 grant from the French Ministry of Health, French National Hospital Program for Clinical Research Cancer	The study was funded by the Programme Hospitalier de Recherche Clinique-Cancer 2009 grant from the French Ministry of Health, French National Hospital Program for Clinical Research Cancer, 2009. Gambro Dialyzatoren provided the high-cutoff dialyzers used in the study. Janssen France provided bortezomib. The Binding Site company provided kits for measurement of serum-free light chains.	Blade J, 1998, ARCH INTERN MED, V158, P1889, DOI 10.1001/archinte.158.17.1889; Bridoux F, 2015, KIDNEY INT, V87, P698, DOI 10.1038/ki.2014.408; Burnette BL, 2011, NEW ENGL J MED, V364, P2365, DOI 10.1056/NEJMc1101834; Campbell JP, 2013, J IMMUNOL METHODS, V391, P1, DOI 10.1016/j.jim.2013.01.014; Chanan-Khan AA, 2007, BLOOD, V109, P2604, DOI 10.1182/blood-2006-09-046409; Clark WF, 2005, ANN INTERN MED, V143, P777, DOI 10.7326/0003-4819-143-11-200512060-00005; Curti A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159942; Dimopoulos MA, 2016, AM J HEMATOL, V91, P499, DOI 10.1002/ajh.24335; Dimopoulos MA, 2016, J CLIN ONCOL, V34, P1544, DOI 10.1200/JCO.2015.65.0044; Dimopoulos MA, 2009, CLIN LYMPHOMA MYELOM, V9, P302, DOI 10.3816/CLM.2009.n.059; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Ecotiere L, 2016, NEPHROL DIAL TRANSPL, V31, P64, DOI 10.1093/ndt/gfv283; Gerth HU, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154993; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Halekoh U, 2006, J STAT SOFTW, V15, P1, DOI 10.18637/jss.v015.i02; Heyne N, 2012, ANN HEMATOL, V91, P729, DOI 10.1007/s00277-011-1383-0; Hutchison CA, 2016, J AM SOC NEPHROL, V27, p8A, DOI [10.1681/ASN.2015050576, DOI 10.1681/ASN.2015050576]; Hutchison CA, 2007, J AM SOC NEPHROL, V18, P886, DOI 10.1681/ASN.2006080821; Hutchison CA, 2012, NEPHROL DIAL TRANSPL, V27, P3823, DOI 10.1093/ndt/gfr773; Hutchison CA, 2012, NAT REV NEPHROL, V8, P43, DOI 10.1038/nrneph.2011.168; Hutchison CA, 2011, J AM SOC NEPHROL, V22, P1129, DOI 10.1681/ASN.2010080857; Hutchison CA, 2009, CLIN J AM SOC NEPHRO, V4, P745, DOI 10.2215/CJN.04590908; Knudsen LM, 2000, EUR J HAEMATOL, V65, P175, DOI 10.1034/j.1600-0609.2000.90221.x; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Lameire N, 2013, CRIT CARE, V17, DOI 10.1186/cc11455; Leung N, 2008, KIDNEY INT, V73, P1282, DOI 10.1038/ki.2008.108; Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003-4819-145-4-200608150-00004; Lodhi A, 2015, CLIN KIDNEY J, V8, P632, DOI 10.1093/ckj/sfv059; Ludwig H, 2010, J CLIN ONCOL, V28, P4635, DOI 10.1200/JCO.2010.28.1238; Magarotto V, 2016, BLOOD, V127, P1102, DOI 10.1182/blood-2015-08-662627; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Morabito F, 2010, EUR J HAEMATOL, V84, P223, DOI 10.1111/j.1600-0609.2009.01385.x; Nasr SH, 2012, AM J KIDNEY DIS, V59, P786, DOI 10.1053/j.ajkd.2011.12.028; Oiwa K, 2016, ANTICANCER RES, V36, P6655, DOI 10.21873/anticanres.11274; Yadav P, 2016, EUR J HAEMATOL, V96, P610, DOI 10.1111/ejh.12644; Zand L, 2015, LEUKEMIA LYMPHOMA, V56, P3357, DOI 10.3109/10428194.2015.1040011; Zannetti BA, 2015, AM J HEMATOL, V90, P647, DOI 10.1002/ajh.24035	37	77	81	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 5	2017	318	21					2099	2110		10.1001/jama.2017.17924	http://dx.doi.org/10.1001/jama.2017.17924			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO7XT	29209721	Green Published, Bronze			2023-01-03	WOS:000417093500015
J	Topper, MJ; Vaz, M; Chiappinelli, KB; Shields, CED; Niknafs, N; Yen, RWC; Wenzel, A; Hicks, J; Ballew, M; Stone, M; Tran, PT; Zahnow, CA; Hellmann, MD; Anagnostou, V; Strissel, PL; Strick, R; Velculescu, VE; Baylin, SB				Topper, Michael J.; Vaz, Michelle; Chiappinelli, Katherine B.; Shields, Christina E. DeStefano; Niknafs, Noushin; Yen, Ray-Whay Chiu; Wenzel, Alyssa; Hicks, Jessica; Ballew, Matthew; Stone, Meredith; Tran, Phuoc T.; Zahnow, Cynthia A.; Hellmann, Matthew D.; Anagnostou, Valsamo; Strissel, Pamela L.; Strick, Reiner; Velculescu, Victor E.; Baylin, Stephen B.			Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer	CELL			English	Article							HISTONE DEACETYLASE INHIBITOR; REFRACTORY SOLID TUMORS; T-CELL EXHAUSTION; LARGE GENE LISTS; NF-KAPPA-B; DNA METHYLATION; PD-1 BLOCKADE; INTERFERON RESPONSE; PHASE-I; EXPRESSION	Combining DNA-demethylating agents (DNA methyltransferase inhibitors [DNMTis]) with histone deacetylase inhibitors (HDACis) holds promise for enhancing cancer immune therapy. Herein, pharmacologic and isoform specificity of HDACis are investigated to guide their addition to a DNMTi, thus devising a new, low-dose, sequential regimen that imparts a robust anti-tumor effect for non-small-cell lung cancer (NSCLC). Using in-vitro-treated NSCLC cell lines, we elucidate an interferon alpha/beta-based transcriptional program with accompanying upregulation of antigen presentation machinery, mediated in part through double-stranded RNA (dsRNA) induction. This is accompanied by suppression of MYC signaling and an increase in the T cell chemoattractant CCL5. Use of this combination treatment schema in mouse models of NSCLC reverses tumor immune evasion and modulates T cell exhaustion state towards memory and effector T cell phenotypes. Key correlative science metrics emerge for an upcoming clinical trial, testing enhancement of immune checkpoint therapy for NSCLC.	[Topper, Michael J.; Vaz, Michelle; Shields, Christina E. DeStefano; Niknafs, Noushin; Yen, Ray-Whay Chiu; Stone, Meredith; Zahnow, Cynthia A.; Anagnostou, Valsamo; Velculescu, Victor E.; Baylin, Stephen B.] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA; [Topper, Michael J.; Stone, Meredith] Johns Hopkins Univ, Sch Med, Grad Program Cellular & Mol Med, Baltimore, MD 21287 USA; [Ballew, Matthew; Tran, Phuoc T.] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21287 USA; [Chiappinelli, Katherine B.] George Washington Univ, Canc Ctr, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA; [Hellmann, Matthew D.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Strissel, Pamela L.; Strick, Reiner] Univ Clin Erlangen, Lab Mol Med, Dept Gynecol & Obstet, D-91054 Erlangen, Germany; [Hicks, Jessica] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Urol Pathol, Baltimore, MD 21287 USA; [Wenzel, Alyssa] Johns Hopkins Univ, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; George Washington University; Memorial Sloan Kettering Cancer Center; University of Erlangen Nuremberg; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Baylin, SB (corresponding author), Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA.	sbaylin@jhmi.edu	Velculescu, Victor/ABF-4846-2020; Tran, Phuoc/W-2084-2019	Velculescu, Victor/0000-0003-1195-438X; Tran, Phuoc/0000-0002-0147-0376; DeStefano Shields, Christina/0000-0003-4714-3423	Hodson Trust; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Commonwealth Foundation; Stand Up To Cancer Jim Toth Sr. Breakthrough Prize in Lung Cancer; SWCRF Collaboration for a Cure; Defense Health Program (DOD0), through the Department of Defense Ovarian Cancer Research Program, Teal Innovator Award [OC130454/W81XWH-14-1-0385]; National Cancer Institute [CA121113, CA006973, CA180950]; Van Andel Research Institute through the Van Andel Research Institute - Stand Up To Cancer Epigenetics Dream Team; NATIONAL CANCER INSTITUTE [R01CA121113, R01CA166348, P30CA008748, R00CA204592, P30CA006973, U10CA180950] Funding Source: NIH RePORTER	Hodson Trust; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Commonwealth Foundation; Stand Up To Cancer Jim Toth Sr. Breakthrough Prize in Lung Cancer; SWCRF Collaboration for a Cure; Defense Health Program (DOD0), through the Department of Defense Ovarian Cancer Research Program, Teal Innovator Award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Van Andel Research Institute through the Van Andel Research Institute - Stand Up To Cancer Epigenetics Dream Team; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from The Hodson Trust, The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, The Commonwealth Foundation, Stand Up To Cancer Jim Toth Sr. Breakthrough Prize in Lung Cancer, and the SWCRF Collaboration for a Cure. This work is also supported by The Defense Health Program (DOD0), through the Department of Defense Ovarian Cancer Research Program, Teal Innovator Award No. OC130454/W81XWH-14-1-0385 (opinions, interpretations, conclusions, and recommendations are those of the author and not necessarily endorsed by the Department of Defense). Research reported in this publication was supported by the National Cancer Institute under award numbers CA121113, CA006973, and CA180950. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Research funding was also provided by the Van Andel Research Institute through the Van Andel Research Institute - Stand Up To Cancer Epigenetics Dream Team. Stand Up To Cancer is a program of the Entertainment Industry Foundation, administered by AACR. We acknowledge Mrs. Elizabeth Stiegler and Lauren Murphy for expert technical help. We thank Kathy Bender for help with manuscript preparation. V.E.V. is a founder of Personal Genome Diagnostics, a member of its Scientific Advisory Board and Board of Directors, and owns Personal Genome Diagnostics stock, which is subject to certain restrictions under university policy. V.E.V. is also on the Scientific Advisory Board for Ignyta.	Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828; Asthana J, 2013, J BIOL CHEM, V288, P22516, DOI 10.1074/jbc.M113.489328; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Cai Y, 2014, ONCOGENE, V33, P2157, DOI 10.1038/onc.2013.178; Cai Y, 2017, GENOME RES, V27, P533, DOI 10.1101/gr.208108.116; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Furlan A, 2011, MOL MED, V17, P353, DOI 10.2119/molmed.2011.00020; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461; Hong M, 2011, CANCER RES, V71, P6997, DOI 10.1158/0008-5472.CAN-11-1466; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang YH, 2013, CANCER RES, V73, P2943, DOI 10.1158/0008-5472.CAN-12-4354; Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755; Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782; Malvaez M, 2013, P NATL ACAD SCI USA, V110, P2647, DOI 10.1073/pnas.1213364110; Moran CJ, 2002, CLIN CANCER RES, V8, P3803; Moreno-Bost A, 2011, CYTOTHERAPY, V13, P618, DOI 10.3109/14653249.2010.529893; Oi S, 2009, J NEURO-ONCOL, V92, P15, DOI 10.1007/s11060-008-9732-0; Okayama H, 2013, INT J CANCER, V132, P9, DOI 10.1002/ijc.27644; Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056; Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188; Schlee M, 2007, ADV CANCER RES, V97, P167, DOI 10.1016/S0065-230X(06)97007-9; Schlee M, 2007, INT J CANCER, V120, P1387, DOI 10.1002/ijc.22372; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stengel S, 2010, GENE CHROMOSOME CANC, V49, P401, DOI 10.1002/gcc.20751; Strissel PL, 2012, ONCOTARGET, V3, P1204; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542; Zahnow CA, 2016, ADV CANCER RES, V130, P55, DOI 10.1016/bs.acr.2016.01.007; Zehn D, 2015, ADV EXP MED BIOL, V850, P137, DOI 10.1007/978-3-319-15774-0_10	55	235	244	7	64	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 30	2017	171	6					1284	+		10.1016/j.cell.2017.10.022	http://dx.doi.org/10.1016/j.cell.2017.10.022			38	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP1HP	29195073	Green Accepted, Bronze			2023-01-03	WOS:000417362700012
J	Abdel-Naby, W; Cole, B; Liu, AH; Liu, JB; Wan, PX; Schreiner, R; Infanger, DW; Paulson, NB; Lawrence, BD; Rosenblatt, MI				Abdel-Naby, Waleed; Cole, Brigette; Liu, Aihong; Liu, Jingbo; Wan, Pengxia; Schreiner, Ryan; Infanger, David W.; Paulson, Nicholas B.; Lawrence, Brian D.; Rosenblatt, Mark I.			Treatment with solubilized Silk-Derived Protein (SDP) enhances rabbit corneal epithelial wound healing	PLOS ONE			English	Article							AMNIOTIC MEMBRANE; FIBROIN; MATRIX; BIOMATERIALS; ARCHITECTURE; SUBSTRATE	There is a significant clinical need to improve current therapeutic approaches to treat ocular surface injuries and disease, which affect hundreds of millions of people annually worldwide. The work presented here demonstrates that the presence of Silk-Derived Protein (SDP) on the healing rabbit corneal surface, administered in an eye drop formulation, corresponds with an enhanced epithelial wound healing profile. Rabbit corneas were denuded of their epithelial surface, and then treated for 72-hours with either PBS or PBS containing 5 or 20 mg/mL SDP in solution four times per day. Post-injury treatment with SDP formulations was found to accelerate the acute healing phase of the injured rabbit corneal epithelium. In addition, the use of SDP corresponded with an enhanced tissue healing profile through the formation of a multi-layered epithelial surface with increased tight junction formation. Additional biological effects were also revealed that included increased epithelial proliferation, and increased focal adhesion formation with a corresponding reduction in the presence of MMP-9 enzyme. These in vivo findings demonstrate for the first time that the presence of SDP on the injured ocular surface may aid to improve various steps of rabbit corneal wound healing, and provides evidence that SDP may have applicability as an ingredient in therapeutic ophthalmic formulations.	[Abdel-Naby, Waleed] Cornell Univ, Dept Biomed Engn, Ithaca, NY USA; [Abdel-Naby, Waleed; Cole, Brigette; Liu, Aihong; Liu, Jingbo; Wan, Pengxia; Schreiner, Ryan] Weill Cornell Med Coll, Dept Ophthalmol, New York, NY USA; [Infanger, David W.; Paulson, Nicholas B.; Lawrence, Brian D.] Silk Technol Ltd, Dept Res, Plymouth, MN 55447 USA; [Rosenblatt, Mark I.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60607 USA	Cornell University; Cornell University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lawrence, BD (corresponding author), Silk Technol Ltd, Dept Res, Plymouth, MN 55447 USA.; Rosenblatt, MI (corresponding author), Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60607 USA.	brianlawrence@silk-tech.com; mrosenbl@uic.edu	Lawrence, Brian David/AAI-9088-2020	Schreiner, Ryan/0000-0002-7457-6606	Silk Technologies, Ltd.; Research to Prevent Blindness; NSF [DGE-1144153]; NSF SBIR [IIP-1013484]; DOD-DHA SBIR [W81XWH-16-C-0063]; Army SBIR [A151-061-0107]	Silk Technologies, Ltd.; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); NSF(National Science Foundation (NSF)); NSF SBIR(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG)); DOD-DHA SBIR; Army SBIR	Three of the authors (BL, DI, NP) are employed by the commercial company Silk Technologies, Ltd. Silk Technologies, Ltd. provided support in the form of salaries for authors (BL, DI, NP), institutional overhead, and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of these authors are articulated in the 'author contributions' section. This work was supported by a Research to Prevent Blindness Career Development ward to MR, NSF Graduate Research Fellowship Award DGE-1144153 to WA, NSF SBIR Phase II award number IIP-1013484 to BL, DOD-DHA SBIR Phase II award number W81XWH-16-C-0063 to BL, Army SBIR Phase I award number A151-061-0107 to BL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Funding for this work was from Research to Prevent Blindness Career Development Award, NSF Graduate Research Fellowship Award DGE-1144153, NSF SBIR Phase II award number IIP-1013484, DOD-DHA SBIR Phase II award number W81XWH-16-C-0063, Army SBIR Phase I award number A151-061-0107. hCLE cell line provided courtesy of Dr. Ilene Gipson. Silk Technologies, Ltd. kindly provided the SDP solution.	Abdel-Naby W., 2017, INVESTIGATIVE OPHTHA, V58; Agrawal Vinay B, 2003, Indian J Ophthalmol, V51, P5; Bray LJ, 2011, BIOMATERIALS, V32, P5086, DOI 10.1016/j.biomaterials.2011.03.068; Chirila TV, 2008, TISSUE ENG PT A, V14, P1203, DOI [10.1089/ten.tea.2007.0224, 10.1089/tea.2007.0224]; Chon JW, 2012, INT J MOL MED, V30, P1203, DOI 10.3892/ijmm.2012.1120; Cutler TJ, 2004, VET CLIN N AM-EQUINE, V20, P319, DOI 10.1016/j.cveq.2004.04.014; Dieckow J., 2011, OCUL SURF, V9, P3; Fraunfelder FW, 2006, CORNEA, V25, P1133, DOI 10.1097/01.ico.0000240084.27663.fd; Garrett Q, 2008, CURR EYE RES, V33, P567, DOI 10.1080/02713680802140213; Geiger B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005033; Gicquel JJ, 2009, TISSUE ENG PT A, V15, P1919, DOI 10.1089/ten.tea.2008.0432; Gong Y., 2016, PLOS ONE, V11; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harkin DG, 2011, BIOMATERIALS, V32, P2445, DOI 10.1016/j.biomaterials.2010.12.041; Hopkinson A, 2006, INVEST OPHTH VIS SCI, V47, P4316, DOI 10.1167/iovs.05-1415; Hu CL, 2008, INT J FOOD ENG, V4, DOI 10.2202/1556-3758.1298; Irina S. Barequet, 2014, CORNEA, V33; Jia L, 2016, J BIOMED MATER RES B, V104, P431, DOI 10.1002/jbm.b.33408; Kim DW, 2012, J MICROBIOL BIOTECHN, V22, P494, DOI 10.4014/jmb.1111.11024; Kim JC, 2014, PFLUGERS ARCH, V7, P1; Lan WW, 2012, OCUL SURF, V10, P137, DOI 10.1016/j.jtos.2012.04.001; Lawrence B, 2016, US Patent Office, Patent No. [US9394355, 9394355]; Lawrence BD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050190; Lawrence BD, 2009, BIOMATERIALS, V30, P1299, DOI 10.1016/j.biomaterials.2008.11.018; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Liu JB, 2012, INVEST OPHTH VIS SCI, V53, P4130, DOI 10.1167/iovs.12-9876; Market Scope, 2016, DRY EYE PROD REP GLO; Martinez-Mora C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042271; Pflugfelder SC, 2005, AM J PATHOL, V166, P61, DOI 10.1016/S0002-9440(10)62232-8; RHEE D, 1999, WILLS EYE MANUAL OFF; Sengupta S, 2010, BIOMACROMOLECULES, V11, P3592, DOI 10.1021/bm101054q; Stepp MA, 2006, EXP EYE RES, V83, P3, DOI 10.1016/j.exer.2006.01.010; Sugrue SP, 1997, EXP EYE RES, V64, P11, DOI 10.1006/exer.1996.0175; Suzuki K, 2003, PROG RETIN EYE RES, V22, P113, DOI 10.1016/S1350-9462(02)00042-3; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013; Whitcher JP, 2001, B WORLD HEALTH ORGAN, V79, P214; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Wray LS, 2011, J BIOMED MATER RES B, V99B, P89, DOI 10.1002/jbm.b.31875; Zainuddin, 2008, BIOMATERIALS, V29	40	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2017	12	11							e0188154	10.1371/journal.pone.0188154	http://dx.doi.org/10.1371/journal.pone.0188154			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN1NI	29155856	gold, Green Published, Green Submitted			2023-01-03	WOS:000415756700032
J	Pawlowska, S; Nakielski, P; Pierini, F; Piechocka, IK; Zembrzycki, K; Kowalewski, TA				Pawlowska, Sylwia; Nakielski, Pawel; Pierini, Filippo; Piechocka, Izabela K.; Zembrzycki, Krzysztof; Kowalewski, Tomasz A.			Lateral migration of electrospun hydrogel nanofilaments in an oscillatory flow	PLOS ONE			English	Article							SHEAR-INDUCED MIGRATION; POISEUILLE FLOW; INERTIAL MIGRATION; POLYMER-SOLUTIONS; ACTIN-FILAMENTS; FLEXIBLE FIBERS; RIGID SPHERES; DYNAMICS; DNA; FLUID	The recent progress in bioengineering has created great interest in the dynamics and manipulation of long, deformable macromolecules interacting with fluid flow. We report experimental data on the cross-flow migration, bending, and buckling of extremely deformable hydrogel nanofilaments conveyed by an oscillatory flow into a microchannel. The changes in migration velocity and filament orientation are related to the flow velocity and the filament's initial position, deformation, and length. The observed migration dynamics of hydrogel filaments qualitatively confirms the validity of the previously developed worm-like bead-chain hydrodynamic model. The experimental data collected may help to verify the role of hydrodynamic interactions in molecular simulations of long molecular chains dynamics.	[Pawlowska, Sylwia; Nakielski, Pawel; Pierini, Filippo; Piechocka, Izabela K.; Zembrzycki, Krzysztof; Kowalewski, Tomasz A.] Polish Acad Sci, Inst Fundamental Technol Res, Dept Biosyst & Soft Matter, Warsaw, Poland	Polish Academy of Sciences; Institute of Fundamental Technological Research of the Polish Academy of Sciences	Pawlowska, S; Kowalewski, TA (corresponding author), Polish Acad Sci, Inst Fundamental Technol Res, Dept Biosyst & Soft Matter, Warsaw, Poland.	spaw@ippt.pan.pl; tkowale@ippt.pan.pl	Piechocka, Izabela Katarzyna/L-3079-2014; Pawłowska, Sylwia/HIK-1653-2022; Nakielski, Pawel/A-2077-2013; Kowalewski, Tomasz Aleksander/F-2055-2011; Pierini, Filippo/B-5328-2019	Piechocka, Izabela Katarzyna/0000-0002-2877-3924; Nakielski, Pawel/0000-0001-6194-701X; Kowalewski, Tomasz Aleksander/0000-0002-3664-9659; Pierini, Filippo/0000-0002-6526-4141	Polish National Science Center (NCN) [2015/17/N/ST8/02012]; EC structural funds of the Center for Preclinical Research and Technology (CePT), POIG [02.02.00-17-024/08-00]; EC structural funds of the Biocentrum Ochota [POIG.02.03.00-00-003/09-00]	Polish National Science Center (NCN); EC structural funds of the Center for Preclinical Research and Technology (CePT), POIG; EC structural funds of the Biocentrum Ochota	This work was supported by Polish National Science Center (NCN), grant no. 2015/17/N/ST8/02012. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was financially supported by the Polish National Science Center (NCN, grant no. 2015/17/N/5T8/02012). The experiments were performed using apparatus available thanks to the EC structural funds in framework of the Center for Preclinical Research and Technology (CePT), POIG Nr. 02.02.00-17-024/08-00. The computational resources were made available thanks to the EC structural funds in framework of the Biocentrum Ochota, POIG.02.03.00-00-003/09-00.	Bloom KS, 2008, CHROMOSOMA, V117, P103, DOI 10.1007/s00412-007-0138-0; Broedersz CP, 2014, REV MOD PHYS, V86, P995, DOI 10.1103/RevModPhys.86.995; CHAKRABORTY K, 2013, J CHEM PHYS, V139, DOI DOI 10.1063/1.4769980; CHAN PCH, 1979, J FLUID MECH, V92, P131, DOI 10.1017/S0022112079000562; CHAUDHURY K, 2016, PHYS REV E, V93, DOI DOI 10.1063/1.2176587; CHELAKKOT R, 2010, EPL-EUROPHYS LETT, V91, P17060, DOI DOI 10.1017/S0022112006000243; Chen YL, 2014, RSC ADV, V4, P17908, DOI 10.1039/c4ra00837e; Chen YJ, 2014, P NATL ACAD SCI USA, V111, P17396, DOI 10.1073/pnas.1415685111; Chen YL, 2005, MACROMOLECULES, V38, P6680, DOI 10.1021/ma050238d; Chun B, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2176587; Corbin EA, 2013, BIOMED MICRODEVICES, V15, P311, DOI 10.1007/s10544-012-9730-z; DEPABLO JJ, 1992, AICHE J, V38, P273, DOI 10.1002/aic.690380213; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; Doyle PS, 2000, PHYS REV LETT, V84, P4769, DOI 10.1103/PhysRevLett.84.4769; Elbaum M, 1996, PHYS REV LETT, V76, P4078, DOI 10.1103/PhysRevLett.76.4078; Fahraeus R, 1929, PHYSIOL REV, V9, P241, DOI 10.1152/physrev.1929.9.2.241; Farutin A, 2016, SOFT MATTER, V12, P7307, DOI 10.1039/c6sm00819d; GAUTHIER F J, 1972, Biorheology, V9, P205; Geng Y, 2007, NAT NANOTECHNOL, V2, P249, DOI 10.1038/nnano.2007.70; Gerashchenko S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.038304; Gittes F, 1996, BIOPHYS J, V70, P418, DOI 10.1016/S0006-3495(96)79585-1; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Graham MD, 2011, ANNU REV FLUID MECH, V43, P273, DOI 10.1146/annurev-fluid-121108-145523; Guo ZJ, 2008, J PHYS CHEM B, V112, P16163, DOI 10.1021/jp806260h; Harasim M, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.108302; Herczynski R, 2016, ARCH MECH, V68, P81; HILLER W, 1987, EXP FLUIDS, V5, P141, DOI 10.1007/BF00776185; HLADKY SB, 2014, FLUIDS BARRIERS CNS, V11, P17060, DOI DOI 10.1007/S10544-012-9730-Z; HO BP, 1974, J FLUID MECH, V65, P365, DOI 10.1017/S0022112074001431; Izmitli A, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2831777; Jendrejack RM, 2004, J CHEM PHYS, V120, P2513, DOI 10.1063/1.1637331; Jo K, 2009, LAB CHIP, V9, P2348, DOI 10.1039/b902292a; Kantsler V, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.038103; Kirchenbuechler I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6060; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; KUEI S, 2015, NEW J PHYS, V17, DOI DOI 10.1088/0953-8984/19/28/285224; Lamour G, 2014, SOURCE CODE BIOL MED, V9, DOI 10.1186/1751-0473-9-16; Lang PS, 2014, PHYS REV E, V89, DOI 10.1103/PhysRevE.89.022606; LeDuc P, 1999, NATURE, V399, P564, DOI 10.1038/21148; Lei YM, 2017, PROG NEUROBIOL, V157, P230, DOI 10.1016/j.pneurobio.2015.12.007; Lopez HM, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4905920; Ma HB, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2011367; Murrell MP, 2012, P NATL ACAD SCI USA, V109, P20820, DOI 10.1073/pnas.1214753109; Nakielski P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129816; Noding B, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.088101; Pal K, 2009, DES MONOMERS POLYM, V12, P197, DOI 10.1163/156855509X436030; Perez A, 2012, ACCOUNTS CHEM RES, V45, P196, DOI 10.1021/ar2001217; Quennouz N, 2015, J FLUID MECH, V769, P387, DOI 10.1017/jfm.2015.115; Reddig S, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3656070; Sadlej K, 2010, INT J HEAT FLUID FL, V31, P996, DOI 10.1016/j.ijheatfluidflow.2010.02.021; Saintillan D, 2006, J FLUID MECH, V557, P297, DOI 10.1017/S0022112006000243; Schroeder CM, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.018301; SEGRE G, 1962, J FLUID MECH, V14, P136, DOI 10.1017/S0022112062001111; SEGRE G, 1961, NATURE, V189, P209, DOI 10.1038/189209a0; Slowicka AM, 2012, J CHEM PHYS, V136, DOI 10.1063/1.3678852; SLOWICKA AM, 2013, EUR PHYS J E, V36, P17060, DOI DOI 10.1063/1.1637331; Smith DE, 1999, SCIENCE, V283, P1724, DOI 10.1126/science.283.5408.1724; Steinhauser D, 2012, ACS MACRO LETT, V1, P541, DOI 10.1021/mz3000539; Sunyer R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046107; SZYMCZAK P, 2007, J PHYS-CONDENS MAT, V19, DOI DOI 10.1103/PHYSREVLETT.96.038304; Teixeira RE, 2005, MACROMOLECULES, V38, P581, DOI 10.1021/ma048077l; Tornberg AK, 2004, J COMPUT PHYS, V196, P8, DOI 10.1016/j.jcp.2003.10.017; Truong NP, 2015, EXPERT OPIN DRUG DEL, V12, P129, DOI 10.1517/17425247.2014.950564; Vezeridis PS, 2006, BIOCHEM BIOPH RES CO, V348, P1082, DOI 10.1016/j.bbrc.2006.07.146; Wandersman E, 2010, SOFT MATTER, V6, P5715, DOI 10.1039/c0sm00132e; Wang JH, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4769980; Wen Q, 2012, SOFT MATTER, V8, P8039, DOI 10.1039/c2sm25364j; Wiig H, 2012, PHYSIOL REV, V92, P1005, DOI 10.1152/physrev.00037.2011	68	10	11	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2017	12	11							e0187815	10.1371/journal.pone.0187815	http://dx.doi.org/10.1371/journal.pone.0187815			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM7MC	29141043	gold, Green Published, Green Submitted			2023-01-03	WOS:000415260400031
J	Kronenberg, A; Butikofer, L; Odutayo, A; Muhlemann, K; da Costa, BR; Battaglia, M; Meli, DN; Frey, P; Limacher, A; Reichenbach, S; Juni, P				Kronenberg, Andreas; Butikofer, Lukas; Odutayo, Ayodele; Muhlemann, Kathrin; da Costa, Bruno R.; Battaglia, Markus; Meli, Damian N.; Frey, Peter; Limacher, Andreas; Reichenbach, Stephan; Juni, Peter			Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							METAANALYSIS; ANTIBIOTICS; PLACEBO; NITROFURANTOIN; EPIDEMIOLOGY; VALIDATION; RESISTANCE; CYSTITIS; WOMEN	OBJECTIVE To investigate whether symptomatic treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is non-inferior to antibiotics in the treatment of uncomplicated lower urinary tract infection (UTI) in women, thus offering an opportunity to reduce antibiotic use in ambulatory care. DESIGN Randomised, double blind, non-inferiority trial. SETTING 17 general practices in Switzerland. PARTICIPANTS 253 women with uncomplicated lower UTI were randomly assigned 1: 1 to symptomatic treatment with the NSAID diclofenac (n=133) or antibiotic treatment with norfloxacin (n=120). The randomisation sequence was computer generated, stratified by practice, blocked, and concealed using sealed, sequentially numbered drug containers. MAIN OUTCOME MEASURES The primary outcome was resolution of symptoms at day 3 (72 hours after randomisation and 12 hours after intake of the last study drug). The prespecified principal secondary outcome was the use of any antibiotic (including norfloxacin and fosfomycin as trial drugs) up to day 30. Analysis was by intention to treat. RESULTS 72/133 (54%) women assigned to diclofenac and 96/120 (80%) assigned to norfloxacin experienced symptom resolution at day 3 (risk difference 27%, 95% confidence interval 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority). The median time until resolution of symptoms was four days in the diclofenac group and two days in the norfloxacin group. A total of 82 (62%) women in the diclofenac group and 118 (98%) in the norfloxacin group used antibiotics up to day 30 (risk difference 37%, 28% to 46%, P<0.001 for superiority). Six women in the diclofenac group (5%) but none in the norfloxacin group received a clinical diagnosis of pyelonephritis (P=0.03). CONCLUSION Diclofenac is inferior to norfloxacin for symptom relief of UTI and is likely to be associated with an increased risk of pyelonephritis, even though it reduces antibiotic use in women with uncomplicated lower UTI.	[Kronenberg, Andreas; Muhlemann, Kathrin] Univ Bern, Inst Infect Dis, Bern, Switzerland; [Kronenberg, Andreas; Muhlemann, Kathrin] Univ Bern, Bern Univ Hosp, Dept Infect Dis, Bern, Switzerland; [Kronenberg, Andreas; Battaglia, Markus; Meli, Damian N.] Medix Gen Practice Network, Bern, Switzerland; [Butikofer, Lukas; Limacher, Andreas] Univ Bern, CTU Bern, Bern, Switzerland; [Butikofer, Lukas; Limacher, Andreas; Reichenbach, Stephan] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Odutayo, Ayodele; da Costa, Bruno R.; Juni, Peter] Univ Toronto, Dept Med, St Michaels Hosp, Appl Hlth Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Odutayo, Ayodele; da Costa, Bruno R.; Juni, Peter] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [da Costa, Bruno R.; Meli, Damian N.; Frey, Peter; Juni, Peter] Univ Bern, Inst Primary Hlth Care, Bern, Switzerland; [Reichenbach, Stephan] Univ Bern, Bern Univ Hosp, Inselspital, Dept Rheumatol Immunol & Allergol, Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern; University of Bern; University of Bern; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Bern; University of Bern; University Hospital of Bern	Kronenberg, A (corresponding author), Univ Bern, Inst Infect Dis, Bern, Switzerland.; Kronenberg, A (corresponding author), Univ Bern, Bern Univ Hosp, Dept Infect Dis, Bern, Switzerland.; Kronenberg, A (corresponding author), Medix Gen Practice Network, Bern, Switzerland.	andreas.kronenberg@ifik.unibe.ch	Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Butikofer, Lukas/0000-0002-0801-746X; Kronenberg, Andreas/0000-0002-0006-7833	Swiss National Foundation [32003B_130867]; Swiss Academy of Medical Sciences; SwissLife foundation; Else Kroener-Fresenius foundation; Canada research chairs programme	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Swiss Academy of Medical Sciences; SwissLife foundation; Else Kroener-Fresenius foundation; Canada research chairs programme(Canada Research Chairs)	This study was supported by the Swiss National Foundation (project 32003B_130867), Swiss Academy of Medical Sciences, SwissLife foundation, and Else Kroener-Fresenius foundation. PJ is a tier 1 Canada research chair in clinical epidemiology of chronic diseases. This research was completed, in part, with funding from the Canada research chairs programme. The funding bodies were not involved in the design or the conduct of the trial, nor in the writing of the manuscript or the decision to submit the manuscript for publication. The funding bodies only had access to the data after finalisation of the statistical analysis plan and completion of all analyses.	Ahovuo-Saloranta A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000243.pub2; Basille D, 2017, LUNG, V195, P201, DOI 10.1007/s00408-016-9973-1; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Bleidorn J, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-30; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Chow S.C, 2008, SAMPLE SIZE CALCULAT, VSecond; Christiaens TCM, 2002, BRIT J GEN PRACT, V52, P729; Ciragil P, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/269362; Clayson D, 2005, BJU INT, V96, P350, DOI 10.1111/j.1464-410X.2005.05630.x; De Bruyn G, 2000, COCHRANE DB SYST REV, DOI 10.1002/; Del Mar CB, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.cd000023; Falagas ME, 2008, LANCET INFECT DIS, V8, P543, DOI 10.1016/S1473-3099(08)70202-0; Falagas ME, 2009, J INFECTION, V58, P91, DOI 10.1016/j.jinf.2008.12.009; FARKAS A, 1980, J UROLOGY, V124, P455, DOI 10.1016/S0022-5347(17)55493-2; Ferry SA, 2007, SCAND J PRIM HEALTH, V25, P49, DOI 10.1080/02813430601183074; Foxman B, 2003, INFECT DIS CLIN N AM, V17, P227, DOI 10.1016/S0891-5520(03)00005-9; Foxman B, 2002, AM J MED, V113, p5S; Gagyor I, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6544; Genton B, 2007, CLIN INFECT DIS, V44, P1520, DOI 10.1086/517837; Gottesman BS, 2009, CLIN INFECT DIS, V49, P869, DOI 10.1086/605530; Grabe M., 2013, GUIDELINES UROLOGICA; Gupta K, 2007, ARCH INTERN MED, V167, P2207, DOI 10.1001/archinte.167.20.2207; Kjolvmark C, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu004; Lam CW, 2014, CLIN CHIM ACTA, V436, P217, DOI 10.1016/j.cca.2014.05.014; Le Bourgeois M, 2016, J PEDIATR-US, V175, P47, DOI 10.1016/j.jpeds.2016.05.025; Little P, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c199; Little P, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5633; Little P, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13190; Little Paul, 2013, BMJ, V347, pf6041, DOI 10.1136/bmj.f6041; Lundborg CS, 2002, SCAND J INFECT DIS, V34, P442, DOI 10.1080/00365540110080647; Mazumdar K, 2006, IN VIVO, V20, P613; McNulty CAM, 2006, J ANTIMICROB CHEMOTH, V58, P1000, DOI 10.1093/jac/dkl368; Muhlemann K., 2009, SURVEILLANCE ANTIBIO; Obad J, 2015, EUR J PHARM SCI, V71, P93, DOI 10.1016/j.ejps.2015.02.011; Poljakovic M, 2001, KIDNEY INT, V59, P893; Rovers MM, 2006, LANCET, V368, P1429, DOI 10.1016/S0140-6736(06)69606-2; Sanders S, 1999, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000219.PUB2; Schwarz NT, 2002, J UROLOGY, V167, P2603, DOI 10.1016/S0022-5347(05)65045-8; Tan T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a437; Who, 2015, GUID START ANT THER; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	41	78	87	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2017	359								j4784	10.1136/bmj.j4784	http://dx.doi.org/10.1136/bmj.j4784			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM6VM	29113968	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000415199100003
J	Huang, YT; Chang, YL; Chen, CC; Lai, PY; Chan, CK				Huang, Yu-Ting; Chang, Yu-Lin; Chen, Chun-Chung; Lai, Pik-Yin; Chan, C. K.			Positive feedback and synchronized bursts in neuronal cultures	PLOS ONE			English	Article							TERM SYNAPTIC PLASTICITY; REVERBERATORY ACTIVITY; ACTION-POTENTIALS; NETWORKS; MECHANISMS; DYNAMICS; PATTERNS; DENSITY; CALCIUM; CELLS	Synchronized bursts (SBs) with complex structures are common in neuronal cultures. Although the phenomenon of SBs has been discovered for a long time, its origin is still unclear. Here, we investigate the properties of these SBs in cultures grown on a multi -electrode array. We find that structures of these SBs are related to the different developmental stages of the cultures and these structures can be modified by changing the magnesium concentration in the culture medium; indicating that synaptic mechanism is involved in the generation of SBs. A model based on short term synaptic plasticity (STSP), recurrent connections and astrocytic recycling of neurotransmitters has been developed successfully to understand the observed structures of SBs in experiments. A phase diagram obtained from this model shows that networks exhibiting SBs are in a complex oscillatory state due to large enough positive feedback provided by synaptic facilitation and recurrent connections. In this model, while STSP controls the fast oscillations (similar to 100 ms) within a SB, the astrocytic recycling determines the slow time scale (similar to 10 s) of inter-burst intervals. Our study suggests that glia-neuron interactions can be important in the understanding of the complex dynamics of neuronal networks.	[Huang, Yu-Ting; Lai, Pik-Yin; Chan, C. K.] Natl Cent Univ, Dept Phys, Chungli 320, Taiwan; [Huang, Yu-Ting; Lai, Pik-Yin; Chan, C. K.] Natl Cent Univ, Ctr Complex Syst, Chungli 320, Taiwan; [Huang, Yu-Ting; Chang, Yu-Lin; Chen, Chun-Chung; Chan, C. K.] Acad Sinica, Inst Phys, Taipei 115, Taiwan	National Central University; National Central University; Academia Sinica - Taiwan	Lai, PY; Chan, CK (corresponding author), Natl Cent Univ, Dept Phys, Chungli 320, Taiwan.; Lai, PY; Chan, CK (corresponding author), Natl Cent Univ, Ctr Complex Syst, Chungli 320, Taiwan.; Chan, CK (corresponding author), Acad Sinica, Inst Phys, Taipei 115, Taiwan.	pylai@ncu.phy.edu.tw; ckchan@gate.sinica.edu.tw	Chan, Chi-Keung/AAP-7916-2021; Chen, Chun-Chung/A-5905-2008	Chan, Chi-Keung/0000-0002-1496-1086; Chen, Chun-Chung/0000-0002-7664-8300	MOST of ROC [NSC 100-2923-M-001-008-MY3, 102-2112-M-001-009-MY3]	MOST of ROC	This work has been supported by the MOST of ROC under the grant nos. NSC 100-2923-M-001-008-MY3, 102-2112-M-001-009-MY3 and NCTS of Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson CM, 2000, GLIA, V32, P1; Axmacher N, 2006, BRAIN RES REV, V52, P170, DOI 10.1016/j.brainresrev.2006.01.007; Baruchi I, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.050901; Biffi E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083899; Bisio M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107400; Blitz DM, 2004, NAT REV NEUROSCI, V5, P630, DOI 10.1038/nrn1475; Chiappalone M, 2005, NEUROCOMPUTING, V65, P653, DOI 10.1016/j.neucom.2004.10.094; Cohen E, 2008, BRAIN RES, V1235, P21, DOI 10.1016/j.brainres.2008.06.022; Cortes JM, 2013, P NATL ACAD SCI USA, V110, P16610, DOI 10.1073/pnas.1316071110; Czarnecki A, 2012, EUR J NEUROSCI, V35, P375, DOI 10.1111/j.1460-9568.2011.07966.x; De Pitta M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002293; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Gritsun TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043352; Halassa MM, 2010, ANNU REV PHYSIOL, V72, P335, DOI 10.1146/annurev-physiol-021909-135843; Haydon PG, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020438; Hennig MH, 2015, NEURAL INFORM PROCES, P5; Hulata E, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.198105; Ito D, 2010, NEUROSCIENCE, V171, P50, DOI 10.1016/j.neuroscience.2010.08.038; Ivenshitz M, 2010, J NEUROPHYSIOL, V104, P1052, DOI 10.1152/jn.00914.2009; Jia LC, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.088101; Johnson SE, 2015, J NEUROPHYSIOL, V113, P2461, DOI 10.1152/jn.00286.2014; Jolivet R, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004036; Krahe R, 2004, NAT REV NEUROSCI, V5, P13, DOI 10.1038/nrn1296; Lau PM, 2005, P NATL ACAD SCI USA, V102, P10333, DOI 10.1073/pnas.0500717102; MAEDA E, 1995, J NEUROSCI, V15, P6834; Maheswaranathan N, 2012, FRONT COMPUT NEUROSC, V6, DOI 10.3389/fncom.2012.00015; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; Masquelier T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075824; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Mi YY, 2017, NEURON, V93, P323, DOI 10.1016/j.neuron.2016.12.004; Mongillo G, 2008, SCIENCE, V319, P1543, DOI 10.1126/science.1150769; Niedringhaus M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057144; Penn Y, 2016, P NATL ACAD SCI USA, V113, P3341, DOI 10.1073/pnas.1515105113; Poli D, 2015, FRONT NEURAL CIRCUIT, P9; Salinas E, 2001, NAT REV NEUROSCI, V2, P539, DOI 10.1038/35086012; Sara Y, 2002, J NEUROSCI, V22, P1608, DOI 10.1523/JNEUROSCI.22-05-01608.2002; Segev R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.118102; Sibille J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00189; Stephens CL, 2012, EXP NEUROL, V234, P20, DOI 10.1016/j.expneurol.2011.12.009; van Pelt J, 2004, IEEE T BIO-MED ENG, V51, P2051, DOI 10.1109/TBME.2004.827936; Vardi R, 2016, SCI REP-UK, V6, DOI 10.1038/srep36228; Volman V, 2007, PHYS BIOL, V4, P91, DOI 10.1088/1478-3975/4/2/003; Voss LJ, 2010, J NEUROSCI METH, V192, P214, DOI 10.1016/j.jneumeth.2010.07.025; Wagenaar DA, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-11; Wagenaar DA, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.051907; Wilson NR, 2007, J NEUROSCI, V27, P13581, DOI 10.1523/JNEUROSCI.3863-07.2007; Zhan X, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.011907	47	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2017	12	11							e0187276	10.1371/journal.pone.0187276	http://dx.doi.org/10.1371/journal.pone.0187276			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL4VN	29091966	Green Published, Green Submitted, gold			2023-01-03	WOS:000414229700050
J	Fife, D; Cepeda, MS; Baseman, A; Richards, H; Hu, P; Starr, HL; Sena, AG				Fife, Daniel; Cepeda, M. Soledad; Baseman, Alan; Richards, Henry; Hu, Peter; Starr, H. Lynn; Sena, Anthony G.			Medication changes after switching from CONCERTA (R) brand methylphenidate HCI to a generic long-acting formulation: A retrospective database study	PLOS ONE			English	Article							REGRESSION SHRINKAGE; SWITCHBACK RATES; SUBSTITUTION; SELECTION; IMPACT	Background Observational studies of switching from branded to generic formulations of the same drug substance often lack appropriate comparators for the subjects who switched. Three generic formulations were deemed equivalent to Concerta: an authorized generic (AG) identical except for external packaging, and two other generics (EG). Objective Compare the incidence of a combined endpoint (switching back to Concerta, changing the use of immediate release methylphenidate (MPH), stopping all long-acting methylphenidate, or starting a new medication) among people switched from Concerta to the AG versus the EG. Methods Cohort study from the Truven CCAE database of people aged 6 to 65 diagnosed with ADHD, treated with Concerta, and switched to the EG or to the AG formulation. Results In the EG arm 24.6% and in the AG arm 19.7% of subjects switched back to Concerta. The proportion of subjects meeting the combined endpoint was 39.5% in the EG arm, 32.9% in the AG arm, a crude risk ratio of 1.20 (95% CI 0.94, 1.54). After adjustment by propensity score stratification, the adjusted odds ratio (OR) was 1.23 (95% CI 0.90, 1.70). In an unplanned analysis using a different method of adjustment, the adjusted OR was 1.00 (95% CI 0.69, 1.44). Discussion This study did not detect a difference between the proportion of people who met the study endpoint in the two study arms, i.e. between those who switched to a generic formulation that was identical to Concerta except for external packaging and those who switched to the comparison generics. The high incidence of the combined endpoint in the AG arm demonstrates the need for an appropriate comparator in studies of this type.	[Fife, Daniel; Cepeda, M. Soledad; Sena, Anthony G.] Janssen Res & Dev LLC, Epidemiol, Titusville, NJ 08560 USA; [Baseman, Alan] Janssen Res & Dev LLC, Global Med Safety, Horsham, PA USA; [Richards, Henry] Janssen Res & Dev LLC, Established Prod, Titusville, NJ USA; [Hu, Peter] Janssen Res & Dev LLC, Clin Biostat, Raritan, NJ USA; [Starr, H. Lynn] Janssen Sci Affairs LLC, Titusville, NJ USA	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Johnson & Johnson; Janssen Pharmaceuticals	Fife, D (corresponding author), Janssen Res & Dev LLC, Epidemiol, Titusville, NJ 08560 USA.	DFife@jnj.com			Janssen Research & Development, LLC	Janssen Research & Development, LLC	This study was supported by Janssen Research & Development, LLC, who provided financial support for the work in the form of salaries for all the authors, and its commitment to pay the associated publishing fees. Janssen Research & Development, LLC's Standard Operating Procedures require publication of studies that, like this one, concern its products and were intended for publication when they were begun. For the present study, that intention is documented by its registration with ClinicalTrails.gov. The funding organization's Standard Operating Procedures also require that the study undergo a standard internal company review before it is submitted for publication. Internal company review is limited to roles not responsible for sales or marketing functions. Janssen Research & Development, LLC. did not have any additional role in the study design, data collection, analysis, or preparation of the manuscript. The specific roles of the authors are articulated in the 'author contributions' section.	Andermann F, 2007, EPILEPSIA, V48, P464, DOI 10.1111/j.1528-1167.2007.01007.x; ARNOLD P, 1990, Journal of Clinical Research and Pharmacoepidemiology, V4, P139; Banaschewski T, 2016, Z KINDER JUG-PSYCH, V44, P307, DOI 10.1024/1422-4917/a000433; Cheetham TC, 2005, AM J MANAG CARE, V11, P546; Conners CK, 1998, J ABNORM CHILD PSYCH, V26, P257, DOI 10.1023/A:1022602400621; Duh MS, 2009, NEUROLOGY, V72, P2122, DOI 10.1212/WNL.0b013e3181aa5300; Erickson SC, 2011, EPILEPSIA, V52, P1365, DOI 10.1111/j.1528-1167.2011.03130.x; Halkin H, 2007, ANN PHARMACOTHER, V41, P29, DOI 10.1345/aph.1H218; Hansen RA, 2017, PHARMACOTHERAPY, V37, P429, DOI 10.1002/phar.1908; Helin-Salmivaara A, 2012, J CLIN PHARM THER, V37, P58, DOI 10.1111/j.1365-2710.2011.01250.x; Kam-Hansen S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006175; Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023; Lally MD, 2015, CLIN PEDIAT; LeLorier J, 2008, NEUROLOGY, V70, P2179, DOI 10.1212/01.wnl.0000313154.55518.25; Qian J, 2016, CLIN PHARM THER; Schuemie MJ, 2014, STAT MED, V33, P209, DOI 10.1002/sim.5925; Storebo OJ, 2016, Z KINDER JUG-PSYCH, V44, P334, DOI 10.1024/1422-4917/a000472; Storebo OJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009885.pub2; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; Wu EQ, 2011, ANN PHARMACOTHER, V45, P441, DOI 10.1345/aph.1P482	21	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2018	13	2							e0193453	10.1371/journal.pone.0193453	http://dx.doi.org/10.1371/journal.pone.0193453			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX7ND	29489906	Green Published, gold, Green Submitted			2023-01-03	WOS:000426276000078
J	Howell, MD; Davis, AM				Howell, Michael D.; Davis, Andrew M.			Management of ARDS in Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESPIRATORY-DISTRESS-SYNDROME; CLINICAL-PRACTICE GUIDELINE; MECHANICAL VENTILATION; SOCIETY; CARE		[Howell, Michael D.] Google Inc, Google Res, Mountain View, CA 94043 USA; [Davis, Andrew M.] Univ Chicago, Sect Gen Internal Med, Chicago, IL 60637 USA	Google Incorporated; University of Chicago	Howell, MD (corresponding author), Google Inc, Google Res, Mountain View, CA 94043 USA.	mdh@uchicago.edu						Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Ouellette DR, 2017, CHEST, V151, P166, DOI 10.1016/j.chest.2016.10.036; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333	9	30	34	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2018	319	7					711	712		10.1001/jama.2018.0307	http://dx.doi.org/10.1001/jama.2018.0307			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW7MQ	29466577				2023-01-03	WOS:000425508400021
J	Shrestha, M; Moles, R; Ranjit, E; Chaar, B				Shrestha, Mina; Moles, Rebekah; Ranjit, Eurek; Chaar, Betty			Medicine procurement in hospital pharmacies of Nepal: A qualitative study based on the Basel Statements	PLOS ONE			English	Article							LOW-INCOME; HEALTH; CONSEQUENCES; GUIDELINES; COMMITTEES; SHORTAGES; DRUGS; CARE	Background Accessibility and affordability of evidence-based medicines are issues of global concern. For low-income countries like Nepal, it is crucial to have easy and reliable access to affordable, good-quality, evidence-based medicines, especially in the aftermath of natural or man-made disasters. Availability of affordable and evidence-based high quality medicines depends on the medicine procurement procedure, which makes it an important aspect of healthcare delivery. In this study, we aimed to investigate medicine procurement practices in hospital pharmacies of Nepal within the framework of International Pharmaceutical Federation [FIP] hospital pharmacy guidelines "the Basel Statements". Method We conducted semi-structured interviews with hospital pharmacists or procurement officers in hospital pharmacies of four major regions in Nepal to explore procurement practices. Data were collected until saturation of themes, analysed using the framework approach, and organised around the statements within the procurement theme of the Basel Statements. Results Interviews conducted with 53 participants revealed that the procurement guidelines of the Basel Statements were adopted to a certain extent in hospital pharmacies of Nepal. It was found that the majority of hospital pharmacies in Nepal reported using an expensive direct-procurement model for purchasing medicines. Most had no formulary and procured medicines solely based on doctors' prescriptions, which were heavily influenced by pharmaceutical companies' marketing strategies. Whilst most procured only registered medicines, a minority reported purchasing unregistered medicines through unauthorised supply-chains. And although the majority of hospital pharmacies had some contingency plans for managing medicine shortages, a few had none. Conclusions Procurement guidelines of the Basel Statements were thus found to be partially adopted; however, there is room for improvement in current procurement practices in hospital pharmacies of Nepal. Adoption and regulation of national and international policies is recommended for enhancing medicine accessibility, as well as improving preparedness for health emergencies during natural disasters and health epidemics.	[Shrestha, Mina; Moles, Rebekah; Chaar, Betty] Univ Sydney, Fac Pharm, Sydney, NSW, Australia; [Shrestha, Mina; Moles, Rebekah; Ranjit, Eurek; Chaar, Betty] World Hosp Pharm Res Consortium WHoPReC, Kathmandu, Bagmati, Nepal; [Ranjit, Eurek] Kathmandu Med Coll, Dept Pharmacol, Kathmandu, Bagmati, Nepal	University of Sydney	Shrestha, M (corresponding author), Univ Sydney, Fac Pharm, Sydney, NSW, Australia.; Shrestha, M (corresponding author), World Hosp Pharm Res Consortium WHoPReC, Kathmandu, Bagmati, Nepal.	shresthamina@gmail.com						American Medical Association, 2015, AMAS COD MED ETH; American Society of Health System Pharmacists International Pharmaceutical Federation, 2009, AM J HLTH SYST PH S3, V66, pS1; [Anonymous], 2009, AM J HEALTH-SYST PH, V66, pS61, DOI 10.2146/ajhp080666; [Anonymous], 2014, MY REPUBLICA; Arney L, 2014, GLOB HEALTH-SCI PRAC, V2, P295, DOI 10.9745/GHSP-D-14-00068; Baghdadi-Sabeti G, 2010, GOOD GOVERNANCE FOR; Baghdadi-Sabeti G., 2009, MEASURING TRANSPAREN; Barraclough A, 2012, MANAGEMENT SCIENCE F; Bigdeli M, 2013, HEALTH POLICY PLANN, V28, P692, DOI 10.1093/heapol/czs108; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Cameron A., 2011, WORLD MED SITUATION; Condie CK, 2008, AM J HEALTH-SYST PH, V65, P454, DOI 10.2146/ajhp070322; Department of Drug Administration, 2017, GUID SPEC REC MED; Department of Drug Administration, 2007, GUID ETH PROM MED; Dickens T., 2011, WORLD MED SITUATION; Dill S, 2014, EUR J CLIN PHARMACOL, V70, P1405, DOI 10.1007/s00228-014-1747-1; Doloresco F, 2009, AM J HEALTH-SYST PH, V66, pS13, DOI 10.2146/ajhp080674; European Association of Hospital Pharmacists, 2012, WHAT IS HOSPITAL PHA; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Government of Nepal, 2007, NAT MED POL 2007; Government of Nepal, 2014, NAT HLTH POL 2071; Government of Nepal Ministry of Health and Population, 2009, PUBL PROC GUID; Government of Nepal Ministry of Health and Population., 2013, HOSPITAL PHARMACY DI; Government of Nepal Ministry of Health and Population, 2011, NEPAL PHARMACEUTICAL; Hall C, 2012, PATHOG GLOB HEALTH, V106, P73, DOI 10.1179/204777312X13419245939485; Harper I, 2007, DRUG PROCUREMENT NEP; Hatton RC, 2008, PHARMACOTHERAPY, V28, P410, DOI 10.1592/phco.28.3.410; Health Sector Programme Ministry of Health and Population Deutsche Gesellschaft fur Technische Zusammenarbeit., 2009, ESS DRUG PROC SUPPL; Hogerzeil HV, 2006, B WORLD HEALTH ORGAN, V84, P371, DOI 10.2471/BLT.06.031153; Holloway K, 2003, DRUG THERAPEUTIC COM; Hussain Z, 2012, WORKSHOP ON FRAMEWOR; International Council of Nurses International Pharmaceutical Federation World Dental Federation World Medical Association, 2016, BE AWARE HELP FIGHT; Kafle KK, 2010, NEPALESE NATL FORMUL; Levison L., 2003, ESSENT DRUGS MONIT, P31; Manolakis M, 2012, AM J HEALTH-SYST PH, V69, P17, DOI 10.2146/ajhp110640; Mark SM, 2001, AM J HEALTH-SYST PH, V58, P1445, DOI 10.1093/ajhp/58.15.1445; Mason M., 2010, FORUM QUAL SOC RES, V11, P1, DOI DOI 10.17169/FQS-11.3.1428; Medicines Australia, 2015, COD COND; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Milovanovic DR, 2004, EUR J CLIN PHARMACOL, V60, P149, DOI 10.1007/s00228-004-0736-1; Mostert S, 2012, PEDIATR BLOOD CANCER, V58, P325, DOI 10.1002/pbc.23408; Nepal Medical Council, 2016, NMC COD ETH; Nepal Pharmacy Council, 2005, NAT GOOD PHARM PRACT; Nguyen NY, 2013, JAMA INTERN MED, V173, P338, DOI 10.1001/jamainternmed.2013.2522; Noy C, 2008, INT J SOC RES METHOD, V11, P327, DOI 10.1080/13645570701401305; Ombaka E, 2009, AM J HEALTH-SYST PH, V66, pS20, DOI 10.2146/ajhp080604; Penm J, 2014, HEALTH POLICY PLANN, V29, P849, DOI 10.1093/heapol/czt067; Penm J, 2013, AM J HEALTH-SYST PH, V70, P967, DOI 10.2146/ajhp120396; QSR International, 2014, NVIVO 10 WIND GETT S; Rankin J, 1999, OPERATIONAL PRINCIPL; Ritchie J, 2003, QUALITATIVE RES; Roy Nobhojit, 2007, Indian J Med Ethics, V4, P57; Sanyal D, 2015, THE RISING NEPAL; Seiter A, 2009, CLIN PHARMACOL THER, V85, P576, DOI 10.1038/clpt.2009.47; Smith Joanna, 2011, Nurse Res, V18, P52; Spencer L., 2014, QUALITATIVE RESEACH; Thapa BB, 2007, DRUG B NEPAL, V19, P3; The White House Office of Press Secretary, 2011, FACT SHEET OBAMA ADM; Tordoff JM, 2005, VALUE HEALTH, V8, P201, DOI 10.1111/j.1524-4733.2005.04040.x; Transparency International, 2014, CORR COUNTR TERR; Nguyen TA, 2015, HEALTH POLICY PLANN, V30, P267, DOI 10.1093/heapol/czt105; United Kingdom Board of Healthcare Chaplaincy, 2014, COD GOOD SCI PRACT; United Nations Development Programme, 2015, 2014 HUMAN DEVELOPME; United States Pharmacopeia Drug Quality and Information Program, 2007, ENS QUAL MED RES LTD; Vermeulen LC, 2009, AM J HEALTH-SYST PH, V66, pS7, DOI 10.2146/ajhp080690; Ward DJ, 2013, J ADV NURS, V69, P2423, DOI 10.1111/jan.12127; Wertheimer Albert I, 2005, Expert Opin Drug Saf, V4, P619, DOI 10.1517/14740338.4.4.619; Wertheimer AI, 2009, RES SOC ADMIN PHARM, V5, P4, DOI 10.1016/j.sapharm.2008.05.002; WHO, 2007, MOD QUAL ASS SYST PR; WHO Prequalification of Medicines Programme, 2012, WHO DRUG INFORM, V26, P99; World Health Organization, 2014, GOOD GOV MED MOD FRA; World Health Organization, 2014, WHO MOD FORM; World Health Organization, 2016, GUID DEV MEAS COMB C; World Health Organization, 2002, ANTITB OTHER MED PRE; World Health Organization, 2014, NEPAL WHO STATISTICA	75	5	5	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 5	2018	13	2							e0191778	10.1371/journal.pone.0191778	http://dx.doi.org/10.1371/journal.pone.0191778			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU8KH	29401474	Green Submitted, Green Published, gold			2023-01-03	WOS:000424101400019
J	Rutkow, L; Vernick, JS				Rutkow, Lainie; Vernick, Jon S.			Emergency Legal Authority and the Opioid Crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PUBLIC-HEALTH EMERGENCY		[Rutkow, Lainie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Rutkow, L (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.			Rutkow, Helaine/0000-0001-6423-7291				Commission on Combating Drug Addiction and the Opioid Crisis, 2017, INT REP DRAFT; Haffajee R, 2014, NEW ENGL J MED, V371, P986, DOI 10.1056/NEJMp1406167; National Institutes of Health, OV DEATH RAT; Rutkow L, 2017, AM J PUBLIC HEALTH, V107, P240, DOI 10.2105/AJPH.2016.303568; Rutkow L, 2014, AM J PUBLIC HEALTH, V104, P1601, DOI 10.2105/AJPH.2014.301948	5	31	32	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	2017	377	26					2512	2514		10.1056/NEJMp1710862	http://dx.doi.org/10.1056/NEJMp1710862			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR0TX	29140760	Bronze			2023-01-03	WOS:000418777700002
J	Lee, CH; Chang, FC; Hsu, SD; Chi, HY; Huang, LJ; Yeh, MK				Lee, Chun-Hsien; Chang, Fong-Ching; Hsu, Sheng-Der; Chi, Hsueh-Yun; Huang, Li-Jung; Yeh, Ming-Kung			Inappropriate self-medication among adolescents and its association with lower medication literacy and substance use	PLOS ONE			English	Article							HIGH-SCHOOL-STUDENTS; OF-THE-LITERATURE; HEALTH-LITERACY; MEDICINE USE; RISK BEHAVIOR; PRESCRIPTION MEDICATIONS; DRUG-USE; POPULATION; CHILDREN; TAIWAN	Background While self-medication is common, inappropriate self-medication has potential risks. This study assesses inappropriate self-medication among adolescents and examines the relationships among medication literacy, substance use, and inappropriate selfmedication. Method In 2016, a national representative sample of 6,226 students from 99 primary, middle, and high schools completed an online self-administered questionnaire. Multiple logistic regression analysis was used to examine factors related to inappropriate self-medication. Results The prevalence of self-medication in the past year among the adolescents surveyed was 45.8%, and the most frequently reported drugs for self-medication included nonsteroidal anti-inflammatory drugs or pain relievers (prevalence = 31.1%), cold or cough medicines (prevalence = 21.6%), analgesics (prevalence = 19.3%), and antacids (prevalence = 17.3%). Of the participants who practiced self-medication, the prevalence of inappropriate self-medication behaviors included not reading drug labels or instructions (10.1%), using excessive dosages (21.6%), and using prescription and nonprescription medicine simultaneously without advice from a health provider (polypharmacy) (30.3%). The results of multiple logistic regression analysis showed that after controlling for school level, gender, and chronic diseases, the participants with lower medication knowledge, lower self-efficacy, lower medication literacy, and who consumed tobacco or alcohol were more likely to engage in inappropriate self-medication. Conclusion Lower medication literacy and substance use were associated with inappropriate self-medication among adolescents.	[Lee, Chun-Hsien; Chang, Fong-Ching] Natl Taiwan Normal Univ, Dept Hlth Promot & Hlth Educ, Taipei, Taiwan; [Lee, Chun-Hsien] Triserv Gen Hosp, Natl Def Med Ctr, Dept Pharm Practice, Taipei, Taiwan; [Hsu, Sheng-Der] Triserv Gen Hosp, Natl Def Med Ctr, Div Gen Surg, Dept Surg, Taipei, Taiwan; [Chi, Hsueh-Yun] Kainan Univ, Dept Hlth Developing & Mkt, Taoyuan, Taiwan; [Huang, Li-Jung] Chia Nan Univ Pharm & Sci, Tainan, Taiwan; [Yeh, Ming-Kung] Minist Hlth & Welf, Taipei, Taiwan	National Taiwan Normal University; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital; Nan Kai University Technology; Chia Nan University of Pharmacy & Science	Chang, FC (corresponding author), Natl Taiwan Normal Univ, Dept Hlth Promot & Hlth Educ, Taipei, Taiwan.	fongchingchang@ntnu.edu.tw		Hsu, Sheng-Der/0000-0001-9698-8954; Lee, Chun-Hsien/0000-0002-6404-9167	Food and Drug Administration, Ministry of Health and Welfare, Taiwan [105-TFDA-D-061]	Food and Drug Administration, Ministry of Health and Welfare, Taiwan	This work was supported by a research grant from the Food and Drug Administration, Ministry of Health and Welfare, Taiwan (105-TFDA-D-061 to FCC). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abahussain E, 2005, MED PRIN PRACT, V14, P161, DOI 10.1159/000084633; Abahussain NA, 2007, SAUDI MED J, V28, P1723; Abuse S, 2008, NSDUH REPORT MISUSE; Andersen A, 2006, J ADOLESCENT HEALTH, V39, P362, DOI 10.1016/j.jadohealth.2005.12.023; [Anonymous], 1997, AM J HEALTH-SYST PH, V54, P2664; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Bostock S, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1602; Brener ND, 2003, J ADOLESCENT HEALTH, V33, P436, DOI 10.1016/S1054-139X(03)00052-1; Carrasco-Garrido P, 2008, PHARMACOEPIDEM DR S, V17, P193, DOI 10.1002/pds.1455; Chang FC, 2015, J AM PHARM ASSOC, V55, P595, DOI 10.1331/JAPhA.2015.15053; Chi HY, 2014, J FOOD DRUG ANAL, V22, P271, DOI 10.1016/j.jfda.2013.09.013; Chi HY, 2012, J FOOD DRUG ANAL, V20, P561, DOI 10.6227/jfda.2012200301; Choo T, 2008, J DRUG ISSUES, V38, P467, DOI 10.1177/002204260803800205; Cooper RJ, 2013, J SUBST USE, V18, P82, DOI 10.3109/14659891.2011.615002; Davis TC, 2006, ANN INTERN MED, V145, P887, DOI 10.7326/0003-4819-145-12-200612190-00144; DeWalt DA, 2004, J GEN INTERN MED, V19, P1228, DOI 10.1111/j.1525-1497.2004.40153.x; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966; Furu Kari, 2005, Tidsskr Nor Laegeforen, V125, P2759; Gualano MR, 2015, EUR J PUBLIC HEALTH, V25, P444, DOI 10.1093/eurpub/cku207; Hameen-Anttila K, 2010, PHARMACOEPIDEM DR S, V19, P400, DOI 10.1002/pds.1887; Hansen EH, 2003, ANN PHARMACOTHER, V37, P361, DOI 10.1345/aph.1C111; Harris Interactive, 2002, ATTITUDES BELIEFS US; Hsiao YY, 2013, INT J QUAL HEALTH C, V25, P232, DOI 10.1093/intqhc/mzt029; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Hughes GF, 2000, DRUG ABUSE MISUSE CO; Italia S, 2015, PHARMACOEPIDEM DR S, V24, P1133, DOI 10.1002/pds.3829; Kamran A, 2015, INT J PREVENTIVE MED, V6, DOI 10.4103/2008-7802.161264; Kanjanarat P, 2003, AM J HEALTH-SYST PH, V60, P1750, DOI 10.1093/ajhp/60.17.1750; Kirsch I, 1993, ADULT LITERACY AM 1; Kiyingi K, 1992, DRUGS HOME DANGER WA; Kuzman Marina, 2016, Psychiatr Danub, V28 Suppl 2, P223; Lam A, 2006, J AM PHARM ASSOC, V46, P574, DOI 10.1331/1544-3191.46.5.574.Lam; Lee SYD, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-614; Liu C-H, 2016, GLOBAL HLTH PROMOTIO; Lukovic JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114644; MacArthur GJ, 2012, J PUBLIC HEALTH-UK, V34, pI20, DOI 10.1093/pubmed/fds006; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; McCabe SE, 2012, J ADOLESCENT HEALTH, V51, P445, DOI 10.1016/j.jadohealth.2012.02.004; Montagne M, 2013, RES SOC ADMIN PHARM, V9, P609, DOI 10.1016/j.sapharm.2013.04.003; Montastruc JL, 1997, THERAPIE, V52, P105; Ngoh LN, 2009, J AM PHARM ASSOC, V49, pE132, DOI 10.1331/JAPhA.2009.07075; Nutbeam D, 2000, HEALTH PROMOT INT, V15, P259, DOI 10.1093/heapro/15.3.259; Nydert P, 2011, EUR J PEDIATR, V170, P583, DOI 10.1007/s00431-010-1321-5; Saengcharoen W, 2016, INT J PHARM PRACT, V24, P22, DOI 10.1111/ijpp.12201; Sauceda JA, 2012, J AM PHARM ASSOC, V52, pE231, DOI 10.1331/JAPhA.2012.11264; Schabitz WR, 2001, EUR J ANAESTH, V18, P763, DOI 10.1046/j.1365-2346.2001.00913.x; Shehnaz SI, 2014, J ADOLESCENT HEALTH, V55, P467, DOI 10.1016/j.jadohealth.2014.07.001; Shehnaz Syed Ilyas, 2014, Int J Adolesc Med Health, V26, P423, DOI 10.1515/ijamh-2013-0315; Sihvo S, 2000, FAM PRACT, V17, P145, DOI 10.1093/fampra/17.2.145; Steinman KJ, 2006, J ADOLESCENT HEALTH, V38, P445, DOI 10.1016/j.jadohealth.2005.08.010; Stevenson R, 2001, SCOT MED J, V46, P84, DOI 10.1177/003693300104600307; THEO RAYNOR D, 2008, MEDICATION USE INNER; Tobi H, 2003, PHARM WORLD SCI, V25, P203, DOI 10.1023/A:1025836704150; Wazaify M, 2005, FAM PRACT, V22, P170, DOI 10.1093/fampra/cmh723; Weiss B., 1999, 20 COMMON PROBLEMS P; Wood DM, 2010, EMERG MED J, V27, P829, DOI 10.1136/emj.2009.085027; World Health Organization, 2000, REG GUID TEL PROD; Yin HS, 2010, ARCH PEDIAT ADOL MED, V164, P181, DOI 10.1001/archpediatrics.2009.269; Ylinen S, 2010, PHARMACOEPIDEM DR S, V19, P1000, DOI 10.1002/pds.1963; Yousef AMM, 2008, PHARM WORLD SCI, V30, P24, DOI 10.1007/s11096-007-9135-x; Zhong ZQ, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13070720	62	36	36	7	39	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2017	12	12							e0189199	10.1371/journal.pone.0189199	http://dx.doi.org/10.1371/journal.pone.0189199			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FP8OT	29240799	gold, Green Published, Green Submitted			2023-01-03	WOS:000417905600020
J	Grossman, DC; Curry, SJ; Owens, DK; Barry, MJ; Davidson, K; Doubeni, CA; Epling, JW; Kemper, AR; Krist, AH; Kurth, AE; Landefeld, CS; Mangione, CM; Phipps, MG; Silverstein, M; Simon, MA; Tseng, CW				Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael J.; Davidson, KarinaW.; Doubeni, Chyke A.; Epling, John W., Jr.; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Phipps, Maureen G.; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen		US Preventive Serv Task Force	Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; INITIATIVE RANDOMIZED-TRIALS; CONJUGATED EQUINE ESTROGENS; MILD COGNITIVE IMPAIRMENT; ESTROGEN/PROGESTIN REPLACEMENT; CLINICAL ENDOCRINOLOGISTS; CARDIOVASCULAR-DISEASE; AMERICAN ASSOCIATION; URINARY-INCONTINENCE; HEALTH OUTCOMES	IMPORTANCE Menopause occurs at a median age of 51.3 years, and the average US woman who reaches menopause is expected to live another 30 years. The prevalence and incidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and breast cancer, increase with age; however, the excess risk for these conditions that can be attributed to menopause alone is uncertain. Since the publication of findings from the Women's Health Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy has declined. OBJECTIVE To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on the use of menopausal hormone therapy for the primary prevention of chronic conditions. EVIDENCE REVIEW The USPSTF reviewed the evidence on the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal women and whether outcomes vary among women in different subgroups or by timing of intervention after menopause. The review did not address hormone therapy for preventing or treating menopausal symptoms. FINDINGS Although the use of hormone therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, there are also well-documented harms. The USPSTF determined that the magnitude of both the benefits and the harms of hormone therapy in postmenopausal women is small to moderate. Therefore, the USPSTF concluded with moderate certainty that combined estrogen and progestin has no net benefit for the primary prevention of chronic conditions for most postmenopausal women with an intact uterus and that estrogen alone has no net benefit for the primary prevention of chronic conditions for most postmenopausal women who have had a hysterectomy. CONCLUSIONS AND RECOMMENDATION The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy. (D recommendation)	[Grossman, David C.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA 98101 USA; [Curry, Susan J.] Univ Iowa, Iowa City, IA USA; [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA; [Barry, Michael J.] Harvard Med Sch, Boston, MA USA; [Davidson, KarinaW.] Columbia Univ, New York, NY USA; [Doubeni, Chyke A.] Univ Penn, Philadelphia, PA USA; [Epling, John W., Jr.] Virginia Tech, Caril Sch Med, Roanoke, VA USA; [Kemper, Alex R.] Nationwide Childrens Hosp, Columbus, OH USA; [Krist, Alex H.] Fairfax Family Practice Residency, Fairfax, VA USA; [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA USA; [Kurth, Ann E.] Yale Univ, New Haven, CT USA; [Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA; [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA; [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA; [Silverstein, Michael] Boston Univ, Boston, MA 02215 USA; [Simon, Melissa A.] Northwestern Univ, Evanston, IL USA; [Tseng, Chien-Wen] Univ Hawaii, Honolulu, HI 96822 USA; [Tseng, Chien-Wen] Pacific Hlth Res & Educ Inst, Honolulu, HI USA	Kaiser Permanente; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Harvard University; Harvard Medical School; Columbia University; University of Pennsylvania; Virginia Polytechnic Institute & State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Virginia Commonwealth University; Yale University; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; Brown University; Boston University; Northwestern University; University of Hawaii System; Pacific Health Research & Education Institute	Grossman, DC (corresponding author), Kaiser Permanente Washington Hlth Res Inst, Seattle, WA 98101 USA.	david.c.grossman@kp.org	Davidson, Karina/GWC-0996-2022; Davidson, Karina/AAG-2388-2019; Epling, John W/J-1097-2019	Davidson, Karina/0000-0002-9162-477X; Davidson, Karina/0000-0002-9162-477X; Epling, John W/0000-0001-9445-8669; Kemper, Alex/0000-0001-5491-3997	Agency for Healthcare Research and Quality (AHRQ); NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.	American Academy of Family Physicians, 2012, CLIN PREV SERV REC H; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; [Anonymous], 2013, Obstet Gynecol, V121, P1407, DOI 10.1097/01.AOG.0000431053.33593.2d; [Anonymous], 2014, TOT NUMB DISCH AG GR; Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577; Cherry N, 2014, BJOG-INT J OBSTET GY, V121, P700, DOI 10.1111/1471-0528.12598; Cherry N, 2002, LANCET, V360, P2001; Chlebowski RT, 2012, JNCI-J NATL CANCER I, V104, P517, DOI 10.1093/jnci/djs014; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; Cobin RH, 2017, ENDOCR PRACT, V23, P869, DOI 10.4158/EP171828.PS; Ensrud KE, 2013, J GERONTOL A-BIOL, V68, P1236, DOI 10.1093/gerona/glt092; Gartlehner G, 2017, AHRQ PUBLICATION; Goodman NF, 2011, ENDOCR PRACT, V17, P1, DOI 10.4158/EP.17.S6.1; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; LeFevre ML, 2014, ANN INTERN MED, V161, P587, DOI 10.7326/M14-1796; Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; McKinlay SM, 1996, MATURITAS, V23, P137, DOI 10.1016/0378-5122(95)00985-X; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330; Moyer VA, 2013, ANN INTERN MED, V159, P698, DOI [10.7326/0003-4819-159-10-201311190-00717, 10.7326/0003-4819-159-10-201311190-00718]; Pinkerton JV, 2017, MENOPAUSE, V24, P728, DOI 10.1097/GME.0000000000000921; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Social Security Administration, 2014, ACT LIF TABL PER LIF; Steinauer JE, 2005, OBSTET GYNECOL, V106, P940, DOI 10.1097/01.AOG.0000180394.08406.15; Stuenkel CA, 2015, J CLIN ENDOCR METAB, V100, P3975, DOI 10.1210/jc.2015-2236; Tierney MC, 2009, PSYCHONEUROENDOCRINO, V34, P1065, DOI 10.1016/j.psyneuen.2009.02.009; Veerus P, 2006, MATURITAS, V55, P162, DOI 10.1016/j.maturitas.2006.01.012; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239; Waetjen LE, 2005, OBSTET GYNECOL, V106, P946, DOI 10.1097/01.AOG.0000182576.48290.6d; Wathen CN, 2004, CAN MED ASSOC J, V170, P1535, DOI 10.1503/cmaj.1030756; Xu Jiaquan, 2016, Natl Vital Stat Rep, V64, P1	39	96	99	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2017	318	22					2224	2233		10.1001/jama.2017.18261	http://dx.doi.org/10.1001/jama.2017.18261			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP7NR	29234814	Bronze			2023-01-03	WOS:000417822700020
J	Hunter, BR				Hunter, Benton R.			Review: Continuous compression and 30: 2 compression-to-ventilation CPR ratio do not differ for survival	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION; CHEST COMPRESSIONS		[Hunter, Benton R.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Hunter, BR (corresponding author), Indiana Univ Sch Med, Indianapolis, IN 46202 USA.							Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Cheskes S, 2015, RESUSCITATION, V97, P129, DOI 10.1016/j.resuscitation.2015.07.003; Jost D, 2010, CIRCULATION, V121, P1614, DOI 10.1161/CIRCULATIONAHA.109.878389; Li H, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0202-y	4	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2017	167	10					JC51	JC51		10.7326/ACPJC-2017-167-10-051	http://dx.doi.org/10.7326/ACPJC-2017-167-10-051			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO2DP	29159377				2023-01-03	WOS:000416584200003
J	Ma, CH; Avenell, A; Bolland, M; Hudson, J; Stewart, F; Robertson, C; Sharma, P; Fraser, C; MacLennan, G				Ma, Chenhan; Avenell, Alison; Bolland, Mark; Hudson, Jemma; Stewart, Fiona; Robertson, Clare; Sharma, Pawana; Fraser, Cynthia; MacLennan, Graeme			Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LIFE-STYLE INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; ALL-CAUSE MORTALITY; IMPAIRED GLUCOSE-TOLERANCE; BODY-MASS INDEX; TERM-FOLLOW-UP; PRIMARY-CARE; DIABETES PREVENTION; PHYSICAL-ACTIVITY; POSTMENOPAUSAL WOMEN	OBJECTIVE To assess whether weight loss interventions for adults with obesity affect all cause, cardiovascular, and cancer mortality, cardiovascular disease, cancer, and body weight. DESIGN Systematic review and meta-analysis of randomised controlled trials (RCTs) using random effects, estimating risk ratios, and mean differences. Heterogeneity investigated using Cochran's Q and I-2 statistics. Quality of evidence assessed by GRADE criteria. DATA SOURCES Medline, Embase, the Cochrane Central Register of Controlled Trials, and full texts in our trials' registry for data not evident in databases. Authors were contacted for unpublished data. ELIGIBILITY CRITERIA FOR SELECTING STUDIES RCTs of dietary interventions targeting weight loss, with or without exercise advice or programmes, for adults with obesity and follow-up >= 1 year. RESULTS 54 RCTs with 30 206 participants were identified. All but one trial evaluated low fat, weight reducing diets. For the primary outcome, high quality evidence showed that weight loss interventions decrease all cause mortality (34 trials, 685 events; risk ratio 0.82, 95% confidence interval 0.71 to 0.95), with six fewer deaths per 1000 participants (95% confidence interval two to 10). For other primary outcomes moderate quality evidence showed an effect on cardiovascular mortality (eight trials, 134 events; risk ratio 0.93, 95% confidence interval 0.67 to 1.31), and very low quality evidence showed an effect on cancer mortality (eight trials, 34 events; risk ratio 0.58, 95% confidence interval 0.30 to 1.11). Twenty four trials (15 176 participants) reported high quality evidence on participants developing new cardiovascular events 1043 events; risk ratio 0.93, 95% confidence interval 0.83 to 1.04). Nineteen trials (6330 participants) provided very low quality evidence on participants developing new cancers (103 events; risk ratio 0.92, 95% confidence interval 0.63 to 1.36). CONCLUSIONS Weight reducing diets, usually low in fat and saturated fat, with or without exercise advice or programmes, may reduce premature all cause mortality in adults with obesity.	[Ma, Chenhan; Avenell, Alison; Hudson, Jemma; Stewart, Fiona; Robertson, Clare; Sharma, Pawana; Fraser, Cynthia] Univ Aberdeen, Hlth Serv Res Unit, Hlth Sci Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland; [Bolland, Mark] Univ Auckland, Dept Med, Bone & Joint Res Grp, Private Bag 92 019, Auckland 1142, New Zealand; [MacLennan, Graeme] Univ Aberdeen, Ctr Healthcare Randomised Trials, Hlth Sci Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Auckland; University of Aberdeen	Avenell, A (corresponding author), Univ Aberdeen, Hlth Serv Res Unit, Hlth Sci Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland.	a.avenell@abdn.ac.uk	Bolland, Mark J/A-7554-2008	Bolland, Mark J/0000-0003-0465-2674; MacLennan, Graeme/0000-0002-1039-5646	Chief Scientist Office of the Scottish Government Health and Social Care Directorate; Chief Scientist Office [HSRU1] Funding Source: researchfish	Chief Scientist Office of the Scottish Government Health and Social Care Directorate; Chief Scientist Office	The Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorate.	Abbenhardt C, 2013, J INTERN MED, V274, P163, DOI 10.1111/joim.12062; Abed HS, 2013, JAMA-J AM MED ASSOC, V310, P2050, DOI 10.1001/jama.2013.280521; Ackermann RT, 2015, AM J PUBLIC HEALTH, V105, P2328, DOI 10.2105/AJPH.2015.302641; ANDERSON AS, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G1823; Andrews RC, 2011, LANCET, V378, P129, DOI 10.1016/S0140-6736(11)60442-X; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Ard JD, 2018, J GERONTOL A-BIOL, V73, P73, DOI 10.1093/gerona/glw237; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Avenell A, 2016, PROSPERO PROTOCOL; Aveyard P, 2016, LANCET, V388, P2492, DOI 10.1016/S0140-6736(16)31893-1; Bennett GG, 2012, ARCH INTERN MED, V172, P565, DOI 10.1001/archinternmed.2012.1; Bhopal RS, 2014, LANCET DIABETES ENDO, V2, P218, DOI 10.1016/S2213-8587(13)70204-3; BLONK MC, 1994, DIABETIC MED, V11, P449, DOI 10.1111/j.1464-5491.1994.tb00305.x; Burke V, 2008, NUTR METAB CARDIOVAS, V18, P198, DOI 10.1016/j.numecd.2006.10.004; Casagrande DS, 2014, OBES SURG, V24, P1499, DOI 10.1007/s11695-014-1276-0; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; Daumit GL, 2013, NEW ENGL J MED, V368, P1594, DOI 10.1056/NEJMoa1214530; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; de Vos BC, 2016, AM J CLIN NUTR, V104, P33, DOI 10.3945/ajcn.116.133512; de Vos BC, 2014, EUR J NUTR, V53, P95, DOI 10.1007/s00394-013-0505-y; de Waard F, 1993, Eur J Cancer Prev, V2, P233, DOI 10.1097/00008469-199311000-00016; Di Angelantonio E, 2016, LANCET, V388, P776, DOI 10.1016/S0140-6736(16)30175-1; DiabetesPrev D. Prog Res. Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Elmer PJ, 2006, ANN INTERN MED, V144, P485, DOI 10.7326/0003-4819-144-7-200604040-00007; Fitzgibbon ML, 2010, OBESITY, V18, P2317, DOI 10.1038/oby.2010.47; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Foster-Schubert KE, 2012, OBESITY, V20, P1628, DOI 10.1038/oby.2011.76; Gabriel KKP, 2011, MENOPAUSE, V18, P759, DOI 10.1097/gme.0b013e31820acdcc; Glechner A, 2015, DIABETOLOGIA, V58, P242, DOI 10.1007/s00125-014-3439-x; Goodwin PJ, 2014, J CLIN ONCOL, V32, P2231, DOI 10.1200/JCO.2013.53.1517; Greaves C, 2015, INT J BEHAV NUTR PHY, V12, DOI 10.1186/s12966-014-0159-z; Green CA, 2015, OBESITY, V23, P1995, DOI 10.1002/oby.21205; Guh DP, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-88; HELLER SR, 1988, DIABETIC MED, V5, P552, DOI 10.1111/j.1464-5491.1988.tb01050.x; Hemkens LG, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i493; Heshka S, 2003, JAMA-J AM MED ASSOC, V289, P1792, DOI 10.1001/jama.289.14.1792; Hicks KA, 2015, J AM COLL CARDIOL, V66, P403, DOI 10.1016/j.jacc.2014.12.018; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Horie NC, 2016, J CLIN ENDOCR METAB, V101, P1104, DOI 10.1210/jc.2015-2315; Hunt K, 2014, LANCET, V383, P1211, DOI 10.1016/S0140-6736(13)62420-4; Hydrie MZI, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/867604; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Katula JA, 2013, AM J PREV MED, V44, pS324, DOI 10.1016/j.amepre.2012.12.015; Kostis JB, 1998, AM J CARDIOL, V82, P1501, DOI 10.1016/S0002-9149(98)00694-8; Kritchevsky SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121993; Kwok CS, 2014, INT J CARDIOL, V173, P20, DOI 10.1016/j.ijcard.2014.02.026; Lavie CJ, 2014, J AM COLL CARDIOL, V63, P1345, DOI 10.1016/j.jacc.2014.01.022; Li GW, 2014, LANCET DIABETES ENDO, V2, P474, DOI 10.1016/S2213-8587(14)70057-9; Lindstrom J, 2013, DIABETOLOGIA, V56, P284, DOI 10.1007/s00125-012-2752-5; Logue E, 2005, OBES RES, V13, P917, DOI 10.1038/oby.2005.106; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Ma J, 2013, JAMA INTERN MED, V173, P113, DOI 10.1001/2013.jamainternmed.987; Maruthur NM, 2009, CIRCULATION, V119, P2026, DOI 10.1161/CIRCULATIONAHA.108.809491; Mengham LH, 1999, PRACTICAL DIABETES I, V16, P5, DOI [10.1002/pdi.1960160107, DOI 10.1002/PDI.1960160107]; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Messier SP, 2013, JAMA-J AM MED ASSOC, V310, P1263, DOI 10.1001/jama.2013.277669; Misra A, 2009, J Assoc Physicians India, V57, P163; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nathan DM, 2015, LANCET DIABETES ENDO, V3, P866, DOI 10.1016/S2213-8587(15)00291-0; Nilsson G, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000012; Nissen SE, 2016, ANN INTERN MED, V164, P558, DOI 10.7326/M16-0035; O'Neil PM, 2016, OBESITY, V24, P2269, DOI 10.1002/oby.21616; Ogawa W., 2015, HLTH EVAL PROMOT, V42, P301, DOI [10.7143/jhep.42.301, DOI 10.7143/JHEP.42.301]; Oldroyd JC, 2006, DIABETES RES CLIN PR, V72, P117, DOI 10.1016/j.diabres.2005.09.018; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Patrick K, 2011, ANN BEHAV MED, V42, P391, DOI 10.1007/s12160-011-9296-7; Penn L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-342; Perri MG, 2014, OBESITY, V22, P2293, DOI 10.1002/oby.20832; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Ratner R, 2005, DIABETES CARE, V28, P888, DOI 10.2337/diacare.28.4.888; Rejeski WJ, 2011, ARCH INTERN MED, V171, P880, DOI 10.1001/archinternmed.2010.522; Robertson C, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18350; Rock CL, 2015, J CLIN ONCOL, V33, P3169, DOI 10.1200/JCO.2015.61.1095; Ross R, 2012, ARCH INTERN MED, V172, P414, DOI 10.1001/archinternmed.2011.1972; Runhaar J, 2015, AM J MED, V128, P888, DOI 10.1016/j.amjmed.2015.03.006; Saito T, 2011, ARCH INTERN MED, V171, P1352, DOI 10.1001/archinternmed.2011.275; Schunemann H, 2013, GRADE HDB; Schwingshackl L, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-130; Sedjo RL, 2016, SUPPORT CARE CANCER, V24, P3285, DOI 10.1007/s00520-016-3141-2; Shea MK, 2011, AM J CLIN NUTR, V94, P839, DOI 10.3945/ajcn.110.006379; Shea MK, 2010, J GERONTOL A-BIOL, V65, P519, DOI 10.1093/gerona/glp217; StataCorp, 2015, STAT STAT SOFTW REL; Tobias DK, 2015, LANCET DIABETES ENDO, V3, P968, DOI 10.1016/S2213-8587(15)00367-8; Toobert DJ, 2000, ANN BEHAV MED, V22, P1, DOI 10.1007/BF02895162; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; US Department of Health and Human Services; US Department of Agriculture, 2015, 2015 2020 DIET GUID; UUSITUPA M, 1993, DIABETES RES CLIN PR, V19, P227, DOI 10.1016/0168-8227(93)90118-O; Uusitupa M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005656; VANNINEN E, 1993, DIABETIC MED, V10, P66, DOI 10.1111/j.1464-5491.1993.tb01999.x; VANNINEN E, 1992, AM J CARDIOL, V70, P371, DOI 10.1016/0002-9149(92)90622-6; Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234; Wadden TA, 2011, NEW ENGL J MED, V365, P1969, DOI 10.1056/NEJMoa1109220; Wadden TA, 2011, OBESITY, V19, P1987, DOI 10.1038/oby.2011.230; Wei XL, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-354; West DS, 2011, INT J OBESITY, V35, P259, DOI 10.1038/ijo.2010.138; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; WHO, 2004, LANCET, V363, P902; Wing R, 2013, NEW ENGL J MED, V369, P145, DOI 10.1056/NEJMoa1212914; Wing RR, 2010, J UROLOGY, V184, P1005, DOI 10.1016/j.juro.2010.05.031; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; Yardley L, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/1479-5868-11-67; Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83	104	209	221	2	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	2017	359								j4849	10.1136/bmj.j4849	http://dx.doi.org/10.1136/bmj.j4849			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FN4DL	29138133	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000415953500002
J	Ng, YP; Rashid, A; O'Brien, F				Ng, Yin Ping; Rashid, Abdul; O'Brien, Finian			Determining the effectiveness of a video-based contact intervention in improving attitudes of Penang primary care nurses towards people with mental illness	PLOS ONE			English	Article							HEALTH-CARE; INTERGROUP CONTACT; STIGMATIZING ATTITUDES; CLINICIAN ATTITUDES; NEGATIVE ATTITUDES; PUBLIC STIGMA; DISCRIMINATION; PROFESSIONALS; DEPRESSION; SYMPTOMS	Background Mental illness-related stigma is common, and is associated with poorer outcomes in people with mental illness. This study evaluated the attitudes of primary care nurses towards people with mental illness and its associated factors; and the effectiveness of a short video-based contact intervention (VBCI) in improving these attitudes using a Malay version of the 15-item Opening Minds Stigma Scale for Healthcare Providers (OMS-HC-15-M). Methods A 5-minute VBCI was developed comprising elements of psychoeducation and interviews of people with mental illness and the people they interact with, relating to experience of mental illness and recovery. A pre-post cross-sectional study was conducted on 206 randomly selected primary care nurses in Penang, Malaysia. The OMS-HC-15-M questionnaire was administered before and immediately after participants viewed the VBCI. The difference in mean pre-post VBCI scores using paired t-tests, effect size and standardised response mean (SRM) were obtained. Factors correlating to attitudes were obtained using univariate and multivariate regression analyses. Results Differences in pre-post VBCI score were statistically significant (p<0.001) with a 14% score reduction, a moderate effect size and SRM at 0.97 (0.85-0.11) and 1.1 (0.97-1.2) respectively. By factoring in the Minimal Detectable Change statistic of 7.76, the VBCI produced a significant improvement of attitudes in 30% of the participants. Factors associated with less stigmatising attitudes at baseline were previous psychiatry-related training, desiring psychiatric training, and positive contact with people with mental illness. Conclusions This is the first study in Malaysia to show that a brief VBCI is effective in improving attitudes of primary care nurses towards people with mental illness in the immediate term. Further studies are needed to determine if these results can be sustained in the longer term and generalizable to other health care professionals. Qualitative studies are warranted to provide insight to the factors correlating to these attitudes. (300 words)	[Ng, Yin Ping; O'Brien, Finian] Penang Med Coll, Dept Psychiat, George Town, Malaysia; [Rashid, Abdul] Penang Med Coll, Dept Publ Hlth, George Town, Malaysia		Ng, YP (corresponding author), Penang Med Coll, Dept Psychiat, George Town, Malaysia.	ng.yp@pmc.edu.my	Ng, Wing Yin/HHN-1743-2022	rashid, abdul/0000-0003-1520-8480				Allport Gordon, 1954, NATURE PREJUDICE; Angermeyer MC, 2006, ACTA PSYCHIAT SCAND, V113, P163, DOI 10.1111/j.1600-0447.2005.00699.x; Arnold Maggie, 2008, Nurs Older People, V20, P28; Ashencaen Crabtree S, 2003, J Psychiatr Ment Health Nurs, V10, P713, DOI 10.1046/j.1365-2850.2003.00665.x; Atkin K, 2005, INT J GERIATR PSYCH, V20, P1081, DOI 10.1002/gps.1414; Awani A., 2015, ASTRO; Azma B Nur, 2014, INT J COLLABORATIVE, V6; Baker JA, 2005, J ADV NURS, V49, P522, DOI 10.1111/j.1365-2648.2004.03325.x; Bjorkman T, 2008, SCAND J CARING SCI, V22, P170, DOI 10.1111/j.1471-6712.2007.00509.x; Borges TL, 2016, J AM PSYCHIAT NURSES, V22, P378, DOI 10.1177/1078390316655207; Brown SA, 2008, PSYCHIATR REHABIL J, V32, P89, DOI 10.2975/32.2.2008.89.94; Chambers M, 2010, INT J NURS STUD, V47, P350, DOI 10.1016/j.ijnurstu.2009.08.008; Cheang SI, 2014, PSYCH J, V3, P222, DOI 10.1002/pchj.61; Cheung T, 2015, INT J ENV RES PUB HE, V12, P11072, DOI 10.3390/ijerph120911072; Chong S. T., 2013, ASIAN SOCIAL SCI, V9, P1, DOI [DOI 10.5539/ASS.V9N6P1, DOI 10.5539/ass.v9n6p1]; Clement S, 2015, PSYCHOL MED, V45, P11, DOI 10.1017/S0033291714000129; Corrigan PW, 2012, PSYCHIAT SERV, V63, P963, DOI 10.1176/appi.ps.201100529; Corrigan PW, 2005, PSYCHIAT SERV, V56, P544, DOI 10.1176/appi.ps.56.5.544; Couture Shannon M., 2003, J MENTAL HLTH, V12, P291, DOI [10.1080/09638231000118276, DOI 10.1080/09638231000118276]; DESFORGES DM, 1991, J PERS SOC PSYCHOL, V60, P531, DOI 10.1037/0022-3514.60.4.531; Fernandez A, 2016, ACAD PSYCHIATR, V40, P905, DOI 10.1007/s40596-016-0592-1; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Gabbidon J, 2013, PSYCHIAT RES, V206, P81, DOI 10.1016/j.psychres.2012.09.028; Giandinoto Jo-Ann, 2014, Br J Nurs, V23, P728, DOI 10.12968/bjon.2014.23.13.728; Gillies D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007193.pub2; Goffman, 1963, STIGMA NOTES MANAGEM; Gong YH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07109; Goodwin J, 2014, PERSPECT PSYCHIATR C, V50, P224, DOI 10.1111/ppc.12044; Graves RE, 2011, SCHIZOPHR RES, V130, P271, DOI 10.1016/j.schres.2011.04.019; Gronholm PC, 2017, SOC PSYCH PSYCH EPID, V52, P249, DOI 10.1007/s00127-017-1341-9; Gurugopinath S, 2016, P 8 INT C COMM SYST, P1; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P403, DOI 10.1016/0895-4356(89)90128-5; Haddad M, 2005, J CLIN NURS, V14, P976, DOI 10.1111/j.1365-2702.2005.01196.x; Haley SM, 2006, PHYS THER, V86, P735, DOI 10.1093/ptj/86.5.735; Hanafiah AN, 2015, INT J MENT HEALTH SY, V9, DOI 10.1186/s13033-015-0002-1; Hansson L, 2013, INT J SOC PSYCHIATR, V59, P48, DOI 10.1177/0020764011423176; Haque A, 2010, PSYCHOL HEALTH MED, V15, P127, DOI 10.1080/13548501003615266; Hawke LD, 2014, INT J SOC PSYCHIATR, V60, P741, DOI 10.1177/0020764013513443; Henderson C, 2014, LANCET PSYCHIAT, V1, P467, DOI 10.1016/S2215-0366(14)00023-6; Hopkins W., 1997, NEW VIEW STAT EFFECT; [IfPH IPH], 2015, MOHSIKU5215RR IPH IF; ISLAM MR, 1993, PERS SOC PSYCHOL B, V19, P700, DOI 10.1177/0146167293196005; Jones PS, 2001, NURS RES, V50, P300, DOI 10.1097/00006199-200109000-00008; Jorm AF, 2008, ACTA PSYCHIAT SCAND, V118, P315, DOI 10.1111/j.1600-0447.2008.01251.x; Kassam A, 2010, ACTA PSYCHIAT SCAND, V122, P153, DOI 10.1111/j.1600-0447.2010.01562.x; Kassam A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-62; Kassam SP. Aliya, 2013, QUANTITATIVE ANAL ME; Khan TM, 2011, IRAN J PUBLIC HEALTH, V40, P50; Knaak S, 2014, CAN J PSYCHIAT S1, V59, P26; Knaak S HL, 2013, STIGMA OM THATS JUST; Knaak S, 2015, BORDER PERS DIS EMOT, V2, DOI 10.1186/s40479-015-0030-0; Lauber C, 2006, ACTA PSYCHIAT SCAND, V113, P51, DOI 10.1111/j.1600-0447.2005.00718.x; Lauber C, 2007, INT REV PSYCHIATR, V19, P157, DOI 10.1080/09540260701278903; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; Link BG, 2004, SCHIZOPHRENIA BULL, V30, P511, DOI 10.1093/oxfordjournals.schbul.a007098; LINK BG, 1987, AM J SOCIOL, V92, P1461, DOI 10.1086/228672; Luong AS Dorothy, 2013, PROGR PLACE; Martensson G, 2014, J PSYCHIATR MENT HLT, V21, P782, DOI 10.1111/jpm.12145; Middha B, 2002, ISSS'02: 15TH INTERNATIONAL SYMPOSIUM ON SYSTEM SYNTHESIS, P2, DOI 10.1109/ISSS.2002.1227143; Minas H, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-317; Mittal D, 2014, PSYCHIATR REHABIL J, V37, P297, DOI 10.1037/prj0000095; Modgill G, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-120; Mohamad M.S., 2012, ASIAN SOCIAL SCI, V8, P74, DOI 10.5539/ass.v8n9p74; Ndetei DM, 2011, AFR J PSYCHIATRY, V14, P225, DOI [10.4314/ajpsy.v14i3.6, http://dx.doi.org/10.4314/ajpsy.v14i3.6]; Ng J., 2013, THE STORY OF A LENG; Ning Audrey Tan Xiang, 2011, JBI Libr Syst Rev, V9, P1132; Ohler MC, 2010, CAN J NURS RES, V42, P66; Oranye NO, 2016, CONTEMP NURSE, V52, P555, DOI 10.1080/10376178.2016.1194726; Patten SB, 2012, BMC MED EDUC, V12, DOI 10.1186/1472-6920-12-120; Pescosolido BA, 2007, PSYCHIAT SERV, V58, P613, DOI 10.1176/appi.ps.58.5.613; Pettigrew TF, 2008, EUR J SOC PSYCHOL, V38, P922, DOI 10.1002/ejsp.504; Pettigrew TF, 2011, INT J INTERCULT REL, V35, P271, DOI 10.1016/j.ijintrel.2011.03.001; Plummer SE, 2000, PSYCHOL MED, V30, P1233, DOI 10.1017/S0033291799002597; Razali SM, 2014, J MENT HEALTH, V23, P176, DOI 10.3109/09638237.2014.910644; Reilly S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036468; Ross CA, 2009, J PSYCHIATR MENT HLT, V16, P558, DOI 10.1111/j.1365-2850.2009.01399.x; Rusch N, 2014, BRIT J PSYCHIAT, V205, P257, DOI 10.1192/bjp.bp.114.145755; Stefanovics E, 2015, PSYCHIAT Q; Stuart Heather, 2014, Can J Psychiatry, V59, pS13; Suhaimi S N Mohamad Mohd, 2014, PERTANIKA J SOCIAL S, V21, P1; Tanaka G, 2003, PSYCHIAT CLIN NEUROS, V57, P595, DOI 10.1046/j.1440-1819.2003.01173.x; Tay Sim-Eng Clara, 2004, J Psychosoc Nurs Ment Health Serv, V42, P40; Thornicroft G, 2015, LANCET LONDON ENGLAN; van der Kluit Maria Johanna, 2011, Issues Ment Health Nurs, V32, P519, DOI 10.3109/01612840.2011.571360; West K, 2014, J SOC PSYCHOL, V154, P217, DOI 10.1080/00224545.2014.888327; ZamZam Ruzanna, 2009, Int J Ment Health Syst, V3, P13, DOI 10.1186/1752-4458-3-13	86	11	11	4	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2017	12	11							e0187861	10.1371/journal.pone.0187861	http://dx.doi.org/10.1371/journal.pone.0187861			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM4OL	29131841	gold, Green Submitted, Green Published			2023-01-03	WOS:000414997800028
J	Kivelitz, L; Kriston, L; Christalle, E; Schulz, H; Watzke, B; Harter, M; Gotzmann, L; Bailee, H; Zahn, S; Melchior, H				Kivelitz, Laura; Kriston, Levente; Christalle, Eva; Schulz, Holger; Watzke, Birgit; Haerter, Martin; Goetzmann, Lutz; Bailee, Harald; Zahn, Sabine; Melchior, Hanne			Effectiveness of telephone-based aftercare case management for adult patients with unipolar depression compared to usual care: A randomized controlled trial	PLOS ONE			English	Article							MENTAL-DISORDERS; HEALTH-CARE; GERMANY; ANXIETY; SERVICES; IMPROVE; BURDEN; COST	Background Patients with depression often have limited access to outpatient psychotherapy following inpatient treatment. The objective of the study was to evaluate the long-term effectiveness of a telephone-based aftercare case management (ACM) intervention for patients with depression. Methods We performed a prospective randomized controlled trial in four psychotherapeutic inpatient care units with N = 199 patients with major depression or dysthymia (F32.x, F33.x, F34.1, according to the ICD-10). The ACM consisted of six phone contacts at two-week intervals performed by trained and certified psychotherapists. The control group received usual care (UC). The primary outcome was depressive symptom severity (BDI-II) at 9-month follow-up, and secondary outcomes were health-related quality of life (SF-8, EQ-5D), self-efficacy (SWE), and the proportion of patients initiating outpatient psychotherapy. Mixed model analyses were conducted to compare improvements between treatment groups. Results Regarding the primary outcome of symptom severity, the groups did not significantly differ after 3 months (p = .132; ES = -0.23) or at the 9-month follow-up (p = .284; ES = -0.20). No significant differences in health-related quality of life or self-efficacy were found between groups. Patients receiving ACM were more likely to be in outpatient psychotherapy after 3 months (OR: 3.00[1.12-8.07]; p = .029) and 9 months (OR: 4.78 [1.55-14.74]; p = .006) than those receiving UC. Conclusions Although telephone-based ACM did not significantly improve symptom severity, it seems to be a valuable approach for overcoming treatment barriers to the clinical pathways of patients with depression regarding their access to outpatient psychotherapy.	[Kivelitz, Laura; Kriston, Levente; Schulz, Holger; Haerter, Martin; Melchior, Hanne] Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany; [Watzke, Birgit] Univ Zurich, Inst Psychol, Clin Psychol & Psychotherapy Res, Zurich, Switzerland; [Goetzmann, Lutz] Segeberg Hosp, Dept Psychosomat Med & Psychotherapy, Bad Segeberg, Bad Segeberg, Germany; [Bailee, Harald] Luisenklin Zentrum Verhaltensmed, Bad Durrheim, Germany; [Zahn, Sabine] MediClin Seepark Klin, Fachklin Psychosomat Med & Psychotherapie, Bad Bodenteich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Zurich	Kivelitz, L (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany.	l.kivelitz@uke.de	Kriston, Levente/D-1713-2013	Kriston, Levente/0000-0003-0748-264X; Harter, Martin/0000-0001-7443-9890	Germany's Federal Ministry of Education and Research; German Federal Pension Fund as part of the research priority 'Chronic Diseases and Patient Orientation';  [0421-FSCP-Z202]	Germany's Federal Ministry of Education and Research; German Federal Pension Fund as part of the research priority 'Chronic Diseases and Patient Orientation'; 	The study was funded by Germany's Federal Ministry of Education and Research and the German Federal Pension Fund as part of the research priority 'Chronic Diseases and Patient Orientation' (http://www.forschung-patientenoriertierung.de/index.php/home.html). The project was competitively adopted based on a detailed research proposal (grant number: 0421-FSCP-Z202). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barekatain M, 2014, J RES MED SCI, V19, P240; Baron S, 2011, PSYCHIAT PRAX, V38, P342, DOI 10.1055/s-0030-1266091; Beck A.T., 1996, MANUAL BDI 2, DOI [10.1037/t00742-000, DOI 10.1037/T00742-000]; Burcusa SL, 2007, CLIN PSYCHOL REV, V27, P959, DOI 10.1016/j.cpr.2007.02.005; Christensen H, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-25; Collins KA, 2004, CLIN PSYCHOL REV, V24, P583, DOI 10.1016/j.cpr.2004.06.001; Deck R, 2014, REHABILITATION, V53, P305, DOI 10.1055/s-0034-1384594; DGPPNB KBV AWMF AkdA BPtK BApK DAGSHG DEGAM DGPM DGPs DGRW, S3 GUIDL NAT DIS MAN, DOI [10.6101/AZQ/0002622015, DOI 10.6101/AZQ/0002622015]; Dilling H, 1991, INT CLASS DIS; Ellert U, 2005, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V48, P1330, DOI 10.1007/s00103-005-1168-5; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gensichen J, 2006, PSYCHOL MED, V36, P7, DOI 10.1017/S0033291705005568; Gensichen J, 2009, ANN INTERN MED, V151, P369, DOI 10.7326/0003-4819-151-6-200909150-00001; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; Grabe HJ, 2009, SOC PSYCH PSYCH EPID, V44, P835, DOI 10.1007/s00127-009-0005-9; Gunther OH, 2007, PSYCHIAT PRAX, V34, P292, DOI 10.1055/s-2006-940066; Harfst T, 2002, Rehabilitation (Stuttg), V41, P407; Jacobi F, 2014, NERVENARZT, V85, P77, DOI 10.1007/s00115-013-3961-y; Jerusalem M., 1999, SKALEN ERFASSUNG LEH; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kim SE, 2011, AM J MANAG CARE, V17, pE375; Kivelitz L, 2015, PSYCHIAT PRAX, V42, P424, DOI 10.1055/s-0034-1370306; Kivelitz L, 2015, BMC PSYCHIATRY, V15, DOI 10.1186/s12888-015-0469-y; Klesse C, 2007, NERVENARZT, V78, P585, DOI 10.1007/s00115-007-2368-z; Kordy H, 2016, PSYCHOTHER PSYCHOSOM, V85, P91, DOI 10.1159/000441951; Lambert M. J., 2013, BERGIN GARFIELDS HDB, V6th, P169; Lange M., 2011, PHYS MED REHAB KUROR, V21, P1; Lehmann S, 2010, GESUNDHEITSWESEN, V72, pE33, DOI 10.1055/s-0029-1242769; Mack S, 2014, INT J METHODS PSYCHI; Margraf J., 1994, MINI DIPS DIAGNOSTIS; Reiser A., 2013, THESIS; Rosen CS, 2013, PSYCHIAT SERV, V64, P13, DOI 10.1176/appi.ps.201200142; Schneider S., 2011, DIPS DIAGNOSTISCHES, DOI 10.1007/978-3-642-15529-1; Schulz H, 2011, KLIN PSYCHOL PSYCHOT, P361; Simon GE, 2009, ARCH GEN PSYCHIAT, V66, P1081, DOI 10.1001/archgenpsychiatry.2009.123; van den Berg N, 2015, PSYCHOTHER PSYCHOSOM, V84, P82, DOI 10.1159/000369468; Wang PS, 2007, JAMA-J AM MED ASSOC, V298, P1401, DOI 10.1001/jama.298.12.1401; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P629, DOI 10.1001/archpsyc.62.6.629; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wittchen HU, 2011, EUR NEUROPSYCHOPHARM, V21, P655, DOI 10.1016/j.euroneuro.2011.07.018	41	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2017	12	10							e0186967	10.1371/journal.pone.0186967	http://dx.doi.org/10.1371/journal.pone.0186967			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK9WD	29077724	gold, Green Published, Green Accepted			2023-01-03	WOS:000413861200032
J	Li, Y; Cui, T; Kong, XD; Yi, XL; Kong, DX; Zhang, JN; Liu, CX; Gong, M				Li, Ying; Cui, Tao; Kong, Xiaodong; Yi, Xiulin; Kong, Dexin; Zhang, Jianning; Liu, Changxiao; Gong, Min			Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability	FASEB JOURNAL			English	Article						GLP-1; self-assembling peptide; type 2 diabetes mellitus; self-assembling GLP-1	AMINO-ACID-SEQUENCE; SIRNA DELIVERY; MECHANICAL-PROPERTIES; SYSTEMATIC VARIATION; OLIGOPEPTIDE MATRIX; CELL-PROLIFERATION; INSULIN-SECRETION; 7-36 AMIDE; GLP-1; PANCREAS	The multiple physiologic characteristics of glucagon-like peptide 1 (GLP-1) make it a promising drug candidate for treating type 2 diabetes mellitus. However, the half-life of GLP-1 is short as a result of degradation by dipeptidyl peptidase IV and renal clearance. Stabilizing GLP-1 is therefore critical for its use in drug development. Self-assembling peptides are a class of peptides that undergo spontaneous assembly into ordered nanostructures. Recently, studies of self-assembling peptides as drug carriers have increased because of their enhanced stability. In the present study, GLP-1 was modified to incorporate the structural characteristics of self-assembling peptides aiming to generate a self-assembling GLP-1 derivative. Receptor binding capacity and insulinotropic effects were measured to investigate the physiologic functions of GLP-1, along with morphologic approaches to observe supramolecular formation on self-assembly at the nano scale. Finally, blood glucose regulation and body weight were monitored after administration of selected derivatives. Our findings revealed that cadyglple and cadyglp1m both exhibited improved stability even though different nanoshapes were observed for these two self-assembling peptides. Both cadyglple and cadyglp1m retained glucoregulatory activity after insulin stimulation and were potent drug candidates for long-acting GLP-1 derivatives to treat type 2 diabetes mellitus. Our findings support the feasibility of introducing self-assembly functions into peptides with poor stabilities, such as GLP-1.	[Li, Ying; Kong, Xiaodong; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Tianjin, Peoples R China; [Cui, Tao; Liu, Changxiao] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China; [Yi, Xiulin] Tianjin Inst Pharmaceut Res, State Key Lab Drug Delivery Technol & Pharmacokin, Tianjin, Peoples R China; [Kong, Dexin; Gong, Min] Tianjin Med Univ, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin, Peoples R China	Tianjin Medical University; Tianjin University of Traditional Chinese Medicine; Tianjin Medical University	Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Tianjin, Peoples R China.; Gong, M (corresponding author), Tianjin Med Univ, Tianjin Inst Pharmaceut Res, 22 Qixiangtai Rd, Tianjin 300060, Peoples R China.	kahongmg@163.com; gongmin@tmu.edu.cn			National Science and Technology Major Project of the Ministry of Science and Technology of China [2014ZX09507005-003]; National Natural Science Funding [81400932, 81771221]; Major Project of Science and Technology of Tianjin [13RCGFSY19700]; Natural Science Foundation of Tianjin [12JCYBJC31500]; Science and Technology of Tianjin [15JCBJC50500]	National Science and Technology Major Project of the Ministry of Science and Technology of China; National Natural Science Funding(National Natural Science Foundation of China (NSFC)); Major Project of Science and Technology of Tianjin; Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Science and Technology of Tianjin	The authors thank Newman Gong (Tianjun Medical University) for his kind support in the data storage. This study was supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China (2014ZX09507005-003), the National Natural Science Funding (81400932 and 81771221), the Major Project of Science and Technology of Tianjin (13RCGFSY19700), the Natural Science Foundation of Tianjin (12JCYBJC31500), and Science and Technology of Tianjin (15JCBJC50500). The authors declare no conflicts of interest.	ADELHORST K, 1994, J BIOL CHEM, V269, P6275; Al-Sabah S, 2003, BRIT J PHARMACOL, V140, P339, DOI 10.1038/sj.bjp.0705453; Brubaker PL, 2004, ENDOCRINOLOGY, V145, P2653, DOI 10.1210/en.2004-0015; Caplan MR, 2002, J BIOMAT SCI-POLYM E, V13, P225, DOI 10.1163/156856202320176493; Caplan MR, 2002, BIOMATERIALS, V23, P219, DOI 10.1016/S0142-9612(01)00099-0; Crombez L, 2011, METHODS MOL BIOL, V683, P349, DOI [10.1007/978-1-60751-919-2_25, 10.1007/978-1-60761-919-2_25]; Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215; Davidson Jaime A, 2009, Cleve Clin J Med, V76 Suppl 5, pS28, DOI 10.3949/ccjm.76.s5.05; Deshayes S, 2012, SMALL, V8, P2184, DOI 10.1002/smll.201102413; Dhadwar SS, 2003, BIOTECHNOL ADV, V21, P395, DOI 10.1016/S0734-9750(03)00056-9; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Fernandez-Carneado J, 2004, BIOPOLYMERS, V76, P196, DOI 10.1002/bip.10585; Galdiero M, 2012, CURR DRUG METAB, V13, P2, DOI 10.2174/138920012798356925; GALLWITZ B, 1994, EUR J BIOCHEM, V225, P1151, DOI 10.1111/j.1432-1033.1994.1151b.x; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; Hui HX, 2005, DIABETES-METAB RES, V21, P313, DOI 10.1002/dmrr.553; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; KREYMANN B, 1987, LANCET, V2, P1300; Kurzawa L, 2010, BBA-BIOMEMBRANES, V1798, P2274, DOI 10.1016/j.bbamem.2010.02.027; Leon EJ, 1998, J BIOMAT SCI-POLYM E, V9, P297, DOI 10.1163/156856298X00668; Li Y, 2012, INT J PHARMACEUT, V434, P209, DOI 10.1016/j.ijpharm.2012.06.003; Liang J, 2014, COLLOID SURFACE B, V114, P398, DOI 10.1016/j.colsurfb.2013.10.037; Lugari R, 2000, HORM METAB RES, V32, P424, DOI 10.1055/s-2007-978665; Monticelli L, 2008, J CHEM THEORY COMPUT, V4, P819, DOI 10.1021/ct700324x; Nauck MA, 1997, EXP CLIN ENDOCR DIAB, V105, P187, DOI 10.1055/s-0029-1211750; OHNEDA A, 1991, TOHOKU J EXP MED, V165, P209, DOI 10.1620/tjem.165.209; Okerson T, 2012, CARDIOVASC THER, V30, pe146, DOI 10.1111/j.1755-5922.2010.00256.x; Parhofer Klaus G, 2007, MMW Fortschr Med, V149, P41; Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055; RUIZGRANDE C, 1990, CAN J PHYSIOL PHARM, V68, P1568, DOI 10.1139/y90-239; Runge S, 2003, BRIT J PHARMACOL, V138, P787, DOI 10.1038/sj.bjp.0705120; Schneider JP, 2002, J AM CHEM SOC, V124, P15030, DOI 10.1021/ja027993g; SHIMA K, 1988, REGUL PEPTIDES, V22, P245, DOI 10.1016/0167-0115(88)90037-7; Sloop KW, 2010, DIABETES, V59, P3099, DOI 10.2337/db10-0689; Underwood CR, 2010, J BIOL CHEM, V285, P723, DOI 10.1074/jbc.M109.033829; Villanueva-Penacarrillo ML, 2001, ENDOCRINE, V15, P241, DOI 10.1385/ENDO:15:2:241; Wassenaar TA, 2014, J CHEM THEORY COMPUT, V10, P676, DOI 10.1021/ct400617g; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338; YAMATO E, 1990, BIOCHEM BIOPH RES CO, V167, P431, DOI 10.1016/0006-291X(90)92041-W; Yang X, 2014, MOL PHARMACEUT, V11, P4092, DOI 10.1021/mp5002685; Zhang SG, 1997, P NATL ACAD SCI USA, V94, P23, DOI 10.1073/pnas.94.1.23	41	9	10	5	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2018	32	6					2992	3004		10.1096/fj.201701033RRR	http://dx.doi.org/10.1096/fj.201701033RRR			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GG2TP	29401602				2023-01-03	WOS:000432546000009
J	Chang, AY; Nabbaale, J; Nalubwama, H; Okello, E; Ssinabulya, I; Longenecker, CT; Webel, AR				Chang, Andrew Y.; Nabbaale, Juliet; Nalubwama, Haddy; Okello, Emmy; Ssinabulya, Isaac; Longenecker, Christopher T.; Webel, Allison R.			Motivations of women in Uganda living with rheumatic heart disease: A mixed methods study of experiences in stigma, childbearing, anticoagulation, and contraception	PLOS ONE			English	Article							PREGNANCY OUTCOMES; DECISION-MAKING; AFRICA; FOCUS	Background Rheumatic heart disease (RHD) is a leading cause of premature mortality in low- and middle-income countries (LMICs). Women of reproductive age are a unique and vulnerable group of RHD patients, due to increased risk of cardiovascular complications and death during pregnancy. Yet, less than 5% of women of childbearing age with RHD in LMICs use contraceptives, and one in five pregnant women with RHD take warfarin despite known teratogenicity. It is unclear whether this suboptimal contraception and anticoagulant use during pregnancy is due to lack of health system resources, limited health literacy, or social pressure to bear children. Methods We conducted a mixed methods study of 75 women living with RHD in Uganda. Questionnaires were administered to 50 patients. Transcripts from three focus groups with 25 participants were analyzed using qualitative description methodology. Results Several themes emerged from the focus groups, including pregnancy as a calculated risk; misconceptions about side-effects of contraceptives and anticoagulation; reproductive decision -making control by male partners, in-laws, or physicians; abandonment of patients by male partners; and considerable stigma against heart disease patients for both their reproductive and financial limitations (often worse than that directed against HIV patients). All questionnaire respondents were told by physicians that their hearts were not strong enough to support a pregnancy. Only 14% used contraception while taking warfarin. All participants felt that society would look poorly on a woman who cannot have children due to a heart condition. Conclusions To our knowledge, this is the first qualitative study of female RHD patients and their attitudes toward cardiovascular disorders and reproduction. Our results suggest that health programs targeting heart disease in LMICs must pay special attention to the needs of women of childbearing age. There are opportunities for improved family/societal education programs and community engagement, leading to better outcomes and patient empowerment.	[Chang, Andrew Y.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Nabbaale, Juliet; Okello, Emmy; Ssinabulya, Isaac] Mulago Hosp, Uganda Heart Inst, Kampala, Uganda; [Nabbaale, Juliet; Longenecker, Christopher T.] Case Western Reserve Univ, Univ Hosp Harrington Heart & Vasc Inst, Cleveland, OH 44106 USA; [Nalubwama, Haddy] Makerere Univ, Sch Publ Hlth, Kampala, Uganda; [Webel, Allison R.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA	Stanford University; Mulago National Referral Hospital; Case Western Reserve University; Makerere University; Case Western Reserve University	Webel, AR (corresponding author), Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.	Allison.webel@case.edu	Webel, Allison R./ABA-1972-2020; Webel, Allison R./AFW-1806-2022	Chang, Andrew/0000-0002-3009-6678; Webel, Allison/0000-0002-7538-5780; Ssinabulya, Isaac/0000-0001-6521-7778	Medtronic Foundation [FY13-000406]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR001084] Funding Source: NIH RePORTER	Medtronic Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Author C.L. has financial support from the Medtronic Foundation (Grant FY13-000406) for the submitted work. The funder provided support in the form of salary/research materials for author C.L., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors report no financial relationships with any other organizations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced or benefited from the submitted work. The specific roles of these authors are articulated in the 'author contributions' section.	Adongo PB, 1997, SOC SCI MED, V45, P1789, DOI 10.1016/S0277-9536(97)00110-X; Alshawabkeh L, 2016, J AM COLL CARDIOL, V68, P1804, DOI 10.1016/j.jacc.2016.06.076; Behboodi-Moghadam Zahra, 2016, J Int Assoc Provid AIDS Care, V15, P148, DOI 10.1177/2325957415593636; Benin AL, 2006, PEDIATRICS, V117, P1532, DOI 10.1542/peds.2005-1728; Bronfenbrenner U., 1993, INT ENCY ED, V3, P37; Carlsson-Lalloo E, 2016, AIDS PATIENT CARE ST, V30, P56, DOI 10.1089/apc.2015.0260; Corbin J.M., 2008, BASICS QUALITATIVE R, Vthird, DOI DOI 10.4135/9781452230153.N8; Corney R, 2014, EUR J ONCOL NURS, V18, P17, DOI 10.1016/j.ejon.2013.10.003; Curry LA, 2009, CIRCULATION, V119, P1442, DOI 10.1161/CIRCULATIONAHA.107.742775; Diao M, 2011, ARCH CARDIOVASC DIS, V104, P370, DOI 10.1016/j.acvd.2011.04.001; Farmer DB, 2015, GLOB HEALTH, V3, P242, DOI 10.9745/GHSP-D-14-00198; Ginsberg JS, 2001, CHEST, V119, p122S, DOI 10.1378/chest.119.1_suppl.122S; Greutmann M, 2015, EUR HEART J, V36, P2491, DOI 10.1093/eurheartj/ehv288; Haththotuwa HR, 2009, INT J GYNECOL OBSTET, V104, P194, DOI 10.1016/j.ijgo.2008.10.031; Jeng JS, 2004, J NEUROL SCI, V221, P25, DOI 10.1016/j.jns.2004.03.006; Kane S, 2016, BMC PUBLIC HEALTH, P16; Kibira SPS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141998; Liu H, 2013, INT J GYNECOL OBSTET, V120, P245, DOI 10.1016/j.ijgo.2012.09.025; Liu H, 2010, CHINESE MED J-PEKING, V123, P2324, DOI 10.3760/cma.j.issn.0366-6999.2010.17.008; Mocumbi AO, 2012, HEART, V98, P450, DOI 10.1136/heartjnl-2011-301025; Moodley J, 2000, S AFR MED J, V90, P367; Neergaard MA, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-52; Ochako R, 2015, BMC PUBLIC HEALTH, P15; Paar JA, 2010, AM J CARDIOL, V105, P1809, DOI 10.1016/j.amjcard.2010.01.364; Pattenden J, 2002, BMJ-BRIT MED J, V324, P1006, DOI 10.1136/bmj.324.7344.1006; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Sandelowski M., 2009, RES NURS HLTH; Siu SC, 2001, CIRCULATION, V104, P515, DOI 10.1161/hc3001.093437; Terreri MT, 2001, J RHEUMATOL, V28, P1394; Thorne S, 2006, HEART, V92, P1520, DOI 10.1136/hrt.2006.095240; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Tong A, 2015, NEPHROL DIAL TRANSPL, V30, P652, DOI 10.1093/ndt/gfu378; Watkins DA, 2012, BMC CARDIOVASC DISOR, V12, DOI 10.1186/1471-2261-12-23; Zuhlke L, 2015, EUR HEART J, V36, P1115, DOI 10.1093/eurheartj/ehu449	34	19	19	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2018	13	3							e0194030	10.1371/journal.pone.0194030	http://dx.doi.org/10.1371/journal.pone.0194030			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA8PV	29590159	Green Published, gold, Green Submitted			2023-01-03	WOS:000428603100045
J	Lowe, NM; Kershaw, LE; Bernstein, JM; Withey, SB; Mais, K; Homer, JJ; Slevin, NJ; Bonington, SC; Carrington, BM; West, CM				Lowe, Natalie M.; Kershaw, Lucy E.; Bernstein, Jonathan M.; Withey, Stephanie B.; Mais, Kathleen; Homer, Jarrod J.; Slevin, Nicholas J.; Bonington, Suzanne C.; Carrington, Bernadette M.; West, Catharine M.			Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy	PLOS ONE			English	Article							LOCALLY ADVANCED HEAD; CONTRAST-ENHANCED MRI; INTRATUMOR HETEROGENEITY; COMPUTED-TOMOGRAPHY; CT PERFUSION; LOCOREGIONAL CONTROL; RADIATION-THERAPY; UNRESECTABLE HEAD; LUNG-CANCER; CHEMORADIOTHERAPY	Objectives Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes. Methods A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) before and after two cycles of ICT was used to measure Fp and RECIST response. Results Forty-two patients were recruited and 37 underwent two scans. The median follow-up was 36 (range 23-49) months. Pre-treatment tumour Fp (stratified by median) was not prognostic for overall survival (p = 0.42), disease specific survival (p = 0.20) and locoregional control (p = 0.64). Neither change in tumour Fp nor RECIST response post two cycles of ICT was prognostic for any outcome (p>0.21). Conclusion DCE-MRI parameters do not predict long-term survival outcomes following ICT and RECIST response to ICT may not be an appropriate endpoint to determine early efficacy of a treatment in HNSCC patients.	[Lowe, Natalie M.; Kershaw, Lucy E.; Bernstein, Jonathan M.; Homer, Jarrod J.; Slevin, Nicholas J.; West, Catharine M.] Univ Manchester, Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Canc Sci, Manchester, Lancs, England; [Kershaw, Lucy E.] Christie NHS Fdn Trust, Christie Med Phys & Engn, Manchester, Lancs, England; [Bernstein, Jonathan M.] Royal Marsden NHS Fdn Trust, Dept Otorhinolaryngol Head & Neck Surg, London, England; [Withey, Stephanie B.] Univ Hosp Birmingham, Med Phys, Birmingham, W Midlands, England; [Mais, Kathleen; Slevin, Nicholas J.] Christie NHS Fdn Trust, Head & Neck Clin Oncol, Manchester, Lancs, England; [Homer, Jarrod J.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Univ Dept Otolaryngol Head & Neck Surg, Manchester, Lancs, England; [Bonington, Suzanne C.; Carrington, Bernadette M.] Christie NHS Fdn Trust, Dept Radiol, Manchester, Lancs, England; [West, Catharine M.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England	Christie NHS Foundation Trust; University of Manchester; Christie NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Birmingham; Christie NHS Foundation Trust; University of Manchester; Christie NHS Foundation Trust; University of Manchester	West, CM (corresponding author), Univ Manchester, Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Div Canc Sci, Manchester, Lancs, England.; West, CM (corresponding author), Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, England.	Catharine.West@manchester.ac.uk	; West, Catharine/J-4152-2012	Withey, Stephanie/0000-0003-4804-9033; Lowe, Natalie/0000-0002-0348-5184; West, Catharine/0000-0002-0839-3449	Christie Hospital Charitable Trust; Head and Neck Oncology Research Fund; Christie NHS Foundation Trust; Experimental Cancer Medicine Centre Network, UK	Christie Hospital Charitable Trust; Head and Neck Oncology Research Fund; Christie NHS Foundation Trust; Experimental Cancer Medicine Centre Network, UK	The authors thank Helen Valentine for help with p16 staining; Farag Shuweidi and Clare Hodgson for help with statistical analysis and Jason Kennedy for database management. The work was funded by the Christie Hospital Charitable Trust.; This study was funded by the Head and Neck Oncology Research Fund (Prof Nick J Slevin), The Christie NHS Foundation Trust and The Experimental Cancer Medicine Centre Network, UK.	Balluff B, 2015, J PATHOL, V235, P3, DOI 10.1002/path.4436; Bernstein JM, 2015, ORAL ONCOL, V51, P508, DOI 10.1016/j.oraloncology.2015.01.013; Bisdas S, 2010, AM J NEURORADIOL, V31, P576, DOI 10.3174/ajnr.A1852; Bisdas S, 2009, AM J NEURORADIOL, V30, P793, DOI 10.3174/ajnr.A1449; Blanchard P, 2011, J CLIN EPIDEMIOL, V64, P985, DOI 10.1016/j.jclinepi.2010.10.016; Bourhis J, 2012, LANCET ONCOL, V13, P145, DOI 10.1016/S1470-2045(11)70346-1; Brix G, 2004, MAGNET RESON MED, V52, P420, DOI 10.1002/mrm.20161; Brizel DM, 1999, RADIOTHER ONCOL, V53, P113, DOI 10.1016/S0167-8140(99)00102-4; Brookes JA, 1999, JMRI-J MAGN RESON IM, V9, P163, DOI 10.1002/(SICI)1522-2586(199902)9:2<163::AID-JMRI3>3.0.CO;2-L; Buyse M, 2000, LANCET, V356, P373, DOI 10.1016/S0140-6736(00)02528-9; Cao Y, 2008, INT J RADIAT ONCOL, V72, P1287, DOI 10.1016/j.ijrobp.2008.08.024; Clinton B, 1996, REINVENTING REGULATI; Cohen EEW, 2014, J CLIN ONCOL, V32, P2735, DOI 10.1200/JCO.2013.54.6309; Cohen L, 2012, J CLIN ONCOL, V30; Donaldson SB, 2013, EUR J RADIOL, V82, P2161, DOI 10.1016/j.ejrad.2013.08.008; Edge SB, 2009, AJCC CANC STAGING MA, V7; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; El-Maraghi RH, 2008, J CLIN ONCOL, V26, P1346, DOI 10.1200/JCO.2007.13.5913; Ferlay J, 2014, INT J CANC; Gandhi D, 2006, AM J NEURORADIOL, V27, P101; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Ghi M, 2017, ANN ONCOLOGY; Ghi MG, 2017, ANN ONCOL, V28, P2206, DOI 10.1093/annonc/mdx299; Goffin J, 2005, CLIN CANCER RES, V11, P5928, DOI 10.1158/1078-0432.CCR-05-0130; Hermans R, 2003, INT J RADIAT ONCOL, V57, P1351, DOI 10.1016/S0360-3016(03)00764-8; Hitt R, 2014, ANN ONCOL, V25, P216, DOI 10.1093/annonc/mdt461; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1470-2045(10)70279-5; Ma J, 2012, ORAL ONCOL, V48, P1076, DOI 10.1016/j.oraloncology.2012.06.014; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Matoba M, 2015, J RADIAT RES, V56, P553, DOI 10.1093/jrr/rru123; Nguyen-Tan PF, 2014, J CLIN ONCOLOGY; Nordsmark M, 2005, RADIOTHER ONCOL, V77, P18, DOI 10.1016/j.radonc.2005.06.038; O'Connor JPB, 2015, CLIN CANCER RES, V21, P249, DOI 10.1158/1078-0432.CCR-14-0990; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Paesmans M, 1997, EUR J CANCER, V33, P2326, DOI 10.1016/S0959-8049(97)00325-0; Pascal J, 2013, P NATL ACAD SCI USA, V110, P14266, DOI 10.1073/pnas.1300619110; Passero VA, 2010, ANN ONCOL, V21, P2278, DOI 10.1093/annonc/mdq226; Patil V, 2013, ISRN Oncol, V2013, P259154, DOI 10.1155/2013/259154; Petralia G, 2009, J COMPUT ASSIST TOMO, V33, P552, DOI 10.1097/RCT.0b013e31818d446e; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Popovic KS, 2014, J BUON, V19, P937; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Sinek J, 2004, BIOMED MICRODEVICES, V6, P297, DOI 10.1023/B:BMMD.0000048562.29657.64; Stadler P, 1999, INT J RADIAT ONCOL, V44, P749, DOI 10.1016/S0360-3016(99)00115-7; Stokes WA, 2017, HEAD NECK-J SCI SPEC, V39, P1113, DOI 10.1002/hed.24739; Truong MT, 2011, AM J NEURORADIOL, V32, P1195, DOI 10.3174/ajnr.A2501; Urba S, 2006, J CLIN ONCOL, V24, P593, DOI 10.1200/JCO.2005.01.2047; Ursino S, 2017, EUR REV MED PHARMACO, V21, P4882; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Wang P, 2012, MED PHYS, V39, P5277, DOI 10.1118/1.4737022; Weber RS, 2003, ARCH OTOLARYNGOL, V129, P44, DOI 10.1001/archotol.129.1.44; William WN, 2013, J THORAC ONCOL, V8, P222, DOI 10.1097/JTO.0b013e3182774108; Zima A, 2007, AM J NEURORADIOL, V28, P328	54	5	5	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2018	13	3							e0194841	10.1371/journal.pone.0194841	http://dx.doi.org/10.1371/journal.pone.0194841			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8PV	29590180	Green Published, Green Submitted, gold			2023-01-03	WOS:000428603100078
J	Chen, CT; Chen, YL; Lin, YC; Hsieh, CL; Tzeng, JY; Chen, KL				Chen, Cheng-Te; Chen, Yu-Lan; Lin, Yu-Ching; Hsieh, Ching-Lin; Tzeng, Jeng-Yi; Chen, Kuan-Lin			Item-saving assessment of self-care performance in children with developmental disabilities: A prospective caregiver-report computerized adaptive test	PLOS ONE			English	Article								Objective The purpose of this study was to construct a computerized adaptive test (CAT) for measuring self-care performance (the CAT-SC) in children with developmental disabilities (DD) aged from 6 months to 12 years in a content-inclusive, precise, and efficient fashion. Methods The study was divided into 3 phases: (1) item bank development, (2) item testing, and (3) a simulation study to determine the stopping rules for the administration of the CAT-SC. A total of 215 caregivers of children with DD were interviewed with the 73-item CAT-SC item bank. An item response theory model was adopted for examining the construct validity to estimate item parameters after investigation of the unidimensionality, equality of slope parameters, item fitness, and differential item functioning (DIF). In the last phase, the reliability and concurrent validity of the CAT-SC were evaluated. Results The final CAT-SC item bank contained 56 items. The stopping rules suggested were (a) reliability coefficient greater than 0.9 or (b) 14 items administered. The results of simulation also showed that 85% of the estimated self-care performance scores would reach a reliability higher than 0.9 with a mean test length of 8.5 items, and the mean reliability for the rest was 0.86. Administering the CAT-SC could reduce the number of items administered by 75% to 84%. In addition, self-care performances estimated by the CAT-SC and the full item bank were very similar to each other (Pearson r=0.98). Conclusion The newly developed CAT-SC can efficiently measure self-care performance in children with DD whose performances are comparable to those of TD children aged from 6 months to 12 years as precisely as the whole item bank. The item bank of the CAT-SC has good reliability and a unidimensional self-care construct, and the CAT can estimate self-care performance with less than 25% of the items in the item bank. Therefore, the CAT-SC could be useful for measuring self-care performance in children with DD in clinical and research settings.	[Chen, Cheng-Te] Natl Tsing Hua Univ, Dept Educ Psychol & Counseling, Hsinchu, Taiwan; [Chen, Yu-Lan] Taipei Vet Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Lin, Yu-Ching; Chen, Kuan-Lin] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Phys Med & Rehabil, Tainan, Taiwan; [Lin, Yu-Ching] Natl Cheng Kung Univ, Coll Med, Dept Phys Med & Rehabil, Tainan, Taiwan; [Hsieh, Ching-Lin] Natl Taiwan Univ, Coll Med, Sch Occupat Therapy, Taipei, Taiwan; [Hsieh, Ching-Lin] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Hsieh, Ching-Lin] Asia Univ, Coll Med & Hlth Sci, Dept Occupat Therapy, Taichung, Taiwan; [Tzeng, Jeng-Yi] Natl Tsing Hua Univ, Inst Learning Sci & Technol, Hsinchu, Taiwan; [Chen, Kuan-Lin] Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan, Taiwan	National Tsing Hua University; Taipei Veterans General Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Asia University Taiwan; National Tsing Hua University; National Cheng Kung University	Chen, KL (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Phys Med & Rehabil, Tainan, Taiwan.; Chen, KL (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan, Taiwan.	klchen@mail.ncku.edu.tw	Hsieh, Ching-Lin/G-6057-2011; Chen, Kuan-Lin/AAD-4537-2022; Chen, Kuan-Lin/AAC-5430-2021	Hsieh, Ching-Lin/0000-0001-9468-9969; Chen, Kuan-Lin/0000-0001-9996-814X; 	National Science Council [NSC 100-2410-H-006-103-MY3, NSC 103-2511-S-007-006-MY3]	National Science Council(Ministry of Science and Technology, Taiwan)	The study was supported by grants from the National Science Council (NSC 100-2410-H-006-103-MY3 to KLC and NSC 103-2511-S-007-006-MY3 to JYT). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Centers for Disease Control Prevention, DEV DIS; Choi SW, 2011, J STAT SOFTW, V39, P1; Coster W., 1998, SCH FUNCTION ASSESSM; DIMDI, 2005, INT CLASS FUNCT DIS; Haley S.M., 2012, PEDI CAT DEV STANDAR; Haley SM., 1992, PEDIAT EVALUATION DI; Holsbeeke L, 2009, ARCH PHYS MED REHAB, V90, P849, DOI 10.1016/j.apmr.2008.11.015; Jette AM, 2005, J REHABIL MED, V37, P339, DOI 10.1080/16501970500302793; Magis D, 2012, J STAT SOFTW, V48, P1; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; Meijer RR, 1999, APPL PSYCH MEAS, V23, P187, DOI 10.1177/01466219922031310; Muraki E, 2003, PARSCALE IRT ITEM AN; Muraki E., 1992, ETS RES REPORT SERIE, V1992, P30, DOI DOI 10.1002/J.2333-8504.1992.TB01436.X; Muthen B, 1997, TECHNICAL REPORT; Sparrow SS, 2016, VINELAND 2 ADAPTIVE, V3rd; Uniform Data System for Medical Rehabilitation, 2002, WEEFIM IISM SYST CLI; van der Linden W. J., 2000, COMPUTERIZED ADAPTIV; World Health Organisation, 2001, ICF INT CLASFUNCT	18	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2018	13	3							e0193936	10.1371/journal.pone.0193936	http://dx.doi.org/10.1371/journal.pone.0193936			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ9LE	29561879	Green Published, Green Submitted, gold			2023-01-03	WOS:000427931600044
J	Hoang, S; Georget, A; Asselineau, J; Venier, AG; Leroyer, C; Rogues, AM; Thiebaut, R				Hoang, S.; Georget, A.; Asselineau, J.; Venier, A-G.; Leroyer, C.; Rogues, A. M.; Thiebaut, R.			Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France	PLOS ONE			English	Article							ACQUISITION; MORTALITY; CARRIAGE; ROUTES; COSTS	Pseudomonas aeruginosa (P. aeruginosa) remains a prominent nosocomial pathogen responsible for high morbi-mortality in intensive care units (ICUs). P. aeruginosa transmission is known to be partly endogenous and exogenous. Main factors have been highlighted but the precise role of environment in regard to antibiotics use remained unclear. Objective To assess the role of environment, medical care and individual risks factors for P. aeruginosa colonization and infection. Study design and setting A French multicentric prospective study involved ten ICUs for a five months period. Every adult patient newly hospitalized in ICUs with no P. aeruginosa carriage up to 48 hours after admission was included and weekly screened before discharge or death. Screening swabs were either rectal, sputum or oropharyngeal samples. Hydric environment was also sampled each week. Data on patient clinical features, environmental and device exposures, and antibiotics supports were regularly collected. Multivariate analysis was performed with a multistate model. Results The overall prevalence of P. aeruginosa carriage was 15.3% (201/1314). Risk factors associated with patient colonization were: use of inactive antibiotics against P. aeruginosa (HR = 1.60 [1.15-2.21] p< 0.01), tap water contamination at the entry in the room (HR = 1.66 [1.01-2.27] p<0.05) and mechanical invasive ventilation (HR = 4.70 [2.66-8.31] p<0.0001). Active antibiotics prevented from colonization (HR = 0.67 [0.48-0.93] p = 0.02) and from infection (HR = 0.64 [0.41-1.01] p = 0.05). Interaction between hydric environment antibiotics support was not statistically associated with patient colonization. Conclusion Hydric contamination and antibiotics pressure seem to remain key independent risk factors in P. aeruginosa colonization. These results advocate the need to carry on preventive and targeted interventions toward healthcare associated infections.	[Hoang, S.; Venier, A-G.; Leroyer, C.; Rogues, A. M.; Thiebaut, R.] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, UMR 1219,Inria SISTM,ISPED, Bordeaux, France; [Hoang, S.] Ctr Hosp Univ Sud Reunion, Ile De La Reunion, France; [Hoang, S.; Georget, A.; Asselineau, J.; Thiebaut, R.] CHU Bordeaux, Pole Sante Publ, Serv Informat Med, Unite Soutien Methodol Rech Clin & Epiderniol, Bordeaux, France; [Venier, A-G.; Leroyer, C.; Rogues, A. M.] Grp Hosp Pellegrin, Serv Hyg Hosp, Bordeaux, France; [Venier, A-G.] CHU Pellegrin, Ctr Coordinat Comites Lutte Infect Nosocomiales S, Bordeaux, France; [Hoang, S.] Ctr Hosp Andree Rosemon, Ctr Invest Clin Antilles Guyane, Cayenne, Guyane Francais, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Reunion; CHU Bordeaux; CHU Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm)	Thiebaut, R (corresponding author), Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, UMR 1219,Inria SISTM,ISPED, Bordeaux, France.; Thiebaut, R (corresponding author), CHU Bordeaux, Pole Sante Publ, Serv Informat Med, Unite Soutien Methodol Rech Clin & Epiderniol, Bordeaux, France.	Rodolphe.thiebaut@u-bordeaux.fr	Thiebaut, Rodolphe/T-6803-2019	Thiebaut, Rodolphe/0000-0002-5235-3962; leroyer, christophe/0000-0002-7601-1692				Agodi A, 2007, INTENS CARE MED, V33, P1155, DOI 10.1007/s00134-007-0671-6; [Anonymous], 2014, SURV INF NOS REAN AD; [Anonymous], [No title captured]; Bergmans DCJJ, 1998, THORAX, V53, P1053, DOI 10.1136/thx.53.12.1053; Bernard Grynfogel, 2009, HYGIENE; Berthelot P, 2001, INTENS CARE MED, V27, P503, DOI 10.1007/s001340100870; Bertrand X, 2001, INTENS CARE MED, V27, P1263, DOI 10.1007/s001340100979; Cobos-Trigueros N, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0916-7; Cohen R, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-016-0167-7; Falagas ME, 2006, J HOSP INFECT, V64, P7, DOI 10.1016/j.jhin.2006.04.015; Gomez-Zorrilla S, 2015, ANTIMICROB AGENTS CH, V59, P5213, DOI 10.1128/AAC.04636-14; Halwani M, 2006, J HOSP INFECT, V63, P39, DOI 10.1016/j.jhin.2005.10.012; Jackson CH, 2011, J STAT SOFTW, V38, P1; Laupland KB, 2006, J HOSP INFECT, V63, P124, DOI 10.1016/j.jhin.2005.12.016; Manfredi R, 2000, EUR J EPIDEMIOL, V16, P111, DOI 10.1023/A:1007626410724; Martinez J, 2009, INTENS CARE MED, V35, P439, DOI 10.1007/s00134-008-1326-y; Micek ST, 2005, ANTIMICROB AGENTS CH, V49, P1306, DOI 10.1128/AAC.49.4.1306-1311.2005; Obadia T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004170; Ortona L, 1985, Eur J Epidemiol, V1, P94, DOI 10.1007/BF00141799; Petignat C, 2006, INFECT CONT HOSP EP, V27, P953, DOI 10.1086/506409; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712; Rogues AM, 2007, J HOSP INFECT, V67, P72, DOI 10.1016/j.jhin.2007.06.019; Sanchez-Velazquez LD, 2006, ARCH MED RES, V37, P370, DOI 10.1016/j.arcmed.2005.07.004; Slekovec C, 2010, ANN FR ANESTH, V29, P279, DOI 10.1016/j.annfar.2009.12.023; Tacconelli E, 2009, J HOSP INFECT, V72, P97, DOI 10.1016/j.jhin.2008.12.012; Talon D, 1998, AM J RESP CRIT CARE, V157, P978, DOI 10.1164/ajrccm.157.3.9702096; Thuong M, 2003, J HOSP INFECT, V53, P274, DOI 10.1053/jhin.2002.1370; Venier AG, 2014, J HOSP INFECT, V88, P103, DOI 10.1016/j.jhin.2014.06.018; Zhou ZY, 2016, J INFECT CHEMOTHER, V22, P450, DOI 10.1016/j.jiac.2016.03.016	30	25	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2018	13	3							e0193300	10.1371/journal.pone.0193300	http://dx.doi.org/10.1371/journal.pone.0193300			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY7GW	29522559	Green Published, Green Submitted, gold			2023-01-03	WOS:000427030800016
J	Shah, R; Nayyar, M; Jovin, IS; Rashid, A; Bondy, BR; Fan, THM; Flaherty, MP; Rao, SV				Shah, Rahman; Nayyar, Mannu; Jovin, Ion S.; Rashid, Abdul; Bondy, Beatrix R.; Fan, Tai-Hwang M.; Flaherty, Michael P.; Rao, Sunil V.			Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							PERCUTANEOUS CLOSURE; TRANSCATHETER CLOSURE; ISCHEMIC-STROKE; PREVENTION; RISK	Background: The optimal strategy for preventing recurrent stroke in patients with cryptogenic stroke and patent foramen ovale (PFO) is unknown. Purpose: To compare transcatheter PFO closure with medical therapy alone for prevention of recurrent stroke in patients with PFO and cryptogenic stroke. Data Sources: PubMed and the Cochrane Library (without language restrictions) from inception to October 2017, reference lists, and abstracts from cardiology meetings. Study Selection: Randomized trials enrolling adults with PFO and cryptogenic stroke that compared stroke outcomes (main outcome) and potential harms in those receiving transcatheter device closure versus medical therapy alone. Data Extraction: Two investigators independently extracted study data and rated risk of bias. Data Synthesis: Of 5 trials, 1 was excluded because it used a device that is no longer available due to high rates of complications and failure. Four high-quality trials enrolling 2892 patients showed that PFO closure decreased the absolute risk for recurrent stroke by 3.2% (risk difference, -0.032 [95% CI, -0.050 to -0.014]) compared with medical therapy. The treatment strategies did not differ in rates of transient ischemic attack or major bleeding. Closure of PFOs was associated with higher rates of new-onset atrial fibrillation (AF) than medical therapy alone in all trials, but this outcome had marked between-trial heterogeneity (I-2 = 82.5%), and high event rates in some groups resulted in extreme values for CIs. Limitation: Heterogeneity of device type and antithrombotic therapy across trials, small numbers for some outcomes, and heterogeneous and inconclusive AF results. Conclusion: In patients with PFO and cryptogenic stroke, transcatheter device closure decreases risk for recurrent stroke compared with medical therapy alone. Because recurrent stroke rates are low even with medical therapy alone and PFO closure might affect AF risk, shared decision making is crucial for this treatment.	Univ Tennessee, Memphis, TN USA; Vet Affairs Med Ctr, Memphis, TN USA; Virginia Commonwealth Univ, Richmond, VA USA; Jackson Clin, Jackson, TN USA; Univ Tennessee, Jackson, TN USA; [Flaherty, Michael P.] Univ Louisville, Rudd Heart & Lung Bldg,201 Abraham Flexner Way, Louisville, KY 40292 USA; [Rao, Sunil V.] Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA; [Shah, Rahman; Nayyar, Mannu; Bondy, Beatrix R.; Fan, Tai-Hwang M.] Univ Tennessee, Div Cardiovasc Dis, Coleman Coll Med Bldg,956 Court Ave,Suite A312, Memphis, TN 38163 USA; [Jovin, Ion S.] Virginia Commonwealth Univ, Dept Internal Med, POB 980509, Richmond, VA 23298 USA; [Rashid, Abdul] Univ Tennessee, Jackson Clin, 700 West Forest Ave, Jackson, TN 38301 USA	University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Virginia Commonwealth University; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Louisville; Duke University; University of Tennessee System; University of Tennessee Health Science Center; Virginia Commonwealth University; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Shah, R (corresponding author), Univ Tennessee, Sch Med, Div Cardiovasc Dis, Coleman Coll Med Bldg,956 Court Ave,Suite A312, Memphis, TN 38163 USA.	Shahcardiology@yahoo.com	shah, Rahman/AAR-3354-2020					Agarwal S, 2012, JACC-CARDIOVASC INTE, V5, P777, DOI 10.1016/j.jcin.2012.02.021; Carroll JD, 2013, NEW ENGL J MED, V368, P1092, DOI 10.1056/NEJMoa1301440; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Di Tullio MR, 2007, J AM COLL CARDIOL, V49, P797, DOI 10.1016/j.jacc.2006.08.063; Farb A, 2017, NEW ENGL J MED, V377, P1006, DOI 10.1056/NEJMp1700218; Furlan AJ, 2012, NEW ENGL J MED, V366, P991, DOI 10.1056/NEJMoa1009639; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Kent DM, 2016, J AM COLL CARDIOL, V67, P907, DOI 10.1016/j.jacc.2015.12.023; Khairy P, 2003, ANN INTERN MED, V139, P753, DOI 10.7326/0003-4819-139-9-200311040-00010; Khan AR, 2013, JACC-CARDIOVASC INTE, V6, P1316, DOI 10.1016/j.jcin.2013.08.001; Kitsios GD, 2013, STROKE, V44, P2640, DOI 10.1161/STROKEAHA.113.001773; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Li LX, 2015, LANCET NEUROL, V14, P903, DOI 10.1016/S1474-4422(15)00132-5; Mas JL, 2017, NEW ENGL J MED, V377, P1011, DOI 10.1056/NEJMoa1705915; Meier B, 2013, NEW ENGL J MED, V368, P1083, DOI 10.1056/NEJMoa1211716; Messe SR, 2016, NEUROLOGY, V87, P815, DOI 10.1212/WNL.0000000000002961; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Overell JR, 2000, NEUROLOGY, V55, P1172, DOI 10.1212/WNL.55.8.1172; Pickett CA, 2014, TEX HEART I J, V41, P357, DOI 10.14503/THIJ-13-3879; Rao G, 2017, CIRCULATION, V136, pE172, DOI 10.1161/CIR.0000000000000523; Rengifo-Moreno P, 2013, EUR HEART J, V34, P3342, DOI 10.1093/eurheartj/eht285; Saver JL, 2017, NEW ENGL J MED, V377, P1022, DOI 10.1056/NEJMoa1610057; Sondergaard L, 2017, NEW ENGL J MED, V377, P1033, DOI 10.1056/NEJMoa1707404; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Stortecky S, 2015, EUR HEART J, V36, P120, DOI 10.1093/eurheartj/ehu292; Sutton A.J., 2000, METHODS METAANALYSIS; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Taaffe M, 2008, AM J CARDIOL, V101, P1353, DOI 10.1016/j.amjcard.2007.12.040; Thaler DE, 2012, STROKE, V43, P3147, DOI 10.1161/STROKEAHA.112.659599	32	50	53	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 6	2018	168	5					335	+		10.7326/M17-2679	http://dx.doi.org/10.7326/M17-2679			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY2GD	29310136				2023-01-03	WOS:000426632600006
J	Li, N; Kong, H; Li, SL; Zhu, SN; Wang, DX				Li, Nan; Kong, Hao; Li, Shuang-Ling; Zhu, Sai-Nan; Wang, Dong-Xin			Combined epidural-general anesthesia was associated with lower risk of postoperative complications in patients undergoing open abdominal surgery for pheochromocytoma: A retrospective cohort study	PLOS ONE			English	Article							PULMONARY COMPLICATIONS; ANALGESIA; PARAGANGLIOMA; TRANSFUSION; MORBIDITY; OUTCOMES; IMPACT; ADRENALECTOMY; GUIDELINE; MORTALITY	Background Current evidences show that regional anesthesia is associated with decreased risk of complications after major surgery. However, the effects of combined regional-general anesthesia remain controversial. The purpose of our study was to analyze the impact of anesthesia (combined epidural-general anesthesia vs. general anesthesia) on the risk of postoperative complications in patients undergoing open surgery for pheochromocytoma. Methods This was a retrospective cohort study. 146 patients who underwent open surgery for pheochromocytoma (100 received combined epidural-general anesthesia and 46 received general anesthesia) in Peking University First Hospital from January 1, 2002 to December 31, 2015 were enrolled. The primary outcome was the occurrence of postoperative complications during hospital stay after surgery. Multivariate Logistic regression models were used to analyze the association between the choice of anesthetic method and the risk of postoperative complications. Results 17 (11.6%) patients developed complications during postoperative hospital stay. The incidence of postoperative complications was lower in patients with combined epidural-general anesthesia than in those with general anesthesia (6% [6/100] vs. 23.9% [11/46], P = 0.006). Multivariate Logistic regression analysis showed that use of combined epidural-general anesthesia (OR 0.219, 95% CI 0.065-0.741; P = 0.015) was associated with lower risk, whereas male gender (OR 5.213, 95% CI 1.283-21.177; P = 0.021) and perioperative blood transfusion (OR 25.879; 95% CI 3.130-213.961; P = 0.003) were associated with higher risk of postoperative complications. Conclusions For patients undergoing open surgery for pheochromocytoma, use of combined epidural-general anesthesia may decrease the occurrence of postoperative complications.	[Li, Nan; Kong, Hao; Li, Shuang-Ling; Wang, Dong-Xin] Peking Univ, Dept Anesthesiol & Crit Care Med, Hosp 1, Beijing, Peoples R China; [Zhu, Sai-Nan] Peking Univ, Dept Biostat, Hosp 1, Beijing, Peoples R China	Peking University; Peking University	Wang, DX (corresponding author), Peking Univ, Dept Anesthesiol & Crit Care Med, Hosp 1, Beijing, Peoples R China.	wangdongxin@hotmail.com			Peking University First Hospital [2016QN032]	Peking University First Hospital	This study was supported by a scientific research fund from Peking University First Hospital (http://www.bddyyy.com.cn/), grant number: 2016QN032. NL received the funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Chen H, 2010, PANCREAS, V39, P775, DOI 10.1097/MPA.0b013e3181ebb4f0; Conzo G, 2013, INT J SURG, V11, P152, DOI 10.1016/j.ijsu.2012.12.007; de Fourmestraux A, 2015, WORLD J UROL, V33, P1103, DOI 10.1007/s00345-014-1397-z; Elfenbein DM, 2013, J SURG RES, V184, P216, DOI 10.1016/j.jss.2013.04.014; Freise H, 2011, BRIT J ANAESTH, V107, P859, DOI 10.1093/bja/aer339; Guay J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010108.pub2; Guo JR, 2014, ASIAN PAC J CANCER P, V15, P467, DOI 10.7314/APJCP.2014.15.1.467; Hattori S, 2014, J ENDOUROL, V28, P686, DOI 10.1089/end.2013.0706; Haughom BD, 2015, J ARTHROPLASTY, V30, P116, DOI 10.1016/j.arth.2015.01.058; Hausman MS, 2015, ANESTH ANALG, V120, P1405, DOI 10.1213/ANE.0000000000000574; Katayama H, 2016, SURG TODAY, V46, P668, DOI 10.1007/s00595-015-1236-x; Kiernan CM, 2016, SURG ONCOL CLIN N AM, V25, P119, DOI 10.1016/j.soc.2015.08.006; Kiernan CM, 2014, ANN SURG ONCOL, V21, P3865, DOI 10.1245/s10434-014-3847-7; Kim Y, 2017, ANN SURG, V265, P103, DOI 10.1097/SLA.0000000000001647; Lee JH, 2017, INT J COLORECTAL DIS, V32, P521, DOI 10.1007/s00384-016-2739-7; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Licker M, 2013, J CLIN ANESTH, V25, P296, DOI 10.1016/j.jclinane.2013.01.009; Martin AN, 2016, J SURG RES, V206, P106, DOI 10.1016/j.jss.2016.07.013; Martin AN, 2016, J GASTROINTEST SURG, V20, P1554, DOI 10.1007/s11605-016-3195-y; Mohamad MF, 2017, J PAIN RES, V10, P887, DOI 10.2147/JPR.S122918; Muleledhu AL, 2013, INT J EMERG MED, V6, DOI 10.1186/1865-1380-6-43; Nimmo SM., 2004, CONTINUING ED ANAEST, V4, P44, DOI [10.1093/bjaceaccp/mkh014, DOI 10.1093/BJACEACCP/MKH014]; Nizamoglu A, 2011, SURG LAPARO ENDO PER, V21, P372, DOI 10.1097/SLE.0b013e31822dd5e1; Plouin PF, 2016, EUR J ENDOCRINOL, V174, pG1, DOI 10.1530/EJE-16-0033; Popping DM, 2008, ARCH SURG-CHICAGO, V143, P990, DOI 10.1001/archsurg.143.10.990; Qiu L, 2016, TRANSFUS APHER SCI, V54, P235, DOI 10.1016/j.transci.2015.07.004; Rao N, 2016, UROLOGY, V98, P103, DOI 10.1016/j.urology.2016.09.004; Saraste D, 2013, EJSO-EUR J SURG ONC, V39, P634, DOI 10.1016/j.ejso.2013.01.004; Svircevic V, 2011, ANESTHESIOLOGY, V114, P271, DOI 10.1097/ALN.0b013e318201d300; Taqi A, 2007, SURG ENDOSC, V21, P247, DOI 10.1007/s00464-006-0069-5; Venkat R, 2015, J SURG RES, V199, P505, DOI 10.1016/j.jss.2015.06.042; Woodfield JC, 2016, J SURG RES, V206, P77, DOI 10.1016/j.jss.2016.06.073; Zdichavsky M, 2012, EUR J GASTROEN HEPAT, V24, P1033, DOI 10.1097/MEG.0b013e328354ad6e; Zingg U, 2009, SURG ENDOSC, V23, P276, DOI 10.1007/s00464-008-9888-x	36	14	14	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2018	13	2							e0192924	10.1371/journal.pone.0192924	http://dx.doi.org/10.1371/journal.pone.0192924			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW8RO	29466473	Green Published, gold, Green Submitted			2023-01-03	WOS:000425604300075
J	Fan, E; Brodie, D; Slutsky, AS				Fan, Eddy; Brodie, Daniel; Slutsky, Arthur S.			Acute Respiratory Distress Syndrome Advances in Diagnosis and Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE LUNG INJURY; HIGH-FREQUENCY OSCILLATION; LOW TIDAL VOLUME; EXTRACORPOREAL MEMBRANE-OXYGENATION; CARBON-DIOXIDE REMOVAL; MECHANICAL VENTILATION; ADULT PATIENTS; DRIVING PRESSURE; CLINICAL-TRIAL; PROTECTIVE VENTILATION	IMPORTANCE Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure that affects approximately 200 000 patients each year in the United States, resulting in nearly 75 000 deaths annually. Globally, ARDS accounts for 10% of intensive care unit admissions, representing more than 3 million patients with ARDS annually. OBJECTIVE To review advances in diagnosis and treatment of ARDS over the last 5 years. EVIDENCE REVIEW We searched MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from 2012 to 2017 focusing on randomized clinical trials, meta-analyses, systematic reviews, and clinical practice guidelines. Articles were identified for full text review with manual review of bibliographies generating additional references. FINDINGS After screening 1662 citations, 31 articles detailing major advances in the diagnosis or treatment of ARDS were selected. The Berlin definition proposed 3 categories of ARDS based on the severity of hypoxemia: mild (200 mm Hg<PaO2/FIO2 <= 300 mm Hg), moderate (100 mm Hg<PaO2/FIO2 <= 200 mm Hg), and severe (PaO2/FIO2 <= 100 mm Hg), along with explicit criteria related to timing of the syndrome's onset, origin of edema, and the chest radiograph findings. The Berlin definition has significantly greater predictive validity for mortality than the prior American-European Consensus Conference definition. Clinician interpretation of the origin of edema and chest radiograph criteria may be less reliable in making a diagnosis of ARDS. The cornerstone of management remains mechanical ventilation, with a goal to minimize ventilator-induced lung injury (VILI). Aspirin was not effective in preventing ARDS in patients at high-risk for the syndrome. Adjunctive interventions to further minimize VILI, such as prone positioning in patients with a PaO2/FIO2 ratio less than 150 mm Hg, were associated with a significant mortality benefit whereas others (eg, extracorporeal carbon dioxide removal) remain experimental. Pharmacologic therapies such as beta(2) agonists, statins, and keratinocyte growth factor, which targeted pathophysiologic alterations in ARDS, were not beneficial and demonstrated possible harm. Recent guidelines on mechanical ventilation in ARDS provide evidence-based recommendations related to 6 interventions, including low tidal volume and inspiratory pressure ventilation, prone positioning, high-frequency oscillatory ventilation, higher vs lower positive end-expiratory pressure, lung recruitment maneuvers, and extracorporeal membrane oxygenation. CONCLUSIONS AND RELEVANCE The Berlin definition of acute respiratory distress syndrome addressed limitations of the American-European Consensus Conference definition, but poor reliability of some criteria may contribute to underrecognition by clinicians. No pharmacologic treatments aimed at the underlying pathology have been shown to be effective, and management remains supportive with lung-protective mechanical ventilation. Guidelines on mechanical ventilation in patients with acute respiratory distress syndrome can assist clinicians in delivering evidence-based interventions that may lead to improved outcomes.	[Fan, Eddy; Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Fan, Eddy] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Fan, Eddy] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Fan, Eddy] Sinai Hlth Syst, Toronto, ON, Canada; [Fan, Eddy; Slutsky, Arthur S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Brodie, Daniel] Columbia Univ, Coll Phys & Surg, New York Presbyterian Hosp, Div Pulm Allergy & Crit Care Med, New York, NY USA; [Slutsky, Arthur S.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; Columbia University; NewYork-Presbyterian Hospital; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Fan, E (corresponding author), Toronto Gen Hosp, 585 Univ Ave,PMB 11-123, Toronto, ON M5G 2N2, Canada.	eddy.fan@uhn.ca	Slutsky, Arthur/M-3325-2019		Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Dr Fan is supported by a New Investigator Award from the Canadian Institutes of Health Research.	Akoumianaki E, 2014, AM J RESP CRIT CARE, V189, P520, DOI 10.1164/rccm.201312-2193CI; Akoumianaki E, 2013, CHEST, V143, P927, DOI 10.1378/chest.12-1817; Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639; Aoyama H, 2018, CRIT CARE MED, V46, P300, DOI 10.1097/CCM.0000000000002838; ASHBAUGH DG, 1967, LANCET, V2, P319; Bassford CR, 2012, CRIT CARE, V16, DOI 10.1186/cc11221; Bein T, 2013, INTENS CARE MED, V39, P847, DOI 10.1007/s00134-012-2787-6; Beitler JR, 2016, INTENS CARE MED, V42, P756, DOI 10.1007/s00134-016-4331-6; Beitler JR, 2014, INTENS CARE MED, V40, P332, DOI 10.1007/s00134-013-3194-3; Bellani G, 2017, AM J RESP CRIT CARE, V195, P67, DOI 10.1164/rccm.201606-1306OC; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171; Craig TR, 2011, AM J RESP CRIT CARE, V183, P620, DOI 10.1164/rccm.201003-0423OC; Dessap AM, 2016, INTENS CARE MED, V42, P862, DOI 10.1007/s00134-015-4141-2; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Fan E, 2005, JAMA-J AM MED ASSOC, V294, P2889, DOI 10.1001/jama.294.22.2889; Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Fan E, 2017, CRIT CARE MED, V45, P919, DOI 10.1097/CCM.0000000000002386; Fan E, 2016, INTENS CARE MED, V42, P712, DOI 10.1007/s00134-016-4314-7; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Fan E, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-85; Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; Fitzgerald M, 2014, CRIT CARE, V18, DOI 10.1186/cc13875; Frerichs I, 2017, THORAX, V72, P83, DOI 10.1136/thoraxjnl-2016-208357; Gajic O, 2011, AM J RESP CRIT CARE, V183, P462, DOI 10.1164/rccm.201004-0549OC; Gattinoni L, 2016, INTENS CARE MED, V42, P1567, DOI 10.1007/s00134-016-4505-2; Gattinoni L, 2013, AM J RESP CRIT CARE, V188, P1286, DOI 10.1164/rccm.201308-1532CI; Gattinoni L, 2013, INTENS CARE MED, V39, P1909, DOI 10.1007/s00134-013-3066-x; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Goddard S, 2016, AM J RESP CRIT CARE, V193; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Goligher EC, 2017, ANN AM THORAC SOC, V14, pS289, DOI 10.1513/AnnalsATS.201704-341OT; Goligher EC, 2017, ANN AM THORAC SOC, V14, pS304, DOI 10.1513/AnnalsATS.201704-340OT; Goligher EC, 2017, AM J RESP CRIT CARE, V196, P558, DOI 10.1164/rccm.201701-0248CP; Goligher EC, 2016, LANCET, V387, P1856, DOI 10.1016/S0140-6736(16)30176-3; Goligher EC, 2015, AM J RESP CRIT CARE, V192, P1416, DOI 10.1164/rccm.201410-1832CP; Goligher EC, 2015, INTENS CARE MED, V41, P642, DOI 10.1007/s00134-015-3687-3; Grasso S, 2004, CRIT CARE MED, V32, P1018, DOI 10.1097/01.CCM.0000120059.94009.AD; Grasso S, 2007, AM J RESP CRIT CARE, V176, P761, DOI 10.1164/rccm.200702-193OC; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Guervilly C, 2012, CRIT CARE MED, V40, P1539, DOI 10.1097/CCM.0b013e3182451b4a; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hodgson C, 2016, COCHRANE DB SYST REV, V11; Huang DT, 2017, ANN AM THORAC SOC, V14, P124, DOI 10.1513/AnnalsATS.201608-629OT; Iwashyna TJ, 2015, AM J RESP CRIT CARE, V192, P1045, DOI 10.1164/rccm.201411-2125CP; Jacobson JR, 2005, AM J PHYSIOL-LUNG C, V288, pL1026, DOI 10.1152/ajplung.00354.2004; Kacmarek RM, 2016, CRIT CARE MED, V44, P32, DOI 10.1097/CCM.0000000000001383; Karagiannidis C, 2016, INTENS CARE MED, V42, P889, DOI 10.1007/s00134-016-4273-z; Kor DJ, 2016, JAMA-J AM MED ASSOC, V315, P2406, DOI 10.1001/jama.2016.6330; Kor DJ, 2011, CRIT CARE MED, V39, P2393, DOI 10.1097/CCM.0b013e318225757f; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McAuley DF, 2017, LANCET RESP MED, V5, P484, DOI 10.1016/S2213-2600(17)30171-6; McAuley DF, 2014, NEW ENGL J MED, V371, P1695, DOI 10.1056/NEJMoa1403285; Meade MO, 2017, AM J RESP CRIT CARE, V196, P727, DOI 10.1164/rccm.201609-1938OC; Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423; Morelli A, 2017, INTENS CARE MED, V43, P519, DOI 10.1007/s00134-016-4673-0; Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT; Munshi Laveena, 2014, Ann Am Thorac Soc, V11, P802, DOI 10.1513/AnnalsATS.201401-012OC; Nava S, 2009, LANCET, V374, P250, DOI 10.1016/S0140-6736(09)60496-7; Needham DM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2124; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Ou XF, 2017, CAN MED ASSOC J, V189, pE260, DOI 10.1503/cmaj.160570; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Patel BK, 2016, JAMA-J AM MED ASSOC, V315, P2435, DOI 10.1001/jama.2016.6338; Perkins GD, 2014, AM J RESP CRIT CARE, V189, P674, DOI 10.1164/rccm.201308-1549OC; Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC; Pham T, 2017, MAYO CLIN PROC, V92, P1382, DOI 10.1016/j.mayocp.2017.05.004; Pipeling MR, 2010, JAMA-J AM MED ASSOC, V304, P2521, DOI 10.1001/jama.2010.1752; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sahetya SK, 2017, AM J RESP CRIT CARE, V195, P1429, DOI 10.1164/rccm.201610-2035CI; Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC; Sklar MC, 2017, CHEST, V152, P1306, DOI 10.1016/j.chest.2017.06.025; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Slutsky AS, 2010, NEW ENGL J MED, V363, P1176, DOI 10.1056/NEJMe1007136; Smith FG, 2012, LANCET, V379, P229, DOI 10.1016/S0140-6736(11)61623-1; Sud S, 2014, CAN MED ASSOC J, V186, pE381, DOI 10.1503/cmaj.140081; Sud S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2327; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Truwit JD, 2014, NEW ENGL J MED, V370, P2191, DOI 10.1056/NEJMoa1401520; Vaporidi K, 2017, INTENS CARE MED, V43, P184, DOI 10.1007/s00134-016-4593-z; Walkey AJ, 2017, ANN AM THORAC SOC, V14, pS271, DOI 10.1513/AnnalsATS.201704-337OT; Walkey AJ, 2017, ANN AM THORAC SOC, V14, pS297, DOI 10.1513/AnnalsATS.201704-338OT; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Weiss CH, 2017, ANN AM THORAC SOC, V14, P1235, DOI 10.1513/AnnalsATS.201704-332CME; Yadav H, 2015, AM J PHYSIOL-LUNG C, V309, pL915, DOI 10.1152/ajplung.00266.2015; Yoshida T, 2013, AM J RESP CRIT CARE, V188, P1420, DOI 10.1164/rccm.201303-0539OC; Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716	97	639	724	17	149	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 20	2018	319	7					698	710		10.1001/jama.2017.21907	http://dx.doi.org/10.1001/jama.2017.21907			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW7MQ	29466596				2023-01-03	WOS:000425508400020
J	English, T; Ribeiro, B				English, Terence; Ribeiro, Bernard			Should doctor assisted dying be legal?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[English, Terence; Ribeiro, Bernard] Royal Coll Surg, Oxford, England			tenglish@doctors.org.uk; ribeirob@parliament.uk						[Anonymous], 2014, ASSISTED DYING BILL; Morrison RS, 2015, AM CARE SERIOUS ILLN; Ribeiro B., 2015, TELEGRAPH; Royal College of Physicians, 2009, COMMUNICATION; United Nations Department of Economic and Social Affairs, 2014, NON TRADITIONAL REF	5	2	2	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2018	360								k562	10.1136/bmj.k562	http://dx.doi.org/10.1136/bmj.k562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW0HY	29437655				2023-01-03	WOS:000424975900014
J	Rockett, IRH; Caine, ED; Connery, HS; D'Onofrio, G; Gunnell, DJ; Miller, TR; Nolte, KB; Kaplan, MS; Kapusta, ND; Lilly, CL; Nelson, LS; Putnam, SL; Stack, S; Varnik, P; Webster, LR; Jia, H				Rockett, Ian R. H.; Caine, Eric D.; Connery, Hilary S.; D'Onofrio, Gail; Gunnell, David J.; Miller, Ted R.; Nolte, Kurt B.; Kaplan, Mark S.; Kapusta, Nestor D.; Lilly, Christa L.; Nelson, Lewis S.; Putnam, Sandra L.; Stack, Steven; Varnik, Peeter; Webster, Lynn R.; Jia, Haomiao			Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history	PLOS ONE			English	Article							TIME-TRENDS; PSYCHOLOGICAL AUTOPSY; UNDETERMINED DEATHS; UNITED-STATES; RATES; PREVENTION; MORTALITY; VALIDITY; ENGLAND; SYSTEMS	Objective A paucity of corroborative psychological and psychiatric evidence may be inhibiting detection of drug intoxication suicides in the United States. We evaluated the relative importance of suicide notes and psychiatric history in the classification of suicide by drug intoxication versus firearm (gunshot wound) plus hanging/suffocation - the other two major, but overtly violent methods. Methods This observational multilevel (individual/county), multivariable study employed a generalized linear mixed model (GLMM) to analyze pooled suicides and undetermined intent deaths, as possible suicides, among the population aged 15 years and older in the 17 states participating in the National Violent Death Reporting System throughout 2011-2013. The outcome measure was relative odds of suicide versus undetermined classification, adjusted for demographics, precipitating circumstances, and investigation characteristics. Results A suicide note, prior suicide attempt, or affective disorder was documented in less than one-third of suicides and one-quarter of undetermined deaths. The prevalence gaps were larger among drug intoxication cases than gunshot/hanging cases. The latter were more likely than intoxication cases to be classified as suicide versus undetermined manner of death (adjusted odds ratio [OR], 41.14; 95% CI, 34.43-49.15), as were cases documenting a suicide note (OR, 33.90; 95% CI, 26.11-44.05), prior suicide attempt (OR, 2.42; 95% CI, 2.11-2.77), or depression (OR, 1.61; 95% CI, 1.38 to 1.88), or bipolar disorder (OR, 1.41; 95% CI, 1.10-1.81). Stratification by mechanism/cause intensified the association between a note and suicide classification for intoxication cases (OR, 45.43; 95% CI, 31.06-66.58). Prior suicide attempt (OR, 2.64; 95% CI, 2.19-3.18) and depression (OR, 1.48; 95% CI, 1.17-1.87) were associated with suicide classification in intoxication but not gunshot/hanging cases. Conclusions Without psychological/psychiatric evidence contributing to manner of death classification, suicide by drug intoxication in the US is likely profoundly under-reported. Findings harbor adverse implications for surveillance, etiologic understanding, and prevention of suicides and drug deaths.	[Rockett, Ian R. H.] West Virginia Univ, Dept Epidemiol, Morgantown, WV 26506 USA; [Rockett, Ian R. H.; Putnam, Sandra L.] West Virginia Univ, Injury Control Res Ctr, Morgantown, WV 26506 USA; [Caine, Eric D.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14642 USA; [Caine, Eric D.] Univ Rochester, Med Ctr, Injury Control Res Ctr Suicide Prevent, Rochester, NY 14642 USA; [Connery, Hilary S.] McLean Hosp, Div Alcohol & Drug Abuse, Boston, MA USA; [Connery, Hilary S.] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [D'Onofrio, Gail] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA; [Gunnell, David J.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England; [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA; [Miller, Ted R.] Curtin Univ, Perth, WA, Australia; [Nolte, Kurt B.] Univ New Mexico, Sch Med, Off Med Investigator, Albuquerque, NM 87131 USA; [Kaplan, Mark S.] UCLA, Luskin Sch Publ Affairs, Los Angeles, CA USA; [Kapusta, Nestor D.] Med Univ Vienna, Dept Psychoanal & Psychotherapy, Vienna, Austria; [Lilly, Christa L.] West Virginia Univ, Dept Biostat, Morgantown, WV 26506 USA; [Nelson, Lewis S.] Rutgers New Jersey Med Sch, Dept Emergency Med, Newark, NJ USA; [Stack, Steven] Wayne State Univ, Dept Criminal Justice, Detroit, MI USA; [Stack, Steven] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI USA; [Varnik, Peeter] Estonian Swedish Mental Hlth & Suicidol Inst, Tallinn, Estonia; [Webster, Lynn R.] PRA Hlth Sci, Salt Lake City, UT USA; [Jia, Haomiao] Columbia Univ, Dept Biostat, New York, NY USA; [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY USA	West Virginia University; West Virginia University; University of Rochester; University of Rochester; Harvard University; McLean Hospital; Harvard University; Harvard Medical School; Yale University; University of Bristol; Pacific Institute for Research & Evaluation (PIRE); Curtin University; University of New Mexico; University of California System; University of California Los Angeles; Medical University of Vienna; West Virginia University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Wayne State University; Wayne State University; Columbia University; Columbia University	Rockett, IRH (corresponding author), West Virginia Univ, Dept Epidemiol, Morgantown, WV 26506 USA.; Rockett, IRH (corresponding author), West Virginia Univ, Injury Control Res Ctr, Morgantown, WV 26506 USA.	irockett@hsc.wvu.edu	Kapusta, Nestor D/C-9368-2009; Gunnell, David/ABE-6653-2020; Lilly, Christa L/R-6644-2017	Kapusta, Nestor D/0000-0002-0970-4341; Gunnell, David/0000-0002-0829-6470; Lilly, Christa L/0000-0002-0009-0638; Kaplan, Mark/0000-0001-8511-9665; Miller, Ted/0000-0002-0958-2639; Rockett, Ian/0000-0002-4584-9337	National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention [R49CE002109, R49CE002093]; National Institute for Health Research [NF-SI-0512-10068] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104942] Funding Source: NIH RePORTER	National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by Grants R49CE002109 and R49CE002093 from the National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention. They provided salary support for three authors (IRHR, EDC, HJ) and consulting fees for another (SS) (https://www.cdc.gov/injury/index.html). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Arsenault-Lapierre G, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-37; Blair JM, 2016, INJURY PREV, V22, P6, DOI 10.1136/injuryprev-2015-041819; Bohnert ASB, 2013, INJURY PREV, V19, P326, DOI 10.1136/injuryprev-2012-040631; Botello T, 2013, J FORENSIC SCI, V58, P924, DOI 10.1111/1556-4029.12138; Carr JR, 2004, SUICIDE LIFE-THREAT, V34, P233, DOI 10.1521/suli.34.3.233.42785; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; Center for Disease Control and Prevention, 2017, WEB BAS INJ STAT QUE; Centers for Disease Control and Prevention, 2015, PUBL HLTH LAW PROGR; Chan CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125730; Committee on Identifying the Needs of the Forensic Sciences Community: National Research Council, 2009, STRENGTH FOR SCI US; Curphey TJ, 1967, ESSAYS SELF DESTRUCT, P463; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; Gray D, 2014, SUICIDE LIFE-THREAT, V44, P304, DOI 10.1111/sltb.12079; Gunnell D, 2013, PSYCHOL MED, V43, P1415, DOI 10.1017/S0033291712002401; Hanzlick R., 2013, ACAD FORENSIC PATHOL, V4, P2; HARRIS EC, 1994, MEDICINE, V73, P281, DOI 10.1097/00005792-199411000-00001; Health Resources and Services Administration Bureau of Health Workforce National Center for Health Workforce Analysis, 2015, COUNT AR HLTH RES FI; Hedegaard H, 2017, NCHS DATA BRIEF, V273, p1 ; Hsieh ML, 2016, J INTERPERS VIOLENCE; Huguet N, 2012, SUICIDE LIFE-THREAT, V42, P185, DOI 10.1111/j.1943-278X.2012.00081.x; Institute of Medicine, 2006, HOSP BAS EM CAR BREA; Institute of Medicine, 2006, EM MED SERV CROSSR; Institute of Medicine, 2003, WORKSH MED DEATH INV; Kaplan MS, 2017, AM J PREV MED, V53, P130, DOI 10.1016/j.amepre.2017.01.043; Klugman J, 2013, SOC SCI QUART, V94, P462, DOI 10.1111/j.1540-6237.2012.00937.x; Kolves K, 2013, SOCIOL HEALTH ILL, V35, P956, DOI 10.1111/1467-9566.12011; Linsley KR, 2001, BRIT J PSYCHIAT, V178, P465, DOI 10.1192/bjp.178.5.465; National Commission on Forensic Science, 2015, ACCR MED DEATH INV O; Ohberg A, 1998, ACTA PSYCHIAT SCAND, V98, P214, DOI 10.1111/j.1600-0447.1998.tb10069.x; OVENSTONE IM, 1973, BRIT J PSYCHIAT, V123, P15, DOI 10.1192/bjp.123.1.15; Parai JL, 2006, ANN EPIDEMIOL, V16, P805, DOI 10.1016/j.annepidem.2006.01.006; Pritchard C, 2015, COMMUNITY MENT HLT J, V51, P365, DOI 10.1007/s10597-014-9810-z; Rockett IRH, 2007, INJURY PREV, V13, P311, DOI 10.1136/ip.2007.015230; Rockett IRH, 2016, JAMA PSYCHIAT, V73, P1072, DOI 10.1001/jamapsychiatry.2016.1870; Rockett IRH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137933; Rockett IRH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135296; Rockett IRH, 2014, AM J PUBLIC HEALTH, V104, pE49, DOI 10.2105/AJPH.2014.302244; Rockett IRH, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-705; Rockett IRH, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-35; Rockett IRH, 1998, POPUL BULL, V53, P3; Rockett IRH, 1998, PUBLIC HEALTH, V112, P27; ROSENBERG ML, 1988, J FORENSIC SCI, V33, P1445; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Salmeron D, 2013, J PUBLIC HEALTH-UK, V35, P237, DOI 10.1093/pubmed/fds103; Stone DM, 2017, AM J PUBLIC HEALTH, V107, P1233, DOI [10.2105/AJPH.2017.303863, 10.2105/ajph.2017.303863]; Stone DH, 2002, FINAL REPORT EUROPEA; Thomas K, 2010, INT J EPIDEMIOL, V39, P1464, DOI 10.1093/ije/dyq094; UK Department of Health, 2014, STAT UPD SUIC; *US PUBL HLTH SERV, 2001, NAT STRAT SUIC PREV; Varnik P, 2012, INJURY PREV, V18, P321, DOI 10.1136/injuryprev-2011-040070; Waldhoer T, 2003, J CLIN EPIDEMIOL, V56, P891, DOI 10.1016/S0895-4356(03)00076-3; Warner M, 2013, ACAD FORENSIC PATHOL, V3, P231, DOI [DOI 10.23907/2013.029, 10.23907/2013.029]; Webster LR, 2001, PAIN MED S2, pS86	53	60	61	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2018	13	1							e0190200	10.1371/journal.pone.0190200	http://dx.doi.org/10.1371/journal.pone.0190200			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FS3NS	29320540	gold, Green Published, Green Submitted			2023-01-03	WOS:000419689600038
J	Rossi, M; Caruso, F; Kwok, L; Lee, G; Caruso, A; Gionfra, F; Candelotti, E; Belli, SL; Molasky, N; Raley-Susman, KM; Leone, S; Filipsky, T; Tofani, D; Pedersen, J; Incerpi, S				Rossi, Miriam; Caruso, Francesco; Kwok, Lorraine; Lee, Grace; Caruso, Alessio; Gionfra, Fabio; Candelotti, Elena; Belli, Stuart L.; Molasky, Nora; Raley-Susman, Kathleen M.; Leone, Stefano; Filipsky, Tomas; Tofani, Daniela; Pedersen, Jens; Incerpi, Sandra			Protection by extra virgin olive oil against oxidative stress in vitro and in vivo. Chemical and biological studies on the health benefits due to a major component of the Mediterranean diet	PLOS ONE			English	Article							CAENORHABDITIS-ELEGANS; ANTIOXIDANT CAPACITY; APPROXIMATION; RESISTANCE; MOLECULES; MYOBLASTS; EXCHANGE; TYROSOL; SOLIDS; PHENOL	We report the results of in vivo studies in Caenorhabditis elegans nematodes in which addition of extra virgin olive oil (EVOO) to their diet significantly increased their life span with respect to the control group. Furthermore, when nematodes were exposed to the pesticide paraquat, they started to die after two days, but after the addition of EVOO to their diet, both survival percentage and lifespans of paraquat-exposed nematodes increased. Since paraquat is associated with superoxide radical production, a test for scavenging this radical was performed using cyclovoltammetry and the EVOO efficiently scavenged the superoxide. Thus, a linear correlation (y = -0.0838x +19.73, regression factor = 0.99348) was observed for superoxide presence (y) in the voltaic cell as a function of aliquot (x) additions of EVOO, 10 mu L each. The originally generated supoeroxide was approximately halved after 10 aliquots (100 mu L total). The superoxide scavenging ability was analyzed, theoretically, using Density Functional Theory for tyrosol and hydroxytyrosol, two components of EVOO and was also confirmed experimentally for the galvinoxyl radical, using Electron Paramagnetic Resonance (EPR) spectroscopy. The galvinoxyl signal disappeared after adding 1 mu L of EVOO to the EPR cell in 10 minutes. In addition, EVOO significantly decreased the proliferation of human leukemic THP-1 cells, while it kept the proliferation at about normal levels in rat L6 myoblasts, a non-tumoral skeletal muscle cell line. The protection due to EVOO was also assessed in L6 cells and THP-1 exposed to the radical generator cumene hydroperoxide, in which cell viability was reduced. Also in this case the oxidative stress was ameliorated by EVOO, in line with results obtained with tetrazolium dye reduction assays, cell cycle analysis and reactive oxygen species measurements. We ascribe these beneficial effects to EVOO antioxidant properties and our results are in agreement with a clear health benefit of EVOO use in the Mediterranean diet.	[Rossi, Miriam; Caruso, Francesco; Kwok, Lorraine; Lee, Grace; Caruso, Alessio; Belli, Stuart L.; Molasky, Nora] Vassar Coll, Dept Chem, Poughkeepsie, NY 12601 USA; [Gionfra, Fabio; Candelotti, Elena; Leone, Stefano; Tofani, Daniela; Incerpi, Sandra] Univ Roma Tre, Dept Sci, Rome, Italy; [Raley-Susman, Kathleen M.] Vassar Coll, Dept Biol, Poughkeepsie, NY 12601 USA; [Filipsky, Tomas] Charles Univ Prague, Dept Pharmacol & Toxicol Hradec Kralove, Heyrovskeho, Czech Republic; [Pedersen, Jens] Univ Tor Vergata, Dept Biol, Rome, Italy	Vassar College; Italfarmaco; Roma Tre University; Vassar College; Charles University Prague; University of Rome Tor Vergata	Rossi, M (corresponding author), Vassar Coll, Dept Chem, Poughkeepsie, NY 12601 USA.; Incerpi, S (corresponding author), Univ Roma Tre, Dept Sci, Rome, Italy.	rossi@vassar.edu; sandra.incerpi@uniroma3.it	Gionfra, Fabio/ABB-4541-2020; Daniela, Tofani/G-6346-2013	Gionfra, Fabio/0000-0003-2697-6020; Daniela, Tofani/0000-0003-1028-9832; Leone, Stefano/0000-0001-6339-6397; Rossi, Miriam/0000-0001-9609-474X; Caruso, Alessio/0000-0001-5612-8140; Ens, Emilie/0000-0001-7732-5063	Regione Lazio [F83D15000160009']; Department of Sciences, University Roma Tre	Regione Lazio(Regione Lazio); Department of Sciences, University Roma Tre	The contribution of a grant for Progetti coerenti con il Tema di EXPO Milano 2015 "Nutrire il pianeta, Energia per la vita" CUP n. F83D15000160009' from Regione Lazio and a financial support CAL from the Department of Sciences, University Roma Tre to S.I. are gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Besnard G, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2833; Blackwell TK, 2015, FREE RADICAL BIO MED, V88, P290, DOI 10.1016/j.freeradbiomed.2015.06.008; Brody AH, 2013, NEUROTOXICOLOGY, V34, P74, DOI 10.1016/j.neuro.2012.10.007; Budzianowski A, 2006, ACTA CRYSTALLOGR B, V62, P94, DOI 10.1107/S010876810503747X; Canuelo A, 2013, PROTEOMICS, V13, P3064, DOI 10.1002/pmic.201200579; Canuelo A, 2012, MECH AGEING DEV, V133, P563, DOI 10.1016/j.mad.2012.07.004; Coccia A, 2016, ONCOL REP, V36, P3095, DOI 10.3892/or.2016.5150; D'Arezzo S, 2004, ENDOCRINOLOGY, V145, P5694, DOI 10.1210/en.2004-0890; Del Coco L, 2013, EUR J LIPID SCI TECH, V115, P1043, DOI 10.1002/ejlt.201300160; Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015; Efe R, 2012, ENV ECOLOGY MEDITERR, V5, P54; Frankel EN, 2011, J AGR FOOD CHEM, V59, P785, DOI 10.1021/jf103813t; Guasch-Ferre M, 2017, NUTR METAB CARDIOVAS, V27, P624, DOI 10.1016/j.numecd.2017.05.004; Hashim YZHY, 2008, INT J CANCER, V122, P495, DOI 10.1002/ijc.23148; Incerpi S, 2014, AM J PHYSIOL-CELL PH, V307, pC150, DOI 10.1152/ajpcell.00308.2013; Le Bourvellec C, 2008, TALANTA, V75, P1098, DOI 10.1016/j.talanta.2008.01.007; Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005; Lombardo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060796; Luciano M, 2017, NEUROLOGY, V88, P449, DOI 10.1212/WNL.0000000000003559; Monasterio RP, 2013, J AGR FOOD CHEM, V61, P4477, DOI 10.1021/jf400864q; Franco MN, 2014, FOOD CHEM, V163, P289, DOI 10.1016/j.foodchem.2014.04.091; Pedersen JZ, 2007, J PHARM PHARMACOL, V59, P1721, DOI 10.1211/jpp.59.12.0015; PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; Rossi M, 2013, BIOCHIMIE, V95, P1954, DOI 10.1016/j.biochi.2013.07.002; Sacchi R, 1998, J AGR FOOD CHEM, V46, P3947, DOI 10.1021/jf970666l; Samieri C, 2011, NEUROLOGY, V77, P418, DOI 10.1212/WNL.0b013e318220abeb; Tofani D, 2010, J AGR FOOD CHEM, V58, P5292, DOI 10.1021/jf1000716	29	17	18	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2017	12	12							e0189341	10.1371/journal.pone.0189341	http://dx.doi.org/10.1371/journal.pone.0189341			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR4KF	29283995	Green Submitted, gold, Green Published			2023-01-03	WOS:000419033400008
J	Baker, KK; Padhi, B; Torondel, B; Das, P; Dutta, A; Sahoo, KC; Das, B; Dreibelbis, R; Caruso, B; Freeman, MC; Sager, L; Panigrahi, P				Baker, Kelly K.; Padhi, Bijaya; Torondel, Belen; Das, Padmalaya; Dutta, Ambarish; Sahoo, Krushna Chandra; Das, Bhabani; Dreibelbis, Robert; Caruso, Bethany; Freeman, Matthew C.; Sager, Lauren; Panigrahi, Pinaki			From menarche to menopause: A population-based assessment of water, sanitation, and hygiene risk factors for reproductive tract infection symptoms over life stages in rural girls and women in India	PLOS ONE			English	Article							ABNORMAL VAGINAL DISCHARGE; LOW-BIRTH-WEIGHT; BACTERIAL VAGINOSIS; PREGNANT-WOMEN; EMOTIONAL DISTRESS; PRETERM DELIVERY; HEALTH; ASSOCIATION; INSECURITY; STRESS	Women face greater challenges than men in accessing water, sanitation, and hygiene (WASH) resources to address their daily needs, and may respond to these challenges by adopting unsafe practices that increase the risk of reproductive tract infections (RTIs). WASH practices may change as women transition through socially-defined life stage experiences, like marriage and pregnancy. Thus, the relationship between WASH practices and RTIs might vary across female reproductive life stages. This cross-sectional study assessed the relationship between WASH exposures and self-reported RTI symptoms in 3,952 girls and women from two rural districts in India, and tested whether social exposures represented by reproductive life stage was an effect modifier of associations. In fully adjusted models, RTI symptoms were less common in women using a latrine without water for defecation versus open defecation (Odds Ratio (OR) = 0.69; Confidence Interval (CI) = 0.48, 0.98) and those walking shorter distances to a bathing location (OR = 0.79, CI = 0.63, 0.99), but there was no association between using a latrine with a water source and RTIs versus open defecation (OR = 1.09; CI = 0.69, 1.72). Unexpectedly, RTI symptoms were more common for women bathing daily with soap (OR = 6.55, CI = 3.60, 11.94) and for women washing their hands after defecation with soap (OR = 10.27; CI = 5.53, 19.08) or ash/soil/ mud (OR = 6.02; CI = 3.07, 11.77) versus water only or no hand washing. WASH practices of girls and women varied across reproductive life stages, but the associations between WASH practices and RTI symptoms were not moderated by or confounded by life stage status. This study provides new evidence that WASH access and practices are associated with self-reported reproductive tract infection symptoms in rural Indian girls and women from different reproductive life stages. However, the counterintuitive directions of effect for soap use highlights that causality and mechanisms of effect cannot be inferred from this study design. Future research is needed to understand whether improvements in water and sanitation access could improve the practice of safe hygiene behaviors and reduce the global burden of RTIs in women.	[Baker, Kelly K.; Sager, Lauren] Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA; [Padhi, Bijaya; Das, Padmalaya; Dutta, Ambarish; Sahoo, Krushna Chandra; Das, Bhabani] Asian Inst Publ Hlth, Bhubaneswar, India; [Torondel, Belen] London Sch Hyg & Trop Med, London, England; [Dreibelbis, Robert] Univ Oklahoma, Norman, OK 73019 USA; [Caruso, Bethany; Freeman, Matthew C.] Emory Univ, Atlanta, GA 30322 USA; [Panigrahi, Pinaki] Univ Nebraska Med Ctr, Omaha, NE USA	University of Iowa; University of London; London School of Hygiene & Tropical Medicine; University of Oklahoma System; University of Oklahoma - Norman; Emory University; University of Nebraska System; University of Nebraska Medical Center	Baker, KK (corresponding author), Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA.	kelly-k-baker@uiowa.edu	Padhi, Bijaya Kumar/AAW-2384-2021; Padhi, Bijaya K/E-7102-2010; Sahoo, Krushna Chandra/AAF-2813-2020	Padhi, Bijaya Kumar/0000-0002-2828-2375; Padhi, Bijaya K/0000-0002-2828-2375; Caruso, Bethany/0000-0001-9738-9857; Baker, Kelly/0000-0002-3774-2628; Dreibelbis, Robert/0000-0002-9716-0419; Dutta, Ambarish/0000-0002-4019-7472; Das, Bhabani Sankar/0000-0001-8492-9033	Sanitation and Hygiene Applied Research for Equity (SHARE) consortium; UK Department for International Development [PO 6981]	Sanitation and Hygiene Applied Research for Equity (SHARE) consortium; UK Department for International Development	This research received financial support from the Sanitation and Hygiene Applied Research for Equity (SHARE) consortium (https//www..shareresearchorg/), which was funded by the UK Department for International Development (grant no. PO 6981). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal Arun Kumar, 2004, Journal of Communicable Diseases, V36, P1; Ahuja Maninder, 2016, J Midlife Health, V7, P126; Al Riyami A, 2005, MED PRIN PRACT, V14, P92, DOI 10.1159/000083918; Alexander M, 2007, INT FAM PLAN PERSPEC, V33, P150, DOI 10.1363/ifpp.33.150.07; Alijahan Rahele, 2014, Iran J Reprod Med, V12, P47; Anand E, 2015, SEX REPROD HEALTHC, V6, P249, DOI 10.1016/j.srhc.2015.06.001; Ashorn P, 2015, NESTLE NUTR WORKS SE, V81, P37, DOI 10.1159/000365802; Bahram Amini, 2009, Oman Med J, V24, P288, DOI 10.5001/omj.2009.58; Balsara ZP, 2010, J HEALTH POPUL NUTR, V28, P501; Bennett DA, 2001, AUST NZ J PUBL HEAL, V25, P464, DOI 10.1111/j.1467-842X.2001.tb00294.x; Benova L, 2014, TROP MED INT HEALTH, V19, P368, DOI 10.1111/tmi.12275; Betha K, 2016, INFECT DIS OBSTET GY, V2016; Bhilwar Meenakshi, 2015, J Nat Sci Biol Med, V6, pS29, DOI 10.4103/0976-9668.166059; Brotman RM, 2008, AM J EPIDEMIOL, V168, P188, DOI 10.1093/aje/kwn103; Cammack AL, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2011.01.054; Caruso BA, 2015, LANCET, V386, P650, DOI 10.1016/S0140-6736(15)61497-0; Chen QX, 2013, AM J PUBLIC HEALTH, V103, pE67, DOI 10.2105/AJPH.2012.300995; Clasen T, 2014, LANCET GLOB HEALTH, V2, pE645, DOI 10.1016/S2214-109X(14)70307-9; Cohen BE, 2012, WOMEN HEALTH ISS, V22, pE461, DOI 10.1016/j.whi.2012.06.005; Contzen N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136445; Crucitti T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016310; Culhane JF, 2002, AM J OBSTET GYNECOL, V187, P1272, DOI 10.1067/mob.2002.127311; Dambhare Dharampal G, 2012, Glob J Health Sci, V4, P105, DOI 10.5539/gjhs.v4n1p105; Das P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130777; Donati L, 2010, ARCH GYNECOL OBSTET, V281, P589, DOI 10.1007/s00404-009-1318-3; Eschenbach DA, 2007, CLIN INFECT DIS, V44, P220, DOI 10.1086/509584; Fisher J, 2008, P I CIVIL ENG-MUNIC, V161, P223, DOI 10.1680/muen.2008.161.4.223; Goto A, 2005, J EPIDEMIOL, V15, P163, DOI 10.2188/jea.15.163; Hassan WM, 2007, SEX TRANSM DIS, V34, P384, DOI 10.1097/01.olq.0000243624.74573.63; HILL GB, 1993, AM J OBSTET GYNECOL, V169, P450, DOI 10.1016/0002-9378(93)90339-K; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Hulland KRS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141883; Jaya, 2009, INT PERSPECT SEX R H, V35, P97, DOI 10.1363/ipsrh.35.097.09; Kenyon C, 2013, AM J OBSTET GYNECOL, V209, P505, DOI 10.1016/j.ajog.2013.05.006; Kenyon CR, 2014, CURR OPIN OBSTET GYN, V26, P448, DOI 10.1097/GCO.0000000000000112; Kerubo E, 2016, SEX TRANSM INFECT, V92, P251, DOI 10.1136/sextrans-2015-052371; Khanna T, 2016, GLOB PUBLIC HEALTH, V11, P1185, DOI 10.1080/17441692.2015.1062905; Khawaja M, 2009, J WOMENS HEALTH, V18, P1701, DOI 10.1089/jwh.2008.0962; Klebanoff MA, 2010, SEX TRANSM DIS, V37, P94, DOI 10.1097/OLQ.0b013e3181bc063c; Kojima N, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2282-3; Krupp K, 2007, Glob Public Health, V2, P395, DOI 10.1080/17441690701238031; Lata Indu, 2010, Indian J Community Med, V35, P285, DOI 10.4103/0970-0218.66855; Li XD, 2014, EUR J CLIN MICROBIOL, V33, P1525, DOI 10.1007/s10096-014-2103-1; Lien PT, 2002, STUD FAMILY PLANN, V33, P217, DOI 10.1111/j.1728-4465.2002.00217.x; Low N, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000416; ManunEbo M, 1997, TROP MED INT HEALTH, V2, P1015, DOI 10.1046/j.1365-3156.1997.d01-180.x; Mbizvo M E, 2004, Cent Afr J Med, V50, P41; McClelland RS, 2008, SEX TRANSM DIS, V35, P617, DOI 10.1097/OLQ.0b013e31816907fa; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; Murphy K, 2016, J INFECT DIS, V214, pS29, DOI 10.1093/infdis/jiw140; Nagarkar Aarti, 2015, Indian J Sex Transm Dis AIDS, V36, P18, DOI 10.4103/0253-7184.156690; Narayankhedkar A., 2015, J SEX TRANSM DIS, V2015; Ness RB, 2005, AM J EPIDEMIOL, V162, P585, DOI 10.1093/aje/kwi243; Onderdonk AB, 2016, CLIN MICROBIOL REV, V29, P223, DOI 10.1128/CMR.00075-15; Padhi BK, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001851; Paige DM, 1998, J NURSE-MIDWIFERY, V43, P83, DOI 10.1016/S0091-2182(97)00161-4; Patel V, 2006, SEX TRANSM INFECT, V82, P243, DOI 10.1136/sti.2005.016451; Patel V, 2006, ARCH GEN PSYCHIAT, V63, P404, DOI 10.1001/archpsyc.63.4.404; Patel V, 2005, INT J EPIDEMIOL, V34, P853, DOI 10.1093/ije/dyi072; Patel V, 2008, J PSYCHOSOM RES, V64, P255, DOI 10.1016/j.jpsychores.2007.10.015; Payne SC, 2010, J AM ACAD NURSE PRAC, V22, P101, DOI 10.1111/j.1745-7599.2009.00474.x; Romoren M, 2007, B WORLD HEALTH ORGAN, V85, P297, DOI 10.2471/BLT.06.031922; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Sahoo KC, 2015, SOC SCI MED, V139, P80, DOI 10.1016/j.socscimed.2015.06.031; SCHIEVE LA, 1994, AM J PUBLIC HEALTH, V84, P405, DOI 10.2105/AJPH.84.3.405; Sharma A. K., 2004, Journal of Communicable Diseases, V36, P93; Stevenson EGJ, 2012, SOC SCI MED, V75, P392, DOI 10.1016/j.socscimed.2012.03.022; Sumpter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062004; Svare JA, 2006, BJOG-INT J OBSTET GY, V113, P1419, DOI 10.1111/j.1471-0528.2006.01087.x; Sznajder KK, 2014, INT J OCCUP ENV HEAL, V20, P33, DOI 10.1179/2049396713Y.0000000053; Taha TE, 1999, J ACQ IMMUN DEF SYND, V20, P52, DOI 10.1097/00042560-199901010-00008; Tsai AC, 2016, J WATER HEALTH, V14, P280, DOI 10.2166/wh.2015.165; Tumwine JK, 2002, UGANDA COUNTRY STUDY, Vxix; van Eijk AM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010290; Winter SC, 2016, INT J ENVIRON HEAL R, V26, P291, DOI 10.1080/09603123.2015.1111309; Wojcik A, 2013, INT J OCCUP MED ENV, V26, P477, DOI 10.2478/s13382-013-0118-y; Wutich A, 2009, MED ANTHROPOL Q, V23, P436, DOI 10.1111/j.1548-1387.2009.01072.x; Wutich A, 2008, SOC SCI MED, V67, P2116, DOI 10.1016/j.socscimed.2008.09.042; ZURAYK H, 1995, STUD FAMILY PLANN, V26, P14, DOI 10.2307/2138047	79	20	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2017	12	12							e0188234	10.1371/journal.pone.0188234	http://dx.doi.org/10.1371/journal.pone.0188234			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FO8CU	29206842	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000417110700010
J	Loh, YY; Nagao, K; Hoover, AJ; Hesk, D; Rivera, NR; Colletti, SL; Davies, IW; MacMillan, DWC				Loh, Yong Yao; Nagao, Kazunori; Hoover, Andrew J.; Hesk, David; Rivera, Nelo R.; Colletti, Steven L.; Davies, Ian W.; MacMillan, David W. C.			Photoredox-catalyzed deuteration and tritiation of pharmaceutical compounds	SCIENCE			English	Article							BOND-DISSOCIATION ENERGIES; HYDROGEN ISOTOPE-EXCHANGE; DRUG DISCOVERY; AMINES; DESIGN; STABILIZATION; ACTIVATION; COMPLEXES; CHEMISTRY; RHODIUM	Deuterium- and tritium-labeled pharmaceutical compounds are pivotal diagnostic tools in drug discovery research, providing vital information about the biological fate of drugs and drug metabolites. Herein we demonstrate that a photoredox-mediated hydrogen atom transfer protocol can efficiently and selectively install deuterium (D) and tritium (T) at a-amino sp(3) carbon-hydrogen bonds in a single step, using isotopically labeled water (D2O or T2O) as the source of hydrogen isotope. In this context, we also report a convenient synthesis of T2O from T-2, providing access to high-specific-activity T2O. This protocol has been successfully applied to the high incorporation of deuterium and tritium in 18 drug molecules, which meet the requirements for use in ligand-binding assays and absorption, distribution, metabolism, and excretion studies.	[Loh, Yong Yao; Nagao, Kazunori; Davies, Ian W.; MacMillan, David W. C.] Princeton Univ, Merck Ctr Catalysis, Princeton, NJ 08544 USA; [Hoover, Andrew J.; Hesk, David; Rivera, Nelo R.; Davies, Ian W.] Merck & Co Inc, Merck Res Labs, Dept Proc R&D, Labeled Compound Synth Grp, Rahway, NJ 07065 USA; [Colletti, Steven L.] Merck & Co Inc, MRL, Dept Discovery Chem, Kenilworth, NJ 07033 USA	Princeton University; Merck & Company; Merck & Company	MacMillan, DWC (corresponding author), Princeton Univ, Merck Ctr Catalysis, Princeton, NJ 08544 USA.	dmacmill@princeton.edu	Nagao, Kazunori/A-2346-2019	Nagao, Kazunori/0000-0003-3141-5279; Hoover, Andrew/0000-0001-9513-4965; Hesk, David/0000-0003-4059-4168; Loh, Yong Yao/0000-0002-2938-1981; davies, ian/0000-0001-6936-5540	National Institutes of Health (NIH) [R01 GM103558-04]; Agency for Science, Technology and Research (A*STAR); Japan Society for the Promotion of Science; Merck; Abbvie; BMS; Janssen; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM103558] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Merck(Merck & Company); Abbvie(AbbVie); BMS(Bristol-Myers Squibb); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Research reported in this publication was supported by the National Institutes of Health (NIH) under award number R01 GM103558-04 (D.W.C.M., Y.Y.L., and K.N.). Y.Y.L. thanks the Agency for Science, Technology and Research (A*STAR) for a graduate fellowship. K.N. thanks the Japan Society for the Promotion of Science for an overseas postdoctoral fellowship. Additional funding was provided by kind gifts from Merck, Abbvie, BMS, and Janssen. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Additional data supporting the conclusions are available in the supplementary materials.	Allen PH, 2010, J LABELLED COMPD RAD, V53, P731, DOI 10.1002/jlcr.1825; Atzrodt J, 2007, ANGEW CHEM INT EDIT, V46, P7744, DOI 10.1002/anie.200700039; Baillie TA, 2006, CHEM RES TOXICOL, V19, P889, DOI 10.1021/tx060062o; Blanksby SJ, 2003, ACCOUNTS CHEM RES, V36, P255, DOI 10.1021/ar020230d; Czarnik A. W., 2009, U.S. Patent, Patent No. [20,090,062,220, 20090062220]; Derdau V, 2009, CHEM-EUR J, V15, P10397, DOI 10.1002/chem.200901107; Elmore CS, 2015, BIOORG MED CHEM LETT, V25, P167, DOI 10.1016/j.bmcl.2014.11.051; Elmore CS, 2009, ANNU REP MED CHEM, V44, P515, DOI 10.1016/S0065-7743(09)04425-X; Escoubet S, 2006, J ORG CHEM, V71, P7288, DOI 10.1021/jo061033l; Hadad CM, 1998, J ORG CHEM, V63, P8668, DOI 10.1021/jo972180+; Hale LVA, 2016, J AM CHEM SOC, V138, P13489, DOI 10.1021/jacs.6b07879; HESK D, 1995, J LABELLED COMPD RAD, V36, P497, DOI 10.1002/jlcr.2580360514; Heys JR, 2007, J LABELLED COMPD RAD, V50, P770, DOI 10.1002/jlcr.1428; Hulme EC, 2010, BRIT J PHARMACOL, V161, P1219, DOI 10.1111/j.1476-5381.2009.00604.x; Isin EM, 2012, CHEM RES TOXICOL, V25, P532, DOI 10.1021/tx2005212; Karkas MD, 2016, CHEM REV, V116, P9683, DOI 10.1021/acs.chemrev.5b00760; Le CC, 2017, ACS CENTRAL SCI, V3, P647, DOI 10.1021/acscentsci.7b00159; Le C, 2017, NATURE, V547, P79, DOI 10.1038/nature22813; Lockley WJS, 2012, J LABELLED COMPD RAD, V55, P235, DOI 10.1002/jlcr.2928; Lockley WJS, 2010, J LABELLED COMPD RAD, V53, P704, DOI 10.1002/jlcr.1815; Lowry MS, 2005, CHEM MATER, V17, P5712, DOI 10.1021/cm051312+; Lu J, 2017, NAT STRUCT MOL BIOL, V24, P570, DOI 10.1038/nsmb.3417; Luo J, 2016, ACS CATAL, V6, P873, DOI 10.1021/acscatal.5b02204; McGrath NA, 2010, J CHEM EDUC, V87, P1348, DOI 10.1021/ed1003806; McNally A, 2011, SCIENCE, V334, P1114, DOI 10.1126/science.1213920; Meleza C, 2016, ANAL BIOCHEM, V511, P17, DOI 10.1016/j.ab.2016.07.028; MORIMOTO H, 1992, FUSION TECHNOL, V21, P256, DOI 10.13182/FST92-A29754; Neubert L, 2012, J AM CHEM SOC, V134, P12239, DOI 10.1021/ja3041338; Noble A, 2014, J AM CHEM SOC, V136, P11602, DOI 10.1021/ja506094d; OLMSTEAD WN, 1980, J ORG CHEM, V45, P3295, DOI 10.1021/jo01304a032; Pieters G, 2014, ANGEW CHEM INT EDIT, V53, P230, DOI 10.1002/anie.201307930; Plummer CW, 2017, ACS MED CHEM LETT, V8, P221, DOI 10.1021/acsmedchemlett.6b00443; Prier CK, 2014, CHEM SCI, V5, P4173, DOI 10.1039/c4sc02155j; Prier CK, 2013, CHEM REV, V113, P5322, DOI 10.1021/cr300503r; Shaidarova LG, 2003, J ANAL CHEM+, V58, P577, DOI 10.1023/A:1024124421268; Shaw MH, 2016, J ORG CHEM, V81, P6898, DOI 10.1021/acs.joc.6b01449; Stumpf Walter E., 2005, Journal of Pharmacological and Toxicological Methods, V51, P25, DOI 10.1016/j.vascn.2004.09.001; Takahashi M, 2005, CHEM LETT, V34, P192, DOI 10.1246/cl.2005.192; Voges R., 2009, PREPARATION COMPOUND; Wayner DDM, 1997, J AM CHEM SOC, V119, P8925, DOI 10.1021/ja971365v; Yu HZ, 2014, J PHYS CHEM A, V118, P606, DOI 10.1021/jp410274n; Yu RP, 2016, NATURE, V529, P195, DOI 10.1038/nature16464	42	281	282	18	233	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	2017	358	6367					1182	+		10.1126/science.aap9674	http://dx.doi.org/10.1126/science.aap9674			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO2DN	29123019	Green Accepted			2023-01-03	WOS:000416584000041
J	Kancherla, V; Hasan, MOSI; Hamid, R; Paul, L; Selhub, J; Oakley, G; Quamruzzaman, Q; Mazumdar, M				Kancherla, Vijaya; Hasan, Md Omar Sharif Ibne; Hamid, Rezina; Paul, Ligi; Selhub, Jacob; Oakley, Godfrey; Quamruzzaman, Quazi; Mazumdar, Maitreyi			Prenatal folic acid use associated with decreased risk of myelomeningocele: A case-control study offers further support for folic acid fortification in Bangladesh	PLOS ONE			English	Article							NEURAL-TUBE DEFECTS; SPINA-BIFIDA; REPRODUCTIVE AGE; PREVENTION; FOLATE; WOMEN; MORTALITY	Neural tube defects contribute to severe morbidity and mortality in children and adults; however, they are largely preventable through maternal intake of folic acid before and during early pregnancy. We examined the association between maternal prenatal folic acid supplement intake and risk of myelomeningocele (a severe and common type of neural tube defect) in the offspring. We performed secondary analysis using data from a case-control study conducted at Dhaka Community Hospital, Bangladesh between April and November of 2013. Cases and controls included children with and without myelomeningocele, respectively, and their mothers. Cases were identified from local hospitals and rural health clinics served by Dhaka Community Hospital. Controls were selected from pregnancy registries located in the same region as the cases, and matched (1:1) to cases by age and sex. Myelomeningocele in the offspring was confirmed by a pediatrician with expertise in classifying neural tube defects. Maternal prenatal folic acid supplement intake was the main exposure of interest. We estimated crude and adjusted odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic regression analysis. There were 53 pairs of matched cases and controls in our study. Overall, 51% of case mothers reported using folic acid supplements during pregnancy compared to 72% of control mothers (p = 0.03). Median plasma folate concentrations at the time of study visit were 2.79 ng/mL and 2.86 ng/mL among case and control mothers, respectively (p = 0.85). Maternal prenatal folic acid use significantly decreased the odds of myelomeningocele in the offspring (unadjusted OR = 0.42, 95% CI = 0.18-0.96). The association was slightly attenuated after adjusting for maternal age at the time of pregnancy (adjusted OR = 0.43, 95% CI = 0.18-1.02). Our study confirms the protective association between maternal prenatal folic acid supplement use and myelomeningocele among children born in Bangladesh. Our findings point to an overall low folic acid supplement use and low plasma folate concentrations among women of reproductive age in Bangladesh. Mandatory fortification of staple foods with folic acid can address low folate status among women of child-bearing age, and prevent child morbidity and mortality associated with myelomeningocele in Bangladesh.	[Kancherla, Vijaya; Oakley, Godfrey] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Hasan, Md Omar Sharif Ibne; Quamruzzaman, Quazi] Dhaka Community Hosp, Dhaka, Bangladesh; [Hamid, Rezina] Bangladesh Med Coll, Dhaka, Bangladesh; [Paul, Ligi; Selhub, Jacob] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Mazumdar, Maitreyi] Boston Childrens Hosp, Dept Neurol, Boston, MA USA; [Mazumdar, Maitreyi] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA	Emory University; Rollins School Public Health; Tufts University; United States Department of Agriculture (USDA); Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Kancherla, V (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.	vkanche@emory.edu			National Institutes of Environmental Health Sciences (NIEHS), National Institutes of Health [R01 ES 016317]; Child Neurology Foundation; Harvard T.H. Chan School of Public Health NIEHS Center [P30 ES 000002]; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center [P30 HD 18655]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD090255, P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES017437, R01ES026317, P30ES000002] Funding Source: NIH RePORTER	National Institutes of Environmental Health Sciences (NIEHS), National Institutes of Health; Child Neurology Foundation; Harvard T.H. Chan School of Public Health NIEHS Center; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Funding for this study was provided by the National Institutes of Environmental Health Sciences (NIEHS), National Institutes of Health (R01 ES 016317) (Grantee: MM). Additional support was provided by the Child Neurology Foundation, the Harvard T.H. Chan School of Public Health NIEHS Center (P30 ES 000002) and the Boston Children's Hospital Intellectual and Developmental Disabilities Research Center (P30 HD 18655). The authors declare that there are no financial or personal relationships or affiliations that could influence or bias the manuscript, and that there are no conflicts of interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahrens K, 2011, EPIDEMIOLOGY, V22, P731, DOI 10.1097/EDE.0b013e3182227887; Akhtar S, 2016, CRIT REV FOOD SCI, V56, P2320, DOI 10.1080/10408398.2013.832143; Alam N, 2010, J HEALTH POPUL NUTR, V28, P86; Atta CAM, 2016, AM J PUBLIC HEALTH, V106, pE24, DOI 10.2105/AJPH.2015.302902; Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Christianson A., 2006, GLOBAL REPORT BIRTH; Cordero AM, 2015, MMWR-MORBID MORTAL W, V64, P421; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Elwood J H, 1973, Ulster Med J, V42, P213; Gamble MV, 2005, AM J CLIN NUTR, V81, P1372; Grosse SD, 2016, AM J PREV MED, V50, pS74, DOI 10.1016/j.amepre.2015.10.012; HORNE DW, 1988, CLIN CHEM, V34, P2357; Kancherla V, 2014, BIRTH DEFECTS RES A, V100, P563, DOI 10.1002/bdra.23259; Khambalia A, 2009, J NUTR, V139, P1179, DOI 10.3945/jn.108.101022; Kondo A, 2015, BRIT J NUTR, V114, P84, DOI 10.1017/S0007114515001439; Leyvraz M, 2015, NUTRIENTS, V7, P9960, DOI [10.3390/nu7125511, 10.3390/nu8090541]; Lindstrom E, 2011, ACTA OBSTET GYN SCAN, V90, P47, DOI 10.1111/j.1600-0412.2010.01014.x; Mazumdar M, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0020-0; McLean E, 2008, FOOD NUTR BULL, V29, pS38, DOI 10.1177/15648265080292S107; Mosley BS, 2009, AM J EPIDEMIOL, V169, P9, DOI 10.1093/aje/kwn331; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; Oakeshott P, 2010, DEV MED CHILD NEUROL, V52, P749, DOI 10.1111/j.1469-8749.2009.03543.x; Shaheen R, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-5; Sutton M, 2008, BIRTH DEFECTS RES A, V82, P701, DOI 10.1002/bdra.20498; WALD N, 1991, LANCET, V338, P131; World Health Organization, 2012, GUID DAIL IR FOL AC	27	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188726	10.1371/journal.pone.0188726	http://dx.doi.org/10.1371/journal.pone.0188726			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190654	gold, Green Published, Green Submitted			2023-01-03	WOS:000416841900110
J	Contu, S; Hussain, A; Kager, S; Budhota, A; Deshmukh, VA; Kuah, CWK; Yam, LHL; Xiang, LM; Chua, KSG; Masia, L; Campolo, D				Contu, Sara; Hussain, Asif; Kager, Simone; Budhota, Aamani; Deshmukh, Vishwanath A.; Kuah, Christopher W. K.; Yam, Lester H. L.; Xiang, Liming; Chua, Karen S. G.; Masia, Lorenzo; Campolo, Domenico			Proprioceptive assessment in clinical settings: Evaluation of joint position sense in upper limb post-stroke using a robotic manipulator	PLOS ONE			English	Article							ASSISTED THERAPY; MOTOR RECOVERY; BASAL GANGLIA; ARM MOVEMENTS; STROKE; REHABILITATION; SHOULDER; PATTERNS; FINGER; ELBOW	Proprioception is a critical component for motor functions and directly affects motor learning after neurological injuries. Conventional methods for its assessment are generally ordinal in nature and hence lack sensitivity. Robotic devices designed to promote sensorimotor learning can potentially provide quantitative precise, accurate, and reliable assessments of sensory impairments. In this paper, we investigate the clinical applicability and validity of using a planar 2 degrees of freedom robot to quantitatively assess proprioceptive deficits in post-stroke participants. Nine stroke survivors and nine healthy subjects participated in the study. Participants' hand was passively moved to the target position guided by the H-Man robot (Criterion movement) and were asked to indicate during a second passive movement towards the same target (Matching movement) when they felt that they matched the target position. The assessment was carried out on a planar surface for movements in the forward and oblique directions in the contralateral and ipsilateral sides of the tested arm. The matching performance was evaluated in terms of error magnitude (absolute and signed) and its variability. Stroke patients showed higher variability in the estimation of the target position compared to the healthy participants. Further, an effect of target was found, with lower absolute errors in the contralateral side. Pairwise comparison between individual stroke participant and control participants showed significant proprioceptive deficits in two patients. The proposed assessment of passive joint position sense was inherently simple and all participants, regardless of motor impairment level, could complete it in less than 10 minutes. Therefore, the method can potentially be carried out to detect changes in proprioceptive deficits in clinical settings.	[Contu, Sara; Hussain, Asif; Budhota, Aamani; Masia, Lorenzo; Campolo, Domenico] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Robot Res Ctr, Singapore, Singapore; [Kager, Simone] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Budhota, Aamani] Nanyang Technol Univ, Interdisciplinary Grad Sch, Singapore, Singapore; [Deshmukh, Vishwanath A.; Kuah, Christopher W. K.; Yam, Lester H. L.; Chua, Karen S. G.] Tan Tock Seng Hosp, Dept Rehabil Med, Ctr Adv Rehabil Therapeut, Singapore, Singapore; [Xiang, Liming] Nanyang Technol Univ, Sch Phys & Math Sci, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Tan Tock Seng Hospital; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Campolo, D (corresponding author), Nanyang Technol Univ, Sch Mech & Aerosp Engn, Robot Res Ctr, Singapore, Singapore.	d.campolo@ntu.edu.sg	Campolo, Domenico/G-5648-2010; Xiang, Liming/AGF-0351-2022; Xiang, Liming/B-6966-2011	Campolo, Domenico/0000-0001-6930-0413; Xiang, Liming/0000-0003-0698-5173; Xiang, Liming/0000-0003-0698-5173; Chua, Karen/0000-0001-9809-3425	'H-Man' project, Ministry of Health, Singapore [NMRC/BnB/0006b/2013]; Interdisciplinary Graduate School, Nanyang Technological University, Singapore	'H-Man' project, Ministry of Health, Singapore; Interdisciplinary Graduate School, Nanyang Technological University, Singapore	Part of this work was supported by the 'H-Man' project (NMRC/BnB/0006b/2013), Ministry of Health, Singapore; Interdisciplinary Graduate School, Nanyang Technological University, Singapore. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r Part of this work was supported by the 'H-Man' project (NMRC/BnB/0006b/2013), Ministry of Health, Singapore; Interdisciplinary Graduate School, Nanyang Technological University, Singapore.	Aisen ML, 1997, ARCH NEUROL-CHICAGO, V54, P443, DOI 10.1001/archneur.1997.00550160075019; Balasubramanian Sivakumar, 2012, Am J Phys Med Rehabil, V91, pS255, DOI 10.1097/PHM.0b013e31826bcdc1; Beer RF, 2004, EXP BRAIN RES, V156, P458, DOI 10.1007/s00221-003-1807-8; Beer RF, 1999, ARCH PHYS MED REHAB, V80, P766, DOI 10.1016/S0003-9993(99)90225-3; Beer RF, 2000, EXP BRAIN RES, V131, P305, DOI 10.1007/s002219900275; BEVAN L, 1994, J NEUROPHYSIOL, V71, P1862, DOI 10.1152/jn.1994.71.5.1862; Brewer B. R., 2014, TOP STROKE REHABIL; Campolo D, 2014, J NEUROSCI METH, V235, P285, DOI 10.1016/j.jneumeth.2014.07.003; Cappello L, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00198; Carey LM, 1995, CRITICAL REV, V7; Connell LA, 2008, CLIN REHABIL, V22, P758, DOI 10.1177/0269215508090674; Contu S, 2016, IEEE ENG MED BIO, P4614, DOI 10.1109/EMBC.2016.7591755; Desmurget M, 2003, EXP BRAIN RES, V153, P197, DOI 10.1007/s00221-003-1593-3; DEWALD JPA, 1995, BRAIN, V118, P495, DOI 10.1093/brain/118.2.495; Dewald JPA, 2001, MUSCLE NERVE, V24, P273, DOI 10.1002/1097-4598(200102)24:2<273::AID-MUS130>3.0.CO;2-Z; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; Ellis MD, 2007, EXP BRAIN RES, V176, P594, DOI 10.1007/s00221-006-0637-x; Frisoli A, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-36; Fuentes CT, 2010, J NEUROPHYSIOL, V103, P164, DOI 10.1152/jn.00494.2009; Gandevia SC, 2002, ADV EXP MED BIOL, V508, P61; Goble DJ, 2010, PHYS THER, V90, P1176, DOI 10.2522/ptj.20090399; GOBLE DJ, 2016, PHYS THER, V90, P1176, DOI DOI 10.2522/PTJ.20090399; Gradwell E., 2003, 8 INT C REHABILITATI, P55; Haggard P, 2000, PERCEPT PSYCHOPHYS, V62, P363, DOI 10.3758/BF03205556; HALL LA, 1983, J PHYSIOL-LONDON, V335, P519, DOI 10.1113/jphysiol.1983.sp014548; Han J, 2011, APPL MECH MATER, V66-68, P620, DOI 10.4028/www.scientific.net/AMM.66-68.620; Hesse S, 2003, ARCH PHYS MED REHAB, V84, P915, DOI 10.1016/S0003-9993(02)04954-7; Hillier S., 2015, NEUROREHAB NEURAL RE; HUANG CY, 1987, J NEUROL NEUROSUR PS, V50, P720, DOI 10.1136/jnnp.50.6.720; Hussain A, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00477; Ingemanson ML, 2016, EXP BRAIN RES, V234, P83, DOI 10.1007/s00221-015-4440-4; Ishii S, 1989, Rinsho Shinkeigaku, V29, P269; Janwantanakul P, 2001, ARCH PHYS MED REHAB, V82, P840, DOI 10.1053/apmr.2001.21865; Konczak J, 2009, J MOTOR BEHAV, V41, P543, DOI 10.3200/35-09-002; Kosinski R.J, 2008, LIT REV REACTION TIM; Kumral Emre, 2003, J Stroke Cerebrovasc Dis, V12, P66, DOI 10.1053/jscd.2003.11; Kwakkel G., 2007, NEUROREHABILITATION; Leibowitz N, 2008, DISABIL REHABIL, V30, P1829, DOI 10.1080/09638280701640145; Lincoln NB, 1998, PHYSIOTHERAPY, V84, P358, DOI [10.1016/S0031-9406(05)61454-X, DOI 10.1016/S0031-9406(05)61454-X]; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Marini F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161155; Maschke M, 2003, BRAIN, V126, P2312, DOI 10.1093/brain/awg230; MCCLATCHIE G, 1980, MED J AUSTRALIA, V1, P649, DOI 10.5694/j.1326-5377.1980.tb135209.x; Niessen MH, 2008, ARCH PHYS MED REHAB, V89, P333, DOI 10.1016/j.apmr.2007.08.157; Nordin N, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-137; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; REFSHAUGE KM, 1995, J PHYSIOL-LONDON, V488, P231, DOI 10.1113/jphysiol.1995.sp020961; ROTHWELL JC, 1982, BRAIN, V105, P515, DOI 10.1093/brain/105.3.515; Salles JI, 2011, NEUROSCI LETT, V501, P61, DOI 10.1016/j.neulet.2011.05.005; Santisteban L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154792; Schmidt RA, 1988, HUMAN KINETICS; Semrau JA, 2015, STROKE, V46, P3459, DOI 10.1161/STROKEAHA.115.010750; Shimizu T, 2002, BRAIN, V125, P1896, DOI 10.1093/brain/awf183; Simo LS, 2011, IEEE ENG MED BIO, P8227, DOI 10.1109/IEMBS.2011.6092029; Stinear CM, 2007, BRAIN, V130, P170, DOI 10.1093/brain/awl333; Tyson S., 2007, NEUROREHABILITATION; Wilson ET, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011851; Winward CE, 2002, CLIN REHABIL, V16, P523, DOI 10.1191/0269215502cr522oa	60	22	25	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2017	12	11							e0183257	10.1371/journal.pone.0183257	http://dx.doi.org/10.1371/journal.pone.0183257			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN4OQ	29161264	Green Published, gold			2023-01-03	WOS:000415987000002
J	Letson, H; Dobson, G				Letson, Hayley; Dobson, Geoffrey			Adenosine, lidocaine and Mg2+ (ALM) fluid therapy attenuates systemic inflammation, platelet dysfunction and coagulopathy after non-compressible truncal hemorrhage	PLOS ONE			English	Article							7.5-PERCENT NACL ADENOSINE; RAT MODEL; TRAUMA; RESUSCITATION; EPIDEMIOLOGY; INFUSION; IMPACT; MECHANISMS; SURVIVAL; DAMPS	Background Systemic inflammation and coagulopathy are major drivers of injury progression following hemorrhagic trauma. Our aim was to examine the effect of small-volume 3% NaCl adenosine, lidocaine and Mg2+ (ALM) bolus and 0.9% NaCl/ALM 'drip' on inflammation and coagulation in a rat model of hemorrhagic shock. Methods Sprague-Dawley rats (429 +/- 4 g) were randomly assigned to: 1) shams, 2) no-treatment, 3) saline-controls, 4) ALM-therapy, and 5) Hextend (R). Hemorrhage was induced in anesthetized-ventilated animals by liver resection (60% left lateral lobe and 50% medial lobe). After 15 min, a bolus of 3% NaCl +/- ALM (0.7 ml/kg) was administered intravenously (Phase 1) followed 60 min later by 4 hour infusion of 0.9% NaCl +/- ALM (0.5 ml/kg/hour) with 1-hour monitoring (Phase 2). Plasma cytokines were measured on Magpix (R) and coagulation using Stago/Rotational Thromboelastometry. Results After Phase 1, saline-controls, no-treatment and Hextend (R) groups showed significant falls in white and red cells, hemoglobin and hematocrit (up to 30%), whereas ALM animals had similar values to shams (9-15% losses). After Phase 2, these deficits in non-ALM groups were accompanied by profound systemic inflammation. In contrast, after Phase 1 ALM-treated animals had undetectable plasma levels of IL-1 alpha and IL-1 beta, and IL-2, IL-6 and TNF-alpha were below baseline, and after Phase 2 they were less or similar to shams. Non-ALM groups (except shams) also lost their ability to aggregate platelets, had lower plasma fibrinogen levels, and were hypocoagulable. ALM-treated animals had 50-fold higher ADP-induced platelet aggregation, and 9.3-times higher collagen-induced aggregation compared to saline-controls, and had little or no coagulopathy with significantly higher fibrinogen shifting towards baseline. Hextend (R) had poor outcomes. Conclusions Small-volume ALM bolus/drip mounted a frontline defense against non-compressible traumatic hemorrhage by defending immune cell numbers, suppressing systemic inflammation, improving platelet aggregation and correcting coagulopathy. Saline-controls were equivalent to no-treatment. Possible mechanisms of ALM's immune-bolstering effect are discussed.	[Letson, Hayley; Dobson, Geoffrey] James Cook Univ, Heart Trauma & Sepsis Res Lab, Coll Med & Dent, Townsville, Qld, Australia	James Cook University	Dobson, G (corresponding author), James Cook Univ, Heart Trauma & Sepsis Res Lab, Coll Med & Dent, Townsville, Qld, Australia.	geoffrey.dobson@jcu.edu.au	Letson, Hayley Louise/V-4659-2019	Letson, Hayley Louise/0000-0003-0135-134X	USSOCOM [W81XWH-15-1-0002]; IACUC [W81XWH-15-1-0002, A2118]; USAMRMC [W81XWH-15-1-0002, S013004]	USSOCOM; IACUC; USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC))	This work was supported by USSOCOM, IACUC protocol A2118, USAMRMC proposal S013004 under Award No. W81XWH-15-1-0002. The opinions, interpretations, conclusions are those of the authors and are not necessarily endorsed by the US Department of Defense.	Aird WC, 2005, J THROMB HAEMOST, V3, P1392, DOI 10.1111/j.1538-7836.2005.01328.x; [Anonymous], 2011, RSBO, V8, P299; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Brohi K, 2010, J ROY ARMY MED CORPS, V155, P320; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Butler FK., 2014, J SPEC OPER MED, V14, P13; Bynum JA, 2017, J TRAUMA AC IN PRESS, pXX; Danese S, 2007, J IMMUNOL, V178, P6017, DOI 10.4049/jimmunol.178.10.6017; Davenport L, 2017, INNATE IMMUN-LONDON, V23, P482, DOI 10.1177/1753425917718921; de Bruin AM, 2014, BLOOD, V124, P2479, DOI 10.1182/blood-2014-04-568451; Djabir Y, 2013, SHOCK, V40, P222, DOI 10.1097/SHK.0b013e3182a03566; Dobson GP, 2015, J TRAUMA ACUTE CARE, V79, P301, DOI 10.1097/TA.0000000000000729; Dobson GP, 2016, J TRAUMA ACUTE CARE, V80, P135, DOI 10.1097/TA.0000000000000881; DOBSON GP, 2013, FRONT PHYSIOL, V4, P1, DOI DOI 10.3389/FPHYS.2013.00228; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Granfeldt A, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0682-y; Granfeldt A, 2014, CRIT CARE MED, V42, pE329, DOI 10.1097/CCM.0000000000000225; Griffin MJ, 2014, J TRAUMA ACUTE CARE, V77, P471, DOI 10.1097/TA.0000000000000361; Griffin MJ, 2016, CLIN VACCINE IMMUNOL, V23, P863, DOI 10.1128/CVI.00390-16; Groeneveld KM, 2011, CURR OPIN ANESTHESIO, V24, P219, DOI 10.1097/ACO.0b013e32834401e0; Hirsiger S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/315941; Jackman RP, 2013, CURR OPIN ANESTHESIO, V26, P196, DOI 10.1097/ACO.0b013e32835d7160; KASHUK JL, 1982, J TRAUMA, V22, P672, DOI 10.1097/00005373-198208000-00004; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kheirbek T, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-65; Kisat M, 2013, J SURG RES, V184, P414, DOI 10.1016/j.jss.2013.05.099; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lenhardt Rainer, 2010, Front Biosci (Schol Ed), V2, P1145; Letson HL, 2017, J TRAUMA ACUTE CARE, V82, P1063, DOI 10.1097/TA.0000000000001454; Letson HL, 2016, THROMB RES, V141, P58, DOI 10.1016/j.thromres.2016.03.007; Letson HL, 2015, J TRAUMA ACUTE CARE, V78, P773, DOI 10.1097/TA.0000000000000587; Letson HL, 2012, CRIT CARE MED, V40, P2417, DOI 10.1097/CCM.0b013e31825334c3; Letson HL, 2011, J TRAUMA, V71, P708, DOI 10.1097/TA.0b013e3181fa27c7; Maegele M, 2014, EUR J TRAUMA EMERG S, V40, P113, DOI 10.1007/s00068-014-0389-4; Martin SJ, 2016, FEBS J, V283, P2599, DOI 10.1111/febs.13775; Mikhail J, 1999, AACN Clin Issues, V10, P85, DOI 10.1097/00044067-199902000-00008; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Moore EE, 2005, SHOCK, V24, P71, DOI 10.1097/01.shk.0000191336.01036.fe; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; O'Shea JJ, 2008, IMMUNITY, V28, P477, DOI 10.1016/j.immuni.2008.03.002; Pittman K, 2013, J INNATE IMMUN, V5, P315, DOI 10.1159/000347132; Sollberger G, 2014, INNATE IMMUN-LONDON, V20, P115, DOI 10.1177/1753425913484374; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Soreide K, 2014, INJURY, V45, P647, DOI 10.1016/j.injury.2012.12.027; Stahel PF, 2007, INJURY, V38, P1409, DOI 10.1016/j.injury.2007.09.023; Stannard A, 2013, J TRAUMA ACUTE CARE, V74, P830, DOI 10.1097/TA.0b013e31827a3704; Stow JL, 2013, CYTOKINE GROWTH F R, V24, P227, DOI 10.1016/j.cytogfr.2013.04.001; Takizawa H, 2012, BLOOD, V119, P2991, DOI 10.1182/blood-2011-12-380113; White NJ, 2013, HEMATOL-AM SOC HEMAT, P660, DOI 10.1182/asheducation-2013.1.660; Zedler S, 2006, CURR OPIN CRIT CARE, V12, P595, DOI 10.1097/MCC.0b013e3280106806	50	21	22	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2017	12	11							e0188144	10.1371/journal.pone.0188144	http://dx.doi.org/10.1371/journal.pone.0188144			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM8YO	29145467	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000415378800075
J	Gronewold, J; Dahlmann, C; Jager, M; Hermann, DM				Gronewold, Janine; Dahlmann, Christian; Jaeger, Marcus; Hermann, Dirk M.			Identification of hospitalized elderly patients at risk for adverse in-hospital outcomes in a university orthopedics and trauma surgery environment	PLOS ONE			English	Article							CASE-MIX SYSTEM; EMERGENCY-DEPARTMENT; FUNCTIONAL DECLINE; SCREENING TOOL; OLDER-ADULTS; CARE; SENIORS; LENGTH; STAY; ADMISSION	Background As a consequence of demographic changes, hospitals are confronted with increasing numbers of elderly patients, who are at high risk of adverse events during hospitalization. Geriatric risk screening followed by comprehensive geriatric assessment (CGA) and treatment has been requested by geriatric societies and task forces to identify patients at risk. Since empirical evidence on factors predisposing to adverse hospital events is scarce, we now prospectively evaluated implications of geriatric risk screening followed by CGA in a university hospital department of orthopedics and trauma surgery. Methods Three hundred and eighty-one patients >= 75 years admitted to the Department of Orthopedics and Trauma Surgery of the University Hospital Essen received Identification of Seniors at Risk (ISAR) Screening followed by CGA via a geriatric liaison service in case of positive screening results. Associations between ISAR, CGA, comorbid risk factors and diseases, length of hospital stay, number of nursing and physiotherapy hours, and falls during hospital stay were analyzed. Results Of 381 ISAR screenings, 327 (85.8%) were positive, confirming a high percentage of patients at risk of adverse events. Of these, 300 CGAs revealed 82.7% abnormal results, indicating activities of daily living impairment combined with cognitive, emotional or mobility disturbances. Abnormal CGA resulted in a longer hospital stay (14.0 +/- 10.3 days in ISAR +/CGA abnormal compared with 7.6 +/- 7.0 days in ISAR+/CGA normal and 8.1 +/- 5.4 days in ISAR-, both p<0.001), increased nursing hours (3.4 +/- 1.1 hours/day in ISAR+/CGA abnormal compared with 2.5 +/- 1.0 hours/day in ISAR+/CGA normal and 2.2 +/- 0.8 hours/day in ISAR-, both p<0.001), and increased falls (7.3% in ISAR+/CGA abnormal, 0% in ISAR+/CGA normal, 1.9% in ISAR-). Physiotherapy hours were only significantly increased in ISAR+/CGA abnormal (3.0 +/- 2.7 hours) compared with in ISAR+/CGA normal (1.6 +/- 1.4 hours, p<0.001) whereas the comparison with ISAR-(2.4 +/- 2.4 hours) did not reach significance (p = 0.368). In multivariable regressions, the CGA domains activities of daily living impairment (assessed by Barthel-Index) and signs of depression (assessed by geriatric depression scale) predicted longer length of hospital stay. High ISAR score, and impairment in activities of daily living and cognition (assessed by mini-mental state examination and clock-drawing test) predicted increased nursing hours, and impairment in activities of daily living and mobility predicted increased physiotherapy hours. Conclusions An abnormal geriatric screening and assessment is associated with longer hospital stay, more nursing and physiotherapy hours, and more falls.	[Gronewold, Janine; Hermann, Dirk M.] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany; [Dahlmann, Christian] Univ Duisburg Essen, Univ Hosp Essen, Dept Nursing Res, Essen, Germany; [Jaeger, Marcus] Univ Duisburg Essen, Univ Hosp Essen, Dept Orthoped & Trauma Surg, Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Hermann, DM (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Essen, Germany.	dirk.hermann@uk-essen.de	Hermann, Dirk/GZB-9350-2022; Hermann, Dirk M./AAT-3652-2021; Hermann, Dirk M/AAP-5538-2020	Hermann, Dirk M./0000-0003-0198-3152; Jager, Marcus/0000-0001-9516-1058				Alarcon T, 1999, AGE AGEING, V28, P429, DOI 10.1093/ageing/28.5.429; Asomaning N, 2014, J EMERG NURS, V40, P357, DOI 10.1016/j.jen.2013.08.014; Australian New Zealand Soc Geriatr, 2009, AUSTRALAS J AGEING, V28, P153, DOI 10.1111/j.1741-6612.2009.00380.x; Beaton K, 2013, CLIN INTERV AGING, V8, P485, DOI 10.2147/CIA.S42528; Bertozzi B, 1996, AGING CLIN EXP RES, V8, P170, DOI 10.1007/BF03339673; Campbell SE, 2004, AGE AGEING, V33, P110, DOI 10.1093/ageing/afh036; Conroy S, 2016, EUR GERIATR MED, V7, P315, DOI 10.1016/j.eurger.2016.03.011; Dendukuri N, 2004, J AM GERIATR SOC, V52, P290, DOI 10.1111/j.1532-5415.2004.52073.x; Di Bari M, 2012, J GERONTOL A-BIOL, V67, P544, DOI 10.1093/gerona/glr209; Di Iorio A, 1999, AGING CLIN EXP RES, V11, P150, DOI 10.1007/BF03399656; Dunstan EJ, 1996, AGE AGEING, V25, P102, DOI 10.1093/ageing/25.2.102; Ellis G, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6553; Findlay P, 2000, FACTORS AFFECTING DU; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; Inouye SK, 2000, J AM GERIATR SOC, V48, P1697; Ivemeyer D, 2006, DEMENZTESTS PRAXIS W; Jette DU, 2009, PHYS THER, V89, P1158, DOI 10.2522/ptj.20080338; MAGUIRE PA, 1986, BRIT MED J, V292, P1251, DOI 10.1136/bmj.292.6530.1251; MAHONEY F I, 1965, Md State Med J, V14, P61; McCusker J, 2001, J AM GERIATR SOC, V49, P1272, DOI 10.1046/j.1532-5415.2001.49254.x; McCusker J, 1999, J AM GERIATR SOC, V47, P1229, DOI 10.1111/j.1532-5415.1999.tb05204.x; Mion LC, 2001, J AM GERIATR SOC, V49, P1379, DOI 10.1046/j.1532-5415.2001.49270.x; Mueller M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-295; Muir SW, 2012, AGE AGEING, V41, P299, DOI 10.1093/ageing/afs012; NARAIN P, 1988, J AM GERIATR SOC, V36, P775, DOI 10.1111/j.1532-5415.1988.tb04259.x; Perlado F, 1999, AGE AGEING, V28, P581, DOI 10.1093/ageing/28.6.581; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Rock BD, 1996, SOC WORK HEALTH CARE, V22, P21, DOI 10.1300/J010v22n03_02; Rosted E, 2014, DAN MED J, V61; SANDERS AB, 1992, ANN EMERG MED, V21, P830, DOI 10.1016/S0196-0644(05)81030-3; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; SHULMAN KI, 1993, INT J GERIATR PSYCH, V8, P487, DOI 10.1002/gps.930080606; Singler K, 2014, GERONTOLOGY, V60, P413, DOI 10.1159/000358825; SPAITE DW, 1990, ANN EMERG MED, V19, P1418, DOI 10.1016/S0196-0644(05)82611-3; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Suffoletto B, 2016, EMERG MED J, V33, P4, DOI 10.1136/emermed-2014-203936; Sutton M, 2008, INT J CLIN PRACT, V62, P1900, DOI 10.1111/j.1742-1241.2008.01930.x; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Vetrano DL, 2014, EUR J INTERN MED, V25, P56, DOI 10.1016/j.ejim.2013.08.709; Warburton Rebecca N, 2004, Int J Health Care Qual Assur Inc Leadersh Health Serv, V17, P339, DOI 10.1108/09526860410557598; Ziere G, 2006, BRIT J CLIN PHARMACO, V61, P218, DOI 10.1111/j.1365-2125.2005.02543.x	42	12	12	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2017	12	11							e0187801	10.1371/journal.pone.0187801	http://dx.doi.org/10.1371/journal.pone.0187801			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM2XM	29125861	Green Published, gold, Green Submitted			2023-01-03	WOS:000414866000024
J	Raciti, GA; Fiory, F; Campitelli, M; Desiderio, A; Spinelli, R; Longo, M; Nigro, C; Pepe, G; Sommella, E; Campiglia, P; Formisano, P; Beguinot, F; Miele, C				Raciti, Gregory Alexander; Fiory, Francesca; Campitelli, Michele; Desiderio, Antonella; Spinelli, Rosa; Longo, Michele; Nigro, Cecilia; Pepe, Giacomo; Sommella, Eduardo; Campiglia, Pietro; Formisano, Pietro; Beguinot, Francesco; Miele, Claudia			Citrus aurantium L. dry extracts promote C/ebp beta expression and improve adipocyte differentiation in 3T3-L1 cells	PLOS ONE			English	Article							MITOTIC CLONAL EXPANSION; BINDING PROTEIN-BETA; WHITE ADIPOSE-TISSUE; GYMNEMA-SYLVESTRE; DIABETES-MELLITUS; TRANSCRIPTIONAL REGULATION; INSULIN-RESISTANCE; FENUGREEK SEEDS; IN-VIVO; OBESITY	Metabolic and/or endocrine dysfunction of the white adipose tissue (WAT) contribute to the development of metabolic disorders, such as Type 2 Diabetes (T2D). Therefore, the identification of products able to improve adipose tissue function represents a valuable strategy for the prevention and/or treatment of T2D. In the current study, we investigated the potential effects of dry extracts obtained from Citrus aurantium L. fruit juice (CAde) on the regulation of 3T3-L1 cells adipocyte differentiation and function in vitro. We found that CAde enhances terminal adipocyte differentiation of 3T3-L1 cells raising the expression of CCAAT/enhancer binding protein beta (C/Ebp beta), peroxisome proliferator activated receptor gamma (Ppar gamma), glucose transporter type 4 (Glut4) and fatty acid binding protein 4 (Fabp4). CAde improves insulin-induced glucose uptake of 3T3-L1 adipocytes, as well. A focused analysis of the phases occurring in the pre-adipocytes differentiation to mature adipocytes furthermore revealed that CAde promotes the early differentiation stage by up-regulating C/ebp beta expression at 2, 4 and 8 h post the adipogenic induction and anticipating the 3T3-L1 cell cycle entry and progression during mitotic clonal expansion (MCE). These findings provide evidence that the exposure to CAde enhances in vitro fat cell differentiation of pre-adipocytes and functional capacity of mature adipocytes, and pave the way to the development of products derived from Citrus aurantium L. fruit juice, which may improve WAT functional capacity and may be effective for the prevention and/or treatment of T2D.	[Raciti, Gregory Alexander; Fiory, Francesca; Campitelli, Michele; Desiderio, Antonella; Spinelli, Rosa; Longo, Michele; Nigro, Cecilia; Formisano, Pietro; Beguinot, Francesco; Miele, Claudia] CNR, URT Inst Expt Endocrinol & Oncol G Salvatore, Naples, Italy; [Raciti, Gregory Alexander; Fiory, Francesca; Campitelli, Michele; Desiderio, Antonella; Spinelli, Rosa; Longo, Michele; Nigro, Cecilia; Formisano, Pietro; Beguinot, Francesco; Miele, Claudia] Federico II Univ Naples, Dept Translat Med Sci, Naples, Italy; [Pepe, Giacomo; Sommella, Eduardo; Campiglia, Pietro] Univ Salerno, Dept Pharm, Sch Pharm, Fisciano, Italy; [Campiglia, Pietro] European Biomed Res Inst Salerno, Salerno, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Salerno	Raciti, GA; Miele, C (corresponding author), CNR, URT Inst Expt Endocrinol & Oncol G Salvatore, Naples, Italy.; Raciti, GA; Miele, C (corresponding author), Federico II Univ Naples, Dept Translat Med Sci, Naples, Italy.	gregoryraciti@gmail.com; c.miele@ieos.cnr.it	Campiglia, Pietro/J-5625-2018; Formisano, Pietro/J-4237-2018; LONGO, Michele/AAB-9188-2019; Longo, Michele/AAB-5972-2020; Campitelli, Michele/AAB-9734-2019; NIGRO, Cecilia/AAB-9189-2019; Nigro, Cecilia/K-7338-2016	LONGO, Michele/0000-0003-4798-0504; Campitelli, Michele/0000-0001-7592-5022; NIGRO, Cecilia/0000-0001-8924-9731; Desiderio, Antonella/0000-0002-3510-7663; RACITI, GREGORYALEXANDER/0000-0003-2742-5634; Formisano, Pietro/0000-0001-7020-6870; Sommella, Eduardo/0000-0001-8654-6431				Al-Romaiyan A, 2010, PHYTOTHER RES, V24, P1370, DOI 10.1002/ptr.3125; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ANDERSON JW, 2008, NUTRACEUTICALS GLYCE; Arbo MD, 2008, FOOD CHEM TOXICOL, V46, P2770, DOI 10.1016/j.fct.2008.04.037; Arias BA, 2005, J ETHNOPHARMACOL, V97, P89, DOI 10.1016/j.jep.2004.10.019; Armstrong WJ, 2001, J EXERC PHYSL, V4, P28; Basch Ethan, 2003, Altern Med Rev, V8, P20; Cassese A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060555; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Coelho M, 2013, ARCH MED SCI, V9, P191, DOI 10.5114/aoms.2013.33181; Dey Lucy, 2002, Altern Med Rev, V7, P45; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Fiory F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113655; Fox KAA, 2009, EUR HEART J, V30, P3055, DOI 10.1093/eurheartj/ehp371; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Grover JK, 2002, J ETHNOPHARMACOL, V81, P81, DOI 10.1016/S0378-8741(02)00059-4; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Guo L, 2015, J BIOL CHEM, V290, P755, DOI 10.1074/jbc.R114.619957; Gupta A, 2001, J Assoc Physicians India, V49, P1057; Gustafson B, 2013, DIABETES, V62, P2997, DOI 10.2337/db13-0473; Haaz S, 2006, OBES REV, V7, P79, DOI 10.1111/j.1467-789X.2006.00195.x; Jefcoate Colin R., 2008, V456, P173, DOI 10.1007/978-1-59745-245-8_13; Karimi E, 2012, MOLECULES, V17, P1203, DOI 10.3390/molecules17021203; Karoui IJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/345415; Kassaian N, 2009, INT J VITAM NUTR RES, V79, P34, DOI 10.1024/0300-9831.79.1.34; Kim GS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-31; Kim HG, 2012, BIOMED CHROMATOGR, V26, P464, DOI 10.1002/bmc.1688; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Leach MJ, 2007, J ALTERN COMPLEM MED, V13, P977, DOI 10.1089/acm.2006.6387; Lee DH, 2012, EVID-BASED COMPL ALT, V2012; Leung L, 2009, BRIT J NUTR, V102, P1703, DOI 10.1017/S0007114509992054; Liu XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038130; Longo M, 2016, BBA-MOL CELL RES, V1863, P1146, DOI 10.1016/j.bbamcr.2016.02.019; Lonn M, 2010, FASEB J, V24, P326, DOI 10.1096/fj.09-133058; Mattoli L, 2005, J AGR FOOD CHEM, V53, P9860, DOI 10.1021/jf051270+; Mecocci P, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00147; Nair HB, 2010, BIOCHEM PHARMACOL, V80, P1833, DOI 10.1016/j.bcp.2010.07.021; Nasri H, 2014, INT J PREVENTIVE MED, V5, P1487; Neelakantan N, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-7; Passaretti F, 2014, PLATELETS, V25, P252, DOI 10.3109/09537104.2013.809060; Pellati F, 2002, J PHARMACEUT BIOMED, V29, P1113, DOI 10.1016/S0731-7085(02)00153-X; Pellegrinelli V, 2016, DIABETOLOGIA, V59, P1075, DOI 10.1007/s00125-016-3933-4; Porchezhian E, 2003, PHARMAZIE, V58, P5; Raciti GA, 2010, DIABETOLOGIA, V53, P955, DOI 10.1007/s00125-010-1676-1; Raciti GA, 2017, SCI REP-UK, V7, DOI 10.1038/srep43526; Ramaa CS, 2006, CURR PHARM BIOTECHNO, V7, P15, DOI 10.2174/138920106775789647; Rayalam S, 2008, J NUTR BIOCHEM, V19, P717, DOI 10.1016/j.jnutbio.2007.12.007; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2006, NATURE, V444, P847, DOI 10.1038/nature05483; Shi Jun, 2008, V456, P307, DOI 10.1007/978-1-59745-245-8_23; Song Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069925; Stohs SJ, 2012, INT J MED SCI, V9, P527, DOI 10.7150/ijms.4446; Summers SA, 2000, INT J OBESITY, V24, pS67, DOI 10.1038/sj.ijo.0801509; Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev-biochem-052110-115718; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Weisiger RA, 2002, MOL CELL BIOCHEM, V239, P35, DOI 10.1023/A:1020550405578; Wronkowitz N, 2014, FRONT HORM RES, V43, P79, DOI 10.1159/000360560; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101; Zhang JW, 2004, J BIOL CHEM, V279, P4471, DOI 10.1074/jbc.M311327200	62	10	10	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2018	13	3							e0193704	10.1371/journal.pone.0193704	http://dx.doi.org/10.1371/journal.pone.0193704			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8ZI	29596447	gold, Green Published			2023-01-03	WOS:000428630000011
J	De Rosa, S; Sievert, H; Sabatino, J; Polimeni, A; Sorrentino, S; Indolfi, C				De Rosa, Salvatore; Sievert, Horst; Sabatino, Jolanda; Polimeni, Alberto; Sorrentino, Sabato; Indolfi, Ciro			Percutaneous Closure Versus Medical Treatment in Stroke Patients With Patent Foramen Ovale A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSIENT ISCHEMIC ATTACK; CRYPTOGENIC STROKE; RECURRENT STROKE; CLINICAL-TRIALS; THERAPY; GUIDELINE; SIZE; ADD	Background: New evidence emerged recently regarding the percutaneous closure of patent foramen ovale (PFO) to prevent recurrent stroke in patients with cryptogenic stroke. Purpose: To compare risks for recurrent cerebrovascular events in adults with PFO and cryptogenic stroke who underwent PFO closure versus those who received medical therapy alone. Data Sources: PubMed, Scopus, and Google Scholar from 1 December 2004 through 14 September 2017; references of eligible studies; relevant scientific session abstracts; and cardiology Web sites. Study Selection: Randomized controlled trials, published in English, that compared PFO closure using a currently available device with medical treatment alone and that reported, at minimum, the rates of stroke or transient ischemic attack (TIA) or of new-onset atrial fibrillation (AF) or atrial flutter (AFL). Data Extraction: 2 investigators independently extracted study data and assessed study quality. Data Synthesis: 4 of 5 trials comparing PFO closure with medical therapy used commercially available devices. These 4 trials, involving 2531 patients, found that PFO closure reduced the risk for the main outcome of stroke or TIA (risk difference [RD], -0.029 [95% CI, -0.050 to -0.007]) and increased the risk for new-onset AF or AFL (RD, 0.033 [CI, 0.012 to 0.054]). The beneficial effect of PFO closure was associated with larger interatrial shunts (P = 0.034). Limitation: Trials were not double-blind, and inclusion criteria were heterogeneous. Conclusion: Compared with medical treatment, PFO closure prevents recurrent stroke and TIA but increases the incidence of AF or AFL in PFO carriers with cryptogenic stroke.	Magna Graecia Univ Catanzaro, Catanzaro, Italy; Cardiovasc Ctr Frankfurt, Frankfurt, Germany; Anglia Ruskin Univ, Cambridge, England; Anglia Ruskin Univ, Chelmsford, Essex, England; CNR, Catanzaro, Italy; [De Rosa, Salvatore; Sabatino, Jolanda; Polimeni, Alberto; Sorrentino, Sabato; Indolfi, Ciro] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Div Cardiol, Viale Europa S-N, I-88100 Catanzaro, CZ, Italy; [Sievert, Horst] Cardiovasc Ctr Frankfurt CVC, Seckbacher Landstr 65, D-60389 Frankfurt, Germany	Magna Graecia University of Catanzaro; Cardiovascular Center (CVC) Frankfurt; Anglia Ruskin University; Anglia Ruskin University; Consiglio Nazionale delle Ricerche (CNR); Magna Graecia University of Catanzaro; Cardiovascular Center (CVC) Frankfurt	Indolfi, C (corresponding author), Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Viale Europa S-N, I-88100 Catanzaro, CZ, Italy.	saderosa@unicz.it; indolfi@unicz.it	Sabatino, Jolanda/AAO-5173-2020; De Rosa, Salvatore/J-6350-2012; Sorrentino, Sabato/D-3297-2019; Polimeni, Alberto/M-9243-2019; Sabatino, Jolanda/M-2506-2017; Polimeni, Alberto AP/K-4731-2018	Sabatino, Jolanda/0000-0002-1661-5419; De Rosa, Salvatore/0000-0001-5388-942X; Sorrentino, Sabato/0000-0002-8316-7134; Polimeni, Alberto/0000-0002-9166-3031; Polimeni, Alberto AP/0000-0002-9166-3031	Italian Ministry of Education, University and Research (MIUR) [OPTIMA CARDIOPATHS PON03PE_00009_4]	Italian Ministry of Education, University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was partly supported by a grant (OPTIMA CARDIOPATHS PON03PE_00009_4) from the Italian Ministry of Education, University and Research (MIUR).	Agmon Y, 1999, CIRCULATION, V99, P1942, DOI 10.1161/01.CIR.99.15.1942; Capodanno D, 2014, EUROINTERVENTION, V9, P1342, DOI 10.4244/EIJV9I11A225; Carroll JD, 2013, NEW ENGL J MED, V368, P1092, DOI 10.1056/NEJMoa1301440; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; FISHER DC, 1995, CHEST, V107, P1504, DOI 10.1378/chest.107.6.1504; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Furlan AJ, 2012, NEW ENGL J MED, V366, P991, DOI 10.1056/NEJMoa1009639; Goel SS, 2009, AM J CARDIOL, V103, P124, DOI 10.1016/j.amjcard.2008.08.036; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Guolo A, 2017, STAT METHODS MED RES, V26, P1500, DOI 10.1177/0962280215583568; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Hedges LV, 2016, PSYCHOL METHODS, V21, P61, DOI 10.1037/met0000042; HICKIE JB, 1956, BRIT HEART J, V18, P320; HOMMA S, 1994, STROKE, V25, P582, DOI 10.1161/01.STR.25.3.582; IntHout J, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-25; Jarral OA, 2011, INT J CARDIOL, V153, P4, DOI 10.1016/j.ijcard.2011.02.027; Jung JM, 2013, J STROKE CEREBROVASC, V22, P1399, DOI 10.1016/j.jstrokecerebrovasdis.2013.04.034; Kent DM, 2013, NEUROLOGY, V81, P619, DOI 10.1212/WNL.0b013e3182a08d59; Kent DM, 2010, STROKE, V41, pS26, DOI 10.1161/STROKEAHA.110.595140; Kizer JR, 2005, NEW ENGL J MED, V353, P2361, DOI 10.1056/NEJMcp043981; Kwong JSW, 2013, INT J CARDIOL, V168, P4132, DOI 10.1016/j.ijcard.2013.07.077; MANTEL N, 1959, J NATL CANCER I, V22, P719; Mas JL, 2017, NEW ENGL J MED, V377, P1011, DOI 10.1056/NEJMoa1705915; Mattioli AV, 2001, EUR HEART J, V22, P261, DOI 10.1053/euhj.2001.2293; Meier B, 2013, NEW ENGL J MED, V368, P1083, DOI 10.1056/NEJMoa1211716; Messe SR, 2016, NEUROLOGY, V87, P815, DOI 10.1212/WNL.0000000000002961; Mojadidi MK, 2017, JACC-CARDIOVASC INTE, V10, P2228, DOI 10.1016/j.jcin.2017.09.002; MORISHITA Y, 1985, ANN THORAC SURG, V40, P614, DOI 10.1016/S0003-4975(10)60359-1; Nagaraja V, 2013, HEART LUNG CIRC, V22, P903, DOI 10.1016/j.hlc.2013.07.022; Pandit A, 2014, HEART LUNG CIRC, V23, P303, DOI 10.1016/j.hlc.2013.12.003; Prefasi D, 2016, INT J STROKE, V11, pNP7, DOI 10.1177/1747493015607505; Rucker G, 2009, STAT MED, V28, P721, DOI 10.1002/sim.3511; Saver JL, 2017, NEW ENGL J MED, V377, P1022, DOI 10.1056/NEJMoa1610057; Shuster JJ, 2016, STAT MED, V35, P2467, DOI 10.1002/sim.6844; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Sondergaard L, 2017, NEW ENGL J MED, V377, P1033, DOI 10.1056/NEJMoa1707404; Sun YP, 2016, CIRC J, V80, P1665, DOI 10.1253/circj.CJ-16-0534; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Villareal RP, 2004, J AM COLL CARDIOL, V43, P742, DOI 10.1016/j.jacc.2003.11.023; Zier LS, 2016, EXPERT REV CARDIOVAS, V14, P1235, DOI 10.1080/14779072.2016.1224178	41	45	45	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 6	2018	168	5					343	+		10.7326/M17-3033	http://dx.doi.org/10.7326/M17-3033			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY2GD	29310133				2023-01-03	WOS:000426632600007
J	Bail, K; Draper, B; Berry, H; Karmel, R; Goss, J				Bail, Kasia; Draper, Brian; Berry, Helen; Karmel, Rosemary; Goss, John			Predicting excess cost for older inpatients with clinical complexity: A retrospective cohort study examining cognition, comorbidities and complications	PLOS ONE			English	Article							LENGTH-OF-STAY; HOSPITAL-ACQUIRED COMPLICATIONS; PATIENT SAFETY PROGRAMS; ADVERSE EVENTS; CONDITIONS INFORMATION; FUNCTIONAL DECLINE; ELDERLY-PATIENTS; AFTER-DISCHARGE; MARGINAL COSTS; HIP-FRACTURES	Background Hospital-acquired complications increase length of stay and contribute to poorer patient outcomes. Older adults are known to be at risk for four key hospital-acquired complications (pressure injuries, pneumonia, urinary tract infections and delirium). These complications have been identified as sensitive to nursing characteristics such as staffing levels and level of education. The cost of these complications compared to the cost of admission severity, dementia, other comorbidities or age has not been established. Method To investigate costs associated with nurse-sensitive hospital-acquired complications in an older patient population 157,178 overnight public hospital episodes for all patients over age 50 from one Australian state, 2006/07 were examined. A retrospective cohort study design with linear regression analysis provided modelling of length-of-stay costs. Explanatory variables included patient age, sex, comorbidities, admission severity, dementia status, surgical status and four complications. Extra costs were based on above-average length-of-stay for each patient's Diagnosis Related Group from hospital discharge data. Results For adults over 50 who have length of stay longer than average for their diagnostic condition, comorbid dementia predicts an extra cost of A$874, (US$1,247); any one of four key complications predicts A$812 (US$1,159); each increase in admission severity score predicts A $295 ($US421); each additional comorbidity predicts A$259 (US$370), and for each year of age above 50 predicts A$20 (US$29) (all estimates significant at p< 0.0001). Discussion Hospital-acquired complications and dementia cost more than other kinds of inpatient complexity, but admission severity is a better predictor of excess cost. Because complications are potentially preventable and dementia care in hospitals can be improved, risk-reduction strategies for common complications, particularly for patients with dementia could be cost effective. Conclusions Complications and dementia were found to cost more than other kinds of inpatient complexity.	[Bail, Kasia; Goss, John] Univ Canberra, Hlth Res Inst, Canberra, ACT, Australia; [Draper, Brian] Univ New South Wales, Prince Wales Hosp, Acad Dept Old Age Psychiat, Sch Psychiat, Sydney, NSW, Australia; [Berry, Helen] Univ Sydney, Sydney Med Sch, Sydney Sch Publ Hlth, Climate Change & Mental Hlth, Sydney, NSW, Australia; [Karmel, Rosemary] Australian Inst Hlth & Welf, Canberra, ACT, Australia	University of Canberra; University of New South Wales Sydney; University of Sydney	Bail, K (corresponding author), Univ Canberra, Hlth Res Inst, Canberra, ACT, Australia.	Kasia.Bail@canberra.edu.au	Bail, Kasia/AAN-7143-2020	Bail, Kasia/0000-0002-4797-0042	Dementia Collaborative Research Centre; National Health and Medical Research Council [465701]	Dementia Collaborative Research Centre; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	KB was sponsored by PhD Scholarship provided by Dementia Collaborative Research Centre. http://www.dementiaresearch.org.au. The PhD was nested in BD and RK's project that was supported by the National Health and Medical Research Council (grant number 465701). https://www.nhmrc.gov.au/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ackroyd-Stolarz Stacy, 2009, Healthc Manage Forum, V22, P32; Ackroyd-Stolarz Stacy, 2009, Healthc Q, V12 Spec No Patient, P34; Adams PD, 2014, AM J SURG, V208, P656, DOI 10.1016/j.amjsurg.2014.03.006; [Anonymous], AARHUS U DET JORDBRU; Arora V, 2007, J AM GERIATR SOC, V55, pS198; Australian Government, 2008, NAT HOSP COST DAT CO; Australian Institute of Health and Welfare, 2013, DEM CAR HOSP COSTS S; Australian Institute of Health and Welfare, 2013, HLTH EXP AUSTR 2011; Australian Institute of Health and Welfare, 2008, AUSTR HOSP STAT 2006; Australian Institute of Health and Welfare, 2001, EXP HLTH SERV AB TOR; Australian Institute of Health and Welfare, 2011, HOSP DEM SERV PROJ S; Australian Institute of Health and Welfare, 2013, AUSTR HOSP STAT 2011; Australian Institute of Health and Welfare, 2012, DER KEY PAT VAR TECH; Bail K, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0743-1; Bail K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002770; Bolbocean C, 2011, J HEALTH SERV RES PO, V16, P141; Bolbocean C, 2012, J HEALTH SERV RES PO, V17, P127, DOI 10.1258/jhsrp.2012.012007; Boltz M, 2012, GERIATR NURS, V33, P272, DOI 10.1016/j.gerinurse.2012.01.008; Borbasi S, 2006, GERIATR NURS, V27, P300, DOI 10.1016/j.gerinurse.2006.08.013; Briggs R, 2016, QJM-INT J MED, V109, P41, DOI 10.1093/qjmed/hcv085; Buurman BM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029621; Calver J, 2006, MED J AUSTRALIA, V184, P393, DOI 10.5694/j.1326-5377.2006.tb00289.x; Chen LT, 2007, ANN ACAD MED SINGAP, V36, P784; Cho SH, 2003, NURS RES, V52, P71, DOI 10.1097/00006199-200303000-00003; Chuang KH, 2003, J AM GERIATR SOC, V51, P1729, DOI 10.1046/j.1532-5415.2003.51556.x; Dahl D, 2012, J HEALTHC MANAG, V57, P421, DOI 10.1097/00115514-201211000-00009; Dasgupta M, 2016, GERIATRICS, V1, P4; Dementia Australia, 2021, DEM AUSTR PREV EST 2; Diya L, 2012, J ADV NURS, V68, P1073, DOI 10.1111/j.1365-2648.2011.05812.x; Draper B, 2011, INT PSYCHOGERIATR, V23, P1649, DOI 10.1017/S1041610211001694; Duffield C, 2007, GLUEING IT TOGETHER; Ellidokuz H, 2003, ARCH GERONTOL GERIAT, V37, P259, DOI 10.1016/S0167-4943(03)00062-1; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Garcia AE, 2012, J ORTHOP TRAUMA, V26, P620, DOI 10.1097/BOT.0b013e3182695416; George J, 2013, J ROY SOC MED, V106, P355, DOI 10.1177/0141076813476497; Graves N, 2002, HEALTH ECON, V11, P735, DOI 10.1002/hec.683; Graves N, 2007, INFECT CONT HOSP EP, V28, P280, DOI 10.1086/512642; Graves N, 2007, INFECT CONT HOSP EP, V28, P178, DOI 10.1086/510787; Hickman L, 2007, J ADV NURS, V60, P113, DOI 10.1111/j.1365-2648.2007.04417.x; Hofmann W, 2013, Z GERONTOL GERIATR, V46, P198, DOI 10.1007/s00391-013-0485-9; Hu CJ, 2012, WORLD J SURG, V36, P2051, DOI 10.1007/s00268-012-1609-x; Ireland AW, 2015, BMC HEALTH SERV RES, P15; Jackson T, 2011, J HEALTH SERV RES PO, V16, P141, DOI 10.1258/jhsrp.2010.010050; Jackson TA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002247; Kalisch Beatrice J, 2012, Nurs Outlook, V60, pe32, DOI 10.1016/j.outlook.2012.04.006; Kane RL, 2007, MED CARE, V45, P1195, DOI 10.1097/MLR.0b013e3181468ca3; Kay HF, 2014, J ORTHOP TRAUMA, V28, pE153, DOI 10.1097/01.bot.0000437568.84322.cd; Kuo YF, 2011, ANN INTERN MED, V155, P152, DOI 10.7326/0003-4819-155-3-201108020-00005; Long SJ, 2013, INT J QUAL HEALTH C, V25, P542, DOI 10.1093/intqhc/mzt056; Madden RH, 2015, INT J ENV RES PUB HE, V12, P5815, DOI 10.3390/ijerph120605815; Martin L, 2012, J CLIN NURS, V21, P2219, DOI 10.1111/j.1365-2702.2011.03862.x; Moerer O, 2007, CRIT CARE, V11, DOI 10.1186/cc5952; Mudge AM, 2008, J AM GERIATR SOC, V56, P630, DOI 10.1111/j.1532-5415.2007.01607.x; Naessens JM, 2012, AM J MED QUAL, V27, P48, DOI 10.1177/1062860611413456; Needleman J, 2001, NURSE STAFFING PATIE; Nikkel LE, 2012, J BONE JOINT SURG AM, V94A, P9, DOI [10.2106/JBJS.J.01077, 10.2106/JBJS.K.01214]; Olds DM, 2010, J SAFETY RES, V41, P153, DOI 10.1016/j.jsr.2010.02.002; Organisation for Economic Co-operation and Development, 2017, OECD HLTH STAT; Paddock S, 2006, TECHNICAL REPORT; Pappas SH, 2008, J NURS ADMIN, V38, P230, DOI 10.1097/01.NNA.0000312770.19481.ce; Parke B, 2010, J AGING STUD, V24, P115, DOI 10.1016/j.jaging.2008.09.003; Pitkaaho T, 2015, J ADV NURS, V71, P458, DOI 10.1111/jan.12550; Pugely AJ, 2014, CLIN ORTHOP RELAT R, V472, P3943, DOI 10.1007/s11999-014-3918-x; Rowell D, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.032235; Sari ABA, 2008, AGE AGEING, V37, P265, DOI 10.1093/ageing/afn043; Schneider MA, 2012, ORTHOP NURS, V31, P12, DOI 10.1097/NOR.0b013e3182419619; Schubert M, 2013, INT J NURS STUD, V50, P230, DOI 10.1016/j.ijnurstu.2012.09.016; Shah AN, 2004, J ARTHROPLASTY, V19, P700, DOI 10.1016/j.arth.2004.02.034; Stahl J. E., 2002, Infectious Diseases in Clinical Practice, V11, P46, DOI 10.1097/00019048-200202000-00002; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Taheri PA, 2000, J AM COLL SURGEONS, V191, P123, DOI 10.1016/S1072-7515(00)00352-5; Thornlow DK, 2014, RES GERONTOL NURS, V7, P66, DOI 10.3928/19404921-20131126-01; Trentino KM, 2013, MED J AUSTRALIA, V199, P543, DOI 10.5694/mja12.11640; Twigg D, 2015, J ADV NURSING, V71; van Oostveen CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098102; Vermeulen H, 2013, BMC HEALTH SERV RES, P13; Warshawsky N, 2013, J NURS MANAGE, V21, P725, DOI 10.1111/jonm.12101; Wilson M, 2014, ACAD EMERG MED, V21, P1101, DOI 10.1111/acem.12486; Wright CD, 2008, ANN THORAC SURG, V85, P1857, DOI 10.1016/j.athoracsur.2008.03.024; Zekry D, 2011, DEMENT GERIATR COGN, V32, P103, DOI 10.1159/000326950	80	15	15	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2018	13	2							e0193319	10.1371/journal.pone.0193319	http://dx.doi.org/10.1371/journal.pone.0193319			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FX4LV	29474407	Green Submitted, Green Published, gold			2023-01-03	WOS:000426049500082
J	Li, J; Piermattei, A; Wang, P; Kang, SW; Xiao, MY; Tang, B; Liao, XF; Xin, X; Grusio, M; Orlandini, LC				Li, Jie; Piermattei, Angelo; Wang, Pei; Kang, Shengwei; Xiao, Mingyong; Tang, Bin; Liao, Xiongfei; Xin, Xin; Grusio, Mattia; Orlandini, Lucia Clara			Setup in a clinical workflow and impact on radiotherapy routine of an in vivo dosimetry procedure with an electronic portal imaging device	PLOS ONE			English	Article							EPID DOSIMETRY; EXPERIENCE; VERIFICATION; SYSTEM; IMRT	High conformal techniques such as intensity-modulated radiation therapy and volumetric-modulated arc therapy are widely used in overloaded radiotherapy departments. In vivo dosimetric screening is essential in this environment to avoid important dosimetric errors. This work examines the feasibility of introducing in vivo dosimetry (IVD) checks in a radiotherapy routine. The causes of dosimetric disagreements between delivered and planned treatments were identified and corrected during the course of treatment. The efficiency of the corrections performed and the added workload needed for the entire procedure were evaluated. The IVD procedure was based on an electronic portal imaging device. A total of 3682 IVD tests were performed for 147 patients who underwent head and neck, abdomen, pelvis, breast, and thorax radiotherapy treatments. Two types of indices were evaluated and used to determine if the IVD tests were within tolerance levels: the ratio R between the reconstructed and planned isocentre doses and a transit dosimetry based on the gamma-analysis of the electronic portal images. The causes of test outside tolerance level were investigated and corrected and IVD test was repeated during subsequent fraction. The time needed for each step of the IVD procedure was registered. Pelvis, abdomen, and head and neck treatments had 10% of tests out of tolerance whereas breast and thorax treatments accounted for up to 25%. The patient setup was the main cause of 90% of the IVD tests out of tolerance and the remaining 10% was due to patient morphological changes. An average time of 42 min per day was sufficient to monitor a daily workload of 60 patients in treatment. This work shows that IVD performed with an electronic portal imaging device is feasible in an overloaded department and enables the timely realignment of the treatment quality indices in order to achieve a patient's final treatment compliant with the one prescribed.	[Li, Jie; Wang, Pei; Kang, Shengwei; Xiao, Mingyong; Tang, Bin; Liao, Xiongfei; Xin, Xin; Orlandini, Lucia Clara] Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China; [Piermattei, Angelo; Grusio, Mattia] Fdn Policlin Univ Agostino Gemelli, UOC Fis Sanit, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Wang, P (corresponding author), Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China.	dengwangpei@163.com						Andreo P, 2000, REPORT NEWSMAGAZ OCT, V11; British Institute of Radiology IoPaEiM Society an College of Radiographers The Royal College of Radiologists, 2008, IMPL VIV DOS; Celi S, 2016, J APPL CLIN MED PHYS, V17, P262, DOI 10.1120/jacmp.v17i3.6070; Cilia S, 2007, PHYS MEDICA, V23, P25, DOI 10.1016/j.ejmp.2006.12.001; Cilla S, 2016, PHYS MEDICA, V32, P52, DOI 10.1016/j.ejmp.2015.09.007; Dunlop A, 2015, STRAHLENTHER ONKOL, V191, P970, DOI 10.1007/s00066-015-0890-7; Fidanzio A, 2016, RADIOTHER ONCOL, V119, pS852, DOI 10.1016/S0167-8140(16)33068-7; Fidanzio A, 2014, MED PHYS, V41, DOI 10.1118/1.4875685; Ford EC, 2012, INT J RADIAT ONCOL, V84, pE263, DOI 10.1016/j.ijrobp.2012.04.036; Francois P, 2011, PHYS MEDICA, V27, P1, DOI 10.1016/j.ejmp.2010.06.002; Fuangrod T, 2017, INT J HEALTH CARE Q, V30, P90, DOI 10.1108/IJHCQA-03-2016-0028; Fuangrod T, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0682-y; Hansen EK, 2006, INT J RADIAT ONCOL, V64, P355, DOI 10.1016/j.ijrobp.2005.07.957; Hartford AC, 2012, AM J CLIN ONCOL-CANC, V35, P612, DOI 10.1097/COC.0b013e31826e0515; Holm L, 2000, 20004 SSI; Klein EE, 2009, MED PHYS, V36, P4197, DOI 10.1118/1.3190392; Kruse JJ, 2010, MED PHYS, V37, P2516, DOI 10.1118/1.3425781; Low DA, 1998, MED PHYS, V25, P656, DOI 10.1118/1.598248; Mans A, 2010, MED PHYS, V37, P2638, DOI 10.1118/1.3397807; McCowan PM, 2017, INT J RADIAT ONCOL, V97, P1077, DOI 10.1016/j.ijrobp.2017.01.227; McDermott LN, 2007, INT J RADIAT ONCOL, V67, P1568, DOI 10.1016/j.ijrobp.2006.11.047; McKenzie EM, 2014, MED PHYS, V41, DOI 10.1118/1.4899177; Mijnheer B, 2013, MED PHYS, V40, DOI 10.1118/1.4811216; Mijnheer BJ, 2015, PRACT RADIAT ONCOL, V5, pE679, DOI 10.1016/j.prro.2015.07.001; Piermattei A, 2015, NUCL INSTRUM METH A, V796, P93, DOI 10.1016/j.nima.2015.02.024; Piermattei A, 2006, MED PHYS, V33, P4414, DOI 10.1118/1.2360014; Piermattei A, 2012, NUCL INSTRUM METH B, V274, P42, DOI 10.1016/j.nimb.2011.12.004; Piermattei A, 2009, MED PHYS, V36, P2206, DOI 10.1118/1.3129158; Ricketts K, 2016, INT J RADIAT ONCOL, V95, P1513, DOI 10.1016/j.ijrobp.2016.03.021; Yorke E AR, 2005, MED PHYS, V87; [No title captured]	31	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2018	13	2							e0192686	10.1371/journal.pone.0192686	http://dx.doi.org/10.1371/journal.pone.0192686			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV8DE	29432473	Green Published, Green Submitted, gold			2023-01-03	WOS:000424814300036
J	Brat, GA; Agniel, D; Beam, A; Yorkgitis, B; Bicket, M; Homer, M; Fox, KP; Knecht, DB; McMahill-Walraven, CN; Palmer, N; Kohane, I				Brat, Gabriel A.; Agniel, Denis; Beam, Andrew; Yorkgitis, Brian; Bicket, Mark; Homer, Mark; Fox, Kathe P.; Knecht, Daniel B.; McMahill-Walraven, Cheryl N.; Palmer, Nathan; Kohane, Isaac			Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRESCRIBING PATTERNS; UNITED-STATES; RISK-FACTORS; CHRONIC PAIN; ABUSE; ANALGESICS; DEPENDENCE; DRUG; RECIPIENTS; MORTALITY	OBJECTIVE To quantify the effects of varying opioid prescribing patterns after surgery on dependence, overdose, or abuse in an opioid naive population. DESIGN Retrospective cohort study. SETTING Surgical claims from a linked medical and pharmacy administrative database of 37 651 619 commercially insured patients between 2008 and 2016. PARTICIPANTS 1 015 116 opioid naive patients undergoing surgery. MAIN OUTCOME MEASURES Use of oral opioids after discharge as defined by refills and total dosage and duration of use. The primary outcome was a composite of misuse identified by a diagnostic code for opioid dependence, abuse, or overdose. RESULTS 568 612 (56.0%) patients received postoperative opioids, and a code for abuse was identified for 5906 patients (0.6%, 183 per 100 000 person years). Total duration of opioid use was the strongest predictor of misuse, with each refill and additional week of opioid use associated with an adjusted increase in the rate of misuse of 44.0% (95% confidence interval 40.8% to 47.2%, P< 0.001), and 19.9% increase in hazard (18.5% to 21.4%, P< 0.001), respectively. CONCLUSIONS Each refill and week of opioid prescription is associated with a large increase in opioid misuse among opioid naive patients. The data from this study suggest that duration of the prescription rather than dosage is more strongly associated with ultimate misuse in the early postsurgical period. The analysis quantifies the association of prescribing choices on opioid misuse and identifies levers for possible impact.	[Brat, Gabriel A.; Agniel, Denis; Beam, Andrew; Homer, Mark; Palmer, Nathan; Kohane, Isaac] Harvard Med Sch, Countway Lib, Dept Biomed Informat, Boston, MA 02215 USA; [Brat, Gabriel A.] Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA; [Yorkgitis, Brian] Univ Florida, Dept Surg, Jacksonville, FL USA; [Yorkgitis, Brian] Univ Florida, Coll Med, Div Acute Care Surg, Jacksonville, FL USA; [Bicket, Mark] Johns Hopkins Univ, Dept Anesthesia & Crit Care Med, Baltimore, MD USA; [Fox, Kathe P.; Knecht, Daniel B.; McMahill-Walraven, Cheryl N.] Aetna, Dept Analyt & Behav Change, Blue Bell, PA USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Johns Hopkins University	Brat, GA (corresponding author), Harvard Med Sch, Countway Lib, Dept Biomed Informat, Boston, MA 02215 USA.; Brat, GA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA.	gbrat@bidmc.harvard.edu		Bicket, Mark/0000-0001-9406-5953; Beam, Andrew/0000-0002-6657-2787	National Institute of General Medical Sciences of the National Institutes of Health [T32GM075774]	National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Aetna for donating the dataset. MB was supported by the National Institute of General Medical Sciences of the National Institutes of Health (award No T32GM075774).	ACS, 2015, ACS NAT SURG QUAL IM; Bateman BT, 2016, JAMA INTERN MED, V176, P583, DOI 10.1001/jamainternmed.2016.0544; Bedard NA, 2017, J ARTHROPLASTY; Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Calcaterra SL, 2016, J GEN INTERN MED, V31, P478, DOI 10.1007/s11606-015-3539-4; Cerner Corporation, 2016, MULT LEX; Ciesielski T, 2016, AM J MED, V129, P699, DOI 10.1016/j.amjmed.2016.02.014; Clarke Hance, 2014, BMJ, V348, pg1251, DOI 10.1136/bmj.g1251; Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907; Deyo RA, 2017, J GEN INTERN MED, V32, P21, DOI 10.1007/s11606-016-3810-3; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017; Elzey MJ, 2016, PAIN PHYSICIAN, V19, P215; Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Hill MV, 2018, ANN SURG, V267, P468, DOI 10.1097/SLA.0000000000002198; Hill MV, 2017, ANN SURG, V265, P709, DOI 10.1097/SLA.0000000000001993; Jena AB, 2016, JAMA INTERN MED, V176, P990, DOI 10.1001/jamainternmed.2016.2737; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Ladha KS, 2016, ANESTHESIOLOGY, V124, P837, DOI 10.1097/ALN.0000000000001034; Lenguerrand E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149306; McCarty D, 2014, PRESENTATION TO FDA; Medicaid C for M and, 2014, OP MORPH EQ CONV FAC, P1; Menendez ME, 2015, CLIN ORTHOP RELAT R, V473, P2402, DOI 10.1007/s11999-015-4173-5; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Mosher HJ, 2016, PAIN MED, V17, P1282, DOI 10.1093/pm/pnw058; Passik Steven D, 2006, J Pain Palliat Care Pharmacother, V20, P5; Paulozzi LJ, 2015, MMWR SURVEILL SUMM, V64, P1, DOI 10.15585/mmwr.ss6409a1; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P60; Ronan MV, 2016, HEALTH AFFAIR, V35, P832, DOI 10.1377/hlthaff.2015.1424; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Strassels SA, 2002, ANESTH ANALG, V94, P130, DOI 10.1097/00000539-200201000-00025; Sullivan MD, 2015, PHARMACOEPIDEM DR S, V24, P893, DOI 10.1002/pds.3821; Sun EC, 2016, JAMA INTERN MED, V176, P1286, DOI 10.1001/jamainternmed.2016.3298; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Volkow ND, 2011, JAMA-J AM MED ASSOC, V305, P1299, DOI 10.1001/jama.2011.401; Waljee JF, 2017, ANN SURG, V265, P728, DOI 10.1097/SLA.0000000000001904; Waljee JF, 2016, PLAST RECONSTR SURG, V137, p355E, DOI 10.1097/01.prs.0000475788.52446.7b; Waxman BP, 2015, ANZ J SURG, V85, P210, DOI 10.1111/ans.13026; Wilkerson Richard Gentry, 2016, Emerg Med Clin North Am, V34, pe1, DOI 10.1016/j.emc.2015.11.002; Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6; Wunsch Hannah, 2016, JAMA, V315, P1654, DOI 10.1001/jama.2016.0130	47	281	284	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 17	2018	360								j5790	10.1136/bmj.j5790	http://dx.doi.org/10.1136/bmj.j5790			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT5QK	29343479	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000423208100002
J	Gayet-Ageron, A; Prieto-Merino, D; Ker, K; Shakur, H; Ageron, FX; Roberts, I				Gayet-Ageron, Angele; Prieto-Merino, David; Ker, Katharine; Shakur, Haleema; Ageron, Francois-Xavier; Roberts, Ian		Antifibrinolytic Trials	Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients	LANCET			English	Article							TRANEXAMIC ACID; POSTPARTUM HEMORRHAGE; TRAUMA PATIENTS; DOUBLE-BLIND; MORTALITY; DEATH; CRASH-2; DISEASE	Background Antifibrinolytics reduce death from bleeding in trauma and post-partum haemorrhage. We examined the effect of treatment delay on the effectiveness of antifibrinolytics. Methods We did an individual patient-level data meta-analysis of randomised trials done with more than 1000 patients that assessed antifibrinolytics in acute severe bleeding. We identified trials done between Jan 1, 1946, and April 7, 2017, from MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, PubMed, Popline, and the WHO International Clinical Trials Registry Platform. The primary measure of treatment benefit was absence of death from bleeding. We examined the effect of treatment delay on treatment effectiveness using logistic regression models. We investigated the effect of measurement error (misclassification) in sensitivity analyses. This study is registered with PROSPERO, number 42016052155. Findings We obtained data for 40 138 patients from two randomised trials of tranexamic acid in acute severe bleeding (traumatic and post-partum haemorrhage). Overall, there were 3558 deaths, of which 1408 (40%) were from bleeding. Most (884 [63%] of 1408) bleeding deaths occurred within 12 h of onset. Deaths from post-partum haemorrhage peaked 2-3 h after childbirth. Tranexamic acid significantly increased overall survival from bleeding (odds ratio [OR] 1.20, 95% CI 1.08-1.33; p=0.001), with no heterogeneity by site of bleeding (interaction p=0.7243). Treatment delay reduced the treatment benefit (p<0.0001). Immediate treatment improved survival by more than 70% (OR 1.72, 95% CI 1.42-2.10; p<0.0001). Thereafter, the survival benefit decreased by 10% for every 15 min of treatment delay until 3 h, after which there was no benefit. There was no increase in vascular occlusive events with tranexamic acid, with no heterogeneity by site of bleeding (p=0.5956). Treatment delay did not modify the effect of tranexamic acid on vascular occlusive events. Interpretation Death from bleeding occurs soon after onset and even a short delay in treatment reduces the benefit of tranexamic acid administration. Patients must be treated immediately. Further research is needed to deepen our understanding of the mechanism of action of tranexamic acid.	[Gayet-Ageron, Angele; Ker, Katharine; Shakur, Haleema; Ageron, Francois-Xavier; Roberts, Ian] London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England; [Prieto-Merino, David] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England; [Gayet-Ageron, Angele] Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland; [Ageron, Francois-Xavier] Annecy Genevois Hosp, Dept Emergency Med, Northern French Alps Emergency Network, Annecy, France	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Geneva; Centre Hospitalier Annecy Genevois	Roberts, I (corresponding author), London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England.	ian.roberts@lshtm.ac.uk		Edwards, Phil/0000-0003-4431-8822; Arribas, Monica/0000-0002-1405-9391; Shakur-Still, Haleema/0000-0002-6511-109X; Gayet-Ageron, Angele/0000-0002-6164-9693; AGERON, Francois-Xavier/0000-0003-0520-3619	UK NIHR Health Technology Assessment programme; Pfizer; BUPA Foundation; J P Moulton Charitable Foundation (CRASH-2 trial); London School of Hygiene & Tropical Medicine; UK Department of Health; Wellcome Trust; Bill & Melinda Gates Foundation (WOMAN trial)	UK NIHR Health Technology Assessment programme(National Institute for Health Research (NIHR)); Pfizer(Pfizer); BUPA Foundation; J P Moulton Charitable Foundation (CRASH-2 trial); London School of Hygiene & Tropical Medicine; UK Department of Health; Wellcome Trust(Wellcome TrustEuropean Commission); Bill & Melinda Gates Foundation (WOMAN trial)	UK NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foundation (CRASH-2 trial). London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation (WOMAN trial).	Brown JB, 2015, PREHOSP EMERG CARE, V19, P79, DOI 10.3109/10903127.2014.936635; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cesarman-Maus G, 2005, BRIT J HAEMATOL, V129, P307, DOI 10.1111/j.1365-2141.2005.05444.x; Curry N., 2014, SCAND J TRAUMA RESUS, V22, P1, DOI DOI 10.1186/1757-7241-22-S1-A5; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Gayat E, 2011, INTENS CARE MED, V37, P1816, DOI 10.1007/s00134-011-2315-0; Hearnshaw SA, 2011, GUT, V60, P1327, DOI 10.1136/gut.2010.228437; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Hutcheon J.A., 2010, BMJ-BRIT MED J, V340, P1402, DOI DOI 10.1136/BMJ.C2289; Karkouti K, 2004, TRANSFUSION, V44, P1453, DOI 10.1111/j.1537-2995.2004.04144.x; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; Maddula M, 2016, INT J STROKE, V11, P65; Mitra B, 2014, EMERG MED AUSTRALAS, V26, P194, DOI 10.1111/1742-6723.12172; Myles PS, 2017, NEW ENGL J MED, V376, P136, DOI 10.1056/NEJMoa1606424; Oakland K, 2018, GUT, V67, P654, DOI 10.1136/gutjnl-2016-313428; OKAMOTO SHOSUKE, 1962, KEIO JOUR MED, V11, P105; Perel P, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5166; Prieto-Merino D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6782; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Roberts I, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0685-8; Roberts I, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0056-1; Roberts I, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-450; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Sentilhes L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0573-5; Shakur H, 2017, LANCET, V389, P2105, DOI 10.1016/S0140-6736(17)30638-4; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stewart GB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046042; Tierney JF, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001855; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; World Health Organization, 2012, WHO REC PREV TREATM	32	158	163	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2018	391	10116					125	132		10.1016/S0140-6736(17)32455-8	http://dx.doi.org/10.1016/S0140-6736(17)32455-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT0EG	29126600	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000422793400027
J	Camacho-Ortiz, A; Gutierrez-Delgado, EM; Garcia-Mazcorro, JF; Mendoza-Olazaran, S; Martinez-Melendez, A; Palau-Davila, L; Baines, SD; Maldonado-Garza, H; Garza-Gonzalez, E				Camacho-Ortiz, Adrian; Maria Gutierrez-Delgado, Eva; Garcia-Mazcorro, Jose F.; Mendoza-Olazaran, Soraya; Martinez-Melendez, Adrian; Palau-Davila, Laura; Baines, Simon D.; Maldonado-Garza, Hector; Garza-Gonzalez, Elvira			Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome	PLOS ONE			English	Article							RECURRENT; VANCOMYCIN; METRONIDAZOLE; COLONOSCOPY; TCDA	Objective The aim of this study was to evaluate the impact of fecal donor-unrelated donor mix (FMT-FURM) transplantation as first-line therapy for C. difficile infection (CDI) in intestinal microbiome. Methods We designed an open, two-arm pilot study with oral vancomycin (250 mg every 6 h for 10-14 days) or FMT-FURM as treatments for the first CDI episode in hospitalized adult patients in Hospital Universitario "Dr. Jose Eleuterio Gonzalez". Patients were randomized by a closed envelope method in a 1: 1 ratio to either oral vancomycin or FMT-FURM. CDI resolution was considered when there was a reduction on the Bristol scale of at least 2 points, a reduction of at least 50% in the number of bowel movements, absence of fever, and resolution of abdominal pain (at least two criteria). From each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. Specimens were cultured to isolate C. difficile, and isolates were characterized by PCR. Susceptibility testing of isolates was performed using the agar dilution method. Fecal samples and FMT-FURM were analyzed by 16S rRNA sequencing. Results We included 19 patients; 10 in the vancomycin arm and 9 in the FMT-FURM arm. However, one of the patients in the vancomycin arm and two patients in the FMT-FURM arm were eliminated. Symptoms resolved in 8/9 patients (88.9%) in the vancomycin group, while symptoms resolved in 4/7 patients (57.1%) after the first FMT-FURM dose (P = 0.26) and in 5/7 patients (71.4%) after the second dose (P = 0.55). During the study, no adverse effects attributable to FMT-FURM were observed in patients. Twelve isolates were recovered, most isolates carried tcdB, tcdA, cdtA, and cdtB, with an 18-bp deletion in tcdC. All isolates were resistant to ciprofloxacin and moxifloxacin but susceptible to metronidazole, linezolid, fidaxomicin, and tetracycline. In the FMT-FURM group, the bacterial composition was dominated by Firmicutes, Bacteroidetes, and Proteobacteria at all-time points and the microbiota were remarkably stable over time. The vancomycin group showed a very different pattern of the microbial composition when comparing to the FMT-FURM group over time. Conclusion The results of this preliminary study showed that FMT-FURM for initial CDI is associated with specific bacterial communities that do not resemble the donors' sample.	[Camacho-Ortiz, Adrian; Palau-Davila, Laura] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Coordinac Epidemiol Hosp, Monterrey, Nuevo Leon, Mexico; [Camacho-Ortiz, Adrian; Maria Gutierrez-Delgado, Eva] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Infectol, Monterrey, Nuevo Leon, Mexico; [Garcia-Mazcorro, Jose F.] Univ Veracruzana, Inst Invest Med Biol, Lab Fisiol Digest & Motilidad Gastrointestinal, Xalapa, Veracruz, Mexico; [Mendoza-Olazaran, Soraya; Maldonado-Garza, Hector; Garza-Gonzalez, Elvira] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Gastroenterol, Monterrey, Nuevo Leon, Mexico; [Martinez-Melendez, Adrian] Univ Autonoma Nuevo Leon, Fac Ciencias Biol, Dept Microbiol & Inmunol, San Nicolas De Los Garza, Nuevo Leon, Mexico; [Baines, Simon D.] Univ Hertfordshire, Dept Biol & Environm Sci, Sch Life & Med Sci, Hatfield, Herts, England	Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon; Universidad Veracruzana; Universidad Autonoma de Nuevo Leon; University Hospital Autonomous University of Nuevo Leon; Universidad Autonoma de Nuevo Leon; University of Hertfordshire	Garza-Gonzalez, E (corresponding author), Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Serv Gastroenterol, Monterrey, Nuevo Leon, Mexico.	elvira_garza_gzz@yahoo.com	Martinez-Melendez, Adrian/AAS-4267-2021; Garcia-Mazcorro, Jose F./O-5799-2018	Garza-Gonzalez, Elvira/0000-0001-5831-9661; Garcia-Mazcorro, Jose F./0000-0001-6047-4361; Mendoza-Olazaran, Soraya/0000-0001-5649-4810; Martinez-Melendez, Adrian/0000-0003-2936-1347				Bent SJ, 2008, ISME J, V2, P689, DOI 10.1038/ismej.2008.44; Brandt LJ, 2012, AM J GASTROENTEROL, V107, P1079, DOI 10.1038/ajg.2012.60; Buchler AC, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0607-z; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Caporaso JG, 2012, ISME J, V6, P1621, DOI 10.1038/ismej.2012.8; CLSI, 2016, M100S26 CLSI, P1624; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; DAT H, 2001, PALAEONTOL ELECTRON, P1; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Freeman J, 2001, J ANTIMICROB CHEMOTH, V47, P244, DOI 10.1093/jac/47.2.244; Goldstein EJC, 2003, ANTIMICROB AGENTS CH, V47, P337, DOI 10.1128/AAC.47.1.337-341.2003; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Lemee L, 2004, J CLIN MICROBIOL, V42, P5710, DOI 10.1128/JCM.42.12.5710-5714.2004; Lessa FC., 2015, NEW ENGL J MED, V372, P2369, DOI DOI 10.1056/NEJMC1505190; Lozupone C, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-371; Lozupone CA, 2007, APPL ENVIRON MICROB, V73, P1576, DOI 10.1128/AEM.01996-06; Mattila E, 2012, GASTROENTEROLOGY, V142, P490, DOI 10.1053/j.gastro.2011.11.037; Navas-Molina JA, 2013, METHOD ENZYMOL, V531, P371, DOI 10.1016/B978-0-12-407863-5.00019-8; O'Connor JR, 2008, ANTIMICROB AGENTS CH, V52, P2813, DOI 10.1128/AAC.00342-08; Oake N, 2010, ARCH INTERN MED, V170, P1804, DOI 10.1001/archinternmed.2010.405; Pepin J, 2007, AM J GASTROENTEROL, V102, P2781, DOI 10.1111/j.1572-0241.2007.01539.x; Persson S, 2011, J CLIN MICROBIOL, V49, P4299, DOI 10.1128/JCM.05161-11; Quraishi MN, 2017, ALIMENT PHARM THER, V46, P479, DOI 10.1111/apt.14201; Rideout JR, 2014, PEERJ, V2, DOI 10.7717/peerj.545; Rineh A, 2014, EXPERT REV ANTI-INFE, V12, P131, DOI 10.1586/14787210.2014.866515; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vardakas KZ, 2012, INT J ANTIMICROB AG, V40, P1, DOI 10.1016/j.ijantimicag.2012.01.004; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	30	30	32	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2017	12	12							e0189768	10.1371/journal.pone.0189768	http://dx.doi.org/10.1371/journal.pone.0189768			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7SY	29261736	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000418564200064
J	Audet, CM; Ngobeni, S; Graves, E; Wagner, RG				Audet, Carolyn M.; Ngobeni, Sizzy; Graves, Erin; Wagner, Ryan G.			Mixed methods inquiry into traditional healers' treatment of mental, neurological and substance abuse disorders in rural South Africa	PLOS ONE			English	Article							HEALTH-CARE; SEEKING BEHAVIOR; GLOBAL BURDEN; ALCOHOL-USE; SCHIZOPHRENIA; PREVALENCE; AGINCOURT; DISEASE; DISABILITY; MORTALITY	Background Traditional healers are acceptable and highly accessible health practitioners throughout sub-Saharan Africa. Patients in South Africa often seek concurrent traditional and allopathic treatment leading to medical pluralism. Methods & findings We studied the cause of five traditional illnesses known locally as "Mavabyi ya nhloko" (sickness of the head), by conducting 27 in-depth interviews and 133 surveys with a randomly selected sample of traditional healers living and working in rural, northeastern South Africa. These interviews were carried out to identify treatment practices of mental, neurological, and substance abuse (MNS) disorders. Participating healers were primarily female (77%), older in age (median: 58.0 years; interquartile range [IQR]: 50-67), had very little formal education (median: 3.7 years; IQR: 3.2-4.2), and had practiced traditional medicine for many years (median: 17 years; IQR: 9.5-30). Healers reported having the ability to successfully treat: seizure disorders (47%), patients who have lost touch with reality (47%), paralysis on one side of the body (59%), and substance abuse (21%). Female healers reported a lower odds of treating seizure disorders (Odds Ratio (OR): 0.47), patients who had lost touch with reality (OR: 0.26; p-value<0.05), paralysis of one side of the body (OR: 0.36), and substance abuse (OR: 0.36) versus males. Each additional year of education received was found to be associated with lower odds, ranging from 0.13-0.27, of treating these symptoms. Each additional patient seen by healers in the past week was associated with roughly 1.10 higher odds of treating seizure disorders, patients who have lost touch with reality, paralysis of one side of the body, and substance abuse. Healers charged a median of 500 South African Rand (similar to US$35) to treat substance abuse, 1000 Rand (similar to US$70) for seizure disorders or paralysis of one side of the body, and 1500 Rand (similar to US$105) for patients who have lost touch with reality. Conclusions While not all healers elect to treat MNS disorders, many continue to do so, delaying allopathic health services to acutely ill patients.	[Audet, Carolyn M.; Graves, Erin] Vanderbilt Univ, Vanderbilt Inst Global Hlth, Nashville, TN 37235 USA; [Ngobeni, Sizzy; Wagner, Ryan G.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC,Wits Agincourt Res Unit, Johannesburg, South Africa; [Wagner, Ryan G.] Umea Univ, Umea Ctr Global Hlth Res, Umea, Sweden; [Ngobeni, Sizzy] Univ Witwatersrand, Agincourt Res Unit, Acornhoek, South Africa	Vanderbilt University; University of Witwatersrand; Umea University; University of Witwatersrand	Audet, CM (corresponding author), Vanderbilt Univ, Vanderbilt Inst Global Hlth, Nashville, TN 37235 USA.	carolyn.m.audet@vanderbilt.edu	Wagner, Ryan G/AFK-7323-2022	Wagner, Ryan G/0000-0003-2741-3676	National Institute of Mental Health [1K01MH107255-01]; National Institutes of Health [KL2TR0000446]; NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH107255] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The study was supported by the National Institute of Mental Health (1K01MH107255-01) and the National Institutes of Health (KL2TR0000446). The funders had no role in study design, data collection and analysis, decision or publish or preparation of the manuscript.	Audet C, 2017, MENTAL HLTH TREATMEN; Audet C. M., 2016, USE CD4 CELL COUNT R; Audet CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070326; Audet CM, 2012, SAHARA J-J SOC ASP H, V9, P41, DOI 10.1080/17290376.2012.665257; Babb Dale A, 2007, Psychol Health Med, V12, P314, DOI 10.1080/13548500600621511; Banda Y, 2007, J ALTERN COMPLEM MED, V13, P123, DOI 10.1089/acm.2006.6225; Barker RD, 2006, INT J TUBERC LUNG D, V10, P670; Bowie CR, 2010, AM J PSYCHIAT, V167, P1116, DOI 10.1176/appi.ajp.2010.09101406; Brown S, 2000, BRIT J PSYCHIAT, V177, P212, DOI 10.1192/bjp.177.3.212; Buckley PF, 2009, SCHIZOPHRENIA BULL, V35, P383, DOI 10.1093/schbul/sbn135; Charlson FJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110208; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Department of Health, 2013, NAT MENT HEL POL FRA; Dewey ME, 2001, INT J GERIATR PSYCH, V16, P751, DOI 10.1002/gps.397.abs; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fela-Thomas A, 2016, EPILEPSY BEHAV, V54, P58, DOI 10.1016/j.yebeh.2015.11.008; Ferrari AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091936; Ferrari AJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001547; Goudge J, 2009, TROP MED INT HEALTH, V14, P458, DOI 10.1111/j.1365-3156.2009.02256.x; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; Hundt GL, 2004, J BIOSOC SCI, V36, P433, DOI 10.1017/S0021932004006662; Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders Uganda National Academy of Sciences Forum on Health and Nutrition, 2010, MENT NEUR SUBST DIS; Kahn K, 2012, INT J EPIDEMIOL, V41, P988, DOI 10.1093/ije/dys115; Kakuma R, 2010, AFR J PSYCHIATRY, V13, P116; KALE R, 1995, BRIT MED J, V310, P1182, DOI 10.1136/bmj.310.6988.1182; Lund C, 2015, S AFR MED J, V92, P161; Makundi EA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-58; Marais DL, 2015, INT J MENT HEALTH SY, V9, DOI 10.1186/s13033-015-0004-z; McGrath J, 2008, EPIDEMIOL REV, V30, P67, DOI 10.1093/epirev/mxn001; McKibbin C, 2004, J NERV MENT DIS, V192, P405, DOI 10.1097/01.nmd.0000130133.32276.83; Meretoja A, 2014, STROKE, V45, P1053, DOI 10.1161/STROKEAHA.113.002910; Moshabela M, 2011, AIDS BEHAV, V15, P842, DOI 10.1007/s10461-010-9747-3; Muliyala KP, 2010, ANN INDIAN ACAD NEUR, V13, P69, DOI 10.4103/0972-2327.74248; Nortje G, 2016, LANCET PSYCHIAT, V3, P154, DOI 10.1016/S2215-0366(15)00515-5; Okasha Ahmed, 2002, World Psychiatry, V1, P32; Opara Jozef A, 2010, J Med Life, V3, P216; Parham GP, 2006, GYNECOL ONCOL, V103, P1017, DOI 10.1016/j.ygyno.2006.06.015; Patel V, 2010, WORLD PSYCHIATRY, V9, P169; Pinkoane M G, 2005, Curationis, V28, P20; PlusNews, 2010, S AFR TRAD HEAL EXT; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; Ritsner Michael S, 2015, Clin Schizophr Relat Psychoses, V9, P125, DOI 10.3371/CSRP.RIGR.030813; Rotheram-Borus MJ, 2015, AM J PREV MED, V49, P715, DOI 10.1016/j.amepre.2015.05.004; Schneider M, 2007, SAMJ S AFR MED J, V97, P664; Sibuye R, 2012, PARTICIPATORY LEARNI, V65, P101; Sorsdahl K, 2013, AFR J PSYCHIATRY, V16, P35, DOI [http://dx.doi.org/10.4314/ajpsy.v16i1.6, 10.4314/ajpsy.v16i1.6]; Sorsdahl K, 2010, TRANSCULT PSYCHIATRY, V47, P591, DOI 10.1177/1363461510383330; Sorsdahl K, 2009, J NERV MENT DIS, V197, P434, DOI 10.1097/NMD.0b013e3181a61dbc; Sorsdahl KR, 2010, J NERV MENT DIS, V198, P742, DOI 10.1097/NMD.0b013e3181f4b2d7; Stekelenburg J, 2005, HEALTH POLICY, V71, P67, DOI 10.1016/j.healthpol.2004.05.008; Tollman SM, 1999, S AFR MED J, V89, P858; Tollman SM, 1999, S AFR MED J, V89, P853; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wagner RG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129097; Wandwalo ER, 2000, INT J TUBERC LUNG D, V4, P133; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; Williams DR, 2008, PSYCHOL MED, V38, P211, DOI 10.1017/S0033291707001420; Wilson DA, 2014, EPILEPSY BEHAV, V32, P42, DOI 10.1016/j.yebeh.2013.12.035	58	18	19	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2017	12	12							e0188433	10.1371/journal.pone.0188433	http://dx.doi.org/10.1371/journal.pone.0188433			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FQ7PP	29261705	Green Submitted, Green Published, gold			2023-01-03	WOS:000418554900004
J	Barnett, ML; Gray, J; Zink, A; Jena, AB				Barnett, Michael L.; Gray, Josh; Zink, Anna; Jena, Anupam B.			Coupling Policymaking with Evaluation - The Case of the Opioid Crisis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RATES		[Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Barnett, Michael L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Jena, Anupam B.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Jena, Anupam B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Gray, Josh] athenahealth, Watertown, MA USA; [Zink, Anna] Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA; [Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; National Bureau of Economic Research	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.; Barnett, ML (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.		Barnett, Michael/AAF-4017-2019; Barnett, Michael/ABA-4159-2021	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609				Buchmueller TC, 2017, EFFECT PRESCRIPTION; Larochelle MR, 2015, JAMA INTERN MED, V175, P978, DOI 10.1001/jamainternmed.2015.0914; Meara E, 2016, NEW ENGL J MED, V375, P44, DOI 10.1056/NEJMsa1514387; Patrick SW, 2016, HEALTH AFFAIR, V35, P1324, DOI 10.1377/hlthaff.2015.1496; Sacarny A, 2016, HEALTH AFFAIR, V35, P471, DOI 10.1377/hlthaff.2015.1025	5	30	31	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 14	2017	377	24					2306	2309		10.1056/NEJMp1710014	http://dx.doi.org/10.1056/NEJMp1710014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FP8VG	29236636	Bronze			2023-01-03	WOS:000417923600002
J	Wang, YT; Jiang, SL; Wang, HL; Bie, HY				Wang, Yingting; Jiang, Shulong; Wang, Hongli; Bie, Haiyan			A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases	PLOS ONE			English	Article							DRUG-DELIVERY; FORMING SYSTEMS; FORMULATION; POLOXAMER; HYDROGELS; OPTIMIZATION; TEMPERATURE; BIOADHESIVE; COPOLYMERS; CELLS	Neurodegenerative diseases are becoming prevalent as the population ages. Geniposide could inhibit oxidative stress, reduce apoptosis, protect neuron, and has been used for therapy of the neurodegenerative diseases. The bioavailability of geniposide by nasal route is greater than that by oral administration. However, mucociliary clearance is a rate-limiting factor for nasal route administration. The objective of this study was to develop and evaluate a mucoadhesive, thermoreversible in situ nasal gel of geniposide. The poloxamers (P407, P188) and the hydroxypropyl methylcellulose were used as thermoreversible and mucoadhesive polymers, respectively. Borneol was used as a permeation enhancer. The hydrogel was prepared with the cold method and optimized by the response surface methodologycentral composite design. Gelation temperature, pH, clarity, gel strength, mucoadhesive strength, in vitro and ex vivo release kinetics of formulations were evaluated. The optimized amounts of poloxamer407 (P407), poloxamer188 (P188) and hydroxypropyl methylcellulose were determined to be 19.4 +/- 20.5%, 1.1 +/- 4.0% and 0.3 +/- 0.6% respectively. The secondorder polynomial equation in terms of actual factors indicated a satisfactory correlation between the independent variables and the response (R-2 = 0.9760). An ANOVA of the empirical second-order polynomial model indicated the model was significant (P< 0.01). P407, P188, P407xP188, P407 2 and P188(2) were significant model terms. The effects of P407 on gelation temperature were greater than those of other independent variables. The pH values of all the formulations were found to be within 6.3 +/- 6.5 which was in the nasal physiological pH range 4.5 +/- 6.5. The drug content, gel strength, mucoadhesive strength of the optimized formulations were 97 +/- 101%, 25 +/- 50 sec and 4000 +/- 6000 dyn/cm(2) respectively. The in vitro release kinetics of cumulative release of geniposide was fitted to the zeroorder model. The ex vivo cumulative release kinetics of geniposide was fitted to the Weibull model. This study concludes that the release of geniposide is controlled by gel corrosion, and that the permeation of geniposide is time-dependent. The more residence time, mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases is of compliance and potential application.	[Wang, Yingting; Jiang, Shulong; Wang, Hongli; Bie, Haiyan] Jining 1 Peoples Hosp, Jining, Shandong, Peoples R China		Jiang, SL (corresponding author), Jining 1 Peoples Hosp, Jining, Shandong, Peoples R China.	3416048269@qq.com			Natural Science Foundation of Shandong Province [ZR2014HL095]	Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This work was supported by The Natural Science Foundation of Shandong Province, ZR2014HL095 (http://www.sdnsf.gov.cn/sdnsfms/jsp/loginUp2.jsp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asasutjarit R, 2011, INT J PHARMACEUT, V411, P128, DOI 10.1016/j.ijpharm.2011.03.054; Belgamwar VS, 2009, PHARM DEV TECHNOL, V14, P240, DOI 10.1080/10837450802498910; Bhandwalkar MJ, 2013, AAPS PHARMSCITECH, V14, P101, DOI 10.1208/s12249-012-9893-1; Bie HY, 2016, CHINESE JOURNAL NEW, V25, P1; Bryan L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153683; Callegari L, 2016, NEURODEGENER DIS, V16, P352; Chen P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113307; Chen ZZ, PLOS ONE; Chu KD, 2013, INT J MOL SCI, V14, P6499, DOI 10.3390/ijms14036499; Dash S, 2010, ACTA POL PHARM, V67, P217; De A, 2013, IJRPC, V3, P659; Dondeti P, 1996, INT J PHARM, V127, P115, DOI 10.1016/0378-5173(95)04115-X; Du SY, 2012, CHINESE J EXPT TRADI, V18, P146; Fernandez E, 2008, J POLYM SCI POL PHYS, V46, P322, DOI 10.1002/polb.21370; Galgatte UC, 2014, DRUG DELIV, V21, P62, DOI 10.3109/10717544.2013.849778; Gratieri T, 2010, EUR J PHARM BIOPHARM, V75, P186, DOI 10.1016/j.ejpb.2010.02.011; Illum L, 2002, DRUG DISCOV TODAY, V7, P1184, DOI 10.1016/S1359-6446(02)02529-1; Illum L, 2003, J CONTROL RELEASE, V87, P187, DOI 10.1016/S0168-3659(02)00363-2; Jabarian LE, 2013, EUR J PHARM SCI, V48, P87, DOI 10.1016/j.ejps.2012.09.017; Jadhav KR, 2007, CURR DRUG THER, V2, P27, DOI 10.2174/157488507779422374; Jagdale S, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/6401267; Jiang J, 2008, POLYMER, V49, P3561, DOI 10.1016/j.polymer.2008.05.038; Junn E, 2012, PHARMACOL THERAPEUT, V133, P142, DOI 10.1016/j.pharmthera.2011.10.002; Karavasili C, 2016, DRUG DISCOV TODAY, V21, P157, DOI 10.1016/j.drudis.2015.10.016; Kempwade A, 2014, J SOL-GEL SCI TECHN, V72, P43, DOI 10.1007/s10971-014-3422-5; Klouda L, 2008, EUR J PHARM BIOPHARM, V68, P34, DOI 10.1016/j.ejpb.2007.02.025; Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011; Kuo CH, 2013, INT J ELECTROCHEM SC, V8, P9242; Lai MC, 2014, BIOMED MATER, V9, DOI 10.1088/1748-6041/9/1/015011; Li L, 2015, NEURAL REGEN RES, V10, P1617, DOI 10.4103/1673-5374.167760; Liu JH, 2007, NEUROCHEM INT, V51, P361, DOI 10.1016/j.neuint.2007.04.021; Lu CC, 2015, EUR J PHARM SCI, V77, P24, DOI 10.1016/j.ejps.2015.05.014; Lu Y, 2012, INT J MOL SCI, V13, P14127, DOI 10.3390/ijms131114127; Lv C, 2014, CURR ALZHEIMER RES, V11, P430, DOI 10.2174/1567205011666140514111204; Madan M, 2009, INDIAN J PHARM SCI, V71, P242, DOI 10.4103/0250-474X.56015; Marwah H, 2016, DRUG DELIV, V23, P1636, DOI 10.3109/10717544.2016.1155243; dos Santos ACM, 2015, INT J NANOMED, V10, P2391, DOI 10.2147/IJN.S72337; Nour V, 2015, J FOOD BIOCHEM, V39, P179, DOI 10.1111/jfbc.12119; Patel N, 2015, J PHARM INNOV, V10, P357, DOI 10.1007/s12247-015-9232-7; Pathak R, 2014, ACTA PHARM SIN B, V4, P151, DOI 10.1016/j.apsb.2014.02.002; Phaechamud T, 2016, MATER DESIGN, V89, P294, DOI 10.1016/j.matdes.2015.09.138; Pires A, 2009, J PHARM PHARM SCI, V12, P288, DOI 10.18433/J3NC79; Radivojsa M, 2013, EUR J PHARM SCI, V50, P93, DOI 10.1016/j.ejps.2013.03.002; Rao M, 2017, DRUG DEV IND PHARM, V43, P142, DOI 10.1080/03639045.2016.1225754; Rokade M, 2015, INT J PHARM SCI RES, V6, P4958, DOI 10.13040/IJPSR.0975-8232.6(12).4958-66; Seo HJ, 2012, J IND ENG CHEM, V18, P88, DOI 10.1016/j.jiec.2011.11.077; Sharma N, 2013, TROP J PHARM RES, V12, P149, DOI 10.4314/tjpr.v12i2.3; Shelke S, 2016, J MATER SCI-MATER M, V27, DOI 10.1007/s10856-016-5713-6; Shi XL, 2015, INT J BIOL MACROMOL, V72, P553, DOI 10.1016/j.ijbiomac.2014.09.009; Singh RMP, 2013, AAPS PHARMSCITECH, V14, P412, DOI 10.1208/s12249-013-9921-9; Ugwoke MI, 2005, ADV DRUG DELIVER REV, V57, P1640, DOI 10.1016/j.addr.2005.07.009; Ur-Rehman T, 2011, INT J PHARMACEUT, V409, P19, DOI 10.1016/j.ijpharm.2011.02.017; Wang CY, 2012, PROTEIN ENG DES SEL, V25, P1, DOI 10.1093/protein/gzs078; Wang HL, 2016, CHINA PHARM, V27, P98; [杨明 Yang Ming], 2010, [中国新药杂志, Chinese Journal New Drugs], V19, P746; Yapar EA, 2012, TROP J PHARM RES, V11, P855, DOI 10.4314/tjpr.v11i5.20; Yeole PG, 2011, RES J PHARM BIOL CHE, V2, P1048; Yong CS, 2001, INT J PHARM, V226, P195, DOI 10.1016/S0378-5173(01)00809-2; Yu L, 2010, BIOMACROMOLECULES, V11, P2169, DOI 10.1021/bm100549q; Yu ZG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173949; Zhang K, 2015, DRUG DELIV, V22, P375, DOI 10.3109/10717544.2014.891272; Zhao CH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152551; Zhou TT, 2005, J CHROMATOGR A, V1100, P76, DOI 10.1016/j.chroma.2005.09.026	63	30	30	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2017	12	12							e0189478	10.1371/journal.pone.0189478	http://dx.doi.org/10.1371/journal.pone.0189478			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP8OT	29240797	Green Submitted, Green Published, gold			2023-01-03	WOS:000417905600035
J	den Heijer, M; Bakker, A; Gooren, L				den Heijer, Martin; Bakker, Alex; Gooren, Louis			THERAPEUTICS Long term hormonal treatment for transgender people	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							THERAPY		[den Heijer, Martin] Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands; [den Heijer, Martin; Gooren, Louis] Vrije Univ Amsterdam Med Ctr, Ctr Expertise Gender Dysphoria, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	den Heijer, M (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Internal Med, Amsterdam, Netherlands.; den Heijer, M (corresponding author), Vrije Univ Amsterdam Med Ctr, Ctr Expertise Gender Dysphoria, Amsterdam, Netherlands.	m.denheijer@vumc.nl	den Heijer, Martin/J-8036-2015	den Heijer, Martin/0000-0003-3620-5617				Arnold JD, 2016, J SEX MED, V13, P1773, DOI 10.1016/j.jsxm.2016.09.001; Asscheman H, 2014, ANDROLOGIA, V46, P791, DOI 10.1111/and.12150; Bachman E, 2014, J GERONTOL A-BIOL, V69, P725, DOI 10.1093/gerona/glt154; Brown GR, 2015, BREAST CANCER RES TR, V149, P191, DOI 10.1007/s10549-014-3213-2; Cauley JA, 2015, STEROIDS, V99, P11, DOI 10.1016/j.steroids.2014.12.010; Coleman E, 2012, INT J TRANSGENDERISM, V13, P165, DOI 10.1080/15532739.2011.700873; Collin L, 2016, J SEX MED, V13, P613, DOI 10.1016/j.jsxm.2016.02.001; Deutsch MB, 2015, OBSTET GYNECOL, V125, P605, DOI 10.1097/AOG.0000000000000692; Elamin MB, 2010, CLIN ENDOCRINOL, V72, P1, DOI 10.1111/j.1365-2265.2009.03632.x; Gava G, 2016, CLIN ENDOCRINOL, V85, P239, DOI 10.1111/cen.13050; Gil M, 2011, BRIT J CLIN PHARMACO, V72, P965, DOI 10.1111/j.1365-2125.2011.04031.x; Gomez-Gil E, 2012, PSYCHONEUROENDOCRINO, V37, P662, DOI 10.1016/j.psyneuen.2011.08.010; Gooren L, 2015, ANDROLOGIA, V47, P1202, DOI 10.1111/and.12399; Gooren L, 2014, ANDROLOGIA, V46, P1156, DOI 10.1111/and.12208; Gooren L, 2014, J SEX MED, V11, P2012, DOI 10.1111/jsm.12563; Gooren LJ, 2014, EUR J ENDOCRINOL, V170, P809, DOI 10.1530/EJE-14-0011; Gooren LJ, 2011, NEW ENGL J MED, V364, P1251, DOI 10.1056/NEJMcp1008161; Gorin-Lazard A, 2013, J NERV MENT DIS, V201, P996, DOI 10.1097/NMD.0000000000000046; Hembree WC, 2017, J CLIN ENDOCR METAB, V102, P3869, DOI [10.1210/jc.2017-01658, 10.1210/jc.2017-02548]; Irwig MS, 2017, LANCET DIABETES ENDO, V5, P301, DOI 10.1016/S2213-8587(16)00036-X; Klaver M, 2017, ANDROLOGIA, V49, DOI 10.1111/and.12660; Mohammed K, 2015, J CLIN ENDOCR METAB, V100, P4012, DOI 10.1210/jc.2015-2237; Murad MH, 2010, CLIN ENDOCRINOL, V72, P214, DOI 10.1111/j.1365-2265.2009.03625.x; Nota NM, 2017, ANDROLOGIA, V49, DOI 10.1111/and.12666; Roberts TK, 2014, AM J MED, V127, P159, DOI 10.1016/j.amjmed.2013.10.009; Tangpricha V, 2016, LANCET DIABETES ENDO, V359, P1; Turo R, 2013, CUAJ-CAN UROL ASSOC, V7, pE544, DOI 10.5489/cuaj.175; Van Caenegem E, 2013, BONE, V54, P92, DOI 10.1016/j.bone.2013.01.039; Vasilakis-Scaramozza C, 2001, LANCET, V358, P1427, DOI 10.1016/S0140-6736(01)06522-9; Weinand JD, 2015, J CLIN TRANSL ENDOCR, V2, P55, DOI 10.1016/j.jcte.2015.02.003; Wiepjes CM, 2017, J BONE MINER RES, V32, P1252, DOI 10.1002/jbmr.3102; Wierckx K, 2014, J SEX MED, V11, P1999, DOI 10.1111/jsm.12571	32	17	17	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2017	359								j5027	10.1136/bmj.j5027	http://dx.doi.org/10.1136/bmj.j5027			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO9MO	29192092				2023-01-03	WOS:000417211800001
J	Pauchard, LA; Blot, M; Bruyere, R; Barbar, SD; Croisier, D; Piroth, L; Charles, PE				Pauchard, Laure-Anne; Blot, Mathieu; Bruyere, Remi; Barbar, Saber-Davide; Croisier, Delphine; Piroth, Lionel; Charles, Pierre-Emmanuel			Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation	PLOS ONE			English	Article							INDUCED LUNG INJURY; TIDAL-VOLUME; OUTCOMES; STATINS; MODEL; INFLAMMATION; MORTALITY; THERAPY; PATHWAY; SEPSIS	Pneumonia may involve methicillin-resistant Staphylococcus aureus (MRSA), with elevated rates of antibiotics failure. The present study aimed to assess the effect of statins given prior to pneumonia development. Spontaneously breathing (SB) or mechanically ventilated (MV) rabbits with pneumonia received atorvastatin alone, linezolid (LNZ) alone, or a combination of both (n = 5 in each group). Spontaneously breathing and MV untreated infected animals (n = 11 in each group), as well as uninfected animals (n = 5 in each group) were used as controls. Microbiological features and inflammation were evaluated. Data are presented as medians (interquartile range). Linezolid alone tended to reduce pulmonary MRSA load in both SB and MV rabbits, but failed to prevent bacteremia (59%) in the latter. Linezolid alone dampened TNF-alpha lung production in both SB and MV rabbits (e.g., 2226 [789] vs. 11478 [10251] pg/g; p = 0.022). Statins alone did the same in both SB and MV animals (e.g., 2040 [133]; p = 0.016), and dampened systemic inflammation in the latter, possibly through TLR2 down-regulation within the lung. However, the combination of LNZ and statin led to an increased rate of bacteremia in MV animals up to 75%. Statins provide an anti-inflammatory effect in rabbits with MRSA pneumonia, especially in MV ones. However, dampening the systemic inflammatory response with statins could impede blood defenses against MRSA.	[Pauchard, Laure-Anne; Blot, Mathieu; Bruyere, Remi; Barbar, Saber-Davide; Charles, Pierre-Emmanuel] Univ Bourgogne, Lab Lipides Nutr Canc, UMR 1231, INSERM,UFR Sci Sante, Dijon, France; [Blot, Mathieu; Piroth, Lionel] Hop F Mitterrand, Serv Malad Infect & Tropicales, Dijon, France; [Croisier, Delphine] Vivexia SARL, Gemeaux, France; [Charles, Pierre-Emmanuel] Hop F Mitterrand, Serv Reanimat Med, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne; CHU Dijon Bourgogne	Charles, PE (corresponding author), Univ Bourgogne, Lab Lipides Nutr Canc, UMR 1231, INSERM,UFR Sci Sante, Dijon, France.; Charles, PE (corresponding author), Hop F Mitterrand, Serv Reanimat Med, Dijon, France.	pierre-emmanuel.charles@chu-dijon.fr	Blot, Mathieu/D-4508-2019	Blot, Mathieu/0000-0001-6541-2434; Charles, Pierre-Emmanuel/0000-0002-0201-9544; Barbar, Saber Davide/0000-0002-5089-8088	Pfizer	Pfizer(Pfizer)	DC is an employee of the "Vivexia S.A.R. L." company and as such received a salary. This funder only provided a part of the research materials (i.e., catheter insertion in rabbits). This funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Pfizer (i.e., Aspire grant) has provided support in the form of the remaining research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbar SD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158799; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001; Bruyere R, 2014, CRIT CARE, V18, DOI 10.1186/cc13845; Calisto KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014232; Chalmers JD, 2008, AM J MED, V121, P1002, DOI 10.1016/j.amjmed.2008.06.030; Charles PE, 2005, CRIT CARE MED, V33, P1029, DOI 10.1097/01.CCM.0000163404.35338.72; Charles PE, 2004, INTENS CARE MED, V30, P2263, DOI 10.1007/s00134-004-2442-y; Charles PE, 2002, CRIT CARE MED, V30, P2278, DOI 10.1097/00003246-200210000-00016; Charles PE, 2011, CRIT CARE, V15, DOI 10.1186/cc10330; Chow OA, 2010, CELL HOST MICROBE, V8, P445, DOI 10.1016/j.chom.2010.10.005; Christaki E, 2014, VIRULENCE, V5, P57, DOI 10.4161/viru.26514; Diep BA, 2013, J INFECT DIS, V208, P75, DOI 10.1093/infdis/jit129; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Jacqueline C, 2014, J INFECT DIS, V210, P814, DOI 10.1093/infdis/jiu145; Kajikawa O, 2005, GENE, V344, P193, DOI 10.1016/j.gene.2004.09.032; Kruger P, 2013, AM J RESP CRIT CARE, V187, P743, DOI 10.1164/rccm.201209-1718OC; Ladoire S, 2013, ANESTHESIOLOGY, V118, P1150, DOI 10.1097/ALN.0b013e31828a7016; Leung S, 2012, CRIT CARE MED, V40, P1064, DOI 10.1097/CCM.0b013e31823bc9e7; Magret M, 2011, CRIT CARE, V15, DOI 10.1186/cc10036; Makris D, 2011, CRIT CARE MED, V39, P2440, DOI 10.1097/CCM.0b013e318225742c; McAuley D, 2016, INTENSIVE CARE MED; Moriyama K, 2004, AM J PHYSIOL-LUNG C, V286, pL1114, DOI 10.1152/ajplung.00296.2003; Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079; Papazian L, 2013, JAMA-J AM MED ASSOC, V310, P1692, DOI 10.1001/jama.2013.280031; Shyamsundar M, 2009, AM J RESP CRIT CARE, V179, P1107, DOI 10.1164/rccm.200810-1584OC; Siempos II, 2010, CRIT CARE MED, V38, P1321, DOI 10.1097/CCM.0b013e3181d9dad6; Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707; Taubert M, 2016, ANTIMICROB AGENTS CH; Terblanche M, 2007, LANCET INFECT DIS, V7, P358, DOI 10.1016/S1473-3099(07)70111-1; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; van der Poll T, 2008, LANCET INFECT DIS, V8, P32, DOI 10.1016/S1473-3099(07)70265-7; Vaneker M, 2008, ANESTHESIOLOGY, V109, P465, DOI 10.1097/ALN.0b013e318182aef1; Wang Y, 2011, AM J PHYSIOL-HEART C, V300, pH1743, DOI 10.1152/ajpheart.01335.2008; Wu BQ, 2014, CLIN EXP MED, V14, P151, DOI 10.1007/s10238-013-0231-z; Wunderink RG, 2012, CLIN INFECT DIS, V54, P621, DOI 10.1093/cid/cir895; Yoshizawa S, 2012, ANTIMICROB AGENTS CH, V56, P1744, DOI 10.1128/AAC.05430-11	39	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2017	12	11							e0187187	10.1371/journal.pone.0187187	http://dx.doi.org/10.1371/journal.pone.0187187			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN0DI	29149185	gold, Green Published, Green Submitted			2023-01-03	WOS:000415646100008
J	Amorim, JL; Figueiredo, JD; Amaral, ACF; Barros, EGD; Palmero, C; MPalantinos, MA; Ramos, AD; Ferreira, JLP; Silva, JRD; Benjamim, CF; Basso, SL; Nasciutti, LE; Fernandes, PD				Amorim, Jorge Luis; Figueiredo, Janaina de Barros; Fernandes Amaral, Ana Claudia; de Oliveira Barros, Eliane Gouvea; Palmero, Celia; MPalantinos, Maria Athana; Ramos, Aline de Souza; Pinto Ferreira, Jose Luiz; de Andrade Silva, Jefferson Rocha; Benjamim, Claudia Farias; Basso, Silvia Luciane; Nasciutti, Luiz Eurico; Fernandes, Patricia Dias			Wound healing properties of Copaifera paupera in diabetic mice	PLOS ONE			English	Article							MULTIJUGA HAYNE; COPAIBA OILS; EXTRACELLULAR-MATRIX; RETICULATA DUCKE; GROWTH-FACTORS; VENOUS ULCERS; OLEORESIN; RATS; FRACTIONS; CYTOKINES	Copaifera oleoresin is one of the most used natural products in popular medicine all over the world. Among other effects (i.e., anti-inflammatory, antinociceptive, microbicidal) one of the most well-known is its wound healing capacity. However, the mechanism by which the oleoresin presents its effect is still not clear. In this study, our aim was to evaluate the wound healing capacity of oleoresin obtained from Copaifera paupera, its mechanism of action and identify its major components. For these purposes, diabetic Swiss Webster mice were topically treated with oleoresin (100, 150 or 200 mg/kg) for 14 consecutive days after an excision was performed in the back of the mice. Cytokines, wound retraction and histological evaluation were conducted at 3, 7 and 10 days (for cytokines); 0, 3, 7, 10 and 14 days (for wound retraction); and 7 and 14 days (for histological evaluation). Our data indicate that oleoresin significantly reduced production of MCP-1 and TNF-alpha at days 7 and 10 post-excision and increased IL-10 production at both days. All treatments demonstrated an effect similar or higher to that in collagenase-treated mice. Histological evaluations demonstrated that higher dose treatment resulted in better resolution and closure of the wound and higher levels of collagen deposition and indexes of re-epithelialization even when compared with the collagenase-treated group. The treatment with oleoresin from Copaifera paupera demonstrated that it is even better than an ointment routinely used for improvement of wound healing, suggesting this oleoresin as an option for use in diabetic patients.	[Amorim, Jorge Luis; Fernandes, Patricia Dias] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Farmacol Dor & Inflamacao, Rio De Janeiro, Brazil; [Figueiredo, Janaina de Barros; Benjamim, Claudia Farias] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil; [Fernandes Amaral, Ana Claudia; MPalantinos, Maria Athana; Ramos, Aline de Souza; Pinto Ferreira, Jose Luiz; de Andrade Silva, Jefferson Rocha] Fiocruz MS, Farmanguinhos, Rio De Janeiro, Brazil; [de Oliveira Barros, Eliane Gouvea; Palmero, Celia; Nasciutti, Luiz Eurico] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Interacoes Celulares, Rio De Janeiro, Brazil; [Basso, Silvia Luciane] Univ Fed Amazonas, Dept Quim, Lab Cromatog, Manaus, Amazonas, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Universidade Federal de Amazonas	Fernandes, PD (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Farmacol Dor & Inflamacao, Rio De Janeiro, Brazil.	patricia.dias@icb.ufrj.br	Fernandes, Patricia Dias/W-1565-2019; Amaral, Ana/Y-7832-2018; SILVA, JEFFERSON RA/A-6845-2008; Benjamim, Claudia/T-5090-2019; Ramos, Aline de Souza/M-1575-2018	Fernandes, Patricia Dias/0000-0001-6870-6745; Benjamim, Claudia/0000-0001-6247-9596; Ramos, Aline de Souza/0000-0002-3478-1904; Fernandes AMARAL, ANA CLAUDIA/0000-0002-2532-471X; SILVA, JEFFERSON/0000-0003-2569-1306; Barros, Janaina/0000-0002-3642-3035; Gouvea de Oliveira Barros, Eliane/0000-0002-0020-6653; Ferreira, Jose Luiz Pinto/0000-0003-1027-9861	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [303033/2013-4, 405332/20165]; Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro (FAPERJ) [E-26/203.018/2015]; Conselho de Administracao de Pessoal de Ensino Superior (CAPES); FAPEAM (REDEBIO); FAPEAM (PAPAC)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Conselho de Administracao de Pessoal de Ensino Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPEAM (REDEBIO); FAPEAM (PAPAC)	We would like to thank Mr. Alan Minho for technical assistance, Institute Vital Brazil (Niteroi City, Brazil) for mouse donation and Prof. Fabio Boylan (Trinity University, Dublin) for English revision. This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, grant support and fellowship #303033/2013-4 and 405332/20165 to PDF), Fundacao Carlos Chagas Filho de Apoio a Pesquisa do Estado do Rio de Janeiro (FAPERJ, grant support #E-26/203.018/2015 to PDF), Conselho de Administracao de Pessoal de Ensino Superior (CAPES, fellowship to JLA) and FAPEAM (REDEBIO and PAPAC projects, fellowship to SLB).	[Anonymous], [No title captured]; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Comelli E, 2010, ACTA CIR BRAS, V25, P362, DOI 10.1590/S0102-86502010000400012; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Gomes ND, 2008, J ETHNOPHARMACOL, V119, P179, DOI 10.1016/j.jep.2008.06.033; Gomes ND, 2010, J ETHNOPHARMACOL, V128, P177, DOI 10.1016/j.jep.2010.01.005; Gomes NM, 2007, J ETHNOPHARMACOL, V109, P486, DOI 10.1016/j.jep.2006.08.018; Greaves NS, 2013, J DERMATOL SCI, V72, P206, DOI 10.1016/j.jdermsci.2013.07.008; Herrero-Jauregui C, 2011, CHEM BIODIVERS, V8, P674, DOI 10.1002/cbdv.201000258; HERRICK SE, 1992, AM J PATHOL, V141, P1085; Lee K, 2015, ORIENTAL PHARM EXP M, V15, P1, DOI 10.1007/s13596-014-0159-1; Loots MAM, 1998, J INVEST DERMATOL, V111, P850, DOI 10.1046/j.1523-1747.1998.00381.x; Martins-da-Silva Regina C. V., 2008, Rodriguésia, V59, P455, DOI 10.1590/2175-7860200859304; Nogueira E. de O., 2012, Brazilian Journal of Veterinary Research and Animal Science, V49, P293, DOI 10.11606/issn.1678-4456.v49i4p293-300; Paiva LAF, 2002, PHYTOTHER RES, V16, P737, DOI 10.1002/ptr.1049; Peranteau WH, 2008, J INVEST DERMATOL, V128, P1852, DOI 10.1038/sj.jid.5701232; Ram M, 2015, EUR J PHARMACOL, V764, P9, DOI 10.1016/j.ejphar.2015.06.029; Souza Barbosa PC, 2013, CHEM BIODIVERS, V10, P1350, DOI 10.1002/cbdv.201200356; Tincusi BM, 2002, PLANTA MED, V68, P808, DOI 10.1055/s-2002-34399; Veiga VF, 2007, J ETHNOPHARMACOL, V112, P248, DOI 10.1016/j.jep.2007.03.005; Veiga-Junior VF, 2011, PHYTOTHER RES, V15, P476; Vieira RC, 2008, PESQUISA VET BRASIL, V28, P358, DOI 10.1590/S0100-736X2008000800002; Westphal Fernando Luiz, 2007, Rev. Col. Bras. Cir., V34, P170; Wong V, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/969618; Zoghbi MDB, 2009, J ESSENT OIL RES, V21, P403	25	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0187380	10.1371/journal.pone.0187380	http://dx.doi.org/10.1371/journal.pone.0187380			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL2ZD	29088304	Green Published, gold, Green Submitted			2023-01-03	WOS:000414088900078
J	van der Zwaard, S; van der Laarse, WJ; Weide, G; Bloemers, FW; Hofmijster, MJ; Levels, K; Noordhof, DA; de Koning, JJ; de Ruiter, CJ; Jaspers, RT				van der Zwaard, Stephan; van der Laarse, Willem J.; Weide, Guido; Bloemers, Frank W.; Hofmijster, Mathijs J.; Levels, Koen; Noordhof, Dionne A.; de Koning, Jos J.; de Ruiter, Cornelis J.; Jaspers, Richard T.			Critical determinants of combined sprint and endurance performance: an integrative analysis from muscle fiber to the human body	FASEB JOURNAL			English	Article						skeletal muscle; oxidative capacity; oxygen transport; muscle architecture; muscle biopsy	HUMAN SKELETAL-MUSCLE; QUADRICEPS FEMORIS MUSCLE; HEART-FAILURE PATIENTS; CALIBRATED HISTOCHEMISTRY; MYOGLOBIN CONCENTRATION; VELOCITY RELATIONSHIPS; CONTRACTILE PROPERTIES; EXERCISE PERFORMANCE; ANAEROBIC THRESHOLD; OXIDATIVE CAPACITY	Optimizing physical performance is a major goal in current physiology. However, basic understanding of combining high sprint and endurance performance is currently lacking. This study identifies critical determinants of combined sprint and endurance performance using multiple regression analyses of physiologic determinants at different biologic levels. Cyclists, including 6 international sprint, 8 team pursuit, and 14 road cyclists, completed a Wingate test and 15-km time trial to obtain sprint and endurance performance results, respectively. Performance was normalized to lean body mass(2/3) to eliminate the influence of body size. Performance determinants were obtained from whole-body oxygen consumption, blood sampling, knee-extensor maximal force, muscle oxygenation, whole-muscle morphology, and muscle fiber histochemistry of musculus vastus lateralis. Normalized sprint performance was explained by percentage of fast-type fibers and muscle volume (R-2 = 0.65; P < 0.001) and normalized endurance performance by performance oxygen consumption (V.o(2)), mean corpuscular hemoglobin concentration, and muscle oxygenation (R-2 = 0.92; P < 0.001). Combined sprint and endurance performance was explained by gross efficiency, performance V.o(2), and likely by muscle volume and fascicle length (P = 0.056; P = 0.059). High performance V.o(2) related to a high oxidative capacity, high capillarization x myoglobin, and small physiologic cross-sectional area (R-2 = 0.67; P < 0.001). Results suggest that fascicle length and capillarization are important targets for training to optimize sprint and endurance performance simultaneously.	[van der Zwaard, Stephan; Weide, Guido; Jaspers, Richard T.] VU Univ Med Ctr Amsterdam, Fac Behav & Movement Sci, Dept Human Movement Sci, Amsterdam, Netherlands; [van der Zwaard, Stephan; Weide, Guido; Hofmijster, Mathijs J.; Levels, Koen; Noordhof, Dionne A.; de Koning, Jos J.; de Ruiter, Cornelis J.; Jaspers, Richard T.] VU Univ Med Ctr Amsterdam, Fac Behav & Movement Sci, Lab Myol, Amsterdam, Netherlands; [Bloemers, Frank W.] VU Univ Med Ctr Amsterdam, Amsterdam Movement Sci, Dept Trauma Surg, Amsterdam, Netherlands; [van der Laarse, Willem J.] VU Univ Med Ctr Amsterdam, Inst Cardiovasc Res, Dept Physiol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Jaspers, RT (corresponding author), Vrije Univ, Fac Behav & Movement Sci, Dept Human Movement Sci, Amsterdam Movement Sci, De Boelelaan 1108,van der Boechorststr 9, NL-1081 BT Amsterdam, Netherlands.	r.t.jaspers@vu.nl	Noordhof, Dionne/AFR-6657-2022; van der Zwaard, Stephan/J-9622-2019; Bloemers, Frank/P-5436-2019	van der Zwaard, Stephan/0000-0002-8296-828X; Bloemers, Frank/0000-0002-8393-4946; de Koning, Jos J/0000-0002-5596-0282; van der Laarse, Willem J/0000-0002-8391-0354; Jaspers, Richard/0000-0002-6951-0952	Dutch Olympic Committee-Dutch Sports Federation (NOC*NSF); Royal Dutch Cycling Federation (KNSB); Royal Dutch Rowing Federation (KNRB); Center for Elite Sports and Education (CTO) Amsterdam; TulipMed; Artinis Medical Systems; SporterOnline; b-Cat High Altitude; Foundation for Technical Sciences (STW) of the Netherlands Organization for Scientific Research (NWO) [12891]	Dutch Olympic Committee-Dutch Sports Federation (NOC*NSF); Royal Dutch Cycling Federation (KNSB); Royal Dutch Rowing Federation (KNRB); Center for Elite Sports and Education (CTO) Amsterdam; TulipMed; Artinis Medical Systems; SporterOnline; b-Cat High Altitude; Foundation for Technical Sciences (STW) of the Netherlands Organization for Scientific Research (NWO)	The authors thank Wendy Noort, David Comerford, Wouter Ruchtie, Jelmer Nuijten, Victor Vane, Niels Daems, Niels Waterval, Nienke de Jong, Isabelle van Dongen and Myriam Sillevis Smitt (Vrije Universiteit Amsterdam) for their excellent assistance with the data collection. The authors thank the Dutch Olympic Committee-Dutch Sports Federation (NOC*NSF), The Royal Dutch Cycling Federation (KNSB), the Royal Dutch Rowing Federation (KNRB), the Center for Elite Sports and Education (CTO) Amsterdam, TulipMed, Artinis Medical Systems, SporterOnline, and b-Cat High Altitude for their support. This work was supported by the Foundation for Technical Sciences (STW) of the Netherlands Organization for Scientific Research (NWO) under Grant 12891. The authors declare no conflicts of interest.	Abe T, 2000, MED SCI SPORT EXER, V32, P1125, DOI 10.1097/00005768-200006000-00014; Andersen JL, 2010, SCAND J MED SCI SPOR, V20, P32, DOI 10.1111/j.1600-0838.2010.01196.x; Andersen JL, 2000, SCI AM, V283, P48, DOI 10.1038/scientificamerican0900-48; ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975; Atkinson G, 2003, J SPORT SCI, V21, P767, DOI 10.1080/0264041031000102097; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; Bekedam MA, 2003, CLIN PHYSIOL FUNCT I, V23, P337, DOI 10.1046/j.1475-0961.2003.00517.x; Beneke R, 2002, EUR J APPL PHYSIOL, V87, P388, DOI 10.1007/s00421-002-0622-4; Blazevich AJ, 2003, MED SCI SPORT EXER, V35, P2013, DOI 10.1249/01.MSS.0000099092.83611.20; Bloemberg D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035273; Bottinelli R, 1996, J PHYSIOL-LONDON, V495, P573, DOI 10.1113/jphysiol.1996.sp021617; Calbet JAL, 2003, J APPL PHYSIOL, V94, P668, DOI 10.1152/japplphysiol.00128.2002; Coffey VG, 2017, J PHYSIOL-LONDON, V595, P2883, DOI 10.1113/JP272270; CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677; COSTILL DL, 1976, J APPL PHYSIOL, V40, P149, DOI 10.1152/jappl.1976.40.2.149; COYLE EF, 1988, J APPL PHYSIOL, V64, P2622, DOI 10.1152/jappl.1988.64.6.2622; COYLE EF, 1991, MED SCI SPORT EXER, V23, P93; COYLE EF, 1992, MED SCI SPORT EXER, V24, P782; COYLE EF, 1986, J APPL PHYSIOL, V60, P95, DOI 10.1152/jappl.1986.60.1.95; Craig NP, 2001, SPORTS MED, V31, P457, DOI 10.2165/00007256-200131070-00001; de Koning JJ, 2012, INT J SPORTS MED, V33, P880, DOI 10.1055/s-0032-1306285; Des Tombe AL, 2002, MICROSC RES TECHNIQ, V58, P412, DOI 10.1002/jemt.10153; Dorel S, 2005, INT J SPORTS MED, V26, P739, DOI 10.1055/s-2004-830493; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012; Ema R, 2016, SCAND J MED SCI SPOR, V26, P782, DOI 10.1111/sms.12511; Erskine RM, 2010, ACTA PHYSIOL, V199, P83, DOI 10.1111/j.1748-1716.2010.02085.x; Erskine RM, 2009, EUR J APPL PHYSIOL, V106, P827, DOI 10.1007/s00421-009-1085-7; Faria EW, 2005, SPORTS MED, V35, P313, DOI 10.2165/00007256-200535040-00003; Folland JP, 2007, SPORTS MED, V37, P145, DOI 10.2165/00007256-200737020-00004; Franchi MV, 2014, ACTA PHYSIOL, V210, P642, DOI 10.1111/apha.12225; Gardner SA., 2005, INT J PERFORM ANAL S, V5, P149, DOI [10.1080/24748668.2005.11868345, DOI 10.1080/24748668.2005.11868345]; Harridge SDR, 1996, PFLUG ARCH EUR J PHY, V432, P913, DOI 10.1007/s004240050215; Hautier CA, 1996, EUR J APPL PHYSIOL, V74, P114, DOI 10.1007/BF00376503; He ZH, 2000, BIOPHYS J, V79, P945, DOI 10.1016/S0006-3495(00)76349-1; Hill AV., 1965, TRAILS TRIALS PHYSL; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Hoppeler H, 2001, J EXP BIOL, V204, P3133; HOPPELER H, 1973, PFLUG ARCH EUR J PHY, V344, P217, DOI 10.1007/BF00588462; Huijing PA, 1998, J ELECTROMYOGR KINES, V8, P61, DOI 10.1016/S1050-6411(97)00023-0; JACOBS I, 1983, J APPL PHYSIOL, V55, P365, DOI 10.1152/jappl.1983.55.2.365; Jacobs RA, 2011, J APPL PHYSIOL, V111, P1422, DOI 10.1152/japplphysiol.00625.2011; Jeukendrup A E, 2000, J Sci Med Sport, V3, P414, DOI 10.1016/S1440-2440(00)80008-0; Joyner MJ, 2008, J PHYSIOL-LONDON, V586, P35, DOI 10.1113/jphysiol.2007.143834; KINDERMANN W, 1979, EUR J APPL PHYSIOL O, V42, P25, DOI 10.1007/BF00421101; Korhonen MT, 2006, J APPL PHYSIOL, V101, P906, DOI 10.1152/japplphysiol.00299.2006; Kumagai K, 2000, J APPL PHYSIOL, V88, P811, DOI 10.1152/jappl.2000.88.3.811; Lee-de Groot MBE, 1998, J HISTOCHEM CYTOCHEM, V46, P1077; Lucia A, 2001, SPORTS MED, V31, P325, DOI 10.2165/00007256-200131050-00004; Martin JC, 2007, INT J SPORT PHYSIOL, V2, P5, DOI 10.1123/ijspp.2.1.5; Martin JC, 2000, J GERONTOL A-BIOL, V55, pM311, DOI 10.1093/gerona/55.6.M311; Martin JC, 1997, MED SCI SPORT EXER, V29, P1505, DOI 10.1097/00005768-199711000-00018; Mujika I, 2001, SPORTS MED, V31, P479, DOI 10.2165/00007256-200131070-00003; Nader GA, 2006, MED SCI SPORT EXER, V38, P1965, DOI 10.1249/01.mss.0000233795.39282.33; Pearson SJ, 2006, MED SCI SPORT EXER, V38, P1601, DOI 10.1249/01.mss.0000227638.75983.9d; Perez-Gomez J, 2008, EUR J APPL PHYSIOL, V102, P685, DOI 10.1007/s00421-007-0648-8; Peters EL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091889; Plas RLC, 2015, J EXP BIOL, V218, P2166, DOI 10.1242/jeb.117655; POOL CW, 1979, HISTOCHEMISTRY, V64, P251, DOI 10.1007/BF00495025; Prior BM, 2004, J APPL PHYSIOL, V97, P1119, DOI 10.1152/japplphysiol.00035.2004; Qu ZQ, 1997, HISTOCHEM CELL BIOL, V107, P169, DOI 10.1007/s004180050101; Ronnestad BR, 2014, SCAND J MED SCI SPOR, V24, P603, DOI 10.1111/sms.12104; Saltin B, 1977, Ann N Y Acad Sci, V301, P3, DOI 10.1111/j.1749-6632.1977.tb38182.x; Saltin B, 2010, COMPREHENSIVE PHYSL; Santalla A, 2012, INT J SPORT PHYSIOL, V7, P200, DOI 10.1123/ijspp.7.3.200; SCHENAU GJV, 1994, SPORTS MED, V17, P259, DOI 10.2165/00007256-199417040-00006; SIECK GC, 1995, J APPL PHYSIOL, V79, P1629, DOI 10.1152/jappl.1995.79.5.1629; Trappe S, 2015, J APPL PHYSIOL, V118, P1460, DOI 10.1152/japplphysiol.00037.2015; van Beek-Harmsen BJ, 2004, HISTOCHEM CELL BIOL, V121, P335, DOI 10.1007/s00418-004-0641-9; van der Laarse WJ, 2005, J APPL PHYSIOL, V99, P2173, DOI 10.1152/japplphysiol.00470.2005; van der Zwaard S, 2017, MED SCI SPORT EXER, V49, P768, DOI 10.1249/01.mss.0000519047.24644.bc; van der Zwaard S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162914; van der Zwaard S, 2016, J APPL PHYSIOL, V121, P636, DOI 10.1152/japplphysiol.00355.2016; van Wessel T, 2010, EUR J APPL PHYSIOL, V110, P665, DOI 10.1007/s00421-010-1545-0; Verdijk LB, 2009, J GERONTOL A-BIOL, V64, P332, DOI 10.1093/gerona/gln050; Vogt M, 2001, J APPL PHYSIOL, V91, P173, DOI 10.1152/jappl.2001.91.1.173; VONDOBELN W, 1956, ACTA PHYSIOL SCAND, V38, P193; WASSERMAN K, 1987, CIRCULATION, V76, P29; Weibel ER, 2005, J EXP BIOL, V208, P1635, DOI 10.1242/jeb.01548; Weide G, 2017, JOVE-J VIS EXP, DOI 10.3791/55943; WICKIEWICZ TL, 1984, J APPL PHYSIOL, V57, P435, DOI 10.1152/jappl.1984.57.2.435	81	29	29	2	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2018	32	4					2110	2123		10.1096/fj.201700827R	http://dx.doi.org/10.1096/fj.201700827R			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB4SP	29217665	Green Submitted			2023-01-03	WOS:000429051400031
J	Spencer, K; Parrish, R; Barton, R; Henry, A				Spencer, Katie; Parrish, Rhona; Barton, Rachael; Henry, Ann			Palliative radiotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SPINAL-CORD COMPRESSION; DIAGNOSED BRAIN METASTASES; PAINFUL BONE METASTASES; RADIATION-THERAPY; RANDOMIZED-TRIAL; PHASE-III; SURGICAL RESECTION; DOUBLE-BLIND; 8 GY; HYPOFRACTIONATED RADIOTHERAPY		[Spencer, Katie; Henry, Ann] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS2 9NL, W Yorkshire, England; [Parrish, Rhona] Garforth Med Ctr, Leeds LS25 1HB, W Yorkshire, England; [Barton, Rachael] Castle Hill Hosp, Queens Ctr Oncol & Haematol, Cottingham HU16 5JQ, England	University of Leeds; University of Hull	Spencer, K (corresponding author), Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS2 9NL, W Yorkshire, England.	KSpencerkatie.spencer1@nhs.net		Spencer, Katie/0000-0002-6846-4341; Henry, Ann/0000-0002-5379-6618	Medical Research Council on a Clinical Research Training Fellowship [MR/N021339/1]; MRC [MR/N021339/1] Funding Source: UKRI	Medical Research Council on a Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	While undertaking this work KS was funded by the Medical Research Council on a Clinical Research Training Fellowship (MR/N021339/1).	Adderley UJ, 2014, COCHRANE DB SYST REV, V1; Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8; Andreyev HJN, 2012, GUT, V61, P179, DOI 10.1136/gutjnl-2011-300563; [Anonymous], 2018, WHOS CANC PAIN LADD; Ashton A, 1999, RADIOTHER ONCOL, V52, P111; Baker S, 2016, LUNG CANCER-TARGETS, V7, P119, DOI 10.2147/LCTT.S96443; Barnes EA, 2010, CLIN ONCOL-UK, V22, P844, DOI 10.1016/j.clon.2010.07.014; Braam P, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1178-7; Cameron MG, 2016, ACTA ONCOL, V55, P1400, DOI 10.1080/0284186X.2016.1191666; Cameron MG, 2014, RADIOTHER ONCOL, V110, P55, DOI 10.1016/j.radonc.2013.08.008; Cancer Research UK, 2016, LOC CANC STAT; Cancer Research UK, 2015, LUNG CANC INC STAT; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; Chow E, 2012, CLIN ONCOL-UK, V24, P112, DOI 10.1016/j.clon.2011.11.004; Chow E, 2015, LANCET ONCOL, V16, P1463, DOI 10.1016/S1470-2045(15)00199-0; Chow E, 2014, LANCET ONCOL, V15, P164, DOI 10.1016/S1470-2045(13)70556-4; Clarkson JE, 2010, COCHRANE DB SYST REV, V1; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Corry J, 2005, RADIOTHER ONCOL, V77, P137, DOI 10.1016/j.radonc.2005.10.008; Cramp F, 2012, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD006145.PUB3; Dai YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005048.pub4; Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324; Department of Health, 2012, RAD SERV ENGL 2012; Duchesne GM, 2000, INT J RADIAT ONCOL, V47, P379, DOI 10.1016/S0360-3016(00)00430-2; Fairchild A, 2008, J CLIN ONCOL, V26, P4001, DOI 10.1200/JCO.2007.15.3312; Feyer PC, 2011, SUPPORT CARE CANCER, V19, pS5, DOI 10.1007/s00520-010-0950-6; Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0; George R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006716.pub3; Halkett GKB, 2014, FAM PRACT, V31, P60, DOI 10.1093/fampra/cmt068; Hamilton K, 2015, SUPPORT CARE CANCER, V23, P95, DOI 10.1007/s00520-014-2335-8; Health & Social Care Information Centre, 2016, GEN PRACT TRENDS UK; HELLMAN S, 1995, J CLIN ONCOL, V13, P8, DOI 10.1200/JCO.1995.13.1.8; Hoskin PJ, 2013, CLIN ONCOL-UK, V25, P531, DOI 10.1016/j.clon.2013.04.006; Hoskin P, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv197; Huang J, 2001, J CLIN ONCOL, V19, P137, DOI 10.1200/JCO.2001.19.1.137; Independent Cancer Taskforce, 2015, ACH WORLD CLASS CANC; Javed Amit, 2012, J Gastrointest Cancer, V43, P63, DOI 10.1007/s12029-010-9206-4; Joiner Michael, 2009, BASIC CLIN RADIOBIOL, DOI DOI 10.1201/B15450; Kalkanis SN, 2010, J NEURO-ONCOL, V96, P33, DOI 10.1007/s11060-009-0061-8; Kancherla KN, 2011, CLIN ONCOL-UK, V23, P141, DOI 10.1016/j.clon.2010.09.006; Kane CM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h315; Kassam Z, 2008, CLIN ONCOL-UK, V20, P53, DOI 10.1016/j.clon.2007.10.003; Kedge EM, 2009, RADIOGRAPHY, V15, P247, DOI 10.1016/j.radi.2008.08.002; Kerr CW, 2012, J PAIN SYMPTOM MANAG, V43, P68, DOI 10.1016/j.jpainsymman.2011.03.026; Kirkpatrick JP, 2010, INT J RADIAT ONCOL, V76, pS42, DOI 10.1016/j.ijrobp.2009.04.095; Kocher M, 2011, J CLIN ONCOL, V29, P134, DOI 10.1200/JCO.2010.30.1655; Koswig S, 1999, STRAHLENTHER ONKOL, V175, P500, DOI 10.1007/s000660050061; Kramer GWPM, 2005, J CLIN ONCOL, V23, P2962, DOI 10.1200/JCO.2005.01.685; Kumar S, 2010, J MED IMAG RADIAT ON, V54, P264, DOI 10.1111/j.1754-9485.2010.02170.x; Lalla RV, 2014, CANCER-AM CANCER SOC, V120, P1453, DOI 10.1002/cncr.28592; Lawrence D.P., 2004, J NATL CANCER INST M, P40; Leeds Teaching Hospitals NHS Trust, 2017, RAD BLADD; Linskey ME, 2010, J NEURO-ONCOL, V96, P45, DOI 10.1007/s11060-009-0073-4; Loblaw DA, 2007, SUPPORT CARE CANCER, V15, P451, DOI 10.1007/s00520-006-0166-y; Lutz S, 2004, J CLIN ONCOL, V22, P3581, DOI 10.1200/JCO.2004.11.151; Lutz ST, 2014, J CLIN ONCOL, V32, P2913, DOI 10.1200/JCO.2014.55.1143; Macbeth F R, 1996, Clin Oncol (R Coll Radiol), V8, P167, DOI 10.1016/S0936-6555(96)80041-0; Macmillan Cancer Support, CHANG APP BOD IM DEA; Maranzano E, 2005, J CLIN ONCOL, V23, P3358, DOI 10.1200/JCO.2005.08.193; Maranzano E, 2009, RADIOTHER ONCOL, V93, P174, DOI 10.1016/j.radonc.2009.05.012; McQuestion Maurene, 2011, Semin Oncol Nurs, V27, pe1, DOI 10.1016/j.soncn.2011.02.009; MIRELS H, 1989, CLIN ORTHOP RELAT R, P256; Molassiotis A, 2015, COCHRANE DB SYST REV, V5; Moraska AR, 2010, J CLIN ONCOL, V28, P3673, DOI 10.1200/JCO.2010.28.1444; Mucke M, 2015, COCHRANE DB SYST REV, V1; Mulvenna P, 2016, LANCET, V388, P2004, DOI 10.1016/S0140-6736(16)30825-X; Murphy JD, 2013, J ONCOL PRACT, V9, pE220, DOI 10.1200/JOP.2012.000835; National Institute for Health and Care Excellence, BRIT NAT FORM MED GU; National Institute for Health and Care Excellence, MET SPIN CORD COMPR; NCRI, 2016, CTRAD ID OPP PROM PR; NHS Choices, 2017, CANC AND HAIR LOSS; NHS Quality Improvement Scotland, 2010, SKINC PAT REC RAD; Northern Ireland Cancer Network, 2015, NICAN AC ONC CLIN GU; Palma DA, 2014, NAT REV CLIN ONCOL, V11, P549, DOI 10.1038/nrclinonc.2014.96; Palma DA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-305; Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Patil CG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006121.pub3; Peterson DE, 2011, ANN ONCOL, V22, pvi78, DOI 10.1093/annonc/mdr391; Porceddu SV, 2007, RADIOTHER ONCOL, V85, P456, DOI 10.1016/j.radonc.2007.10.020; Princess Royal Radiotherapy Review Team, 2011, MAN RAD IND SKIN REA; Radbruch L, 2008, PALLIATIVE MED, V22, P13, DOI 10.1177/0269216307085183; Rades D, 2016, J CLIN ONCOL, V34, P597, DOI 10.1200/JCO.2015.64.0862; Rades D, 2011, INT J RADIAT ONCOL, V79, P1503, DOI 10.1016/j.ijrobp.2010.01.024; Rades D, 2010, CANCER-AM CANCER SOC, V116, P3670, DOI 10.1002/cncr.25223; Roos DE, 2005, RADIOTHER ONCOL, V75, P54, DOI 10.1016/j.radonc.2004.09.017; Rosenblatt E, 2010, RADIOTHER ONCOL, V97, P488, DOI 10.1016/j.radonc.2010.09.001; Round CE, 2013, CLIN ONCOL-UK, V25, P522, DOI 10.1016/j.clon.2013.05.005; Royal College of Radiologists, 2016, RAD DOS FRACT; Salvo N, 2012, INT J RADIAT ONCOL, V82, P408, DOI 10.1016/j.ijrobp.2010.08.060; Samant RS, 2007, ACTA ONCOL, V46, P659, DOI 10.1080/02841860600979005; Samant RS, 2006, RADIOTHER ONCOL, V78, P101, DOI 10.1016/j.radonc.2005.11.008; Sourati A, 2017, ACUTE SIDE EFFECTS R, P47, DOI [10.1007/978-3-319-55950-6_5, DOI 10.1007/978-3-319-55950-6_5]; Spencer K, 2015, RADIOTHER ONCOL, V115, P264, DOI 10.1016/j.radonc.2015.03.023; Sperduto PW, 2008, INT J RADIAT ONCOL, V70, P510, DOI 10.1016/j.ijrobp.2007.06.074; Spratt DE, 2014, J CLIN ONCOL, V32, P3144, DOI 10.1200/JCO.2014.55.4634; Steenland E, 1999, RADIOTHER ONCOL, V52, P101, DOI 10.1016/S0167-8140(99)00110-3; Stevens R, 2015, COCHRANE DB SYST REV, P1, DOI 10.1002/14651858.CD002143.pub4; Sundstrom S, 2004, J CLIN ONCOL, V22, P801, DOI 10.1200/JCO.2004.06.123; Sze WM, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004721; Tey J, 2017, ONCOTARGET, V8, P25797, DOI 10.18632/oncotarget.15554; Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5; TOWNSEND PW, 1995, INT J RADIAT ONCOL, V31, P43, DOI 10.1016/0360-3016(94)E0310-G; Tsao MN, 2012, COCHRANE DB SYST REV, V1; UKOMiC, 2015, MOUTH CAR GUID SUPP; van der Velden JM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2947-0; van Lonkhuijzen L, 2011, RADIOTHER ONCOL, V98, P287, DOI 10.1016/j.radonc.2011.01.009; Walters S, 2013, THORAX, V68, P551, DOI 10.1136/thoraxjnl-2012-202297; Williams M, 2013, CLIN ONCOL-UK, V25, P668, DOI 10.1016/j.clon.2013.06.003; Wong CYB, 2014, INT J DERMATOL, V53, P56, DOI 10.1111/j.1365-4632.2012.05635.x; Worthington HV, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub2; Yan J, 2011, CLIN ONCOL-UK, V23, P476, DOI 10.1016/j.clon.2011.01.001	112	54	55	2	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2018	360								k821	10.1136/bmj.k821	http://dx.doi.org/10.1136/bmj.k821			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB1LW	29572337	Green Published, hybrid			2023-01-03	WOS:000428813300013
J	Liu, F; Jin, T; Liu, L; Xiang, ZZ; Yan, RN; Yang, H				Liu, Fang; Jin, Tao; Liu, Lei; Xiang, Zhongzheng; Yan, Ruonan; Yang, Hui			The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis	PLOS ONE			English	Article							CONVENTIONAL 2-DIMENSIONAL RADIOTHERAPY; RADIATION-THERAPY; CLINICAL-OUTCOMES; CHEMORADIOTHERAPY; SURVIVAL; TRIAL; BIAS	Objectives To compare clinical outcomes of concurrent chemoradiotherapy (CCRT) with those of radiotherapy alone for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy (IMRT) era. Materials and methods We comprehensively searched PubMed, Embase, and the Cochrane Library to identify eligible studies. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) with hazard ratios (HRs), and toxicities with odd ratios (ORs) were analyzed. Results A total of seven studies met the criteria, with 1302 patients who were treated with IMRT alone or IMRT plus concurrent chemotherapy. No significant survival benefit was shown by CCRT regardless of OS (HR = 1.17, 95% CI 0.73-1.89, P = 0.508), PFS (HR = 0.76, 95% CI 0.38-1.50, P = 0.430), DMFS (HR = 0.89, 95% CI 0.33-2.41, P = 0.816), or LRRFS (HR = 1.03, 95% CI 0.95-1.12, P = 0.498). Additionally, CCRT notably increased the risk of acute grade 3-4 leukopenia (OR = 4.432, 95% CI 2.195-8.952, P < 0.001), compared to IMRT alone. Conclusion Adding concurrent chemotherapy to IMRT led to no survival benefit and increased acute toxicity reactions for stage II nasopharyngeal carcinoma.	[Liu, Fang; Liu, Lei; Xiang, Zhongzheng; Yan, Ruonan] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol,State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China; [Jin, Tao] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Sichuan, Peoples R China; [Yang, Hui] Sichuan Univ, West China Hosp, Dept Otolaryngol Head & Neck Surg, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Liu, L (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol,State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China.; Yang, H (corresponding author), Sichuan Univ, West China Hosp, Dept Otolaryngol Head & Neck Surg, Chengdu, Sichuan, Peoples R China.	liuleihx@gmail.com; yangfree1966@163.com			Major programs of Sichuan Science and Technology Department [2017SZ0015]	Major programs of Sichuan Science and Technology Department	This work was sponsored by the Major programs of Sichuan Science and Technology Department (No. 2017SZ0015). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], BMJ, V339, pb2700; [Anonymous], 2009, EPIDEMIOLOGY BIOSTAT, V6, pe1; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Cao Su-Mei, 2011, Chin J Cancer, V30, P114; Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266; Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353; Chen KH, 2016, ONCOTARGET, V7, P69041, DOI 10.18632/oncotarget.11978; Chen QY, 2011, JNCI-J NATL CANCER I, V103, P1761, DOI 10.1093/jnci/djr432; Cheng SH, 2000, J CLIN ONCOL, V18, P2040, DOI 10.1200/JCO.2000.18.10.2040; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fang FM, 2008, INT J RADIAT ONCOL, V72, P356, DOI 10.1016/j.ijrobp.2007.12.054; Guo QJ, 2016, JPN J CLIN ONCOL, V46, P241, DOI 10.1093/jjco/hyv192; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian PT, 2008, COCHRANE HDB SYSTEMA, P102; Lai SZ, 2011, INT J RADIAT ONCOL, V80, P661, DOI 10.1016/j.ijrobp.2010.03.024; Lee N, 2009, J CLIN ONCOL, V27, P3684, DOI 10.1200/JCO.2008.19.9109; Luo SQ, 2014, HEAD NECK-J SCI SPEC, V36, P841, DOI 10.1002/hed.23386; MANTEL N, 1959, J NATL CANCER I, V22, P719; Ng AWY, 2015, INT J RADIAT ONCOL, V93, pE306, DOI 10.1016/j.ijrobp.2015.07.1329; Ng WT, 2011, INT J RADIAT ONCOL, V79, P420, DOI 10.1016/j.ijrobp.2009.11.024; Peng G, 2012, RADIOTHER ONCOL, V104, P286, DOI 10.1016/j.radonc.2012.08.013; Phillips B, 2009, LEVELS EVIDENCE; Su SF, 2012, INT J RADIAT ONCOL, V82, P327, DOI 10.1016/j.ijrobp.2010.09.011; Su Z, 2016, TUMOR BIOL, V37, P4429, DOI 10.1007/s13277-015-4266-5; Tham IWK, 2010, AM J CLIN ONCOL-CANC, V33, P294, DOI 10.1097/COC.0b013e3181d2edab; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wells G.A., 2014, APPL ENG AGRIC, V18, P727; Xiao WW, 2009, INT J RADIAT ONCOL, V74, P1070, DOI 10.1016/j.ijrobp.2008.09.008; Xu C, 2017, J CANCER, V8, P287, DOI 10.7150/jca.17317; Xu T, 2015, MEDICINE, V94, pE293; Xu TT, 2011, ORAL ONCOL, V47, P408, DOI 10.1016/j.oraloncology.2011.03.008; Yi J, 2015, INT J RADIAT ONCOL, V93, pS128, DOI 10.1016/j.ijrobp.2015.07.305; Zhang AM, 2012, RADIOTHER ONCOL, V104, P279, DOI 10.1016/j.radonc.2012.08.022; Zhang LN, 2015, ONCOTARGET, V6, P44019, DOI 10.18632/oncotarget.5806	35	28	35	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194733	10.1371/journal.pone.0194733	http://dx.doi.org/10.1371/journal.pone.0194733			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA1RF	29566078	Green Submitted, Green Published, gold			2023-01-03	WOS:000428093900098
J	Yasuoka, J; Nanishi, K; Kikuchi, K; Suzuki, S; Ly, P; Thavrin, B; Omatsu, T; Mizutani, T				Yasuoka, Junko; Nanishi, Keiko; Kikuchi, Kimiyo; Suzuki, Sumihiro; Ly, Po; Thavrin, Boukheng; Omatsu, Tsutomu; Mizutani, Tetsuya			Barriers for pregnant women living in rural, agricultural villages to accessing antenatal care in Cambodia: A community-based cross-sectional study combined with a geographic information system	PLOS ONE			English	Article							MATERNAL MORTALITY; HEALTH-CARE; SOUTH-AFRICA; DETERMINANTS; CONTINUUM; DELIVERY; NEWBORN	Background Maternal morbidity and mortality is still a major public health issue in low-and middle-income countries such as Cambodia. Improving access to antenatal care (ANC) services for pregnant women has been widely recognized as one of the most effective means of reducing maternal mortality and morbidity. As such, this study examined the barriers for pregnant women living in rural, agricultural villages to accessing ANC based on data collected in the Ratanakiri province, one of the least developed provinces in Cambodia, using a combination of a community-based cross-sectional survey and a geographic information system (GIS). Methods A community-based cross-sectional survey was conducted among 377 mothers with children under the age of two living in 62 villages in the Ratanakiri province, Cambodia, in December 2015. Face-to-face interviews were conducted to ask mothers about their ANC service use, knowledge of ANC, barriers to accessing health facilities, and complications they experienced during the most recent pregnancy. At the same time, GIS data were also collected using a Global Positioning System (GPS) to accurately measure actual travel distance of pregnant women to access health facilities and to examine geographical and environmental barriers in greater detail. Results Only a third of the mothers met the recommendations made by the World Health Organization (WHO) of receiving ANC four times or more (achieved ANC4+), and a quarter of the mothers had never received ANC during their most recent pregnancy. Factors positively associated with achieving ANC4+ were mother's secondary or higher education (adjusted odds ratio [AOR] = 5.50, 95% confidence interval [CI]: 1.74, 17.37), being aware that receiving ANC is recommended (AOR = 2.74, 95% CI: 1.25, 6.00), and knowledge about the recommended frequency for ANC (AOR = 2.26, 95% CI: 7.22). Actual travel distance was negatively associated with achieving ANC4+. Mothers who had to travel 10.0 +/- 14.9 km were 68% less likely (AOR = 0.32, 95% CI: 0.10, 0.99), and those who had to travel 15.0 km or longer were 79% less likely (AOR = 0.21, 95% CI: 0.07, 0.62) to have achieved ANC 4+, both compared to those who travelled 5.0 km or less. While most previous studies have used a straight-line to measure distance traveled, this study much more accurately measured the actual distance traveled by using a GIS. As a result, there was a statistically significant discrepancy between actual travel distance and straight-line distance. Conclusions This study revealed promoting factors and barriers for ANC use among pregnant women living in remote, agricultural villages in Cambodia. Furthermore, this study highlights the importance of measuring travel distances accurately to ensure that targeted interventions for ANC are not misguided by straight-line distances. The methodology used in this study can be applied widely to other developing countries, especially in remote areas with limited road networks where there may be a large discrepancy between actual and straight-line distances.	[Yasuoka, Junko; Omatsu, Tsutomu; Mizutani, Tetsuya] Tokyo Univ Agr & Technol, Res & Educ Ctr Prevent Global Infect Dis Anim, Tokyo, Japan; [Nanishi, Keiko] Univ Tokyo, Off Int Acad Affairs, Grad Sch Med, Tokyo, Japan; [Nanishi, Keiko] Univ Tokyo, Fac Med, Tokyo, Japan; [Kikuchi, Kimiyo] Kyushu Univ, Grad Educ & Res Training Program Decis Sci Sustai, Fukuoka, Japan; [Suzuki, Sumihiro] Univ North Texas, Hlth Sci Ctr, Denton, TX USA; [Ly, Po; Thavrin, Boukheng] Minist Hlth, Natl Ctr Parasitol Entomol Malaria Control CNM, Phnom Penh, Cambodia	Tokyo University of Agriculture & Technology; University of Tokyo; University of Tokyo; Kyushu University; University of North Texas System; University of North Texas Denton; National Center Parasitology, Entomology & Malaria Control	Yasuoka, J (corresponding author), Tokyo Univ Agr & Technol, Res & Educ Ctr Prevent Global Infect Dis Anim, Tokyo, Japan.	jyasuoka@post.harvard.edu	Yasuoka, Junko/GVT-8950-2022; Omatsu, Tsutomu/C-8344-2013; MIZUTANI, Tetsuya/G-1086-2013	Omatsu, Tsutomu/0000-0001-7860-7409; MIZUTANI, Tetsuya/0000-0003-2570-0452; Nanishi, Keiko/0000-0001-7067-8413	JSPS KAKENHI [JP15H05284]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number JP15H05284. (Japan Society for the Promotion of Science: http://www.jsps.go.jp/english/index.html) The funder had no role in study design, data collection and analysis,	Abrahams N, 2001, J MIDWIFERY WOM HEAL, V46, P240, DOI 10.1016/S1526-9523(01)00138-6; Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Andrew EVW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093025; [Anonymous], 2016, WHO WHO MMEND ANT CA; [Anonymous], 2011, WHO GLOB HLTH OBS GH; Asian Development Bank (ADB), 2016, KEY IND AS PAC 2016; Atuyambe L, 2009, J ADOLESCENCE, V32, P781, DOI 10.1016/j.adolescence.2008.10.012; Auriault F, 2016, ACCIDENT ANAL PREV, V97, P96, DOI 10.1016/j.aap.2016.08.026; Bustreo F, 2013, LANCET GLOB HEALTH, V1, pE176, DOI 10.1016/S2214-109X(13)70059-7; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Carroli G, 2001, PAEDIATR PERINAT EP, V15, P1; Choudhury N, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-15; Cudnik MT, 2012, PREHOSP EMERG CARE, V16, P266, DOI 10.3109/10903127.2011.615009; Finlayson K, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001373; Hasegawa A, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-292; Kabakian-Khasholian T, 2000, SOC SCI MED, V51, P103, DOI 10.1016/S0277-9536(99)00443-8; Karra M, 2016, INT J EPIDEMIOL; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Khanam R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167814; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Kisuule I, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-121; Martin D, 2008, ENVIRON PLANN A, V40, P2510, DOI 10.1068/a4024; Mason L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0453-z; Matsuoka S, 2010, HEALTH POLICY, V95, P255, DOI 10.1016/j.healthpol.2009.12.011; Moore N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171136; Mrisho M, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-10; Mubyazi GM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-54; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; National Institute of Statistics Directorate General for Health and ICF International, 2015, CAMB DEM HLTH SURV 2; Okawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130712; Redelmeier DA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011972; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Rurangirwa AA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1328-2; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Tinoco-Ojanguren R, 2008, SOC SCI MED, V66, P1057, DOI 10.1016/j.socscimed.2007.11.006; Titaley CR, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-485; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Wampler PJ, 2013, INT J HEALTH GEOGR, V12, DOI 10.1186/1476-072X-12-3; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; Yao J, 2013, SOC SCI MED, V96, P60, DOI [10.1016/j.socscimed.2013.07.025, 10.1016/j.socscimed.2012.11.005]; Yasuoka J, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-4; Yasuoka J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-109; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	45	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2018	13	3							e0194103	10.1371/journal.pone.0194103	http://dx.doi.org/10.1371/journal.pone.0194103			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FZ7QU	29554118	gold, Green Submitted, Green Published			2023-01-03	WOS:000427796800024
J	Jansen, L; van Schijndel, M; van Waarde, J; van Busschbach, J				Jansen, Luc; van Schijndel, Maarten; van Waarde, Jeroen; van Busschbach, Jan			Health-economic outcomes in hospital patients with medical-psychiatric comorbidity: A systematic review and meta-analysis	PLOS ONE			English	Review							LENGTH-OF-STAY; MENTAL-ILLNESS; PSYCHOLOGICAL COMORBIDITY; PHYSICAL ILLNESS; OLDER-ADULTS; DEPRESSION; IMPACT; CARE; INCREASE; COSTS	Background Hospital inpatients often experience medical and psychiatric problems simultaneously. Although this implies a certain relationship between healthcare utilization and costs, this relationship has never been systematically reviewed. Objective The objective is to examine the extent to which medical-psychiatric comorbidities relate to health-economic outcomes in general and in different subgroups. If the relationship is significant, this would give additional reasons to facilitate the search for targeted and effective treatments for this complex population. Method A systematic review in Embase, Medline, Psycinfo, Cochrane, Web of Science and Google Scholar was performed up to August 2016 and included cross-references from included studies. Only peer-reviewed empirical studies examining the impact of inpatient medical psychiatric comorbidities on three health-economic outcomes (length of stay (LOS), medical costs and rehospitalizations) were included. Study design was not an exclusion criterion, there were no restrictions on publication dates and patients included had to be over 18 years. The examined populations consisted of inpatients with medical-psychiatric comorbidities and controls. The controls were inpatients without a comorbid medical or psychiatric disorder. Non-English studies were excluded. Results From electronic literature databases, 3165 extracted articles were scrutinized on the basis of title and abstract. This resulted in a full-text review of 86 articles: 52 unique studies were included. The review showed that the presence of medical-psychiatric comorbidity was related to increased LOS, higher medical costs and more rehospitalizations. The meta-analysis revealed that patients with comorbid depression had an increased mean LOS of 4.38 days compared to patients without comorbidity (95% CI: 3.07 to 5.68,12 = 31%). Conclusions Medical-psychiatric comorbidity is related to increased LOS, medical costs and rehospitalization; this is also shown for specific subgroups. This study had some limitations; namely, that the studies were very heterogenetic and, in some cases, of poor quality in terms of risk of bias. Nevertheless, the findings remain valid and justify the search for targeted and effective interventions for this complex population.	[Jansen, Luc; van Schijndel, Maarten; van Busschbach, Jan] Univ Med Ctr Rotterdam, Erasmus MC, Dept Psychiat, Rotterdam, Netherlands; [Jansen, Luc] Zilveren Kruis Achmea, Dept Hlth Procurement, Leusden, Netherlands; [van Schijndel, Maarten; van Waarde, Jeroen] Rijnstate Hosp, Dept Psychiat, Arnhem, Netherlands	Erasmus University Rotterdam; Erasmus MC; Rijnstate Hospital	Jansen, L (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Psychiat, Rotterdam, Netherlands.; Jansen, L (corresponding author), Zilveren Kruis Achmea, Dept Hlth Procurement, Leusden, Netherlands.	l.jansen@erasmusmc.nl	Busschbach, Jan/P-1584-2019; van Waarde, Jeroen A./N-1720-2019	Busschbach, Jan/0000-0002-8602-0381; van Waarde, Jeroen A./0000-0001-6792-5727				Abbate-Daga G., 2013, BMC PSYCHIAT, V13; ACKERMAN AD, 1988, HOSP COMMUNITY PSYCH, V39, P173; Adams LY, 2015, J PSYCHIATR MENT HLT, V22, P39, DOI 10.1111/jpm.12169; Benzer JK, 2012, PSYCHIAT SERV, V63, P672, DOI 10.1176/appi.ps.201100457; Borckardt Jeffrey J, 2011, Qual Manag Health Care, V20, P98, DOI 10.1097/QMH.0b013e3182134af0; Bourgeois JA, 2005, PSYCHOSOMATICS, V46, P431, DOI 10.1176/appi.psy.46.5.431; Bourgeois JA, 2006, PSYCHOSOMATICS, V47, P414, DOI 10.1176/appi.psy.47.5.414; Bourgeois JA, 2009, PSYCHOSOMATICS, V50, P622, DOI 10.1176/appi.psy.50.6.622; Boustani M, 2010, J HOSP MED, V5, P69, DOI 10.1002/jhm.589; Bressi SK, 2006, PSYCHIAT QUART, V77, P203, DOI 10.1007/s11126-006-9007-x; Ceilley JW, 2005, ADDICT DISORD TREAT, V4, P65, DOI 10.1097/01.adt.0000153726.38195.fc; Chang C M, 2001, Chang Gung Med J, V24, P34; Chwastiak LA, 2014, PSYCHOSOMATICS, V55, P134, DOI 10.1016/j.psym.2013.08.012; Creed F., 2002, PSYCHOSOMATICS; Davydow DS, 2011, PSYCHOSOMATICS, V52, P117, DOI 10.1016/j.psym.2010.12.020; Doherty AM, 2014, SOC PSYCH PSYCH EPID, V49, P673, DOI 10.1007/s00127-014-0847-7; Douzenis A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-166; Druss BG, 1999, PSYCHIATR SERV, V50, P214, DOI 10.1176/ps.50.2.214; Egeto P, 2014, INT PSYCHOGERIATR, V26, P1101, DOI 10.1017/S1041610214000568; Erdur L, 2012, BIOPSYCHOSOC MED, V6, DOI 10.1186/1751-0759-6-4; EVANS RL, 1988, PSYCHOL REP, V62, P519, DOI 10.2466/pr0.1988.62.2.519; FULOP G, 1989, HOSP COMMUNITY PSYCH, V40, P80; Fulop G, 1998, PSYCHOSOMATICS, V39, P273, DOI 10.1016/S0033-3182(98)71344-1; Fulop G., 1987, AM J; Furlanetto LM, 2003, GEN HOSP PSYCHIAT, V25, P14, DOI 10.1016/S0163-8343(02)00236-0; Gur S, 2018, PSYCHIAT RES, V260, P177, DOI 10.1016/j.psychres.2017.11.042; Haas L, 2012, INT J EAT DISORDER, V45, P214, DOI 10.1002/eat.20903; Hansen MS, 2001, GEN HOSP PSYCHIAT, V23, P319, DOI 10.1016/S0163-8343(01)00162-1; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hochlehnert A, 2011, J PSYCHOSOM RES, V70, P135, DOI 10.1016/j.jpsychores.2010.09.010; Hosaka T, 1999, PSYCHIAT CLIN NEUROS, V53, P491, DOI 10.1046/j.1440-1819.1999.00580.x; Jiang W, 2001, ARCH INTERN MED, V161, P1849, DOI 10.1001/archinte.161.15.1849; Johansen H, 2012, HEALTH REP, V23, P61; Kartha Anand, 2007, Prim Care Companion J Clin Psychiatry, V9, P256; Kathol RG, 2005, J GEN INTERN MED, V20, P160, DOI 10.1111/j.1525-1497.2005.40099.x; Kathol R, 2006, MED CLIN N AM, V90, P549, DOI 10.1016/j.mcna.2006.04.002; Kishi Y, 1999, PSYCHOSOMATICS, V40, P345, DOI 10.1016/S0033-3182(99)71230-2; Koenig HG, 1998, AM J PSYCHIAT, V155, P871, DOI 10.1176/ajp.155.7.871; LEVENSON JL, 1990, AM J PSYCHIAT, V147, P1498; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Mai Q, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-163; McCusker J, 2003, J AM GERIATR SOC, V51, P1539, DOI 10.1046/j.1532-5415.2003.51509.x; Michael FD., 2015, METHODS EC EVALUATIO, VFourth Edi; Mojet Eveline J., 1990, INT J PSYCHIAT MED, V19, P227; MORRIS PLP, 1990, GEN HOSP PSYCHIAT, V12, P77, DOI 10.1016/0163-8343(90)90018-8; Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0; Rotter T, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-265; SARAVAY SM, 1991, AM J PSYCHIAT, V148, P324; Saravay SM, 1996, AM J PSYCHIAT, V153, P397; Sayers SL, 2007, J AM GERIATR SOC, V55, P1585, DOI 10.1111/j.1532-5415.2007.01368.x; SCHUBERT DSP, 1995, GEN HOSP PSYCHIAT, V17, P326, DOI 10.1016/0163-8343(95)00065-Y; SCHUBERT DSP, 1992, PSYCHOTHER PSYCHOSOM, V57, P61, DOI 10.1159/000288575; Shen C, 2008, DIS MANAGE, V11, P153, DOI 10.1089/dis.2007.0012; Sloan DM, 1999, PSYCHOSOM MED, V61, P21, DOI 10.1097/00006842-199901000-00005; Smith P. J., 2014, J CRIT CARE; Stevens LE, 1998, AUST NZ J PSYCHIAT, V32, P805, DOI 10.3109/00048679809073869; Tan SS, 2012, INT J TECHNOL ASSESS, V28, P152, DOI 10.1017/S0266462312000062; ULDALL KK, 1994, AM J PSYCHIAT, V151, P1475; Uldall KK, 1998, GEN HOSP PSYCHIAT, V20, P292, DOI 10.1016/S0163-8343(98)00041-3; van Waarde J A, 2004, Ned Tijdschr Geneeskd, V148, P209; VERBOSKY LA, 1993, J CLIN PSYCHIAT, V54, P177; Wancata J, 2001, GEN HOSP PSYCHIAT, V23, P8, DOI 10.1016/S0163-8343(00)00110-9; Welch CA, 2009, PSYCHOSOMATICS, V50, P392, DOI 10.1176/appi.psy.50.4.392; Wells G.A., 2000, NEWCASTLE OTTAWA SCA; Zatzick DF, 2000, J TRAUMA, V49, P487, DOI 10.1097/00005373-200009000-00017	66	63	67	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2018	13	3							e0194029	10.1371/journal.pone.0194029	http://dx.doi.org/10.1371/journal.pone.0194029			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FZ0JA	29534097	Green Published, Green Submitted, gold			2023-01-03	WOS:000427253500020
J	Kolling, Y; Salva, S; Villena, J; Alvarez, S				Kolling, Yanina; Salva, Susana; Villena, Julio; Alvarez, Susana			Are the immunomodulatory properties of Lactobacillus rhamnosus CRL1505 peptidoglycan common for all Lactobacilli during respiratory infection in malnourished mice?	PLOS ONE			English	Article							STREPTOCOCCUS-PNEUMONIAE; ALVEOLAR MACROPHAGES; HOST-DEFENSE; MICROBIOTA; RESPONSES; RECOVERY; IMMUNITY; PROTEIN; SEPSIS; ADULTS	Previously, we reported that Lactobacillus rhamnosus CRL1505 peptidoglycan (PG05) improves the innate immune response in immunocompromised-malnourished mice after Streptococcus pneumoniae infection. This study extends those previous findings by demonstrating that the dietary recovery of malnourished mice with nasal administration of PG05 improves not only the innate immune response but the respiratory and systemic adaptive humoral response as well. PG05 enhanced the Th2 response, the recovery of B cells, and the concentration and opsonophagocytic activity of anti-pneumococcal antibodies. In addition, by performing comparative studies with the peptidoglycans from lactobacilli of the same species (L. rhamnosus CRL534) or with similar immunomodulatory properties (L. plantarum CRL1506), we demonstrated here that PG05 has unique immunomodulatory properties that cannot be extended to peptidoglycans from other probiotic strains. However, the knowledge of the molecular characteristics of PG05 is indispensable to understand immunomodulatory abilities of L. rhamnosus CRL1505.	[Kolling, Yanina; Salva, Susana; Villena, Julio; Alvarez, Susana] Reference Ctr Lactobacilli CERELA CONICET, Lab Immunobiotechnol, San Miguel De Tucuman, Tucuman, Argentina; [Alvarez, Susana] Tucuman Univ, Inst Appl Biochem, San Miguel De Tucuman, Tucuman, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Alvarez, S (corresponding author), Reference Ctr Lactobacilli CERELA CONICET, Lab Immunobiotechnol, San Miguel De Tucuman, Tucuman, Argentina.; Alvarez, S (corresponding author), Tucuman Univ, Inst Appl Biochem, San Miguel De Tucuman, Tucuman, Argentina.	salvarez@cerela.org.ar		Salva, Susana/0000-0001-9571-1259	CIUNT [26D/403]; PICT [1381, 3209]	CIUNT; PICT(ANPCyT)	This work was supported by grants from CIUNT 26D/403, PICT 2010 no. 1381 and PICT 2013 no. 3209. The authors declare no conflict of interest.; This work was supported by grants from CIUNT 26D/403, PICT 2010 no. 1381 and PICT 2013 no. 3209. The authors declare no conflict of interest.	Aberdein JD, 2013, CLIN EXP IMMUNOL, V174, P193, DOI 10.1111/cei.12170; Aktas B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156374; Aslam A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025367; Bandera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010788; Barbieri N, 2017, BENEF MICROBES; Barbieri N, 2013, J NUTR, V143, P227, DOI 10.3945/jn.112.165811; Blok DC, 2014, J INNATE IMMUN, V6, P542, DOI 10.1159/000358239; Brouwer N, 2008, J IMMUNOL, V180, P4124, DOI 10.4049/jimmunol.180.6.4124; Clarke TB, 2010, NAT MED, V16, P228, DOI 10.1038/nm.2087; Dalpke AH, 2002, IMMUNOBIOLOGY, V206, P392, DOI 10.1078/0171-2985-00189; Das R, 2014, J IMMUNOL, V193, P764, DOI 10.4049/jimmunol.1400133; Findlay EG, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/140937; Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524; Herrera M, 2014, PLOS ONE, V9; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Jensen H, 2015, PROBIOTICS ANTIMICRO, V7, P14, DOI 10.1007/s12602-014-9174-2; Karmakar M, 2015, J IMMUNOL, V194, P1763, DOI 10.4049/jimmunol.1401624; Kirby AC, 2009, AM J PATHOL, V175, P1107, DOI 10.2353/ajpath.2009.090258; Kitazawa H, 2008, ANIM SCI J, V79, P11, DOI [10.1111/j.1740-0929.2007.00492.x, 10.1111/j.1740-0929.2007.00491.x-i1]; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Kolling Y, 2015, INT IMMUNOPHARMACOL, V25, P474, DOI 10.1016/j.intimp.2015.02.006; Lebeer S, 2010, NAT REV MICROBIOL, V8, P171, DOI 10.1038/nrmicro2297; Levine AP, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0018-2015; Malley R, 2005, P NATL ACAD SCI USA, V102, P4848, DOI 10.1073/pnas.0501254102; Markowicz C, 2016, CAN J MICROBIOL, V62, P72, DOI 10.1139/cjm-2015-0249; Marranzino G, 2012, MICROBIOL IMMUNOL, V56, P771, DOI 10.1111/j.1348-0421.2012.00495.x; Matsuguchi T, 2003, CLIN DIAGN LAB IMMUN, V10, P259, DOI 10.1128/CDLI.10.2.259-266.2003; Overweg K, 2000, INFECT IMMUN, V68, P4180, DOI 10.1128/IAI.68.7.4180-4188.2000; Passera M, 2016, J HOSP INFECT, V94, P361, DOI 10.1016/j.jhin.2016.09.018; Penaloza HF, 2015, IMMUNOLOGY, V146, P100, DOI 10.1111/imm.12486; Racedo S, 2006, MICROBES INFECT, V8, P2359, DOI 10.1016/j.micinf.2006.04.022; Rachmilewitz D, 2002, GASTROENTEROLOGY, V122, P1428, DOI 10.1053/gast.2002.32994; Rodriguez AV, 2001, FEMS MICROBIOL LETT, V204, P33, DOI 10.1111/j.1574-6968.2001.tb10858.x; Salva S, 2008, FOOD AGR IMMUNOL, V19, P195, DOI 10.1080/09540100802247243; Salva S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031171; Salva S, 2011, J SCI FOOD AGR, V91, P2355, DOI 10.1002/jsfa.4467; Salva S, 2010, INT J FOOD MICROBIOL, V141, P82, DOI 10.1016/j.ijfoodmicro.2010.03.013; Savino W, 2010, P NUTR SOC, V69, P636, DOI 10.1017/S0029665110002545; Sharma SK, 2013, VACCINE, V31, P3090, DOI 10.1016/j.vaccine.2013.03.060; Shida K, 2009, IMMUNOLOGY, V128, pe858, DOI 10.1111/j.1365-2567.2009.03095.x; Shimosato T, 2011, J AGR FOOD CHEM, V59, P2646, DOI 10.1021/jf104240d; Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40; Villena J, 2005, J NUTR, V135, P1462, DOI 10.1093/jn/135.6.1462; Villena J., 2012, International Journal of Biotechnology for Wellness Industries, V1, P189; Villena J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00563; Villena J, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-53; Villena J, 2009, MICROBIOL IMMUNOL, V53, P636, DOI 10.1111/j.1348-0421.2009.00171.x; Zelaya H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00633	49	28	28	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2018	13	3							e0194034	10.1371/journal.pone.0194034	http://dx.doi.org/10.1371/journal.pone.0194034			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5UV	29518131	Green Published, Green Submitted, gold			2023-01-03	WOS:000426902900062
J	Manickasamy, K				Manickasamy, Kumari			Patient Commentary: I was pregnant, in pain, and desperate when I chose acupuncture	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												kumari_m@hotmail.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2018	360								k990	10.1136/bmj.k990	http://dx.doi.org/10.1136/bmj.k990			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ1ZG	29514784				2023-01-03	WOS:000427375500007
J	Berry, JG; Gay, JC; Maddox, KJ; Coleman, EA; Bucholz, EM; O'Neill, MR; Blaine, K; Hall, M				Berry, Jay G.; Gay, James C.; Maddox, Karen Joynt; Coleman, Eric A.; Bucholz, Emily M.; O'Neill, Margaret R.; Blaine, Kevin; Hall, Matthew			Age trends in 30 day hospital readmissions: US national retrospective analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE CHRONIC CONDITIONS; SICKLE-CELL-DISEASE; HEALTH-CARE; REDUCTION PROGRAM; TREATMENT GUIDELINES; MEDICAL ADVICE; HEART-FAILURE; UNITED-STATES; YOUNG-PEOPLE; TRANSITION	OBJECTIVE To assess trends in and risk factors for readmission to hospital across the age continuum. DESIGN Retrospective analysis. SETTING AND PARTICIPANTS 31 729 762 index hospital admissions for all conditions in 2013 from the US Agency for Healthcare Research and Quality Nationwide Readmissions Database. MAIN OUTCOME MEASURE 30 day, all cause, unplanned hospital readmissions. Odds of readmission were compared by patients' age in one year epochs with logistic regression, accounting for sex, payer, length of stay, discharge disposition, number of chronic conditions, reason for and severity of admission, and data clustering by hospital. The middle (45 years) of the age range (0-90+ years) was selected as the age reference group. RESULTS The 30 day unplanned readmission rate following all US index admissions was 11.6% (n= 3 678 018). Referenced by patients aged 45 years, the adjusted odds ratio for readmission increased between ages 16 and 20 years (from 0.70 (95% confidence interval 0.68 to 0.71) to 1.04 (1.02 to 1.06)), remained elevated between ages 21 and 44 years (range 1.02 (1.00 to 1.03) to 1.12 (1.10 to 1.14)), steadily decreased between ages 46 and 64 years (range 1.02 (1.00 to 1.04) to 0.91 (0.90 to 0.93)), and decreased abruptly at age 65 years (0.78 (0.77 to 0.79)), after which the odds remained relatively constant with advancing age. Across all ages, multiple chronic conditions were associated with the highest adjusted odds of readmission (for example, 3.67 (3.64 to 3.69) for six or more versus no chronic conditions). Among children, young adults, and middle aged adults, mental health was one of the most common reasons for index admissions that had high adjusted readmission rates (>= 75th centile). CONCLUSIONS The likelihood of readmission was elevated for children transitioning to adulthood, children and younger adults with mental health disorders, and patients of all ages with multiple chronic conditions. Further attention to the measurement and causes of readmission and opportunities for its reduction in these groups is warranted.	[Berry, Jay G.; Bucholz, Emily M.; O'Neill, Margaret R.; Blaine, Kevin] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA; [Berry, Jay G.; Bucholz, Emily M.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Gay, James C.] Vanderbilt Univ, Med CtrMonroe Carell Jr Childrens Hosp Vanderbilt, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Maddox, Karen Joynt] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO 80045 USA; [Hall, Matthew] Childrens Hosp Assoc, Lenexa, KS 66219 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Vanderbilt University; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus	Berry, JG (corresponding author), Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA.; Berry, JG (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.	Jay.berry@childrens.harvard.edu	Hall, Matt/AAT-1349-2021	Hall, Matt/0000-0001-7778-5887	Agency for Healthcare Research and Quality [R21 HS023092-01]; Lucile Packard Foundation for Children's Health; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R21HS023092] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL109177] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Lucile Packard Foundation for Children's Health; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	JGB and MH were supported by the Agency for Healthcare Research and Quality (R21 HS023092-01). JGB, KB, and MRO were supported by the Lucile Packard Foundation for Children's Health. The funders were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The researchers conducted the work independently of the funders.	Adams-Graves P, 2016, EXPERT REV HEMATOL, V9, P541, DOI 10.1080/17474086.2016.1180242; Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP), 2013, INTR HCUP NAT READM; Alfandre DJ, 2009, MAYO CLIN PROC, V84, P255, DOI 10.1016/S0025-6196(11)61143-9; Amoah D, 2016, AUSTIN J PUBLIC HLTH, V3; Bailey H, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.4.21475; Bardach NS, 2014, PEDIATRICS, V133, P602, DOI 10.1542/peds.2013-3165; Berry JG, 2016, JAMA PEDIATR, V170, P326, DOI 10.1001/jamapediatrics.2015.4836; Berry JG, 2014, JAMA PEDIATR, V168, P955, DOI 10.1001/jamapediatrics.2014.891; Berry JG, 2013, INT J QUAL HEALTH C, V25, P573, DOI 10.1093/intqhc/mzt051; Berry JG, 2013, JAMA-J AM MED ASSOC, V309, P372, DOI 10.1001/jama.2012.188351; Berry JG, 2011, JAMA-J AM MED ASSOC, V305, P682, DOI 10.1001/jama.2011.122; Bibbins-Domingo K, 2007, NEW ENGL J MED, V357, P2371, DOI 10.1056/NEJMsa073166; Blum RW, 2002, PEDIATRICS, V110, P1304; Bower WF, 2017, NEUROUROL URODYNAM, V36, P811, DOI 10.1002/nau.23039; Callahan ST, 2006, ARCH PEDIAT ADOL MED, V160, P178, DOI 10.1001/archpedi.160.2.178; Chang DW, 2015, CRIT CARE MED, V43, P2085, DOI 10.1097/CCM.0000000000001159; Coleman EA, 2005, MED CARE, V43, P246, DOI 10.1097/00005650-200503000-00007; Considine J, 2019, AUST HEALTH REV, V43, P1, DOI 10.1071/AH16287; Dharmarajan K, 2017, JAMA-J AM MED ASSOC, V318, P270, DOI 10.1001/jama.2017.8444; Eapen ZJ, 2013, CIRC-HEART FAIL, V6, P727, DOI 10.1161/CIRCHEARTFAILURE.112.000265; Fair C, 2016, JAMA PEDIATR, V170, P205, DOI 10.1001/jamapediatrics.2015.3168; Ferro MA, 2015, J AFFECT DISORDERS, V174, P594, DOI 10.1016/j.jad.2014.12.014; Fonarow GC, 2017, J AM COLL CARDIOL, V70, P1931, DOI 10.1016/j.jacc.2017.08.046; Freeland KN, 2015, AM J HEALTH-SYST PH, V72, pS156, DOI 10.2146/sp150023; Fuller RL, 2013, J AMBUL CARE MANAG, V36, P147, DOI 10.1097/JAC.0b013e3182866c1c; Garland A, 2013, CAN MED ASSOC J, V185, P1207, DOI 10.1503/cmaj.130029; Gerhardt Geoffrey, 2013, Medicare Medicaid Res Rev, V3, DOI 10.5600/mmrr.003.02.b01; Goossens E, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2413; Greutmann M, 2015, CONGENIT HEART DIS, V10, P117, DOI 10.1111/chd.12201; Hamilton JE, 2016, AUST NZ J PSYCHIAT, V50, P584, DOI 10.1177/0004867415605171; Healthcare Cost and Utilization Project (HCUP), 2016, CHRON COND IND ICD 9; Honda M, 2014, CLIN EXP NEPHROL, V18, P939, DOI 10.1007/s10157-014-0941-x; Hoy AR, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3891-2; Huffman KF, 2018, J AM GERIATR SOC, V66, P25, DOI 10.1111/jgs.15227; Hung D, 2018, J NURS CARE QUAL, V33, P221, DOI 10.1097/NCQ.0000000000000294; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jenq GY, 2016, JAMA INTERN MED, V176, P681, DOI 10.1001/jamainternmed.2016.0833; Joynt KE, 2016, AM J MANAG CARE, V22, pE287; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Kassler WJ, 2015, NEW ENGL J MED, V372, P109, DOI 10.1056/NEJMp1406838; Kristensen SR, 2015, HEALTH POLICY, V119, P264, DOI 10.1016/j.healthpol.2014.12.009; Lafeuille MH, 2014, CURR MED RES OPIN, V30, P1643, DOI 10.1185/03007995.2014.915211; Lora A, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796017000075; Martins SS, 2015, AM J PUBLIC HEALTH, V105, P2373, DOI 10.2105/AJPH.2015.302843a; National Quality Forum, 2012, END SUMM ALL CAUS RE; National Quality Forum, 2015, ALL CAUS ADM READM M; Parekh AK, 2014, JAMA-J AM MED ASSOC, V312, P1199, DOI 10.1001/jama.2014.10181; Quinn CT, 2013, PEDIATR CLIN N AM, V60, P1363, DOI 10.1016/j.pcl.2013.09.006; Ranasinghe I, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001737; Sambamoorthi U, 2015, EXPERT REV PHARM OUT, V15, P823, DOI 10.1586/14737167.2015.1091730; Sawicki GS, 2012, PEDIATR PULM, V47, P523, DOI 10.1002/ppul.22546; Schuster MA, 2014, PEDIAT ALL CONDITION; Strom JB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180767; Suter LG, 2014, J GEN INTERN MED, V29, P1333, DOI 10.1007/s11606-014-2862-5; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Torio CM, 2015, ACAD PEDIATR, V15, P19, DOI 10.1016/j.acap.2014.07.007; Treuer T, 2017, ASIA-PAC PSYCHIAT, V9, DOI 10.1111/appy.12254; van den Bosch WF, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-57; Vogeli C, 2007, J GEN INTERN MED, V22, P391, DOI 10.1007/s11606-007-0322-1; Wijlaars LPMM, 2016, ARCH DIS CHILD, V101, P714, DOI 10.1136/archdischild-2015-309290; Zhou HQ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011060; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	62	57	57	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2018	360								k497	10.1136/bmj.k497	http://dx.doi.org/10.1136/bmj.k497			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FY4IH	29487063	hybrid, Green Published			2023-01-03	WOS:000426785400001
J	Eggimann, L; Blum, S; Aeschbacher, S; Reusser, A; Ammann, P; Erne, P; Moschovitis, G; Di Valentino, M; Shah, D; Schlapfer, J; Mondet, N; Kuhne, M; Sticherling, C; Osswald, S; Conen, D				Eggimann, Lucien; Blum, Steffen; Aeschbacher, Stefanie; Reusser, Andreas; Ammann, Peter; Erne, Paul; Moschovitis, Giorgio; Di Valentino, Marcello; Shah, Dipen; Schlapfer, Jurg; Mondet, Nadine; Kuhne, Michael; Sticherling, Christian; Osswald, Stefan; Conen, David			Risk factors for heart failure hospitalizations among patients with atrial fibrillation	PLOS ONE			English	Article							BRAIN NATRIURETIC PEPTIDE; DIASTOLIC BLOOD-PRESSURE; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; PROGNOSTIC IMPLICATIONS; DIABETES-MELLITUS; JAPANESE PATIENTS; OBESITY PARADOX; SERUM CHLORIDE; MORTALITY	Background Patients with atrial fibrillation (AF) have an increased risk for the development of heart failure (HF). In this study, we aimed to detect predictors of HF hospitalizations in an unselected AF population. Methods The Basel Atrial Fibrillation Cohort Study is an ongoing observational multicenter cohort study in Switzerland. For this analysis, 1193 patients with documented AF underwent clinical examination, venous blood sampling and resting 12-lead ECG at baseline. Questionnaires about lifestyle and medical history were obtained in person at baseline and during yearly follow-up phone calls. HF hospitalizations were validated by two independent physicians. Cox regression analyses were performed using a forward selection strategy. Results Overall, 29.8% of all patients were female and mean age was 69 +/- 12 years. Mean follow-up time was 3.7 +/- 1.5 years. Hospitalization for HF occurred in 110 patients, corresponding to an incidence of 2.5 events per 100 person years of follow-up. Independent predictors for HF were body mass index (HR 1.40 [95% CI 1.17; 1.66], p = 0.0002), chronic kidney disease (2.27 [1.49; 3.45], p = 0.0001), diabetes mellitus (2.13 [1.41; 3.24], p = 0.0004), QTc interval (1.25 [1.04; 1.49], p = 0.02), brain natriuretic peptide (2.19 [1.73; 2.77], p< 0.0001), diastolic blood pressure (0.79 [0.65; 0.96], p = 0.02), history of pulmonary vein isolation or electrical cardioversion (0.54 [0.36; 0.80], p = 0.003) and serum chloride (0.82 [0.70; 0.96], p = 0.02). Conclusions In this unselected AF population, several traditional cardiovascular risk factors and arrhythmia interventions predicted HF hospitalizations, providing potential opportunities for the implementation of strategies to reduce HF among AF patients.	[Eggimann, Lucien; Blum, Steffen; Aeschbacher, Stefanie; Reusser, Andreas; Kuhne, Michael; Sticherling, Christian; Osswald, Stefan; Conen, David] Univ Basel, Univ Hosp Basel, Dept Med, Div Cardiol, Basel, Switzerland; [Eggimann, Lucien; Blum, Steffen; Aeschbacher, Stefanie; Reusser, Andreas; Mondet, Nadine; Kuhne, Michael; Sticherling, Christian; Osswald, Stefan; Conen, David] Univ Basel, Univ Hosp Basel, Cardiovasc Res Inst Basel, Basel, Switzerland; [Blum, Steffen] Univ Basel, Univ Hosp Basel, Dept Med, Div Internal Med, Basel, Switzerland; [Ammann, Peter] Kantonsspital, Div Cardiol, St Gallen, Switzerland; [Erne, Paul] Univ Hosp Basel, Dept Biomed, Lab Signal Transduct, Basel, Switzerland; [Moschovitis, Giorgio] Osped Reg Lugano, Div Cardiol, Ticino, Switzerland; [Di Valentino, Marcello] Osped San Giovanni Bellinzona, Div Cardiol, Ticino, Switzerland; [Shah, Dipen] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland; [Schlapfer, Jurg] Univ Hosp Lausanne, Serv Cardiol, Lausanne, Switzerland; [Conen, David] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada	University of Basel; University of Basel; University of Basel; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; University of Basel; Regional Hospital of Bellinzona & Valleys, San Giovanni; University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); McMaster University; Population Health Research Institute	Conen, D (corresponding author), Univ Basel, Univ Hosp Basel, Dept Med, Div Cardiol, Basel, Switzerland.; Conen, D (corresponding author), Univ Basel, Univ Hosp Basel, Cardiovasc Res Inst Basel, Basel, Switzerland.; Conen, D (corresponding author), McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.	conend@mcmaster.ca	Osswald, Stefan/A-6904-2018; Aeschbacher, Stefanie/E-4935-2017; Kühne, Michael/AAB-5202-2022; Sticherling, Christian/AAY-4435-2021	Osswald, Stefan/0000-0002-9240-6731; Kühne, Michael/0000-0002-2937-3711; Sticherling, Christian/0000-0001-8428-7050; /0000-0001-8134-2421	Swiss National Science Foundation; Swiss Heart Foundation; University of Basel; Boehringer Ingelheim; Sanofi-Aventis; Merck Sharp Dome; Bayer; Daiichi-Sankyo; Pfizer/Bristol-Myers Squibb	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Heart Foundation; University of Basel; Boehringer Ingelheim(Boehringer Ingelheim); Sanofi-Aventis(Sanofi-Aventis); Merck Sharp Dome; Bayer(Bayer AG); Daiichi-Sankyo(Daiichi Sankyo Company Limited); Pfizer/Bristol-Myers Squibb(Bristol-Myers SquibbPfizer)	This study was supported by the Swiss National Science Foundation, the Swiss Heart Foundation, the University of Basel, Boehringer Ingelheim, Sanofi-Aventis, Merck Sharp & Dome, Bayer, Daiichi-Sankyo and Pfizer/Bristol-Myers Squibb. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ardestani A, 2010, AM J CARDIOL, V106, P369, DOI 10.1016/j.amjcard.2010.03.036; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; Beinart R, 2014, J AM COLL CARDIOL, V64, P2111, DOI 10.1016/j.jacc.2014.08.039; Berger R, 2002, CIRCULATION, V105, P2392, DOI 10.1161/01.CIR.0000016642.15031.34; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; Bunch TJ, 2010, HEART RHYTHM, V7, P433, DOI 10.1016/j.hrthm.2009.12.004; Burger M, 2004, PREV MED, V39, P111, DOI 10.1016/j.ypmed.2003.11.011; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]; Cavender MA, 2015, CIRCULATION, V132, P923, DOI 10.1161/CIRCULATIONAHA.114.014796; Chen CY, 2012, CIRC J, V76, P2372, DOI 10.1253/circj.CJ-12-0040; Conen D, 2011, JAMA-J AM MED ASSOC, V305, P2080, DOI 10.1001/jama.2011.659; Cox DR, 1972, J ROY STAT SOC B; De Bacquer D, 1998, J Cardiovasc Risk, V5, P177; Dunlay SM, 2009, J AM COLL CARDIOL, V54, P1695, DOI 10.1016/j.jacc.2009.08.019; Ellinor PT, 2005, J AM COLL CARDIOL, V45, P82, DOI 10.1016/j.jacc.2004.09.045; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fukuda T, 2007, CIRC J, V71, P308, DOI 10.1253/circj.71.308; Grodin JL, 2015, J AM COLL CARDIOL, V66, P659, DOI 10.1016/j.jacc.2015.06.007; Heo S, 2007, HEART LUNG, V36, P16, DOI 10.1016/j.hrtlng.2006.06.003; Hillege HL, 2006, CIRCULATION, V113, P671, DOI 10.1161/CIRCULATIONAHA.105.580506; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Imai K, 2014, INTERNAL MED, V53, P7, DOI 10.2169/internalmedicine.53.0962; Javaheri S, 2007, J AM COLL CARDIOL, V49, P2028, DOI 10.1016/j.jacc.2007.01.084; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Krijthe BP, 2013, EUR HEART J, V34, P2746, DOI 10.1093/eurheartj/eht280; Lee DS, 2007, HYPERTENSION, V50, P869, DOI 10.1161/HYPERTENSIONAHA.107.095380; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin ER, 1998, NEW ENGL J MED, V339, P321; Lip GYH, 2015, EUR J HEART FAIL, V17, P570, DOI 10.1002/ejhf.254; Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42; McCallum L, 2013, HYPERTENSION, V62, P836, DOI 10.1161/HYPERTENSIONAHA.113.01793; Nieuwlaat R, 2007, AM HEART J, V153, P1006, DOI 10.1016/j.ahj.2007.03.008; Pandey A, 2017, JACC-HEART FAIL, V5, P44, DOI 10.1016/j.jchf.2016.09.016; Potpara TS, 2013, EUR J HEART FAIL, V15, P415, DOI 10.1093/eurjhf/hft004; Sandhu RK, 2016, EUR HEART J, V37, P2869, DOI 10.1093/eurheartj/ehw124; Santhanakrishnan R, 2016, CIRCULATION, V133, P484, DOI 10.1161/CIRCULATIONAHA.115.018614; Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80; Schnabel RB, 2013, EUR J HEART FAIL, V15, P843, DOI 10.1093/eurjhf/hft041; Schoen T, 2012, J AM COLL CARDIOL, V60, P1421, DOI 10.1016/j.jacc.2012.06.030; Steinberg BA, 2014, AM HEART J, V167, P735, DOI 10.1016/j.ahj.2014.02.003; Suzuki S, 2012, AM J CARDIOL, V110, P678, DOI 10.1016/j.amjcard.2012.04.049; Tedrow UB, 2010, J AM COLL CARDIOL, V55, P2319, DOI 10.1016/j.jacc.2010.02.029; Testani JM, 2016, EUR J HEART FAIL, V18, P660, DOI 10.1002/ejhf.477; Thihalolipavan S, 2015, PROG CARDIOVASC DIS, V58, P126, DOI 10.1016/j.pcad.2015.07.004; Wang J, 2014, INT J CARDIOL, V176, P1356, DOI 10.1016/j.ijcard.2014.07.264; Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wozakowska-Kaplon B, 2004, AM J CARDIOL, V93, P1555, DOI 10.1016/j.amjcard.2004.03.013; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328	49	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2018	13	2							e0191736	10.1371/journal.pone.0191736	http://dx.doi.org/10.1371/journal.pone.0191736			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU7VI	29394253	Green Submitted, Green Published, gold			2023-01-03	WOS:000424060400018
J	Chen, CH; Xin, Y; Lee, KW; Lin, MJ; Lin, JJ				Chen, Che Hsiu; Xin, Ye; Lee, Kuang Wu; Lin, Ming Ju; Lin, Jiu Jenq			Acute effects of different dynamic exercises on hamstring strain risk factors	PLOS ONE			English	Article							PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION; KNEE PROPRIOCEPTION; ISOKINETIC STRENGTH; PASSIVE PROPERTIES; SPINAL CURVATURES; MUSCLE; QUADRICEPS; POSITION; FLEXIBILITY; PERFORMANCE	The purpose of the study was to examine the acute effects of different dynamic exercise interventions on hamstring muscle performance. Thirty-six young men with poor hamstring flexibility were randomly assigned to three intervention groups: jogging combined with dynamic open kinetic chain stretching (DS), jogging combined with dynamic closed kinetic chain stretching (lunge with eccentric hamstring windmills, LEC), and jogging only (CON) groups. Hamstring flexibility, muscle stiffness (area under the curve, AUC), joint position sense (JPS), maximal eccentric strength (ECC), and angle of peak torque (APT) were recorded before and immediately after the exercise interventions. The results showed that the hamstring flexibility increased in DS (p < 0.001); muscle stiffness decreased in DS and was lower than jogging (p < 0.001). Moreover, ECC increased in LEC and was higher than jogging and DS (p < 0.001). APT was different among 3 groups (p < 0.001). Decreased accuracy of JPS was found in DS and jogging (p < 0.001). In conclusion, the dynamic closed kinetic chain stretching (LEC) as compared to open kinetic chain stretching (DS) or jogging group, may be an effective technique to enhance muscle performance during the pre-competition warm-up routine.	[Chen, Che Hsiu] Natl Taiwan Univ Sport, Dept Sport Performance, Taichung, Taiwan; [Chen, Che Hsiu; Lee, Kuang Wu] Univ Taipei, Grad Inst Sports Training, Taipei, Taiwan; [Xin, Ye] Univ Mississippi, Dept Hlth Exercise Sci & Recreat Management, University, MS 38677 USA; [Lin, Ming Ju] Natl Chiayi Univ, Dept Phys Educ, 85 Wenlong Village, Minsyong Township, Chiayi, Taiwan; [Lin, Jiu Jenq] Natl Taiwan Univ, Coll Med, Sch & Grad Inst Phys Therapy, Taipei, Taiwan	National Taiwan University of Sport; University of Taipei; University of Mississippi; National Chiayi University; National Taiwan University	Lin, JJ (corresponding author), Natl Taiwan Univ, Coll Med, Sch & Grad Inst Phys Therapy, Taipei, Taiwan.	jiujlin@ntu.edu.tw	lin, jiu jenq/H-4604-2014; Lin, Jiu/GRJ-5213-2022	lin, jiu jenq/0000-0001-9070-7939; 	Ministry of Science and Technology in Taiwan [101-2410-H-259-082]	Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	Funded by Ministry of Science and Technology in Taiwan (101-2410-H-259-082) to Che Hsiu Chen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarrestad DD, 2004, J CHILD NEUROL, V19, P894, DOI 10.1177/08830738040190110801; [Anonymous], 1988, J C STAT POWER ANAL; Avela J, 1999, J APPL PHYSIOL, V86, P1283, DOI 10.1152/jappl.1999.86.4.1283; Ayala F, 2013, J SPORT SCI, V31, P831, DOI 10.1080/02640414.2012.751119; Bartlett MJ, 2002, BRIT J SPORT MED, V36, P132, DOI 10.1136/bjsm.36.2.132; Batista LH, 2009, AM J PHYS MED REHAB, V88, P815, DOI 10.1097/PHM.0b013e3181b72149; Behm DG, 2011, APPL PHYSIOL NUTR ME, V36, P790, DOI [10.1139/H11-107, 10.1139/h11-107]; Behm DG, 2011, EUR J APPL PHYSIOL, V111, P2633, DOI 10.1007/s00421-011-1879-2; Bjorklund M, 2006, J ATHL TRAINING, V41, P270; Chen CH, 2013, J SPORT REHABIL, V22, P59, DOI 10.1123/jsr.22.1.59; Chen CH, 2011, MED SCI SPORT EXER, V43, P491, DOI 10.1249/MSS.0b013e3181f315ad; Costa PB, 2014, MED SCI SPORT EXER, V46, P586, DOI 10.1249/MSS.0000000000000138; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fletcher IM, 2007, J STRENGTH COND RES, V21, P784; Fletcher IM, 2010, EUR J APPL PHYSIOL, V109, P491, DOI 10.1007/s00421-010-1386-x; Gleim GW, 1997, SPORTS MED, V24, P291; Herda TJ, 2013, J SPORT SCI, V31, P479, DOI 10.1080/02640414.2012.736632; Larsen R, 2005, BRIT J SPORT MED, V39, P43, DOI 10.1136/bjsm.2003.011056; Lopez-Minarro PA, 2012, J HUM KINET, V31, P69, DOI 10.2478/v10078-012-0007-7; Magnusson SP, 1998, SCAND J MED SCI SPOR, V8, P65; Manoel ME, 2008, J STRENGTH COND RES, V22, P1528, DOI 10.1519/JSC.0b013e31817b0433; Muyor JM, 2016, J HUM KINET, V53, P23, DOI 10.1515/hukin-2016-0007; Muyor JM, 2011, J HUM KINET, V29, P15, DOI 10.2478/v10078-011-0035-8; Pacheco L, 2011, J STRENGTH COND RES, V25, P2991, DOI 10.1519/JSC.0b013e318212dac0; Sekir U, 2010, SCAND J MED SCI SPOR, V20, P268, DOI 10.1111/j.1600-0838.2009.00923.x; Streepey JW, 2010, J STRENGTH COND RES, V24, P1037, DOI 10.1519/JSC.0b013e3181d09e87; SULLIVAN MK, 1992, MED SCI SPORT EXER, V24, P1383; Thacker SB, 2004, MED SCI SPORT EXER, V36, P371, DOI 10.1249/01.MSS.0000117134.83018.F7; Thompsen AG, 2007, J STRENGTH COND RES, V21, P52, DOI 10.1519/00124278-200702000-00010; Torres R, 2010, INT J SPORTS MED, V31, P410, DOI 10.1055/s-0030-1248285; Watsford ML, 2010, AM J SPORT MED, V38, P2058, DOI 10.1177/0363546510370197; Witvrouw E, 2003, AM J SPORT MED, V31, P41, DOI 10.1177/03635465030310011801	32	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2018	13	2							e0191801	10.1371/journal.pone.0191801	http://dx.doi.org/10.1371/journal.pone.0191801			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU3ZZ	29390001	gold, Green Published, Green Submitted			2023-01-03	WOS:000423793400036
J	Honig, LS; Vellas, B; Woodward, M; Boada, M; Bullock, R; Borrie, M; Hager, K; Andreasen, N; Scarpini, E; Liu-Seifert, H; Case, M; Dean, RA; Hake, A; Sundell, K; Hoffmann, VP; Carlson, C; Khanna, R; Mintun, M; DeMattos, R; Selzler, KJ; Siemers, E				Honig, Lawrence S.; Vellas, Bruno; Woodward, Michael; Boada, Merce; Bullock, Roger; Borrie, Michael; Hager, Klaus; Andreasen, Niels; Scarpini, Elio; Liu-Seifert, Hong; Case, Michael; Dean, Robert A.; Hake, Ann; Sundell, Karen; Hoffmann, Vicki Poole; Carlson, Christopher; Khanna, Rashna; Mintun, Mark; DeMattos, Ronald; Selzler, Katherine J.; Siemers, Eric			Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							A-BETA BURDEN; AMYLOID HYPOTHESIS; CLINICAL-TRIALS; RATING-SCALE; BAPINEUZUMAB; MODEL	BACKGROUND Alzheimer's disease is characterized by amyloid-beta (A beta) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble A beta, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or A beta 1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P = 0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline.	[Honig, Lawrence S.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA; [Honig, Lawrence S.] Columbia Univ, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA; [Vellas, Bruno] Univ Toulouse III Paul Sabatier, INSERM, CHU Toulouse, Gerontopole,Unite Mixte Rech,Unite 1027, Toulouse, France; [Woodward, Michael] Austin Hlth Continuing Care Clin Serv Unit, Heidelberg, Vic, Australia; [Woodward, Michael] Univ Melbourne, Melbourne, Vic, Australia; [Boada, Merce] Fundacio ACE, Alzheimer Res Ctr, Barcelona, Spain; [Boada, Merce] Inst Catala Neurociencies Aplicades, Memory Clin, Barcelona, Spain; [Bullock, Roger] Victoria Hosp, Kingshill Res Ctr, Swindon, Wilts, England; [Borrie, Michael] Western Univ, Schulich Sch Med & Dent, Div Geriatr Med, London, ON, Canada; [Hager, Klaus] Diakovere Henriettenstift, Clin Med Elderly, Hannover, Germany; [Andreasen, Niels] Karolinska Univ Hosp, Karolinska Inst, Alzheimers Dis Res Ctr, Huddinge, Sweden; [Andreasen, Niels] Karolinska Univ Hosp, Clin Trial Unit, Geriatr Clin, Huddinge, Sweden; [Scarpini, Elio] Univ Milan, Fdn Ca Granda,Dino Ferrari Ctr, Ist Ricovero & Cura Carattere Sci,Neurol Unit, Osped Policlin,Dept Pathophysiol & Transplantat, Milan, Italy; [Liu-Seifert, Hong; Case, Michael; Hake, Ann; Sundell, Karen; Hoffmann, Vicki Poole; Carlson, Christopher; Khanna, Rashna; Mintun, Mark; DeMattos, Ronald; Selzler, Katherine J.; Siemers, Eric] Eli Lilly, Indianapolis, IN USA; [Dean, Robert A.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Mintun, Mark] Avid Radiopharmaceut, Philadelphia, PA USA	Columbia University; Columbia University; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Melbourne; Western University (University of Western Ontario); Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Eli Lilly; Indiana University System; Indiana University Bloomington	Honig, LS (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, 630 W 168th St P&S Unit 16, New York, NY 10032 USA.	lh456@cumc.columbia.edu	Borrie, Michael/G-3280-2011; Iwata, Atsushi/AAH-8924-2019	Iwata, Atsushi/0000-0001-7308-5314	Eli Lilly; Bristol-Myers Squibb; Eisai; Forum Pharmaceuticals; Lundbeck; Fujirebio; AbbVie; Axovant; Biogen; C2N Diagnostics; Genentech; Janssen-Johnson Johnson; Merck; Pfizer; Roche; TauRx; vTv Therapeutics; Pierre Fabre; Regeneron; AstraZeneca; LPG Systems; Alzheon; MSD; Otsuka; Sanofi; Nestle; Transition Therapeutics; Takeda Pharmaceutical; Cognition Therapeutics (CogRx); Nutricia; Buck Institute for Research on Aging; Servier; Prana Biotechnology; Takeda Pharmaceutical-Zinfandel Pharmaceuticals; Novartis; Araclon Biotech; Grifols; Krka; Dr. Willmar Schwabe Pharmaceuticals; Janssen; Kyowa Hakko Kirin; Piramal; Fundacio La Caixa; Bioiberica; Mediti Pharma; Seqirus	Eli Lilly(Eli Lilly); Bristol-Myers Squibb(Bristol-Myers Squibb); Eisai(Eisai Co Ltd); Forum Pharmaceuticals; Lundbeck(Lundbeck Corporation); Fujirebio; AbbVie(AbbVie); Axovant; Biogen(Biogen); C2N Diagnostics; Genentech(Roche HoldingGenentech); Janssen-Johnson Johnson(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Pfizer(Pfizer); Roche(Roche Holding); TauRx; vTv Therapeutics; Pierre Fabre; Regeneron(Regeneron); AstraZeneca(AstraZeneca); LPG Systems; Alzheon; MSD; Otsuka(Otsuka Pharmaceutical); Sanofi; Nestle(Nestle SA); Transition Therapeutics; Takeda Pharmaceutical(Takeda Pharmaceutical Company Ltd); Cognition Therapeutics (CogRx); Nutricia(Danone Nutricia); Buck Institute for Research on Aging; Servier(Servier); Prana Biotechnology; Takeda Pharmaceutical-Zinfandel Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Novartis(Novartis); Araclon Biotech; Grifols; Krka; Dr. Willmar Schwabe Pharmaceuticals; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Kyowa Hakko Kirin(Kyowa Kirin Ltd); Piramal; Fundacio La Caixa(La Caixa FoundationEuropean Commission); Bioiberica; Mediti Pharma(Dexcel Pharma); Seqirus	Supported by Eli Lilly.; Dr. Honig reports receiving grant support and consulting fees from Bristol-Myers Squibb, Eisai, Forum Pharmaceuticals, and Lundbeck, grant support and travel support from Eli Lilly, consulting fees from Fujirebio, and grant support from AbbVie, AstraZeneca, Axovant, Biogen, C2N Diagnostics, Genentech, Janssen-Johnson & Johnson, Merck, Pfizer, Roche, TauRx, and vTv Therapeutics; Dr. Vellas, receiving grant support from AbbVie, Pierre Fabre, Regeneron, AstraZeneca, LPG Systems, and Alzheon, grant support and consulting fees from Eli Lilly, Lundbeck, MSD, Otsuka, Roche, Sanofi, and Nestle, and consulting fees from Biogen, Transition Therapeutics, and Takeda Pharmaceutical; Dr. Woodward, receiving grant and travel support and consulting fees from Cognition Therapeutics (CogRx), Nutricia, Merck, Eli Lilly, and Lundbeck, consulting fees and travel support from Seqirus, and grant support from Bristol-Myers Squibb, Eisai, Forum Pharmaceuticals, AbbVie, AstraZeneca, Axovant, Biogen, Buck Institute for Research on Aging, Servier, Sanofi, Genentech, Janssen-Johnson & Johnson, Pfizer, Roche, Prana Biotechnology, Takeda Pharmaceutical-Zinfandel Pharmaceuticals, Novartis, TauRx, and vTv Therapeutics; Dr. Boada, receiving consulting fees, lecture fees, and grant support from Araclon Biotech and Grifols, consulting fees and grant support from Eli Lilly, MSD, Nutricia, and Roche, lecture fees and grant support from Krka, consulting fees and lecture fees from Dr. Willmar Schwabe Pharmaceuticals, consulting fees from AstraZeneca, Janssen, Kyowa Hakko Kirin, and Servier, and grant support from Piramal, Biogen, Fundacio La Caixa, and Bioiberica; Dr. Bullock, serving on an advisory board for Eli Lilly; Dr. Borrie, receiving consulting fees and fees for serving on an advisory board from Eli Lilly and Roche, consulting fees from Mediti Pharma, and grant support from Bristol-Myers Squibb, Eisai, Forum Pharmaceuticals, Lundbeck, Biogen, Genentech, Janssen-Johnson & Johnson, Merck, and Pfizer; Dr. Scarpini, receiving fees for serving on an advisory board for Eli Lilly; Dr. Liu-Seifert, Mr. Case, Dr. Hake, Dr. Khanna, and Dr. Selzler, being employed by and being shareholders in Eli Lilly; Dr. Dean, Ms. Sundell, Dr. Poole Hoffmann, Dr. Carlson, and Dr. Siemers, being formerly employed by and holding stock in Eli Lilly; Dr. Mintun, being employed by Eli Lilly and Avid Radiopharmaceuticals; and Dr. DeMattos, being employed by Eli Lilly and holding a patent (U.S. patent number, 7195761 B2) for humanized antibodies that sequester amyloid-beta peptide, for which no royalties have been received. No other potential conflict of interest relevant to this article was reported.	Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; BERG L, 1992, ANN NEUROL, V31, P242, DOI 10.1002/ana.410310303; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Doody RS, 2014, NEW ENGL J MED, V370, P311, DOI 10.1056/NEJMoa1312889; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 2004, J AM GERIATR SOC, V52, P1070, DOI 10.1111/j.1532-5415.2004.52303.x; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hardy J, 2017, BRAIN, V140, P853, DOI 10.1093/brain/awx059; Harrison JR, 2016, BRIT J PSYCHIAT, V208, P1, DOI 10.1192/bjp.bp.115.167569; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jucker M, 2013, NATURE, V501, P45, DOI 10.1038/nature12481; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mohs RC, 1997, ALZ DIS ASSOC DIS, V11, pS13; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P1091, DOI 10.1001/archneur.65.8.1091; Ostrowitzki S, 2012, ARCH NEUROL-CHICAGO, V69, P198, DOI 10.1001/archneurol.2011.1538; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Siemers ER, 2016, ALZHEIMERS DEMENT, V12, P110, DOI [10.1016/j.jalz.2015.06.1893, 10.1016/j.dadm.2016.02.006]; Sperling R, 2012, LANCET NEUROL, V11, P241, DOI 10.1016/S1474-4422(12)70015-7; Wessels AM, 2015, J PREZ ALZ DIS, V2, P227	27	536	546	4	118	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2018	378	4					321	330		10.1056/NEJMoa1705971	http://dx.doi.org/10.1056/NEJMoa1705971			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT5ZX	29365294	Green Published, Bronze			2023-01-03	WOS:000423233400005
J	Haas, D; Galler, H; Fritz, C; Hasler, C; Habib, J; Reinthaler, FF				Haas, Doris; Galler, Herbert; Fritz, Carola; Hasler, Christina; Habib, Juliana; Reinthaler, Franz F.			Comparative study of impaction and sedimentation in an aerosol chamber using defined fungal spore and bacterial concentrations	PLOS ONE			English	Article							SAMPLING PERFORMANCE; AIR; BIOEFFICIENCY; BIOAEROSOLS; COLLECTION; PARTICLES; INDOOR	Biocontamination control is a very significant part of the manufacturing process of sterile drugs. Sterility is frequently monitored by active or passive air sampling measurements, but there are no specific rules as to how this is to be done. This study tested air sampling methods of active impaction and passive sedimentation under standardized conditions. Aspergillus niger (A. niger) and Staphylococcus aureus (S. aureus) were selected in this experiment to examine parallels, correlations and differences between the two methods. The results show that the number of colony forming units per plate (CFU/plate) was higher for A. niger in the active method, whereas for S. aureus it was higher in the sedimentation method. A high correlation coefficient was found between the impaction and sedimentation methods for A. niger. For S. aureus, depending on the culture media used and the time for passive air sampling, a larger number of CFU/plate was found than in active air sampling. This study concludes that active and passive air sampling can be used for monitoring the air in clean rooms. For fungal spore detection, the impaction is more efficient, as it is possible to sample a higher volume of air in a shorter period of time, whereas the optimal measurement methods for S. aureus depend on a number of factors.	[Haas, Doris; Galler, Herbert; Fritz, Carola; Hasler, Christina; Habib, Juliana; Reinthaler, Franz F.] ZWT Med Univ Graz, Inst Hyg Microbiol & Environm Med, Dept Environm Hyg, Neue Stiftingtalstr 2, Graz, Austria		Haas, D (corresponding author), ZWT Med Univ Graz, Inst Hyg Microbiol & Environm Med, Dept Environm Hyg, Neue Stiftingtalstr 2, Graz, Austria.	doris.haas@medunigraz.at		Haas, Doris/0000-0003-0374-7153				Amato P, 2015, ATMOS CHEM PHYS, V15, P6455, DOI 10.5194/acp-15-6455-2015; Asefa DT, 2009, FOOD CONTROL, V20, P997, DOI 10.1016/j.foodcont.2008.11.011; Brotto P, 2015, AEROBIOLOGIA, V31, P445, DOI 10.1007/s10453-015-9378-2; Burrows S.M., 2009, ATMOS CHEM PHYS DISC, V9, P10777, DOI DOI 10.5194/ACPD-9-10829-2009; Canha N, 2015, ARCH ENVIRON PROT, V41, P11, DOI 10.1515/aep-2015-0034; Cohen BS, 2001, AIR SAMPLING INSTRUM, P662; Docampo S, 2010, AEROBIOLOGIA, V26, P89, DOI 10.1007/s10453-009-9146-2; EU-GMP, 2008, EU GUID GOOD MAN PRA, V4, P1; Farrell FF, 2017, BIOL PHYS UNPUB; Fyske EM, 2008, VALIDATION AIR COLLE, P1; Gorecki T, 2002, TRAC-TREND ANAL CHEM, V21, P276, DOI 10.1016/S0165-9936(02)00407-7; Gutschi AM, 2014, VERGLEICHENDE UNTERS; Haas D, 2007, ATMOS ENVIRON, V41, P5192, DOI 10.1016/j.atmosenv.2006.07.062; Haig CW, 2016, J HOSP INFECT, V93, P242, DOI 10.1016/j.jhin.2016.03.017; JENSEN PA, 1992, AM IND HYG ASSOC J, V53, P660, DOI 10.1202/0002-8894(1992)053<0660:EOEBSC>2.0.CO;2; Konlechner A, 2013, GEFAHRST REINHALT L, V73, P471; Kramer A., 2008, WALLHAUBETAERS PRAXI; Lee JH, 2006, ENVIRON RES, V101, P11, DOI 10.1016/j.envres.2005.08.009; Li CS, 1999, AEROSOL SCI TECH, V31, P226, DOI 10.1080/027868299304273; Li CS, 1999, AEROSOL SCI TECH, V30, P280, DOI 10.1080/027868299304633; Lin WH, 1998, AEROSOL SCI TECH, V28, P511, DOI 10.1080/02786829808965542; Marthi B., 1994, ATMOSPHERIC MICROBIA, P192, DOI [10.1007/978-1-4684-6438-2_7, DOI 10.1007/978-1-4684-6438-2_7]; Meier R, 2000, SWISS CHEM, V12; Montacutelli R, 2000, AEROBIOLOGIA, V16, P441, DOI 10.1023/A:1026525432412; Napoli C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-594; Neumeister B., 2009, MIKROBIOLOGISCHE DIA; Ng TW, 2017, AMB EXPRESS, V7, DOI 10.1186/s13568-017-0376-3; OSBORNE AD, 1985, CAN J COMP MED, V49, P434; Pasquarella C, 2012, J HOSP INFECT, V81, P50, DOI 10.1016/j.jhin.2012.01.007; Pasquarella C, 2000, J HOSP INFECT, V46, P241, DOI 10.1053/jhin.2000.0820; Petti S, 2003, Ann Ig, V15, P725; Sandle T, 2015, EUR J PARENTER PHARM, V20, P94; Simon X, 2011, J AEROSOL SCI, V42, P517, DOI 10.1016/j.jaerosci.2011.05.002; STEWART SL, 1995, APPL ENVIRON MICROB, V61, P1232, DOI 10.1128/AEM.61.4.1232-1239.1995; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181, DOI 10.1128/AEM.58.1.181-186.1992; Trunov M, 2001, AEROSOL SCI TECH, V35, P617, DOI 10.1080/02786820152051472; VERHOEFF AP, 1990, ALLERGY, V45, P275, DOI 10.1111/j.1398-9995.1990.tb00496.x; Whyte W, 1996, PDA J Pharm Sci Technol, V50, P201; WUST G, 2003, AEROBIOLOGIA, V19, P125; Yao MS, 2006, AEROSOL SCI TECH, V40, P595, DOI 10.1080/02786820600729146	40	8	8	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2017	12	12							e0187039	10.1371/journal.pone.0187039	http://dx.doi.org/10.1371/journal.pone.0187039			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7PP	29261663	Green Submitted, Green Published, gold			2023-01-03	WOS:000418554900001
J	Jonsdottir, J; Thorsen, R; Aprile, I; Galeri, S; Spannocchi, G; Beghi, E; Bianchi, E; Montesano, A; Ferrarin, M				Jonsdottir, Johanna; Thorsen, Rune; Aprile, Irene; Galeri, Silvia; Spannocchi, Giovanna; Beghi, Ettore; Bianchi, Elisa; Montesano, Angelo; Ferrarin, Maurizio			Arm rehabilitation in post stroke subjects: A randomized controlled trial on the efficacy of myoelectrically driven FES applied in a task-oriented approach	PLOS ONE			English	Article							FUNCTIONAL ELECTRICAL-STIMULATION; INDUCED MOVEMENT THERAPY; UPPER EXTREMITY FUNCTION; ROBOT-ASSISTED THERAPY; UPPER-LIMB RECOVERY; MOTOR RECOVERY; NEUROMUSCULAR STIMULATION; INTERRATER RELIABILITY; DYSFUNCTION; POSTSTROKE	Purpose Motor recovery of persons after stroke may be enhanced by a novel approach where residual muscle activity is facilitated by patient-controlled electrical muscle activation. Myoelectric activity from hemiparetic muscles is then used for continuous control of functional electrical stimulation (MeCFES) of same or synergic muscles to promote restoration of movements during task-oriented therapy (TOT). Use of MeCFES during TOT may help to obtain a larger functional and neurological recovery than otherwise possible. Study design Multicenter randomized controlled trial. Methods Eighty two acute and chronic stroke victims were recruited through the collaborating facilities and after signing an informed consent were randomized to receive either the experimental (MeCFES assisted TOT (M-TOT) or conventional rehabilitation care including TOT (CTOT). Both groups received 45 minutes of rehabilitation over 25 sessions. Outcomes were Action Research Arm Test (ARAT), Upper Extremity Fugl-Meyer Assessment (FMA-UE) scores and Disability of the Arm Shoulder and Hand questionnaire. Results Sixty eight subjects completed the protocol (Mean age 66.2, range 36.5 +/- 88.7, onset months 12.7, range 0.8 +/- 19.1) of which 45 were seen at follow up 5 weeks later. There were significant improvements in both groups on ARAT (median improvement: MeCFES TOT group 3.0; C-TOT group 2.0) and FMA-UE (median improvement: M-TOT 4.5; C-TOT 3.5). Considering subacute subjects (time since stroke < 6 months), there was a trend for a larger proportion of improved patients in the M-TOT group following rehabilitation (57.9%) than in the C-TOT group (33.2%) (difference in proportion improved 24.7%; 95% CI -4.0; 48.6), though the study did not meet the planned sample size. Conclusion This is the first large multicentre RCT to compare MeCFES assisted TOT with conventional care TOT for the upper extremity. No adverse events or negative outcomes were encountered, thus we conclude that MeCFES can be a safe adjunct to rehabilitation that could promote recovery of upper limb function in persons after stroke, particularly when applied in the subacute phase.	[Jonsdottir, Johanna; Thorsen, Rune; Aprile, Irene; Galeri, Silvia; Spannocchi, Giovanna; Montesano, Angelo; Ferrarin, Maurizio] IRCCS Don Gnocchi Fdn Onlus, Milan, Italy; [Beghi, Ettore; Bianchi, Elisa] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Thorsen, R (corresponding author), IRCCS Don Gnocchi Fdn Onlus, Milan, Italy.	rthorsen@dongnocchi.it	Beghi, Ettore/AAA-7426-2020; Montesano, Angelo/Y-9596-2019; aprile, irene/AAC-4986-2022; Ferrarin, Maurizio/I-3230-2012; JONSDOTTIR, JOHANNA/X-9348-2019; Bianchi, Elisa/ABF-8173-2020	Beghi, Ettore/0000-0003-2542-0469; Ferrarin, Maurizio/0000-0002-7797-2399; JONSDOTTIR, JOHANNA/0000-0002-8287-4881; Bianchi, Elisa/0000-0002-0279-0128; Aprile, Irene/0000-0001-8123-9977; Thorsen, Rune/0000-0003-1990-8839	Italian region Lombardia 'Regione Lombardia, Ricerca Indipendente'; Italian Ministry of Health 'Ricerca Corrente'	Italian region Lombardia 'Regione Lombardia, Ricerca Indipendente'; Italian Ministry of Health 'Ricerca Corrente'(Ministry of Health, Italy)	This project was funded by a research grant from the Italian region Lombardia 'Regione Lombardia, Ricerca Indipendente' and the Italian Ministry of Health 'Ricerca Corrente'.	Alon G, 2007, NEUROREHAB NEURAL RE, V21, P207, DOI 10.1177/1545968306297871; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P58; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Cauraugh J, 2000, STROKE, V31, P1360, DOI 10.1161/01.STR.31.6.1360; Chae J, 1998, STROKE, V29, P975, DOI 10.1161/01.STR.29.5.975; de Kroon JR, 2005, J REHABIL MED, V37, P65, DOI 10.1080/16501970410024190; Dorsch S, 2014, CLIN REHABIL, V28, P482, DOI 10.1177/0269215513510011; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; Fugl-Meyer AR, 1975, SCAND J REHAB MED, V7; Houwink A, 2013, ARCH PHYS MED REHAB, V94, P839, DOI 10.1016/j.apmr.2012.11.031; Howlett OA, 2015, ARCH PHYS MED REHAB, V96, P934, DOI 10.1016/j.apmr.2015.01.013; Jonsdottir J, 2010, NEUROREHAB NEURAL RE, V24, P478, DOI 10.1177/1545968309355986; Kendall FP, 1983, MUSCLES TESTING FUNC; Kennedy CA, 2011, DASH QUICK DASH OUTC, V3rd; Knutson JS, 2016, STROKE, V47, P2596, DOI 10.1161/STROKEAHA.116.013791; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Kwakkel G, 2016, NEUROREHAB NEURAL RE, V30, P804, DOI 10.1177/1545968315624784; Kwakkel G, 2015, ARCH PHYS MED REHAB, V96, P991, DOI 10.1016/j.apmr.2015.02.004; Langhorne P, 2011, LANCET, V377, P1693, DOI 10.1016/S0140-6736(11)60325-5; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Nijland RHM, 2010, STROKE, V41, P745, DOI 10.1161/STROKEAHA.109.572065; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Page SJ, 2012, ARCH PHYS MED REHAB, V93, P200, DOI 10.1016/j.apmr.2011.09.016; Patel AT, 2000, ARCH PHYS MED REHAB, V81, P1357, DOI 10.1053/apmr.2000.9397; Pomeroy VM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003241.pub2; Quandt Fanny, 2014, Exp Transl Stroke Med, V6, P9, DOI 10.1186/2040-7378-6-9; Shin HK, 2008, NEUROSCI LETT, V442, P174, DOI 10.1016/j.neulet.2008.07.026; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Subramanian SK, 2010, NEUROREHAB NEURAL RE, V24, P113, DOI 10.1177/1545968309349941; Taub E, 2012, BEHAV ANALYST, V35, P155, DOI 10.1007/BF03392276; Thorsen R, 2001, IEEE T NEUR SYS REH, V9, P161, DOI 10.1109/7333.928576; Thorsen R, 2013, SCI WORLD J, DOI 10.1155/2013/836959; Thorsen R, 2013, J REHABIL RES DEV, V50, P785, DOI 10.1682/JRRD.2012.07.0123; Thorsen R, 2009, MED ENG PHYS, V31, P1032, DOI 10.1016/j.medengphy.2009.06.006; Thorsen RA, 2006, J REHABIL RES DEV, V43, P247, DOI 10.1682/JRRD.2005.04.0068; Thrasher TA, 2008, NEUROREHAB NEURAL RE, V22, P706, DOI 10.1177/1545968308317436; van der Lee JH, 2002, CLIN REHABIL, V16, P646, DOI 10.1191/0269215502cr534oa; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Wilson RD, 2016, NEUROREHAB NEURAL RE, V30, P978, DOI 10.1177/1545968316650278; Winstein CJ, 2016, JAMA-J AM MED ASSOC, V315, P571, DOI 10.1001/jama.2016.0276; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; World Health Organisation, 2001, ICF INT CLASFUNCT	46	21	24	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2017	12	12							e0188642	10.1371/journal.pone.0188642	http://dx.doi.org/10.1371/journal.pone.0188642			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FO7EC	29200424	Green Submitted, Green Published, gold			2023-01-03	WOS:000417033200010
J	Yoon, J; Kim, Y; Kym, D; Hur, J; Yim, H; Cho, YS; Chun, W				Yoon, Jaechul; Kim, Youngmin; Kym, Dohern; Hur, Jun; Yim, Haejun; Cho, Yong-Suk; Chun, Wook			Subgroup analysis of continuous renal replacement therapy in severely burned patients	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; CONSENSUS CONFERENCE; PROGNOSTIC-FACTORS; FAILURE; SEPSIS	Continuous renal replacement therapy (CRRT) is administered to critically ill patients with renal injuries as renal replacement or renal support. We aimed to identify predictors of mortality among burn patients receiving CRRT, and to investigate clinical differences according to acute kidney injury (AKI) status. This retrospective observational study evaluated 216 Korean burn patients who received CRRT at a burn intensive care unit. Patients were categorized by AKI status. Data were collected regarding arterial pH, laboratory results, ratio of arterial oxygen partial pressure to fractional inspired oxygen (PF ratio), and urine production. Among surviving patients, CRRT duration and the sequential organ failure assessment score were 6.5 days and 4.7 in the non-AKI group and 23.4 days and 7.4 in the AKI group, respectively (p = 0.003 and p = 0.008). On logistic regression analyses, mortality was significantly associated with a pH of < 7.2 (p = 0.004), potassium levels of > 5.0 mEg/L (p = 0.045), creatinine levels of > 2.0 mg/dL (p = 0.011), lactate levels of > 2 mmol/L (p< 0.001),a PF ratio of < 200 (p = 0.042), and a platelet count of < 100,000/mu L (p< 0.001). In the AKI group, poor outcomes were associated with a pH of < 7.2, potassium levels of < 5.0 mEg/L, lactate levels of > 2 mmol/L, and a platelet count of < 100,000/mu L, while good outcomes were associated with creatinine levels of > 2 mg/dL. In the non-AKI group, poor outcomes were associated with lactate levels of > 1.5 mmol/L, a PF ratio of < 200, and a platelet count of < 100,000/mu L, while good outcomes were associated with creatinine levels of > 1.2 mg/dL. Duration of the CRRT application and the requirement for either renal replacement or renal support at the initiation of CRRT application are important considerations depending on its application.	[Yoon, Jaechul; Kim, Youngmin; Kym, Dohern; Hur, Jun; Yim, Haejun; Cho, Yong-Suk; Chun, Wook] Hallym Univ, Hangang Sacred Heart Hosp, Dept Surg & Crit Care, Coll Med,Burn Ctr,Med Ctr, Seoul, South Korea	Hallym University	Kym, D; Hur, J (corresponding author), Hallym Univ, Hangang Sacred Heart Hosp, Dept Surg & Crit Care, Coll Med,Burn Ctr,Med Ctr, Seoul, South Korea.	dohern@hallym.or.kr; hammerj@hallym.or.kr	Kym, Dohern/B-8966-2014	Kym, Dohern/0000-0001-9178-0599; Yim, Haejun/0000-0002-1566-5000; Yoon, Jaechul/0000-0001-5206-3378	Korean Health Technology R&D Project, Ministry of Health & Welfare, and Republic of Korea [HI15C1486]	Korean Health Technology R&D Project, Ministry of Health & Welfare, and Republic of Korea	This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, and Republic of Korea (HI15C1486).	Aldawood A, 2010, SAUDI J KIDNEY DIS T, V21, P1106; Allegretti AS, 2013, CRIT CARE, V17, DOI 10.1186/cc12780; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Brusselaers N, 2010, INTENS CARE MED, V36, P915, DOI 10.1007/s00134-010-1861-1; Cerda J, 2007, NEPHROL DIAL TRANSPL, V22, P2781, DOI 10.1093/ndt/gfm395; Chung KK, 2009, CRIT CARE, V13, DOI 10.1186/cc7801; Church D, 2006, CLIN MICROBIOL REV, V19, P403, DOI 10.1128/CMR.19.2.403-434.2006; Dokter J, 2015, BURNS, V41, P235, DOI 10.1016/j.burns.2014.10.009; Greenhalgh DG, 2007, J BURN CARE RES, V28, P776, DOI 10.1097/BCR.0b013e3181599bc9; Kym D, 2015, ANN SURG TREAT RES, V88, P281, DOI 10.4174/astr.2015.88.5.281; Lee Jeong Ho, 2017, Chonnam Med J, V53, P64, DOI 10.4068/cmj.2017.53.1.64; Lee KC, 2014, BURNS TRAUMA, V2, DOI 10.4103/2321-3868.143620; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Park HS, 2012, HEMODIAL INT, V16, P559, DOI 10.1111/j.1542-4758.2011.00650.x; Ronco C, 2002, CRIT CARE MED, V30, P1250, DOI 10.1097/00003246-200206000-00015; Ronco C, 2001, NEPHROL DIAL TRANSPL, V16, P67, DOI 10.1093/ndt/16.suppl_5.67; Soubrier S, 2006, J CRIT CARE, V21, P66, DOI 10.1016/j.jcrc.2005.08.004; TOBIASEN J, 1982, ANN EMERG MED, V11, P260, DOI 10.1016/S0196-0644(82)80096-6; Tumlin JA, 2013, SEMIN DIALYSIS, V26, P616, DOI 10.1111/sdi.12032; Venkata C, 2013, J INTENSIVE CARE, V1, DOI 10.1186/2052-0492-1-9; Wang TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094124; Wu C, 2016, ASIA PAC J CLIN NUTR, V25, P300, DOI 10.6133/apjcn.2016.25.2.29; Yang W, 2016, GLOBAL PEDIAT HLTH, V3	23	9	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0189057	10.1371/journal.pone.0189057	http://dx.doi.org/10.1371/journal.pone.0189057			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190735	gold, Green Published, Green Submitted			2023-01-03	WOS:000416841900197
J	Shimoni, Z; Glick, J; Hermush, V; Froom, P				Shimoni, Zvi; Glick, Joseph; Hermush, Vered; Froom, Paul			Sensitivity of the dipstick in detecting bacteremic urinary tract infections in elderly hospitalized patients	PLOS ONE			English	Article							NURSING-HOME RESIDENTS; DIAGNOSTIC-ACCURACY; OLDER WOMEN; URINALYSIS; COHORT	Background The sensitivity of the dipstick in elderly patients with a suspected urinary tract infection (UTI) is unclear because of the inclusion of patients with urine contamination or asymptomatic bacteriuria in previous studies. Methods We selected consecutive patients aged 65 years or older hospitalized in internal medicine departments with bacteremic UTI (same organism in blood and urine cultures) minimizing misclassifications. The false positive rate was determined in consecutive patients with negative culture results. A positive dipstick was a test result with a trace leukocyte esterase and/or nitrite positivity. Bacteriuria was the growth of at least 10(5) colony-forming units per milliliter of urine. Results Of 20,555 consecutive patients, 228 had a bacteremic UTI, and 4069 a negative culture result. The sensitivity of the dipstick was 96.9% (95% CI-93.7-98.6) with a false positive rate of 42.4% (95% CI, 41.0-43.8) in those with a negative culture result. Conclusions In elderly hospitalized patients with a bacteremic UTI, the dipstick urinalysis is highly sensitive, much higher than reported previously in studies of UTIs in the elderly. It is unclear whether the observed high sensitivity of the dipstick was due to the exclusion of patients with asymptomatic bacteriuria or to spectrum bias. Studies of the clinical utility/disutility of using a negative dipstick to rule out a urinary tract infection are warranted.	[Shimoni, Zvi] Laniado Hosp, Sanz Med Ctr, Dept Internal Med B, Netanya, Israel; [Shimoni, Zvi] Ruth & Bruce Rappaport Sch Med, Haifa, Israel; [Glick, Joseph] Laniado Hosp, Sanz Med Ctr, Cent Lab, Netanya, Israel; [Hermush, Vered] Laniado Hosp, Sanz Med Ctr, Dept Geriatr, Netanya, Israel; [Froom, Paul] Laniado Hosp, Sanz Med Ctr, Dept Clin Util, Netanya, Israel; [Froom, Paul] Tel Aviv Univ, Sch Publ Hlth, Ramat Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University	Froom, P (corresponding author), Laniado Hosp, Sanz Med Ctr, Dept Clin Util, Netanya, Israel.; Froom, P (corresponding author), Tel Aviv Univ, Sch Publ Hlth, Ramat Aviv, Israel.	froomp@gmail.com		Froom, Paul/0000-0001-5126-8590				Chen MC, 2016, ACS NANO, V10, P93, DOI 10.1021/acsnano.5b05043; Clinical and Laboratory Standards Institute, 2011, PHYS NONPH PROV PERF; Detweiler K, 2015, UROL CLIN N AM, V42, P561, DOI 10.1016/j.ucl.2015.07.002; Deville Walter L J M, 2004, BMC Urol, V4, P4, DOI 10.1186/1471-2490-4-4; Froom P, 2000, CLIN CHEM, V46, P1384; Froom P, 2012, AM J CLIN PATHOL, V137, P486, DOI 10.1309/AJCPLJFSS62YBAWN; Jones CW, 2014, J EMERG MED, V46, P71, DOI 10.1016/j.jemermed.2013.08.042; Juthani-Mehta M, 2007, J AM GERIATR SOC, V55, P1072, DOI 10.1111/j.1532-5415.2007.01217.x; Juthani-Mehta M, 2009, J AM GERIATR SOC, V57, P963, DOI 10.1111/j.1532-5415.2009.02227.x; Kayalp D, 2013, CLIN BIOCHEM, V46, P1285, DOI 10.1016/j.clinbiochem.2013.06.015; Kaye D, 1989, Trans Am Clin Climatol Assoc, V100, P155; Mayo S, 2008, J CLIN LAB ANAL, V22, P262, DOI 10.1002/jcla.20257; Mody L, 2014, JAMA-J AM MED ASSOC, V311, P844, DOI 10.1001/jama.2014.303; MONANE M, 1995, J AM GERIATR SOC, V43, P618, DOI 10.1111/j.1532-5415.1995.tb07194.x; Ouslander JG, 1996, J AM GERIATR SOC, V44, P420, DOI 10.1111/j.1532-5415.1996.tb06414.x; Schroeder AR, 2015, PEDIATRICS, V135, P965, DOI 10.1542/peds.2015-0012; Shimoni Z, 2008, EUR J INTERN MED, V19, P494, DOI 10.1016/j.ejim.2007.04.028; Shimoni Z, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013696; Woodford HJ, 2009, J AM GERIATR SOC, V57, P107, DOI 10.1111/j.1532-5415.2008.02073.x	19	19	19	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0187381	10.1371/journal.pone.0187381	http://dx.doi.org/10.1371/journal.pone.0187381			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL2ZD	29088289	Green Published, Green Submitted, gold			2023-01-03	WOS:000414088900079
J	Mimoto, MS; Oyler, JL; Davis, AM				Mimoto, Mizuho S.; Oyler, Julie L.; Davis, Andrew M.			Evaluation and Treatment of Hirsutism in Premenopausal Women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Mimoto, Mizuho S.; Oyler, Julie L.; Davis, Andrew M.] Univ Chicago, 5841 S Maryland Ave,MC1027, Chicago, IL 60637 USA	University of Chicago	Mimoto, MS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC1027, Chicago, IL 60637 USA.	mizulio.mimoto@uchospitals.edu	Oyler, Julie/AAP-6792-2020		NIDDK NIH HHS [P30 DK020595, T32 DK007011] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007011, P30DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Martin KA, 2008, J CLIN ENDOCR METAB, V93, P1105, DOI 10.1210/jc.2007-2437; Martin KA, 2018, J CLIN ENDOCR METAB, V103, P1233, DOI 10.1210/jc.2018-00241; Pasch L, 2016, JAMA DERMATOL, V152, P783, DOI 10.1001/jamadermatol.2016.0358; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Sam S, 2015, JAMA-J AM MED ASSOC, V314, P2557, DOI 10.1001/jama.2015.11612; Stegeman BH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5298	6	12	12	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2018	319	15					1613	1614		10.1001/jama.2018.2611	http://dx.doi.org/10.1001/jama.2018.2611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD0UT	29522641	Green Accepted, Bronze			2023-01-03	WOS:000430217100021
J	Liakoni, E; Gartwyl, F; Ricklin, M; Exadaktylos, AK; Krahenbuhl, S				Liakoni, Evangelia; Gartwyl, Fabienne; Ricklin, Meret; Exadaktylos, Aristomenis K.; Krahenbuhl, Stephan			Psychoactive substances and violent offences: A retrospective analysis of presentations to an urban emergency department in Switzerland	PLOS ONE			English	Article							ACUTE RECREATIONAL DRUG; CANNABIS USE; COCAINE; ALCOHOL; ABUSE; MARIJUANA; HOMICIDE; TOXICITY; INJURIES	Background Psychoactive substances are often regarded as causal factors contributing to violent injuries, sexual abuse and homicides. While these effects have been demonstrated for some substances (e.g. cocaine), current available data for others are more controversial (e.g. cannabis) or very limited (e.g. ecstasy). Aims of the study To collect data on the type and frequency of psychoactive substance use in cases of emergency department (ED) presentations related to interpersonal violence. Methods Retrospective study at the University Hospital of Bern, Switzerland, between May 2012 and June 2016. The study covered cases of violent crime associated with psychoactive substances. Cases of isolated ethanol intoxication, suicide attempts, and substance use for medical purposes were excluded. Results The study included 103 cases among the 164,846 ED attendances. In the majority of the cases, the type of violence was bodily force (52%) related to urban violence (83%). The mean patient age was 29 years and 79% were male. 63% of the patients reported use of more than one drug; alcohol co-use was reported in 60% of the cases. Besides alcohol, the substances most often reported were cannabis (50%) and cocaine (21%). Alcohol and cannabis was also the most commonly reported substance combination (36% of the total cases). Urine drug screening was performed in 34% of the cases and cannabis and cocaine were the most commonly detected substances (46% and 19%, respectively). There were no cases of novel substances. 23% of the patients were admitted to a hospital ward, 10% to a psychiatric clinic. Conclusion Cannabis and cocaine were, besides alcohol, the substances most often reported in ED presentations related to offences of violence. Because of the high prevalence of alcohol co-use, no final conclusions can be drawn on the contribution of single substances.	[Liakoni, Evangelia; Gartwyl, Fabienne; Krahenbuhl, Stephan] Univ Bern, Bern Univ Hosp, Inselspital, Clin Pharmacol & Toxicol,Dept Gen Internal Med, Bern, Switzerland; [Liakoni, Evangelia; Gartwyl, Fabienne] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Ricklin, Meret; Exadaktylos, Aristomenis K.] Univ Bern, Bern Univ Hosp, Emergency Dept, Inselspital, Bern, Switzerland; [Krahenbuhl, Stephan] Basel Univ Hosp, Div Clin Pharmacol & Toxicol, Basel, Switzerland; [Krahenbuhl, Stephan] Univ Basel, Basel, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; University of Basel; University of Basel	Liakoni, E (corresponding author), Univ Bern, Bern Univ Hosp, Inselspital, Clin Pharmacol & Toxicol,Dept Gen Internal Med, Bern, Switzerland.; Liakoni, E (corresponding author), Univ Bern, Inst Pharmacol, Bern, Switzerland.	Evangelia.liakoni@insel.ch	Krähenbühl, Stephan/Z-4744-2019; Ricklin, Meret Elisabeth/AAY-7948-2021	Ricklin, Meret Elisabeth/0000-0003-3047-9350				Aderjan R, 2011, RICHTLINIEN BESTIMMU; [Anonymous], 2013, TOX DRUG SCREEN PROD; [Anonymous], 2016, TRENDS DEV; Blondell RD, 2005, J TRAUMA, V58, P561, DOI 10.1097/01.TA.0000152638.54978.53; Boles SM, 2003, AGGRESS VIOLENT BEH, V8, P155, DOI 10.1016/S1359-1789(01)00057-X; Buchan BJ, 2002, ADDICTION, V97, P98, DOI 10.1046/j.1360-0443.97.s01.1.x; Capriola M, 2013, CLIN PHARMACOL-ADV A, V5, P109, DOI 10.2147/CPAA.S42832; Chermack ST, 2002, DRUG ALCOHOL DEPEN, V66, P29, DOI 10.1016/S0376-8716(01)00180-6; Cherpitel CJ, 2013, AM J ADDICTION, V22, P87, DOI 10.1111/j.1521-0391.2013.00316.x; Dines AM, 2015, J MED TOXICOL, V11, P415, DOI 10.1007/s13181-014-0460-x; Dines AM, 2015, CLIN TOXICOL, V53, P893, DOI 10.3109/15563650.2015.1088157; EMCDDA (European Drug Report), 2014, TRENDS DEV; Falck R S, 2001, Violence Vict, V16, P79; Franklin FA, 2010, WEST J EMERG MED, V11, P283; Freeman D, 2015, SCHIZOPHRENIA BULL, V41, P391, DOI 10.1093/schbul/sbu098; Friedman AS, 2001, J ADDICT DIS, V20, P49, DOI 10.1300/J069v20n01_06; Gmel G, 2014, SUCHTMONITORING SCHW; Gmel G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-40; Grisso JA, 1999, NEW ENGL J MED, V341, P1899, DOI 10.1056/NEJM199912163412506; Gunderson EW, 2014, SUBST ABUS, V35, P184, DOI 10.1080/08897077.2013.846288; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V265, P760, DOI 10.1001/jama.265.6.760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; Hill SL, 2011, CLIN TOXICOL PHILA, V49; Hoaken PNS, 2003, ADDICT BEHAV, V28, P1533, DOI 10.1016/j.addbeh.2003.08.033; Kilpatrick DG, 1997, J CONSULT CLIN PSYCH, V65, P834, DOI 10.1037/0022-006X.65.5.834; Korcha RA, 2014, DRUG ALCOHOL REV, V33, P43, DOI 10.1111/dar.12087; Liakoni E, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0369-x; Liakoni E, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0068-7; Liakoni E, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14166; LICATA A, 1993, PHARMACOL BIOCHEM BE, V45, P549, DOI 10.1016/0091-3057(93)90504-M; Lupi M, 2017, EAT WEIGHT DISORD-ST, V22, P619, DOI 10.1007/s40519-017-0429-2; Lynd LD, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-5; Macdonald S, 2008, ADDICT BEHAV, V33, P201, DOI 10.1016/j.addbeh.2007.07.002; Martinotti G, 2017, CNS NEUROL DISORD-DR, V16, P567, DOI 10.2174/1871527316666170413101839; Martinotti G, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2586; Moore TM, 2005, AGGRESS VIOLENT BEH, V10, P171, DOI 10.1016/j.avb.2003.10.002; Shafi A, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2606; Tardiff K, 1997, AM J PSYCHIAT, V154, P88; Vaughn MG, 2010, AM J DRUG ALCOHOL AB, V36, P181, DOI 10.3109/00952990.2010.491877; Wood DM, 2014, CLIN TOXICOL, V52, P239, DOI 10.3109/15563650.2014.898771	40	4	4	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2018	13	3							e0195234	10.1371/journal.pone.0195234	http://dx.doi.org/10.1371/journal.pone.0195234			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA8ZI	29596473	Green Published, Green Submitted, gold			2023-01-03	WOS:000428630000096
J	Turton, JL; Raab, R; Rooney, KB				Turton, Jessica L.; Raab, Ron; Rooney, Kieron B.			Low-carbohydrate diets for type 1 diabetes mellitus: A systematic review	PLOS ONE			English	Review							GLYCEMIC CONTROL; METABOLIC-CONTROL; INSULIN THERAPY; RISK; HYPERINSULINEMIA; COMPLICATIONS; MORTALITY; DISEASE; WEIGHT; ADULTS	Type 1 diabetes is an autoimmune condition characterised by pancreatic beta cell destruction and absolute insulin deficiency. The strongest predictor of diabetes complications is glycaemic control and achieving HbA1c <= 7.0% is the primary management target. However, standard treatment appears to be lacking and adjunctive strategies require consideration. A systematic review was conducted to examine the effect of low-carbohydrate diets on type 1 diabetes management. Four databases were searched from inception until 28 March 2017: MEDLINE; CINAHL; Cochrane Library; and EMBASE. All primary studies containing a methods section (excluding cross-sectional) were included. Reports had to quantitatively measure the effect(s) of a dietary intervention or observed intake over at least two weeks where carbohydrate is below 45% total energy in adults and/or children with type 1 diabetes. The primary outcome was HbA1c and secondary outcomes were severe hypoglycaemia, total daily insulin, BMI, quality of life and mean daily glucose. Seventy-nine full-text articles were assessed for eligibility and nine were included (two randomised controlled trials, four pre-post interventions, two case-series, one case-report). Eight studies reported a mean change in HbA1c with a low-carbohydrate diet. Of these, four reported a non-significant change (P >= 0.05) and three reported statistically significant reductions (P < 0.05). Two studies reported severe hypoglycaemia, five reported total insulin, three reported BMI, and one reported blood glucose. Due to the significant heterogeneity of included studies, an overall effect could not be determined. This review presents all available evidence on low-carbohydrate diets for type 1 diabetes and suggests an urgent need for more primary studies.	[Turton, Jessica L.] Univ Sydney, Fac Sci, Sch Life & Environm Sci, Discipline Nutr & Dietet, Sydney, NSW, Australia; [Raab, Ron] Insulin Life Australia, Melbourne, Vic, Australia; [Rooney, Kieron B.] Univ Sydney, Charles Perkins Ctr, Fac Hlth Sci, Discipline Exercise & Sport Sci, Sydney, NSW, Australia	University of Sydney; University of Sydney	Rooney, KB (corresponding author), Univ Sydney, Charles Perkins Ctr, Fac Hlth Sci, Discipline Exercise & Sport Sci, Sydney, NSW, Australia.	kieron.rooney@sydney.edu.au	Rooney, Kieron/I-6252-2018	Rooney, Kieron/0000-0001-6563-7617; Turton, Jessica/0000-0003-2263-9350				ANDERSON JW, 1991, AM J CLIN NUTR, V54, P936, DOI 10.1093/ajcn/54.5.936; [Anonymous], 2006, NUTR REF VAL AUSTR N; BERNSTEIN RK, 1980, DIABETES CARE, V3, P140, DOI 10.2337/diacare.3.1.140; Bernstein RK, 2011, BERNSTEINS DIABETES; Buyken AE, 2000, DIABETIC MED, V17, P351, DOI 10.1046/j.1464-5491.2000.00283.x; CHANTELAU E, 1982, DIABETES CARE, V5, P612, DOI 10.2337/diacare.5.6.612; Chartres N, 2017, ASS IND SPONSORSHIP; Cheung NW, 2009, AUSTR DIABETES SOC P; Cochrane Collaboration, 2014, DAT COLL FORMS INT R; Cochrane Methods Bias Group, 2016, RISK BIAS NON RAND S; Craig M., 2011, NATL EVIDENCE BASED; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; Feinman RD, 2015, NUTRITION, V31, P1, DOI 10.1016/j.nut.2014.06.011; Garcia-Romero G, 2006, CURR DIABETES REV, V2, P39, DOI 10.2174/157339906775473635; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; IRELAND P, 1992, DIABETES CARE, V15, P1499, DOI 10.2337/diacare.15.11.1499; Juutilainen A, 2008, DIABETES CARE, V31, P714, DOI 10.2337/dc07-2124; Knight BA, 2016, DIABETES RES CLIN PR, V116, P36, DOI 10.1016/j.diabres.2016.03.016; Krebs JD, 2016, ASIA PAC J CLIN NUTR, V25, P78, DOI 10.6133/apjcn.2016.25.1.11; Lawton J, 2011, DIABETES RES CLIN PR, V91, P87, DOI 10.1016/j.diabres.2010.11.007; Lehto S, 1999, ARTERIOSCL THROM VAS, V19, P1014, DOI 10.1161/01.ATV.19.4.1014; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; McKnight JA, 2015, DIABETIC MED, V32, P1036, DOI 10.1111/dme.12676; Merlin T, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-34; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nathan DM, 2014, DIABETES CARE, V37, P9, DOI 10.2337/dc13-2112; National Institutes of Health, 2014, QUAL ASS TOOL PREP S; Nielsen JV, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-23; O' Neill Daniel F, 2003, Metab Syndr Relat Disord, V1, P291, DOI 10.1089/1540419031361345; Osler W, 1920, PRINCIPLES PRACTICE; Purnell JQ, 1998, JAMA-J AM MED ASSOC, V280, P140, DOI 10.1001/jama.280.2.140; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; The Joanna Briggs Institute, 2016, JOANN BRIGGS I REV M; Thorn LM, 2009, DIABETES CARE, V32, P950, DOI 10.2337/dc08-2022; Vernon MC, 2003, METAB SYNDR RELAT D, V1, P233, DOI 10.1089/154041903322716714; Wang MY, 2013, J DIABETES COMPLICAT, V27, P70, DOI 10.1016/j.jdiacomp.2012.08.008; Yang YX, 2004, GASTROENTEROLOGY, V127, P1044, DOI 10.1053/j.gastro.2004.07.011	37	51	52	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2018	13	3							e0194987	10.1371/journal.pone.0194987	http://dx.doi.org/10.1371/journal.pone.0194987			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8ZI	29596460	Green Published, gold, Green Submitted			2023-01-03	WOS:000428630000061
J	Ribeiro, AF; Pellini, ACG; Kitagawa, BY; Marques, D; Madalosso, G; Fred, J; Albernaz, RKM; Carvalhanas, TRMP; Zanetta, DMT				Ribeiro, Ana Freitas; Guedes Pellini, Alessandra Cristina; Kitagawa, Beatriz Yuko; Marques, Daniel; Madalosso, Geraldine; Fred, Joao; Mangabeira Albernaz, Ricardo Kerti; Marques Pinto Carvalhanas, Telma Regina; Trevisan Zanetta, Dirce Maria			Severe influenza A(H1N1)pdm09 in pregnant women and neonatal outcomes, State of Sao Paulo, Brazil, 2009	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; A H1N1; UNITED-STATES; HOSPITALIZED-PATIENTS; POSTPARTUM WOMEN; INFECTION	To investigate the factors associated with death and describe the gestational outcomes in pregnant women with influenza A(H1N1)pdm09, we conducted a case-control study (deaths and recovered) in hospitalized pregnant women with laboratory-confirmed influenza A (H1N1)pdm09 with severe acute respiratory illness (SARI) in the state of Sao Paulo from June 9 to December 1, 2009. All cases were evaluated, and four controls that were matched by the epidemiological week of hospitalization of the case were randomly selected for each case. Cases and controls were selected from the National Disease Notification System-SINAN Influenza-web. The hospital records from 126 hospitals were evaluated, and home interviews were conducted using standardized forms. A total of 48 cases and 185 controls were investigated. Having had a previous health visit to a healthcare provider for an influenza episode before hospital admission was a risk factor for death (adjusted OR (ORadi)of 7.93, 95% CI 2.19-28.69). Although not significant in the multiple analysis (OR (adj) of 2.13, 95% CI 0.91-5.00), the 3rd trimester deserves attention, with an OR = 2.22, 95% CI 1.13-4.37 in the univariate analysis. Antiviral treatment was a protective factor when administered within 48 hours of symptom onset (ORadj= 0.16, 95% CI 0.05-0.50) and from 48 to 72 hours (ORadj= 0.09, 95% CI 0.01-0.87). There was a higher proportion of fetal deaths and preterm births among cases (p = 0.001) and live births with low weight (p = 0.019), compared to control subjects who gave birth during hospitalization. After discharge, control subjects had a favorable neonatal outcome. Early antiviral treatment during the presence of a flu-like illness is an important factor in reducing mortality from influenza in pregnant women and unfavorable neonatal outcomes. It is important to monitor pregnant women, particularly in the 3rd trimester of gestation, with influenza illness for diagnosis and early treatment.	[Ribeiro, Ana Freitas; Guedes Pellini, Alessandra Cristina; Kitagawa, Beatriz Yuko; Marques, Daniel; Madalosso, Geraldine; Fred, Joao; Mangabeira Albernaz, Ricardo Kerti; Marques Pinto Carvalhanas, Telma Regina] Sao Paulo State Secretary Hlth, Epidemiol Surveillance Ctr, Sao Paulo, SP, Brazil; [Trevisan Zanetta, Dirce Maria] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, SP, Brazil; [Ribeiro, Ana Freitas] Emilio Ribas Inst Infectol, Sao Paulo, SP, Brazil; [Ribeiro, Ana Freitas] Univ Nove Julho, Hlth Adm Grad Dept, Sao Paulo, SP, Brazil; [Kitagawa, Beatriz Yuko] Municipal Hlth Dept Sao Paulo, Sao Paulo, SP, Brazil	Universidade Estadual Paulista; Universidade de Sao Paulo; Universidade Nove de Julho	Ribeiro, AF (corresponding author), Sao Paulo State Secretary Hlth, Epidemiol Surveillance Ctr, Sao Paulo, SP, Brazil.; Ribeiro, AF (corresponding author), Emilio Ribas Inst Infectol, Sao Paulo, SP, Brazil.; Ribeiro, AF (corresponding author), Univ Nove Julho, Hlth Adm Grad Dept, Sao Paulo, SP, Brazil.	anafribeiro@uol.com.br	Alessandra, Pellini C. G./K-5156-2013; Zanetta, Dirce M T/G-4950-2013; Ribeiro, Ana Freitas/P-6862-2015	Alessandra, Pellini C. G./0000-0002-3799-9415; MARQUES, DANIEL/0000-0001-7281-3316; Madalosso, Geraldine/0000-0001-9501-6205; Zanetta, Dirce Maria/0000-0002-7273-5087	Sao Paulo State Secretary of Health	Sao Paulo State Secretary of Health	Sao Paulo State Secretary of Health financed the data collection. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Chowell G, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-97; Creanga AA, 2010, OBSTET GYNECOL, V115, P717, DOI 10.1097/AOG.0b013e3181d57947; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Doyle TJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079040; Dubar G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013112; Ellington SR, 2011, AM J OBSTET GYNECOL, V204, pS21, DOI 10.1016/j.ajog.2011.02.038; Fuhrman C, 2010, EUROSURVEILLANCE, V15, P17; Fukasawa L. O., 2010, Revista do Instituto Adolfo Lutz, V69, P131; Gonzalez-Velez AE, 2011, MED INTENSIVA, V35, P463, DOI 10.1016/j.medin.2011.03.007; GREENBERG M, 1958, AM J OBSTET GYNECOL, V76, P897, DOI 10.1016/0002-9378(58)90027-9; Hansen C, 2012, J INFECT DIS, V206, P1260, DOI 10.1093/infdis/jis488; Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Lee EH, 2010, CLIN INFECT DIS, V50, P1498, DOI 10.1086/652446; Lenzi L, 2012, CAD SAUDE PUBLICA, V28, P395, DOI 10.1590/S0102-311X2012000200018; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Mertz D, 2013, BMJ-BRIT MED J, V347, P2; Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033; Newsome Kimberly, 2011, Morbidity and Mortality Weekly Report, V60, P1193; Pan American Health Organization - World Health Organization, OP GUID INT NAT SARI; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Ribeiro AF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118772; Seppelt I, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1279; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Skarbinski J, 2011, CLIN INFECT DIS, V52, pS50, DOI 10.1093/cid/ciq021; Varner MW, 2011, OBSTET GYNECOL, V118, P593, DOI 10.1097/AOG.0b013e318229e484; WHO-World Health Organization, PAND H1N1 2009 WORLD; Zhang PJ, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-29	33	6	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2018	13	3							e0194392	10.1371/journal.pone.0194392	http://dx.doi.org/10.1371/journal.pone.0194392			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA5DH	29579099	Green Submitted, Green Published, gold			2023-01-03	WOS:000428351800028
J	Shafie, M; Eyasu, M; Muzeyin, K; Worku, Y; Martin-Aragon, S				Shafie, Mensur; Eyasu, Mebrahtu; Muzeyin, Kedija; Worku, Yoseph; Martin-Aragon, Sagrario			Prevalence and determinants of self-medication practice among selected households in Addis Ababa community	PLOS ONE			English	Article							UNIVERSITY; STUDENTS	Background and aim Self-medication (SM) is one part of self-care which is known to contribute to primary health care. If practiced appropriately, it has major benefits for the consumers such as self-reliance and decreased expense. However, inappropriate practice can have potential dangers such as incorrect self-diagnosis, dangerous drug-drug interactions, incorrect manner of administration, incorrect dosage, incorrect choice of therapy, masking of a severe disease, and/or risk of dependence and abuse. The main objective of this study was to assess the prevalence and determinants of the self-medication practice (SMP) in Addis Ababa. Methodology A community based cross-sectional study was conducted among selected households in Addis Ababa from April 2016 to May 2016, with a recall period of two months before its conduction. Trained data collectors were employed to collect the data from the 604 sampled participants using pre-tested and validated questionnaires. Result Among the 604 participants involved in this study, 422 (69.9%) were female and 182 (30.1%) were male and there was a mean age of 41.04 ( 13.45) years. The prevalence of SM in this study was 75.5%. The three most frequently reported ailments were headache 117 (25.7%), abdominal pain 59 (12.9%) and cough 54 (11.8%). The two main reasons for SM were mildness of illness 216 (47.4%) and previous knowledge about the drug 106 (23.2%). The two most frequently consumed medications were paracetamol 92 (20.2%) and traditional remedies 73 (16.0%), while drug retail outlets 319 (83.3%) were the main source of drugs. The two most frequently reported source of drug information were health professionals 174 (45.4%) and experience from previous treatment 82 (21.4%). Moreover, there were statistically significant differences among respondents who reported practicing SM based on income and knowledge about appropriate SMP. Conclusion and recommendation Self-medication was practiced with a range of drugs from the conventional paracetamol and NSAIDs to antimicrobials. Being that the practice of SM is inevitable, health authorities and professionals are highly demanded to educate the public not only on the advantages and disadvantages of SM but on its proper use.	[Shafie, Mensur; Eyasu, Mebrahtu] St Pauls Hosp Millennium Med Coll, Dept Pharmacol, Addis Ababa, Ethiopia; [Muzeyin, Kedija] St Pauls Hosp Millennium Med Coll, Dept Nursing, Addis Ababa, Ethiopia; [Worku, Yoseph] St Pauls Hosp Millennium Med Coll, Dept Publ Hlth, Addis Ababa, Ethiopia; [Martin-Aragon, Sagrario] Univ Complutense Madrid, Sch Pharm, Dept Pharmacol, Madrid, Spain	Complutense University of Madrid	Shafie, M; Eyasu, M (corresponding author), St Pauls Hosp Millennium Med Coll, Dept Pharmacol, Addis Ababa, Ethiopia.	mensur2007@gmail.com; wedidellameb@gmail.com	Martín-Aragón, Sagrario/K-2052-2014; Worku, Yoseph/AAX-3398-2021	Martín-Aragón, Sagrario/0000-0003-1612-2726; Worku, Yoseph/0000-0002-6885-0437	Saint Paul's Hospital Millennium Medical College; Democratic Republic of Ethiopia	Saint Paul's Hospital Millennium Medical College; Democratic Republic of Ethiopia	This work was supported by Saint Paul's Hospital Millennium Medical College, Research Directorate Director, and Democratic Republic of Ethiopia. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abay SM, 2010, J YOUNG PHARM, V2, P306, DOI 10.4103/0975-1483.66798; Abrha S, 2014, IJPSR, V5, P670; ADDIS ABABA CITY ADMINISTRATION, 2016, ADD AB HLTH BUR FACT; Ali A.N., 2012, INT CURR PHARM J, V1, P302, DOI DOI 10.3329/ICPJ.V1I10.11846; Andualem T., 2004, ETHIOP J HEALTH SCI, V14, P1; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Belachew G., 2011, J APPL PHARM SCI, V1, P183; da Silva MGC, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-339; Eticha T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097464; GORE PR, 1994, J CLIN PHARM THER, V19, P17, DOI 10.1111/j.1365-2710.1994.tb00803.x; Gupta P., 2011, ASIAN J PHARM CLIN R, V4, P54; Home W, 2000, WHO DRUG INF, P14; Hussain S, 2011, AFR J PHARM PHARMACO, V5, P972; Jaleta A, 2016, CUKUROVA MED J, V41, P447, DOI 10.17826/cukmedj.237467; Jalilian F, 2013, J RES HEALTH SCI, V13, P81; James H, 2006, MED PRIN PRACT, V15, P270, DOI 10.1159/000092989; Mishra Divya, 2016, International Journal of Medicine and Public Health, V6, P126, DOI 10.5530/ijmedph.2016.3.6; Mossa D. A., 2012, Turk Silahli Kuvvetleri,  Koruyucu Hekimlik Bulteni, V11, P529; Pagan J.A., 2006, HLTH POLICY, V75, P170, DOI [10. 1016/j. healthpol. 2005. 03. 007 16338480, DOI 10.1016/J.HEALTHP0L.2005.03.007]; Sado E., 2014, OPEN ACCESS LIB J, V1, P1, DOI [10.4236/oalib.1100651, DOI 10.4236/OALIB.1100651]; Shankar P R, 2002, BMC Fam Pract, V3, P17, DOI 10.1186/1471-2296-3-17; Skliros E, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-58; Solomon Worku, 2003, Ethiopian Journal of Health Development, V17, P111; Suleman S, 2009, RES SOC ADMIN PHARM, V5, P76, DOI 10.1016/j.sapharm.2008.04.002; United Nations, 2008, MILL DEV GOALS IND; Verma RK, 2010, ASIAN J PHARM CLIN R, V3, P60; Wijesinghe Pushpa R, 2012, WHO South East Asia J Public Health, V1, P28, DOI 10.4103/2224-3151.206911; World Health Organization (WHO), 2020, ROL PHARM SELFC SELF; World Self-medication Industry (WSMI), 2010, STOR SELF CAR SELF	29	35	36	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2018	13	3							e0194122	10.1371/journal.pone.0194122	http://dx.doi.org/10.1371/journal.pone.0194122			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA5DH	29579074	gold, Green Published, Green Submitted			2023-01-03	WOS:000428351800020
J	Vilar, JM; Manera, ME; Santana, A; Spinella, G; Rodriguez, O; Rubio, M; Carrillo, JM; Sopena, J; Batista, M				Vilar, Jose M.; Manera, Maria E.; Santana, Angelo; Spinella, Giuseppe; Rodriguez, Oliver; Rubio, Monica; Carrillo, Jose M.; Sopena, Joaquin; Batista, Miguel			Effect of leukocyte-reduced platelet-rich plasma on osteoarthritis caused by cranial cruciate ligament rupture: A canine gait analysis model	PLOS ONE			English	Review							DOGS; DEFICIENCY; EFFICACY; THERAPY; DISEASE; FORCE; KNEE; TENDINOPATHY; INJECTIONS; SURGERY	The goal of this study was to objectively assess the effect of a platelet-rich plasma (PRP) derivate in English bulldogs with stifle degenerative joint disease secondary to cranial cruciate ligament rupture (CCLR). We used a force platform and affixed electrogoniometers to measure peak vertical force (PVF), vertical impulse (VI), stance time (ST), and angular range of motion (AROM), from 12 lame client-owned English bulldogs with post-CCLR stifle joint abnormalities. The 12 affected subjects were treated with 4 intra-articular injections of PRP, at 30-day intervals. Ten untreated, sound English bulldogs were used as a reference group. Clinical outcomes were evaluated using a linear mixed effects model. Mean values of PVF, VI, ST, and AROM were improved within the first 3 months post-treatment in the CCLR group, with mean measured changes increasing to maximum 4.56% body weight gain, 1.5% body weight/second, 0.07 seconds, and 6.18 degrees, respectively. The effects declined progressively after the treatment interval, ending at nearly initial levels after 6 months. This study demonstrates that dogs with CCLR treated with intra-articular PRP had improved PVF, VI, ST, and AROM over time; the duration of effect was waning by the end of the post-treatment period.	[Vilar, Jose M.; Manera, Maria E.; Santana, Angelo; Rodriguez, Oliver; Batista, Miguel] Univ Las Palmas Gran Canaria, Fac Vet, Dept Patol Anim, Trasmontana S-N, Arucas, Las Palmas, Spain; [Vilar, Jose M.; Batista, Miguel] Univ Las Palmas Gran Canaria, Inst Univ Invest Biomed & Sanitarias, Juan de Quesada 30, Las Palmas Gran Canaria, Las Palmas, Spain; [Spinella, Giuseppe] Univ Bologna, Fac Vet, Dipartimento Sci Med Vet, Via Tolara 50, Bologna, Italy; [Rubio, Monica; Carrillo, Jose M.; Sopena, Joaquin] Univ CEU Cardenal Herrera, Dept Med & Cirugia Anim, C Tirant lo Blanc 7, Valencia, Spain	Universidad de Las Palmas de Gran Canaria; Universidad de Las Palmas de Gran Canaria; University of Bologna; Universidad CEU Cardenal Herrera	Vilar, JM (corresponding author), Univ Las Palmas Gran Canaria, Fac Vet, Dept Patol Anim, Trasmontana S-N, Arucas, Las Palmas, Spain.; Vilar, JM (corresponding author), Univ Las Palmas Gran Canaria, Inst Univ Invest Biomed & Sanitarias, Juan de Quesada 30, Las Palmas Gran Canaria, Las Palmas, Spain.	jose.vilar@ulpgc.es	Vilar, José Manuel/AAA-7925-2019; Santana, Angelo/H-6012-2011; Sopena, Joaquín/AAF-7088-2019; Batista-Arteaga, Miguel/ABC-7868-2021; POVEDA, JOSE MARIA CARRILLO/ABG-2030-2020	Vilar, José Manuel/0000-0002-2060-2274; Santana, Angelo/0000-0002-6513-4814; Sopena, Joaquín/0000-0002-3601-9745; POVEDA, JOSE MARIA CARRILLO/0000-0002-9789-8886; BATISTA ARTEAGA, MIGUEL/0000-0001-9753-4786; Rodriguez, David O./0000-0003-4040-1266				Souza ANA, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-51; ANDERSON MA, 1994, COMP CONT EDUC PRACT, V16, P857; Bennett RL, 1996, AM J VET RES, V57, P966; Beraud R, 2010, VET COMP ORTHOPAED, V23, P87, DOI 10.3415/VCOT-09-06-0068; Rodriguez-Merchan EC, 2013, ARCH BONE JT SURG-AB, V1, P5; Colin A., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P107, DOI 10.1080/10255840701479230; Comerford EJ, 2011, VET COMP ORTHOPAED, V24, P91, DOI 10.3415/VCOT-10-04-0055; Cook JL, 2016, J ORTHOP RES, V34, P607, DOI 10.1002/jor.23054; David FH, 2012, VET COMP ORTHOPAED, V25, P488, DOI 10.3415/VCOT-12-03-0031; DeCamp CE, 1996, AM J VET RES, V57, P120; Fahie MA, 2013, JAVMA-J AM VET MED A, V243, P1291, DOI 10.2460/javma.243.9.1291; Filardo G, 2011, KNEE SURG SPORT TR A, V19, P528, DOI 10.1007/s00167-010-1238-6; Franklin SP, 2015, AM J VET RES, V76, P822, DOI 10.2460/ajvr.76.9.822; Gonzalez JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19623; Grierson J, 2011, VET COMP ORTHOPAED, V24, P192, DOI 10.3415/VCOT-10-03-0030; Hansen RA, 2008, J NUTR BIOCHEM, V19, P101, DOI 10.1016/j.jnutbio.2007.01.008; Hart R, 2013, ARCH ORTHOP TRAUM SU, V133, P1295, DOI 10.1007/s00402-013-1782-x; Innes JF, 2000, VET REC, V147, P325, DOI 10.1136/vr.147.12.325; Johnson KA, 2011, VET COMP ORTHOPAED T, V24, P3; Kon E, 2010, KNEE SURG SPORT TR A, V18, P472, DOI 10.1007/s00167-009-0940-8; Molsa SH, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0266-8; Moraes VY, 2014, COCHRANE DB SYST REV, P4; Moreau M, 2007, VET REC, V160, P584, DOI 10.1136/vr.160.17.584; Moreau M, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3373; Piermattei DL., 2006, HDB SMALL ANIMAL ORT, P562; Raeissadat SA, 2014, BMC SPORTS SCI MED R, V6, DOI 10.1186/2052-1847-6-12; Ragetly CA, 2012, VET SURG, V41, P973, DOI 10.1111/j.1532-950X.2012.01042.x; Rayegani SM, 2014, ORTHOP REV, V6, P112, DOI 10.4081/or.2014.5405; RUMPH PF, 1995, VET SURG, V24, P384, DOI 10.1111/j.1532-950X.1995.tb01348.x; Sanchez M, 2008, CLIN EXP RHEUMATOL, V26, P910; Silva RF, 2013, VET COMP ORTHOPAED, V26, P285, DOI 10.3415/VCOT-12-06-0075; Vilar JM, 2013, PAK VET J, V33, P229; Vilar JM, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-131; Xie XX, 2013, J SURG RES, V183, P214, DOI 10.1016/j.jss.2013.01.020; Yoshida M, 2016, MLTJ-MUSCLE LIGAMENT, V6, P205, DOI 10.11138/mltj/2016.6.2.205; Zhu Y, 2013, OSTEOARTHR CARTILAGE, V21, P1627, DOI 10.1016/j.joca.2013.07.017	36	15	15	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2018	13	3							e0194752	10.1371/journal.pone.0194752	http://dx.doi.org/10.1371/journal.pone.0194752			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ7QU	29554150	Green Published, gold, Green Submitted			2023-01-03	WOS:000427796800053
J	Maheswaran, H; Petrou, S; Cohen, D; MacPherson, P; Kumwenda, F; Lalloo, DG; Corbett, EL; Clarke, A				Maheswaran, Hendramoorthy; Petrou, Stavros; Cohen, Danielle; MacPherson, Peter; Kumwenda, Felistas; Lalloo, David G.; Corbett, Elizabeth L.; Clarke, Aileen			Economic costs and health-related quality of life outcomes of hospitalised patients with high HIV prevalence: A prospective hospital cohort study in Malawi	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; DEVELOPING-COUNTRIES; UNINFECTED CHILDREN; SOUTH-AFRICA; TUBERCULOSIS; ADULTS; CARE; INITIATION; INFECTION; SETTINGS	Introduction Although HIV infection and its associated co-morbidities remain the commonest reason for hospitalisation in Africa, their impact on economic costs and health-related quality of life (HRQoL) are not well understood. This information is essential for decision-makers to make informed choices about how to best scale-up anti-retroviral treatment (ART) programmes. This study aimed to quantify the impact of HIV infection and ART on economic outcomes in a prospective cohort of hospitalised patients with high HIV prevalence. Methods Sequential medical admissions to Queen Elizabeth Central Hospital, Malawi, between June-December 2014 were followed until discharge, with standardised classification of medical diagnosis and estimation of healthcare resources used. Primary costing studies estimated total health provider cost by medical diagnosis. Participants were interviewed to establish direct non-medical and indirect costs. Costs were adjusted to 2014 US$ and INT$. HRQoL was measured using the EuroQol EQ-5D. Multivariable analyses estimated predictors of economic outcomes. Results Of 892 eligible participants, 80.4% (647/892) were recruited and medical notes found. In total, 447/647 (69.1%) participants were HIV-positive, 339/447 (75.8%) were on ART prior to admission, and 134/647 (20.7%) died in hospital. Mean duration of admission for HIV-positive participants not on ART and HIV-positive participants on ART was 15.0 days (95% CI: 12.0-18.0) and 12.2 days (95%Cl: 10.8-13.7) respectively, compared to 10.8 days (95%Cl: 8.8-12.8) for HIV-negative participants. Mean total provider cost per hospital admission was US$74.78 (bootstrap 95%Cl: US$25.41-US$124.15) higher for HIV-positive than HIV-negative participants. Amongst HIV-positive participants, the mean total provider cost was US$106.87 (bootstrap 95%Cl: US$25.09-US$106.87) lower for those on ART than for those not on ART. The mean total direct non-medical and indirect cost per hospital admission was US$87.84. EQ-5D utility scores were lower amongst HIV-positive participants, but not significantly different between those on and not on ART. Conclusions HIV-related hospital care poses substantial financial burdens on health systems and patients; however, per-admission costs are substantially lower for those already initiated onto ART prior to admission. These potential cost savings could offset some of the additional resources needed to provide universal access to ART.	[Maheswaran, Hendramoorthy; Petrou, Stavros; Clarke, Aileen] Univ Warwick, Med Sch, Div Hlth Sci, Coventry, W Midlands, England; [Maheswaran, Hendramoorthy; Cohen, Danielle; Kumwenda, Felistas; Lalloo, David G.; Corbett, Elizabeth L.] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; [Maheswaran, Hendramoorthy; MacPherson, Peter] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool, Merseyside, England; [Cohen, Danielle; MacPherson, Peter; Lalloo, David G.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Liverpool, Merseyside, England; [Corbett, Elizabeth L.] London Sch Hyg & Trop Med, London, England	University of Warwick; University of Malawi; University of Liverpool; Liverpool School of Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Maheswaran, H (corresponding author), Univ Warwick, Med Sch, Div Hlth Sci, Coventry, W Midlands, England.; Maheswaran, H (corresponding author), Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.; Maheswaran, H (corresponding author), Univ Liverpool, Dept Publ Hlth & Policy, Liverpool, Merseyside, England.	hendym1@liverpoolac.uk	Clarke, Aileen/I-5679-2012; MacPherson, Peter/AHD-2477-2022; Petrou, Stavros/ABD-8323-2021	Clarke, Aileen/0000-0001-8299-3146; MacPherson, Peter/0000-0002-0329-9613; Petrou, Stavros/0000-0003-3121-6050; Maheswaran, Hendramoorthy/0000-0002-7375-4845; Lalloo, David/0000-0001-7680-2200; Cohen, Danielle/0000-0002-8694-3522; Corbett, Elizabeth/0000-0002-3552-3181	Wellcome Trust [WT097973, WT097466/6/11/Z]; NIHR CLAHRC West Midlands initiative; MRC [G0501681, G0700452] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); NIHR CLAHRC West Midlands initiative; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	HM was supported by the Wellcome Trust (grant number: WT097973). DC was supported by the Wellcome Trust (grant number: WT097466/6/11/Z). AC is supported by the NIHR CLAHRC West Midlands initiative. This paper presents independent research and the views expressed are those of the authors and not necessarily those of the Wellcome Trust, the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2014, CLIN CLASS SOFTW CCS; [Anonymous], 2014, CONS GUID HIV PREV D; Austin PC, 2000, QUAL LIFE RES, V9, P901, DOI 10.1023/A:1008938326604; Bachelet M., 2012, SOCIAL PROTECTION FL; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249; Bates M, 2015, LANCET INFECT DIS, V15, P544, DOI 10.1016/S1473-3099(15)70058-7; Beard J, 2009, AIDS CARE, V21, P1343, DOI 10.1080/09540120902889926; Beck EJ, 2010, CURR OPIN HIV AIDS, V5, P215, DOI 10.1097/COH.0b013e32833860e9; Chopra M, 2009, LANCET, V374, P1023, DOI 10.1016/S0140-6736(09)61122-3; Corbett EL, 2013, INT J TUBERC LUNG D, V17, P1125, DOI 10.5588/ijtld.13.0117; de Cherif TKS, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-205; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Dolan P, 1996, HEALTH ECON, V5, P141, DOI 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Floyd K, 2003, INT J TUBERC LUNG D, V7, pS29; Goodacre SW, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-20; Havlir DV, 2011, NEW ENGL J MED, V365, P1482, DOI 10.1056/NEJMoa1013607; International Drug Price Indicator Guide, 2013, INT DRUG PRIC IND GU; Jelsma Jennifer, 2003, Popul Health Metr, V1, P11, DOI 10.1186/1478-7954-1-11; Lewis DK, 2003, T ROY SOC TROP MED H, V97, P91, DOI 10.1016/S0035-9203(03)90035-6; Long LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148546; Maheswaran H, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0577-7; Mandalia S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015677; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Meyer-Rath G, 2013, JAIDS-J ACQ IMM DEF, V62, P322, DOI 10.1097/QAI.0b013e31827e8785; Papke LE, 1996, J APPL ECONOM, V11, P619, DOI 10.1002/(SICI)1099-1255(199611)11:6<619::AID-JAE418>3.0.CO;2-1; POWELL JL, 1984, J ECONOMETRICS, V25, P303, DOI 10.1016/0304-4076(84)90004-6; Pritchard C., 2000, PRODUCTIVITY COSTS P; Rizzardini G, 2011, JAIDS-J ACQ IMM DEF, V57, P211, DOI 10.1097/QAI.0b013e31821fdee2; Robberstad Bjarne, 2010, Cost Eff Resour Alloc, V8, P5, DOI 10.1186/1478-7547-8-5; SanJoaquin MA, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001400; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Tagar E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108304; Thomas LS, 2007, JAIDS-J ACQ IMM DEF, V46, P410, DOI 10.1097/QAI.0b013e318156ec90; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; UNAIDS, 2011, MAN COST HIV FAC SER; WHO, 2015, PREQ PROGR; World Bank, 2010, GROSS NAT INC PER CA; Yone EWP, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-46	43	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2018	13	3							e0192991	10.1371/journal.pone.0192991	http://dx.doi.org/10.1371/journal.pone.0192991			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FZ3GA	29543818	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000427473500007
J	Massawe, A; Kidanto, HL; Moshiro, R; Majaliwa, E; Chacha, F; Shayo, A; Mdoe, P; Ringia, P; Azayo, M; Msemo, G; Mduma, E; Ersdal, HL; Perlman, JM				Massawe, Augustine; Kidanto, Hussein L.; Moshiro, Robert; Majaliwa, Edna; Chacha, Flora; Shayo, Aisa; Mdoe, Paschal; Ringia, Prisca; Azayo, Mary; Msemo, Georgina; Mduma, Estomih; Ersdal, Hege L.; Perlman, Jeffrey M.			A care bundle including antenatal corticosteroids reduces preterm infant mortality in Tanzania a low resource country	PLOS ONE			English	Article								Background Preterm neonatal mortality (NM) has remained high and unchanged for many years in Tanzania, a resource-limited country. Major causes of mortality include birth asphyxia, respiratory insufficiency and infections. Antenatal corticosteroids (ACS) have been shown to significantly reduce mortality in developed countries. There is inconsistent use of ACS in Tanzania. Objective To determine whether implementation of a care bundle that includes ACS, maternal antibiotics (MA), neonatal antibiotics (NA) and avoidance of moderate hypothermia (temperature < 36 degrees C) targeting infants of estimated gestational age (EGA) 28 to 34 6/7 weeks would reduce NM (<7 days) by 35%. Methods A Pre (September 2014 to May 2015) and Post (June 2015 to June 2017) Implementation strategy was used and introduced at three University-affiliated and one District Hospital. Dexamethasone, as the ACS, was added to the national formulary in May 2015, facilitating its free use down to the district level. Findings NM was reduced 26% from 166 to 122/1000 livebirths (P = 0.005) and fresh stillbirths (FSB) 33% from 162/1000 to 111/1000 (p = 0.0002) Pre versus Post Implementation. Medications including combinations increased significantly at all sites (p<0.0001). By logistic regression, combinations of ACS, maternal and NA (odds ratio (OR) 0.33), ACS and NA (OR 0.30) versus no treatment were significantly associated with reduced NM. NM significantly decreased per 250g birthweight increase (OR 0.59), and per one week increase in EGA (OR 0.87). Moderate hypothermia declined pre versus post implementation (p<0.0001) and was two-fold more common in infants who died versus survivors. Interpretation A low-cost care bundle, similar to$6 per patient, was associated with a significant reduction in NM and FSB rates. The former presumably by reducing respiratory morbidity with ACS and minimizing infections with antibiotics. If these findings can be replicated in other resource-limited settings, the potential for further reduction of <5 year mortality rates becomes enormous.	[Massawe, Augustine; Moshiro, Robert; Majaliwa, Edna] Muhimbili Univ Hlth & Allied Sci, Sch Med, Paediat & Child Hlth, Dar Es Salaam, Tanzania; [Kidanto, Hussein L.] Muhimbili Univ Hlth & Allied Sci, Obstet & Gynecol, Dar Es Salaam, Tanzania; [Chacha, Flora] Catholic Univ Hlth & Allied Sci Bugando, Paediat, Mwanza, Tanzania; [Shayo, Aisa] Kilimanjaro Christian Med Ctr, Dept Paediat, Moshi, Tanzania; [Mdoe, Paschal; Mduma, Estomih] Haydom Lutheran Hosp, Obstet & Gynecol, Haydom, Tanzania; [Ringia, Prisca] Weill Bugando Hosp, Div Obstet Nursing, Mwanza, Tanzania; [Azayo, Mary; Msemo, Georgina] Minist Hlth & Social Serv, Reprod & Child Hlth Serv, Dar Es Salaam, Tanzania; [Ersdal, Hege L.] Stavanger Univ Hosp, Dept Anaesthesiol & Intens Care, Stavanger, Norway; [Perlman, Jeffrey M.] Weill Cornell Med, Dept Pediat, New York, NY 10021 USA	Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Kilimanjaro Christian Medical Centre; Stavanger University Hospital; Cornell University	Perlman, JM (corresponding author), Weill Cornell Med, Dept Pediat, New York, NY 10021 USA.	jmp2007@med.cornell.edu			Laerdal Foundation for Acute Medicine	Laerdal Foundation for Acute Medicine	Jeffrey Perlman has received a research travel award from the Laerdal Foundation for Acute Medicine for work in Tanzania but does not have any financial or personal relationships with other people or organizations. The study has been funded in part by Bloomberg Philanthropies. Bloomberg Philanthropies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agren J, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/789729; Althabe F, 2015, LANCET, V385, P629, DOI 10.1016/S0140-6736(14)61651-2; American Academy of Pediatrics, HELP BAB SURV; [Anonymous], 2011, Obstet Gynecol, V117, P1472, DOI 10.1097/AOG.0b013e3182238c31; [Anonymous], 2013, MAN COMPL PREGN CHIL; Castrodale V, 2014, ADV NEONAT CARE, V14, P9, DOI 10.1097/ANC.0b013e31828d0289; GILSTRAP LC, 1995, AM J OBSTET GYNECOL, V173, P246; Laptook AR, 2007, PEDIATRICS, V119, pE643, DOI 10.1542/peds.2006-0943; Liu G, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S3; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Msemo G, 2013, PEDIATRICS, V131, pE353, DOI 10.1542/peds.2012-1795; Mullany LC, 2010, ARCH PEDIAT ADOL MED, V164, P650, DOI 10.1001/archpediatrics.2010.103; Perlman J, 2015, LANCET, V385, P1944, DOI 10.1016/S0140-6736(15)60954-0; Perlman JM, 2015, CIRCULATION, V132, pS204, DOI 10.1161/CIR.0000000000000276; Roberts D, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub3; UNICEF, LEV TRENDS CHILD MOR; Verani J, 2010, MORBIDITY MORTALITY; White LJ, 2012, J R SOC INTERFACE, V9, P503, DOI 10.1098/rsif.2011.0376; World Health Organization, 1997, MEAS QUAL LIF, P1; World Health Organization, 2010, MAT NEWB CHILD AD HL; You D, 2014, LEVELS TRENDS CHILD	21	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0193146	10.1371/journal.pone.0193146	http://dx.doi.org/10.1371/journal.pone.0193146			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513706	Green Published, Green Submitted, gold			2023-01-03	WOS:000426896800040
J	Volpe, MS; Naves, JM; Ribeiro, GG; Ruas, G; Tucci, MR				Volpe, Marcia S.; Naves, Juliane M.; Ribeiro, Gabriel G.; Ruas, Gualberto; Tucci, Mauro R.			Effects of manual hyperinflation, clinical practice versus expert recommendation, on displacement of mucus simulant: A laboratory study	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; EXTUBATION OUTCOMES; SECRETION MOVEMENT; INTENSIVE-CARE; COUGH STRENGTH; PHYSIOTHERAPY; CLEARANCE; PERFORMANCE; SETTINGS	Introduction Manual hyperinflation (MH), a maneuver applied in mechanically ventilated patients to facilitate secretion removal, has large variation in its performance. Effectiveness of MH is usually evaluated by its capacity to generate an expiratory flow bias. The aim of this study was to compare the effects of MH-and its resulting flow bias D applied according to clinical practice versus according to expert recommendation on mucus movement in a lung model simulating a mechanically ventilated patient. Methods Twelve physiotherapists were asked to apply MH, using a self-inflating manual resuscitator, to a test lung as if to remove secretions under two conditions: according to their usual clinical practice (pre-instruction phase) and after verbal instruction to perform MH according to expert recommendation was given (post-instruction phase). Mucus simulant movement was measured with a photodensitometric technique. Peak inspiratory flow (PIF), peak inspiratory pressure (P-IP), inspiratory time (T-INSP), tidal volume (V-T) and peak expiratory flow (PEF) were measured continuously. Results It was found that MH performed post-instruction delivered a smaller VT (643.1 +/- 57.8 ml) at a lower P-IP (15.0 +/- 1.5 cmH(2)O), lower PIF (38.0 +/- 9.6 L/min), longer T-INSP (1.84 +/- 0.54 s) and lower PEF (65.4 +/- 6.7L/min) compared to MH pre-instruction. In the pre-instruction phase, MH resulted in a mean PIF/PEF ratio of 1.73 +/- 0.38 and mean PEF-PIF difference of -54.6 +/- 28.3 L/min, both out of the range for secretion removal. In the post-instruction phase both indexes were in the adequate range. Consequently, the mucus simulant was moved outward when MH was applied according to expert recommendation and towards the test lung when it was applied according to clinical practice. Conclusions Performance of MH during clinical practice with PIF higher than PEF was ineffective to clear secretion in a lung model simulating a mechanically ventilated patient. In order to remove secretion, MH should result in an adequate expiratory flow bias.	[Volpe, Marcia S.] Univ Fed Sao Paulo, Dept Human Movement Sci, Sao Paulo, Brazil; [Naves, Juliane M.; Ribeiro, Gabriel G.; Ruas, Gualberto] Univ Fed Triangulo Mineiro, Dept Appl Physiotherapy, Uberaba, MG, Brazil; [Tucci, Mauro R.] Univ Sao Paulo, Sch Med, Lab Med Res 09, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do Triangulo Mineiro; Universidade de Sao Paulo	Volpe, MS (corresponding author), Univ Fed Sao Paulo, Dept Human Movement Sci, Sao Paulo, Brazil.	marciasvolpe@gmail.com						Ambrosino N, 2011, REV PORT PNEUMOL, V17, P283, DOI 10.1016/j.rppneu.2011.06.004; [Anonymous], PHYSIOTHERAPY; BENJAMIN RG, 1989, CHEST, V95, P658, DOI 10.1378/chest.95.3.658; Bennett BG, 2015, RESP CARE, V60, P1449, DOI 10.4187/respcare.04066; Boussarsar M, 2002, INTENS CARE MED, V28, P406, DOI 10.1007/s00134-001-1178-1; Denehy L, 1999, EUR RESPIR J, V14, P958, DOI 10.1034/j.1399-3003.1999.14d38.x; Duan J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1493-0; França Eduardo Ériko Tenório de, 2012, Rev. bras. ter. intensiva, V24, P6; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Hanekom S, 2011, J EVAL CLIN PRACT, V17, P801, DOI 10.1111/j.1365-2753.2010.01480.x; Hodgson C, 1999, AUST J PHYSIOTHER, V45, P185, DOI 10.1016/S0004-9514(14)60349-4; Hodgson C, 2000, ANAESTH INTENS CARE, V28, P255, DOI 10.1177/0310057X0002800302; Jham K, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2009.06.008; Jones AM, 2009, HEART LUNG, V38, P513, DOI 10.1016/j.hrtlng.2009.06.002; Jones AYM, 2002, RESP PHYSIOL NEUROBI, V132, P321, DOI 10.1016/S1569-9048(02)00071-X; KIM CS, 1987, J APPL PHYSIOL, V62, P959, DOI 10.1152/jappl.1987.62.3.959; Bassi GL, 2011, CURR OPIN CRIT CARE, V17, P57, DOI 10.1097/MCC.0b013e3283428b31; LIBASSI G, 2012, CRIT CARE MED, V40, P895, DOI DOI 10.1097/CCM.00013e318236efb5; Maxwell L, 2002, ANAESTH INTENS CARE, V30, P283, DOI 10.1177/0310057X0203000304; Maxwell LJ, 2007, ANAESTHESIA, V62, P27, DOI 10.1111/j.1365-2044.2006.04898.x; Maxwell LJ, 2003, AUST J PHYSIOTHER, V49, P31, DOI 10.1016/S0004-9514(14)60186-0; Ortiz TD, 2013, J BRAS PNEUMOL, V39, P205, DOI 10.1590/S1806-37132013000200012; Paulus F, 2012, CRIT CARE, V16, DOI 10.1186/cc11457; Paulus F, 2016, NURS CRIT CARE, V21, P36, DOI 10.1111/nicc.12068; Paulus Frederique, 2009, Intensive Crit Care Nurs, V25, P199, DOI 10.1016/j.iccn.2009.04.003; Redfern J, 2001, AUST J PHYSIOTHER, V47, P121, DOI 10.1016/S0004-9514(14)60303-2; Salam A, 2004, INTENS CARE MED, V30, P1334, DOI 10.1007/s00134-004-2231-7; Shah S, 2005, CHEST, V128, P3699, DOI 10.1378/chest.128.5.3699; Sigera PC, 2016, PHYS THER, V96, P933, DOI 10.2522/ptj.20150363; Smailes ST, 2013, BURNS, V39, P236, DOI 10.1016/j.burns.2012.09.028; Smina M, 2003, CHEST, V124, P262, DOI 10.1378/chest.124.1.262; Stiller K, 2013, CHEST, V144, P825, DOI 10.1378/chest.12-2930; Thomas PJ, 2015, ANAESTH INTENS CARE, V43, P81, DOI 10.1177/0310057X1504300112; Turki Mohamed, 2005, Respir Care, V50, P340; Volpe MS, 2008, RESP CARE, V53, P1287	35	5	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 12	2018	13	2							e0191787	10.1371/journal.pone.0191787	http://dx.doi.org/10.1371/journal.pone.0191787			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV8DE	29432468	gold, Green Published, Green Submitted			2023-01-03	WOS:000424814300011
J	Levin, RK; Katz, M; Saldiva, PHN; Caixeta, A; Franken, M; Pereira, C; Coslovsky, SV; Pesaro, AE				Levin, Renato Kawahisa; Katz, Marcelo; Saldiva, Paulo H. N.; Caixeta, Adriano; Franken, Marcelo; Pereira, Carolina; Coslovsky, Salo V.; Pesaro, Antonio E.			Increased hospitalizations for decompensated heart failure and acute myocardial infarction during mild winters: A seven-year experience in the public health system of the largest city in Latin America	PLOS ONE			English	Article							COLD PRESSOR TEST; SEASONAL-VARIATION; AIR-POLLUTION; SAO-PAULO; HONG-KONG; MORTALITY; ADMISSIONS; WEATHER; CLIMATE; RISK	Background In high-income temperate countries, the number of hospitalizations for heart failure (HF) and acute myocardial infarction (AMI) increases during the winter. This finding has not been fully investigated in low-and middle-income countries with tropical and subtropical climates. We investigated the seasonality of hospitalizations for HF and AMI in Sao Paulo (Brazil), the largest city in Latin America. Methods This was a retrospective study using data for 76,474 hospitalizations for HF and 54,561 hospitalizations for AMI obtained from public hospitals, from January 2008 to April 2015. The average number of hospitalizations for HF and AMI per month during winter was compared to each of the other seasons. The autoregressive integrated moving average (ARIMA) model was used to test the association between temperature and hospitalization rates. Findings The highest average number of hospital admissions for HF and AMI per month occurred during winter, with an increase of up to 30% for HF and 16% for AMI when compared to summer, the season with lowest figures for both diseases (respectively, HF: 996 vs. 767 per month, p<0.001; and AMI: 678 vs. 586 per month, p<0.001). Monthly average temperatures were moderately lower during winter than other seasons and they were not associated with hospitalizations for HF and AMI. Interpretation The winter season was associated with a greater number of hospitalizations for both HF and AMI. This increase was not associated with seasonal oscillations in temperature, which were modest. Our study suggests that the prevention of cardiovascular disease decompensation should be emphasized during winter even in low to middle-income countries with tropical and subtropical climates.	[Levin, Renato Kawahisa; Katz, Marcelo; Caixeta, Adriano; Franken, Marcelo; Pereira, Carolina; Pesaro, Antonio E.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil; [Saldiva, Paulo H. N.] Univ Sao Paulo, Inst Estudos Avancados, Sao Paulo, Brazil; [Coslovsky, Salo V.] NYU, Robert F Wagner Sch Publ Serv, New York, NY USA	Hospital Israelita Albert Einstein; Universidade de Sao Paulo; New York University	Pesaro, AE (corresponding author), Hosp Israelita Albert Einstein, Sao Paulo, Brazil.	antonioepp@einstein.br	Faria, Carolina Pereira de Morais/HHT-0142-2022; Saldiva, Paulo HN/D-7385-2012; Caixeta, Adriano/AAT-1447-2021	Saldiva, Paulo HN/0000-0003-2005-8253; Caixeta, Adriano/0000-0002-6287-5414; Pesaro, Antonio/0000-0003-3133-4989				Albuquerque DC, 2015, ARQ BRAS CARDIOL, V104, P433, DOI [10.5935/abc.20150031, DOI 10.5935/ABC.20150031]; Barnes M, 2015, HEART, V101, P1738, DOI 10.1136/heartjnl-2015-307691; Boulay F, 1999, CIRCULATION, V100, P280, DOI 10.1161/01.CIR.100.3.280; Box G.E., 2015, REV; Brasil. Ministerio da Saude, DAT INF SAUD MORB IN; Brasil. Ministerio do Planejamento Orcamento e Instituto Brasileiro de Geografia e Estatistica, 2013, PESQ NAC AM DOM AC U; Campos AM, 2016, BBA CLIN, V6, P108, DOI 10.1016/j.bbacli.2016.09.001; CETESB-SP, 2013, EM VEIC EST SAO PAUL; CETESB-SP, COMP TECN SAN AMB RE; Diaz Alejandro, 2007, Congest Heart Fail, V13, P263, DOI 10.1111/j.1527-5299.2007.07124.x; Fares Auda, 2013, N Am J Med Sci, V5, P266, DOI 10.4103/1947-2714.110430; Gallerani M, 2011, CLIN CARDIOL, V34, P389, DOI 10.1002/clc.20895; Gasparrini A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; Godoy HL, 2011, ARQ BRAS CARDIOL, V97, P402, DOI 10.1590/S0066-782X2011005000096; Goggins WB, 2017, INT J CARDIOL, V228, P537, DOI 10.1016/j.ijcard.2016.11.106; Goggins WB, 2013, INT J CARDIOL, V168, P243, DOI 10.1016/j.ijcard.2012.09.087; Healy JD, 2003, J EPIDEMIOL COMMUN H, V57, P784, DOI 10.1136/jech.57.10.784; Khan RC, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-76; Loughnan ME, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-42; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Qiu H, 2013, CIRC-HEART FAIL, V6, P930, DOI 10.1161/CIRCHEARTFAILURE.113.000360; Rivero A, 2015, MEDICC REV, V17, P14, DOI 10.37757/MR2015.V17.N2.5; Rodriguez-Garcia JL, 1999, INT J CARDIOL, V70, P293, DOI 10.1016/S0167-5273(99)00095-9; SALDIVA PHN, 1995, ARCH ENVIRON HEALTH, V50, P159, DOI 10.1080/00039896.1995.9940893; Sanchez-Ccoyllo OR, 2002, ENVIRON POLLUT, V116, P257, DOI 10.1016/S0269-7491(01)00129-4; Shah ASV, 2013, LANCET, V382, P1039, DOI 10.1016/S0140-6736(13)60898-3; Sharovsky Rodolfo, 2002, Arq. Bras. Cardiol., V78, P106, DOI 10.1590/S0066-782X2002000100009; Spencer FA, 1998, J AM COLL CARDIOL, V31, P1226, DOI 10.1016/S0735-1097(98)00098-9; Stewart S, 2002, J AM COLL CARDIOL, V39, P760, DOI 10.1016/S0735-1097(02)01685-6; WESTHEIM A, 1992, CLIN PHYSIOL, V12, P95, DOI 10.1111/j.1475-097X.1992.tb00296.x; World Health Organization, INT CLASS DIS; Yeh C J, 1996, Chin J Physiol, V39, P111	32	13	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2018	13	1							e0190733	10.1371/journal.pone.0190733	http://dx.doi.org/10.1371/journal.pone.0190733			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR7HZ	29300764	Green Published, gold, Green Submitted			2023-01-03	WOS:000419239900042
J	Yang, M; Jiang, L; Wang, Q; Chen, H; Xu, GH				Yang, Min; Jiang, Li; Wang, Qing; Chen, Hao; Xu, Guihua			Traditional Chinese medicine for knee osteoarthritis: An overview of systematic review	PLOS ONE			English	Review							TAI-CHI; CLINICAL-TRIALS; ACUPUNCTURE; RECOMMENDATIONS; PREVALENCE; GUIDELINES; MANAGEMENT; QUALITY; SAFETY; LIFE	Background Traditional Chinese medicine (TCM) has been accepted as a complementary therapy for knee osteoarthritis. However, the efficacy and safety of the intervention were still conflicting and uncertain. Meanwhile, the quality of methodology and evidence in the field was unknown. Objective To summarize the characteristics and critically evaluate the quality of methodology, as well as the evidence of systematic reviews (SRs) on TCM for knee osteoarthritis. Methods Five electronic databases were searched from inception to April 2016. The methodological quality of the included studies was assessed by AMSTAR and ROBIS. The quality of the evidence was determined using the GRADE approach. Results Ten SRs were included. The conclusions suggest that TCM provides potential benefits for patients with knee osteoarthritis. These benefits include pain relief, functional improvement, and presence of few adverse events. Limitations of the methodological quality mainly included the lack of a-priori protocol or protocol registration and incomprehensive literature search. A list of excluded studies was also not provided. The overall quality of evidence in the SRs was poor, ranging from "very low" to "low," mainly because of the serious risk of bias of original trials, inconsistencies, and imprecision in the outcomes. Conclusions TCM generally appears to be effective for knee osteoarthritis treatment. However, the evidence is not robust enough because of the methodological flaws in SRs. Hence, these conclusions on available SRs should be treated with caution for clinical practice.	[Yang, Min; Wang, Qing; Xu, Guihua] Nanjing Univ Chinese Med, Sch Nursing, Nanjing, Jiangsu, Peoples R China; [Jiang, Li] Jiangsu Univ, Jingjiang Coll, Zhenjiang, Jiangsu, Peoples R China; [Chen, Hao] Nanjing Univ Chinese Med, Clin Med Sch 2, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Jiangsu University; Nanjing University of Chinese Medicine	Xu, GH (corresponding author), Nanjing Univ Chinese Med, Sch Nursing, Nanjing, Jiangsu, Peoples R China.	drghxu@sina.com			National Natural Science Foundation of China [81473791]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by National Natural Science Foundation of China (No. 81473791).	[Anonymous], 2015, SHOCK VIB, DOI DOI 10.1155/2015/949172; Bellamy N, 1997, J RHEUMATOL, V24, P799; Branco JC, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000166; Brismee JM, 2007, CLIN REHABIL, V21, P99, DOI 10.1177/0269215506070505; Cao L, 2012, SAUDI MED J, V33, P526; Essex MN, 2016, INT J RHEUM DIS, V19, P262, DOI 10.1111/1756-185X.12667; Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hou Pu-Wei, 2015, J Tradit Complement Med, V5, P182, DOI 10.1016/j.jtcme.2015.06.002; Hsiao WLW, 2010, PLANTA MED, V76, P1118, DOI 10.1055/s-0030-1250186; [靳英辉 Jin Yinghui], 2012, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V12, P1148; Kang D, 2012, EVID-BASED COMPL ALT, V2012; Kang DY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/732195; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Lee HJ, 2009, CLIN REHABIL, V23, P504, DOI 10.1177/0269215508101746; Li A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003244; Li XH, 2010, J TRADIT CHIN MED, V30, P108, DOI 10.1016/S0254-6272(10)60024-6; Liu Y, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2782-x; Luo J, 2015, AM J CHINESE MED, V43, P25, DOI 10.1142/S0192415X15500020; Manheimer E, 2007, ANN INTERN MED, V146, P868, DOI 10.7326/0003-4819-146-12-200706190-00008; McAlindon TE, 2015, OSTEOARTHR CARTILAGE, V23, P747, DOI 10.1016/j.joca.2015.03.005; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Nyvang J, 2016, INT J QUAL STUD HEAL, V11, DOI 10.3402/qhw.v11.30193; Sharma L, 2016, OSTEOARTHR CARTILAGE, V24, P36, DOI 10.1016/j.joca.2015.07.026; Shea BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001350; Song GM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002790; Tang X, 2016, ARTHRITIS RHEUMATOL, V68, P648, DOI 10.1002/art.39465; Viera AJ, 2005, FAM MED, V37, P360; Wei X, 2015, INT J AEROSPACE ENG, V2015, DOI 10.1155/2015/479427; Wells GA, 2012, APPL ENG AGRIC, V18, P727; Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005; Williamson L, 2007, RHEUMATOLOGY, V46, P1445, DOI 10.1093/rheumatology/kem119; Wong L Y, 2015, East Asian Arch Psychiatry, V25, P150; Yamashita H, 2006, ACUPUNCT MED S, V24, pS49; Yang SB, 2013, CLIN THER, V35, P1690, DOI 10.1016/j.clinthera.2013.09.022; Ye JJ, 2014, J PHYS THER SCI, V26, P1133, DOI 10.1589/jpts.26.1133; Zhang W, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/417432; Zhang XX, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/358028; Zhu LG, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/328642; Zorzela L, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7668	40	40	44	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2017	12	12							e0189884	10.1371/journal.pone.0189884	http://dx.doi.org/10.1371/journal.pone.0189884			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ8BI	29267324	Green Published, Green Submitted, gold			2023-01-03	WOS:000418587400058
J	Van de Ven, RM; Murre, JMJ; Buitenweg, JIV; Veltman, DJ; Aaronson, JA; Nijboer, TCW; Kruiper-Doesborgh, SJC; van Bennekom, CAM; Ridderinkhof, KR; Schmand, B				van de Ven, Renate M.; Murre, Jaap M. J.; Buitenweg, Jessika I. V.; Veltman, Dick J.; Aaronson, Justine A.; Nijboer, Tanja C. W.; Kruiper-Doesborgh, Suzanne J. C.; van Bennekom, Coen A. M.; Ridderinkhof, K. Richard; Schmand, Ben			The influence of computer-based cognitive flexibility training on subjective cognitive well-being after stroke: A multi-center randomized controlled trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; ACQUIRED BRAIN-INJURY; WORKING-MEMORY; INSTRUMENTAL ACTIVITIES; FAILURES QUESTIONNAIRE; EXECUTIVE DYSFUNCTION; ATTENTIONAL DEFICITS; UTRECHT SCALE; HEALTH SURVEY; REHABILITATION	Background Stroke can result in cognitive complaints that can have a large impact on quality of life long after its occurrence. A number of computer-based training programs have been developed with the aim to improve cognitive functioning. Most studies investigating their efficacy used only objective outcome measures, whereas a reduction of subjective cognitive complaints may be equally important for improving quality of life. A few studies used subjective outcome measures but were inconclusive, partly due to methodological shortcomings such as lack of proper active and passive control groups. Objective The aim of the current study was to investigate whether computer-based cognitive flexibility training can improve subjective cognitive functioning and quality of life after stroke. Methods We performed a randomized controlled double blind trial (RCT). Adults (30-80 years old) who had a stroke 3 months to 5 years ago, were randomly assigned to either an intervention group (n = 38), an active control group (i.e., mock training; n = 35), or a waiting list control group (n = 24). The intervention and mock training consisted of 58 half-hour sessions within 12 weeks. The primary subjective outcome measures were cognitive functioning (Cognitive Failure Questionnaire), executive functioning (Dysexecutive Functioning Questionnaire), quality of life (Short Form Health Survey), instrumental activities of daily living (IADL; Lawton & Brody IADL scale), and participation in society (Utrecht Scale for Evaluation of Rehabilitation-Participation). Secondary subjective outcome measures were recovery after stroke, depressive symptoms (Hospital Anxiety Depression Scale-depression subscale), fatigue (Checklist Individual Strength D Fatigue subscale), and subjective cognitive improvement (exit list). Finally, a proxy of the participant rated the training effects in subjective cognitive functioning, subjective executive functioning, and IADL. Results and conclusions All groups improved on the two measures of subjective cognitive functioning and subjective executive functioning, but not on the other measures. These cognitive and executive improvements remained stable 4 weeks after training completion. However, the intervention group did not improve more than the two control groups. This suggests that improvement was due to training-unspecific effects. The proxies did not report any improvements. We, therefore, conclude that the computer-based cognitive flexibility training did not improve subjective cognitive functioning or quality of life after stroke.	[van de Ven, Renate M.; Murre, Jaap M. J.; Buitenweg, Jessika I. V.; Ridderinkhof, K. Richard; Schmand, Ben] Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands; [Veltman, Dick J.] Vrije Univ Amsterdam, Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Aaronson, Justine A.; van Bennekom, Coen A. M.] Heliomare Rehabil Ctr, Dept Res & Dev, Wijk Aan Zee, Netherlands; [Nijboer, Tanja C. W.] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Ctr Excellence Rehabil Med, Utrecht, Netherlands; [Nijboer, Tanja C. W.] Hoogstr Rehabil, Utrecht, Netherlands; [Nijboer, Tanja C. W.] Univ Utrecht, Dept Expt Psychol, Utrecht, Netherlands; [Kruiper-Doesborgh, Suzanne J. C.] Reade, Amsterdam Rehabil Res Ctr, Amsterdam, Netherlands; [Ridderinkhof, K. Richard] Univ Amsterdam, ABC, Amsterdam, Netherlands; [Schmand, Ben] Univ Amsterdam, Acad Med Ctr, Dept Med Psychol, Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; Utrecht University; Utrecht University Medical Center; Utrecht University; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Van de Ven, RM (corresponding author), Univ Amsterdam, Dept Psychol, Amsterdam, Netherlands.	r.m.vandeven@uva.nl	Murre, Jaap MJ/A-3813-2010	van Bennekom, coen/0000-0002-9754-261X	Netherlands Initiative Brain and Cognition, a part of the Organization for Scientific Research (NWO) [056-14-013]	Netherlands Initiative Brain and Cognition, a part of the Organization for Scientific Research (NWO)	This project is part of the research program "Treatment of cognitive disorders based on functional brain imaging" funded by the Netherlands Initiative Brain and Cognition, a part of the Organization for Scientific Research (NWO) under grant number 056-14-013 to JMJM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Akerlund E, 2013, BRAIN INJURY, V27, P1649, DOI 10.3109/02699052.2013.830195; Bjorkdahl A, 2013, BRAIN INJURY, V27, P1658, DOI 10.3109/02699052.2013.830196; Blomer AMV, 2015, ARCH PHYS MED REHAB, V96, P456, DOI 10.1016/j.apmr.2014.09.003; Boelen DHE, 2009, NEUROPSYCHOL REHABIL, V19, P625, DOI 10.1080/09602010802613853; Bridger RS, 2013, ERGONOMICS, V56, P1515, DOI 10.1080/00140139.2013.821172; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cerniauskaite M, 2012, AM J PHYS MED REHAB, V91, pS39, DOI 10.1097/PHM.0b013e31823d4df7; Corbett A, 2015, J AM MED DIR ASSOC, V16, P990, DOI 10.1016/j.jamda.2015.06.014; De Luca R, 2014, DISABIL HEALTH J, V7, P356, DOI 10.1016/j.dhjo.2014.04.003; Evans, 1996, BEHAV ASSESSMENT DYS; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fride Y, 2015, TOP STROKE REHABIL, V22, P317, DOI 10.1179/1074935714Z.0000000013; Gauggel S, 1996, INT J REHABIL RES, V19, P229, DOI 10.1097/00004356-199609000-00004; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI [10.1080/09602019208401399, DOI 10.1080/09602019208401399]; GRUBBS FE, 1950, ANN MATH STAT, V21, P27, DOI 10.1214/aoms/1177729885; Gunaydin R, 2011, ARCH GERONTOL GERIAT, V53, P19, DOI 10.1016/j.archger.2010.06.004; Hardy JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134467; Hauke J, 2011, NEUROPSYCHOL REHABIL, V21, P164, DOI 10.1080/09602011.2010.541792; Karbach J, 2009, DEVELOPMENTAL SCI, V12, P978, DOI 10.1111/j.1467-7687.2009.00846.x; Katona M, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0258-9; Kielbergerova L, 2015, TRANSL STROKE RES, V6, P375, DOI 10.1007/s12975-015-0418-6; LAWTON MP, 1988, PSYCHOPHARMACOL BULL, V24, P789; Liu KPY, 2016, EUR J NEUROL, V23, P1351, DOI 10.1111/ene.13037; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Maaijwee NAMM, 2014, J NEUROL, V261, P1300, DOI 10.1007/s00415-014-7346-3; Oczkowski C, 2010, J STROKE CEREBROVASC, V19, P410, DOI 10.1016/j.jstrokecerebrovasdis.2009.08.002; Olazaran J, 2005, NEUROLOGIA, V20, P395; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Post MWM, 2009, CLIN REHABIL, V23, P909, DOI 10.1177/0269215509341524; Prokopenko SV, 2013, J NEUROL SCI, V325, P148, DOI 10.1016/j.jns.2012.12.024; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Saghaei M., 2011, J BIOMED SCI ENG, V4, P734, DOI [10.4236/jbise.2011.411090, DOI 10.4236/JBISE.2011.411090]; Saghaei Mahmoud, 2011, J Med Signals Sens, V1, P55; Schwarz KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130492; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Van de Ven R. M., 2015, BIOMED CENTRAL NEURO, V20, P15; van de Ven RM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00150; van de Ven RM, 2017, PLOS ONE, P12; van der Zee CH, 2010, J REHABIL MED, V42, P752, DOI 10.2340/16501977-0589; van Rijsbergen MWA, 2015, J STROKE CEREBROVASC, V24, P1823, DOI 10.1016/j.jstrokecerebrovasdis.2015.04.017; van Rijsbergen MWA, 2014, J STROKE CEREBROVASC, V23, P408, DOI 10.1016/j.jstrokecerebrovasdis.2013.05.003; Vercoulen JHMM, 1997, J PSYCHIATR RES, P31; Vittengl JR, 2006, AGING MENT HEALTH, V10, P40, DOI 10.1080/13607860500307944; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wentink MM, 2016, NEUROPSYCHOL REHABIL, V26, P847, DOI 10.1080/09602011.2016.1162175; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Westerberg H, 2007, PHYSIOL BEHAV, V92, P186, DOI 10.1016/j.physbeh.2007.05.041; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wilz G, 2007, BRAIN INJURY, V21, P39, DOI 10.1080/02699050601121996; Worm-Smeitink M, 2017, J PSYCHOSOM RES, V98, P40, DOI 10.1016/j.jpsychores.2017.05.007; Zigmond AS, 1983, ACTA PSYCHIAT SCAND, P67; Zinn S, 2004, ARCH PHYS MED REHAB, V85, P1084, DOI 10.1016/j.apmr.2003.10.022	54	15	16	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2017	12	11							e0187582	10.1371/journal.pone.0187582	http://dx.doi.org/10.1371/journal.pone.0187582			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM8YO	29145410	Green Submitted, Green Published, gold			2023-01-03	WOS:000415378800020
J	Gutierrez, JKT; Zanatta, GC; Ortega, ALM; Balastegui, MIC; Sanita, PV; Pavarina, AC; Barbugli, PA; Mima, EGD				Trigo Gutierrez, Jeffersson Krishan; Zanatta, Gabriela Cristina; Mira Ortega, Ana Laura; Cuba Balastegui, Maria Isabella; Sanita, Paula Volpato; Pavarina, Ana Claudia; Barbugli, Paula Aboud; de Oliveira Mima, Ewerton Garcia			Encapsulation of curcumin in polymeric nanoparticles for antimicrobial Photodynamic Therapy	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; STREPTOCOCCUS-MUTANS; CANDIDA-ALBICANS; BIOFILM FORMATION; LOADED PLGA; ALAMAR BLUE; FORMULATION; INACTIVATION; PHARMACOKINETICS; PHOTOSENSITIZER	Curcumin (CUR) has been used as photosensitizer in antimicrobial Photodynamic Therapy (aPDT). However its poor water solubility, instability, and scarce bioavalibility hinder its in vivo application. The aim of this study was to synthesize curcumin in polymeric nanoparticles (NP) and to evaluate their antimicrobial photodynamic effect and cytoxicity. CUR in anionic and cationic NP was synthesized using polylactic acid and dextran sulfate by the nanoprecipitation method. For cationic NP, cetyltrimethylammonium bromide was added. CUR-NP were characterized by physicochemical properties, photodegradation, encapsulation efficiency and release of curcumin from nanoparticles. CUR-NP was compared with free CUR in 10% dimethyl sulfoxide (DMSO) as a photosensitizer for aPDT against planktonic and biofilms (mono-, dual-and triple-species) cultures of Streptococcus mutans, Candida albicans and Methicillin-Resistant Staphylococcus aureus. The cytotoxicity effect of formulations was evaluated on keratinocytes. Data were analysed by parametric (ANOVA) and non-parametric (Kruskal-Wallis) tests (alpha = 0.05). CUR-NP showed alteration in the physicochemical properties along time, photodegradation similar to free curcumin, encapsulation efficiency up to 67%, and 96% of release after 48h. After aPDT planktonic cultures showed reductions from 0.78 loglo to complete eradication, while biofilms showed no antimicrobial effect or reductions up to 4.44 loglo. Anionic CUR-NP showed reduced photoinactivation of biofilms. Cationic CUR-NP showed microbicidal effect even in absence of light. Anionic formulations showed no cytotoxic effect compared with free CUR and cationic CURNP and NP. The synthesized formulations improved the water solubility of CUR, showed higher antimicrobial photodynamic effect for planktonic cultures than for biofilms, and the encapsulation of CUR in anionic NP reduced the cytotoxicity of 10% DMSO used for free CUR.	[Trigo Gutierrez, Jeffersson Krishan; Zanatta, Gabriela Cristina; Mira Ortega, Ana Laura; Cuba Balastegui, Maria Isabella; Sanita, Paula Volpato; Pavarina, Ana Claudia; Barbugli, Paula Aboud; de Oliveira Mima, Ewerton Garcia] Sao Paulo State Univ, UNESP, Sch Dent, Dept Dent Mat & Prosthodont, Araraquara, SP, Brazil	Universidade Estadual Paulista	Mima, EGD (corresponding author), Sao Paulo State Univ, UNESP, Sch Dent, Dept Dent Mat & Prosthodont, Araraquara, SP, Brazil.	ewertonmima@foar.unesp.br	Barbugli, Paula/D-7148-2013; Pavarina, Ana Claudia/J-8640-2013; Trigo-Gutierrez, Jeffersson K./G-2648-2019; Trigo-Gutierrez, Jeffersson Krishan/F-9246-2017; Mima, Ewerton/F-9496-2014; Sanitá, Paula/A-7777-2015; Mima, Ewerton/X-5176-2019; Barbugli, Paula/AAK-8605-2021	Trigo-Gutierrez, Jeffersson Krishan/0000-0002-1004-2429; Mima, Ewerton/0000-0002-9575-7625; Mima, Ewerton/0000-0002-9575-7625; Ortega Granados, Ana Laura/0000-0002-5727-3371; Barbugli, Paula/0000-0002-0078-1172	Sao Paulo Research Foundation (FAPESP) [2013/23165-5, 2014/18345-7, 2014/20119-5]; National Counsel of Technological and Scientific Development [446401/2014-5]; Coordination for the Improvement of Higher Education Personnel (CAPES); Program of Scientific Initiation [30641, 34828, 34848, 30288]; PROINTER PROPe/PROPG [1732]; Sao Paulo Research Foundation (FAPESP, RIDC, CEPOF) [2013/07276-1]	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); National Counsel of Technological and Scientific Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Program of Scientific Initiation; PROINTER PROPe/PROPG; Sao Paulo Research Foundation (FAPESP, RIDC, CEPOF)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by Sao Paulo Research Foundation (FAPESP): grant numbers 2013/23165-5 (EGOM), 2014/18345-7 (ALMO), 2014/20119-5 (EGOM), www.fapesp.br; Sao Paulo Research Foundation (FAPESP, RIDC, CEPOF): grant number 2013/07276-1 (ACP), http://cepid.fapesp.br/en/centro/17/; National Counsel of Technological and Scientific Development: grant number 446401/2014-5 (EGOM), www.cnpq.br; Coordination for the Improvement of Higher Education Personnel (CAPES) (JKTG), www.capes.gov.br; Program of Scientific Initiation: 30641, 34828 (MICB), 30288, and 34848 (GCZ), http://prope.unesp.br/pibic/; PROINTER PROPe/PROPG 03/2017, grant 1732 (EGOM), www.unesp.br/prope.	Al-Fattani MA, 2006, J MED MICROBIOL, V55, P999, DOI 10.1099/jmm.0.46569-0; Andrade MC, 2013, ARCH ORAL BIOL, V58, P200, DOI 10.1016/j.archoralbio.2012.10.011; Araujo NC, 2012, PHOTOMED LASER SURG, V30, P393, DOI 10.1089/pho.2011.3195; Arunraj TR, 2014, J BIOMED NANOTECHNOL, V10, P238, DOI 10.1166/jbn.2014.1786; Baltazar LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120179; BENTRIVEDI A, 1990, AGR BIOL CHEM TOKYO, V54, P2961; Bhawana, 2011, J AGR FOOD CHEM, V59, P2056, DOI 10.1021/jf104402t; Cassone A, 2012, AIDS, V26, P1457, DOI 10.1097/QAD.0b013e3283536ba8; Castilho RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010503; Chereddy KK, 2013, J CONTROL RELEASE, V171, P208, DOI 10.1016/j.jconrel.2013.07.015; Cieplik F, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00405; Quishida CCC, 2016, LASER MED SCI, V31, P997, DOI 10.1007/s10103-016-1942-7; Couvreur P, 2002, CRIT REV THER DRUG, V19, P99, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i2.10; DAHL TA, 1989, ARCH MICROBIOL, V151, P183, DOI 10.1007/BF00414437; Dias KD, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-1031-5; Ribeiro APD, 2015, LASER MED SCI, V30, P549, DOI 10.1007/s10103-013-1354-x; Ribeiro APD, 2013, LASER MED SCI, V28, P391, DOI 10.1007/s10103-012-1064-9; Dovigo LN, 2011, LASER SURG MED, V43, P927, DOI 10.1002/lsm.21110; Dovigo LN, 2011, PHOTOCHEM PHOTOBIOL, V87, P895, DOI 10.1111/j.1751-1097.2011.00937.x; Falsetta ML, 2014, INFECT IMMUN, V82, P1968, DOI 10.1128/IAI.00087-14; Farah S, 2016, ADV DRUG DELIVER REV, V107, P367, DOI 10.1016/j.addr.2016.06.012; Gaumet M, 2008, EUR J PHARM BIOPHARM, V69, P1, DOI 10.1016/j.ejpb.2007.08.001; Ghosh D, 2012, CHEM-BIOL INTERACT, V195, P206, DOI 10.1016/j.cbi.2011.12.004; Gunes H, 2016, TOXICOL IND HEALTH, V32, P246, DOI 10.1177/0748233713498458; Hamblin MR, 2016, CURR OPIN MICROBIOL, V33, P67, DOI 10.1016/j.mib.2016.06.008; Hamid R, 2004, TOXICOL IN VITRO, V18, P703, DOI 10.1016/j.tiv.2004.03.012; Hazzah HA, 2015, J PHARM SCI-US, V104, P3913, DOI 10.1002/jps.24590; Hegge AB, 2012, EUR J PHARM SCI, V47, P65, DOI 10.1016/j.ejps.2012.05.002; Hu P, 2013, ARCH ORAL BIOL, V58, P1343, DOI 10.1016/j.archoralbio.2013.05.004; Junqueira JC, 2012, LASER MED SCI, V27, P1205, DOI 10.1007/s10103-012-1050-2; Khalil NM, 2013, COLLOID SURFACE B, V101, P353, DOI 10.1016/j.colsurfb.2012.06.024; Kiesslich T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/840417; Krausz AE, 2015, NANOMED-NANOTECHNOL, V11, P195, DOI 10.1016/j.nano.2014.09.004; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Lemos JA, 2013, MICROBIOL-SGM, V159, P436, DOI 10.1099/mic.0.066134-0; Loo CY, 2016, J AGR FOOD CHEM, V64, P2513, DOI 10.1021/acs.jafc.5b04559; Maghsoudi A, 2017, MAT SCI ENG C-MATER, V75, P1259, DOI 10.1016/j.msec.2017.03.032; Martins CVB, 2009, J ANTIMICROB CHEMOTH, V63, P337, DOI 10.1093/jac/dkn488; Moghadamtousi SZ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/186864; Mohamed F, 2008, J PHARM SCI-US, V97, P71, DOI 10.1002/jps.21082; Mohanty C, 2010, BIOMATERIALS, V31, P6597, DOI 10.1016/j.biomaterials.2010.04.062; Mukerjee A, 2009, ANTICANCER RES, V29, P3867; Mun SH, 2014, MOLECULES, V19, P18283, DOI 10.3390/molecules191118283; Nakonieczna J, 2017, LASER MED SCI, V32, P1667, DOI 10.1007/s10103-016-2107-4; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; Oud Lavi, 2016, J Clin Med Res, V8, P40, DOI 10.14740/jocmr2387w; Paschoal MA, 2013, PHOTODIAGN PHOTODYN, V10, P313, DOI 10.1016/j.pdpdt.2013.02.002; Pereira CA, 2011, LASER MED SCI, V26, P341, DOI 10.1007/s10103-010-0852-3; Ramalingam N, 2015, J BIOMED MATER RES A, V103, P16, DOI 10.1002/jbm.a.35138; Russotto V, 2015, INFECT DRUG RESIST, V8, P287, DOI 10.2147/IDR.S48810; SALTON MRJ, 1951, J GEN MICROBIOL, V5, P391, DOI 10.1099/00221287-5-2-391; Sardi JCO, 2013, J MED MICROBIOL, V62, P10, DOI 10.1099/jmm.0.045054-0; Sartori T, 2008, J CHROMATOGR SCI, V46, P505, DOI 10.1093/chromsci/46.6.505; Shah AA, 2014, APPL MICROBIOL BIOT, V98, P3437, DOI 10.1007/s00253-014-5558-1; Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019; Song J, 2012, EUR J CLIN MICROBIOL, V31, P1347, DOI 10.1007/s10096-011-1448-y; Soukos NS, 2011, PERIODONTOL 2000, V55, P143, DOI 10.1111/j.1600-0757.2010.00346.x; Taraszkiewicz A, 2013, APPL ENVIRON MICROB, V79, P3692, DOI 10.1128/AEM.00748-13; Tortik N, 2016, PHOTOCH PHOTOBIO SCI, V15, P187, DOI 10.1039/c5pp00393h; Tortik N, 2014, PHOTOCH PHOTOBIO SCI, V13, P1402, DOI 10.1039/c4pp00123k; Tsai YM, 2011, INT J PHARMACEUT, V416, P331, DOI 10.1016/j.ijpharm.2011.06.030; Tyagi P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121313; Udompornmongkol P, 2015, J BIOMATER APPL, V30, P537, DOI 10.1177/0885328215594479; Vauthier C, 2009, PHARM RES-DORDR, V26, P1025, DOI 10.1007/s11095-008-9800-3; Vrignaud S, 2011, BIOMATERIALS, V32, P8593, DOI 10.1016/j.biomaterials.2011.07.057; Winter S, 2013, PHOTOCH PHOTOBIO SCI, V12, P1795, DOI 10.1039/c3pp50095k; Yallapu MM, 2010, J COLLOID INTERF SCI, V351, P19, DOI 10.1016/j.jcis.2010.05.022; Ye Y, 2014, INT J NANOMED, V9, P5157, DOI 10.2147/IJN.S71365; Zago CE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123206; Zou WW, 2009, NANOSCALE RES LETT, V4, P982, DOI 10.1007/s11671-009-9345-3	70	61	63	2	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2017	12	11							e0i 87418	10.1371/journal.pone.0187418	http://dx.doi.org/10.1371/journal.pone.0187418			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL7JU	29107978	Green Submitted, gold, Green Published			2023-01-03	WOS:000414424600028
J	Furukawa, K; Tanemura, M; Miyoshi, E; Eguchi, H; Nagano, H; Matsunami, K; Nagaoka, S; Yamada, D; Asaoka, T; Noda, T; Wada, H; Kawamoto, K; Goto, K; Taniyama, K; Mori, M; Doki, Y				Furukawa, Kenta; Tanemura, Masahiro; Miyoshi, Eiji; Eguchi, Hidetoshi; Nagano, Hiroaki; Matsunami, Katsuyoshi; Nagaoka, Satoshi; Yamada, Daisaku; Asaoka, Tadafumi; Noda, Takehiro; Wada, Hiroshi; Kawamoto, Koichi; Goto, Kunihito; Taniyama, Kiyomi; Mori, Masaki; Doki, Yuichiro			A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express alpha-gal epitopes	PLOS ONE			English	Article							ANTI-GAL; DENDRITIC CELLS; PREOPERATIVE CHEMORADIATION; INCREASED IMMUNOGENICITY; COMBINATION THERAPY; IMMUNE-RESPONSES; IN-VITRO; T-CELLS; ADENOCARCINOMA; GEMCITABINE	Objectives Single-agent immunotherapy is ineffective against poorly immunogenic cancers, including pancreatic ductal adenocarcinoma (PDAC). The aims of this study were to demonstrate the feasibility of production of novel autologous tumor lysate vaccines from resected PDAC tumors, and verify vaccine safety and efficacy. Methods Fresh surgically resected tumors obtained from human patients were processed to enzymatically synthesize alpha-gal epitopes on the carbohydrate chains of membrane glycoproteins. Processed membranes were analyzed for the expression of alpha-gal epitopes and the binding of anti-Gal, and vaccine efficacy was assessed in vitro and in vivo. Results Effective synthesis of alpha-gal epitopes was demonstrated after processing of PDAC tumor lysates from 10 different patients, and tumor lysates readily bound an anti-Gal monoclonal antibody. alpha-gal(+) PDAC tumor lysate vaccines elicited strong antibody production against multiple tumor-associated antigens and activated multiple tumor-specific T cells. The lysate vaccines stimulated a robust immune response in animal models, resulting in tumor suppression and a significant improvement in survival without any adverse events. Conclusions Our data suggest that alpha- gal(+) PDAC tumor lysate vaccination may be a practical and effective new immunotherapeutic approach for treating pancreatic cancer.	[Furukawa, Kenta; Tanemura, Masahiro] Osaka Police Hosp, Dept Gastroenterol Surg, Osaka, Japan; [Miyoshi, Eiji] Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Osaka, Japan; [Eguchi, Hidetoshi; Nagaoka, Satoshi; Yamada, Daisaku; Asaoka, Tadafumi; Noda, Takehiro; Wada, Hiroshi; Kawamoto, Koichi; Goto, Kunihito; Mori, Masaki; Doki, Yuichiro] Osaka Univ, Grad Sch Med, Dept Surg, Osaka, Japan; [Nagano, Hiroaki] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol Breast & Endocrine Surg, Yamaguchi, Japan; [Matsunami, Katsuyoshi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Phamacognosy, Hiroshima, Japan; [Taniyama, Kiyomi] Natl Hosp Org, Kure Med Ctr, Inst Clin Res, Kure, Japan; [Taniyama, Kiyomi] Chugoku Canc Ctr, Kure, Japan	Osaka Police Hospital; Osaka University; Osaka University; Yamaguchi University; Hiroshima University	Tanemura, M (corresponding author), Osaka Police Hosp, Dept Gastroenterol Surg, Osaka, Japan.	tanemuram@oph.gr.jp	Matsunami, Katsuyoshi/AHC-4234-2022	Matsunami, Katsuyoshi/0000-0002-8034-0253; Noda, Takehiro/0000-0002-6768-5783	Ministry of Education, Sports and Culture of Japan [16K10618]	Ministry of Education, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by a grant from the Ministry of Education, Sports and Culture of Japan to M. T. (No. 16K10618).	Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brossart Peter, 1997, Blood, V90, P1594; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Chen ZC, 2001, GLYCOBIOLOGY, V11, P577, DOI 10.1093/glycob/11.7.577; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Deguchi T, 2010, CANCER RES, V70, P5259, DOI 10.1158/0008-5472.CAN-09-4313; Dodson LF, 2011, IMMUNOTHERAPY-UK, V3, P517, DOI [10.2217/IMT.11.10, 10.2217/imt.11.10]; Eguchi H, 2014, CANCER CHEMOTH PHARM, V73, P309, DOI 10.1007/s00280-013-2357-9; Eguchi H, 2013, HEPATO-GASTROENTEROL, V60, P904, DOI 10.5754/hge12974; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; EVANS DB, 1992, ARCH SURG-CHICAGO, V127, P1335; Evans DB, 2008, J CLIN ONCOL, V26, P3496, DOI 10.1200/JCO.2007.15.8634; Fields RC, 1998, P NATL ACAD SCI USA, V95, P9482, DOI 10.1073/pnas.95.16.9482; Galili U, 2003, GYNECOL ONCOL, V90, P100, DOI 10.1016/S0090-8258(03)00148-3; Galili U, 1997, IMMUNOL TODAY, V18, P281, DOI 10.1016/S0167-5699(97)80024-2; Galili U, 2013, IMMUNOLOGY, V140, P1, DOI 10.1111/imm.12110; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Gillen S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000267; Guillerey C, 2015, J CLIN INVEST, V125, P2077, DOI 10.1172/JCI77181; Hartwig W, 2013, LANCET ONCOL, V14, pE476, DOI 10.1016/S1470-2045(13)70172-4; Hassan R, 2005, AM J CLIN PATHOL, V124, P838, DOI 10.1309/F1B64CL7H8VJKEAF; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; HOFFMAN JP, 1995, AM J SURG, V169, P71, DOI 10.1016/S0002-9610(99)80112-3; Kakizaki A, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1047584; Kobayashi T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.990793; Koido S, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/267539; LaTemple DC, 1998, XENOTRANSPLANTATION, V5, P191, DOI 10.1111/j.1399-3089.1998.tb00027.x; LaTemple DC, 1999, CANCER RES, V59, P3417; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; Motta JM, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4753607; Ohigashi H, 2009, ANN SURG, V250, P88, DOI 10.1097/SLA.0b013e3181ad65cc; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Pandolfi F, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/894704; Qu CF, 2004, BRIT J CANCER, V91, P2086, DOI 10.1038/sj.bjc.6602232; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Saito H, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1621; Schnurr M, 2002, CANCER RES, V62, P2347; Shen ZH, 1997, J IMMUNOL, V158, P2723; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soares KC, 2012, CANCER J, V18, P642, DOI 10.1097/PPO.0b013e3182756903; Spitz FR, 1997, J CLIN ONCOL, V15, P928, DOI 10.1200/JCO.1997.15.3.928; Tanemura M, 2000, J CLIN INVEST, V105, P301, DOI 10.1172/JCI7358; Tanemura M, 2013, CANCER SCI, V104, P282, DOI 10.1111/cas.12084; Tanida T, 2015, INT J ONCOL, V46, P78, DOI 10.3892/ijo.2014.2717; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369	48	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2017	12	10							e0184901	10.1371/journal.pone.0184901	http://dx.doi.org/10.1371/journal.pone.0184901			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9WD	29077749	Green Published, Green Submitted, gold			2023-01-03	WOS:000413861200002
J	Zaman, M; Hanif, M; Shaheryar, ZA				Zaman, Muhammad; Hanif, Muhammad; Shaheryar, Zaib Ali			Development of Tizanidine HCI-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation	PLOS ONE			English	Article							ARABINOXYLAN; FORMULATION; DELIVERY; PHARMACOKINETICS; RABBITS; SINGLE	The purpose of the study was to develop Tizanidine HCI (TZN) and Meloxicam (MLX) loaded bilayer mucoadhesive films intended for buccal administration, aiming to enhance the bioavailability. Bilayer films were prepared by solvent evaporation technique selecting arabinoxylan (ARX) as a sustained release (SR) layer forming polymer and hydroxypropyl methylcellulose (HPMC) E-15 as an immediate release (IR) layer-forming polymer. Prepared films were subjected to in-vitro drug release, surface morphology, mechanical strength, compatibility of the ingredients, drug contents, ex-vivo mucoadhesion strength and drug permeation. Crossover study design was applied to study the in-vivo pharmacokinetics by using albino rabbits. Various pharmacokinetic parameters including AUC, C-max, t(max) and t(1/2) of both drugs loaded in films were compared with standard solution/dispersion administered to the rabbits at the dose of 1 mg/kg. The results unveiled instant release and permeation of MLX from IR layer, while good controlled release and permeation characteristics of TZN from SR films over 8 h. films were of uniform thickness with smooth surface and satisfactory mechanical strength. Mucoadhesion strength was sufficient to provide suitable contact time with mucosal membrane. The pharmacokinetic study exhibited prompt absorption of MLX with better AUC (0-t) (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and C-max (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion. Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC (0-t) (1043.4 ng/ml*h vs 149.1 ng/ml*h) and C-max (91.92 ng/ml vs 42.29 ng/ml) from oral solution. A statistical investigation disclosed a significantly improved pharmacokinetics of TZN and MLX after their absorption across buccal route following administration of buccal film (p<0.05). ARX proved expedient and bilayer buccal films as a drug delivery system ascertained the dual effect of providing instant release of one active agent and persistent release of another one with improved pharmacokinetics.	[Zaman, Muhammad; Hanif, Muhammad] Bahauddin Zakariya Univ, Dept Pharm, Multan, Pakistan; [Zaman, Muhammad; Shaheryar, Zaib Ali] Univ Lahore, Fac Pharm, Lahore, Pakistan	Bahauddin Zakariya University; University of Lahore	Hanif, M (corresponding author), Bahauddin Zakariya Univ, Dept Pharm, Multan, Pakistan.	muhammadhanif14@yahoo.com						Abd Elbary A, 2012, B FACULTY PHARM, V50, P89; Aher ND, 2014, SCI WORLD J, DOI 10.1155/2014/297603; Akbar J, 2012, CARBOHYD POLYM, V88, P1348, DOI 10.1016/j.carbpol.2012.02.016; Bahri-Najafi GK, 2012, RES PHARM SCI, V7, pS343; Bashir S, 2014, PAK J PHARM SCI, V27, P1761; Dodla S, 2013, ASIAN J PHARM CLIN R, V6, P39; El-Mahrouk GM, 2014, INT J PHARMACEUT, V467, P100, DOI 10.1016/j.ijpharm.2014.03.049; Eroglu H., 2009, HACETTEPE U J FACULT, P115; Erum A, 2015, DRUG CHEM TOXICOL, V38, P300, DOI 10.3109/01480545.2014.956219; Hanif M, 2017, DARU, V25, DOI 10.1186/s40199-017-0172-2; Henney HR, 2008, CLIN THER, V30, P2263, DOI 10.1016/j.clinthera.2008.12.014; Iqbal MS, 2011, CARBOHYD POLYM, V83, P1218, DOI 10.1016/j.carbpol.2010.09.024; Jain NK, 2002, LIFE SCI, V70, P2857, DOI 10.1016/S0024-3205(02)01549-7; Jay S, 2002, J PHARM SCI, V91, P2016, DOI 10.1002/jps.10198; Ketul P., 2013, IJPTP, V4, P655; Kimble B, 2013, J VET PHARMACOL THER, V36, P486, DOI 10.1111/jvp.12038; Koland M, 2011, INT J PHARM INVESTIG, V1, P164, DOI 10.4103/2230-973X.85967; Kreuder AJ, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-85; Kumar R, 2014, ASIAN J PHARM RES, V4, P47; Moawad FA, 2017, DRUG DELIV, V24, P252, DOI 10.1080/10717544.2016.1245369; Montoya L, 2004, VET RES COMMUN, V28, P415, DOI 10.1023/B:VERC.0000034995.81994.49; Patel MM, 2011, DRUG DELIV, V18, P281, DOI 10.3109/10717544.2010.538447; Prabhu P, 2011, INT J PHARM INVESTIG, V1, P99, DOI 10.4103/2230-973X.82417; Rajesh K., 2012, INT J PHARM RES, V3, P212; Rana P, 2013, DRUG DELIV, V20, P224, DOI 10.3109/10717544.2013.779331; Saghir S, 2008, CARBOHYD POLYM, V74, P309, DOI 10.1016/j.carbpol.2008.02.019; Singh AV, 2011, J PHARM ANA, V1, P251, DOI 10.1016/j.jpha.2011.08.001; Singla R, 2003, PHARM DEV TECHNOL, V8, P229, DOI 10.1081/PDT-120022152; Thimmasetty J, 2008, PAK J PHARM SCI, V21, P241; Turner PV, 2006, COMPARATIVE MED, V56, P63; Zaman M, 2016, ACTA POL PHARM, V73, P1351; Zaman M, 2016, BRIT J PHARM RES, V11, DOI 10.9734/BJPR/2016/23976	32	19	20	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194410	10.1371/journal.pone.0194410	http://dx.doi.org/10.1371/journal.pone.0194410			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA1RF	29566073	Green Published, gold, Green Submitted			2023-01-03	WOS:000428093900062
J	Yoon, J; Kanamori, A; Fujii, K; Isoda, H; Okura, T				Yoon, Jieun; Kanamori, Akihiro; Fujii, Keisuke; Isoda, Hiroko; Okura, Tomohiro			Evaluation of maslinic acid with whole -body vibration training in elderly women with knee osteoarthritis	PLOS ONE			English	Article							FUNCTIONAL PERFORMANCE; JAPANESE WOMEN; PAIN; INDIVIDUALS; ACTIVATION; STRENGTH; EFFUSION; EXERCISE; WEAKNESS; PROGRAM	Purpose Maslinic acid (MA) is a component derived from a natural olive-based extract known to have pharmacological functions that include suppressing inflammation. This study examined how MA, in conjunction with whole-body vibration training (WBVT), can improve knee and muscle function in elderly women with knee osteoarthritis (OA). Methods The study was a double-blinded, placebo-controlled, randomized intervention study that enrolled individuals with knee pain. Participants were 26 females aged 65-85 years with knee OA. They performed WBVT and ingested either 16.7 mg of MA or a placebo daily for 20 weeks. We compared the effect of WBVT with placebo (WBVT/P) and WBVT with MA (WBVT/MA) in participants with various degrees of knee OA (Kellgren and Lawrence (K-L) grade) using the Japanese Orthopaedic Association (JOA) score and isokinetic dynamometer measurements to evaluate knee and muscle function with two-way ANOVA. Results Based on the results of two-way ANOVA analysis of muscle function measurements, there was significant interaction (time x group) (P = 0.03) in the "isokinetic extension peak torque" domain for severe OA (K-L grade >= 3). The simple main effect of time in the WBVT/MA group (P = 0.04) contributed to this interaction. The JOA score for WBVT/MA supported the main effect of group as having a significant correlation in the "pain on walking" (P = 0.04) and "range of motion" (P < 0.01) domains. Participants with severe knee OA in the WBVT/MA group improved in these domains, whereas the WBVT/P group had few positive results. Conclusions Participants with severe OA who ingested MA in conjunction with WBVT improved their knee and muscle function. This study suggests that ingesting the anti-inflammatory supplement MA while participating in WBVT, elderly women can reduce knee OA and improve their knee muscle strength.	[Yoon, Jieun; Okura, Tomohiro] Univ Tsukuba, Fac Hlth & Sport Sci, Tsukuba, Ibaraki, Japan; [Kanamori, Akihiro] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki, Japan; [Fujii, Keisuke] Univ Tsukuba, Doctoral Program Phys Educ Hlth & Sport Sci, Tsukuba, Ibaraki, Japan; [Isoda, Hiroko] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki, Japan; [Isoda, Hiroko] Univ Tsukuba, Alliance Res North Africa ARENA, Tsukuba, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba	Yoon, J (corresponding author), Univ Tsukuba, Fac Hlth & Sport Sci, Tsukuba, Ibaraki, Japan.	yoon.jieun.fu@u.tsukuba.ac.jp	FUJII, KEISUKE/AAQ-8188-2021	FUJII, KEISUKE/0000-0002-8257-0503; YOON, Jieun/0000-0003-2934-8337; Isoda, Hiroko/0000-0002-1399-9541	Japan Science and Technology Agency	Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	The Japan Science and Technology Agency funded this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The Japan Science and Technology Agency funded this study. The results of the study are presented clearly, honestly and without fabrication, falsification or inappropriate data manipulation. The authors have no relevant conflicts of interest. The results of the present study do not constitute endorsement by PLOS ONE.	BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Chouiab K, 2016, IND CROP PROD, V85, P287, DOI 10.1016/j.indcrop.2016.03.024; D'Agostino MA, 2005, ANN RHEUM DIS, V64, P1703, DOI 10.1136/ard.2005.037994; Fransen M, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2015-095424; Fukumitsu S, 2016, J CLIN BIOCHEM NUTR, V59, P220, DOI 10.3164/jcbn.16-40; Fukumitsu S, 2016, MOL NUTR FOOD RES, V60, P399, DOI 10.1002/mnfr.201500465; Fukutani N, 2016, CLIN RHEUMATOL, V35, P2307, DOI 10.1007/s10067-016-3251-8; Hopson Scott C JM, 2007, HDB ACCELERATION TRA; Huang LF, 2011, EUR J PHARMACOL, V672, P169, DOI 10.1016/j.ejphar.2011.09.175; Ikeda S, 2005, J ORTHOP SCI, V10, P121, DOI 10.1007/s00776-004-0876-2; Konishi I, 2009, TOHOKU J EXP MED, V219, P91, DOI 10.1620/tjem.219.91; Koshino T, 1988, J JPN ORTHOP ASSOC, V62, P901; Lewek MD, 2004, J ORTHOP RES, V22, P110, DOI 10.1016/S0736-0266(03)00154-2; Martin AM, 2006, FREE RADICAL RES, V40, P295, DOI 10.1080/10715760500467935; Mathers JL, 2012, MUSCLE NERVE, V46, P407, DOI 10.1002/mus.23317; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Okuda M, 2012, J ORTHOP SCI, V17, P750, DOI 10.1007/s00776-012-0274-0; Patel S, 2010, ANN ROY COLL SURG, V92, P467, DOI 10.1308/003588410X12664192076052; Avelar NCP, 2011, J ALTERN COMPLEM MED, V17, P1149, DOI 10.1089/acm.2010.0782; Phueanpinit P, 2016, INT J CLIN PHARM-NET, V38, P1269, DOI 10.1007/s11096-016-0363-9; Rutherford DJ, 2012, OSTEOARTHR CARTILAGE, V20, P974, DOI 10.1016/j.joca.2012.05.014; Sanchez-Quesada C, 2015, EVID-BASED COMPL ALT, V2015, P1; Simao AP, 2012, ARCH PHYS MED REHAB, V93, P1692, DOI 10.1016/j.apmr.2012.04.017; Slemenda C, 1997, ANN INTERN MED, V127, P97, DOI 10.7326/0003-4819-127-2-199707150-00001; Suetta C, 2007, J APPL PHYSIOL, V102, P942, DOI 10.1152/japplphysiol.00067.2006; Symons TB, 2005, J GERONTOL A-BIOL, V60, P114, DOI 10.1093/gerona/60.1.114; Thorstensson CA, 2004, ANN RHEUM DIS, V63, P402, DOI 10.1136/ard.2003.007583; Torry MR, 2005, J SPORT SCI MED, V4, P1; Trans T, 2009, KNEE, V16, P256, DOI 10.1016/j.knee.2008.11.014; Tsuji T, 2014, KNEE, V21, P1088, DOI 10.1016/j.knee.2014.07.015; van den Tillaar R, 2006, J STRENGTH COND RES, V20, P192; Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774-009-0080-8	32	11	12	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2018	13	3							e0194572	10.1371/journal.pone.0194572	http://dx.doi.org/10.1371/journal.pone.0194572			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ9AH	29558490	Green Submitted, Green Published, gold			2023-01-03	WOS:000427901500044
J	Sharoni, SKA; Rahman, HA; Minhat, HS; Shariff-Ghazali, S; Ong, MHA				Sharoni, Siti Khuzaimah Ahmad; Rahman, Hejar Abdul; Minhat, Halimatus Sakdiah; Shariff-Ghazali, Sazlina; Ong, Mohd Hanafi Azman			The effects of self-efficacy enhancing program on foot self-care behaviour of older adults with diabetes: A randomised controlled trial in elderly care facility, Peninsular Malaysia	PLOS ONE			English	Article							QUALITY-OF-LIFE; HEALTH-PROMOTION; LOW-RISK; PEOPLE; VALIDATION; KNOWLEDGE; EDUCATION; ULCERATION; SCALE	Background Self-care behaviour is essential in preventing diabetes foot problems. This study aimed to evaluate the effectiveness of health education programs based on the self-efficacy theory on foot self-care behaviour for older adults with diabetes. Methods A randomised controlled trial was conducted for 12 weeks among older adults with diabetes in elderly care facility in Peninsular Malaysia. Six elderly care facility were randomly allocated by an independent person into two groups (intervention and control). The intervention group (three elderly care facility) received a health education program on foot self-care behaviour while the control group (three elderly care facility) received standard care. Participants were assessed at baseline, and at week-4 and week-12 follow-ups. The primary outcome was foot-self-care behaviour. Foot care self-efficacy (efficacy expectation), foot care outcome expectation, knowledge of foot care and quality of life were the secondary outcomes. Data were analysed with Mixed Design Analysis of Variance using the Statistical Package for the Social Sciences version 22.0. Results 184 respondents were recruited but only 76 met the selection criteria and were included in the analysis. Foot self-care behaviour, foot care self-efficacy (efficacy expectation), foot care outcome expectation and knowledge of foot care improved in the intervention group compared to the control group (p < 0.05). However, some of these improvements did not significantly differ compared to the control group for QoL physical symptoms and QoL psychosocial functioning (p > 0.05). Conclusion The self-efficacy enhancing program improved foot self-care behaviour with respect to the delivered program. It is expected that in the future, the self-efficacy theory can be incorporated into diabetes education to enhance foot self-care behaviour for elderly with diabetes living in other institutional care facilities.	[Sharoni, Siti Khuzaimah Ahmad] Univ Teknol MARA, Fac Hlth Sci, Ctr Nursing Studies, Puncak Alam Campus, Puncak Alam, Selangor, Malaysia; [Sharoni, Siti Khuzaimah Ahmad; Rahman, Hejar Abdul; Minhat, Halimatus Sakdiah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Community Hlth, Upm Serdang, Selangor, Malaysia; [Shariff-Ghazali, Sazlina] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Family Med, Upm Serdang, Selangor, Malaysia; [Ong, Mohd Hanafi Azman] Univ Teknol MARA, Fac Comp Sci & Math, Dept Stat, Segamat Campus, Segamat, Johor, Malaysia	Universiti Teknologi MARA; Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Teknologi MARA	Rahman, HA (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Community Hlth, Upm Serdang, Selangor, Malaysia.	hejar@upm.edu.my	Ong, Mohd Hanafi Azman/AAZ-9956-2020; Ahmad Sharoni, Siti Khuzaimah/HGU-9626-2022	Ong, Mohd Hanafi Azman/0000-0001-7964-7429; minhat, halimatus/0000-0001-9134-3284; Ahmad Sharoni, Siti Khuzaimah/0000-0002-6352-929X	Universiti Putra Malaysia Grant [GP-IPS/2015/9463500]; Malaysian Ministry of Education and Universiti Teknologi MARA	Universiti Putra Malaysia Grant; Malaysian Ministry of Education and Universiti Teknologi MARA	This work was supported by Universiti Putra Malaysia Grant (Project Code: GP-IPS/2015/9463500). Special thanks to the Malaysian Ministry of Education and Universiti Teknologi MARA for the scholarship support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas MY, 2012, PROCD SOC BEHV, V49, P127, DOI 10.1016/j.sbspro.2012.07.012; Abdullah MAH, 2009, ANN REPORT NATL ORTH; Adam J, 2014, JNP-J NURSE PRACT, V10, P42, DOI 10.1016/j.nurpra.2014.07.033; Aday L.A., 2006, DESIGNING CONDUCTING; [Anonymous], 2010, CONS STAND REP TRAIL; [Anonymous], 2012, J AM SCI; Baba M, 2015, PRIM CARE DIABETES, V9, P155, DOI 10.1016/j.pcd.2014.05.004; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Bandura A., 2016, ENCY HUMAN BEHAV, V4, P71; Bandura A, 1997, EFFICACY EXERCISE CO; Barlow J, 2002, PATIENT EDUC COUNS, V48, P177, DOI 10.1016/S0738-3991(02)00032-0; Borges WJ, 2008, WESTERN J NURS RES, V30, P325, DOI 10.1177/0193945907303104; Boutron I, 2008, ANN INTERN MED, P148; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Chen MY, 2011, J ADV NURS, V67, P2060, DOI 10.1111/j.1365-2648.2011.05678.x; Chin YF, 2013, J NURS RES, V21, P19, DOI 10.1097/jnr.0b013e3182828e59; Deakin TA, 2006, DIABETIC MED, V23, P944, DOI 10.1111/j.1464-5491.2006.01906.x; Desalu O O, 2011, Ghana Med J, V45, P60; Dorresteijn JA, 2014, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD001488.PUB5.REVIEW; Eigenmann CA, 2011, PRACT DIABETES, V28, P166, DOI 10.1002/pdi.1586; Fan LF, 2014, CLIN NURS RES, V23, P627, DOI 10.1177/1054773813491282; Fan LF, 2013, CAN J DIABETES, V37, P195, DOI 10.1016/j.jcjd.2013.03.020; Fernando ME, 2016, COCHRANE DB SYST REV, V1; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; IBM Corp, IBM SPSS STAT WINDOW; IDF (International Diabetes Federation), 2019, IDF DIABETES ATLAS; Institute for Public Health (IPH), 2015, NONC DIS RISK FACT O, VII; Institute of Medicine (U. S.), 2001, IMPR QUAL LONG TERM; International Diabetes Federation, 2013, IDF GLOB GUID MAN OL; International Working Group on the Diabetic Foot, 2014, INT CONS DIAB FOOT; Johnston P., 2009, NATL FORUM TEACHER E, V19, P1; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kawamura T, 2012, J DIABETES INVEST, V3, P413, DOI 10.1111/j.2040-1124.2012.00234.x; LAWSHE CH, 1975, PERS PSYCHOL, V28, P563, DOI 10.1111/j.1744-6570.1975.tb01393.x; letchuman G. R., 2010, Medical Journal of Malaysia, V65, P173; Lincoln NB, 2008, DIABETOLOGIA, V51, P1954, DOI 10.1007/s00125-008-1110-0; Litwak L, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-57; Maddux J.E., 1995, SELF EFFICACY ADAPTA; Mafauzy M, 2011, Med J Malaysia, V66, P175; Malaysian Diabetes Association, 2016, DIAB MAL 2013; Martin JJ, 2020, ROUT INT HANDB, P280; Ministry of Health Guideline Group New Zealand, 2011, RAP CHRON CAR SYST R; Ministry of Health Malaysia, 2007, MOD LAT PENG KES DEM; MOH, 2015, CLIN PRACT GUID MAN; National Diabetes Registry, 2013, NAT DIAB REG NAT DIA, V1; Netuveli G, 2008, BRIT MED BULL, V85, P113, DOI 10.1093/bmb/ldn003; Nezu S, 2014, J EPIDEMIOL, V24, P259, DOI 10.2188/jea.JE20130131; Ooi C P, 2011, Med J Malaysia, V66, P108; Poi PJH, 2004, AGE AGEING, V33, P444, DOI 10.1093/ageing/afh182; Pollock RD, 2004, DIABETES RES CLIN PR, V64, P117, DOI 10.1016/j.diabres.2003.10.014; Prazeres F, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/2251-6581-13-68; Resnick B, 2000, J GERONTOL B-PSYCHOL, V55, pS352, DOI 10.1093/geronb/55.6.S352; Seyyedrasooli Alehe, 2015, Int J Community Based Nurs Midwifery, V3, P141; Sharoni SKA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014393; Sheridan J, 2010, SPSS VERSION 17 0 WI; Shortridge-Baggett ERLaLM, 2002, SELF EFFICACY NURSIN; Sloan HL, 1998, THESIS; Social Welfare Department Malaysia, 2013, HOM OLD PERS; Standards of medical care in diabetes, 2015, DIABETES CARE, V38, pS56; Suhl EBP., 2006, DIABETES SPECTR, V19, P234, DOI [10.2337/diaspect.19.4.234, DOI 10.2337/DIASPECT.19.4.234]; Tan MY, 2008, PATIENT EDUC COUNS, V72, P252, DOI 10.1016/j.pec.2008.03.017; van der Bijl J J, 2001, Sch Inq Nurs Pract, V15, P189; Vileikyte L, 2003, DIABETES CARE, V26, P2549, DOI 10.2337/diacare.26.9.2549; Visvanathan R, 2005, EUR J CLIN NUTR, V59, P318, DOI 10.1038/sj.ejcn.1602075; Wan-Ibrahim WA, 2014, MIDDLE E J SCI RES, V20, P1457; Wan-Ibrahim WA, 2014, MIDDLE E J SCI RES, V20, P1461; Waxman R, 2003, J CLIN EPIDEMIOL, V56, P1092, DOI 10.1016/S0895-4356(03)00197-5; Williams IC, 2014, DIABETES EDUCATOR, V40, P231, DOI 10.1177/0145721713520570; Wu SFV, 2008, J FORMOS MED ASSOC, V107, P232, DOI 10.1016/S0929-6646(08)60141-2; Wu SFV, 2011, NURS HEALTH SCI, V13, P335, DOI 10.1111/j.1442-2018.2011.00625.x	70	31	31	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2018	13	3							e0192417	10.1371/journal.pone.0192417	http://dx.doi.org/10.1371/journal.pone.0192417			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FZ0JA	29534070	Green Submitted, gold, Green Published			2023-01-03	WOS:000427253500003
J	An, ZY; Aksoy, O; Zheng, TN; Fan, QW; Weiss, WA				An, Zhenyi; Aksoy, Ozlem; Zheng, Tina; Fan, Qi-Wen; Weiss, William A.			Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies	ONCOGENE			English	Review							PHASE-II; INTRATUMORAL HETEROGENEITY; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; TUMOR-SUPPRESSOR; GLIOMA GROWTH; CELL-SURVIVAL; IN-VITRO; ACTIVATION; AKT	Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.	[An, Zhenyi; Aksoy, Ozlem; Zheng, Tina; Fan, Qi-Wen; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94131 USA; [Weiss, William A.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94131 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94131 USA.; Weiss, WA (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.; Weiss, WA (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94131 USA.	waweiss@gmail.com		Weiss, William/0000-0003-2230-9132	Alex's Lemonade Stand Foundation; Program for Breakthrough Biomedical Research - Sandler Foundation; NIH [CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, CA82103]; Children's Tumor Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Ross K. MacNeill Foundation; St. Baldrick Foundation; Samuel G. Waxman Foundation; Evelyn and Mattie Anderson Chair; NATIONAL CANCER INSTITUTE [P30CA082103, U01CA217864, P01CA217959, R01CA159859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS089868, R01NS088355, R01NS091620] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Program for Breakthrough Biomedical Research - Sandler Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Ross K. MacNeill Foundation; St. Baldrick Foundation; Samuel G. Waxman Foundation; Evelyn and Mattie Anderson Chair; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	ZA is supported by the Alex's Lemonade Stand Foundation and by Program for Breakthrough Biomedical Research, which is partially funded by the Sandler Foundation. The Weiss lab is supported by NIH grants CA148699, NS091620, NS0883555, NS089868, CA183692, CA176287, and CA82103; the Alex's Lemonade Stand, Children's Tumor, Katie Dougherty, Pediatric Brain Tumor, Ross K. MacNeill, St. Baldrick, and Samuel G. Waxman Foundations; and the Evelyn and Mattie Anderson Chair.	Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Appelboom G, 2016, NEURO-ONCOLOGY, V18, P1601, DOI 10.1093/neuonc/now137; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Babic I, 2013, CELL METAB, V17, P1000, DOI 10.1016/j.cmet.2013.04.013; Barkovich KJ, 2012, CANCER DISCOV, V2, P450, DOI 10.1158/2159-8290.CD-11-0287; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bonavia R, 2012, ONCOGENE, V31, P4054, DOI 10.1038/onc.2011.563; Boyd PS, 2016, NANOSCALE, V8, P20037, DOI 10.1039/c6nr05880a; Brand TM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag1064; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chakravarti A, 2002, CANCER RES, V62, P200; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi BD, 2013, P NATL ACAD SCI USA, V110, P270, DOI 10.1073/pnas.1219817110; Chong DQ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1191-3; Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008; Chow KKH, 2011, IMMUNOTHERAPY-UK, V3, P423, DOI 10.2217/IMT.10.110; Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432; Cleary JM, 2015, INVEST NEW DRUG, V33, P671, DOI 10.1007/s10637-015-0234-6; Cloughesy TF, 2014, ANNU REV PATHOL-MECH, V9, P1, DOI 10.1146/annurev-pathol-011110-130324; Congdon KL, 2014, NEURO-ONCOLOGY, V16, pviii20, DOI 10.1093/neuonc/nou236; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Cvrljevic AN, 2011, J CELL SCI, V124, P2938, DOI 10.1242/jcs.083295; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Iglesia N, 2008, GENE DEV, V22, P449, DOI 10.1101/gad.1606508; Deschenes-Simard X, 2014, CANCER RES, V74, P412, DOI 10.1158/0008-5472.CAN-13-2381; Ding H, 2003, CANCER RES, V63, P1106; Dreier A, 2012, TUMOR BIOL, V33, P85, DOI 10.1007/s13277-011-0248-4; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Er EE, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004015; Eskilsson E, 2016, NEURO-ONCOLOGY, V18, P1644, DOI 10.1093/neuonc/now113; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Feng H, 2014, ONCOGENE, V33, P2504, DOI 10.1038/onc.2013.198; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109; Fousek K, 2015, CLIN CANCER RES, V21, P3384, DOI 10.1158/1078-0432.CCR-14-2675; Francis JM, 2014, CANCER DISCOV, V4, P956, DOI 10.1158/2159-8290.CD-13-0879; Furnari FB, 2015, NAT REV CANCER, V15, P302, DOI 10.1038/nrc3918; Gan HK, 2012, CANCER RES, V72, P2924, DOI 10.1158/0008-5472.CAN-11-3898; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garner JM, 2013, J BIOL CHEM, V288, P26167, DOI 10.1074/jbc.M113.477950; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Gong AH, 2015, CANCER RES, V75, P2337, DOI 10.1158/0008-5472.CAN-14-2800; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Greenall SA, 2015, ONCOGENE, V34, P5277, DOI 10.1038/onc.2014.448; Guo G, 2015, CANCER RES, V75, P3436, DOI 10.1158/0008-5472.CAN-15-0989; Halatsch ME, 2000, J NEUROSURG, V92, P297, DOI 10.3171/jns.2000.92.2.0297; Halatsch ME, 2004, J NEUROSURG, V100, P523, DOI 10.3171/jns.2004.100.3.0523; Han JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep11483; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Horvath S, 2006, P NATL ACAD SCI USA, V103, P17402, DOI 10.1073/pnas.0608396103; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iwanami A, 2013, P NATL ACAD SCI USA, V110, P4339, DOI 10.1073/pnas.1217602110; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318; Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963; Jun HJ, 2014, STEM CELLS, V32, P338, DOI 10.1002/stem.1554; Kadamur G, 2013, ANNU REV PHYSIOL, V75, P127, DOI 10.1146/annurev-physiol-030212-183750; Kancha RK, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-39; Katanasaka Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-31; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim J, 2007, CANCER RES, V67, P9229, DOI 10.1158/0008-5472.CAN-07-1333; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Lal A, 2002, CANCER RES, V62, P3335; Latha K, 2013, INT J CANCER, V132, P509, DOI 10.1002/ijc.27690; Lee JV, 2014, CELL METAB, V20, P306, DOI 10.1016/j.cmet.2014.06.004; Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Li LN, 2010, J NEUROSURG, V113, P192, DOI 10.3171/2010.2.JNS091211; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Liu F, 2015, MOL CELL, V60, P307, DOI 10.1016/j.molcel.2015.09.002; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Malkki H, 2016, NAT REV NEUROL, V12, DOI [10.1038/nrneurol.2016.79, 10.1038/nrneurol.2016.22, 10.1038/nrneurol.2016.78, 10.1038/nrneurol.2016.30, 10.1038/nrneurol.2016.117, 10.1038/nrneurol.2016.52, 10.1038/nrneurol.2016.58, 10.1038/nrneurol.2016.151, 10.1038/nrneurol.2016.139, 10.1038/nrneurol.2016.175]; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Mawrin C, 2003, INT J ONCOL, V23, P641; Mayer BJ, 2015, NAT REV MOL CELL BIO, V16, P691, DOI 10.1038/nrm4068; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Neyns B, 2009, ANN ONCOL, V20, P1596, DOI 10.1093/annonc/mdp032; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Novellasdemunt L, 2013, J BIOL CHEM, V288, P10640, DOI 10.1074/jbc.M113.455998; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Ozes ON, 1999, NATURE, V401, P82; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Reardon DA, 2015, NEURO-ONCOLOGY, V17, P430, DOI 10.1093/neuonc/nou160; Reardon DA, 2013, CLIN CANCER RES, V19, P900, DOI 10.1158/1078-0432.CCR-12-1707; Rosell R, 2006, CLIN CANCER RES, V12, P7222, DOI 10.1158/1078-0432.CCR-06-0627; Roth P, 2014, NEURO-ONCOLOGY, V16, pviii14, DOI 10.1093/neuonc/nou222; Sampson JH, 2009, MOL CANCER THER, V8, P2773, DOI 10.1158/1535-7163.MCT-09-0124; Schijns VEJC, 2015, VACCINE, V33, P2690, DOI 10.1016/j.vaccine.2015.03.095; Schuster J, 2015, NEURO-ONCOLOGY, V17, P854, DOI 10.1093/neuonc/nou348; See AP, 2012, J NEURO-ONCOL, V110, P359, DOI 10.1007/s11060-012-0981-6; Shinojima N, 2003, CANCER RES, V63, P6962; Shir A, 2002, NAT BIOTECHNOL, V20, P895, DOI 10.1038/nbt730; Singh B, 2014, ANNU REV PHYSIOL, V76, P275, DOI 10.1146/annurev-physiol-021113-170406; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Swartz AM, 2014, IMMUNOTHERAPY-UK, V6, P679, DOI [10.2217/IMT.14.21, 10.2217/imt.14.21]; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Tan CS, 2015, LANCET ONCOL, V16, pE447, DOI 10.1016/S1470-2045(15)00246-6; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; Uht RM, 2007, ONCOGENE, V26, P2885, DOI 10.1038/sj.onc.1210090; Unni AM, 2015, ELIFE, V4, DOI 10.7554/eLife.06907; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Weiss WA, 2003, CANCER RES, V63, P1589; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zahonero C, 2015, MOL CANCER THER, V14, P1548, DOI 10.1158/1535-7163.MCT-14-0736; ZUSSMAN BM, 2015, NEUROSURGERY, V76	149	228	237	5	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1561	1575		10.1038/s41388-017-0045-7	http://dx.doi.org/10.1038/s41388-017-0045-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29321659	Green Submitted, Green Accepted			2023-01-03	WOS:000428626700002
J	Corrales-Medina, VF; Dwivedi, G; Taljaard, M; Petrcich, W; Lima, JA; Yende, S; Kronmal, RA; Chirinos, JA				Corrales-Medina, Vicente F.; Dwivedi, Girish; Taljaard, Monica; Petrcich, William; Lima, Joao A.; Yende, Sachin; Kronmal, Richard A.; Chirinos, Julio A.			Coronary artery calcium before and after hospitalization with pneumonia: The MESA study	PLOS ONE			English	Article							RISK; ATHEROSCLEROSIS; EPIDEMIOLOGY; BURDEN; PLAQUE; TESTS	Background Epidemiological analyses demonstrate that pneumonia survivors have a higher risk of myocardial infarction than people with similar load of risk factors for atherosclerotic cardiovascular disease (ASCVD) but without pneumonia. This may be due to a higher baseline burden of ASCVD in patients with pneumonia that is not captured by the accounting of known ASCVD risk factors in epidemiological analyses or to unfavorable accelerating effects of pneumonia on atherosclerosis. Methods We analyzed data from the Multi-Ethnic Study of Atherosclerosis. We identified 54 participants that were hospitalized for pneumonia during study follow-up and that also had assessment of coronary artery calcium (CAC, an objective marker of coronary atherosclerotic burden) before and after this hospitalization. We matched them to 54 participants who were not hospitalized for pneumonia but that had CAC assessments at the same study visits as the pneumonia cases. We compared baseline CAC scores and their progression between groups. Results Baseline CAC scores were similar in both groups (median [IQR]; 6.3 [0-356.8] in pneumonia participants vs. 10.8 [0-178.3] in controls; p = 0.25). After a median of 4.8 years, the direction and magnitude of CAC score change, and the slope of CAC score progression between groups was also similar (median change [IQR], 21.8 [0 to 287.29] in participants with pneumonia versus 15.8 [0 to 140.94] in controls, p = 0.28; difference in slope, 7.7, 95% CI -9.0 to 24.6, p = 0.18). However, among participants with high baseline ASCVD risk (i.e. ACC/AHA 10-year risk estimate >= 7.5%), participants with pneumonia showed a larger increase in CAC scores ( median change [IQR]; 159.10 [38.55-407.34] versus 48.72 [0.97-246.99] in controls; p = 0.02) and a trend towards a steeper slope of CAC score progression (difference in slope, 19.7, 95% CI -6.6 to 45.6, p = 0.07). Conclusion Pneumonia may accelerate the progression of atherosclerosis in people with high baseline ASCVD risk.	[Corrales-Medina, Vicente F.; Dwivedi, Girish] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Corrales-Medina, Vicente F.; Taljaard, Monica; Petrcich, William] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Dwivedi, Girish] Univ Western Australia, Harry Perkins Inst Med Res, Perth, WA, Australia; [Dwivedi, Girish] Univ Western Australia, Fiona Stanley Hosp, Perth, WA, Australia; [Lima, Joao A.] Johns Hopkins Univ, Dept Cardiol, Baltimore, MD USA; [Yende, Sachin] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA USA; [Kronmal, Richard A.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; [Chirinos, Julio A.] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; University of Pennsylvania	Corrales-Medina, VF (corresponding author), Univ Ottawa, Dept Med, Ottawa, ON, Canada.; Corrales-Medina, VF (corresponding author), Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.	vcorrales@toh.on.ca		Taljaard, Monica/0000-0002-3978-8961; Corrales-Medina, Vicente/0000-0002-9691-491X	National Heart, Lung, and Blood Institute [HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; NCATS [UL1-TR-000040, UL1-TR-001079, UL1-TR-001420]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This research was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexopoulos N, 2011, NAT REV CARDIOL, V8, P616, DOI 10.1038/nrcardio.2011.149; Alexopoulos N, 2009, NAT REV CARDIOL, V6, P681, DOI 10.1038/nrcardio.2009.165; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; BLAND JM, 1994, BRIT MED J, V309, P248, DOI 10.1136/bmj.309.6949.248; Carr JJ, 2005, RADIOLOGY, V234, P35, DOI 10.1148/radiol.2341040439; Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229; File TM, 2010, POSTGRAD MED, V122, P130, DOI 10.3810/pgm.2010.03.2130; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Goff David C Jr, 2014, J Am Coll Cardiol, V63, P2935, DOI 10.1016/j.jacc.2013.11.005; Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011-JLR200; Hecht HS, 2015, JACC-CARDIOVASC IMAG, V8, P580, DOI 10.1016/j.jcmg.2015.02.006; Hecht HS, 2010, J AM COLL CARDIOL, V55, P1118, DOI 10.1016/j.jacc.2009.09.064; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Herrington W, 2016, CIRC RES, V118, P535, DOI 10.1161/CIRCRESAHA.115.307611; Kaynar AM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0469-1; Ludbrook J, 2013, CLIN EXP PHARMACOL P, V40, P357, DOI 10.1111/1440-1681.12086; Marrie Thomas J, 2005, Can Respir J, V12, P139; McEvoy JW, 2010, J AM COLL CARDIOL, V56, P1613, DOI 10.1016/j.jacc.2010.06.038; Min JK, 2010, J AM COLL CARDIOL, V55, P1110, DOI 10.1016/j.jacc.2009.08.088; Nadra I, 2005, CIRC RES, V96, P1248, DOI 10.1161/01.RES.0000171451.88616.c2; Naghavi M, 2003, CIRCULATION, V108, P1664, DOI 10.1161/01.CIR.0000087480.94275.97; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Wang CC, 2013, INT J CARDIOL, V168, P4480, DOI 10.1016/j.ijcard.2013.06.134	23	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2018	13	2							e0191750	10.1371/journal.pone.0191750	http://dx.doi.org/10.1371/journal.pone.0191750			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV4BG	29420547	Green Published, gold, Green Submitted			2023-01-03	WOS:000424517900021
J	Cheng, ML; Solit, DB				Cheng, Michael L.; Solit, David B.			Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TUMOR; DNA		[Cheng, Michael L.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave,Box 8, New York, NY 10065 USA; [Solit, David B.] Mem Sloan Kettering Canc Ctr, Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Solit, DB (corresponding author), Mem Sloan Kettering Canc Ctr, Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10065 USA.	solitd@mskcc.org	Solit, David B./AAC-5309-2019	Solit, David/0000-0002-6614-802X	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Garofalo A, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0333-9; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Hyman DM, 2017, J CLIN ONCOL, V35, P2501, DOI [10.1200/JCO.2017.35.18_suppl.LBA2501, DOI 10.1200/JCO.2017.35.18_SUPPL.LBA2501]; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Mandelker D, 2017, JAMA-J AM MED ASSOC, V318, P825, DOI 10.1001/jama.2017.11137; Middha S, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00084; Quigley D, 2017, CANCER DISCOV, V7, P999, DOI 10.1158/2159-8290.CD-17-0146; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	10	6	6	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2018	168	3					221	+		10.7326/M17-2940	http://dx.doi.org/10.7326/M17-2940			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV0CU	29310131	Green Accepted			2023-01-03	WOS:000424224300011
J	Johnson, JR; Russo, TA				Johnson, James R.; Russo, Thomas A.			Acute Pyelonephritis in Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							URINARY-TRACT-INFECTIONS; ACUTE UNCOMPLICATED PYELONEPHRITIS; DOUBLE-BLIND; TRIMETHOPRIM-SULFAMETHOXAZOLE; ANTIBIOTIC-TREATMENT; PRACTICE GUIDELINES; RANDOMIZED-TRIAL; BLOOD CULTURES; UNITED-STATES; CIPROFLOXACIN	An otherwise healthy 35-year-old woman presents with urinary urgency, dysuria, fever, malaise, nausea, and flank pain. During a recent trip to India, she took a fluoroquinolone for diarrhea. On examination, the temperature is 38.6 degrees C, the pulse 110 beats per minute, and the blood pressure 105/50 mm Hg; she has suprapubic and flank tenderness, without abdominal tenderness. The white-cell count is 16,500 per cubic millimeter, and the serum creatinine concentration 1.4 mg per deciliter (124 mu mol per liter) (most recent measurement before presentation, 0.8 mg per deciliter [71 mu mol per liter]). Urinalysis is positive for leukocyte esterase and nitrites. How would you evaluate and manage this case?	[Johnson, James R.] Minneapolis Vet Affairs VA Hlth Care Syst, Minneapolis, MN USA; [Johnson, James R.] Univ Minnesota, Minneapolis, MN USA; [Russo, Thomas A.] Univ Buffalo State Univ New York, Buffalo, NY USA; [Russo, Thomas A.] VA Western New York Hlth Care Syst, Buffalo, NY USA	University of Minnesota System; University of Minnesota Twin Cities; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Johnson, JR (corresponding author), Minneapolis VA Hlth Care Syst, 1 Vet Dr,Infect Dis 111F, Minneapolis, MN 55417 USA.	johns007@umn.edu	Russo, Thomas/ABE-9633-2020		Actavis; Merck; Tetraphase; Medicines Company; Syntiron; Crucell/Janssen; National Institutes of Health	Actavis; Merck(Merck & Company); Tetraphase; Medicines Company; Syntiron; Crucell/Janssen; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr. Johnson reports receiving grant support from Actavis, Merck, Tetraphase, the Medicines Company, and Syntiron and consulting fees from Crucell/Janssen, being named on pending patents on high-resolution two-locus clonal typing of extraintestinal pathogenic Escherichia coli (61/749,144) and on primers, assays, and methods for detecting an E. coli subtype (61/667,402), and serving as coinvestigator on a project that received support from a grant from the National Institutes of Health to IDGenomics; and Dr. Russo, holding a patent (6,410,703) on "Identification of a vaccine candidate from an extraintestinal isolate of E. coli." No other potential conflict of interest relevant to this article was reported.	Brown P, 2005, PHARMACOECONOMICS, V23, P1123, DOI 10.2165/00019053-200523110-00005; CARDENAS DD, 1995, ARCH PHYS MED REHAB, V76, P272, DOI 10.1016/S0003-9993(95)80615-6; Craig WD, 2008, RADIOGRAPHICS, V28, P255, DOI 10.1148/rg.281075171; Cronberg S, 2001, SCAND J INFECT DIS, V33, P339, DOI 10.1080/003655401750173922; Czaja CA, 2007, CLIN INFECT DIS, V45, P273, DOI 10.1086/519268; Eliakim-Raz N, 2013, J ANTIMICROB CHEMOTH, V68, P2183, DOI 10.1093/jac/dkt177; Godaly G, 2015, CURR OPIN INFECT DIS, V28, P88, DOI 10.1097/QCO.0000000000000127; Gupta K, 2011, CLIN INFECT DIS, V52, pE103, DOI [10.1093/cid/ciq257, 10.1093/cid/cir102]; Ikaheimo R, 1996, CLIN INFECT DIS, V22, P91, DOI 10.1093/clinids/22.1.91; JACKSON GG, 1958, JAMA-J AM MED ASSOC, V166, P14, DOI 10.1001/jama.1958.02990010016004; JERNELIUS H, 1988, ACTA MED SCAND, V223, P469; Johnson JR, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx089; JOHNSON JR, 1991, J INFECT DIS, V163, P325, DOI 10.1093/infdis/163.2.325; Jolley JA, 2010, DRUGS, V70, P1643, DOI 10.2165/11538050-000000000-00000; Ki M, 2004, AM J EPIDEMIOL, V160, P985, DOI 10.1093/aje/kwh308; Kim Y, 2017, INFECT CHEMOTHER, V49, P22, DOI 10.3947/ic.2017.49.1.22; Kochanek Kenneth D, 2016, Natl Vital Stat Rep, V65, P1; Kyriakidou KG, 2008, CLIN THER, V30, P1859, DOI 10.1016/j.clinthera.2008.10.007; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Long B, 2016, J EMERG MED, V51, P529, DOI 10.1016/j.jemermed.2016.07.003; Monmaturapoj T, 2012, INT J INFECT DIS, V16, pE843, DOI 10.1016/j.ijid.2012.07.009; Naber KG, 2004, INT J ANTIMICROB AG, V23, pS41, DOI 10.1016/j.ijantimicag.2003.09.002; Owens RC, 2011, J CLIN MICROBIOL, V49, P3406, DOI 10.1128/JCM.00993-11; Peterson J, 2008, UROLOGY, V71, P17, DOI 10.1016/j.urology.2007.09.002; Piccoli GB, 2006, INT J ANTIMICROB AG, V28, pS49, DOI 10.1016/j.ijantimicag.2006.05.017; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rubenstein JN, 2003, INFECT DIS CLIN N AM, V17, P333, DOI 10.1016/S0891-5520(03)00012-6; Sanchez M, 2002, EMERG MED J, V19, P19, DOI 10.1136/emj.19.1.19; Sandberg T, 2012, LANCET, V380, P484, DOI 10.1016/S0140-6736(12)60608-4; Scholes D, 2005, ANN INTERN MED, V142, P20, DOI 10.7326/0003-4819-142-1-200501040-00008; Schrock JW, 2010, AM J EMERG MED, V28, P682, DOI 10.1016/j.ajem.2009.03.003; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Singh R, 2015, CURR OPIN INFECT DIS, V28, P112, DOI 10.1097/QCO.0000000000000120; Smaill FM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000490.pub3; STAMM WE, 1989, J INFECT DIS, V159, P400, DOI 10.1093/infdis/159.3.400; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; Talan DA, 2004, J UROLOGY, V171, P734, DOI 10.1097/01.ju.0000106191.11936.64; Talan DA, 2016, EMERG INFECT DIS, V22, P1594, DOI 10.3201/eid2209.160148; Tchesnokova V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174132; Tice AD, 2004, CLIN INFECT DIS, V38, P1651, DOI 10.1086/420939; Ubee SS, 2011, BJU INT, V107, P1474, DOI 10.1111/j.1464-410X.2010.09660.x; Ulleryd P, 2003, SCAND J INFECT DIS, V35, P34, DOI 10.1080/0036554021000026988; van Nieuwkoop C, 2010, CLIN INFECT DIS, V51, P1266, DOI 10.1086/657071; van Nieuwkoop C, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0835-3; Velasco M, 2003, CLIN INFECT DIS, V37, P1127, DOI 10.1086/378291; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427	47	58	60	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	2018	378	1					48	59		10.1056/NEJMcp1702758	http://dx.doi.org/10.1056/NEJMcp1702758			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR7BE	29298155				2023-01-03	WOS:000419220500016
J	Hijikata, Y; Okazaki, T; Tanaka, Y; Murahashi, M; Yamada, Y; Yamada, K; Takahashi, A; Inoue, H; Kishimoto, J; Nakanishi, Y; Oda, Y; Nakamura, Y; Tani, K				Hijikata, Yasuki; Okazaki, Toshihiko; Tanaka, Yoshihiro; Murahashi, Mutsunori; Yamada, Yuichi; Yamada, Kazunari; Takahashi, Atsushi; Inoue, Hiroyuki; Kishimoto, Junji; Nakanishi, Yoichi; Oda, Yoshinao; Nakamura, Yusuke; Tani, Kenzaburo			A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors	PLOS ONE			English	Article							REGULATORY T-CELLS; RING FINGER PROTEIN; MELANOMA PATIENTS; METASTATIC MELANOMA; DENDRITIC CELLS; COLORECTAL-CANCER; VACCINE; IMMUNOTHERAPY; IL-2; VIVO	The objective of this study was to investigate the safety and the tolerability of combined cellular immunotherapy with low-dose cyclophosphamide (CPA) in patients with advanced solid tumors. This study targeted a novel tumor-associated antigen, ring finger protein 43 (RNF43). Eligible patients were resistant to standard therapy, HLA-A*24:02- or A*02:01-positive and exhibiting high RNF43 expression in their tumor cells. They were administered 300 mg/m(2) CPA followed by autologous lymphocytes, preliminarily cultured with autologous RNF43 peptide-pulsed dendritic cells (DCs), RNF43 peptide-pulsed DCs and systemic low dose interleukin-2. The primary endpoint was safety whereas the secondary endpoint was immunological and clinical response to treatment. Ten patients, in total, were enrolled in this trial. Primarily, no adverse events greater than Grade 3 were observed. Six out of 10 patients showed stable disease (SD) on day 49, while 4 other patients showed progressive disease. In addition, one patient with SD exhibited a partial response after the second trial. The frequency of regulatory T cells (Tregs) in patients with SD significantly decreased after CPA administration. The ratio of interferon-gamma-producing, tumor-reactive CD8(+) T cells increased with time in patients with SD. We successfully showed that the combination of immune cell therapy and CPA was safe, might induce tumor-specific immune responses and clinical efficacy, and was accompanied by a decreased ratio of Tregs in patients with RNF43-positive advanced solid tumors.	[Hijikata, Yasuki; Murahashi, Mutsunori; Yamada, Kazunari; Takahashi, Atsushi; Inoue, Hiroyuki; Tani, Kenzaburo] Kyushu Univ Hosp, Dept Adv Cell & Mol Therapy, Fukuoka, Japan; [Okazaki, Toshihiko; Tanaka, Yoshihiro; Kishimoto, Junji] Kyushu Univ Hosp, ARO Adv Med Ctr, Fukuoka, Japan; [Yamada, Yuichi; Oda, Yoshinao] Kyushu Univ, Dept Anatom Pathol, Pathol Sci, Fukuoka, Japan; [Nakanishi, Yoichi] Kyushu Univ, Res Inst Dis Chest, Fukuoka, Japan; [Nakamura, Yusuke] Univ Tokyo, Human Genome Ctr, Inst Med Sci, Tokyo, Japan; [Tani, Kenzaburo] Univ Tokyo, Inst Med Sci, Adv Med Sci Internal Med, Project Div ALA Adv Med Res, Tokyo, Japan	Kyushu University; Kyushu University; Kyushu University; Kyushu University; University of Tokyo; University of Tokyo	Tani, K (corresponding author), Kyushu Univ Hosp, Dept Adv Cell & Mol Therapy, Fukuoka, Japan.; Tani, K (corresponding author), Univ Tokyo, Inst Med Sci, Adv Med Sci Internal Med, Project Div ALA Adv Med Res, Tokyo, Japan.	k-tani@ims.u-tokyo.ac.jp	Yamada, Yuichi/ABG-4561-2021	Yamada, Yuichi/0000-0002-5516-4737; Yamada, Kazunari/0000-0002-3610-1802	Japan Society for the Promotion of Science [Y524790708, YS22790651]; Ministry of Education, Culture, Sports, Science and Technology [08061012]; OncoTherapy Science, Inc.	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); OncoTherapy Science, Inc.	This study was financially supported by Grant-in-Aid for Scientific Research of Japan Society for the Promotion of Science (Y524790708, YS22790651) and Ministry of Education, Culture, Sports, Science and Technology for the Coordination, Support and Training Program for Translational Research (08061012). Additionally, K.T. received a commercial research grant from OncoTherapy Science, Inc. in 2007. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anguille S, 2014, LANCET ONCOL, V15, pE257, DOI 10.1016/S1470-2045(13)70585-0; Camisaschi C, 2013, CANCER IMMUNOL IMMUN, V62, P897, DOI 10.1007/s00262-013-1397-7; Charles D, 2008, IMMUNITY, V29, P848; Cherryholmes GA, 2015, VACCINE, V15; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Fousek K, 2015, CLIN CANCER RES, V21, P3384, DOI 10.1158/1078-0432.CCR-14-2675; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Hao HX, 2016, CANCERS, V8, DOI 10.3390/cancers8060054; Hazama S, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-63; Hersey P, 2008, CANCER IMMUNOL IMMUN, V57, P1039, DOI 10.1007/s00262-007-0435-8; Horton H, 2007, J IMMUNOL METHODS, V323, P39, DOI 10.1016/j.jim.2007.03.002; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Koike N, 2008, J IMMUNOTHER, V31, P402, DOI 10.1097/CJI.0b013e31816cabbb; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2012, CANCER RES, V72, P3439, DOI 10.1158/0008-5472.CAN-11-3912; Ledford H, 2015, NATURE, V519, P17, DOI 10.1038/nature.2015.16990; Lou YY, 2004, CANCER RES, V64, P6783, DOI 10.1158/0008-5472.CAN-04-1621; Mackensen A, 2006, J CLIN ONCOL, V24, P5060, DOI 10.1200/JCO.2006.07.1100; Matsushita N, 2013, ONCOL REP, V29, P951, DOI 10.3892/or.2013.2231; Meidenbauer N, 2003, J IMMUNOL, V170, P2161, DOI 10.4049/jimmunol.170.4.2161; Murahashi M, 2016, CLIN IMMUNOL, V166, P48, DOI 10.1016/j.clim.2016.03.015; Nagayama H, 2003, MELANOMA RES, V13, P521, DOI 10.1097/00008390-200310000-00011; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Park MY, 2007, VACCINE, V25, P7322, DOI 10.1016/j.vaccine.2007.08.037; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Peng SW, 2013, CANCER IMMUNOL IMMUN, V62, P171, DOI 10.1007/s00262-012-1322-5; Radojcic V, 2010, CANCER IMMUNOL IMMUN, V59, P137, DOI 10.1007/s00262-009-0734-3; Ring S, 2010, J IMMUNOL, V184, P3408, DOI 10.4049/jimmunol.0901751; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Sakamoto H, 2015, MODERN PATHOL, V28, P261, DOI 10.1038/modpathol.2014.98; Schadendorf D, 2006, ANN ONCOL, V17, P563, DOI 10.1093/annonc/mdj138; Schwartzentruber DJ, 2011, NEW ENGL J MED, V364, P2119, DOI 10.1056/NEJMoa1012863; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sugiura T, 2008, EXP CELL RES, V314, P1519, DOI 10.1016/j.yexcr.2008.01.013; TARTOUR E, 1994, BRIT J CANCER, V69, P911, DOI 10.1038/bjc.1994.175; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uchida N, 2004, CLIN CANCER RES, V10, P8577, DOI 10.1158/1078-0432.CCR-04-0104; Walker EB, 2004, CLIN CANCER RES, V10, P668, DOI 10.1158/1078-0432.CCR-0095-03; Walker EB, 2008, CLIN CANCER RES, V14, P5270, DOI 10.1158/1078-0432.CCR-08-0022; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Xing CY, 2013, MOL CANCER THER, V12, P94, DOI 10.1158/1535-7163.MCT-12-0672; Yagyu R, 2004, INT J ONCOL, V25, P1343; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	48	9	9	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2018	13	1							e0187878	10.1371/journal.pone.0187878	http://dx.doi.org/10.1371/journal.pone.0187878			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR5JA	29293510	Green Submitted, Green Published, gold			2023-01-03	WOS:000419101600005
J	Krebs, E; Enns, B; Evans, E; Urada, D; Anglin, MD; Rawson, RA; Hser, YI; Nosyk, B				Krebs, Emanuel; Enns, Benjamin; Evans, Elizabeth; Urada, Darren; Anglin, M. Douglas; Rawson, Richard A.; Hser, Yih-Ing; Nosyk, Bohdan			Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; METHADONE-MAINTENANCE TREATMENT; AFFORDABLE CARE ACT; UNITED-STATES; ECONOMIC-EVALUATION; HEALTH-CARE; TASK-FORCE; DRUG-USE; DEPENDENCE; HEROIN	Background: Only 1 in 5 of the nearly 2.4 million Americans with an opioid use disorder received treatment in 2015. Fewer than half of Californians who received treatment in 2014 received opioid agonist treatment (OAT), and regulations for admission to OAT in California are more stringent than federal regulations. Objective: To determine the cost-effectiveness of OAT for all treatment recipients compared with the observed standard of care for patients presenting with opioid use disorder to California's publicly funded treatment facilities. Design: Model-based cost-effectiveness analysis. Data Sources: Linked population-level administrative databases capturing treatment and criminal justice records for California (2006 to 2010); published literature. Target Population: Persons initially presenting for publicly funded treatment of opioid use disorder. Time Horizon: Lifetime. Perspective: Societal. Intervention: Immediate access to OAT with methadone for all treatment recipients compared with the observed standard of care (54.3% initiate opioid use disorder treatment with medically managed withdrawal). Outcome Measures: Discounted quality-adjusted life-years (QALYs) and discounted costs. Results of Base-Case Analysis: Immediate access to OAT for all treatment recipients costs less (by $78 257), with patients accumulating more QALYs (by 0.42) than with the observed standard of care. In a hypothetical scenario where all Californians starting treatment of opioid use disorder in 2014 had immediate access to OAT, total lifetime savings for this cohort could be as high as $3.8 billion. Results of Sensitivity Analysis: 99.6% of the 2000 simulations resulted in lower costs and more QALYs. Limitation: Nonrandomized delivery of OAT or medically managed withdrawal. Conclusion: The value of publicly funded treatment of opioid use disorder in California is maximized when OAT is delivered to all patients presenting for treatment, providing greater health benefits and cost savings than the observed standard of care.	British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; UCLA, Integrated Subst Abuse Programs & Vet Affairs Gre, Los Angeles, CA USA; [Evans, Elizabeth] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, 311 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA; [Urada, Darren; Anglin, M. Douglas; Hser, Yih-Ing] UCLA, Integrated Subst Abuse Programs, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA 90025 USA; Simon Fraser Univ, Fac Hlth Sci, Vancouver, BC, Canada; [Krebs, Emanuel; Enns, Benjamin; Nosyk, Bohdan] St Pauls Hosp, BC Ctr Excellence HIV AIDS, 613-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada; [Rawson, Richard A.] 1952 Route 73, Brandon, VT 05733 USA	B.C. Centre for Excellence in HIV/AIDS; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Amherst; University of California System; University of California Los Angeles; Simon Fraser University; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan	Nosyk, B (corresponding author), St Pauls Hosp, BC Ctr Excellence HIV AIDS, 613-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	bnosyk@cfenet.ubc.ca	Enns, Benjamin/GYU-3276-2022; Evans, Elizabeth/T-8683-2018	Enns, Benjamin/0000-0002-4865-1510; Evans, Elizabeth/0000-0002-3478-9957; Krebs, Emanuel/0000-0002-6590-8728	National Institute on Drug Abuse [R01DA031727, R01DA032551, P30DA016383]	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	By grants R01DA031727 (Dr. Nosyk), R01DA032551 (Dr. Nosyk), and P30DA016383 (Dr. Hser) from the National Institute on Drug Abuse. The funding agreement ensured the authors' independence in designing the study, interpreting the data, and writing and publishing the report.	Abraham AJ, 2017, AM J PUBLIC HEALTH, V107, P31, DOI 10.2105/AJPH.2016.303558; Aden B, 2015, JAIDS-J ACQ IMM DEF, V70, P304, DOI 10.1097/QAI.0000000000000768; Amato L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005031.pub3; Andrews CM, 2014, MED CARE RES REV, V71, P43, DOI 10.1177/1077558713503188; Barua S, 2015, ANN INTERN MED, V163, P215, DOI 10.7326/M15-0406; Baser O, 2014, PAIN PRACT, V14, P437, DOI 10.1111/papr.12097; Bayoumi AM, 2008, CAN MED ASSOC J, V179, P1143, DOI 10.1503/cmaj.080808; Bovasso G, 2003, J BEHAV HEALTH SER R, V30, P290, DOI 10.1007/BF02287318; Broz D, 2014, HIV INFECT RISK PREV; Caro JJ, 2012, MED DECIS MAKING, V32, P667, DOI 10.1177/0272989X12454577; Center for Behavioral Health Statistics and Quality, 2017, TREATM EP DAT SET TE; Centers for Disease Control and Prevention, 2016, ATLASPLUS PERS LIV D; Chong CAKY, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-78; Cuckler Gigi, 2011, Medicare Medicaid Res Rev, V1, DOI 10.5600/mmrr.001.04.a03; Deck D, 2009, J ADDICT DIS, V28, P89, DOI 10.1080/10550880902772373; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Dijkgraaf MGW, 2005, BMJ-BRIT MED J, V330, P1297, DOI 10.1136/bmj.330.7503.1297; Doran CM, 2008, PHARMACOECONOMICS, V26, P371, DOI 10.2165/00019053-200826050-00003; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Evans E, 2015, ADDICTION, V110, P996, DOI 10.1111/add.12863; Fryback DG, 2007, MED CARE, V45, P1162, DOI 10.1097/MLR.0b013e31814848f1; Garrison LP, 2010, VALUE HEALTH, V13, P8, DOI 10.1111/j.1524-4733.2009.00660.x; Gebo KA, 2010, AIDS, V24, P2705, DOI 10.1097/QAD.0b013e32833f3c14; Gough E, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-777; Harris M, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-7; [HIV/AIDS Bureau Health Resources and Services Administration], 2017, HIV AIDS BUREAU ABOU; Hser YI, 2007, EVALUATION REV, V31, P515, DOI 10.1177/0193841X07307316; Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Krebs E, 2017, MED DECIS MAKING, V37, P483, DOI 10.1177/0272989X16683928; Krebs E, 2017, ADDICTION, V112, P838, DOI 10.1111/add.13729; Krebs E, 2014, DRUG ALCOHOL DEPEN, V144, P193, DOI 10.1016/j.drugalcdep.2014.09.007; Legislative Analysts Office, MUCH DOES IT COST IN; Los Angeles County Department of Public Health, 2016, 2014 ANN HIV STD SUR; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Medical Board of California, 2014, GUID PRESCR CONTR SU; Mohlman MK, 2016, J SUBST ABUSE TREAT, V67, P9, DOI 10.1016/j.jsat.2016.05.002; Murphy SM, 2016, PHARMACOECONOMICS, V34, P863, DOI 10.1007/s40273-016-0400-5; Murthy VH, 2016, NEW ENGL J MED, V375, P2413, DOI 10.1056/NEJMp1612578; Nosyk B, 2015, DRUG ALCOHOL DEPEN, V157, P121, DOI 10.1016/j.drugalcdep.2015.10.009; Nosyk B, 2014, DRUG ALCOHOL DEPEN, V140, P69, DOI 10.1016/j.drugalcdep.2014.03.029; Nosyk B, 2014, DRUG ALCOHOL DEPEN, V143, P149, DOI 10.1016/j.drugalcdep.2014.07.020; Nosyk B, 2013, HEALTH AFFAIR, V32, P1462, DOI 10.1377/hlthaff.2012.0846; Nosyk B, 2012, CAN MED ASSOC J, V184, pE317, DOI 10.1503/cmaj.110669; Nosyk B, 2009, AM J EPIDEMIOL, V170, P783, DOI 10.1093/aje/kwp186; O'Connor PG, 2005, JAMA-J AM MED ASSOC, V294, P961, DOI 10.1001/jama.294.8.961; Polsky D, 2010, ADDICTION, V105, P1616, DOI 10.1111/j.1360-0443.2010.03001.x; R-Core-Team, 2016, LANG ENV STAT COMP; Saloner B, 2017, PSYCHIAT SERV, V68, P542, DOI 10.1176/appi.ps.201600182; Saloner B, 2015, JAMA-J AM MED ASSOC, V314, P1515, DOI 10.1001/jama.2015.10345; Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339; Sculpher MJ, 2006, HEALTH ECON, V15, P677, DOI 10.1002/hec.1093; Siebert U, 2012, VALUE HEALTH, V15, P812, DOI 10.1016/j.jval.2012.06.014; Springborn RR, 2006, ABR LIF TABL CAL 200; Stephenson D., 2008, GUIDELINE PHYS WORKI, P1; Substance Abuse and Mental Health Services Administration, 2015, 2013 STAT PROF CAL; Substance Abuse and Mental Health Services Administration, 2016, KEY SUBST US MENT HL; Substance Abuse and Mental Health Services Administration, 2016, TREATM EP DAT SET AD; Substance Abuse and Mental Health Services Administration (SAMHSA), 2015, FED GUID OP TREATM P; Termorshuizen F, 2005, DRUG ALCOHOL DEPEN, V79, P231, DOI 10.1016/j.drugalcdep.2005.01.013; Tookes H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129360; U.S. Department of Health and Human Services Office of the Surgeon General, 2016, OFF SURG GEN FAC ADD; Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x; White House, 2016, J PAIN PALLIAT CARE, V30, P134, DOI 10.3109/15360288.2016.1173760; Williams AR, 2016, NEW ENGL J MED, V375, P813, DOI 10.1056/NEJMp1604223; World Health Organization, 2009, GUID PSYCH ASS PHARM; Zaric GS, 2000, AM J PUBLIC HEALTH, V90, P1100, DOI 10.2105/AJPH.90.7.1100; Zarkin GA, 2005, HEALTH ECON, V14, P1133, DOI 10.1002/hec.999; Zlotorzynska M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009778	72	31	31	1	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2018	168	1					10	+		10.7326/M17-0611	http://dx.doi.org/10.7326/M17-0611			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR5SO	29159398				2023-01-03	WOS:000419126700003
J	Hewitt, DB; Barnard, C; Bilimoria, KY				Hewitt, D. Brock; Barnard, Cynthia; Bilimoria, Karl Y.			Insulin Dosing Error in a Patient With Severe Hyperkalemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Hewitt, D. Brock; Barnard, Cynthia] Northwestern Univ, Chicago, IL 60611 USA; [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, 633 N St Clair St,20th Floor, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Feinberg School of Medicine	Bilimoria, KY (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Surg, SOQIC, 633 N St Clair St,20th Floor, Chicago, IL 60611 USA.	k-bilimoria@northwestern.edu			American College of Surgeons; American Board of Surgeons; Accreditation Council for Graduate Medical Education	American College of Surgeons; American Board of Surgeons; Accreditation Council for Graduate Medical Education	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Bilimoria reports receipt of grants from the American College of Surgeons, the American Board of Surgeons, and the Accreditation Council for Graduate Medical Education and personal fees from the American College of Surgeons. No other disclosures were reported.	Benner P, 2008, PATIENT SAFETY QUALI; Gundgurthi Abhay, 2012, Indian J Endocrinol Metab, V16 Suppl 1, pS120, DOI 10.4103/2230-8210.94254; Iglesias P, 2008, DIABETES OBES METAB, V10, P811, DOI 10.1111/j.1463-1326.2007.00802.x; Institute for Safe Medication Practices, 2014, ISMP LIST HIGH AL ME; Kim HJ, 2002, NEPHRON, V92, P33, DOI 10.1159/000065375; Martinez-Vea A, 1999, J ELECTROCARDIOL, V32, P45, DOI 10.1016/S0022-0736(99)90020-1; The Joint Commission, 2017, ESS ROL LEAD DEV SAF	7	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2017	318	24					2485	2486		10.1001/jama.2017.7964	http://dx.doi.org/10.1001/jama.2017.7964			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ9ZO	29279937				2023-01-03	WOS:000418720700026
J	Gomez, AM				Gomez, Anu Manchikanti			Availability of Pharmacist-Prescribed Contraception in California, 2017	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROVISION		[Gomez, Anu Manchikanti] Univ Calif Berkeley, Sch Social Welf, Sexual Hlth & Reprod Equ Program, 110 Haviland Hall MC 7400, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Gomez, AM (corresponding author), Univ Calif Berkeley, Sch Social Welf, Sexual Hlth & Reprod Equ Program, 110 Haviland Hall MC 7400, Berkeley, CA 94720 USA.	anugomez@berkeley.edu		Gomez, Anu Manchikanti/0000-0002-9461-4411				California State Board of Pharmacy, 2016, SELF ADM HORM CONTR; Gonsalves L, 2017, CONTRACEPTION, V95, P339, DOI 10.1016/j.contraception.2016.12.002; National Alliance of State Pharmacy Associations (NASPA), 2017, PHARM AUTH PRESCR BI; Rodriguez MI, 2016, J AM PHARM ASSOC, V56, P521, DOI 10.1016/j.japh.2016.05.003	4	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2017	318	22					2253	2254		10.1001/jama.2017.15674	http://dx.doi.org/10.1001/jama.2017.15674			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP7NR	29234797	Bronze, Green Published			2023-01-03	WOS:000417822700023
J	Karimkhani, C; Reddy, BY; Dellavalle, RP; Sundararajan, S				Karimkhani, Chante; Reddy, Bobby Y.; Dellavalle, Robert P.; Sundararajan, Srinath			THERAPEUTICS Novel therapies for unresectable and metastatic melanoma	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Karimkhani, Chante; Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA; [Reddy, Bobby Y.] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Dept Dermatol, Boston, MA USA; [Dellavalle, Robert P.] US Dept Vet Affairs, Dermatol Serv, Eastern Colorado Hlth Care Syst, Denver, CO USA; [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA; [Sundararajan, Srinath] Univ Arizona, Dept Med, Div Hematol & Oncol, Tucson, AZ USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Harvard Medical School; Massachusetts General Hospital; US Department of Veterans Affairs; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Arizona	Karimkhani, C (corresponding author), Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA.	ck2525@caa.columbia.edu						American Cancer Society, CANC FACTS FIG 2016; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Eton O, 1998, J CLIN ONCOL, V16, P1103, DOI 10.1200/JCO.1998.16.3.1103; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; Hamid O, 2016, ANN ONCOL, V359, P1107, DOI [10.1093/annonc/mdw379.02, DOI 10.1093/ANNONC/MDW379.02]; Hauschild A, 2014, ANN ONCOL         S4, V25, piv378, DOI DOI 10.1093/ANNONC/MDU344.8; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2016, CANCER RES, V76, pCT001, DOI DOI 10.1158/1538-7445.AM2016-CT001; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; James K, 1999, J NATL CANCER I, V91, P523, DOI 10.1093/jnci/91.6.523; Karimkhani C, 2017, BRIT J DERMATOL, V177, P134, DOI 10.1111/bjd.15510; Kink A, 2016, HEALTHCARE RESOURCE; Kohlhapp FJ, 2016, CLIN CANCER RES, V22, P1048, DOI 10.1158/1078-0432.CCR-15-2667; Larkin J, 2017, J CLIN ONCOL, DOI DOI 10.1200/JCO.2016.71.8023; Liu MD, 2017, ONCOTARGET, V8, P32258, DOI 10.18632/oncotarget.15632; Long GV, 2016, ANN ONCOL, V27, P1940, DOI 10.1093/annonc/mdw265; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Lui P, 2007, CANCER TREAT REV, V33, P665, DOI 10.1016/j.ctrv.2007.06.004; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Melanoma research foundation, CUT MEL MEL SKIN; National Cancer Institute, NCI DICT CANC TERMS; National Comprehensive Cancer Network, 2016, NCCN GUID PAT VERS 1; National Institute for Health and Care Excellence, 2015, MEL ASS MAN; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel PM, 2011, EUR J CANCER, V47, P1476, DOI 10.1016/j.ejca.2011.04.030; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Ribas A, 2015, LANCET ONCOL, V16, P908, DOI 10.1016/S1470-2045(15)00083-2; Robert C, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_supll.9503; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Schachter J, 2016, J CLIN ONCOL, V359, P9504; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Shih V, 2015, J SKIN CANCER, V2015, DOI 10.1155/2015/505302; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Voskens CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053745; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8	44	7	7	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 30	2017	359								j5174	10.1136/bmj.j5174	http://dx.doi.org/10.1136/bmj.j5174			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO9MO	29191943				2023-01-03	WOS:000417211800002
J	Pan, JH; Lim, Y; Kim, JH; Heo, W; Lee, KY; Shin, HJ; Kim, JK; Lee, JH; Kim, YJ				Pan, Jeong Hoon; Lim, Yejin; Kim, Jun Ho; Heo, Wan; Lee, Ki Yong; Shin, Hye Ji; Kim, Jae Kyeom; Lee, Jin Hyup; Kim, Young Jun			Root bark of Ulmus davidiana var. japonica restrains acute alcohol-induced hepatic steatosis onset in mice by inhibiting ROS accumulation	PLOS ONE			English	Article							INDUCED LIVER-INJURY; SYNTHESIZED FATTY-ACIDS; NF-KAPPA-B; OXIDATIVE STRESS; ANTIINFLAMMATORY ACTIVITY; LIPID-METABOLISM; DIETARY ADIPOSE; KUPFFER CELLS; ETHANOL; DISEASE	Alcohol-induced hepatic steatosis and inflammation are key drivers of alcohol-induced liver injury, mainly caused by oxidative stress. The roots bark of Ulmus davidiana var. japonica is well known for its substantial antioxidative and antitumorigenic potency. In this study, we examined whether this plant can ameliorate alcohol -induced liver injuries characterized by hepatic steatosis and inflammation through its antioxidative activity. C57BL/6J mice were treated with the root bark extract of Ulmus davidiana var. japonica (RUE; 100 mg of extract/kg bodyweight; oral gavage) and alcohol (1 g/kg of bodyweight; oral gavage) for 5 days. Markers of acute alcohol -induced hepatic steatosis were determined and putative molecular mechanisms responsible for the protection of RUE were investigated. RUE noticeably protected against alcohol -induced hepatic steatosis and inflammation. Reactive oxygen species (ROS), over-produced by alcohol, negatively orchestrated various signaling pathways involved in the lipid metabolism and inflammation. These pathways were restored through the ROS scavenging activity of RUE in the liver. In particular, the expression of lipogenic genes (e.g., SREBP-1, ACC, and FAS) and inflammatory cytokines (e.g., IL-1(3, and NF-kappa B p65) significantly decreased with RUE treatment. Conversely, the expression of fatty acid oxidation-related genes (e.g., SI RT1, AMPK alpha, and PGC1 alpha) were increased in mice treated with RUE. Thus, the results indicate that RUE counteracts and thus attenuates alcoholic hepatic steatosis onset in mice, possibly by suppressing ROS-mediated steatosis and inflammation.	[Pan, Jeong Hoon; Lim, Yejin; Kim, Jun Ho; Heo, Wan; Lee, Jin Hyup; Kim, Young Jun] Korea Univ, Dept Food & Biotechnol, Sejong, South Korea; [Pan, Jeong Hoon; Kim, Jae Kyeom] Univ Arkansas, Sch Human Environm Sci, Fayetteville, AR 72701 USA; [Lee, Ki Yong; Shin, Hye Ji] Korea Univ, Coll Pharm, Sejong, South Korea	Korea University; University of Arkansas System; University of Arkansas Fayetteville; Korea University	Lee, JH; Kim, YJ (corresponding author), Korea Univ, Dept Food & Biotechnol, Sejong, South Korea.; Kim, JK (corresponding author), Univ Arkansas, Sch Human Environm Sci, Fayetteville, AR 72701 USA.	jkk003@uark.edu; jinhyuplee@korea.ac.kr; yk46@korea.ac.kr			International Science and Business Belt Program through the Ministry of Science, ICT and Future Planning [2015K000388]	International Science and Business Belt Program through the Ministry of Science, ICT and Future Planning	The research was supported by the International Science and Business Belt Program through the Ministry of Science, ICT and Future Planning (Grant Number: 2015K000388).	Bharrhan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020635; Cao Q, 2002, BIOCHEM BIOPH RES CO, V294, P849, DOI 10.1016/S0006-291X(02)00586-7; Cederbaum AI, 2009, ARCH TOXICOL, V83, P519, DOI 10.1007/s00204-009-0432-0; Choi SY, 2010, J MED FOOD, V13, P1019, DOI 10.1089/jmf.2009.1207; Dey A, 2006, HEPATOLOGY, V43, pS63, DOI 10.1002/hep.20957; Garcia-Villafranca J, 2008, BIOCHIMIE, V90, P460, DOI 10.1016/j.biochi.2007.09.019; Gobejishvili L, 2006, AM J PHYSIOL-GASTR L, V291, pG681, DOI 10.1152/ajpgi.00098.2006; Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200; Hou ZH, 2010, J AGR FOOD CHEM, V58, P3191, DOI 10.1021/jf904407x; Hritz I, 2008, HEPATOLOGY, V48, P1224, DOI 10.1002/hep.22470; Huang J, 2008, J PHARMACOL SCI, V107, P370, DOI 10.1254/jphs.08044FP; Ivanov AV, 2013, VIRUSES-BASEL, V5, P439, DOI 10.3390/v5020439; James LP, 2003, DRUG METAB DISPOS, V31, P1499, DOI 10.1124/dmd.31.12.1499; Jung HJ, 2008, BIOMOL THER, V16, P9, DOI 10.4062/biomolther.2008.16.1.009; Jung MJ, 2008, FOOD CHEM, V108, P482, DOI 10.1016/j.foodchem.2007.10.081; Jung MJ, 2010, FOOD CHEM, V120, P313, DOI 10.1016/j.foodchem.2009.09.085; Kim YC, 2007, FITOTERAPIA, V78, P196, DOI 10.1016/j.fitote.2006.11.013; Koch Osvaldo R., 2004, Molecular Aspects of Medicine, V25, P191, DOI 10.1016/j.mam.2004.02.019; Kodama Y, 2009, GASTROENTEROLOGY, V137, P1467, DOI 10.1053/j.gastro.2009.06.045; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; LIEBER CS, 1966, J CLIN INVEST, V45, P1400, DOI 10.1172/JCI105448; LIEBER CS, 1966, J CLIN INVEST, V45, P51, DOI 10.1172/JCI105323; Lluis JM, 2003, GASTROENTEROLOGY, V124, P708, DOI 10.1053/gast.2003.50089; Mendez-Sanchez N, 2007, LIVER INT, V27, P423, DOI 10.1111/j.1478-3231.2007.01483.x; Norris AW, 2003, J CLIN INVEST, V112, P608, DOI 10.1172/JCI200317305; Pan JH, 2016, J FUNCT FOODS, V25, P135, DOI 10.1016/j.jff.2016.04.024; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shivashankara AR, 2012, FOOD FUNCT, V3, P101, DOI 10.1039/c1fo10170f; Siler SQ, 1999, AM J CLIN NUTR, V70, P928; Song YX, 2016, J DAIRY SCI, V99, P9184, DOI 10.3168/jds.2016-11219; Sozio M, 2008, AM J PHYSIOL-ENDOC M, V295, pE10, DOI 10.1152/ajpendo.00011.2008; Sumida Y, 2013, FREE RADICAL RES, V47, P869, DOI 10.3109/10715762.2013.837577; Sun Q, 2016, ALCOHOL CLIN EXP RES, V40, P2076, DOI 10.1111/acer.13172; Tang CC, 2013, FOOD CHEM TOXICOL, V62, P786, DOI 10.1016/j.fct.2013.10.011; Tang YH, 2012, FOOD CHEM TOXICOL, V50, P1194, DOI 10.1016/j.fct.2012.02.008; Wakil SJ, 2009, J LIPID RES, V50, pS138, DOI 10.1194/jlr.R800079-JLR200; Wang SG, 2016, ALCOHOL CLIN EXP RES, V40, P1215, DOI 10.1111/acer.13078; Xiong SG, 2003, ALCOHOL, V30, P107, DOI 10.1016/S0741-8329(03)00100-9; Yang LL, 2012, FREE RADICAL BIO MED, V53, P1170, DOI 10.1016/j.freeradbiomed.2012.06.029; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200; You M, 2008, AM J PHYSIOL-GASTR L, V294, pG892, DOI 10.1152/ajpgi.00575.2007; You M, 2015, HEPATOBIL SURG NUTR, V4, P88, DOI 10.3978/j.issn.2304-3881.2014.12.06; Zheng MS, 2011, ARCH PHARM RES, V34, P1443, DOI 10.1007/s12272-011-0905-6; Zheng MS, 2010, BIOMOL THER, V18, P321, DOI 10.4062/biomolther.2010.18.3.321	44	19	20	4	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2017	12	11							e0188381	10.1371/journal.pone.0188381	http://dx.doi.org/10.1371/journal.pone.0188381			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN8QZ	29176803	Green Published, gold, Green Submitted			2023-01-03	WOS:000416291900068
J	Fujishima, H; Fumoto, S; Shibata, T; Nishiki, K; Tsukamoto, Y; Etoh, T; Moriyama, M; Shiraishi, N; Inomata, M				Fujishima, Hajime; Fumoto, Shoichi; Shibata, Tomotaka; Nishiki, Kohei; Tsukamoto, Yoshiyuki; Etoh, Tsuyoshi; Moriyama, Masatsugu; Shiraishi, Norio; Inomata, Masafumi			A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer	PLOS ONE			English	Article							PERIOPERATIVE CHEMOTHERAPY; TRIMODALITY THERAPY; GENE-EXPRESSION; FLUOROURACIL; SENSITIVITY; CARCINOMA; SURGERY; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; PHARMACOGENOMICS	Background Recently, neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil (NAC-DCF) was identified as a novel strong regimen with a high rate of pathological complete response (pCR) in advanced esophageal cancer in Japan. Predicting pCR will contribute to the therapeutic strategy and the prevention of surgical invasion. However, a predictor of pCR after NAC-DCF has not yet been developed. The aim of this study was to identify a novel predictor of pCR in locally advanced esophageal cancer treated with NAC-DCF. Patients and methods A total of 32 patients who received NAC-DCF followed by esophagectomy between June 2013 and March 2016 were enrolled in this study. We divided the patients into the following 2 groups: pCR group (9 cases) and non-pCR group (23 cases), and compared gene expressions between these groups using DNA microarray data and KeyMolnet. Subsequently, a validation study of candidate molecular expression was performed in 7 additional cases. Results Seventeen molecules, including transcription factor E2F, T-cell-specific transcription factor, Src (known as "proto-oncogene tyrosine-protein kinase of sarcoma-), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase (CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. The molecules were mainly associated with pathways, such as transcriptional regulation by SMAD, RB/E2F, and STAT. The validation study indicated that 12 of the 17 molecules (71%) matched the trends of molecular expression. Conclusions A 17-molecule set that predicts pCR after NAC-DCF for locally advanced esophageal cancer was identified.	[Fujishima, Hajime; Shibata, Tomotaka; Etoh, Tsuyoshi; Inomata, Masafumi] Oita Univ, Fac Med, Dept Gastroenterol & Pediat Surg, Oita, Japan; [Fumoto, Shoichi; Nishiki, Kohei] Oita Nakamura Hosp, Dept Surg, Oita, Japan; [Tsukamoto, Yoshiyuki; Moriyama, Masatsugu] Oita Univ, Dept Mol Pathol, Fac Med, Oita, Japan; [Shiraishi, Norio] Oita Univ, Fac Med, Comprehens Surg Community Med, Oita, Japan	Oita University; Oita University; Oita University	Fujishima, H (corresponding author), Oita Univ, Fac Med, Dept Gastroenterol & Pediat Surg, Oita, Japan.	hajime-f@oita-u.ac.jp		Fujishima, Hajime/0000-0002-0858-8967	Grants-in-Aid for Scientific Research [15K10106, 15K08405] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Adenis A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-413; Ando N, 2012, ANN SURG ONCOL, V19, P68, DOI 10.1245/s10434-011-2049-9; Ando T, 2008, DIS ESOPHAGUS, V21, P15, DOI 10.1111/j.1442-2050.2007.00700.x; Bancewicz J, 2002, LANCET, V359, P1727; Batchu RB, 2014, PHARMACEUTICALS, V7, P46, DOI 10.3390/ph7010046; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Empuku S, 2016, MOL CLIN ONCOL, V4, P733, DOI 10.3892/mco.2016.806; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fumoto S, 2008, INT J ONCOL, V32, P413; Gao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058453; Hara H, 2013, CANCER SCI, V104, P1455, DOI 10.1111/cas.12274; Harpole DH, 2001, CLIN CANCER RES, V7, P562; Hato SV, 2017, ONCOTARGET; Hiyoshi Y, 2017, WORLD J SURG, V41, P480, DOI 10.1007/s00268-016-3649-0; Huang RW, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-170; Japan Esophageal Soc, 2017, ESOPHAGUS-TOKYO, V14, P37, DOI 10.1007/s10388-016-0556-2; Japan Esophageal Soc, 2017, ESOPHAGUS-TOKYO, V14, P1, DOI 10.1007/s10388-016-0551-7; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kitagawa Y, 2015, ASIAN J ENDOSC SURG, V8, P114, DOI 10.1111/ases.12185; Kurtyka CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096357; Kuzuhara T, 2007, J CANCER RES CLIN, V133, P287, DOI 10.1007/s00432-006-0169-6; Li L, 2015, ONCOL REP, V34, P2325, DOI 10.3892/or.2015.4211; Liu JK, 2015, BRAIN RES, V1610, P1, DOI 10.1016/j.brainres.2015.03.044; McLeod HL, 2001, ANNU REV PHARMACOL, V41, P101, DOI 10.1146/annurev.pharmtox.41.1.101; Molena D, 2014, DIS ESOPHAGUS, V27, P355, DOI 10.1111/dote.12126; Mori R, 2008, ONCOL REP, V20, P1345, DOI 10.3892/or_00000150; Nakano J, 2006, BRIT J CANCER, V95, P607, DOI 10.1038/sj.bjc.6603297; Nomura M, 2015, CANCER CHEMOTH PHARM, V76, P357, DOI 10.1007/s00280-015-2806-8; Ojima T, 2016, ANTICANCER RES, V36, P829; Reed MF, 2007, J SURG RES, V142, P364, DOI 10.1016/j.jss.2007.03.038; Romano G, 2016, ONCOTARGET, V7, P22077, DOI 10.18632/oncotarget.7895; Satoh J, 2009, NEUROPATH APPL NEURO, V35, P16, DOI 10.1111/j.1365-2990.2008.00947.x; Satoh J, 2007, NEUROSCI LETT, V422, P30, DOI 10.1016/j.neulet.2007.05.056; Satoh J, 2015, J CENT NERV SYST DIS, V7, P1, DOI [10.4137/JCNSNSD.S23210, 10.4137/JCNSD.S23210]; Smit JK, 2013, RADIOTHER ONCOL, V107, P434, DOI 10.1016/j.radonc.2013.03.027; Sohda M, 2014, ANTICANCER RES, V34, P909; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Sun ZF, 2006, CANCER EPIDEM BIOMAR, V15, P2063, DOI 10.1158/1055-9965.EPI-06-0505; Tanaka E, 2012, ASIAN J ENDOSC SURG, V5, P111, DOI [10.1111/j.1758-5910.2012.00131.x, 10.1111/j.1758-5910.2012.00147.x]; Wang W, 2014, THORAC CANCER, V5, P139, DOI 10.1111/1759-7714.12061; Wang Y, 2007, CANCER RES, V67, P2535, DOI 10.1158/0008-5472.CAN-06-3530; Watanabe M, 2014, ANN SURG ONCOL, V21, P2838, DOI 10.1245/s10434-014-3684-8; Wendling J, 2003, MOL PHARMACOL, V64, P707, DOI 10.1124/mol.64.3.707; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597	46	8	10	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 14	2017	12	11							e0188098	10.1371/journal.pone.0188098	http://dx.doi.org/10.1371/journal.pone.0188098			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM5YZ	29136005	Green Published, Green Submitted, gold			2023-01-03	WOS:000415121200065
J	Woldemichael, T; Rosania, GR				Woldemichael, Tehetina; Rosania, Gus R.			The physiological determinants of drug induced lysosomal stress resistance	PLOS ONE			English	Article							RENAL TUBULAR-ACIDOSIS; MUCOLIPIDOSIS TYPE-IV; CELL-DEATH; H+-ATPASE; V-ATPASE; MEMBRANE PERMEABILIZATION; CHLORIDE CHANNELS; VACUOLAR ATPASE; PROTON PUMP; GENE	Many weakly basic, lipophilic drugs accumulate in lysosomes and exert complex, pleiotropic effects on organelle structure and function. Thus, modeling how perturbations of lysosomal physiology affect the maintenance of lysosomal ion homeostasis is necessary to elucidate the key factors which determine the toxicological effects of lysosomotropic agents, in a cell type dependent manner. Accordingly, a physiologically-based mathematical modeling and simulation approach was used to explore the dynamic, multi-parameter phenomenon of lysosomal stress. With this approach, parameters that are either directly involved in lysosomal ion transportation or lysosomal morphology were transiently altered to investigate their downstream effects on lysosomal physiology reflected by the changes they induce in lysosomal pH, chloride, and membrane potential. In addition, combinations of parameters were simultaneously altered to assess which parameter was most critical for recovery of normal lysosomal physiology. Lastly, to explore the relationship between organelle morphology and induced stress, we investigated the effects of parameters controlling organelle geometry on the restoration of normal lysosomal physiology following a transient perturbation. Collectively, our results indicate a key, interdependent role of V-ATPase number and membrane proton permeability in lysosomal stress tolerance. This suggests that the cell type dependent regulation of V-ATPase subunit expression and turnover, together with the proton permeability properties of the lysosomal membrane, is critical to understand the differential sensitivity or resistance of different cell types to the toxic effects of lysosomotropic drugs.	[Woldemichael, Tehetina] Univ Michigan, Coll Literature Sci & Arts, Biophys Program, Ann Arbor, MI 48109 USA; [Rosania, Gus R.] Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rosania, GR (corresponding author), Univ Michigan, Coll Pharm, Dept Pharmaceut Sci, 428 Church St, Ann Arbor, MI 48109 USA.	grosania@umich.edu			National Institutes of Health grant [R01GM078200]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078200] Funding Source: NIH RePORTER	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grant R01GM078200 to GRR (https://grants.nih.gov/grants/oer.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2013, P NATL ACAD SCI USA, V110, P17247, DOI 10.1073/pnas.1305000110; Alberts Bruce, 2002, MOL BIOL CELL; Ashoor R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082481; Bach G, 2010, BIOCHEM SOC T, V38, P1432, DOI 10.1042/BST0381432; Bargal R, 2000, NAT GENET, V26, P118, DOI 10.1038/79095; Berkovic SE, 2008, AM J HUM GENET, V82, P673, DOI 10.1016/j.ajhg.2007.12.019; Bourdenx M, 2016, AUTOPHAGY, V12, P472, DOI 10.1080/15548627.2015.1136769; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Boyle J., 2008, BIOCH MOL BIOL ED, V36, P317, DOI DOI 10.1002/BMB.20192; Bruns H, 2012, J IMMUNOL, V189, P4069, DOI 10.4049/jimmunol.1201538; BUTLER JD, 1993, BIOCHEM BIOPH RES CO, V196, P154, DOI 10.1006/bbrc.1993.2228; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Dehay B, 2010, J NEUROSCI, V30, P12535, DOI 10.1523/JNEUROSCI.1920-10.2010; Deng D, 2009, BBA-BIOMEMBRANES, V1788, P470, DOI 10.1016/j.bbamem.2008.11.018; Dielschneider RF, 2016, LEUKEMIA, V30, P1290, DOI 10.1038/leu.2016.4; Doshi N, 2009, P NATL ACAD SCI USA, V106, P21495, DOI 10.1073/pnas.0907127106; Emanuel R, 2014, ARTERIOSCL THROM VAS, V34, P1942, DOI 10.1161/ATVBAHA.114.303342; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; GAMBALE F, 1994, EUR BIOPHYS J BIOPHY, V22, P399, DOI 10.1007/BF00180161; Goldman A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023835; Grabe M, 2001, J GEN PHYSIOL, V117, P329, DOI 10.1085/jgp.117.4.329; Grabe M, 2000, BIOPHYS J, V78, P2798, DOI 10.1016/S0006-3495(00)76823-8; Graham RM, 2014, ONCOTARGET, V5, P1162, DOI 10.18632/oncotarget.1699; Graves AR, 2008, NATURE, V453, P788, DOI 10.1038/nature06907; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; Hosogi S, 2014, J CELL MOL MED, V18, P1124, DOI 10.1111/jcmm.12257; Ishida Y, 2013, J GEN PHYSIOL, V141, P705, DOI 10.1085/jgp.201210930; Johansson AC, 2010, APOPTOSIS, V15, P527, DOI 10.1007/s10495-009-0452-5; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710; Kiselyov K, 2011, CELL CALCIUM, V50, P288, DOI 10.1016/j.ceca.2011.04.009; KNAPP PE, 1990, J CELL SCI, V95, P433; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535; Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008; Li XR, 2013, J PHYSIOL-LONDON, V591, P4389, DOI 10.1113/jphysiol.2013.258301; Logan R, 2014, J PHARM SCI-US, V103, P3287, DOI 10.1002/jps.24087; Logan R, 2012, EXPERT OPIN DRUG MET, V8, P943, DOI 10.1517/17425255.2012.691165; Lu SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173771; Luellmann-Rauch Renate, 2005, P1; Manchon JFM, 2016, AGING-US, V8, P3507, DOI 10.18632/aging.101144; Mitragotri S, 2009, NAT MATER, V8, P15, DOI [10.1038/NMAT2344, 10.1038/nmat2344]; Morissette G, 2008, TOXICOL APPL PHARM, V228, P364, DOI 10.1016/j.taap.2007.12.031; Nilsson C, 2006, APOPTOSIS, V11, P1149, DOI 10.1007/s10495-006-7108-5; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nyman JKE, 2010, CALCIFIED TISSUE INT, V87, P273, DOI 10.1007/s00223-010-9395-7; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; Orlowski J, 2007, CURR OPIN CELL BIOL, V19, P483, DOI 10.1016/j.ceb.2007.06.001; Padman BS, 2013, AUTOPHAGY, V9, P1862, DOI 10.4161/auto.26557; Pangrazio A, 2006, J BONE MINER RES, V21, P1098, DOI 10.1359/JBMR.060403; Parks A, 2016, TOXICOL APPL PHARM, V305, P55, DOI 10.1016/j.taap.2016.06.006; Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257; Petersen NHT, 2013, CANCER CELL, V24, P379, DOI 10.1016/j.ccr.2013.08.003; Quarello P, 2004, J BONE MINER RES, V19, P1194, DOI 10.1359/JBMR.040407; Repnik U, 2014, MITOCHONDRION, V19, P49, DOI 10.1016/j.mito.2014.06.006; Rutsch F, 2009, NAT GENET, V41, P234, DOI 10.1038/ng.294; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Samie MA, 2014, J LIPID RES, V55, P995, DOI 10.1194/jlr.R046896; Sardiello M, 2009, CELL CYCLE, V8, P4021, DOI 10.4161/cc.8.24.10263; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Shayman JA, 2013, BBA-MOL CELL BIOL L, V1831, P602, DOI 10.1016/j.bbalip.2012.08.013; Siintola E, 2007, AM J HUM GENET, V81, P136, DOI 10.1086/518902; Slaugenhaupt SA, 1999, AM J HUM GENET, V65, P773, DOI 10.1086/302549; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; STRAUSBAUCH P, 1989, J LEUKOCYTE BIOL, V46, P441, DOI 10.1002/jlb.46.5.441; SWANSON J, 1987, J CELL BIOL, V104, P1217, DOI 10.1083/jcb.104.5.1217; TAPPER H, 1990, BIOCHEM J, V272, P407, DOI 10.1042/bj2720407; VANDYKE RW, 1993, AM J PHYSIOL, V265, pC901, DOI 10.1152/ajpcell.1993.265.4.C901; Verkman AS, 2009, NAT REV DRUG DISCOV, V8, P153, DOI 10.1038/nrd2780; von Schwarzenberg K, 2013, J BIOL CHEM, V288, P1385, DOI 10.1074/jbc.M112.412007; Vruchte DT, 2004, J BIOL CHEM, V279, P26167, DOI 10.1074/jbc.M311591200; Wang WY, 2015, P NATL ACAD SCI USA, V112, pE1373, DOI 10.1073/pnas.1419669112; Xie XS, 2004, J BIOL CHEM, V279, P19755, DOI 10.1074/jbc.M313796200; Yang QQ, 2006, J AM SOC NEPHROL, V17, P1858, DOI 10.1681/ASN.2005121277; Zeevi DA, 2007, BBA-MOL BASIS DIS, V1772, P851, DOI 10.1016/j.bbadis.2007.01.004; Zhang GJ, 2000, J MEMBRANE BIOL, V175, P53, DOI 10.1007/s002320001054; Zhang LS, 2009, ACTA BIOCH BIOPH SIN, V41, P437, DOI 10.1093/abbs/gmp031; Zhao H, 2005, RADIAT RES, V164, P250, DOI 10.1667/RR3436.1	82	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2017	12	11							e0187627	10.1371/journal.pone.0187627	http://dx.doi.org/10.1371/journal.pone.0187627			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM0ME	29117253	Green Published, Green Submitted, gold			2023-01-03	WOS:000414659600051
J	Sans, MB; Perez-Fontan, M; Martinez-Alonso, M; Bajo, A; Betriu, A; Valdivielso, JAM; Fernandez, E				Borras Sans, Mercs; Perez-Fontan, Miguel; Martinez-Alonso, Montserrat; Bajo, Auxiliadora; Betriu, Angels; Valdivielso, Jose A. M.; Fernandez, Elvira		NEFRONA INVESTIGATORS	The modality of dialysis does not influence atheromatous vascular disease progression or cardiovascular outcomes in dialysis patients without previous cardiovascular disease	PLOS ONE			English	Article							INTIMA-MEDIA THICKNESS; CHRONIC KIDNEY-DISEASE; CAROTID ATHEROSCLEROSIS; HEMODIALYSIS-PATIENTS; RISK-FACTORS; URIC-ACID; MYOCARDIAL-INFARCTION; PERITONEAL-DIALYSIS; PROGNOSTIC VALUE; PREDICTIVE-VALUE	Background There is limited and inconclusive information regarding the influence of the modality of renal replacement therapy on the atherosclerotic burden of patients on dialysis. The aim of this study was to compare the prevalence of asymptomatic atheromatous carotid disease, as also its rate of progression and cardiovascular outcomes, in two matched populations of patients treated with hemodialysis (HD) and peritoneal dialysis (PD). Methods Following a prospective, observational and multicenter design, we compared 237 PD and 237 HD patients without previous cardiovascular disease, included in the NEFRONA study, and matched for age, sex, diabetes and time on dialysis. Carotid ultrasound study was performed at baseline and after two years of follow-up in 6 carotid territories. Atheromatous vascular disease (AVD) progression was defined as any increase in the number of territories with plaques after 2 years. Fatal and non fatal cardiovascular events were also recorded during 36-month of follow-up. Main results At baseline, PD patients presented a worse general cardiovascular risk profile than mHD patients. On the contrary, some markers of prevalent atherosclerotic disease (common carotid intima-media thickness and ankle-brachial index) were more favorable in PD patients. During follow-up, we observed no differences either in the rate of progression of atheromatous vascular disease (OR 1.78, 95% CI 0.80-4.06, p = 0.161) or in the incidence of cardiovascular events (OR 1.51, 95% CI 0.85-2.66, p = 0.159), according to the modality of dialysis. Conclusion Dialysis modality did not impact on atherosclerotic carotid disease progression or cardiovascular outcomes, in two groups of patients treated with PD or HD.	[Borras Sans, Mercs; Fernandez, Elvira] Univ Hosp Arnau Vilanova Lleida, Dept Nephrol, Lleida, Spain; [Borras Sans, Mercs; Martinez-Alonso, Montserrat; Betriu, Angels; Valdivielso, Jose A. M.; Fernandez, Elvira] UDETMA Unitat Deteccio Malalties Aterotrombot, Lleida, Spain; [Borras Sans, Mercs; Martinez-Alonso, Montserrat; Betriu, Angels; Valdivielso, Jose A. M.; Fernandez, Elvira] IRBLleida, REDinREN ISCIII, UDETMA, Vasc & Renal Translat Res Grp, Lleida, Spain; [Perez-Fontan, Miguel] Univ Hosp A Coruna, Dept Nephrol, La Coruna, Spain; [Bajo, Auxiliadora] Univ Hosp La Paz, REDinREN ISCIII, Dept Nephrol, Madrid, Spain	University Hospital Arnau de Vilanova; Complejo Hospitalario Universitario A Coruna; Hospital Universitario La Paz	Sans, MB (corresponding author), Univ Hosp Arnau Vilanova Lleida, Dept Nephrol, Lleida, Spain.; Sans, MB (corresponding author), UDETMA Unitat Deteccio Malalties Aterotrombot, Lleida, Spain.; Sans, MB (corresponding author), IRBLleida, REDinREN ISCIII, UDETMA, Vasc & Renal Translat Res Grp, Lleida, Spain.	mmborras.lleida.ics@gencat.cat	Bajo, Maria A/ABF-6991-2020; Valdivielso, Jose M/B-5673-2009; Perez-Fontán, Miguel/ABG-4064-2020	Bajo, Maria A/0000-0001-7364-557X; Valdivielso, Jose M/0000-0003-1343-0184; Perez-Fontán, Miguel/0000-0001-7027-2296; Borras, Merce/0000-0002-7498-4773	AbbVie	AbbVie(AbbVie)	The NEFRONA study is funded by a research grant from AbbVie. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Arroyo D, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-168; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Barrios C, 2015, ATHEROSCLEROSIS, V242, P37, DOI 10.1016/j.atherosclerosis.2015.06.048; Bayes B, 2003, NEPHROL DIAL TRANSPL, V18, P106, DOI 10.1093/ndt/18.1.106; Benedetto FA, 2001, J AM SOC NEPHROL, V12, P2458, DOI 10.1681/ASN.V12112458; Collado S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127344; Covic A, 2010, NEPHROL DIAL TRANSPL, V25, P1757, DOI 10.1093/ndt/gfq206; de La Piedra C, 2008, NEFROLOGIA, V28, P123; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Foley RN, 2003, KIDNEY INT, V63, P1462, DOI 10.1046/j.1523-1755.2003.00860.x; Garcia-Lopez E, 2007, PERITON DIALYSIS INT, V27, pS205; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hollander M, 2002, CIRCULATION, V105, P2872, DOI 10.1161/01.CIR.0000018650.58984.75; Iseki K, 2002, KIDNEY INT, V61, P1887, DOI 10.1046/j.1523-1755.2002.00324.x; Johnsen SH, 2007, STROKE, V38, P2873, DOI 10.1161/STROKEAHA.107.487264; Junyent M, 2010, NEFROLOGIA, V30, P119, DOI 10.3265/Nefrologia.pre2010.Jan.10216; Junyent M, 2010, BMC NEPHROL, V11, DOI 10.1186/1471-2369-11-14; Kilpatrick RD, 2007, J AM SOC NEPHROL, V18, P293, DOI 10.1681/ASN.2006070795; Korevaar JC, 2003, KIDNEY INT, V64, P2222, DOI 10.1046/j.1523-1755.2003.00321.x; Kumral E, 2014, ACTA NEUROL SCAND, V130, P11, DOI 10.1111/ane.12208; Lertdumrongluk P, 2013, AM J NEPHROL, V3, P144; Li Q, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-72; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Maeda S, 2009, ATHEROSCLEROSIS, V204, P549, DOI 10.1016/j.atherosclerosis.2008.09.028; Mutluay R, 2012, ADV THER, V29, P370, DOI 10.1007/s12325-012-0011-2; Neogi T, 2009, J RHEUMATOL, V36, P378, DOI 10.3899/jrheum.080646; Nishizawa Y, 2003, AM J KIDNEY DIS, V41, pS76, DOI 10.1053/ajkd.2003.50090; Nishizawa Y, 1997, KIDNEY INT, V52, pS90; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; Oyama J, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0409-2; Sanchez-Alvarez JE, 2010, NEFROLOGIA, V30, P427, DOI 10.3265/Nefrologia.pre2010.Mar.10277; Schneider A, 2013, J RENAL NUTR, V23, P411; Schwaiger JP, 2006, AM J KIDNEY DIS, V47, P888, DOI 10.1053/j.ajkd.2006.01.011; Shi ZQ, 2012, RENAL FAILURE, V34, P1206, DOI 10.3109/0886022X.2012.718954; Stein JH, 2008, J AM SOC ECHOCARDIOG, V21, P93, DOI 10.1016/j.echo.2007.11.011; Tattersall MC, 2014, STROKE, V45, P3257, DOI 10.1161/STROKEAHA.114.005669; Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145; Yilmaz FM, 2007, CLIN BIOCHEM, V40, P1361, DOI 10.1016/j.clinbiochem.2007.07.017; Zoccali C, 2005, SEMIN NEPHROL, V25, P358, DOI 10.1016/j.semnephrol.2005.05.002	39	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2017	12	11							e0186921	10.1371/journal.pone.0186921	http://dx.doi.org/10.1371/journal.pone.0186921			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL6FI	29095847	Green Published, gold, Green Submitted			2023-01-03	WOS:000414340200032
J	[Anonymous]				[Anonymous]			RET-oncogene-targeting drugs draw notice	NATURE BIOTECHNOLOGY			English	News Item																			0	0	0	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2017	35	11					996	996		10.1038/nbt1117-996	http://dx.doi.org/10.1038/nbt1117-996			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FU7MU	29121012	Bronze			2023-01-03	WOS:000424037000001
J	Croles, FN; Nasserinejad, K; Duvekot, JJ; Kruip, MJHA; Meijer, K; Leebeek, FWG				Croles, F. Nanne; Nasserinejad, Kazem; Duvekot, Johannes J.; Kruip, Marieke J. H. A.; Meijer, Karina; Leebeek, Frank W. G.			Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FACTOR-V-LEIDEN; VTE	Objective To provide evidence to support updated guidelines for the management of pregnant women with hereditary thrombophilia in order to reduce the risk of a first venous thromboembolism (VTE) in pregnancy. Design Systematic review and bayesian meta-analysis. Data sources Embase, Medline, Web of Science, Cochrane Library, and Google Scholar from inception through 14 November 2016. Review methods Observational studies that reported on pregnancies without the use of anticoagulants and the outcome of first VTE for women with thrombophilia were eligible for inclusion. VTE was considered established if it was confirmed by objective means, or when the patient had received a full course of a full dose anticoagulant treatment without objective testing. Results 36 studies were included in the meta-analysis. All thrombophilias increased the risk for pregnancy associated VTE (probabilities = 91%). Regarding absolute risks of pregnancy associated VTE, high risk thrombophilias were antithrombin deficiency (antepartum: 7.3%, 95% credible interval 1.8% to 15.6%; post partum: 11.1%, 3.7% to 21.0%), protein C deficiency (antepartum: 3.2%, 0.6% to 8.2%; post partum: 5.4%, 0.9% to 13.8%), protein S deficiency (antepartum: 0.9%, 0.0% to 3.7%; post partum: 4.2%; 0.7% to 9.4%), and homozygous factor V Leiden (antepartum: 2.8%, 0.0% to 8.6%; post partum: 2.8%, 0.0% to 8.8%). Absolute combined antepartum and postpartum risks for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutations, or compound heterozygous factor V Leiden and prothrombin G20210A mutations were all below 3%. Conclusions Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both. Women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation should generally not be prescribed thrombosis prophylaxis on the basis of thrombophilia and family history alone. These data should be considered in future guidelines on pregnancy associated VTE risk.	[Croles, F. Nanne; Nasserinejad, Kazem; Kruip, Marieke J. H. A.; Leebeek, Frank W. G.] Erasmus Univ, Med Ctr, Dept Hematol, Postbus 2040, NL-3000 CA Rotterdam, Netherlands; [Duvekot, Johannes J.] Erasmus Univ, Med Ctr, Dept Obstet & Gynaecol, Rotterdam, Netherlands; [Meijer, Karina] Univ Groningen, Univ Med Ctr Groningen, Dept Haematol, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Groningen	Croles, FN (corresponding author), Erasmus Univ, Med Ctr, Dept Hematol, Postbus 2040, NL-3000 CA Rotterdam, Netherlands.	f.croles@erasmusmc.nl		Nasserinejad, Kazem/0000-0002-5666-5015; Leebeek, Frank/0000-0001-5677-1371; Croles, Nanne/0000-0001-7722-1862				Bain E, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001689.pub3; Bank I, 2004, ARCH INTERN MED, V164, P1932, DOI 10.1001/archinte.164.17.1932; Bates SM, 2016, J THROMB THROMBOLYS, V41, P92, DOI 10.1007/s11239-015-1309-0; Bates Shannon M, 2012, Chest, V141, pe691S, DOI 10.1378/chest.11-2300; Bezemer ID, 2009, ARCH INTERN MED, V169, P610, DOI 10.1001/archinternmed.2008.589; Biron-Andreani C, 2006, THROMB HAEMOSTASIS, V96, P14, DOI 10.1160/TH06-02-0086; Bleker SM, 2016, THROMB RES, V144, P62, DOI 10.1016/j.thromres.2016.06.001; Boven HHV, 1999, GENE GENE GENE ENV I; Braekkan SK, 2016, J THROMB HAEMOST, V14, P1978, DOI 10.1111/jth.13411; Bucciarelli P, 1999, ARTERIOSCL THROM VAS, V19, P1026, DOI 10.1161/01.ATV.19.4.1026; Chan WS, 2014, J OBSTET GYNAECOL CA, V36, P527, DOI 10.1016/S1701-2163(15)30569-7; Clark P, 2008, BRIT J HAEMATOL, V140, P236, DOI 10.1111/j.1365-2141.2007.06902.x; Cochery-Nouvellon E, 2007, J THROMB HAEMOST, V5, P700, DOI 10.1111/j.1538-7836.2007.02423.x; Coppens M, 2006, BLOOD, V108, P2604, DOI 10.1182/blood-2006-04-016527; Cordoba I, 2012, EUR J HAEMATOL, V89, P250, DOI 10.1111/j.1600-0609.2012.01809.x; Couturaud F, 2008, THROMB HAEMOSTASIS, V99, P793, DOI 10.1160/TH07-12-0720; de Jong PG, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0719-9; Dilley A, 2000, AM J OBSTET GYNECOL, V183, P1271, DOI 10.1067/mob.2000.106820; Dizon-Townson D, 2005, OBSTET GYNECOL, V106, P517, DOI 10.1097/01.AOG.0000173986.32528.ca; Eichinger S, 1999, THROMB HAEMOSTASIS, V82, P1232; Folkeringa N, 2007, BRIT J HAEMATOL, V138, P110, DOI 10.1111/j.1365-2141.2007.06624.x; Friederich PW, 1996, ANN INTERN MED, V125, P955, DOI 10.7326/0003-4819-125-12-199612150-00003; Gerhardt A, 2016, BLOOD, V128, P2343, DOI 10.1182/blood-2016-03-703728; Grandone E, 1998, AM J OBSTET GYNECOL, V179, P1324, DOI 10.1016/S0002-9378(98)70155-3; Hammerova L'ubica, 2011, Acta Medica (Hradec Kralove), V54, P117; Hasegawa J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010304; Heit JA, 2005, J THROMB HAEMOST, V3, P305, DOI 10.1111/j.1538-7836.2004.01117.x; Huisman MV, 2016, RICHTLIJN ANTITROMBO; Jacobsen AF, 2010, J THROMB HAEMOST, V8, P2443, DOI 10.1111/j.1538-7836.2010.04038.x; Kjellberg U, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.08.011; Klai S, 2012, BLOOD COAGUL FIBRIN, V23, P649, DOI 10.1097/MBC.0b013e3283574f05; Lindqvist PG, 1999, THROMB HAEMOSTASIS, V81, P532; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Martinelli I, 2008, J THROMB HAEMOST, V6, P494, DOI 10.1111/j.1538-7836.2007.02880.x; Martinelli I, 2002, THROMB HAEMOSTASIS, V87, P791; Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P800; Meglic L, 2003, EUR J OBSTET GYN R B, V111, P157, DOI 10.1016/S0301-2115(03)00212-4; Melis F, 2004, AM J OBSTET GYNECOL, V191, P825, DOI 10.1016/j.ajog.2004.02.004; Middeldorp S, 1998, ANN INTERN MED, V128, P15, DOI 10.7326/0003-4819-128-1-199801010-00003; Middeldorp S, 2001, ANN INTERN MED, V135, P322, DOI 10.7326/0003-4819-135-5-200109040-00008; Middeldorp S, 2001, BRIT J HAEMATOL, V113, P553, DOI 10.1046/j.1365-2141.2001.02766.x; Mitic G, 2011, GYNECOL OBSTET INVES, V72, P103, DOI 10.1159/000323828; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Mulder R, 2010, THROMB HAEMOSTASIS, V104, P618, DOI 10.1160/TH10-02-0113; Murphy RP, 2000, ARTERIOSCL THROM VAS, V20, P266, DOI 10.1161/01.ATV.20.1.266; Oates M, 2011, BJOG-INT J OBSTET GY, V118, P132, DOI 10.1111/j.1471-0528.2010.02847.x; Ogunyemi D, 2003, AM J PERINAT, V20, P17, DOI 10.1055/s-2003-37947; Plummer M, 2003, P 3 INT WORKSHOP DIS, P1; R Core Team, R LANG ENV STAT COMP; Rheaume M, 2016, OBSTET GYNECOL, V127, P649, DOI 10.1097/AOG.0000000000001347; Robertson L, 2006, BRIT J HAEMATOL, V132, P171, DOI 10.1111/j.1365-2141.2005.05847.x; Samama MM, 1996, HAEMOSTASIS, V26, P315; Simioni P, 1999, THROMB HAEMOSTASIS, V81, P198, DOI 10.1055/s-0037-1614442; Simioni P, 2002, INCIDENCE VENOUS THR; Simpson EL, 2001, BRIT J OBSTET GYNAEC, V108, P56, DOI 10.1111/j.1471-0528.2001.00004.x; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; Sweeting MJ, 2004, STAT MED, V23, P1351, DOI 10.1002/sim.1761; Tam WH, 2012, GYNECOL OBSTET INVES, V73, P183, DOI 10.1159/000331648; Tormene D, 2007, J THROMB HAEMOST, V5, P2193, DOI 10.1111/j.1538-7836.2007.02727.x; Tormene D, 2001, HAEMATOLOGICA, V86, P1305; Tosetto A, 2003, J THROMB HAEMOST, V1, P1724, DOI 10.1046/j.1538-7836.2003.00313.x; van Lennep JER, 2011, J THROMB HAEMOST, V9, P473, DOI 10.1111/j.1538-7836.2011.04186.x; Vora Sonal, 2007, Thromb J, V5, P9, DOI 10.1186/1477-9560-5-9; Wells GA, NEWCASTLE OTTAWA SCA; Wik HS, 2012, J THROMB HAEMOST, V10, P840, DOI 10.1111/j.1538-7836.2012.04690.x; Yilmazer Mehmet, 2003, Archives of Gynecology and Obstetrics, V268, P304, DOI 10.1007/s00404-002-0430-4; Ziakas PD, 2015, EUR J OBSTET GYN R B, V191, P106, DOI 10.1016/j.ejogrb.2015.06.005	67	57	67	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2017	359								j4452	10.1136/bmj.j4452	http://dx.doi.org/10.1136/bmj.j4452			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL4AO	29074563	hybrid, Green Published			2023-01-03	WOS:000414168600001
J	Mazza, A; Cavallin, F; Cappellari, A; Divisic, A; Grbin, I; Akakpo, J; Moukaila, AR; Trevisanuto, D				Mazza, Alessandro; Cavallin, Francesco; Cappellari, Anita; Divisic, Antuan; Grbin, Ivana; Akakpo, Jean; Moukaila, Abdou Razak; Trevisanuto, Daniele			Effect of a short training on neonatal face-mask ventilation performance in a low resource setting	PLOS ONE			English	Article							RESUSCITATION; GUIDELINES; MORTALITY; BABIES	Background We assessed whether a short training, effective in a high resource country, was able to improve the quality of face-mask ventilation (FMV) in a low resource setting. Methods Local healthcare providers at the Centre Me A dico-Social, Kouve, Togo were asked to ventilate a neonatal leak-free manikin before (time-t(1)) and after (t(2)) a two-minute training session. Immediately after this section, a further two-minute training with participants aware of the data monitor was offered. Finally, a third 1-minute FMV round (t(3)) was performed by each participant. Ventilatory parameters were recorded using a computerized system. Primary outcome was the percentage of breaths with relevant mask leak (>25%). Secondary outcomes were percentages of breaths with a low peak inspiratory pressure (PIP<20 cm H2O), within the recommended PIP (20-35 cm H2O) and with a high PIP (>35 cm H2O). Results Twenty-six subjects participated in the study. The percentage of relevant mask leak significantly decreased (p<0.0001; beta = -0.76, SE = 0.10) from 89.7% (SD 21.5%) at t(1) to 45.4% (SD 27.2%) at t(2) and to 18.3% (SD 20.1%) at t(3). The percentage of breaths within the recommended PIP significantly increased (p<0.0001; beta = +0.54, SE = 0.12). The percentage of breaths with PIP>35 cm H2O was 19.5% (SD 32.8%) at t(1) and 39.2% (SD 37.7%) at t(2) (padj = 0.27; beta = +0.61, SE = 0.36) and significantly decreased (padj = 0.01; beta = -1.61, SE = 0.55) to 6.0% (SD 15.4%) at t(3). Conclusions A 2-minute training on FMV, effective in a high resource country, had a positive effect also in a low resource setting. FMV performance further improved after an extra 2-minute verbal recall plus real time feedback. Although the training was extended, it still does not cost much time and effort. Further studies are needed to establish if these basic skills are transferred in real patients and if they are maintained over time.	[Mazza, Alessandro; Cappellari, Anita; Divisic, Antuan; Grbin, Ivana; Trevisanuto, Daniele] Univ Padua, Azienda Osped Padova, Dept Womens & Childrens Hlth, Padua, Italy; [Akakpo, Jean; Moukaila, Abdou Razak] Ctr Med Social, Maternite, Marie Mere Providence, Kouve, Togo	University of Padua; Azienda Ospedaliera - Universita di Padova	Trevisanuto, D (corresponding author), Univ Padua, Azienda Osped Padova, Dept Womens & Childrens Hlth, Padua, Italy.	daniele.trevisanuto@gmail.com	Divisic, Antuan/AAG-2819-2022; Divisic, Antuan/AFK-4023-2022	Trevisanuto, Daniele/0000-0002-7126-5298	Autonomous Province of Trento; Autonomous Region Trentino-Alto Adige, Italy	Autonomous Province of Trento(Autonomous Province of Trento); Autonomous Region Trentino-Alto Adige, Italy	Autonomous Province of Trento and Autonomous Region Trentino-Alto Adige, Italy, supported the project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the Autonomous Province of Trento and Autonomous Region Trentino-Alto Adige, Italy that supported the project.	Kelm M, 2012, J PERINAT MED, V40, P583, DOI 10.1515/jpm-2012-0023; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Lee ACC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S12; Mduma E, 2015, RESUSCITATION, V93, P1, DOI 10.1016/j.resuscitation.2015.04.019; Msemo G, 2013, PEDIATRICS, V131, pE353, DOI 10.1542/peds.2012-1795; Newton O, 2006, T ROY SOC TROP MED H, V100, P899, DOI 10.1016/j.trstmh.2006.02.012; R Development Core Team, 2017, R LANG ENV STAT COMP; Singhal N, 2006, CLIN PERINATOL, V33, P219, DOI 10.1016/j.clp.2005.11.009; Trevisanuto D, 2015, PLOS ONE, V11, P10; Unicef Levels & Trends in Child Mortality, 2013, LEV TRENDS CHILD MOR; van Vonderen JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109049; WHO, 2014, WORLD HLTH STAT; Wood FE, 2008, ARCH DIS CHILD-FETAL, V93, pF230, DOI 10.1136/adc.2007.117788; Wyckoff MH, 2015, CIRCULATION, V132, pS543, DOI 10.1161/CIR.0000000000000267; Wyllie J, 2015, RESUSCITATION, V95, P249, DOI 10.1016/j.resuscitation.2015.07.029	15	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0186731	10.1371/journal.pone.0186731	http://dx.doi.org/10.1371/journal.pone.0186731			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9QH	29073266	Green Submitted, gold, Green Published			2023-01-03	WOS:000413845400046
J	Rand, D				Rand, Debbie			Proprioception deficits in chronic stroke-Upper extremity function and daily living	PLOS ONE			English	Article							FUGL-MEYER ASSESSMENT; SENSORIMOTOR SYSTEM; POSITION SENSE; BLOCK TEST; RELIABILITY; RECOVERY; VALIDITY; PERFORMANCE; IMPAIRMENT; ARM	Background Proprioception deficits are common post-stroke and predict poor functional outcome. It is unknown if the presence of proprioception deficits is negatively associated with the motor and functional ability of the affected upper extremity and daily living at the chronic stage post-stroke. Aims 1) To describe proprioception deficits of individuals with chronic stroke, 2) to correlate the severity of proprioception deficits with the motor and functional ability of the upper extremity, and 3) to compare independence in basic and instrumental activities in daily living (BADL, IADL), upper extremity motor and functional abilities between individuals with and without proprioception deficits. Methods 102 adults aged 29-85 years with chronic stroke participated in this cross sectional study. The upper extremity was assessed for proprioception (Thumb localization Test), motor [Fugl-Meyer Motor Assessment (FMA)] and functional ability [Action Research Arm Test (ARAT), Box and Block Test (BBT)], grip strength and daily use [Motor Activity Log (MAL)]. Independence in BADL and IADL was also assessed. Results 71 participants had intact proprioception, 31 participants had mild-moderate proprioception deficits. Negative significant (p<.001) correlations were found between the severity of proprioception deficits to the motor ability (FMA) (r = -.41), functional ability (ARAT) (r = -.48), dexterity (BBT) (r = -.43), grip strength (r = -.41) and daily-use (MAL amount and quality) (r = -.55 and r = -.54, respectively) of the affected upper extremity. Significant between-group differences were found for BADL, IADL and upper extremity measures. Conclusion Proprioception deficits of individuals with chronic stroke are negatively associated with upper extremity motor and functional abilities and independence in daily living. Therefore, proprioception should be assessed at the chronic stage post-stroke.	[Rand, Debbie] Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Dept Occupat Therapy, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Rand, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Hlth Profess, Dept Occupat Therapy, Tel Aviv, Israel.	drand@post.tau.ac.il		Rand, Debbie/0000-0001-6410-2389				Berthoz A., 2000, BRAINS SENSE MOVEMEN; Bohannon Richard W, 2005, J Hand Ther, V18, P426, DOI 10.1197/j.jht.2005.07.003; Carey L.M., 1995, CRIT REV PHYS REHABI, V7, P51, DOI [10.1615/CritRevPhysRehabilMed.v7.i1.40, DOI 10.1615/CRITREVPHYSREHABILMED.V7.I1.40]; Chalsen GG, 1987, J NEUROL REHABIL, V1, P137; Cohen J., 2013, STAT POWER ANAL BEHA; Connell LA, 2008, CLIN REHABIL, V22, P758, DOI 10.1177/0269215508090674; Cromwell FS, 1965, OCCUPATIONAL THERAPI, P29; Desrosiers J, 1996, STROKE, V27, P1564, DOI 10.1161/01.STR.27.9.1564; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; Fess EE., 1992, CLIN ASSESSMENT RECO, P41; Findlater SE, 2017, J MOTOR BEHAV, V49, P27, DOI 10.1080/00222895.2016.1219303; Findlater SE, 2016, CORTEX, V79, P42, DOI 10.1016/j.cortex.2016.03.008; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gottlieb D, 1997, J NEUROL REHABIL, V11, P239; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Haerer AF, 1997, DEJONGS NEUROLOGIC E; Harris JE, 2006, NEUROREHAB NEURAL RE, V20, P380, DOI 10.1177/1545968305284528; Hillier S, 2015, NEUROREHAB NEURAL RE, V29, P933, DOI 10.1177/1545968315573055; Jeannerod M., 1988, NEURAL BEHAV ORG GOA; Kenzie JM, 2014, J NEUROL SCI, V342, P52, DOI 10.1016/j.jns.2014.04.025; Kessner SS, 2016, TOP STROKE REHABIL, V23, P136, DOI 10.1080/10749357.2015.1116822; Kielhofner G., 2006, RES OCCUPATIONAL THE, P155, DOI DOI 10.1136/JNNP.73.2.188; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; Lephart SM, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, pXVII; Lin JH, 2004, CLIN REHABIL, V18, P391, DOI 10.1191/0269215504cr737oa; Masedo AI, 2005, AM J PHYS MED REHAB, V84, P167, DOI 10.1097/01.PHM.0000154898.25609.4A; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; MATHIOWETZ V, 1984, J HAND SURG-AM, V9A, P222, DOI 10.1016/S0363-5023(84)80146-X; Niessen MHM, 2009, AM J PHYS MED REHAB, V88, P979, DOI 10.1097/PHM.0b013e3181c1eac1; Ogard WK, 2011, STRENGTH COND J, V33, P111, DOI 10.1519/SSC.0b013e31821bf3ae; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Portney L.G., 2000, FDN CLIN RES APPL PR, P560; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; Proske U, 2012, PHYSIOL REV, V92, P1651, DOI 10.1152/physrev.00048.2011; Rand D, 1999, NEUROREHAB NEURAL RE, V13, P15, DOI 10.1177/154596839901300104; Rand D., 2001, PHYS OCCUPATIONAL TH, V18, P69, DOI DOI 10.1080/J148v18n03_05; Rand D, 2015, J STROKE CEREBROVASC, V24, P274, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.039; REDING MJ, 1988, STROKE, V19, P1354, DOI 10.1161/01.STR.19.11.1354; REDING MJ, 1990, STROKE, V21, P35; Riemann BL, 2002, J ATHL TRAINING, V37, P71; Riemann BL, 2002, J ATHL TRAINING, V37, P80; Semrau JA, 2013, STROKE, V44, P3414, DOI 10.1161/STROKEAHA.113.002058; SMITH DL, 1983, AGE AGEING, V12, P63, DOI 10.1093/ageing/12.1.63; Stern PH, 1971, STROKE, V2, P213, DOI 10.1161/01.STR.2.3.213; Sunderland A, 2000, STROKE, V31, P430, DOI 10.1161/01.STR.31.2.430; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Uswatte G, 2005, STROKE, V36, P2493, DOI 10.1161/01.STR.0000185928.90848.2e; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; Wetter S, 2005, ARCH PHYS MED REHAB, V86, P776, DOI 10.1016/j.apmr.2004.08.009; Winward CE, 2002, CLIN REHABIL, V16, P523, DOI 10.1191/0269215502cr522oa; Ziegler DK, 1975, MAJORS PHYS DIAGNOSI, P118	56	28	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2018	13	3							e0195043	10.1371/journal.pone.0195043	http://dx.doi.org/10.1371/journal.pone.0195043			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB1XW	29601594	gold, Green Published, Green Submitted			2023-01-03	WOS:000428845900015
J	Baker, J; Dickman, A; Mason, S; Ellershaw, J				Baker, James; Dickman, Andrew; Mason, Stephen; Ellershaw, John			The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review	PLOS ONE			English	Review							N-BUTYL BROMIDE; POLYPROPYLENE SYRINGES; PALLIATIVE CARE; PHYSICAL COMPATIBILITY; DRUG-COMBINATIONS; SODIUM-CHLORIDE; CANCER-PATIENTS; STABILITY; HALOPERIDOL; MORPHINE	Background A continuous subcutaneous infusion (CSCI) is an effective method of multiple drug administration commonly encountered in end of life care when the oral route is compromised. At present, current practice is to limit syringe driver infusion time to a maximum of 24 hours as dictated by available chemical stability data. However, the ability to deliver prescribed medication by a CSCI over 48 hours may have numerous benefits in both patient care and health service resource utilisation. Aim To examine and present the current evidence base for the stability of 48-hour multiple-drug CSCIs in current clinical practice. Design A systematically-structured review following PRISMA guidelines. Data sources Three electronic databases and the grey literature were searched with no time limits. Empirical studies reporting data on the chemical stability of continuous subcutaneous infusions or solutions stored in polypropylene syringes were included. Results Twenty-one empirical studies were included in this review reporting chemical compatibility and stability of 32 discrete combinations of twenty-four drugs tested at a variety of different drug concentrations. The majority of combinations reported were assessed as being chemically compatible. The greatest risk of clinically significant chemical degradation was observed with midazolam. Only one study reported the microbiological stability of the solution examined. Conclusions There is currently limited evidence for the physical, chemical and microbiological stability of solutions for continuous subcutaneous infusion over a period of 48 hours. More stability data is required before the use of 48-hour CSCIs can be evaluated for use within clinical practice.	[Baker, James] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Pharm Dept, Liverpool, Merseyside, England; [Baker, James; Dickman, Andrew; Mason, Stephen; Ellershaw, John] Univ Liverpool, Palliat Care Inst Liverpool, Liverpool, Merseyside, England; [Dickman, Andrew; Ellershaw, John] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Acad Palliat & End Life Care Dept, Liverpool, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital	Baker, J (corresponding author), Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Pharm Dept, Liverpool, Merseyside, England.; Baker, J (corresponding author), Univ Liverpool, Palliat Care Inst Liverpool, Liverpool, Merseyside, England.	J.baker6@nhs.net		Baker, James/0000-0001-9134-5538; Ellershaw, John/0000-0001-9789-3180; Mason, Stephen/0000-0002-4020-6869	NHS Liverpool Clinical Commisioning Group	NHS Liverpool Clinical Commisioning Group	This review was funded by a project grant issued by NHS Liverpool Clinical Commisioning Group (http://www.liverpoolccg.nhs.uk) to AD, SM and JE without a grant number. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLWOOD M C, 1991, Palliative Medicine, V5, P330, DOI 10.1177/026921639100500409; Baker J, 2017, APM SUPP PALL CAR C; Barcia E, 2005, SUPPORT CARE CANCER, V13, P239, DOI 10.1007/s00520-004-0719-x; Barcia E, 2003, SUPPORT CARE CANCER, V11, P107, DOI 10.1007/s00520-002-0415-7; Blessy M, 2014, J Pharm Anal, V4, P159, DOI 10.1016/j.jpha.2013.09.003; Clark D, 2014, PALLIATIVE MED, V28, P474, DOI 10.1177/0269216314526443; Collins AJ, 1986, J PHARM PHARM, V38; Destro M, 2012, SUPPORT CARE CANCER, V20, P2501, DOI 10.1007/s00520-011-1363-x; Dickman A, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0195-y; Donnelly Ronald F, 2009, Can J Hosp Pharm, V62, P28; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Ensom Mary H H, 2009, Can J Hosp Pharm, V62, P112; Fielding H, 2000, PALLIATIVE MED, V14, P205, DOI 10.1191/026921600666997498; Good PD, 2004, J PAIN SYMPTOM MANAG, V27, P471, DOI 10.1016/j.jpainsymman.2004.02.002; Grassby PF, 1997, PALLIATIVE MED, V11, P217, DOI 10.1177/026921639701100306; Hawker S, 2002, QUAL HEALTH RES, V12, P1284, DOI 10.1177/1049732302238251; Hor MMS, 1997, J CLIN PHARM THER, V22, P339, DOI 10.1046/j.1365-2710.1997.00113.x; Jappinen A, 1999, PHARM WORLD SCI, V21, P272, DOI 10.1023/A:1008771621812; LACH JL, 1956, J AM PHARM ASSOC, V45, P611, DOI 10.1002/jps.3030450909; Masman AD, 2015, INT J CLIN PHARM-NET, V37, P767, DOI 10.1007/s11096-015-0094-3; Nassr S, 2003, J LIQ CHROMATOGR R T, V26, P2909, DOI 10.1081/JLC-120025053; Nassr S, 2001, J LIQ CHROMATOGR R T, V24, P265, DOI 10.1081/JLC-100001487; National Institute for Health and Care Excellence (NICE), 2012, PALL CAR AD STRONG O; National Patient Safety Agency (NPSA), 2007, PROM SAF US INJ MED; Negro S, 2007, J CLIN PHARM THER, V32, P441, DOI 10.1111/j.1365-2710.2007.00839.x; Negro S, 2006, INT J PHARMACEUT, V307, P278, DOI 10.1016/j.ijpharm.2005.10.017; Negro S, 2002, SUPPORT CARE CANCER, V10, P65, DOI 10.1007/s005200100303; Negro S, 2006, ARZNEIMITTELFORSCH, V56, P714; NHS, 2016, OUT COMM YOU END LIF; Office for National Statistics, 2016, DEATHS REG AR US RES; Office for National Statistics, 2015, 2014 BAS NAT POP PRO; PETERSON G M, 1991, Australian Journal of Hospital Pharmacy, V21, P115; Peterson GM, 1998, J CLIN PHARM THER, V23, P67, DOI 10.1046/j.1365-2710.1998.00141.x; Targett Paul L., 1997, Australian Journal of Hospital Pharmacy, V27, P207; Trissel L, 2010, HDB INJECTABLE DRUGS; Watson DG, 2005, J PAIN SYMPTOM MANAG, V30, P80, DOI 10.1016/j.jpainsymman.2005.01.018; Wilson KM, 1998, J PAIN SYMPTOM MANAG, V16, P52, DOI 10.1016/S0885-3924(98)00024-4	37	0	0	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2018	13	3							e0194236	10.1371/journal.pone.0194236	http://dx.doi.org/10.1371/journal.pone.0194236			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ2XG	29538455	Green Published, Green Submitted, gold			2023-01-03	WOS:000427446400072
J	Tauriello, DVF; Palomo-Ponce, S; Stork, D; Berenguer-Llergo, A; Badia-Ramentol, J; Iglesias, M; Sevillano, M; Ibiza, S; Canellas, A; Momblona, XH; Byrom, D; Matarin, JA; Calon, A; Rivas, EI; Nebreda, AR; Riera, A; Attolini, CSO; Batlle, E				Tauriello, Daniele V. F.; Palomo-Ponce, Sergio; Stork, Diana; Berenguer-Llergo, Antonio; Badia-Ramentol, Jordi; Iglesias, Mar; Sevillano, Marta; Ibiza, Sales; Canellas, Adria; Hernando Momblona, Xavier; Byrom, Daniel; Matarin, Joan A.; Calon, Alexandre; Rivas, Elisa I.; Nebreda, Angel R.; Riera, Antoni; Stephan-Otto Attolini, Camille; Batlle, Eduard			TGF beta drives immune evasion in genetically reconstituted colon cancer metastasis	NATURE			English	Article							GROWTH-FACTOR; COLORECTAL-CANCER; STEM-CELLS; MICE; GENE; EXPRESSION; LEADS; TRANSPLANTATION; PROGRESSION; DISRUPTION	Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers(1,2). Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration(3), low type 1 T-helper cell (T(H)1) activity and reduced immune cytotoxicity(2) or increased TGF beta levels(4) predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden(5), T-cell exclusion(3) and TGF beta-activated stroma(4,6,7). Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGF beta unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGF beta signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGF beta in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the THI-effector phenotype. Immunotherapies directed against TGF beta signalling may therefore have broad applications in treating patients with advanced colorectal cancer.	[Tauriello, Daniele V. F.; Palomo-Ponce, Sergio; Stork, Diana; Berenguer-Llergo, Antonio; Badia-Ramentol, Jordi; Sevillano, Marta; Ibiza, Sales; Canellas, Adria; Hernando Momblona, Xavier; Byrom, Daniel; Matarin, Joan A.; Calon, Alexandre; Rivas, Elisa I.; Nebreda, Angel R.; Riera, Antoni; Stephan-Otto Attolini, Camille; Batlle, Eduard] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Baldiri & Reixac 10, Barcelona 08028, Spain; [Tauriello, Daniele V. F.; Palomo-Ponce, Sergio; Iglesias, Mar; Sevillano, Marta; Hernando Momblona, Xavier; Batlle, Eduard] Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain; [Iglesias, Mar] Hosp del Mar, Dept Pathol, Barcelona 08003, Spain; [Iglesias, Mar; Calon, Alexandre; Rivas, Elisa I.] Hosp del Mar, Res Inst IMIM, Canc Res Programme, Barcelona 08003, Spain; [Iglesias, Mar] Autonomous Univ Barcelona UAB, Barcelona, Spain; [Nebreda, Angel R.; Batlle, Eduard] Passeig Lluis Co 23, ICREA, Barcelona 08010, Spain; [Riera, Antoni] Univ Barcelona, Dept Organ Chem, Marti & Franques 1-11, E-08028 Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; ICREA; University of Barcelona	Batlle, E (corresponding author), Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Baldiri & Reixac 10, Barcelona 08028, Spain.; Batlle, E (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain.; Batlle, E (corresponding author), Passeig Lluis Co 23, ICREA, Barcelona 08010, Spain.	eduard.batlle@irbbarcelona.org	Hernando-Momblona, Xavier/ABH-4881-2020; Tauriello, Daniele/H-4644-2018; Batlle, Eduard/K-8080-2014; Calon, Alexandre/GPK-2061-2022; Nebreda, Angel Rodriguez/R-9594-2019; Riera, Antoni/C-4385-2008; Palomo-Ponce, Sergio/L-2749-2017	Tauriello, Daniele/0000-0003-1522-3496; Batlle, Eduard/0000-0003-2422-0326; Riera, Antoni/0000-0001-7142-7675; Hernando-Momblona, Xavier/0000-0003-0755-333X; Palomo-Ponce, Sergio/0000-0002-3371-6457; SEVILLANO, MARTA/0000-0001-5761-0879; Stephan-Otto Attolini, Camille/0000-0001-8045-320X; Berenguer-LLergo, Antoni/0000-0002-3742-8161; Canellas-Socias, Adria/0000-0002-8373-7803	MINECO; Doctor Josef Steiner Foundation; ERC advanced grant [340176]; Instituto de Salud Carlos III; Olga Torres Foundation; BBVA Foundation [SAF-2014-53784]; Fundacion Botin; Severo Ochoa Award of Excellence from MINECO	MINECO(Spanish Government); Doctor Josef Steiner Foundation; ERC advanced grant(European Research Council (ERC)); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Olga Torres Foundation; BBVA Foundation(BBVA Foundation); Fundacion Botin; Severo Ochoa Award of Excellence from MINECO(Spanish Government)	We thank E. Sancho for critical reading of this manuscript, all members of the Batlle laboratory for support and discussions, and members of the Lopez-Bigas laboratory for help with revising the manuscript. We are grateful for the assistance of the IRB Barcelona core facilities for histopathology, functional genomics, mouse mutant and advanced digital microscopy; the flow cytometry and animal facilities of the UB/PCB; and the CRG genomic unit. D.V.FT. held a Juan de la Cierva postdoctoral fellowship from MINECO. This work was supported by grants from the Doctor Josef Steiner Foundation, ERC advanced grant 340176, Instituto de Salud Carlos III, Olga Torres Foundation, BBVA Foundation, grant SAF-2014-53784 (MINECO) and by Fundacion Botin. IRB Barcelona is the recipient of a Severo Ochoa Award of Excellence from MINECO.	Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gelman A., 2009, J STAT SOFTW, V30, P1; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Marino S, 2000, GENE DEV, V14, P994; Mehal WZ, 2005, INT IMMUNOL, V17, P531, DOI 10.1093/intimm/dxh233; Mlecnik B, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6352; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; R Core Team, 2021, R LANG ENV STAT COMP; Rodon J, 2015, CLIN CANCER RES, V21, P553, DOI 10.1158/1078-0432.CCR-14-1380; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	43	949	965	13	406	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 22	2018	554	7693					538	+		10.1038/nature25492	http://dx.doi.org/10.1038/nature25492			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW8PA	29443964	Green Accepted			2023-01-03	WOS:000425597400049
J	Miao, D; Margolis, CA; Gao, WH; Voss, MH; Li, W; Martini, DJ; Norton, C; Bosse, D; Wankowicz, SM; Cullen, D; Horak, C; Wind-Rotolo, M; Tracy, A; Giannakis, M; Hodi, FS; Drake, CG; Ball, MW; Allaf, ME; Snyder, A; Hellmann, MD; Ho, T; Motzer, RJ; Signoretti, S; Kaelin, WG; Choueiri, TK; Van Allen, EM				Miao, Diana; Margolis, Claire A.; Gao, Wenhua; Voss, Martin H.; Li, Wei; Martini, Dylan J.; Norton, Craig; Bosse, Dominick; Wankowicz, Stephanie M.; Cullen, Dana; Horak, Christine; Wind-Rotolo, Megan; Tracy, Adam; Giannakis, Marios; Hodi, Frank Stephen; Drake, Charles G.; Ball, Mark W.; Allaf, Mohamad E.; Snyder, Alexandra; Hellmann, Matthew D.; Ho, Thai; Motzer, Robert J.; Signoretti, Sabina; Kaelin, William G., Jr.; Choueiri, Toni K.; Van Allen, Eliezer M.			Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma	SCIENCE			English	Article							CTLA-4 BLOCKADE; PD-1 BLOCKADE; PBRM1; TUMORS; MUTATIONS; EXPRESSION; EVEROLIMUS; RESISTANCE; SUNITINIB; NIVOLUMAB	Immune checkpoint inhibitors targeting the programmed cell death 1 receptor (PD-1) improve survival in a subset of patients with clear cell renal cell carcinoma (ccRCC). To identify genomic alterations in ccRCC that correlate with response to anti-PD-1 monotherapy, we performed whole-exome sequencing of metastatic ccRCC from 35 patients. We found that clinical benefit was associated with loss-of-function mutations in the PBRM1 gene (P = 0.012), which encodes a subunit of the PBAF switch-sucrose nonfermentable (SWI/SNF) chromatin remodeling complex. We confirmed this finding in an independent validation cohort of 63 ccRCC patients treated with PD-1 or PD-L1 (PD-1 ligand) blockade therapy alone or in combination with anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) therapies (P = 0.0071). Gene-expression analysis of PBAF-deficient ccRCC cell lines and PBRM1-deficient tumors revealed altered transcriptional output in JAK-STAT (Janus kinase-signal transducers and activators of transcription), hypoxia, and immune signaling pathways. PBRM1 loss in ccRCC may alter global tumor-cell expression profiles to influence responsiveness to immune checkpoint therapy.	[Miao, Diana; Margolis, Claire A.; Gao, Wenhua; Martini, Dylan J.; Norton, Craig; Bosse, Dominick; Wankowicz, Stephanie M.; Giannakis, Marios; Hodi, Frank Stephen; Signoretti, Sabina; Kaelin, William G., Jr.; Choueiri, Toni K.; Van Allen, Eliezer M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Miao, Diana; Margolis, Claire A.; Wankowicz, Stephanie M.; Tracy, Adam; Giannakis, Marios; Van Allen, Eliezer M.] MIT, Broad Inst, Cambridge, MA 02142 USA; [Miao, Diana; Margolis, Claire A.; Wankowicz, Stephanie M.; Tracy, Adam; Giannakis, Marios; Van Allen, Eliezer M.] Harvard, Cambridge, MA 02142 USA; [Voss, Martin H.; Snyder, Alexandra; Hellmann, Matthew D.; Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA; [Voss, Martin H.; Hellmann, Matthew D.; Motzer, Robert J.] Weill Cornell Med Coll, New York, NY 10065 USA; [Li, Wei] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA; [Cullen, Dana; Horak, Christine; Wind-Rotolo, Megan] Bristol Myers Squibb, New York, NY 10154 USA; [Drake, Charles G.] Columbia Univ, Med Ctr, New York, NY 10032 USA; [Ball, Mark W.; Allaf, Mohamad E.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA; [Ball, Mark W.; Allaf, Mohamad E.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA; [Ho, Thai] Mayo Clin, Scottsdale, AZ 85259 USA; [Kaelin, William G., Jr.] Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02215 USA; [Snyder, Alexandra] Adapt Biotechnol, Seattle, WA 98102 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Memorial Sloan Kettering Cancer Center; Cornell University; Harvard University; Dana-Farber Cancer Institute; Bristol-Myers Squibb; Columbia University; Johns Hopkins University; Johns Hopkins University; Mayo Clinic; Mayo Clinic Phoenix; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Choueiri, TK; Van Allen, EM (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Van Allen, EM (corresponding author), MIT, Broad Inst, Cambridge, MA 02142 USA.; Van Allen, EM (corresponding author), Harvard, Cambridge, MA 02142 USA.	toni_choueiri@dfci.harvard.edu; eliezerm_vanallen@dfci.harvard.edu	Giannakis, Marios/Z-4908-2019; Choueiri, Toni/K-5238-2019; Ball, Mark/H-3915-2019	Choueiri, Toni/0000-0002-9201-3217; Ball, Mark/0000-0003-1780-2627; Li, Wei/0000-0002-2163-7903; Martini, Dylan/0000-0002-0843-1222; Voss, Martin/0000-0003-0551-5807; Wankowicz, Stephanie/0000-0002-4225-7459; Ho, Thai/0000-0003-0023-2939; Margolis, Claire/0000-0002-1019-2419; Bosse, Dominick/0000-0003-2992-5632	Bristol-Myers Squibb II-ON consortium; American Association for Cancer Research KureIt Grant for Kidney Cancer Research; Cancer Immunologic Data Commons [NIH U24CA224316]; Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence (SPORE); Kohlberg chair at Harvard Medical School; Trust Family; Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute; Gerstner Family Career Development Award; National Cancer Institute [K12CA90628]; U.S. Department of Defense [W81XWH-17-1-0546]; NATIONAL CANCER INSTITUTE [P30CA008748, K08CA188615, K12CA090628, U24CA224316] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001100] Funding Source: NIH RePORTER	Bristol-Myers Squibb II-ON consortium(Bristol-Myers Squibb); American Association for Cancer Research KureIt Grant for Kidney Cancer Research; Cancer Immunologic Data Commons; Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence (SPORE); Kohlberg chair at Harvard Medical School; Trust Family; Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute; Gerstner Family Career Development Award; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This project was supported by the Bristol-Myers Squibb II-ON consortium, the American Association for Cancer Research KureIt Grant for Kidney Cancer Research (E.M.V. and T.K.C.), and the Cancer Immunologic Data Commons (NIH U24CA224316). D.M. is a Howard Hughes Medical Institute Medical Research Fellow. T.K.C. is supported in part by the Dana-Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence (SPORE); the Kohlberg chair at Harvard Medical School; and the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at the Dana-Farber Cancer Institute. T.H. is supported by the Gerstner Family Career Development Award, the National Cancer Institute (K12CA90628), and the U.S. Department of Defense (W81XWH-17-1-0546). Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the U.S. Department of Defense.	Beuselinck B, 2015, CLIN CANCER RES, V21, P1329, DOI 10.1158/1078-0432.CCR-14-1128; Carlo MI, 2017, KIDNEY CANCER, V1, P49, DOI 10.3233/KCA-160003; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Choueiri TK, 2016, CLIN CANCER RES, V22, P5461, DOI 10.1158/1078-0432.CCR-15-2839; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; de Velasco G, 2016, CANCER IMMUNOL RES, V4, P820, DOI 10.1158/2326-6066.CIR-16-0110; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fay AP, 2016, J NATL COMPR CANC NE, V14, P820, DOI 10.6004/jnccn.2016.0086; Gao WH, 2017, P NATL ACAD SCI USA, V114, P1027, DOI 10.1073/pnas.1619726114; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gofrit ON, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1385-9; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; Hsieh JJ, 2017, EUR UROL, V71, P405, DOI 10.1016/j.eururo.2016.10.007; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kapur P, 2013, LANCET ONCOL, V14, P159, DOI 10.1016/S1470-2045(12)70584-3; Kwiatkowski DJ, 2016, CLIN CANCER RES, V22, P2445, DOI 10.1158/1078-0432.CCR-15-2631; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Nam S. J., 2015, UROL ONCOL, V33; Nargund AM, 2017, CELL REP, V18, P2893, DOI 10.1016/j.celrep.2017.02.074; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pawlowski R, 2013, INT J CANCER, V132, pE11, DOI 10.1002/ijc.27822; Ramsay AG, 2013, BRIT J HAEMATOL, V162, P313, DOI 10.1111/bjh.12380; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624	37	614	631	9	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 16	2018	359	6377					801	805	aan5951	10.1126/science.aan5951	http://dx.doi.org/10.1126/science.aan5951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW2ET	29301960	Green Accepted			2023-01-03	WOS:000425116200047
J	Jayaraman, K				Jayaraman, Killugudi			A shot at contraception In India, a nonagenarian renews testing of a birth control vaccine	NATURE MEDICINE			English	News Item							HUMAN CHORIONIC-GONADOTROPIN; BETA-SUBUNIT; PREGNANCY; WOMEN											ALDHOUS P, 1994, SCIENCE, V266, P1484, DOI 10.1126/science.7985014; Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1; NASH H, 1980, FERTIL STERIL, V34, P328; Singh M, 1998, AM J REPROD IMMUNOL, V39, P395; Singh S, 2018, LANCET GLOB HEALTH, V6, pE111, DOI 10.1016/s2214-109x(17)30453-9; TALWAR GP, 1976, P NATL ACAD SCI USA, V73, P218, DOI 10.1073/pnas.73.1.218; TALWAR GP, 1976, CONTRACEPTION, V13, P237, DOI 10.1016/0010-7824(76)90037-8; TALWAR GP, 1994, P NATL ACAD SCI USA, V91, P8532, DOI 10.1073/pnas.91.18.8532; van Kammen J.R., 2000, THESIS	9	1	1	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2018	24	2					118	120		10.1038/nm0218-118	http://dx.doi.org/10.1038/nm0218-118			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	FV1MQ	29414934				2023-01-03	WOS:000424327200004
J	Vareki, SM; Salim, KY; Danter, WR; Koropatnick, J				Vareki, Saman Maleki; Salim, Kowthar Y.; Danter, Wayne R.; Koropatnick, James			Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines	PLOS ONE			English	Article							LUNG-CANCER; PACLITAXEL; CARCINOMA; CYTOTOXICITY; CHEMOTHERAPY; GEMCITABINE; COMBINATION; CISPLATIN; SURVIVAL; PLUS	Emerging drug-resistance and drug-associated toxicities are two major factors limiting successful cancer therapy. Combinations of chemotherapeutic drugs have been used in the clinic to improve patient outcome. However, cancer cells can acquire resistance to drugs, alone or in combination. Resistant tumors can also exhibit cross-resistance to other chemotherapeutic agents, resulting in sub-optimal treatment and/or treatment failure. Therefore, developing novel oncology drugs that induce no or little acquired resistance and with a favorable safety profile is essential. We show here that combining COTI-2, a novel clinical stage agent, with multiple chemotherapeutic and targeted agents enhances the activity of these drugs in vitro and in vivo. Importantly, no overt toxicity was observed in the combination treatment groups in vivo. Furthermore, unlike the tested chemotherapeutic drugs, cancer cells did not develop resistance to COTI-2. Finally, some chemo-resistant tumor cell lines only showed mild cross-resistance to COTI-2 while most remained sensitive to it.	[Vareki, Saman Maleki; Koropatnick, James] Lawson Hlth Res Inst, Canc Res Lab Program, London, ON, Canada; [Salim, Kowthar Y.; Danter, Wayne R.] Cotinga Pharmaceut, London, ON, Canada; [Koropatnick, James] Western Univ, Dept Microbiol & Immunol, London, ON, Canada; [Koropatnick, James] Western Univ, Dept Pathol, London, ON, Canada; [Koropatnick, James] Western Univ, Dept Oncol, London, ON, Canada; [Koropatnick, James] Western Univ, Dept Physiol & Pharmacol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Koropatnick, J (corresponding author), Lawson Hlth Res Inst, Canc Res Lab Program, London, ON, Canada.; Koropatnick, J (corresponding author), Western Univ, Dept Microbiol & Immunol, London, ON, Canada.; Koropatnick, J (corresponding author), Western Univ, Dept Pathol, London, ON, Canada.; Koropatnick, J (corresponding author), Western Univ, Dept Oncol, London, ON, Canada.; Koropatnick, J (corresponding author), Western Univ, Dept Physiol & Pharmacol, London, ON, Canada.	jkoropat@uwo.ca		Koropatnick, James/0000-0001-6144-5941	Cotinga Pharmaceuticals, Inc.; Critical Outcome Technologies Inc.	Cotinga Pharmaceuticals, Inc.(Takeda Pharmaceutical Company Ltd); Critical Outcome Technologies Inc.	Because this work was supported by unrestricted grants from Critical Outcome Technologies Inc. (now known as Cotinga Pharmaceuticals, Inc.) to James Koropatnick, and Critical Outcome Technologies Inc. provided support in the form of salaries for two of the co-authors [KYS, WRD], further explanation is required. KYS and WRD played no role in the study design, data collection, or decision to publish. However, KYS and WRD reviewed the draft manuscript generated solely by SMV (a research associate supervised solely by JK) and JK, and made suggestions to JK with respect to data analysis and text to be included in the final manuscript. JK accepted, accepted with modification, or rejected those suggestions at his sole and exclusive discretion. JK made those decisions purely on the basis of their verifiability, accuracy, conservative interpretation of results, and suitability for publication in this journal: there was no pressure from those authors or Critical Outcome Technologies, Inc., implicit or explicit, to include/exclude data, analysis, or interpretation of data.	Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Britten CD, 1999, CANCER RES, V59, P1049; Broxterman Henk J., 1995, Current Opinion in Oncology, V7, P532, DOI 10.1097/00001622-199511000-00011; Delaney C, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0007-9; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Fennell DA, 2016, CANCER TREAT REV, V44, P42, DOI 10.1016/j.ctrv.2016.01.003; Ferguson PJ, 2009, CANCER LETT, V274, P279, DOI 10.1016/j.canlet.2008.09.021; Ferguson PJ, 1999, BRIT J PHARMACOL, V127, P1777, DOI 10.1038/sj.bjp.0702728; Fojo T, 2007, ANN ONCOL, V18, pV3, DOI 10.1093/annonc/mdm172; Fox JL, 2016, BRIT J CANCER, V115, P5, DOI 10.1038/bjc.2016.111; GUPTA RS, 1988, BRIT J CANCER, V58, P441, DOI 10.1038/bjc.1988.237; Hanigan MH, 2014, ADV CANCER RES, V122, P103, DOI 10.1016/B978-0-12-420117-0.00003-7; Hirsch FR, 2016, LANCET, V388, P1012, DOI 10.1016/S0140-6736(16)31473-8; Ismae GFV, 2008, CANCER TREAT REV, V34, P81, DOI 10.1016/j.ctrv.2007.08.001; Jain RK, 2012, J CLIN ONCOL, V30, P2684, DOI 10.1200/JCO.2011.36.4752; Kavallaris M, 2001, DRUG RESIST UPDATE, V4, P392, DOI 10.1054/drup.2002.0230; LAPOINTE H, 1992, OTOLARYNG HEAD NECK, V106, P149, DOI 10.1177/019459989210600205; Li CG, 2010, LUNG, V188, P359, DOI 10.1007/s00408-010-9258-z; Lopez JS, 2016, NAT REV CLIN ONCOL; Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609; Moxley KM, 2010, ONCOLOGIST, V15, P1026, DOI 10.1634/theoncologist.2010-0087; Petrelli F, 2015, EUR J CANCER, V51, P800, DOI 10.1016/j.ejca.2015.02.011; Raja FA, 2012, ANN ONCOL, V23, P118, DOI 10.1093/annonc/mds315; Salim KY, 2016, ONCOTARGET, V7, P41363, DOI 10.18632/oncotarget.9133; Salim KY, 2016, EORTC NCI AACR MOL T; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042; Zanardi E, 2015, SEMIN ONCOL, V42, P887, DOI 10.1053/j.seminoncol.2015.09.029	30	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2018	13	1							e0191766	10.1371/journal.pone.0191766	http://dx.doi.org/10.1371/journal.pone.0191766			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT8OQ	29364966	Green Published, gold, Green Submitted			2023-01-03	WOS:000423412500074
J	Spoorenberg, SLW; Wynia, K; Uittenbroek, RJ; Kremer, HPH; Reijneveld, SA				Spoorenberg, Sophie L. W.; Wynia, Klaske; Uittenbroek, Ronald J.; Kremer, Hubertus P. H.; Reijneveld, Sijmen A.			Effects of a population-based, person-centred and integrated care service on health, wellbeing and self-management of community-living older adults: A randomised controlled trial on Embrace	PLOS ONE			English	Article							QUALITY-OF-LIFE; AGING IN-PLACE; ELDERLY-PEOPLE; PERCEIVED CONTROL; CHRONIC ILLNESS; HOME VISITS; MODEL; OUTCOMES; COMPLEX; FRAILTY	Objective To evaluate the effects of the population-based, person-centred and integrated care service 'Embrace' at twelve months on three domains comprising health, wellbeing and self-management among community-living older people. Methods Embrace supports older adults to age in place. A multidisciplinary team provides care and support, with intensity depending on the older adults' risk profile. A randomised controlled trial was conducted in fifteen general practices in the Netherlands. Older adults (>= 75 years) were included and stratified into three risk profiles: Robust, Frail and Complex care needs, and randomised to Embrace or care as usual (CAU). Outcomes were recorded in three domains. The EuroQol-5D-3L and visual analogue scale, INTERMED for the Elderly Self-Assessment, Groningen Frailty Indicator and Katz-15 were used for the domain 'Health.' The Groningen Well-being Indicator and two quality of life questions measured 'Wellbeing.' The Self-Management Ability Scale and Partners in Health scale for older adults (PIH-OA) were used for 'Self-management.' Primary and secondary outcome measurements differed per risk profile. Data were analysed with multilevel mixed-model techniques using intention-to-treat and complete case analyses, for the whole sample and per risk profile. Results 1456 eligible older adults participated (49%) and were randomized to Embrace (n(T0) = 747, n(T1) = 570, mean age 80.6 years (SD 4.5), 54.2% female) and CAU (n(T0) = 709, n (T1) = 561, mean age 80.8 years (SD 4.7), 55.6% female). Embrace participants showed a greater-but clinically irrelevant-improvement in self-management (PIH-OA Knowledge subscale effect size [ES] = 0.14), and a greater-but clinically relevant-deterioration in health (ADL ES = 0.10; physical ADL ES = 0.13) compared to CAU. No differences in change in wellbeing were observed. This picture was also found in the risk profiles. Complete case analyses showed comparable results. Conclusions This study found no clear benefits to receiving person-centred and integrated care for twelve months for the domains of health, wellbeing and self-management in community-living older adults.	[Spoorenberg, Sophie L. W.; Wynia, Klaske; Uittenbroek, Ronald J.; Reijneveld, Sijmen A.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci Community & Occupat Med, Groningen, Netherlands; [Wynia, Klaske; Kremer, Hubertus P. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands	University of Groningen; University of Groningen	Spoorenberg, SLW (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci Community & Occupat Med, Groningen, Netherlands.	s.l.w.spoorenberg@umcg.nl		Reijneveld, Sijmen/0000-0002-1206-7523	Netherlands Organisation for Health Research and Development (ZonMw) [314010201]; Dutch Healthcare Authority (NZa) [300-1021]	Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Dutch Healthcare Authority (NZa)	The Embrace study was funded by the Netherlands Organisation for Health Research and Development (ZonMw: grant number 314010201; http://www.zonmw.nl). The health care professionals involved are funded by the Dutch Healthcare Authority (NZa: file number 300-1021; http://www.nza.nl). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Battersby MW., 2003, AUSTR J PRIM HLTH, V9, P41, DOI [10.1071/PY03022, DOI 10.1071/PY03022]; Beard JR, 2015, LANCET, V385, P658, DOI 10.1016/S0140-6736(14)61461-6; Beland F, 2006, J GERONTOL A-BIOL, V61, P367, DOI 10.1093/gerona/61.4.367; Bernabei R, 1998, BMJ-BRIT MED J, V316, P1348, DOI 10.1136/bmj.316.7141.1348; Beswick AD, 2008, LANCET, V371, P725, DOI 10.1016/S0140-6736(08)60342-6; Bjornberg A, 2015, EURO HLTH CONSUMER I; Bleijenberg N, 2016, J AM GERIATR SOC, V64, P1779, DOI 10.1111/jgs.14325; Boult C, 2013, J GEN INTERN MED, V28, P612, DOI 10.1007/s11606-012-2287-y; Bouman A, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-74; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Chen YX, 2014, J SOC PERS RELAT, V31, P141, DOI 10.1177/0265407513488728; Claassens L, 2014, J AGING STUD, V31, P159, DOI 10.1016/j.jaging.2014.09.008; Cohen J., 2013, STAT POWER ANAL BEHA; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Counsell SR, 2007, JAMA-J AM MED ASSOC, V298, P2623, DOI 10.1001/jama.298.22.2623; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Deveugele M, 2002, BRIT MED J, V325, P472, DOI 10.1136/bmj.325.7362.472; Devlin NJ, 2007, EQ 5D VALUE SETS INV, DOI 10.1007/1-4020-5511-0; Eklund K, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-76; GUSTAFSSON M, 2013, BMC HLTH SERV RES, V13; Hammar Teija, 2007, Int J Integr Care, V7, pe29; Haywood KL, 2005, J EVAL CLIN PRACT, V11, P315, DOI 10.1111/j.1365-2753.2005.00538.x; Hoogendijk EO, 2016, EUR J INTERN MED, V28, P43, DOI 10.1016/j.ejim.2015.10.023; Huss A, 2008, J GERONTOL A-BIOL, V63, P298, DOI 10.1093/gerona/63.3.298; Kang M, 2008, J ATHL TRAINING, V43, P215, DOI 10.4085/1062-6050-43.2.215; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Laan W, 2014, J NUTR HEALTH AGING, V18, P848, DOI [10.1007/s12603-014-0558-5, 10.1007/s12603-014-0479-3]; Lachman ME, 2006, CURR DIR PSYCHOL SCI, V15, P282, DOI 10.1111/j.1467-8721.2006.00453.x; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; Leveille SG, 1998, J AM GERIATR SOC, V46, P1191, DOI 10.1111/j.1532-5415.1998.tb04533.x; Lin JS, 2012, J AM GERIATR SOC, V60, P2157, DOI 10.1111/j.1532-5415.2012.04214.x; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Lofqvist C, 2013, GERONTOLOGIST, V53, P919, DOI 10.1093/geront/gnt034; Metzelthin SF, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5264; Middel B, 2001, J EVAL CLIN PRACT, V7, P399, DOI 10.1046/j.1365-2753.2001.00298.x; Nolte E, 2008, CARING PEOPLE CHRONI, P222; Nolte E., 2008, CARING PEOPLE CHRONI, P64; Peters LL, 2013, J PSYCHOSOM RES, V74, P518, DOI 10.1016/j.jpsychores.2013.02.003; Peters LL, 2012, J AM MED DIR ASSOC, V13, P546, DOI 10.1016/j.jamda.2012.04.007; Polit DF, 2010, RES NURS HEALTH, V33, P355, DOI 10.1002/nur.20386; Schafer Willemijn, 2010, Health Syst Transit, V12, pv; Schols J M G A, 2004, J Am Med Dir Assoc, V5, P207, DOI 10.1097/01.JAM.0000123031.43619.60; Schuurmans H, 2005, QUAL LIFE RES, V14, P2215, DOI 10.1007/s11136-005-8166-9; Singh D, 2006, IMPROVING CARE PEOPL; Sixsmith J, 2014, SOC SCI MED, V106, P1, DOI 10.1016/j.socscimed.2014.01.006; Spoorenberg SLW, 2015, DISABIL REHABIL, V37, P2337, DOI 10.3109/09638288.2015.1024337; Spoorenberg SLW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137803; Spoorenberg SLW, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-62; Steverink N, 2001, GERONTOLOGIST, V41, P236; Steverink N., SELF MANAGEMENT ABIL; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; Tai-Seale M, 2007, HEALTH SERV RES, V42, P1871, DOI 10.1111/j.1475-6773.2006.00689.x; Tappenden P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16200; Toseland RW, 1997, GERONTOLOGIST, V37, P324, DOI 10.1093/geront/37.3.324; Uittenbroek RJ, 2016, J GEN INTERN MED; Uittenbroek RJ, 2016, HEALTH EXPECT, V19, P962, DOI 10.1111/hex.12391; Van Buuren S, 2006, J STAT COMPUT SIM, V76, P1049, DOI 10.1080/10629360600810434; van der Zee KI, 1996, INT J BEHAV MED, V3, P104, DOI 10.1207/s15327558ijbm0302_2; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754; Veldman K, HLTH EXPECT; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wiles JL, 2012, GERONTOLOGIST, V52, P357, DOI 10.1093/geront/gnr098; Wolinsky FD, 2003, J GERONTOL B-PSYCHOL, V58, pS212, DOI 10.1093/geronb/58.4.S212; World Medical Association Declaration of Helsinki, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]; You EC, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-395	65	30	30	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2018	13	1							e0190751	10.1371/journal.pone.0190751	http://dx.doi.org/10.1371/journal.pone.0190751			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FT1QM	29351295	Green Published, Green Submitted, gold			2023-01-03	WOS:000422911300023
J	Sannachi, L; Gangeh, M; Tadayyon, H; Sadeghi-Nainil, A; Gandhi, S; Wright, FC; Slodkowska, E; Curpen, B; Tran, W; Czarnota, GJ				Sannachi, Lakshmanan; Gangeh, Mehrdad; Tadayyon, Hadi; Sadeghi-Nainil, All; Gandhi, Sonal; Wright, Frances C.; Slodkowska, Elzbieta; Curpen, Belinda; Tran, William; Czarnota, Gregory J.			Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using quantitative ultrasound, texture, and molecular features	PLOS ONE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; LIVER EXAMINATIONS; TUMOR RESPONSE; IN-VIVO; PREDICTION; PARAMETERS; APOPTOSIS; PROSTATE; MODELS; MRI	Background Pathological response of breast cancer to chemotherapy is a prognostic indicator for long-term disease free and overall survival. Responses of locally advanced breast cancer in the neoadjuvant chemotherapy (NAC) settings are often variable, and the prediction of response is imperfect. The purpose of this study was to detect primary tumor responses early after the start of neoadjuvant chemotherapy using quantitative ultrasound (QUS), textural analysis and molecular features in patients with locally advanced breast cancer. Methods The study included ninety six patients treated with neoadjuvant chemotherapy. Breast tumors were scanned with a clinical ultrasound system prior to chemotherapy treatment, during the first, fourth and eighth week of treatment, and prior to surgery. Quantitative ultrasound parameters and scatterer-based features were calculated from ultrasound radio frequency (RF) data within tumor regions of interest. Additionally, texture features were extracted from QUS parametric maps. Prior to therapy, all patients underwent a core needle biopsy and histological subtypes and biomarker ER, PR, and HER2 status were determined. Patients were classified into three treatment response groups based on combination of clinical and pathological analyses: complete responders (CR), partial responders (PR), and non-responders (NR). Response classifications from QUS parameters, receptors status and pathological were compared. Discriminant analysis was performed on extracted parameters using a support vector machine classifier to categorize subjects into CR, PR, and NR groups at all scan times. Results Of the 96 patients, the number of CR, PR and NR patients were 21, 52, and 23, respectively. The best prediction of treatment response was achieved with the combination mean QUS values, texture and molecular features with accuracies of 78%, 86% and 83% at weeks 1, 4, and 8, after treatment respectively. Mean QUS parameters or clinical receptors status alone predicted the three response groups with accuracies less than 60% at all scan time points. Recurrence free survival (RFS) of response groups determined based on combined features followed similar trend as determined based on clinical and pathology. Conclusions This work demonstrates the potential of using QUS, texture and molecular features for predicting the response of primary breast tumors to chemotherapy early, and guiding the treatment planning of refractory patients.	[Sannachi, Lakshmanan; Gangeh, Mehrdad; Tadayyon, Hadi; Sadeghi-Nainil, All; Tran, William; Czarnota, Gregory J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Phys Sci, Toronto, ON, Canada; [Sannachi, Lakshmanan; Gangeh, Mehrdad; Tadayyon, Hadi; Sadeghi-Nainil, All; Tran, William; Czarnota, Gregory J.] Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Odette Canc Ctr, Toronto, ON, Canada; [Sannachi, Lakshmanan; Sadeghi-Nainil, All; Czarnota, Gregory J.] Univ Toronto, Dept Med Biophys, Fac Med, Toronto, ON, Canada; [Gandhi, Sonal] Sunnybrook Hlth Sci Ctr, Div Med Oncol, Toronto, ON, Canada; [Wright, Frances C.] Sunnybrook Hlth Sci Ctr, Div Gen Surg, Toronto, ON, Canada; [Slodkowska, Elzbieta] Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON, Canada; [Curpen, Belinda] Sunnybrook Hlth Sci Ctr, Div Breast Imaging, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Czarnota, GJ (corresponding author), Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Phys Sci, Toronto, ON, Canada.; Czarnota, GJ (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Odette Canc Ctr, Toronto, ON, Canada.; Czarnota, GJ (corresponding author), Univ Toronto, Dept Med Biophys, Fac Med, Toronto, ON, Canada.	Gregory.Czarnota@sunnybrook.ca	Sadeghi-Naini, Ali/C-2818-2013	Sadeghi-Naini, Ali/0000-0001-5055-339X; TRAN, WILLIAM T/0000-0002-0733-7234; Gandhi, Sonal/0000-0001-8993-1327	Terry Fox Foundation; Breast Cancer Society of Canada; Canadian Breast Cancer Foundation Ontario Region; Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada	Terry Fox Foundation; Breast Cancer Society of Canada; Canadian Breast Cancer Foundation Ontario Region; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work was supported by the Terry Fox Foundation, the Breast Cancer Society of Canada, the Canadian Breast Cancer Foundation Ontario Region, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada. GJC holds the University of Toronto James and Mary Davie Chair in Breast Cancer Imaging and Ablation.; This project was funded by the Terry Fox Foundation, the Natural Sciences and Engineering Research Council of Canada, and the Canadian Institutes of Health Research. The authors disclose no conflict of interest. Clinical trial number: ClinicalTrials.gov NCT00437879.	Andre F, 2008, BREAST CANCER RES TR, V108, P183, DOI 10.1007/s10549-007-9594-8; Baek HM, 2008, MAGN RESON IMAGING, V26, P523, DOI 10.1016/j.mri.2007.10.002; Banihashemi B, 2008, CANCER RES, V68, P8590, DOI 10.1158/0008-5472.CAN-08-0006; Belli P, 2011, BREAST J, V17, P610, DOI 10.1111/j.1524-4741.2011.01160.x; Bige Y, 2006, ULTRASONICS, V44, P211, DOI 10.1016/j.ultras.2005.11.001; Cerussi A, 2007, P NATL ACAD SCI USA, V104, P4014, DOI 10.1073/pnas.0611058104; Czarnota GJ, 1999, BRIT J CANCER, V81, P520, DOI 10.1038/sj.bjc.6690724; Czarnota GJ, 2012, P NATL ACAD SCI USA, V109, pE2033, DOI 10.1073/pnas.1200053109; Feleppa EJ, 1997, INT J IMAG SYST TECH, V8, P11, DOI 10.1002/(SICI)1098-1098(1997)8:1<11::AID-IMA3>3.0.CO;2-W; HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314; Heys Steven D, 2002, Clin Breast Cancer, V3 Suppl 2, pS69, DOI 10.3816/CBC.2002.s.015; INSANA MF, 1990, ULTRASONIC IMAGING, V12, P245, DOI 10.1016/0161-7346(90)90002-F; Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819; Jiang L, 2013, J MAGN RESON IMAGING, V37, P1083, DOI 10.1002/jmri.23891; Kim SJ, 2004, ANN ONCOL, V15, P1352, DOI 10.1093/annonc/mdh345; Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014; Li S, 2011, ANN SURG ONCOL, V18, P2492, DOI 10.1245/s10434-011-1626-2; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lizzi FL, 1997, IEEE T ULTRASON FERR, V44, P935, DOI 10.1109/58.655209; LIZZI FL, 1988, ULTRASOUND MED BIOL, V14, P377, DOI 10.1016/0301-5629(88)90073-7; Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Miller M, 2014, ANN SURG ONCOL, V21, P3317, DOI 10.1245/s10434-014-3922-0; O'Flynn EAM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2815; Oelze ML, 2006, ULTRASONIC IMAGING, V28, P83, DOI 10.1177/016173460602800202; Padhani AR, 2002, RADIOTHER ONCOL, V64, P157, DOI 10.1016/S0167-8140(02)00137-8; Roblyer D, 2011, P NATL ACAD SCI USA, V108, P14626, DOI 10.1073/pnas.1013103108; Sadeghi-Naini A., 2013, CLIN CANC RES; Sadeghi-Naini A, 2014, ONCOTARGET, V5, P3497, DOI 10.18632/oncotarget.1950; Sadeghi-Naini A, 2013, MED PHYS, V40, DOI 10.1118/1.4812683; Sannachi L, 2015, MED IMAGE ANAL, V20, P224, DOI 10.1016/j.media.2014.11.009; SCHOLL SM, 1994, EUR J CANCER, V30A, P645, DOI 10.1016/0959-8049(94)90537-1; Sethi Divya, 2012, Int J Appl Basic Med Res, V2, P111, DOI 10.4103/2229-516X.106353; Tadayyon H, 2014, MED PHYS, V41, DOI 10.1118/1.4852875; Therasse P, 2000, NEW GUIDELINES EVALU, P92; Ueda S, 2012, CANCER RES, V72, P4318, DOI 10.1158/0008-5472.CAN-12-0056; Vlad RM, 2009, CLIN CANCER RES, V15, P2067, DOI 10.1158/1078-0432.CCR-08-1970; von Minckwitz G, 2013, J CLIN ONCOL, V31, P3623, DOI 10.1200/JCO.2012.45.0940; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; WEAR KA, 1993, IEEE T ULTRASON FERR, V40, P50, DOI 10.1109/58.184998	40	29	29	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2018	13	1							e0189634	10.1371/journal.pone.0189634	http://dx.doi.org/10.1371/journal.pone.0189634			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR6OK	29298305	gold, Green Submitted, Green Published			2023-01-03	WOS:000419185200016
J	Bick, D; Howard, LM; Oram, S; Zimmerman, C				Bick, Debra; Howard, Louise M.; Oram, Sian; Zimmerman, Cathy			Maternity care for trafficked women: Survivor experiences and clinicians' perspectives in the United Kingdom's National Health Service	PLOS ONE			English	Review							ACCESS	Background Although trafficked women and adolescents are at risk of unprotected or forced sex, there is little research on maternity care among trafficking survivors. We explored health care needs, service use and challenges among women who became pregnant while in the trafficking situation in the United Kingdom (UK) and clinicians' perspectives of maternity care for trafficked persons. Methods Cross-sectional survey and qualitative interviews with trafficking survivors recruited from statutory and voluntary sector organisations in England and qualitative interviews with maternity clinicians and family doctors undertaken to offer further insight into experiences reported by these women. Findings Twenty-eight (29%) of 98 women who took part in a large study of trafficking survivors reported one or more pregnancies while trafficked, whose data are reported here. Twelve (42.8%) of these women reported at least one termination of pregnancy while in the trafficking situation and 25 (89.3%) experienced some form of mental health disorder. Nineteen (67.9%) women experienced pre-trafficking physical abuse and 9 (32.%) sexual abuse. A quarter of women were trafficked for sexual exploitation, six for domestic servitude and two for manual labour. Survivors and clinicians described service challenges, including restrictions placed on women's movements by traffickers, poor knowledge on how to access maternity care, poor understanding of healthcare entitlements and concerns about confidentiality. Maternity care clinicians recognised potential indicators of trafficking, but considered training would help them identify and respond to victims. Main limitations include that findings reflect women who had exited the trafficking situation, however as some had only recently exited the trafficking situation, difficulties with recall were likely to be low. Conclusions More than one in four women became pregnant while trafficked, indicating that maternity services offer an important contact point for identification and care. Given the prevalence of sexual exploitation and abuse among trafficking survivors, clinicians should ensure antenatal care and screening for sexually transmitted infections can be readily accessed by women. Clinicians require specialised training alongside designated pathways and protocols with clear referral options to ensure confidential maternity care tailored to each woman's needs.	[Bick, Debra] Kings Coll London, St Thomas Hosp London, Dept Women & Childrens Hlth, Sch Life Course Sci, London, England; [Howard, Louise M.; Oram, Sian] Kings Coll London, David Goldberg Ctr, Inst Psychiat & Neurosci, Sect Womens Mental Hlth, De Crespigny Pk, London, England; [Zimmerman, Cathy] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Gender Violence & Hlth Ctr, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine	Bick, D (corresponding author), Kings Coll London, St Thomas Hosp London, Dept Women & Childrens Hlth, Sch Life Course Sci, London, England.	debra.bick@kcl.ac.uk	Oram, Sian/G-3342-2013; Bick, Debra/P-9575-2018	Bick, Debra/0000-0002-8557-7276; Oram, Sian/0000-0001-8704-0379; Howard, Louise/0000-0001-9942-744X	Department of Health Policy Research Programme (Optimising Identification, Referral and Care of Trafficked People) [NHS 115/0006]; National Institute for Health Research, through the Comprehensive Clinical Research Network; Department of Health Policy Research Programme [115/0006]; NIHR South London and Maudsley NHS Foundation Trust Biomedical Research Centre-Mental Health; NIHR Research Professorship [NIHR-RP-R3-12-011]; NIHR CLAHRC South London; King's College London; National Institute for Health Research [NIHR-RP-R3-12-011] Funding Source: researchfish	Department of Health Policy Research Programme (Optimising Identification, Referral and Care of Trafficked People); National Institute for Health Research, through the Comprehensive Clinical Research Network(National Institute for Health Research (NIHR)); Department of Health Policy Research Programme; NIHR South London and Maudsley NHS Foundation Trust Biomedical Research Centre-Mental Health; NIHR Research Professorship; NIHR CLAHRC South London; King's College London; National Institute for Health Research(National Institute for Health Research (NIHR))	This independent research was commissioned and funded by the Department of Health Policy Research Programme (Optimising Identification, Referral and Care of Trafficked People within the NHS 115/0006). The authors acknowledge the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. LMH, SO and CZ were supported by the Department of Health Policy Research Programme (115/0006). LMH is supported by the NIHR South London and Maudsley NHS Foundation Trust Biomedical Research Centre-Mental Health and an NIHR Research Professorship (NIHR-RP-R3-12-011). DB is part funded by the NIHR CLAHRC South London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Open access for this article was funded by King's College London.	American College of Obstetrics and Gynecology, INT PARTN VIOL COMM; Bick D, 2015, POSTPREGNANCY CARE M; Campbell OMR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001972; Cuadra CB, 2012, EUR J PUBLIC HEALTH, V22, P267, DOI 10.1093/eurpub/ckr049; Department of Health England, 2015, GUID IMPL OV VIS HOS; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Hegarty K, 2011, AUST FAM PHYSICIAN, V40, P852; International Labour Office Global Estimate of Forced Labour, 2012, RES METH; Knight MTD, 2015, BEHALF MBRRACE UK SA; Konstantopoulos WM, 2013, J URBAN HEALTH, V90, P1194, DOI 10.1007/s11524-013-9837-4; Lederer L, 2014, ANN HLTH LAW, V23, P16; McCauley HL, 2010, INT J GYNECOL OBSTET, V110, P266, DOI 10.1016/j.ijgo.2010.04.016; National Institute for Health and Care Excellence, 2014, INTR CAR HLTH WOM TH, V190; National Institute for Health and Care Excellence, 2015, ANT CAR UNC PREGN, V62; National Institute of Clinical Excellence (NICE), 2010, PREGN COMPL SOC FACT; Oram S, 2016, AM J PUBLIC HEALTH, V106, P1073, DOI 10.2105/AJPH.2016.303095; Oram S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001224; Ottisova L., 2016, EPIDEMIOLOGY PSYCHIA; Provider Responses Treatment and Care for Trafficked People, 2015, OPT ID REF CAR TRAFF; Ross C, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008682; Sandall J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004667.pub4; Small R, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-152; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Stewart E., 2011, J REFUG STUD, V25, P1; Tamara Windau-Melmer, 2013, GUIDE ADVOCATING RES; The Anti Trafficking Monitoring Group, 2013, DOCK EX UKS CRIM JUS; UK National Crime Agency, 2016, NAT REF MECH STAT EN; UK Visas and Immigration, 2016, HEALTHC NEEDS PREGN; United Nations Office on Drugs and Crime, 2014, GLOB REP TRAFF PERS; Westwood J, 2016, BRIT J GEN PRACT, V66, pE794, DOI 10.3399/bjgp16X687073; White Ribbon Alliance, 2011, RESP MAT CAR UN RIGH; World Health Organization (WHO), 2013, RESPONDING INTIMATE; Zimmerman C., 2003, WHO ETHICAL SAFETY R; Zimmerman C, 2003, FINDINGS EUROPEAN ST; Zimmerman C., 2006, STOLEN SMILES SUMMAR; Zimmerman C, 2014, STUDY TRAFFICKING EX; Zimmerman C, 2008, AM J PUBLIC HEALTH, V98, P55, DOI 10.2105/AJPH.2006.108357; Zimmerman Z, 2009, CARING TRAFFICKED PE	38	12	12	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2017	12	11							e0187856	10.1371/journal.pone.0187856	http://dx.doi.org/10.1371/journal.pone.0187856			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN5GQ	29166394	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000416035300020
J	Belknap, R; Holland, D; Feng, PJ; Millet, JP; Cayla, JA; Martinson, NA; Wright, A; Chen, MP; Moro, RN; Scott, NA; Arevalo, B; Miro, JM; Villarino, ME; Weiner, M; Borisov, AS				Belknap, Robert; Holland, David; Feng, Pei-Jean; Millet, Joan-Pau; Cayla, Joan A.; Martinson, Neil A.; Wright, Alicia; Chen, Michael P.; Moro, Ruth N.; Scott, Nigel A.; Arevalo, Bert; Miro, Jose M.; Villarino, Margarita E.; Weiner, Marc; Borisov, Andrey S.		TB Trials Consortium Iadhere	Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; PREEXPOSURE PROPHYLAXIS; ADHERENCE; RIFAMPIN; THERAPY; REGIMEN; 3-MONTH; COSTS; CARE	Background: Expanding latent tuberculosis treatment is important to decrease active disease globally. Once-weekly isoniazid and rifapentine for 12 doses is effective but limited by requiring direct observation. Objective: To compare treatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observation. Design: An open-label, phase 4 randomized clinical trial designed as a noninferiority study with a 15% margin. Seventy-five percent or more of study patients were enrolled from the United States for a prespecified subgroup analysis. (ClinicalTrials. gov: NCT01582711) Setting: Outpatient tuberculosis clinics in the United States, Spain, Hong Kong, and South Africa. Participants: 1002 adults (aged >= 18 years) recommended for treatment of latent tuberculosis infection. Intervention: Participants received once-weekly isoniazid and rifapentine by direct observation, self-administration with monthly monitoring, or self-administration with weekly text message reminders and monthly monitoring. Measurements: The primary outcome was treatment completion, defined as 11 or more doses within 16 weeks and measured using clinical documentation and pill counts for direct observation, and self-reports, pill counts, and medication eventmonitoring devices for self-administration. The main secondary outcome was adverse events. Results: Median age was 36 years, 48% of participants were women, and 77% were enrolled at the U. S. sites. Treatment completion was 87.2% (95% CI, 83.1% to 90.5%) in the directobservation group, 74.0% (CI, 68.9% to 78.6%) in the selfadministration group, and 76.4% (CI, 71.3% to 80.8%) in the self-administration-with-reminders group. In the United States, treatment completion was 85.4% (CI, 80.4% to 89.4%), 77.9% (CI, 72.7% to 82.6%), and 76.7% (CI, 70.9% to 81.7%), respectively. Self-administered therapy without reminders was noninferior to direct observation in the United States; no other comparisons met noninferiority criteria. A few drug-related adverse events occurred and were similar across groups. Limitation: Persons with latent tuberculosis infection enrolled in South Africa would not routinely be treated programmatically. Conclusion: These results support using self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection in the United States, and such treatment could be considered in similar settings when direct observation is not feasible.	Denver Hlth & Hosp Author, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA; Emory Univ, Atlanta, GA 30322 USA; Fulton Cty Dept Hlth & Wellness, Atlanta, GA USA; Ctr Dis Control & Prevent, Atlanta, GA USA; [Millet, Joan-Pau; Cayla, Joan A.] Publ Hlth Agcy Barcelona, Epidemiol Serv, 5 St Cugat Valles Planes, Barcelona 08196, Spain; CIBER Epidemiol & Salud Publ, Barcelona, Spain; Univ Witwatersrand, Johannesburg, South Africa; Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; Westat Corp, Ft Lauderdale, FL USA; Univ Barcelona, Barcelona, Spain; Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; Vet Adm Med Ctr, San Antonio, TX USA; [Belknap, Robert] Denver Publ Hlth, 605 Bannock St, Denver, CO 80204 USA; [Holland, David] Emory Healthcare, Dept Med, Div Infect Dis, 49 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA; [Feng, Pei-Jean; Chen, Michael P.; Moro, Ruth N.; Scott, Nigel A.; Villarino, Margarita E.; Borisov, Andrey S.] US Ctr Dis Control & Prevent, Mail Stop E-10,1600 Clifton Rd, Atlanta, GA 30329 USA; [Cayla, Joan A.] Publ Hlth Agcy Barcelona, Epidemiol Serv, 50 Atic 2A, Badalona 08911, Spain; [Martinson, Neil A.] Perinatal HIV Res Unit, POB 144, ZA-1864 Diepkloof, South Africa; [Wright, Alicia] Vanderbilt Univ, TB Trials Consortium Unit, Nashville Davidson Cty Publ Hlth Dept, 2500 Charlotte Ave, Nashville, TN 37209 USA; [Arevalo, Bert] Westat Corp, 237 SE 3rd Terrace, Dania, FL 33004 USA; [Miro, Jose M.] Univ Barcelona, Hosp Clin IDIBAPS, Paseo San Juan 104,5-2A, Barcelona 08037, Spain; [Weiner, Marc] South Texas Vet Hlth Care Syst, Med Infect Dis 111F, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Emory University; Centers for Disease Control & Prevention - USA; Public Health Agency of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Witwatersrand; Vanderbilt University; Westat; University of Barcelona; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Emory University; Centers for Disease Control & Prevention - USA; Public Health Agency of Barcelona; Vanderbilt University; Westat; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Belknap, R (corresponding author), 605 Bannock St, Denver, CO 80204 USA.	robert.belknap@dhha.org		Curran, Adrian/0000-0002-1263-0814; Borisov, Andrey/0000-0001-9124-8877; Salvador, Fernando/0000-0002-0546-1354	Centers for Disease Control and Prevention's Tuberculosis Trials Consortium	Centers for Disease Control and Prevention's Tuberculosis Trials Consortium	By the Centers for Disease Control and Prevention's Tuberculosis Trials Consortium.	Alsdurf H, 2016, LANCET INFECT DIS, V16, P1269, DOI 10.1016/S1473-3099(16)30216-X; American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_3.ATS600; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V316, P962, DOI 10.1001/jama.2016.11046; Chan PC, 2012, INT J TUBERC LUNG D, V16, P633, DOI 10.5588/ijtld.11.0504; Dye C, 2013, ANNU REV PUBL HEALTH, V34, P271, DOI 10.1146/annurev-publhealth-031912-114431; Farmer KC, 1999, CLIN THER, V21, P1074, DOI 10.1016/S0149-2918(99)80026-5; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; Getahun H, 2015, EUR RESPIR J, V46, P1563, DOI 10.1183/13993003.01245-2015; Hill AN, 2012, EPIDEMIOL INFECT, V140, P1862, DOI 10.1017/S095026881100286X; Hirsch-Moverman Y, 2015, INT J TUBERC LUNG D, V19, P31, DOI 10.5588/ijtld.14.0373; Holland DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022276; Holland DP, 2009, AM J RESP CRIT CARE, V179, P1055, DOI 10.1164/rccm.200901-0153OC; Horsburgh CR, 2011, NEW ENGL J MED, V364, P1441, DOI 10.1056/NEJMcp1005750; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Li JH, 2010, INT J INFECT DIS, V14, pE292, DOI 10.1016/j.ijid.2009.05.007; Menzies D, 2004, AM J RESP CRIT CARE, V170, P445, DOI 10.1164/rccm.200404-478OC; Menzies D, 2008, ANN INTERN MED, V149, P689, DOI 10.7326/0003-4819-149-10-200811180-00003; Montgomery ET, 2017, AIDS BEHAV, V21, P481, DOI 10.1007/s10461-016-1609-1; Moro RN, 2016, CLIN INFECT DIS, V62, P1390, DOI 10.1093/cid/ciw126; Nglazi MD, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-566; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Page KR, 2006, ARCH INTERN MED, V166, P1863, DOI 10.1001/archinte.166.17.1863; Pop-Eleches C, 2011, AIDS, V25, P825, DOI 10.1097/QAD.0b013e32834380c1; Rubinowicz A, 2014, INT J TUBERC LUNG D, V18, P1449, DOI 10.5588/ijtld.14.0166; Schmit KM, 2017, MMWR-MORBID MORTAL W, V66, P289, DOI 10.15585/mmwr.mm6611a2; SOARES JF, 1983, COMMUN STAT-THEOR M, V12, P2017, DOI 10.1080/03610928308828586; Stagg HR, 2014, ANN INTERN MED, V161, P419, DOI 10.7326/M14-1019; Sterling TR, 2015, CLIN INFECT DIS, V61, P527, DOI 10.1093/cid/civ323; Sterling TR, 2011, NEW ENGL J MED, V365, P2155, DOI 10.1056/NEJMoa1104875; Sterling TR, 2006, AM J RESP CRIT CARE, V173, P927, DOI 10.1164/rccm.200510-1563OC; Strandbygaard U, 2010, RESP MED, V104, P166, DOI 10.1016/j.rmed.2009.10.003; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; van der Straten A, 2012, AIDS, V26, pF13, DOI 10.1097/QAD.0b013e3283522272; Villarino ME, 2015, JAMA PEDIATR, V169, P247, DOI 10.1001/jamapediatrics.2014.3158; Yuen CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153728	36	86	88	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2017	167	10					689	+		10.7326/M17-1150	http://dx.doi.org/10.7326/M17-1150			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO2DP	29114781	Green Accepted			2023-01-03	WOS:000416584200012
J	Najafi, H; Yarijani, ZM; Changizi-Ashtiyani, S; Mansouri, K; Modarresi, M; Madani, SH; Bastani, B				Najafi, Houshang; Yarijani, Zeynab Mohamadi; Changizi-Ashtiyani, Saeed; Mansouri, Kamran; Modarresi, Masoud; Madani, Seyed Hamid; Bastani, Bahar			Protective effect of Malva sylvestris L. extract in ischemia-reperfusion induced acute kidney and remote liver injury	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; INDUCED HEPATOTOXICITY; ANTIOXIDANT ACTIVITY; RATS; INFLAMMATION; DYSFUNCTION; TARGETS; DAMAGE; PATHOPHYSIOLOGY; POLYSACCHARIDE	Mallow (Malva sylvestris L.) has had medicinal and therapeutic uses in addition to its oral consumption. The present study was conducted to examine the protective effect of Malva sylvestris L. extract on ischemia-reperfusion-induced kidney injury and remote organ injuries in the liver. Before ischemia-reperfusion, rats in the different groups received intraperitoneal normal saline or mallow extract at the doses of 200, 400 or 600 mg/kg of body weight. After 30-minutes of bilateral renal ischemia followed by 24-hours of reperfusion, tissue damage in the kidney and liver samples were determined through studying H&E-stained slides under a light microscope. The degree of leukocyte infiltration and tissue mRNA expressions of TNF- and ICAM-1 were then measured to examine the degree of renal inflammation. The renal tissue MDA and FRAP levels were measured for determining the amount of oxidative stress. Plasma concentrations of creatinine, urea, ALT and ALP were also measured. Ischemia- reperfusion led to a significant increase in plasma concentrations of creatinine, urea, ALT and ALP, and renal tissue MDA, and a significant decrease in renal tissue FRAP. The expression of pro-inflammatory factors in the kidney tissue, the level of leukocyte infiltration and the amount of tissue damage in the kidney and liver also increased. Pretreatment by mallow extract led to a significant improvement in all the variables measured. The 200- and 400-mg doses yielded better results in most parameters compared to the 600-mg dose. The findings showed that mallow extract protects the kidney against ischemia-reperfusion and reduces remote organ injury in the liver.	[Najafi, Houshang; Yarijani, Zeynab Mohamadi; Mansouri, Kamran] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran; [Changizi-Ashtiyani, Saeed] Arak Univ Med Sci, Sch Paramed Sci, Dept Physiol, Arak, Iran; [Modarresi, Masoud] Kermanshah Univ Med Sci, Fac Pharm, Sch Paramed Sci, Dept Physiol, Kermanshah, Iran; [Madani, Seyed Hamid] Kermanshah Univ Med Sci, Sch Med, Dept Pathol, Kermanshah, Iran; [Bastani, Bahar] St Louis Univ, Sch Med, Div Nephrol, St Louis, MO 63103 USA	Kermanshah University of Medical Sciences; Kermanshah University of Medical Sciences; Kermanshah University of Medical Sciences; Saint Louis University	Bastani, B (corresponding author), St Louis Univ, Sch Med, Div Nephrol, St Louis, MO 63103 USA.	bastanib@slu.edu	Najafi, Houshang/K-1597-2017; yarijani, zeynab mohamadi/AAY-4850-2020; SaberiNajafi, Hashem/AFS-6719-2022	Mohamadi Yarijani, Zeynab/0000-0002-0693-6788; Bastani, Bahar/0000-0002-2138-4248; Najafi, Houshang/0000-0001-9642-9124	Kermanshah University of Medical Sciences [93422]	Kermanshah University of Medical Sciences	This work was funded by grant # 93422, research deputy of Kermanshah University of Medical Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors gratefully acknowledge the research deputy of Kermanshah University of medical sciences for financial support (research project 93422 to HN).	Abuelo JG, 2007, NEW ENGL J MED, V357, P797, DOI 10.1056/NEJMra064398; Akcay A, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/137072; Anders HJ, 2014, J AM SOC NEPHROL, V25, P1387, DOI 10.1681/ASN.2014010117; Arabaci G, J CHEM, V2013; Ashtiyani SC, 2012, IRAN J KIDNEY DIS, V6, P275; Barros L, 2010, FOOD CHEM TOXICOL, V48, P1466, DOI 10.1016/j.fct.2010.03.012; Basile David P., 2014, Cardiovascular & Hematological Disorders - Drug Targets, V14, P3; Basile DP, 2012, COMPR PHYSIOL, V2, P1303, DOI 10.1002/cphy.c110041; Becker GJ, 2013, NEPHROL DIAL TRANSPL, V28, P2432, DOI 10.1093/ndt/gft071; Benso B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162728; Benso B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140331; BILLETER M, 1991, PHYTOCHEMISTRY, V30, P987, DOI 10.1016/0031-9422(91)85292-8; Blunden G, 2001, PHYTOCHEMISTRY, V58, P451, DOI 10.1016/S0031-9422(01)00263-1; Bonventre JV, 2003, J AM SOC NEPHROL, V14, P2199, DOI 10.1097/01.ASN.0000079785.13922.F6; Changizi-Ashtiyani S, 2016, CANCER GENE THER, V23, P235, DOI 10.1038/cgt.2016.24; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chiclana CF, 2009, LAT AM J PHARM, V28, P275; Choi KS, 2014, ARCH BIOCHEM BIOPHYS, V559, P38, DOI 10.1016/j.abb.2014.05.016; Classen B, 2002, PLANTA MED, V68, P232, DOI 10.1055/s-2002-23127; Conforti F, 2008, J ETHNOPHARMACOL, V116, P144, DOI 10.1016/j.jep.2007.11.015; Cutillo F, 2006, PHYTOCHEMISTRY, V67, P481, DOI 10.1016/j.phytochem.2005.11.023; Dagher PC, 2003, J AM SOC NEPHROL, V14, P2188, DOI 10.1097/01.ASN.0000079790.91292.4A; Doi K, 2016, KIDNEY INT, V89, P555, DOI 10.1016/j.kint.2015.11.019; Donnahoo KK, 1999, J UROLOGY, V162, P196, DOI 10.1097/00005392-199907000-00068; Elsagh M, 2015, COMPLEMENT THER CLIN, V21, P105, DOI 10.1016/j.ctcp.2015.02.003; Fadillioglu E, 2008, ARCH PHARM RES, V31, P705, DOI 10.1007/s12272-001-1216-3; Martins CAF, 2014, BIOMED CHROMATOGR, V28, P986, DOI 10.1002/bmc.3106; Ganai BA, 1997, PHYTOCHEMISTRY, V45, P879, DOI 10.1016/S0031-9422(97)82709-4; Ganai BA, 2006, J IND POLLUT CONTR, V22, P77; Gardner DS, 2016, AM J PHYSIOL-RENAL, V310, pF259, DOI 10.1152/ajprenal.00389.2015; Gasparetto JC, 2012, J PHARM PHARMACOL, V64, P172, DOI 10.1111/j.2042-7158.2011.01383.x; Golab F, 2009, KIDNEY INT, V75, P783, DOI 10.1038/ki.2008.683; GONDA R, 1990, CARBOHYD RES, V198, P323, DOI 10.1016/0008-6215(90)84302-B; Grams ME, 2012, KIDNEY INT, V81, P942, DOI 10.1038/ki.2011.241; Guarrera PM, 2005, FITOTERAPIA, V76, P1, DOI 10.1016/j.fitote.2004.09.006; Guil JL, 1996, J CHROMATOGR A, V719, P229, DOI 10.1016/0021-9673(95)00414-9; Hamedi A, 2016, J EVID-BASED INTEGR, V21, P14, DOI 10.1177/2156587215589184; Hicsonmez U, 2009, BIOL TRACE ELEM RES, V128, P248, DOI 10.1007/s12011-008-8270-0; Hussain L, 2014, TURK J BIOL, V38, P396, DOI 10.3906/biy-1312-32; Javanmardi J, 2003, FOOD CHEM, V83, P547, DOI 10.1016/S0308-8146(03)00151-1; Kauss T, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2372; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523; Lee CG, 2014, KIDNEY INT, V86, P943, DOI 10.1038/ki.2014.117; Mahmoudzadeh L, 2017, NEPHROLOGY, V22, P748, DOI 10.1111/nep.12849; Marouane W, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-65; Matejovic M, 2016, J AM SOC NEPHROL, V27, P49, DOI 10.1681/ASN.2015030234; Najafi H, 2016, EXP PHYSIOL, V101, P913, DOI 10.1113/EP085583; Prudente AS, 2013, FOOD CHEM TOXICOL, V58, P324, DOI 10.1016/j.fct.2013.04.042; Rabb H, 2016, J AM SOC NEPHROL, V27, P371, DOI 10.1681/ASN.2015030261; Samavati V, 2013, INT J BIOL MACROMOL, V60, P427, DOI 10.1016/j.ijbiomac.2013.04.050; Sleiman NH, 2009, PLANTA MED, V75, P1010; Sreelatha S, 2009, FOOD CHEM TOXICOL, V47, P702, DOI 10.1016/j.fct.2008.12.022; Sutton TA, 2002, KIDNEY INT, V62, P1539, DOI 10.1046/j.1523-1755.2002.00631.x; Thurman JM, 2007, CLIN IMMUNOL, V123, P7, DOI 10.1016/j.clim.2006.09.008; Yarijani ZM, 2016, IRAN J BASIC MED SCI, V19, P337	56	16	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2017	12	11							e0188270	10.1371/journal.pone.0188270	http://dx.doi.org/10.1371/journal.pone.0188270			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN1NI	29155898	Green Submitted, gold, Green Published			2023-01-03	WOS:000415756700040
J	Candeo, LC; Rigonato-Oliveira, NC; Brito, AA; Marcos, RL; Franca, CM; Fernandes, KPS; Mesquita-Ferrari, RA; Bussadori, SK; Vieira, RP; Lino-dos-Santos-Franco, A; Ligeiro-Oliveira, AP; Horliana, ACRT				Candeo, Larissa Carbonera; Rigonato-Oliveira, Nicole Cristine; Brito, Aurileia Aparecida; Marcos, Rodrigo Labat; Franca, Cristiane Miranda; Santos Fernandes, Kristianne Porta; Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil; Vieira, Rodolfo Paula; Lino-dos-Santos-Franco, Adriana; Ligeiro-Oliveira, Ana Paula; Ratto Tempestini Horliana, Anna Carolina			Effects of periodontitis on the development of asthma: The role of photodynamic therapy	PLOS ONE			English	Article							GINGIVAL CREVICULAR FLUID; DIABETES-MELLITUS; METHYLENE-BLUE; ASSOCIATION; HEALTH; MODEL; INFECTIONS; MECHANISMS; RESISTANCE; REDUCTION	To evaluate whether periodontitis modulates lung inflammation in an experimental model of asthma as well as the photodynamic therapy (PDT) is associated with a reduction of lung inflammation. Seventy-two BALB/c male mice (similar to 2 months) were randomly divided into 8 groups (n = 9): Basal, Periodontitis (P), P+PT, P+PT+PDT, Asthma (A), A+P, A+P+PT, and A+P+PT+PDT. Periodontitis was induced by using the ligature technique and asthma was induced by ovalbumin (OVA). PT was performed with curettes and PDT with methylene blue (0.005%), lambda = 660nm, with a radiant exposure of 318J/cm(2). After 43 days, euthanasia was carried out prior to lung and mandible morphological analyzes. All of the manipulations of the animals were performed by only one operator. The total and differential cell counts and cytokines IL-4, IL-5, IL-10, IFN-gamma, TNF-alpha, IL-1 beta, and IL-6 were evaluated in the bronchoalveolar lavage (BAL) and in the serum. Mucus and alkaline phosphatase were also quantified. Statistical analyzes were performed by a blinded statistician. One-way analysis of variance (ANOVA) was employed, followed by the Student-Newman-Keuls test. Periodontitis group (P) increased alkaline phosphatase and bone resorption (p<0.05), validating the experimental model of periodontitis. The A group and the P group increased the total amount of cells (p<0.05) in the BAL. However, in the A+P group, there was a decrease in these cells, except for in the A+P+PT+PDT group (p< 0.05). The asthma group increased the Th2 cytokines and P group increased the Th1 cytokine profile, and A+P+PT+PDT group increased IL-10 cytokine. Mucus was increased for the A and P groups. In conclusion, periodontitis in the asthmatic mice reduced the inflammatory migrated cells in the BAL (eosinophils, lymphocytes, macrophages). In addition, it reduced the levels of the IL-4 and TNF-alpha cytokines, which was also accompanied by a decreased mucus production. After PDT treatment the total cell count increased however, this increase was not accompanied by a pro-inflammatory cytokines release. Only in PDT group the anti-inflammatory IL-10 was increased. Further studies are needed to understand this mechanism of action.	[Candeo, Larissa Carbonera; Rigonato-Oliveira, Nicole Cristine; Brito, Aurileia Aparecida; Marcos, Rodrigo Labat; Santos Fernandes, Kristianne Porta; Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil; Lino-dos-Santos-Franco, Adriana; Ligeiro-Oliveira, Ana Paula; Ratto Tempestini Horliana, Anna Carolina] Univ Nove Julho UNINOVE, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil; [Franca, Cristiane Miranda] OHSU Sch Dent, Dept Restorat Dent, Div Biomat & Biomech, Portland, OR USA; [Mesquita-Ferrari, Raquel Agnelli; Bussadori, Sandra Kalil] Univ Nove Julho, UNINOVE, Post Grad Program Rehabil Sci, Sao Paulo, Brazil; [Vieira, Rodolfo Paula] Inst Brasileiro Ensino Pesquisa Imunol Pulm & Exer, Sao Jose Dos Campos, SP, Brazil	Universidade Nove de Julho; Universidade Nove de Julho	Horliana, ACRT (corresponding author), Univ Nove Julho UNINOVE, Post Grad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil.	annacrth@gmail.com	Marcos, Rodrigo Labat/F-3524-2015; Franca, Cristiane/B-2563-2014; Ferrari, Raquel/I-4419-2016; Franco, Adriana Lino dos Santos/AAA-7081-2019; Bussadori, Sandra/J-5458-2014; de Paula Vieira, Rodolfo/E-9315-2011; Horliana, Anna Carolina Ratto Tempestini/J-3257-2015; Lino-dos-Santos-Franco, Adriana/F-6336-2012; Fernandes, Kristianne Porta Santos/I-4417-2016; Horliana, Anna/ABH-9640-2020	Marcos, Rodrigo Labat/0000-0002-9750-6491; Franca, Cristiane/0000-0002-9285-4622; Ferrari, Raquel/0000-0001-5142-9526; Franco, Adriana Lino dos Santos/0000-0002-7854-2833; Bussadori, Sandra/0000-0002-9853-1138; de Paula Vieira, Rodolfo/0000-0001-6379-1143; Horliana, Anna Carolina Ratto Tempestini/0000-0003-3476-9064; Fernandes, Kristianne Porta Santos/0000-0001-7156-9286; Ligeiro de Oliveira, Ana Paula/0000-0001-6089-5107; Brito, Aurileia/0000-0001-9683-4410	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP [2015/20535-1, 2012/16498-5, 2015/00830-9]; FAPESP [2015/23152-6]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP: Process Number #2015/20535-1 (Dr. Anna Carolina Ratto Tempestini Horliana), Process Number #2012/16498-5 (Dr. Ana Paula Ligeiro-Oliveira), Process Number #2015/00830-9 (Dr. Adriana Lino-dos-Santos-Franco) and a Grant from FAPESP # 2015/23152-6 (Nicole Cristine Rigonato-Oliveira- PhD student). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002; Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Alvarenga LH, 2015, PHOTODIAGN PHOTODYN, V12, P131, DOI 10.1016/j.pdpdt.2014.10.002; Arbes SJ, 2011, J ALLERGY CLIN IMMUN, V127, P1119, DOI 10.1016/j.jaci.2011.03.023; Armitage GC, 2003, J PERIODONTOL, V74, P1237, DOI 10.1902/jop.2003.74.8.1237; Azarpazhooh A, 2006, J PERIODONTOL, V77, P1465, DOI 10.1902/jop.2006.060010; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Betsy J, 2014, J CLIN PERIODONTOL, V41, P573, DOI 10.1111/jcpe.12249; Blaizot A, 2009, INT DENT J, V59, P197, DOI 10.1922/IDJ_2114Sixou13; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Cai JL, 2007, DEV BIOL, V304, P499, DOI 10.1016/j.ydbio.2007.01.002; Card JW, 2010, INFECT IMMUN, V78, P2488, DOI 10.1128/IAI.01270-09; Carvalho VF, 2015, J CLIN PERIODONTOL, V42, P440, DOI 10.1111/jcpe.12393; Castro A, 2005, PLOS MED, V2, P1217, DOI 10.1371/journal.pmed.0020338; CHEN AC, 1995, SCAND J INFECT DIS, V27, P289, DOI 10.3109/00365549509019023; da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x; dos Santos JD, 2017, MICROB PATHOGENESIS, V110, P507, DOI 10.1016/j.micpath.2017.07.045; Eke P. I., 2015, J PERIODONTOL, V86, P611, DOI DOI 10.1902/J0P.2015.140520; Evangelista EE, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0757-3; Friedrich N, 2006, CLIN EXP ALLERGY, V36, P495, DOI 10.1111/j.1365-2222.2006.02455.x; Gemmell E, 2004, PERIODONTOL 2000, V35, P21, DOI 10.1111/j.0906-6713.2004.003557.x; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Gomes IS, 2014, J PERIODONTOL, V85, pE179, DOI [10.1902/jop.2013.130369, 10.1902/jop.2013.130509]; GROSSI SG, 1994, J PERIODONTOL, V65, P260, DOI 10.1902/jop.1994.65.3.260; Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a; Hujoel PP, 2008, J PERIODONTOL, V79, P1330, DOI [10.1902/jop.2008.070648, 10.1902/jop.2008.070648 ]; HYYPPA T, 1981, J CLIN PERIODONTOL, V8, P500, DOI 10.1111/j.1600-051X.1981.tb00899.x; Irwin C R, 1998, Oral Dis, V4, P43; Jori G, 2006, LASER SURG MED, V38, P468, DOI 10.1002/lsm.20361; Kharkwal GB, 2011, LASER SURG MED, V43, P755, DOI 10.1002/lsm.21080; Kim JH, 2015, J PERIODONTOL, V86, P1005, DOI 10.1902/jop.2015.150083; Komerik N, 2003, ANTIMICROB AGENTS CH, V47, P932, DOI 10.1128/AAC.47.3.932-940.2003; Konopka K, 2007, J DENT RES, V86, P694, DOI 10.1177/154405910708600803; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; Kubota M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155594; Kunna R, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0578-y; Laidlaw BJ, 2015, NAT IMMUNOL, V16, P871, DOI 10.1038/ni.3224; Lee SW, 2017, J PERIODONTOL, V88, P575, DOI 10.1902/jop.2017.160706; Lenander-Lumikari M, 1998, ARCH ORAL BIOL, V43, P151, DOI 10.1016/S0003-9969(97)00110-6; de Oliveira APL, 2007, AM J PHYSIOL-CELL PH, V293, pC1120, DOI 10.1152/ajpcell.00286.2006; de Oliveira APL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-115; McDevitt MJ, 2000, J PERIODONTOL, V71, P156, DOI 10.1902/jop.2000.71.2.156; Mistry A, 2016, J LASERS MED SCI, V7, P250, DOI 10.15171/jlms.2016.44; NAKASHIMA K, 1994, J CLIN PERIODONTOL, V21, P327, DOI 10.1111/j.1600-051X.1994.tb00721.x; Nibali L, 2013, CURR PHARM DESIGN, V19, P2687, DOI 10.2174/1381612811319150003; Peron JP, 2015, PLOS ONE, V31; Prates RA, 2011, PHOTOMED LASER SURG, V29, P835, DOI 10.1089/pho.2010.2984; Preshaw PM, 2012, DIABETOLOGIA, V55, P21, DOI 10.1007/s00125-011-2342-y; Rai M, 2016, J BREATH RES, V10, DOI 10.1088/1752-7155/10/4/046009; Rams TE, 2014, J PERIODONTOL, V85, P160, DOI 10.1902/jop.2013.130142; Rivera R, 2016, J CLIN PERIODONTOL, V43, P566, DOI 10.1111/jcpe.12553; Rocha JA, 2016, AM J PHYSIOL-REG I, V310, pR697, DOI 10.1152/ajpregu.00328.2015; Sabino CP, 2016, J PHOTOCH PHOTOBIO B, V160, P72, DOI 10.1016/j.jphotobiol.2016.03.047; Santana CD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122042; Segarra-Vidal M, 2017, J CLIN PERIODONTOL, V44, P915, DOI 10.1111/jcpe.12768; Sperandio Felipe F, 2013, Recent Pat Antiinfect Drug Discov, V8, P108; Sridharan Gokul, 2012, J Oral Maxillofac Pathol, V16, P251, DOI 10.4103/0973-029X.99081; Stensson M, 2010, CARIES RES, V44, P540, DOI 10.1159/000321566; Sullivan PW, 2018, J ASTHMA, V55, P659, DOI 10.1080/02770903.2017.1350972; Tardivo JP, 2005, PHOTODIAGN PHOTODYN, V2, P175, DOI 10.1016/S1572-1000(05)00097-9; Tegos GP, 2006, ANTIMICROB AGENTS CH, V50, P196, DOI 10.1128/AAC.50.1.196-203.2006; Thomas MS, 2010, AUST DENT J, V55, P128, DOI 10.1111/j.1834-7819.2010.01226.x; Tillie-Leblond I, 2005, ALLERGY, V60, P23, DOI 10.1111/j.1398-9995.2005.00632.x; Umeda M, 2011, J INVESTIG CLIN DENT, V2, P268, DOI 10.1111/j.2041-1626.2011.00071.x; Vargas MH, 2015, J ASTHMA, V52, P376, DOI 10.3109/02770903.2014.974816; Vieira RP, 2014, INT J SPORTS MED, V35, P629, DOI 10.1055/s-0033-1358477; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P334, DOI 10.1016/j.jaci.2005.11.013; Yaghobee S., 2008, Journal of Dentistry of Tehran University of Medical Sciences, V5, P47; Zeng XT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046508	69	9	10	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2017	12	11							e0187945	10.1371/journal.pone.0187945	http://dx.doi.org/10.1371/journal.pone.0187945			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM8YO	29145431	Green Published, gold, Green Submitted			2023-01-03	WOS:000415378800041
J	Kuo, SCH; Kuo, PJ; Chen, YC; Chien, PC; Hsieh, HY; Hsieh, CH				Kuo, Spencer C. H.; Kuo, Pao-Jen; Chen, Yi-Chun; Chien, Peng-Chen; Hsieh, Hsiao-Yun; Hsieh, Ching-Hua			Comparison of the new Exponential Injury Severity Score with the Injury Severity Score and the New Injury Severity Score in trauma patients: A cross-sectional study	PLOS ONE			English	Article							CARE-UNIT ADMISSION; IMPROVES ACCURACY; MORTALITY; PREDICTOR; ISS	Objective To compare Exponential Injury Severity Score (EISS) with Injury Severity Score (ISS) and New Injury Severity Score (NISS) in terms of their predictive capability of the outcomes and medical expenses of hospitalized adult trauma patients. Setting This study was based at a level I trauma center in Taiwan. Methods Data for 17,855 adult patients hospitalized from January 1, 2009 to December 31, 2015 were retrieved from the Trauma Registry System. The primary outcome was in-hospital mortality. Secondary outcomes were the hospital length of stay (LOS), intensive care unit (ICU) admission rate, ICU LOS, and medical expenses. Chi-square tests were used for categorical variables to determine the significance of the associations between the predictor and outcome variables. Student t-tests were applied to analyze normally distributed data for continuous variables, while Mann-Whitney U tests were used to compare non-normally distributed data. Results According to the survival rate-to-severity score relationship curve, we grouped all adult trauma patients based on EISS scores of >= 27, 9-26, and < 9. Significantly higher mortality rates were noted in patients with EISS >= 27 and those with EISS of 9-26 when compared to patients with EISS < 9; this finding concurred to the findings for groups classified by the ISS and NISS with the cut-off points set between 25 and 16. The hospital LOS, ICU admission rates, and medical expenses for patients with EISS >= 27 and patients with EISS of 9-26 were also significantly longer and higher than that of patients with EISS < 9. When comparing the demographics and detailed medical expenses of very severely injured adult trauma patients classified according to ISS, NISS, and EISS, patients with ISS >= 25 and NISS >= 25 both had significantly lower mortality rates, lower ICU admission rates, and shorter ICU LOS compared to patients with EISS >= 27. Conclusions EISS 9 and 27 can serve as two cut-off points regarding injury severity, and patients with EISS >= 27 have the greatest injury severity. Additionally, these patients have the highest mortality rate, the highest ICU admission rate, and the longest ICU LOS compared to those with ISS >= 25 and NISS >= 25, suggesting that patients with EISS >= 27 have the worst outcome.	[Hsieh, Ching-Hua] Kaohsiung Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Kaohsiung, Taiwan; Chang Gung Univ, Coll Med, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Hsieh, CH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Kaohsiung, Taiwan.	m93chinghua@gmail.com			Chang Gung Memorial Hospital [CMRPG8F0801]	Chang Gung Memorial Hospital(Chang Gung Memorial Hospital)	This research was supported by a grant from Chang Gung Memorial Hospital (CMRPG8F0801). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aydin SA, 2008, ULUS TRAVMA ACIL CER, V14, P308; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balogh ZJ, 2003, J ORTHOP TRAUMA, V17, P508, DOI 10.1097/00005131-200308000-00006; Bulut M, 2006, EMERG MED J, V23, P540, DOI 10.1136/emj.2005.029439; Cook Alan, 2014, J Trauma Acute Care Surg, V76, P47, DOI 10.1097/TA.0b013e3182ab0d5d; Deng QY, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13080825; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P1053, DOI 10.1016/S0196-0644(89)80930-8; Frankema SPG, 2005, J TRAUMA, V58, P596, DOI 10.1097/01.TA.0000152551.39400.6F; Hsieh CH, 2017, BIOMED J, V40, P113, DOI 10.1016/j.bj.2016.10.005; Hsieh CH, 2017, BIOMED J, V40, P121, DOI 10.1016/j.bj.2016.10.006; Hu Y, 2010, WORLD J SURG, V34, P728, DOI 10.1007/s00268-010-0427-2; Husum Hans, 2002, Prehosp Disaster Med, V17, P27; Jamulitrat Silom, 2001, Journal of the Medical Association of Thailand, V84, P1416; Lavoie A, 2004, J TRAUMA, V56, P1312, DOI 10.1097/01.TA.0000075342.36072.EF; Lossius HM, 2001, RESUSCITATION, V50, P263, DOI 10.1016/S0300-9572(01)00361-6; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Smith BP, 2015, J TRAUMA ACUTE CARE, V79, P269, DOI 10.1097/TA.0000000000000753; Stephenson SCR, 2002, J TRAUMA, V53, P326, DOI 10.1097/00005373-200208000-00023; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Tamim H, 2008, INJURY, V39, P115, DOI 10.1016/j.injury.2007.06.007; Tay SY, 2004, J TRAUMA, V56, P162, DOI 10.1097/01.TA.0000058311.67607.07; Wang MD, 2014, EUR J TRAUMA EMERG S, V40, P287, DOI 10.1007/s00068-013-0331-1; ZOLTIE N, 1993, BMJ-BRIT MED J, V307, P906, DOI 10.1136/bmj.307.6909.906	23	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2017	12	11							e0187871	10.1371/journal.pone.0187871	http://dx.doi.org/10.1371/journal.pone.0187871			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM1VI	29121653	gold, Green Published, Green Submitted			2023-01-03	WOS:000414769900087
J	Omwenga, EO; Hensel, A; Pereira, S; Shitandi, AA; Goycoolea, FM				Omwenga, Eric Omori; Hensel, Andreas; Pereira, Susana; Shitandi, Alfred Anakalo; Goycoolea, Francisco M.			Antiquorum sensing, antibiofilm formation and cytotoxicity activity of commonly used medicinal plants by inhabitants of Borabu sub-county, Nyamira County, Kenya	PLOS ONE			English	Article							BIOFILM FORMATION; GENE-EXPRESSION; QUORUM; COMMUNICATION; DIGUANYLATE; EXTRACTS	Productions of various bacterial traits like production of virulence factors (e.g. toxins, enzymes), biofilm formation, luminescence among others, have been known to be controlled by quorum sensing (QS), a process that is dependent on chemical signals or autoinducers (Als). Bacteria known to rely on such Als are known to be virulent and tend to be resistant against various antimicrobial agents. Therefore, strategies aimed at the inhibition of QS pathways, are regarded as potential novel therapies in managing bacterial virulence hence reducing their ability to induce infections in humans. In the present study, a portfolio of 25 medicinal plant extracts (ethanol 50% v/v) used in southwestern Kenya were assayed against a transformed E. coliTop 10 reporter QS strain. This biosensor responds to the exogenous addition of 3-oxo-N-hexanoyl homoserine lactone (3OC6HSL) expressing green fluorescent protein (GFP). The large majority of the screened medicinal plants seemed to exhibit toxic effects and almost none of them induced antiquorum sensing (AQS) activity. This could be the consequence of the presence of mixed compounds in the extracts. Elaeodendron buchananii Loes and Acacia gerrardii Benth extracts that seemed to show AQS activity were further proved found to possess mild AQS but with defined antimicrobial activities, and no antibiofilm formation inhibition. Asa control, an E. colipBCA9145 jtk2828:: sfGFP strain that produces constitutively GFP was used and confirmed that none of the two extracts quenched the fluorescence of sfGFP. Cytotoxicity assays with mammalian MDCK cells also did indicate that the selected extracts with putative AQS activity, also reduced the cell viability. Therefore, further studies will be needed to separate and re-test the individual compounds especially from the selected two promising plants.	[Omwenga, Eric Omori] Kisii Univ, Sch Hlth Sci, Kisii, Kenya; [Omwenga, Eric Omori; Pereira, Susana; Goycoolea, Francisco M.] Univ Munster, Inst Plant Biotechnol & Biol, Nanobiotechnol Grp, Munster, Germany; [Hensel, Andreas] Univ Munster, Inst Pharmaceut Biol & Phytochem, Munster, Germany; [Shitandi, Alfred Anakalo] Kisii Univ, Fac Sci Appl, Kisii, Kenya; [Goycoolea, Francisco M.] Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England	University of Munster; University of Munster; University of Leeds	Goycoolea, FM (corresponding author), Univ Munster, Inst Plant Biotechnol & Biol, Nanobiotechnol Grp, Munster, Germany.; Goycoolea, FM (corresponding author), Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England.	fm.goycoolea@gmail.com	Goycoolea, Francisco M./Q-5841-2017	Goycoolea, Francisco M./0000-0001-7949-5429	DAAD [A/13/93803]; NACOSTI - Kenya	DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); NACOSTI - Kenya	NACOSTI - Kenya sponsored the fieldwork of this project and 90% of the joint scholarship with DAAD awarded to E00 (grant A/13/93803).	Abraham WR, 2016, ANTIBIOTICS-BASEL, V5, DOI 10.3390/antibiotics5010003; Almasoud A, 2016, LWT-FOOD SCI TECHNOL, V66, P560, DOI 10.1016/j.lwt.2015.11.013; Antunes LCM, 2010, MICROBIOL-SGM, V156, P2271, DOI 10.1099/mic.0.038794-0; Auchtung JM, 2006, J BACTERIOL, V188, P5273, DOI 10.1128/JB.00300-06; Banskota AH, 2000, J ETHNOPHARMACOL, V72, P239, DOI 10.1016/S0378-8741(00)00252-X; Bassler BL, 1999, CURR OPIN MICROBIOL, V2, P582, DOI 10.1016/S1369-5274(99)00025-9; Corral-Lugo A, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaa8271; Even-Tov E, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002386; Gopu V, 2016, RSC ADV, V6, P2592, DOI 10.1039/c5ra20677d; Greenberg EP, 2003, J CLIN INVEST, V112, P1288, DOI 10.1172/JCI200320099; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; Jung SA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004837; Kaiser M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10048; Kalia VC, 2013, BIOTECHNOL ADV, V31, P224, DOI 10.1016/j.biotechadv.2012.10.004; Kareru PG, 2008, AFR J TRADIT COMPLEM, V5, P51; Kumar VP, 2006, J ETHNOPHARMACOL, V107, P182, DOI 10.1016/j.jep.2006.03.013; Lade H, 2014, INT J BIOL SCI, V10, P547, DOI 10.7150/ijbs.9028; Lewis K, 2006, NAT BIOTECHNOL, V24, P1504, DOI 10.1038/nbt1206-1504; Lu LG, 2005, FOODBORNE PATHOG DIS, V2, P242, DOI 10.1089/fpd.2005.2.242; Luo Jing, 2016, Drug Des Devel Ther, V10, P183, DOI 10.2147/DDDT.S97221; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Moreira CG, 2006, J BACTERIOL, V188, P3952, DOI 10.1128/JB.00177-06; Mwitari PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065619; Nazzaro F, 2013, INT J MOL SCI, V14, P12607, DOI 10.3390/ijms140612607; Ng WL, 2009, ANNU REV GENET, V43, P197, DOI 10.1146/annurev-genet-102108-134304; Njeru SN, 2016, J INTERCULT ETHNOPHA, V5, P226, DOI 10.5455/jice.20160416122003; Omwenga EO, 2015, J ETHNOPHARMACOL, V176, P508, DOI 10.1016/j.jep.2015.11.032; Omwenga E. O., 2012, South Asian Journal of Experimental Biology, V2, P217; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Peng L, 2005, COLLOID SURFACE B, V45, P108, DOI 10.1016/j.colsurfb.2005.07.014; Qin X, 2016, COLLOID SURFACE B, V149, P358, DOI DOI 10.1016/J.COLSURFB.2016.10.031; Rajamani S, 2008, MOL PLANT MICROBE IN, V21, P1184, DOI 10.1094/MPMI-21-9-1184; Ram Irez-Castillo ML, 2004, LETT, V26, P1301; Reading NC, 2007, J BACTERIOL, V189, P2468, DOI 10.1128/JB.01848-06; Rezk A, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0860-8; Rios JL, 2005, J ETHNOPHARMACOL, V100, P80, DOI 10.1016/j.jep.2005.04.025; Sambanthamoorthy K, 2012, ANTIMICROB AGENTS CH, V56, P5202, DOI 10.1128/AAC.01396-12; Si XR, 2015, APPL MICROBIOL BIOT, V99, P10861, DOI 10.1007/s00253-015-6943-0; Singh S. A., 2010, Journal of Chemical and Pharmaceutical Research, V2, P304; Spoering AL, 2001, J BACTERIOL, V183, P6746, DOI 10.1128/JB.183.23.6746-6751.2001; Sulaiman G. M., 2013, African Journal of Microbiology Research, V7, P1548; Tamayo R, 2007, ANNU REV MICROBIOL, V61, P131, DOI 10.1146/annurev.micro.61.080706.093426; Truchado P, 2015, TRENDS FOOD SCI TECH, V43, P189, DOI 10.1016/j.tifs.2015.02.009; Vila-Sanjurjo C, 2016, BIORXIV; Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001	45	16	16	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2017	12	11							e0185722	10.1371/journal.pone.0185722	http://dx.doi.org/10.1371/journal.pone.0185722			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL4VN	29091715	Green Published, gold			2023-01-03	WOS:000414229700010
J	Xu, Y; Li, N; Lu, MS; Dixon, E; Myers, RP; Jelley, RJ; Quan, HD				Xu, Yuan; Li, Ning; Lu, Mingshan; Dixon, Elijah; Myers, Robert P.; Jelley, Rachel J.; Quan, Hude			The effects of patient cost sharing on inpatient utilization, cost, and outcome	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELECTRONIC HEALTH RECORDS; RURAL CHINA; PROVIDER PAYMENT; MEDICAL-RECORD; CARE; DEMAND; INSURANCE; VALIDATION; BURDEN	Background Health insurance and provider payment reforms all over the world beg a key empirical question: what are the potential impacts of patient cost-sharing on health care utilization, cost and outcomes? The unique health insurance system and rich electronic medical record (EMR) data in China provides us a unique opportunity to study this topic. Methods Four years (2010 to 2014) of EMR data from one medical center in China were utilized, including 10,858 adult patients with liver diseases. We measured patient cost-sharing using actual reimbursement ratio (RR) which is allowed us to better capture financial incentive than using type of health insurance. A rigorous risk adjustment method was employed with both comorbidities and disease severity measures acting as risk adjustors. Associations between RR and health use, costs and outcome were analyzed by multivariate analyses. Results After risk adjustment, patients with more generous health insurance coverage (higher RR) were found to have longer hospital stay, higher total cost, higher medication cost, and higher ratio of medication to total cost, as well as higher number and likelihood that specific procedures were performed. Conclusion Our study implied that patient cost-sharing affects health care services use and cost. This reflects how patients and physicians respond to financial incentives in the current healthcare system in China, and the responses could be a joint effect of both demand and supply side moral hazard. In order to contain cost and improve efficiency in the system, reforming provide payment and insurance scheme is urgently needed.	[Xu, Yuan; Li, Ning] Capital Med Univ, Beijing YouAn Hosp, Beijing, Peoples R China; [Xu, Yuan; Lu, Mingshan; Dixon, Elijah; Myers, Robert P.; Jelley, Rachel J.; Quan, Hude] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Lu, Mingshan] Univ Calgary, Dept Econ, Calgary, AB, Canada; [Dixon, Elijah] Univ Calgary, Div Gen Surg, Dept Med, Calgary, AB, Canada; [Myers, Robert P.] Univ Calgary, Div Gastroenterol & Hepatol, Dept Med, Liver Unit, Calgary, AB, Canada	Capital Medical University; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Li, N (corresponding author), Capital Med Univ, Beijing YouAn Hosp, Beijing, Peoples R China.	lirungya@ccmu.edu.cn		Xu, Yuan/0000-0003-2100-9437; Quan, Hude/0000-0002-7848-7256	Alberta Health Service (AHS); Libin Cardiovascular Institute of Alberta	Alberta Health Service (AHS); Libin Cardiovascular Institute of Alberta	The authors thank Dr. Guanmin Chen from Alberta Health Service (AHS) and Libin Cardiovascular Institute of Alberta and Dr. Mingfu Liu from Alberta Health Service (AHS) for their supports on data mining and analysis.	Bao XY, 2015, BMJ OPEN GASTROENTER, V2, DOI 10.1136/bmjgast-2015-000051; Borah BJ, 2011, HEALTH ECON, V20, P1025, DOI 10.1002/hec.1757; Chang GM, 2011, MED CARE, V49, P1054, DOI 10.1097/MLR.0b013e318235382b; Devlin SS, 2008, J HLTH EC, V27, P1168; Farinati F, 2012, J HEPATOL, V57, P221, DOI 10.1016/j.jhep.2011.12.022; Ginsburg PB, 2013, HEALTH AFFAIR, V32, P929, DOI 10.1377/hlthaff.2012.1007; Ginsburg PB, 2011, NEW ENGL J MED, V365, P1268, DOI 10.1056/NEJMp1107019; Group NJaTIE, 1993, FREE ALL LESSONS RAN; Huang H, 2015, J EPIDEMIOL, V25, P626, DOI 10.2188/jea.JE20140215; Lei JB, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-96; Liang XF, 2009, VACCINE, V27, P6550, DOI 10.1016/j.vaccine.2009.08.048; Liu DH, 2010, INT J MED INFORM, V79, P450, DOI 10.1016/j.ijmedinf.2010.03.002; Liu XQ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007362; Ma J, 2008, HEALTH AFFAIR, V27, P937, DOI 10.1377/hlthaff.27.4.937; MANNING WG, 1987, AM ECON REV, V77, P251; Mort EA, 1996, MED CARE, V34, P783, DOI 10.1097/00005650-199608000-00006; Newhouse J.P., 2000, HDB HLTH EC; Powell-Jackson T, 2015, HEALTH ECON, V24, P755, DOI 10.1002/hec.3060; Remler DK, 2003, HEALTH ECON, V12, P269, DOI 10.1002/hec.725; Roayaie S, 2014, J HEPATOL, V61, P3, DOI 10.1016/j.jhep.2014.04.005; Sada Y, 2016, MED CARE, V54, pE9, DOI 10.1097/MLR.0b013e3182a30373; Tian Z, 2015, AUTOMATED EXTRACTION; Van de Voorde C, 2001, HEALTH ECON, V10, P457, DOI 10.1002/hec.631; Wang H, 2011, HEALTH AFFAIR, V30, P2427, DOI 10.1377/hlthaff.2009.0022; Williamson T, 2014, ANN FAM MED, V12, P367, DOI 10.1370/afm.1644; Winkelmann R, 2004, HEALTH ECON, V13, P1081, DOI 10.1002/hec.868; Xu Y, 2014, J AM MED INFORM ASSN, V21, pE84, DOI 10.1136/amiajnl-2013-001806; Xu Y, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-016-0559-4; Xu Y, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0348-6; Yang G, 2013, LANCET, V381, P1987, DOI DOI 10.1016/S0140-6736(13)61097-1; Yip W, 2014, HEALTH AFFAIR, V33, P502, DOI 10.1377/hlthaff.2013.0702; Yip W, 2009, CHINA ECON REV, V20, P613, DOI 10.1016/j.chieco.2009.08.003; Yip WCM, 2012, LANCET, V379, P833, DOI 10.1016/S0140-6736(11)61880-1; Yuan SW, 2014, PHARMACOECONOMICS, V32, P265, DOI 10.1007/s40273-013-0079-9; Zhao T, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2995-z	35	4	4	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0187096	10.1371/journal.pone.0187096	http://dx.doi.org/10.1371/journal.pone.0187096			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK9QH	29073234	Green Published, gold, Green Submitted			2023-01-03	WOS:000413845400113
J	Motzer, RJ; Tannir, NM; McDermott, DF; Frontera, OA; Melichar, B; Choueiri, TK; Plimack, ER; Barthelemy, P; Porta, C; George, S; Powles, T; Donskov, F; Neiman, V; Kollmannsberger, CK; Salman, P; Gurney, H; Hawkins, R; Ravaud, A; Grimm, MO; Bracarda, S; Barrios, CH; Tomita, Y; Castellano, D; Rini, BI; Chen, AC; Mekan, S; McHenry, MB; Wind-Rotolo, M; Doan, J; Sharma, P; Hammers, HJ; Escudier, B				Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Frontera, O. Aren; Melichar, B.; Choueiri, T. K.; Plimack, Elizabeth R.; Barthelemy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Neiman, V.; Kollmannsberger, C. K.; Salman, P.; Gurney, H.; Hawkins, R.; Ravaud, A.; Grimm, M. -O.; Bracarda, S.; Barrios, C. H.; Tomita, Y.; Castellano, D.; Rini, B. I.; Chen, A. C.; Mekan, S.; McHenry, M. B.; Wind-Rotolo, M.; Doan, J.; Sharma, P.; Hammers, H. J.; Escudier, B.		CheckMate 214 Investigators	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; INTERFERON-ALPHA; UNTREATED MELANOMA; 1ST-LINE TREATMENT; SYMPTOM INDEX; KIDNEY CANCER; OPEN-LABEL; PAZOPANIB; THERAPY; MULTICENTER	BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate-and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P = 0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment- related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate-and poor-risk patients with previously untreated advanced renal-cell carcinoma.	[Tannir, N. M.; Sharma, P.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [George, S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA; [McDermott, D. F.] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Choueiri, T. K.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA; [Choueiri, T. K.] Harvard Med Sch, Boston, MA USA; [Frontera, O. Aren] Ctr Internac Estudios Clin, Santiago, Chile; [Salman, P.] Fdn Arturo Lopez Perez, Santiago, Chile; [Melichar, B.] Palacky Univ, Olomouc, Czech Republic; [Melichar, B.] Univ Hosp Olomouc, Olomouc, Czech Republic; [Plimack, Elizabeth R.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Barthelemy, P.] Hop Univ Strasbourg, Strasbourg, France; [Ravaud, A.] Bordeaux Univ Hosp, Hop St Andre, Bordeaux, France; [Escudier, B.] Inst Gustave Roussy, Villejuif, France; [Porta, C.] San Matteo Univ Hosp Fdn, Ist Ricovero & Cura Carattere Sci, Pavia, Italy; [Bracarda, S.] Osped San Donato, Azienda Unita Sanit Locale Toscana Sud Est, Ist Toscano Tumori, Arezzo, Italy; [Powles, T.] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free NHS Trust, London, England; [Hawkins, R.] Canc Res UK, London, England; [Donskov, F.] Aarhus Univ Hosp, Aarhus, Denmark; [Neiman, V.] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel; [Neiman, V.] Tel Aviv Univ, Tel Aviv, Israel; [Kollmannsberger, C. K.] British Columbia Canc Agcy, Vancouver, BC, Canada; [Gurney, H.] Westmead Hosp, Sydney, NSW, Australia; [Gurney, H.] Macquarie Univ, Sydney, NSW, Australia; [Grimm, M. -O.] Jena Univ Hosp, Jena, Germany; [Barrios, C. H.] Hosp Sao Lucas, Ctr Pesquisa Oncol, Porto Alegre, RS, Brazil; [Tomita, Y.] Niigata Univ, Niigata, Japan; [Castellano, D.] Hosp Univ 12 Octubre, Madrid, Spain; [Rini, B. I.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Chen, A. C.; Mekan, S.; McHenry, M. B.; Wind-Rotolo, M.; Doan, J.] Bristol Myers Squibb, Princeton, NJ USA; [Hammers, H. J.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Roswell Park Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Palacky University Olomouc; University Hospital Olomouc; Fox Chase Cancer Center; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Bordeaux; UNICANCER; Gustave Roussy; IRCCS Policlinico San Donato; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Cancer Research UK; University of London; Queen Mary University London; University College London; Cancer Research UK; Aarhus University; Rabin Medical Center; Tel Aviv University; British Columbia Cancer Agency; University of Sydney; Macquarie University; Friedrich Schiller University of Jena; Niigata University; Hospital Universitario 12 de Octubre; Cleveland Clinic Foundation; Bristol-Myers Squibb; Johns Hopkins University; Johns Hopkins Medicine	Motzer, RJ (corresponding author), Mem Hosp, Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.; Sharma, P (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	motzerr@mskcc.org; padsharma@mdanderson.org	Basso, Umberto/F-4229-2014; Gurney, Howard/ABF-6924-2020; Kimura, Go/Y-7843-2018; Recondo, Gonzalo/GNP-1009-2022; Choueiri, Toni/K-5238-2019; Gravis, Gwenaelle/CAG-3019-2022; Barrios, Carlos/HJG-7197-2022; de Azevedo, Sergio Jobim/P-5115-2015; Porta, Camillo/AAB-9482-2020	Basso, Umberto/0000-0002-5075-2177; Gurney, Howard/0000-0003-0217-5261; Kimura, Go/0000-0003-0088-9324; Recondo, Gonzalo/0000-0002-4755-9325; Choueiri, Toni/0000-0002-9201-3217; Gravis, Gwenaelle/0000-0002-3127-1554; Barrios, Carlos/0000-0001-6021-667X; McDermott, Ray/0000-0002-8952-4315; Zakharia, Yousef/0000-0001-9480-2626; OUDARD, Stephane/0000-0003-0893-285X; George, Saby/0000-0002-0444-5870; Hutson, Thomas/0000-0002-4529-4212; Grimm, Marc-Oliver/0000-0003-3084-8654; Bracarda, Sergio/0000-0002-0703-2959; Donskov, Frede/0000-0002-8449-863X; Hadaschik, Boris/0000-0002-1052-2692; Ravaud, Alain/0000-0001-9455-6744; DURAN, IGNACIO/0000-0001-8571-7163	Bristol-Myers Squibb; Ono Pharmaceutical; Memorial Sloan Kettering Cancer Center [P30 CA008748]; Pfizer; Novartis; Eisai; Exelixis; Genentech/Roche; Epizyme; Mirati Therapeutics; Argos Therapeutics; Nektar; Oncorena; Merck; Array BioPharma; Genentech BioOncology; Prometheus Laboratories; Merck Sharp Dohme; Astellas Pharma; Bayer; AstraZeneca; Genentech; Peloton Therapeutics; Tracon Pharmaceuticals; Cerulean Pharma; Foundation Medicine; GlaxoSmithKline; Corvus Pharmaceuticals; Acceleron Pharma; Aveo Pharmaceuticals; Dendreon; Eli Lilly; Clovis Oncology; Horizon Pharma; Inovio Pharmaceuticals; SynerGene Therapeutics; Ipsen; Sanofi; EUSA Pharma; Janssen; Celldex Therapeutics; Bayer HealthCare; Hexal; Apogepha; Intuitive Surgical; Sanofi-Aventis; Amgen; MedUpdate; Novartger Ingelheim; Taiho Pharmaceutical; Mylan; Merrimack Pharmaceuticals; AbbVie; BioMarin Pharmaceutical; Daiichi Sankyo; Abraxis BioScience; Asana BioSciences; AB Science; Mediis; Boehrinvation; ImClone; LEO Pharma; Millennium Pharmaceuticals; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical; Memorial Sloan Kettering Cancer Center; Pfizer(Pfizer); Novartis(Novartis); Eisai(Eisai Co Ltd); Exelixis; Genentech/Roche(Roche HoldingGenentech); Epizyme; Mirati Therapeutics; Argos Therapeutics; Nektar; Oncorena; Merck(Merck & Company); Array BioPharma(Pfizer); Genentech BioOncology; Prometheus Laboratories; Merck Sharp Dohme(Merck & Company); Astellas Pharma(Astellas Pharmaceuticals); Bayer(Bayer AG); AstraZeneca(AstraZeneca); Genentech(Roche HoldingGenentech); Peloton Therapeutics; Tracon Pharmaceuticals; Cerulean Pharma(Dexcel Pharma); Foundation Medicine; GlaxoSmithKline(GlaxoSmithKline); Corvus Pharmaceuticals; Acceleron Pharma; Aveo Pharmaceuticals; Dendreon; Eli Lilly(Eli Lilly); Clovis Oncology; Horizon Pharma; Inovio Pharmaceuticals; SynerGene Therapeutics; Ipsen(Ipsen); Sanofi; EUSA Pharma; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Celldex Therapeutics; Bayer HealthCare(Bayer AGBayer Healthcare Pharmaceuticals); Hexal; Apogepha; Intuitive Surgical; Sanofi-Aventis(Sanofi-Aventis); Amgen(Amgen); MedUpdate; Novartger Ingelheim; Taiho Pharmaceutical; Mylan; Merrimack Pharmaceuticals; AbbVie(AbbVie); BioMarin Pharmaceutical(Johnson & Johnson); Daiichi Sankyo(Daiichi Sankyo Company Limited); Abraxis BioScience; Asana BioSciences; AB Science; Mediis; Boehrinvation; ImClone; LEO Pharma(LEO Pharma); Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Bristol-Myers Squibb and Ono Pharmaceutical. The authors received no financial support or compensation for publication of this manuscript. Patients treated at the Memorial Sloan Kettering Cancer Center were supported in part by a Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).; Dr. Motzer reports receiving grant support and consulting fees from Pfizer, Novartis, Eisai, and Exelixis and grant support from Genentech/Roche; Dr. Tannir, receiving grant support, consulting fees, and honoraria from Bristol-Myers Squibb, receiving grant support from Epizyme and Mirati Therapeutics, receiving grant support, consulting fees, and honoraria from and serving on an advisory board for Exelixis and Novartis, receiving consulting fees and honoraria from Argos Therapeutics and Pfizer, and receiving consulting fees and honoraria from and serving on an advisory board for Eisai, Nektar, and Oncorena; Dr. McDermott, receiving honoraria and consulting fees from Bristol-Myers Squibb, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharma, and Genentech BioOncology and grant support from Prometheus Laboratories; Dr. Melichar, receiving advisory board fees and lecture fees from Bristol-Myers Squibb, Merck, Merck Sharp & Dohme, Roche, Novartis, Astellas Pharma, Pfizer, and Bayer; Dr. Choueiri, receiving grant support, paid to his institution, consulting fees, and advisory fees from AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, Merck, Novartis, Peloton Therapeutics, Pfizer, Roche, and Eisai, grant support, paid to his institution, from Tracon Pharmaceuticals, and consulting fees and advisory fees from Bayer, Cerulean Pharma, Foundation Medicine, GlaxoSmithKline, Prometheus Laboratories, and Corvus Pharmaceuticals; Dr. Plimack, receiving grant support, paid to her institution, from Acceleron Pharma, AstraZeneca, Aveo Pharmaceuticals, Bristol-Myers Squibb, Dendreon, Eli Lilly, GlaxoSmithKline, Merck, Peloton Therapeutics, and Pfizer, receiving consulting fees from Acceleron Pharma, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Eli Lilly, Exelixis, Genentech/Roche, GlaxoSmithKline, Horizon Pharma, Inovio Pharmaceuticals, Merck, Novartis, Pfizer, and SynerGene Therapeutics, receiving fees for the development of educational presentations from Bristol-Myers Squibb, Merck, Novartis, and Roche, holding a pending patent (14/588,503) on methods for screening patients with muscle-invasive bladder cancer for neoadjuvant chemotherapy responsiveness, and holding a pending patent (15/226,474) on the combination of an immunomodulatory agent with PD-1 or PD-L1 checkpoint inhibitors in the treatment of cancer; Dr. Barthelemy, receiving advisory board fees from Bristol-Myers Squibb, Pfizer, Novartis, Roche, Ipsen, and Sanofi; Dr. Porta, receiving consulting fees and lecture fees from Bristol-Myers Squibb, Novartis, Ipsen, Eisai, and EUSA Pharma, grant support, consulting fees, and lecture fees from Pfizer, and consulting fees from Janssen; Dr. George, receiving consulting fees from AstraZeneca, Exelixis, and Janssen, grant support and consulting fees from Bayer, Bristol-Myers Squibb, Corvus Pharmaceuticals, Novartis, and Pfizer, and grant support from Celldex Therapeutics and Merck; Dr. Powles, receiving grant support and honoraria from AstraZeneca and Roche, grant support from Novartis, and honoraria from Bristol-Myers Squibb, Merck, and Pfizer; Dr. Donskov, receiving grant support from Pfizer and Novartis; Dr. Kollmannsberger, receiving advisory board fees and honoraria from Bristol-Myers Squibb and Pfizer; Dr. Gurney, receiving advisory board fees from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, and AstraZeneca and grant support and advisory board fees from Pfizer; Dr.; Hawkins, receiving lecture fees from Novartis, Ipsen and Pfizer, lecture fees and travel support from Bristol-Myers Squibb, and royalties for a patent (WO 90/05144) on the phage antibody patent family collectively known as Winter II; Dr. Ravaud, receiving grant support, advisory board fees, and travel support from Pfizer, advisory board fees and travel support from Bristol-Myers Squibb, travel support from Novartis and Merck Sharp & Dohme, and advisory board fees from Roche; Dr. Grimm, receiving grant support, consulting fees, and lecture fees from Novartis and Bristol-Myers Squibb, consulting fees and lecture fees from Pfizer, Bayer HealthCare, and AstraZeneca, lecture fees from Astellas Pharma, Hexal, and Apogepha, and consulting fees from Intuitive Surgical, Sanofi-Aventis, Amgen, Merck Sharp & Dohme, and MedUpdate; Dr. Bracarda, receiving consulting fees, lecture fees, and travel support from Pfizer, Astellas Pharma, Bristol-Myers Squibb, Roche, and Janssen, travel support from Novartis and Bayer, consulting fees and travel support from Ipsen, and consulting fees from EUSA Pharma and Merck Sharp & Dohme; Dr. Barrios, receiving grant support and consulting fees from Novartger Ingelheim, GlaxoSmithKline, Roche, and Pfizer, grant support from Amgen, AstraZeneca, Taiho Pharmaceutical, Eli Lilly, Sanofi, Mylan, Merrimack Pharmaceuticals, Merck, AbbVie, Astellas Pharma, BioMarin Pharmaceutical, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis BioScience, Asana BioSciences, AB Science, Mediis, Boehrinvation, Exelixis, ImClone, LEO Pharma, Millennium Pharmaceuticals, and consulting fees from Eisai; Dr. Tomita, receiving grant support and honoraria from Astellas Pharma and Pfizer, grant support from AstraZeneca, honoraria from Bristol-Myers Squibb, honoraria and consulting fees from Novartis, grant support, honoraria, and consulting fees from Ono Pharmaceutical, and consulting fees from Taiho Pharmaceutical; Dr. Rini, receiving grant support, paid to his institution, and consulting fees from Bristol-Myers Squibb; Dr. Chen, being employed by Bristol-Myers Squibb; Drs. Mekan, McHenry, and Wind-Rotolo and Mr. Doan, being employed by and owning stock in Bristol-Myers Squibb; Dr. Sharma, owning stock in Jounce Therapeutics, Kite Pharma, Constellation Pharmaceuticals, and Neon Therapeutics and receiving consulting fees from Merck and Astellas Pharma; and Dr. Escudier, receiving honoraria from Bayer, Novartis, Pfizer, Exelixis, and Roche. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2017, OPD NIV INJ INTR US; [Anonymous], 2017, YERV IP INJ INTR US; Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; Choueiri TK, 2015, CLIN CANCER RES, V21, P1071, DOI 10.1158/1078-0432.CCR-14-1993; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2009, J CLIN ONCOL, V27, P1280, DOI 10.1200/JCO.2008.19.3342; Hammers HJ, 2017, J CLIN ONCOL, V35, P3851, DOI 10.1200/JCO.2016.72.1985; Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]; Heng DYC, 2013, LANCET ONCOL, V14, P141, DOI 10.1016/S1470-2045(12)70559-4; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Hodi FS, 2016, LANCET ONCOL, V17, P1558, DOI 10.1016/S1470-2045(16)30366-7; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Kalra S, 2015, ANN ONCOL, V26, P1300, DOI 10.1093/annonc/mdv030; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2017, J NATL COMPR CANC NE, V15, P804, DOI 10.6004/jnccn.2017.0100; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; National Cancer Institute (U.S.), 2010, COMMON TERMINOLOGY C, DOI DOI 10.1080/00140139.2010.489653; Rao D, 2009, J PAIN SYMPTOM MANAG, V38, P291, DOI 10.1016/j.jpainsymman.2008.08.013; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Rothrock NE, 2013, VALUE HEALTH, V16, P789, DOI 10.1016/j.jval.2013.04.015; SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yang JC, 2007, J IMMUNOTHER, V30, P825, DOI 10.1097/CJI.0b013e318156e47e	32	2307	2352	7	128	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 5	2018	378	14					1277	1290		10.1056/NEJMoa1712126	http://dx.doi.org/10.1056/NEJMoa1712126			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB5LN	29562145	Green Published, Bronze, Green Submitted, Green Accepted			2023-01-03	WOS:000429105700004
J	Bai, G; Sen, AP; Anderson, GF				Bai, Ge; Sen, Aditi P.; Anderson, Gerard F.			Pharmacy Benefit Managers, Brand-Name Drug Prices, and Patient Cost Sharing	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Bai, Ge] Johns Hopkins Carey Business Sch, 100 Int Dr, Baltimore, MD 21202 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Sen, Aditi P.; Anderson, Gerard F.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 North Broadway, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bai, G (corresponding author), Johns Hopkins Carey Business Sch, 100 Int Dr, Baltimore, MD 21202 USA.	gbai@jhu.edu						Anderson GF, 2017, TESTIMONY SENATE COM; Balto DA, 2015, STATE COMPETITION PH; Barrett P, 2017, BLOOMBERG BUSIN 0629; Fein AJ, 2017, 2017 EC REPORT US PH; IQVIA Institute for Human Data Science, 2019, MED US SPEND US REV; Walker J, 2016, WALL STREET J; Weinberg N, 2017, BLOOMBERG BUSINESSWE	7	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2018	168	6					436	+		10.7326/M17-2506	http://dx.doi.org/10.7326/M17-2506			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ8AM	29435565				2023-01-03	WOS:000427827400019
J	Jimenez, S; Mordillo-Mateos, L; Dileone, M; Campolo, M; Carrasco-Lopez, C; Moitinho-Ferreira, F; Gallego-Izquierdo, T; Siebner, HR; Valls-Sole, J; Aguilar, J; Oliviero, A				Jimenez, Samuel; Mordillo-Mateos, Laura; Dileone, Michele; Campolo, Michela; Carrasco-Lopez, Carmen; Moitinho-Ferreira, Fabricia; Gallego-Izquierdo, Tomas; Siebner, Hartwig R.; Valls-Sole, Josep; Aguilar, Juan; Oliviero, Antonio			Effects of patterned peripheral nerve stimulation on soleus spinal motor neuron excitability	PLOS ONE			English	Article							POST-ACTIVATION DEPRESSION; RECIPROCAL IA INHIBITION; THETA-BURST STIMULATION; LOWER-LIMB MOTONEURONS; H-REFLEX; PRESYNAPTIC INHIBITION; POTENTIATION; MODULATION; INDUCTION; PLASTICITY	Spinal plasticity is thought to contribute to sensorimotor recovery of limb function in several neurological disorders and can be experimentally induced in animals and humans using different stimulation protocols. In healthy individuals, electrical continuous Theta Burst Stimulation (TBS) of the median nerve has been shown to change spinal motoneuron excitability in the cervical spinal cord as indexed by a change in mean H-reflex amplitude in the flexor carpi radialis muscle. It is unknown whether continuous TBS of a peripheral nerve can also shift motoneuron excitability in the lower limb. In 26 healthy subjects, we examined the effects of electrical TBS given to the tibial nerve in the popliteal fossa on the excitability of lumbar spinal motoneurons as measured by H-reflex amplitude of the soleus muscle evoked by tibial nerve stimulation. Continuous TBS was given at 110% of H-reflex threshold intensity and compared to non-patterned regular electrical stimulation at 15 Hz. To disclose any pain-induced effects, we also tested the effects of TBS at individual sensory threshold. Moreover, in a subgroup of subjects we evaluated paired-pulse inhibition of H-reflex. Continuous TBS at 110% of H-reflex threshold intensity induced a short-term reduction of H-reflex amplitude. The other stimulation conditions produced no after effects. Paired-pulse H-reflex inhibition was not modulated by continuous TBS or non-patterned repetitive stimulation at 15 Hz. An effect of pain on the results obtained was discarded, since non-patterned 15 Hz stimulation at 110% HT led to pain scores similar to those induced by EcTBS at 110% HT, but was not able to induce any modulation of the H reflex amplitude. Together, the results provide first time evidence that peripheral continuous TBS induces a short-lasting change in the excitability of spinal motoneurons in lower limb circuitries. Future studies need to investigate how the TBS protocol can be optimized to produce a larger and longer effect on spinal cord physiology and whether this might be a useful intervention in patients with excessive excitability of the spinal motorneurons.	[Jimenez, Samuel; Mordillo-Mateos, Laura; Dileone, Michele; Campolo, Michela; Carrasco-Lopez, Carmen; Moitinho-Ferreira, Fabricia; Oliviero, Antonio] SESCAM, Hosp Nacl Paraplejicos, FENNSI Grp, Toledo, Spain; [Jimenez, Samuel] Univ Autonoma Madrid, Physiotherapy Dept, Ctr Super Estudios Univ La Salle, Madrid, Spain; [Jimenez, Samuel; Gallego-Izquierdo, Tomas] Alcala de Henares Univ, Physiotherapy Dept, Alcala De Henares, Spain; [Dileone, Michele] Hosp Madrid, HM Puerta Sur, CINAC, Mostoles, Spain; [Campolo, Michela; Valls-Sole, Josep] Univ Barcelona, Hosp Clin, Neurol Dept, EMG & Motor Control Sect, Barcelona, Spain; [Moitinho-Ferreira, Fabricia] Sarah Network Rehabil Hosp, Salvador De Bahia, Brazil; [Siebner, Hartwig R.] Copenhagen Univ Hosp, Ctr Funct & Diagnost Imaging & Res, Danish Res Ctr Magnet Resonance, Hvidovre, Denmark; [Siebner, Hartwig R.] Copenhagen Univ Hosp Bispebjerg, Dept Neurol, Copenhagen, Denmark; [Aguilar, Juan] SESCAM, Hosp Nacl Paraplejicos, Expt Neurophysiol Grp, Toledo, Spain	Hospital Nacional de Paraplejicos; Autonomous University of Madrid; Universidad de Alcala; University of Barcelona; Hospital Clinic de Barcelona; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; Hospital Nacional de Paraplejicos	Oliviero, A (corresponding author), SESCAM, Hosp Nacl Paraplejicos, FENNSI Grp, Toledo, Spain.	antonioo@sescam.jccm.es	Dileone, Michele/J-5255-2019; Aguilar, Juan/N-3850-2019; Mordillo-Mateos, Laura/M-2548-2014; Oliviero, Antonio/ABH-4485-2020; Aguilar, Juan/Q-2206-2015	Dileone, Michele/0000-0001-9871-6581; Aguilar, Juan/0000-0002-8070-3923; Mordillo-Mateos, Laura/0000-0003-3754-2279; Oliviero, Antonio/0000-0001-7723-0478; Aguilar, Juan/0000-0002-8070-3923; Carrasco-Lopez, Carmen/0000-0003-1280-5087	"Ministerio de Economia y Competitividad" of Spain; Fondo Europeo de Desarrollo Regional- FEDER [SAF2012- 39589, SAF2016- 80647]; Lundbeck Foundation [R59 A5399]; Novo Nordisk Foundation [NNF14OC0011413]	"Ministerio de Economia y Competitividad" of Spain; Fondo Europeo de Desarrollo Regional- FEDER(European Commission); Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	This research was funded by the "Ministerio de Economia y Competitividad" of Spain and the "Fondo Europeo de Desarrollo Regional- FEDER" (SAF2012- 39589 and SAF2016- 80647). H.R.S. was supported by the Lundbeck Foundation (Grant of Excellence "ContAct" R59 A5399) and the Novo Nordisk Foundation (Interdisciplinary Synergy Programme Grant "BASICS" NNF14OC0011413). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen OK, 2000, PAIN, V84, P29, DOI 10.1016/S0304-3959(99)00174-8; Andrews JC, 2015, NEUROSCI LETT, V589, P144, DOI 10.1016/j.neulet.2015.01.041; Aymard C, 2000, BRAIN, V123, P1688, DOI 10.1093/brain/123.8.1688; BROUWER B, 1992, EXP BRAIN RES, V89, P649; BURKE D, 1989, BRAIN, V112, P417, DOI 10.1093/brain/112.2.417; CAPOCCHI G, 1992, BRAIN RES, V591, P332, DOI 10.1016/0006-8993(92)91715-Q; Cortes M, 2011, CLIN NEUROPHYSIOL, V122, P2254, DOI 10.1016/j.clinph.2011.02.038; CRONE C, 1985, EXP BRAIN RES, V59, P418; CRONE C, 1990, EXP BRAIN RES, V81, P35; CRONE C, 1989, EXP BRAIN RES, V78, P28, DOI 10.1007/bf00230683; Dalpozzo F, 2002, CLIN NEUROPHYSIOL, V113, P284, DOI 10.1016/S1388-2457(01)00732-5; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; ELIOT LS, 1994, J NEUROSCI, V14, P3280; Hosoido T, 2009, NEUROSCI LETT, V450, P239, DOI 10.1016/j.neulet.2008.11.045; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hultborn H, 1996, EXP BRAIN RES, V108, P450; Kaczmarek D, 2017, J PHYSIOL-LONDON, V595, P1743, DOI 10.1113/JP272902; Kitago T, 2004, CLIN NEUROPHYSIOL, V115, P858, DOI 10.1016/j.clinph.2003.11.029; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Lamy JC, 2012, J NEUROPHYSIOL, V108, P906, DOI 10.1152/jn.10898.2011; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LARSON J, 1989, BRAIN RES, V489, P49, DOI 10.1016/0006-8993(89)90007-3; Le Pera D, 2001, CLIN NEUROPHYSIOL, V112, P1633, DOI 10.1016/S1388-2457(01)00631-9; Leukel C, 2012, EUR J NEUROSCI, V35, P1622, DOI 10.1111/j.1460-9568.2012.08067.x; LEVTOV A, 1992, J PHYSIOL-LONDON, V447, P149, DOI 10.1113/jphysiol.1992.sp018996; McNulty PA, 2008, J NEUROPHYSIOL, V100, P3275, DOI 10.1152/jn.90435.2008; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Perez MA, 2003, J NEUROSCI, V23, P2014; POCKETT S, 1993, NEUROREPORT, V4, P97, DOI 10.1097/00001756-199301000-00025; Ridding MC, 2000, EXP BRAIN RES, V131, P135, DOI 10.1007/s002219900269; ROSSI A, 1995, BRAIN RES, V700, P164, DOI 10.1016/0006-8993(95)00947-O; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Suppa A, 2016, BRAIN STIMUL, V9, P323, DOI 10.1016/j.brs.2016.01.006; Taube W, 2015, CEREB CORTEX, V25, P1629, DOI 10.1093/cercor/bht359; Winkler T, 2010, CLIN NEUROPHYSIOL, V121, P957, DOI 10.1016/j.clinph.2010.01.014; Wolpaw JR, 1983, J NEUROSCIENCE BRAIN, V4, P2718; Yeh KL, 2015, NEURAL PLAST, V2015, DOI 10.1155/2015/704849	38	5	5	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2018	13	2							e0192471	10.1371/journal.pone.0192471	http://dx.doi.org/10.1371/journal.pone.0192471			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW5PR	29451889	Green Published, gold, Green Submitted			2023-01-03	WOS:000425369800015
J	Desai, M; Field, N; Grant, R; McCormack, S				Desai, Monica; Field, Nigel; Grant, Robert; McCormack, Sheena			Recent advances in pre-exposure prophylaxis for HIV	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BONE-MINERAL DENSITY; HIGH-RISK MEN; COST-EFFECTIVENESS; TRANSGENDER WOMEN; UNITED-STATES; ANTIRETROVIRAL PROPHYLAXIS; SERODISCORDANT COUPLES; HETEROSEXUAL MEN; DOUBLE-BLIND; PREVENTION	Although pre-exposure prophylaxis (PrEP)-the use of antiretroviral drugs by noninfected people to prevent the acquisition of HIV-is a promising preventive option, important public health questions remain. Daily oral emtricitabine (FTC)-tenofovir disoproxil fumarate (TDF) is highly efficacious in preventing the acquisition of HIV in people at risk as a result of a range of different types of sexual exposure. There is good evidence of efficacy in women and men, and when men who have sex with men use event based dosing. Studies have been conducted in several countries and epidemics. Because adherence to this treatment varies greatly there are questions about its public health benefit. Oral FTC-TDF is extremely safe, with minimal impact on kidney, bone, or pregnancy outcomes, and there is no evidence that its effectiveness has been reduced by risk compensation during open label and programmatic follow-up. It is too early to assess the impact of this treatment on the incidence of sexually transmitted infections (STIs) at a population level. Many challenges remain. Access to pre-exposure prophylaxis is limited and disparities exist, including those governed by race and sex. Different pricing and access models need to be explored to avoid further widening inequalities. The optimal combination prevention program needs to be defined, and this will depend on local epidemiology, service provision, and cost effectiveness. This review updates the evidence base for pre-exposure prophylaxis regarding its effectiveness, safety, and risk compensation.	[Desai, Monica] Publ Hlth England, IHIV & STI Dept, London NW9 5EQ, England; [Field, Nigel] UCL, Ctr Mol Epidemiol & Translat Res, London WC1E 6BT, England; [Grant, Robert] Univ Calif San Francisco, Sch Med, San Francisco, CA 94115 USA; [Grant, Robert] Gladstone Inst, San Francisco, CA 94115 USA; [Grant, Robert] San Francisco AIDS Fdn, San Francisco, CA 94115 USA; [McCormack, Sheena] UCL, MRC Clin Trials Unit, London, England; [McCormack, Sheena] Chelsea & Westminster Hosp, London SW10 9BH, England	Public Health England; University of London; University College London; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes; Medical Research Council Clinical Trials Unit; University of London; University College London; Imperial College London	Desai, M (corresponding author), Publ Hlth England, IHIV & STI Dept, London NW9 5EQ, England.	desai.monica@gmail.com	Field, Nigel/ABG-3948-2020	Field, Nigel/0000-0002-2825-6652	Medical Research Council [MRC_UU_12023/23]; MRC [MC_UU_12023/1] Funding Source: UKRI; Medical Research Council [MC_UU_12023/1, MC_UU_12023/23] Funding Source: researchfish; National Institute for Health Research [CL-2010-18-010, ACF-2008-20-002] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	SMcC was supported by the Medical Research Council (MRC_UU_12023/23).	Aghaizu A, 2016, LANCET HIV, V3, pE431, DOI 10.1016/S2352-3018(16)30037-6; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; Antoni AG, 2017, IS ON DEMAND PREP WI; Arnold T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172354; Baeten J, 2016, INTEGRATED DELIVERY; Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Bauermeister JA, 2014, CURR HIV RES, V11, P520, DOI 10.2174/1570162X12666140129100411; Bernard CL, 2016, ANN INTERN MED, V165, P10, DOI 10.7326/M15-2634; British Columbia Centre for Excellence in HIV/ AIDS, 2016, GUIDANCE FOR THE USE; Brown AE, 2017, EUROSURVEILLANCE, V22, P4, DOI 10.2807/1560-7917.ES.2017.22.25.30553; Buchbinder SP, 2014, LANCET INFECT DIS, V14, P468, DOI 10.1016/S1473-3099(14)70025-8; Cambiano V, 2015, SEX TRANSM INFECT, V91, pA1, DOI 10.1136/sextrans-2015-052126.1; Castillo-Mancilla JR, 2013, AIDS RES HUM RETROV, V29, P384, DOI [10.1089/aid.2012.0089, 10.1089/AID.2012.0089]; Centers for Disease Control and Prevention, 2014, PREEXPOSURE PROPHYLA; Chen A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108742; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Coates TJ, 2008, LANCET, V372, P669, DOI 10.1016/S0140-6736(08)60886-7; Cohen S., 2016, EXPANDING PREP ACCES; Collins S., 2016, HIV TREATMENT BULLET; Dai JY, 2016, J INFECT DIS, V213, P335, DOI 10.1093/infdis/jiv333; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Delpech V, TOWARDS ELIMINATION; Department: Health. Republic of South Africa, 2016, NATIONAL POLICY ON H; Desai K, 2008, AIDS, V22, P1829, DOI 10.1097/QAD.0b013e32830e00f5; Desai M, 2016, HIV MED, V17, P133, DOI 10.1111/hiv.12285; Deutsch MB, 2015, LANCET HIV, V2, pE512, DOI 10.1016/S2352-3018(15)00206-4; Dolling D, 2014, THIRD JOINT CONFEREN; Dolling DI, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1286-4; European AIDS Clinical Society, 2015, GUIDELINES VERSION 8; Fonner VA, 2016, AIDS, V30, P1973, DOI 10.1097/QAD.0000000000001145; French National Agency for AIDS Research (ANRS), 2015, PRISE EN CHARGE MEDI; Giller RM, 2017, CHANGES IN TRUVADA T; Grant JM, 2016, SOC STUD SCI, V46, P236, DOI 10.1177/0306312716632617; Grant R, 2016, RECOVERY OF BONE MIN; Grant RM, 2014, LANCET INFECT DIS, V14, P820, DOI 10.1016/S1473-3099(14)70847-3; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grohskopf LA, 2013, JAIDS-J ACQ IMM DEF, V64, P79, DOI 10.1097/QAI.0b013e31828ece33; Grossman HA, 2016, HIVR4P CONFERENCE; Gulick R, 2016, CONFERENCE ON RETROV, P103; Heffron R, 2014, AIDS, V28, P2771, DOI 10.1097/QAD.0000000000000493; Hoornenborg E, 2017, CONFERENCE ON RETROV, P953; Hoots BE, 2016, CLIN INFECT DIS, V63, P672, DOI 10.1093/cid/ciw367; Hosek SG, 2013, J HIV-AIDS SOC SERV, V12, P333, DOI 10.1080/15381501.2013.773575; Hughes G, 2015, FUTURE MICROBIOL, V10, P35, DOI 10.2217/fmb.14.110; JUUSOLA JL, 2012, ANN INTERN MED, V156, P541, DOI DOI 10.1059/0003-4819-156-8-201204170-00001; Karim SSA, 2015, CURR OPIN HIV AIDS, V10, P183, DOI 10.1097/COH.0000000000000147; Kessler J, 2014, AIDS, V28, P2683, DOI 10.1097/QAD.0000000000000460; Kibengo FM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074314; Knox DC, 2016, HIV 1 INFECTION WITH; La Direction des Communications du Ministere de la Sante et des Services Sociaux, 2013, AVIS INTERIMAIRE SUR; Lal L, 2017, AIDS, V31, P1709, DOI [10.1097/QAD.0000000000001519, 10.1097/qad.0000000000001519]; Letchumanan M, 2015, ANTIVIR THER, V20, P613, DOI 10.3851/IMP2956; Liu AY, 2016, JAMA INTERN MED, V176, P75, DOI 10.1001/jamainternmed.2015.4683; Liu AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023688; Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129; Marrazzo JM, 2015, NEW ENGL J MED, V372, P509, DOI 10.1056/NEJMoa1402269; Martin M, 2015, CONFERENCE ON RETROV; Martin M, 2017, LANCET HIV, V4, pE59, DOI 10.1016/S2352-3018(16)30207-7; Martin M, 2015, AIDS, V29, P819, DOI 10.1097/QAD.0000000000000613; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; McGowan I, 2016, CONFERENCE ON RETROV; Mirembe BG, 2016, JAIDS-J ACQ IMM DEF, V71, P287, DOI 10.1097/QAI.0000000000000858; Mitchell KM, 2015, AIDS, V29, P2035, DOI 10.1097/QAD.0000000000000798; Mofenson LM, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002133; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Molina JM, 2017, INTERNATIONAL AIDS C; Molina JM, 2016, INTERNATIONAL AIDS C; Montano MA, 2017, CONFERENCE ON RETROV, P979; Mugo NR, 2014, JAMA-J AM MED ASSOC, V312, P362, DOI 10.1001/jama.2014.8735; Mugo Nelly R, 2011, AIDS, V25, P1887, DOI 10.1097/QAD.0b013e32834a9338; Mugwanya KK, 2013, SEX TRANSM INFECT, V89, pA46, DOI 10.1136/sextrans-2013-051184.0144; Mugwanya KK, 2016, JAIDS-J ACQ IMM DEF, V71, P374, DOI 10.1097/QAI.0000000000000868; Mugwanya KK, 2015, JAMA INTERN MED, V175, P246, DOI 10.1001/jamainternmed.2014.6786; Mugwanya KK, 2015, TOP ANTIVIR MED, V23, P451; Mulligan K, 2015, CLIN INFECT DIS, V61, P572, DOI 10.1093/cid/civ324; Murnane PM, 2014, AIDS, V28, P1825, DOI 10.1097/QAD.0000000000000290; Mutua G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033103; Nel A, 2016, CONFERENCE ON RETROV; New South Wales, 2017, NSW HIV STRATEGY 201; Nichols BE, 2016, LANCET INFECT DIS, V16, P1423, DOI 10.1016/S1473-3099(16)30311-5; Ong K, 2015, POSTER PRESENTATION; Ong KJ, 2015, LANCET, V386, pS16, DOI 10.1016/S0140-6736(15)00854-5; Ouellet E, 2015, CAN J INFECT DIS MED, V26, P23, DOI 10.1155/2015/964512; Padian NS, 2011, LANCET, V378, P269, DOI 10.1016/S0140-6736(11)60877-5; Paltiel AD, 2009, CLIN INFECT DIS, V48, P806, DOI 10.1086/597095; Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027; Public Health England, 2015, HEALTH PROTECTION RE; Ross EL, 2016, JAIDS-J ACQ IMM DEF, V72, pE61, DOI 10.1097/QAI.0000000000000987; Sagaon-Teyssier L, 2016, AIDS CARE, V28, P48, DOI 10.1080/09540121.2016.1146653; San Francisco Department of Public Health, HIV EPIDEMIOLOGY ANN; Shen Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100863; Sivay MV, 2017, JAIDS-J ACQ IMM DEF, V75, P271, DOI 10.1097/QAI.0000000000001374; Thigpen MC, 2011, DAILY ORAL ANTIRETRO; UNAIDS, 2016, FACT SHEET 2016; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778; Weber S, 2016, AIDS 2016; Whiteman MK, 2016, CONTRACEPTION, V93, P17, DOI 10.1016/j.contraception.2015.07.003; WHO, 2017, WHO IMPLEMENTATION T; WHO, 2016, CONSOLIDATED GUIDANC; Yaylali E, 2016, CONFERENCE ON RETROV	102	65	66	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2017	359								j5011	10.1136/bmj.j5011	http://dx.doi.org/10.1136/bmj.j5011			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ4KT	29229609	Green Accepted, Green Submitted			2023-01-03	WOS:000418327000001
J	Ludin, A; Zon, LI				Ludin, Aye; Zon, Leonard I.			CANCER IMMUNOTHERAPY The dark side of PD-1 receptor inhibition	NATURE			English	Editorial Material							NIVOLUMAB	Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves.	[Ludin, Aye; Zon, Leonard I.] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Zon, Leonard I.] Boston Childrens Hosp, Stem Cell Program, Boston, MA USA; [Zon, Leonard I.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Zon, Leonard I.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Zon, Leonard I.] Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Zon, LI (corresponding author), Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.	zon@enders.tch.harvard.edu			Howard Hughes Medical Institute Funding Source: Medline; NHLBI NIH HHS [R01 HL048801] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048801] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borghaei H, 2017, NEW ENGL J MED, V373, P1627; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Hude I, 2017, HAEMATOLOGICA, V102, P30, DOI 10.3324/haematol.2016.150656; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Navarro MN, 2014, NAT IMMUNOL, V15, P808, DOI 10.1038/ni.2941; Sharpe A. H., 2017, NATURE REV IMMUNOL; Wartewig T, 2017, NATURE, V552, P121, DOI 10.1038/nature24649; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684	9	29	31	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 7	2017	552	7683					41	42		10.1038/nature24759	http://dx.doi.org/10.1038/nature24759			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FP4BA	29143822	Green Accepted			2023-01-03	WOS:000417560500038
J	Carter, AC; Chang, HY; Church, G; Dombkowski, A; Ecker, JR; Gil, E; Giresi, PG; Greely, H; Greenleaf, WJ; Hacohen, N; He, C; Hill, D; Ko, J; Kohane, I; Kundaje, A; Palmer, M; Snyder, MP; Tung, J; Urban, A; Vidal, M; Wong, W				Carter, Ava C.; Chang, Howard Y.; Church, George; Dombkowski, Ashley; Ecker, Joseph R.; Gil, Elad; Giresi, Paul G.; Greely, Henry; Greenleaf, William J.; Hacohen, Nir; He, Chuan; Hill, David; Ko, Justin; Kohane, Isaac; Kundaje, Anshul; Palmer, Megan; Snyder, Michael P.; Tung, Joyce; Urban, Alexander; Vidal, Marc; Wong, Wing			Challenges and recommendations for epigenomics in precision health	NATURE BIOTECHNOLOGY			English	Article							DNA ELEMENTS; LOW-INPUT; LANDSCAPE; CHROMATIN; HALLMARKS; SEQ		[Carter, Ava C.; Chang, Howard Y.; Greenleaf, William J.; Snyder, Michael P.; Urban, Alexander; Wong, Wing] Stanford Univ, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA; [Church, George] Harvard Med Sch, Dept Genet, Boston, MA USA; [Church, George] Wyss Inst, Boston, MA USA; [Dombkowski, Ashley] BEFORE Brands, Menlo Pk, CA USA; [Ecker, Joseph R.] Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA; [Ecker, Joseph R.; He, Chuan] Howard Hughes Med Inst, Chevy Chase, MD USA; [Gil, Elad] Color Genom, Burlingame, CA USA; [Giresi, Paul G.] Epinomics, Menlo Pk, CA USA; [Greely, Henry] Stanford Univ, Ctr Law & Biosci, Stanford, CA 94305 USA; [Greenleaf, William J.; Kundaje, Anshul; Snyder, Michael P.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Hacohen, Nir] Massachusetts Gen Hosp, Boston, MA 02114 USA; [He, Chuan] Univ Chicago, Chicago, IL 60637 USA; [Hill, David; Vidal, Marc] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; [Ko, Justin] Stanford Univ, Dept Dermatol, Stanford, CA 94305 USA; [Kohane, Isaac] Harvard Med Sch, Dept Med Informat, Boston, MA USA; [Kundaje, Anshul] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Palmer, Megan] Stanford Univ, Ctr Int Secur & Cooperat, Stanford, CA 94305 USA; [Tung, Joyce] 23andMe, Mountain View, CA USA; [Urban, Alexander] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Wong, Wing] Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Harvard University; Harvard Medical School; Salk Institute; Howard Hughes Medical Institute; Stanford University; Stanford University; Harvard University; Massachusetts General Hospital; University of Chicago; Harvard University; Dana-Farber Cancer Institute; Stanford University; Harvard University; Harvard Medical School; Stanford University; Stanford University; Stanford University; Stanford University	Chang, HY (corresponding author), Stanford Univ, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA.	howchang@stanford.edu	Kundaje, Anshul/Y-2739-2019; Ecker, Joseph R/B-9144-2008; Kundaje, Anshul/Y-2598-2019; Ko, Justin/Y-7233-2019	Kundaje, Anshul/0000-0003-3084-2287; Ecker, Joseph R/0000-0001-5799-5895; Kundaje, Anshul/0000-0003-3084-2287; Snyder, Michael/0000-0003-0784-7987; Palmer, Megan/0000-0001-8310-2325; church, george/0000-0001-6232-9969; Carter, Ava/0000-0002-1892-8742	National Human Genome Research Institute; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG007735, RM1HG008935, R01HG007834, P50HG002357, P50HG004233, P50HG005550, RM1HG008525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH106933] Funding Source: NIH RePORTER	National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank J.A. Stamatoyannopoulos (U. Washington), C.-T. Wu (Harvard Medical School) and J. Schloss (NHGRI) for input. We thank the National Human Genome Research Institute for support.	Adey A, 2012, GENOME RES, V22, P1139, DOI 10.1101/gr.136242.111; Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; [Anonymous], 2017, GWG LIFE BECOMES 1 I; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Castillo-Fernandez JE, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0060-z; Chen BH, 2016, AGING-US, V8, P1844, DOI 10.18632/aging.101020; Cloud J., 2010, TIME; Fan HC, 2012, NATURE, V487, P320, DOI 10.1038/nature11251; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gray KA, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0062-6; Jiang LC, 2011, GENOME RES, V21, P1543, DOI 10.1101/gr.121095.111; Joehanes R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506; Kellis M, 2014, P NATL ACAD SCI USA, V111, P6131, DOI 10.1073/pnas.1318948111; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Malladi VS, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav010; McGuire AL, 2008, NAT REV GENET, V9, P152, DOI 10.1038/nrg2302; Mockus SM, 2016, CLIN CHEM, V62, P442, DOI 10.1373/clinchem.2015.247437; Moskowitz X., 2016, SCI IMMUNOL, V2, P1; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Qu K, 2017, CANCER CELL, V32, P27, DOI 10.1016/j.ccell.2017.05.008; Schmidt C, 2015, NAT METHODS, V12, P963, DOI [10.1038/NMETH.3542, 10.1038/nmeth.3542]; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Snyder MW, 2016, CELL, V164, P57, DOI 10.1016/j.cell.2015.11.050; Soon WW, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.61; Soshnev AA, 2016, MOL CELL, V62, P681, DOI 10.1016/j.molcel.2016.05.004; Wright Mathew W., 2011, Human Genomics, V5, P90; Zook JM, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.25	30	13	13	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2017	35	12					1128	1132		10.1038/nbt.4030	http://dx.doi.org/10.1038/nbt.4030			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FP4TQ	29220033	Green Accepted			2023-01-03	WOS:000417609700014
J	Navarro-Haro, MV; Lopez del Hoyo, Y; Campos, D; Linehan, MM; Hoffman, HG; Garcia-Palacios, A; Modrego-Alarcon, M; Borao, L; Garcia-Campayo, J				Navarro-Haro, Maria V.; Lopez del Hoyo, Yolanda; Campos, Daniel; Linehan, Marsha M.; Hoffman, Hunter G.; Garcia-Palacios, Azucena; Modrego-Alarcon, Marta; Borao, Luis; Garcia-Campayo, Javier			Meditation experts try Virtual Reality Mindfulness: A pilot study evaluation of the feasibility and acceptability of Virtual Reality to facilitate mindfulness practice in people attending a Mindfulness conference.	PLOS ONE			English	Article							BORDERLINE PERSONALITY-DISORDER; BEHAVIOR-THERAPY; SELF-COMPASSION; PAIN-CONTROL; IMPACT; QUESTIONNAIRE; INDIVIDUALS; BENEFITS; SENSE	Regular mindfulness practice benefits people both mentally and physically, but many populations who could benefit do not practice mindfulness. Virtual Reality (VR) is a new technology that helps capture participants' attention and gives users the illusion of "being there" in the 3D computer generated environment, facilitating sense of presence. By limiting distractions from the real world, increasing sense of presence and giving people an interesting place to go to practice mindfulness, Virtual Reality may facilitate mindfulness practice. Traditional Dialectical Behavioral Therapy (DBT (R)) mindfulness skills training was specifically designed for clinical treatment of people who have trouble focusing attention, however severe patients often show difficulties or lack of motivation to practice mindfulness during the training. The present pilot study explored whether a sample of mindfulness experts would find useful and recommend a new VR Dialectical Behavioral Therapy (DBT (R)) mindfulness skills training technique and whether they would show any benefit. Forty four participants attending a mindfulness conference put on an Oculus Rift DK2 Virtual Reality helmet and floated down a calm 3D computer generated virtual river while listening to digitized DBT (R) mindfulness skills training instructions. On subjective questionnaires completed by the participants before and after the VR DBT (R) mindfulness skills training session, participants reported increases/improvements in state of mindfulness, and reductions in negative emotional states. After VR, participants reported significantly less sadness, anger, and anxiety, and reported being significantly more relaxed. Participants reported a moderate to strong illusion of going inside the 3D computer generated world (i.e., moderate to high "presence" in VR) and showed high acceptance of VR as a technique to practice mindfulness. These results show encouraging preliminary evidence of the feasibility and acceptability of using VR to practice mindfulness based on clinical expert feedback. VR is a technology with potential to increase computerized dissemination of DBT (R) skills training modules. Future research is warranted.	[Navarro-Haro, Maria V.] Hosp Gen Cataluna, Barcelona, Spain; [Lopez del Hoyo, Yolanda] Univ Zaragoza, Zaragoza, Spain; [Lopez del Hoyo, Yolanda; Modrego-Alarcon, Marta; Borao, Luis; Garcia-Campayo, Javier] Red Invest Atenc Primaria REDIAPP, Zaragoza, Spain; [Campos, Daniel; Garcia-Palacios, Azucena] Univ Jaume 1, Castellon de La Plana, Spain; [Linehan, Marsha M.] Univ Washington, Behav Res & Therapy Clin, Seattle, WA 98195 USA; [Hoffman, Hunter G.] Univ Washington, Virtual Real Res Ctr, Human Photon Lab, Mech Engn, Seattle, WA 98195 USA; [Garcia-Palacios, Azucena] Inst Salud Carlos III, CIBER Physiopathol Obes & Nutr CIBERobn, CB06-03, Madrid, Spain; [Garcia-Campayo, Javier] Hosp Univ Miguel Servet, ISS Aragon, Zaragoza, Spain	University of Zaragoza; Universitat Jaume I; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III; Miguel Servet University Hospital	Campos, D (corresponding author), Univ Jaume 1, Castellon de La Plana, Spain.	camposdcb@gmail.com	Haro, Maria Vicenta Navarro/AAM-8500-2020; Bacas, Daniel Campos/AAA-3440-2020; Hoffman, hunter/AGE-1376-2022; López del Hoyo, Yolanda/W-4602-2018	Haro, Maria Vicenta Navarro/0000-0001-9726-3250; Bacas, Daniel Campos/0000-0001-9903-4064; López del Hoyo, Yolanda/0000-0002-1690-4130; Borao, Luis/0000-0002-1437-2353; Garcia-Campayo, Javier/0000-0002-3797-4218; Modrego, Marta/0000-0003-1575-7738	NIH [R01GM042725, R01AR054115, R01-DA026438]; Effat University, Jeddah Saudi Arabia Research and Consultancy Institute; Master of Mindfulness, University of Zaragoza, Zaragoza, Spain; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042725] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Effat University, Jeddah Saudi Arabia Research and Consultancy Institute; Master of Mindfulness, University of Zaragoza, Zaragoza, Spain; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	NIH grants to David Patterson R01GM042725, R01AR054115, and an NIH grant to Sam Sharar R01-DA026438, and by Effat University, Jeddah Saudi Arabia Research and Consultancy Institute. This project was also funded by the Master of Mindfulness, University of Zaragoza, Zaragoza, Spain.	Baer RA, 2008, ASSESSMENT, V15, P329, DOI 10.1177/1073191107313003; Banos RM, 2009, BRIT J GUID COUNS, V37, P347, DOI 10.1080/03069880902957064; Banos RM, 2004, CYBERPSYCHOL BEHAV, V7, P734, DOI 10.1089/cpb.2004.7.734; Bishop SR, 2004, CLIN PSYCHOL-SCI PR, V11, P230, DOI 10.1093/clipsy/bph077; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Botella C, 2007, CLIN PSYCHOL PSYCHOT, V14, P164, DOI 10.1002/cpp.524; Botella J., 2015, META ANAALISIS CIENC; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Campbell D. T., 1963, HDB RES TEACHING, P171; Campos D, 2016, PERS INDIV DIFFER, V93, P80, DOI 10.1016/j.paid.2015.08.040; Cebolla A, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-6; Chambers R, 2008, COGNITIVE THER RES, V32, P303, DOI 10.1007/s10608-007-9119-0; Cohen J., 1988, STAT POWER ANAL BEHA, V567; Elices M, 2016, MINDFULNESS, V7, P584, DOI 10.1007/s12671-016-0492-1; Erisman SM, 2010, EMOTION, V10, P72, DOI 10.1037/a0017162; Garcia-Palacios A, 2002, BEHAV RES THER, V40, P983, DOI 10.1016/S0005-7967(01)00068-7; GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Hoffman HG, 2000, PAIN, V85, P305, DOI 10.1016/S0304-3959(99)00275-4; Hoffman HG, 2003, INT J HUM-COMPUT INT, V15, P469, DOI 10.1207/S15327590IJHC1503_10; Hoffman HG, 2011, ANN BEHAV MED, V41, P183, DOI 10.1007/s12160-010-9248-7; Irving Julie Anne, 2009, Complement Ther Clin Pract, V15, P61, DOI 10.1016/j.ctcp.2009.01.002; Jha AP, 2010, EMOTION, V10, P54, DOI 10.1037/a0018438; Kabat-Zinn J., 2016, MINDFULNESS COMPASSI, V1, P2, DOI [10.1016/j.mincom.2016.09.007, DOI 10.1016/J.MINCOM.2016.09.007]; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Keune PM., 2010, PSYCHOL TOP, V19, P373; Lancaster Gillian A, 2015, Pilot Feasibility Stud, V1, P1, DOI 10.1186/2055-5784-1-1; Lessiter J, 2001, PRESENCE-TELEOP VIRT, V10, P282, DOI 10.1162/105474601300343612; Linehan M., 2002, SUFFERING FREEDOM AC; Linehan M.M., 2015, DBT R SKILLS TRAININ, V2nd; Linehan M. M., 1993, COGNITIVE BEHAV TREA; Linehan MM, 2015, JAMA PSYCHIAT, V72, P475, DOI 10.1001/jamapsychiatry.2014.3039; Lopez A, 2016, MINDFULNESS, V7, P1289, DOI 10.1007/s12671-016-0568-y; Maani CV, 2011, J TRAUMA, V71, pS125, DOI 10.1097/TA.0b013e31822192e2; Montero-Marin J, 2016, FRONT PSYCHOL, P7; Montero-Marin J, 2015, FRONT PSYCHOL, P6; Navarro-Haro MV, 2016, FRONT PSYCHOL; Riva G, 2007, CYBERPSYCHOL BEHAV, V10, P45, DOI 10.1089/cpb.2006.9993; Slater Mel, 1994, PRESENCE-VIRTUAL AUG, V3, P130, DOI [10.1007/s13398-014-0173-7.2, DOI 10.1007/S13398-014-0173-7.2, 10.1162/pres.1994.3.2.130, DOI 10.1162/PRES.1994.3.2.130]; Soler J, 2012, PSYCHOM PROPR SPANIS, V40, P19; Soler J, 2016, BORDER PERS DIS EMOT, V3, DOI 10.1186/s40479-015-0035-8; Soler J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086622; Soler J, 2012, BEHAV RES THER, V50, P150, DOI 10.1016/j.brat.2011.12.002; Taylor VA, 2011, NEUROIMAGE, V57, P1524, DOI 10.1016/j.neuroimage.2011.06.001; Valentine SE, 2015, J CLIN PSYCHOL, V71, P1, DOI 10.1002/jclp.22114; Wilks CR, 2017, COGN BEHAV PRACT, V24, P288, DOI 10.1016/j.cbpra.2016.06.004	46	51	56	3	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2017	12	11							e0187777	10.1371/journal.pone.0187777	http://dx.doi.org/10.1371/journal.pone.0187777			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN5GQ	29166665	Green Published, Green Submitted, gold			2023-01-03	WOS:000416035300019
J	Shekelle, PG; Cook, IA; Miake-Lye, IM; Booth, MS; Beroes, JM; Mak, S				Shekelle, Paul G.; Cook, Ian A.; Miake-Lye, Isomi M.; Booth, Marika Suttorp; Beroes, Jessica M.; Mak, Selene			Benefits and Harms of Cranial Electrical Stimulation for Chronic Painful Conditions, Depression, Anxiety, and Insomnia A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Article							NONINVASIVE BRAIN-STIMULATION; ELECTROTHERAPY STIMULATION; TRANSCRANIAL ELECTROSTIMULATION; ELECTROSLEEP THERAPY; EFFICACY; SAFETY; INDIVIDUALS; HEADACHE; DISORDER	Background: Cranial electrical stimulation (CES) is increasingly popular as a treatment, yet its clinical benefit is unclear. Purpose: To review evidence about the benefits and harms of CES for adult patients with chronic painful conditions, depression, anxiety, and insomnia. Data Sources: Several databases from inception to 10 October 2017 without language restrictions and references from experts, prior reviews, and manufacturers. Study Selection: Randomized controlled trials of CES versus usual care or sham CES that reported pain, depression, anxiety, or sleep outcomes in any language. Data Extraction: Single-reviewer extraction checked by another; dual independent quality assessment; strength-of-evidence grading by the first author with subsequent group discussion. Data Synthesis: Twenty-eight articles from 26 randomized trials met eligibility criteria. The 2 trials that compared CES with usual care were small, and neither reported a statistically significant benefit in pain or anxiety outcomes for patients with fibromyalgia or anxiety, respectively. Fourteen trials with sham or placebo controls involving patients with painful conditions, such as headache, neuromuscular pain, or musculoskeletal pain, had conflicting results. Four trials done more than 40 years ago and 1 from 2014 provided low-strength evidence of a possible modest benefit compared with sham treatments in patients with anxiety and depression. Trials in patients with insomnia (n = 2), insomnia and anxiety (n = 1), or depression (n = 3) had inconclusive or conflicting results. Low-strength evidence suggested that CES does not cause serious side effects. Limitation: Most trials had small sample sizes and short durations; all had high risk of bias due to inadequate blinding. Conclusion: Evidence is insufficient that CES has clinically important effects on fibromyalgia, headache, neuromusculoskeletal pain, degenerative joint pain, depression, or insomnia; low-strength evidence suggests modest benefit in patients with anxiety and depression.	[Shekelle, Paul G.; Miake-Lye, Isomi M.; Beroes, Jessica M.] West Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA; [Cook, Ian A.] Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Ave, Santa Monica, CA 90401 USA; [Booth, Marika Suttorp] RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA; [Mak, Selene] Univ Calif Los Angeles, Fielding Sch Publ Hlth, 650 Charles E Young Dr South, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; University of California System; University of California Los Angeles	Shekelle, PG (corresponding author), West Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	paul.shekelle@va.gov						Boldt I, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009177.pub2; Bystritsky A, 2008, J CLIN PSYCHIAT, V69, P412, DOI 10.4088/JCP.v69n0311; CARTWRIGHT RD, 1975, J NERV MENT DIS, V161, P134, DOI 10.1097/00005053-197508000-00008; Cork RC, 2004, INTERNET J ANESTHESI, V8; FEIGHNER JP, 1973, J NERV MENT DIS, V157, P121, DOI 10.1097/00005053-197308000-00004; Feusner JD, 2012, BRAIN BEHAV, V2, P211, DOI 10.1002/brb3.45; Gabis L, 2003, AM J PHYS MED REHAB, V82, P81, DOI 10.1097/00002060-200302000-00001; Gabis L, 2009, J REHABIL MED, V41, P256, DOI 10.2340/16501977-0315; Gibson TH., 1987, AM J ELECTROMED, V4, P18; Guleyupoglu B, 2013, J NEUROSCI METH, V219, P297, DOI 10.1016/j.jneumeth.2013.07.016; HEARST ED, 1974, ARCH GEN PSYCHIAT, V30, P463; Heffernan M., 1996, CANADIAN J CLIN MED, V4, P4; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Katsnelson Y, 2004, P ANN INT IEEE EMBS, V26, P4087; Kavirajan HC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010521.pub2; KLAWANSKY S, 1995, J NERV MENT DIS, V183, P478, DOI 10.1097/00005053-199507000-00010; Lichtbroun AS, 2001, JCR-J CLIN RHEUMATOL, V7, P72, DOI 10.1097/00124743-200104000-00003; Lisanby SH, 2017, NEW ENGL J MED, V376, P2593, DOI 10.1056/NEJMe1702492; Masson SC, 2013, J CLIN EPIDEMIOL, V66, P805, DOI 10.1016/j.jclinepi.2013.01.010; McClure D, 2015, J NERV MENT DIS, V203, P827, DOI 10.1097/NMD.0000000000000378; Mindes J, 2015, CRANIAL ELECT STIMUL; Mischoulon D, 2015, J PSYCHIATR RES, V70, P98, DOI 10.1016/j.jpsychires.2015.08.016; Moncrieff J, 2015, CONTEMP CLIN TRIALS, V43, P60, DOI 10.1016/j.cct.2015.05.005; MOORE JA, 1975, BIOL PSYCHIAT, V10, P59; Moreno-Duarte I, 2014, NEUROIMAGE, V85, P1003, DOI 10.1016/j.neuroimage.2013.05.097; O'Connell NE, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008208.pub3; Rintala DH, 2010, PARKINSONS DIS-US, V2010, DOI 10.4061/2010/569154; ROSENTHAL SH, 1972, BIOL PSYCHIAT, V4, P179; Scallet A, 1976, COMPLEMENT THER MED, V37, P347, DOI DOI 10.1016/J.CTIM.2012.11.007; Shekelle PG, 2016, EFFECTIVENESS RISKS; SOLOMON S, 1989, HEADACHE, V29, P445, DOI 10.1111/j.1526-4610.1989.hed2907445.x; SOLOMON S, 1985, HEADACHE, V25, P12, DOI 10.1111/j.1526-4610.1985.hed2501012.x; Tan G, 2000, AM J PAIN MANAG, V10, P35; Tan G, 2006, J REHABIL RES DEV, V43, P461, DOI 10.1682/JRRD.2005.04.0066; Tan G, 2011, J SPINAL CORD MED, V34, P285, DOI 10.1179/2045772311Y.0000000008; Taylor AG, 2013, PAIN MANAG NURS, V14, P327, DOI 10.1016/j.pmn.2011.07.002; Taylor AG, 2013, EXPLORE-NY, V9, P32, DOI 10.1016/j.explore.2012.10.006; Tietjen G, 2013, CEPHALALGIA, V33, P963; Turner MD, 2016, J AFFECT DISORDERS, V76, DOI DOI 10.1016/J.JAD.2014.04.029; Wang W, 2000, PSYCHIAT RES, V96, P149, DOI 10.1016/S0165-1781(00)00194-3; WEISS MF, 1973, J NERV MENT DIS, V157, P108, DOI 10.1097/00005053-197308000-00003; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227	42	25	29	5	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 20	2018	168	6					414	+		10.7326/M17-1970	http://dx.doi.org/10.7326/M17-1970			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ8AM	29435567				2023-01-03	WOS:000427827400016
J	Scheibenbogen, C; Loebel, M; Freitag, H; Krueger, A; Bauer, S; Antelmann, M; Doehner, W; Scherbakov, N; Heidecke, H; Reinke, P; Volk, HD; Grabowski, P				Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaels; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald; Reinke, Petra; Volk, Hans-Dieter; Grabowski, Patricia			Immunoadsorption to remove beta 2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME	PLOS ONE			English	Article							DILATED CARDIOMYOPATHY; ENDOTHELIAL DYSFUNCTION; PLASMA-EXCHANGE; AUTOANTIBODIES; THERAPY	Introduction Infection-triggered disease onset, chronic immune activation and autonomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) point to an autoimmune disease directed against neurotransmitter receptors. We had observed elevated autoantibodies against beta 2 adrenergic receptors, and muscarinic 3 and 4 acetylcholine receptors in a subset of patients. lmmunoadsorption (IA) was shown to be effective in removing autoantibodies and improve outcome in various autoimmune diseases. Methods 10 patients with post-infectious CFS/ME and elevated beta 2 autoantibodies were treated with IA with an IgG-binding column for 5 days. We assessed severity of symptoms as outcome parameter by disease specific scores. Antibodies were determined by ELISA and B cell phenotype by flow cytometry. Results IgG levels dropped to median 0.73 g/l (normal 7-16 g/l) after the 4th cycle of IA, while IgA and IgM levels remained unchanged. Similarly, elevated beta 2 IgG antibodies rapidly decreased during IA in 9 of 10 patients. Also 6 months later beta 2 autoantibodies were significantly lower compared to pretreatment. Frequency of memory B cells significantly decreased and frequency of plasma cells increased after the 4th IA cycle. A rapid improvement of symptoms was reported by 7 patients during the IA. 3 of these patients had long lasting moderate to marked improvement for 6-12+ months, 2 patients had short improvement only and 2 patients improved for several months following initial worsening. Conclusions IA can remove autoantibodies against beta 2 adrenergic receptor and lead to clinical improvement. B cell phenotyping provides evidence for an effect of IA on memory B cell development. Data from our pilot trial warrants further studies in CFS/ME.	[Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Bauer, Sandra; Antelmann, Michaels; Volk, Hans-Dieter; Grabowski, Patricia] Charite, Inst Med Immunol, Berlin, Germany; [Scheibenbogen, Carmen; Reinke, Petra; Volk, Hans-Dieter] Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany; [Krueger, Anne; Reinke, Petra] Charite, Dept Nephrol, Berlin, Germany; [Doehner, Wolfram; Scherbakov, Nadja] Charite, Ctr Stroke Res Berlin, Berlin, Germany; [Heidecke, Harald] CellTrend GmbH, Luckenwalde, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scheibenbogen, C (corresponding author), Charite, Inst Med Immunol, Berlin, Germany.; Scheibenbogen, C (corresponding author), Berlin Brandenburg Ctr Regenerat Therapies BCRT, Berlin, Germany.	Carmen.Scheibenbogen@charite.de	volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Scheibenbogen, Carmen/0000-0002-8554-9638; Doehner, Wolfram/0000-0001-7598-708X; Freitag, Helma/0000-0001-5950-0489; Reinke, Petra/0000-0003-0771-4375	Fresenius Medical Care	Fresenius Medical Care	This trial was supported with a grant by Fresenius Medical Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CellTrend GmbH provided support in the form of measurement of autoantibodies and salary for author HH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the author contributions section.	Bell DS., 1995, DOCTORS GUIDE CHRONI; Braun N, 2000, EXPERT OPIN INV DRUG, V9, P2017, DOI 10.1517/13543784.9.9.2017; Carruthers BM, 2011, J INTERN MED, V270, P327, DOI 10.1111/j.1365-2796.2011.02428.x; Cella D, 1997, SEMIN HEMATOL, V34, P13; Dandel M, 2013, ATHEROSCLEROSIS SUPP, V14, P203, DOI 10.1016/j.atherosclerosissup.2012.10.029; Dandel M, 2012, EUR J HEART FAIL, V14, P1374, DOI 10.1093/eurjhf/hfs123; Fluge O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129898; Fluge O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026358; Haupt W F, 2000, Ther Apher, V4, P195, DOI 10.1046/j.1526-0968.2000.00183.x; Heine J, 2016, J NEUROL, V263, P2395, DOI 10.1007/s00415-016-8277-y; Kavelaars A, 2000, J CLIN ENDOCR METAB, V85, P692, DOI 10.1210/jc.85.2.692; Kronbichler A, 2016, AUTOIMMUN REV, V15, P38, DOI 10.1016/j.autrev.2015.08.010; Loebel M, 2016, BRAIN BEHAV IMMUN, V52, P32, DOI 10.1016/j.bbi.2015.09.013; MATHIOWETZ V, 1984, J HAND SURG-AM, V9A, P222, DOI 10.1016/S0363-5023(84)80146-X; Newton DJ, 2012, INT J CARDIOL, V154, P335, DOI 10.1016/j.ijcard.2011.10.030; Onugoren MD, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000207; Podojil JR, 2005, TRENDS IMMUNOL, V26, P180, DOI 10.1016/j.it.2005.02.005; Scherbakov N, 2012, CEREBROVASC DIS, V33, P37, DOI 10.1159/000332809; Schneidewind-Muller JM, 2002, ARTIF ORGANS, V26, P140, DOI 10.1046/j.1525-1594.2002.06920.x; Slota C, 2015, BRAIN BEHAV IMMUN, V46, P168, DOI 10.1016/j.bbi.2015.01.015; Tanaka S, 2003, INT J MOL MED, V12, P225; Wallukat G, 2002, NEW ENGL J MED, V347, P1806, DOI 10.1056/NEJM200211283472220; Wallukat G, 2014, SEMIN IMMUNOPATHOL, V36, P351, DOI 10.1007/s00281-014-0425-9; Yamamoto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051515	24	48	49	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2018	13	3							e0193672	10.1371/journal.pone.0193672	http://dx.doi.org/10.1371/journal.pone.0193672			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ3GA	29543914	Green Published, gold, Green Submitted			2023-01-03	WOS:000427473500023
J	Muth, CC				Muth, Christopher C.			The Humans in Health Care-A Review of The American Mercy Tour	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Muth, Christopher C.] JAMA, 330 N Wabash Ave, Chicago, IL 60611 USA; [Muth, Christopher C.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA	Rush University	Muth, CC (corresponding author), JAMA, 330 N Wabash Ave, Chicago, IL 60611 USA.	christopher.muth@jamanetwork.org							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 6	2018	319	9					850	851		10.1001/jama.2018.0315	http://dx.doi.org/10.1001/jama.2018.0315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY3FW	29509846				2023-01-03	WOS:000426705100001
J	Tanuseputro, P; Beach, S; Chalifoux, M; Wodchis, WP; Hsu, AT; Seow, H; Manuel, DG				Tanuseputro, Peter; Beach, Sarah; Chalifoux, Mathieu; Wodchis, Walter P.; Hsu, Amy T.; Seow, Hsien; Manuel, Douglas G.			Associations between physician home visits for the dying and place of death: A population-based retrospective cohort study	PLOS ONE			English	Article							OF-LIFE CARE; PALLIATIVE CARE; CANCER-PATIENTS; PEOPLE DIE; SITE; DETERMINANTS; INVOLVEMENT; HOSPICE	Background While most individuals wish to die at home, the reality is that most will die in hospital. Aim To determine whether receiving a physician home visit near the end-of-life is associated with lower odds of death in a hospital. Design Observational retrospective cohort study, examining location of death and health care in the last year of life. Setting/Participants Population-level study of Ontarians, a Canadian province with over 13 million residents. All decedents from April 1, 2010 to March 31, 2013 (n = 264,754) Results More than half of 264,754 decedents died in hospital: 45.7% died in an acute care hospital and 7.7% in complex continuing care. After adjustment for multiple factors-including patient illness, home care services, and days of being at home-receiving at least one physician home visit from anon-palliative care physician was associated with a 47% decreased odds (odds-ratio, 0.53; 95% CI: 0.51-0.55) of dying in a hospital. When a palliative care physician specialist was involved, the overall odds declined by 59% (odds ratio, 0.41; 95% CI: 0.39-0.43). The same model, adjusting for physician home visits, showed that receiving palliative home care was associated with a similar reduction (odds ratio, 0.49; 95% CI: 0.47-0.51). Conclusion Location of death is strongly associated with end-of-life health care in the home. Less than one-third of the population, however, received end-of-life home care or a physician visit in their last year of life, revealing large room for improvement.	[Tanuseputro, Peter; Manuel, Douglas G.] Bruyere Res Inst, Ottawa, ON, Canada; [Tanuseputro, Peter; Beach, Sarah; Hsu, Amy T.; Manuel, Douglas G.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Tanuseputro, Peter] Univ Ottawa, Div Palliat Care, Dept Med, Ottawa, ON, Canada; [Tanuseputro, Peter; Chalifoux, Mathieu; Wodchis, Walter P.; Hsu, Amy T.; Seow, Hsien; Manuel, Douglas G.] Inst Clin Evaluat Sci Populat Hlth & Primary Care, Ottawa, ON, Canada; [Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Seow, Hsien] McMaster Univ, Dept Oncol, Hamilton, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Toronto; McMaster University	Tanuseputro, P (corresponding author), Bruyere Res Inst, Ottawa, ON, Canada.; Tanuseputro, P (corresponding author), Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.; Tanuseputro, P (corresponding author), Univ Ottawa, Div Palliat Care, Dept Med, Ottawa, ON, Canada.; Tanuseputro, P (corresponding author), Inst Clin Evaluat Sci Populat Hlth & Primary Care, Ottawa, ON, Canada.	peter.tanuseputro@mail.utoronto.ca	Seow, Hsien/AAQ-1438-2021; Manuel, Doug/D-7100-2014	Seow, Hsien/0000-0001-6701-1714; Manuel, Doug/0000-0003-0912-0845; Beach, Sarah/0000-0002-4660-0509; wodchis, walter/0000-0003-2494-7031; Tanuseputro, Peter/0000-0002-4409-0795	Ontario Ministry of Health and Long Term Care (MOHLTC) [06034]; Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC; Bruyere Research Institute	Ontario Ministry of Health and Long Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Institute for Clinical Evaluative Sciences (ICES) - Ontario MOHLTC; Bruyere Research Institute	This research was supported by a research grant from the Ontario Ministry of Health and Long Term Care (MOHLTC) to the Health System Performance Research Network Grant (HSPRN #06034). This study was also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario MOHLTC. PT is supported through the Bruyere Research Institute. The views expressed in this paper are the views of the authors and do not necessarily reflect those of the funder. The funders had no influence on the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Aabom B, 2005, BRIT J GEN PRACT, V55, P684; Aabom B, 2005, J CLIN ONCOL, V23, P7411, DOI 10.1200/JCO.2005.16.493; Aabom B, 2006, PALLIATIVE MED, V20, P507, DOI 10.1191/0269216306pm1169oa; Ahmad S, 2005, QJM-INT J MED, V98, P865, DOI 10.1093/qjmed/hci138; [Anonymous], 2015, HIGHL NAT PALL MED S; Austin PC, 2011, MED CARE, V49, P932, DOI 10.1097/MLR.0b013e318215d5e2; Barbera L, 2015, CMAJ OPEN, V3; Barbera L, 2015, J ONCOL PRACT, V11, pE279, DOI 10.1200/JOP.2015.004416; Bekelman JE, 2016, JAMA-J AM MED ASSOC, V315, P272, DOI 10.1001/jama.2015.18603; Blackmore S., 2011, PREDICTING DEATH EST; Bluebond-Langner M, 2013, PALLIATIVE MED, V27, P705, DOI 10.1177/0269216313483186; Brazil K, 2005, PALLIATIVE MED, V19, P492, DOI 10.1191/0269216305pm1050oa; Broad JB, 2013, INT J PUBLIC HEALTH, V58, P257, DOI 10.1007/s00038-012-0394-5; Costa V, 2014, Ont Health Technol Assess Ser, V14, P1; Fowler R, 2013, CLIN INVEST MED, V36, pE127; Fukui S, 2011, ANN ONCOL, V22, P2113, DOI 10.1093/annonc/mdq719; Fukui S, 2011, J PAIN SYMPTOM MANAG, V42, P882, DOI 10.1016/j.jpainsymman.2011.02.024; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; Georghiou T, 2014, EXPLORING COSTS CARE, P1; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Goodridge D, 2010, RURAL REMOTE HEALTH, V10; House of Commons Public Accounts Committee, 2009, 19 HOUS COMM PUBL AC; Jayaraman J, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-19; Kimura T, 2015, GERIATR GERONTOL INT, V15, P465, DOI 10.1111/ggi.12297; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Menec V., 2004, PATTERNS HLTH CARE U; MOR V, 1983, J HEALTH SOC BEHAV, V24, P375, DOI 10.2307/2136403; Muggah E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-452; Nakamura S, 2010, GERIATR GERONTOL INT, V10, P154, DOI 10.1111/j.1447-0594.2009.00570.x; Neergaard MA, 2009, BRIT J GEN PRACT, V59, P671, DOI 10.3399/bjgp09X454133; Ontario Medical Association, 2014, PALL CAR BACKGR OMAS; Reich O, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-116; Remington R, 2010, J GERONTOL NURS, V36, P16, DOI 10.3928/00989134-20100730-06; Seow H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3496; Statistics Canada, 2014, TABL 102 0540 DEATHS; Statistics Canada, 2013, TABL 102 0509 DEATHS; Tang ST, 2001, CANCER INVEST, V19, P165, DOI 10.1081/CNV-100000151; Tanuseputro P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121759; Teno JM, 2013, JAMA-J AM MED ASSOC, V309, P470, DOI 10.1001/jama.2012.207624; Unwin BK, 2011, AM FAM PHYSICIAN, V83, P925	41	42	43	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2018	13	2							e0191322	10.1371/journal.pone.0191322	http://dx.doi.org/10.1371/journal.pone.0191322			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW4LB	29447291	Green Published, gold, Green Submitted			2023-01-03	WOS:000425283900012
J	Van Dyck, L; Casaer, MP				Van Dyck, Lisa; Casaer, Michael P.			Nutrition in the ICU: sometimes route does matter	LANCET			English	Editorial Material							CRITICALLY-ILL ADULTS; PARENTERAL-NUTRITION; CONTROLLED-TRIAL		[Casaer, Michael P.] Univ Hosp, Clin Dept, B-3000 Leuven, Belgium; Univ Hosp, Lab Intens Care Med, B-3000 Leuven, Belgium; Katholieke Univ Leuven, B-3000 Leuven, Belgium	KU Leuven	Casaer, MP (corresponding author), Univ Hosp, Clin Dept, B-3000 Leuven, Belgium.	michael.casaer@uzleuven.be	Casaer, Michael/Y-7131-2019	Casaer, Michael/0000-0002-7087-0795	FWO Flanders [1151018N]; C-2 Research Project Grant from Catholic University Leuven [C24/17/070]; Start-Up grant from Catholic University Leuven [STG/16/021]; MPC a post-doctoral research grant from FWO Flanders [1832817N]	FWO Flanders(FWO); C-2 Research Project Grant from Catholic University Leuven; Start-Up grant from Catholic University Leuven; MPC a post-doctoral research grant from FWO Flanders	LVD receives a doctoral research grant from FWO Flanders (1151018N) and MPC a post-doctoral research grant from FWO Flanders (1832817N), a C-2 Research Project Grant (C24/17/070), and Start-Up grant (STG/16/021) from the Catholic University Leuven. We declare no other competing interests.	Arabi YM, 2017, INTENS CARE MED, V43, P1239, DOI 10.1007/s00134-017-4711-6; Blaser AR, 2017, INTENS CARE MED, V43, P380, DOI 10.1007/s00134-016-4665-0; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Doig GS, 2015, LANCET RESP MED, V3, P943, DOI 10.1016/S2213-2600(15)00418-X; Doig GS, 2013, JAMA-J AM MED ASSOC, V309, P2130, DOI 10.1001/jama.2013.5124; Elke G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1298-1; Harvey SE, 2014, NEW ENGL J MED, V371, P1673, DOI 10.1056/NEJMoa1409860; Reignier J, 2017, LANCET; Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Trial Investigators and the Clinical Research in Intensive Care and Sepsis (CRICS) group, 2017, LANCET; Weijs PJM, 2012, JPEN-PARENTER ENTER, V36, P60, DOI 10.1177/0148607111415109; Zimmerman JE, 2013, CRIT CARE, V17, DOI 10.1186/cc12695	13	0	0	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2018	391	10116					98	100		10.1016/S0140-6736(17)32815-5	http://dx.doi.org/10.1016/S0140-6736(17)32815-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT0EG	29128299				2023-01-03	WOS:000422793400005
J	Butler, M; Nelson, VA; Davila, H; Ratner, E; Fink, HA; Hemmy, LS; McCarten, JR; Barclay, TR; Brasure, M; Kane, RL				Butler, Mary; Nelson, Victoria A.; Davila, Heather; Ratner, Edward; Fink, Howard A.; Hemmy, Laura S.; McCarten, J. Riley; Barclay, Terry R.; Brasure, Michelle; Kane, Robert L.			Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							SOY ISOFLAVONE SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; GINKGO-BILOBA EXTRACT; DOUBLE-BLIND; OLDER-ADULTS; B-VITAMINS; POSTMENOPAUSAL WOMEN; FATTY-ACIDS; FISH-OIL; PERFORMANCE	Background: Optimal interventions to prevent or delay cognitive decline, mild cognitive impairment (MCI), or dementia are uncertain. Purpose: To summarize the evidence on efficacy and harms of over-the-counter (OTC) supplements to prevent or delay cognitive decline, MCI, or clinical Alzheimer-type dementia in adults with normal cognition or MCI but no dementia diagnosis. Data Sources: Multiple electronic databases from 2009 to July 2017 and bibliographies of systematic reviews. Study Selection: English-language trials of at least 6 months' duration that enrolled adults without dementia and compared cognitive outcomes with an OTC supplement versus placebo or active controls. Data Extraction: Extraction performed by a single reviewer and confirmed by a second reviewer; dual-reviewer assessment of risk of bias; consensus determination of strength of evidence. Data Synthesis: Thirty-eight trials with low to medium risk of bias compared omega-3 fatty acids, soy, ginkgo biloba, B vitamins, vitamin D plus calcium, vitamin C or beta-carotene, multi-ingredient supplements, or other OTC interventions with placebo or other supplements. Few studies examined effects on clinical Alzheimer-type dementia or MCI, and those that did suggested no benefit. Daily folic acid plus vitamin B-12 was associated with improvements in performance on some objectively measured memory tests that were statistically significant but of questionable clinical significance. Moderate-strength evidence showed that vitamin E had no benefit on cognition. Evidence about effects of omega-3 fatty acids, soy, ginkgo biloba, folic acid alone or with other B vitamins, beta-carotene, vitamin C, vitamin D plus calcium, and multivitamins or multi-ingredient supplements was either insufficient or low-strength, suggesting that these supplements did not reduce risk for cognitive decline. Adverse events were rarely reported. Limitation: Studies had high attrition and short follow-up and used a highly variable set of cognitive outcome measures. Conclusion: Evidence is insufficient to recommend any OTC supplement for cognitive protection in adults with normal cognition or MCI.	[Butler, Mary; Nelson, Victoria A.; Davila, Heather; Brasure, Michelle] Univ Minnesota, Div Hlth Policy & Management, 420 Delaware St Southeast,Mayo Mem Bldg D351, Minneapolis, MN 55455 USA; [Ratner, Edward; Fink, Howard A.; Hemmy, Laura S.; McCarten, J. Riley] Minneapolis VA Hlth Care Syst, Geriatr Res Educ & Clin Ctr, One Vet Dr,11-G, Minneapolis, MN 55417 USA; HealthPartners, Minneapolis, MN USA; [Barclay, Terry R.] Univ Minnesota, Dept Neurol, 295 Phalen Blvd,Mailstop 41203C, St Paul, MN 55130 USA	University of Minnesota System; University of Minnesota Twin Cities; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Butler, M (corresponding author), Univ Minnesota, Div Hlth Policy & Management, 420 Delaware St Southeast,Mayo Mem Bldg D351, Minneapolis, MN 55455 USA.	butl0092@umn.edu		Davila, Heather/0000-0003-1832-7901	Agency for Healthcare Research and Quality [290-2015-00008-I]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This manuscript is based on research conducted by the Minnesota Evidence-based Practice Center under AHRQ contract 290-2015-00008-I.	Abraham RP, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011905, DOI 10.1002/14651858.CD011905]; Alzheimers Research and Prevention Foundation, 2017, PILL 1 DIETS SUPPL; Andreeva VA, 2011, AM J CLIN NUTR, V94, P278, DOI 10.3945/ajcn.110.006320; [Anonymous], 2015, NUTR BUSINESS J; Balk EM, 2015, ANN INTERN MED, V163, P437, DOI 10.7326/M15-0452; Berkman ND, 2013, METHODS GUIDE EFFECT; Birks J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003120.pub3; Charernboon Thammanard, 2015, Journal of the Medical Association of Thailand, V98, P508; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Cukierman-Yaffe T, 2014, LANCET DIABETES ENDO, V2, P562, DOI 10.1016/S2213-8587(14)70062-2; Dangour AD, 2010, J ALZHEIMERS DIS, V22, P205, DOI 10.3233/JAD-2010-090940; Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121; de Jager CA, 2012, INT J GERIATR PSYCH, V27, P592, DOI 10.1002/gps.2758; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Dodge HH, 2008, NEUROLOGY, V70, P1809, DOI 10.1212/01.wnl.0000303814.13509.db; Douaud G, 2013, P NATL ACAD SCI USA, V110, P9523, DOI 10.1073/pnas.1301816110; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; Gavrilova SI, 2014, INT J GERIATR PSYCH, V29, P1087, DOI 10.1002/gps.4103; Geleijnse JM, 2012, ALZHEIMERS DEMENT, V8, P278, DOI 10.1016/j.jalz.2011.06.002; Gleason CE, 2009, AGE AGEING, V38, P86, DOI 10.1093/ageing/afn227; Grodstein F, 2013, ANN INTERN MED, V159, P806, DOI 10.7326/0003-4819-159-12-201312170-00006; Henderson VW, 2012, NEUROLOGY, V78, P1841, DOI 10.1212/WNL.0b013e318258f822; Howes JB, 2004, CLIMACTERIC, V7, P70, DOI 10.1080/13697130310001651490; Kane R. L., 2017, COMP EFFECTIVENESS R, V188, P86; Kang JH, 2009, CIRCULATION, V119, P2772, DOI 10.1161/CIRCULATIONAHA.108.816900; Kang JH, 2006, ARCH INTERN MED, V166, P2462, DOI 10.1001/archinte.166.22.2462; Kato-Kataoka A, 2010, J CLIN BIOCHEM NUTR, V47, P246, DOI 10.3164/jcbn.10-62; Kreijkamp-Kaspers S, 2004, JAMA-J AM MED ASSOC, V292, P65, DOI 10.1001/jama.292.1.65; Kritz-Silverstein D, 2003, MENOPAUSE, V10, P196, DOI 10.1097/00042192-200310030-00004; Kritz-Silverstein D, 2008, J AM GERIATR SOC, V56, P1292, DOI 10.1111/j.1532-5415.2008.01768.x; Kryscio RJ, 2017, JAMA NEUROL, V74, P567, DOI 10.1001/jamaneurol.2016.5778; Lee LK, 2013, PSYCHOPHARMACOLOGY, V225, P605, DOI 10.1007/s00213-012-2848-0; Malouf R, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004514.pub2; McMahon JA, 2006, NEW ENGL J MED, V354, P2764, DOI 10.1056/NEJMoa054025; McNeill G, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-10; Naeini AMA, 2014, EUR J NUTR, V53, P1255, DOI 10.1007/s00394-013-0628-1; Oulhaj A, 2016, J ALZHEIMERS DIS, V50, P547, DOI 10.3233/JAD-150777; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Qato DM, 2016, JAMA INTERN MED, V176, P473, DOI 10.1001/jamainternmed.2015.8581; Ro SC, 2007, MENOPAUSE, V14, P489, DOI 10.1097/gme.0b013e31802v4f4f; Rossom RC, 2012, J AM GERIATR SOC, V60, P2197, DOI 10.1111/jgs.12032; Schiepers OJG, 2009, J NUTR, V139, P1368, DOI 10.3945/jn.108.103721; Smith AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012244; Snitz BE, 2009, JAMA-J AM MED ASSOC, V302, P2663, DOI 10.1001/jama.2009.1913; Stott DJ, 2005, AM J CLIN NUTR, V82, P1320, DOI 10.1093/ajcn/82.6.1320; Strike SC, 2016, J GERONTOL A-BIOL, V71, P236, DOI 10.1093/gerona/glv109; Sydenham E, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005379.pub3; van de Rest O, 2008, NEUROLOGY, V71, P430, DOI 10.1212/01.wnl.0000324268.45138.86; van der Zwaluw NL, 2014, NEUROLOGY, V83, P2158, DOI 10.1212/WNL.0000000000001050; Vellas B, 2012, LANCET NEUROL, V11, P851, DOI 10.1016/S1474-4422(12)70206-5; Viswanathan M., 2012, SYSTEMATIC REV HLTH; Walker JG, 2012, AM J CLIN NUTR, V95, P194, DOI 10.3945/ajcn.110.007799; Williams J. W., 2010, 2902007100661 HHSA A; Witte AV, 2014, CEREB CORTEX, V24, P3059, DOI 10.1093/cercor/bht163; Witte AV, 2014, J NEUROSCI, V34, P7862, DOI 10.1523/JNEUROSCI.0385-14.2014; Wolters M, 2005, PREV MED, V41, P253, DOI 10.1016/j.ypmed.2004.11.007; Yurko-Mauro K, 2010, ALZHEIMERS DEMENT, V6, P456, DOI 10.1016/j.jalz.2010.01.013	57	75	78	6	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2018	168	1					52	+		10.7326/M17-1530	http://dx.doi.org/10.7326/M17-1530			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR5SO	29255909				2023-01-03	WOS:000419126700007
J	Wang, TL; Fang, YW; Leu, JG; Tsai, MH				Wang, Tzu-Lin; Fang, Yu-Wei; Leu, Jyh-Gang; Tsai, Ming-Hsien			Association between serum aluminum levels and cardiothoracic ratio in patients on chronic hemodialysis	PLOS ONE			English	Article							LONG-TERM DIALYSIS; CHEST RADIOGRAPHS; HEART; MORTALITY; DISEASE; MALNUTRITION; INFLAMMATION; DIAGNOSIS; MARKER; COHORT	The cardiothoracic ratio (CTR) and serum aluminum levels are both associated with mortality in hemodialysis patients. However, limited data regarding the association between serum aluminum levels and the CTR have been published to date. Therefore, we aimed to elucidate this association in patients on chronic hemodialysis (CHD). We investigated the association between the serum aluminum level and the CTR in CHD in a retrospective cross-sectional study of 547 Taiwanese patients on CHD. The mean age of patients was 62.5 +/- 13.2 years, with a mean hemodialysis time of 7.1 +/- 5.2 years. Among the patients, 36.9% were diabetic and 47.9% were male. After natural logarithmic transformation (ln(aluminum)), the serum aluminum level exhibited an independent and linear relationship with the CTR (beta: 1.40, 95% confidence interval (CI), 0.6-2.2). A high serum aluminum level (>= 6 ng/dL) was significantly associated with a CTR >0.5 in the crude analysis (odds ratio (OR): 2.15, 95% CI, 1.52-3.04) and remained significant after multivariable adjustment (OR: 2.45, 95% CI, 1.63-3.67). Moreover, the ln(aluminum) value was significantly associated with a CTR >0.5 (OR: 1.71, 95% CI, 1.28-2.29) in multivariable analysis, indicating a dose effect of aluminum on cardiomegaly. In conclusion, the serum aluminum level was independently associated with cardiac remodeling (elevated CTR) in patients on CHD.	[Wang, Tzu-Lin] Shin Kong Wu Ho Su Mem Hosp, Div Cardiol, Dept Internal Med, Taipei, Taiwan; [Fang, Yu-Wei; Leu, Jyh-Gang; Tsai, Ming-Hsien] Shin Kong Wu Ho Su Mem Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan; [Fang, Yu-Wei; Leu, Jyh-Gang; Tsai, Ming-Hsien] Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan; [Tsai, Ming-Hsien] Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Div Biostat, Taipei, Taiwan	Shin Kong Wu Ho Su Memorial Hospital; Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic University; National Taiwan University	Tsai, MH (corresponding author), Shin Kong Wu Ho Su Mem Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan.; Tsai, MH (corresponding author), Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan.; Tsai, MH (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol & Prevent Med, Div Biostat, Taipei, Taiwan.	chaosmyth.tw@gmail.com		Tsai, Ming Hsien/0000-0003-3561-4689				Adamek S, 2011, ACTA CHIR ORTHOP TR, V78, P355; Agarwal AK, 2006, J AM MED DIR ASSOC, V7, pS7, DOI 10.1016/j.jamda.2006.09.005; ANDRESS DL, 1986, J BONE MINER RES, V1, P391; Asakawa T, 2014, CARDIORENAL MED, V4, P189, DOI 10.1159/000368200; Bikbov B, 2017, HEMODIAL INT, V21, P393, DOI 10.1111/hdi.12503; Bohrer D, 2007, NEPHROL DIAL TRANSPL, V22, P605, DOI 10.1093/ndt/gfl569; Bohrer D, 2009, NEPHROL DIAL TRANSPL, V24, P1277, DOI 10.1093/ndt/gfn631; CHAZAN JA, 1991, ARCH INTERN MED, V151, P319, DOI 10.1001/archinte.151.2.319; Chen KH, 2008, KIDNEY BLOOD PRESS R, V31, P143, DOI 10.1159/000127388; Chen KH, 2011, THER APHER DIAL, V15, P81, DOI 10.1111/j.1744-9987.2010.00860.x; Clark AL, 2000, POSTGRAD MED J, V76, P289, DOI 10.1136/pmj.76.895.289; Dimopoulos K, 2013, INT J CARDIOL, V166, P453, DOI 10.1016/j.ijcard.2011.10.125; Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272-6386(03)00111-2; FRISHMAN WH, 1992, AM HEART J, V124, P1026, DOI 10.1016/0002-8703(92)90987-7; Gault PM, 2005, ANN CLIN BIOCHEM, V42, P51, DOI 10.1258/0004563053026862; Ghorbel I, 2015, FOOD FUNCT, V6, P3098, DOI [10.1039/c5fo00342c, 10.1039/C5FO00342C]; Giamouzis G, 2008, AM J CARDIOL, V101, P343, DOI 10.1016/j.amjcard.2007.08.039; Gura KM, 2014, CURR OPIN CLIN NUTR, V17, P551, DOI 10.1097/MCO.0000000000000091; Gura KM, 2010, NUTRITION, V26, P585, DOI 10.1016/j.nut.2009.10.015; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P89, DOI 10.1161/01.CIR.59.1.89; Jaffe JA, 2005, AM J KIDNEY DIS, V46, P316, DOI 10.1053/j.ajkd.2005.04.020; Kearney MT, 2004, HEART, V90, P1137, DOI 10.1136/hrt.2003.021733; KONO T, 1992, JPN CIRC J, V56, P359, DOI 10.1253/jcj.56.359; Liou KY, 2016, SCI REP-UK, V6, DOI 10.1038/srep38458; Mihl C, 2008, NETH HEART J, V16, P129, DOI 10.1007/BF03086131; Morena Marion, 2005, Hemodial Int, V9, P37, DOI 10.1111/j.1492-7535.2005.01116.x; Murakami K, 2004, J CELL BIOCHEM, V93, P1267, DOI 10.1002/jcb.20261; MURPHY ML, 1985, INVEST RADIOL, V20, P21, DOI 10.1097/00004424-198501000-00005; NAKAMORI N, 1991, INVEST RADIOL, V26, P546, DOI 10.1097/00004424-199106000-00008; Neophytou AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156613; Ogata H, 2017, CLIN EXP NEPHROL, V21, P797, DOI 10.1007/s10157-017-1380-2; Okute Y, 2017, J ATHEROSCLER THROMB, V24, P412, DOI 10.5551/jat.36426; Philbin EF, 1998, ARCH INTERN MED, V158, P501, DOI 10.1001/archinte.158.5.501; Rayner BL, 2004, AM J HYPERTENS, V17, P507, DOI 10.1016/j.amjhyper.2004.02.012; Reinke CM, 2003, DRUG SAFETY, V26, P1011, DOI 10.2165/00002018-200326140-00003; Rob PM, 2001, CNS DRUGS, V15, P691, DOI 10.2165/00023210-200115090-00003; SALUSKY IB, 1991, NEW ENGL J MED, V324, P527, DOI 10.1056/NEJM199102213240804; Tsai MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128968; Yen TH, 2009, AM J MED SCI, V337, P421, DOI 10.1097/MAJ.0b013e31819bbec1; Yotsueda R, 2017, AM J KIDNEY DIS, V70, P84, DOI 10.1053/j.ajkd.2016.11.026	40	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2017	12	12							e0190008	10.1371/journal.pone.0190008	http://dx.doi.org/10.1371/journal.pone.0190008			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7SY	29261793	gold, Green Published, Green Submitted			2023-01-03	WOS:000418564200082
J	Mitra, S; Schiller, D; Anderson, C; Gamboni, F; D'Alessandro, A; Kelher, M; Silliman, CC; Banerjee, A; Jones, KL				Mitra, Sanchayita; Schiller, Daran; Anderson, Cameron; Gamboni, Fabia; D'Alessandro, Angelo; Kelher, Margeurite; Silliman, Christopher C.; Banerjee, Anirban; Jones, Kenneth L.			Hypertonic saline attenuates the cytokine-induced pro-inflammatory signature in primary human lung epithelia	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INNATE IMMUNE-RESPONSE; MULTIPLE-ORGAN FAILURE; HEMORRHAGIC-SHOCK; NEUTROPHIL ACTIVATION; PREVENTS INFLAMMATION; AIRWAY INFLAMMATION; RESUSCITATION; INJURY; CELLS	Trauma/hemorrhagic shock is a complex physiological phenomenon that leads to dysregulation of many molecular pathways. For over a decade, hypertonic saline (HTS) has been used as an alternative resuscitation fluid in the setting of trauma/hemorrhagic shock. In addition to restoring circulating volume within the vascular space, studies have shown a positive immunomodulatory effect of HTS. Targeted studies have shown that HTS affects the transcription of several pro-inflammatory cytokines by inhibiting the NF-kappa B-I kappa B pathway in model cell lines and rats. However, few studies have been undertaken to assess the unbiased effects of HTS on the whole transcriptome. This study was designed to interrogate the global transcriptional responses induced by HTS and provides insight into the underlying molecular mechanisms and pathways affected by HTS. In this study, RNA sequencing was employed to explore early changes in transcriptional response, identify key mediators, signaling pathways, and transcriptional modules that are affected by HTS in the presence of a strong inflammatory stimulus. Our results suggest that primary human small airway lung epithelial cells (SAECS) exposed to HTS in the presence and absence of a strong pro-inflammatory stimulus exhibit very distinct effects on cellular response, where HTS is highly effective in attenuating cytokine-induced pro-inflammatory responses via mechanisms that involve transcriptional regulation of inflammation which is cell type and stimulus specific. HTS is a highly effective anti-inflammatory agent that inhibits the chemotaxis of leucocytes towards a pro-inflammatory gradient and may attenuate the progression of both the innate and adaptive immune response.	[Mitra, Sanchayita; Schiller, Daran; Anderson, Cameron; Gamboni, Fabia; D'Alessandro, Angelo; Kelher, Margeurite; Silliman, Christopher C.; Banerjee, Anirban] Univ Colorado Denver, Sch Med, Trauma Res Ctr, Dept Surg, Aurora, CO USA; [D'Alessandro, Angelo] Univ Colorado Denver, Sch Med, Dept Biochem & Mol Genet, Aurora, CO USA; [Kelher, Margeurite; Silliman, Christopher C.] Bonfils Blood Ctr, Denver, CO USA; [Jones, Kenneth L.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Jones, KL (corresponding author), Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO 80045 USA.	Kenneth.L.Jones@ucdenver.edu	Jones, Kenneth/GXF-4945-2022; D'Alessandro, Angelo/AAA-4695-2019	D'Alessandro, Angelo/0000-0002-2258-6490	National Institute of General Medical Sciences; National Institutes of Health [P50GM049222]; Cancer Center Support Grant [P30CA046934]; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Institute of General Medical Sciences and National Institutes of Health under award no. P50GM049222.; We want to thank the Protein Production, Monoclonal Antibody and Tissue Culture, Genomics, and Bioinformatics Shared Resources of the University of Colorado Cancer Center (supported by the Cancer Center Support Grant, P30CA046934) for their help with this project. The authors are grateful to Ms. Victoria Bress (Research Manager Trauma Res. Ctr) for administrative help and support.	Albaiceta GM, 2010, AM J RESP CELL MOL, V43, P555, DOI 10.1165/rcmb.2009-0034OC; Angle N, 1998, SHOCK, V9, P164, DOI 10.1097/00024382-199803000-00002; Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Baird NL, 2014, J VIROL, V88, P5877, DOI 10.1128/JVI.00476-14; Bakowitz M, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-54; Banerjee A, 2013, SHOCK, V39, P366, DOI 10.1097/SHK.0b013e3182894016; Bastarache JA, 2011, EXP LUNG RES, V37, P509, DOI 10.3109/01902148.2011.605512; Brunner PM, 2015, EXP DERMATOL, V24, P522, DOI 10.1111/exd.12709; Chan JK, 2012, J CLIN INVEST, V122, P2711, DOI 10.1172/JCI62423; Ciesla DJ, 2005, SURGERY, V138, P749, DOI 10.1016/j.surg.2005.07.020; Cuschieri J, 2002, J IMMUNOL, V168, P1389, DOI 10.4049/jimmunol.168.3.1389; Davidson G, 2010, TRENDS CELL BIOL, V20, P453, DOI 10.1016/j.tcb.2010.05.002; Deitch EA, 2003, SHOCK, V19, P328, DOI 10.1097/00024382-200304000-00006; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Eklund KK, 2012, CRIT REV IMMUNOL, V32, P335; Gamboni F, 2016, J PROTEOME RES, V15, P3813, DOI 10.1021/acs.jproteome.6b00602; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Groppera MA, 2008, CURR OPIN CRIT CARE, V14, P11, DOI 10.1097/MCC.0b013e3282f417a0; Hastbacka J, 2014, ANESTH ANALG, V118, P790, DOI 10.1213/ANE.0000000000000120; Henderson HH, 2016, J VIROL, V90, P1231, DOI 10.1128/JVI.02617-15; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hsu AT, 2015, SHOCK, V44, P128, DOI 10.1097/SHK.0000000000000386; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Junger WG, 1997, SHOCK, V8, P235, DOI 10.1097/00024382-199710000-00001; Kelly EAB, 2009, J IMMUNOL, V182, P1404, DOI 10.4049/jimmunol.182.3.1404; Knight D, 2001, PULM PHARMACOL THER, V14, P169, DOI 10.1006/pupt.2001.0282; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Kudo M, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-19; Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63; Manson J, 2012, BRIT J SURG, V99, P12, DOI 10.1002/bjs.7717; Matthay MA, J CLIN INVESTIGATION, V122, P2731; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Murphy GEJ, 2010, ANN RHEUM DIS, V69, P43, DOI 10.1136/ard.2009.120113; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Nydam TL, 2009, SHOCK, V31, P466, DOI 10.1097/SHK.0b013e31818ec47d; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Powers KA, 2005, SURGERY, V137, P66, DOI 10.1016/j.surg.2004.05.051; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Reeves Emer P, 2015, World J Crit Care Med, V4, P179, DOI 10.5492/wjccm.v4.i3.179; Reeves EP, 2011, AM J RESP CRIT CARE, V183, P1517, DOI 10.1164/rccm.201101-0072OC; Richie JP, 2015, J UROLOGY, V194, P706, DOI 10.1016/j.juro.2015.06.010; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Sauaia A, 2014, J TRAUMA ACUTE CARE, V76, P582, DOI 10.1097/TA.0000000000000147; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Silva MT, 2010, J LEUKOCYTE BIOL, V87, P805, DOI 10.1189/jlb.1109767; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Su R, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-121; Sun Y, 2013, CYTOKINE, V63, P303, DOI 10.1016/j.cyto.2013.06.256; Teng MWL, 2015, NAT MED, V21, P719, DOI 10.1038/nm.3895; Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Tohyama M, 2007, INT IMMUNOL, V19, P1095, DOI 10.1093/intimm/dxm083; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wang Z, 2015, ONCOL REP, V33, P1097, DOI 10.3892/or.2014.3704; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Weigand Markus A, 2004, Best Pract Res Clin Anaesthesiol, V18, P455, DOI 10.1016/j.bpa.2003.12.005; Wohlauer M, 2012, CRIT CARE MED, V40, P2647, DOI 10.1097/CCM.0b013e3182592006; Wright FL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114129; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057	65	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2017	12	12							e0189536	10.1371/journal.pone.0189536	http://dx.doi.org/10.1371/journal.pone.0189536			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ5HM	29253007	Green Published, Green Submitted, gold			2023-01-03	WOS:000418389500037
J	Warfel, JD; Vandanmagsar, B; Wicks, SE; Zhang, JY; Noland, RC; Mynatt, RL				Warfel, Jaycob D.; Vandanmagsar, Bolormaa; Wicks, Shawna E.; Zhang, Jingying; Noland, Robert C.; Mynatt, Randall L.			A low fat diet ameliorates pathology but retains beneficial effects associated with CPT1b knockout in skeletal muscle	PLOS ONE			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; INSULIN-RESISTANCE; ACID OXIDATION; ADIPOSE-TISSUE; EXPRESSION; MICE; INHIBITION; ADIPOCYTES; ISOFORM; GROWTH	Inhibiting fatty acid oxidation is one approach to lowering glucose levels in diabetes. Skeletal muscle specific Carnitine Palmitoyltransferase 1b knockout mice (Cpt1b m(-/-)) comprise a model of impaired fat oxidation; and have decreased fat mass and enhanced glucose disposal and muscle oxidative capacity compared to controls. However, unfavorable effects occur relative to controls when Cpt1b m(-/-) mice are fed a 25% fat diet, including decreased activity and fat free mass and increased intramuscular lipid and serum myoglobin. In this study we explore if a low fat, high carbohydrate diet can ablate the unfavorable effects while maintaining the favorable phenotype in Cpt1b m-/- mice. Mice were fed either 10% fat (low fat) or 25% fat (chow) diet. Body composition was measured biweekly and indirect calorimetry was performed. Low fat diet abolishes the decreased activity, fat, and fat free mass seen in Cpt1b m(-/-) mice fed chow diet. Low fat diet also reduces serum myoglobin levels in Cpt1b m(-/-) mice and diminishes differences in IGF- 1 seen between Cpt1b m(-/-) mice and control mice fed chow diet. Glucose tolerance tests reveal that glucose clearance is improved in Cpt1b m(-/-) mice relative to controls regardless of diet, and serum analysis shows increased levels of muscle derived FGF21. Electron microscopic analyses and measurements of mRNA transcripts show increased intramuscular lipids, FGF21, mitochondrial and oxidative capacity markers regardless of diet. The favorable metabolic phenotype of Cpt1b m-/- mice therefore remains consistent regardless of diet; and a combination of a low fat diet and pharmacological inhibition of CPT1b may offer remedies to reduce blood glucose.	[Warfel, Jaycob D.; Vandanmagsar, Bolormaa; Wicks, Shawna E.; Zhang, Jingying; Noland, Robert C.; Mynatt, Randall L.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Mynatt, RL (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.	mynattrl@pbrc.edu	Mynatt, Randall L/N-1980-2017; Warfel, Jaycob/R-4495-2018; zhang, jingying R/R-4262-2018; Vandanmagsar, Bolormaa/R-4565-2018; Noland, Robert/N-1982-2017	Mynatt, Randall L/0000-0003-4399-0019; Warfel, Jaycob/0000-0001-7501-0631; Noland, Robert/0000-0001-5543-3450	NIDDK [T32DK-6458413, R01DK-089641]; COBRE (National Institute of General Medical Sciences Grant) [8P2OGM-103528]; Nutrition Obesity Research Centers (National Institute of Diabetes and Digestive and Kidney Diseases Grant) [2P30-DK-072476-11A1]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476, T32DK064584] Funding Source: NIH RePORTER	NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); COBRE (National Institute of General Medical Sciences Grant); Nutrition Obesity Research Centers (National Institute of Diabetes and Digestive and Kidney Diseases Grant); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Support for this work was provided by NIDDK Fellowship T32DK-6458413 to J.D.W., and grant R01DK-089641 to R.L.M. This work used the Pennington Biomedical Research Center facilities of the Transgenic, Comparative Biology, and Genomics Cores supported in part by COBRE (National Institute of General Medical Sciences Grant 8P2OGM-103528) and the Nutrition Obesity Research Centers (National Institute of Diabetes and Digestive and Kidney Diseases Grant 2P30-DK-072476-11A1).	Albarado DC, 2004, ENDOCRINOLOGY, V145, P243, DOI 10.1210/en.2003-0452; Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F; Brown NF, 1997, BIOCHEM J, V327, P225, DOI 10.1042/bj3270225; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; Haynie KR, 2014, DIABETES OBES METAB, V16, P757, DOI 10.1111/dom.12248; Keung W, 2013, DIABETES, V62, P711, DOI 10.2337/db12-0259; Kim T, 2014, J DIABETES METAB, V5; Kim T, 2014, J DIABETES METAB, V5, DOI [10.4172/2155-6156.1000361, 10.4172/2155-6156.1000401]; Koteish A, 2001, SEMIN LIVER DIS, V21, P89, DOI 10.1055/s-2001-12932; Kruger C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041709; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Saudubray JM, 1999, J INHERIT METAB DIS, V22, P488; STEPHENS TW, 1985, BIOCHEM J, V227, P651, DOI 10.1042/bj2270651; STRAUS DS, 1991, J NUTR, V121, P1279, DOI 10.1093/jn/121.8.1279; STRAUS DS, 1994, FASEB J, V8, P6, DOI 10.1096/fasebj.8.1.8299891; Timmers S, 2012, P NATL ACAD SCI USA, V109, P11711, DOI 10.1073/pnas.1206868109; Vandanmagsar B, 2016, CELL REP, V15, P1686, DOI 10.1016/j.celrep.2016.04.057; Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279; Warfel JD, 2017, AM J PHYSIOL-REG I, V312, pR816, DOI 10.1152/ajpregu.00520.2016; Wicks SE, 2015, P NATL ACAD SCI USA, V112, pE3300, DOI 10.1073/pnas.1418560112; Wicks SE, 2011, BEHAV BRAIN RES, V225, P415, DOI 10.1016/j.bbr.2011.07.051	22	7	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2017	12	12							e0188850	10.1371/journal.pone.0188850	http://dx.doi.org/10.1371/journal.pone.0188850			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP8OT	29240830	Green Published, gold, Green Submitted			2023-01-03	WOS:000417905600012
J	Hueber, S; Kuehlein, T; Gerlach, R; Tauscher, M; Schedlbauer, A				Hueber, Susann; Kuehlein, Thomas; Gerlach, Roman; Tauscher, Martin; Schedlbauer, Angela			"What they see is what you get": Prescribing antibiotics for respiratory tract infections in primary care: Do high prescribers diagnose differently? An analysis of German routine data	PLOS ONE			English	Article							GENERAL-PRACTITIONERS; EUROPE; INDEX; RATES	Background Characteristics of high and low prescribers of antibiotics in German primary care were analysed using population data. We aimed to evaluate differences in prescribing rates and factors being associated with high prescribing, and whether high prescribers made the diagnosis of perceived bacterial infections more often. Methods Routine data were provided by the Bavarian Association of Statutory Health Insurance Physicians. Routine data are delivered by primary care practices on a quarterly basis. We analysed data from 2011 and 2012. Patients older than 15 years with respiratory tract infections consulting a primary care physician were selected (6.647 primary care practices). Patient and physician characteristics associated with high prescribing were identified using stepwise logistic regression. Results Mean prescribing rate of antibiotics was 24.9%. Prescribing rate for high prescribers was 43.5% compared to 8.5% for low prescribers. High prescribers made the diagnosis of perceived bacterial infections more often (Mhigh = 64.5%, Mlow = 45.2%). In the adjusted regression model, perceived bacterial infections were strongly associated with high prescribing (OR = 13.9, 95% CI [10.2, 18.8]). Treating patients with comorbidities was associated with lower prescribing of antibiotics (OR = 0.6, 95% CI [0.4, 0.8]). High prescribers had a higher practice volume, a higher degree of prescribing dominance, and were situated more often in deprived areas and in rural settings. Interpretation Compared to findings of studies in other European countries, prescribing rates were low. There was a considerable difference between prescribing rates of high and low prescribers. Diagnostic labelling was the best predictor for high prescribing. Current guidelines recommend considering antibiotic treatment for patients with co-morbidities. In our study, treating a large number of high-risk patients was not associated with high prescribing.	[Hueber, Susann; Kuehlein, Thomas; Schedlbauer, Angela] Univ Klinikum Erlangen, Erlangen, Germany; [Gerlach, Roman; Tauscher, Martin] Kassenarztl Vereinigung Bayern, Munich, Germany	University of Erlangen Nuremberg	Hueber, S (corresponding author), Univ Klinikum Erlangen, Erlangen, Germany.	susann.hueber@uk-erlangen.de	Hueber, Susann/U-9754-2018	Hueber, Susann/0000-0003-0844-0919				Adriaenssens N, 2011, J ANTIMICROB CHEMOTH, V66, P3, DOI 10.1093/jac/dkr453; [Anonymous], 2005, ICPC 2 R INT CLASSIF; Aspinall SL, 2009, AM J EMERG MED, V27, P544, DOI 10.1016/j.ajem.2008.04.015; Barlam TF, 2015, INFECT CONT HOSP EP, V36, P153, DOI 10.1017/ice.2014.21; Blommaert A, 2014, J ANTIMICROB CHEMOTH, V69, P535, DOI 10.1093/jac/dkt377; Cadieux G, 2007, CAN MED ASSOC J, V177, P877, DOI 10.1503/cmaj.070151; Coenen Samuel, 2002, BMC Fam Pract, V3, P16, DOI 10.1186/1471-2296-3-16; Cohen J., 2013, STAT POWER ANAL BEHA; De Sutter AI, 2001, FAM PRACT, V18, P209, DOI 10.1093/fampra/18.2.209; Dekker ARJ, 2015, FAM PRACT, V32, P401, DOI 10.1093/fampra/cmv019; Deschepper R, 2002, PATIENT EDUC COUNS, V48, P161, DOI 10.1016/S0738-3991(02)00017-4; Duijn HJ, 2007, BMC FAMILY PRACTICE, V8, P1; Fiegen H, 2002, Z ALLG MED, V81, P372; GERRITY MS, 1990, MED CARE, V28, P724, DOI 10.1097/00005650-199008000-00005; Gerrity MS, 1995, MOTIV EMOTION, V19, P175, DOI 10.1007/BF02250510; Gjelstad S, 2011, J ANTIMICROB CHEMOTH, V66, P2425, DOI 10.1093/jac/dkr295; Gjelstad S, 2009, SCAND J PRIM HEALTH, V27, P208, DOI 10.3109/02813430903438718; Grover ML, 2012, J FAM PRACTICE, V61, P330; Gulliford MC, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006245; Gulliford MC, 2014, ANN FAM MED, V12, P344, DOI 10.1370/afm.1659; Hering R, 2014, ENTWICKLUNG AMBULANT; Howie J G, 1972, J R Coll Gen Pract, V22, P310; Hutchinson JM, 2001, CAN FAM PHYSICIAN, V47, P1217; Hutchinson JM, 1999, CAN MED ASSOC J, V160, P1013; Koller D, 2013, INFECTION, V41, P121, DOI 10.1007/s15010-012-0302-1; Linder JA, 2003, CLIN THER, V25, P2419, DOI 10.1016/S0149-2918(03)80284-9; Maier W, 2012, GESUNDHEITSWESEN, V74, P416, DOI 10.1055/s-0031-1280846; Mainous AG, 1998, ARCH PEDIAT ADOL MED, V152, P349; Mazzaglia G, 2003, EUR J CLIN PHARMACOL, V59, P651, DOI 10.1007/s00228-003-0669-0; NICE CfCPa, 2008, RESP TRACT INF ANT P; Schulz M, 2014, ANTIBIOTIKAVERORDU 2; Steffensen FH, 1997, SCAND J INFECT DIS, V29, P409, DOI 10.3109/00365549709011839; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Tell D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008096; Velasco E, 2011, Infection, V39, P289, DOI 10.1007/s15010-011-0137-1; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; Wang KY, 2009, BRIT J GEN PRACT, V59, P724, DOI 10.3399/bjgp09X472593	37	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2017	12	12							e0188521	10.1371/journal.pone.0188521	http://dx.doi.org/10.1371/journal.pone.0188521			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP2SV	29220399	Green Published, gold			2023-01-03	WOS:000417469900010
J	Hsu, SD; Lee, SY; Lin, KT; Lin, CS; Chien, WC; Chen, CJ; Chung, CH; Chang, WK				Hsu, Sheng-Der; Lee, Shih-Yu; Lin, Kuen-Tze; Lin, Chun-Shu; Chien, Wu-Chien; Chen, Cheng-Jueng; Chung, Chi-Hsiang; Chang, Wei-Kuo			Risk of infertility following pelvic angiographic embolization in female patients with pelvic fractures: A nationwide population-based cohort study in Taiwan	PLOS ONE			English	Article							INTERNAL ILIAC ARTERY; POSTPARTUM HEMORRHAGE; GLUTEAL NECROSIS; TRAUMA; PREGNANCY; FERTILITY; CANCER	Pelvic angiographic embolization is an effective procedure to provide haemostasis in patients with pelvic fractures. However, management with repeated follow-up radiographs may result in infertility. The study aimed to evaluate the risk of infertility following pelvic fracture treated with pelvic angiographic embolization in female patients. We used data from the National Health Insurance Research Database (NHIRD) provided by the Bureau of National Health Insurance of the Department of Health in Taiwan from the period of 1997 +/- 2010. A total of 36 and 18,029 patients were included in the case and control cohorts, respectively. The risk estimations for the case and control cohorts were compared using a Cox's proportional hazards regression model. The significance level was set at < 0.05. After adjusting for possible confounding factors, the incidence of infertility in the case cohort was nearly 30.7-fold higher than that in the control cohort (adjust hazard ratio [HR] = 30.7, 95% confidence interval [CI] = 10.643 +/- 70.109). Patients between 15 +/- 35 years of age had a much higher incidence of infertility in the case cohort than in the control cohort (adjusted HR = 49.9, 95% CI = 15.177 +/- 64.099). Taken together, pelvic fractures in female patients treated with arter-ioembolization for haemostasis might be associated with a higher risk of infertility in Taiwan. Physicians should be aware of the link and inform patients of this risk prior to arterioembolization.	[Hsu, Sheng-Der; Chen, Cheng-Jueng] Natl Def Med Ctr, Triserv Gen Hosp, Dept Surg, Div Traumat & Gen Surg, Taipei, Taiwan; [Lee, Shih-Yu] Natl Def Med Ctr, Grad Inst Aerosp & Undersea Med, Taipei, Taiwan; [Lin, Kuen-Tze; Lin, Chun-Shu] Natl Def Med Ctr, Triserv Gen Hosp, Dept Radiat Oncol, Taipei, Taiwan; [Chien, Wu-Chien; Chung, Chi-Hsiang] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Chien, Wu-Chien; Chung, Chi-Hsiang] Natl Def Med Ctr, Triserv Gen Hosp, Dept Med Res, Taipei, Taiwan; [Chang, Wei-Kuo] Natl Def Med Ctr, Triserv Gen Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital	Chang, WK (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan.	weikuohome@hotmail.com	Chung, Chi-Hsiang/AAY-3386-2021	Hsu, Sheng-Der/0000-0001-9698-8954; Lee, Shih-Yu/0000-0002-4713-6410; Chang, Wei-Kuo/0000-0002-5738-2797				Amer Soc Reprod Med, 2008, FERTIL STERIL, V90, pS60, DOI 10.1016/j.fertnstert.2008.08.065; [Anonymous], 1992, World Health Organ Tech Rep Ser, V820, P1; Auerbach AD, 2012, J ORTHOP TRAUMA, V26, P290, DOI 10.1097/BOT.0b013e31821f9574; Barton SE, 2013, LANCET ONCOL, V14, P873, DOI 10.1016/S1470-2045(13)70251-1; Chauleur C, 2008, HUM REPROD, V23, P1553, DOI 10.1093/humrep/den122; Chiang TL, 1997, HEALTH POLICY, V39, P225, DOI 10.1016/S0168-8510(96)00877-9; COLLINS JA, 1992, INT J GYNECOL OBSTET, V39, P267, DOI 10.1016/0020-7292(92)90257-J; Copeland CE, 1997, J ORTHOP TRAUMA, V11, P73, DOI 10.1097/00005131-199702000-00001; Croce MA, 2007, J AM COLL SURGEONS, V204, P935, DOI 10.1016/j.jamcollsurg.2007.01.059; Giannoudis PV, 2007, J TRAUMA, V63, P875, DOI 10.1097/01.ta.0000242259.67486.15; HARE WSC, 1983, RADIOLOGY, V146, P47, DOI 10.1148/radiology.146.1.6849068; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Huang WY, 2012, RADIOTHER ONCOL, V104, P338, DOI 10.1016/j.radonc.2012.08.015; Lin KT, 2015, HEAD NECK-J SCI SPEC, V37, P413, DOI 10.1002/hed.23617; Liu FX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001462; Salomon LJ, 2003, HUM REPROD, V18, P849, DOI 10.1093/humrep/deg168; Suzuki T, 2005, ARCH ORTHOP TRAUM SU, V125, P448, DOI 10.1007/s00402-005-0827-1; Takahira N, 2001, INJURY, V32, P27, DOI 10.1016/S0020-1383(00)00098-X; THONNEAU P, 1992, HUM REPROD, V7, P55, DOI 10.1093/oxfordjournals.humrep.a137557; THONNEAU P, 1993, INT J FERTIL, V38, P37; van Vugt AB, 2006, J BONE JOINT SURG BR, V88B, P427, DOI 10.1302/0301-620x.88b4.16693	21	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2017	12	12							e0174733	10.1371/journal.pone.0174733	http://dx.doi.org/10.1371/journal.pone.0174733			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO5CX	29194450	gold, Green Published, Green Submitted			2023-01-03	WOS:000416867800001
J	Rogal, SS; Udawatta, V; Akpan, I; Moghe, A; Chidi, A; Shetty, A; Szigethy, E; Bielefeldt, K; DiMartini, A				Rogal, Shari S.; Udawatta, Viyan; Akpan, Imo; Moghe, Akshata; Chidi, Alexis; Shetty, Amit; Szigethy, Eva; Bielefeldt, Klaus; DiMartini, Andrea			Risk factors for hospitalizations among patients with cirrhosis: A prospective cohort study	PLOS ONE			English	Article							MCGILL PAIN QUESTIONNAIRE; HEALTH-CARE; OPIOID USE; DEPRESSION; FIBROMYALGIA; INFLAMMATION; MORTALITY; QUALITY; ANXIETY; SLEEP	This study was designed to assess unique baseline factors associated with subsequent hospitalizations in a cohort of outpatients with cirrhosis. A cohort of 193 patients with cirrhosis was recruited from an outpatient liver disease clinic at a single, tertiary medical center. Comorbidities, prescription medications, liver disease symptoms and severity, and psychiatric and pain symptoms were assessed at baseline using validated instruments. Inflammatory markers were measured using standardized Luminex assays. Subsequent hospitalizations and the primary admission diagnoses were collected via chart review. Multivariable models were used to evaluate which baseline factors were associated with time to hospitalization and number of hospitalizations. The cohort consisted of 193 outpatients, with an average age of 58 +/- 9 and model for end-stage liver disease (MELD) score of 12 +/- 5. Over follow-up, 57 (30%) were admitted to the hospital. The factors associated with time to hospitalization included the severity of liver disease (HR/MELD point: 1.10, 95% CI: 1.04,1.16), ascites (HR: 1.90, 95% CI: 1.01, 3.58), baseline symptoms of depression (HR: 2.34, 95% CI: 1.28,4.25), sleep medications (HR: 1.81, 95% CI: 1.01, 3.22) and IL-6 (HR: 1.43, 95% CI: 1.10, 1.84). Similarly the number admissions was significantly associated with MELD (IIR: 1.08, CI: 1.07,1.09), ascites (IIR: 4.15, CI: 3.89, 4.43), depressive symptoms (IIR: 1.54, CI: 1.44,1.64), IL-6 (IIR: 1.26, CI: 1.23,1.30), sleep medications (IIR: 2.74, CI: 2.57, 2.93), and widespread pain (IIR: 1.61, CI: 1.50, 1.73). In conclusion, consistent with prior studies, MELD and ascites were associated with subsequent hospitalization. However, this study also identified other factors associated with hospitalization including inflammation, depressive symptoms, sleep medication use, and pain.	[Rogal, Shari S.; DiMartini, Andrea] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; [Rogal, Shari S.; Chidi, Alexis] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA; [Rogal, Shari S.; Akpan, Imo; Bielefeldt, Klaus] Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA; [Udawatta, Viyan; Moghe, Akshata; Chidi, Alexis] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA; [Shetty, Amit] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Szigethy, Eva; DiMartini, Andrea] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rogal, SS (corresponding author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.; Rogal, SS (corresponding author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15213 USA.; Rogal, SS (corresponding author), Univ Pittsburgh, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15260 USA.	rogalss@upmc.edu	Moghe, Akshata/V-4963-2019; Moghe, Akshata/V-4632-2019	Rogal, Shari/0000-0001-8184-1546	National Institutes of Health [DK063922]; University of Pittsburgh	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pittsburgh(University of Pittsburgh)	The primary data were collected while Shari S. Rogal was a T-32 fellow on the National Institutes of Health DK063922. The funds for the study were provided by the University of Pittsburgh, Thomas E. Starzl Young Investigator Award to Shari S. Rogal. Study sponsors had no involvement in the study design; in collection, analysis, interpretation of data; in the writing of the report; or in the decision to submit the manuscript for publication.	Allegretti JR, 2015, INFLAMM BOWEL DIS, V21, P2583, DOI 10.1097/MIB.0000000000000537; Andersen NLT, 2013, PSYCHOSOMATICS, V54, P132, DOI 10.1016/j.psym.2012.07.007; [Anonymous], [No title captured]; [Anonymous], J IMMUNOL METHODS; Berman K, 2011, CLIN GASTROENTEROL H, V9, P254, DOI 10.1016/j.cgh.2010.10.035; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Buysse D J, 1989, Psychiatry Res, V28, P193; Cervoni JP, 2012, J HEPATOL, V56, P1299, DOI 10.1016/j.jhep.2011.12.030; CHAMPANERIA S, 1989, BIOCHEM CELL BIOL, V67, P128, DOI 10.1139/o89-020; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chojnacki C, 2012, GASTROENT RES PRACT, V2012; Davies S, 2013, HEALTH SERV RES, V48, P1978, DOI 10.1111/1475-6773.12075; DiMartini A, 2011, CLIN LIVER DIS, V15, P727, DOI 10.1016/j.cld.2011.08.002; Dirchwolf M, 2015, WORLD J HEPATOL, V7, P1974, DOI 10.4254/wjh.v7.i16.1974; Fagan KJ, 2014, INTERN MED J, V44, P865, DOI 10.1111/imj.12491; Freedland KE, 2016, CLIN CARDIOL, V39, P257, DOI 10.1002/clc.22520; Ganesh S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055140; Grandner Michael A, 2006, Sleep Biol Rhythms, V4, P129, DOI 10.1111/j.1479-8425.2006.00207.x; Guthrie EA, 2016, J PSYCHOSOM RES, V82, P54, DOI 10.1016/j.jpsychores.2014.10.002; Ho SB, 2015, CLIN GASTROENTEROL H; Kanwal F, 2014, GASTROENTEROLOGY, V147, P1204, DOI 10.1053/j.gastro.2014.10.029; Knudsen KB, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2862-5; Lazzarotto Cesar, 2013, Ann Hepatol, V12, P599; Lee FY, 1996, SCAND J GASTROENTERO, V31, P500, DOI 10.3109/00365529609006772; Lotrich FE, 2011, J RHEUMATOL, V38, P48, DOI 10.3899/jrheum.110903; Martinez-Esparza M, 2015, WORLD J GASTROENTERO, V21, P11522, DOI 10.3748/wjg.v21.i41.11522; McBeth J, 2012, NAT REV RHEUMATOL, V8, P108, DOI 10.1038/nrrheum.2011.216; Melzack R, 2005, ANESTHESIOLOGY, V103, P199, DOI 10.1097/00000542-200507000-00028; MELZACK R, 1971, ANESTHESIOLOGY, V34, P50; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Moise N, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003767; Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009; Mosher HJ, 2014, J HOSP MED, V9, P82, DOI 10.1002/jhm.2113; Penn CA, 2016, OBSTET GYNECOL; R Core Team, 2012, R LANG ENV STAT COMP; Rogal SS, 2015, CLIN GASTROENTEROL H, V13, P1009, DOI 10.1016/j.cgh.2014.10.029; Rogal SS, 2013, LIVER INT, V33, P1497, DOI 10.1111/liv.12215; Rogal SS, 2013, DIGEST DIS SCI, V58, P2976, DOI 10.1007/s10620-013-2638-5; Rowan PJ, 2004, J CLIN GASTROENTEROL, V38, P530, DOI 10.1097/01.mcg.0000123203.36471.70; Spahr L, 2007, AM J GASTROENTEROL, V102, P744, DOI 10.1111/j.1572-0241.2006.01028.x; STEINDL PE, 1995, ANN INTERN MED, V123, P274, DOI 10.7326/0003-4819-123-4-199508150-00005; Tsai CF, 2016, ALIMENT PHARM THER; Venables W.N., 2002, MODERN APPL STAT S; Volk ML, 2012, AM J GASTROENTEROL, V107, P247, DOI 10.1038/ajg.2011.314; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	47	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2017	12	11							e0187176	10.1371/journal.pone.0187176	http://dx.doi.org/10.1371/journal.pone.0187176			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN0DI	29149171	Green Published, Green Submitted, gold			2023-01-03	WOS:000415646100007
J	Shackelford, SA; del Junco, DJ; Powell-Dunford, N; Mazuchowski, EL; Howard, JT; Kotwal, RS; Gurney, J; Butler, FK; Gross, K; Stockinger, ZT				Shackelford, Stacy A.; del Junco, Deborah J.; Powell-Dunford, Nicole; Mazuchowski, Edward L.; Howard, Jeffrey T.; Kotwal, Russ S.; Gurney, Jennifer; Butler, Frank K., Jr.; Gross, Kirby; Stockinger, Zsolt T.			Association of Prehospital Blood Product Transfusion During Medical Evacuation of Combat Casualties in Afghanistan With Acute and 30-Day Survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMA; MORTALITY; BIAS; RESUSCITATION; RATIO; CARE; MANAGEMENT; DEATHS; IMPACT; INJURY	IMPORTANCE Prehospital blood product transfusion in trauma care remains controversial due to poor-quality evidence and cost. Sequential expansion of blood transfusion capability after 2012 to deployed military medical evacuation (MEDEVAC) units enabled a concurrent cohort study to focus on the timing as well as the location of the initial transfusion. OBJECTIVE To examine the association of prehospital transfusion and time to initial transfusion with injury survival. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of US military combat casualties in Afghanistan between April 1, 2012, and August 7, 2015. Eligible patients were rescued alive by MEDEVAC from point of injury with either (1) a traumatic limb amputation at or above the knee or elbow or (2) shock defined as a systolic blood pressure of less than 90 mm Hg or a heart rate greater than 120 beats per minute. EXPOSURES Initiation of prehospital transfusion and time from MEDEVAC rescue to first transfusion, regardless of location (ie, prior to or during hospitalization). Transfusion recipients were compared with nonrecipients (unexposed) for whom transfusion was delayed or not given. MAIN OUTCOMES AND MEASURES Mortality at 24 hours and 30 days after MEDEVAC rescue were coprimary outcomes. To balance injury severity, nonrecipients of prehospital transfusion were frequency matched to recipients by mechanism of injury, prehospital shock, severity of limb amputation, head injury, and torso hemorrhage. Cox regression was stratified by matched groups and also adjusted for age, injury year, transport team, tourniquet use, and time to MEDEVAC rescue. RESULTS Of 502 patients (median age, 25 years [interquartile range, 22 to 29 years]; 98% male), 3 of 55 prehospital transfusion recipients (5%) and 85 of 447 nonrecipients (19%) died within 24 hours of MEDEVAC rescue (between-group difference, -14%[95% CI, -21% to -6%]; P =.01). By day 30, 6 recipients (11%) and 102 nonrecipients (23%) died (between-group difference, -12%[95% CI, -21% to -2%]; P =.04). For the 386 patients without missing covariate data among the 400 patients within the matched groups, the adjusted hazard ratio for mortality associated with prehospital transfusion was 0.26 (95% CI, 0.08 to 0.84, P = .02) over 24 hours (3 deaths among 54 recipients vs 67 deaths among 332 matched nonrecipients) and 0.39 (95% CI, 0.16 to 0.92, P = .03) over 30 days (6 vs 76 deaths, respectively). Time to initial transfusion, regardless of location (prehospital or during hospitalization), was associated with reduced 24-hour mortality only up to 15 minutes after MEDEVAC rescue (median, 36 minutes after injury; adjusted hazard ratio, 0.17 [95% CI, 0.04 to 0.73], P = .02; there were 2 deaths among 62 recipients vs 68 deaths among 324 delayed transfusion recipients or nonrecipients). CONCLUSIONS AND RELEVANCE Among medically evacuated US military combat causalities in Afghanistan, blood product transfusion prehospital or within minutes of injury was associated with greater 24-hour and 30-day survival than delayed transfusion or no transfusion. The findings support prehospital transfusion in this setting.	[Shackelford, Stacy A.; del Junco, Deborah J.; Howard, Jeffrey T.; Kotwal, Russ S.; Gurney, Jennifer; Butler, Frank K., Jr.; Stockinger, Zsolt T.] Def Ctr Excellence Trauma, Joint Trauma Syst, 3698 Chambers Pass,Ste B, San Antonio, TX 78234 USA; [del Junco, Deborah J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Powell-Dunford, Nicole] US Army Aeromed Res Lab, Ft Rucker, AL USA; [Mazuchowski, Edward L.] Dover Air Force Base, Armed Forces Med Examiner Syst, Delaware, OH USA; [Gross, Kirby] Army Trauma Training Dept, Miami, FL USA	University of Texas System; University of Texas Health San Antonio; United States Department of Defense; United States Army	Shackelford, SA (corresponding author), Def Ctr Excellence Trauma, Joint Trauma Syst, 3698 Chambers Pass,Ste B, San Antonio, TX 78234 USA.	stacy.a.shackelford.mil@mail.mil	Mazuchowski, Edward/CAA-3217-2022	Gross, Kirby/0000-0002-1390-8865				Apodaca A, 2013, J TRAUMA ACUTE CARE, V75, pS157, DOI 10.1097/TA.0b013e318299da3e; Azzato EM, 2009, BRIT J CANCER, V100, P1806, DOI 10.1038/sj.bjc.6605062; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brewer HF, 1949, BLOOD TRANSFUSION; Butler FK, 2014, PREHOSPITAL TRAUMA L, V8th; Butler FK., 2014, J SPEC OPER MED, V14, P13; Carrick MM, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8901938; Davis JS, 2014, J TRAUMA ACUTE CARE, V77, P213, DOI 10.1097/TA.0000000000000292; del Junco DJ, 2015, INJURY, V46, P775, DOI 10.1016/j.injury.2015.01.043; del Junco DJ, 2013, J TRAUMA ACUTE CARE, V75, pS97, DOI 10.1097/TA.0b013e318298b0a4; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Gomez D, 2009, J TRAUMA, V66, P1218, DOI 10.1097/TA.0b013e31819a04d2; Handley MA, 2011, J AM BOARD FAM MED, V24, P589, DOI 10.3122/jabfm.2011.05.110067; Ho AMH, 2013, ANAESTHESIA, V68, P126, DOI 10.1111/anae.12120; Holcomb JB, 2017, J TRAUMA ACUTE CARE, V83, pS83, DOI 10.1097/TA.0000000000001484; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; Keiding N., 2005, ENCY BIOSTATISTICS, V2, P1; Klein JP, 2005, SURVIVAL ANAL TECHNI; Kotwal RS, 2016, JAMA SURG, V151, P15, DOI 10.1001/jamasurg.2015.3104; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Mabry RL, 2012, J TRAUMA ACUTE CARE, V73, pS32, DOI 10.1097/TA.0b013e3182606001; MacKenzie EJ, 2008, J BONE JOINT SURG AM, V90A, P101, DOI 10.2106/JBJS.F.01225; Morrison JJ, 2013, ANN SURG, V257, P330, DOI 10.1097/SLA.0b013e31827eefcf; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; National Academies of Sciences Engineering and Medicine, 2016, NAT TRAUM CAR SYST I; O'Reilly DJ, 2014, J TRAUMA ACUTE CARE, V77, pS114, DOI 10.1097/TA.0000000000000328; Powell EK, 2016, J TRAUMA ACUTE CARE, V81, P458, DOI 10.1097/TA.0000000000001078; Powell-Dunford N, 2014, AVIAT SPACE ENVIR MD, V85, P1130, DOI 10.3357/ASEM.3851.2014; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sjolander A, 2013, STAT MED, V32, P4696, DOI 10.1002/sim.5879; Smith IM, 2016, SHOCK, V46, P3, DOI 10.1097/SHK.0000000000000569; Stannard A, 2013, J TRAUMA ACUTE CARE, V74, P830, DOI 10.1097/TA.0b013e31827a3704; Tchetgen EJT, 2015, EPIDEMIOLOGY, V26, P473, DOI 10.1097/EDE.0000000000000317; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; UK Clinical Trials Gateway, RES PREH BLOOD PROD	36	236	241	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2017	318	16					1581	1591		10.1001/jama.2017.15097	http://dx.doi.org/10.1001/jama.2017.15097			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FK6EX	29067429	Green Published, Bronze			2023-01-03	WOS:000413597200023
J	Li, MJ; Guttman, M; Atkins, WM				Li, Mavis Jiarong; Guttman, Miklos; Atkins, William M.			Conformational dynamics of P-glycoprotein in lipid nanodiscs and detergent micelles reveal complex motions on a wide time scale	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						drug transport; conformational change; protein dynamic; protein conformation; ATPase; conformational selection; multidrug resistance	EXCHANGE MASS-SPECTROMETRY; NUCLEOTIDE-BINDING DOMAINS; MULTIDRUG ABC TRANSPORTER; ATP HYDROLYSIS; INDUCED FIT; GLUTAMATE RESIDUES; ALTERNATING ACCESS; CATALYTIC CYCLE; MECHANISM; FLEXIBILITY	P-glycoprotein (P-gp) is a highly substrate-promiscuous efflux transporter that plays a critical role in drug disposition. P-gp utilizes ATP hydrolysis by nucleotide-binding domains (NBDs) to drive transitions between inward-facing (IF) conformations that bind drugs and outward-facing (OF) conformations that release them to the extracellular solution. However, the details of the protein dynamics within either macroscopic IF or OF conformation remain uncharacterized, and the functional role of local dynamics has not been determined. In this work we measured the local dynamics of the IF state of P-gp in lipid nanodiscs and in detergent solution by hydrogen-deuterium (H/D) exchange MS. We observed EX1 exchange kinetics, or bimodal kinetics, for several peptides distributed in both NBDs, particularly for P-gp in the lipid nanodiscs. Remarkably, the EX1 kinetics occurred on several time scales, ranging from seconds to hours, suggesting highly complex, and correlated, motions. The results indicate at least three distinct conformational states in the ligand-free P-gp and suggest a rough conformational landscape. Addition of excess ATP and vanadate, to favor the OF conformations, caused a generalized, but modest, decrease in H/D exchange throughout the NBDs and slowed the EX1 kinetic transitions of several peptides. The functional implications of the results are consistent with the possibility that conformational selection provides a source of substrate promiscuity.	[Li, Mavis Jiarong; Guttman, Miklos; Atkins, William M.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.	winky@uw.edu			NIGMS NIH HHS [R01 GM121603] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM121603] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burkitt W, 2008, RAPID COMMUN MASS SP, V22, P3893, DOI 10.1002/rcm.3794; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; Chakraborty P, 2017, BIOCHEMISTRY-US, V56, P2853, DOI 10.1021/acs.biochem.7b00340; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; Dawson RJP, 2007, FEBS LETT, V581, P935, DOI 10.1016/j.febslet.2007.01.073; Esser L, 2017, J BIOL CHEM, V292, P446, DOI 10.1074/jbc.M116.755884; Fang J, 2011, INT J MASS SPECTROM, V302, P19, DOI 10.1016/j.ijms.2010.06.039; Frank GA, 2016, MOL PHARMACOL, V90, P35, DOI 10.1124/mol.116.104190; Hammes GG, 2009, P NATL ACAD SCI USA, V106, P13737, DOI 10.1073/pnas.0907195106; Honaker MT, 2013, J BIOL CHEM, V288, P18599, DOI 10.1074/jbc.M112.445767; Houde D, 2011, J PHARM SCI-US, V100, P2071, DOI 10.1002/jps.22432; Jin MS, 2012, NATURE, V490, P566, DOI 10.1038/nature11448; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Li MJ, 2017, BIOCHEMISTRY-US, V56, P2506, DOI 10.1021/acs.biochem.6b01245; Livnat-Levanon N, 2016, SCI REP-UK, V6, DOI 10.1038/srep21696; Loo TW, 2015, J BIOL CHEM, V290, P16954, DOI 10.1074/jbc.M115.652602; Loo TW, 2014, J BIOL CHEM, V289, P229, DOI 10.1074/jbc.M113.527804; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2005, BIOCHEMISTRY-US, V44, P10250, DOI 10.1021/bi050705j; Mehmood S, 2012, P NATL ACAD SCI USA, V109, P10832, DOI 10.1073/pnas.1204067109; Mishra S, 2014, ELIFE, V3, DOI 10.7554/eLife.02740; Moeller A, 2015, STRUCTURE, V23, P450, DOI 10.1016/j.str.2014.12.013; Pan LR, 2015, SCI REP-UK, V5, DOI 10.1038/srep07880; Ritchie TK, 2009, METHOD ENZYMOL, V464, P211, DOI 10.1016/S0076-6879(09)64011-8; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Sauna ZE, 2006, J BIOL CHEM, V281, P26501, DOI 10.1074/jbc.M601917200; Subramanian N, 2016, NEUROCHEM INT, V98, P146, DOI 10.1016/j.neuint.2016.05.005; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Verhalen B, 2017, NATURE, V543, P738, DOI 10.1038/nature21414; Verhalen B, 2012, J BIOL CHEM, V287, P1112, DOI 10.1074/jbc.M111.301192; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200; Ward A, 2007, P NATL ACAD SCI USA, V104, P19005, DOI 10.1073/pnas.0709388104; Ward AB, 2013, P NATL ACAD SCI USA, V110, P13386, DOI 10.1073/pnas.1309275110; Weis DD, 2006, J AM SOC MASS SPECTR, V17, P1498, DOI 10.1016/j.jasms.2006.05.014; Wen PC, 2013, J BIOL CHEM, V288, P19211, DOI 10.1074/jbc.M113.450114; Yang ZR, 2017, BBA-BIOMEMBRANES, V1859, P48, DOI 10.1016/j.bbamem.2016.10.009	42	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2018	293	17					6297	6307		10.1074/jbc.RA118.002190	http://dx.doi.org/10.1074/jbc.RA118.002190			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GE3JC	29511086	hybrid, Green Published			2023-01-03	WOS:000431108600007
J	Maximiano, C; Lopez, I; Martin, C; Zugazabeitia, L; Marti-Ciriquian, JL; Nunez, MA; Contreras, J; Herdman, M; Traseira, S; Provencio, M				Maximiano, Constanza; Lopez, Iker; Martin, Cristina; Zugazabeitia, Luis; Marti-Ciriquian, Juan L.; Nunez, Miguel A.; Contreras, Jorge; Herdman, Michael; Traseira, Susana; Provencio, Mariano			An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement	PLOS ONE			English	Article							HEAD; PREVALENCE; RADIOTHERAPY	Background There have been few large-scale, real world studies in Spain to assess change in pain and quality of life (QOL) outcomes in cancer patients with moderate to severe pain. This study aimed to assess changes on both outcomes after 3 months of usual care and to investigate factors associated with change in QoL. Patients and methods Large, multi-centre, observational study in patients with lung, head and neck, colorectal or breast cancer experiencing a first episode of moderate to severe pain while attending one of the participating centres. QoL was assessed using the EuroQol-5D questionnaire and pain using the Brief Pain Inventory (BPI). Instruments were administered at baseline and after 3 months of follow up. Multivariate analyses were used to assess the impact of treatment factors, demographic and clinical variables, pain and other symptoms on QoL scores. Results 1711 patients were included for analysis. After 3 months of usual care, a significant improvement was observed in pain and QoL in all four cancer groups (p<0.001). Effect sizes were medium to large on the BPI and EQ-5D Index and Visual Analogue Scale (VAS). Improvements were seen on the majority of EQ-5D dimensions in all patient groups, though breast cancer patients showed the largest gains. Poorer baseline performance status (ECOG) and the presence of anxiety/depression were associated with significantly poorer QOL outcomes. Improvements in BPI pain scores were associated with improved QoL. Conclusion In the four cancer types studied, pain and QoL outcomes improved considerably after 3 months of usual care. Improvements in pain made a substantial contribution to QoL gains whilst the presence of anxiety and depression and poor baseline performance status significantly constrained improvement.	[Maximiano, Constanza; Provencio, Mariano] Hosp Puerta Hierro Majadahonda, Med Oncol, Madrid, Spain; [Lopez, Iker] Hosp Univ Virgen Rode, Med Oncol, Seville, Spain; [Martin, Cristina] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain; [Zugazabeitia, Luis] Hosp Povisa, Radiat Oncol, Pontevedra, Spain; [Marti-Ciriquian, Juan L.] Univ Alicante, Hosp Gen, Med Oncol, Alicante, Spain; [Nunez, Miguel A.] Hosp Santa Maria Nai, Med Oncol, Orense, Spain; [Contreras, Jorge] Complejo Hosp Reg Carlos Haya, Radiat Oncol, Malaga, Spain; [Herdman, Michael] Insight Consulting & Res, Barcelona, Spain; [Traseira, Susana] Mundipharma Pharmaceut SL, Med Dept, Madrid, Spain	Hospital Puerta de Hierro-Majadahonda; Hospital of Santa Creu i Sant Pau; General University Hospital of Alicante; Universitat d'Alacant	Provencio, M (corresponding author), Hosp Puerta Hierro Majadahonda, Med Oncol, Madrid, Spain.	mprovenciop@gmail.com	Alonso, Constanza Maximiano/AAE-9102-2021; Provencio, Mariano/ABE-8586-2020	Alonso, Constanza Maximiano/0000-0002-4051-3965; Provencio, Mariano/0000-0001-9053-9197; Provencio Pulla, Mariano/0000-0001-6315-7919	Mundipharma Pharmaceuticals S.L.	Mundipharma Pharmaceuticals S.L.	Financial support for this research was provided by Mundipharma Pharmaceuticals S.L. The funder contracted Insight Consulting and Research for support with interpretation of results and manuscript organisation and development. The funder had limited input into study design, but no role in data collection and analysis, decision to publish, or preparation of the manuscript. The funder provided support for the study through unrestricted grants to the participating centres but did not pay a salary to any of the authors. The specific roles of the authors are articulated in the 'author contributions' section.	Bradley N, 2005, J PAIN SYMPTOM MANAG, V30, P123, DOI 10.1016/j.jpainsymman.2005.02.015; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Bruera E, 1991, J Palliat Care, V7, P6; Cleeland C. S., 2009, BRIEF PAIN INVENTORY; Cohen J., 2013, STAT POWER ANAL BEHA; Cramarossa G, 2013, SUPPORT CARE CANCER, V21, P1709, DOI 10.1007/s00520-013-1717-7; Dawson J, 2010, BMJ-BRIT MED J, V340, pc186, DOI DOI 10.1136/BMJ.C186; de Andres Ares J, 2014, PAIN PRACT; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Epstein JB, 2010, SUPPORT CARE CANCER, V18, P1023, DOI 10.1007/s00520-010-0897-7; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; Herdman M, 2001, Aten Primaria, V28, P425; Hird AE, 2008, J PALLIAT MED, V11, P1156, DOI 10.1089/jpm.2008.9846; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jordhoy MS, 2001, BRIT J CANCER, V85, P1478, DOI 10.1054/bjoc.2001.2116; Jost L, 2010, ANN ONCOL, V21, pv257, DOI 10.1093/annonc/mdq224; National Comprehensive Cancer Network (NCCN), 2010, NCCN CLIN PRACT GUID, V2; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-70; Rathkopf DE, 2014, EUR UROL, V66, P815, DOI 10.1016/j.eururo.2014.02.056; Rentz A M, 2009, J Med Econ, V12, P371, DOI 10.3111/13696990903430481; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Romanus D, 2012, J PAIN SYMPTOM MANAG, V43, P205, DOI 10.1016/j.jpainsymman.2011.09.001; Ronis DL, 2008, ARCH OTOLARYNGOL, V134, P241, DOI 10.1001/archoto.2007.43; Shuman AG, 2012, ARCH OTOLARYNGOL, V138, P1147, DOI 10.1001/jamaoto.2013.853; Terrell JE, 2004, ARCH OTOLARYNGOL, V130, P401, DOI 10.1001/archotol.130.4.401; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8; Velazquez Rivera I, PAIN PRACTI IN PRESS; Whynes DK, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-155; Whynes DK, 2009, J EVAL CLIN PRACT, V15, P820, DOI 10.1111/j.1365-2753.2008.01102.x; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Zimmermann C, 2011, SUPPORT CARE CANCER, V19, P621, DOI 10.1007/s00520-010-0866-1	32	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2018	13	4							e0193233	10.1371/journal.pone.0193233	http://dx.doi.org/10.1371/journal.pone.0193233			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB5DC	29614068	Green Submitted, Green Published, gold			2023-01-03	WOS:000429081600003
J	Mackall, CL				Mackall, Crystal L.			Engineering a designer immunotherapy Tailoring cytokine selectivity by engineering receptor-ligand pairs circumvents toxicity	SCIENCE			English	Editorial Material							T-CELLS; LYMPHOBLASTIC-LEUKEMIA; INTERLEUKIN-2; CHEMOTHERAPY; THERAPY; ADULTS		[Mackall, Crystal L.] Stanford Univ, Dept Pediat & Med, 265 Campus Way,G3141A, Stanford, CA 94305 USA; [Mackall, Crystal L.] Stanford Univ, Stanford Canc Inst, 265 Campus Way,G3141A, Stanford, CA 94305 USA	Stanford University; Stanford Cancer Institute; Stanford University	Mackall, CL (corresponding author), Stanford Univ, Dept Pediat & Med, 265 Campus Way,G3141A, Stanford, CA 94305 USA.; Mackall, CL (corresponding author), Stanford Univ, Stanford Canc Inst, 265 Campus Way,G3141A, Stanford, CA 94305 USA.	cmackall@stanford.edu						Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; Casadevall N, 2002, NEW ENGL J MED, V346, P469, DOI 10.1056/NEJMoa011931; Cui YZ, 2009, BLOOD, V114, P3831, DOI 10.1182/blood-2009-03-212134; Hakim FT, 2005, J CLIN INVEST, V115, P930, DOI 10.1172/JCI200522492; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Krieg C, 2010, P NATL ACAD SCI USA, V107, P11906, DOI 10.1073/pnas.1002569107; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Locke FL, 2017, MOL THER, V25, P285, DOI 10.1016/j.ymthe.2016.10.020; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; WHITE RL, 1994, CANCER, V74, P3212, DOI 10.1002/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I; Zhang H, 2005, NAT MED, V11, P1238, DOI 10.1038/nm1312	15	10	10	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 2	2018	359	6379					990	991		10.1126/science.aas9434	http://dx.doi.org/10.1126/science.aas9434			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FX8SV	29496866				2023-01-03	WOS:000426366200025
J	Jung, HY; Kim, SH; Jang, HM; Lee, S; Kim, YS; Kang, SW; Yang, CW; Kim, NH; Choi, JY; Cho, JH; Kim, CD; Park, SH; Kim, YL				Jung, Hee-Yeon; Kim, Su Hee; Jang, Hye Min; Lee, Sukyung; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Park, Sun-Hee; Kim, Yong-Lim			Individualized prediction of mortality using multiple inflammatory markers in patients on dialysis	PLOS ONE			English	Article							C-REACTIVE PROTEIN; HEMODIALYSIS-PATIENTS; CARDIOVASCULAR MORTALITY; RISK STRATIFICATION; DECISION-MAKING; SERUM-ALBUMIN; DISEASE; BIOMARKERS	This study aimed to evaluate whether the combination of inflammatory markers could provide predictive powers for mortality in individual patients on dialysis and develop a predictive model for mortality according to dialysis modality. Data for inflammatory markers were obtained at the time of enrollment from 3,309 patients on dialysis from a prospective multicenter cohort. Net reclassification index ( NRI) and integrated discrimination improvement ( IDI) were calculated. Cox proportional hazards regression analysis was used to derive a prediction model of mortality and the integrated area under the curve (iAUC) was calculated to compare the predictive accuracy of the models. The incremental additions of albumin, high-sensitive C-reactive protein ( hsCRP), white blood count ( WBC), and ferritin to the conventional risk factors showed the highest predictive powers for all-cause mortality in the entire population ( NRI, 21.0; IDI, 0.045) and patients on peritoneal dialysis ( NRI, 25.7; IDI, 0.061). The addition of albumin and hsCRP to the conventional risk factors markedly increased predictive powers for all-cause mortality in HD patients ( NRI, 19.0; IDI, 0.035). The prediction model for all-cause mortality using conventional risk factors and combination of inflammatory markers with highest NRI value (iAUC, 0.741; 95% CI, 0.722-0.761) was the most accurate in the entire population compared with a model including conventional risk factors alone ( iAUC, 0.719; 95% CI, 0.700-0.738) or model including only significant conventional risk factors and inflammatory markers ( iAUC, 0.734; 95% CI, 0.714-0.754). Using multiple inflammatory markers practically available in a clinic can provide higher predictive power for all-cause mortality in patients on dialysis. The predictive model for mortality based on combinations of inflammatory markers enables a stratified risk assessment. However, the optimal combination for the predictive model was different in each dialysis modality.	[Jung, Hee-Yeon; Kim, Su Hee; Lee, Sukyung; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Park, Sun-Hee; Kim, Yong-Lim] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; [Jung, Hee-Yeon; Kim, Su Hee; Lee, Sukyung; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Park, Sun-Hee; Kim, Yong-Lim] Kyungpook Natl Univ, Sch Med, Daegu, South Korea; [Jung, Hee-Yeon; Kim, Su Hee; Jang, Hye Min; Lee, Sukyung; Kim, Yon Su; Kang, Shin-Wook; Yang, Chul Woo; Kim, Nam-Ho; Choi, Ji-Young; Cho, Jang-Hee; Kim, Chan-Duck; Park, Sun-Hee; Kim, Yong-Lim] Clin Res Ctr End Stage Renal Dis, Daegu, South Korea; [Jang, Hye Min] Kyungpook Natl Univ, Dept Stat, Daegu, South Korea; [Kim, Yon Su] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Yang, Chul Woo] Catholic Univ Korea, Dept Internal Med, Coll Med, Seoul, South Korea; [Kim, Nam-Ho] Chonnam Natl Univ, Med Sch, Dept Internal Med, Gwangju, South Korea; [Kim, Yong-Lim] Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program Bk21, Daegu, South Korea	Kyungpook National University; Kyungpook National University Hospital; Kyungpook National University; Kyungpook National University; Seoul National University (SNU); Yonsei University; Yonsei University Health System; Catholic University of Korea; Chonnam National University; Kyungpook National University	Park, SH; Kim, YL (corresponding author), Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea.; Park, SH; Kim, YL (corresponding author), Kyungpook Natl Univ, Sch Med, Daegu, South Korea.; Park, SH; Kim, YL (corresponding author), Clin Res Ctr End Stage Renal Dis, Daegu, South Korea.; Kim, YL (corresponding author), Kyungpook Natl Univ, Dept Biomed Sci, Plus KNU Biomed Convergence Program Bk21, Daegu, South Korea.	sh-park@knu.ac.kr; ylkim@knu.ac.kr	Cho, Jang-hee/ABD-3534-2020; Jung, Hee-Yeon/AFB-8578-2022; Park, Sun/GSD-9620-2022	Cho, Jang-hee/0000-0002-7031-5214; Jung, Hee-Yeon/0000-0003-0232-7202; 	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C0001, HC15C1129, HI13C1232]	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), which is funded by the Ministry of Health & Welfare, Republic of Korea (HI15C0001 and HC15C1129 to YLK and HI13C1232 to CDK). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bargnoux AS, 2013, CLIN CHEM LAB MED, V51, P1865, DOI 10.1515/cclm-2012-0664; Bazeley J, 2011, CLIN J AM SOC NEPHRO, V6, P2452, DOI 10.2215/CJN.00710111; Coe CL, 2011, BRAIN BEHAV IMMUN, V25, P494, DOI 10.1016/j.bbi.2010.11.013; Cohen LM, 2010, CLIN J AM SOC NEPHRO, V5, P72, DOI 10.2215/CJN.03860609; Cohen SD, 2010, NEPHROL DIAL TRANSPL, V25, P1239, DOI 10.1093/ndt/gfp625; Couchoud CG, 2015, KIDNEY INT, V88, P1178, DOI 10.1038/ki.2015.245; Hallen J, 2011, SCAND J UROL NEPHROL, V45, P151, DOI 10.3109/00365599.2010.529819; Herzig KA, 2001, J AM SOC NEPHROL, V12, P814, DOI 10.1681/ASN.V124814; Hung SC, 2012, CLIN J AM SOC NEPHRO, V7, P1257, DOI 10.2215/CJN.08410811; Ishii J, 2015, CIRC J, V79, P656, DOI 10.1253/circj.CJ-14-0915; Johnson DW, 2005, KIDNEY INT, V67, P738, DOI 10.1111/j.1523-1755.2005.67135.x; Kalantar-Zadeh K, 2001, AM J KIDNEY DIS, V37, P564, DOI 10.1053/ajkd.2001.22433; Kato A, 2010, HEMODIAL INT, V14, P226, DOI 10.1111/j.1542-4758.2009.00432.x; Maruyama Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143430; Mehrotra R, 2011, AM J KIDNEY DIS, V58, P418, DOI 10.1053/j.ajkd.2011.03.018; Oldroyd JC, 2009, ATHEROSCLEROSIS, V207, P227, DOI 10.1016/j.atherosclerosis.2009.03.045; Park SH, 2012, J RENAL NUTR, V22, P120, DOI 10.1053/j.jrn.2011.10.021; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Reddan DN, 2003, NEPHROL DIAL TRANSPL, V18, P1167, DOI 10.1093/ndt/gfg066; Shoji T, 2016, CLIN EXP NEPHROL; Thamer M, 2015, AM J KIDNEY DIS, V66, P1024, DOI 10.1053/j.ajkd.2015.05.014; Tsirpanlis G, 2004, NEPHROL DIAL TRANSPL, V19, P150, DOI 10.1093/ndt/gfg486; Westra WM, 2007, PERITON DIALYSIS INT, V27, P192; Wick JP, 2016, AM J KIDNEY DIS; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Yeun JY, 2000, AM J KIDNEY DIS, V35, P469, DOI 10.1016/S0272-6386(00)70200-9	26	8	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2018	13	3							e0193511	10.1371/journal.pone.0193511	http://dx.doi.org/10.1371/journal.pone.0193511			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX8RR	29494637	Green Published, Green Submitted, gold			2023-01-03	WOS:000426363200057
J	Trappey, BE				Trappey, Bernard E.			Please, Doc, Take It All This Time	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Trappey, Bernard E.] Univ Minnesota, Div Gen Internal Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Trappey, BE (corresponding author), Univ Minnesota, Div Gen Internal Med, Dept Med & Pediat, 420 Delaware St SE,MMC 741, Minneapolis, MN 55455 USA.	trappey@umn.edu							0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	2018	319	8					769	770		10.1001/jama.2018.0499	http://dx.doi.org/10.1001/jama.2018.0499			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX6GK	29486043				2023-01-03	WOS:000426181300016
J	Gumus, HG; Illa, M; Pla, L; Zamora, M; Crispi, F; Gratacos, E				Gulcin Gumus, Hatice; Illa, Miriam; Pla, Laura; Zamora, Monica; Crispi, Fatima; Gratacos, Eduard			Nutritional intra-amniotic therapy increases survival in a rabbit model of fetal growth restriction	PLOS ONE			English	Article							AMNIOTIC-FLUID; ANIMAL-MODEL; TRANSPORT; INFUSION	Objective To evaluate the perinatal effects of a prenatal therapy based on intra-amniotic nutritional supplementation in a rabbit model of intrauterine growth restriction (IUGR). Methods IUGR was surgically induced in pregnant rabbits at gestational day 25 by ligating 40-50% of uteroplacental vessels of each gestational sac. At the same time, modified-parenteral nutrition solution (containing glucose, amino acids and electrolytes) was injected into the amniotic sac of nearly half of the IUGR fetuses (IUGR-T group n = 106), whereas sham injections were performed in the rest of fetuses (IUGR group n = 118). A control group without IUGR induction but sham injection was also included (n = 115). Five days after the ligation procedure, a cesarean section was performed to evaluate fetal cardiac function, survival and birth weight. Results Survival was significantly improved in the IUGR fetuses that were treated with intra-amniotic nutritional supplementation as compared to non-treated IUGR animals (survival rate: controls 71% vs. IUGR 44% p = 0.003 and IUGR-T 63% vs. IUGR 44% p = 0.02), whereas, birth weight (controls mean 43g +/- SD 9 vs. IUGR 36g +/- SD 9 vs. IUGR-T 35g +/- SD 8, p = 0.001) and fetal cardiac function were similar among the IUGR groups. Conclusion Intra-amniotic injection of a modified-parenteral nutrient solution appears to be a promising therapy for reducing mortality among IUGR. These results provide an opportunity to develop new intra-amniotic nutritional strategies to reach the fetus by bypassing the placental insufficiency.	[Gulcin Gumus, Hatice; Illa, Miriam; Pla, Laura; Zamora, Monica; Crispi, Fatima; Gratacos, Eduard] Univ Barcelona, BCNatal Barcelona Ctr Maternal Fetal & Neonatal M, Hosp Clin, Fetal I D Fetal Med Res Ctr, Barcelona, Spain; [Gulcin Gumus, Hatice; Illa, Miriam; Pla, Laura; Zamora, Monica; Crispi, Fatima; Gratacos, Eduard] Univ Barcelona, Hosp San Juan Deu, Inst Clin Ginecol Obstet & Neonatal, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain; [Crispi, Fatima; Gratacos, Eduard] Ctr Biomed Res Rare Dis CIBER ER, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Gumus, HG (corresponding author), Univ Barcelona, BCNatal Barcelona Ctr Maternal Fetal & Neonatal M, Hosp Clin, Fetal I D Fetal Med Res Ctr, Barcelona, Spain.; Gumus, HG (corresponding author), Univ Barcelona, Hosp San Juan Deu, Inst Clin Ginecol Obstet & Neonatal, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.	hgumusgu8@alumnes.ub.edu	Gratacos, Eduard/AAR-4939-2020	Gratacos, Eduard/0000-0002-7405-7224; Gumus, Hatice Gulcin/0000-0002-1613-1721; Illa, Miriam/0000-0002-8366-830X	Plan Nacional de I+D+I from Instituto de Salud Carlos III -Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER) [PI15/00130]; "la Caixa" Foundation; AGAUR SGR grant [928]; Erasmus + Programme of the European Union [2013-0040]	Plan Nacional de I+D+I from Instituto de Salud Carlos III -Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER); "la Caixa" Foundation(La Caixa Foundation); AGAUR SGR grant; Erasmus + Programme of the European Union	This study was supported by Plan Nacional de I+D+I (PI15/00130) from Instituto de Salud Carlos III -Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER) Una manera de hacer Europa. Additionally, the research leading to these results has received funding from la Caixa Foundation and AGAUR 2014 SGR grant no 928. This project has been funded with support of the Erasmus + Programme of the European Union (Framework Agreement number: 2013-0040). This publication reflects the views only of the author, and the Commission cannot be held responsible for any use, which may be made of the information contained therein. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashworth CJ, 2001, REPRODUCTION, V122, P527, DOI 10.1530/rep.0.1220527; Bautista A, 2015, PHYSIOL BEHAV, V138, P101, DOI 10.1016/j.physbeh.2014.10.028; Bernstein IM, 1997, AM J OBSTET GYNECOL, V176, P176; Buchmiller TL, 1992, UPREGULATION NUTR TR, V447, P443; Cetin I, 2005, ACTA PAEDIATR, V94, P7, DOI 10.1080/08035320510043709; Crispi F, 2010, CIRCULATION, V121, P2427, DOI 10.1161/CIRCULATIONAHA.110.937995; Eixarch E, 2011, PLACENTA, V32, P304, DOI 10.1016/j.placenta.2011.01.014; Eixarch E, 2009, FETAL DIAGN THER, V26, P203, DOI 10.1159/000264063; Eixarch E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031497; FLAKE AW, 1986, J PEDIATR SURG, V21, P481, DOI 10.1016/S0022-3468(86)80216-0; FOWDEN AL, 1989, Q J EXP PHYSIOL CMS, V74, P703, DOI 10.1113/expphysiol.1989.sp003322; GULMEZOGLU AM, 2001, COCHRANE DB SYST REV; GULMEZOGLU AM, 2000, COCHRANE DB SYST REV; HARRISON MR, 1982, J PEDIATR SURG, V17, P376, DOI 10.1016/S0022-3468(82)80493-4; Hofmeyr G.J., 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000148, DOI 10.1002/14651858.CD000148]; Illa M, 2013, PLOS ONE, V8; Illa M, 2017, FETAL DIAGN THER, P1; Kady SM, 2004, BEST PRACT RES CL OB, V18, P397, DOI 10.1016/j.bpobgyn.2004.02.009; Kilkenny C., 2013, ANIMALS, V4, P35, DOI DOI 10.3390/ani4010035; Lassala A, 2010, J NUTR, V140, P1242, DOI 10.3945/jn.110.125658; LAURIN J, 1987, ACTA OBSTET GYN SCAN, V66, P407, DOI 10.3109/00016348709022043; Liberato SC, 2013, FOOD NUTR RES, V57, DOI 10.3402/fnr.v57i0.20499; Lin G, 2014, AMINO ACIDS, V46, P1605, DOI 10.1007/s00726-014-1725-z; Makrides M, 2003, AM J CLIN NUTR, V78, P145, DOI 10.1093/ajcn/78.1.145; Marconi AM, 2008, SEMIN PERINATOL, V32, P178, DOI 10.1053/j.semperi.2008.02.007; Merialdi M, 2003, J NUTR, V133, p1626S, DOI 10.1093/jn/133.5.1626S; MULVIHILL SJ, 1986, J SURG RES, V40, P291, DOI 10.1016/0022-4804(86)90189-7; MULVIHILL SJ, 1985, SURGERY, V98, P500; ORLIC D, 1973, J CELL BIOL, V56, P106, DOI 10.1083/jcb.56.1.106; PHILLIPS JD, 1991, J PEDIATR SURG, V26, P374, DOI 10.1016/0022-3468(91)90982-Y; Pritchard J., 1966, OBSTET GYNECOL, V606, P610; Regnault TRH, 2005, PLACENTA, V26, pS52, DOI 10.1016/j.placenta.2005.01.003; SIMMER K, 1985, CLIN SCI, V68, P395, DOI 10.1042/cs0680395; Skarsgard ED, 2001, J SURG RES, V99, P142, DOI 10.1006/jsre.2001.6120; Somm E, 2014, PEDIATR RES, V75, P51, DOI 10.1038/pr.2013.199; Tarrade A, 2013, SEXUAL DIMORPHISM FE, V8; Torre I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113067; Trahair JF, 2000, REPROD FERT DEVELOP, V12, P87, DOI 10.1071/RD00024; Wallace JM, 2003, J PHYSIOL-LONDON, V547, P85, DOI 10.1113/jphysiol.2002.023333; Wu GY, 2004, J NUTR, V134, P2169, DOI 10.1093/jn/134.9.2169	40	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2018	13	2							e0193240	10.1371/journal.pone.0193240	http://dx.doi.org/10.1371/journal.pone.0193240			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW8RO	29466434	Green Published, Green Submitted, gold			2023-01-03	WOS:000425604300102
J	Yano, R; Inadomi, C; Luo, L; Goto, S; Hara, T; Li, TS				Yano, Rintaro; Inadomi, Chiaki; Luo, Lan; Goto, Shinji; Hara, Tetsuya; Li, Tao-Sheng			The effect of transient oxygenation on stem cell mobilization and ischemia/reperfusion heart injury	PLOS ONE			English	Article							ENDOTHELIAL PROGENITOR CELLS; MYOCARDIUM; GROWTH; RECRUITMENT; ISCHEMIA; HYPOXIA; GLIOMA; MODEL	For general anesthesia, pre-oxygenation is routinely performed prior to intubation. It is well-known that ischemic/hypoxic preconditioning induces stem cell mobilization and protects against ischemia/reperfusion (I/R) injury. In this study, we investigated the effect of transient oxygenation on stem cell mobilization and I/R injury of the heart. Mice were exposed to 100% oxygen for 5 or 20 minutes. We evaluated the number of c-kit + stem/progenitor cells and the levels of SDF-1 alpha and VEGF in peripheral blood at 1, 3, 6, and 24 hours after oxygenation. We also induced I/R injury of the heart at 3 hours post-oxygenation for 5 minutes and then examined stem cell recruitment and fibrotic changes in the heart 3 or 14 days later. The number of c-kit(+) cells in peripheral blood was significantly increased at 1 or 24 hours after oxygenation for either 5 or 20 minutes. Oxygenation for 5 or 20 minutes did not significantly change the SDF-1 alpha level measured in plasma. However, the plasma VEGF level was decreased at 3 hours post-oxygenation for 20 minutes (p = 0.051). Oxygenation for 5 minutes did not significantly alter the fibrotic area or cell apoptosis. Although oxygenation for 5 minutes increased the number of c-kit(+) cells in hearts damaged by I/R injury, this difference was not significant between groups due to large variation between individuals (p = 0.14). Although transient oxygenation induces stem cell mobilization, it does not appear to protect against I/R injury of the heart in mice.	[Yano, Rintaro; Inadomi, Chiaki; Hara, Tetsuya] Nagasaki Univ, Grad Sch Biomed Sci, Dept Anesthesiol, 1-7-1 Sakamoto, Nagasaki, Japan; [Yano, Rintaro; Luo, Lan; Goto, Shinji; Li, Tao-Sheng] Nagasaki Univ, Atom Bomb Dis Inst, Dept Stem Cell Biol, 1-12-4 Sakamoto, Nagasaki, Japan	Nagasaki University; Nagasaki University	Inadomi, C (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Anesthesiol, 1-7-1 Sakamoto, Nagasaki, Japan.; Li, TS (corresponding author), Nagasaki Univ, Atom Bomb Dis Inst, Dept Stem Cell Biol, 1-12-4 Sakamoto, Nagasaki, Japan.	inadomic@nagasaki-u.ac.jp; litaoshe@nagasaki-u.ac.jp		Li, Tao-Sheng/0000-0002-7653-8873; Luo, Lan/0000-0001-7549-9852	Japan Society for the Promotion of Science [26462339]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by the Japan Society for the Promotion of Science, Award Number:26462339 (https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-26462339/) to Cl. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ballas CB, 2002, J CELL BIOCHEM, P20, DOI 10.1002/jcb.10127; De Kok IJ, 2003, CLIN ORAL IMPLAN RES, V14, P481, DOI 10.1034/j.1600-0501.2003.110770.x; Di Felice V, 2013, EUR J HISTOCHEM, V57, P83, DOI 10.4081/ejh.2013.e14; Edmark L, 2003, ANESTHESIOLOGY, V98, P28, DOI 10.1097/00000542-200301000-00008; Fransioli J, 2008, STEM CELLS, V26, P1315, DOI 10.1634/stemcells.2007-0751; HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756-3282(92)90363-2; Ii M, 2005, CIRCULATION, V111, P1114, DOI 10.1161/01.CIR.0000157144.24888.7E; Kamota T, 2009, J AM COLL CARDIOL, V53, P1814, DOI 10.1016/j.jacc.2009.02.015; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Koti RS, 2005, CLIN SCI, V108, P55, DOI 10.1042/CS20040130; KUZUYA T, 1993, CIRC RES, V72, P1293, DOI 10.1161/01.RES.72.6.1293; Lazaris AM, 2009, J SURG RES, V154, P267, DOI 10.1016/j.jss.2008.06.037; McCord J M, 1985, Adv Myocardiol, V5, P183; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Murakami J, 2009, INT J CANCER, V124, P1685, DOI 10.1002/ijc.24085; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Noel Daniele, 2002, Curr Opin Investig Drugs, V3, P1000; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Sheng T, 2005, CIRCULATION, V111, P2438, DOI 10.1161/01.CIR.0000167553.49133.81; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Tang XL, 1996, CIRC RES, V79, P424, DOI 10.1161/01.RES.79.3.424; Wu GD, 2003, TRANSPLANTATION, V75, P679, DOI 10.1097/01.TP.0000048488.35010.95	25	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2018	13	2							e0192733	10.1371/journal.pone.0192733	http://dx.doi.org/10.1371/journal.pone.0192733			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW1TV	29438409	Green Submitted, Green Published, gold			2023-01-03	WOS:000425083400050
J	Polania, R; Nitsche, MA; Ruff, CC				Polania, Rafael; Nitsche, Michael A.; Ruff, Christian C.			Studying and modifying brain function with non-invasive brain stimulation	NATURE NEUROSCIENCE			English	Review							TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; THETA-BURST-STIMULATION; MEP AMPLITUDE-MODULATION; RANDOM NOISE STIMULATION; SPATIAL WORKING-MEMORY; HEALTHY-HUMAN SUBJECTS; ELECTRICAL-STIMULATION; VISUAL-CORTEX; EXCITABILITY CHANGES	In the past three decades, our understanding of brain-behavior relationships has been significantly shaped by research using non-invasive brain stimulation (NIBS) techniques. These methods allow non-invasive and safe modulation of neural processes in the healthy brain, enabling researchers to directly study how experimentally altered neural activity causally affects behavior. This unique property of NIBS methods has, on the one hand, led to groundbreaking findings on the brain basis of various aspects of behavior and has raised interest in possible clinical and practical applications of these methods. On the other hand, it has also triggered increasingly critical debates about the properties and possible limitations of these methods. In this review, we discuss these issues, clarify the challenges associated with the use of currently available NIBS techniques for basic research and practical applications, and provide recommendations for studies using NIBS techniques to establish brain-behavior relationships.	[Polania, Rafael; Ruff, Christian C.] Univ Zurich, Dept Econ, Lab Social & Neural Syst Res, SNS Lab, Zurich, Switzerland; [Nitsche, Michael A.] TU Dortmund, Dept Psychol & Neurosci, Leibniz Res Ctr Working Environm & Human Factors, Dortmund, Germany; [Nitsche, Michael A.] Univ Med Hosp Bergmannsheil, Dept Neurol, Bochum, Germany	University of Zurich; Dortmund University of Technology; Leibniz Institut for Arbeitsforschung an der TU Dortmund (IFADO); Ruhr University Bochum	Polania, R; Ruff, CC (corresponding author), Univ Zurich, Dept Econ, Lab Social & Neural Syst Res, SNS Lab, Zurich, Switzerland.	rafael.polania@econ.uzh.ch; christian.ruff@econ.uzh.ch	Nitsche, Michael A/B-6755-2012; Ruff, Christian/N-9552-2016	Polania, Rafael/0000-0002-6176-6806; Ruff, Christian/0000-0002-3964-2364	EC; FET [686764-LUMINOUS]; German ministry of Research and Education (GCBS) [01EE1403C]; German ministry of Research and Education (TRAINSTIM) [01GQ1424E]; Deutsche Forschungsgemeinschaft - Germany [SFB 1280]; Swiss National Science Foundation [105314_152891, 100019L_173248]; ERC consolidator grant (BRAINCODES)	EC(European CommissionEuropean Commission Joint Research Centre); FET; German ministry of Research and Education (GCBS); German ministry of Research and Education (TRAINSTIM); Deutsche Forschungsgemeinschaft - Germany(German Research Foundation (DFG)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); ERC consolidator grant (BRAINCODES)	Michael A. Nitsche receives support by the EC Horizon 2020 Program, FET Grant, 686764-LUMINOUS, grants from the German ministry of Research and Education (GCBS grant 01EE1403C, TRAINSTIM grant 01GQ1424E), and by a grant from the Deutsche Forschungsgemeinschaft - Germany (SFB 1280 Extinction Learning). Christian C. Ruff is supported by the Swiss National Science Foundation (grants 105314_152891 and 100019L_173248) and by an ERC consolidator grant (BRAINCODES).	Aarts AA, 2015, SCIENCE, V349, DOI 10.1126/science.aac4716; Albouy P, 2017, NEURON, V94, P193, DOI 10.1016/j.neuron.2017.03.015; Alekseichuk I, 2016, CURR BIOL, V26, P1513, DOI 10.1016/j.cub.2016.04.035; Ali MM, 2013, J NEUROSCI, V33, P11262, DOI 10.1523/JNEUROSCI.5867-12.2013; AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; Amedi A, 2004, NAT NEUROSCI, V7, P1266, DOI 10.1038/nn1328; [Anonymous], 2017, Nat Commun, V8, P14748, DOI 10.1038/ncomms14748; Antal A, 2015, BRAIN STIMUL, V8, P846, DOI 10.1016/j.brs.2015.05.010; Antal A, 2004, J COGNITIVE NEUROSCI, V16, P521, DOI 10.1162/089892904323057263; Antal A, 2014, NEUROIMAGE, V85, P1040, DOI 10.1016/j.neuroimage.2012.10.026; Antal A, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00317; Ashbridge E, 1997, NEUROPSYCHOLOGIA, V35, P1121, DOI 10.1016/S0028-3932(97)00003-1; Bachinger M, 2017, J NEUROSCI, V37, P4766, DOI 10.1523/JNEUROSCI.1756-16.2017; Barron HC, 2016, NEURON, V90, P191, DOI 10.1016/j.neuron.2016.02.031; Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Beharelle AR, 2015, J NEUROSCI, V35, P14544, DOI 10.1523/JNEUROSCI.2322-15.2015; Berenyi A, 2012, SCIENCE, V337, P735, DOI 10.1126/science.1223154; Blankenburg F, 2010, CEREB CORTEX, V20, P2702, DOI 10.1093/cercor/bhq015; Bolognini N, 2011, HUM BRAIN MAPP, V32, P2104, DOI 10.1002/hbm.21172; Bolzoni F, 2013, J PHYSIOL-LONDON, V591, P3381, DOI 10.1113/jphysiol.2012.244764; Buch ER, 2017, CLIN NEUROPHYSIOL, V128, P589, DOI 10.1016/j.clinph.2017.01.004; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cabrera LY, 2014, BRAIN TOPOGR, V27, P33, DOI 10.1007/s10548-013-0296-8; Cecere R, 2015, CURR BIOL, V25, P231, DOI 10.1016/j.cub.2014.11.034; Chaieb L, 2014, NEUROGENETICS, V15, P1, DOI 10.1007/s10048-014-0393-1; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; Chipchase L, 2012, CLIN NEUROPHYSIOL, V123, P1698, DOI 10.1016/j.clinph.2012.05.003; Datta A, 2009, BRAIN STIMUL, V2, P201, DOI 10.1016/j.brs.2009.03.005; DAY BL, 1989, BRAIN, V112, P649, DOI 10.1093/brain/112.3.649; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449, DOI 10.1113/jphysiol.1989.sp017626; Du XM, 2014, J MOTOR BEHAV, V46, P39, DOI 10.1080/00222895.2013.850401; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Fenno L, 2011, ANNU REV NEUROSCI, V34, P389, DOI 10.1146/annurev-neuro-061010-113817; Feredoes E, 2011, P NATL ACAD SCI USA, V108, P17510, DOI 10.1073/pnas.1106439108; Fertonani A, 2011, J NEUROSCI, V31, P15416, DOI 10.1523/JNEUROSCI.2002-11.2011; Fitz NS, 2015, J MED ETHICS, V41, P410, DOI 10.1136/medethics-2013-101458; Fresnoza S, 2014, J NEUROSCI, V34, P2744, DOI 10.1523/JNEUROSCI.3655-13.2014; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gamboa OL, 2010, EXP BRAIN RES, V204, P181, DOI 10.1007/s00221-010-2293-4; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; Gentner R, 2008, CEREB CORTEX, V18, P2046, DOI 10.1093/cercor/bhm239; Gerloff C, 1997, BRAIN, V120, P1587, DOI 10.1093/brain/120.9.1587; Grossman N, 2017, CELL, V169, P1029, DOI 10.1016/j.cell.2017.05.024; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Hanslmayr S, 2014, CURR BIOL, V24, P904, DOI 10.1016/j.cub.2014.03.007; Hill CA, 2017, NAT NEUROSCI, V20, P1142, DOI 10.1038/nn.4602; Holland R, 2011, CURR BIOL, V21, P1403, DOI 10.1016/j.cub.2011.07.021; Horvath JC, 2015, BRAIN STIMUL, V8, P535, DOI 10.1016/j.brs.2015.01.400; Horvath JC, 2015, NEUROPSYCHOLOGIA, V66, P213, DOI 10.1016/j.neuropsychologia.2014.11.021; Huang YZ, 2007, CLIN NEUROPHYSIOL, V118, P1028, DOI 10.1016/j.clinph.2007.01.021; Huang Y, 2017, ELIFE, V6, DOI 10.7554/eLife.18834; Huys QJM, 2016, NAT NEUROSCI, V19, P404, DOI 10.1038/nn.4238; Joundi RA, 2012, CURR BIOL, V22, P403, DOI 10.1016/j.cub.2012.01.024; Kadosh RC, 2012, CURR BIOL, V22, pR108, DOI 10.1016/j.cub.2012.01.013; Kadosh RC, 2010, CURR BIOL, V20, P2016, DOI 10.1016/j.cub.2010.10.007; Kanai R, 2008, CURR BIOL, V18, P1839, DOI 10.1016/j.cub.2008.10.027; Kar K, 2017, J NEUROSCI, V37, P2325, DOI 10.1523/JNEUROSCI.2266-16.2016; Kar K, 2012, J NEUROPHYSIOL, V108, P2173, DOI 10.1152/jn.00505.2012; Katz LN, 2016, NATURE, V535, P285, DOI 10.1038/nature18617; Knoch D, 2006, SCIENCE, V314, P829, DOI 10.1126/science.1129156; Koch G, 2009, BEHAV BRAIN RES, V202, P147, DOI 10.1016/j.bbr.2009.03.023; Kuo HI, 2013, BRAIN STIMUL, V6, P644, DOI 10.1016/j.brs.2012.09.010; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Legon W, 2014, NAT NEUROSCI, V17, P322, DOI 10.1038/nn.3620; Lin CH, 2012, NEUROIMAGE, V62, P2007, DOI 10.1016/j.neuroimage.2012.05.015; Lomber SG, 1999, J NEUROSCI METH, V86, P179, DOI 10.1016/S0165-0270(98)00165-4; Lopez-Alonso V, 2014, BRAIN STIMUL, V7, P372, DOI 10.1016/j.brs.2014.02.004; Lustenberger C, 2016, CURR BIOL, V26, P2127, DOI 10.1016/j.cub.2016.06.044; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Marechal MA, 2017, P NATL ACAD SCI USA, V114, P4360, DOI 10.1073/pnas.1614912114; MERTON PA, 1980, NATURE, V285, P227, DOI 10.1038/285227a0; Minami S, 2017, CURR BIOL, V27, P2344, DOI 10.1016/j.cub.2017.06.033; Miniussi C, 2013, NEUROSCI BIOBEHAV R, V37, P1702, DOI 10.1016/j.neubiorev.2013.06.014; Moisa M, 2016, J NEUROSCI, V36, P12053, DOI 10.1523/JNEUROSCI.2044-16.2016; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Monte-Silva K, 2011, NEUROPSYCHOPHARMACOL, V36, P2097, DOI 10.1038/npp.2011.100; Morbidi F, 2007, J NEUROSCI METH, V162, P293, DOI 10.1016/j.jneumeth.2006.12.013; Muellbacher W, 2002, NATURE, V415, P640, DOI 10.1038/nature712; Ngo HVV, 2013, NEURON, V78, P545, DOI 10.1016/j.neuron.2013.03.006; Nitsche MA, 2006, EUR J NEUROSCI, V23, P1651, DOI 10.1111/j.1460-9568.2006.04676.x; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2015, BRAIN STIMUL, V8, P666, DOI 10.1016/j.brs.2015.03.008; Nitsche MA, 2012, J PHYSIOL-LONDON, V590, P4641, DOI 10.1113/jphysiol.2012.232975; Noury N, 2017, NEUROIMAGE, V158, P406, DOI 10.1016/j.neuroimage.2017.07.010; Noury N, 2016, NEUROIMAGE, V140, P99, DOI 10.1016/j.neuroimage.2016.03.065; Oliveri M, 2001, CEREB CORTEX, V11, P606, DOI 10.1093/cercor/11.7.606; Opitz A, 2017, P NATL ACAD SCI USA, V114, P5243, DOI 10.1073/pnas.1617024114; Opitz A, 2013, NEUROIMAGE, V81, P253, DOI 10.1016/j.neuroimage.2013.04.067; Ozen S, 2010, J NEUROSCI, V30, P11476, DOI 10.1523/JNEUROSCI.5252-09.2010; Parazzini M, 2017, IEEE T BIO-MED ENG, V64, P184, DOI 10.1109/TBME.2016.2553177; Pascual-Leone A, 2001, SCIENCE, V292, P510, DOI 10.1126/science.1057099; PASCUALLEONE A, 1991, NEUROLOGY, V41, P697, DOI 10.1212/WNL.41.5.697; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Pashler H, 2012, PERSPECT PSYCHOL SCI, V7, P528, DOI 10.1177/1745691612465253; Philiastides MG, 2011, CURR BIOL, V21, P980, DOI 10.1016/j.cub.2011.04.034; Plewnia C, 2007, HUM BRAIN MAPP, V28, P238, DOI 10.1002/hbm.20270; Polania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9090; Polania R, 2012, HUM BRAIN MAPP, V33, P2499, DOI 10.1002/hbm.21380; Polania R, 2012, CURR BIOL, V22, P1314, DOI 10.1016/j.cub.2012.05.021; Polania R, 2011, HUM BRAIN MAPP, V32, P1236, DOI 10.1002/hbm.21104; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Rahman A, 2017, J PHYSIOL-LONDON, V595, P3535, DOI 10.1113/JP273005; Reardon S, 2016, NATURE, V531, P283, DOI 10.1038/nature.2016.19534; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Ridding MC, 2010, J PHYSIOL-LONDON, V588, P2291, DOI 10.1113/jphysiol.2010.190314; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Romei V, 2012, CURR BIOL, V22, P807, DOI 10.1016/j.cub.2012.03.025; Romei V, 2011, CURR BIOL, V21, P334, DOI 10.1016/j.cub.2011.01.035; Rose NS, 2016, SCIENCE, V354, P1136, DOI 10.1126/science.aah7011; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Roth Y, 2002, J CLIN NEUROPHYSIOL, V19, P361, DOI 10.1097/00004691-200208000-00008; Roth Y, 2007, J CLIN NEUROPHYSIOL, V24, P31, DOI 10.1097/WNP.0b013e31802fa393; Ruff CC, 2013, SCIENCE, V342, P482, DOI 10.1126/science.1241399; Saiote C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059669; Santarnecchi E, 2013, CURR BIOL, V23, P1449, DOI 10.1016/j.cub.2013.06.022; Saturnino GB, 2017, NEUROIMAGE, V163, P68, DOI 10.1016/j.neuroimage.2017.09.024; Schmidt F.L., 2014, METHODS META ANAL CO; Schwiedrzik CM, 2009, FRONT INTEGR NEUROSC, V3, DOI 10.3389/neuro.07.006.2009; Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137; Silvanto J, 2005, NAT NEUROSCI, V8, P143, DOI 10.1038/nn1379; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Simonsohn U, 2014, PERSPECT PSYCHOL SCI, V9, P666, DOI 10.1177/1745691614553988; Sparing R, 2009, BRAIN, V132, P3011, DOI 10.1093/brain/awp154; Stagg CJ, 2011, CURR BIOL, V21, P480, DOI 10.1016/j.cub.2011.01.069; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Strang S, 2015, SOC COGN AFFECT NEUR, V10, P790, DOI 10.1093/scan/nsu114; Strube W, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12884; Tarapore PE, 2013, NEUROIMAGE, V82, P260, DOI 10.1016/j.neuroimage.2013.05.018; Tehovnik EJ, 2006, J NEUROPHYSIOL, V96, P512, DOI 10.1152/jn.00126.2006; Terney D, 2008, J NEUROSCI, V28, P14147, DOI 10.1523/JNEUROSCI.4248-08.2008; Thielscher A, 2011, NEUROIMAGE, V54, P234, DOI 10.1016/j.neuroimage.2010.07.061; Thirugnanasambandam N, 2011, RESTOR NEUROL NEUROS, V29, P311, DOI 10.3233/RNN-2011-0601; Thut G, 2011, CURR BIOL, V21, P1176, DOI 10.1016/j.cub.2011.05.049; Trepel C, 2000, SYNAPSE, V35, P120, DOI 10.1002/(SICI)1098-2396(200002)35:2<120::AID-SYN4>3.0.CO;2-6; Tufail Y, 2010, NEURON, V66, P681, DOI 10.1016/j.neuron.2010.05.008; Ueyama E, 2011, PSYCHIAT CLIN NEUROS, V65, P77, DOI 10.1111/j.1440-1819.2010.02170.x; van der Groen O, 2016, J NEUROSCI, V36, P5289, DOI 10.1523/JNEUROSCI.4519-15.2016; Violante IR, 2017, ELIFE, V6, DOI [10.7554/elife.22001.001, 10.7554/eLife.22001]; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Wang JX, 2014, SCIENCE, V345, P1054, DOI 10.1126/science.1252900; Wiethoff S, 2014, BRAIN STIMUL, V7, P468, DOI 10.1016/j.brs.2014.02.003; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; Wurzman R, 2016, ANN NEUROL, V80, P1, DOI 10.1002/ana.24689	150	341	346	24	239	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	FEB	2018	21	2					174	187		10.1038/s41593-017-0054-4	http://dx.doi.org/10.1038/s41593-017-0054-4			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FV0TB	29311747	Green Accepted, Green Published			2023-01-03	WOS:000424269900008
J	Lee, JD; Nunes, EV; Novo, P; Bachrach, K; Bailey, GL; Bhatt, S; Farkas, S; Fishman, M; Gauthier, P; Hodgkins, CC; King, J; Lindblad, R; Liu, D; Matthews, AG; May, J; Peavy, KM; Ross, S; Salazar, D; Schkolnik, P; Shmueli-Blumberg, D; Stablein, D; Subramaniam, G; Rotrosen, J				Lee, Joshua D.; Nunes, Edward V., Jr.; Novo, Patricia; Bachrach, Ken; Bailey, Genie L.; Bhatt, Snehal; Farkas, Sarah; Fishman, Marc; Gauthier, Phoebe; Hodgkins, Candace C.; King, Jacquie; Lindblad, Robert; Liu, David; Matthews, Abigail G.; May, Jeanine; Peavy, K. Michelle; Ross, Stephen; Salazar, Dagmar; Schkolnik, Paul; Shmueli-Blumberg, Dikla; Stablein, Don; Subramaniam, Geetha; Rotrosen, John			Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial	LANCET			English	Article							LONG-TERM OUTCOMES; DOUBLE-BLIND; DEPENDENCE; METHADONE; DESIGN	Background Extended-release naltrexone (XR-NTX), an opioid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmacologically and conceptually distinct interventions to prevent opioid relapse. We aimed to estimate the difference in opioid relapse-free survival between XR-NTX and BUP-NX. Methods We initiated this 24 week, open-label, randomised controlled, comparative effectiveness trial at eight US community-based inpatient services and followed up participants as outpatients. Participants were 18 years or older, had Diagnostic and Statistical Manual of Mental Disorders-5 opioid use disorder, and had used non-prescribed opioids in the past 30 days. We stratified participants by treatment site and opioid use severity and used a web-based permuted block design with random equally weighted block sizes of four and six for randomisation (1:1) to receive XR-NTX or BUP-NX. XR-NTX was monthly intramuscular injections (Vivitrol; Alkermes) and BUP-NX was daily self-administered buprenorphine-naloxone sublingual film (Suboxone; Indivior). The primary outcome was opioid relapse-free survival during 24 weeks of outpatient treatment. Relapse was 4 consecutive weeks of any non-study opioid use by urine toxicology or self-report, or 7 consecutive days of self-reported use. This trial is registered with ClinicalTrials.gov,NCT02032433. Findings Between Jan 30, 2014, and May 25, 2016, we randomly assigned 570 participants to receive XR-NTX (n=283) or BUP-NX (n=287). The last follow-up visit was Jan 31, 2017. As expected, XR-NTX had a substantial induction hurdle: fewer participants successfully initiated XR-NTX (204 [72%] of 283) than BUP-NX (270 [94%] of 287; p<0.0001). Among all participants who were randomly assigned (intention-to-treat population, n= 570) 24 week relapse events were greater for XR-NTX (185 [65%] of 283) than for BUP-NX (163 [57%] of 287; hazard ratio [HR] 1.36, 95% CI 1.10-1.68), most or all of this difference accounted for by early relapse in nearly all (70 [89%] of 79) XR-NTX induction failures. Among participants successfully inducted (per-protocol population, n=474), 24 week relapse events were similar across study groups (p=0.44). Opioid-negative urine samples (p<0.0001) and opioid-abstinent days (p<0.0001) favoured BUP-NX compared with XR-NTX among the intention-to-treat population, but were similar across study groups among the per-protocol population. Self-reported opioid craving was initially less with XR-NTX than with BUP-NX (p=0.0012), then converged by week 24 (p=0.20). With the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse events including overdose did not differ between treatment groups. Five fatal overdoses occurred (two in the XR-NTX group and three in the BUP-NX group). Interpretation In this population it is more difficult to initiate patients to XR-NTX than BUP-NX, and this negatively affected overall relapse. However, once initiated, both medications were equally safe and effective. Future work should focus on facilitating induction to XR-NTX and on improving treatment retention for both medications.	[Lee, Joshua D.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA; [Novo, Patricia; Farkas, Sarah; Gauthier, Phoebe; Ross, Stephen; Rotrosen, John] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; [Nunes, Edward V., Jr.] Columbia Univ, Dept Psychiat, New York State Psychiat Inst, Med Ctr, New York, NY USA; [Bachrach, Ken] Tarzana Treatment Centers, Tarzana, CA USA; [Bailey, Genie L.] Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Med Sch, Providence, RI 02912 USA; [Bailey, Genie L.] Stanley St Treatment & Resources, Fall River, MA USA; [Bhatt, Snehal] Univ New Mexico, Sch Med, Dept Psychiat & Behav Sci, Albuquerque, NM 87131 USA; [Fishman, Marc] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Fishman, Marc] Maryland Treatment Ctr, Baltimore, MD USA; [Hodgkins, Candace C.] Gateway Community Serv Inc, Jacksonville, FL USA; [King, Jacquie; Lindblad, Robert; Matthews, Abigail G.; May, Jeanine; Salazar, Dagmar; Shmueli-Blumberg, Dikla; Stablein, Don] Emmes Corp, Rockville, MD USA; [Liu, David; Subramaniam, Geetha] NIDA, Rockville, MD USA; [Peavy, K. Michelle] Evergreen Treatment Serv, Seattle, WA USA; [Schkolnik, Paul] Maryhaven Inc, Columbus, OH USA	New York University; New York University; Columbia University; New York State Psychiatry Institute; Brown University; University of New Mexico; Johns Hopkins University; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Lee, JD (corresponding author), NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA.	joshua.lee@nyumc.org		Nunes, Edward/0000-0002-2055-3425; Lee, Joshua/0000-0003-3161-2950; Shmueli-Blumberg, Dikla/0000-0002-0788-5767	NIDA Clinical Trials Network; NATIONAL INSTITUTE ON DRUG ABUSE [UG1DA013720, UG1DA013034, UG1DA013714, UG1DA013035, U10DA013714, K24DA022412] Funding Source: NIH RePORTER	NIDA Clinical Trials Network; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	NIDA Clinical Trials Network.	Alkermes Inc, HIGHL PRESCR INF VIV; Comer SD, 2006, ARCH GEN PSYCHIAT, V63, P210, DOI 10.1001/archpsyc.63.2.210; Gibson AE, 2007, DRUG ALCOHOL REV, V26, P405, DOI 10.1080/09595230701373834; Hser YI, 2017, J ADDICT MED, V11, P63, DOI 10.1097/ADM.0000000000000274; Hser YI, 2016, ADDICTION, V111, P695, DOI 10.1111/add.13238; IMS Institute for Healthcare Informatics, 2016, US OP REC MED; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Kelty E, 2017, INT J DRUG POLICY, V46, P54, DOI 10.1016/j.drugpo.2017.05.039; Krupitsky E, 2011, LANCET, V377, P1506, DOI 10.1016/S0140-6736(11)60358-9; Kunoe N, 2016, BMC PHARMACOL TOXICO, V17, DOI 10.1186/s40360-016-0061-1; Lee JD, 2016, CONTEMP CLIN TRIALS, V50, P253, DOI 10.1016/j.cct.2016.08.004; Lee JD, 2016, NEW ENGL J MED, V374, P1232, DOI 10.1056/NEJMoa1505409; Lee JD, 2015, ADDICTION, V110, P1008, DOI 10.1111/add.12894; Lobmaier PP, 2010, EUR ADDICT RES, V16, P139, DOI 10.1159/000313336; Mannelli P, 2014, DRUG ALCOHOL DEPEN, V138, P83, DOI 10.1016/j.drugalcdep.2014.02.002; Mattick RP, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub4; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Mokri A, 2016, ADDICTION, V111, P874, DOI 10.1111/add.13259; Morgan JR, 2018, J SUBST ABUSE TREAT, V85, P90, DOI 10.1016/j.jsat.2017.07.001; Nunes EV, 2018, J SUBST ABUSE TREAT, V85, P49, DOI 10.1016/j.jsat.2017.04.016; Nunes EV, 2016, CONTEMP CLIN TRIALS, V51, P34, DOI 10.1016/j.cct.2016.09.006; Reckitt Benckiser Pharmaceuticals Inc, HIGHL PRESCR INF SUB; Sobell L. C.., 1995, ALCOHOL TIMELINE FOL; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Sullivan M, 2017, AM J PSYCHIAT, V174, P459, DOI 10.1176/appi.ajp.2016.16050548; Tanum L, 2017, JAMA PSYCHIAT, V74, P1197, DOI 10.1001/jamapsychiatry.2017.3206; Weiss RD, 2015, DRUG ALCOHOL DEPEN, V150, P112, DOI 10.1016/j.drugalcdep.2015.02.030; Weiss RD, 2011, ARCH GEN PSYCHIAT, V68, P1238, DOI 10.1001/archgenpsychiatry.2011.121	28	363	365	5	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 27	2018	391	10118					309	318		10.1016/S0140-6736(17)32812-X	http://dx.doi.org/10.1016/S0140-6736(17)32812-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU5CE	29150198	Green Accepted			2023-01-03	WOS:000423869500026
J	Eich, G; Bartosova, M; Tischer, C; Wlodkowski, TT; Schaefer, B; Pichl, S; Kraewer, N; Ranchin, B; Vondrak, K; Liebau, MC; Hackert, T; Schmitt, CP				Eich, Gwendolyn; Bartosova, Maria; Tischer, Christian; Wlodkowski, Tanja Tamara; Schaefer, Betti; Pichl, Sebastian; Kraewer, Nicole; Ranchin, Bruno; Vondrak, Karel; Liebau, Max Christoph; Hackert, Thilo; Schmitt, Claus Peter			Bicarbonate buffered peritoneal dialysis fluid upregulates angiopoietin-1 and promotes vessel maturation	PLOS ONE			English	Article							MESOTHELIAL CELLS; INDUCED ANGIOGENESIS; MEMBRANE; GLUCOSE; TRANSPORT; CHILDREN; LACTATE; MODEL	Background Ultrafiltration decline is a progressive issue for patients on chronic peritoneal dialysis (PD) and can be caused by peritoneal angiogenesis induced by PD fluids. A recent pediatric trial suggests better preservation of ultrafiltration with bicarbonate versus lactate buffered fluid; underlying molecular mechanisms are unknown. Methods Angiogenic cytokine profile, tube formation capacity and Receptor Tyrosine Kinase translocation were assessed in primary human umbilical vein endothelial cells following incubation with bicarbonate (BPDF) and lactate buffered (LPDF), pH neutral PD fluid with low glucose degradation product content and lactate buffered, acidic PD fluid with high glucose degradation product content (CPDF). Peritoneal biopsies from age-, PD-vintage- and dialytic glucose exposure matched, peritonitis-free children on chronic PD underwent automated histomorphometry and immunohistochemistry. Results In endothelial cells angiopoietin-1 mRNA and protein abundance increased 200% upon incubation with BPDF, but decreased by 70% with LPDF as compared to medium control; angiopoietin-2 remained unchanged. Angiopoietin-1/Angiopoietin-2 protein ratio was 15 and 3-fold increased with BPDF compared to LPDF and medium. Time-lapse microscopy with automated network analysis demonstrated less endothelial cell tube formation with BPDF compared to LPDF and CPDF incubation. Receptor Tyrosine Kinase translocated to the cell membrane in BPDF but not in LPDF or CPDF incubated endothelial cells. In children dialyzed with BPDF peritoneal vessels were larger and angiopoietin-1 abundance in CD31 positive endothelium higher compared to children treated with LPDF. Conclusion Bicarbonate buffered PD fluid promotes vessel maturation via upregulation of angiopoietin-1 in vitro and in children on dialysis. Our findings suggest a molecular mechanism for the observed superior preservation of ultrafiltration capacity with bicarbonate buffered PD fluid with low glucose degradation product content.	[Eich, Gwendolyn; Bartosova, Maria; Wlodkowski, Tanja Tamara; Schaefer, Betti; Pichl, Sebastian; Kraewer, Nicole; Schmitt, Claus Peter] Univ Hosp Heidelberg, Ctr Pediat & Adolescent Med, Heidelberg, Germany; [Tischer, Christian] European Mol Biol Lab, Heidelberg, Germany; [Ranchin, Bruno] Hosp Civils Lyon, Hop Femme Mere Enfant, Serv Nephrol Pediat, Lyon, France; [Vondrak, Karel] Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; [Liebau, Max Christoph] Univ Hosp Cologne, Dept Pediat, Pediat Nephrol, Cologne, Germany; [Liebau, Max Christoph] Univ Hosp Cologne, Ctr Mol Med, Cologne, Germany; [Hackert, Thilo] Univ Hosp Heidelberg, Dept Surg, Heidelberg, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL); CHU Lyon; Motol University Hospital; University of Cologne; University of Cologne; Ruprecht Karls University Heidelberg	Schmitt, CP (corresponding author), Univ Hosp Heidelberg, Ctr Pediat & Adolescent Med, Heidelberg, Germany.	claus.peter.schmitt@med.uni-heidelberg.de	Liebau, Max Christoph/K-3470-2019	Liebau, Max Christoph/0000-0003-0494-9080	European Training and Research in Peritoneal Dialysis Programme - European Union [287813]; Fresenius Medical Care; Amgen	European Training and Research in Peritoneal Dialysis Programme - European Union; Fresenius Medical Care; Amgen(Amgen)	The study was supported by the European Training and Research in Peritoneal Dialysis Programme, funded by the European Union within the Marie Curie Scheme (287813). http://www.eutripd.eu (Maria Bartosova). Claus Peter Schmitt obtained lecturing and consulting honoraria (Baxter, Fresenius Medical Care) and financial research support (Fresenius Medical Care, Amgen). The other authors have declared that no competing interests exist.	Albrektsson A, 2006, ASAIO J, V52, P276, DOI 10.1097/01.mat.0000219065.26807.27; Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4; Borzych D, 2011, CLIN J AM SOC NEPHRO, V6, P1934, DOI 10.2215/CJN.11411210; Buchel J, 2015, PERITON DIALYSIS INT, V35, P259, DOI 10.3747/pdi.2013.00010; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chen YT, 2014, J AM SOC NEPHROL, V25, P2847, DOI 10.1681/ASN.2013101079; Cooker LA, 2001, PERITON DIALYSIS INT, V21, pS102; Davies SJ, 1998, KIDNEY INT, V54, P2207, DOI 10.1046/j.1523-1755.1998.00180.x; Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Eklund L, 2013, EXP CELL RES, V319, P1271, DOI 10.1016/j.yexcr.2013.03.011; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Fagiani E, 2013, CANCER LETT, V328, P18, DOI 10.1016/j.canlet.2012.08.018; Flessner M, 2003, PERITON DIALYSIS INT, V23, P542; Forster B, 2004, MICROSC RES TECHNIQ, V65, P33, DOI 10.1002/jemt.20092; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Grossin N, 2006, PERITON DIALYSIS INT, V26, P664; Inagi R, 1999, FEBS LETT, V463, P260, DOI 10.1016/S0014-5793(99)01642-7; Johnson DW, 2012, J AM SOC NEPHROL, V23, P1097, DOI 10.1681/ASN.2011121201; Korhonen EA, 2016, J CLIN INVEST, V126, P3495, DOI 10.1172/JCI84923; Margetts PJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133721; Plum J, 2001, AM J KIDNEY DIS, V38, P867, DOI 10.1053/ajkd.2001.27709; Rippe B, 2001, KIDNEY INT, V59, P348, DOI 10.1046/j.1523-1755.2001.00497.x; Rippe B, 2007, AM J PHYSIOL-RENAL, V292, pF1035, DOI 10.1152/ajprenal.00251.2006; Schaefer B, 2016, SCI REP-UK, V6, DOI 10.1038/srep21344; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmitt CP, 2013, CLIN J AM SOC NEPHRO, V8, P108, DOI 10.2215/CJN.00690112; STYLIANOU E, 1990, KIDNEY INT, V37, P1563, DOI 10.1038/ki.1990.150; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470; Williams JD, 2004, KIDNEY INT, V66, P408, DOI 10.1111/j.1523-1755.2004.00747.x; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Zhai YH, 2012, PEDIATR NEPHROL, V27, P1165, DOI 10.1007/s00467-012-2120-1	33	8	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2017	12	12							e0189903	10.1371/journal.pone.0189903	http://dx.doi.org/10.1371/journal.pone.0189903			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ5HM	29253861	Green Published, gold, Green Submitted			2023-01-03	WOS:000418389500073
J	Li, DY; Dai, YK; Zhang, YZ; Huang, MX; Li, RL; Ou-Yang, J; Chen, WJ; Hu, L				Li, Dan-yan; Dai, Yun-kai; Zhang, Yun-zhan; Huang, Meng-xin; Li, Ru-liu; Ou-yang, Jia; Chen, Wei-jing; Hu, Ling			Systematic review and meta-analysis of traditional Chinese medicine in the treatment of constipation-predominant irritable bowel syndrome	PLOS ONE			English	Review							FUNCTIONAL GASTROINTESTINAL DISORDERS; PERMEABILITY; DIAGNOSIS	Aim This meta-analysis analyzed the efficacy and safety of traditional Chinese medicine (TCM) for the treatment of irritable bowel syndrome with constipation (IBS-C). Methods We searched seven electronic databases for randomized controlled trials investigating the efficacy of TCM in the treatment of IBS-C. The search period was from inception to June 1, 2017. Eligible RCTs compared TCM with cisapride and mosapride. Article quality was evaluated with the Cochrane Risk Bias Tool in the Cochrane Handbook by two independent reviewers. Begg's test was performed to evaluate publication bias. Review Manager 5.3 and Stata 12.0 were used for analyses. Results Eleven eligible studies comprising a total of 906 participants were identified. In the primary outcome, TCM showed significant improvement in overall clinical efficacy compared with cisapride and mosapride (odds ratio [OR] = 4.00; 95% confidence interval [CI]: 2.74,5.84; P < 0.00001). In terms of secondary outcomes, TCM significantly alleviated abdominal pain (OR = 5.69; 95% CI: 2.35, 13.78; P = 0.0001), defecation frequency (OR = 4.38; 95% CI: 1.93, 9.93. P = 0.0004), and stool form (OR = 4.96; 95% CI: 2.11, 11.65; P = 0.0002) in the treatment group as compared to the control group. A lower recurrence rate was associated with TCM as compared to cisapride and mosapride (OR = 0.15; 95% CI: 0.08, 0.27; P < 0.00001). No adverse effects were observed during TCM treatment. Conclusions TCM showed greater improvement in terms of clinical efficacy in the treatment of IBS-C than cisapride and mosapride, although it was not possible to draw a definitive conclusion due to the small sample size, high risk, and low quality of the studies. Large multi-center and long-term high-quality randomized control trials are needed.	[Li, Dan-yan; Dai, Yun-kai; Zhang, Yun-zhan; Huang, Meng-xin; Li, Ru-liu; Chen, Wei-jing; Hu, Ling] Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Ou-yang, Jia] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Jiangsu, Peoples R China	Guangzhou University of Chinese Medicine; Soochow University - China	Hu, L (corresponding author), Guangzhou Univ Chinese Med, Inst Gastroenterol, Guangzhou, Guangdong, Peoples R China.	drhuling@163.com	hu, ling/GWC-1104-2022		National Natural Science Foundation of China [81373563, 81774238]; Innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine [7, 2016KYTD07]; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine [64]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine	This research was supported by National Natural Science Foundation of China, No.81373563; Innovation team to foster scientific research projects of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine (2016) No.7, No.2016KYTD07; Construction of high-level university of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine (2016) No.64; National Natural Science Foundation of China, No.81774238. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, CHINA J TRAD CHIN ME, V25, P1062; Barbara G, 2012, J CLIN GASTROENTEROL, V46, pS52, DOI 10.1097/MCG.0b013e318264e918; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Brandt LJ, 2009, AM J GASTROENTEROL, V104, pS1, DOI 10.1038/ajg.2008.122; Cai W., 2005, SHANGHAI ZHONG YI YA, V39, P14; Camilleri M, 2012, AM J PHYSIOL-GASTR L, V303, pG775, DOI 10.1152/ajpgi.00155.2012; Chang JY, 2010, TRENDS PHARMACOL SCI, V31, P326, DOI 10.1016/j.tips.2010.04.008; Chen JF, 2013, MATH PROBL ENG, V2013, P11; Chen XG, 2005, SHANDONG ZHONG YI ZA, V24, P526; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Drossman DA, 1999, GUT, V45, P1; Drossman DA, 2006, GASTROENTEROLOGY, V130, P1377, DOI 10.1053/j.gastro.2006.03.008; Enck P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.14; Everhart JE, 2009, GASTROENTEROLOGY, V136, P376, DOI 10.1053/j.gastro.2008.12.015; Fan L, 2009, CHINA PHARMACIST, V9, P1360; Fu F., 2015, CLIN STUDY MAREN PIL; Grundmann O, 2010, J GASTROEN HEPATOL, V25, P691, DOI 10.1111/j.1440-1746.2009.06120.x; Gwee KA, 2010, J GASTROEN HEPATOL, V25, P1189, DOI 10.1111/j.1440-1746.2010.06353.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hussain Z, 2006, ALIMENT PHARM THER, V23, P465, DOI 10.1111/j.1365-2036.2006.02776.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jiang XY, 2013, CLIN STUDY MECH KUAN; Krogius-Kurikka L, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-95; Leung WK, 2006, AM J GASTROENTEROL, V101, P1574, DOI 10.1111/j.1572-0241.2006.00576.x; Li HY, 2011, ZHEJIANG J TRADITION, V46, P788; Li Q, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/232147; Liao J, 2011, J SICHUAN TRADITIONA, V29, P59; Lin ZY, 2014, MODERN J INTEGRATED, V23, P343; Liu JP, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004116.pub2; Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061; Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029; National TCM Authority, 1994, TCM ILLN DIAGN EFF S, P11; Pan G, 2000, Zhonghua Liu Xing Bing Xue Za Zhi, V21, P26; Qian CJ, 2011, CLIN STUDY SUPPLEMEN; Qiu B., 2013, EXPT STUDY MA ZHI JI; Schmulson MJ, 2017, J NEUROGASTROENTEROL, V23, P151, DOI 10.5056/jnm16214; Shi J, 2008, WORLD J GASTROENTERO, V14, P454, DOI 10.3748/wjg.14.454; Stanghellini V, 2002, AM J GASTROENTEROL, V97, P2738; Sung JJY, 2004, ALIMENT PHARM THER, V20, P1205, DOI 10.1111/j.1365-2036.2004.02242.x; Tillisch K, 2011, GASTROENTEROLOGY, V140, P407, DOI 10.1053/j.gastro.2010.12.014; Tillisch K, 2011, GASTROENTEROLOGY, V140, P91, DOI 10.1053/j.gastro.2010.07.053; Wang CL, 2008, JIANGXI J TRADITIONA, V39, P21; Wang FD, 2015, CLIN STUDY SAN ZANG; Wu JH, 2006, GUANGMING J CHINESE, V21, P34; Xiao Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122397; Xiong Li-shou, 2004, Zhonghua Yi Xue Za Zhi, V84, P278; Xu YY, 2014, LISHIZHEN MED MATERI, P2192; Yang SW, 2016, ZHEJIANG J TRADITION; Yuan R, 2000, PHARMACOL THERAPEUT, V86, P191, DOI 10.1016/S0163-7258(00)00039-5; Yue C, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002126; Zhang XP, 2014, CHINA J CHINESE MED, V29, P1667; Zhang ZY, 2016, CHINA PRACTICAL MED, V11, P37; Zheng X.Y., 2002, CHINESE HERBAL MED N, P124	53	16	17	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2017	12	12							e0189491	10.1371/journal.pone.0189491	http://dx.doi.org/10.1371/journal.pone.0189491			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ5HM	29253850	gold, Green Submitted, Green Published			2023-01-03	WOS:000418389500033
J	Lai, Q; Wang, HY; Li, AG; Xu, YH; Tang, L; Chen, Q; Zhang, CF; Gao, Y; Song, JF; Du, ZZ				Lai, Qi; Wang, Haiyong; Li, Angui; Xu, Yinhui; Tang, Liang; Chen, Qiang; Zhang, Chunfang; Gao, Yang; Song, Jianfei; Du, Zhenzong			Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells	ONCOGENE			English	Article							PD-L1 EXPRESSION; GENE-EXPRESSION; IFN-GAMMA; IMMUNOTHERAPY; PATHWAY	IFN-gamma-induced PD-L1 expression represents the existence of tumor-specific T cells, which predicts high-response rate to anti-PD-1/L1 therapy, but loss-of-function of IFN signals (e.g., JAK mutation) induces adaptive immune resistance in patients with low-response rate. Interferon regulatory factors (IRF) are frequently epigenetic silenced in carcinogenesis, while the role of methylation in anti-PD-1/L1 therapy remains unclear. We here investigated the methylation status of IFN-gamma related genes IRF1/8 and IFN-alpha/beta-related genes IRF3/7 in lung cancer tissues and found that only highly methylated IRF1 and 7 negatively correlated to cd274 (coding PD-L1) expression, similar to JAK mutation. Interestingly, decitibine (DAC) as methylation inhibitor could hypomethylate IRF1/7 to restore PD-L1 level. Meanwhile, IRF7 enhanced constitutive PD-L1 expression, which was independent of IFN-gamma though directly promote transcription of PD-L1, leading to abrogating cytotoxic T lymphocytes (CTLs) generation which could be restored by anti-PD-L1 antibody, or siRNA-IRF7. The supplement of DAC to anti-PD-1 therapy in vivo improve the efficiency of anti-tumor with less methylated IRF1/7, more interferon-related genes expression (e.g., CXCL9) and IFN-gamma/CD8+ T-cells infiltrations, suggesting that additional treatment of DAC could rescue the ability to response to IFN in lung cancer patients with anti-PD-1/L1 therapy resistance.	[Lai, Qi; Zhang, Chunfang; Gao, Yang; Du, Zhenzong] Cental South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Lai, Qi] Southwest Med Univ, Dept Thorac Surg, Affiliated Tradit Med Hosp, Luzhou, Sichuan, Peoples R China; [Wang, Haiyong; Li, Angui] Guilin Med Univ, Affiliated Hosp, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China; [Xu, Yinhui; Tang, Liang; Du, Zhenzong] Guilin Med Univ, Affiliated Nanxi Shan Hosp, Dept Cardiothorac Surg, Guilin, Guangxi, Peoples R China; [Xu, Yinhui; Tang, Liang; Du, Zhenzong] Nanxi Shan Hosp Guangxi Zhuang Autonomous Reg, Guilin, Guangxi, Peoples R China; [Chen, Qiang; Song, Jianfei] Guilin Med Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China	Central South University; Southwest Medical University; Guilin Medical University; Guilin Medical University; Guilin Medical University	Du, ZZ (corresponding author), Cental South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China.; Du, ZZ (corresponding author), Guilin Med Univ, Affiliated Nanxi Shan Hosp, Dept Cardiothorac Surg, Guilin, Guangxi, Peoples R China.; Du, ZZ (corresponding author), Nanxi Shan Hosp Guangxi Zhuang Autonomous Reg, Guilin, Guangxi, Peoples R China.; Song, JF (corresponding author), Guilin Med Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China.	guilinsjf@163.com; duzhenzong@sina.com			Natural Science Foundation of Guangxi [2016GXNSFAA380138]; Science Research and Technology Development Plan of Guangxi [2015BC12007]	Natural Science Foundation of Guangxi(National Natural Science Foundation of Guangxi Province); Science Research and Technology Development Plan of Guangxi	This work was supported by the Natural Science Foundation of Guangxi (2016GXNSFAA380138) and Science Research and Technology Development Plan of Guangxi (2015BC12007).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Breugom AJ, 2015, LANCET ONCOL, V16, P200, DOI 10.1016/S1470-2045(14)71199-4; Ding L, 2017, MOL CANCER THER, V16, P1068, DOI 10.1158/1535-7163.MCT-16-0454; Dunn GP, 2005, CANCER RES, V65, P3447, DOI 10.1158/0008-5472.CAN-04-4316; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Ma D, 2014, SCI REP-UK, V4, DOI 10.1038/srep06331; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mehta A, 2015, CANCER METAST REV, V34, P229, DOI 10.1007/s10555-015-9563-3; Naylor EC, 2016, SURG ONCOL CLIN N AM, V25, P601, DOI 10.1016/j.soc.2016.02.011; Ortmann CA, 2005, NUCLEIC ACIDS RES, V33, P6895, DOI 10.1093/nar/gki1001; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Ribas A, 2016, J EXP MED, V213, P2835, DOI 10.1084/jem.20161462; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Socinski MA, 2016, J THORAC ONCOL, V11, P1411, DOI 10.1016/j.jtho.2016.05.024; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542; Yamashita M, 2010, CANCER SCI, V101, P1708, DOI 10.1111/j.1349-7006.2010.01581.x; Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355; Zhang Z, 2017, LEUKEMIA LYMPHOMA, V58, P969, DOI 10.1080/10428194.2016.1219903	22	38	40	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2302	2312		10.1038/s41388-018-0125-3	http://dx.doi.org/10.1038/s41388-018-0125-3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29422611				2023-01-03	WOS:000431100200007
J	Floreani, M; Enrico, R; Taboga, P; Ganzini, A; Pisot, R; Simunic, B; Biolo, G; Reggiani, C; Passaro, A; Narici, M; Rittweger, J; di Prampero, PE; Lazzer, S				Floreani, Mirco; Rejc, Enrico; Taboga, Paolo; Ganzini, Alessandro; Pisot, Rado; Simunic, Bostjan; Biolo, Gianni; Reggiani, Carlo; Passaro, Angelina; Narici, Marco; Rittweger, Joern; di Prampero, Pietro Enrico; Lazzer, Stefano			Effects of 14 days of bed rest and following physical training on metabolic cost, mechanical work, and efficiency during walking in older and young healthy males	PLOS ONE			English	Article							FUNCTIONAL IMPAIRMENT; HINDLIMB SUSPENSION; LEVEL WALKING; MUSCLE VOLUME; BODY-MASS; ADULTS; GAIT; BALANCE; AGE; MEN	In this study, we investigated: i) the effects of bed rest and a subsequent physical training program on metabolic cost (Cw), mechanical work and efficiency during walking in older and young men; ii) the mechanisms underlying the higher Cw observed in older than young men. Twenty-three healthy male subjects (N = 16 older adults, age 59.6 +/- 3.4 years; N = 7 young, age: 23.1 +/- 2.9 years) participated in this study. The subjects underwent 14 days of bed rest followed by two weeks of physical training (6 sessions). Cw, mechanical work, efficiency, and co-contraction time of proximal muscles (vastus lateralis and biceps femoris) and distal muscles (gastrocnemius medialis and tibialis anterior) were measured during walking at 0.83, 1.11, 1.39, 1.67 m.s(-1) before bed rest (pre-BR), after bed rest (post-BR) and after physical training (post-PT). No effects of bed rest and physical training were observed on the analysed parameters in either group. Older men showed higher Cw and lower efficiency at each speed (average + 25.1 and -20.5%, P<0.001, respectively) compared to young. Co-contraction time of proximal and distal muscles were higher in older than in young men across the different walking speeds (average +30.0 and +110.3%, P<0.05, respectively). The lack of bed rest and physical training effects on the parameters analyzed in this study may be explained by the healthy status of both young and older men, which could have mitigated the effects of these interventions on walking motor function. On the other hand, the fact that older adults showed greater Cw, overall higher co-contraction time of antagonist lower limb muscles, and lower efficiency compared to the young cohort throughout a wide range of walking speed may suggest that older adults sacrificed economy of walking to improve stability.	[Floreani, Mirco; Rejc, Enrico; Taboga, Paolo; Ganzini, Alessandro; di Prampero, Pietro Enrico; Lazzer, Stefano] Univ Udine, Dept Med Area, Udine, Italy; [Floreani, Mirco; Ganzini, Alessandro; di Prampero, Pietro Enrico; Lazzer, Stefano] Univ Udine, Sch Sport Sci, Udine, Italy; [Taboga, Paolo] Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; [Taboga, Paolo] Calif State Univ Sacramento, Dept Kinesiol & Hlth Sci, Sacramento, CA 95819 USA; [Pisot, Rado; Simunic, Bostjan] Sci & Res Ctr Koper, Inst Kinesiol Res, Koper, Slovenia; [Biolo, Gianni] Univ Trieste, Dept Med Surg & Hlth Sci, Div Internal Med, Trieste, Italy; [Reggiani, Carlo] Univ Padua, Dept Biomed Sci, Padua, Italy; [Passaro, Angelina] Univ Ferrara, Sect Internal & Cardioresp Med, Dept Med Sci, Ferrara, Italy; [Narici, Marco] Univ Nottingham, Derby Royal Hosp, MRC ARUK Ctr Musculoskeletal Ageing Res, Derby, England; [Rittweger, Joern] German Aerosp Ctr DLR, Inst Aerosp Med, Cologne, Germany; [Rittweger, Joern] Univ Cologne, Dept Pediat & Adolescent Med, Cologne, Germany	University of Udine; University of Udine; University of Louisville; California State University System; California State University Sacramento; University of Trieste; University of Padua; University of Ferrara; University of Nottingham; Helmholtz Association; German Aerospace Centre (DLR); University of Cologne	Lazzer, S (corresponding author), Univ Udine, Dept Med Area, Udine, Italy.; Lazzer, S (corresponding author), Univ Udine, Sch Sport Sci, Udine, Italy.	stefano.lazzer@uniud.it	Rittweger, Jörn/A-4308-2009; Passaro, Angelina/P-3401-2015; Biolo, Gianni/AAB-4983-2022	Rittweger, Jörn/0000-0002-2223-8963; Passaro, Angelina/0000-0001-8462-7000; Floreani, Mirco/0000-0002-4417-9597; TABOGA, PAOLO/0000-0001-6529-8299; Simunic, Bostjan/0000-0003-1565-7833; BIOLO, GIANNI/0000-0002-6397-1598	Cross-border Cooperation Program Slovenia - Italy; European Regional Development Fund [042-417 2/2009-18/052012]	Cross-border Cooperation Program Slovenia - Italy; European Regional Development Fund(European Commission)	The study was conducted in the framework of the project PANGeA: CB147 - Physical Activity and Nutrition for Quality Ageing, supported by the Cross-border Cooperation Program Slovenia - Italy 2007-2013 and co-financed by the European Regional Development Fund (grant no. 042-417 2/2009-18/052012) to RP.	Aboutorabi A, 2016, AGING CLIN EXP RES, V28, P393, DOI 10.1007/s40520-015-0420-6; Alkner BA, 2004, EUR J APPL PHYSIOL, V93, P294, DOI 10.1007/s00421-004-1172-8; Bauby CE, 2000, J BIOMECH, V33, P1433, DOI 10.1016/S0021-9290(00)00101-9; Bean J, 2002, J AM GERIATR SOC, V50, P663; Bean JF, 2004, J AM GERIATR SOC, V52, P799, DOI 10.1111/j.1532-5415.2004.52222.x; Belavy DL, 2009, EUR J APPL PHYSIOL, V107, P489, DOI 10.1007/s00421-009-1136-0; Biolo G, 2008, AM J CLIN NUTR, V88, P950, DOI 10.1093/ajcn/88.4.950; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; CAVAGNA GA, 1977, J PHYSIOL-LONDON, V268, P467, DOI 10.1113/jphysiol.1977.sp011866; CHEN L, 1994, J BIOMECH, V27, P493, DOI 10.1016/0021-9290(94)90024-8; Coker RH, 2015, J GERONTOL A-BIOL, V70, P91, DOI 10.1093/gerona/glu123; Conley KE, 2000, J PHYSIOL-LONDON, V526, P211, DOI 10.1111/j.1469-7793.2000.00211.x; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dean JC, 2007, IEEE T BIO-MED ENG, V54, P1919, DOI 10.1109/TBME.2007.901031; Delmonico MJ, 2007, J AM GERIATR SOC, V55, P769, DOI 10.1111/j.1532-5415.2007.01140.x; DEMPSTER WT, 1959, AM J PHYS ANTHROPOL, V17, P289, DOI 10.1002/ajpa.1330170405; ELBLE RJ, 1991, J NEUROL, V238, P1, DOI 10.1007/BF00319700; Enoka RM., 2015, NEUROMECHANICS HUMAN, P285; FERRANDO AA, 1995, AVIAT SPACE ENVIR MD, V66, P976; Finley F R, 1969, Arch Phys Med Rehabil, V50, P140; Frost G, 1997, J ELECTROMYOGR KINES, V7, P179, DOI 10.1016/S1050-6411(97)84626-3; GARBY L, 1987, ACTA PHYSIOL SCAND, V129, P443, DOI 10.1111/j.1365-201X.1987.tb10613.x; GARDETTO PR, 1989, J APPL PHYSIOL, V66, P2739, DOI 10.1152/jappl.1989.66.6.2739; Goodpaster BH, 2006, J GERONTOL A-BIOL, V61, P1059, DOI 10.1093/gerona/61.10.1059; Grabowski A, 2005, J APPL PHYSIOL, V98, P579, DOI 10.1152/japplphysiol.00734.2004; Gu MJ, 1996, J BIOMECH, V29, P319, DOI 10.1016/0021-9290(95)00052-6; HAGEMAN PA, 1986, PHYS THER, V66, P1382, DOI 10.1093/ptj/66.9.1382; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Hess JA, 2005, J MANIP PHYSIOL THER, V28, P582, DOI 10.1016/j.jmpt.2005.08.013; Hess JA, 2006, AGING CLIN EXP RES, V18, P107, DOI 10.1007/BF03327425; HOENIG HM, 1991, J AM GERIATR SOC, V39, P220, DOI 10.1111/j.1532-5415.1991.tb01632.x; Hortobagyi T, 2000, J ELECTROMYOGR KINES, V10, P117, DOI 10.1016/S1050-6411(99)00026-7; Hortobagyi T, 2011, J GERONTOL A-BIOL, V66, P541, DOI 10.1093/gerona/glr008; Hortobagyi T, 2009, GAIT POSTURE, V29, P558, DOI 10.1016/j.gaitpost.2008.12.007; Janssen I, 2002, J AM GERIATR SOC, V50, P889, DOI 10.1046/j.1532-5415.2002.50216.x; Judge JO, 1996, J GERONTOL A-BIOL, V51, pM303, DOI 10.1093/gerona/51A.6.M303; Kerrigan DC, 1998, ARCH PHYS MED REHAB, V79, P317, DOI 10.1016/S0003-9993(98)90013-2; Ko SU, 2009, J BIOMECH, V42, P1834, DOI 10.1016/j.jbiomech.2009.05.037; Kolahi A, 2007, BIOMED SIGNAL PROCES, V2, P59, DOI 10.1016/j.bspc.2007.02.001; Kortebein P, 2008, J GERONTOL A-BIOL, V63, P1076, DOI 10.1093/gerona/63.10.1076; Kubo K, 2004, BRIT J SPORT MED, V38, P324, DOI 10.1136/bjsm.2003.005595; Laughton CA, 2003, GAIT POSTURE, V18, P101, DOI 10.1016/S0966-6362(02)00200-X; Macaluso A, 2002, MUSCLE NERVE, V25, P858, DOI 10.1002/mus.10113; Malatesta D, 2003, J APPL PHYSIOL, V95, P2248, DOI 10.1152/japplphysiol.01106.2002; Malone LA, 2010, J NEUROPHYSIOL, V103, P1954, DOI 10.1152/jn.00832.2009; MARTIN PE, 1992, J APPL PHYSIOL, V73, P200; Marusic U, 2015, PSYCHOL AGING, V30, P334, DOI 10.1037/pag0000021; Mian OS, 2006, ACTA PHYSIOL, V186, P127, DOI 10.1111/j.1748-1716.2006.01522.x; MINETTI AE, 1993, J PHYSIOL-LONDON, V472, P725, DOI 10.1113/jphysiol.1993.sp019969; Mulder E, 2014, J MUSCULOSKEL NEURON, V14, P359; Nardello F, 2011, HUM MOVEMENT SCI, V30, P90, DOI 10.1016/j.humov.2010.05.012; Narici MV, 2011, EUR J APPL PHYSIOL, V111, P403, DOI 10.1007/s00421-010-1556-x; NIGG BM, 1992, FOOT ANKLE, V13, P336, DOI 10.1177/107110079201300608; OHIRA Y, 1992, J APPL PHYSIOL, V73, pS51, DOI 10.1152/jappl.1992.73.2.S51; Onambele GL, 2008, J BIOMECH, V41, P3133, DOI 10.1016/j.jbiomech.2008.09.004; Pavei G, 2016, J APPL PHYSIOL, V120, P1223, DOI 10.1152/japplphysiol.00839.2015; Peterka R J, 1990, J Vestib Res, V1, P49; Peterson DS, 2010, GAIT POSTURE, V31, P355, DOI 10.1016/j.gaitpost.2009.12.005; Petrella RJ, 1997, AM J PHYS MED REHAB, V76, P235, DOI 10.1097/00002060-199705000-00015; Pigos G., 2006, SPORT J; Pisot R, 2016, J APPL PHYSIOL, V120, P922, DOI 10.1152/japplphysiol.00858.2015; Rejc E, 2015, EUR J APPL PHYSIOL, V115, P1323, DOI 10.1007/s00421-015-3111-2; Saibene F, 2003, EUR J APPL PHYSIOL, V88, P297, DOI 10.1007/s00421-002-0654-9; Santilli V, 2014, CLIN CASES MINER BON, V11, P177, DOI 10.11138/ccmbm/2014.11.3.177; Schuch CP, 2011, BIOL SPORT, V28, P165, DOI 10.5604/959282; SHAPIRO R, 1978, RES QUART, V49, P197, DOI 10.1080/10671315.1978.10615524; Stelmach G E, 1985, Clin Geriatr Med, V1, P679; Sudarsky L, 2001, ADV NEUROL, V87, P111; Taboga P, 2012, EUR J APPL PHYSIOL, V112, P4027, DOI 10.1007/s00421-012-2389-6; Winiarski S., 2003, ACTA BIOENG BIOMECH, V5, P544; WINTER DA, 1990, PHYS THER, V70, P340, DOI 10.1093/ptj/70.6.340	71	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2018	13	3							e0194291	10.1371/journal.pone.0194291	http://dx.doi.org/10.1371/journal.pone.0194291			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FY9MC	29529070	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000427189300048
J	Dobbie, F; MacKintosh, AM; Clegg, G; Stirzaker, R; Bauld, L				Dobbie, Fiona; MacKintosh, Anne Marie; Clegg, Gareth; Stirzaker, Rebecca; Bauld, Linda			Attitudes towards bystander cardiopulmonary resuscitation: Results from a cross-sectional general population survey	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; SOCIOECONOMIC-STATUS; SCHOOL-STUDENTS; CPR; SURVIVAL; INTERVENTION; KNOWLEDGE	Survival from out-of-hospital cardiac arrest (OHCA) varies across the developed world. Although not all OHCA are recoverable, the survival rate in Scotland is lower than in comparable countries, with higher average survival rates of 7.9% in England and 9% across Europe. The purpose of this paper is to explore the barriers, facilitators and public attitudes to administering bystander cardiopulmonary resuscitation (CPR) which could inform future policy and initiatives to improve the rate of bystander CPR. Data was collected via a cross-sectional general population survey of 1027 adults in Scotland. 52% of respondents had been trained in CPR. Of those who were not trained, two fifths (42%) expressed a willingness to receive CPR training. Fewer than half (49%) felt confident administering CPR, rising to 82% if they were talked through it by a call handler. Multivariate analyses identified that people in social grade C2DE were less likely than those in social grade ABC1 to be CPR trained and less confident to administer CPR if talked through by a call handler. The older a person was, the less likely they were to be CPR trained, show willingness to be CPR trained or be confident to administer bystander CPR with or without instruction from an emergency call handler. These findings are particularly relevant considering that most OHCA happen in the homes of older people. In a developed country such as Scotland with widely available CPR training, only half of the adult population reported feeling confident about administering bystander CPR. Further efforts tailored specifically for people who are older, unemployed and have a lower social grade are required to increase knowledge, confidence and uptake of training in bystander CPR.	[Dobbie, Fiona; MacKintosh, Anne Marie; Bauld, Linda] Univ Stirling, Fac Hlth Sci & Sport, Inst Social Mkt, Stirling, Scotland; [Clegg, Gareth] Univ Edinburgh, Resuscitat Res Grp, Edinburgh, Midlothian, Scotland; [Stirzaker, Rebecca] Heriot Watt Univ, Sch Social Sci, Edinburgh, Midlothian, Scotland	University of Stirling; University of Edinburgh; Heriot Watt University	Dobbie, F (corresponding author), Univ Stirling, Fac Hlth Sci & Sport, Inst Social Mkt, Stirling, Scotland.	fiona.dobbie@stir.ac.uk	Stirzaker, Rebecca/AAA-9713-2021; Dobbie, Fiona/L-5858-2016	Dobbie, Fiona/0000-0002-8294-8203; Clegg, Gareth/0000-0002-4314-611X; Stirzaker, Rebecca/0000-0002-0962-3664	Resuscitation Research Group, University of Edinburgh	Resuscitation Research Group, University of Edinburgh	The study was funded by the Resuscitation Research Group, University of Edinburgh. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaberg AMR, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-24; Axelsson A, 2000, RESUSCITATION, V47, P71, DOI 10.1016/S0300-9572(00)00209-4; Coons SJ, 2009, RESUSCITATION, V80, P334, DOI 10.1016/j.resuscitation.2008.11.024; Donohoe RT, 2006, RESUSCITATION, V71, P70, DOI 10.1016/j.resuscitation.2006.03.003; Fischer P, 2011, PSYCHOL BULL, V137, P517, DOI 10.1037/a0023304; Ghose R, 2010, RESUSCITATION, V81, P1488, DOI 10.1016/j.resuscitation.2010.06.012; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Hasselqvist-Ax I, 2015, NEW ENGL J MED, V372, P2307, DOI 10.1056/NEJMoa1405796; Hawkes C, 2017, RESUSCITATION, V133; Johnston TC, 2003, RESUSCITATION, V56, P67, DOI 10.1016/S0300-9572(02)00277-0; Kanstad BK, 2011, RESUSCITATION, V82, P1053, DOI 10.1016/j.resuscitation.2011.03.033; Lindner TW, 2011, RESUSCITATION, V82, P1508, DOI 10.1016/j.resuscitation.2011.06.016; Lynch B, 2010, RESUSCITATION, V81, P568, DOI 10.1016/j.resuscitation.2009.12.022; Mitchell MJ, 2009, PREHOSP EMERG CARE, V13, P478, DOI 10.1080/10903120903144833; Perkins GD, 2012, HEART, V98, P529, DOI 10.1136/heartjnl-2011-300802; Public Health Seattle & King Country Division of Emergency Medical Services, 2013, 2013 ANN REP KING CO; Riegel B, 2006, RESUSCITATION, V70, P98, DOI 10.1016/j.resuscitation.2005.10.029; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Stromsoe A, 2015, EUR HEART J, V36, P863, DOI 10.1093/eurheartj/ehu240; Swor R, 2006, ACAD EMERG MED, V13, P596, DOI 10.1197/j.aem.2005.12.021; Vaillancourt C, 2008, RESUSCITATION, V79, P417, DOI 10.1016/j.resuscitation.2008.07.012	21	34	34	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0193391	10.1371/journal.pone.0193391	http://dx.doi.org/10.1371/journal.pone.0193391			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513722	Green Submitted, Green Published, gold			2023-01-03	WOS:000426896800056
J	Wakeman, SE; Raja, AS				Wakeman, Sarah E.; Raja, Ali S.			Case 37-2017: A Man with Unintentional Opioid Overdose REPLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Wakeman, Sarah E.; Raja, Ali S.] Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Wakeman, SE (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.		Raja, Ali S./AAE-5103-2019					Carlson RG, 2016, DRUG ALCOHOL DEPEN, V160, P127, DOI 10.1016/j.drugalcdep.2015.12.026; Fox AD, 2015, J SUBST ABUSE TREAT, V48, P112, DOI 10.1016/j.jsat.2014.07.015; Weiss RD, 2015, DRUG ALCOHOL DEPEN, V150, P112, DOI 10.1016/j.drugalcdep.2015.02.030	3	0	0	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 1	2018	378	9					873	873						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX7GP	29490179				2023-01-03	WOS:000426256300027
J	Goel, R; Chappidi, MR; Patel, EU; Ness, PM; Cushing, MM; Frank, SM; Tobian, AAR				Goel, Ruchika; Chappidi, Meera R.; Patel, Eshan U.; Ness, Paul M.; Cushing, Melissa M.; Frank, Steven M.; Tobian, Aaron A. R.			Trends in Red Blood Cell, Plasma, and Platelet Transfusions in the United States, 1993-2014	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							COLLECTION		[Goel, Ruchika; Cushing, Melissa M.] Weill Cornell Med Coll, Dept Pathol, New York, NY USA; [Chappidi, Meera R.; Patel, Eshan U.; Ness, Paul M.; Tobian, Aaron A. R.] Johns Hopkins Univ, Dept Pathol, Carnegie 437,600 N Wolfe St, Baltimore, MD 21287 USA; [Frank, Steven M.] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA	Cornell University; Johns Hopkins University; Johns Hopkins University	Tobian, AAR (corresponding author), Johns Hopkins Univ, Dept Pathol, Carnegie 437,600 N Wolfe St, Baltimore, MD 21287 USA.	atobian1@jhmi.edu	Callahan, Charles D/L-1641-2013	Patel, Eshan/0000-0003-2174-5004	National Institutes of Health [NIH 5R01AI120938-02, 1R01AI128779-01]; Weill Cornell Medical College; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI128779, R01AI120938] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Weill Cornell Medical College; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by grants NIH 5R01AI120938-02 and 1R01AI128779-01 from the National Institutes of Health (Dr Tobian) and from Weill Cornell Medical College (Dr Goel).	Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Chung KW, 2016, TRANSFUSION, V56, P2184, DOI 10.1111/trf.13644; Ellingson KD, 2017, TRANSFUSION, V57, P1588, DOI 10.1111/trf.14165; Kaufman RM, 2015, ANN INTERN MED, V162, P205, DOI 10.7326/M14-1589; West KA, 2006, TRENDS HOSPITALIZATI; Whitaker B, 2016, TRANSFUSION, V56, P2173, DOI 10.1111/trf.13676	6	37	38	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	2018	319	8					825	+		10.1001/jama.2017.20121	http://dx.doi.org/10.1001/jama.2017.20121			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX6GK	29486023	Green Published, Bronze			2023-01-03	WOS:000426181300027
J	Kouyoumdjian, FG; Patel, A; To, MJ; Kiefer, L; Regenstreif, L				Kouyoumdjian, Fiona G.; Patel, Alexandra; To, Matthew J.; Kiefer, Lori; Regenstreif, Leonora			Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey	PLOS ONE			English	Article							MEDICATION-ASSISTED TREATMENT; DRUG-USE; HEPATITIS-C; SUBSTITUTION TREATMENT; UNITED-STATES; SUBSTANCE USE; RISK; HIV; INMATES; PRISON	Background Substance use and substance use disorders are common in people who experience detention or incarceration in Canada, and opioid agonist treatment (OAT) may reduce the harms associated with substance use disorders. We aimed to define current physician practice in provincial correctional facilities in Ontario with respect to prescribing OAT and to identify potential barriers and facilitators to prescribing OAT. Methods We invited all physicians practicing in the 26 provincial correctional facilities for adults in Ontario to participate in an online survey. Results Twenty-seven physicians participated, with representation from most correctional facilities in Ontario. Of participating physicians, 52% reported prescribing methadone and 48% reported prescribing buprenorphine/naloxone to patients in provincial correctional facilities. Nineteen percent of participants reported initiating methadone treatment and 11% reported initiating buprenorphine/naloxone for patients in custody. Participants identified multiple barriers to initiating OAT in provincial correctional facilities including concerns about medication diversion and safety, concerns about initiating treatment in patients who are not currently using opioids, lack of linkage with community-based providers and the Ministry of Community Safety and Correctional Services policy. Identified facilitators to initiating OAT were support from institutional health care staff and administrative staff, adequate resources for program delivery and access to linkage with community-based OAT providers. Conclusions This study identifies opportunities to improve OAT programs and to improve access to OAT for persons in provincial correctional facilities in Ontario.	[Kouyoumdjian, Fiona G.; Regenstreif, Leonora] McMaster Univ, Dept Family Med, Hamilton, ON, Canada; [Kouyoumdjian, Fiona G.; To, Matthew J.] St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada; [Patel, Alexandra] Univ Toronto, Toronto, ON, Canada; [To, Matthew J.] Dalhousie Univ, Fac Med, Halifax, NS, Canada; [Kiefer, Lori] Ontario Minist Community Safety & Correct Serv, Toronto, ON, Canada; [Kiefer, Lori] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Dalhousie University; University of Toronto	Kouyoumdjian, FG (corresponding author), McMaster Univ, Dept Family Med, Hamilton, ON, Canada.; Kouyoumdjian, FG (corresponding author), St Michaels Hosp, Ctr Urban Hlth Solut, Toronto, ON, Canada.	kouyouf@mcmaster.ca		Kouyoumdjian, Fiona/0000-0002-6869-7516; Regenstreif, Leonora Julie/0000-0001-7161-1712	Canadian Institutes of Health Research; Royal College of Physicians and Surgeons of Canada Regional Professional Development Grant	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Royal College of Physicians and Surgeons of Canada Regional Professional Development Grant	Fiona Kouyoumdjian received salary support from a Fellowship from the Canadian Institutes of Health Research and from a Royal College of Physicians and Surgeons of Canada Regional Professional Development Grant. The The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2004, Can J Public Health, V95 Suppl 1, pS9; [Anonymous], 2004, HIV AIDS Policy Law Rev, V9, P45; [Anonymous], 2011, METH MAINT TREATM PR; Beaudette J, 2013, PREVALENCE MENTAL HL; Bell A, 2004, NEEDS ASSESSMENT FED; Bland RC, 1998, INT J LAW PSYCHIAT, V21, P273, DOI 10.1016/S0160-2527(98)00005-3; Boutwell Amy E, 2007, J Opioid Manag, V3, P328; Brink JH, 2001, INT J LAW PSYCHIAT, V24, P339, DOI 10.1016/S0160-2527(01)00071-1; Burchell AN, 2003, JAIDS-J ACQ IMM DEF, V32, P534, DOI 10.1097/00126334-200304150-00011; Buxton JA, 2009, CAN J PUBLIC HEALTH, V100, P121, DOI 10.1007/BF03405520; Calzavara LM, 2003, ADDICTION, V98, P1257, DOI 10.1046/j.1360-0443.2003.00466.x; Carrieri MP, 2006, CLIN INFECT DIS, V43, pS197, DOI 10.1086/508184; Connery HS, 2015, HARVARD REV PSYCHIAT, V23, P63, DOI 10.1097/HRP.0000000000000075; Crocker AG, 2007, J INTELLECT DEV DIS, V32, P143, DOI 10.1080/13668250701314053; Cropsey KL, 2012, J NATL MED ASSOC, V104, P487, DOI 10.1016/S0027-9684(15)30214-5; DeBeck K, 2009, ADDICTION, V104, P69, DOI 10.1111/j.1360-0443.2008.02387.x; Degenhardt L, 2014, ADDICTION, V109, P1306, DOI 10.1111/add.12536; Derkzen DM, 2012, ASSESSMENT ABORIGINA; Dufour A, 1996, AIDS, V10, P1009, DOI 10.1097/00002030-199610090-00012; Elgar FJ, 2003, CAN J PSYCHIAT, V48, P633, DOI 10.1177/070674370304800911; Farrell S., 2010, PREVALENCE INJECTION; Ford PM, 2000, QJM-MON J ASSOC PHYS, V93, P113, DOI 10.1093/qjmed/93.2.113; Fullerton CA, 2014, PSYCHIAT SERV, V65, P146, DOI 10.1176/appi.ps.201300235; Gordon AJ, 2011, PSYCHOL ADDICT BEHAV, V25, P215, DOI 10.1037/a0022776; Government of Canada, 2017, METH PROGR 2017; Grant B, 2004, HIGH INTENSITY SUBST; Grant BA., 2005, INTENSIVE SUPPORT UN; Groot E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157512; Hopley AAB, 2012, ADDICT BEHAV, V37, P947, DOI 10.1016/j.addbeh.2012.03.031; Johnson S, 2011, CHARACTERISTICS PART; Johnson S, 2010, ASSESSING IMPACT ENH; Kelsey CM, 2017, MATERN CHILD HLTH J, V21, P1260, DOI 10.1007/s10995-016-2224-5; Kiefer L., 2017, E COMMUNICATION, V13; Kitson A, 2011, IDENTIFYING KNOWLEDG; Kouyoumdjian Fiona G, 2016, CMAJ Open, V4, pE153, DOI 10.9778/cmajo.20150098; Kouyoumdjian FG, 2014, CAN J PUBLIC HEALTH, V105, pE198, DOI 10.17269/cjph.105.4193; Kunic D., 2006, COMPUTERIZED ASSESSM; Legare F., 2017, ASSESSING BARRIERS F; Marsden J, 2017, ADDICTION, V112, P1408, DOI 10.1111/add.13779; Martin RE, 2005, CAN J PUBLIC HEALTH, V96, P97, DOI 10.1007/BF03403669; Martin RE, 2008, CAN J PUBLIC HEALTH, V99, P262, DOI 10.1007/BF03403751; Mattick R, 2003, COCHRANE DATABASE SY; Methadone Treatment and Services Advisory Committee, 2016, METH TREATM SERV ADV; Mullins P., 2012, OFFENDER SUBSTANCE U; Murphy A, 2005, TIME OUT 2 PROFILE B; Nicholls T., 2004, INT J FORENSIC MENT, V3, P167, DOI [DOI 10.1080/14999013.2004.10471205, 10.1080/14999013.2004.10471205]; Nosyk B, 2013, HEALTH AFFAIR, V32, P1462, DOI 10.1377/hlthaff.2012.0846; Nunn A, 2009, DRUG ALCOHOL DEPEN, V105, P83, DOI 10.1016/j.drugalcdep.2009.06.015; Perry AE, 2015, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD010862.PUB2; Plourde C, 2002, SUBST USE MISUSE, V37, P47, DOI 10.1081/JA-120001496; Plourde C, 2012, PRISON J, V92, P506, DOI 10.1177/0032885512457555; Poulin C, 2007, CAN MED ASSOC J, V177, P252, DOI 10.1503/cmaj.060760; Power J, 2011, 250 CORR SERV CAN; Reitano Julie, 2017, ADULT CORRECTIONAL S; Rezansoff SN, 2013, PSYCHOL PUBLIC POL L, V19, P443, DOI 10.1037/a0033907; Robinson D., 1996, SUMMARY FINDINGS 199; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Smith A, 2013, TIME OUT 3 PROFILE B; Sordo L, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1550; Springer Sandra A, 2008, J Opioid Manag, V4, P81; Thompson J, 2011, ABORIGINAL MEN SUMMA; United Nations Human Rights, 1990, BAS PRINC TREATM PRI; United Nations Office on Drugs and Crime, 2006, HIV AIDS PREV CAR TR; Wakeman SE, 2017, J ADDICT MED, V11, P1, DOI 10.1097/ADM.0000000000000275; Walley AY, 2008, J GEN INTERN MED, V23, P1393, DOI 10.1007/s11606-008-0686-x; Young L., 2017, GLOBAL NEWS     0731; Zakaria D, 2012, RELATIONSHIPS LIFETI; Zakaria D., 2010, SUMMARY EMERGING FIN	68	15	15	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2018	13	2							e0192431	10.1371/journal.pone.0192431	http://dx.doi.org/10.1371/journal.pone.0192431			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FW4LB	29447177	Green Published, Green Submitted, gold			2023-01-03	WOS:000425283900034
J	Mateos, MV; Dimopoulos, MA; Cavo, M; Suzuki, K; Jakubowiak, A; Knop, S; Doyen, C; Lucio, P; Nagy, Z; Kaplan, P; Pour, L; Cook, M; Grosicki, S; Crepaldi, A; Liberati, AM; Campbell, P; Shelekhova, T; Yoon, SS; Iosava, G; Fujisaki, T; Garg, M; Chiu, C; Wang, J; Carson, R; Crist, W; Deraedt, W; Nguyen, H; Qi, M; San-Miguel, J				Mateos, M. -V.; Dimopoulos, M. A.; Cavo, M.; Suzuki, K.; Jakubowiak, A.; Knop, S.; Doyen, C.; Lucio, P.; Nagy, Z.; Kaplan, P.; Pour, L.; Cook, M.; Grosicki, S.; Crepaldi, A.; Liberati, A. M.; Campbell, P.; Shelekhova, T.; Yoon, S. -S.; Iosava, G.; Fujisaki, T.; Garg, M.; Chiu, C.; Wang, J.; Carson, R.; Crist, W.; Deraedt, W.; Nguyen, H.; Qi, M.; San-Miguel, J.		ALCYONE Trial Investigators	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIPLE-MYELOMA; ANTIBODY DARATUMUMAB; INITIAL TREATMENT; DEXAMETHASONE; LENALIDOMIDE; DIAGNOSIS; CRITERIA	BACKGROUND The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. METHODS In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival. RESULTS At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold of 1 tumor cell per 105 white cells), as compared with 6.2% of those in the control group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab-associated infusion-related reactions occurred in 27.7% of the patients. CONCLUSIONS Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. The daratumumab-containing regimen was associated with more grade 3 or 4 infections.	Univ Hosp Salamanca, Inst Invest Biomed Salamanca, Salamanca, Spain; [San-Miguel, J.] Clin Univ Navarra, Ctr Invest Med Aplicada, Inst Invest Sanitaria Navarra, Ctr Invest Biomed Red Canc, Pamplona, Spain; [Dimopoulos, M. A.] Natl & Kapodistrian Univ Athens, Athens, Greece; [Cavo, M.] Univ Bologna, Inst Hematol, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Liberati, A. M.] Azienda Osped Santa Maria, Terni, Italy; [Suzuki, K.] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan; [Jakubowiak, A.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA; [Knop, S.] Wurzburg Univ, Med Ctr, Wurzburg, Germany; [Doyen, C.] UCL, Ctr Hosp Univ UCL Namur, Yvoir, Belgium; [Deraedt, W.] Janssen Res & Dev, Beerse, Belgium; [Lucio, P.] Champalimaud Ctr Unknown, Lisbon, Portugal; [Nagy, Z.] Semmelweis Egyet, Budapest, Hungary; [Kaplan, P.] Dnepropetrovsk City Clin Hosp 4, Dnepropetrovsk, Ukraine; [Pour, L.] Univ Hosp Brno, Brno, Czech Republic; [Cook, M.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Garg, M.] Leicester Royal Infirmary Haematol, Leicester, Leics, England; [Grosicki, S.] Silesian Med Univ, Sch Publ Hlth, Dept Canc Prevent, Katowice, Poland; [Crepaldi, A.] Clin Tratamento E, Cuiaba, Brazil; [Campbell, P.] Andrew Love Canc Ctr, Geelong, Vic, Australia; [Shelekhova, T.] Clin Profess Pathol, Saratov, Russia; [Yoon, S. -S.] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Iosava, G.] LTD Medinvent Inst Hlth, Tbilisi, Georgia; [Fujisaki, T.] Matsuyama Red Cross Hosp, Matsuyama, Ehime, Japan; [Chiu, C.; Carson, R.; Crist, W.; Qi, M.] Janssen Res & Dev, Spring House, PA USA; [Wang, J.; Nguyen, H.] Janssen Res & Dev, Raritan, NJ USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Navarra; National & Kapodistrian University of Athens; University of Bologna; Japanese Red Cross Medical Center; University of Tokyo; University of Chicago; University of Chicago Medical Center; University of Wurzburg; Universite Catholique Louvain; Johnson & Johnson; Janssen Pharmaceuticals; Fundacao Champalimaud; Semmelweis University; University Hospital Brno; University of Birmingham; Medical University Silesia; Seoul National University (SNU); Matsuyama Red Cross Hospital; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson; Janssen Pharmaceuticals	Mateos, MV (corresponding author), Paseo San Vicente 58, Salamanca 37007, Spain.	mvmateos@usal.es	de Oteyza, Jaime Perez/K-5514-2012; Dimopoulos, Meletios Athanasios/AAD-4130-2019; Yoon, Sung-Soo/J-2773-2012; San-Miguel, Jesús F./V-8977-2018; martinez, joaquin/AAN-6939-2020; CAVO, MICHELE/AAK-8274-2020; Grosicki, Sebastian/AAG-2917-2019; , Van Eygen Koen/AAF-7668-2020; Symeonidis, Argiris/K-2287-2019; Shelekhova, Tatiana Vladimirovna/B-2812-2014; Maisnar, Vladimir/Q-8579-2017; Oriol, Albert/K-9923-2017	de Oteyza, Jaime Perez/0000-0002-8338-2037; San-Miguel, Jesús F./0000-0002-9183-4857; martinez, joaquin/0000-0001-7908-0063; CAVO, MICHELE/0000-0003-4514-3227; , Van Eygen Koen/0000-0001-8285-906X; Symeonidis, Argiris/0000-0002-3685-3473; Berneman, Zwi/0000-0002-9133-4588; Chiu, Christopher W./0000-0001-9744-991X; Hus, Marek/0000-0002-9036-6625; Cook, Mark/0000-0001-8647-9208; Grosicki, Sebastian/0000-0003-2644-1050; Lucio, Paulo/0000-0003-0175-7534; Maisnar, Vladimir/0000-0003-1738-4920; Garg, Mamta/0000-0002-3560-0132; Encinas, Cristina/0000-0002-9001-9754; Martin Sanchez, Jesus/0000-0003-4250-4824; Oriol, Albert/0000-0001-6804-2221	Janssen Research and Development; ALCYONE [NCT02195479]	Janssen Research and Development; ALCYONE	Supported by Janssen Research and Development.r Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479.)	Anderson KC, 2016, J NATL COMPR CANC NE, V14, P389, DOI 10.6004/jnccn.2016.0046; Attal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750; AVETLOISEAU H, 2016, BLOOD, V128; Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; de Weers M, 2011, J IMMUNOL, V186, P1840, DOI 10.4049/jimmunol.1003032; Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Howlader NNA, 2020, SEER CANC STAT REV; Krejcik J, 2016, BLOOD, V128, P384, DOI 10.1182/blood-2015-12-687749; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Kumar SK, 2017, J NATL COMPR CANC NE, V15, P230, DOI 10.6004/jnccn.2017.0023; Mateos MV, 2015, HAEMATOLOGICA, V100, P84; Mateos MV, 2010, LANCET ONCOL, V11, P934, DOI 10.1016/S1470-2045(10)70187-X; McCudden C, 2016, CLIN CHEM LAB MED, V54, P1095, DOI 10.1515/cclm-2015-1031; Merz M, 2017, ANN HEMATOL, V96, P987, DOI 10.1007/s00277-017-2991-0; Millennium Pharmaceuticals, 2017, VELC BORT INJ SUBC I; Moreau P, 2017, ANN ONCOL, V28, P52, DOI 10.1093/annonc/mdx096; National Cancer Institute (U.S.), 2009, COMMON TERMINOLOGY C; Overdijk MB, 2016, J IMMUNOL, V197, P807, DOI 10.4049/jimmunol.1501351; Overdijk MB, 2015, MABS-AUSTIN, V7, P311, DOI 10.1080/19420862.2015.1007813; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Palumbo A, 2010, J CLIN ONCOL, V28, P5101, DOI 10.1200/JCO.2010.29.8216; Rajkumar SV, 2016, MAYO CLIN PROC, V91, P101, DOI 10.1016/j.mayocp.2015.11.007; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rajkumar SV, 2011, BLOOD, V117, P4691, DOI 10.1182/blood-2010-10-299487; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; San Miguel JF, 2013, J CLIN ONCOL, V31, P448, DOI 10.1200/JCO.2012.41.6180; Song X, 2016, CURR MED RES OPIN, V32, P95, DOI 10.1185/03007995.2015.1105202	29	590	604	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 8	2018	378	6					518	528		10.1056/NEJMoa1714678	http://dx.doi.org/10.1056/NEJMoa1714678			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV1OX	29231133	Bronze			2023-01-03	WOS:000424335200007
J	van Loenhout, JAF; Cuesta, JG; Abello, JE; Isiderio, JM; de Lara-Banquesio, ML; Guha-Sapir, D				van Loenhout, Joris Adriaan Frank; Cuesta, Julita Gil; Abello, Jason Echavez; Mari Isiderio, Juan; Lourdes de Lara-Banquesio, Maria; Guha-Sapir, Debarati			The impact of Typhoon Haiyan on admissions in two hospitals in Eastern Visayas, Philippines	PLOS ONE			English	Article							HURRICANE KATRINA; JAPAN EARTHQUAKE; HEALTH; MANAGEMENT; PNEUMONIA; MORTALITY; TSUNAMI; WOMEN; LEYTE; RISK	Objectives We investigated the short-term impact of Typhoon Haiyan, one of the strongest typhoons ever to make landfall, on the pattern of admissions in two hospitals in Eastern Visayas, the Philippines. Methods This study took place at Eastern Visayas Regional Medical Center (EVRMC) in Tacloban, and Ormoc District Hospital (ODH) in Ormoc. We determined whether there were differences in the pattern of admissions between the week before and the three weeks after Haiyan by using information on sex, age, diagnosis, ward and outcome at discharge from patient records. Results There was a drop in admissions in both hospitals after Haiyan as compared to before. Admissions climbed back to the baseline after ten days in EVRMC and after two weeks in ODH. When comparing the period after Haiyan to the period before, there was a relative increase in male versus female admissions in ODH (OR 2.8, 95%CI1.7-4.3), but not in EVRMC. Patients aged >= 50 years and 0-14 years had the highest relative increase in admissions. There was a relative decrease in admissions for the ICD10 group 'Pregnancy, childbirth and the puerperium' (OR 0.4, 95%CI 0.3-0.6), and an increase in 'Certain infectious and parasitic diseases' (OR 2.1, 95%CI 1.2-3.5), mainly gastroenteritis, and 'Diseases of the respiratory system' (OR 1.8, 95%CI 1.0-3.0), mainly pneumonia, compared to all other diagnosis groups in ODH. Out of all reasons for admission within the study period, 66% belong to these three ICD-10 groups. Data on reasons for admission were not available for EVRMC. Conclusions The observed reduction in patients after the Typhoon calls for ensuring that hospital accessibility should be protected and reinforced, especially for pregnant women, by trying to remove debris in the direct hospital vicinity. Hospitals in areas prone to tropical cyclones should be prepared to treat large numbers of patients with gastroenteritis and pneumonia, as part of their disaster plans.	[van Loenhout, Joris Adriaan Frank; Cuesta, Julita Gil; Abello, Jason Echavez; Guha-Sapir, Debarati] Catholic Univ Louvain, Inst Hlth & Soc, CRED, Brussels, Belgium; [Mari Isiderio, Juan] Eastern Visayas Reg Med Ctr, Tacloban, Philippines; [Lourdes de Lara-Banquesio, Maria] Ormoc Dist Hosp, Ormoc, Philippines	Universite Catholique Louvain	van Loenhout, JAF (corresponding author), Catholic Univ Louvain, Inst Hlth & Soc, CRED, Brussels, Belgium.	Joris.vanloenhout@uclouvain.be	van Loenhout, Joris/AAV-2075-2020; Gil-Cuesta, Julita/AFV-5338-2022	van Loenhout, Joris/0000-0001-7810-7738; Gil-Cuesta, Julita/0000-0002-8291-9701	United States Agency for International Development (USAID), Office of U.S. Disaster Assistance (OFDA) [AID-OFDA-A-15-00036]	United States Agency for International Development (USAID), Office of U.S. Disaster Assistance (OFDA)(United States Agency for International Development (USAID))	This study is part of the EM-DAT project and has been financed by the United States Agency for International Development (USAID), Office of U.S. Disaster Assistance (OFDA), agreement n degrees: AID-OFDA-A-15-00036. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson AH, 2009, KIDNEY INT, V75, P1202, DOI 10.1038/ki.2009.5; Bambaren C, 2017, PREHOSP DISASTER MED, V32, P106, DOI 10.1017/S1049023X16001254; Brolin K, 2015, PLOS CURR, V7; Carter Chelsea J., 2013, CNN; Chang MP, 2016, DISASTER MED PUBLIC, V10, P240, DOI 10.1017/dmp.2015.165; CRED, 2017, CTR RES EP DIS INT D; Daito H, 2013, THORAX, V68, P544, DOI 10.1136/thoraxjnl-2012-202658; Doocy S, 2013, PLOS CURR, V5; Guha-Sapir D, 2009, PREHOSP DISASTER MED, V24, P493, DOI 10.1017/S1049023X00007391; Harville E, 2010, OBSTET GYNECOL SURV, V65, P713, DOI 10.1097/OGX.0b013e31820eddbe; Kang P, 2012, J TRAUMA ACUTE CARE, V72, P1626, DOI 10.1097/TA.0b013e3182479e07; Ching PK, 2015, WEST PAC SURVEILL RE, V6, DOI [10.5365/wpsar.2015.6.2.HYN_005, 10.5365/WPSAR.2015.6.2.HYN_005]; Lin G, 2016, WORLD J SURG; Mori N, 2014, GEOPHYS RES LETT, V41, P5106, DOI 10.1002/2014GL060689; OCHA, 8 OCHA; Oni O, 2015, JOGNN-J OBST GYN NEO, V44, P256, DOI 10.1111/1552-6909.12560; Ram PK, 2014, AM J TROP MED HYG, V90, P968, DOI 10.4269/ajtmh.13-0532; Read DJ, 2016, ANZ J SURG, V86, P361, DOI 10.1111/ans.13175; Saito-Obata M, 2016, PLOS CURR, V8; Smith CM, 2005, ACAD EMERG MED, V12, P1201, DOI [10.1111/j.1553-2712.2005.tb01498.x, 10.1197/j.aem.2005.06.024]; Suzuki K, 2016, J OBSTET GYNAECOL RE, V42, P1704, DOI 10.1111/jog.13102; Suzuki K, 2016, J EPIDEMIOL, V26, P76, DOI 10.2188/jea.JE20150055; Ventura RJ, 2015, WEST PAC SURVEILL RE, V6, DOI [10.2471/WPSAR.2014.5.1.010, 10.5365/wpsar.2014.5.1.010]; World Health Organization Western Pacific Region, 1 WHO W PAC REG; World Health Organization (WHO), ICD 10 VERS 2016; Yamanda S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-000865; Yonkers KA, 2014, JAMA PSYCHIAT, V71, P897, DOI 10.1001/jamapsychiatry.2014.558	27	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2018	13	1							e0191516	10.1371/journal.pone.0191516	http://dx.doi.org/10.1371/journal.pone.0191516			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU1NX	29381720	Green Published, gold			2023-01-03	WOS:000423617800023
J	Cormier, N; McGlone, JJ; Leszyk, J; Hardy, DM				Cormier, Nathaly; McGlone, John J.; Leszyk, John; Hardy, Daniel M.			Immunocontraceptive target repertoire defined by systematic identification of sperm membrane alloantigens in a single species	PLOS ONE			English	Article							ZONA-PELLUCIDA; LIPID RAFTS; ANCHORED PROTEINS; BOAR SPERMATOZOA; BINDING-ACTIVITY; AUTO-ANTIGENS; FAMILY; FERTILIZATION; MOUSE; EXPRESSION	Sperm competence in animal fertilization requires the collective activities of numerous sperm-specific proteins that are typically alloimmunogenic in females. Consequently, sperm membrane alloantigens are potential targets for contraceptives that act by blocking the proteins' functions in gamete interactions. Here we used a targeted proteomics approach to identify the major alloantigens in swine sperm membranes and lipid rafts, and thereby systematically defined the repertoire of these sperm-specific proteins in a single species. Gilts with high alloantibody reactivity to proteins in sperm membranes or lipid rafts produced fewer offspring (73% decrease) than adjuvant-only or nonimmune control animals. Alloantisera recognized more than 20 potentially unique sperm membrane proteins and five sperm lipid raft proteins resolved on two-dimensional immunoblots with or without prior enrichment by anion exchange chromatography. Dominant sperm membrane alloantigens identified by mass spectrometry included the ADAMs fertilin a, fertilin 13, and cyritestin. Less abundant alloantigens included ATP synthase Fl p subunit, myo-inositol monophosphatase-1, and zymogen granule membrane glycoprotein-2. Immunodominant sperm lipid raft alloantigens included SAMP14, lymphocyte antigen 6K, and the epididymal sperm protein E12. Of the fifteen unique membrane alloantigens identified, eleven were known sperm-specific proteins with uncertain functions in fertilization, and four were not previously suspected to exist as sperm-specific isoforms. De novo sequences of tryptic peptides from sperm membrane alloantigen "M6" displayed no evident homology to known proteins, so is a newly discovered sperm-specific gene product in swine. We conclude that alloimmunizing gilts with sperm membranes or lipid rafts evokes formation of antibodies to a relatively small number of dominant alloantigens that include known and novel sperm-specific proteins with possible functions in fertilization and potential utility as targets for immunocontraception.	[Cormier, Nathaly; Hardy, Daniel M.] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; [McGlone, John J.] Texas Tech Univ, Dept Anim & Food Sci, Lubbock, TX 79409 USA; [Leszyk, John] Univ Massachusetts, Sch Med, Prote & Mass Spectrometry Facil, Shrewsbury, MA USA; [Leszyk, John] Univ Massachusetts, Sch Med, Dept Biochem & Pharmacol, Shrewsbury, MA USA; [Cormier, Nathaly] Univ Wisconsin, Dept Biol Sci, Whitewater, WI 53190 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; University of Massachusetts System; University of Massachusetts System; University of Wisconsin System	Hardy, DM (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.	Daniel.Hardy@TTUHSC.edu	Hardy, Daniel/AAP-5823-2020; McGlone, John/AAJ-7362-2021	Hardy, Daniel/0000-0002-7297-3093; 	Texas Department of Agriculture; National Institutes of Health [HD35166]	Texas Department of Agriculture; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funded in part by a grant from the Texas Department of Agriculture to JJM and DMH and by grant HD35166 from the National Institutes of Health to DMH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aitken RJ, 2002, J REPROD IMMUNOL, V57, P273, DOI 10.1016/S0165-0378(02)00010-4; ALEXANDER NJ, 1989, CURR OPIN IMMUNOL, V1, P1125, DOI 10.1016/0952-7915(89)90003-4; Alonso MA, 2001, J CELL SCI, V114, P3957; BABA T, 1989, BIOCHEM BIOPH RES CO, V160, P1026, DOI 10.1016/S0006-291X(89)80105-6; BABA T, 1994, J BIOL CHEM, V269, P10133; Bae TJ, 2004, PROTEOMICS, V4, P3536, DOI 10.1002/pmic.200400952; Bi M, 2003, BIOCHEM J, V375, P477, DOI 10.1042/BJ20030753; Bradley Mark P., 2002, P401, DOI 10.1016/B978-012311629-1/50016-4; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CALVETE JJ, 1993, FEBS LETT, V334, P37, DOI 10.1016/0014-5793(93)81675-P; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Cho C, 2012, NAT REV UROL, V9, P550, DOI 10.1038/nrurol.2012.167; Cross NL, 2004, BIOL REPROD, V71, P1367, DOI 10.1095/biolreprod.104.030502; DOSTALOVA Z, 1995, EUR J BIOCHEM, V230, P329, DOI 10.1111/j.1432-1033.1995.tb20567.x; Druce HC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027952; Ekhlasi-Hundrieser M, 2007, GENE, V392, P253, DOI 10.1016/j.gene.2007.01.002; Ensslin M, 1998, BIOL REPROD, V58, P1057, DOI 10.1095/biolreprod58.4.1057; Flesch FM, 1998, BIOL REPROD, V59, P1530, DOI 10.1095/biolreprod59.6.1530; FREUND J, 1953, J EXP MED, V97, P711, DOI 10.1084/jem.97.5.711; Fujihara Y, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.112888; Fujinoki M, 2003, J BIOCHEM, V134, P559, DOI 10.1093/jb/mvg174; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; Gibbs GM, 2010, ENDOCRINOLOGY, V151, P2331, DOI 10.1210/en.2009-1255; GOLDBERG E, 1973, SCIENCE, V181, P458, DOI 10.1126/science.181.4098.458; GUMLEY TP, 1995, IMMUNOL CELL BIOL, V73, P277, DOI 10.1038/icb.1995.45; Haden NP, 2000, BIOL REPROD, V63, P1839, DOI 10.1095/biolreprod63.6.1839; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hao ZL, 2002, BIOL REPROD, V66, P735, DOI 10.1095/biolreprod66.3.735; Hardy D. M., 2002, FERTILIZATION; HARDY DM, 1988, BIOL REPROD, V38, P423, DOI 10.1095/biolreprod38.2.423; Hickox JR, 2001, J BIOL CHEM, V276, P41502, DOI 10.1074/jbc.M106795200; Huang SY, 2005, PROTEOMICS, V5, P4205, DOI 10.1002/pmic.200401284; HUANG TTF, 1981, SCIENCE, V213, P1267, DOI 10.1126/science.7268435; Jonakova V, 1998, J REPROD FERTIL, V114, P25, DOI 10.1530/jrf.0.1140025; JONAKOVA V, 1991, FEBS LETT, V280, P183, DOI 10.1016/0014-5793(91)80233-S; Khalil MB, 2006, DEV BIOL, V290, P220, DOI 10.1016/j.ydbio.2005.11.030; Kim T, 2006, BIOL REPROD, V74, P744, DOI 10.1095/biolreprod.105.048892; Kirkpatrick JF, 2011, AM J REPROD IMMUNOL, V66, P40, DOI 10.1111/j.1600-0897.2011.01003.x; Lahm HW, 2000, ELECTROPHORESIS, V21, P2105, DOI 10.1002/1522-2683(20000601)21:11<2105::AID-ELPS2105>3.0.CO;2-M; Luo LL, 2016, ONCOTARGET, V7, P11165, DOI 10.18632/oncotarget.7163; Martinez-Heredia J, 2006, PROTEOMICS, V6, P4356, DOI 10.1002/pmic.200600094; Maruyama M, 2010, BIOCHEM BIOPH RES CO, V402, P75, DOI 10.1016/j.bbrc.2010.09.117; Naz RK, 2011, AM J REPROD IMMUNOL, V66, P5, DOI 10.1111/j.1600-0897.2011.01000.x; Nickels JD, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002214; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Nixon B, 2009, J CELL PHYSIOL, V218, P122, DOI 10.1002/jcp.21575; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; ORAND MG, 1981, BIOL REPROD, V25, P621, DOI 10.1095/biolreprod25.3.621; ORAND MG, 1988, DEV BIOL, V129, P231, DOI 10.1016/0012-1606(88)90177-7; PARRY RV, 1992, MOL REPROD DEV, V33, P108, DOI 10.1002/mrd.1080330115; Peddinti D, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-19; POLLACK SJ, 1994, P NATL ACAD SCI USA, V91, P5766, DOI 10.1073/pnas.91.13.5766; PRIMAKOFF P, 1983, DEV BIOL, V98, P417, DOI 10.1016/0012-1606(83)90371-8; PRIMAKOFF P, 1988, NATURE, V335, P543, DOI 10.1038/335543a0; Quill TA, 1996, J BIOL CHEM, V271, P33509, DOI 10.1074/jbc.271.52.33509; Rajendran L, 2005, J CELL SCI, V118, P1099, DOI 10.1242/jcs.01681; SALING PM, 1986, DEV BIOL, V117, P511, DOI 10.1016/0012-1606(86)90318-0; Schafer B, 2003, REPROD DOMEST ANIM, V38, P111, DOI 10.1046/j.1439-0531.2003.00403.x; Shadan S, 2004, BIOL REPROD, V71, P253, DOI 10.1095/biolreprod.103.026435; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Shetty J, 2003, J BIOL CHEM, V278, P30506, DOI 10.1074/jbc.M301713200; Sleight SB, 2005, BIOL REPROD, V73, P721, DOI 10.1095/biolreprod.105.041533; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tanphaichitr N, 1998, MOL REPROD DEV, V49, P203, DOI 10.1002/(SICI)1098-2795(199802)49:2&lt;203::AID-MRD11&gt;3.0.CO;2-Z; Travis AJ, 2001, DEV BIOL, V240, P599, DOI 10.1006/dbio.2001.0475; Tung KSK, 2017, J CLIN INVEST, V127, P1046, DOI 10.1172/JCI89927; TUNG KSK, 1980, BIOL REPROD, V23, P877, DOI 10.1095/biolreprod23.4.877; TUNG KSK, 1981, IMMUNOL REV, V55, P217, DOI 10.1111/j.1600-065X.1981.tb00344.x; van Gestel RA, 2005, MOL HUM REPROD, V11, P583, DOI 10.1093/molehr/gah200; Vazquez-Levin MH, 2014, AM J REPROD IMMUNOL, V72, P206, DOI 10.1111/aji.12272; Verdier Y, 2002, J ANDROL, V23, P529; Wang DX, 2004, RAPID COMMUN MASS SP, V18, P96, DOI 10.1002/rcm.1289; Wheeler K, 2011, P NATL ACAD SCI USA, V108, P7511, DOI 10.1073/pnas.1017615108; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu A, 2007, J CELL PHYSIOL, V213, P201, DOI 10.1002/jcp.21113; Yanagimachi R., 1994, P189; YANAGIMACHI R, 1981, BIOL REPROD, V24, P512, DOI 10.1095/biolreprod24.3.512; Yoshitake H, 2008, BIOCHEM BIOPH RES CO, V372, P277, DOI 10.1016/j.bbrc.2008.05.088; Yoshitake Y, 2015, CLIN CANCER RES, V21, P312, DOI 10.1158/1078-0432.CCR-14-0202	81	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2018	13	1							e0190891	10.1371/journal.pone.0190891	http://dx.doi.org/10.1371/journal.pone.0190891			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FS8II	29342175	Green Published, Green Submitted, gold			2023-01-03	WOS:000422653800035
J	Vavilala, MS; Lujan, SB; Qiu, Q; Bell, MJ; Ballarini, NM; Guadagnoli, N; Depetris, MA; Faguaga, GA; Baggio, GM; Busso, LO; Garcia, ME; Carrillo, ORG; Medici, PL; Saenz, SS; Vanella, EE; Farr, CK; Petroni, GJ				Vavilala, Monica S.; Lujan, Silvia B.; Qiu, Qian; Bell, Michael J.; Ballarini, Nicolas M.; Guadagnoli, Nahuel; Alejandra Depetris, Maria; Faguaga, Gabriela A.; Baggio, Gloria M.; Busso, Leonardo O.; Garcia, Mirta E.; Gonzalez Carrillo, Osvaldo R.; Medici, Paula L.; Saenz, Silvia S.; Vanella, Elida E.; Farr, Carly K.; Petroni, Gustavo J.			Intensive care treatments associated with favorable discharge outcomes in Argentine children with severe traumatic brain injury: For the South American Guideline Adherence Group	PLOS ONE			English	Article							PERFORMANCE CATEGORY; PRESSURE	Objective Little is known about the critical care management of children with traumatic brain injury (TBI) in low middle income countries. We aimed to identify indicators of intensive care unit (ICU) treatments associated with favorable outcomes in Argentine children with severe TBI. Methods We conducted a secondary analysis of data from patients previously enrolled in a prospective seven center study of children with severe TBI who were admitted to an ICU in one of the seven study centers. Severe TBI was defined by head AIS >= 3, head CT with traumatic lesion, and admission GCS < 9. Seven indicators of best practice TBI care were examined. The primary outcome was discharge Pediatric Cerebral Performance Category Scale [PCPC] and Pediatric Overall Performance category Scale [POPC]. We also examined variation in ICU care and in- patient mortality. Results Of the 117 children, 67% were male and 7.5 (4.3) years on average, 92% had isolated TBI. Hypotension (54%) was more common than hypoxia (28%) and clinical or radiographic signs of high intracranial pressure (ICP) were observed in 92%. Yet, ICP monitoring occurred in 60% and hyperosmolar therapy was used in only 36%. Adherence to indicators of best TBI practice ranged from 55.6% to 83.7% across the seven centers and adherence was associated with favorable discharge PCPC (aRR 0.98; 95% CI [0.96, 0.99]), and POPC (aRR 0.98; 95% CI [0.96, 0.99]). Compared to patients whose adherence rates were below 65%, patients whose adherence rates were higher between 75%- 100% had better discharge PCPC (aRR 0.28; 95% CI [0.10, 0.83]) and POPC (aRR 0.32; 95% CI [0.15, 0.73]. Two indicators were associated with favorable discharge PCPC: Avoidance of hypoxia (aRR 0.46; 95% CI [0.23, 0.93]), and Nutrition started in 72 hours (aRR 0.45; 95% CI [0.21, 0.99]). Avoiding hypoxia was also associated with favorable discharge POPC (aRR 0.47; 95% CI [0.22, 0.99]). Conclusion There is variation in Argentine ICU practice in the care of children with severe TBI. Second insults are common and hyperosmolar therapy use is uncommon. Adherence to best practice TBI care by avoiding hypoxia and providing timely nutrition were associated with significantly favorable discharge outcomes. Implementing strategies that prevent hypoxia and facilitate early nutrition in the ICUs are urgently needed to improve pediatric TBI outcomes.	[Vavilala, Monica S.; Qiu, Qian; Farr, Carly K.] Univ Washington, Harborview Injury Prevent & Res Ctr, Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Lujan, Silvia B.; Ballarini, Nicolas M.; Guadagnoli, Nahuel; Alejandra Depetris, Maria; Petroni, Gustavo J.] Ctr Informat & Invest Clin, Rosario, Santa Fe, Argentina; [Lujan, Silvia B.; Petroni, Gustavo J.] Hosp Emergencias Dr Clemente Alvarez, Rosario, Santa Fe, Argentina; [Bell, Michael J.] Childrens Natl Hosp, Crit Care Med, Pediat, Washington, DC USA; [Faguaga, Gabriela A.; Baggio, Gloria M.] Hosp Ninos Victor J Vilela, Rosario, Santa Fe, Argentina; [Busso, Leonardo O.] Hosp El Cruce Ezpeleta Oeste, Buenos Aires, DF, Argentina; [Garcia, Mirta E.] Hosp Ninos Sor Maria Ludovica, La Plata, Buenos Aires, Argentina; [Gonzalez Carrillo, Osvaldo R.] Hosp Ninos Dr Orlando Alassia, Santa Fe, Santa Fe, Argentina; [Medici, Paula L.] Hosp Interzonal Especializado Materno Infantil Dr, Mar Del Plata, Buenos Aires, Argentina; [Saenz, Silvia S.] Hosp Ninos Santisima Trinidad, Cordoba, Argentina; [Vanella, Elida E.] Hosp Pediat Dr Humberto Notti, Mendoza, Argentina	University of Washington; University of Washington Seattle; Children's National Health System	Vavilala, MS (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Anesthesiol & Pain Med, Seattle, WA 98195 USA.	vavilala@uw.edu		Ballarini, Nicolas/0000-0002-3432-8931				Bureau of Statistics and Information, 2016, BUR STAT INF VIT STA; Carney NA, 2016, PEDIATR CRIT CARE ME, V17, P658, DOI 10.1097/PCC.0000000000000772; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Curry Parichat, 2011, Int J Crit Illn Inj Sci, V1, P27, DOI 10.4103/2229-5151.79279; Dewan MC, 2016, WORLD NEUROSURG, V91, P497, DOI 10.1016/j.wneu.2016.03.045; Doshi H, 2015, PLOS ONE, V10; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Graves JM, 2016, PEDIATR CRIT CARE ME, V17, P438, DOI 10.1097/PCC.0000000000000698; Hardcastle N, 2014, PEDIATR ANESTH, V24, P703, DOI 10.1111/pan.12415; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; National Institute of Neurological Disorders and Stroke, 2017, TRAUM BRAIN INJ NIND; Nenadovic V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094942; Petroni G, 2010, J TRAUMA, V68, P564, DOI 10.1097/TA.0b013e3181ce1eed; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Pollack MM, 2014, JAMA PEDIATR, V168, P671, DOI 10.1001/jamapediatrics.2013.5316; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; Vavilala MS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166478; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57	21	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2017	12	12							e0189296	10.1371/journal.pone.0189296	http://dx.doi.org/10.1371/journal.pone.0189296			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ2KG	29244842	Green Published, gold, Green Submitted			2023-01-03	WOS:000418184700027
J	Al Slamah, T; Nicholl, BI; Alslail, FY; Melville, CA				Al Slamah, Thamer; Nicholl, Barbara I.; Alslail, Fatima Y.; Melville, Craig A.			Self-management of type 2 diabetes in gulf cooperation council countries: A systematic review	PLOS ONE			English	Review							CULTURAL-ADAPTATION; EDUCATION-PROGRAM; PEOPLE	Aims This study aimed to systematically review intervention studies on self-management of type 2 diabetes in Gulf Cooperation Council (GCC) countries to determine the most effective self-management strategies for individuals with type 2 diabetes in this region. Methods A search strategy was developed using multiple databases: Medline and Embase (via Ovid), CINAHL (via EBSCO), and PubMed. Study and intervention characteristics, intervention structure, content, cultural adaptation, and outcomes were extracted from the included studies. To be included in the review the studies should have met the following criteria: have examined the effectiveness of at least one intervention involving a type 2 DSME programme, have involved participants over 18 years old diagnosed with type 2 diabetes, have taken place to in a GCC country, have a study design that was observational, quasi-experimental or controlled, have reported at least one individual and have a quantitative outcome. A narrative data synthesis was used to describe the studies and comment on their methodological quality. Results Of the 737 retrieved papers, only eight met the inclusion criteria. Only one study was a randomised controlled trial. A statistically significant improvement in HbA1c was reported in five of the eight studies. There was a significant improvement in physical activity levels as reported in four of the eight studies. Only three studies referred to aspects of cultural design or adaptation of the intervention implemented. Conclusions Self-management interventions may have a positive impact on HbA1 levels in patients with type 2 diabetes in the GCC area. A greater emphasis placed on culturally appropriate self-management programmes may improve the effectiveness of self-management interventions for adults with type 2 diabetes in the GCC.	[Al Slamah, Thamer; Nicholl, Barbara I.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Gen Practice & Primary Care, Glasgow, Lanark, Scotland; [Alslail, Fatima Y.] Minist Hlth, Natl Diabet Control & Prevent Program, Riyadh, Saudi Arabia; [Melville, Craig A.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Mental Hlth & Wellbeing, Glasgow, Lanark, Scotland	University of Glasgow; Ministry of Health - Saudi Arabia; University of Glasgow	Melville, CA (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Mental Hlth & Wellbeing, Glasgow, Lanark, Scotland.	Craig.Melville@glasgow.ac.uk	Nicholl, Barbara/AAY-3598-2020	Nicholl, Barbara/0000-0001-5639-0130; Alslamah, Thamer/0000-0001-8776-9514; Melville, Craig/0000-0001-7234-2382	Qassim University of Saudi Arabia	Qassim University of Saudi Arabia	The first author of the paper is a PhD student at the University of Glasgow, funded by the Qassim University of Saudi Arabia. The authors are grateful to Dr David Blane, Clinical Academic Fellow and Ms Heather Worlledge-Andrew, Medical Research Librarian, for their advice on searching and conducting systematic reviews for the first author.	Abduelkarem AR, 2009, LIBYAN J MED, V4, P31, DOI 10.4176/080918; Abuyassin B, 2016, WORLD J DIABETES, V7, P165, DOI 10.4239/wjd.v7.i8.165; Al Asmary SM, 2013, JCOM, V20, P356; Al Hayek AA, 2013, J FAM COMMUNITY MED, V20, P77, DOI 10.4103/2230-8229.114766; Al-Daghri NM, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-87; Al-Shahrani AM, 2012, PAK J MED SCI, V28, P925; Al-Sinani Mohammed, 2010, Sultan Qaboos Univ Med J, V10, P341; Alhyas L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022186; Bagnasco A, 2014, J ADV NURS, V70, P187, DOI 10.1111/jan.12178; BERNAL G, 1995, J ABNORM CHILD PSYCH, V23, P67, DOI 10.1007/BF01447045; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Brown SA, 2002, DIABETES CARE, V25, P259, DOI 10.2337/diacare.25.2.259; Chrvala C. A., 2015, PATIENT ED COUNSELIN; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Fan LF, 2009, CAN J DIABETES, V33, P18, DOI 10.1016/S1499-2671(09)31005-9; Galdas P, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006620; Gao JL, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-100; Haas L, 2013, DIABETES CARE, V36, pS100, DOI [10.2337/dc13-S100, 10.2337/dc13-S004]; Herek GM, 2011, HOW TO WRITE A SUCCESSFUL RESEARCH GRANT APPLICATION: A GUIDE FOR SOCIAL AND BEHAVIORAL SCIENTISTS, SECOND EDITION, P137, DOI 10.1007/978-1-4419-1454-5_12; International Diabetes Federation, 2021, IDF DIAB ATL; Kara M, 2006, INT J NURS STUD, V43, P611, DOI 10.1016/j.ijnurstu.2005.07.008; Kmet L. M., 2004, STANDARD QUALITY ASS; Mohamed H, 2013, PRIM CARE DIABETES, V7, P199, DOI 10.1016/j.pcd.2013.05.002; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Newlin K, 2012, J RELIG HEALTH, V51, P1075, DOI 10.1007/s10943-011-9481-9; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Omar Muhamed Shahed, 2016, Indian J Endocrinol Metab, V20, P219, DOI 10.4103/2230-8210.176347; Omer S. H., 2015, PHARM GLOBALE, V6, P1, DOI DOI 10.1111/J.1753-0407.2010.00081.X; Peeples M, 2007, DIABETES EDUCATOR, V33, P794, DOI 10.1177/0145721707307615; Riazi Hossein, 2016, Acta Inform Med, V24, P186, DOI 10.5455/aim.2016.24.186-192; Steinsbekk A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-213; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; Vincent D, 2006, DIABETES EDUCATOR, V32, P89, DOI 10.1177/0145721705284372; World Health Organisation, 2015, WORLD DIAB DAY; World Health Organization, 2016, GLOB REP DIAB; Xu Y, 2008, RES NURS HEALTH, V31, P613, DOI 10.1002/nur.20293	36	16	16	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2017	12	12							e0189160	10.1371/journal.pone.0189160	http://dx.doi.org/10.1371/journal.pone.0189160			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FP5YF	29232697	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000417698200023
J	Abdalla, T; Hendrickx, D; Fathima, P; Walker, R; Blyth, CC; Carapetis, JR; Bowen, AC; Moore, HC				Abdalla, Tasnim; Hendrickx, David; Fathima, Parveen; Walker, Roz; Blyth, Christopher C.; Carapetis, Jonathan R.; Bowen, Asha C.; Moore, Hannah C.			Hospital admissions for skin infections among Western Australian children and adolescents from 1996 to 2012	PLOS ONE			English	Article							REMOTE ABORIGINAL COMMUNITIES; DISEASE BURDEN; NEW-ZEALAND; SWIMMING POOLS; GLOBAL BURDEN; SCABIES; PREVALENCE; IMPETIGO; EPIDEMIOLOGY; SEASONALITY	The objective of this study was to describe the occurrence of skin infection associated hospitalizations in children born in Western Australia (WA). We conducted a retrospective cohort study of all children born in WA between 1996 and 2012 (n = 469,589). Of these, 31,348 (6.7%) were Aboriginal and 240,237 (51.2%) were boys. We report the annual age-specific hospital admission rates by geographical location and diagnostic category. We applied log-linear regression modelling to analyse changes in temporal trends of hospitalizations. Hospitalization rates for skin infections in Aboriginal children (31.7/1000 child-years; 95% confidence interval [CI] 31.0-32.4) were 15.0 times higher (95% CI 14.5-15.5; P< 0.001) than those of non-Aboriginal children (2.1/1000 child-years; 95% CI 2.0-2.1). Most admissions in Aboriginal children were due to abscess, cellulitis and scabies (84.3%), while impetigo and pyoderma were the predominant causes in non-Aboriginal children (97.7%). Admissions declined with age, with the highest rates for all skin infections observed in infants. Admissions increased with remoteness. Multiple admissions were more common in Aboriginal children. Excess admissions in Aboriginal children were observed during the wet season in the Kimberley and during summer in metropolitan areas. Our study findings show that skin infections are a significant cause of severe disease, requiring hospitalization in Western Australian children, with Aboriginal children at a particularly high risk. Improved community-level prevention of skin infections and the provision of effective primary care are crucial in reducing the burden of skin infection associated hospitalizations. The contribution of sociodemographic and environmental risk factors warrant further investigation.	[Abdalla, Tasnim; Hendrickx, David; Fathima, Parveen; Walker, Roz; Blyth, Christopher C.; Carapetis, Jonathan R.; Bowen, Asha C.; Moore, Hannah C.] Univ Western Australia, Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Perth, WA, Australia; [Hendrickx, David; Walker, Roz; Moore, Hannah C.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia; [Hendrickx, David; Walker, Roz] Univ Western Australia, Telethon Kids Inst, NHMRC Ctr Res Excellence Aboriginal Hlth & Wellbe, Perth, WA, Australia; [Blyth, Christopher C.; Carapetis, Jonathan R.; Bowen, Asha C.] Univ Western Australia, Sch Med, Perth, WA, Australia; [Blyth, Christopher C.; Carapetis, Jonathan R.; Bowen, Asha C.] Princess Margaret Hosp Children, Dept Infect Dis, Perth, WA, Australia; [Bowen, Asha C.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia	Telethon Kids Institute; University of Western Australia; Wesfarmers Limited; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia; Charles Darwin University; Menzies School of Health Research	Hendrickx, D (corresponding author), Univ Western Australia, Telethon Kids Inst, Wesfarmers Ctr Vaccines & Infect Dis, Perth, WA, Australia.; Hendrickx, D (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Perth, WA, Australia.; Hendrickx, D (corresponding author), Univ Western Australia, Telethon Kids Inst, NHMRC Ctr Res Excellence Aboriginal Hlth & Wellbe, Perth, WA, Australia.	david.hendrickx@telethonkids.org.au	Moore, Hannah/AAA-4107-2019; Moore, Hannah C/W-4727-2018; Moore, Hannah/AHH-1092-2022; Carapetis, Jonathan R/H-8933-2014; Walker, Roz/AAB-8038-2021; Blyth, Christopher/ABG-8231-2020; Bowen, Asha Clare/X-5221-2018; Fathima, Parveen/J-5502-2013	Moore, Hannah/0000-0001-6434-8290; Moore, Hannah C/0000-0001-6434-8290; Moore, Hannah/0000-0001-6434-8290; Carapetis, Jonathan R/0000-0002-1182-9792; Blyth, Christopher/0000-0003-2017-0683; Bowen, Asha Clare/0000-0002-3242-1155; Walker, Roz/0000-0002-3140-7036; Fathima, Parveen/0000-0002-4516-4127; Abdalla, Tasnim/0000-0002-4934-6876	National Health and Medical Research Council (NHMRC) [APP1045668]; University of Western Australia International Scholarship; Stan Perron Charitable Trust; NHMRC Centre for Research Excellence in Aboriginal Health and Wellbeing [APP1000886]; NHMRC [APP1111596, APP1034254, APP1088735]	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Western Australia International Scholarship; Stan Perron Charitable Trust; NHMRC Centre for Research Excellence in Aboriginal Health and Wellbeing(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This study was funded through a National Health and Medical Research Council (NHMRC; www.nhmrc.gov.au) Project Grant (APP1045668). DH was supported by a University of Western Australia International Scholarship and the Stan Perron Charitable Trust. DH and RW were supported with funding through the NHMRC Centre for Research Excellence in Aboriginal Health and Wellbeing (APP1000886). CCB, HCM and ACB are supported by NHMRC Fellowships (APP1111596, APP1034254 and APP1088735 respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARLIAN LG, 1989, ANNU REV ENTOMOL, V34, P139, DOI 10.1146/annurev.en.34.010189.001035; Australian Bureau of Statistics, 2014, POP AG SEX REG AUSTR; Australian Bureau of Statistics, 2018, CENSUS POPULATION HO; Australian Bureau of Statistics, 2013, EST AB TORR STRAIT I; Australian Institute of Health and Welfare, 2004, RURAL HLTH SERIES; Bowen AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136789; Burgner DP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125342; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f; Christensen D, 2014, AUST J SOC ISSUES, V49, P423, DOI 10.1002/j.1839-4655.2014.tb00322.x; Clucas DB, 2008, B WORLD HEALTH ORGAN, V86, P275, DOI 10.2471/BLT.07.043034; Cohen PR, 2007, INT J DERMATOL, V46, P1, DOI 10.1111/j.1365-4632.2007.03215.x; Commissioner for Children and Young People, 2014, STAT W AUSTR CHILDR; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; DAVIS DP, 1987, J PARASITOL, V73, P661, DOI 10.2307/3282154; Elliot AJ, 2006, FAM PRACT, V23, P490, DOI 10.1093/fampra/cml042; Fahridin S, 2009, GEN PRACTICE AUSTR H, V24, P87; Franklin DC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008296; Grassly NC, 2006, P ROY SOC B-BIOL SCI, V273, P2541, DOI 10.1098/rspb.2006.3604; Hartman-Adams H, 2014, AM FAM PHYSICIAN, V90, P229; Hay RJ, 2012, CLIN MICROBIOL INFEC, V18, P313, DOI 10.1111/j.1469-0691.2012.03798.x; Hay RJ, 2014, J INVEST DERMATOL, V134, P1527, DOI 10.1038/jid.2013.446; Hengge UR, 2006, LANCET INFECT DIS, V6, P769, DOI 10.1016/S1473-3099(06)70654-5; Hogan AB, 2016, EPIDEMICS-NETH, V16, P49, DOI 10.1016/j.epidem.2016.05.001; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Kariuki M, 2016, J PAEDIATR CHILD H, V52, P882, DOI 10.1111/jpc.13239; Kearns T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058231; Kelman CW, 2002, AUST NZ J PUBL HEAL, V26, P251, DOI 10.1111/j.1467-842X.2002.tb00682.x; KRISTENSEN JK, 1991, INT J DERMATOL, V30, P699, DOI 10.1111/j.1365-4362.1991.tb02612.x; Lehmann D, 2003, BRIT MED J, V327, P415, DOI 10.1136/bmj.327.7412.415; Lim A, 2017, EPIDEMIOL INFECT, V145, P678, DOI 10.1017/S0950268816002685; Loffeld A, 2005, CLIN EXP DERMATOL, V30, P512, DOI 10.1111/j.1365-2230.2005.01847.x; McMeniman E, 2011, AUSTRALAS J DERMATOL, V52, P270, DOI 10.1111/j.1440-0960.2011.00806.x; Mermel LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017925; Mishra Arun K, 2016, Open Microbiol J, V10, P150, DOI 10.2174/1874285801610010150; O'Sullivan CE, 2011, EPIDEMIOL INFECT, V139, P1794, DOI 10.1017/S0950268810002761; O'Sullivan C, 2012, NEW ZEAL MED J, V125, P70; O'Sullivan C, 2012, NEW ZEAL MED J, V125, P55; O'Sullivan C, 2012, NEW ZEAL MED J, V125, P40; Quinn EK, 2015, RURAL REMOTE HEALTH, V15; Romani L, 2015, LANCET INFECT DIS, V15, P960, DOI 10.1016/S1473-3099(15)00132-2; Seale AC, 2016, EMERG INFECT DIS, V22, P224, DOI 10.3201/eid2202.151358; Silva DT, 2008, MED J AUSTRALIA, V188, P594, DOI 10.5694/j.1326-5377.2008.tb01800.x; SINGH G, 1973, DERMATOLOGICA, V147, P342, DOI 10.1159/000251891; Sitali L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0935-7; Steiger DBM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1675-2; Stewart D, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2149; Tamer E, 2008, J DERMATOL, V35, P413, DOI 10.1111/j.1346-8138.2008.00495.x; TAPLIN D, 1973, LANCET, V1, P501; TAPLIN D, 1965, ARCH ENVIRON HEALTH, V11, P546, DOI 10.1080/00039896.1965.10664255; Tong SYC, 2011, DERMATOL CLIN, V29, P21, DOI 10.1016/j.det.2010.09.005; Vaska VL, 2012, EUR J CLIN MICROBIOL, V31, P93, DOI 10.1007/s10096-011-1281-3; Whitehall J, 2013, J PAEDIATR CHILD H, V49, P141, DOI 10.1111/jpc.12095; Yeoh DK, 2016, J INFECTION, V72, pS61, DOI 10.1016/j.jinf.2016.04.024; Yeoh DK, 2016, INT C TROP MED MAL B	56	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188803	10.1371/journal.pone.0188803	http://dx.doi.org/10.1371/journal.pone.0188803			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FO4UI	29190667	Green Published, Green Submitted, gold			2023-01-03	WOS:000416841900129
J	Khumpirapang, N; Pikulkaew, S; Mullertz, A; Rades, T; Okonogi, S				Khumpirapang, Nattakanwadee; Pikulkaew, Surachai; Mullertz, Anette; Rades, Thomas; Okonogi, Siriporn			Self-microemulsifying drug delivery system and nanoemulsion for enhancing aqueous miscibility of Alpinia galanga oil	PLOS ONE			English	Article							L.; ZEBRAFISH; ABSORPTION; ANESTHESIA; SURFACTANT; STABILITY; EMULSIONS; EXPOSURE; ETHANOL; REGION	Alpinia galanga oil (AGO) possesses various activities but low aqueous solubility limits its application particularly in aquatic animals. AGO has powerful activity on fish anesthesia. Ethanol used for enhancing water miscible of AGO always shows severe side effects on fish. The present study explores the development of self-microemulsifying drug delivery systems (SMEDDS) and nanoemulsions (NE) to deliver AGO for fish anesthesia with less or no alcohol. Pseudoternary phase diagrams were constructed to identify the best SMEDDS-AGO formulation, whereas NE-AGO were developed by means of high-energy emulsification. The mean droplet size of the best SMEDDS-AGO was 82 +/- 0.5 nm whereas that of NE-AGO was 48 +/- 1.6 nm. The anesthetic effect of the developed SMEDDS-AGO and NE-AGO in koi (Cyprinus carpio) was evaluated and compared with AGO ethanolic solution (EtOH-AGO). It was found that the time of induction the fish to reach the surgical stage of anesthesia was dose dependent. NE-AGO showed significantly higher activity than SMEDDS-AGO and EtOH-AGO, respectively. EtOH-AGO caused unwanted hyperactivity in the fish. This side effect did not occur in the fish anesthetized with SMEDDS-AGO and NE-AGO. In conclusion, SMEDDS and NE are promising delivery systems for AGO.	[Khumpirapang, Nattakanwadee] Chiang Mai Univ, Grad Sch, Interdisciplinary Program Nanosci & Nanotechnol, Chiang Mai, Thailand; [Pikulkaew, Surachai] Chiang Mai Univ, Dept Food Anim Clin, Fac Vet Med, Chiang Mai, Thailand; [Mullertz, Anette; Rades, Thomas] Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, Copenhagen, Denmark; [Okonogi, Siriporn] Chiang Mai Univ, Dept Pharmaceut Sci, Fac Pharm, Chiang Mai, Thailand	Chiang Mai University; Chiang Mai University; University of Copenhagen; Chiang Mai University	Okonogi, S (corresponding author), Chiang Mai Univ, Dept Pharmaceut Sci, Fac Pharm, Chiang Mai, Thailand.	okng2000@gmail.com	pikulkaew, surachai/AAO-5512-2021; Okonogi, Siriporn/AAB-7172-2022; Müllertz, Anette/ABF-6935-2021; pikulkaew, surachai/GSM-8561-2022; Rades, Thomas/ABE-9953-2021	Müllertz, Anette/0000-0003-3020-8892; Rades, Thomas/0000-0002-7521-6020; Khumpirapang, Nattakanwadee/0000-0001-9069-4509; pikulkaew, surachai/0000-0002-9922-7357	Thailand Research Fund (TRF) via the Research and Researchers for Industries (RRI) [PHD56I0040]; Research and Researchers for Industries, Thailand [PHD56I0040]	Thailand Research Fund (TRF) via the Research and Researchers for Industries (RRI); Research and Researchers for Industries, Thailand	This study is financially supported by the Thailand Research Fund (TRF) via the Research and Researchers for Industries (RRI) grant no. PHD56I0040.; The authors are grateful for the financial support from the Research and Researchers for Industries, Thailand (grant no. PHD56I0040). We also thank Bioneer:FARMA, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, the National Research Council of Thailand, and the Research Center of Pharmaceutical Nanotechnology, Chiang Mai University, Thailand for the equipment and facility support.	Aboalnaja KO, 2016, EXPERT OPIN DRUG DEL, V13, P1327, DOI 10.1517/17425247.2016.1162154; Bernardi DS, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-44; Bernstein PS, 1997, AM J OPHTHALMOL, V124, P843, DOI 10.1016/S0002-9394(14)71705-2; Capek I, 2004, ADV COLLOID INTERFAC, V107, P125, DOI 10.1016/S0001-8686(03)00115-5; Carvan MJ, 2004, NEUROTOXICOL TERATOL, V26, P757, DOI 10.1016/j.ntt.2004.06.016; Chaiyana W, 2010, INT J PHARMACEUT, V401, P32, DOI 10.1016/j.ijpharm.2010.09.005; Chalchat JC, 2008, FOOD CHEM, V110, P501, DOI 10.1016/j.foodchem.2008.02.018; Charles D. J., 1992, Journal of Essential Oil Research, V4, P81; Chaudhary A., 2012, J ADV PHARM ED RES, V2, P32, DOI DOI 10.4103/2231-4040.90872; Chudiwal A. K., 2010, Indian Journal of Natural Products and Resources, V1, P143; CORDES EH, 1974, CHEM REV, V74, P581, DOI 10.1021/cr60291a004; Donsi F, 2011, LWT-FOOD SCI TECHNOL, V44, P1908, DOI 10.1016/j.lwt.2011.03.003; Eid AM, 2014, INT J NANOMED, V9, P4685, DOI 10.2147/IJN.S66180; Gardeli C, 2008, FOOD CHEM, V107, P1120, DOI 10.1016/j.foodchem.2007.09.036; Grzanna R, 2005, J MED FOOD, V8, P125, DOI 10.1089/jmf.2005.8.125; Ho HO, 1996, J PHARM SCI, V85, P138, DOI 10.1021/js950352h; Holm R, 2003, EUR J PHARM SCI, V20, P91, DOI 10.1016/S0928-0987(03)00174-X; Jantan I. B., 2004, J ESSENT OIL RES, V16, P174, DOI DOI 10.1080/; Kawabata Y, 2011, INT J PHARMACEUT, V420, P1, DOI 10.1016/j.ijpharm.2011.08.032; Krishnan S, 2005, CARBOHYD POLYM, V61, P95, DOI 10.1016/j.carbpol.2005.02.020; Krone PH, 1997, CELL MOL LIFE SCI, V53, P122, DOI 10.1007/PL00000574; Mahae N., 2009, Kasetsart Journal, Natural Sciences, V43, P358; Marinova KG, 1996, LANGMUIR, V12, P2045, DOI 10.1021/la950928i; Mathur P, 2011, BEHAV BRAIN RES, V217, P128, DOI 10.1016/j.bbr.2010.10.015; McClements DJ, 2011, SOFT MATTER, V7, P2297, DOI 10.1039/c0sm00549e; Mehyar GF, 2014, J FOOD SCI, V79, pC1939, DOI 10.1111/1750-3841.12652; Okonogi S, 2012, DRUG DISCOV THER, V6, P249, DOI 10.5582/ddt.2012.v6.5.249; Oonmetta-aree H, 2006, LWT-FOOD SCI TECHNOL, V39, P1214, DOI 10.1016/j.lwt.2005.06.015; Oprean R, 2001, J PHARMACEUT BIOMED, V24, P1163, DOI 10.1016/S0731-7085(00)00578-1; Pikulkaew S, 2017, DRUG DISCOV THER, V11, P186, DOI 10.5582/ddt.2017.01035; Prakatthagomol W, 2011, DRUG DISCOV THER, V5, P84, DOI 10.5582/ddt.2011.v5.2.84; Raina VK, 2003, FLAVOUR FRAG J, V18, P18, DOI 10.1002/ffj.1136; Raina VK, 2002, FLAVOUR FRAG J, V17, P358, DOI 10.1002/ffj.1105; Saeio K, 2011, DRUG DISCOV THER, V5, P246, DOI 10.5582/ddt.2011.v5.5.246; Sakulku U, 2009, INT J PHARMACEUT, V372, P105, DOI 10.1016/j.ijpharm.2008.12.029; Saupe A, 2006, INT J PHARM, V314, P56, DOI 10.1016/j.ijpharm.2006.01.022; Solans C, 2012, CURR OPIN COLLOID IN, V17, P246, DOI 10.1016/j.cocis.2012.07.003; Srivastava B, 2008, WORLD J MICROB BIOT, V24, P693, DOI 10.1007/s11274-007-9526-0; Tenjarla S, 1999, CRIT REV THER DRUG, V16, P461; Turek C, 2013, COMPR REV FOOD SCI F, V12, P40, DOI 10.1111/1541-4337.12006; Wang XY, 2008, FOOD CHEM, V108, P419, DOI 10.1016/j.foodchem.2007.10.086; Wang YJ, 2011, DRUG DEV IND PHARM, V37, P1225, DOI 10.3109/03639045.2011.565774; Yang XG, 1999, J AGR FOOD CHEM, V47, P1657, DOI 10.1021/jf9808224; Zahl IH, 2012, FISH PHYSIOL BIOCHEM, V38, P201, DOI 10.1007/s10695-011-9565-1; Zhang HJ, 2003, ARCH PHARM RES, V26, P768, DOI 10.1007/BF02976689; Zhao Y, 2010, INT J PHARMACEUT, V383, P170, DOI 10.1016/j.ijpharm.2009.08.035	46	13	13	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188848	10.1371/journal.pone.0188848	http://dx.doi.org/10.1371/journal.pone.0188848			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190663	gold, Green Published, Green Submitted			2023-01-03	WOS:000416841900142
J	McPeake, J; Shaw, M; Iwashyna, TJ; Daniel, M; Devine, H; Jarvie, L; Kinsella, J; MacTavish, P; Quasim, T				McPeake, Joanne; Shaw, Martin; Iwashyna, Theodore J.; Daniel, Malcolm; Devine, Helen; Jarvie, Lyndsey; Kinsella, John; MacTavish, Pamela; Quasim, Tara			Intensive Care Syndrome: Promoting Independence and Return to Employment (InS:PIRE). Early evaluation of a complex intervention	PLOS ONE			English	Article							FUNCTIONAL DISABILITY; PEER SUPPORT; REHABILITATION; SURVIVORS; DISCHARGE; OUTCOMES	Background Many patients suffer significant physical, social and psychological problems in the months and years following critical care discharge. At present, there is minimal evidence of any effective interventions to support this patient group following hospital discharge. The aim of this project was to understand the impact of a complex intervention for ICU survivors. Methods Quality improvement project conducted between September 2014 and June 2016, enrolling 49 selected patients from one ICU in Scotland. To evaluate the impact of this programme outcomes were compared to an existing cohort of patients from the same ICU from 2008-2009. Patients attended a five week peer supported rehabilitation programme. This multidisciplinary programme included pharmacy, physiotherapy, nursing, medical, and psychology input. The primary outcome in this evaluation was the EQ-5D, a validated measure of health-related quality of life. The minimally clinically important difference (MCID) in the EQ-5D is 0.08. We also measured change in self-efficacy over the programme duration. Based on previous research, this study utilised a 2.4 (6%) point change in self-efficacy scores as a MCID. Results 40 patients (82%) completed follow-up surveys at 12 months. After regression adjustment for those factors known to impact recovery from critical care, there was a 0.07-0.16 point improvement in quality of life for those patients who took part in the intervention compared to historical controls from the same institution, depending on specific regression strategy used. Self-efficacy scores increased by 2.5 points (6.25%) over the duration of the five week programme (p = 0.003), and was sustained at one year post intervention. In the year following ICU, 15 InS:PIRE patients returned to employment or volunteering roles (88%) compared with 11 (46%) in the historical control group (p = 0.15). Conclusions and relevance This historical control study suggests that a complex intervention may improve quality of life and self-efficacy in survivors of ICU. A larger, multi-centre study is needed to investigate this intervention further.	[McPeake, Joanne; Shaw, Martin; Kinsella, John; MacTavish, Pamela; Quasim, Tara] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland; [McPeake, Joanne; Daniel, Malcolm; Devine, Helen; Jarvie, Lyndsey; Kinsella, John; Quasim, Tara] Glasgow Royal Infirm, NHS Greater Glasgow & Clyde, Intens Care Unit, Glasgow, Lanark, Scotland; [Shaw, Martin] Glasgow Royal Infirm, NHS Greater Glasgow & Clyde, Clin Phys Dept, Glasgow, Lanark, Scotland; [Iwashyna, Theodore J.] VA Ann Arbor Hlth Syst, Ctr Clin Management Res, Ann Arbor, MI USA; [Iwashyna, Theodore J.] Univ Michigan, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA	University of Glasgow; University of Glasgow; University of Glasgow; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	McPeake, J (corresponding author), Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland.; McPeake, J (corresponding author), Glasgow Royal Infirm, NHS Greater Glasgow & Clyde, Intens Care Unit, Glasgow, Lanark, Scotland.	joanne.mcpeake@glasgow.ac.uk	Daniel, Malcolm/AFL-1547-2022	McPeake, Joanne/0000-0001-8206-6801; Quasim, Tara/0000-0002-9872-3623	CNO Scotland Fellowship; Health Foundation; US Department of Veterans Affairs, Health Services Research Development [IIR 13-079]	CNO Scotland Fellowship; Health Foundation; US Department of Veterans Affairs, Health Services Research Development(US Department of Veterans Affairs)	JMcP is supported by a CNO Scotland Fellowship and the Health Foundation. TJI's work was supported, in part, by US Department of Veterans Affairs, Health Services Research & Development, IIR 13-079. MD, HD, PMacT, JK and TQ are supported by the Health Foundation. This study does not necessarily represent the official views of the US Government or Department of Veterans Affairs. The Health Foundation is a charitable organisation. They had no role in the design, collection, analysis, interpretation of data or in the writing of this manuscript. They had no role in the decision to submit the manuscript for publication.	Bambra C, 2009, J EPIDEMIOL COMMUN H, V63, P92, DOI 10.1136/jech.2008.077354; Bandura A., 1971, SOCIAL LEARNING THEO; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Battle CE, 2013, CRIT CARE, V17, DOI 10.1186/cc12746; Bland M., 2000, INTRO STAT; Burnard P, 1991, Nurse Educ Today, V11, P461, DOI 10.1016/0260-6917(91)90009-Y; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Cameron LD, 2007, PSYCHO-ONCOLOGY, V16, P171, DOI 10.1002/pon.1050; CUTHBERTSON BH, 2009, BMJ-BRIT MED J, V339, DOI DOI 10.1136/BMJ.B3723; Davis T, 2014, J BURN CARE RES, V35, P416, DOI 10.1097/BCR.0000000000000011; Davydow DS, 2008, GEN HOSP PSYCHIAT, V30, P421, DOI 10.1016/j.genhosppsych.2008.05.006; Deacon Kate S, 2012, Intensive Crit Care Nurs, V28, P114, DOI 10.1016/j.iccn.2011.11.008; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Diamond A, 2013, REV ECON STAT, V95, P932, DOI 10.1162/REST_a_00318; Griffiths J, 2013, CRIT CARE, V17, DOI 10.1186/cc12745; Harrell Frank E., 2001, REGRESSION MODELING; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Intensive Care Society, 2009, LEV CRIT CAR AD PAT; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Lone NI, 2013, CRIT CARE MED, V41, P1832, DOI 10.1097/CCM.0b013e31828a409c; McPeake J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009944; Mehlhorn J, 2014, CRIT CARE MED, V42, P1263, DOI 10.1097/CCM.0000000000000148; Mikkelsen ME, 2016, AACN ADV CRIT CARE, V27, P221, DOI 10.4037/aacnacc2016667; Moody A, 2004, THORAX, V59, P1; Needham DM, 2012, CRIT CARE MED, V40, P502, DOI 10.1097/CCM.0b013e318232da75; Orwelius L, 2010, CRIT CARE, V14, DOI 10.1186/cc8967; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pickard AS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-70; Quasim Tara, 2015, J Intensive Care Soc, V16, P31, DOI 10.1177/1751143714556238; R-Core-Team, 2016, LANG ENV STAT COMP; Schwarzer R., 1995, MEASURES HLTH PSYCHO, P35, DOI DOI 10.1037/T00393-000; Scottish Government, 2012, NAT STAT PUBL SCOTL; Szende A., 2006, EQ 5D VALUE SETS INV; Tsay SL, 2002, INT J NURS STUD, V39, P245, DOI 10.1016/S0020-7489(01)00030-X; Vainiola T, 2010, INTENS CARE MED, V36, P2090, DOI 10.1007/s00134-010-1979-1; Vincent E, 2011, CHEST, V140, P1534, DOI 10.1378/chest.10-2649; Wade DM, 2012, CRIT CARE, V16, DOI 10.1186/cc11677; Walker Wendy, 2015, J Intensive Care Soc, V16, P37, DOI 10.1177/1751143714554896; Walsh TS, 2015, JAMA INTERN MED, V175, P901, DOI 10.1001/jamainternmed.2015.0822; Welch CA, 2010, J CRIT CARE, V25, P382, DOI 10.1016/j.jcrc.2009.11.003	41	38	39	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2017	12	11							e0188028	10.1371/journal.pone.0188028	http://dx.doi.org/10.1371/journal.pone.0188028			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FO0ZL	29186177	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000416484900021
J	Franse, CB; van Grieken, A; Qin, L; Melis, RJF; Rietjens, JAC; Raat, H				Franse, Carmen B.; van Grieken, Amy; Qin, Li; Melis, Rene J. F.; Rietjens, Judith A. C.; Raat, Hein			Socioeconomic inequalities in frailty and frailty components among community-dwelling older citizens	PLOS ONE			English	Article							LONG-TERM MORTALITY; EUROPEANS ASSOCIATION; CLINICAL FRAILTY; ELDERLY SUBJECTS; HEALTH; INDEX; ADULTS; SELECTION; DETERMINANTS; OUTCOMES	Background So far, it has not yet been studied whether socioeconomic status is associated with distinct frailty components and for which frailty component this association is the strongest. We aimed to examine the association between socioeconomic status and frailty and frailty components. In addition we assessed the mediating effect of the number of morbidities on the association between socioeconomic status and other frailty components. Methods This is a cross-sectional study of pooled data of The Older Persons and Informal Caregivers Survey Minimum DataSet in the Netherlands among community-dwelling persons aged 55 years and older (n = 26,014). Frailty was measured with a validated Frailty Index that consisted of 45 items. The Frailty Index contained six components: morbidities, limitations in activities of daily living (ADL), limitations in instrumental ADL (IADL), health-related quality of life, psychosocial health and self-rated health. Socioeconomic indicators used were education level and neighbourhood socioeconomic status. Results Persons with primary or secondary education had higher overall frailty and frailty component scores compared to persons with tertiary education (P < .001). Lower education levels were most consistently associated with higher overall frailty, more morbidities and worse selfrated health (P < .05 in all age groups). The strongest association was found between primary education and low psychosocial health for persons aged 55-69 years and more IADL limitations for persons aged 80+ years. Associations between neighborhood socioeconomic status and frailty (components) also showed inequalities, although less strong. The number of morbidities moderately to strongly mediated the association between socioeconomic indicators and other frailty components. Conclusion There are socioeconomic inequalities in frailty and frailty components. Inequalities in frailty, number of morbidities and self-rated health are most consistent across age groups. The number of morbidities a person has play an important role in explaining socioeconomic inequalities in frailty and should be taken into account in the management of frailty.	[Franse, Carmen B.; van Grieken, Amy; Rietjens, Judith A. C.; Raat, Hein] Erasmus Univ, Dept Publ Hlth, Med Ctr, Rotterdam, Netherlands; [Qin, Li; Melis, Rene J. F.] Radboud Univ Nijmegen, Dept Geriatr Med, Med Ctr, Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen	Franse, CB (corresponding author), Erasmus Univ, Dept Publ Hlth, Med Ctr, Rotterdam, Netherlands.	c.franse@erasmusmc.nl	Melis, René/J-5943-2012; Qin, Li/A-3244-2016; van Grieken, Amy/N-1583-2014	Melis, René/0000-0002-7863-4738; Qin, Li/0000-0001-5002-3372; van Grieken, Amy/0000-0001-6767-9159	National Care for older citizens Programme on behalf of the Organisation of Health Research and Development (ZonMw-The Netherlands) [310300002]; Organisation of Health Research and Development (ZonMw-The Netherlands) [633400009]	National Care for older citizens Programme on behalf of the Organisation of Health Research and Development (ZonMw-The Netherlands); Organisation of Health Research and Development (ZonMw-The Netherlands)	Funding for the TOPICS-MDS project was provided by the National Care for older citizens Programme on behalf of the Organisation of Health Research and Development (ZonMw-The Netherlands, Grant reference 310300002). Funding was provided to the first author (Carmen B. Franse) by the Organisation of Health Research and Development (ZonMw-The Netherlands, Grant No. 633400009). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bell CL, 2014, J AM GERIATR SOC, V62, P880, DOI 10.1111/jgs.12796; Benzeval M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-947; Cacciatore F, 2013, ACTA DIABETOL, V50, P251, DOI 10.1007/s00592-012-0413-2; Chamberlain AM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011410; Clegg A, 2013, LANCET, V381, P752, DOI 10.1016/S0140-6736(12)62167-9; Edjolo A, 2016, AM J EPIDEMIOL, V183, P277, DOI 10.1093/aje/kwv223; Enroth L, 2015, AGE AGEING, V44, P123, DOI 10.1093/ageing/afu092; Etman A, 2014, EUR J PUBLIC HLTH; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Galizia G, 2011, AGING CLIN EXP RES, V23, P118, DOI 10.1007/BF03351076; Gobbens RJJ, 2014, ARCH GERONTOL GERIAT, V59, P280, DOI 10.1016/j.archger.2014.06.008; Gobbens RJJ, 2010, J AM MED DIR ASSOC, V11, P356, DOI 10.1016/j.jamda.2009.11.008; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Hajizadeh M, 2016, HEALTH POLICY, V120, P1040, DOI 10.1016/j.healthpol.2016.07.019; Harttgen K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075847; Hoogendijk EO, 2014, ANN EPIDEMIOL, V24, P538, DOI 10.1016/j.annepidem.2014.05.002; Huisman M, 2003, SOC SCI MED, V57, P861, DOI 10.1016/S0277-9536(02)00454-9; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Knol F.A, 1998, HOOG NAAR LAAG LAAG; Krabbe PFM, 1999, J CLIN EPIDEMIOL, V52, P293, DOI 10.1016/S0895-4356(98)00163-2; Kroger H, 2015, EUR J PUBLIC HEALTH, V25, P951, DOI 10.1093/eurpub/ckv111; Laan W, 2014, J NUTR HEALTH AGING, V18, P848, DOI [10.1007/s12603-014-0558-5, 10.1007/s12603-014-0479-3]; Lang IA, 2009, J AM GERIATR SOC, V57, P1776, DOI 10.1111/j.1532-5415.2009.02480.x; Leopold L, 2013, INT J PUBLIC HEALTH, V58, P23, DOI 10.1007/s00038-012-0399-0; Lutomski JE, 2016, J CLIN EPIDEMIOL, V74, P207, DOI 10.1016/j.jclinepi.2015.11.006; Lutomski JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081673; Lutomski JE, 2013, J AM GERIATR SOC, V61, P1625, DOI 10.1111/jgs.12430; Mcdonald JH, 2009, HDB BIOL STAT; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mitnitski A, 2005, J AM GERIATR SOC, V53, P2184, DOI 10.1111/j.1532-5415.2005.00506.x; Mitnitski A B, 2001, ScientificWorldJournal, V1, P323; Morley JE, 2013, J AM MED DIR ASSOC, V14, P392, DOI 10.1016/j.jamda.2013.03.022; Organisation for Economic C-o Development, 1999, CLASS ED PROGR MAN I; Palacios-Cena D, 2012, J AM MED DIR ASSOC, V13, P136, DOI 10.1016/j.jamda.2010.05.007; Rockwood K, 2007, J GERONTOL A-BIOL, V62, P722, DOI 10.1093/gerona/62.7.722; Romero-Ortuno R, 2014, GERIATR GERONTOL INT, V14, P420, DOI 10.1111/ggi.12122; Romero-Ortuno R, 2012, AGE AGEING, V41, P684, DOI 10.1093/ageing/afs051; Searle Samuel D, 2008, BMC Geriatr, V8, P24, DOI 10.1186/1471-2318-8-24; Snijders T.A.B., 2012, MULTILEVEL ANAL INTR, Vsecond; Soler-Vila H, 2016, J EPIDEMIOL COMMUN H, V70, P354, DOI 10.1136/jech-2015-206406; Statistics Netherlands (CBS), 1999, STAND OND; Statistics Netherlands (CBS), 2012, KERNC POST 2008 2010; Stolz E, 2016, J EPIDEMIOL COMMUNIT; Theou O, 2013, J AM GERIATR SOC, V61, P1537, DOI 10.1111/jgs.12420; Tsai Y, 2016, J PUBLIC HLTH OXF; Vaughan L, 2016, J GERONTOL A-BIOL, V71, pS79, DOI 10.1093/gerona/glv061; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; World Health Organisation, 2001, ICF INT CLASFUNCT; Yang F, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0317-z	51	43	43	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 9	2017	12	11							e0187946	10.1371/journal.pone.0187946	http://dx.doi.org/10.1371/journal.pone.0187946			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM1VI	29121677	gold, Green Published, Green Submitted			2023-01-03	WOS:000414769900100
J	Briceno, B; Coville, A; Gertler, P; Martinez, S				Briceno, Bertha; Coville, Aidan; Gertler, Paul; Martinez, Sebastian			Are there synergies from combining hygiene and sanitation promotion campaigns: Evidence from a large-scale cluster-randomized trial in rural Tanzania	PLOS ONE			English	Article							CHILD UNDERNUTRITION; DIARRHEA; COMMUNITY; INDIA; INTERVENTION; BEHAVIOR; HEALTH; HANDS; WATER; RISK	The current evidence on handwashing and sanitation programs suggests limited impacts on health when at-scale interventions have been tested in isolation. However, no published experimental evidence currently exists that tests the interaction effects between sanitation and handwashing. We present the results of two large-scale, government-led handwashing and sanitation promotion campaigns in rural Tanzania, with the objective of tracing the causal chain from hygiene and sanitation promotion to changes in child health outcomes and specifically testing for potential interaction effects of combining handwashing and sanitation interventions. Methods The study is a factorial cluster-randomized control trial where 181 rural wards from 10 districts in Tanzania were randomly assigned to receive sanitation promotion, handwashing promotion, both interventions together or neither (control). Interventions were rolled out from February 2009 to June 2011 and the endline survey was conducted from May to November 2012, approximately one year after program completion. The sample was composed of households with children under 5 years old in the two largest villages in each ward. Masking was not possible due to the nature of the intervention, but enumerators played no part in the intervention and were blinded to treatment status. The primary outcome of interest was 7-day diarrhea prevalence for children under five. Intermediate outcomes of behavior change including improved latrine construction, levels of open defecation and handwashing with soap were also analyzed. Secondary health outcomes included anemia, height-for-age and weight-for-age of children under 5. An intention-to-treat analysis was used to assess the relationship between the interventions and outcomes of interest. Findings One year after the end of the program, ownership of improved latrines increased from 49.7% to 64.8% (95% CI 57.9%-71.7%) and regular open defecation decreased from 23.1% to 11.1% (95% CI 3.5%-18.7%) in sanitation promotion-only wards. Households in hand washing promotion-only wards showed marginal improvements in handwashing behavior related to food preparation but not at other critical junctures. There were no detectable interaction effects for the combined intervention. The associated cost-per-household gaining access to improved sanitation is estimated to be USD $194. Final effects on child health measured through diarrhea, anemia, stunting and wasting were absent in all treatment groups. Interpretation Although statistically significant, the changes in intermediate outcomes achieved through each intervention in isolation were not large enough to generate meaningful health impacts. With no observable signs of interaction, the combined intervention produced similar results. The study highlights the importance of focusing on intermediate outcomes of take up and behavior change as a critical first step in large-scale programs before realizing the changes in health that sanitation and hygiene interventions aim to deliver.	[Briceno, Bertha] Interamer Dev Bank, Knowledge & Learning Sect, Washington, DC USA; [Coville, Aidan] World Bank, Dev Impact Evaluat Unit, 1818 H St NW, Washington, DC 20433 USA; [Gertler, Paul] Univ Calif Berkeley, Haas Sch Business, Berkeley, CA 94720 USA; [Martinez, Sebastian] Interamer Dev Bank, Off Strateg Planning & Dev Effectiveness, Washington, DC USA	Inter-American Development Bank; The World Bank; University of California System; University of California Berkeley; Inter-American Development Bank	Coville, A (corresponding author), World Bank, Dev Impact Evaluat Unit, 1818 H St NW, Washington, DC 20433 USA.	acoville@worldbank.org		Martinez, Sebastian/0000-0002-7651-6674	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This work was supported by a grant from the Bill & Melinda Gates Foundation to the Water and Sanitation Program. The funder provided support in the form of salaries for BB and AC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	BAQUI AH, 1991, INT J EPIDEMIOL, V20, P1057, DOI 10.1093/ije/20.4.1057; Biran A, 2014, LANCET GLOB HEALTH, V2, pE145, DOI 10.1016/S2214-109X(13)70160-8; Briceno B, 2015, J DEV EFFECT, V7, P423, DOI 10.1080/19439342.2015.1105848; Bruhn M, 2008, WORLD BANK POLICY RE; Cameron LA, 2013, WORLD BANK POLICY RE; Chase C, 2012, WORLD BANK POLICY RE; Clasen T, 2014, LANCET GLOB HEALTH, V2, pE645, DOI 10.1016/S2214-109X(14)70307-9; Crocker J, 2016, ENVIRON SCI TECHNOL, V50, P6517, DOI 10.1021/acs.est.6b01021; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Department of Maternal and Child Health and Community Health Ministry of Health PRC, 2009, CHILD GROWTH STAND I; Dreibelbis R, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13010129; Duflo E., 2015, TOILETS CAN WORK SHO; Ejemot R. I., 2009, EVIDENCE BASED CHILD, V4, P893, DOI DOI 10.1002/EBCH.373; Fewtrell L, 2005, LANCET INFECT DIS, V5, P42, DOI 10.1016/S1473-3099(04)01253-8; Freeman MC, 2014, TROP MED INT HEALTH, V19, P906, DOI 10.1111/tmi.12339; Fuller JA, 2016, AM J TROP MED HYG, P15; Galiani S, 2015, HLTH EC; Garn J. V., 2016, INT J HYGIENE ENV HL; Guiteras R, 2015, SCIENCE, V348, P903, DOI 10.1126/science.aaa0491; Humphrey JH, 2009, LANCET, V374, P1032, DOI 10.1016/S0140-6736(09)60950-8; Kling JR, 2007, ECONOMETRICA, V75, P83, DOI 10.1111/j.1468-0262.2007.00733.x; Lavelle MJ, 2015, GLOBAL ENVIRON CHANG, V35, P368, DOI 10.1016/j.gloenvcha.2015.09.021; Luby SP, 2004, JAMA-J AM MED ASSOC, V291, P2547, DOI 10.1001/jama.291.21.2547; Patil SR, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001709; Pickering AJ, 2015, LANCET GLOB HEALTH, V3, pE701, DOI 10.1016/S2214-109X(15)00144-8; Ram P., 2010, PRACTICAL GUIDANCE M; Schmidt WP, 2015, LANCET GLOB HEALTH, V3, pE659, DOI 10.1016/S2214-109X(15)00182-5; Schmidt WP, 2009, ENVIRON SCI TECHNOL, V43, P986, DOI 10.1021/es802232w; Schriewer A, 2015, AM J TROP MED HYG, V93, P509, DOI 10.4269/ajtmh.14-0824; Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4; WHO- Unicef, LEV TRENDS CHILD MOR; World Health Organization (WHO), 2013, HAEM CONC DIAGN AN A	32	28	28	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2017	12	11							e0186228	10.1371/journal.pone.0186228	http://dx.doi.org/10.1371/journal.pone.0186228			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL4VN	29091726	gold, Green Published, Green Submitted			2023-01-03	WOS:000414229700012
J	Scudellari, M				Scudellari, Megan			To stay young, kill zombies	NATURE			English	News Item							SENESCENT CELLS; CELLULAR SENESCENCE; CLEARANCE											Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744; Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Biran A, 2017, AGING CELL, V16, P661, DOI 10.1111/acel.12592; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z; Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324; Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190; Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	16	17	17	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2017	550	7677					448	450		10.1038/550448a	http://dx.doi.org/10.1038/550448a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK7OW	29072283	Bronze			2023-01-03	WOS:000413697800016
J	Mitja, O; Godornes, C; Houinei, W; Kapa, A; Paru, R; Abel, H; Gonzalez-Beiras, C; Bieb, SV; Wangi, J; Barry, AE; Sanz, S; Bassat, Q; Lukehart, SA				Mitja, Oriol; Godornes, Charmie; Houinei, Wendy; Kapa, August; Paru, Raymond; Abel, Haina; Gonzalez-Beiras, Camila; Bieb, Sibauk V.; Wangi, James; Barry, Alyssa E.; Sanz, Sergi; Bassat, Quique; Lukehart, Sheila A.			Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study	LANCET			English	Article							PAPUA-NEW-GUINEA; TREPONEMA-PALLIDUM; MACROLIDE RESISTANCE; HAEMOPHILUS-DUCREYI; DOSE AZITHROMYCIN; POINT MUTATION; UNITED-STATES; SKIN ULCERS; PREVALENCE; CHILDREN	Background Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO strategy for yaws eradication. Methods Between April 15, 2013, and Oct 24, 2016, we did a longitudinal study on a Papua New Guinea island (Lihir; 16 092 population) in which yaws was endemic. In the initial study, the participants were followed for 12 months; in this extended follow-up study, clinical, serological, and PCR surveys were continued every 6 months for 42 months. We used genotyping and travel history to identify importation events. Active yaws confirmed by PCR specific for Treponema pallidum was the primary outcome indicator. The study is registered with ClinicalTrials.gov, number NCT01955252. Findings Mass azithromycin treatment (coverage rate of 84%) followed by targeted treatment programmes reduced the prevalence of active yaws from 1.8% to a minimum of 0.1% at 18 months (difference from baseline -1.7%, 95% CI, -1.9 to -1.4; p<0.0001), but the infection began to re-emerge after 24 months with a significant increase to 0.4% at 42 months (difference from 18 months 0.3%, 95% CI 0.1 to 0.4; p<0.0001). At each timepoint after baseline, more than 70% of the total community burden of yaws was found in individuals who had not had the mass treatment or as new infections in non-travelling residents. At months 36 and 42, five cases of active yaws, all from the same village, showed clinical failure following azithromycin treatment, with PCR-detected mutations in the 23S ribosomal RNA genes conferring resistance to azithromycin. A sustained decrease in the prevalence of high-titre latent yaws from 13.7% to <1.5% in asymptomatic children aged 1-5 years old and of genetic diversity of yaws strains from 0.139 to less than 0.046 between months 24 and 42 indicated a reduction in transmission of infection. Interpretation The implementation of the WHO strategy did not, in the long-term, achieve elimination in a high-endemic community mainly due to the individuals who were absent at the time of mass treatment in whom yaws reactivated; repeated mass treatment might be necessary to eliminate yaws. To our knowledge, this is the first report of the emergence of azithromycin-resistant T p pertenue and spread within one village. Communities' surveillance should be strengthened to detect any possible treatment failure and biological markers of resistance.	[Mitja, Oriol; Gonzalez-Beiras, Camila; Sanz, Sergi; Bassat, Quique] Univ Barcelona, Hosp Clin, Barcelona Inst Global Hlth, Barcelona, Spain; [Mitja, Oriol] Univ Papua New Guinea, Sch Med & Hlth Sci, Div Publ Hlth, Port Moresby, Papua N Guinea; [Mitja, Oriol; Kapa, August; Paru, Raymond; Abel, Haina] Int SOS Newcrest Min, Lihir Med Ctr, Lihir Isl, Papua N Guinea; [Godornes, Charmie; Lukehart, Sheila A.] Univ Washington, Dept Med, Seattle, WA USA; [Lukehart, Sheila A.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Houinei, Wendy; Bieb, Sibauk V.] Natl Dept Hlth, Dis Control Branch, Port Moresby, Papua N Guinea; [Gonzalez-Beiras, Camila] Lisbon Inst Hyg & Trop Med, Lisbon, Portugal; [Wangi, James] WHO, Off World Hlth Org WHO Representat Papua New Guin, Port Moresby, Papua N Guinea; [Barry, Alyssa E.] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Parkville, Vic, Australia; [Barry, Alyssa E.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Bassat, Quique] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain; [Bassat, Quique] Ctr Invest Saude Manhica, Maputo, Mozambique; [Sanz, Sergi] Univ Barcelona, Dept Publ Hlth, Biostat Unit, Fac Med, Barcelona, Spain; [Bassat, Quique] Hosp St Joan de Deu, Dept Paediat, Paediat Infect Dis Unit, Barcelona, Spain	ISGlobal; University of Barcelona; Hospital Clinic de Barcelona; University of Papua New Guinea; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; World Health Organization; Walter & Eliza Hall Institute; University of Melbourne; ICREA; Centro de Investigacao em Saude de Manhica; University of Barcelona; University of Barcelona	Mitja, O (corresponding author), Lihir Med Ctr, Dept Community Hlth, POB 34, Lihir Isl, New Ireland Pro, Papua N Guinea.	oriol.mitja@isglobal.org	Sanz, Sergi/AAY-7211-2020; Mitjà, Oriol/W-4181-2018; Bassat, Quique/P-2341-2016	Mitjà, Oriol/0000-0003-3266-8868; Bassat, Quique/0000-0003-0875-7596; Gonzalez-Beiras, Camila/0000-0001-6617-0748; Barry, Alyssa/0000-0002-1189-2310; Sanz Bravo, Sergi/0000-0001-5010-4527	ISDIN laboratories; Newcrest Mining Limited; US Public Health Service National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042143] Funding Source: NIH RePORTER	ISDIN laboratories; Newcrest Mining Limited; US Public Health Service National Institutes of Health(United States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	ISDIN laboratories, Newcrest Mining Limited, and US Public Health Service National Institutes of Health.	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P189; Chi KH, 2015, AM J TROP MED HYG, V92, P134, DOI 10.4269/ajtmh.14-0459; Ghinai R, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003496; Godornes C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006113; Grillova L, 2014, J CLIN MICROBIOL, V52, P3693, DOI 10.1128/JCM.01292-14; Grimes M, 2012, SEX TRANSM DIS, V39, P954, DOI 10.1097/OLQ.0b013e31826ae7a8; HACKETT C J, 1956, Bull World Health Organ, V15, P869; Hinman AR, 1988, ERADICATION INFECT D, P19; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Kwakye-Maclean C, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005154; Lee SY, 2002, FEMS MICROBIOL LETT, V207, P39, DOI 10.1111/j.1574-6968.2002.tb11025.x; Li Z, 2013, J CLIN MICROBIOL, V51, P4270, DOI 10.1128/JCM.01261-13; Lukehart SA, 2004, NEW ENGL J MED, V351, P154, DOI 10.1056/NEJMoa040216; Marks M, 2017, EMERG INFECT DIS, V23, P22, DOI 10.3201/eid2301.160487; Marks M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004927; Marks M, 2015, LANCET INFECT DIS, V15, P1220, DOI 10.1016/S1473-3099(15)00136-X; Marks M, 2014, EMERG INFECT DIS, V20, P1705, DOI 10.3201/eid2010.140573; Marra CM, 2006, J INFECT DIS, V194, P1771, DOI 10.1086/509512; Matejkova P, 2009, J MED MICROBIOL, V58, P832, DOI 10.1099/jmm.0.007542-0; Mitja O, 2015, NEW ENGL J MED, V372, P703, DOI 10.1056/NEJMoa1408586; Mitja O, 2014, LANCET GLOB HEALTH, V2, pE235, DOI 10.1016/S2214-109X(14)70019-1; Mitja O, 2012, LANCET, V379, P342, DOI 10.1016/S0140-6736(11)61624-3; Mitja O, 2011, EMERG INFECT DIS, V17, P1083, DOI [10.3201/eid1706.101575, 10.3201/eid/1706.101575]; Muldoon EG, 2012, SEX TRANSM DIS, V39, P784, DOI 10.1097/OLQ.0b013e318269995f; Orle KA, 1996, J CLIN MICROBIOL, V34, P49, DOI 10.1128/JCM.34.1.49-54.1996; REIN C R, 1949, J Natl Med Assoc, V41, P60; Samajs D, 2015, AM J TROP MED HYG, V93, P678, DOI 10.4269/ajtmh.15-0316; Su JR, 2012, SEX TRANSM DIS, V39, P794, DOI 10.1097/OLQ.0b013e31826f36de; WHO, 2012, SUMM REP CONS ER YAW; ZAHRA A, 1956, Bull World Health Organ, V15, P911	30	41	41	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2018	391	10130					1599	1607		10.1016/S0140-6736(18)30204-6	http://dx.doi.org/10.1016/S0140-6736(18)30204-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD5JG	29428183	Green Accepted, Green Submitted			2023-01-03	WOS:000430542700029
J	Seymour, JF; Kipps, TJ; Eichhorst, B; Hillmen, P; D'Rozario, J; Assouline, S; Owen, C; Gerecitano, J; Robak, T; De la Serna, J; Jaeger, U; Cartron, G; Montillo, M; Humerickhouse, R; Punnoose, EA; Li, Y; Boyer, M; Humphrey, K; Mobasher, M; Kater, AP				Seymour, J. F.; Kipps, T. J.; Eichhorst, B.; Hillmen, P.; D'Rozario, J.; Assouline, S.; Owen, C.; Gerecitano, J.; Robak, T.; De la Serna, J.; Jaeger, U.; Cartron, G.; Montillo, M.; Humerickhouse, R.; Punnoose, E. A.; Li, Y.; Boyer, M.; Humphrey, K.; Mobasher, M.; Kater, A. P.			Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINIMAL RESIDUAL DISEASE; INDEPENDENT PREDICTOR; PROGRESSION-FREE; PLUS RITUXIMAB; TARGETING BCL2; TP53 MUTATION; 17P DELETION; OPEN-LABEL; SURVIVAL; TRIAL	BACKGROUND Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. METHODS In this randomized, open-label, phase 3 trial, we randomly assigned 389 patients to receive venetoclax for up to 2 years (from day 1 of cycle 1) plus rituximab for the first 6 months (venetoclax-rituximab group) or bendamustine plus rituximab for 6 months (bendamustine-rituximab group). The trial design did not include crossover to venetoclax plus rituximab for patients in the bendamustine-rituximab group in whom progression occurred. The primary end point was investigator-assessed progression-free survival. RESULTS After a median follow-up period of 23.8 months, the rate of investigator-assessed progression-free survival was significantly higher in the venetoclax-rituximab group (32 events of progression or death in 194 patients) than in the bendamustine-rituximab group (114 events in 195 patients); the 2-year rates of progression-free survival were 84.9% and 36.3%, respectively (hazard ratio for progression or death, 0.17; 95% confidence interval [CI], 0.11 to 0.25; P<0.001 by the stratified log-rank test). The benefit was maintained across all clinical and biologic subgroups, including the subgroup of patients with chromosome 17p deletion; the 2-year rate of progression-free survival among patients with chromosome 17p deletion was 81.5% in the venetoclax-rituximab group versus 27.8% in the bendamustine-rituximab group (hazard ratio, 0.13; 95% CI, 0.05 to 0.29), and the 2-year rate among those without chromosome 17p deletion was 85.9% versus 41.0% (hazard ratio, 0.19; 95% CI, 0.12 to 0.32). The benefit of venetoclax plus rituximab over bendamustine plus rituximab was confirmed by an independent review committee assessment of progression-free survival and other secondary efficacy end points. The rate of grade 3 or 4 neutropenia was higher in the venetoclax-rituximab group than in the bendamustine-rituximab group, but the rates of grade 3 or 4 febrile neutropenia and infections or infestations were lower with venetoclax than with bendamustine. The rate of grade 3 or 4 tumor lysis syndrome in the venetoclax-rituximab group was 3.1% (6 of 194 patients). CONCLUSIONS Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression-free survival than bendamustine plus rituximab.	[Seymour, J. F.] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Seymour, J. F.] Univ Melbourne, Melbourne, Vic, Australia; [D'Rozario, J.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia; [Kipps, T. J.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Punnoose, E. A.; Li, Y.; Mobasher, M.] Genentech Inc, San Francisco, CA USA; [Eichhorst, B.] Univ Hosp Cologne, Cologne, Germany; [Eichhorst, B.] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany; [Hillmen, P.] St James Univ Hosp, Leeds, W Yorkshire, England; [Boyer, M.; Humphrey, K.] F Hofmann La Roche, Welwyn Garden City, Herts, England; [Assouline, S.] Jewish Gen Hosp, Lady Davis Inst, Segal Canc Ctr, Montreal, PQ, Canada; [Owen, C.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Owen, C.] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Gerecitano, J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Robak, T.] Med Univ Lodz, Dept Hematol, Lodz, Poland; [Robak, T.] Copernicus Mem Hosp, Lodz, Poland; [De la Serna, J.] Hosp Univ 12 Octubre, Madrid, Spain; [Jaeger, U.] Med Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Vienna, Austria; [Cartron, G.] CHU Montpellier, Dept Hematol, Montpellier, France; [Montillo, M.] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Dept Oncohematol, Div Hematol, Milan, Italy; [Humerickhouse, R.] AbbVie, N Chicago, IL USA; [Kater, A. P.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands	Peter Maccallum Cancer Center; Royal Melbourne Hospital; University of Melbourne; Australian National University; John Curtin School of Medical Research; University of California System; University of California San Diego; Roche Holding; Genentech; University of Cologne; University of Cologne; Saint James's University Hospital; Lady Davis Institute; McGill University; University of Calgary; University of Calgary; Memorial Sloan Kettering Cancer Center; Medical University Lodz; Hospital Universitario 12 de Octubre; Medical University of Vienna; Universite de Montpellier; CHU de Montpellier; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; AbbVie; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Seymour, JF (corresponding author), Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic 3000, Australia.	john.seymour@petermac.org	DE LA SERNA, JAVIER/B-1735-2012; Robak, Tadeusz/AAW-7365-2021; Seymour, John/K-7326-2019; Robak, Tadeusz/ABA-5496-2020	DE LA SERNA, JAVIER/0000-0003-3904-1101; Robak, Tadeusz/0000-0002-3411-6357; Seymour, John/0000-0003-2188-6835; 	Genentech; AbbVie	Genentech(Roche HoldingGenentech); AbbVie(AbbVie)	Funded by Genentech and AbbVie.	Anderson MA, 2016, BLOOD, V127, P3215, DOI 10.1182/blood-2016-01-688796; [Anonymous], 1997, Int Dig Health Legis, V48, P231; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Burger JA, 2014, LANCET ONCOL, V15, P1090, DOI 10.1016/S1470-2045(14)70335-3; Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376; Byrd JC, 2003, BLOOD, V101, P6, DOI 10.1182/blood-2002-04-1258; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Chanan-Khan A, 2016, LANCET ONCOL, V17, P200, DOI 10.1016/S1470-2045(15)00465-9; Cheson BD, 2010, CL LYMPH MYELOM LEUK, V10, P21, DOI 10.3816/CLML.2010.n.002; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cory S, 2016, TRENDS CANCER, V2, P443, DOI 10.1016/j.trecan.2016.07.001; Davids MS, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.7528; Dimier N, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.720.720; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst B, 2015, ANN ONCOL, V26, pV78, DOI 10.1093/annonc/mdv303; Ferrajoli A, 2011, CANCER-AM CANCER SOC, V117, P3182, DOI 10.1002/cncr.25853; Fischer K, 2011, J CLIN ONCOL, V29, P3559, DOI 10.1200/JCO.2010.33.8061; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M., 2017, 17 INT WORKSH CHRON; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Kovacs G, 2016, J CLIN ONCOL, V34, P3758, DOI 10.1200/JCO.2016.67.1305; Kwok M, 2016, BLOOD, V128, P2770, DOI 10.1182/blood-2016-05-714162; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; National Comprehensive Cancer Network, 2017, NCCN GUID CHRON LYMP; Pospisilova S, 2012, LEUKEMIA, V26, P1458, DOI 10.1038/leu.2012.25; Robak T, 2010, J CLIN ONCOL, V28, P1756, DOI 10.1200/JCO.2009.26.4556; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Robertson LE, 1996, LEUKEMIA, V10, P456; Seymour JF, 2017, LANCET ONCOL, V18, P230, DOI 10.1016/S1470-2045(17)30012-8; Shanafelt Tait D, 2009, Hematology Am Soc Hematol Educ Program, P421, DOI 10.1182/asheducation-2009.1.421; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Stilgenbauer S, 2016, LANCET ONCOL, V17, P768, DOI 10.1016/S1470-2045(16)30019-5; Tam CS, 2015, LEUKEMIA LYMPHOMA, V56, P587, DOI 10.3109/10428194.2015.1011641; Thijssen R, 2015, HAEMATOLOGICA, V100, pE302, DOI 10.3324/haematol.2015.124560; Westfall PH, 2001, J STAT PLAN INFER, V99, P25, DOI 10.1016/S0378-3758(01)00077-5; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Zelenetz AD, 2017, LANCET ONCOL, V18, P297, DOI 10.1016/S1470-2045(16)30671-4	39	513	529	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2018	378	12					1107	1120		10.1056/NEJMoa1713976	http://dx.doi.org/10.1056/NEJMoa1713976			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ9OV	29562156	Bronze, Green Published			2023-01-03	WOS:000427942300007
J	Zhang, SL; Yue, ZF; Arnold, DM; Artiushin, G; Sehgal, A				Zhang, Shirley L.; Yue, Zhifeng; Arnold, Denice M.; Artiushin, Gregory; Sehgal, Amita			A Circadian Clock in the Blood-Brain Barrier Regulates Xenobiotic Efflux	CELL			English	Article							P-GLYCOPROTEIN; ANTIEPILEPTIC DRUGS; DIURNAL-VARIATION; DROSOPHILA; BEHAVIOR; CELLS; GAP; INNEXINS; TRANSPORTERS; MECHANISMS	Endogenous circadian rhythms are thought to modulate responses to external factors, but mechanisms that confer time-of-day differences in organismal responses to environmental insults/therapeutic treatments are poorly understood. Using a xenobiotic, we find that permeability of the Drosophila "blood''-brain barrier (BBB) is higher at night. The permeability rhythm is driven by circadian regulation of efflux and depends on a molecular clock in the perineurial glia of the BBB, although efflux transporters are restricted to subperineurial glia (SPG). We show that transmission of circadian signals across the layers requires cyclically expressed gap junctions. Specifically, during nighttime, gap junctions reduce intracellular magnesium ([Mg2+]i), a positive regulator of efflux, in SPG. Consistent with lower nighttime efflux, nighttime administration of the anti-epileptic phenytoin is more effective at treating a Drosophila seizure model. These findings identify a novel mechanism of circadian regulation and have therapeutic implications for drugs targeted to the central nervous system.	[Zhang, Shirley L.; Sehgal, Amita] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA; [Zhang, Shirley L.; Yue, Zhifeng; Arnold, Denice M.; Artiushin, Gregory; Sehgal, Amita] Univ Penn, Perelman Sch Med, Chronobiol Program Penn, Philadelphia, PA 19104 USA; [Zhang, Shirley L.; Yue, Zhifeng; Arnold, Denice M.; Artiushin, Gregory; Sehgal, Amita] Univ Penn, Perelman Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine	Sehgal, A (corresponding author), Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA.; Sehgal, A (corresponding author), Univ Penn, Perelman Sch Med, Chronobiol Program Penn, Philadelphia, PA 19104 USA.; Sehgal, A (corresponding author), Univ Penn, Perelman Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.	amita@pennmedicine.upenn.edu	Zhang, Shirley/AAL-7187-2021	Zhang, Shirley/0000-0002-6672-2044	NIH [T32HL07713, R37NS048471]; Howard Hughes Medical Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH060490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS048471] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the NIH (T32HL07713) (to S.L.Z.) and R37NS048471 (to A.S.) and by the Howard Hughes Medical Institute (to A.S.). We thank Dr. John Hogenesch for assistance with statistical analysis and Dr. Annika Barber for assistance with visual representation of data.	Abbott NJ, 2013, J INHERIT METAB DIS, V36, P437, DOI 10.1007/s10545-013-9608-0; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Antoch MP, 2005, CELL CYCLE, V4, P901, DOI 10.4161/cc.4.7.1792; Bainton RJ, 2005, CELL, V123, P145, DOI 10.1016/j.cell.2005.07.029; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; BENZER S, 1971, J AMER MED ASSOC, V218, P1015, DOI 10.1001/jama.218.7.1015; Booth CL, 2000, BIOCHEMISTRY-US, V39, P5518, DOI 10.1021/bi992931x; Brancaccio M, 2017, NEURON, V93, P1420, DOI 10.1016/j.neuron.2017.02.030; Chatterjee A, 2016, RES PERSPECT END INT, P71, DOI 10.1007/978-3-319-27069-2_8; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Dallmann R, 2016, TRENDS MOL MED, V22, P430, DOI 10.1016/j.molmed.2016.03.004; Dallmann R, 2014, ANNU REV PHARMACOL, V54, P339, DOI 10.1146/annurev-pharmtox-011613-135923; Damulewicz M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073690; DeSalvo MK, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00346; Desalvo MK, 2011, GLIA, V59, P1322, DOI 10.1002/glia.21147; Deshpande SA, 2014, NAT METHODS, V11, P535, DOI [10.1038/nmeth.2899, 10.1038/NMETH.2899]; Feeney KA, 2016, NATURE, V532, P375, DOI 10.1038/nature17407; Feng YF, 2004, J NEUROGENET, V18, P377, DOI 10.1080/01677060490894522; Garbe DS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003749; Guo F, 2014, ELIFE, V3, DOI 10.7554/eLife.02780; Hindle SJ, 2017, CELL REP, V21, P1304, DOI 10.1016/j.celrep.2017.10.026; Holcroft CE, 2013, J CELL SCI, V126, P3823, DOI 10.1242/jcs.117994; Hughes ME, 2010, J BIOL RHYTHM, V25, P372, DOI 10.1177/0748730410379711; Ito C, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00008; Jackson FR, 2015, METHOD ENZYMOL, V552, P45, DOI 10.1016/bs.mie.2014.10.016; Kaur G, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8020013; Kervezee L, 2014, AAPS J, V16, P1029, DOI 10.1208/s12248-014-9625-4; Liang XT, 2017, NEURON, V94, P1173, DOI 10.1016/j.neuron.2017.05.007; Liang XJ, 2000, BIOSCIENCE REP, V20, P129, DOI 10.1023/A:1005530501137; Limmer S, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00365; Loscher W, 2011, CURR PHARM DESIGN, V17, P2808, DOI 10.2174/138161211797440212; Masuyama K, 2012, J NEUROGENET, V26, P89, DOI 10.3109/01677063.2011.642910; Mayer F, 2009, J NEUROSCI, V29, P3538, DOI 10.1523/JNEUROSCI.5564-08.2009; Mohawk JA, 2012, ANNU REV NEUROSCI, V35, P445, DOI 10.1146/annurev-neuro-060909-153128; Pan WH, 2002, J APPL PHYSIOL, V92, P1357, DOI 10.1152/japplphysiol.00915.2001; Pan WH, 2001, LIFE SCI, V68, P2705, DOI 10.1016/S0024-3205(01)01085-2; Peschel N, 2011, FEBS LETT, V585, P1435, DOI 10.1016/j.febslet.2011.02.028; Phelan P, 2001, BIOESSAYS, V23, P388, DOI 10.1002/bies.1057; Pinsonneault RL, 2011, METHODS MOL BIOL, V686, P357, DOI 10.1007/978-1-60761-938-3_17; Reynolds ER, 2004, J NEUROBIOL, V58, P503, DOI 10.1002/neu.10297; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Skerrett IM, 2017, DEV NEUROBIOL, V77, P522, DOI 10.1002/dneu.22447; Smendziuk CM, 2015, DEVELOPMENT, V142, P2598, DOI 10.1242/dev.123448; Speder P, 2014, DEV CELL, V30, P309, DOI 10.1016/j.devcel.2014.05.021; Stork T, 2008, J NEUROSCI, V28, P587, DOI 10.1523/JNEUROSCI.4367-07.2008; Thews O, 2006, NEOPLASIA, V8, P143, DOI 10.1593/neo.05697; Tso CF, 2017, CURR BIOL, V27, P1055, DOI 10.1016/j.cub.2017.02.037; Volkenhoff A, 2015, CELL METAB, V22, P437, DOI 10.1016/j.cmet.2015.07.006; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu KY, 2008, CELL METAB, V8, P289, DOI 10.1016/j.cmet.2008.09.006; Yegnanarayan R, 2006, CHRONOBIOL INT, V23, P1035, DOI 10.1080/07420520600921112; Yoon SS, 2012, BIOMOL THER, V20, P245, DOI 10.4062/biomolther.2012.20.3.245; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x	54	100	101	4	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	2018	173	1					130	+		10.1016/j.cell.2018.02.017	http://dx.doi.org/10.1016/j.cell.2018.02.017			20	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA3MT	29526461	Green Accepted, Bronze, Green Submitted			2023-01-03	WOS:000428234200013
J	Katz, SJ; Jagsi, R; Morrow, M				Katz, Steven J.; Jagsi, Reshma; Morrow, Monica			Reducing Overtreatment of Cancer With Precision Medicine Just What the Doctor Ordered	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICAN SOCIETY; BREAST IRRADIATION; GUIDELINE		[Katz, Steven J.] Univ Michigan, Dept Med, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Katz, Steven J.] Univ Michigan, Dept Hlth Management & Policy, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Jagsi, Reshma] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Morrow, Monica] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY 10021 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cornell University; Memorial Sloan Kettering Cancer Center	Katz, SJ (corresponding author), Univ Michigan, Dept Med, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.; Katz, SJ (corresponding author), Univ Michigan, Dept Hlth Management & Policy, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	skatz@umich.edu	KATZ, STEVEN/ABH-8886-2020		National Cancer Institute; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA163233] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding was provided by grants from the National Cancer Institute (P01) (Drs Katz and Jagsi).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Correa C, 2017, PRACT RADIAT ONCOL, V7, P73, DOI 10.1016/j.prro.2016.09.007; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Katz SJ, 2018, JAMA SURG, V153, P29, DOI 10.1001/jamasurg.2017.3415; Kurian AW, 2017, JNCI-J NATL CANCER I, DOI [10.1093/jnctidjx239, DOI 10.1093/JNCTIDJX239]; Lyman GH, 2017, J CLIN ONCOL, V35, P561, DOI 10.1200/JCO.2016.71.0947; Moran MS, 2014, INT J RADIAT ONCOL, V88, P553, DOI 10.1016/j.ijrobp.2013.11.012; Morrow M, 2017, JAMA ONCOL, V3, P1352, DOI 10.1001/jamaoncol.2017.0774; Wong SM, 2017, ANN SURG, V265, P581, DOI 10.1097/SLA.0000000000001698	9	18	18	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2018	319	11					1091	1092		10.1001/jama.2018.0018	http://dx.doi.org/10.1001/jama.2018.0018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ8LL	29470568				2023-01-03	WOS:000427860200009
J	Li, SP; Jiang, Q; Liu, SL; Zhang, YL; Tian, YH; Song, C; Wang, J; Zou, YG; Anderson, GJ; Han, JY; Chang, Y; Liu, Y; Zhang, C; Chen, L; Zhou, GB; Nie, GJ; Yan, H; Ding, BQ; Zhao, YL				Li, Suping; Jiang, Qiao; Liu, Shaoli; Zhang, Yinlong; Tian, Yanhua; Song, Chen; Wang, Jing; Zou, Yiguo; Anderson, Gregory J.; Han, Jing-Yan; Chang, Yung; Liu, Yan; Zhang, Chen; Chen, Liang; Zhou, Guangbiao; Nie, Guangjun; Yan, Hao; Ding, Baoquan; Zhao, Yuliang			A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo	NATURE BIOTECHNOLOGY			English	Article							TUMOR VASCULATURE; DRUG-DELIVERY; TISSUE FACTOR; ORIGAMI; NUCLEOLIN; CELL; NANOTECHNOLOGY; THROMBOSIS; NANOSCALE; PROTEINS	Nanoscale robots have potential as intelligent drug delivery systems that respond to molecular triggers(1-4). Using DNA origami we constructed an autonomous DNA robot programmed to transport payloads and present them specifically in tumors. Our nanorobot is functionalized on the outside with a DNA aptamer that binds nucleolin, a protein specifically expressed on tumor-associated endothelial cells(5), and the blood coagulation protease thrombin within its inner cavity. The nucleolin-targeting aptamer serves both as a targeting domain and as a molecular trigger for the mechanical opening of the DNA nanorobot. The thrombin inside is thus exposed and activates coagulation at the tumor site. Using tumor-bearing mouse models, we demonstrate that intravenously injected DNA nanorobots deliver thrombin specifically to tumor-associated blood vessels and induce intravascular thrombosis, resulting in tumor necrosis and inhibition of tumor growth. The nanorobot proved safe and immunologically inert in mice and Bama miniature pigs. Our data show that DNA nanorobots represent a promising strategy for precise drug delivery in cancer therapy.	[Li, Suping; Jiang, Qiao; Liu, Shaoli; Zhang, Yinlong; Tian, Yanhua; Song, Chen; Wang, Jing; Zou, Yiguo; Nie, Guangjun; Ding, Baoquan; Zhao, Yuliang] Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Nanosyst & Hierarch Fabricat, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China; [Li, Suping; Liu, Shaoli; Nie, Guangjun; Ding, Baoquan; Zhao, Yuliang] Univ Chinese Acad Sci, Beijing, Peoples R China; [Zhang, Yinlong] Jilin Univ, Coll Pharmaceut Sci, Changchun, Jilin, Peoples R China; [Tian, Yanhua] Peking Univ, Acad Adv Interdisciplinary Studies, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Anderson, Gregory J.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Han, Jing-Yan] Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, Beijing, Peoples R China; [Chang, Yung; Liu, Yan; Yan, Hao] Arizona State Univ, Ctr Mol Design & Biomimet, Sch Mol Sci, Tempe, AZ USA; [Chang, Yung; Liu, Yan; Yan, Hao] Arizona State Univ, Sch Life Sci, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ USA; [Zhang, Chen; Zhou, Guangbiao] Chinese Acad Sci, Inst Zool, Beijing, Peoples R China; [Chen, Liang] Jinan Univ, Coll Life Sci & Technol, Inst Life & Hlth Engn, Guangzhou, Guangdong, Peoples R China	Chinese Academy of Sciences; National Center for Nanoscience & Technology - China; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Jilin University; Peking University; QIMR Berghofer Medical Research Institute; Peking University; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Chinese Academy of Sciences; Institute of Zoology, CAS; Jinan University	Nie, GJ; Ding, BQ; Zhao, YL (corresponding author), Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Nanosyst & Hierarch Fabricat, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing, Peoples R China.; Nie, GJ; Ding, BQ; Zhao, YL (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.; Yan, H (corresponding author), Arizona State Univ, Ctr Mol Design & Biomimet, Sch Mol Sci, Tempe, AZ USA.; Yan, H (corresponding author), Arizona State Univ, Sch Life Sci, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ USA.	niegj@nanoctr.cn; hao.yan@asu.edu; dingbq@nanoctr.cn; zhaoyl@nanoctr.cn	han, jingyan/HJG-6568-2022; Tian, Yanhua/AAE-9384-2021; Liu, Yan/K-1999-2014; Zhou, Guang-Biao/ABG-5795-2021; Zhou, Guangbiao/J-6575-2017; Nie, Guangjun/A-9954-2011; Anderson, Gregory/G-4148-2013	Liu, Yan/0000-0003-0906-2606; Zhou, Guangbiao/0000-0002-6327-2316; Zhou, Guang-Biao/0000-0001-6778-7133; Chen, Liang/0000-0001-7300-6604; Anderson, Gregory/0000-0002-8814-5866	National Basic Research Plan of China (MoST Program) [2016YFA0201601]; National Natural Science Foundation of China [31730032, 21222311, 21573051, 91127021]; National Distinguished Young Scientists program [31325010]; Innovation Research Group of National Natural Science Foundation [11621505, 21721002]; Beijing Municipal Science & Technology Commission [Z161100000116035, Z161100000116036]; CAS Interdisciplinary Innovation Team; Key Research Program of Frontier Sciences, CAS [QYZDB-SSW-SLH029]; US National Institute of Health [R01GM104960-01]	National Basic Research Plan of China (MoST Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Distinguished Young Scientists program; Innovation Research Group of National Natural Science Foundation; Beijing Municipal Science & Technology Commission(Beijing Municipal Science & Technology Commission); CAS Interdisciplinary Innovation Team; Key Research Program of Frontier Sciences, CAS; US National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank L.Z. Xu (Medical and Health Analysis Center of Peking University) for animal imaging and G.Z. Shi (Laboratory Animal Center of Institute of Biophysics, Chinese Academy of Sciences) for histological examination of minipigs. We also thank A. Sheftel from High Impact Editing for improving the English of the manuscript. This work was supported by grants from National Basic Research Plan of China (MoST Program 2016YFA0201601 to G.N. and B.D.), the National Natural Science Foundation of China (31730032 to G.N., 21222311, 21573051, 91127021 to B.D., the National Distinguished Young Scientists program 31325010 to G.N.), Innovation Research Group of National Natural Science Foundation (11621505 to G.N. and Yuliang Z., 21721002 to B.D.), Beijing Municipal Science & Technology Commission (Z161100000116035 to G.N., Z161100000116036 to B.D.), CAS Interdisciplinary Innovation Team to B.D., G.N. & Yuliang Z., Key Research Program of Frontier Sciences, CAS, Grant No. QYZDB-SSW-SLH029 to B.D. and US National Institute of Health Director's Transformative Research Award (R01GM104960-01 to H.Y.).	Agemy L, 2010, BLOOD, V116, P2847, DOI 10.1182/blood-2010-03-274258; Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Amir Y, 2014, NAT NANOTECHNOL, V9, P353, DOI [10.1038/nnano.2014.58, 10.1038/NNANO.2014.58]; Benson E, 2015, NATURE, V523, P441, DOI 10.1038/nature14586; Bhatia D, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1337; Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330; Chauhan VP, 2013, NAT MATER, V12, P958, DOI 10.1038/nmat3792; Chen YJ, 2015, NAT NANOTECHNOL, V10, P748, DOI [10.1038/nnano.2015.195, 10.1038/NNANO.2015.195]; Douglas SM, 2007, P NATL ACAD SCI USA, V104, P6644, DOI 10.1073/pnas.0700930104; Douglas SM, 2012, SCIENCE, V335, P831, DOI 10.1126/science.1214081; Gerling T, 2015, SCIENCE, V347, P1446, DOI 10.1126/science.aaa5372; Goldberg SN, 2003, RADIOLOGY, V228, P335, DOI 10.1148/radiol.2282021787; Gottfries J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030005; Guyer RA, 2015, J BIOL CHEM, V290, P8457, DOI 10.1074/jbc.M114.621011; Hu PS, 2003, CANCER RES, V63, P5046; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jiang Q, 2012, J AM CHEM SOC, V134, P13396, DOI 10.1021/ja304263n; Jungmann R, 2014, NAT METHODS, V11, P313, DOI [10.1038/NMETH.2835, 10.1038/nmeth.2835]; Kong G, 2000, CANCER RES, V60, P4440; Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/NNANO.2012.73, 10.1038/nnano.2012.73]; Liu Y, 2008, COMPARATIVE MED, V58, P580; Miniard AC, 2010, NUCLEIC ACIDS RES, V38, P4807, DOI 10.1093/nar/gkq247; Modi S, 2013, NAT NANOTECHNOL, V8, P459, DOI [10.1038/nnano.2013.92, 10.1038/NNANO.2013.92]; Nutiu R, 2003, J AM CHEM SOC, V125, P4771, DOI 10.1021/ja028962o; O'Callaghan P, 2015, J BIOL CHEM, V290, P14904, DOI 10.1074/jbc.M114.634337; Pinheiro AV, 2011, NAT NANOTECHNOL, V6, P763, DOI [10.1038/nnano.2011.187, 10.1038/NNANO.2011.187]; Rothemund PWK, 2006, NATURE, V440, P297, DOI 10.1038/nature04586; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Schuller VJ, 2011, ACS NANO, V5, P9696, DOI 10.1021/nn203161y; Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723; Surana S, 2015, NAT NANOTECHNOL, V10, P741, DOI [10.1038/nnano.2015.180, 10.1038/NNANO.2015.180]; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Zhang HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11805; Zhang Q, 2014, ACS NANO, V8, P6633, DOI 10.1021/nn502058j	36	699	724	112	1803	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2018	36	3					258	+		10.1038/nbt.4071	http://dx.doi.org/10.1038/nbt.4071			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FY3DS	29431737				2023-01-03	WOS:000426698700021
J	Chavez, G; Richman, IB; Kaimal, R; Bentley, J; Yasukawa, LA; Altman, RB; Periyakoil, VS; Chen, JH				Chavez, Gustavo; Richman, Ilana B.; Kaimal, Rajani; Bentley, Jason; Yasukawa, Lee Ann; Altman, Russ B.; Periyakoil, Vyjeyanthi S.; Chen, Jonathan H.			Reversals and limitations on high-intensity, life-sustaining treatments	PLOS ONE			English	Article							NOT-RESUSCITATE ORDERS; CARDIOPULMONARY-RESUSCITATION; CARDIAC-ARREST; LIVING WILLS; CARE; PREFERENCES; WITHDRAWAL; DECISIONS; OUTCOMES; DNR	Importance Critically ill patients often receive high-intensity life sustaining treatments (LST) in the intensive care unit (ICU), although they can be ineffective and eventually undesired. Determining the risk factors associated with reversals in LST goals can improve patient and provider appreciation for the natural history and epidemiology of critical care and inform decision making around the (continued) use of LSTs. Methods This is a single institution retrospective cohort study of patients receiving life sustaining treatment in an academic tertiary hospital from 2009 to 2013. Deidentified patient electronic medical record data was collected via the clinical data warehouse to study the outcomes of treatment limiting Comfort Care and do-not-resuscitate (DNR) orders. Extended multivariable Cox regression models were used to estimate the association of patient and clinical factors with subsequent treatment limiting orders. Results 10,157 patients received life-sustaining treatment while initially Full Code (allowing all resuscitative measures). Of these, 770 (8.0%) transitioned to Comfort Care (with discontinuation of any life-sustaining treatments) while 1,669 (16%) patients received new DNR orders that reflect preferences to limit further life-sustaining treatment options. Patients who were older (Hazard Ratio(HR) 1.37 [95% CI 1.28-1.47] per decade), with cerebrovascular disease (HR 2.18 [95% CI 1.69-2.81]), treated by the Medical ICU (HR 1.92 [95% CI 1.49-2.49]) and Hematology-Oncology (HR 1.87 [95% CI 1.27-2.74]) services, receiving vasoactive infusions (HR 1.76 [95% CI 1.28, 2.43]) or continuous renal replacement (HR 1.83 [95% CI 1.34, 2.48]) were more likely to transition to Comfort Care. Any new DNR orders were more likely for patients who were older (HR 1.43 [95% CI 1.38-1.48] per decade), female (HR 1.30 [95% CI 1.17-1.44]), with cerebrovascular disease (HR 1.45 [95% CI 1.25-1.67]) or metastatic solid cancers (HR 1.92 [95% CI 1.48-2.49]), or treated by Medical ICU (HR 1.63 [95% CI 1.42-1.86]), Hematology-Oncology (HR 1.63 [95% CI 1.33-1.98]) and Cardiac Care Unit-Heart Failure (HR 1.41 [95% CI 1.15-1.72]). Conclusion Decisions to reverse or limit treatment goals occurs after more than 1 in 13 trials of LST, and is associated with older female patients, receiving non-ventilator forms of LST, cerebrovascular disease, and treatment by certain medical specialty services.	[Chavez, Gustavo] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Richman, Ilana B.] Yale Med, Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Kaimal, Rajani; Bentley, Jason] Stanford Quantitat Sci, Stanford, CA USA; [Yasukawa, Lee Ann] Stanford Ctr Clin Informat, Stanford, CA USA; [Altman, Russ B.] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA; [Periyakoil, Vyjeyanthi S.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Periyakoil, Vyjeyanthi S.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA; [Chen, Jonathan H.] Stanford Univ, Ctr Biomed Informat Res, Sch Med, Stanford, CA 94305 USA; [Chen, Jonathan H.] Stanford Univ, Dept Med, Sch Med, Div Hosp Med, Stanford, CA 94305 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; Stanford University	Chen, JH (corresponding author), Stanford Univ, Ctr Biomed Informat Res, Sch Med, Stanford, CA 94305 USA.; Chen, JH (corresponding author), Stanford Univ, Dept Med, Sch Med, Div Hosp Med, Stanford, CA 94305 USA.	jonc101@stanford.edu		Altman, Russ/0000-0003-3859-2905; Chen, Jonathan H./0000-0002-4387-8740	Stanford University School of Medicine Center of Excellence; Stanford University School of Medicine Medical Scholars Research Program; NIH Big Data 2 Knowledge Award through the National Institutes of Health and National Institute of Environmental Health Sciences [K01ES026837]; US Department of Veterans Affairs Office of Academic Affiliations and Health Services Research and Development Service Research Funds; Department of Veterans Affairs; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [UL1 RR025744];  [R25 MD006857];  [5U54MD010724]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K01ES026837] Funding Source: NIH RePORTER	Stanford University School of Medicine Center of Excellence; Stanford University School of Medicine Medical Scholars Research Program; NIH Big Data 2 Knowledge Award through the National Institutes of Health and National Institute of Environmental Health Sciences; US Department of Veterans Affairs Office of Academic Affiliations and Health Services Research and Development Service Research Funds; Department of Veterans Affairs(US Department of Veterans Affairs); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); ; ; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Gustavo A. Chavez was supported by Stanford University School of Medicine Center of Excellence and Stanford University School of Medicine Medical Scholars Research Program. Jonathan H. Chen was supported by NIH Big Data 2 Knowledge Award Number K01ES026837 through the National Institutes of Health and National Institute of Environmental Health Sciences. Ilana Richman was supported by the US Department of Veterans Affairs Office of Academic Affiliations and Health Services Research and Development Service Research Funds. Vyjeyanthi S. Periyakoil's time is supported in part by grants R25 MD006857, 5U54MD010724 and the Department of Veterans Affairs. Patient data extracted and de-identified by Gomathi Krishnan and Lee Ann Yasukawa of the STRIDE (Stanford Translational Research Integrated Database Environment) project, a research and development project at Stanford University to create a standards-based informatics platform supporting clinical and translational research. The STRIDE project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1 RR025744. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson WG, 2011, J GEN INTERN MED, V26, P359, DOI 10.1007/s11606-010-1568-6; [Anonymous], 2011, METR TRANSP COMM GA; [Anonymous], 2015, DYING IN AMERICA IMP; Auriemma CL, 2014, JAMA INTERN MED, V174, P1085, DOI 10.1001/jamainternmed.2014.1183; Bailey FA, 2012, J PALLIAT MED, V15, P751, DOI 10.1089/jpm.2011.0321; Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Boerner K, 2013, J GERONTOL B-PSYCHOL, V68, P246, DOI 10.1093/geronb/gbs161; Boyd K, 1996, ARCH INTERN MED, V156, P1821, DOI 10.1001/archinte.156.16.1821; Bureau UC, 2014, 2009 2013 5 YEAR AM; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Diem SJ, 1996, NEW ENGL J MED, V334, P1578, DOI 10.1056/NEJM199606133342406; Downar J, 2011, J GEN INTERN MED, V26, P582, DOI 10.1007/s11606-010-1616-2; Einav S, 2012, EMERG MED J, V29, P709, DOI 10.1136/emermed-2011-200206; Elmer J, 2016, RESUSCITATION, V102, P127, DOI 10.1016/j.resuscitation.2016.01.016; Field M.J, 1997, APPROACHING DEATH IM; Frank C, 2003, CAN MED ASSOC J, V169, P795; Garland A, 2007, J PALLIAT MED, V10, P1298, DOI 10.1089/jpm.2007.0061; Goodlin SJ, JAMA, V282, P2333; Jawa RS, 2015, AM J SURG, V210, P814, DOI 10.1016/j.amjsurg.2015.04.007; Jayes RL, 1996, CHEST, V110, P1332, DOI 10.1378/chest.110.5.1332; Kelly WF, 2002, CHEST, V121, P957, DOI 10.1378/chest.121.3.957; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kostoulakos NM, 1997, PERCEPT MOTOR SKILL, V84, P1409, DOI 10.2466/pms.1997.84.3c.1409; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Love A, 2014, PALLIATIVE MED, V28, P1026, DOI 10.1177/0269216314531313; Lowe Henry J, 2009, AMIA Annu Symp Proc, V2009, P391; Mirarchi FL, 2007, J EMERG MED, V33, P299, DOI 10.1016/j.jemermed.2007.02.026; Mirarchi FL, 2015, J PATIENT SAF, V11, P1, DOI 10.1097/PTS.0000000000000165; Mirarchi FL, 2012, J EMERG MED, V42, P511, DOI 10.1016/j.jemermed.2011.07.015; Mirarchi FL, 2017, J PATIENT SAF, P1; Moore KA, 2016, JAMA-J AM MED ASSOC, V315, P259, DOI 10.1001/jama.2015.17362; Periyakoil VS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098246; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rajan S, 2016, RESUSCITATION, V105, P45, DOI 10.1016/j.resuscitation.2016.05.004; Roberts D, 2000, AM J EMERG MED, V18, P465, DOI 10.1053/ajem.2000.7338; Siracuse JJ, 2015, ANN VASC SURG, V29, P1339, DOI 10.1016/j.avsg.2015.05.014; US Census, 2015, ED ATT US 2015; Van den Bulck Jan J M, 2002, Eur J Emerg Med, V9, P325; Zingmond DS, 2005, ARCH INTERN MED, V165, P1705, DOI 10.1001/archinte.165.15.1705	39	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2018	13	2							e0190569	10.1371/journal.pone.0190569	http://dx.doi.org/10.1371/journal.pone.0190569			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX7ND	29489814	Green Published, Green Submitted, gold			2023-01-03	WOS:000426276000005
J	Croxford, S; Yin, Z; Burns, F; Copas, A; Town, K; Desai, S; Skingsley, A; Delpech, V				Croxford, Sara; Yin, Zheng; Burns, Fiona; Copas, Andrew; Town, Katy; Desai, Sarika; Skingsley, Andrew; Delpech, Valerie		OptTEST Project	Linkage to HIV care following diagnosis in the WHO European Region: A systematic review and meta-analysis, 2006-2017	PLOS ONE			English	Review							RETENTION; SERVICES; HEALTH; MEN; SEX	Background Timely linkage to care after HIV diagnosis is crucial as delayed access can result in poor patient outcomes. The aim of this systematic review was to synthesise the evidence to achieve a better understanding of what proportion of patients are linked to care and what factors impact linkage. Methods Systematic searches were run in six databases up to the end of February 2017. The grey literature was also reviewed. Inclusion criteria were: sample size >= 50 people (aged >= 15), from the WHO European Region, published 2006-2017 and in English. Linkage to care was defined as a patient seen for HIV care after diagnosis. Study selection, data extraction and quality assurance were performed by two independent reviewers. Random-effects meta-analysis was carried out to summarise linkage to care within three months of diagnosis. Results Twenty-four studies were included; 22 presented linkage to care data and seven examined factors for linkage. Linkage among 89,006 people in 19 countries was captured. Meta-analysis, restricted to 12 studies and measuring prompt linkage within three months, gave a pooled estimate of 85% (95% CI: 75%-93%). Prompt linkage was higher in studies including only people in care (94%; 95% CI: 91%-97%) than in those of all new diagnoses (71%; 95% CI: 50%-87%). Heterogeneity was high across and within strata (>99%). Factors associated with delaying or not linking to care included: acquiring HIV through heterosexual contact/injecting drug use, younger age at diagnosis, lower levels of education, feeling well at diagnosis and diagnosis outside an STI clinic. Conclusion Overall, linkage to care was high, though estimates were lower in studies with a high proportion of people who inject drugs. The high heterogeneity between studies made it challenging to synthesise findings. Studies should adopt a standardised definition with a three month cut-off to measure prompt linkage to care to ensure comparability.	[Croxford, Sara; Yin, Zheng; Town, Katy; Desai, Sarika; Skingsley, Andrew; Delpech, Valerie] Publ Hlth England, Ctr Infect Dis Surveillance & Control, London, England; [Croxford, Sara; Burns, Fiona; Copas, Andrew; Town, Katy] UCL, Inst Global Hlth, Ctr Populat Res Sexual Hlth & HIV, London, England; [Burns, Fiona] Royal Free London NHS Fdn Trust, London, England; [Yin, Zheng] Evidera, Dept Real World Evidence, London, England; [Copas, Andrew] GlaxoSmithKline, Dept Res & Dev, Global Hlth, London, England	Public Health England; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; Evidera; GlaxoSmithKline	Croxford, S (corresponding author), Publ Hlth England, Ctr Infect Dis Surveillance & Control, London, England.; Croxford, S (corresponding author), UCL, Inst Global Hlth, Ctr Populat Res Sexual Hlth & HIV, London, England.	sara.croxford@phe.gov.uk	Town, Katy/S-9780-2019	Copas, Andrew/0000-0001-8968-5963; delpech, valerie/0000-0002-9952-8109; Town, Katy/0000-0002-3481-5019; Croxford, Sara/0000-0003-2220-623X	Optimising testing and linkage to care for HIV project (OptTEST); European Union; Public Health England [20131102]	Optimising testing and linkage to care for HIV project (OptTEST); European Union(European Commission); Public Health England	This work was funded by the Optimising testing and linkage to care for HIV project (OptTEST)-co-funded by the 2nd Health Programme of the European Union and Public Health England (grant agreement number: 20131102) (www.opttest.eu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2006, PAT MON GUID HIV CAR; Apea V, 2009, HIV MED, V10, P14; Burns FM, 2007, AIDS CARE, V19, P102, DOI 10.1080/09540120600908440; Centers for Disease Control and Prevention, 2017, SURVEILLANCE SUPPLEM, V22; Chernyshev A, 2017, GET TEST PROJECT INN; Chkhartishvili N, 2015, INT AIDS C 2015 18 2; Croxford S, 2015, EUR AIDS CLIN SOC C; Croxford S, 2017, FACTORS DELAYED LINK; Croxford S, 2016, SYSTEMATIC REV PROTO; Cuzin L, 2013, JAIDS-J ACQ IMM DEF, V62, pE119, DOI 10.1097/QAI.0b013e3182809f08; del Campo S, 2016, HIV DRUG THERAPY; Downes MJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011458; Elliot E, 2016, SEX TRANSM INFECT, V92, P470, DOI 10.1136/sextrans-2015-052090; EuroHIV, 2007, REP EUROHIV 2006 SUR; European AIDS Clinical Society, 2017, EACS GUID 2017 V9 0; European Centre for Disease Prevention and Control, 2015, OPT AN HIV CONT CAR; European Centre for Disease Prevention and Control, 2017, HIV TREATM CAR MON I; European Centre for Disease Prevention and Control/ WHO Regional Office for Europe, 2017, HIV AIDS SURV EUR 20; Fernandez-Lopez L, 2016, AIDS CARE, V28, P32, DOI 10.1080/09540121.2016.1146218; Freeman-Romilly N, 2017, INT J STD AIDS, V28, P1098, DOI 10.1177/0956462416688573; Girometti N, 2016, ANTIVIR THER, V2; Govindasamy D, 2014, J INT AIDS SOC, V17, DOI 10.7448/IAS.17.1.19032; Hall H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064844; Joint United Nations on HIV/ AIDS, 2014, 90 90 90 AN AMB TREA; Kelly J, 2014, J INT AIDS SOC, V17, P85, DOI 10.7448/IAS.17.4.19618; Kiriazova TK, 2013, HIV MED, V14, P38, DOI 10.1111/hiv.12059; Kirwan PDC, 2016, HIV UK 2016 REPORT; Kowalska JD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162739; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Medley A, 2015, JAIDS-J ACQ IMM DEF, V68, pS286, DOI 10.1097/QAI.0000000000000520; Meulbroek M, 2013, HIV MED, V14, P25, DOI 10.1111/hiv.12054; Michie K, 2015, HIV MED, V16, P68; Mugavero MJ, 2010, AIDS PATIENT CARE ST, V24, P607, DOI 10.1089/apc.2010.0086; Mugavero MJ, 2009, CLIN INFECT DIS, V48, P248, DOI 10.1086/595705; Neale J, 2008, HEALTH SOC CARE COMM, V16, P147, DOI 10.1111/j.1365-2524.2007.00739.x; Neduzhko Oleksandr, 2017, J Int Assoc Provid AIDS Care, V16, P168, DOI 10.1177/2325957416686194; OptTEST by HIV in Europe, 2017, ADDR BARR EARL UPT H; OptTEST by HIV in Europe, 2017, WHAT TYP LEG REG BAR; OptTEST by HIV in Europe; Global Network of People Living with HIV, BARR WAY HLTH LEG RE; Raffo M, 2015, EUR AIDS CLIN SOC C; Sprague L., 2011, HIV RELATED STIGMA L; Ulett KB, 2009, AIDS PATIENT CARE ST, V23, P41, DOI 10.1089/apc.2008.0132; Van Beckhoven D, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1230-3; Van Sighem A, 2015, TOPICS ANTIVIRAL MED, V23, P462; van Veen MG, 2015, SEX TRANSM INFECT, V91, P603, DOI 10.1136/sextrans-2014-051980; WHO, 2015, CONSOLIDATED GUIDELI; World Health Organization, 2015, CONS STRAT INF GUID; Yin Z, 2012, HIV MED, V13, P67; Zakowicz AM, 2015, INT AIDS C 2015 18 2	49	20	20	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2018	13	2							e0192403	10.1371/journal.pone.0192403	http://dx.doi.org/10.1371/journal.pone.0192403			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FW5PR	29451875	Green Published, gold			2023-01-03	WOS:000425369800011
J	Jung, SY; Kwon, J; Park, S; Jhee, JH; Yun, HR; Kim, H; Kee, YK; Yoon, CY; Chang, TI; Kang, EW; Park, JT; Yoo, TH; Kang, SW; Han, SH				Jung, Su-Young; Kwon, Jaeyeol; Park, Seohyun; Jhee, Jong Hyun; Yun, Hae-Ryong; Kim, HyoungNae; Kee, Youn Kyung; Yoon, Chang-Yun; Chang, Tae-Ik; Kang, Ea Wha; Park, Jung Tak; Yoo, Tae-Hyun; Kang, Shin-Wook; Han, Seung Hyeok			Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy	PLOS ONE			English	Article							CHRONIC-HEMODIALYSIS PATIENTS; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; GROWTH-FACTOR 23; MORTALITY RISK; PARATHYROID-HORMONE; FAILURE; HYPERPHOSPHATEMIA; ASSOCIATION; PHOSPHORUS	Hyperphosphatemia is associated with mortality in patients with chronic kidney disease, and is common in critically ill patients with acute kidney injury (AKI); however, its clinical implication in these patients is unknown. We conducted an observational study in 1144 patients (mean age, 63.2 years; male, 705 [61.6%]) with AKI who received continuous renal replacement therapy (CRRT) between January 2009 and September 2016. Phosphate levels were measured before (0 h) and 24 h after CRRT initiation. We assessed disease severity using various clinical parameters. Phosphate at 0 h positively correlated with the Acute Physiology and Chronic Health Evaluation II (APACHE II; P < 0.001) and Sequential Organ Failure Assessment (SOFA; P < 0.001) scores, and inversely with mean arterial pressure (MAP; P = 0.02) and urine output (UO; P = 0.01). In a fully adjusted linear regression analysis for age, sex, Charlson comorbidity index (CCI), MAP, and estimated glomerular filtration rate (eGFR), higher 0 h phosphate level was significantly associated with high APACHE II (P < 0.001) and SOFA (P = 0.04) scores, suggesting that phosphate represents disease severity. A multivariable Cox model also showed that hyperphosphatemia was significantly associated with increased 28-day (HR 1.05, 95% CI 1.02 +/- 1.08, P = 0.001) and 90-day (HR 1.05, 95% CI 1.02 +/- 1.08, P = 0.001) mortality. Furthermore, patients with increased phosphate level during 24 h were at higher risk of death than those with stable or decreased phosphate levels. Finally, c-statistics significantly increased when phosphate was added to a model that included age, sex, CCI, body mass index, eGFR, MAP, hemoglobin, serum albumin, C-reactive protein, and APACHE II score. This study shows that phosphate is a potential biomarker that can reflect disease severity and predict mortality in critically ill patients receiving CRRT.	[Jung, Su-Young; Kwon, Jaeyeol; Park, Seohyun; Jhee, Jong Hyun; Yun, Hae-Ryong; Kim, HyoungNae; Kee, Youn Kyung; Yoon, Chang-Yun; Park, Jung Tak; Yoo, Tae-Hyun; Kang, Shin-Wook; Han, Seung Hyeok] Yonsei Univ, Inst Kidney Dis Res, Coll Med, Dept Internal Med, Seoul, South Korea; [Chang, Tae-Ik; Kang, Ea Wha] Ilsan Hosp, NHIS Med Ctr, Dept Internal Med, Ilsan, South Korea	Yonsei University; Yonsei University Health System; NHIS Ilsan Hospital	Han, SH (corresponding author), Yonsei Univ, Inst Kidney Dis Res, Coll Med, Dept Internal Med, Seoul, South Korea.	hansh@yuhs.ac	Han, Seung Hyeok/W-8825-2019; Han, Seung Hyeok/K-4559-2018	Han, Seung Hyeok/0000-0001-7923-5635; Han, Seung Hyeok/0000-0001-7923-5635; Yoo, Tae-Hyun/0000-0002-9183-4507; Park, Jung Tak/0000-0002-2325-8982; Yun, Hae-Ryong/0000-0002-7038-0251; Kang, Shin-Wook/0000-0002-5677-4756				Ali FN, 2013, PEDIATR NEPHROL, V28, P959, DOI 10.1007/s00467-012-2395-2; Badve SV, 2016, AM J KIDNEY DIS, V68, P554, DOI 10.1053/j.ajkd.2016.03.418; Baker SG, 2014, STAT MED, V33, P3946, DOI 10.1002/sim.6195; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Buckley MS, 2010, CRIT CARE MED, V38, pS253, DOI 10.1097/CCM.0b013e3181dda0be; Chawla LS, 2012, KIDNEY INT, V82, P516, DOI 10.1038/ki.2012.208; Cook NR, 2007, CIRCULATION, V115, P928, DOI 10.1161/CIRCULATIONAHA.106.672402; Demirjian S, 2011, CLIN J AM SOC NEPHRO, V6, P2114, DOI 10.2215/CJN.02900311; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Foley RN, 2009, CLIN J AM SOC NEPHRO, V4, P1136, DOI 10.2215/CJN.01660309; Gail MH, 2008, J NATL CANCER I, V100, P1037, DOI 10.1093/jnci/djn180; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Haase M, 2009, AM J KIDNEY DIS, V54, P1012, DOI 10.1053/j.ajkd.2009.07.020; Isakova T, 2011, JAMA-J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826; Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609; Jimbo R, 2014, KIDNEY INT, V85, P1103, DOI 10.1038/ki.2013.332; Jung SY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004542; Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602; Leaf DE, 2012, CLIN J AM SOC NEPHRO, V7, P1217, DOI 10.2215/CJN.00550112; Leaf DE, 2016, J AM SOC NEPHROL; Liangos O, 2007, J AM SOC NEPHROL, V18, P904, DOI 10.1681/ASN.2006030221; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Ozmen S, 2007, RENAL FAILURE, V29, P509, DOI 10.1080/08860220701275006; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; PEPPERS MP, 1991, CRIT CARE CLIN, V7, P201, DOI 10.1016/S0749-0704(18)30332-4; Sanjeevani Scienthia, 2014, Int J Crit Illn Inj Sci, V4, P223, DOI 10.4103/2229-5151.141420; Sullivan C, 2009, JAMA-J AM MED ASSOC, V301, P629, DOI 10.1001/jama.2009.96; Titan SM, 2011, CLIN J AM SOC NEPHRO, V6, P241, DOI 10.2215/CJN.04250510; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Zhang M, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-21	33	31	34	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2018	13	2							e0191290	10.1371/journal.pone.0191290	http://dx.doi.org/10.1371/journal.pone.0191290			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV1MC	29415048	Green Published, gold, Green Submitted			2023-01-03	WOS:000424325300022
J	Pugliese, M; Ramsay, T; Johnson, D; Dowlatshahi, D				Pugliese, Michael; Ramsay, Tim; Johnson, Dylan; Dowlatshahi, Dar			Mobile tablet-based therapies following stroke: A systematic scoping review of administrative methods and patient experiences	PLOS ONE			English	Review							SELF-DIRECTED THERAPY; CHRONIC APHASIA; REHABILITATION; COMPUTERS; RECOVERY; TELEREHABILITATION; SURVIVORS; PROGRAM; IPAD	Background and purpose Stroke survivors are often left with deficits requiring rehabilitation to recover function and yet, many are unable to access rehabilitative therapies. Mobile tablet-based therapies (MTBTs) may be a resource-efficient means of improving access to timely rehabilitation. It is unclear what MTBTs have been attempted following stroke, how they were administered, and how patients experienced the therapies. The review summarizes studies of MTBTs following stroke in terms of administrative methods and patient experiences to inform treatment feasibility. Methods Articles were eligible if they reported the results of an MTBT attempted with stroke participants. Six research databases were searched along with grey literature sources, trial registries, and article references. Intervention administration details and patient experiences were summarized. Results The search returned 903 articles of which 23 were eligible for inclusion. Most studies were small, observational, and enrolled chronic stroke patients. Interventions commonly targeted communication, cognition, or fine-motor skills. Therapies tended to be personalized based on patient deficits using commercially available applications. The complexity of therapy instructions, fine-motor requirements, and unreliability of internet or cellular connections were identified as common barriers to tablet-based care. Conclusions Stroke patients responded positively to MTBTs in both the inpatient and home settings. However, some support from therapists or caregivers may be required for patients to overcome barriers to care. Feasibility studies should continue to identify the administrative methods that minimize barriers to care and maximize patient adherence to prescribed therapy regiments.	[Pugliese, Michael; Ramsay, Tim; Johnson, Dylan; Dowlatshahi, Dar] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Ramsay, Tim] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Dowlatshahi, Dar] Ottawa Hosp, Res Inst, Neurosci Program, Ottawa, ON, Canada; [Dowlatshahi, Dar] Ottawa Hosp, Med Neurol, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Pugliese, M (corresponding author), Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada.	mpugl038@uottawa.ca		Johnson, Dylan/0000-0003-1196-6962; Pugliese, Michael/0000-0003-2794-1436; Dowlatshahi, Dar/0000-0003-1379-3612; Ramsay, Tim/0000-0001-8478-8170	Canadian Institutes of Health Research Canadian Graduate Scholarship Master's Award; University of Ottawa Ontario Graduate Scholarship; University of Ottawa Brain and Mind Research Institute; Canadian Partnership for Stroke Recovery; University of Ottawa Department of Medicine	Canadian Institutes of Health Research Canadian Graduate Scholarship Master's Award; University of Ottawa Ontario Graduate Scholarship; University of Ottawa Brain and Mind Research Institute; Canadian Partnership for Stroke Recovery; University of Ottawa Department of Medicine	This work was supported by a Canadian Institutes of Health Research Canadian Graduate Scholarship Master's Award (http://www.cihr-irsc.gc.ca/e/49440.html; M.P.), a University of Ottawa Ontario Graduate Scholarship (https://www.uottawa.ca/graduate-studies/students/awards/ontario-graduate-scholarship; M.P.), the University of Ottawa Brain and Mind Research Institute (https://www.uottawa.ca/brain/; D.D), the Canadian Partnership for Stroke Recovery (http://www.canadianstroke.ca/en/; D.D.), and the University of Ottawa Department of Medicine (https://med.uottawa.ca/en; D.D.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews G, 2010, PLOS ONE, V5; Ansari MT, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000151; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; Carabeo CGG, 2014, SIMULAT GAMING, V45, P151, DOI 10.1177/1046878114531102; Choi YH, 2016, RESTOR NEUROL NEUROS, V34, P455, DOI 10.3233/RNN-150626; Choi YH, 2016, TELEMED E-HEALTH, V22, P434, DOI 10.1089/tmj.2015.0138; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, pS35, DOI 10.1016/S0003-9993(99)90101-6; Consensus Panel on the Stroke Rehabilitation System, 2007, TIM IS FUNCT REP CON; Crotty M, 2014, J TELEMED TELECARE, V20, P370, DOI 10.1177/1357633X14552382; Davis B, INT BRAIN INJ ASS C, P1; Des Roches CA, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01015; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Foley N, EVIDENCE BASED SYSTE; Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003437.pub3; Hiyamizu M, 2013, CEREBROVASC DIS, V35, P778; Hoover EL, 2014, SEMIN SPEECH LANG, V35, P25, DOI 10.1055/s-0033-1362990; Jang SH, 2016, SOMATOSENS MOT RES, V33, P124, DOI 10.1080/08990220.2016.1197117; Janssen H, 2016, INT J STROKE, V11, P15; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Katalinic O, 2013, J TELEMED TELECARE, V19, P418, DOI 10.1177/1357633X13506513; Kizony R, 2016, J NEUROL PHYS THER, V40, P31, DOI 10.1097/NPT.0000000000000110; Kurland J, 2014, SEMIN SPEECH LANG, V35, P51, DOI 10.1055/s-0033-1362991; Lavoie M, 2016, NEUROCASE, V22, P109, DOI 10.1080/13554794.2015.1051055; Lawrence M, 2013, INT J STROKE, V8, P465, DOI 10.1111/ijs.12135; Mallet KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167950; Mallet KH, 2016, INT J STROKE, V11, P73; McCormick SA, 2016, STROKE, V47; Mehrholz J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub3; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006876.pub3, 10.1002/14651858.CD006876.pub4]; Moher D, 2015, STATEMENT SYST REV, V4, DOI [10.1186/2046-4053-4-1, DOI 10.1186/2046-4053-4-1, 10.1186/s13643-015-0163-7, DOI 10.14306/RENHYD.20.2.223]; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050; Rand D., 2013, 2013 International Conference on Virtual Rehabilitation (ICVR), P109, DOI 10.1109/ICVR.2013.6662068; Routhier S, 2016, APHASIOLOGY, V30, P269, DOI 10.1080/02687038.2014.973361; Salaris M, 2016, INT J STROKE, V11, P21; Salaris M, 2016, INT J STROKE, V11, P13; Salter K, EVIDENCE BASED SYSTE; Stark BC, 2018, NEUROPSYCHOL REHABIL, V28, P818, DOI 10.1080/09602011.2016.1146150; Teasell R, EVIDENCE BASED SYSTE; The Heart and Stroke Foundation, 2014, CAN STORK BEST PRACT; White JH, 2015, DISABIL REHABIL, V37, P593, DOI 10.3109/09638288.2014.935876; Williams AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057447; Xie J., 2007, Morbidity and Mortality Weekly Report, V56, P504	44	22	22	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2018	13	1							e0191566	10.1371/journal.pone.0191566	http://dx.doi.org/10.1371/journal.pone.0191566			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT4YS	29360872	gold, Green Published, Green Submitted			2023-01-03	WOS:000423161800037
J	Ramirez-Ramirez, A; Sanchez-Serrano, E; Loaiza-Flores, G; Plazola-Camacho, N; Rodriguez-Delgado, RG; Figueroa-Damian, R; Dominguez-Castro, M; Lopez-Martinez, M; Flores-Garcia, Z; Hernandez-Pineda, J				Ramirez-Ramirez, Alicia; Sanchez-Serrano, Elias; Loaiza-Flores, Giselle; Plazola-Camacho, Noemi; Georgina Rodriguez-Delgado, Rosa; Figueroa-Damian, Ricardo; Dominguez-Castro, Mauricio; Lopez-Martinez, Margarita; Flores-Garcia, Zayra; Hernandez-Pineda, Jessica			Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method	PLOS ONE			English	Article							CLINICAL-APPLICATION; LC-MS/MS; PHARMACOKINETICS; VALIDATION; PREGNANCY; SPOTS	The primary strategy to avoid mother-to-child transmission of human immunodeficiency virus (HIV) through breastfeeding is administration of highly active antiretroviral therapy (HAART) to HIV-positive pregnant women. Because significant changes in the pharmacokinetics of antiretroviral (ARV) drugs occur during pregnancy, quantifying HAART and the viral load in breast milk in this population is essential. Here, we developed an analytical assay for the simultaneous quantification of four ARV drugs in breast milk using ultra-performance liquid chromatography coupled to tandem mass spectrometry. We validated this method following Mexican and international guidelines. ARV drugs. We extracted the ARV drugs from 200 mu L samples of breast milk and detected these drugs in a triple quadrupole mass spectrometer with positive electrospray ionization. The validated concentration ranges (ng/mL) for zidovudine, lamivudine, lopinavir, and ritonavir were 12.5-750, 50-2500, 100-5000 and 5 to 250, respectively. Additionally, the absolute recovery percentages (and matrix effects) were 91.4 (8.39), 88.78 (28.75), 91.38 (11.77) and 89.78 (12.37), respectively. We determined that ARV drugs are stable for 24 h at 8 degrees C and 24 degrees C for 15 days at - 80 degrees C. This methodology had the capacity for simultaneous detection; separation; and accurate, precise quantification of ARV drugs in human breast milk samples according to Mexican standard laws and United States Food and Drug Administration guidelines.	[Ramirez-Ramirez, Alicia; Plazola-Camacho, Noemi; Georgina Rodriguez-Delgado, Rosa; Figueroa-Damian, Ricardo; Hernandez-Pineda, Jessica] Natl Inst Perinatol, Dept Infectol & Immunol, Mexico City, DF, Mexico; [Sanchez-Serrano, Elias; Loaiza-Flores, Giselle] Univ Nacl Autonoma Mexico, Chem Fac, Mexico City, DF, Mexico; [Dominguez-Castro, Mauricio; Lopez-Martinez, Margarita] Natl Inst Perinatol, Dept Physiol & Cellular Dev, Mexico City, DF, Mexico; [Flores-Garcia, Zayra] Univ Nacl Autonoma Mexico, Fac Higher Educ, Cuautitlan, Mexico State, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Hernandez-Pineda, J (corresponding author), Natl Inst Perinatol, Dept Infectol & Immunol, Mexico City, DF, Mexico.	jesspinq@yahoo.com.mx	Hernández-Pineda, Jessica/AAT-1090-2020; HERNÁNDEZ-PINEDA, JESSICA/AAS-2439-2020; Ramirez-Ramirez, Alicia/J-3768-2017	Hernández-Pineda, Jessica/0000-0003-3698-0912; Ramirez-Ramirez, Alicia/0000-0002-5111-8936; Dominguez Castro, Mauricio/0000-0001-5659-8468	Institute Nacional de Perinatologia (INPer, Mexico) [(478) 212250-3120771]; Consejo Nacional de Ciencia y Tecnologia (CONACyT, Mexico) [SALUD-14-01-234292]	Institute Nacional de Perinatologia (INPer, Mexico); Consejo Nacional de Ciencia y Tecnologia (CONACyT, Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The authors also acknowledge the Institute Nacional de Perinatologia (INPer, Mexico, http://www.inper.mx/) project (478) 212250-3120771 to Jessica Hernandez-Pineda and Consejo Nacional de Ciencia y Tecnologia (CONACyT, Mexico, http://www.conacyt.gob.mx/) project SALUD-14-01-234292 to Jessica Hernandez-Pineda for support. MAMH thanks CONACYT for providing a graduate scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adaway JE, 2012, J CHROMATOGR B, V883, P33, DOI 10.1016/j.jchromb.2011.09.041; [Anonymous], 2011, COCHRANE DATABASE SY; [Anonymous], 2014, COCHRANE DATABASE SY; Bazzoli C, 2010, CLIN PHARMACOKINET, V49, P17, DOI 10.2165/11318110-000000000-00000; Becka Chandra M, 2015, J Int Assoc Provid AIDS Care, V14, P72, DOI 10.1177/2325957414557262; Buckoreelall K, 2012, CLIN PHARMACOKINET, V51, P639, DOI 10.1007/s40262-012-0002-0; Decosterd LA, 2016, TRAC-TREND ANAL CHEM, V84, P5, DOI 10.1016/j.trac.2016.03.019; Giuliano M, 2007, JAIDS-J ACQ IMM DEF, V44, P286, DOI 10.1097/QAI.0b013e31802c5441; Hennet T, 2016, TRENDS BIOCHEM SCI, V41, P508, DOI 10.1016/j.tibs.2016.02.008; Jevtovic D, 2010, BIOMED PHARMACOTHER, V64, P692, DOI 10.1016/j.biopha.2010.08.004; Koehn J, 2015, ANTIMICROB AGENTS CH, V59, P6682, DOI 10.1128/AAC.00869-15; Mirochnick M, 2009, ANTIMICROB AGENTS CH, V53, P1170, DOI 10.1128/AAC.01117-08; Mugwanya KK, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002132; Olagunju A, 2015, J ANTIMICROB CHEMOTH, V70, P2816, DOI 10.1093/jac/dkv174; Olagunju A, 2015, J ANTIMICROB CHEMOTH, V70, P555, DOI 10.1093/jac/dku420; Roustit M, 2008, BRIT J CLIN PHARMACO, V66, P179, DOI 10.1111/j.1365-2125.2008.03220.x; Slater Mackenzie, 2010, Paediatr Drugs, V12, P1, DOI 10.2165/11316130-000000000-00000; Vazquez-Rosales JG, 2016, GUIA PRACTICA CLIN C, V246, P1; Wahl A, 2015, J VIROL, V89, P10868, DOI 10.1128/JVI.01702-15; Waitt CJ, 2015, J ANTIMICROB CHEMOTH, V70, P1928, DOI 10.1093/jac/dkv080; Widdrington J, 2011, J INFECTION, V62, P87, DOI 10.1016/j.jinf.2010.11.001	21	11	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2018	13	1							e0191236	10.1371/journal.pone.0191236	http://dx.doi.org/10.1371/journal.pone.0191236			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT1QM	29351333	Green Published, Green Submitted, gold			2023-01-03	WOS:000422911300060
J	Yamanaka, S; Huh, JY; Nishiyama, K; Hayashi, H				Yamanaka, Syunsuke; Huh, Ji Young; Nishiyama, Kei; Hayashi, Hiroyuki			The optimal number of personnel for good quality of chest compressions: A prospective randomized parallel manikin trial	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; RESCUER FATIGUE; RATES; CPR; PERFORMANCE; DEPTH; GUIDELINES; SURVIVAL	Background Long durational chest compression (CC) deteriorates cardiopulmonary resuscitation (CPR) quality. The appropriate number of CC personnel for minimizing rescuer's fatigue is mostly unknown. Objective We determined the optimal number of personnel needed for 30-min CPR in a rescue-team. Methods We conducted a randomized, manikin trial on healthcare providers. We divided them into Groups A to D according to the assigned different rest period to each group between the 2 min CCs. Groups A, B, C, and D performed CCs at 2, 4, 6, and 8 min rest period. All participants performed CCs for 30 min with a different rest period; participants allocated to Groups A, B, C, and D performed, eight, five, four, and three cycles, respectively. We compared a quality change of CCs among these groups to investigate how the assigned rest period affects the maintenance of CC quality during the 30-min CPR. Results This study involved 143 participants (male 58 [41%]; mean age, 24 years,) for the evaluation. As participants had less rest periods, the quality of their CCs such as sufficient depth ratio declined over 30-min CPR. A significant decrease in the sufficient CC depth ratio was observed in the second to the last cycle as compared to the first cycle. (median changes; A: -4%, B: -3%, C: 0%, and D: 0% p < 0.01). Conclusions A 6 min rest period after 2 min CC is vital in order to sustain the quality of CC during a 30min CPR cycle. At least four personnel may be needed to reduce rescuer's fatigue for a 30min CPR cycle when the team consists of men and women.	[Yamanaka, Syunsuke] Univ Fukui Hosp, Dept Emergency Med, Fukui, Japan; [Huh, Ji Young] Adventist Med Ctr, Dept Family Med, Okinawa, Japan; [Nishiyama, Kei] Natl Hosp Org, Kyoto Med Ctr, Dept Trauma, Kyoto, Japan; [Nishiyama, Kei] Natl Hosp Org, Kyoto Med Ctr, Crit Care Ctr, Kyoto, Japan; [Hayashi, Hiroyuki] Univ Fukui Hosp, Dept Family Med, Family Med, Fukui, Japan	University of Fukui; University of Fukui	Yamanaka, S (corresponding author), Univ Fukui Hosp, Dept Emergency Med, Fukui, Japan.	yamanakasyunsuke@yahoo.co.jp	Yamanaka, Syunsuke/AAT-9326-2021	Yamanaka, Syunsuke/0000-0003-4510-1959; Nishiyama, Kei/0000-0003-3676-0135				Abella BS, 2005, CIRCULATION, V111, P428, DOI 10.1161/01.CIR.0000153811.84257.59; Ashton A, 2002, RESUSCITATION, V55, P151, DOI 10.1016/S0300-9572(02)00168-5; Bae J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010873; Bridgewater FHG, 2000, RESUSCITATION, V45, P97, DOI 10.1016/S0300-9572(00)00172-6; Edelson DP, 2006, RESUSCITATION, V71, P137, DOI 10.1016/j.resuscitation.2006.04.008; Field JM, 2010, CIRCULATION, V122, pS640, DOI 10.1161/CIRCULATIONAHA.110.970889; Field RA, 2012, RESUSCITATION, V83, P360, DOI 10.1016/j.resuscitation.2011.07.012; Finn JC, 2015, RESUSCITATION, V95, pE203, DOI 10.1016/j.resuscitation.2015.07.046; Goldberger ZD, 2012, LANCET, V380, P1473, DOI 10.1016/S0140-6736(12)60862-9; Hasegawa T, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-16; Hong MY, 2014, AM J EMERG MED, V32, P1455, DOI 10.1016/j.ajem.2014.08.074; Kramer-Johansen J, 2006, RESUSCITATION, V71, P283, DOI 10.1016/j.resuscitation.2006.05.011; Lucia A, 1999, CHEST, V115, P158, DOI 10.1378/chest.115.1.158; Monsieurs KG, 2012, RESUSCITATION, V83, P1319, DOI 10.1016/j.resuscitation.2012.07.015; Riera SQ, 2007, RESUSCITATION, V74, P108, DOI 10.1016/j.resuscitation.2006.10.031; Shimizu Yoshitaka, 2014, Hiroshima Journal of Medical Sciences, V63, P7; Stiell IG, 2012, CRIT CARE MED, V40, P1192, DOI 10.1097/CCM.0b013e31823bc8bb; Wang J, 2015, WORLD J EMERG MED, V6, P179, DOI 10.5847/wjem.j.1920-8642.2015.03.003	23	5	5	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2017	12	12							e0189412	10.1371/journal.pone.0189412	http://dx.doi.org/10.1371/journal.pone.0189412			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ8BI	29267300	gold, Green Submitted, Green Published			2023-01-03	WOS:000418587400029
J	Lin, YC; Lin, JW; Wu, MS; Chen, KC; Peng, CC; Kang, YN				Lin, Yen-Chung; Lin, Jheng-Wei; Wu, Mai-Szu; Chen, Kuan-Chou; Peng, Chiung-Chi; Kang, Yi-No			Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis	PLOS ONE			English	Article							BLOOD-PRESSURE; RENAL OUTCOMES; DOUBLE-BLIND; CARDIOVASCULAR OUTCOMES; DIABETES-MELLITUS; RANDOMIZED-TRIAL; AMLODIPINE; RISK; PROTEINURIA; ANTAGONIST	Background Calcium channel blocker (CCB) or two renin angiotensin aldosterone system blockades (RAAS), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are major potent and prevalently used as initial antihypertensive agents for mild to moderate hypertension, but no uniform agreement as to which antihypertensive drugs should be given for initial therapy, especially among chronic kidney disease (CKD) patients. Design A systematic review and meta-analysis comparing CCBs and the two RAAS blockades for hypertensive patients with CKD stage 3 to 5D. The inclusion criteria for this systematic review was RCT that compared the effects of CCBs and the two RAAS blockades in patients with hypertension and CKD. The exclusion criteria were (1) renal transplantation, (2) CKD stage 1 or 2, (3) combined therapy (data cannot be extracted separately). Outcomes were blood pressure change, mortality, heart failure, stroke or cerebrovascular events, and renal outcomes. Results 21 randomized controlled trials randomized 9,492 patients with hypertensive and CKD into CCBs and the two RAAS blockades treatments. The evidence showed no significant differences in blood presser change, mortality, heart failure, stroke or cerebrovascular events, and renal outcomes between CCBs group and the two RAAS blockades group. The publication bias of pooled mean blood presser change that was detected by Egger's test was nonsignificant. Conclusions CCBs has similar effects on long term blood pressure, mortality, heart failure, stroke or cerebrovascular events, and renal function to RAAS blockades in patients CKD stage 3 to 5D and hypertension.	[Lin, Yen-Chung; Lin, Jheng-Wei; Kang, Yi-No] Taipei Med Univ Hosp, Dept Educ, Ctr Evidence Based Med, Taipei, Taiwan; [Lin, Yen-Chung; Wu, Mai-Szu; Chen, Kuan-Chou; Peng, Chiung-Chi] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Lin, Yen-Chung] Taipei Med Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan; [Lin, Yen-Chung] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University	Lin, JW; Kang, YN (corresponding author), Taipei Med Univ Hosp, Dept Educ, Ctr Evidence Based Med, Taipei, Taiwan.	b101100072@tmu.edu.tw; academicnono@gmail.com	/AAD-5199-2021	lin, yenchung/0000-0002-8981-8671	Taipei Medical University [106TMU-TMUH-23]	Taipei Medical University	This research received a grant from Taipei Medical University 106TMU-TMUH-23 (http://219.87.146.141/rd/htdocs/modules/tadnews/index.php?nsn=248). The first author Yen-Chung Lin M.D. received the grant, and initiated this study. He wrote the first draft.; This research received grant from Taipei Medical University 106TMU-TMUH-23.	Abernethy DR, 1999, NEW ENGL J MED, V341, P1447, DOI 10.1056/NEJM199911043411907; Agodoa LY, 2001, JAMA-J AM MED ASSOC, V285, P2719, DOI 10.1001/jama.285.21.2719; Atkins RC, 2005, AM J KIDNEY DIS, V45, P281, DOI 10.1053/j.ajkd.2004.10.019; Berl T, 2003, ANN INTERN MED, V138, P542, DOI 10.7326/0003-4819-138-7-200304010-00010; Campo C, 1997, J HYPERTENS, V15, P1803, DOI 10.1097/00004872-199715120-00093; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Del Vecchio L, 2004, J NEPHROL, V17, P261; Douglas JG, 2003, KIDNEY INT, V63, P74, DOI 10.1046/j.1523-1755.63.s83.15.x; El Ters M, 2012, AM J KIDNEY DIS, V60, P601, DOI 10.1053/j.ajkd.2012.05.007; Elliott WJ, 2011, J CLIN HYPERTENS, V13, P687, DOI 10.1111/j.1751-7176.2011.00513.x; Esnault VLM, 2008, CLIN THER, V30, P482, DOI 10.1016/j.clinthera.2008.03.006; FOGARI R, 1995, J HUM HYPERTENS, V9, P131; Formica RN, 2006, NEPHROL DIAL TRANSPL, V21, P1389, DOI 10.1093/ndt/gfk058; Giri S, 2002, J Assoc Physicians India, V50, P1245; Hayashi K, 2003, AM J NEPHROL, V23, P229, DOI 10.1159/000072054; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hornig B, 1997, CIRCULATION, V95, P1115; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Iino Y, 2004, HYPERTENS RES, V27, P21, DOI 10.1291/hypres.27.21; Iino Yasuhiko, 2003, Clin Exp Nephrol, V7, P221, DOI 10.1007/s10157-003-0241-3; Jamerson K, 2008, NEW ENGL J MED, V359, P2417, DOI 10.1056/NEJMoa0806182; James PA, 2014, JAMA-J AM MED ASSOC, V311, P507, DOI 10.1001/jama.2013.284427; Laragh J, 2001, AM J HYPERTENS, V14, P186, DOI 10.1016/S0895-7061(00)01317-0; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lim HJ, 2016, TOHOKU J EXP MED, V238, P17, DOI 10.1620/tjem.238.17; Lopez-Sendon J, 2004, EUR HEART J, V25, P1454, DOI 10.1016/j.ehj.2004.06.003; MacGregor Mark S, 2005, Nephron Clin Pract, V101, pc139, DOI 10.1159/000086714; Mancia G, 2007, J HYPERTENS, V25, P909, DOI 10.1097/HJH.0b013e328048d004; Marin R, 2001, J HYPERTENS, V19, P1871, DOI 10.1097/00004872-200110000-00023; MATERSON BJ, 1995, AM J HYPERTENS, V8, P325, DOI 10.1016/0895-7061(94)00247-9; Messerli FH, 2000, LANCET, V356, P608, DOI 10.1016/S0140-6736(00)02596-4; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nakamura T, 2008, HYPERTENS RES, V31, P841, DOI 10.1291/hypres.31.841; Petersen LJ, 2001, CLIN NEPHROL, V55, P375; PITT B, 1995, CARDIOVASC DRUG THER, V9, P145, DOI 10.1007/BF00877755; Preston RA, 1997, CLIN NEPHROL, V47, P310; Rahman M, 2006, ANN INTERN MED, V144, P172, DOI 10.7326/0003-4819-144-3-200602070-00005; Rahman M, 2005, ARCH INTERN MED, V165, P936, DOI 10.1001/archinte.165.8.936; Rahman M, 2012, CLIN J AM SOC NEPHRO, V7, P989, DOI 10.2215/CJN.07800811; Rose GW, 2001, HYPERTENS RES, V24, P377, DOI 10.1291/hypres.24.377; Rosendorff Clive, 2007, J Clin Hypertens (Greenwich), V9, P790; Schmidt CO, 2008, INT J PUBLIC HEALTH, V53, P165, DOI 10.1007/s00038-008-7068-3; Shibasaki Y, 2005, HYPERTENS RES, V28, P787, DOI 10.1291/hypres.28.787; Shibasaki Y, 2002, NEPHRON, V90, P256, DOI 10.1159/000049060; SPRINT Research Group, 2015, N Engl J Med, V373, P2103, DOI 10.1056/NEJMoa1511939; Stare J, 2016, METODOLOSKI ZVEZKI, V13, P59; Thamcharoen N, 2015, HYPERTENS RES, V38, P902, DOI 10.1038/hr.2015.95; Weinberg JM, 2009, ARCH INTERN MED, V169, P1587, DOI 10.1001/archinternmed.2009.284; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Yilmaz R, 2010, RENAL FAILURE, V32, P903, DOI 10.3109/0886022X.2010.502276; Zhao HJ, 2016, RENAL FAILURE, V38, P849, DOI 10.3109/0886022X.2016.1165065; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309	52	18	18	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2017	12	12							e0188975	10.1371/journal.pone.0188975	http://dx.doi.org/10.1371/journal.pone.0188975			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP8OT	29240784	Green Submitted, Green Published, gold			2023-01-03	WOS:000417905600014
J	Brown, RT; Diaz-Ramirez, LG; Boscardin, WJ; Lee, SJ; Steinman, MA				Brown, Rebecca T.; Diaz-Ramirez, L. Grisell; Boscardin, W. John; Lee, Sei J.; Steinman, Michael A.			Functional Impairment and Decline in Middle Age A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							LIVING OLDER PERSONS; COMPETING RISK; PHYSICAL-DISABILITY; HEALTH; ADULTS; MORTALITY; PATTERNS; TRENDS; SEX; POPULATIONS	Background: Difficulties with daily functioning are common in middle-aged adults. However, little is known about the epidemiology or clinical course of these problems, including the extent to which they share common features with functional impairment in older adults. Objective: To determine the epidemiology and clinical course of functional impairment and decline in middle age. Design: Cohort study. Setting: The Health and Retirement Study. Participants: 6874 community-dwelling adults aged 50 to 56 years who did not have functional impairment at enrollment. Measurements: Impairment in activities of daily living (ADLs), defined as self-reported difficulty performing 1 or more ADLs, assessed every 2 years for a maximum follow-up of 20 years, and impairment in instrumental ADLs (IADLs), defined similarly. Data were analyzed by using multistate models that estimate probabilities of different outcomes. Results: Impairment in ADLs developed in 22% of participants aged 50 to 64 years, in whom further functional transitions were common. Two years after the initial impairment, 4% (95% CI, 3% to 5%) of participants had died, 9% (CI, 8% to 11%) had further ADL decline, 50% (CI, 48% to 52%) had persistent impairment, and 37% (CI, 35% to 39%) had recovered independence. In the 10 years after the initial impairment, 16% (CI, 14% to 18%) had 1 or more episodes of functional decline and 28% (CI, 26% to 30%) recovered from their initial impairment and remained independent throughout this period. The pattern of findings was similar for IADLs. Limitation: Functional status was self-reported. Conclusion: Functional impairment and decline are common in middle age, as are transitions from impairment to independence and back again. Because functional decline in older adults has similar features, current interventions used for prevention in older adults may hold promise for those in middle age.	Univ Calif San Francisco, San Francisco, CA 94143 USA; [Brown, Rebecca T.; Diaz-Ramirez, L. Grisell; Boscardin, W. John; Lee, Sei J.; Steinman, Michael A.] San Francisco VA Med Ctr, 181G,4150 Clement St, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Brown, RT (corresponding author), San Francisco VA Med Ctr, 181G,4150 Clement St, San Francisco, CA 94121 USA.	rebecca.brown@ucsf.edu		Brown, Rebecca/0000-0001-7483-4137	National Institute on Aging; National Center for Advancing Translational Sciences through the University of California, San Francisco; Clinical and Translational Sciences Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG044281, K24AG049057, K23AG045290] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Advancing Translational Sciences through the University of California, San Francisco; Clinical and Translational Sciences Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institute on Aging and National Center for Advancing Translational Sciences through the University of California, San Francisco, Clinical and Translational Sciences Institute.	ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; Berry SD, 2010, J AM GERIATR SOC, V58, P783, DOI 10.1111/j.1532-5415.2010.02767.x; Bhattacharya J, 2008, MED CARE, V46, P92, DOI 10.1097/MLR.0b013e3181484335; BREITNER JCS, 1995, ARCH NEUROL-CHICAGO, V52, P763, DOI 10.1001/archneur.1995.00540320035011; Brown RT, 2014, J AM GERIATR SOC, V62, P2056, DOI 10.1111/jgs.13103; Cai LM, 2006, J ROY STAT SOC C-APP, V55, P477, DOI 10.1111/j.1467-9876.2006.00548.x; Cai LM, 2010, DEMOGR RES, V22, P129, DOI 10.4054/DemRes.2010.22.6; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; Centers for Medicare & Medicaid Services, 2015, PROGR ALL INCL CAR E; Cimino T, 2015, JAMA INTERN MED, V175, P1237, DOI 10.1001/jamainternmed.2015.1562; Dunlop DD, 1997, AM J PUBLIC HEALTH, V87, P378, DOI 10.2105/AJPH.87.3.378; Ferrucci L, 1998, GERONTOLOGIST, V38, P286, DOI 10.1093/geront/38.3.286; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Freedman VA, 2013, DEMOGRAPHY, V50, P661, DOI 10.1007/s13524-012-0167-z; Fried TR, 2008, J AM GERIATR SOC, V56, P1839, DOI 10.1111/j.1532-5415.2008.01923.x; Fried TR, 2001, ARCH INTERN MED, V161, P2602, DOI 10.1001/archinte.161.21.2602; Gardener EA, 2006, J GEN INTERN MED, V21, P1091, DOI 10.1111/j.1525-1497.2006.00564.x; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Gill TM, 2014, GERONTOLOGIST, V54, P533, DOI 10.1093/geront/gnu067; Gill TM, 2003, AM J EPIDEMIOL, V158, P1090, DOI 10.1093/aje/kwg237; Gill TM, 2003, J GERONTOL A-BIOL, V58, P70; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Hardy SE, 2005, AM J EPIDEMIOL, V161, P575, DOI 10.1093/aje/kwi083; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; He XXZ, 2004, AM J PUBLIC HEALTH, V94, P1567, DOI 10.2105/AJPH.94.9.1567; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Jagger C, 2001, J AM GERIATR SOC, V49, P404, DOI 10.1046/j.1532-5415.2001.49083.x; KEMPEN GIJM, 1995, J CLIN EPIDEMIOL, V48, P1299, DOI 10.1016/0895-4356(95)00043-7; Leveille SG, 2000, J GERONTOL B-PSYCHOL, V55, pS41; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Martin LG, 2014, DISABIL HEALTH J, V7, pS4, DOI 10.1016/j.dhjo.2013.06.007; Martin LG, 2010, HEALTH AFFAIR, V29, P725, DOI 10.1377/hlthaff.2008.0746; Miller DK, 2005, J GERONTOL A-BIOL, V60, P207, DOI 10.1093/gerona/60.2.207; Murtagh KN, 2004, AM J PUBLIC HEALTH, V94, P1406, DOI 10.2105/AJPH.94.8.1406; Naik AD, 2004, J AM GERIATR SOC, V52, P1805, DOI 10.1111/j.1532-5415.2004.52513.x; Oman D, 1999, AM J EPIDEMIOL, V150, P834; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ritchie C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148096; Seeman TE, 2010, AM J PUBLIC HEALTH, V100, P100, DOI 10.2105/AJPH.2008.157388; Sonnega A, 2014, INT J EPIDEMIOL, V43, P576, DOI 10.1093/ije/dyu067; Southern DA, 2006, J CLIN EPIDEMIOL, V59, P1110, DOI 10.1016/j.jclinepi.2006.07.002; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Szanton SL, 2016, HEALTH AFFAIR, V35, P1558, DOI 10.1377/hlthaff.2016.0140; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; TINETTI ME, 1995, JAMA-J AM MED ASSOC, V273, P1348, DOI 10.1001/jama.273.17.1348; Whitson HE, 2010, J GERONTOL A-BIOL, V65, P1325, DOI 10.1093/gerona/glq139; Wray LA, 2001, GERONTOLOGIST, V41, P499, DOI 10.1093/geront/41.4.499	48	45	45	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 5	2017	167	11					761	+		10.7326/M17-0496	http://dx.doi.org/10.7326/M17-0496			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FO8KS	29132150	Green Accepted			2023-01-03	WOS:000417135900004
J	Szakacs, Z; Matrai, P; Hegyi, P; Szabo, I; Vincze, A; Balasko, M; Mosdosi, B; Sarlos, P; Simon, M; Marta, K; Miko, A; Pecsi, D; Demcsak, A; Bajor, J				Szakacs, Zsolt; Matrai, Peter; Hegyi, Peter; Szabo, Imre; Vincze, Aron; Balasko, Marta; Mosdosi, Bernadett; Sarlos, Patrcia; Simon, Maria; Marta, Katalin; Miko, Alexandra; Pecsi, Daniel; Demcsak, Alexandra; Bajor, Judit			Younger age at diagnosis predisposes to mucosal recovery in celiac disease on a gluten-free diet: A meta-analysis	PLOS ONE			English	Article							HISTOLOGICAL FOLLOW-UP; VILLOUS ATROPHY; TRANSGLUTAMINASE ANTIBODIES; DUODENAL BIOPSIES; INTESTINAL-MUCOSA; ADULT PATIENTS; CHILDREN; PREVALENCE; DENSITY; PREDICTORS	Background and aims Persistent intestinal damage is associated with higher complication rates in celiac disease. We aimed to assess the potential modifiers of mucosal recovery. Materials and methods We screened databases (PubMed, Embase, Cochrane Trials, and Web of Science) for papers on celiac disease. Papers discussing (1) celiac patients (2) follow-up biopsy and (3) mucosal recovery after commencement of a gluten-free diet were included. The primary outcome was to produce a comprehensive analysis of complete mucosal recovery (i.e., Marsh 0 on follow-up). We compared children's recovery ratios to those of adults. Patients following a strict gluten-free dietary regimen were included in a subgroup. Summary point estimates, 95% confidence intervals (CIs), and 95% predictive intervals (Pis) were calculated. Heterogeneity was tested with l(2)-statistic. The PROSPERO registration number is CRD42016053482. Results The overall complete mucosal recovery ratio, calculated from 37 observational studies, was 0.36 (Cl: 0.28-0.44, PI:-0.12-0.84; I-2: 98.4%, p<0.01). Children showed higher complete mucosal recovery ratio than adults (p<0.01): 0.65 (Cl: 0.44-0.85, PI:-0.10-1.39; I-2: 96.5%, p<0.01) as opposed to 0.24 (Cl: 0.15-0.33, PI:-0.19-1.08; I-2: 96.3%, p<0.01). In the strict dietary adherence subgroup, complete mucosal recovery ratio was 0.47 (Cl: 0.24-0.70, PI:-0.47-1.41; I-2: 98.8%, p<0.001). On meta-regression, diagnostic villous atrophy (Marsh 3) ratio (-8.97, p<0.01) and male ratio (+6.04, p<0.01) proved to be a significant determinant of complete mucosal recovery, unlike duration of gluten-free diet (+0.01, p = 0.62). The correlation between complete mucosal recovery ratio and age on diagnosis is of borderline that no competing interests exist. significance (-0.03, p = 0.05). Conclusions There is considerable heterogeneity across studies concerning complete mucosal recovery ratios achieved by a gluten-free diet in celiac disease. Several celiac patients fail to achieve complete mucosal recovery even if a strict dietary regimen is followed. Younger age on diagnosis, less severe initial histologic damage and male gender predispose for achieving mucosal recovery.	[Szakacs, Zsolt; Hegyi, Peter; Balasko, Marta; Marta, Katalin; Miko, Alexandra; Pecsi, Daniel] Univ Pecs, Inst Translat Med, Pecs, Hungary; [Matrai, Peter] Univ Pecs, Inst Bioanal, Pecs, Hungary; [Hegyi, Peter] Univ Szeged, Hungarian Acad Sci, Momentum Gastroenterol Multidisciplinary Res Grp, Szeged, Hungary; [Szabo, Imre; Vincze, Aron; Sarlos, Patrcia; Bajor, Judit] Univ Pecs, Dept Internal Med 1st, Div Gastroenterol, Pecs, Hungary; [Mosdosi, Bernadett] Univ Pecs, Dept Paediat, Pecs, Hungary; [Simon, Maria] Univ Pecs, Dept Psychiat & Psychotherapy, Pecs, Hungary; [Demcsak, Alexandra] Univ Szeged, Dept Pediat, Szeged, Hungary	University of Pecs; University of Pecs; Hungarian Academy of Sciences; Szeged University; University of Pecs; University of Pecs; University of Pecs; Szeged University	Szakacs, Z (corresponding author), Univ Pecs, Inst Translat Med, Pecs, Hungary.	szaki92@gmail.com	Pecsi, Daniel/J-7408-2019; Mikó, Alexandra/AAE-6190-2020; Vincze, Aron/J-6724-2019; Vincze, Aron/A-7048-2011; Sarlos, Patricia/V-6890-2017	Pecsi, Daniel/0000-0003-0499-6004; Vincze, Aron/0000-0003-2217-7686; Vincze, Aron/0000-0003-2217-7686; Sarlos, Patricia/0000-0002-5086-9455; Demcsak, Alexandra/0000-0002-5391-6931; Szakacs, Zsolt/0000-0002-7035-941X	Economic Development and Innovation Operative Programme Grant of the National Research, Development and Innovation Office [GINOP 2.3.2-15-2016-00048]; New National Excellence Program of the Ministry of Human Capacities [UNKP-17-3-I, UNKP-17-3-II]	Economic Development and Innovation Operative Programme Grant of the National Research, Development and Innovation Office(National Research, Development & Innovation Office (NRDIO) - Hungary); New National Excellence Program of the Ministry of Human Capacities	This work was supported by the Economic Development and Innovation Operative Programme Grant of the National Research, Development and Innovation Office (GINOP 2.3.2-15-2016-00048) STAY ALIVE grant and by the UNKP-17-3-I, UNKP-17-3-II New National Excellence Program of the Ministry of Human Capacities.	Abdulkarim AS, 2002, AM J GASTROENTEROL, V97, P2016; Annibale B, 2001, AM J GASTROENTEROL, V96, P132, DOI 10.1111/j.1572-0241.2001.03463.x; Assiri Asaad M A, 2008, Trop Gastroenterol, V29, P217; BAKER PG, 1975, BRIT MED J, V1, P486, DOI 10.1136/bmj.1.5956.486; Bannister EG, 2014, AM J GASTROENTEROL, V109, P1478, DOI 10.1038/ajg.2014.200; Bardella MT, 2007, HISTOPATHOLOGY, V50, P465, DOI 10.1111/j.1365-2559.2007.02621.x; Baudon JJ, 2005, GASTROEN CLIN BIOL, V29, P1097, DOI 10.1016/S0399-8320(05)82173-6; Bhasin TS, 2010, J CLIN DIAGN RES, V4, P2217; Biagi F, 2012, BRIT J NUTR, V108, P1884, DOI 10.1017/S0007114511007367; Cammarota G, 2007, ENDOSCOPY, V39, P46, DOI 10.1055/s-2006-945044; Capristo E, 2009, J CLIN GASTROENTEROL, V43, P946, DOI 10.1097/MCG.0b013e3181978e4d; Carroccio A, 2008, SCAND J GASTROENTERO, V43, P1315, DOI 10.1080/00365520802200044; Caruso R, 2014, DIGEST LIVER DIS, V46, P323, DOI 10.1016/j.dld.2013.12.005; Casella S, 2012, J AM GERIATR SOC, V60, P1064, DOI 10.1111/j.1532-5415.2012.03997.x; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; Ciacci C, 2005, ALIMENT PHARM THERAP, V21, P421, DOI 10.1111/j.1365-2036.2005.02345.x; Ciacci C, 2002, DIGESTION, V66, P178, DOI 10.1159/000066757; Collin P, 2004, GASTROINTEST ENDOSC, V59, P158, DOI 10.1016/S0016-5107(03)01311-7; COLLINS BJ, 1986, J ROY SOC MED, V79, P206, DOI 10.1177/014107688607900406; CONGDON P, 1981, AM J DIS CHILD, V135, P118, DOI 10.1001/archpedi.1981.02130260010004; Corazza GR, 2007, CLIN GASTROENTEROL H, V5, P838, DOI 10.1016/j.cgh.2007.03.019; Corazza GR, 2005, J CLIN PATHOL, V58, P573, DOI 10.1136/jcp.2004.023978; CORAZZA GR, 1994, J INTERN MED, V236, P183, DOI 10.1111/j.1365-2796.1994.tb01281.x; Cuoco L, 1998, SCAND J GASTROENTERO, V33, P401; de Chaisemartin L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136745; Dickey W, 2000, AM J GASTROENTEROL, V95, P712, DOI 10.1111/j.1572-0241.2000.01838.x; Donaldson MR, 2008, J CLIN GASTROENTEROL, V42, P256, DOI 10.1097/MCG.0b013e31802e70b1; Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014; Duerksen DR, 2010, DIGEST DIS SCI, V55, P1026, DOI 10.1007/s10620-009-0813-5; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elli L, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0361-8; Fine KD, 1997, GASTROENTEROLOGY, V112, P1830, DOI 10.1053/gast.1997.v112.pm9178673; Galli G, 2014, ALIMENT PHARM THER, V40, P639, DOI 10.1111/apt.12893; Ghazzawi Y, 2014, J PEDIATR GASTR NUTR, V59, P229, DOI 10.1097/MPG.0000000000000390; Gorgun J, 2009, VIRCHOWS ARCH, V455, P363, DOI 10.1007/s00428-009-0832-9; Green PHR, 2015, J ALLERGY CLIN IMMUN, V135, P1099, DOI 10.1016/j.jaci.2015.01.044; GREFTE JMM, 1988, J CLIN PATHOL, V41, P886, DOI 10.1136/jcp.41.8.886; Gunther U, 2010, ENDOSCOPY, V42, P197, DOI 10.1055/s-0029-1243937; Gujral N, 2012, WORLD J GASTROENTERO, V18, P6036, DOI 10.3748/wjg.v18.i42.6036; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Haere P, 2016, SCAND J GASTROENTERO, V51, P1439, DOI 10.1080/00365521.2016.1218540; Hansen D, 2006, DIABETES CARE, V29, P2452, DOI 10.2337/dc06-0990; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hogberg L, 2003, SCAND J GASTROENTERO, V38, P751, DOI 10.1080/00365520310003318; Hopper AD, 2008, CLIN GASTROENTEROL H, V6, P314, DOI 10.1016/j.cgh.2007.12.008; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Hutchinson JM, 2010, QJM-INT J MED, V103, P511, DOI 10.1093/qjmed/hcq076; Iltanen S, 1999, AUTOIMMUNITY, V29, P179, DOI 10.3109/08916939908998533; Iltanen S, 1999, CLIN EXP IMMUNOL, V117, P51; Kapur G, 2004, J TROP PEDIATRICS, V50, P37, DOI 10.1093/tropej/50.1.37; Karinen H, 2006, SCAND J GASTROENTERO, V41, P191, DOI 10.1080/00365520500206277; Kaukinen K, 2007, ALIMENT PHARM THER, V25, P1237, DOI 10.1111/j.1365-2036.2007.03311.x; Kaukinen K, 2002, EUR J GASTROEN HEPAT, V14, P311, DOI 10.1097/00042737-200203000-00017; Kemppainen TA, 1998, AM J CLIN NUTR, V67, P482, DOI 10.1093/ajcn/67.3.482; Koskinen O, 2010, J CLIN GASTROENTEROL, V44, P483, DOI 10.1097/MCG.0b013e3181b64557; KUMAR PJ, 1988, ARCH DIS CHILD, V63, P916, DOI 10.1136/adc.63.8.916; Lahdenpera A, 2011, SCAND J GASTROENTERO, V46, P538, DOI 10.3109/00365521.2011.551888; Lanzini A, 2009, ALIMENT PHARM THER, V29, P1299, DOI 10.1111/j.1365-2036.2009.03992.x; Lebwohl B, 2014, Aliment Pharmacol Ther, V39, P488, DOI 10.1111/apt.12621; Lebwohl B, 2013, ALIMENT PHARM THER, V37, P332, DOI 10.1111/apt.12164; Lebwohl B, 2015, CLIN GASTROENTEROL H, V13, P1111, DOI 10.1016/j.cgh.2014.11.018; Lebwohl B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117529; Lebwohl B, 2014, J CLIN ENDOCR METAB, V99, P609, DOI 10.1210/jc.2013-3164; Lebwohl B, 2013, ANN INTERN MED, V159, P169, DOI 10.7326/0003-4819-159-3-201308060-00006; Lee SK, 2003, GASTROINTEST ENDOSC, V57, P187, DOI 10.1067/mge.2003.54; Leffler DA, 2008, DIGEST DIS SCI, V53, P1573, DOI 10.1007/s10620-007-0055-3; Leffler DA, 2007, CLIN GASTROENTEROL H, V5, P445, DOI 10.1016/j.cgh.2006.12.006; Lichtwark IT, 2014, ALIMENT PHARM THER, V40, P160, DOI 10.1111/apt.12809; Lidums Ilmars, 2011, Clin Transl Gastroenterol, V2, pe4, DOI 10.1038/ctg.2011.3; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Martini S, 2002, CLIN CHEM, V48, P960; MAYER M, 1991, GUT, V32, P881, DOI 10.1136/gut.32.8.881; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; McMillan SA, 2001, J CLIN PATHOL, V54, P783, DOI 10.1136/jcp.54.10.783; Metzger MH, 2006, EUR J EPIDEMIOL, V21, P359, DOI 10.1007/s10654-006-9002-4; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MONTGOMERY AMP, 1988, GUT, V29, P1564, DOI 10.1136/gut.29.11.1564; Murray JA, 2004, AM J CLIN NUTR, V79, P669; Newnham ED, 2016, J GASTROEN HEPATOL, V31, P342, DOI 10.1111/jgh.13060; Nieminen U, 2001, SCAND J GASTROENTERO, V36, P507, DOI 10.1080/003655201750153331; O'Keeffe J, 2001, CLIN EXP IMMUNOL, V125, P376, DOI 10.1046/j.1365-2249.2001.01594.x; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; ODERDA G, 1993, J PEDIATR GASTR NUTR, V16, P172, DOI 10.1097/00005176-199302000-00013; Pekki H, 2015, AM J GASTROENTEROL, V110, P1078, DOI 10.1038/ajg.2015.155; Peraaho M, 2003, ALIMENT PHARM THER, V17, P587, DOI 10.1046/j.1365-2036.2003.01425.x; Raivio T, 2006, ALIMENT PHARM THER, V24, P147, DOI 10.1111/j.1365-2036.2006.02957.x; Rubio-Tapia A, 2013, AM J GASTROENTEROL, V108, P656, DOI 10.1038/ajg.2013.79; Rubio-Tapia A, 2012, AM J GASTROENTEROL, V107, P1538, DOI 10.1038/ajg.2012.219; Rubio-Tapia A, 2010, AM J GASTROENTEROL, V105, P1412, DOI 10.1038/ajg.2010.10; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Selby WS, 1999, SCAND J GASTROENTERO, V34, P909, DOI 10.1080/003655299750025390; Sharkey LM, 2013, ALIMENT PHARM THER, V38, P1278, DOI 10.1111/apt.12510; SHMERLING DH, 1986, J PEDIATR GASTR NUTR, V5, P565, DOI 10.1097/00005176-198607000-00010; Silvester JA, 2017, GASTROENTEROLOGY; Sjoberg V, 2014, CLIN TRANSL GASTROEN, V5, DOI 10.1038/ctg.2014.9; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tuire I, 2012, AM J GASTROENTEROL, V107, P1563, DOI 10.1038/ajg.2012.220; Tursi A, 2006, ENDOSCOPY, V38, P702, DOI 10.1055/s-2006-925178; Uil JJ, 1996, EUR J GASTROEN HEPAT, V8, P219, DOI 10.1097/00042737-199603000-00006; Vahedi K, 2003, AM J GASTROENTEROL, V98, P1079, DOI [10.1016/S0002-9270(02)06006-9, 10.1111/j.1572-0241.2003.07284.x]; Valdimarsson T, 2000, SCAND J GASTROENTERO, V35, P274; VALDIMARSSON T, 1994, SCAND J GASTROENTERO, V29, P457, DOI 10.3109/00365529409096838; Vecsei AKW, 2009, ENDOSCOPY, V41, P123, DOI 10.1055/s-0028-1103484; Vecsei E, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-28; Vivas S, 2009, WORLD J GASTROENTERO, V15, P4775, DOI 10.3748/wjg.15.4775; Volta U, 2008, DIGEST DIS SCI, V53, P1582, DOI 10.1007/s10620-007-0058-0; Wahab PJ, 2002, AM J CLIN PATHOL, V118, P459; Wahab PJ, 2001, JPN J CANCER RES, V92, P279, DOI 10.1111/j.1349-7006.2001.tb01092.x; Wells GA, 2011, NEWCASTLE OTTAWA SCA; Yachha SK, 2007, J GASTROEN HEPATOL, V22, P1300, DOI 10.1111/j.1440-1746.2007.04929.x; Zanini B, 2012, DIGEST LIVER DIS, V44, P280, DOI 10.1016/j.dld.2011.10.013	112	17	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2017	12	11							e0187526	10.1371/journal.pone.0187526	http://dx.doi.org/10.1371/journal.pone.0187526			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL6FI	29095937	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000414340200110
J	Chea, SK; Mwangi, TW; Ndirangu, KK; Abdullahi, OA; Munywoki, PK; Abubakar, A; Hassan, AS				Chea, Stevenson K.; Mwangi, Tabitha W.; Ndirangu, Kennedy K.; Abdullahi, Osman A.; Munywoki, Patrick K.; Abubakar, Amina; Hassan, Amin S.			Prevalence and correlates of home delivery amongst HIV-infected women attending care at a rural public health facility in Coastal Kenya	PLOS ONE			English	Article							BIRTH ATTENDANTS; NEVIRAPINE; SYSTEM	Background Home delivery, referring to pregnant women giving birth in the absence of a skilled birth attendant, is a significant contributor to maternal mortality, and is encouragingly reported to be on a decline in the general population in resource limited settings. However, much less is known about home delivery amongst HIV-infected women in sub-Saharan Africa (sSA). We described the prevalence and correlates of home delivery among HIV-infected women attending care at a rural public health facility in Kilifi, Coastal Kenya. Methods A cross-sectional design using mixed methods was used. Quantitative data were collected using interviewer-administered questionnaires from HIV-infected women with a recent pregnancy (within 5 years, n = 425), whilst qualitative data were collected using focused group discussions (FGD, n = 5). Data were analysed using logistic regression and a thematic framework approach respectively. Results Overall, 108 (25.4%, [95% CI: 21.3-29.8]) participants delivered at home. Correlates of home delivery included lack of formal education (aOR 12.4 [95% CI: 3.4-46.0], p<0.001), history of a previous home delivery (2.7 [95% CI:1.2-6.0], p = 0.019) and being on highly active antiretroviral therapy (HAART, 0.4 [95% Cl:0.2-0.8], p = 0.006).Despite a strong endorsement against home delivery, major thematic challenges included consumer-associated barriers, health care provider associated barriers and structural barriers. Conclusion A quarter of HIV-infected women delivered at home, which is comparable to estimates reported from the general population in this rural setting, and much lower than estimates from other sSA settings. A tailored package of care targeting women with no formal education and with a history of a previous home delivery, coupled with interventions towards scaling up HAART and improving the quality of maternal care in HIV-infected women may positively contribute to a decline in home delivery and subsequent maternal mortality in this setting.	[Chea, Stevenson K.; Munywoki, Patrick K.] Pwani Univ, Sch Hlth & Human Sci, Dept Nursing Sci, Kilifi, Kenya; [Mwangi, Tabitha W.; Abdullahi, Osman A.; Munywoki, Patrick K.; Abubakar, Amina; Hassan, Amin S.] Pwani Univ, Sch Hlth & Human Sci, Dept Publ Hlth, Kilifi, Kenya; [Ndirangu, Kennedy K.] Kilifi Cty Hosp, Dept Hlth, Kilifi, Kilifi County, Kenya; [Munywoki, Patrick K.; Abubakar, Amina; Hassan, Amin S.] Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya; [Abubakar, Amina] Univ Oxford, Dept Psychiat, Oxford, England	Pwani University; Pwani University; Kenya Medical Research Institute; University of Oxford	Chea, SK (corresponding author), Pwani Univ, Sch Hlth & Human Sci, Dept Nursing Sci, Kilifi, Kenya.	cheastevenson@gmail.com	Chea, Stevenson K./AAK-7502-2021; Munywoki, Patrick K./GQP-4775-2022; Abubakar, Amina/F-1479-2017	Munywoki, Patrick K./0000-0001-9419-7155; Hassan, Amin S./0000-0001-5296-4264; Abubakar, Amina/0000-0002-3686-7904; Chea, Stevenson/0000-0002-8096-711X	Pwani University; county government of Kilifi through the department of health; Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [DEL-15-006]; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) [107752/Z/15/Z]; Wellcome Trust; UK government	Pwani University; county government of Kilifi through the department of health; Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative; New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Wellcome Trust(Wellcome Trust); UK government	SKC, TWM and OAA were supported by Pwani University. KKN was supported by the county government of Kilifi, through the department of health. ASH was supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant # 107752/Z/15/Z) and the UK government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2003, PRECISION AND POWER; Bank TW, 2008, ORGANIZATION, V32, P1; Benfield N, 2015, INT J GYNECOL OBSTET, V130, P157, DOI 10.1016/j.ijgo.2015.02.032; Brennan AT, 2014, J MIDWIFERY WOM HEAL, V59, P198, DOI 10.1111/jmwh.12038; Buzdugan R, 2015, BMC PREGNANCY CHILDB, P1; Choulagai B, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-49; Cofie LE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0604-2; Diamond-Smith N, 2015, REPROD HEALTH, V12, DOI 10.1186/1742-4755-12-6; Fapohunda BM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069569; Faye A, 2011, ACTA OBSTET GYN SCAN, V90, P1239, DOI 10.1111/j.1600-0412.2011.01163.x; Guliani H, 2012, SOC SCI MED, V74, P1882, DOI 10.1016/j.socscimed.2012.02.008; Johnson FA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065527; Kasenga F, 2007, AIDS CARE, V19, P646, DOI 10.1080/09540120701235651; Kasenga F, 2010, MIDWIFERY, V26, P27, DOI 10.1016/j.midw.2008.04.007; KDHS, 2014, KEN DEM HLTH SURV KE, P1; Kinuthia J, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0467-6; Kinuthia J, 2011, J INT AIDS SOC, V14, DOI 10.1186/1758-2652-14-61; Kitui J, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-40; Lussiana C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036381; Magoma M, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-13; Medema-Wijnveen JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051492; Ministry of Health, 2015, STAT IMPL FREE MAT S, V61, pi; Mohammed AA, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-102; Moindi RO, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2780-z; Moyer CA, 2013, INT J GYNECOL OBSTET, V123, P217, DOI 10.1016/j.ijgo.2013.06.030; Moyer CA, 2013, INT J GYNECOL OBSTET, V122, P224, DOI 10.1016/j.ijgo.2013.04.005; NASCOP Ministry of public Health and Sanitation, 2009, PREVENTION, P1; National AIDS Control Council & UNAIDS, 2011, HIV AIDS PROF KIL CO; Ng SK, 2014, BMC PREGNANCY CHILDB, V14, DOI [10.1186/1471-2393-14-314, 10.1186/1471-2393-14-323]; Peltzer K, 2006, Curationis, V29, P54; Polit D. F., 2017, NURSING RES GENERATI, V10th; R Core Team, 2021, R LANG ENV STAT COMP; Renner M., 2003, QUALITATIVE DATA ANA, P1, DOI DOI 10.1207/S15430421TIP3903; Rollins NC, 2007, JAIDS-J ACQ IMM DEF, V44, P321, DOI 10.1097/QAI.0b013e31802ea4b0; Scott JAG, 2012, INT J EPIDEMIOL, V41, P650, DOI 10.1093/ije/dys062; Sipsma H, 2013, GLOB PUBLIC HEALTH, V8, P1014, DOI 10.1080/17441692.2013.835434; Smith Joanna, 2011, Nurse Res, V18, P52; Tebekaw Y, 2015, OBSTET GYNECOL INT, V2015, DOI 10.1155/2015/439748; Turan JM, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001295; Varga CA, 2006, AIDS CARE, V18, P952, DOI 10.1080/09540120500356906; Waiswa P, 2015, GLOB HLTH ACTION, V8, P1; Weeks AD, 2015, BMC PREGNANCY CHILDB, P1; Wilunda C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-259; World Health Organization, 1999, RED MAT MORT JOINT W; World Health Organization, 2015, TRENDS MAT MORT 1990	45	9	9	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2018	13	3							e0194028	10.1371/journal.pone.0194028	http://dx.doi.org/10.1371/journal.pone.0194028			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FZ9AH	29558474	Green Published, Green Submitted, gold			2023-01-03	WOS:000427901500015
J	Carey, M; Donaldson, E; Signes-Pastor, AJ; Meharg, AA				Carey, Manus; Donaldson, Emily; Signes-Pastor, Antonio J.; Meharg, Andrew A.			Dilution of rice with other gluten free grains to lower inorganic arsenic in foods for young children in response to European Union regulations provides impetus to setting stricter standards	PLOS ONE			English	Article							INFANT FORMULAS; EXPOSURE; HEALTH	There has been an increasing realisation that young infants are exposed to elevated concentrations of the carcinogen inorganic arsenic, relative to adults. This is because many infant food products are rice based, and rice is similar to 10-fold elevated in inorganic arsenic compared to most other foods. The European Commission (EC) has acted on this concern setting stricter standards for infants, 100 mu g of inorganic arsenic per kg of food (100 mu g/kg), as compared to adults (200 mu g/kg), for rice based foods, a law that was brought into place in 1st January 2016. Here we investigate how this law has impacted on inorganic arsenic in baby food products in the UK market, and compare the findings to previous baby food surveys taken before and just after the law came into place. We find that for a wide range of UK infant products that the new regulations are being adhered to, with all samples surveyed, being under 100 mu g/kg inorganic arsenic. The prevalence of pure rice products had decreased in the UK, and there appears to be careful sourcing of the rice used in these products to ensure conformity with regulations. There has been an increased presence of mixed cereal products, with rice and maize as the main ingredient, appearing on the UK market, with varying rice contents for infant porridges, cakes and mueslis, with the latter being a relatively innovative product for infant foods. There was a highly significant correlation (P<0.0001) between rice content and inorganic arsenic concentration across all infant foods. When UK infant rice cakes, breakfast cereals and porridges were compare to their general, i.e. not labelled specifically for being for infant consumption, equivalent it was found that the adult foods generally exceeded the 100 mu g/kg inorganic arsenic standard for infant foods. Thus, infants should not be given rice products not specifically labelled as being for them if a lower inorganic arsenic diet is to be maintained.	[Carey, Manus; Donaldson, Emily; Signes-Pastor, Antonio J.; Meharg, Andrew A.] Queens Univ Belfast, Inst Global Food Secur, Belfast, Antrim, North Ireland; [Signes-Pastor, Antonio J.] Dartmouth Coll, Dept Epidemiol, Geisel Sch Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA	Queens University Belfast; Dartmouth College	Meharg, AA (corresponding author), Queens Univ Belfast, Inst Global Food Secur, Belfast, Antrim, North Ireland.	aa.meharg@qub.ac.uk	Signes-Pastor, Antonio/N-9700-2019; Meharg, Andrew Alexander/F-8182-2014; Carey, Manus/K-8180-2015	Signes-Pastor, Antonio/0000-0003-4898-2480; Meharg, Andrew Alexander/0000-0003-2019-0449; Carey, Manus/0000-0002-1065-4943				Burlo F, 2012, J FOOD SCI, V77, pT15, DOI 10.1111/j.1750-3841.2011.02502.x; Carbonell-Barrachina AA, 2010, ARSEN ENVIR, P219; Carbonell-Barrachina AA, 2012, ENVIRON POLLUT, V163, P77, DOI 10.1016/j.envpol.2011.12.036; Carey M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131608; Carignan CC, 2015, ENVIRON HEALTH PERSP, V123, P500, DOI 10.1289/ehp.1408789; EFSA, 2009, UPD SAF ADV 6 FOOD C; Farzan SF, 2013, TOXICOL APPL PHARM, V272, P384, DOI 10.1016/j.taap.2013.06.030; Gamage HKAH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14707-z; Goswami RS, 2004, MOL PLANT PATHOL, V5, P515, DOI [10.1111/j.1364-3703.2004.00252.x, 10.1111/J.1364-3703.2004.00252.X]; Hernandez-Martinez R, 2010, FOOD ADDIT CONTAM B, V3, P275, DOI 10.1080/19393210.2010.531402; IARC, 2004, INT AG RES CANC MON; Jackson BP, 2012, PURE APPL CHEM, V84, P215, DOI 10.1351/PAC-CON-11-09-17; Juan C, 2014, FOOD CONTROL, V39, P227, DOI 10.1016/j.foodcont.2013.10.036; Martins C, 2018, FOOD CHEM, V239, P132, DOI 10.1016/j.foodchem.2017.06.088; Meharg AA, 2008, ENVIRON POLLUT, V152, P746, DOI 10.1016/j.envpol.2008.01.043; Meharg AA, 2010, ENVIRON SCI TECHNOL, V44, P4395, DOI 10.1021/es9034304; Meharg AA, 2009, ENVIRON SCI TECHNOL, V43, P1612, DOI 10.1021/es802612a; NRC, 2001, ARS DRINK WAT; Pingali P, 2015, FOOD SECUR, V7, P583, DOI 10.1007/s12571-015-0461-x; Railoa A, 2014, FOOD CHEM TOXICOL, V84; Rintala EM, 2014, FOOD CHEM, V150, P199, DOI 10.1016/j.foodchem.2013.10.155; Rodriguez-Barranco M, 2016, CORTEX, P4; Sanchez TR, 2016, ENVIRON RES, V147, P537, DOI 10.1016/j.envres.2016.02.009; Signes-Pastor AJ, 2017, PLOSONE; Signes-Pastor AJ, 2016, FOOD CHEM, V191, P128, DOI 10.1016/j.foodchem.2014.11.078; Vahter M, 2009, ANNU REV NUTR, V29, P381, DOI 10.1146/annurev-nutr-080508-141102; WHO. Codex Alimentarius Commission, 2014, JOINT FAO WHO FOOD S; Williams PN, 2007, ENVIRON SCI TECHNOL, V41, P6854, DOI 10.1021/es070627i	28	15	15	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2018	13	3							e0194700	10.1371/journal.pone.0194700	http://dx.doi.org/10.1371/journal.pone.0194700			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ6JH	29547635	Green Published, Green Submitted, gold			2023-01-03	WOS:000427703500052
J	Swetz, KM; Kamal, AH				Swetz, Keith M.; Kamal, Arif H.			Palliative Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL; DOUBLE-BLIND; ADVANCED CANCER; CLASSIFICATION-SYSTEM; REFRACTORY DYSPNEA; ADVANCED DEMENTIA; POLICY STATEMENT; HEART-FAILURE; LIVER-DISEASE; ADVANCED LUNG		[Swetz, Keith M.] UAB Ctr Palliat & Support Care, Birmingham, AL 35205 USA; Duke Canc Inst, Durham, NC USA	University of Alabama System; University of Alabama Birmingham; Duke University	Swetz, KM (corresponding author), UAB Ctr Palliat & Support Care, Birmingham, AL 35205 USA.		Swetz, Keith/AAO-9336-2020	Swetz, Keith/0000-0001-9893-6517	American College of Physicians; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS023681] Funding Source: NIH RePORTER	American College of Physicians; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	American College of Physicians.	Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Agar MR, 2017, JAMA INTERN MED, V177, P34, DOI 10.1001/jamainternmed.2016.7491; Anderson F, 1996, J PALLIAT CARE, V12, P5, DOI 10.1177/082585979601200102; Andrew B, 2017, CURR DRUG TARGETS; Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362; Barnes H, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011008.pub2; Bausewein C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005623.pub2; Berger MJ, 2017, J NATL COMPR CANC NE, V15, P883, DOI 10.6004/jnccn.2017.0117; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Biggins SW, 2006, GASTROENTEROLOGY, V130, P1652, DOI 10.1053/j.gastro.2006.02.010; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Braun LT, 2016, CIRCULATION, V134, pE198, DOI 10.1161/CIR.0000000000000438; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Campbell ML, 2013, J PALLIAT MED, V16, P1255, DOI 10.1089/jpm.2013.0122; Candy B, 2009, INT J PALLIAT NURS, V15, P396, DOI 10.12968/ijpn.2009.15.8.43799; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Child CG, 1964, LIVER PORTAL HYPERTE, P50; Childers JW, 2017, J ONCOL PRACT, V13, P700, DOI 10.1200/JOP.2016.018796; Cohen LM, 2010, CLIN J AM SOC NEPHRO, V5, P72, DOI 10.2215/CJN.03860609; Currow DC, 2011, J PAIN SYMPTOM MANAG, V42, P388, DOI 10.1016/j.jpainsymman.2010.11.021; DeMartino ES, 2017, NEW ENGL J MED, V376, P1478, DOI 10.1056/NEJMms1611497; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn W, 2005, HEPATOLOGY, V41, P353, DOI 10.1002/hep.20503; Ekstrom MP, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g445; El-Jawahri A, 2017, J CLIN ONCOL, V35, P3714, DOI 10.1200/JCO.2017.73.2800; El-Jawahri Areej, 2011, J Support Oncol, V9, P87; Ferrell BR, 2017, J CLIN ONCOL, V35, P96, DOI 10.1200/JCO.2016.70.1474; Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Guan NC, 2014, EUR NEUROPSYCHOPHARM, V24, P491, DOI 10.1016/j.euroneuro.2014.01.016; Hanson LC, 2011, J AM GERIATR SOC, V59, P463, DOI 10.1111/j.1532-5415.2011.03320.x; Haun MW, 2017, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD011129.PUB2; Hui D, 2017, JAMA-J AM MED ASSOC, V318, P1047, DOI 10.1001/jama.2017.11468; Juurlink D, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i5309; Kamal AH, 2012, J PALLIAT MED, V15, P106, DOI 10.1089/jpm.2011.0110; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Landry DL, 2017, J AM SOC NEPHROL, V28, P643; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Loprinzi CL, 1999, J CLIN ONCOL, V17, P3299, DOI 10.1200/JCO.1999.17.10.3299; Mahler DA, 2010, POL ARCH MED WEWN, V120, P160, DOI 10.20452/pamw.915; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; McMahon MM, 2005, MAYO CLIN PROC, V80, P1461, DOI 10.4065/80.11.1461; Meisel Alan, 2005, J Palliat Med, V8, P609, DOI 10.1089/jpm.2005.8.609; Miro O, 2017, ANN INTERN MED, V167, P698, DOI 10.7326/M16-2726; Mitchell SL, 2004, JAMA-J AM MED ASSOC, V291, P2734, DOI 10.1001/jama.291.22.2734; Navari RM, 2016, NEW ENGL J MED, V375, P134, DOI 10.1056/NEJMoa1515725; O'Sullivan R, 2014, LANCET PSYCHIAT, V1, P303, DOI 10.1016/S2215-0366(14)70281-0; Obita GP, 2016, J PAIN SYMPTOM MANAG, V52, P901, DOI 10.1016/j.jpainsymman.2016.05.032; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pirovano M, 1999, J PAIN SYMPTOM MANAG, V17, P231, DOI 10.1016/S0885-3924(98)00145-6; Prescott AT, 2017, HEALTH PSYCHOL, V36, P1140, DOI 10.1037/hea0000544; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Radinovic KS, 2014, J AM GERIATR SOC, V62, P1640, DOI 10.1111/jgs.12992; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Smith TJ, 2010, ONCOLOGY-NY, V24, P521; Sudore RL, 2017, JAMA INTERN MED, V177, P1102, DOI 10.1001/jamainternmed.2017.1607; Sullivan DR, 2017, PSYCHO-ONCOLOGY, V26, P1763, DOI 10.1002/pon.4220; Sulmasy LS, 2017, ANN INTERN MED, V167, P576, DOI 10.7326/M17-0938; Tarumi Y, 2013, J PAIN SYMPTOM MANAG, V45, P2, DOI 10.1016/j.jpainsymman.2012.02.008; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Weissman DE, 2011, J PALLIAT MED, V14, P17, DOI 10.1089/jpm.2010.0347; Wendler D, 2011, ANN INTERN MED, V154, P336, DOI 10.7326/0003-4819-154-5-201103010-00008; Witlox J, 2010, JAMA-J AM MED ASSOC, V304, P443, DOI 10.1001/jama.2010.1013; Wood GJ, 2007, JAMA-J AM MED ASSOC, V298, P1196, DOI 10.1001/jama.298.10.1196; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Yavuzsen T, 2005, J CLIN ONCOL, V23, P8500, DOI 10.1200/JCO.2005.01.8010; Yourman LC, 2012, JAMA-J AM MED ASSOC, V307, P182, DOI 10.1001/jama.2011.1966; Zubrod C.G., 1960, J CHRON DIS, V11, P7	76	15	15	4	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 6	2018	168	5					ITC33	U30		10.7326/AITC201803060	http://dx.doi.org/10.7326/AITC201803060			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY2GD	29507970				2023-01-03	WOS:000426632600002
J	Semler, MW; Self, WH; Wanderer, JP; Ehrenfeld, JM; Wang, L; Byrne, DW; Stollings, JL; Kumar, AB; Hughes, CG; Hernandez, A; Guillamondegui, OD; May, AK; Weavind, L; Casey, JD; Siew, ED; Shaw, AD; Bernard, GR; Rice, TW				Semler, Matthew W.; Self, Wesley H.; Wanderer, Jonathan P.; Ehrenfeld, Jesse M.; Wang, Li; Byrne, Daniel W.; Stollings, Joanna L.; Kumar, Avinash B.; Hughes, Christopher G.; Hernandez, Antonio; Guillamondegui, Oscar D.; May, Addison K.; Weavind, Liza; Casey, Jonathan D.; Siew, Edward D.; Shaw, Andrew D.; Bernard, Gordon R.; Rice, Todd W.		SMART Investigators; Pragmatic Critical Care Res Grp	Balanced Crystalloids versus Saline in Critically Ill Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE KIDNEY INJURY; CIRCULATING INFLAMMATORY MOLECULES; IN-HOSPITAL MORTALITY; INTENSIVE-CARE-UNIT; RENAL BLOOD-FLOW; HYPERCHLOREMIC ACIDOSIS; FLUID RESUSCITATION; 0.9-PERCENT SALINE; CROSSOVER; SEPSIS	BACKGROUND Both balanced crystalloids and saline are used for intravenous fluid administration in critically ill adults, but it is not known which results in better clinical outcomes. METHODS In a pragmatic, cluster-randomized, multiple-crossover trial conducted in five intensive care units at an academic center, we assigned 15,802 adults to receive saline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) according to the randomization of the unit to which they were admitted. The primary outcome was a major adverse kidney event within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to >= 200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first. RESULTS Among the 7942 patients in the balanced-crystalloids group, 1139 (14.3%) had a major adverse kidney event, as compared with 1211 of 7860 patients (15.4%) in the saline group (marginal odds ratio, 0.91; 95% confidence interval [CI], 0.84 to 0.99; conditional odds ratio, 0.90; 95% CI, 0.82 to 0.99; P = 0.04). In-hospital mortality at 30 days was 10.3% in the balanced-crystalloids group and 11.1% in the saline group (P = 0.06). The incidence of new renal-replacement therapy was 2.5% and 2.9%, respectively (P = 0.08), and the incidence of persistent renal dysfunction was 6.4% and 6.6%, respectively (P = 0.60). CONCLUSIONS Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration resulted in a lower rate of the composite outcome of death from any cause, new renal-replacement therapy, or persistent renal dysfunction than the use of saline.	[Semler, Matthew W.; Casey, Jonathan D.; Bernard, Gordon R.; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Self, Wesley H.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN 37232 USA; [Wanderer, Jonathan P.; Kumar, Avinash B.; Hughes, Christopher G.; Hernandez, Antonio; Weavind, Liza; Shaw, Andrew D.] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; [Wanderer, Jonathan P.; Ehrenfeld, Jesse M.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37232 USA; [Ehrenfeld, Jesse M.; Guillamondegui, Oscar D.; May, Addison K.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [Ehrenfeld, Jesse M.] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN 37232 USA; [Wang, Li; Byrne, Daniel W.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Stollings, Joanna L.] Vanderbilt Univ, Med Ctr, Dept Pharmaceut Serv, Nashville, TN 37232 USA; [Siew, Edward D.] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Vanderbilt Ctr Kidney Dis, Nashville, TN 37232 USA; [Siew, Edward D.] Vanderbilt Univ, Med Ctr, Integrated Program Acute Kidney Dis, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Rice, TW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, T-1218 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	todd.rice@vanderbilt.edu	Ehrenfeld, Jesse/AAI-2951-2020; Casey, Jonathan/AAG-1211-2020; Byrne, Daniel/GRE-6302-2022; Rice, Todd/X-7853-2019	Casey, Jonathan/0000-0002-0977-290X; Pretorius, Mias/0000-0002-8777-3940; Wanderer, Jonathan/0000-0002-3119-6873; Siew, Edward/0000-0003-1343-8784; Rice, Todd/0000-0002-7136-5408; Self, Wesley/0000-0002-9300-3045	Vanderbilt Institute for Clinical and Translational Research (National Center for Advancing Translational Sciences) [UL1 TR000445, UL1TR002243]; National Heart, Lung, and Blood Institute (NHLBI) [HL087738-09, K12HL133117]; National Institute of General Medical Sciences (NIGMS) [K23GM110469]; American Geriatrics Society Jahnigen Career Development Award; National Institutes of Health (NIH) [HL111111, AG045085, GM120484]; NIGMS [1R01GM115353-01]; Department of Defense [12277261]; NHLBI [HL087738-09]; Vanderbilt Center for Kidney Disease; Department of Veterans Affairs' Health Services Research and Development Service; NIH [R34HL105869]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002243, UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL111111, T32HL087738, R34HL105869, K12HL133117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM115353, K23GM110469, R01GM120484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG045085] Funding Source: NIH RePORTER	Vanderbilt Institute for Clinical and Translational Research (National Center for Advancing Translational Sciences); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); American Geriatrics Society Jahnigen Career Development Award; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Department of Defense(United States Department of Defense); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Vanderbilt Center for Kidney Disease; Department of Veterans Affairs' Health Services Research and Development Service(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the Vanderbilt Institute for Clinical and Translational Research (through grants UL1 TR000445 and UL1TR002243 from the National Center for Advancing Translational Sciences). Dr. Semler was supported in part by grants from the National Heart, Lung, and Blood Institute (NHLBI) (HL087738-09 and K12HL133117). Dr. Self was supported in part by a grant from the National Institute of General Medical Sciences (NIGMS) (K23GM110469). Dr. Hughes was supported by an American Geriatrics Society Jahnigen Career Development Award and by grants from the National Institutes of Health (NIH) (HL111111, AG045085, and GM120484). Dr. May was supported in part by grants from the NIGMS (1R01GM115353-01) and the Department of Defense (12277261). Dr. Casey was supported in part by a grant from the NHLBI (HL087738-09). Dr. Siew was supported by the Vanderbilt Center for Kidney Disease and the Department of Veterans Affairs' Health Services Research and Development Service. Dr. Rice was supported in part by a grant from the NIH (R34HL105869).	Awad S, 2008, CLIN NUTR, V27, P179, DOI 10.1016/j.clnu.2008.01.008; Chowdhury AH, 2012, ANN SURG, V256, P18, DOI 10.1097/SLA.0b013e318256be72; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Finfer S, 2010, CRIT CARE, V14, DOI 10.1186/cc9293; Hammond NE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176292; Kashani K, 2013, CRIT CARE, V17, DOI 10.1186/cc12503; Kellum JA, 1998, SHOCK, V9, P364, DOI 10.1097/00024382-199805000-00009; Kellum JA, 2002, CRIT CARE MED, V30, P300, DOI 10.1097/00003246-200202000-00006; Kellum JA, 2004, CHEST, V125, P243, DOI 10.1378/chest.125.1.243; Kellum JA, 2006, CHEST, V130, P962, DOI 10.1378/chest.130.4.962; Kellum JA, 2017, INTENS CARE MED, V43, P901, DOI 10.1007/s00134-017-4732-1; Krajewski ML, 2015, BRIT J SURG, V102, P24, DOI 10.1002/bjs.9651; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627; Palevsky PM, 2012, CLIN J AM SOC NEPHRO, V7, P844, DOI 10.2215/CJN.12791211; Parienti JJ, 2007, CONTEMP CLIN TRIALS, V28, P316, DOI 10.1016/j.cct.2006.10.004; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Rochwerg B, 2015, INTENS CARE MED, V41, P1561, DOI 10.1007/s00134-015-3794-1; Rochwerg B, 2014, ANN INTERN MED, V161, P347, DOI 10.7326/M14-0178; Self WH, 2018, NEW ENGL J MED, V378, P819, DOI 10.1056/NEJMoa1711586; Self WH, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1923-6; Semler MW, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1871-1; Semler MW, 2017, AM J RESP CRIT CARE, V195, P1362, DOI 10.1164/rccm.201607-1345OC; Semler MW, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0528-z; Sen A, 2017, CRIT CARE MED, V45, pE146, DOI 10.1097/CCM.0000000000002063; Shahian DM, 2010, NEW ENGL J MED, V363, P2530, DOI 10.1056/NEJMsa1006396; Shaw A, 2011, CONTRIB NEPHROL, V174, P156, DOI 10.1159/000329387; Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Turner RM, 2007, STAT MED, V26, P274, DOI 10.1002/sim.2537; WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8; Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Yunos NM, 2011, CRIT CARE MED, V39, P2419, DOI 10.1097/CCM.0b013e31822571e5; Zavada J, 2010, NEPHROL DIAL TRANSPL, V25, P3911, DOI 10.1093/ndt/gfp766; Zhou F, 2014, CRIT CARE MED, V42, pE270, DOI 10.1097/CCM.0000000000000145	37	589	610	3	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 1	2018	378	9					829	839		10.1056/NEJMoa1711584	http://dx.doi.org/10.1056/NEJMoa1711584			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX7GP	29485925	Bronze, Green Accepted			2023-01-03	WOS:000426256300008
J	Alyami, H; Koner, J; Huynh, C; Terry, D; Mohammed, AR				Alyami, Hamad; Koner, Jasdip; Huynh, Chi; Terry, David; Mohammed, Afzal R.			Current opinions and recommendations of paediatric healthcare professionals - The importance of tablets: Emerging orally disintegrating versus traditional tablets	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CHILDREN; ANTIRETROVIRAL MEDICATION; ADHERENCE; PALATABILITY; FORMULATIONS; FORMS	The appropriate prescribing of paediatric dosage forms is paramount in providing the desired therapeutic effect alongside successful medication adherence with the paediatric population. Often it is the opinion of the healthcare practitioner that dictates which type of dosage form would be most appropriate for the paediatric patient, with liquids being both the most commonly available and most commonly used. Orally disintegrating tablets (ODTs) are an emerging dosage form which provide many benefits over traditional dosage forms for paediatric patients, such as rapid disintegration within the oral cavity, and the reduction in the risk of choking. However the opinion and professional use of healthcare practitioners regarding ODT's is not known. This study was designed to assess the opinions of several types of healthcare professionals (n = 41) regarding ODTs, using a survey across two hospital sites. Results reaffirmed the popularity of liquids for prescribing in paediatrics, with 58.0% of participants preferring this dosage form. ODTs emerged as the second most popular dosage form (30.0%), with healthcare practitioners indicating an increasing popularity amongst patients in the hospital setting, belief with 63.0% of practitioners agreeing that many liquid formulations could be substituted with a suitable ODT. The desired properties of an ideal ODT were also identified by healthcare practitioners preferring a small, fast disintegrating tablet (90.2% and 95.1% respectively), with the taste, disintegration time and flavour being the three most important attributes identified (29.5%, 28.7% and 21.7% respectively). This study provided a pragmatic approach in assessing healthcare professional's opinions on ODTs, highlighting the ideas and thoughts of practitioners who are on the frontline of paediatric prescribing and treatment and gave an indication to their preference for ODT properties.	[Alyami, Hamad; Koner, Jasdip; Huynh, Chi; Terry, David; Mohammed, Afzal R.] Aston Univ, Aston Pharm Sch, Birmingham, W Midlands, England; [Terry, David] Birmingham Childrens Hosp, Acad Practice Unit, Birmingham, W Midlands, England	Aston University; University of Birmingham	Huynh, C; Terry, D; Mohammed, AR (corresponding author), Aston Univ, Aston Pharm Sch, Birmingham, W Midlands, England.; Terry, D (corresponding author), Birmingham Childrens Hosp, Acad Practice Unit, Birmingham, W Midlands, England.	c.huynh3@aston.ac.uk; d.terry@aston.ac.uk; a.u.r.mohammed@aston.ac.uk		Mohammed, Afzal-Ur-Rahman/0000-0002-5212-3040; Huynh, Chi/0000-0001-6982-6642; Terry, David/0000-0001-7599-0916; Alyami, Hamad/0000-0003-3513-4976				Adams LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058303; Akram Gazala, 2012, Int J Pharm Pract, V20, P191, DOI 10.1111/j.2042-7174.2011.00179.x; Alyami H, 2016, EUROPEAN J HOSP PHAR, V24, P332; Ansah EK, 2001, TROP MED INT HEALTH, V6, P496, DOI 10.1046/j.1365-3156.2001.00740.x; Bagenda A, 2011, ANN TROP PAEDIATR, V31, P235, DOI 10.1179/1465328111Y.0000000025; Barr H., 2014, REV INTERPROFESSIONA; Bauman LJ, 2000, PROMOTING ADHERENCE TO MEDICAL TREATMENT IN CHRONIC CHILDHOOD ILLNESS: CONCEPTS, METHODS, AND INTERVENTIONS, P71; Benkert O, 2006, J CLIN PSYCHOPHARM, V26, P75, DOI 10.1097/01.jcp.0000194622.99986.d6; Brooks J, 2015, QUAL RES PSYCHOL, V12, P202, DOI 10.1080/14780887.2014.955224; Bryson SP, 2014, INT J PHARMACEUT, V469, P257, DOI 10.1016/j.ijpharm.2014.04.069; Carnaby-Mann G, 2005, ARCH OTOLARYNGOL, V131, P970, DOI 10.1001/archotol.131.11.970; Cheng A, 2007, PEDIATR EMERG CARE, V23, P384, DOI 10.1097/01.pec.0000278402.45321.f6; European Medicines Agency (EMA), 2006, REFL PAP FORM CHOIC; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; Hasamnis AA, 2011, J PHARMACOL PHARMACO, V2, P119, DOI 10.4103/0976-500X.81909; Hirani JJ, 2009, TROP J PHARM RES, V8, P161; Ilieva J, 2002, INT J MARKET RES, V44, P361; Jacobsen L, 2016, PEDIATR DRUGS, V18, P65, DOI 10.1007/s40272-015-0156-y; Lajoinie A, 2014, BRIT J CLIN PHARMACO, V78, P1080, DOI 10.1111/bcp.12442; Levitan CA, 2008, CHEM SENSES, V33, P415, DOI 10.1093/chemse/bjn008; MacGregor EA, 2003, HEADACHE, V43, P19, DOI 10.1046/j.1526-4610.2003.03004.x; MATSUI D, 2007, PAEDIATR PERINAT DRU, V8, P55, DOI DOI 10.1185/146300907X178941; Michaud PA, 2004, ARCH DIS CHILD, V89, P943, DOI 10.1136/adc.2003.045377; Mukattash T, 2011, EUR J CLIN PHARMACOL, V67, P449, DOI 10.1007/s00228-010-0978-z; Paranthaman K, 2009, AIDS CARE, V21, P1025, DOI 10.1080/09540120802612857; Parkash V, 2011, J ADV PHARM TECHNOL, V2, P223, DOI 10.4103/2231-4040.90877; Patel A, 2015, PEDIATRICS, V135, P883, DOI 10.1542/peds.2014-2114; Rabiee F, 2004, P NUTR SOC, V63, P655, DOI 10.1079/PNS2004399; Reddington C, 2000, PEDIATR INFECT DIS J, V19, P1148, DOI 10.1097/00006454-200012000-00005; Ricci G, 2016, BRAZ J INFECT DIS, V20, P429, DOI 10.1016/j.bjid.2016.05.009; Ritchie J, 1994, ANAL QUALITATIVE DAT, P173, DOI DOI 10.4324/9780203413081; Roberts KJ, 2005, YOUTH SOC, V37, P230, DOI 10.1177/0044118X05278269; Siccama CJ, 2008, QUAL RES J, V8, P91, DOI 10.3316/QRJ0802091; Squires LA, 2013, THER INNOV REGUL SCI, V47, P533, DOI 10.1177/2168479013500288; Sumiya K, 2000, YAKUGAKU ZASSHI, V120, P652, DOI 10.1248/yakushi1947.120.7_652; Walsh D, 2005, J ADV NURS, V50, P204, DOI 10.1111/j.1365-2648.2005.03380.x	36	6	6	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2018	13	2							e0193292	10.1371/journal.pone.0193292	http://dx.doi.org/10.1371/journal.pone.0193292			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FX7ND	29489871	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000426276000063
J	Tasbihgou, SR; Netkova, M; Kalmar, AF; Doorduin, J; Struys, MMRF; Schoemaker, RG; Absalom, AR				Tasbihgou, Setayesh R.; Netkova, Mina; Kalmar, Alain F.; Doorduin, Janine; Struys, Michel M. R. F.; Schoemaker, Regien G.; Absalom, Anthony R.			Brain changes due to hypoxia during light anaesthesia can be prevented by deepening anaesthesia; a study in rats	PLOS ONE			English	Article							POSTOPERATIVE COGNITIVE DYSFUNCTION; GENERAL-ANESTHESIA; NEUROTROPHIC FACTOR; BEHAVIORAL-CHANGES; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; NEUROPROTECTION; SURGERY; AGENTS; BDNF	In anaesthetic practice the risk of cerebral ischemic/hypoxic damage is thought to be attenuated by deep anaesthesia. The rationale is that deeper anaesthesia reduces cerebral oxygen demand more than light anaesthesia, thereby increasing the tolerance to ischemia or hypoxia. However, evidence to support this is scarce. We thus investigated the influence of light versus deep anaesthesia on the responses of rat brains to a period of hypoxia. In the first experiment we exposed adult male Wistar rats to deep or light propofol anaesthesia and then performed [F-18]-Fludeoxyglucose (FDG) Positron Emission Tomography (PET) scans to verify the extent of cerebral metabolic suppression. In subsequent experiments, rats were subjected to light/deep propofol anaesthesia and then exposed to a period of hypoxia or ongoing normoxia (n = 9-11 per group). A further 5 rats, not exposed to anaesthesia or hypoxia, served as controls. Four days later a Novel Object Recognition (NOR) test was performed to assess mood and cognition. After another 4 days, the animals were sacrificed for later immunohistochemical analyses of neurogenesis/neuroplasticity (Doublecortin; DCX), Brain Derived Neurotrophic Factor (BDNF) expression and neuroinflammation (Ionized calcium-binding adaptor protein-1; Iba-1) in hippocampal and piriform cortex slices. The hippocampi of rats subjected to hypoxia during light anaesthesia showed lower DCX positivity, and therefore lower neurogenesis, but higher BDNF levels and microglia hyper-ramification. Exploration was reduced, but no significant effect on NOR was observed. In the piriform cortex, higher DCX positivity was observed, associated with neuroplasticity. All these effects were attenuated by deep anaesthesia. Deepening anaesthesia attenuated the brain changes associated with hypoxia. Hypoxia during light anaesthesia had a prolonged effect on the brain, but no impairment in cognitive function was observed. Although reduced hippocampal neurogenesis may be considered unfavourable, higher BDNF expression, associated with microglia hyper-ramification may suggest activation of repair mechanisms. Increased neuroplasticity observed in the piriform cortex supports this, and might reflect a prolonged state of alertness rather than damage.	[Tasbihgou, Setayesh R.; Netkova, Mina; Kalmar, Alain F.; Struys, Michel M. R. F.; Absalom, Anthony R.] Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, Groningen, Netherlands; [Doorduin, Janine] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands; [Struys, Michel M. R. F.] Univ Ghent, Dept Anaesthesia, Ghent, Belgium; [Schoemaker, Regien G.] Univ Groningen, GELIFES, Dept Mol Neurobiol, Groningen, Netherlands	University of Groningen; University of Groningen; Ghent University; University of Groningen	Tasbihgou, SR (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Anaesthesiol, Groningen, Netherlands.	s.r.tasbihgou@umcg.nl	Absalom, Anthony/GPG-1582-2022	Doorduin, Janine/0000-0003-2925-9959; Kalmar, Alain/0000-0003-2036-9019; Absalom, Anthony/0000-0001-7563-9157; Tasbihgou, Setayesh/0000-0002-6147-6163; Struys, Michel/0000-0003-0421-536X	Dutch association of anaesthesiology (Nederlandse verenining voor anesthesiologie); Dutch association of anaesthesiology (Nederlandse verenining voor anesthesiologie)	Dutch association of anaesthesiology (Nederlandse verenining voor anesthesiologie); Dutch association of anaesthesiology (Nederlandse verenining voor anesthesiologie)	The study qualified for the Young Investigator Grant from the Dutch association of anaesthesiology (Nederlandse verenining voor anesthesiologie http://www.anesthesiologie.nl/wetenschap/yong-investigator-grant) to AFK. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Barrientos RM, 2004, J NEUROIMMUNOL, V155, P119, DOI 10.1016/j.jneuroim.2004.06.009; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Cacciaglia R, 2017, PSYCHONEUROENDOCRINO, V76, P19, DOI 10.1016/j.psyneuen.2016.11.012; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Clarkson AN, 2007, LIFE SCI, V80, P1157, DOI 10.1016/j.lfs.2006.12.022; Cortese GP, 2011, J NEUROSCI, V31, P4274, DOI 10.1523/JNEUROSCI.5818-10.2011; Deng M, 2014, BRIT J ANAESTH, V113, P443, DOI 10.1093/bja/aet469; Deshmukh SS, 2012, WIRES COGN SCI, V3, P231, DOI 10.1002/wcs.1164; Dong YL, 2009, ARCH NEUROL-CHICAGO, V66, P620, DOI 10.1001/archneurol.2009.48; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; Eggen BJL, 2013, J NEUROIMMUNE PHARM, V8, P807, DOI 10.1007/s11481-013-9490-4; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Head BP, 2009, ANESTHESIOLOGY, V110, P813, DOI 10.1097/ALN.0b013e31819b602b; Hellwig S, 2016, BRAIN BEHAV IMMUN, V55, P126, DOI 10.1016/j.bbi.2015.11.008; Hovens I.B., 2014, NEUROIMMUNOL NEUROIN, V1, P82, DOI DOI 10.4103/2347-8659.139719; Hovens IB, 2015, AM J PHYSIOL-REG I, V309, pR148, DOI 10.1152/ajpregu.00002.2015; Hovens IB, 2014, BRAIN BEHAV IMMUN, V38, P202, DOI 10.1016/j.bbi.2014.02.002; Hovens IB, 2013, EXP GERONTOL, V48, P1204, DOI 10.1016/j.exger.2013.07.011; Jevtovic-Todorovic V, 2013, BRIT J ANAESTH, V111, P143, DOI 10.1093/bja/aet177; Kawaguchi Masahiko, 2005, J Anesth, V19, P150, DOI 10.1007/s00540-005-0305-5; Klempin F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025760; Knibbe CAJ, 2005, BRIT J CLIN PHARMACO, V59, P705, DOI 10.1111/j.1365-2125.2005.02239.x; Koerner IP, 2006, CURR OPIN ANESTHESIO, V19, P481, DOI 10.1097/01.aco.0000245271.84539.4c; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lindholm ML, 2009, ANESTH ANALG, V108, P508, DOI 10.1213/ane.0b013e31818f603c; Lu LX, 2006, APOPTOSIS, V11, P1603, DOI 10.1007/s10495-006-8762-3; Lu Y, 2008, NEUROBIOL LEARN MEM, V89, P312, DOI 10.1016/j.nlm.2007.08.018; Luikart BW, 2005, J NEUROSCI, V25, P3774, DOI 10.1523/JNEUROSCI.0041-05.2005; McAuliffe JJ, 2009, ANESTHESIOLOGY, V111, P533, DOI 10.1097/ALN.0b013e3181b060d3; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Monk TG, 2011, CURR OPIN CRIT CARE, V17, P376, DOI 10.1097/MCC.0b013e328348bece; Mortier E, 2000, ACTA NEUROL BELG, V100, P225; Pandit JJ, 2014, BRIT J ANAESTH, V113, P549, DOI 10.1093/bja/aeu313; Perez-Gomez A, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-72; Raj DDA, 2015, AGING CELL, V14, P1003, DOI 10.1111/acel.12370; Raj DDA, 2014, NEUROBIOL AGING, V35, P2147, DOI 10.1016/j.neurobiolaging.2014.03.025; Sanders RD, 2005, BEST PRACT RES-CLIN, V19, P461, DOI 10.1016/j.bpa.2005.01.005; Schifilliti D, 2010, CNS DRUGS, V24, P893, DOI 10.2165/11584760-000000000-00000; SCHOEMAKER RG, 1994, PHYSIOL BEHAV, V56, P585, DOI 10.1016/0031-9384(94)90305-0; Tong LQ, 2012, J NEUROSCI, V32, P17714, DOI 10.1523/JNEUROSCI.1253-12.2012; Vinet J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-27; Walker FR, 2013, CURR DRUG TARGETS, V14, P1262; Wang L, 2008, CURR OPIN PHARMACOL, V8, P104, DOI 10.1016/j.coph.2007.09.005; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; Xie ZC, 2006, EXP GERONTOL, V41, P346, DOI 10.1016/j.exger.2006.01.014; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Zwerus R, 2015, CURR OPIN ANESTHESIO, V28, P424, DOI 10.1097/ACO.0000000000000212	50	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2018	13	2							e0193062	10.1371/journal.pone.0193062	http://dx.doi.org/10.1371/journal.pone.0193062			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW5PR	29451906	Green Published, gold, Green Submitted			2023-01-03	WOS:000425369800038
J	Crellin, E; Mansfield, KE; Leyrat, C; Nitsch, D; Douglas, IJ; Root, A; Williamson, E; Smeeth, L; Tomlinson, LA				Crellin, Elizabeth; Mansfield, Kathryn E.; Leyrat, Clemence; Nitsch, Dorothea; Douglas, Ian J.; Root, Adrian; Williamson, Elizabeth; Smeeth, Liam; Tomlinson, Laurie A.			Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE KIDNEY INJURY; PATIENTS RECEIVING INHIBITORS; HIGH-DOSE TRIMETHOPRIM; INDUCED HYPERKALEMIA; SERUM CREATININE; CO-TRIMOXAZOLE; SULFAMETHOXAZOLE; COTRIMOXAZOLE; FAILURE	OBJECTIVE To determine if trimethoprim use for urinary tract infection (UTI) is associated with an increased risk of acute kidney injury, hyperkalaemia, or sudden death in the general population. DESIGN Cohort study. SETTING UK electronic primary care records from practices contributing to the Clinical Practice Research Datalink linked to the Hospital Episode Statistics database. PARTICIPANTS Adults aged 65 and over with a prescription for trimethoprim, amoxicillin, cefalexin, ciprofloxacin, or nitrofurantoin prescribed up to three days after a primary care diagnosis of UTI between April 1997 and September 2015. MAIN OUTCOME MEASURES The outcomes were acute kidney injury, hyperkalaemia, and death within 14 days of a UTI treated with antibiotics. RESULTS Among a cohort of 1 191 905 patients aged 65 and over, 178 238 individuals were identified with at least one UTI treated with antibiotics, comprising a total of 422 514 episodes of UTIs treated with antibiotics. The odds of acute kidney injury in the 14 days following antibiotic initiation were higher following trimethoprim (adjusted odds ratio 1.72, 95% confidence interval 1.31 to 2.24) and ciprofloxacin (1.48, 1.03 to 2.13) compared with amoxicillin. The odds of hyperkalaemia in the 14 days following antibiotic initiation were only higher following trimethoprim (2.27, 1.49 to 3.45) compared with amoxicillin. However, the odds of death within the 14 days following antibiotic initiation were not higher with trimethoprim than with amoxicillin: in the whole population the adjusted odds ratio was 0.90 (95% confidence interval 0.76 to 1.07) while among users of renin-angiotensin system blockers the odds of death within 14 days of antibiotic initiation was 1.12 (0.80 to 1.57). The results suggest that, for 1000 UTIs treated with antibiotics among people 65 and over, treatment with trimethoprim instead of amoxicillin would result in one to two additional cases of hyperkalaemia and two admissions with acute kidney injury, regardless of renin-angiotensin system blockade. However, for people taking renin-angiotensin system blockers and spironolactone treatment with trimethoprim instead of amoxicillin there were 18 additional cases of hyperkalaemia and 11 admissions with acute kidney injury. CONCLUSION Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia compared with other antibiotics used to treat UTIs, but not a greater risk of death. The relative risk increase is similar across population groups, but the higher baseline risk among those taking renin-angiotensin system blockers and potassium-sparing diuretics translates into higher absolute risks of acute kidney injury and hyperkalaemia in these groups.	[Crellin, Elizabeth; Mansfield, Kathryn E.; Nitsch, Dorothea; Douglas, Ian J.; Root, Adrian; Smeeth, Liam; Tomlinson, Laurie A.] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England; [Leyrat, Clemence; Williamson, Elizabeth] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Med Stat, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Mansfield, KE (corresponding author), London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England.	kathryn.mansfield@lshtm.ac.uk	Leyrat, Clémence/I-9413-2019; Smeeth, Liam/X-5862-2018	Leyrat, Clémence/0000-0002-4097-4577; Crellin, Elizabeth/0000-0001-8774-224X; Smeeth, Liam/0000-0002-9168-6022; Tomlinson, Laurie/0000-0001-8848-9493; Nitsch, Dorothea/0000-0001-5767-248X	Wellcome Trust [101143/Z/13/Z, 098504/Z/12/Z]; MRC [MR/M013278/1, G0802403] Funding Source: UKRI; Medical Research Council [G0802403, MR/M013278/1] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	LAT and KEM were funded by a Wellcome Trust intermediate clinical fellowship (101143/Z/13/Z). LS and EC were supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (098504/Z/12/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alappan R, 1999, AM J NEPHROL, V19, P389, DOI 10.1159/000013483; Antoniou T, 2015, C CAN MED ASS J, V187, P1; Antoniou T, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5228; Antoniou T, 2010, ARCH INTERN MED, V170, P1045, DOI 10.1001/archinternmed.2010.142; Bhaskaran K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003389; Bird ST, 2013, CAN MED ASSOC J, V185, pE475, DOI 10.1503/cmaj.121730; Butler CC, 2007, BRIT J GEN PRACT, V57, P785; Center for Disease Dynamics Economics and Policy, STAT WORLDS ANT 2015; Chan WY, 2017, BRIT J CLIN PHARMACO, V83, P1808, DOI 10.1111/bcp.13263; Fralick M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6196; Fraser TN, 2012, J ANTIMICROB CHEMOTH, V67, P1271, DOI 10.1093/jac/dks030; Gentry CA, 2013, ANN PHARMACOTHER, V47, P1618, DOI 10.1177/1060028013509973; Herrett E, 2015, INT J EPIDEMIOL, V44, P827, DOI 10.1093/ije/dyv098; Higashioka K, 2016, INTERNAL MED, V55, P467, DOI 10.2169/internalmedicine.55.5697; HSCIC, HOSP EP STAT; Joint Formulary Committee, 2016, BRIT NAT FORM BNF 72; Kolhe NV, 2016, INT J CLIN PRACT, V70, P330, DOI 10.1111/ijcp.12774; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; London School of Hygiene & Tropical Medicine, COD LISTS ADV OUTC F; Mansfield KE, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012690; Mathur R, 2014, J PUBLIC HEALTH-UK, V36, P684, DOI 10.1093/pubmed/fdt116; Michel A, 2015, EUR J HEART FAIL, V17, P205, DOI 10.1002/ejhf.226; MIHM LB, 1995, PHARMACOTHERAPY, V15, P793; Naderer O, 1997, ANTIMICROB AGENTS CH, V41, P2466, DOI 10.1128/AAC.41.11.2466; NHS England/Commissioning Strategy/Contracts and Incentives, 2017, TECHN GUID ANN B INF; Pannu N, 2008, CRIT CARE MED, V36, pS216, DOI 10.1097/CCM.0b013e318168e375; Perazella MA, 2000, DRUG SAFETY, V22, P227, DOI 10.2165/00002018-200022030-00006; Public Health England, 2017, MAN INF GUID PRIM CA; RUDRA T, 1989, NEPHRON, V53, P85, DOI 10.1159/000185711; SALTISSI D, 1979, BRIT MED J, V1, P1182, DOI 10.1136/bmj.1.6172.1182-a; Sawhney S, 2015, NEPHROL DIAL TRANSPL, V30, P1853, DOI 10.1093/ndt/gfv094; Scottish Intercollegiate Guidelines Network. Scottish Intercollegiate Guidelines Network (SIGN), 2012, MAN SUSP BACT UR TRA; Siew ED, 2015, KIDNEY INT, V87, P46, DOI 10.1038/ki.2014.293; SMITH EJ, 1980, JAMA-J AM MED ASSOC, V244, P360, DOI 10.1001/jama.244.4.360; Tomlinson LA, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-58; TROLLFORS B, 1980, J INFECTION, V2, P221, DOI 10.1016/S0163-4453(80)90626-X	36	28	28	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	2018	360								k341	10.1136/bmj.k341	http://dx.doi.org/10.1136/bmj.k341			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW0IE	29438980	Green Published, Green Accepted, hybrid, Green Submitted			2023-01-03	WOS:000424976600001
J	Roislien, J; Sovik, S; Eken, T				Roislien, Jo; Sovik, Signe; Eken, Torsten			Seasonality in trauma admissions - Are daylight and weather variables better predictors than general cyclic effects?	PLOS ONE			English	Article							TIME-SERIES REGRESSION; SIBERIAN HAMSTERS; ADAPTATIONS; PATTERN	Background Trauma is a leading global cause of death, and predicting the burden of trauma admissions is vital for good planning of trauma care. Seasonality in trauma admissions has been found in several studies. Seasonal fluctuations in daylight hours, temperature and weather affect social and cultural practices but also individual neuroendocrine rhythms that may ultimately modify behaviour and potentially predispose to trauma. The aim of the present study was to explore to what extent the observed seasonality in daily trauma admissions could be explained by changes in daylight and weather variables throughout the year. Methods Retrospective registry study on trauma admissions in the 10-year period 2001-2010 at Oslo University Hospital, Ulleval, Norway, where the amount of daylight varies from less than 6 hours to almost 19 hours per day throughout the year. Daily number of admissions was analysed by fitting non-linear Poisson time series regression models, simultaneously adjusting for several layers of temporal patterns, including a non-linear long-term trend and both seasonal and weekly cyclic effects. Five daylight and weather variables were explored, including hours of daylight and amount of precipitation. Models were compared using Akaike's Information Criterion (AIC). Results A regression model including daylight and weather variables significantly outperformed a traditional seasonality model in terms of AIC. A cyclic week effect was significant in all models. Conclusion Daylight and weather variables are better predictors of seasonality in daily trauma admissions than mere information on day-of-year.	[Roislien, Jo] Univ Stavanger, Fac Hlth Sci, Stavanger, Norway; [Roislien, Jo] Norwegian Air Ambulance Fdn, Dept Res, Drobak, Norway; [Sovik, Signe] Akershus Univ Hosp, Dept Anaesthesiol, Lorenskog, Norway; [Sovik, Signe; Eken, Torsten] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway; [Eken, Torsten] Oslo Univ Hosp, Dept Anaesthesiol, Oslo, Norway	Universitetet i Stavanger; University of Oslo; University of Oslo; University of Oslo	Roislien, J (corresponding author), Univ Stavanger, Fac Hlth Sci, Stavanger, Norway.; Roislien, J (corresponding author), Norwegian Air Ambulance Fdn, Dept Res, Drobak, Norway.	jo.roislien@norskluftambulanse.no	Søvik, Signe/O-4185-2016; Røislien, Jo/AAF-2265-2020; Eken, Torsten/B-4994-2013	Søvik, Signe/0000-0003-4524-2268; Røislien, Jo/0000-0002-7168-2833; Eken, Torsten/0000-0002-5943-4538				Aguglia A, 2016, INT J PSYCHIAT CLIN, V20, P232, DOI 10.1080/13651501.2016.1214736; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Atherton WG, 2005, INJURY, V36, P40, DOI 10.1016/j.injury.2003.10.027; Bauer M, 2017, ACTA PSYCHIAT SCAND, V136, P571, DOI 10.1111/acps.12772; Bhaskaran K, 2013, INT J EPIDEMIOL, V42, P1187, DOI 10.1093/ije/dyt092; Bhattacharyya T, 2001, J TRAUMA, V51, P118, DOI 10.1097/00005373-200107000-00019; Bramness JG, 2015, AM J EPIDEMIOL, V182, P244, DOI 10.1093/aje/kwv064; Burnham KP, 2013, MODEL SELECTION INFE; Canner JK, 2018, EPIDEMIOL PSYCH SCI, V27, P94, DOI 10.1017/S2045796016000871; Dawson NV, 2012, MED DECIS MAKING, V32, P225, DOI 10.1177/0272989X12437605; Friede Kevin A, 2009, Minn Med, V92, P47; GORMAN MR, 1995, BIOL REPROD, V53, P116, DOI 10.1095/biolreprod53.1.116; GORMAN MR, 1995, BIOL REPROD, V53, P110, DOI 10.1095/biolreprod53.1.110; Gorman MR, 1997, BIOL REPROD, V56, P668, DOI 10.1095/biolreprod56.3.668; Griffith JE, 2013, J WILDLIFE DIS, V49, P18, DOI 10.7589/2012-05-135; Harrison F, 2017, INT J BEHAV NUTR PHY, V14, DOI [DOI 10.1186/S12966-017-0526-7, 10.1186/s12966-017-0526-7, DOI 10.1186/s12966-017-0526-7]; Kieffer WKM, 2016, ANN ROY COLL SURG, V98, P128, DOI 10.1308/rcsann.2016.0040; KUHN L, 1994, AM J EPIDEMIOL, V140, P943, DOI 10.1093/oxfordjournals.aje.a117183; Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5; Lu L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-395; Macoveanu J, 2016, NEUROIMAGE, V139, P37, DOI 10.1016/j.neuroimage.2016.06.024; Medici CR, 2016, J AFFECT DISORDERS, V205, P81, DOI 10.1016/j.jad.2016.06.053; Observatory AADotUSN, DUR DAYL DARKN TABL; Pape-Kohler CIA, 2014, INJURY, V45, pS93, DOI 10.1016/j.injury.2014.08.027; Parsons N, 2011, EMERG MED J, V28, P851, DOI 10.1136/emj.2010.091058; Perez K, 2009, B WORLD HEALTH ORGAN, V87, P497, DOI 10.2471/BLT.08.051847; Prendergast BJ, 2005, HORM BEHAV, V48, P503, DOI 10.1016/j.yhbeh.2005.05.013; Rising WR, 2006, J TRAUMA, V60, P1096, DOI 10.1097/01.ta.0000197435.82141.27; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Sovik S, 2014, INJURY, V45, P1722, DOI 10.1016/j.injury.2014.05.038; Stolwijk AM, 1999, J EPIDEMIOL COMMUN H, V53, P235, DOI 10.1136/jech.53.4.235; Svege I RO, 2015, NORW TRAUM REG ANN R; TNM I, KLIM FRA EKLIMA; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Walraven C, 2008, NEUROEPIDEMIOLOGY, V30, P138, DOI 10.1159/000126908; Wood S.N, 2017, GEN ADDITIVE MODELS	38	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2018	13	2							e0192568	10.1371/journal.pone.0192568	http://dx.doi.org/10.1371/journal.pone.0192568			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV6OL	29425210	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000424700800030
J	de Flon, P; Soderstrom, L; Laurell, K; Dring, A; Sundstrom, P; Gunnarsson, M; Svenningsson, A				de Flon, Pierre; Soderstrom, Lars; Laurell, Katarina; Dring, Ann; Sundstrom, Peter; Gunnarsson, Martin; Svenningsson, Anders			Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls	PLOS ONE			English	Article							B-CELL DEPLETION; DOUBLE-BLIND; PHASE-II; CYTOKINES; BIOMARKERS; THERAPY; DISEASE; TRIAL; AGE	Objective To investigate changes in the cerebrospinal fluid (CSF) immunological profile after treatment switch from first-line injectables to rituximab in patients with relapsing-remitting MS (RRMS), and to compare the profile in MS patients with healthy controls (HC). Method Cerebrospinal fluid from 70 patients with clinically stable RRMS and 55 HC was analysed by a multiplex electrochemiluminescence method for a broad panel of cytokines and immunoactive substances before, and over a two-year period after, treatment switch to rituximab. After quality assessment of data, using a predefined algorithm, 14 analytes were included in the final analysis. Results Ten of the 14 analytes differed significantly in MS patients compared with HC at baseline. Levels of IP-10 (CXCL10), IL-12/23p40, IL-6, sVCAM1, IL-15, sICAM1 and IL-8 (CXCL8) decreased significantly after treatment switch to rituximab. The cytokines IP-10 and IL-12/IL-23p40 displayed the largest difference versus HC at baseline and also the largest relative reduction after therapy switch to rituximab. Conclusion We found significant changes in the immunological profile after therapy switch to rituximab in RRMS in the direction towards the values of HC. IP-10 and IL12/IL-23p40 deserve further studies as part of the immunopathogenesis of MS as well as for the mode of action of rituximab in MS.	[de Flon, Pierre; Laurell, Katarina; Dring, Ann; Sundstrom, Peter; Svenningsson, Anders] Umea Univ, Dept Pharmacol & Clin Neurosci, Neurol, Umea, Sweden; [Soderstrom, Lars] Ostersund Hosp, Unit Res Educ & Dev, Osersund, Region Jamtland, Sweden; [Gunnarsson, Martin] Orebro Univ, Fac Med & Hlth, Dept Neurol, Orebro, Sweden; [Svenningsson, Anders] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden	Umea University; Orebro University; Danderyds Hospital; Karolinska Institutet	de Flon, P (corresponding author), Umea Univ, Dept Pharmacol & Clin Neurosci, Neurol, Umea, Sweden.	pierre.deflon@regionjh.se		Laurell, Katarina/0000-0002-7504-8354; Svenningsson, Anders/0000-0003-0663-2220	County Councils of Vasterbotten, Jamtland/Harjedalen and Orebro; Unit of Research, Education and Development, Region Jamtland Harjedalen [JLL-379731, JLL-649011, JLL 467731]; Syskonen Perssons Donationsfond [JLL-467381, JLL-652541]	County Councils of Vasterbotten, Jamtland/Harjedalen and Orebro; Unit of Research, Education and Development, Region Jamtland Harjedalen; Syskonen Perssons Donationsfond	This study was funded by The County Councils of Vasterbotten, Jamtland/Harjedalen and Orebro, https://www.vll.se/, http://www.regionih. se/,https://www.regienorebrolan.se/; Unit of Research, Education and Development, Region Jamtland Harjedalen (JLL-379731, JLL-649011, JLL 467731), http://www.researchweb.org/is/jll; Syskonen Perssons Donationsfond (JLL-467381, JLL-652541), http://www.researchweb.org/is/jll. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; Bittner S, 2017, THER ADV NEUROL DISO, V10, P51, DOI 10.1177/1756285616666741; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Burman J, 2014, J NEUROIMMUNOL, V277, P153, DOI 10.1016/j.jneuroim.2014.10.005; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; de Flon P, 2016, NEUROLOGY, V87, P141, DOI 10.1212/WNL.0000000000002832; Guerrero-Garcia JD, 2016, NEUROIMMUNOMODULAT, V23, P8, DOI 10.1159/000441004; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hawker K, 2009, ANN NEUROL, V66, P460, DOI 10.1002/ana.21867; Kothur K, 2016, CYTOKINE, V77, P227, DOI 10.1016/j.cyto.2015.10.001; Larsson A, 2015, J IMMUNOL METHODS, V425, P58, DOI 10.1016/j.jim.2015.06.009; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Mellergard J, 2010, MULT SCLER J, V16, P208, DOI 10.1177/1352458509355068; Moynes DM, 2014, BRAIN BEHAV IMMUN, V41, P1, DOI 10.1016/j.bbi.2014.03.004; Naismith RT, 2010, NEUROLOGY, V74, P1860, DOI 10.1212/WNL.0b013e3181e24373; Piccio L, 2010, ARCH NEUROL-CHICAGO, V67, P707, DOI 10.1001/archneurol.2010.99; Segal BM, 2008, LANCET NEUROL, V7, P796, DOI 10.1016/S1474-4422(08)70173-X; Studer V, 2014, J NEUROIMMUNOL, V276, P229, DOI 10.1016/j.jneuroim.2014.08.617; Sun L, 2015, CYTOKINE, V75, P249, DOI 10.1016/j.cyto.2015.01.030; Topping J, 2016, MULT SCLER RELAT DIS, V6, P49, DOI 10.1016/j.msard.2016.01.001; Luu VP, 2014, AUTOIMMUNITY, V47, P1, DOI 10.3109/08916934.2013.856006; Vazirinejad R, 2014, NEUROIMMUNOMODULAT, V21, P322, DOI 10.1159/000357780	23	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2018	13	2							e0192516	10.1371/journal.pone.0192516	http://dx.doi.org/10.1371/journal.pone.0192516			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV4BG	29420590	Green Submitted, gold, Green Published			2023-01-03	WOS:000424517900086
J	Cannon, JW				Cannon, Jeremy W.			Hemorrhagic Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOVASCULAR BALLOON OCCLUSION; DAMAGE CONTROL RESUSCITATION; MASSIVE TRANSFUSION; PLATELET DYSFUNCTION; HYPOTENSIVE PATIENTS; FLUID RESUSCITATION; BRAIN-INJURY; OXYGEN DEBT; TRAUMA; MORTALITY		[Cannon, Jeremy W.] Univ Penn, Perelman Sch Med, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA; [Cannon, Jeremy W.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD USA	University of Pennsylvania; Pennsylvania Medicine; Uniformed Services University of the Health Sciences - USA	Cannon, JW (corresponding author), Div Traumatol Surg Crit Care & Emergency Surg, 51 N 39th St,Med Off Bldg 120, Philadelphia, PA 19104 USA.	jeremy.cannon@uphs.upenn.edu	Cannon, Jeremy/T-3875-2019; Kox, Matthijs/L-4454-2015	Cannon, Jeremy/0000-0002-2969-9316; 				Achneck HE, 2010, ANN SURG, V251, P217, DOI 10.1097/SLA.0b013e3181c3bcca; American College of Surgeons Committee on Trauma, 2012, ADV TRAUM LIF SUPP A, P69; [Anonymous], COCHRANE DATABASE SY; Barbee RW, 2010, SHOCK, V33, P113, DOI 10.1097/SHK.0b013e3181b8569d; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Brown LM, 2011, J TRAUMA, V71, pS337, DOI 10.1097/TA.0b013e318227f67c; Bulger EM, 2014, PREHOSP EMERG CARE, V18, P163, DOI 10.3109/10903127.2014.896962; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Callcut RA, 2013, J TRAUMA ACUTE CARE, V74, P59, DOI 10.1097/TA.0b013e3182788b34; Cannon JW, 2017, J TRAUMA ACUTE CARE, V82, P605, DOI 10.1097/TA.0000000000001333; Carson JL, 2017, NEW ENGL J MED, V377, P1261, DOI 10.1056/NEJMra1612789; Champion HR, 2016, J TRAUMA ACUTE CARE, V81, P420, DOI 10.1097/TA.0000000000001124; Chang R, 2016, BLOOD, V128, P1043, DOI 10.1182/blood-2016-01-636423; CHAUDRY IH, 1983, AM J PHYSIOL, V245, pR117, DOI 10.1152/ajpregu.1983.245.2.R117; Chovanes J, 2012, SURG CLIN N AM, V92, P859, DOI 10.1016/j.suc.2012.04.002; Christensen Steffen, 2007, BMC Geriatr, V7, P8, DOI 10.1186/1471-2318-7-8; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; Cotton BA, 2009, J TRAUMA, V67, P389, DOI 10.1097/TA.0b013e3181a8b26f; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Etchill EW, 2017, CRIT CARE MED, V45, P1311, DOI 10.1097/CCM.0000000000002498; Fortuna G, 2016, J TRAUMA ACUTE CARE, V81, P63, DOI 10.1097/TA.0000000000000996; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Gralnek IM, 2017, NEW ENGL J MED, V376, P1054, DOI 10.1056/NEJMcp1603455; Halmin M, 2016, CRIT CARE MED, V44, P468, DOI 10.1097/CCM.0000000000001410; HIRSHBERG A, 1995, J TRAUMA, V39, P225, DOI 10.1097/00005373-199508000-00007; Hoffman M, 2013, TRANSFUSION, V53, P1594, DOI 10.1111/trf.12201; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Hunt BJ, 2014, NEW ENGL J MED, V370, P847, DOI 10.1056/NEJMra1208626; Hutchings S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010893; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Johansson PI, 2017, ANN SURG, V265, P597, DOI 10.1097/SLA.0000000000001751; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kotwal RS, 2016, JAMA SURG, V151, P15, DOI 10.1001/jamasurg.2015.3104; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Laine L, 2017, GASTROINTEST ENDOSC, V86, P1028, DOI 10.1016/j.gie.2017.03.1549; Laine L, 2016, NEW ENGL J MED, V374, P2367, DOI 10.1056/NEJMcp1514257; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; MacKay EJ, 2017, ANESTH ANALG, V125, P895, DOI 10.1213/ANE.0000000000002312; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Maier RV, 2014, J AM COLL SURGEONS, V219, P335, DOI 10.1016/j.jamcollsurg.2014.04.011; Mannucci PM, 2007, NEW ENGL J MED, V356, P2301, DOI 10.1056/NEJMra067742; Meizoso JP, 2016, J TRAUMA ACUTE CARE, V81, P685, DOI 10.1097/TA.0000000000001198; Meyer DE, 2017, J TRAUMA ACUTE CARE, V83, P19, DOI 10.1097/TA.0000000000001531; Mitra B, 2014, SHOCK, V42, P307, DOI 10.1097/SHK.0000000000000219; Moore HB, 2016, J AM COLL SURGEONS, V222, P347, DOI 10.1016/j.jamcollsurg.2016.01.006; Morrison JJ, 2016, J TRAUMA ACUTE CARE, V80, P324, DOI 10.1097/TA.0000000000000913; Nadler R, 2014, SHOCK, V42, P93, DOI 10.1097/SHK.0000000000000178; National Academies of Sciences Engineering and Medicine, 2016, NAT TRAUM CAR SYST I; Norton R, 2013, NEW ENGL J MED, V368, P1723, DOI 10.1056/NEJMra1109343; Pusateri AE, 2016, TRANSFUSION, V56, pS128, DOI 10.1111/trf.13580; Rasmussen TE, 2016, NEW ENGL J MED, V375, P1612, DOI 10.1056/NEJMp1607636; Raux M, 2015, J VASC SURG, V61, P304, DOI 10.1016/j.jvs.2014.07.098; Rozycki GS, 1998, ANN SURG, V228, P557, DOI 10.1097/00000658-199810000-00012; Ruseckaite R, 2017, VOX SANG, V112, P240, DOI 10.1111/vox.12487; Russo RM, 2016, J AM COLL SURGEONS, V223, P359, DOI 10.1016/j.jamcollsurg.2016.04.037; Salhab M, 2006, VASCULAR, V14, P38, DOI 10.2310/6670.2006.00011; Schochl H, 2014, ANESTH ANALG, V119, P1064, DOI 10.1213/ANE.0b013e318270a6f7; Schroll R, 2015, J TRAUMA ACUTE CARE, V79, P10, DOI 10.1097/TA.0000000000000689; Shackelford SA, 2017, JAMA-J AM MED ASSOC, V318, P1581, DOI 10.1001/jama.2017.15097; Shafi S, 2016, J TRAUMA ACUTE CARE, V81, P780, DOI 10.1097/TA.0000000000001161; Shokoohi H, 2015, CRIT CARE MED, V43, P2562, DOI 10.1097/CCM.0000000000001285; Sihler KC, 2010, CHEST, V137, P209, DOI 10.1378/chest.09-0252; Singletary EM, 2015, CIRCULATION, V132, pS574, DOI 10.1161/CIR.0000000000000269; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Spann AP, 2016, BIOPHYS J, V111, P577, DOI 10.1016/j.bpj.2016.06.024; Spinella PC, 2016, CURR OPIN HEMATOL, V23, P536, DOI 10.1097/MOH.0000000000000284; Tesoriero RB, 2017, J TRAUMA ACUTE CARE, V82, P18, DOI 10.1097/TA.0000000000001259; Tisherman SA, 2017, J TRAUMA ACUTE CARE, V83, P803, DOI 10.1097/TA.0000000000001585; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Tompkins RG, 2015, J TRAUMA ACUTE CARE, V78, P671, DOI 10.1097/TA.0000000000000568; Wandling MW, 2016, J TRAUMA ACUTE CARE, V81, P931, DOI 10.1097/TA.0000000000001228; White NJ, 2017, J TRAUMA ACUTE CARE, V82, pS41, DOI 10.1097/TA.0000000000001436; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Yazer MH, 2016, J TRAUMA ACUTE CARE, V81, P21, DOI 10.1097/TA.0000000000001100; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	79	274	303	12	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2018	378	4					370	379		10.1056/NEJMra1705649	http://dx.doi.org/10.1056/NEJMra1705649			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT5ZX	29365303				2023-01-03	WOS:000423233400009
J	Hruby, LA; Pittermann, A; Sturma, A; Aszmann, OC				Hruby, Laura Antonia; Pittermann, Anna; Sturma, Agnes; Aszmann, Oskar Christian			The Vienna psychosocial assessment procedure for bionic reconstruction in patients with global brachial plexus injuries	PLOS ONE			English	Article							QUALITY-OF-LIFE; AVULSION INJURY; LESIONS; SURGERY; DEAFFERENTATION; PLEXOPATHIES; SATISFACTION; VALIDATION; OUTCOMES; REPAIR	Background Global brachial plexopathies cause major sensory and motor deficits in the affected arm and hand. Many patients report of psychosocial consequences including chronic pain, decreased self-sufficiency, and poor body image. Bionic reconstruction, which includes the amputation and prosthetic replacement of the functionless limb, has been shown to restore hand function in patients where classic reconstructions have failed. Patient selection and psychological evaluation before such a life-changing procedure are crucial for optimal functional outcomes. In this paper we describe a psychosocial assessment procedure for bionic reconstruction in patients with complete brachial plexopathies and present psychosocial outcome variables associated with bionic reconstruction. Methods Between 2013 and 2017 psychosocial assessments were performed in eight patients with global brachial plexopathies. We conducted semi-structured interviews exploring the psychosocial adjustment related to the accident, the overall psychosocial status, as well as motivational aspects related to an anticipated amputation and expectations of functional prosthetic outcome. During the interview patients were asked to respond freely. Their answers were transcribed verbatim by the interviewer and analyzed afterwards on the basis of a pre-defined item scoring system. The interview was augmented by quantitative evaluation of self-reported mental health and social functioning (SF-36 Health Survey), body image (FKB-20) and deafferentation pain (VAS). Additionally, psychosocial outcome variables were presented for seven patients before and after bionic reconstruction. Results Qualitative data revealed several psychological stressors with long-term negative effects on patients with complete brachial plexopathies. 88% of patients felt functionally limited to a great extent due to their disability, and all of them reported constant, debilitating pain in the deafferented hand. After bionic reconstruction the physical component summary scale increased from 30.80 +/- 5.31 to 37.37 +/- 8.41 (p-value = 0.028), the mental component summary scale improved from 43.19 +/- 8.32 to 54.76 +/- 6.78 (p-value = 0.018). VAS scores indicative of deafferentation pain improved from 7.8 to 5.6 after prosthetic hand replacement (p-value = 0.018). Negative body evaluation improved from 60.71 +/- 12.12 to 53.29 +/- 11.03 (p-value = 0.075). Vital body dynamics increased from 38.57 +/- 13.44 to 44.43 +/- 16.15 (p-value = 0.109). Conclusions Bionic reconstruction provides hope for patients with complete brachial plexopathies who have lived without hand function for years or even decades. Critical patient selection is crucial and the psychosocial assessment procedure including a semi-structured interview helps identify unresolved psychological issues, which could preclude or delay bionic reconstruction. Bionic reconstruction improves overall quality of life, restores an intact self-image and reduces deafferentation pain.	[Hruby, Laura Antonia; Sturma, Agnes; Aszmann, Oskar Christian] Med Univ Vienna, Div Plast & Reconstruct Surg, Dept Surg, Christian Doppler Lab Restorat Extrem Funct, Vienna, Austria; [Pittermann, Anna] Gen Hosp Vienna, Dept Clin Psychol, Vienna, Austria; [Pittermann, Anna; Aszmann, Oskar Christian] Med Univ Vienna, Div Plast & Reconstruct Surg, Dept Surg, Vienna, Austria; [Sturma, Agnes] Univ Appl Sci, Hlth Assisting Engn, FH Campus, Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Aszmann, OC (corresponding author), Med Univ Vienna, Div Plast & Reconstruct Surg, Dept Surg, Christian Doppler Lab Restorat Extrem Funct, Vienna, Austria.; Aszmann, OC (corresponding author), Med Univ Vienna, Div Plast & Reconstruct Surg, Dept Surg, Vienna, Austria.	oskar.aszmann@meduniwien.ac.at	Sturma, Agnes/AAO-1489-2021	Sturma, Agnes/0000-0003-2066-1394; Aszmann, Oskar/0000-0001-5530-726X	Christian Doppler Research Foundation of the Austrian Federal Ministry of Science, Research and Economy	Christian Doppler Research Foundation of the Austrian Federal Ministry of Science, Research and Economy	This work was supported by the Christian Doppler Research Foundation of the Austrian Federal Ministry of Science, Research and Economy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALNOT JY, 1995, HAND CLIN, V11, P623; ASZMANN O., 2015, LANCET; Beisteiner R, 2011, ARCH NEUROL-CHICAGO, V68, P1467, DOI 10.1001/archneurol.2011.596; Berman JS, 1998, PAIN, V75, P199, DOI 10.1016/S0304-3959(97)00220-0; Bertelli JA, 2011, J BRACHIAL PLEX PERI, V6, DOI 10.1186/1749-7221-6-2; Bertelli JA, 2010, J HAND SURG-AM, V35A, P1640, DOI 10.1016/j.jhsa.2010.06.019; BIRCH R, 1984, BRIT J HOSP MED, V32, P140; Breznikar B, 2009, J INT MED RES, V37, P1632, DOI 10.1177/147323000903700543; Carlstedt T, 2008, RESTOR NEUROL NEUROS, V26, P225; Choi PD, 1997, J HAND SURG-AM, V22A, P605, DOI 10.1016/S0363-5023(97)80116-5; Clement U, 1996, PSYCHOTHER PSYCH MED, V46, P254; Duerinckx N, 2014, TRANSPL INT, V27, P2, DOI 10.1111/tri.12154; Flor Herta, 2008, Expert Rev Neurother, V8, P809, DOI 10.1586/14737175.8.5.809; Franzblau L, 2015, DISABIL REHABIL, V37, P135, DOI 10.3109/09638288.2014.911971; Franzblau LE, 2014, J HAND SURG-AM, V39, P948, DOI 10.1016/j.jhsa.2014.01.022; Gallagher P, 1999, BEHAV MED, V25, P117, DOI 10.1080/08964289909596741; Guenot M, 2002, J NEUROSURG, V97, P1402, DOI 10.3171/jns.2002.97.6.1402; Hruby LA, 2017, J NEUROSURG, V127, P1163, DOI 10.3171/2016.6.JNS16154; Htut M, 2006, J HAND SURG-BRIT EUR, V31B, P596, DOI 10.1016/j.jhsb.2006.04.027; Kersten P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099485; Kim DH, 2003, J NEUROSURG, V98, P1005, DOI 10.3171/jns.2003.98.5.1005; Kretschmer T, 2009, NEUROSURGERY, V65, pA189, DOI 10.1227/01.NEU.0000335646.31980.33; Kumnig M., 2012, TRANSPLANT INTERNATI; Kumnig M, 2014, TRANSPL INT, V27, P417, DOI 10.1111/tri.12220; Liu Y, 2012, J HAND SURG-EUR VOL, V37E, P413, DOI 10.1177/1753193411425330; LOESER JD, 1968, J NEUROSURG, V29, P48, DOI 10.3171/jns.1968.29.1.0048; Lowe B, 1996, DIAGNOSTICA, V42, P352; Moran SL, 2005, HAND CLIN, V21, P13, DOI 10.1016/j.hcl.2004.09.004; Papachristou C, 2010, ACTA GASTRO-ENT BELG, V73, P383; Salminger S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162507; Terzis JK, 2000, PLAST RECONSTR SURG, V106, P1097, DOI 10.1097/00006534-200010000-00022; Terzis Julia K, 2010, Hand (N Y), V5, P160, DOI 10.1007/s11552-009-9223-6; Terzis JK, 2010, ANN PLAS SURG, V65, P312, DOI 10.1097/SAP.0b013e3181cbfe9d; Ware Jr JE, 1993, SF 36 HEALTH SURVEY; Wellington B, 2010, INT J ORTHOP TRAUMA, V14, P5, DOI 10.1016/j.joon.2009.07.046	35	11	12	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2018	13	1							e0189592	10.1371/journal.pone.0189592	http://dx.doi.org/10.1371/journal.pone.0189592			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FR6OK	29298304	Green Published, gold, Green Submitted			2023-01-03	WOS:000419185200014
J	Melamed, A; Fink, G; Wright, AA; Keating, NL; Gockley, AA; del Carmen, MG; Schorge, JO; Rauh-Hain, JA				Melamed, Alexander; Fink, Gunther; Wright, Alexi A.; Keating, Nancy L.; Gockley, Allison A.; del Carmen, Marcela G.; Schorge, John O.; Rauh-Hain, J. Alejandro			Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REGRESSION DISCONTINUITY DESIGNS; PRIMARY CYTOREDUCTIVE SURGERY; ADVANCED-STAGE OVARIAN; DEBULKING SURGERY; SURVIVAL; TRIAL; WOMEN	OBJECTIVE To estimate the causal effect of increased use of neoadjuvant chemotherapy (NACT) on all cause mortality in advanced epithelial ovarian cancer. DESIGN Quasi-experimental fuzzy regression discontinuity design and cross sectional analysis. SETTING Cancer programs throughout the United States accredited by the Commission on Cancer. PARTICIPANTS 6034 women with a diagnosis of stage 3C or 4 epithelial ovarian cancer from regions that rapidly adopted use of NACT from 2011 to 2012 (27% increase in the New England and east south central regions) or remained unchanged (control regions, south Atlantic, west north central, and east north central regions). MAIN OUTCOME MEASURE All cause mortality within three years of diagnosis. Kaplan-Meier curves and proportional hazard models were estimated to compare mortality differences between rapidly adopting regions and controls. RESULTS 1156 women were treated for advanced epithelial ovarian cancer during 2011 and 2012 in the two rapidly adopting regions and 4878 women in the three control regions. In the rapidly adopting regions, patients treated in 2012 compared with 2011 had a mortality hazard ratio of 0.81 (95% confidence interval 0.71 to 0.94) after adjusting for mortality time trends, whereas no difference was observed in control regions (1.02, 0.93 to 1.12). Compared with control regions, larger declines in 90 day surgical mortality (7.0% to 4.0% v 5.0% to 4.3%, P=0.01) and in the proportion of women not receiving surgery and chemotherapy (20.0% to 17.4% v 19.0 to 19.5%, P=0.04) were observed in rapidly adopting regions. Cross sectional analysis confirmed that treatment in regions with greater use of NACT was associated was lower mortality (P=0.001). CONCLUSIONS Adoption of NACT for advanced epithelial ovarian cancer in New England and east south central regions led to a sizable reduction in mortality within three years after diagnosis.	[Melamed, Alexander; del Carmen, Marcela G.; Schorge, John O.] Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA; [Fink, Gunther] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA; [Wright, Alexi A.] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA; [Keating, Nancy L.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Gockley, Allison A.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA; [Rauh-Hain, J. Alejandro] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Texas System; UTMD Anderson Cancer Center	Melamed, A (corresponding author), Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.	alexander.melamed@mgh.harvard.edu	Wright, Alexi/T-5793-2019; Melamed, Alexander/R-8299-2019; Keating, Nancy L/I-9968-2019	Melamed, Alexander/0000-0002-0654-0863; Keating, Nancy L/0000-0002-8274-4681	National Cancer Institute at the National Institutes of Health [R25CA092203, K24CA181510, K07CA166210]; Deborah Kelly Center for Outcome Research at Massachusetts General Hospital; NATIONAL CANCER INSTITUTE [K07CA166210, K24CA181510, R25CA092203] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deborah Kelly Center for Outcome Research at Massachusetts General Hospital; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute at the National Institutes of Health (R25CA092203 JAR-H, K24CA181510 NLK, and K07CA166210 AAW), and the Deborah Kelly Center for Outcome Research at Massachusetts General Hospital. The funders had no role in the design and execution of this study.	Bor J, 2014, EPIDEMIOLOGY, V25, P729, DOI 10.1097/EDE.0000000000000138; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chi DS, 2012, GYNECOL ONCOL, V124, P10, DOI 10.1016/j.ygyno.2011.08.014; Chi DS, 2011, J CLIN ONCOL, V29, P4073, DOI 10.1200/JCO.2011.35.9935; Fagotti A, 2016, EUR J CANCER, V59, P22, DOI 10.1016/j.ejca.2016.01.017; Hausman C, 2017, NBER WORKING PAPER S; Imbens GW, 2008, J ECONOMETRICS, V142, P615, DOI 10.1016/j.jeconom.2007.05.001; Kehoe S, 2015, LANCET, V386, P249, DOI 10.1016/S0140-6736(14)62223-6; Lee DS, 2010, J ECON LIT, V48, P281, DOI 10.1257/jel.48.2.281; Melamed A, 2016, GYNECOL ONCOL, V143, P236, DOI 10.1016/j.ygyno.2016.09.002; Meyer LA, 2016, J CLIN ONCOL, V34, P3854, DOI 10.1200/JCO.2016.68.1239; Mueller JJ, 2016, GYNECOL ONCOL, V140, P436, DOI 10.1016/j.ygyno.2016.01.008; O'Keeffe AG, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5293; Rauh-Hain JA, 2017, JAMA ONCOL, V3, P76, DOI 10.1001/jamaoncol.2016.4411; Raval MV, 2009, J SURG ONCOL, V99, P488, DOI 10.1002/jso.21173; Rosen B, 2014, GYNECOL ONCOL, V134, P462, DOI 10.1016/j.ygyno.2014.07.004; Terza JV, 2008, J HEALTH ECON, V27, P531, DOI 10.1016/j.jhealeco.2007.09.009; Thrall MM, 2011, OBSTET GYNECOL, V118, P537, DOI 10.1097/AOG.0b013e31822a6d56; Vergote I, 2011, J CLIN ONCOL, V29, P4076, DOI 10.1200/JCO.2011.36.9785; Vergote I, 2010, NEW ENGL J MED, V363, P943, DOI 10.1056/NEJMoa0908806; Vergote IB, 2016, J CLIN ONCOL, V34, P3827, DOI 10.1200/JCO.2016.69.7458; Wright AA, 2016, GYNECOL ONCOL, V143, P3, DOI 10.1016/j.ygyno.2016.05.022; Wright JD, 2014, CANCER-AM CANCER SOC, V120, P1246, DOI 10.1002/cncr.28508	23	20	20	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2018	360								j5463	10.1136/bmj.j5463	http://dx.doi.org/10.1136/bmj.j5463			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FS3UP	29298771	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000419709400004
J	Abbasi, J				Abbasi, Jennifer			Emergency Department Opioid Misuse Diagnoses Increasing in Adolescents and Young Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	4	4	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 26	2017	318	24					2416	2417		10.1001/jama.2017.16586	http://dx.doi.org/10.1001/jama.2017.16586			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ9ZO	29214309				2023-01-03	WOS:000418720700002
J	Heaf, J; Petersons, A; Vernere, B; Heiro, M; Povlsen, JV; Sorensen, AB; Rosenberg, M; Lokkegaard, N; Alonso-Garcia, F; Kampmann, JD; Clyne, N; Randers, E; Heimburger, O; Lindholm, B				Heaf, James; Petersons, Aivars; Vernere, Baiba; Heiro, Maija; Povlsen, Johan V.; Sorensen, Anette Bagger; Rosenberg, Mai; Lokkegaard, Niels; Alonso-Garcia, Fabiola; Kampmann, Jan Dominik; Clyne, Naomi; Randers, Else; Heimburger, Olof; Lindholm, Bengt			Why do physicians prescribe dialysis? A prospective questionnaire study	PLOS ONE			English	Article							STAPHYLOCOCCUS-AUREUS BACTEREMIA; HEMODIALYSIS-PATIENTS; INITIATION; SURVIVAL; START; COMORBIDITY; MORTALITY; OUTCOMES; DISEASE; COHORT	Introduction The incidence of unplanned dialysis initiation (DI) with consequent increased comorbidity, mortality and reduced modality choice remains high, but the optimal timing of dialysis initiation (DI) remains controversial, and there is a lack of studies of specific reasons for DI. We investigated why and when physicians prescribe dialysis and hypothesized that physician motivation for DI is an independent factor which may have clinical consequences. Methods In the Peridialysis study, an ongoing multicenter prospective study assessing the causes and timing of DI and consequences of unplanned dialysis, physicians in 11 hospitals were asked to describe their primary, secondary and further reasons for prescribing DI. The stated reasons for DI were analyzed in relation to clinical and biochemical data at DI, and characteristics of physicians. Results In 446 patients (median age 67 years; 38% females; diabetes 25.6%), DI was prescribed by 84 doctors who stated 23 different primary reasons for DI. The primary indication was clinical in 63% and biochemical in 37%; 23% started for life-threatening conditions. Reduced renal function accounted for only 19% of primary reasons for DI but was a primary or contributing reason in 69%. The eGFR at DI was 7.2 +/- 3.4 ml/min/1.73 m(2), but varied according to comorbidity and cause of DI. Patients with cachexia, anorexia and pulmonary stasis (34% with heart failure) had the highest eGFR (8.2 +/- 9.8 ml/min/1.73 m(2)), and those with edema, "low GFR", and acidosis, the lowest (4.6 +/- 6.1 ml/min/1.73 m(2)). Patients with multiple comorbidity including diabetes started at a high eGFR (8.7 ml/min/1.73 m(2)). Physician experience played a role in dialysis prescription. Non-specialists were more likely to prescribe dialysis for life-threatening conditions, while older and more experienced physicians were more likely to start dialysis for clinical reasons, and at a lower eGFR. Female doctors started dialysis at a higher eGFR than males (8.0 vs. 7.1 ml/min/1.73 m(2)). Conclusions DI was prescribed mainly based on clinical reasons in accordance with current recommendations while low renal function accounted for only 19% of primary reasons for DI. There are considerable differences in physicians A stated motivations for DI, related to their age, clinical experience and interpretation of biochemical variables. These differences may be an independent factor in the clinical treatment of patients, with consequences for the risk of unplanned DI.	[Heaf, James] Zealand Univ Hosp, Dept Med, Roskilde, Denmark; [Petersons, Aivars; Vernere, Baiba] P Stradins Univ Hosp, Riga, Latvia; [Heiro, Maija] Univ Hosp Turku, Turku, Finland; [Povlsen, Johan V.; Sorensen, Anette Bagger] Aarhus Univ Hosp, Dept Nephrol, Aarhus, Denmark; [Rosenberg, Mai] Univ Hosp Tartu, Tartu, Estonia; [Lokkegaard, Niels] Holbaek Cent Hosp, Dept Med, Holbaek, Denmark; [Alonso-Garcia, Fabiola; Kampmann, Jan Dominik] Hosp Southern Jutland, Dept Nephrol, Sonderborg, Denmark; [Clyne, Naomi] Skane Univ Hosp, Dept Nephrol Lund, Clin Sci Lund, Lund, Sweden; [Clyne, Naomi] Lund Univ, Lund, Sweden; [Randers, Else] Viborg Reg Hosp, Dept Med, Viborg, Denmark; [Heimburger, Olof; Lindholm, Bengt] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden	Pauls Stradins Clinical University Hospital; University of Turku; Aarhus University; Holbaek Hospital; Lund University; Skane University Hospital; Lund University; Aarhus University; Karolinska Institutet	Heaf, J (corresponding author), Zealand Univ Hosp, Dept Med, Roskilde, Denmark.	heaf@dadlnet.dk	Kampmann, Jan/GNW-6067-2022; Petersons, Aivars/AAO-3945-2020; Lindholm, Bengt/P-1334-2017	Kampmann, Jan/0000-0002-8844-8242; Heimburger, Olof/0000-0003-0901-4145; Lindholm, Bengt/0000-0003-4269-4293; Petersons, Aivars/0000-0001-8109-1968	Baxter Healthcare International [14CECPDEU1001]; Baxter Healthcare, Deerfield, Illinois, USA; Baxter Healthcare; Baxter Healthcare Corporation	Baxter Healthcare International; Baxter Healthcare, Deerfield, Illinois, USA; Baxter Healthcare; Baxter Healthcare Corporation	This study was supported by an unrestricted grant 14CECPDEU1001 from Baxter Healthcare International. Baxter Novum is the result of a grant from Baxter Healthcare Corporation to Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, to support research activities at Karolinska Institutet to promote the understanding and treatment of renal disease. Bengt Lindholm is employed by Baxter Healthcare Corporation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.; We thank all physicians and other staff members who participated in this study. The project was supported by an unrestricted grant from Baxter Healthcare, Deerfield, Illinois, USA. Baxter Novum is the result of a grant from Baxter Healthcare to Karolinska Institutet.	Beddhu S, 2003, J AM SOC NEPHROL, V14, P2366, DOI 10.1097/01.ASN.0000083905.72794.E6; Beddhu S, 2003, J AM SOC NEPHROL, V14, P1000, DOI 10.1097/01.ASN.0000057856.88335.DD; Clark WF, 2011, CAN MED ASSOC J, V183, P47, DOI 10.1503/cmaj.100349; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Crews DC, 2010, NEPHRON CLIN PRACT, V114, pC19, DOI 10.1159/000245066; Curtis BM, 2002, CLIN NEPHROL, V58, P282; Da Silva-Gane M, 2012, CLIN J AM SOC NEPHRO, V7, P2002, DOI 10.2215/CJN.01130112; Daugirdas JT, 2015, AM J KIDNEY DIS, V66, P884, DOI 10.1053/j.ajkd.2015.07.015; Engemann JJ, 2005, INFECT CONT HOSP EP, V26, P534, DOI 10.1086/502580; Fysaraki M, 2013, INT J MED SCI, V10, P1632, DOI 10.7150/ijms.6710; Grootendorst DC, 2011, NEPHROL DIAL TRANSPL, V26, P1932, DOI 10.1093/ndt/gfq667; Hwang SJ, 2010, NEPHROL DIAL TRANSPL, V25, P2616, DOI 10.1093/ndt/gfq308; Jones C, 2006, NEPHROL DIAL TRANSPL, V21, P2133, DOI 10.1093/ndt/gfl198; Kazmi WH, 2005, AM J KIDNEY DIS, V46, P887, DOI 10.1053/j.ajkd.2005.08.005; Klevens RM, 2008, SEMIN DIALYSIS, V21, P24, DOI 10.1111/j.1525-139X.2007.00379.x; Lassalle M, 2010, KIDNEY INT, V77, P700, DOI 10.1038/ki.2010.14; Ledebo Ingrid, 2001, Nephrology Dialysis Transplantation, V16, P1132, DOI 10.1093/ndt/16.6.1132; Mendelssohn DC, 2011, NEPHROL DIAL TRANSPL, V26, P2959, DOI 10.1093/ndt/gfq843; Mendelssohn DC, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-22; Nesrallah GE, 2014, CAN MED ASSOC J, V186, P112, DOI 10.1503/cmaj.130363; Nielsen LH, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0740-8; O'Hare AM, 2015, J AM SOC NEPHROL, V26, P1975, DOI 10.1681/ASN.2013050531; Rosansky S, 2011, CLIN J AM SOC NEPHRO, V6, P1222, DOI 10.2215/CJN.09301010; Rosansky SJ, 2013, SEMIN DIALYSIS, V26, P650, DOI 10.1111/sdi.12134; Rosansky SJ, 2009, KIDNEY INT, V76, P257, DOI 10.1038/ki.2009.161; Tamura MK, 2010, AM J KIDNEY DIS, V56, P1117, DOI 10.1053/j.ajkd.2010.08.017; Tattersall J, 2011, NEPHROL DIAL TRANSPL, V26, P2082, DOI 10.1093/ndt/gfr168; van de Luijtgaarden MWM, 2012, AM J KIDNEY DIS, V60, P940, DOI 10.1053/j.ajkd.2012.07.015	28	9	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2017	12	12							e0188309	10.1371/journal.pone.0188309	http://dx.doi.org/10.1371/journal.pone.0188309			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7SY	29261657	Green Published, gold, Green Submitted			2023-01-03	WOS:000418564200007
J	De Silva, NH; Akazawa, T; Wijewardana, V; Inoue, N; Oyamada, M; Ohta, A; Tachibana, Y; Wijesekera, DPH; Kuwamura, M; Nishizawa, Y; Itoh, K; Izawa, T; Hatoya, S; Hasegawa, T; Yamate, J; Inaba, T; Sugiura, K				De Silva, Nadeeka H.; Akazawa, Takashi; Wijewardana, Viskam; Inoue, Norimitsu; Oyamada, Maremichi; Ohta, Atsuko; Tachibana, Yuki; Wijesekera, Daluthgamage Patsy H.; Kuwamura, Mitsuru; Nishizawa, Yasuko; Itoh, Kazuyuki; Izawa, Takeshi; Hatoya, Shingo; Hasegawa, Tetsuya; Yamate, Jyoji; Inaba, Toshio; Sugiura, Kikuya			Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand	PLOS ONE			English	Article							SUPPRESSOR-CELLS; PHASE-II; HEPATOCELLULAR-CARCINOMA; CANCER-IMMUNOTHERAPY; METASTATIC MELANOMA; CLINICAL-TRIAL; BEARING MICE; IFN; CYCLOPHOSPHAMIDE; VACCINATION	Although dendritic cell (DC)-based immunotherapy shows little toxicity, improvements should be necessary to obtain satisfactory clinical outcome. Using interferon-gamma injection along with DCs, we previously obtained significant clinical responses against small or early stage malignant tumors in dogs. However, improvement was necessary to be effective to largely developed or metastatic tumors. To obtain effective methods applicable to those tumors, we herein used a DC-targeting Toll-like receptor ligand, h11c, and examined the therapeutic effects in murine subcutaneous and visceral tumor models and also in the clinical treatment of canine cancers. In murine experiments, most and significant inhibition of tumor growth and extended survival was observed in the group treated with the combination of h11c-activated DCs in combination with interferon-gamma and a cyclooxygenase2 inhibitor. Both monocytic and granulocytic myeloid-derived suppressor cells were significantly reduced by the combined treatment. Following the successful results in mice, the combined treatment was examined against canine cancers, which spontaneously generated like as those in human. The combined treatment elicited significant clinical responses against a nonepithelial malignant tumor and a malignant fibrous histiocytoma. The treatment was also successful against a bone-metastasis of squamous cell carcinoma. In the successful cases, the marked increase of tumor-responding T cells and decrease of myeloid-derived suppressor cells and regulatory T cells was observed in their peripheral blood. Although the combined treatment permitted the growth of lung cancer of renal carcinoma-metastasis, the marked elevated and long-term maintaining of the tumor-responding T cells was observed in the patient dog. Overall, the combined treatment gave rise to emphatic amelioration in DC-based cancer therapy.	[De Silva, Nadeeka H.; Wijewardana, Viskam; Ohta, Atsuko; Tachibana, Yuki; Wijesekera, Daluthgamage Patsy H.; Hatoya, Shingo; Inaba, Toshio; Sugiura, Kikuya] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Adv Pathobiol, Izumisano, Japan; [Akazawa, Takashi; Inoue, Norimitsu] Osaka Int Canc Inst, Dept Tumor Immunol, Osaka, Japan; [Oyamada, Maremichi; Hasegawa, Tetsuya] Kakogawa Anim Hosp, Kakogawa, Hyogo, Japan; [Kuwamura, Mitsuru; Izawa, Takeshi; Yamate, Jyoji] Osaka Prefecture Univ, Dept Integrated Struct Biosci, Grad Sch Life & Environm Sci, Izumisano, Japan; [Nishizawa, Yasuko; Itoh, Kazuyuki] Nozaki Tokushukai, Res Inst, Daito, Japan	Osaka Metropolitan University; Osaka Metropolitan University	Sugiura, K (corresponding author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Dept Adv Pathobiol, Izumisano, Japan.	sugiura@vet.osakafu-u.ac.jp	Hatoya, Shingo/ABE-5457-2020; Hatoya, Shingo/ABE-7060-2020	Hatoya, Shingo/0000-0001-5944-1394; Hatoya, Shingo/0000-0001-5944-1394; Sugiura, Kikuya/0000-0003-3366-237X; Wijewardana, Viskam/0000-0002-5787-8792; Izawa, Takeshi/0000-0003-3236-6050	Japan Society for the Promotion of Science [23380174]; Grants-in-Aid for Scientific Research [15K15560] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grant-in-Aid for Science Research (B) No. 23380174 from the Japan Society for the Promotion of Science, https://www.jsps.go.jp/english/e-grants/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akazawa T, 2004, CANCER RES, V64, P757, DOI 10.1158/0008-5472.CAN-03-1518; Akazawa T, 2007, FEBS LETT, V581, P3334, DOI 10.1016/j.febslet.2007.06.019; Akazawa T, 2014, INT J CANCER, V135, P2847, DOI 10.1002/ijc.28939; Akazawa T, 2010, CANCER SCI, V101, P1596, DOI 10.1111/j.1349-7006.2010.01583.x; Alfaro C, 2011, J IMMUNOL, V187, P6130, DOI 10.4049/jimmunol.1102209; Asai T, 1998, INT J CANCER, V76, P418, DOI 10.1002/(SICI)1097-0215(19980504)76:3<418::AID-IJC21>3.3.CO;2-E; de Rosa F, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-209; Edele F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105266; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Gao DQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093886; Goulart MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033274; Guo QM, 2012, INT IMMUNOPHARMACOL, V12, P425, DOI 10.1016/j.intimp.2011.12.016; Iclozan C, 2013, CANCER IMMUNOL IMMUN, V62, P909, DOI 10.1007/s00262-013-1396-8; Jackson AM, 2008, INT J CANCER, V123, P623, DOI 10.1002/ijc.23530; Kodama K, 2009, SURG TODAY, V39, P194, DOI 10.1007/s00595-008-3826-3; Kohler C, 2007, CELL TISSUE RES, V330, P291, DOI 10.1007/s00441-007-0474-7; Koizumi S, 2012, CELL IMMUNOL, V276, P153, DOI 10.1016/j.cellimm.2012.05.002; Liu CC, 2008, CANCER IMMUNOL IMMUN, V57, P479, DOI 10.1007/s00262-007-0386-0; Matsushita H, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0030-4; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mito K, 2010, CANCER RES, V70, P7093, DOI 10.1158/0008-5472.CAN-10-0600; Mizuno T, 2009, J VET MED SCI, V71, P1561, DOI 10.1292/jvms.001561; Ning YL, 2016, INT J CANCER, V138, P2713, DOI 10.1002/ijc.30002; Ochoa MT, 2003, IMMUNOLOGY, V108, P10, DOI 10.1046/j.1365-2567.2003.01563.x; Oshita C, 2012, ONCOL REP, V28, P1131, DOI 10.3892/or.2012.1956; Palmer DH, 2009, HEPATOLOGY, V49, P124, DOI 10.1002/hep.22626; Ribas A, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-89; Ridolfi L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-135; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Tada F, 2012, INT J ONCOL, V41, P1601, DOI 10.3892/ijo.2012.1626; Toh HC, 2009, CLIN CANCER RES, V15, P7726, DOI 10.1158/1078-0432.CCR-09-1537; Trapani JA, 2001, GENOME BIOL, V2; Yamamoto E, 2010, HISTOL HISTOPATHOL, V25, P995, DOI 10.14670/HH-25.995; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791	35	6	6	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188738	10.1371/journal.pone.0188738	http://dx.doi.org/10.1371/journal.pone.0188738			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190690	Green Published, gold, Green Submitted			2023-01-03	WOS:000416841900113
J	Huang, YK; Yen, CL; Shiu, SI; Lee, SW; Chang, PY; Yeh, HZ; Lee, TY				Huang, Yao-Kuang; Yen, Chieh-Ling; Shiu, Sz-Iuan; Lee, Shou-Wu; Chang, Pi-Yi; Yeh, Hong-Zen; Lee, Teng-Yu			Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINES; TRANSARTERIAL CHEMOEMBOLIZATION; EXTRAHEPATIC METASTASIS; SURVIVAL; DIAGNOSIS; PROGNOSIS; FAILURE	Targeted therapy is currently the standard treatment for advanced hepatocellular carcinoma (HCC), but an effective treatment after the discontinuation of sorafenib therapy remains uncertain. We aim to investigate the survival benefits of transcatheter arterial chemoembolization (TACE) after stopping sorafenib therapy. We retrospectively analyzed all patients with advanced HCC, who had received palliative TACE after terminating sorafenib therapy, from January 2008 to June 2016. Patients who were in the terminal stage (Child-Pugh class C or performance status 3-4), who received a liver transplantation, or who had received any HCC treatment other than TACE, were excluded. Finally, 28 patients were recruited as the TACE group, and were randomly matched 1: 1 by age, gender, Child-Pugh class, extrahepatic metastasis, and portal vein thrombosis with 28 controls who only received supportive care. For avoiding any immortal time bias, the index date of outcome follow-up was also matched. Cumulative incidences of, and hazard ratios (HRs) for, patient mortality were analyzed. The baseline demographic data between the TACE group and the control group were similar, but the 1-year overall survival rate in the TACE group was significantly higher than that of the control group (41.2%, 95% confidence interval [CI]: 19.4-63.0% vs. 24.5%, 95% CI: 6.3-42.7%; p < 0.01). In multivariate analysis, after adjusting for alpha-fetoprotein > 400ng/mL, Child-Pugh class B, and tumor extension > 50% of liver volume, TACE was independently associated with a decreased mortality risk(HR 0.19, 95% CI: 0.08-0.42). In addition, tumor extension > 50% of the liver was another independent prognostic factor associated with an increased mortality risk (HR 2.99, 95% CI: 1.31-6.82). Multivariate stratified analyses verified the association of TACE with a decreased mortality rate in each patient subgroup (all HR < 1.0). By controlling intrahepatic tumor growth, TACE may be a treatment option for use in improving patient survival in advanced HCC, after the termination of sorafenib therapy.	[Huang, Yao-Kuang; Yen, Chieh-Ling; Shiu, Sz-Iuan; Lee, Shou-Wu; Yeh, Hong-Zen; Lee, Teng-Yu] Taichung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung, Taiwan; [Lee, Shou-Wu; Lee, Teng-Yu] Chung Shan Med Univ, Dept Med, Taichung, Taiwan; [Chang, Pi-Yi] Taichung Vet Gen Hosp, Dept Radiol, Taichung, Taiwan	Taichung Veterans General Hospital; Chung Shan Medical University; Taichung Veterans General Hospital	Lee, TY (corresponding author), Taichung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung, Taiwan.; Lee, TY (corresponding author), Chung Shan Med Univ, Dept Med, Taichung, Taiwan.	tylee@vghtc.gov.tw	Huang, Yao-Kuang/AAK-5137-2021; Shiu, Sz-Iuan/AAE-1560-2022; Shiu, Sz-Iuan/AAK-3359-2020; Lee, Teng-Yu/H-4312-2019	Huang, Yao-Kuang/0000-0003-2699-2207; Shiu, Sz-Iuan/0000-0003-4385-5095; Shiu, Sz-Iuan/0000-0003-4385-5095; Lee, Teng-Yu/0000-0002-4097-4315	Taichung Veterans General Hospital, Taiwan [100DHA0500062]	Taichung Veterans General Hospital, Taiwan	This work was supported in part by Taichung Veterans General Hospital (100DHA0500062), Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Georgiades CS, 2005, J VASC INTERV RADIOL, V16, P1653, DOI 10.1097/01.RVI.0000182185.47500.7A; Giannini EG, 2015, HEPATOLOGY, V61, P184, DOI 10.1002/hep.27443; Jelic S, 2010, ANN ONCOL, V21, pv59, DOI 10.1093/annonc/mdq166; Lee IC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000688; Lee JE, 2014, WORLD J GASTROENTERO, V20, P235, DOI 10.3748/wjg.v20.i1.235; Lee TY, 2016, HEPATOLOGY, V63, P1517, DOI 10.1002/hep.28266; Leng JJ, 2016, ANZ J SURG, V86, P816, DOI 10.1111/ans.12803; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2013, J CLIN ONCOL, V31, P3509, DOI 10.1200/JCO.2012.47.3009; Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001; Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8; Niu ZJ, 2012, MED ONCOL, V29, P2992, DOI 10.1007/s12032-011-0145-0; Ogasawara S, 2011, HEPATOL INT, V5, P850, DOI 10.1007/s12072-010-9249-4; Reig M, 2013, HEPATOLOGY, V58, P2023, DOI 10.1002/hep.26586; Shariff SZ, 2008, J AM SOC NEPHROL, V19, P841, DOI 10.1681/ASN.2007121354; Silva JP, 2017, HPB, V19, P659, DOI 10.1016/j.hpb.2017.04.016; [TACE/TARE/HAI group Local ablation group Surgery group Staging group Diagnosis group Surveillance group], 2017, J FORMOS ME IN PRESS; Tan CH, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/519783; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Uka K, 2007, WORLD J GASTROENTERO, V13, P414, DOI 10.3748/wjg.v13.i3.414; Xue TC, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-60; Yau T, 2012, INVEST NEW DRUG, V30, P2384, DOI 10.1007/s10637-012-9808-8; Yoo DJ, 2011, J GASTROEN HEPATOL, V26, P145, DOI 10.1111/j.1440-1746.2010.06341.x; Yoo JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113926; Zhao Y, 2016, J GASTROINTEST SURG, V20, P2002, DOI 10.1007/s11605-016-3285-x; Zhao Y, 2013, ASIA-PAC J CLIN ONCO, V9, P357, DOI 10.1111/ajco.12081; Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189	32	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188999	10.1371/journal.pone.0188999	http://dx.doi.org/10.1371/journal.pone.0188999			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190692	Green Submitted, Green Published, gold			2023-01-03	WOS:000416841900186
J	Hanigan, IC; Cochrane, T; Davey, R				Hanigan, Ivan C.; Cochrane, Thomas; Davey, Rachel			Impact of scale of aggregation on associations of cardiovascular hospitalization and socioeconomic disadvantage	PLOS ONE			English	Article							DISEASE; INEQUALITIES; MORTALITY	Background There are numerous studies that show an increased incidence of cardiovascular disease with increasing levels of socio-economic disadvantage. Exposures that might influence the relationship include elements of the built environment and social systems that shape lifestyle risk behaviors. In Canberra (the Australian capital city) there has been a particular housing policy to create 'mixed-tenure' neighborhoods so that small pockets of disadvantage are surrounded by more affluent residences (known as a 'salt-and-pepper' pattern). This may contribute to a scatter of higher incidence rates in very small areas in this population that may be obscured if aggregated data are used. This study explored the effect of changing the scale of the spatial units used in small area disease modelling, aiming to understand the impact of this issue and the implications for local public health surveillance. Methods The residence location of hospitalized individuals were aggregated to two differently scaled area units. First, the Australian Bureau of Statistics Statistical Area 2 (SA2) which is normally used as the basis for deidentification and release of health data. Second, these data were aggregated to a smaller level: the Statistical Area 1 (SA1). Generalized Additive Models with penalized regression splines were used to assess the association of age-sex-standardized rates for cardiovascular disease hospital admissions with disadvantage. Results The relationships observed were different between the two types of spatial units. The SA1 level exposure-response curve for rates against the disadvantage index extended in a linear fashion above the midrange level, while that found at SA2-level suggested a curvilinear form with no evidence that rates increased with higher disadvantage beyond the midrange. Conclusion Our result supports findings of other work that has found disadvantage increases risk of cardiovascular disease. The shape of the curves suggest a difference in associations of cardiovascular disease rates with disadvantage scores between SA1 versus SA2. From these results it can be concluded that scale of analysis does influence the understanding of geographical patterns of socio-economic disadvantage and cardiovascular disease morbidity. Health surveillance and interventions in Canberra should take into account the impact of the scale of aggregation on the association between disadvantage and cardiovascular disease observed.	[Hanigan, Ivan C.; Cochrane, Thomas; Davey, Rachel] Univ Canberra, Hlth Res Inst, Ctr Res & Act Publ Hlth, Spatial Epidemiol Grp, Canberra, ACT, Australia; [Hanigan, Ivan C.] Univ Sydney, Sydney Med Sch, Univ Ctr Rural Hlth, Sydney, NSW, Australia	University of Canberra; University of Sydney	Hanigan, IC (corresponding author), Univ Canberra, Hlth Res Inst, Ctr Res & Act Publ Hlth, Spatial Epidemiol Grp, Canberra, ACT, Australia.; Hanigan, IC (corresponding author), Univ Sydney, Sydney Med Sch, Univ Ctr Rural Hlth, Sydney, NSW, Australia.	ivan.hanigan@canberra.edu.au	Cochrane, Tom/M-8588-2015	Cochrane, Tom/0000-0002-6391-2109; Hanigan, Ivan/0000-0002-6360-6793				[Anonymous], 2013, SOC IND AR SEIFA; Australian Bureau of Statistics, 2015, AUSTR BUR STAT 3101; Australian Bureau of Statistics, 2011, CENS 2011 TABLEBUILD; Australian Bureau of Statistics, 2018, AUSTR STAT GEOGR STA; Australian Institute for Health and Welfare, 2011, AUSTR I HLTH WELF HL, V39; Bivand RS, 2008, USE R, P1; Bynum JPW, 2011, HEALTH AFFAIR, V30, P975, DOI 10.1377/hlthaff.2010.1102; Chomistek AK, 2013, J AM COLL CARDIOL, V61, P2346, DOI 10.1016/j.jacc.2013.03.031; Dixon J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6608; Eagleson S, 1999, P 6 S E AS SURV C FR; Fotheringham A, 1991, ENV PLANNING A, V23; Goldie X, 2014, AUST GEOGR, V45, P521, DOI 10.1080/00049182.2014.953737; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Institute of Health Metrics and Evaluation, 2015, GBD PROF AUSTR 2015; Kang SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075957; Kawachi I, 2010, EXPLORATION HLTH DIS; Krieger N, 2003, J EPIDEMIOL COMMUN H, V57, P186, DOI 10.1136/jech.57.3.186; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; Marmot M, 2012, PUBLIC HEALTH, V126, pS4, DOI 10.1016/j.puhe.2012.05.014; Matisziw TC, 2008, COMPUT ENVIRON URBAN, V32, P81, DOI 10.1016/j.compenvurbsys.2007.06.002; Mazumdar S, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012548; Meade M., 2000, MED GEOGRAPHY; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; Openshaw S., 1984, MODIFIABLE AREAL UNI; Pink B, 2013, SOCIO EC INDEXES ARE; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709, DOI 10.1080/10473289.2006.10464545; Reynolds L, 2012, J ROY SOC MED, V105, P7, DOI 10.1258/jrsm.2011.110195; Stallings-Smith S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062063; Stephens AS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013227; Tanton R, 2015, POLICY STUD-UK, V36, P92, DOI 10.1080/01442872.2014.981062; Te Grotenhuis M, 2011, INT J EPIDEMIOL, V40, P1123, DOI 10.1093/ije/dyr081; Turrell G, 2001, INT J EPIDEMIOL, V30, P231, DOI 10.1093/ije/30.2.231; Unal B, 2005, BMJ-BRIT MED J, V331, P614, DOI 10.1136/bmj.38561.633345.8F; Warren TY, 2010, MED SCI SPORT EXER, V42, P879, DOI 10.1249/MSS.0b013e3181c3aa7e; Wood SN, 2008, J R STAT SOC B, V70, P495, DOI 10.1111/j.1467-9868.2007.00646.x; Wrigley N, 1996, SPATIAL ANAL MODELLI, P23; Yu Y, 2017, PREV MED, V99, P134, DOI 10.1016/j.ypmed.2017.02.008	37	2	2	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2017	12	11							e0188161	10.1371/journal.pone.0188161	http://dx.doi.org/10.1371/journal.pone.0188161			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN9ZL	29182618	Green Published, gold, Green Submitted			2023-01-03	WOS:000416402000011
J	Trewin, AJ; Levinger, I; Parker, L; Shaw, CS; Serpiello, FR; Anderson, MJ; McConell, GK; Hare, DL; Stepto, NK				Trewin, Adam J.; Levinger, Itamar; Parker, Lewan; Shaw, Christopher S.; Serpiello, Fabio R.; Anderson, Mitchell J.; McConell, Glenn K.; Hare, David L.; Stepto, Nigel K.			Acute exercise alters skeletal muscle mitochondrial respiration and H2O2 emission in response to hyperinsulinemic-euglycemic clamp in middle-aged obese men	PLOS ONE			English	Article							HIGH-INTENSITY EXERCISE; INSULIN SENSITIVITY; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; TBC1D1 PHOSPHORYLATION; AS160 PHOSPHORYLATION; SIGNALING PATHWAYS; PROTEIN-SYNTHESIS; ATP PRODUCTION; IN-VIVO	Obesity, sedentary lifestyle and aging are associated with mitochondrial dysfunction and impaired insulin sensitivity. Acute exercise increases insulin sensitivity in skeletal muscle; however, whether mitochondria are involved in these processes remains unclear. The aim of this study was to investigate the effects of insulin stimulation at rest and after acute exercise on skeletal muscle mitochondrial respiratory function (JO(2)) and hydrogen peroxide emission (JH(2)O(2)), and the associations with insulin sensitivity in obese, sedentary men. Nine men (means +/- SD: 57 +/- 6 years; BMI 33 +/- 5 kg. m(2)) underwent hyperinsulinemic-euglycemic clamps in two separate trials 1-3 weeks apart: one under resting conditions, and another 1 hour after high-intensity exercise (4x4 min cycling at 95% HRpeak). Muscle biopsies were obtained at baseline, and pre/post clamp to measure JO(2) with high-resolution respirometry and JH(2)O(2) via Amplex UltraRed from permeabilized fibers. Post-exercise, both JO(2) and JH(2)O(2) during ADP stimulated state-3/OXPHOS respiration were lower compared to baseline (P<0.05), but not after subsequent insulin stimulation. JH(2)O(2) was lower post-exercise and after subsequent insulin stimulation compared to insulin stimulation in the rest trial during succinate supported state-4/leak respiration (P<0.05). In contrast, JH(2)O(2) increased during complex-I supported leak respiration with insulin after exercise compared with resting conditions (P<0.05). Resting insulin sensitivity and JH(2)O(2) during complex-I leak respiration were positively correlated (r = 0.77, P<0.05). We conclude that in obese, older and sedentary men, acute exercise modifies skeletal muscle mitochondrial respiration and H2O2 emission responses to hyperinsulinemia in a respiratory state-specific manner, which may have implications for metabolic diseases involving insulin resistance.	[Trewin, Adam J.; Levinger, Itamar; Parker, Lewan; Shaw, Christopher S.; Serpiello, Fabio R.; Anderson, Mitchell J.; McConell, Glenn K.; Stepto, Nigel K.] Victoria Univ, ISEAL, Melbourne, Vic, Australia; [Levinger, Itamar; Stepto, Nigel K.] Victoria Univ, Australian Inst Musculoskeletal Sci AIMSS, St Albans, Australia; [Parker, Lewan; Shaw, Christopher S.] Deakin Univ, Inst Phys Act & Nutr, Sch Exercise & Nutr Sci, Geelong, Vic, Australia; [Hare, David L.] Univ Melbourne, Melbourne, Vic, Australia; [Hare, David L.] Austin Hlth, Dept Cardiol, Melbourne, Vic, Australia; [Stepto, Nigel K.] Monash Univ, MCHRI, Clayton, Vic, Australia; [Stepto, Nigel K.] Monash Hlth, Clayton, Vic, Australia; [Trewin, Adam J.] Univ Rochester, Med Ctr, Dept Anesthesiol & Perioperat Med, Rochester, NY 14642 USA	Victoria University; Victoria University; Deakin University; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University; University of Rochester	Stepto, NK (corresponding author), Victoria Univ, ISEAL, Melbourne, Vic, Australia.; Stepto, NK (corresponding author), Victoria Univ, Australian Inst Musculoskeletal Sci AIMSS, St Albans, Australia.; Stepto, NK (corresponding author), Monash Univ, MCHRI, Clayton, Vic, Australia.; Stepto, NK (corresponding author), Monash Hlth, Clayton, Vic, Australia.	Nigel.Stepto@vu.edu.au	Trewin, Adam/M-1584-2019	Trewin, Adam/0000-0001-7322-4054; McConell, Glenn/0000-0002-8572-9065; Levinger, Itamar/0000-0001-9194-2033; Stepto, Nigel/0000-0002-0875-6836; Parker, Lewan/0000-0002-5372-1851	Victoria University Research Development Grant Scheme; Australian Government through the National Collaborative Research Network Grant Scheme	Victoria University Research Development Grant Scheme; Australian Government through the National Collaborative Research Network Grant Scheme	This research was funded by the Victoria University Research Development Grant Scheme (I.L., D.L.H. and G.K.M.) This funding was from the authors institution and they had no input into study design and data analysis. They have no embargo on publication of results. Two authors received funding to support their salaries to undertake this investigator initiated research. I.L. is a Heart Foundation Future Leader Fellow (ID No.100040). N.K.S. was supported by the Australian Government through the National Collaborative Research Network Grant Scheme.	Amati F, 2009, DIABETES CARE, V32, P1547, DOI 10.2337/dc09-0267; Anderson EJ, 2007, J BIOL CHEM, V282, P31257, DOI 10.1074/jbc.M706129200; Aon MA, 2012, J GEN PHYSIOL, V139, P479, DOI 10.1085/jgp.201210772; Asmann YW, 2006, DIABETES, V55, P3309, DOI 10.2337/db05-1230; Barazzoni R, 2012, AM J PHYSIOL-ENDOC M, V303, pE1117, DOI 10.1152/ajpendo.00067.2012; Brand MD, 2016, CELL METABOLISM; Campbell PT, 2010, MED SCI SPORT EXER, V42, P1448, DOI 10.1249/MSS.0b013e3181cfc908; Chow LS, 2016, DIABETOLOGIA, P1; ConstantinTeodosiu D, 1996, EUR J APPL PHYSIOL, V73, P186, DOI 10.1007/BF00262830; COSTILL DL, 1988, J APPL PHYSIOL, V64, P2245, DOI 10.1152/jappl.1988.64.5.2245; Fabbri E, 2016, DIABETES; Fisher-Wellman Kelsey, 2009, Dyn Med, V8, P1, DOI 10.1186/1476-5918-8-1; Fisher-Wellman KH, 2014, DIABETES, V63, P132, DOI 10.2337/db13-0940; Fisher-Wellman KH, 2012, TRENDS ENDOCRIN MET, V23, P142, DOI 10.1016/j.tem.2011.12.008; Funai K, 2009, AM J PHYSIOL-ENDOC M, V297, pE242, DOI 10.1152/ajpendo.00194.2009; Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013; GOLLNICK PD, 1990, PFLUG ARCH EUR J PHY, V415, P407, DOI 10.1007/BF00373617; Goncalves RLS, 2015, J BIOL CHEM, V290, P209, DOI 10.1074/jbc.M114.619072; Green HJ, 2008, J APPL PHYSIOL, V104, P931, DOI 10.1152/japplphysiol.01151.2007; Hawley JA, 2007, DIABETOLOGIA, V50, P699, DOI 10.1007/s00125-007-0595-2; Henriksen EJ, 2011, FREE RADICAL BIO MED, V51, P993, DOI 10.1016/j.freeradbiomed.2010.12.005; Hickey AJR, 2012, J COMP PHYSIOL B, V182, P91, DOI 10.1007/s00360-011-0599-6; Hordern MD, 2012, J SCI MED SPORT, V15, P25, DOI 10.1016/j.jsams.2011.04.005; Howlett KF, 2008, AM J PHYSIOL-ENDOC M, V294, pE401, DOI 10.1152/ajpendo.00542.2007; Jessen N, 2011, AM J PHYSIOL-ENDOC M, V301, pE164, DOI 10.1152/ajpendo.00042.2011; Konopka AR, 2015, DIABETES, V64, P2104, DOI 10.2337/db14-1701; Kramer PA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00347; Krumschnabel Gerhard, 2015, Methods Mol Biol, V1264, P245, DOI 10.1007/978-1-4939-2257-4_22; Levinger I, 2007, DIABETES CARE, V30, P2205, DOI 10.2337/dc07-0841; Levinger I, 2014, J BONE MINER RES, V29, P2571, DOI 10.1002/jbmr.2285; Loh K, 2009, CELL METAB, V10, P260, DOI 10.1016/j.cmet.2009.08.009; Lundby C, 2005, EUR J APPL PHYSIOL, V95, P351, DOI 10.1007/s00421-005-0022-7; Makrecka-Kuka M, 2015, BIOMOLECULES, V5, P1319, DOI 10.3390/biom5031319; MIKINES KJ, 1988, AM J PHYSIOL, V254, pE248, DOI 10.1152/ajpendo.1988.254.3.E248; Montgomery MK, 2015, ENDOCR CONNECT, V4, DOI 10.1530/EC-14-0092; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Murphy RM, 2013, J PHYSIOL-LONDON, V591, P5823, DOI 10.1113/jphysiol.2013.263251; Ng M, 2014, LANCET, V384, P766, DOI 10.1016/S0140-6736(14)60460-8; Parker L, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00087; Parker L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171613; Parker L, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00411; Perry CGR, 2012, J PHYSIOL-LONDON, V590, P5475, DOI 10.1113/jphysiol.2012.234682; Petersen KF, 2005, PLOS MED, V2, P879, DOI 10.1371/journal.pmed.0020233; Phielix E, 2008, DIABETES, V57, P2943, DOI 10.2337/db08-0391; Powers SK, 2011, J PHYSIOL-LONDON, V589, P2129, DOI 10.1113/jphysiol.2010.201327; Powers SK, 2010, EXP PHYSIOL, V95, P1, DOI 10.1113/expphysiol.2009.050526; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Richter EA, 2013, PHYSIOL REV, V93, P993, DOI 10.1152/physrev.00038.2012; Sakellariou GK, 2013, ANTIOXID REDOX SIGN, V18, P603, DOI 10.1089/ars.2012.4623; Sivitz WI, 2010, ANTIOXID REDOX SIGN, V12, P537, DOI 10.1089/ars.2009.2531; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Stephenson EJ, 2012, J APPL PHYSIOL, V113, P1403, DOI 10.1152/japplphysiol.00788.2012; Stephenson EJ, 2012, AM J PHYSIOL-ENDOC M, V302, pE1541, DOI 10.1152/ajpendo.00590.2011; Stepto NK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053080; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Szendroedi J, 2007, PLOS MED, V4, P858, DOI 10.1371/journal.pmed.0040154; Tiganis T, 2011, TRENDS PHARMACOL SCI, V32, P82, DOI 10.1016/j.tips.2010.11.006; Timpani C. A., 2016, NEUROTHERAPEUTICS, P1; Tonkonogi M, 1998, J PHYSIOL-LONDON, V510, P279, DOI 10.1111/j.1469-7793.1998.279bz.x; Tonkonogi M, 1999, PFLUG ARCH EUR J PHY, V437, P562, DOI 10.1007/s004240050818; Treebak JT, 2009, DIABETOLOGIA, V52, P891, DOI 10.1007/s00125-009-1294-y; Trewin AJ, 2015, AM J PHYSIOL-ENDOC M, V309, pE388, DOI 10.1152/ajpendo.00605.2014; Votion DM, 2010, EQUINE VET J, V42, P268, DOI 10.1111/j.2042-3306.2010.00271.x; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Woo HA, 2010, CELL, V140, P517, DOI 10.1016/j.cell.2010.01.009; Zhao XL, 2014, J PROTEOME RES, V13, P2359, DOI 10.1021/pr401163t; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	67	14	14	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2017	12	11							e0188421	10.1371/journal.pone.0188421	http://dx.doi.org/10.1371/journal.pone.0188421			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN4OQ	29161316	Green Published, gold, Green Accepted			2023-01-03	WOS:000415987000053
J	Fahey, JM; Stancill, JS; Smith, BC; Girotti, AW				Fahey, Jonathan M.; Stancill, Jennifer S.; Smith, Brian C.; Girotti, Albert W.			Nitric oxide antagonism to glioblastoma photodynamic therapy and mitigation thereof by BET bromodomain inhibitor JQ1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						glioblastoma; photodynamic therapy; nitric oxide; nitric-oxide synthase; NF-kB transcription factor; bromodomain-containing protein 4 (BRD4); acetylation	NF-KAPPA-B; MALIGNANT BRAIN-TUMORS; LUNG-CANCER CELLS; 5-AMINOLEVULINIC ACID; UP-REGULATION; IN-VITRO; CONVENTIONAL THERAPIES; SYNTHASE INHIBITION; SELECTIVE INHIBITOR; BREAST-CANCER	Endogenous nitric oxide (NO) generated by inducible NO synthase (iNOS) promotes glioblastoma cell proliferation and invasion and also plays a key role in glioblastoma resistance to chemotherapy and radiotherapy. Non-ionizing photodynamic therapy (PDT) has anti-tumor advantages over conventional glioblastoma therapies. Our previous studies revealed that glioblastoma U87 cells up-regulate iNOS after a photodynamic challenge and that the resulting NO not only increases resistance to apoptosis but renders surviving cells more proliferative and invasive. These findings were largely based on the effects of inhibiting iNOS activity and scavenging NO. Demonstrating now that iNOS expression in photostressed U87 cells is mediated by NF-B, we hypothesized that (i) recognition of acetylated lysine (acK) on NF-B p65/RelA by bromodomain and extra-terminal (BET) protein Brd4 is crucial; and (ii) by suppressing iNOS expression, a BET inhibitor (JQ1) would attenuate the negative effects of photostress. The following evidence was obtained. (i) Like iNOS, Brd4 protein and p65-acK levels increased severalfold in photostressed cells. (ii) JQ1 at minimally toxic concentrations had no effect on Brd4 or p65-acK up-regulation after PDT but strongly suppressed iNOS, survivin, and Bcl-xL up-regulation, along with the growth and invasion spurt of PDT-surviving cells. (iii) JQ1 inhibition of NO production in photostressed cells closely paralleled that of growth/invasion inhibition. (iv) Finally, at 1% the concentration of iNOS inhibitor 1400W, JQ1 reduced post-PDT cell aggressiveness to a far greater extent. This is the first evidence for BET inhibitor targeting of iNOS expression in cancer cells and how such targeting can markedly improve therapeutic efficacy.	[Fahey, Jonathan M.; Stancill, Jennifer S.; Smith, Brian C.; Girotti, Albert W.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Girotti, AW (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	agirotti@mcw.edu	Smith, Brian C/D-9949-2013; Girotti, Albert/AAF-6910-2020	Smith, Brian C/0000-0001-6330-2768; Stancill, Jennifer/0000-0002-1612-4695	National Institutes of Health from NCI [CA70823]; Advancing a Healthier Wisconsin Research and Education Program [5520347]; BSC from the MCW Cancer Center [3308238/9]; American Heart Association Scientist Development Grant [15SDG25830057]; American Cancer Society [14-247-29-IRG, 86-004-26-IRG]; Advancing a Healthier Wisconsin Endowment [5520310]; NATIONAL CANCER INSTITUTE [R01CA070823] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL134643] Funding Source: NIH RePORTER	National Institutes of Health from NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Advancing a Healthier Wisconsin Research and Education Program; BSC from the MCW Cancer Center; American Heart Association Scientist Development Grant(American Heart Association); American Cancer Society(American Cancer Society); Advancing a Healthier Wisconsin Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by National Institutes of Health Grant CA70823 from NCI (to A. W. G.). This work also was supported by Grant 5520347 from the Advancing a Healthier Wisconsin Research and Education Program (to A. W. G.), BSC Grant 3308238/9 from the MCW Cancer Center (to A. W. G.), American Heart Association Scientist Development Grant 15SDG25830057 (to B. C. S.), Institutional Research Grants 14-247-29-IRG and 86-004-26-IRG from the American Cancer Society (to B. C. S.), and Grant 5520310 from the Advancing a Healthier Wisconsin Endowment (to B. C. S.). The authors declare that they have no conflicts of interest with the contents of this publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Akaike T, 1996, METHOD ENZYMOL, V268, P211; Andrieu Guillaume, 2016, Drug Discov Today Technol, V19, P45, DOI 10.1016/j.ddtec.2016.06.004; Bechet D, 2014, CANCER TREAT REV, V40, P229, DOI 10.1016/j.ctrv.2012.07.004; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Benov L, 2015, MED PRIN PRACT, V24, P14, DOI 10.1159/000362416; Berenguer-Daize C, 2016, INT J CANCER, V139, P2047, DOI 10.1002/ijc.30256; Bhowmick R, 2014, CANCER LETT, V343, P115, DOI 10.1016/j.canlet.2013.09.025; Bhowmick R, 2013, FREE RADICAL BIO MED, V57, P39, DOI 10.1016/j.freeradbiomed.2012.12.005; Bhowmick R, 2011, PHOTOCHEM PHOTOBIOL, V87, P378, DOI 10.1111/j.1751-1097.2010.00877.x; Bhowmick R, 2010, FREE RADICAL BIO MED, V48, P1296, DOI 10.1016/j.freeradbiomed.2010.01.040; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Burke AJ, 2017, ANTIOXID REDOX SIGN, V26, P1078, DOI 10.1089/ars.2017.7004; Cekaite L, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-273; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Engels K, 2008, CANCER RES, V68, P5159, DOI 10.1158/0008-5472.CAN-08-0406; Eyler CE, 2011, CELL, V146, P53, DOI 10.1016/j.cell.2011.06.006; Fahey JM, 2017, NITRIC OXIDE-BIOL CH, V62, P52, DOI 10.1016/j.niox.2016.12.003; Fahey JM, 2016, PHOTOCHEM PHOTOBIOL, V92, P842, DOI 10.1111/php.12636; Fahey JM, 2015, NITRIC OXIDE-BIOL CH, V49, P47, DOI 10.1016/j.niox.2015.05.006; Fetz V, 2009, INT J CANCER, V124, P2033, DOI 10.1002/ijc.24182; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fionda C, 2016, CURR MED CHEM, V23, P2618, DOI 10.2174/0929867323666160727105101; Fu LL, 2015, ONCOTARGET, V6, P5501, DOI 10.18632/oncotarget.3551; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Garg H, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0326-1; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Henderson BW, 1999, PHOTOCHEM PHOTOBIOL, V70, P64, DOI 10.1562/0031-8655(1999)070<0064:POPTAA>2.3.CO;2; Hirst D, 2010, CURR PHARM DESIGN, V16, P411, DOI 10.2174/138161210790232185; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Ishida CT, 2017, ONCOTARGET, V8, P29558, DOI 10.18632/oncotarget.16365; Kim RK, 2013, CANCER SCI, V104, P1172, DOI 10.1111/cas.12207; Kleszcz R, 2015, PHARMACOL REP, V67, P1068, DOI 10.1016/j.pharep.2015.03.021; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Korbelik M, 2000, BRIT J CANCER, V82, P1835, DOI 10.1054/bjoc.2000.1157; Kostourou V, 2011, BRIT J CANCER, V104, P83, DOI 10.1038/sj.bjc.6606034; Krishnan N, 2013, FEBS J, V280, P2830, DOI 10.1111/febs.12283; Li F, 2015, ARCH TOXICOL, V89, P711, DOI 10.1007/s00204-015-1470-4; Li WN, 2017, PHOTODIAGN PHOTODYN, V18, P83, DOI 10.1016/j.pdpdt.2017.02.001; LUNA MC, 1994, CANCER RES, V54, P1374; Marelli G, 2017, CURR OPIN PHARMACOL, V35, P57, DOI 10.1016/j.coph.2017.05.007; Matsunaga T, 2014, FREE RADICAL RES, V48, P1371, DOI 10.3109/10715762.2014.957694; Meloche J, 2015, CIRC RES, V117, P525, DOI 10.1161/CIRCRESAHA.115.307004; Olzowy B, 2002, J NEUROSURG, V97, P970, DOI 10.3171/jns.2002.97.4.0970; Pan L, 2017, LASER SURG MED, V49, P719, DOI 10.1002/lsm.22661; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; Perez-Salvia M, 2017, ONCOTARGET, V8, P51621, DOI 10.18632/oncotarget.18255; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Quirk BJ, 2015, PHOTODIAGN PHOTODYN, V12, P530, DOI 10.1016/j.pdpdt.2015.04.009; Raber PL, 2014, INT J CANCER, V134, P2853, DOI 10.1002/ijc.28622; Reeves KJ, 2010, J PHOTOCH PHOTOBIO B, V101, P224, DOI 10.1016/j.jphotobiol.2010.07.007; Rollakanti KR, 2015, CANCER MED-US, V4, P633, DOI 10.1002/cam4.361; Sahni JM, 2016, J BIOL CHEM, V291, P23756, DOI 10.1074/jbc.M116.738666; Saleem W, 2011, CANCER SCI, V102, P2150, DOI 10.1111/j.1349-7006.2011.02095.x; Sanovic R, 2009, INT J ONCOL, V35, P921, DOI 10.3892/ijo_00000407; Shacter E, 2002, ONCOLOGY-NY, V16, P217; Shu SK, 2016, COLD SH Q B, V81, P123, DOI 10.1101/sqb.2016.81.030908; Singh D, 2007, AM J RESP CRIT CARE, V176, P988, DOI 10.1164/rccm.200704-588OC; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Tetard MC, 2014, PHOTODIAGN PHOTODYN, V11, P319, DOI 10.1016/j.pdpdt.2014.04.004; Uzdensky A, 2012, BBA-GEN SUBJECTS, V1820, P795, DOI 10.1016/j.bbagen.2012.03.008; Vannini F, 2015, REDOX BIOL, V6, P334, DOI 10.1016/j.redox.2015.08.009; Wali VB, 2017, CANCER RES, V77, P566, DOI 10.1158/0008-5472.CAN-16-1901; Wang J, 2017, CANCER LETT, V391, P141, DOI 10.1016/j.canlet.2017.01.031; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Whelan HT, 2012, J NATL COMPR CANC NE, V10, pS31, DOI 10.6004/jnccn.2012.0171; Wienerroither S, 2014, MOL CELL BIOL, V34, P415, DOI 10.1128/MCB.01353-13; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; Wink DA, 2008, NITRIC OXIDE-BIOL CH, V19, P65, DOI 10.1016/j.niox.2008.05.003; Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zanca C, 2017, GENE DEV, V31, P1212, DOI 10.1101/gad.300079.117; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	77	23	25	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2018	293	14					5345	5359		10.1074/jbc.RA117.000443	http://dx.doi.org/10.1074/jbc.RA117.000443			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB9QQ	29440272	Green Published, hybrid			2023-01-03	WOS:000429409300037
J	Aziz, MM; Masood, I; Yousaf, M; Saleem, H; Ye, D; Fang, Y				Aziz, Muhammad Majid; Masood, Imran; Yousaf, Mahreen; Saleem, Hammad; Ye, Dan; Fang, Yu			Pattern of medication selling and self medication practices: A study from Punjab, Pakistan	PLOS ONE			English	Article							ANTIBIOTICS; COMMUNITY; PHARMACIES; URBAN; PRESCRIPTION; PREVALENCE; MEDICINE; CHILDREN; DRUGS	Background Access to medicines without prescription is a major contributing factor for self-medication practices. This study was designed to examine the ratio of non-prescribed medicines sales and self-medication practices in Punjab, Pakistan. This study also evaluates the reasons for self-medication within its communities. Methods An observational study was conducted in 272 systemically selected pharmacies to analyze medicines-related sales, with or without prescription. A cross-sectional survey was performed between June 2015 and November 2016. Consumers were interviewed about their self-medication practices. Results Of the pharmacies surveyed, 65.3% participated in the study. A total of 4348 medicines were purchased for self-medication by 3037 consumers (15.2% of all study participants), of which 873 (28.7%) participated in an interview. Majority (81.2%) medicine purchaser, (90.9%) interview participants, and (59.4%) drug users were male. On average, each community pharmacy sold 7.9 medicines without prescription each day, to an average of 5.5 customers. Many participants (28.9%) had matriculation in their formal education. The medicines most often sold for self-medication were analgesics and antipyretics(39.4%). More than 25% of participants reported fever symptoms and 47.8% assumed their illness was too trivial to consult a doctor. Media advertisements were the most common source of information for participants (46.7%). Conclusion Many types of medicines were often sold without prescription from community pharmacies. Self-medication was common practice for a wide range of illnesses. Pakistan also needs effective implementation of policies to monitor medication sales. Public education about rational medication and limits to advertising medicine are very necessary.	[Aziz, Muhammad Majid; Ye, Dan; Fang, Yu] XianJiaotong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Shaanxi, Peoples R China; [Aziz, Muhammad Majid; Ye, Dan; Fang, Yu] Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian, Shaanxi, Peoples R China; [Aziz, Muhammad Majid; Ye, Dan; Fang, Yu] Xi An Jiao Tong Univ, Global Hlth Inst, Xian, Shaanxi, Peoples R China; [Aziz, Muhammad Majid; Ye, Dan; Fang, Yu] Shaanxi Ctr Hlth Reform & Dev Res, Xian, Shaanxi, Peoples R China; [Masood, Imran] Islamia Univ Bahawalpur, Fac Pharm & Alternat Med, Bahawalpur, Punjab, Pakistan; [Yousaf, Mahreen] Bahauddin Zakariya Univ, Fac Pharm, Multan, Pakistan; [Saleem, Hammad] Univ Vet & Anim Sci, Inst Pharmaceut Sci, Lahore, Pakistan	Xi'an Jiaotong University; Xi'an Jiaotong University; Islamia University of Bahawalpur; Bahauddin Zakariya University; University of Veterinary & Animal Science - Pakistan	Fang, Y (corresponding author), XianJiaotong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian, Shaanxi, Peoples R China.; Fang, Y (corresponding author), Xi An Jiao Tong Univ, Ctr Drug Safety & Policy Res, Xian, Shaanxi, Peoples R China.; Fang, Y (corresponding author), Xi An Jiao Tong Univ, Global Hlth Inst, Xian, Shaanxi, Peoples R China.; Fang, Y (corresponding author), Shaanxi Ctr Hlth Reform & Dev Res, Xian, Shaanxi, Peoples R China.	yufang@xjtu.edu.cn	Aziz, Muhammad Majid/AAX-8750-2021	Aziz, Muhammad Majid/0000-0002-6462-052X	"Young Talent Support Plan" of Xian Jiaotong University	"Young Talent Support Plan" of Xian Jiaotong University	This work was supported by "Young Talent Support Plan" of Xian Jiaotong University (YF).	Adverse reaction newsletter, 1999, ADVERSE REACTION NEW; Ahmad H, 2013, INT J PHARM SCI RES, V4, P1809, DOI 10.13040/IJPSR.0975-8232.4(5).1808-14; Alam Naznin, 2015, BMC Res Notes, V8, P763, DOI 10.1186/s13104-015-1737-0; [Anonymous], 2016, PHARMAGUIDE, P987; [Anonymous], 2012, THE NEWS        0329; Anwar M, 2015, HEALTH PSYCHOL BEHAV, V3, P281, DOI 10.1080/21642850.2015.1088387; Aqeel T, 2014, TROP J PHARM RES, V13, P627, DOI 10.4314/tjpr.v13i4.22; Arshad M.S., 2010, PAK J PHARM, V23, P15, DOI [10.1371/journal.pone.0194240, DOI 10.1371/JOURNAL.PONE.0194240]; Aslam N, 2012, ARCH PHARM PRACT, V3, P297, DOI 10.4103/2045-080X.106259; Auta A, 2012, N AM J MED SCI, V4, P24, DOI 10.4103/1947-2714.92899; Banks J, CLIN PHARM; Bochenek T, 2016, EXPERT REV PHARM OUT, V16, P199, DOI 10.1586/14737167.2016.1154790; Ehsan M, 2012, 22 PAKISTAN SAY THEY; El-Nimr NA, 2015, E MEDITERR HEALTH J, V21, P256, DOI 10.26719/2015.21.4.256; Ernst PE, 2002, BJOG-INT J OBSTET GY, V109, P227; Eticha T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097464; Galea S, 2007, ANN EPIDEMIOL, V17, P643, DOI 10.1016/j.annepidem.2007.03.013; Garofalo L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/580650; Geissler PW, 2000, SOC SCI MED, V50, P1771, DOI 10.1016/S0277-9536(99)00428-1; Guinovart MC, 2015, J ANTIMICROB CHEMOTH, V70, P1270, DOI 10.1093/jac/dku526; Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002; Hussain Azhar, 2012, Int J Pharm Pract, V20, P183, DOI 10.1111/j.2042-7174.2011.00178.x; Hussain S, 2010, S MED REV, V3, P32; Iqbal Q, 2017, POSTGRAD MED, V129, P637, DOI 10.1080/00325481.2017.1328251; Jha N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-652; Kamat VR, 1998, SOC SCI MED, V47, P779, DOI 10.1016/S0277-9536(98)00134-8; Kaushal Jyoti, 2012, Indian J Community Med, V37, P16, DOI 10.4103/0970-0218.94013; Khalid L, 2016, RES SOC ADMIN PHARM, V12, P801, DOI 10.1016/j.sapharm.2016.03.003; Khan H, 2014, TROP J PHARM RES, V13, P437, DOI 10.4314/tjpr.v13i3.19; Kloosterboer SM, 2015, AUST FAM PHYSICIAN, V44, P497; Lukovic JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114644; Mansoor H., 2013, EXCESSIVE USE DRUGS; MNYIKA KS, 1995, TROP GEOGR MED, V47, P32; Murnion BP, 2010, AUST PRESCR, V33, P113, DOI 10.18773/austprescr.2010.056; Nyazema N, 2007, J ANTIMICROB CHEMOTH, V59, P718, DOI 10.1093/jac/dkm013; Ortiz MI, 2012, PAIN RES TREAT; Polonia J, 1997, CARDIOLOGY, V88, P47, DOI 10.1159/000177507; Rein M F, 1979, West J Med, V131, P97; Riaz H, 2016, EXPERT REV CLIN PHAR, V9, P329, DOI 10.1586/17512433.2016.1122519; Riaz H, 2015, J PHARM HEALTH SERV, V6, P111, DOI 10.1111/jphs.12091; Saleem Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149929; Sclafer J, 1997, J CLIN PHARM THER, V22, P261, DOI 10.1046/j.1365-2710.1997.10075100.x; Shaikh Babar Tasneem, 2015, J Ayub Med Coll Abbottabad, V27, P496; Shuai G, 2014, CHIN MED, V9, P1; Silva MGC, 2012, BMC PUBLIC HLTH, P12; Singh Jagjit, 2012, Indian J Endocrinol Metab, V16, P662, DOI 10.4103/2230-8210.98041; Togoobaatar G, 2010, B WORLD HEALTH ORGAN, V88, P930, DOI 10.2471/BLT.10.079004; World Health Organization, 2000, REG GUID TEL PROD	48	42	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194240	10.1371/journal.pone.0194240	http://dx.doi.org/10.1371/journal.pone.0194240			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA1RF	29566014	gold, Green Published, Green Submitted			2023-01-03	WOS:000428093900044
J	Timofeev, I; Chauvette, S				Timofeev, Igor; Chauvette, Sylvain			Sleep, Anesthesia, and Plasticity	NEURON			English	Editorial Material							NEURONS; WAKING	Two theories continuously clash: does sleep downscale or potentiate synapses? A study in Neuron by Gonzalez-Rueda et al. (2018) demonstrates overall synaptic depression during anesthesia-induced slow-wave activity. Because anesthesia is typically associated with amnesia, the question of whether slow-wave sleep potentiates or depresses cortical synapses remains open.	[Timofeev, Igor] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ G1V 0A6, Canada; [Timofeev, Igor; Chauvette, Sylvain] Univ Laval, CERVO Brain Res Ctr, Quebec City, PQ G1J 2G3, Canada	Laval University; Laval University	Timofeev, I (corresponding author), Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ G1V 0A6, Canada.; Timofeev, I (corresponding author), Univ Laval, CERVO Brain Res Ctr, Quebec City, PQ G1J 2G3, Canada.	Igor.Timofeev@fmed.ulaval.ca	Timofeev, Igor/E-8828-2012; Timofeev, Igor/AAP-7529-2021	Timofeev, Igor/0000-0002-1389-5857	CIHR; NSERC; FRQNT	CIHR(Canadian Institutes of Health Research (CIHR)); NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); FRQNT	We would like to thank CIHR, NSERC, and FRQNT for support.	Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Frank MG, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/394946; Gonzalez-Rueda A, 2018, NEURON, V97, P1244, DOI 10.1016/j.neuron.2018.01.047; Maret S, 2011, NAT NEUROSCI, V14, P1418, DOI 10.1038/nn.2934; Rasch B, 2013, PHYSIOL REV, V93, P681, DOI 10.1152/physrev.00032.2012; Reyes A, 1999, J NEUROSCI, V19, P3827; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; Timofeev I, 2017, CURR OPIN NEUROBIOL, V44, P116, DOI 10.1016/j.conb.2017.03.019; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004	10	5	5	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	MAR 21	2018	97	6					1200	1202		10.1016/j.neuron.2018.03.013	http://dx.doi.org/10.1016/j.neuron.2018.03.013			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GA3NE	29566787	Bronze			2023-01-03	WOS:000428235400002
J	Kwon, H; Kim, Y; Kim, K; Jung, JY; Kim, J; Choi, SI; Chun, EJ; Bae, WK				Kwon, Hyuksool; Kim, Yeokoon; Kim, Kyuseok; Jung, Jae Yun; Kim, Joonghee; Choi, Sang Ii; Chun, Eun Ju; Bae, Woo Kyung			Where is the left ventricle during cardiopulmonary resuscitation based on chest computed tomography in the expiration with arms down position?	PLOS ONE			English	Article							AUTOMATED EXTERNAL DEFIBRILLATION; BASIC LIFE-SUPPORT; 2015 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; TREATMENT RECOMMENDATIONS; CARDIAC RESUSCITATION; COMPRESSION; COMPLICATIONS; CHILDREN; ARREST	Objective Patients usually receive cardiopulmonary resuscitation during ventilatory expiration and with their arms down, which does not reflect the normal imaging position. This study used scout images from low-dose chest computed tomography to compare the locations of the left ventricle (LV) in the expiration with arms down position (EAD) and in the full inspirational with arms raised position (IAR). Methods This cross-sectional study used a convenience sample and evaluated scout images that were obtained during screening with the participants in the EAD and IAR positions. The effective compression point was defined as being on the sternum above the longest anteroposterior diameter (APD) of the LV (using axial computed tomography images). The sternum was divided into three parts and the heart's position was evaluated on the EAD and the IAR images, and the distance from the xiphoid process to the LV's sternum landmark (XLVD) was measured. We also examined the compressible organs during CPR based on the EAD and IAR images. Results We enrolled 127 participants. The LVs were located in the middle of the sternum at EAD for 117 participants (92%) and in the lower half of the sternum at IAR for 107 participants (84%). The mean XLVD was significantly different between the EAD and IAR positions (mean: 85 +/- 21 mm vs. 33 +/- 17 mm, respectively). The liver's left lobe was located in the lower half of the sternum at EAD for 118 participants (93%). Conclusions These findings indicate that the location of the LV during cardiopulmonary resuscitation might be in the middle of the sternum if the patient is treated in the EAD position.	[Kwon, Hyuksool; Kim, Kyuseok; Jung, Jae Yun; Kim, Joonghee] Seoul Natl Univ, Dept Emergency Med, Bundang Hosp, Sungnam Si, Gyeonggi Do, South Korea; [Kim, Yeokoon; Choi, Sang Ii; Chun, Eun Ju] Seoul Natl Univ, Dept Radiol, Bundang Hosp, Sungnam Si, Gyeonggi Do, South Korea; [Bae, Woo Kyung] Seoul Natl Univ, Dept Family Med, Bundang Hosp, Hlth Promot Ctr, Sungnam Si, Gyeonggi Do, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, K (corresponding author), Seoul Natl Univ, Dept Emergency Med, Bundang Hosp, Sungnam Si, Gyeonggi Do, South Korea.	dremkks@snu.ac.kr	Lee, Jae Hyuk/W-5616-2018; Kim, Joonghee/C-9811-2014; Kwon, Hyuksool/R-5142-2016	Lee, Jae Hyuk/0000-0003-2429-4085; Kim, Joonghee/0000-0001-5080-7097; Kim, Kyuseok/0000-0002-7991-9428; Kwon, Hyuksool/0000-0002-0960-0198	Seoul National University Bundang Hospital [02-2014-004]; Seoul National University Invitation Program for Distinguished Scholar	Seoul National University Bundang Hospital; Seoul National University Invitation Program for Distinguished Scholar	This study was supported, in part, by Seoul National University Bundang Hospital (Grant 02-2014-004) and Seoul National University Invitation Program for Distinguished Scholar. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Abed Y, 2008, BRIT J RADIOL, V81, P855, DOI 10.1259/bjr/73789148; Buschmann CT, 2009, INTENS CARE MED, V35, P397, DOI 10.1007/s00134-008-1255-9; Cha KC, 2013, J EMERG MED, V44, P691, DOI 10.1016/j.jemermed.2012.09.026; FITZGERALD KR, 1981, AM J PHYSIOL, V241, pH442, DOI 10.1152/ajpheart.1981.241.3.H442; Klouche K, 2002, CRIT CARE MED, V30, P2626, DOI 10.1097/00003246-200212000-00002; KRISCHER JP, 1987, CHEST, V92, P287, DOI 10.1378/chest.92.2.287; ORLOWSKI JP, 1986, ANN EMERG MED, V15, P667, DOI 10.1016/S0196-0644(86)80423-1; Park YS, 2011, RESUSCITATION, V82, P1030, DOI 10.1016/j.resuscitation.2010.11.004; Perkins GD, 2015, RESUSCITATION, V95, pE43, DOI 10.1016/j.resuscitation.2015.07.041; Pickard A, 2006, RESUSCITATION, V71, P387, DOI 10.1016/j.resuscitation.2006.04.012; Qvigstad E, 2013, RESUSCITATION, V84, P1203, DOI 10.1016/j.resuscitation.2013.03.010; Seung MK, 2016, RESUSCITATION, V98, P64, DOI 10.1016/j.resuscitation.2015.11.004; Shin J, 2007, RESUSCITATION, V75, P305, DOI 10.1016/j.resuscitation.2007.05.003; Travers AH, 2015, CIRCULATION, V132, pS51, DOI 10.1161/CIR.0000000000000272; VOORHEES WD, 1980, CRIT CARE MED, V8, P134, DOI 10.1097/00003246-198003000-00008; Zhang Z., 2016, ANN TRANSLATIONAL ME, V4	17	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2018	13	2							e0193364	10.1371/journal.pone.0193364	http://dx.doi.org/10.1371/journal.pone.0193364			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX4LV	29474460	Green Submitted, gold, Green Published			2023-01-03	WOS:000426049500094
J	Busse, P; Miranda, JJ				Busse, Peter; Jaime Miranda, J.			Perceived behavioral control as a potential precursor of walking three times a week: Patient's perspectives	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; PLANNED BEHAVIOR; REASONED ACTION; PROMOTION; CAMPAIGNS; SMOKING	Background Behavior change theories can identify people's main motivations to engage in recommended health practices and thus provide better tools to design interventions, particularly human centered design interventions. Objectives This study had two objectives: (a) to identify salient beliefs about walking three times a week for 30 minutes nonstop among patients with hypertension in a low-resource setting and, (b) to measure the relationships among intentions, attitudes, perceived social pressure and perceived behavioral control about this behavior. Methods Face-to-face interviews with 34 people living with hypertension were conducted in September-October 2011 in Lima, Peru, and data analysis was performed in 2015. The Reasoned Action Approach was used to study the people's decisions to walk. We elicited people's salient beliefs and measured the theoretical constructs associated with this behavior. Results Results pointed at salient key behavioral, normative and control beliefs. In particular, perceived behavioral control appeared as an important determinant of walking and a small set of control beliefs were identified as potential targets of health communication campaigns, including (not) having someone to walk with, having work or responsibilities, or having no time. Conclusions This theory-based study with a focus on end-users provides elements to inform the design of an intervention that would motivate people living with hypertension to walk on a regular basis in low-resource settings.	[Busse, Peter] Univ Lima, Inst Invest Cient, Lima, Peru; [Busse, Peter] Inst Estudios Peruanos, Lima, Peru; [Jaime Miranda, J.] Univ Peruana Cayetano Heredia, CRONICAS Ctr Excellence Chron Dis, Lima, Peru; [Jaime Miranda, J.] Univ Peruana Cayetano Heredia, Sch Med, Dept Med, Lima, Peru	Universidad de Lima; Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia	Busse, P (corresponding author), Univ Lima, Inst Invest Cient, Lima, Peru.; Busse, P (corresponding author), Inst Estudios Peruanos, Lima, Peru.	pbusse@ulima.edu.pe		Miranda, J. Jaime/0000-0002-4738-5468; Busse, Peter/0000-0002-5570-1299	International Development Research Centre-IDRC, Canada, under the Think Tank Initiative program; International Development Research Centre-IDRC, Canada, under the Think Tank Initiative program, within Instituto de Estudios Peruanos	International Development Research Centre-IDRC, Canada, under the Think Tank Initiative program; International Development Research Centre-IDRC, Canada, under the Think Tank Initiative program, within Instituto de Estudios Peruanos	The study reported in this article was possible thanks to the financial support of International Development Research Centre-IDRC, Canada, under the Think Tank Initiative program. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The study reported in this article was possible thanks to the financial support of International Development Research Centre-IDRC, Canada, under the Think Tank Initiative program, within Instituto de Estudios Peruanos. The authors thank Lic. Sarita Moran and Lic. Diamante Fernandez for their support with the research tasks involved in this project, and Andrea O. Ruiz-Alejos for editorial assistance.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Albarracin D, 2001, PSYCHOL BULL, V127, P142, DOI 10.1037//0033-2909.127.1.142; Atkin CK, THEORY PRINCIPLES ME, P3; Busse P., 2014, DESIGUALDAD HIPERTEN, P55; Cappella JN, 2006, J COMMUN, V56, pS265, DOI 10.1111/j.1460-2466.2006.00293.x; Centers Disease Control and Prevention, 2014, HIGH BLOOD PRESSURE; Chib A, 2015, J HEALTH COMMUN, V20, P4, DOI 10.1080/10810730.2013.864735; Fishbein M., 1975, BELIEF ATTITUDE INTE; Fishbein M, 2011, PREDICTING CHANGING, DOI 10.4324/9780203838020; Fishbein M, 2008, MED DECIS MAKING, V28, P834, DOI 10.1177/0272989X08326092; Hagger MS, 2002, J SPORT EXERCISE PSY, V24, P3, DOI 10.1123/jsep.24.1.3; Hennessy M, 2014, AM J PUBLIC HEALTH, V104, P721, DOI 10.2105/AJPH.2013.301634; Hennessy M, 2014, NICOTINE TOB RES, V16, P69, DOI 10.1093/ntr/ntt119; Hernandez-Hernandez R, 2010, J HYPERTENS, V28, P24, DOI 10.1097/HJH.0b013e328332c353; Hornik R., 1999, SOCIAL MARKETING Q, V5, P34, DOI [10.1080/15245004.1999.9961044, DOI 10.1080/15245004.1999.9961044]; Jordan A, 2012, ANN AM ACAD POLIT SS, V640, P118, DOI 10.1177/0002716211425656; Kallgren CA, 2000, PERS SOC PSYCHOL B, V26, P1002, DOI 10.1177/01461672002610009; Lee LL, 2010, INT J NURS STUD, V47, P1545, DOI 10.1016/j.ijnurstu.2010.08.008; Mendez RD, 2012, REV LAT-AM ENFERM, V20, P1015, DOI 10.1590/S0104-11692012000600002; Noar SM, 2010, HEALTH COMMUN, V25, P593, DOI 10.1080/10410236.2010.496832; Noar SM, 2009, J HEALTH COMMUN, V14, P15, DOI 10.1080/10810730802592239; Noar SM, 2006, J HEALTH COMMUN, V11, P21, DOI 10.1080/10810730500461059; Perel P, 2006, PLOS MED, V3, P1448, DOI 10.1371/journal.pmed.0030344; Rebar AL, 2014, J SPORT EXERCISE PSY, V36, P157, DOI 10.1123/jsep.2013-0173; Riley WT, 2011, TRANSL BEHAV MED, V1, P53, DOI 10.1007/s13142-011-0021-7; Sanchez RA, 2009, J HYPERTENS, V27, P905, DOI 10.1097/HJH.0b013e32832aa6d2; Seclén-Palacín Juan A., 2003, Rev Panam Salud Publica, V14, P255, DOI 10.1590/S1020-49892003000900006; World Health Organization, 2013, SIL KILL GLOB PUBL H	28	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2018	13	2							e0192915	10.1371/journal.pone.0192915	http://dx.doi.org/10.1371/journal.pone.0192915			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FW5PR	29451917	Green Published, Green Submitted, gold			2023-01-03	WOS:000425369800024
J	Bintabara, D; Mpondo, BCT				Bintabara, Deogratius; Mpondo, Bonaventura C. T.			Preparedness of lower-level health facilities and the associated factors for the outpatient primary care of hypertension: Evidence from Tanzanian national survey	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; NONCOMMUNICABLE DISEASES; RISK-FACTORS; BURDEN; PREVALENCE; MANAGEMENT; READINESS; AVAILABILITY; PREVENTION	Introduction Sub-Saharan Africa is experiencing a rapid rise in the burden of non-communicable diseases in both urban and rural areas. Data on health system preparedness to manage hypertension and other non-communicable diseases remains scarce. This study aimed to assess the preparedness of lower-level health facilities for outpatient primary care of hypertension in Tanzania. Methods This study used data from the 2014-2015 Tanzania Service Provision Assessment survey. The facility was considered as prepared for the outpatient primary care of hypertension if reported at least half (>= 50%) of the items listed from each of the three domains (staff training and guideline, basic diagnostic equipment, and basic medicines) as identified by World Health Organization-Service Availability and Readiness Assessment manual. Data were analyzed using Stata 14. An unadjusted logistic regression model was used to assess the association between outcome and explanatory variables. All variables with a P value < 0.2 were fitted into the multiple logistic regression models using a 5% significance level. Results Out of 725 health facilities involved in the current study, about 68% were public facilities and 73% located in rural settings. Only 28% of the assessed facilities were considered prepared for the outpatient primary care of hypertension. About 9% and 42% of the assessed facilities reported to have at least one trained staff and guidelines for hypertension respectively. In multivariate analysis, private facilities [AOR = 2.7, 95% CI; 1.2-6.1], urban location [AOR = 2.2, 95% CI; 1.2-4.2], health centers [AOR = 5.2, 95% CI; 3.1-8.7] and the performance of routine management meetings [AOR = 2.6, 95% CI; 1.1-5.9] were significantly associated with preparedness for the outpatient primary care of hypertension. Conclusion The primary healthcare system in Tanzania is not adequately equipped to cope with the increasing burden of hypertension and other non-communicable diseases. Rural location, public ownership, and absence of routine management meetings were associated with being not prepared. There is a need to strengthen the primary healthcare system in Tanzania for better management of chronic diseases and curb their rising impact on health outcomes.	[Bintabara, Deogratius] Univ Dodoma, Coll Hlth Sci, Dept Publ Hlth, Dodoma, Tanzania; [Mpondo, Bonaventura C. T.] Univ Dodoma, Coll Hlth Sci, Dept Internal Med, Dodoma, Tanzania		Bintabara, D (corresponding author), Univ Dodoma, Coll Hlth Sci, Dept Publ Hlth, Dodoma, Tanzania.	bintabaradeo@gmail.com		Bintabara, Deogratius/0000-0001-7877-870X				Addo J, 2007, HYPERTENSION, V50, P1012, DOI 10.1161/HYPERTENSIONAHA.107.093336; Agwanda A, 2009, ASSESSMENT FAMILY PL; Ali MK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005121; Ataklte F, 2015, HYPERTENSION, V65, P291, DOI 10.1161/HYPERTENSIONAHA.114.04394; Basu S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001244; Beaglehole R, 2008, LANCET, V372, P940, DOI 10.1016/S0140-6736(08)61404-X; Boutayeb A, 2006, T ROY SOC TROP MED H, V100, P191, DOI 10.1016/j.trstmh.2005.07.021; Cooper RS, 1998, BMJ-BRIT MED J, V316, P614, DOI 10.1136/bmj.316.7131.614; Daar AS, 2007, NATURE, V450, P494, DOI 10.1038/450494a; Dalal S, 2011, INT J EPIDEMIOL, V40, P885, DOI 10.1093/ije/dyr050; Department of Health Statistics and Informatics, 2008, GLOB BURD DIS 2004 U; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Frenk J, 2010, LANCET, V376, P1923, DOI 10.1016/S0140-6736(10)61854-5; Hancock C, 2011, GLOBALIZATION HEALTH, V7, DOI 10.1186/1744-8603-7-23; Hendriks ME, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032638; Minh HV, 2014, INT J HEALTH PLAN M, V29, pE159, DOI 10.1002/hpm.2179; Ifakara Health Institute (IHI) and Ministry of Health and Social Welfare (MOHSW), 2013, TANZ SERV AV READ AS; Jacobs B, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1286-9; Katende D, 2015, TROP MED INT HEALTH, V20, P1385, DOI 10.1111/tmi.12560; Kavishe B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0357-9; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Kengne AP, 2009, J CLIN HYPERTENS, V11, P564, DOI 10.1111/j.1751-7176.2009.00165.x; Leung C, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3661-1; Marquez Patricio V, 2013, CHALLENGE NONCOMMUNI; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mendis S, 2004, J HYPERTENS, V22, P59, DOI 10.1097/00004872-200401000-00013; Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912; Ministry of Health and Social Welfare (MoHSW) [Tanzania Mainland] Ministry of Health (MoH) [Zanzi- bar], 2008, NAT NONC DIS STRAT J; Ministry of Health Community Development Gender Elderly and Children (MoHCDGEC) [Tanzania Mainland] Ministry of Health (MoH) [Zanzibar] National Bureau of Statistics (NBS) Office of the Chief Government Statistician (OCGS) and ICF, 2015, TANZ 2015 16 DEM HLT; Ministry of Labour Employment and Youth Development Tanzania, 2013, NAT FAM PLANN GUID S; Misganaw A, 2014, J HEALTH POPUL NUTR, V32, P1; Mohan V, 2013, INT J HYPERTENS, V2013, DOI 10.1155/2013/409083; Munga MA, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-4; Musinguzi G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142312; Organization WH, 2016, GLOBAL STATUS REPORT; Oyekale AS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2112-8; Peck R, 2014, LANCET GLOB HEALTH, V2, pE285, DOI 10.1016/S2214-109X(14)70033-6; Pires JE, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-90; Poulter NR, 2011, J HYPERTENS, V29, P1281, DOI 10.1097/HJH.0b013e328347f437; Robertson J, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0105-0; Schroth RJ., 2016, SAUDI J DENT RES, V7, P118, DOI DOI 10.1016/J.SJDR.2016.04.006; Settumba SN, 2015, TROP MED INT HEALTH, V20, P781, DOI 10.1111/tmi.12487; Shemdoe A, 2016, HUM RESOUR HEALTH, V14, DOI 10.1186/s12960-016-0098-7; Siering U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082915; Sikika, 2011, MED MED SUPPL AV REP; Sikika, 2015, HLTH SECT BUDG AN FI; Sivaramakrishnan K, 2012, AM J PUBLIC HEALTH, V102, P2010, DOI 10.2105/AJPH.2012.300768; Spasojevic Nada, 2015, Mater Sociomed, V27, P409, DOI 10.5455/msm.2015.27.409-411; Uddin MJ, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-547; Wang WJ, 2017, GLOB HEALTH-SCI PRAC, V5, P244, DOI 10.9745/GHSP-D-16-00311; Ward J, 2000, EUR J CANCER CARE, V9, P80; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; Wiedenmayer K., 2004, ACCESS MED MED SUPPL; World Health Organization, 2015, SERV AV READ ASS SAR	54	29	29	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2018	13	2							e0192942	10.1371/journal.pone.0192942	http://dx.doi.org/10.1371/journal.pone.0192942			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW4LB	29447231	Green Published, gold, Green Submitted			2023-01-03	WOS:000425283900079
J	Backryd, E; Persson, EB; Larsson, AI; Fischer, MR; Gerdle, B				Backryd, Emmanuel; Persson, Elisabeth B.; Larsson, Annelie Inghilesi; Fischer, Marcelo Rivano; Gerdle, Bjorn			Chronic pain patients can be classified into four groups: Clustering-based discriminant analysis of psychometric data from 4665 patients referred to a multidisciplinary pain centre (a SQRP study)	PLOS ONE			English	Article							LOW-BACK-PAIN; FEAR-AVOIDANCE MODEL; COGNITIVE-BEHAVIORAL THERAPY; PERIPHERAL NEUROPATHIC PAIN; QUALITY-OF-LIFE; MUSCULOSKELETAL-PAIN; FIBROMYALGIA PATIENTS; HEALTH-CARE; CEREBROSPINAL-FLUID; SUBGROUP-ANALYSIS	Objective To subgroup chronic pain patients using psychometric data and regress the variables most responsible for subgroup discrimination. Design Cross-sectional, registry-based study. Setting and subjects Chronic pain patients assessed at a multidisciplinary pain centre between 2008 and 2015. Methods Data from the Swedish quality registry for pain rehabilitation (SQRP) were retrieved and analysed by principal component analysis, hierarchical clustering analysis, and partial least squares-discriminant analysis. Results Four subgroups were identified. Group 1 was characterized by low "psychological strain", the best relative situation concerning pain characteristics (intensity and spreading), the lowest frequency of fibromyalgia, as well as by a slightly older age. Group 2 was characterized by high "psychological strain" and by the most negative situation with respect to pain characteristics (intensity and spreading). Group 3 was characterized by high "social distress", the longest pain durations, and a statistically higher frequency of females. The frequency of three neuropathic pain conditions was generally lower in this group. Group 4 was characterized by high psychological strain, low "social distress", and high pain intensity. Conclusions The identification of these four clusters of chronic pain patients could be useful for the development of personalized rehabilitation programs. For example, the identification of a subgroup characterized mainly by high perceived "social distress" raises the question of how to best design interventions for such patients. Differentiating between clinically important subgroups and comparing how these subgroups respond to interventions is arguably an important area for further research.	[Backryd, Emmanuel; Gerdle, Bjorn] Linkoping Univ, Pain & Rehabil Ctr, Linkoping, Sweden; [Backryd, Emmanuel; Gerdle, Bjorn] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Persson, Elisabeth B.; Fischer, Marcelo Rivano] Lund Univ, Dept Hlth Sci, Lund, Sweden; [Persson, Elisabeth B.; Fischer, Marcelo Rivano] Skane Univ Hosp, Dept Pain Rehabil Med, Lund, Sweden; [Larsson, Annelie Inghilesi] Qual Stat AB, Umea, Sweden	Linkoping University; Linkoping University; Lund University; Lund University; Skane University Hospital	Backryd, E (corresponding author), Linkoping Univ, Pain & Rehabil Ctr, Linkoping, Sweden.; Backryd, E (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.	emmanuel.backryd@regionostergotland.se		Backryd, Emmanuel/0000-0003-4420-418X	AFA Insurance, research-ALF (Linkoping University hospital); Swedish Association of Local Authorities and Regions (SALAR)	AFA Insurance, research-ALF (Linkoping University hospital); Swedish Association of Local Authorities and Regions (SALAR)	The present study was sponsored by research grants from AFA Insurance, research-ALF (Linkoping University hospital), and the Swedish Association of Local Authorities and Regions (SALAR). AFA Insurance is a commercial founder, which is owned by Sweden's labour market parties: the Confederation of Swedish Enterprise, the Swedish Trade Union Confederation (LO) and The Council for Negotiation and Co-operation (PTK). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication. The authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Backryd E, 2017, PAIN, V158, P2487, DOI 10.1097/j.pain.0000000000001061; Backryd E, 2017, J PAIN RES, V10, DOI 10.2147/JPR.S128508; Backryd E, 2015, J PAIN RES, V8, P321, DOI 10.2147/JPR.S82970; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Baron R, 2017, PAIN, V158, P261, DOI 10.1097/j.pain.0000000000000753; Baron R, 2012, LANCET NEUROL, V11, P999, DOI 10.1016/S1474-4422(12)70189-8; Beneciuk JM, 2012, CLIN J PAIN, V28, P658, DOI 10.1097/AJP.0b013e31824306ed; Bennett M, 2010, PAIN, V18, P1; Bergstrom G, 1998, PAIN, V75, P101, DOI 10.1016/S0304-3959(97)00210-8; Bernardes SF, 2017, PAIN, V158, P2066, DOI 10.1097/j.pain.0000000000001033; Borsbo B, 2009, DISABIL REHABIL, V31, P1605, DOI 10.1080/09638280903110079; Boersma K, 2006, CLIN J PAIN, V22, P160, DOI 10.1097/01.ajp.0000159582.37750.39; Borrell-Carrio F, 2004, ANN FAM MED, V2, P576, DOI 10.1370/afm.245; Borsbo B., 2008, THESIS; Borsbo B, 2008, J REHABIL MED, V40, P562, DOI 10.2340/16501977-0207; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Buitenhuis J, 2011, SPINE, V36, pS238, DOI 10.1097/BRS.0b013e3182388400; Burns JW, 2017, PAIN; Cherkin DC, 1996, SPINE, V21, P2900, DOI 10.1097/00007632-199612150-00023; Demyttenaere K, 2007, PAIN, V129, P332, DOI 10.1016/j.pain.2007.01.022; Denison E, 2007, J PAIN, V8, P67, DOI 10.1016/j.jpain.2006.06.007; DERRY S, 2016, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD012232.pub2; Dersh J, 2002, PSYCHOSOM MED, V64, P773, DOI 10.1097/01.PSY.0000024232.11538.54; Eccleston C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007407.pub2; Edwards RR, 2016, J PAIN, V17, pT70, DOI 10.1016/j.jpain.2016.01.001; Engel CC, 1996, PAIN, V65, P197, DOI 10.1016/0304-3959(95)00164-6; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Chaparro LE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004959.pub4; Eriksson L, 2013, MULTIAND MEGAVARIATE; Field A., 2013, DISCOVERING STAT USI; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Gerdle B, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1346-7; Giesecke T, 2003, ARTHRITIS RHEUM, V48, P2916, DOI 10.1002/art.11272; Goldsmith KA, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-54; Hall-Lord M L, 1999, Int J Nurs Pract, V5, P78, DOI 10.1046/j.1440-172x.1999.00157.x; Hazard RG, 2012, SPINE J, V12, P1132, DOI 10.1016/j.spinee.2012.09.003; Hill JC, 2011, PHYS THER, V91, P712, DOI 10.2522/ptj.20100280; Hirsch O, 2014, CLIN J PAIN, V30, P1023, DOI 10.1097/AJP.0000000000000080; Hurtig IM, 2001, CLIN J PAIN, V17, P316, DOI 10.1097/00002508-200112000-00005; Jakobsson U, 2003, J PAIN SYMPTOM MANAG, V26, P625, DOI 10.1016/S0885-3924(03)00145-3; Kroenke K, 2001, ANN INTERN MED, V134, P801, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00001; Leeuw M, 2007, J BEHAV MED, V30, P77, DOI 10.1007/s10865-006-9085-0; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Linton SJ, 2011, SCAND J PAIN, V2, P47, DOI 10.1016/j.sjpain.2011.01.005; Linton SJ, 2011, EUR J PAIN, V15, P416, DOI 10.1016/j.ejpain.2010.08.009; McGough James J, 2009, Psychiatry (Edgmont), V6, P21; McWilliams LA, 2003, PAIN, V106, P127, DOI 10.1016/S0304-3959(03)00301-4; Melzack R, 1999, PAIN, pS121, DOI 10.1016/S0304-3959(99)00145-1; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Costa LDM, 2013, SPINE, V38, P148, DOI 10.1097/BRS.0b013e318267a92f; Miller LR, 2009, J PAIN, V10, P619, DOI 10.1016/j.jpain.2008.12.007; Milton MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065483; Morley S, 2008, PAIN, V137, P670, DOI 10.1016/j.pain.2008.02.025; Nijs J, 2011, CLIN RHEUMATOL, V30, P927, DOI 10.1007/s10067-011-1712-7; NRS, SWED QUAL REG PAIN R; Ocanez KLS, 2010, DEPRESS ANXIETY, V27, P760, DOI 10.1002/da.20681; Olausson P, 2015, SCI REP-UK, V5, DOI 10.1038/srep11894; Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766; PARMELEE PA, 1991, J GERONTOL, V46, pP15, DOI 10.1093/geronj/46.1.P15; Petersen KK, 2016, PAIN, V157, P1400, DOI 10.1097/j.pain.0000000000000531; Pfau DB, 2009, PAIN, V147, P72, DOI 10.1016/j.pain.2009.08.010; Pincus Tamar, 2002, Spine (Phila Pa 1976), V27, pE109, DOI 10.1097/00007632-200203010-00017; Quartana PJ, 2009, EXPERT REV NEUROTHER, V9, P745, DOI 10.1586/ERN.09.34; SBU - Swedish Council on Health Technology Assessment, 2010, SYST LIT; Staud R, 2012, EXPERT REV NEUROTHER, V12, P577, DOI [10.1586/ern.12.41, 10.1586/ERN.12.41]; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Sullivan MJL, 2008, PAIN, V135, P151, DOI 10.1016/j.pain.2007.05.021; SULLIVAN MJL, 1992, PAIN, V50, P5, DOI 10.1016/0304-3959(92)90107-M; Svanberg M, 2017, J REHABIL MED, V49, P354, DOI 10.2340/16501977-2212; Tunks ER, 2008, CAN J PSYCHIAT, V53, P224, DOI 10.1177/070674370805300403; Turk DC, 2011, LANCET, V377, P2226, DOI 10.1016/S0140-6736(11)60402-9; van Koulil S, 2008, PATIENT EDUC COUNS, V71, P308, DOI 10.1016/j.pec.2007.11.025; van Koulil S, 2011, ARTHRIT CARE RES, V63, P800, DOI 10.1002/acr.20445; van Koulil S, 2010, ARTHRIT CARE RES, V62, P1377, DOI 10.1002/acr.20268; Viniol A, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-294; Vlaeyen JWS, 2012, PAIN, V153, P1144, DOI 10.1016/j.pain.2011.12.009; VLAEYEN JWS, 1995, PAIN, V62, P363, DOI 10.1016/0304-3959(94)00279-N; von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008; Westman AE, 2011, CLIN J PAIN, V27, P567, DOI 10.1097/AJP.0b013e318219ab6c; Wheelock AM, 2013, MOL BIOSYST, V9, P2589, DOI 10.1039/c3mb70194h; Wicksell RK, 2009, EUR J PAIN, V13, P760, DOI 10.1016/j.ejpain.2008.09.003; Williams LS, 2004, NEUROLOGY, V63, P674, DOI 10.1212/01.WNL.0000134669.05005.95; Wilson HD, 2009, ARTHRIT RHEUM-ARTHR, V61, P527, DOI 10.1002/art.24163; Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304-3959(98)00099-2; Woolf CJ, 2004, ANN INTERN MED, V140, P441, DOI 10.7326/0003-4819-140-8-200404200-00010; Yarnitsky D, 2012, PAIN, V153, P1193, DOI 10.1016/j.pain.2012.02.021; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	89	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2018	13	2							e0192623	10.1371/journal.pone.0192623	http://dx.doi.org/10.1371/journal.pone.0192623			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FV4BG	29420607	Green Published, Green Submitted, gold			2023-01-03	WOS:000424517900099
J	Dor-Haim, H; Barak, S; Horowitz, M; Yaakobi, E; Katzburg, S; Swissa, M; Lotan, C				Dor-Haim, Horesh; Barak, Sharon; Horowitz, Michal; Yaakobi, Eldad; Katzburg, Sara; Swissa, Moshe; Lotan, Chaim			Improvement in cardiac dysfunction with a novel circuit training method combining simultaneous aerobic-resistance exercises. A randomized trial	PLOS ONE			English	Article							CHRONIC HEART-FAILURE; LEFT-VENTRICULAR FUNCTION; SKELETAL-MUSCLE; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; ENDURANCE; REHABILITATION; CAPACITY; RISK; METABOLISM	Introduction Exercise is considered a valuable nonpharmacological intervention modality in cardiac rehabilitation (CR) programs in patients with ischemic heart disease. The effect of aerobic interval exercise combined with alternating sets of resistance training (super-circuit training, SCT) on cardiac patients' with reduced left ventricular function, post-myocardial infarction (MI) has not been thoroughly investigated. Aim of study to improve cardiac function with a novel method of combined aerobic-resistance circuit training in a randomized control trial by way of comparing the effectiveness of continuous aerobic training (CAT) to SCT on mechanical cardiac function. Secondary to compare their effect on aerobic fitness, manual strength, and quality of life in men post MI. Finally, to evaluate the safety and feasibility of SCT. Methods 29 men post-MI participants were randomly assigned to either 12-weeks of CAT (n = 15) or SCT (n = 14). Both groups, CAT and SCT exercised at 60%-70% and 75 +/- 85% of their heart rate reserve, respectively. The SCT group also engaged in intermittently combined resistance training. Primary outcome measure was echocardiography. Secondary outcome measures were aerobic fitness, strength, and quality of life (QoL). The effectiveness of the two training programs was examined via paired t-tests and Cohen's d effect size (ES). Results Post-training, only the SCT group presented significant changes in echocardiography (a reduction in E/e' and an increase in ejection fraction, P<0.05). Similarly, only the SCT group presented significant changes in aerobic fitness (an increase in maximal metabolic equivalent, P<0.05). In addition, SCT improvement in the physical component of QoL was greater than this observed in the CAT group. In both training programs, no adverse events were observed. Conclusion Men post-MI stand to benefit from both CAT and SCT. However, in comparison to CAT, as assessed by echocardiography, SCT may yield greater benefits to the left ventricle mechanical function as well as to the patient's aerobic fitness and physical QoL. Moreover, the SCT program was found to be feasible as well as safe.	[Dor-Haim, Horesh; Yaakobi, Eldad; Katzburg, Sara; Lotan, Chaim] Hadassah Hebrew Univ Hosp, Heart Inst, Jerusalem, Israel; [Barak, Sharon] Edmond & Lily Safra Childrens Hosp, Chaim Sheba Med Ctr, Ramat Gan, Israel; [Barak, Sharon] Kaye Acad Coll Educ, Beer Sheva, Israel; [Horowitz, Michal] Hadassah Hebrew Univ, Med Ctr, Dept Physiol, Jerusalem, Israel; [Swissa, Moshe] Cardiac Res Ctr, Kaplan Med Ctr, Rehovot, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Dor-Haim, H (corresponding author), Hadassah Hebrew Univ Hosp, Heart Inst, Jerusalem, Israel.	horesh@o-2.co.il	Dor-Haim, Horesh/AAG-5001-2019					Adachi H, 1996, EUR HEART J, V17, P1511; ADAMOPOULOS S, 1993, J AM COLL CARDIOL, V21, P1101, DOI 10.1016/0735-1097(93)90231-O; Belardinelli R, 1996, AM HEART J, V132, P61, DOI 10.1016/S0002-8703(96)90391-9; Bjarnason-Wehrens B, 2004, EUR J CARDIOV PREV R, V11, P352, DOI 10.1097/01.hjr.0000137692.36013.27; Braith RW, 2006, CIRCULATION, V113, P2642, DOI 10.1161/CIRCULATIONAHA.105.584060; Cannistra L B, 1999, J Cardiopulm Rehabil, V19, P373, DOI 10.1097/00008483-199911000-00009; Cheetham C, 2002, J APPL PHYSIOL, V93, P175, DOI 10.1152/japplphysiol.01240.2001; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COHEN J, 1977, STAT POWER ANAL BEHA, P20; Dor-Haim H, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005989; Dor-Haim H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066658; Dubach P, 1997, CIRCULATION, V95, P2060, DOI 10.1161/01.CIR.95.8.2060; Edelmann F, 2011, J AM COLL CARDIOL, V58, P1780, DOI 10.1016/j.jacc.2011.06.054; Ellison GM, 2012, HEART, V98, P5, DOI 10.1136/heartjnl-2011-300639; Garner NC, 1992, CLIN ASSESSMENT RECO, P50; GETTMAN LR, 1982, MED SCI SPORT EXER, V14, P229; Giallauria F, 2008, EUR J CARDIOV PREV R, V15, P113, DOI 10.1097/HJR.0b013e3282f00990; Giallauria F, 2009, INT J CARDIOL, V136, P300, DOI 10.1016/j.ijcard.2008.05.026; Gormley SE, 2008, MED SCI SPORT EXER, V40, P1336, DOI 10.1249/MSS.0b013e31816c4839; Gottdiener JS, 2004, J AM SOC ECHOCARDIOG, V17, P1086, DOI 10.1016/j.echo.2004.07.013; Hambrecht R, 2000, JAMA-J AM MED ASSOC, V283, P3095, DOI 10.1001/jama.283.23.3095; Haykowsky MJ, 2007, J AM COLL CARDIOL, V49, P2329, DOI 10.1016/j.jacc.2007.02.055; HEDBACK B, 1990, SCAND J REHABIL MED, V22, P15; La Gerche A, 2012, EUR HEART J, V33, P998, DOI 10.1093/eurheartj/ehr397; LAVIE CJ, 1995, AM J CARDIOL, V76, P177, DOI 10.1016/S0002-9149(99)80054-X; Leon AS, 2005, CIRCULATION, V111, P369, DOI 10.1161/01.CIR.0000151788.08740.5C; Leong DP, 2015, LANCET, V386, P266, DOI 10.1016/S0140-6736(14)62000-6; LIPKIN DP, 1988, INT J CARDIOL, V18, P187, DOI 10.1016/0167-5273(88)90164-7; Maiorana A, 2000, J APPL PHYSIOL, V88, P1565, DOI 10.1152/jappl.2000.88.5.1565; MANCINI DM, 1992, CIRCULATION, V85, P1364, DOI 10.1161/01.CIR.85.4.1364; MATHIOWETZ V, 1985, ARCH PHYS MED REHAB, V66, P69; McKelvie RS, J AM COLL CARDIOL, V195, P789; MINOTTI JR, 1993, J APPL PHYSIOL, V75, P373, DOI 10.1152/jappl.1993.75.1.373; Mora S, 2007, CIRCULATION, V116, P2110, DOI 10.1161/CIRCULATIONAHA.107.729939; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Mosher PE, 1994, J STRENGTH COND RES, V88, P144; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Rognmo O, 2012, CIRCULATION, V126, P1436, DOI 10.1161/CIRCULATIONAHA.112.123117; Selig SE, 2004, J CARD FAIL, V10, P21, DOI 10.1016/S1071-9164(03)00583-9; Shephard RJ, 1999, CIRCULATION, V99, P963, DOI 10.1161/01.CIR.99.7.963; Skidmore BL, 2012, J SPORT SCI MED, V11, P660; Smart NA, 2013, INT J CARDIOL, V166, P352, DOI 10.1016/j.ijcard.2011.10.075; Wilson M, 2011, J APPL PHYSIOL, V110, P1622, DOI 10.1152/japplphysiol.01280.2010	43	12	13	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 29	2018	13	1							e0188551	10.1371/journal.pone.0188551	http://dx.doi.org/10.1371/journal.pone.0188551			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU0AV	29377893	gold, Green Published, Green Submitted			2023-01-03	WOS:000423514700003
J	Martin, EG; Schackman, BR				Martin, Erika G.; Schackman, Bruce R.			Treating and Preventing HIV with Generic Drugs - Barriers in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SAVINGS; THERAPY		[Martin, Erika G.] SUNY Albany, Rockefeller Inst Govt, Albany, NY 12222 USA; [Martin, Erika G.] SUNY Albany, Dept Publ Adm & Policy, Albany, NY 12222 USA; [Schackman, Bruce R.] Weill Cornell Med Coll, Dept Healthcare Policy & Adm, New York, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Cornell University	Martin, EG (corresponding author), SUNY Albany, Rockefeller Inst Govt, Albany, NY 12222 USA.; Martin, EG (corresponding author), SUNY Albany, Dept Publ Adm & Policy, Albany, NY 12222 USA.		Schackman, Bruce R./J-8208-2019	Schackman, Bruce R./0000-0002-1132-2932; Martin, Erika/0000-0003-2607-8933				Colgan S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008915; Jacomet C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117214; Mollan KR, 2014, ANN INTERN MED, V161, P1, DOI 10.7326/M14-0293; Schackman BR, 2015, MED CARE, V53, P293, DOI 10.1097/MLR.0000000000000308; Walensky RP, 2013, ANN INTERN MED, V158, P84, DOI 10.7326/0003-4819-158-2-201301150-00002	5	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2018	378	4					316	319		10.1056/NEJMp1710914	http://dx.doi.org/10.1056/NEJMp1710914			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT5ZX	29365306	Bronze			2023-01-03	WOS:000423233400004
J	DeMichele, A; Yee, D; Esserman, L				DeMichele, Angela; Yee, Douglas; Esserman, Laura			Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[DeMichele, Angela] Univ Penn, Philadelphia, PA 19104 USA; [Yee, Douglas] Univ Minnesota, Minneapolis, MN USA; [Esserman, Laura] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Pennsylvania; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco	DeMichele, A (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.			Yee, Douglas/0000-0002-3387-4009				Begley S., 2017, STAT            0710; Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Esserman LJ, 2017, JAMA ONCOL, V3, P1503, DOI 10.1001/jamaoncol.2017.1261; Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026; Knapton, 2017, TELEGRAPH; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Schwartz RS, 2017, NEW ENGL J MED, V376, P2486, DOI 10.1056/NEJMcibr1701388; Yirka B., 2017, MED PRESS       0706	9	56	59	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2017	377	23					2287	2289		10.1056/NEJMcibr1711545	http://dx.doi.org/10.1056/NEJMcibr1711545			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FO9IL	29211674				2023-01-03	WOS:000417201100015
J	Darrow, JJ; Beall, RF; Kesselheim, AS				Darrow, Jonathan J.; Beall, Reed F.; Kesselheim, Aaron S.			Will inter partes review speed US generic drug entry?	NATURE BIOTECHNOLOGY			English	Editorial Material								A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.	[Darrow, Jonathan J.; Beall, Reed F.; Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, PORTAL, 75 Francis St, Boston, MA 02115 USA; [Darrow, Jonathan J.; Beall, Reed F.; Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Darrow, JJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, PORTAL, 75 Francis St, Boston, MA 02115 USA.; Darrow, JJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	jjdarrow@bwh.harvard.edu	Darrow, J J/R-8365-2019	Darrow, J J/0000-0002-7351-4243				Duffy J. F., 2015, G WASHINGTON LAW REV, V83, P28; Goldstein R. W., 2015, 2015 REPORT EC SURVE; Grabowski H, 2016, J MED ECON, V19, P836, DOI 10.1080/13696998.2016.1176578	3	7	7	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2017	35	12					1139	1141		10.1038/nbt.4036	http://dx.doi.org/10.1038/nbt.4036			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FP4TQ	29220017				2023-01-03	WOS:000417609700016
J	Xi, JJ; Huang, Q; Wang, LD; Ma, XD; Deng, QP; Kumar, M; Zhou, ZY; Li, L; Zeng, ZY; Young, KH; Zhang, MZ; Li, Y				Xi, Jiajia; Huang, Qian; Wang, Lei; Ma, Xiaodong; Deng, Qipan; Kumar, Munish; Zhou, Zhiyuan; Li, Ling; Zeng, Zhaoyang; Young, Ken H.; Zhang, Mingzhi; Li, Yong			miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; INTERFERON-GAMMA; IFN-GAMMA; EXPRESSION; MICRORNAS; CANCER; IDENTIFICATION; CELLS; RNAS; INTERLEUKIN-4	MicroRNA-21 (miR-21) is one of the most abundant microRNAs in mammalian cells. It has been intensively studied for its role in regulating apoptosis and oncogenic transformation. However, the impact of miR-21 on host anti-tumor immunity remains unknown. Tumor-associated macrophages are a major leukocyte type that infiltrates tumors and predominantly develops into immunosuppressive, tumor-promoting M2-like macrophages. In contrast, the pro-inflammatory M1-like macrophages have tumoricidal activity. In this study, we show that genetic deficiency of miR-21 promotes the polarization of macrophages toward an M1-like phenotype in vivo and in vitro in the presence of tumor cells; thus it confers host mice with enhanced anti-tumor immunity. By downregulating JAK2 and STAT1, miR-21 inhibits the IFN-gamma-induced STAT1 signaling pathway, which is required for macrophage M1 polarization. We also show that the expression of miR-21 in macrophages is regulated upon polarization stimuli as well as upon macrophages co-culturing with tumor cells. Thus, tumor cells may stimulate miR-21 expression in tumor-associated macrophages to prevent tumoricidal M1 polarization. However, augmented STAT1 signaling mediated by miR-21 deficiency upregulates PD-L1 expression in macrophages, which is known to inhibit phagocytic anti-tumor activity. This adverse effect can be alleviated by PD-1 blockade; indeed, miR-21 depletion in macrophages and PD-1 antibody treatment offer superior anti-tumor activity than either agent alone. These studies shed lights on potential application of the combination of miR-21 inhibition and immune checkpoint blockade to target the tumor microenvironment.	[Xi, Jiajia; Huang, Qian; Ma, Xiaodong; Deng, Qipan; Kumar, Munish; Zhou, Zhiyuan; Li, Yong] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Wang, Lei; Ma, Xiaodong] South China Normal Univ, Inst Brain Res & Rehabil, Guangzhou 510631, Guangdong, Peoples R China; [Kumar, Munish] Univ Allahabad, Dept Biochem, UGC, Allahabad, Uttar Pradesh, India; [Zhou, Zhiyuan; Li, Ling; Zhang, Mingzhi] Zhengzhou Univ, Affiliated Hosp 1, Lymphoma Diag & Treatment Ctr Henan Prov, Dept Oncol, Zhengzhou 450000, Henan, Peoples R China; [Zeng, Zhaoyang] Cent South Univ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Young, Ken H.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Cleveland Clinic Foundation; South China Normal University; University of Allahabad; Zhengzhou University; Central South University; University of Texas System; UTMD Anderson Cancer Center	Li, Y (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA.	liy2@ccf.org	li, li/HII-4157-2022; LI, LI QING/GRR-8855-2022; Li, Li/AEM-3636-2022; Kumar, Munish/Z-4106-2019; LI, LI/GVS-5344-2022; li, li/AAT-2097-2020; MA, XIAO/HHN-5611-2022; li, li/GPX-3938-2022	Li, Yong/0000-0001-8838-1714; Deng, Qipan/0000-0002-3803-1676; Wang, Lei/0000-0001-5492-5613	NIH [CA138688, CA177810]; Natural Science Foundation of China [81528019]; NATIONAL CANCER INSTITUTE [R01CA177810, R01CA138688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study is supported by NIH R01 grants (CA138688 and CA177810) and Natural Science Foundation of China (No. 81528019).	Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Anaya J., 2016, PEER J COMPUT SCI, V13, P2; Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Buscaglia Lindsey E Becker, 2011, Chin J Cancer, V30, P371; Caescu CI, 2015, BLOOD, V125, pE1, DOI 10.1182/blood-2014-10-608000; Carissimi C, 2014, BIOCHIMIE, V107, P319, DOI 10.1016/j.biochi.2014.09.021; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Duchaine TF, 2009, CURR ONCOL, V16, P265; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Haverkamp JM, 2014, IMMUNITY, V41, P947, DOI 10.1016/j.immuni.2014.10.020; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Liu Y, 2016, CANCER LETT, V370, P125, DOI 10.1016/j.canlet.2015.10.011; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Ma XD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8151; Ma XD, 2013, CARCINOGENESIS, V34, P1216, DOI 10.1093/carcin/bgt044; Ma XD, 2011, P NATL ACAD SCI USA, V108, P10144, DOI 10.1073/pnas.1103735108; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Pratheeshkumar P, 2016, SCI REP-UK, V6, DOI 10.1038/srep37227; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Rutschman R, 2001, J IMMUNOL, V166, P2173, DOI 10.4049/jimmunol.166.4.2173; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAUB DD, 1995, J LEUKOCYTE BIOL, V58, P80, DOI 10.1002/jlb.58.1.80; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Venturutti L, 2016, ONCOGENE, V35, P2208, DOI 10.1038/onc.2015.281; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	49	72	74	0	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	23					3151	3165		10.1038/s41388-018-0178-3	http://dx.doi.org/10.1038/s41388-018-0178-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GI6VO	29540832	Green Accepted			2023-01-03	WOS:000434641400008
J	Ribas, A; Wolchok, JD				Ribas, Antoni; Wolchok, Jedd D.			Cancer immunotherapy using checkpoint blockade	SCIENCE			English	Review							LONG-TERM SURVIVAL; PD-1 BLOCKADE; ACQUIRED-RESISTANCE; CTLA-4 BLOCKADE; ANTITUMOR IMMUNITY; TUMOR RESPONSE; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; MELANOMA	The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumorresponses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination. The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints. Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse. Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-g signaling pathways. New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.	[Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA; [Ribas, Antoni] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Ribas, Antoni] Univ Calif Los Angeles, Parker Inst Canc Immunotherapy, Los Angeles, CA 90095 USA; [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, Dept Med, New York, NY 10065 USA; [Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, New York, NY 10065 USA; [Wolchok, Jedd D.] Weill Cornell Med & Grad Coll, New York, NY 10065 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Ribas, A (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.; Ribas, A (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA.; Ribas, A (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.; Ribas, A (corresponding author), Univ Calif Los Angeles, Parker Inst Canc Immunotherapy, Los Angeles, CA 90095 USA.; Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, Ludwig Ctr, Dept Med, New York, NY 10065 USA.; Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, New York, NY 10065 USA.; Wolchok, JD (corresponding author), Weill Cornell Med & Grad Coll, New York, NY 10065 USA.	aribas@mednet.ucla.edu; wolchokj@mskcc.org		Wolchok, Jedd/0000-0001-6718-2222	NIH [R35 CA197633, P01 CA168585, P30 CA016042, R01 CA056821, P30 CA008748]; Ressler Family Fund; Grimaldi Family Fund; Garcia-Corsini Family Fund; Swim Across America; Ludwig Cancer Research; Hazen-Polsky Family Fund; Hogan Family Fund; Live4Life Foundation; Etta Weinheim Fund; NATIONAL CANCER INSTITUTE [R35CA197633, P30CA008748, P01CA168585, R01CA056821, P30CA016042] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ressler Family Fund; Grimaldi Family Fund; Garcia-Corsini Family Fund; Swim Across America; Ludwig Cancer Research; Hazen-Polsky Family Fund; Hogan Family Fund; Live4Life Foundation; Etta Weinheim Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R35 CA197633, P01 CA168585, and P30 CA016042 (A.R.) and R01 CA056821 and P30 CA008748 (J.D.W.), with additional support from the Ressler Family Fund, the Grimaldi Family Fund, and the Garcia-Corsini Family Fund (A.R.) and Swim Across America, Ludwig Cancer Research, the Hazen-Polsky Family Fund, the Hogan Family Fund, Live4Life Foundation, and the Etta Weinheim Fund (J.D.W.). Both authors are members of the Parker Institute for Cancer Immunotherapy.	Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Blank CU, 2016, SCIENCE, V352, P658, DOI 10.1126/science.aaf2834; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Carthon BC, 2010, CLIN CANCER RES, V16, P2861, DOI 10.1158/1078-0432.CCR-10-0569; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Eroglu Z, 2018, NATURE, V553, P347, DOI 10.1038/nature25187; Eroglu Z, 2015, EUR J CANCER, V51, P2689, DOI 10.1016/j.ejca.2015.08.012; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gettinger S, 2017, CANCER DISCOV, V7, P1420, DOI 10.1158/2159-8290.CD-17-0593; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; Manguso RT, 2017, NATURE, V547, P413, DOI 10.1038/nature23270; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMc1801663, 10.1056/NEJMra1703481]; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Reichel J, 2015, BLOOD, V125, P1061, DOI 10.1182/blood-2014-11-610436; Ribas A, 2005, J CLIN ONCOL, V23, P8968, DOI 10.1200/JCO.2005.01.109; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Sucker A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15440; SZNOL M, 2010, J CLIN ONCOL S, V28; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	61	2794	2890	158	1265	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2018	359	6382			SI		1350	+		10.1126/science.aar4060	http://dx.doi.org/10.1126/science.aar4060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA0ZG	29567705	Green Accepted			2023-01-03	WOS:000428043600036
J	Thomas, C				Thomas, Carolyn			WHAT YOUR PATIENT IS THINKING What I wish I'd known before my hospital discharge	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	2018	360								k1192	10.1136/bmj.k1192	http://dx.doi.org/10.1136/bmj.k1192			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB1LG	29563089	Green Published, Bronze			2023-01-03	WOS:000428811700002
J	Gupta, R; Bollyky, TJ; Cohen, M; Ross, JS; Kesselheim, AS				Gupta, Ravi; Bollyky, Thomas J.; Cohen, Matthew; Ross, Joseph S.; Kesselheim, Aaron S.			Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHARMACEUTICALS; ADHERENCE; OUTCOMES; COHORT	OBJECTIVES To evaluate whether off-patent prescription drugs at risk of sudden price increases or shortages in the United States are available from independent manufacturers approved in other well regulated settings around the world. DESIGN Observational study. SETTING Off-patent drugs in the USA and approved by the Food and Drug Administration, up to 10 April 2017. STUDY COHORT Novel tablet or capsule prescription drugs approved by the FDA since 1939 that were no longer protected by patents or other market exclusivity and had up to three generic versions. MAIN OUTCOME MEASURES Number of additional manufacturers that had obtained approval from any of seven non-US regulators with similar standards (European Medicines Agency (European Union), HealthCanada (Canada), Therapeutic Goods Association (Australia), Medsafe (New Zealand), Swissmedic (Switzerland), Medicines Control Council (South Africa), and the Israel Health Ministry). Association with drug characteristics including US orphan drug designation for drugs treating rare diseases, World Health Organization essential medicine designation, treatment area, drug product complexity (that is, with attributes that could complicate establishing bioequivalence or manufacturing), and total Medicaid spending in 2015. RESULTS Of 170 eligible study drugs, more than half (109, 64%) had at least one manufacturer approved by a non-US regulator and 32 (19%) had four or more. Among 44 (26%) drugs with no FDA approved generic versions, 21 (48%) were available from at least one manufacturer approved by one of the seven non-US regulators, and two (5%) by four or more manufacturers. Across all drugs and regulators (including the FDA), 66 (39%) drugs were available from four or more total manufacturers. Of 109 drugs with at least one non-US regulator approved manufacturer, 12 (11%) were approved for patients with rare diseases and 29 (27%) were WHO designated essential medicines; only 12 (11%) were complex products that might be more complicated to import. The highest numbers of drugs were indicated for treating cardiovascular diseases, diabetes, or hyperlipidemia (19, 17%); psychiatric disease (16, 15%); and infectious diseases (15, 14%). In 2015, Medicaid alone spent nearly US$ 700m (508m; pound (sic)570m) on generic drugs without adequate US competition that could have had a manufacturer approved by non-US peer regulatory agencies. CONCLUSION In this study, more than half the off-patent drugs with no generic competition in the USA had at least one independent manufacturer approved by a non-US peer regulatory agency; slightly fewer than half had four or more total manufacturers. Facilitating US patient access to such manufacturers could help sustain affordable access to essential off-patent drugs.	[Gupta, Ravi] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA; [Gupta, Ravi] Johns Hopkins Sch Med, Baltimore, MD USA; [Bollyky, Thomas J.; Cohen, Matthew] Council Foreign Relat, Global Hlth Econ & Dev, Washington, DC USA; [Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Sect Gen Internal Med, New Haven, CT 06510 USA; [Ross, Joseph S.] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA; [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, 20 York St, New Haven, CT 06504 USA; [Kesselheim, Aaron S.] Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA; [Kesselheim, Aaron S.] Harvard Med Sch, Boston, MA 02120 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Yale University; Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA.; Kesselheim, AS (corresponding author), Harvard Med Sch, Boston, MA 02120 USA.	akesselheim@partners.org		Cohen, Matthew/0000-0001-9087-2678; Ross, Joseph/0000-0002-9218-3320	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science; Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Laura and John Arnold Foundation; Engelberg Foundation; Harvard Program in Therapeutic Science; Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Study funded by the Laura and John Arnold Foundation, with additional support from the Engelberg Foundation, Harvard Program in Therapeutic Science, and Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation. The funders were independent from the research development or conduct.	Ashley DD, 2017, NEW ENGL J MED, V377, P1699, DOI 10.1056/NEJMc1711278; Barbui C, 2015, EPIDEMIOL PSYCH SCI, V24, P23, DOI 10.1017/S2045796014000754; Barua B, 2013, CASE MUTUAL RECOGNIT; Bollyky TJ, 2017, CAN DRUG IMPORTATION; Centers for Medicare & Medicaid Services, 2016, MED DRUG SPEND DASHB; Dave CV, 2017, ANN INTERN MED, V167, P145, DOI 10.7326/M16-1432; De Weerdt E, 2017, APPL HEALTH ECON HEA, V15, P441, DOI 10.1007/s40258-016-0264-z; Feldman R, 2017, DATABASE EMPIRICAL E; Freeh S, 2017, REPORT POTENTIAL IMP; Gagne JJ, 2014, ANN INTERN MED, V161, P400, DOI 10.7326/M13-2942; Generic Pharmaceutical Association, 2016, GEN DRUGS CONT DEL B; Generic Pharmaceutical Association, 2015, GEN DRUG SAV US; Greene JA, 2016, JAMA-J AM MED ASSOC, V315, P461, DOI 10.1001/jama.2015.18720; Gupta R, 2016, JAMA INTERN MED, V176, P1391, DOI 10.1001/jamainternmed.2016.3411; Howard P, 2014, HLTH AFFAIRS BLOG; Hussaarts L, 2017, ANN NY ACAD SCI, V1407, P39, DOI 10.1111/nyas.13347; International Trade Administration US Department of Commerce, 2016, TOP MARK REP PHARM; Kaiser Family Foundation, 2016, KAISER HLTH TRACKING; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Kesselheim AS, 2016, J GEN INTERN MED, V31, P609, DOI 10.1007/s11606-016-3612-7; Kesselheim AS, 2010, DRUGS, V70, P605, DOI 10.2165/10898530-000000000-00000; Labiris G, 2015, SCI CAIRO, V2015, DOI [10.1155/2015/251792/jrn, DOI 10.1155/2015/251792/JRN]; Larochelle M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014582; Lionberger R., 2014, DEV NEW BIOEQUIVALEN; McGinley L, 2017, WASHINGTON POST; Medicaid. gov, 2017, MED CHIP ENR DAT HIG; Pollack A, 2015, NY TIMES, pB2; Ross JS, 2016, JAMA INTERN MED, V176, P776, DOI 10.1001/jamainternmed.2016.2271; Sagonowsky E., 2017, TOP 15 GENERIC DRUGM; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; United States Government Accountability Office, 2016, GEN DRUGS MED D; US Food and Drug Administration, 2017, PRIOR REV OR ANDAS A; US Food and Drug Administration, 2012, TEMP IMP LIP; US Food and Drug Administration, 2017, FDA TAK UNPR STEP MO; US Food and Drug Administration, 2005, FDA AN RET SAL DAT I; US Food and Drug Administration, 2017, REG PROC MAN; US Food and Drug Administration, 2017, DES ORPH PROD DRUGS; US Government Accountability Office, 2016, DRUG SAF FDA HAS IMP; US Government Accountability Office, 2014, DRUG SHORT PUBL HLTH; Ventola C Lee, 2011, P T, V36, P740; Wiske CP, 2015, JAMA-J AM MED ASSOC, V314, P2129, DOI 10.1001/jama.2015.13498; Woodcock J., 2016, IMPLEMENTATION GENER; World Health Organization, 2015, WHO MOD LIST ESS MED; World Health Organization (WHO), 2016, WHO ATC DDD IND 2017	44	12	12	3	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2018	360								k831	10.1136/bmj.k831	http://dx.doi.org/10.1136/bmj.k831			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB1KM	29555641	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000428809700016
J	Menciassi, A				Menciassi, Arianna			Swell Findings in Hydrogels	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Menciassi, Arianna] Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy	Scuola Superiore Sant'Anna	Menciassi, A (corresponding author), Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy.							[Anonymous], 2017, SCIENCE, V357, P1126; Koetting MC, 2015, MAT SCI ENG R, V93, P1, DOI 10.1016/j.mser.2015.04.001	2	2	2	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 1	2018	378	9					864	865		10.1056/NEJMcibr1712116	http://dx.doi.org/10.1056/NEJMcibr1712116			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FX7GP	29490176				2023-01-03	WOS:000426256300015
J	Wagner, J; Strosing, KM; Spassov, SG; Lin, ZW; Engelstaedter, H; Tacke, S; Hoetzel, A; Faller, S				Wagner, Julie; Strosing, Karl M.; Spassov, Sashko G.; Lin, Ziwei; Engelstaedter, Helen; Tacke, Sabine; Hoetzel, Alexander; Faller, Simone			Sevoflurane posttreatment prevents oxidative and inflammatory injury in ventilator-induced lung injury	PLOS ONE			English	Article							POST-CONDITIONING PROTECTS; ISOLATED RAT HEARTS; VOLATILE ANESTHETICS; REPERFUSION INJURY; SURGERY; ACTIVATION; SURVIVAL; BRAIN	Mechanical ventilation is a life-saving clinical treatment but it can induce or aggravate lung injury. New therapeutic strategies, aimed at reducing the negative effects of mechanical ventilation such as excessive production of reactive oxygen species, release of pro-inflammatory cytokines, and transmigration as well as activation of neutrophil cells, are needed to improve the clinical outcome of ventilated patients. Though the inhaled anesthetic sevoflurane is known to exert organ-protective effects, little is known about the potential of sevoflurane therapy in ventilator-induced lung injury. This study focused on the effects of delayed sevoflurane application in mechanically ventilated C57BL/6N mice. Lung function, lung injury, oxidative stress, and inflammatory parameters were analyzed and compared between non-ventilated and ventilated groups with or without sevoflurane anesthesia. Mechanical ventilation led to a substantial induction of lung injury, reactive oxygen species production, pro-inflammatory cytokine release, and neutrophil influx. In contrast, sevoflurane posttreatment time dependently reduced histological signs of lung injury. Most interestingly, increased production of reactive oxygen species was clearly inhibited in all sevoflurane posttreatment groups. Likewise, the release of the pro-inflammatory cytokines interleukin-1 beta and MIP-1 beta and neutrophil transmigration were completely prevented by sevoflurane independent of the onset of sevoflurane administration. In conclusion, sevoflurane posttreatment time dependently limits lung injury, and oxidative and pro-inflammatory responses are clearly prevented by sevoflurane irrespective of the onset of posttreatment. These findings underline the therapeutic potential of sevoflurane treatment in ventilator-induced lung injury.	[Wagner, Julie; Strosing, Karl M.; Spassov, Sashko G.; Lin, Ziwei; Engelstaedter, Helen; Hoetzel, Alexander; Faller, Simone] Univ Freiburg, Fac Med, Dept Anesthesiol & Crit Care Med, Med Ctr, Freiburg, Germany; [Wagner, Julie; Tacke, Sabine] Justus Liebig Univ Giessen, Dept Vet Clin Sci, Clin Small Anim Surg, Giessen, Germany	University of Freiburg; Justus Liebig University Giessen	Faller, S (corresponding author), Univ Freiburg, Fac Med, Dept Anesthesiol & Crit Care Med, Med Ctr, Freiburg, Germany.	simone.faller@uniklinik-freiburg.de	Tacke, Sabine/A-3213-2019; Spassov, Sashko/C-2105-2013	Spassov, Sashko/0000-0002-3585-3682; Faller, Simone/0000-0001-5345-8523	German Research Foundation [DFG HO 2464/3-1]; Department of Anesthesiology and Critical Care Medicine, University Medical Center Freiburg, Freiburg, Germany; German Research Foundation (DFG); University of Freiburg	German Research Foundation(German Research Foundation (DFG)); Department of Anesthesiology and Critical Care Medicine, University Medical Center Freiburg, Freiburg, Germany; German Research Foundation (DFG)(German Research Foundation (DFG)); University of Freiburg	This work was supported by a grant from the German Research Foundation, dedicated to AH (DFG HO 2464/3-1, Bonn, Germany) and by the Department of Anesthesiology and Critical Care Medicine, University Medical Center Freiburg, Freiburg, Germany. The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding programme Open Access Publishing to SF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamczyk S, 2010, BRIT J ANAESTH, V104, P191, DOI 10.1093/bja/aep365; Annecke T, 2008, ACTA ANAESTH SCAND, V52, P977, DOI 10.1111/j.1399-6576.2008.01665.x; Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cai JR, 2014, J THORAC CARDIOV SUR, V148, P3127, DOI 10.1016/j.jtcvs.2014.07.085; Chapman KE, 2005, AM J PHYSIOL-LUNG C, V289, pL834, DOI 10.1152/ajplung.00069.2005; Du GZ, 2017, ANESTH ANALG, V124, P1555, DOI [10.1213/ane.0000000000002034, 10.1213/ANE.0000000000002034]; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Faller S, 2012, LAB INVEST, V92, P999, DOI 10.1038/labinvest.2012.55; Faller S, 2012, ANESTH ANALG, V114, P747, DOI 10.1213/ANE.0b013e31824762f0; Faller S, 2010, ANESTHESIOLOGY, V113, P104, DOI 10.1097/ALN.0b013e3181de7107; Fanelli Vito, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS3, DOI 10.1513/AnnalsATS.201407-340MG; Frank JA, 2008, THORAX, V63, P147, DOI 10.1136/thx.2007.079608; Gong JS, 2012, MOL BIOL REP, V39, P6417, DOI 10.1007/s11033-012-1447-9; Head BP, 2007, CURR OPIN ANESTHESIO, V20, P395, DOI 10.1097/ACO.0b013e3282efa69d; Kalb R, 2008, EUR J ANAESTH, V25, P454, DOI 10.1017/S0265021508003682; Landoni G, 2008, CURR VASC PHARMACOL, V6, P108, DOI 10.2174/157016108783955284; Lee HT, 2007, SHOCK, V27, P373, DOI 10.1097/01.shk.0000248595.17130.24; Li H, 2008, CLIN EXP PHARMACOL P, V35, P1043, DOI 10.1111/j.1440-1681.2008.04952.x; Lionetti V, 2005, CURR OPIN CRIT CARE, V11, P82, DOI 10.1097/00075198-200502000-00013; Mesnil M, 2011, INTENS CARE MED, V37, P933, DOI 10.1007/s00134-011-2187-3; Neto AS, 2015, CRIT CARE MED, V43, P2155, DOI 10.1097/CCM.0000000000001189; Otsuki T, 2015, BIOMED REP, V3, P408, DOI 10.3892/br.2015.428; Pagel PS, 2011, J CARDIOTHOR VASC AN, V25, P1125, DOI 10.1053/j.jvca.2010.09.017; Redel A, 2009, EXP BIOL MED, V234, P1186, DOI 10.3181/0902-RM-58; Ricard JD, 2003, EUR RESPIR J, V22, p2S, DOI 10.1183/09031936.03.00420103; Neto AS, 2015, ANESTHESIOLOGY, V123, P66, DOI 10.1097/ALN.0000000000000706; Spassov SG, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3715037; Strosing KM, 2016, ANESTH ANALG, V123, P143, DOI 10.1213/ANE.0000000000001296; Suter D, 2007, ANESTH ANALG, V104, P638, DOI 10.1213/01.ane.0000255046.06058.58; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Tsushima K, 2009, INTERNAL MED, V48, P621, DOI 10.2169/internalmedicine.48.1741; Voigtsberger S, 2009, ANESTHESIOLOGY, V111, P1238, DOI 10.1097/ALN.0b013e3181bdf857; WRIGHT DT, 1994, ENVIRON HEALTH PERSP, V102, P85, DOI 10.2307/3432221; Xie H, 2014, ACTA PHARMACOL SIN, V35, P1504, DOI 10.1038/aps.2014.78; Xiong XQ, 2013, INT J NANOMED, V8, P1075, DOI 10.2147/IJN.S41625; Yao YT, 2010, MOL BIOL REP, V37, P2439, DOI 10.1007/s11033-009-9755-4; Ye Z, 2015, J NEUROL SCI, V348, P216, DOI 10.1016/j.jns.2014.12.011; Yu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134666; Yu QB, 2015, GENET MOL RES, V14, P19016, DOI 10.4238/2015.December.29.9; Zhang Y, 2017, LIFE SCI, V173, P68, DOI 10.1016/j.lfs.2017.02.006; Zhao SP, 2014, MOL MED REP, V9, P2435, DOI 10.3892/mmr.2014.2094; Zurek M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151211	43	28	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2018	13	2							e0192896	10.1371/journal.pone.0192896	http://dx.doi.org/10.1371/journal.pone.0192896			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX1SB	29470503	gold, Green Published, Green Submitted			2023-01-03	WOS:000425831000021
J	Baecher-Allan, C; Kaskow, BJ; Weiner, HL				Baecher-Allan, Clare; Kaskow, Belinda J.; Weiner, Howard L.			Multiple Sclerosis: Mechanisms and Immunotherapy	NEURON			English	Review							REGULATORY T-CELLS; NATURAL-KILLER-CELLS; PLACEBO-CONTROLLED TRIAL; MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MEMORY B-CELLS; DOUBLE-BLIND; PHASE-II; DISEASE-ACTIVITY; ASTROCYTE ACTIVATION	Multiple sclerosis (MS) is an autoimmune disease triggered by environmental factors that act on a genetically susceptible host. It features three clinical stages: a pre-clinical stage detectable only by MRI; a relapsing- remitting (RRMS) stage characterized by episodes of neurologic dysfunction followed by resolution; and a progressive stage, which usually evolves from the relapsing stage. Advances in our understanding of the immune mechanisms that contribute to MS have led to more than ten FDA-approved immunotherapeutic drugs that target effector T cells, regulatory cells, B cells, and cell trafficking into the nervous system. However, most drugs for relapsing MS are not effective in treating progressive disease. Progressive MS features a compartmentalized immune response in the central nervous system, involving microglia cells and astrocytes, as well as immune-independent processes that drive axonal dysfunction. Major challenges for MS research involve understanding the mechanisms of disease progression, developing treatment for progressive MS, and determining the degree to which progressive disease can be prevented by early treatment. Key priorities for MS research include developing biomarkers, personalized medicine and advanced imaging, and a better understanding of the microbiome. With a better understanding of the genetic and epidemiological aspects of this disease, approaches to prevent MS are now also being considered.	[Baecher-Allan, Clare; Kaskow, Belinda J.; Weiner, Howard L.] Harvard Med Sch, Brigham & Womens Hosp, Evergrande Ctr Immunol Dis, Partners MS Ctr,Dept Neurol,Ann Romney Ctr Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Weiner, HL (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Evergrande Ctr Immunol Dis, Partners MS Ctr,Dept Neurol,Ann Romney Ctr Neurol, Boston, MA 02115 USA.	hweiner@rics.bwh.harvard.edu		Baecher-Allan, Clare/0000-0003-2405-8525; Kaskow, Belinda/0000-0003-3132-4924	National Multiple Sclerosis Society [RR 205-A-13, RG-1507-05029. NMSS ICT 0010, RG-1506-04836]; NIH [R01 NS087226, UH3TR000890]; Evergrande Center for Immunologic Diseases; Nancy Davis Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087226] Funding Source: NIH RePORTER	National Multiple Sclerosis Society(National Multiple Sclerosis Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Evergrande Center for Immunologic Diseases; Nancy Davis Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from the National Multiple Sclerosis Society to H.L.W. (RR 205-A-13, RG-1507-05029. NMSS ICT 0010) and to C.B.-A. (RG-1506-04836), by NIH grants to H.L.W. (R01 NS087226, UH3TR000890), by the Evergrande Center for Immunologic Diseases, and by the Nancy Davis Foundation. We thank Dr. Tanuja Chitnis, Dr. Vijay Kuchroo, and Dr. Rohit Bakshi for their discussions on the manuscript.	Ahlgren C, 2012, MULT SCLER J, V18, P1099, DOI 10.1177/1352458511433062; Annibali V, 2011, BRAIN, V134, P542, DOI 10.1093/brain/awq354; Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755; Arnason BGW, 1999, NEUROLOGY, V53, P457, DOI 10.1212/wnl.53.3.457; Arnon R, 2004, P NATL ACAD SCI USA, V101, P14593, DOI 10.1073/pnas.0404887101; Astier AL, 2006, J CLIN INVEST, V116, P3252, DOI 10.1172/JCI29251; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Baker D, 2017, EBIOMEDICINE, V16, P41, DOI 10.1016/j.ebiom.2017.01.042; Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; Bar-Or A, 2001, J IMMUNOL, V167, P5669, DOI 10.4049/jimmunol.167.10.5669; Baranzini SE, 2017, MULT SCLER J, V23, P100; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Barun B, 2012, CLIN IMMUNOL, V142, P31, DOI 10.1016/j.clim.2011.04.005; Basso AS, 2008, J CLIN INVEST, V118, P1532, DOI 10.1172/JCI33464; Beauchemin P, 2016, MULT SCLER J, V22, P254, DOI 10.1177/1352458515623862; Becher B, 2002, J CLIN INVEST, V110, P493, DOI 10.1172/JCI200215751; Becher B, 2011, CURR OPIN IMMUNOL, V23, P707, DOI 10.1016/j.coi.2011.08.005; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Berghmans N, 2006, J NEUROIMMUNOL, V176, P63, DOI 10.1016/j.jneuroim.2006.04.009; Bermel RA, 2013, ANN NEUROL, V73, P95, DOI 10.1002/ana.23758; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bhela S, 2015, J IMMUNOL, V194, P2180, DOI 10.4049/jimmunol.1303257; Bible Ellen, 2014, Nat Rev Neurol, V10, P182, DOI 10.1038/nrneurol.2014.48; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bielekova B, 2006, P NATL ACAD SCI USA, V103, P5941, DOI 10.1073/pnas.0601335103; Billerbeck E, 2010, P NATL ACAD SCI USA, V107, P3006, DOI 10.1073/pnas.0914839107; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Boneschi FM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002127.pub3; Bosma A, 2012, IMMUNITY, V36, P477, DOI 10.1016/j.immuni.2012.02.008; Brandle SM, 2016, P NATL ACAD SCI USA, V113, P7864, DOI 10.1073/pnas.1522730113; Burt RK, 2015, JAMA-J AM MED ASSOC, V313, P275, DOI 10.1001/jama.2014.17986; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cantarel BL, 2015, J INVEST MED, V63, P729, DOI 10.1097/JIM.0000000000000192; Cao D, 2003, EUR J IMMUNOL, V33, P215, DOI 10.1002/immu.200390024; Cao YH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8038; Caruana P, 2017, MULT SCLER J, V23, P1479, DOI 10.1177/1352458516679267; Castillo-Trivino T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066308; Cepok S, 2001, BRAIN, V124, P2169, DOI 10.1093/brain/124.11.2169; Chataway J, 2018, NEUROLOGY; Chataway J, 2014, LANCET, V383, P2213, DOI 10.1016/S0140-6736(13)62242-4; Chen J, 2016, SCI REP-UK, V6, DOI 10.1038/srep28484; Chiarini M, 2012, MULT SCLER J, V18, P788, DOI 10.1177/1352458511427720; Cohen JA, 2016, LANCET NEUROL, V15, P373, DOI 10.1016/S1474-4422(16)00018-1; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Comabella M, 1998, J CLIN INVEST, V102, P671, DOI 10.1172/JCI3125; Comabella M, 2016, MULT SCLER J, V22, P257, DOI 10.1177/1352458515623863; Comabella M, 2014, LANCET NEUROL, V13, P113, DOI 10.1016/S1474-4422(13)70233-3; Comi G, 2013, MULT SCLER J, V19, P1428, DOI 10.1177/1352458513502572; Comi G, 2012, NEW ENGL J MED, V366, P1000, DOI 10.1056/NEJMoa1104318; Correale J, 2008, ANN NEUROL, V64, P187, DOI 10.1002/ana.21438; Correale J, 2017, BRAIN, V140, P527, DOI 10.1093/brain/aww258; Cosorich I, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700492; Costantino CM, 2008, EUR J IMMUNOL, V38, P921, DOI 10.1002/eji.200738104; Cree BAC, 2016, ANN NEUROL, V80, P443, DOI 10.1002/ana.24718; Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Cuss AK, 2006, J IMMUNOL, V176, P1506, DOI 10.4049/jimmunol.176.3.1506; d'Hennezel E, 2009, NEW ENGL J MED, V361, P1710, DOI 10.1056/NEJMc0907093; Daikeler T, 2012, PEDIATR RES, V71, P439, DOI 10.1038/pr.2011.57; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Duan HX, 2013, SCI REP-UK, V3, DOI 10.1038/srep01687; El Ayoubi NK, 2017, NEUROTHERAPEUTICS, V14, P135, DOI 10.1007/s13311-016-0486-7; ENDO T, 1984, J IMMUNOL, V132, P1793; Farez MF, 2015, J NEUROL NEUROSUR PS, V86, P26, DOI 10.1136/jnnp-2014-307928; Fassas A, 1997, BONE MARROW TRANSPL, V20, P631, DOI 10.1038/sj.bmt.1700944; Fisniku LK, 2008, ANN NEUROL, V64, P247, DOI 10.1002/ana.21423; Flores-Borja F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005407; Franklin RJM, 2017, NAT REV NEUROSCI, V18, P753, DOI 10.1038/nrn.2017.136; Friese MA, 2005, BRAIN, V128, P1747, DOI 10.1093/brain/awh578; Furlan R, 2001, J IMMUNOL, V167, P1821, DOI 10.4049/jimmunol.167.3.1821; Gale CR, 1995, PROG NEUROBIOL, V47, P425, DOI 10.1016/0301-0082(95)00033-X; Gandhi R, 2013, ANN NEUROL, V73, P729, DOI 10.1002/ana.23880; Gaublomme JT, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.009; Gharibi T, 2016, IMMUNOBIOLOGY, V221, P357, DOI 10.1016/j.imbio.2015.09.021; Giovannoni G, 2014, J NEUROL, V261, P316, DOI 10.1007/s00415-013-7196-4; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Gobin SJP, 2001, GLIA, V36, P68, DOI 10.1002/glia.1096; Goodkin D E, 1996, Mult Scler, V1, P321; Gray O, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003208.PUB2; Green AJ, 2017, LANCET, V390, P2481, DOI 10.1016/S0140-6736(17)32346-2; Greenfield A. L, 2017, ANN NEUROL; Gregori S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00030; Gross CC, 2016, P NATL ACAD SCI USA, V113, pE2973, DOI 10.1073/pnas.1524924113; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022; Haas J, 2005, EUR J IMMUNOL, V35, P3343, DOI 10.1002/eji.200526065; Habib Jakob, 2015, J Mult Scler (Foster City), V2; Hafler DA, 2007, NEW ENGL J MED, V357, P851, DOI 10.1056/NEJMoa073493; Harley JB, 2006, BULL HOSP JT DIS, V64, P45; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; HAUSER SL, 1986, ANN NEUROL, V19, P578, DOI 10.1002/ana.410190610; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Hauser SL, 2013, ANN NEUROL, V74, P317, DOI 10.1002/ana.24009; Havrdova E, 2016, J NEUROL, V263, P1287, DOI 10.1007/s00415-016-8128-x; Havrdova E, 2015, THER ADV NEUROL DISO, V8, P31, DOI 10.1177/1756285614563522; Healy BC, 2010, NEUROLOGY, V75, P634, DOI 10.1212/WNL.0b013e3181ed9c9c; Hedstrom AK, 2014, MULT SCLER J, V20, P406, DOI 10.1177/1352458513498126; Hedstrom AK, 2011, MULT SCLER J, V17, P788, DOI 10.1177/1352458511399610; Heidelberger M, 1942, J EXP MED, V75, P35, DOI 10.1084/jem.75.1.35; Hemmer B, 2000, J IMMUNOL, V164, P861, DOI 10.4049/jimmunol.164.2.861; Henderson APD, 2009, ANN NEUROL, V66, P739, DOI 10.1002/ana.21800; Hensiek AE, 2007, NEUROLOGY, V68, P376, DOI 10.1212/01.wnl.0000252822.53506.46; Hohol MJ, 1999, MULT SCLER, V5, P403, DOI 10.1191/135245899678846492; Hollenbach JA, 2015, J AUTOIMMUN, V64, P13, DOI 10.1016/j.jaut.2015.06.010; Hong J, 2009, INT IMMUNOL, V21, P1329, DOI 10.1093/intimm/dxp100; Hu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01571-8; Huber M, 2013, J CLIN INVEST, V123, P247, DOI 10.1172/JCI63681; Huppert J, 2010, FASEB J, V24, P1023, DOI 10.1096/fj.09-141978; Infante-Duarte C, 2005, FASEB J, V19, P1902, DOI 10.1096/fj.05-3832fje; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jacobsen M, 2002, BRAIN, V125, P538, DOI 10.1093/brain/awf059; Jangi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12015; Kalluri HV, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.12955; Kaltsonoudis E, 2014, AUTOIMMUN REV, V13, P54, DOI 10.1016/j.autrev.2013.09.002; Kappos L, 2015, NEW ENGL J MED, V373, P1418, DOI 10.1056/NEJMoa1501481; Kappos L., 2016, P 32 C EUR COMM TREA; Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0; Kappos L, 2017, NEUROLOGY, V88; Kappos L, 2014, LANCET NEUROL, V13, P353, DOI 10.1016/S1474-4422(14)70028-6; Karni A, 2006, J IMMUNOL, V177, P4196, DOI 10.4049/jimmunol.177.6.4196; Kato Hideki, 2003, Nihon Rinsho, V61, P1428; Katz U, 2006, AUTOIMMUNITY, V39, P513, DOI 10.1080/08916930600825867; Keskinen P, 1997, IMMUNOLOGY, V91, P421, DOI 10.1046/j.1365-2567.1997.00258.x; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Kinnunen T, 2013, J CLIN INVEST, V123, P2737, DOI 10.1172/JCI68775; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Kleinewietfeld M, 2014, IMMUNOL REV, V259, P231, DOI 10.1111/imr.12169; Kornek B, 1999, BRAIN PATHOL, V9, P651; Kuenz B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002559; Kuhle J, 2017, NEUROLOGY, V88, P826, DOI 10.1212/WNL.0000000000003653; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Kwidzinski E, 2005, FASEB J, V19, P1347, DOI 10.1096/fj.04-3228fje; Larochelle C, 2015, ANN NEUROL, V78, P39, DOI 10.1002/ana.24415; Laroni A, 2016, J AUTOIMMUN, V72, P8, DOI 10.1016/j.jaut.2016.04.003; Lassmann H, 2012, BRAIN, V135, P2904, DOI 10.1093/brain/aws260; Leandro MJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3908; Lee HM, 2012, IMMUNITY, V37, P475, DOI 10.1016/j.immuni.2012.07.009; Lee SY, 2013, J IMMUNOL, V190, P4991, DOI 10.4049/jimmunol.1300083; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Leist TP, 2014, LANCET NEUROL, V13, P257, DOI 10.1016/S1474-4422(14)70005-5; Li R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab4176; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lindner S, 2013, CANCER RES, V73, P2468, DOI 10.1158/0008-5472.CAN-12-3450; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Losy J, 2013, J NEURAL TRANSM, V120, P1459, DOI 10.1007/s00702-013-1079-9; Lovato L, 2011, BRAIN, V134, P534, DOI 10.1093/brain/awq350; Lu LF, 2009, GENE DEV, V23, P1270, DOI 10.1101/gad.1791009; Lu W, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00134; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Lucas RM, 2015, NEURODEGENER DIS MAN, V5, P413, DOI 10.2217/nmt.15.33; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lucchinetti CF, 2011, NEW ENGL J MED, V365, P2188, DOI 10.1056/NEJMoa1100648; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Lutterotti A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006168; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Ma N, 2014, CELL IMMUNOL, V289, P140, DOI 10.1016/j.cellimm.2014.03.017; Madsen LS, 1999, NAT GENET, V23, P343, DOI 10.1038/15525; Magliozzi R, 2007, BRAIN, V130, P1089, DOI 10.1093/brain/awm038; Magliozzi R, 2010, ANN NEUROL, V68, P477, DOI 10.1002/ana.22230; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Malmestrom C, 2008, J NEUROIMMUNOL, V196, P159, DOI 10.1016/j.jneuroim.2008.03.001; Malpass Katy, 2012, Nat Rev Neurol, V8, P61, DOI 10.1038/nrneurol.2011.217; Mancuso R, 2014, MULT SCLER J, V20, P1900, DOI 10.1177/1352458514538111; Mangalam A, 2017, CELL REP, V20, P1269, DOI 10.1016/j.celrep.2017.07.031; Lozano JM, 2009, VIRAL IMMUNOL, V22, P463, DOI 10.1089/vim.2009.0041; Martin R, 2000, ADV RES NEURODEGENER, V8, P361; Mauri C, 2015, INT IMMUNOL, V27, P479, DOI 10.1093/intimm/dxv038; Mayo L, 2016, BRAIN, V139, P1939, DOI 10.1093/brain/aww113; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; Melzer N, 2009, FASEB J, V23, P3659, DOI 10.1096/fj.09-136200; Michel L, 2014, J NEUROL NEUROSUR PS, V85, P279, DOI 10.1136/jnnp-2013-305298; Michel L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00636; Michel L, 2014, CLIN IMMUNOL, V155, P198, DOI 10.1016/j.clim.2014.09.011; Miyake S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137429; Molnarfi N, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0798-5; Molnarfi N, 2013, J EXP MED, V210, P2921, DOI 10.1084/jem.20130699; Montalban X, 2017, NEW ENGL J MED, V376, P1694, DOI 10.1056/NEJMc1702076; Mouzaki A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135434; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014; Naismith RT, 2010, NEUROLOGY, V74, P1860, DOI 10.1212/WNL.0b013e3181e24373; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; Nourbakhsh B, 2016, J NEUROL NEUROSUR PS, V87, P1350, DOI 10.1136/jnnp-2016-313410; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; O'Connor RA, 2007, J IMMUNOL, V179, P958, DOI 10.4049/jimmunol.179.2.958; Ochoa-Reparaz J, 2010, MUCOSAL IMMUNOL, V3, P487, DOI 10.1038/mi.2010.29; Okuda DT, 2009, BRAIN, V132, P250, DOI 10.1093/brain/awn301; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Ottoboni L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004186; Pacholczyk R, 2008, IMMUNOLOGY, V125, P450, DOI 10.1111/j.1365-2567.2008.02992.x; Palanichamy A, 2014, J IMMUNOL, V193, P580, DOI 10.4049/jimmunol.1400118; Palanichamy A, 2009, J IMMUNOL, V182, P5982, DOI 10.4049/jimmunol.0801859; PANITCH HS, 1987, LANCET, V1, P893; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; Plavina T, 2014, ANN NEUROL, V76, P802, DOI 10.1002/ana.24286; Polman C, 2005, NEUROLOGY, V64, P987, DOI 10.1212/01.WNL.0000154520.48391.69; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Quintana FJ, 2008, P NATL ACAD SCI USA, V105, P18889, DOI 10.1073/pnas.0806310105; Racke MK, 2010, NEUROLOGY, V74, pS25, DOI 10.1212/WNL.0b013e3181c97e39; Ray A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010012; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Roll P, 2012, SCAND J RHEUMATOL, V41, P180, DOI 10.3109/03009742.2011.645056; Rothhammer V, 2017, P NATL ACAD SCI USA, V114, P2012, DOI 10.1073/pnas.1615413114; Rotstein DL, 2015, JAMA NEUROL, V72, P152, DOI 10.1001/jamaneurol.2014.3537; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; SAKAGUCHI S, 1985, J EXP MED, V161, P72, DOI 10.1084/jem.161.1.72; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Saraste M, 2007, NEUROL SCI, V28, P121, DOI 10.1007/s10072-007-0803-3; Sawcer S, 2005, AM J HUM GENET, V77, P454; Sawcer S, 2014, LANCET NEUROL, V13, P700, DOI 10.1016/S1474-4422(14)70041-9; Schadenberg AWL, 2011, EUR J IMMUNOL, V41, P1132, DOI 10.1002/eji.201040363; Schirmer L, 2014, MULT SCLER J, V20, P271, DOI 10.1177/1352458514522104; Schleinitz N, 2010, IMMUNOLOGY, V131, P451, DOI 10.1111/j.1365-2567.2010.03360.x; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; Schneider A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004970; Schubert RD, 2015, J IMMUNOL, V194, P2110, DOI 10.4049/jimmunol.1402029; Sedel F, 2015, MULT SCLER RELAT DIS, V4, P159, DOI 10.1016/j.msard.2015.01.005; Segal BM, 2008, LANCET NEUROL, V7, P796, DOI 10.1016/S1474-4422(08)70173-X; Sellebjerg F, 2016, THER ADV NEUROL DISO, V9, P31, DOI 10.1177/1756285615615257; Selmaj K, 2013, LANCET NEUROL, V12, P756, DOI 10.1016/S1474-4422(13)70102-9; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Sergott RC, 2015, J NEUROL SCI, V351, P174, DOI 10.1016/j.jns.2015.02.019; Shi FD, 2006, NAT REV IMMUNOL, V6, P751, DOI 10.1038/nri1935; Siewe B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092934; Simpson D, 2002, CNS DRUGS, V16, P825, DOI 10.2165/00023210-200216120-00004; Simpson S, 2011, J NEUROL NEUROSUR PS, V82, P1132, DOI 10.1136/jnnp.2011.240432; Sloka JS, 2005, MULT SCLER J, V11, P425, DOI 10.1191/1352458505ms1190oa; Smith AL, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2016.37; Sorensen PS, 2016, THER ADV NEUROL DISO, V9, P44, DOI 10.1177/1756285615601933; Sorensen PS, 2002, EUR J NEUROL, V9, P557, DOI 10.1046/j.1468-1331.2002.00501.x; Souto-Carneiro MM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2718; Spain R, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000374; Srivastava R, 2012, NEW ENGL J MED, V367, P115, DOI 10.1056/NEJMoa1110740; Stangel M, 2017, NAT REV NEUROL, V13, P742, DOI 10.1038/nrneurol.2017.139; Stankiewicz JM, 2013, NEUROTHERAPEUTICS, V10, P77, DOI 10.1007/s13311-012-0172-3; Stein MS, 2011, NEUROLOGY, V77, P1611, DOI 10.1212/WNL.0b013e3182343274; Stephens LA, 2009, EUR J IMMUNOL, V39, P1108, DOI 10.1002/eji.200839073; Streeter HB, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000093; Su KG, 2009, CURR NEUROL NEUROSCI, V9, P411, DOI 10.1007/s11910-009-0060-3; TADA T, 1978, J EXP MED, V147, P446, DOI 10.1084/jem.147.2.446; Tallantyre E, 2008, Int MS J, V15, P62; Tennakoon DK, 2006, J IMMUNOL, V176, P7119, DOI 10.4049/jimmunol.176.11.7119; Tourbah A, 2016, MULT SCLER J, V22, P1719, DOI 10.1177/1352458516667568; Tramacere I, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011381.pub2; Trapp BD, 1999, J NEUROIMMUNOL, V98, P49, DOI 10.1016/S0165-5728(99)00081-8; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; TRAUGOTT U, 1983, J NEUROIMMUNOL, V4, P201, DOI 10.1016/0165-5728(83)90036-X; TRAUGOTT U, 1985, SPRINGER SEMIN IMMUN, V8, P71; Tremlett H, 2016, EUR J NEUROL, V23, P1308, DOI 10.1111/ene.13026; Tremlett H, 2010, NEUROLOGY, V74, P2004, DOI 10.1212/WNL.0b013e3181e3973f; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Uitdehaag BMJ, 2011, CURR MED RES OPIN, V27, P1529, DOI 10.1185/03007995.2011.591370; Uss E, 2006, J IMMUNOL, V177, P2775, DOI 10.4049/jimmunol.177.5.2775; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; vanOosten BW, 1997, NEUROLOGY, V49, P351, DOI 10.1212/WNL.49.2.351; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Villar LM, 2005, J CLIN INVEST, V115, P187, DOI 10.1172/JCI200522833; Vollmer T, 2010, NEUROLOGY, V74, pS41, DOI 10.1212/WNL.0b013e3181c97f5a; von Budingen HC, 2015, EUR NEUROL, V73, P238, DOI 10.1159/000377675; Vuddamalay Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00031; Walczak A, 2013, JAMA NEUROL, V70, P1105, DOI 10.1001/jamaneurol.2013.3022; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1989, NEUROLOGY, V39, P1143, DOI 10.1212/WNL.39.9.1143; Weinshenker BG, 2001, J CLIN APHERESIS, V16, P39, DOI 10.1002/jca.1010; Willis MA, 2013, SEMIN NEUROL, V33, P37, DOI 10.1055/s-0033-1343794; Wingerchuk DM, 2012, THER ADV NEUROL DISO, V5, P13, DOI 10.1177/1756285611425694; Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984; Yang M, 2013, CELL MOL IMMUNOL, V10, P122, DOI 10.1038/cmi.2012.60; Zang YCQ, 2004, J IMMUNOL, V172, P5120, DOI 10.4049/jimmunol.172.8.5120; Zha BB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049835; Zhang B, 2013, J IMMUNOL, V190, P2320, DOI 10.4049/jimmunol.1202922; Zhao YJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174866; Zrzavy T, 2017, BRAIN, V140, P1900, DOI 10.1093/brain/awx113; Zurawski J, 2017, JAMA NEUROL, V74, P100, DOI 10.1001/jamaneurol.2016.4237	278	394	404	14	138	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	FEB 21	2018	97	4					742	768		10.1016/j.neuron.2018.01.021	http://dx.doi.org/10.1016/j.neuron.2018.01.021			27	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FX0EG	29470968	Bronze			2023-01-03	WOS:000425713200006
J	Uusitupa, M				Uusitupa, Matti			Remission of type 2 diabetes: mission not impossible	LANCET			English	Editorial Material							LIFE-STYLE INTERVENTION; FOLLOW-UP; PREVENTION; OUTCOMES; TRIAL		[Uusitupa, Matti] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio 70211, Finland	University of Eastern Finland	Uusitupa, M (corresponding author), Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio 70211, Finland.	matti.uusitupa@uef.fi	Uusitupa, Matti Ilmari Julius/AAX-4929-2020					Gregg EW, 2016, LANCET DIABETES ENDO, V4, P913, DOI 10.1016/S2213-8587(16)30162-0; IDF, 2017, IDF CLIN PRACT REC M; Lean MEJ, 2017, LANCET; Lindstrom J, 2013, DIABETOLOGIA, V56, P284, DOI 10.1007/s00125-012-2752-5; Nathan DM, 2015, LANCET DIABETES ENDO, V3, P866, DOI 10.1016/S2213-8587(15)00291-0; Penn L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057143; Sjostrom L, 2013, J INTERN MED, V273, P219, DOI 10.1111/joim.12012; Taylor R, 2018, DIABETOLOGIA, V61, P273, DOI 10.1007/s00125-017-4504-z; Uusitupa MIJ, 1996, ANN MED, V28, P445, DOI 10.3109/07853899608999106; World Health Organization, 2016, GLOB REP PSOR; Wu JHY, 2017, LANCET DIABETES ENDO, V5, P965, DOI [10.1016/s2213-8587(17)30307-8, 10.1016/S2213-8587(17)30307-8]	11	11	11	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 10	2018	391	10120					515	516		10.1016/S0140-6736(17)33100-8	http://dx.doi.org/10.1016/S0140-6736(17)33100-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FV5VB	29221646				2023-01-03	WOS:000424649400005
J	Zhao, CH; Shen, X; Guo, MR				Zhao, Changhui; Shen, Xue; Guo, Mingruo			Stability of lutein encapsulated whey protein nano-emulsion during storage	PLOS ONE			English	Article							MACULAR PIGMENT; DELIVERY; CANCER; RISK; ANTIOXIDANTS; PRETREATMENT; CAROTENOIDS; TEMPERATURE; ULTRASOUND; PREVENTION	Lutein is a hydrophobic carotenoid that has multiple health functions. However, the application of lutein is limited due to its poor solubility in water and instability under certain conditions during storage. Hereby we generated lutein loaded nano-emulsions using whey protein isolate (WPI) or polymerized whey protein isolate (PWP) with assistance of high intensity ultrasound and evaluate their stability during storage at different conditions. We measured the particle size, zeta-potential, physical stability and lutein content change. Results showed that the PWP based nano-emulsion system was not stable in the tested Oil/Water/Ethanol system indicated by the appearance of stratification within only one week. The WPI based nano-emulsion system showed stable physiochemical stability during the storage at 4 degrees C. The lutein content of the system was reduced by only 4% after four weeks storage at 4 degrees C. In conclusion, our whey protein based nano-emulsion system provides a promising strategy for encapsulation of lutein or other hydrophobic bioactive molecules to expand their applications.	[Zhao, Changhui; Shen, Xue] Jilin Univ, Coll Food Sci & Engn, Changchun, Jilin, Peoples R China; [Shen, Xue] Jilin Univ, Coll Vet Med, Minist Educ, Key Lab Zoonosis, Changchun, Jilin, Peoples R China; [Guo, Mingruo] Northeast Agr Univ, Dept Food Sci, Harbin, Heilongjiang, Peoples R China; [Guo, Mingruo] Univ Vermont, Dept Nutr & Food Sci, Burlington, VT USA	Jilin University; Jilin University; Northeast Agricultural University - China; University of Vermont	Zhao, CH (corresponding author), Jilin Univ, Coll Food Sci & Engn, Changchun, Jilin, Peoples R China.	czhao@jlu.edu.cn	Zhao, Changhui/N-2378-2019	Zhao, Changhui/0000-0002-1882-7490	Fundamental Research Funds for Young Researchers [451160301317];  [419080500712]	Fundamental Research Funds for Young Researchers; 	The research was partly supported by the Fundamental Research Funds for Young Researchers (Grant No. 451160301317) and partly by Startup Funds to Overseas Doctorate Talents Plan B (Grant No. 419080500712). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], INT J FOOD SCI TECHN; BANKS W, 1985, FOOD CHEM, V18, P139, DOI 10.1016/0308-8146(85)90137-2; BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843; Boon CS, 2010, CRIT REV FOOD SCI, V50, P515, DOI 10.1080/10408390802565889; Breithaupt DE, 2007, TRENDS FOOD SCI TECH, V18, P501, DOI 10.1016/j.tifs.2007.04.009; Chen C., 2015, FUNCTIONAL CHARACTER; Cooper DA, 1999, NUTR REV, V57, P201, DOI 10.1111/j.1753-4887.1999.tb06944.x; Davidov-Pardo G, 2016, FOOD CHEM, V196, P821, DOI 10.1016/j.foodchem.2015.10.018; De Stefani E, 1999, NUTR CANCER, V34, P100, DOI 10.1207/S15327914NC340114; Dickinson E, 2010, COLLOID SURFACE B, V81, P130, DOI 10.1016/j.colsurfb.2010.06.033; Frede K, 2014, J FUNCT FOODS, V8, P118, DOI 10.1016/j.jff.2014.03.011; Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929; Gunasekaran S, 2007, J FOOD ENG, V83, P31, DOI 10.1016/j.jfoodeng.2006.11.001; Gunnerud U, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-83; Hadden WL, 1999, J AGR FOOD CHEM, V47, P4189, DOI 10.1021/jf990096k; Halliwell B, 2000, CARDIOVASC RES, V47, P410, DOI 10.1016/S0008-6363(00)00097-3; Helgason T, 2009, FOOD HYDROCOLLOID, V23, P2243, DOI 10.1016/j.foodhyd.2009.05.014; Hidalgo A, 2006, J CEREAL SCI, V44, P182, DOI 10.1016/j.jcs.2006.06.002; Hu H, 2015, J FUNCT FOODS, V19, P182, DOI 10.1016/j.jff.2015.09.023; Hu H, 2013, FOOD HYDROCOLLOID, V32, P303, DOI 10.1016/j.foodhyd.2013.01.016; Jaiswal M, 2015, 3 BIOTECH, V5, P123, DOI 10.1007/s13205-014-0214-0; Jin HY, 2009, CHINESE J CHEM ENG, V17, P672, DOI 10.1016/S1004-9541(08)60262-1; Joye IJ, 2014, TRENDS FOOD SCI TECH, V40, P168, DOI 10.1016/j.tifs.2014.08.006; Lam RSH, 2015, LWT-FOOD SCI TECHNOL, V60, P427, DOI 10.1016/j.lwt.2014.07.031; Landrum J T, 1997, Adv Pharmacol, V38, P537; Li DaJing, 2008, Jiangsu Journal of Agricultural Sciences, V24, P97; Liu D, 2017, JOURNAL OF FOOD PROC; Madadlou A, 2010, ULTRASON SONOCHEM, V17, P153, DOI 10.1016/j.ultsonch.2009.06.009; Marshall Keri, 2004, Altern Med Rev, V9, P136; Mitri K, 2011, INT J PHARMACEUT, V414, P267, DOI 10.1016/j.ijpharm.2011.05.008; Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20; Neuman I, 1999, ANN ALLERG ASTHMA IM, V82, P549, DOI 10.1016/S1081-1206(10)63165-1; Parlak M, 2017, THERMAL THERMOMECHAN; Pratheesh V. B., 2009, Modern Applied Science, V3, P19; Qv XY, 2011, FOOD HYDROCOLLOID, V25, P1596, DOI 10.1016/j.foodhyd.2011.01.006; Reddy L, 2003, PHARMACOL THERAPEUT, V99, P1, DOI 10.1016/S0163-7258(03)00042-1; RIGGS LK, 1955, J AGR FOOD CHEM, V3, P333, DOI 10.1021/jf60050a006; Shen X, 2016, INT J FOOD SCI TECH, P52; Shen X, 2017, ULTRASON SONOCHEM, V39, P810, DOI 10.1016/j.ultsonch.2017.05.039; Shen X, 2017, FOOD HYDROCOLLOID, V63, P668, DOI 10.1016/j.foodhyd.2016.10.003; Shi XM, 1997, NAHRUNG, V41, P38, DOI 10.1002/food.19970410110; Tavani A, 1999, EUR J CANCER, V35, P1361, DOI 10.1016/S0959-8049(99)00139-2; TYCZKOWSKI JK, 1986, POULTRY SCI, V65, P1526, DOI 10.3382/ps.0651526; TYCZKOWSKI JK, 1986, POULTRY SCI, V65, P1141, DOI 10.3382/ps.0651141; Wang YF, 2012, EUR FOOD RES TECHNOL, V234, P157, DOI 10.1007/s00217-011-1630-6; Weigel F, 2018, FOOD CHEM, V242, P395, DOI 10.1016/j.foodchem.2017.09.060; Xie YQ, 2016, INT J PHARMACEUT, V500, P110, DOI 10.1016/j.ijpharm.2016.01.032; Yi J, 2016, FOOD CHEM, V200, P91, DOI 10.1016/j.foodchem.2016.01.035; Yi J, 2014, J AGR FOOD CHEM, V62, P8900, DOI 10.1021/jf502639k; Yu HL, 2013, FOOD CHEM, V141, P29, DOI 10.1016/j.foodchem.2013.03.009; Zhang PP, 2016, ULTRASON SONOCHEM, V29, P380, DOI 10.1016/j.ultsonch.2015.10.014; Zhao CD, 2014, FOOD CHEM, V156, P123, DOI 10.1016/j.foodchem.2014.01.086	52	40	41	4	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2018	13	2							e0192511	10.1371/journal.pone.0192511	http://dx.doi.org/10.1371/journal.pone.0192511			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV1MC	29415071	Green Submitted, gold, Green Published			2023-01-03	WOS:000424325300082
J	Madeo, F; Eisenberg, T; Pietrocola, F; Kroemer, G				Madeo, Frank; Eisenberg, Tobias; Pietrocola, Federico; Kroemer, Guido			Spermidine in health and disease	SCIENCE			English	Review							CALORIC RESTRICTION MIMETICS; DIETARY POLYAMINE INTAKE; BLOOD-BRAIN-BARRIER; LIFE-SPAN; HISTONE DEACETYLASE; NATURAL POLYAMINE; ACETYL-COENZYME; MOUSE MODEL; AUTOPHAGY; MEMORY		[Madeo, Frank; Eisenberg, Tobias] Karl Franzens Univ Graz, NAWI Graz, Inst Mol Biosci, Graz, Austria; [Madeo, Frank; Eisenberg, Tobias] BioTechMed Graz, Graz, Austria; [Pietrocola, Federico; Kroemer, Guido] Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France; [Pietrocola, Federico; Kroemer, Guido] Gustave Roussy Comprehens Canc Ctr, Cell Biol & Metabol Platforms, Villejuif, France; [Pietrocola, Federico; Kroemer, Guido] INSERM, U1138, Paris, France; [Pietrocola, Federico; Kroemer, Guido] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Pietrocola, Federico; Kroemer, Guido] Univ Paris 06, Paris, France; [Kroemer, Guido] Hop Europeen Georges Pompidou, Pole Biol, Paris, France; [Kroemer, Guido] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden	University of Graz; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital	Madeo, F (corresponding author), Karl Franzens Univ Graz, NAWI Graz, Inst Mol Biosci, Graz, Austria.; Madeo, F (corresponding author), BioTechMed Graz, Graz, Austria.; Kroemer, G (corresponding author), Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France.; Kroemer, G (corresponding author), Gustave Roussy Comprehens Canc Ctr, Cell Biol & Metabol Platforms, Villejuif, France.; Kroemer, G (corresponding author), INSERM, U1138, Paris, France.; Kroemer, G (corresponding author), Univ Paris 05, Sorbonne Paris Cite, Paris, France.; Kroemer, G (corresponding author), Univ Paris 06, Paris, France.; Kroemer, G (corresponding author), Hop Europeen Georges Pompidou, Pole Biol, Paris, France.; Kroemer, G (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden.	frank.madeo@uni-graz.at; kroemer@orange.fr	KROEMER, Guido/B-4263-2013; Eisenberg, Tobias/AAV-7806-2021; Pietrocola, Federico/AAW-9621-2020; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Pietrocola, Federico/0000-0002-2930-234X; Eisenberg, Tobias/0000-0003-3559-1130; Madeo, Frank/0000-0002-5070-1329	Austrian Science Fund FWF (Austria) [P23490-B20, P29262, P24381, P29203 P27893, I1000]; "SFB Lipotox" [F3012]; Bundesministerium fur Wissenschaft, Forschung und Wirtschaft; Karl-Franzens University; grant DKplus Metabolic and Cardiovascular Diseases [W1226]; NAWI Graz; BioTechMed-Graz flagship project "EPIAge"; Ligue contre le Cancer Comite de Charente-Maritime; Agence National de la Recherche (ANR)-Projets blancs; ANR; ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LeDucq Foundation; LabEx Immuno-Oncology; Recherche Hospitalo-Universitaire Torino Lumiere; Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); FFG COIN [855987]	Austrian Science Fund FWF (Austria)(Austrian Science Fund (FWF)); "SFB Lipotox"(German Research Foundation (DFG)); Bundesministerium fur Wissenschaft, Forschung und Wirtschaft; Karl-Franzens University; grant DKplus Metabolic and Cardiovascular Diseases; NAWI Graz; BioTechMed-Graz flagship project "EPIAge"; Ligue contre le Cancer Comite de Charente-Maritime(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)-Projets blancs(French National Research Agency (ANR)); ANR(French National Research Agency (ANR)); ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)European Commission); LeDucq Foundation(Leducq Foundation); LabEx Immuno-Oncology; Recherche Hospitalo-Universitaire Torino Lumiere; Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); FFG COIN	F.M., T.E., and G.K. are inventors on a patent application (WO2010081204 A3) submitted by Katholieke Universiteit Leuven that covers the use of spermidine for life-span extension. F.P. and G.K. are inventors on a patent application (WO2015049365 A3) submitted by INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique-Hopitaux De Paris (APHP), Universite Paris Descartes, Universite Pierre et Marie Curie (Paris 6), Universite Paris Diderot-Paris 7, Universite Paris-Sud, Institut Gustave Roussy, that covers the medical use of CRMs. We thank D. Carmona-Gutierrez and P. Royer for critical reading and support. F.M. is grateful to the Austrian Science Fund FWF (Austria) for grants P23490-B20, P29262, P24381, P29203 P27893, I1000, and "SFB Lipotox" (F3012), as well as to Bundesministerium fur Wissenschaft, Forschung und Wirtschaft and the Karl-Franzens University for grant "Unkonventionelle Forschung" and grant DKplus Metabolic and Cardiovascular Diseases (W1226). We acknowledge support from NAWI Graz and the BioTechMed-Graz flagship project "EPIAge." G.K. is supported by the Ligue contre le Cancer Comite de Charente-Maritime (equipe labelisee); Agence National de la Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LeDucq Foundation; the LabEx Immuno-Oncology; the Recherche Hospitalo-Universitaire Torino Lumiere, the Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). T.E. is supported by the FFG COIN-project 855987. F. M. and T.E. have equity interests in TLL (The Longevity Labs), a company founded in 2016 that will develop natural food extracts.	Ali MA, 2011, FOOD NUTR RES, V55, DOI [10.3402/fnr.v55i0.5455, 10.3402/fnr.v55i0.5572]; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Araki K, 2009, NATURE, V460, P108, DOI 10.1038/nature08155; BARDOCZ S, 1995, BRIT J NUTR, V73, P819, DOI 10.1079/BJN19950087; Barger JL, 2017, AGING CELL, V16, P750, DOI 10.1111/acel.12608; Bennetzen MV, 2012, CELL CYCLE, V11, P1827, DOI 10.4161/cc.20233; Bonhoure N, 2015, GENE DEV, V29, P934, DOI 10.1101/gad.258350.115; Buttner S, 2014, CELL CYCLE, V13, P3903, DOI 10.4161/15384101.2014.973309; Chen TT, 2011, AGING CELL, V10, P908, DOI 10.1111/j.1474-9726.2011.00722.x; Cheng ML, 2015, J AM COLL CARDIOL, V65, P1509, DOI 10.1016/j.jacc.2015.02.018; Chrisam M, 2015, AUTOPHAGY, V11, P2142, DOI 10.1080/15548627.2015.1108508; de Cabo R, 2014, CELL, V157, P1515, DOI 10.1016/j.cell.2014.05.031; Deng KW, 2009, J NEUROSCI, V29, P9545, DOI 10.1523/JNEUROSCI.1175-09.2009; Di Biase S, 2016, CANCER CELL, V30, P136, DOI 10.1016/j.ccell.2016.06.005; Diler AS, 2002, NEUROSCI RES, V43, P335, DOI 10.1016/S0168-0102(02)00059-7; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMc1303158, 10.1056/NEJMra1205406]; Eisenberg T, 2016, NAT MED, V22, P1428, DOI 10.1038/nm.4222; Eisenberg T, 2014, CELL METAB, V19, P431, DOI 10.1016/j.cmet.2014.02.010; Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975; Eiyama A, 2015, CURR OPIN CELL BIOL, V33, P95, DOI 10.1016/j.ceb.2015.01.002; Fan JJ, 2017, ONCOTARGET, V8, P17475, DOI [10.18632/oncotarget.15420, 10.18632/oncotarget.15728]; Fernandez AF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.373; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Frake RA, 2015, J CLIN INVEST, V125, P65, DOI 10.1172/JCI73944; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Freedman ND, 2012, NEW ENGL J MED, V366, P1891, DOI 10.1056/NEJMoa1112010; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199; Graham SF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119452; Guerra GP, 2016, PHARMACOL RES, V112, P99, DOI 10.1016/j.phrs.2016.03.023; Guo XL, 2011, INVEST OPHTH VIS SCI, V52, P2696, DOI 10.1167/iovs.10-6015; Gupta VK, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002563; Gupta VK, 2013, NAT NEUROSCI, V16, P1453, DOI 10.1038/nn.3512; Hai Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15368; Hayashi T, 2002, HYPERTENS RES, V25, P787; Hiasa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep06836; Igarashi K, 2006, AMINO ACIDS, V31, P477, DOI 10.1007/s00726-006-0264-7; Igarashi K, 2009, INT J BIOCHEM CELL B, V42, P39, DOI DOI 10.1016/J.BI0CEL.2009.07.009;PMID:19643201; Jell J, 2007, J BIOL CHEM, V282, P8404, DOI 10.1074/jbc.M610265200; Jo S, 2014, NAT MED, V20, P886, DOI 10.1038/nm.3639; Junnila RK, 2013, NAT REV ENDOCRINOL, V9, P366, DOI 10.1038/nrendo.2013.67; Kano Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056056; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kibe R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04548; Knott AB, 2010, DIABETES OBES METAB, V12, P126, DOI 10.1111/j.1463-1326.2010.01267.x; Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198; LaRocca TJ, 2013, MECH AGEING DEV, V134, P314, DOI 10.1016/j.mad.2013.04.004; Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293; Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228; Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Liu P, 2008, NEUROSCIENCE, V155, P789, DOI 10.1016/j.neuroscience.2008.06.033; Longo VD, 2016, CELL METAB, V23, P1048, DOI 10.1016/j.cmet.2016.06.001; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003; Mackeh R, 2014, J BIOL CHEM, V289, P11816, DOI 10.1074/jbc.M113.507400; Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391; Magnes C, 2014, J CHROMATOGR A, V1331, P44, DOI 10.1016/j.chroma.2013.12.061; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Marino G, 2014, AUTOPHAGY, V10, P1879, DOI 10.4161/auto.36413; Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016; Masuko T, 2003, J NEUROCHEM, V84, P610, DOI 10.1046/j.1471-4159.2003.01558.x; Matsumoto M, 2007, MICROBIOL IMMUNOL, V51, P25, DOI 10.1111/j.1348-0421.2007.tb03887.x; Matsumoto M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00233; Matsumoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023652; Miao HM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11716; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Michiels CF, 2016, ATHEROSCLEROSIS, V251, P319, DOI 10.1016/j.atherosclerosis.2016.07.899; Milovic V, 2001, EUR J GASTROEN HEPAT, V13, P1021, DOI 10.1097/00042737-200109000-00004; Minois N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.139; Minois N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102435; Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167; Nishimura K, 2006, J BIOCHEM, V139, P81, DOI 10.1093/jb/mvj003; Nishimura K, 2009, J PARASITOL, V95, P781, DOI 10.1645/GE-1883.1; Noro T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.93; Noro T, 2015, INVEST OPHTH VIS SCI, V56, P5012, DOI 10.1167/iovs.15-17142; Nowotarski SL, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.3; Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110; Ost M, 2015, FASEB J, V29, P1314, DOI 10.1096/fj.14-261503; Pan XB, 2016, NEUROBIOL AGING, V38, P151, DOI 10.1016/j.neurobiolaging.2015.11.014; Park MH, 2013, BIOMOL THER, V21, P1, DOI 10.4062/biomolther.2012.097; Pearce EL, 2009, NATURE, V460, P103, DOI 10.1038/nature08097; Pegg AE, 2016, J BIOL CHEM, V291, P14904, DOI 10.1074/jbc.R116.731661; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Phadwal K, 2012, AUTOPHAGY, V8, P677, DOI 10.4161/auto.18935; Phan Nguyen Thanh Binh, 2010, Health, V2, P1390, DOI 10.4236/health.2010.212206; Pietrocola F, 2015, CELL DEATH DIFFER, V22, P509, DOI 10.1038/cdd.2014.215; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Pietrocola F, 2015, CELL METAB, V21, P805, DOI 10.1016/j.cmet.2015.05.014; Pietrocola F, 2014, CELL CYCLE, V13, P1987, DOI 10.4161/cc.28929; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; Pucciarelli S, 2012, REJUV RES, V15, P590, DOI 10.1089/rej.2012.1349; Puleston DJ, 2015, MICROB CELL, V2, P91, DOI 10.15698/mic2015.03.195; Puleston DJ, 2014, ELIFE, V3, DOI 10.7554/eLife.03706; Qi YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep24700; Ramot Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022564; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Sadasivan SK, 2014, EUR J PHARMACOL, V729, P94, DOI 10.1016/j.ejphar.2014.01.073; Sahin E, 2014, J IMMUNOL, V193, P1717, DOI 10.4049/jimmunol.1302167; Sansbury BE, 2014, CIRC-HEART FAIL, V7, P634, DOI 10.1161/CIRCHEARTFAILURE.114.001151; SAURA J, 1994, NEUROSCIENCE, V62, P15, DOI 10.1016/0306-4522(94)90311-5; SCALABRINO G, 1984, MECH AGEING DEV, V26, P149, DOI 10.1016/0047-6374(84)90090-3; Schwarz C, 2018, AGING-US, V10, P19, DOI 10.18632/aging.101354; Sebti S, 2014, P NATL ACAD SCI USA, V111, P4115, DOI 10.1073/pnas.1313618111; SHIN WW, 1985, J NEUROCHEM, V44, P1056, DOI 10.1111/j.1471-4159.1985.tb08724.x; Soda K, 2005, J IMMUNOL, V175, P237, DOI 10.4049/jimmunol.175.1.237; Soda K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064357; Soda Kuniyasu, 2012, Glob J Health Sci, V4, P170, DOI 10.5539/gjhs.v4n6p170; Soda K, 2009, EXP GERONTOL, V44, P727, DOI 10.1016/j.exger.2009.08.013; Soda K, 2009, J NUTR SCI VITAMINOL, V55, P361, DOI 10.3177/jnsv.55.361; Takeuchi T, 2017, J BIOL CHEM, V292, P3909, DOI 10.1074/jbc.M116.756197; Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779; Vargas AJ, 2015, AM J CLIN NUTR, V102, P411, DOI 10.3945/ajcn.114.103895; Vargas AJ, 2012, AM J CLIN NUTR, V96, P133, DOI 10.3945/ajcn.111.030353; Velloso NA, 2009, NEUROBIOL LEARN MEM, V92, P574, DOI 10.1016/j.nlm.2009.07.006; Wang IF, 2012, P NATL ACAD SCI USA, V109, P15024, DOI 10.1073/pnas.1206362109; Wing RR, 2005, AM J CLIN NUTR, V82, p222S, DOI 10.1093/ajcn/82.1.222S; Yamamoto T, 2012, BRIT J PHARMACOL, V166, P1084, DOI 10.1111/j.1476-5381.2012.01856.x; Yang Q, 2016, CELL DEATH DIFFER, V23, P1850, DOI 10.1038/cdd.2016.71; Yue F, 2017, CANCER RES, V77, P2938, DOI 10.1158/0008-5472.CAN-16-3462; Zhang C, 2008, NAT MED, V14, P959, DOI 10.1038/nm.1851; Zhang Y, 2017, NEUROL RES, V39, P248, DOI 10.1080/01616412.2017.1283830; Zhong Z, 2016, CLIN EXP RHEUMATOL, V34, pS12; Zhu S, 2009, MOL MED, V15, P275, DOI 10.2119/molmed.2009.00062; Zoumas-Morse C, 2007, J AM DIET ASSOC, V107, P1024, DOI 10.1016/j.jada.2007.03.012; Zwighaft Z, 2015, CELL METAB, V22, P874, DOI 10.1016/j.cmet.2015.09.011	131	394	411	24	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 26	2018	359	6374					410	+	eaan2788	10.1126/science.aan2788	http://dx.doi.org/10.1126/science.aan2788			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT6SD	29371440				2023-01-03	WOS:000423283200036
J	Huang, CN; Wang, CJ; Lin, CL; Lin, HT; Peng, CH				Huang, Chien-Ning; Wang, Chau-Jong; Lin, Chih-Li; Lin, Hui-Ting; Peng, Chiung-Huei			The nutraceutical benefits of subfractions of Abelmoschus esculentus in treating type 2 diabetes mellitus	PLOS ONE			English	Article							POLYSACCHARIDE AMELIORATES HYPERGLYCEMIA; INDUCED INSULIN-RESISTANCE; LIPOPROTEIN-LIPASE; SKELETAL-MUSCLE; CELL; GLUCOSIDASE; PATHWAY; AMYLASE; MOENCH; ALPHA	Abelmoschus esculentus (AE), a commonly consumed vegetable, is well-known for its antihyperglycemic effects. However, few scientific reports have identified its targets because mucilage increases the difficulty of manipulation. We recently reported extraction steps to obtain subfractions of AE, which were found to attenuate the adverse effects of high glucose and fatty acid in vitro. In this study, we used modified extraction steps and type 2 diabetic rats to explore whether AE subfractions can improve the metabolic disturbances caused by insulin resistance in vivo. AE subfractions (F1, F2, and FR) were prepared. The type 2 diabetes model was induced by feeding male Sprague-Dawley rats with a high-fat diet and injecting them with 35 mg/kgbw streptozotocin when their body weight reached 475 +/- 15 g. After a hyperglycemic status had been confirmed, the rats were tube-fed with or without different doses of AE subfractions. Serum glucose, lipid markers, insulin, HbA1c and HOMAIR were measured in the following 12 weeks. Serum glucose promptly increased and insulin resistance was noted in the diabetic rats (glucose: 360-500 mg/dl, HOMA-IR 9.8-13.8). F2, rich in polysaccharides and carbohydrates, was most effective in attenuating hyperglycemia and insulin resistance (glucose: 200 mg/dl; HOMA-IR: 5.3) and especially HbA1C (from 8.0% to 6.5%). All of the AE subfractions lowered the level of triglycerides and free fatty acid, but not the level of total cholesterol. FR significantly increased the high-density lipoprotein/low-density lipoprotein ratio, indicating its benefits for lipoprotein profiles. While F2 and FR were associated with weight gain, F1 possessed an anti-obese effect. In conclusion, whether it is consumed as a vegetable or as a nutraceutical, AE has the potential to be an adjuvant therapy for diabetes. AE subfractions could be developed individually and deserve further investigation.	[Huang, Chien-Ning] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan; [Huang, Chien-Ning; Lin, Chih-Li] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Wang, Chau-Jong; Lin, Hui-Ting] Chung Shan Med Univ, Inst Biochem Microbiol & Immunol, Taichung, Taiwan; [Peng, Chiung-Huei] Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Hungkuang University	Peng, CH (corresponding author), Hungkuang Univ, Div Basic Med Sci, Taichung, Taiwan.	a222907@sunrise.hk.edu.tw	Lin, Chih-Li/GQZ-6480-2022; Lin, Chih-Li/H-9515-2019	Lin, Chih-Li/0000-0003-4553-3727; Peng, Chiung-Huei/0000-0003-1833-5522	Ministry of Science and Techonology, Taiwan [MOST 104-2320-B-241-001, MOST 105-2320-B-241-004-MY2]	Ministry of Science and Techonology, Taiwan	This work was supported by the grant MOST 104-2320-B-241-001, and MOST 105-2320-B-241-004-MY2 of Ministry of Science and Techonology, Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; Ahn J, 2008, BIOCHEM BIOPH RES CO, V373, P545, DOI 10.1016/j.bbrc.2008.06.077; Chiu N, 1995, ILLUSTRATED MED PLAN, VI.; Corrado F, 2011, DIABETIC MED, V28, P972, DOI 10.1111/j.1464-5491.2011.03284.x; Despres JP, 2006, ANN MED, V38, P52, DOI 10.1080/07853890500383895; Huang CN, 2017, PLOS ONE, V12; Kitajima S, 2004, DIABETOLOGIA, V47, P1202, DOI 10.1007/s00125-004-1429-0; Li WJ, 2015, J AGR FOOD CHEM, V63, P8182, DOI 10.1021/acs.jafc.5b03462; Lu YY, 2016, J FUNCT FOODS, V20, P463, DOI 10.1016/j.jff.2015.10.037; Ma XL, 2014, GLYCOCONJUGATE J, V31, P355, DOI 10.1007/s10719-014-9526-x; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Panarotto D, 2002, EUR J CLIN INVEST, V32, P84, DOI 10.1046/j.1365-2362.2002.00945.x; Peng CH, 2016, FOOD FUNCT, V7, P728, DOI [10.1039/C5FO01214G, 10.1039/c5fo01214g]; Peng CH, 2009, J AGR FOOD CHEM, V57, P8812, DOI 10.1021/jf902143x; Ravelojaona V, 2006, BIOMED PHARMACOTHER, V60, P359, DOI 10.1016/j.biopha.2006.06.019; Sabitha V., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS162; Sabitha V, 2011, J PHARM BIOALLIED SC, V3, P397, DOI 10.4103/0975-7406.84447; Sabitha Vijayakumar, 2012, J Ayurveda Integr Med, V3, P188, DOI 10.4103/0975-9476.104432; Wang H, 2009, DIABETES, V58, P116, DOI 10.2337/db07-1839; Yang YS, 2013, J FUNCT FOODS, V5, P810, DOI 10.1016/j.jff.2013.01.027; Ye Jianping, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P65; Zhao M, 2012, MOLECULES, V17, P7083, DOI 10.3390/molecules17067083; Zhou J, 2015, J ETHNOPHARMACOL, V164, P229, DOI 10.1016/j.jep.2015.02.026; Zhu KX, 2013, INT J BIOL MACROMOL, V57, P142, DOI 10.1016/j.ijbiomac.2013.03.009	24	16	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2017	12	12							e0189065	10.1371/journal.pone.0189065	http://dx.doi.org/10.1371/journal.pone.0189065			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP0ZD	29216237	gold, Green Submitted, Green Published			2023-01-03	WOS:000417337800063
J	Lion, A				Lion, Alex			The Code, the Cloud, and the Doppler	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lion, Alex] Indiana Univ Sch Med, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Lion, A (corresponding author), Indiana Univ Sch Med, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA.								0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2017	377	20					1915	1917		10.1056/NEJMp1710757	http://dx.doi.org/10.1056/NEJMp1710757			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FM7CU	29141171				2023-01-03	WOS:000415228800004
J	Hohmann, L; Bradt, J; Stegemann, T; Koelsch, S				Hohmann, Louisa; Bradt, Joke; Stegemann, Thomas; Koelsch, Stefan			Effects of music therapy and music-based interventions in the treatment of substance use disorders: A systematic review	PLOS ONE			English	Review							WORKING ALLIANCE; LYRIC ANALYSIS; DETOXIFICATION UNIT; MOOD STATES; MOTIVATION; CLIENTS; ADOLESCENTS; READINESS; OUTCOMES; PROGRAM	Music therapy (MT) and music-based interventions (MBIs) are increasingly used for the treatment of substance use disorders (SUD). Previous reviews on the efficacy of MT emphasized the dearth of research evidence for this topic, although various positive effects were identified. Therefore, we conducted a systematic search on published articles examining effects of music, MT and MBIs and found 34 quantitative and six qualitative studies. There was a clear increase in the number of randomized controlled trials (RCTs) during the past few years. We had planned for a meta-analysis, but due to the diversity of the quantitative studies, effect sizes were not computed. Beneficial effects of MT/MBI on emotional and motivational outcomes, participation, locus of control, and perceived helpfulness were reported, but results were inconsistent across studies. Furthermore, many RCTs focused on effects of single sessions. No published longitudinal trials could be found. The analysis of the qualitative studies revealed four themes: emotional expression, group interaction, development of skills, and improvement of quality of life. Considering these issues for quantitative research, there is a need to examine social and health variables in future studies. In conclusion, due to the heterogeneity of the studies, the efficacy of MT/MBI in SUD treatment still remains unclear.	[Hohmann, Louisa] Free Univ Berlin, Dept Educ Sci & Psychol, Berlin, Germany; [Hohmann, Louisa; Koelsch, Stefan] Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway; [Bradt, Joke] Drexel Univ, Coll Nursing & Hlth Profess, Dept Creat Arts Therapies, Philadelphia, PA 19104 USA; [Stegemann, Thomas] Univ Mus & Performing Arts, Dept Mus Therapy, Vienna, Austria	Free University of Berlin; University of Bergen; Drexel University	Hohmann, L (corresponding author), Free Univ Berlin, Dept Educ Sci & Psychol, Berlin, Germany.; Hohmann, L (corresponding author), Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway.	louisa.hohmann@fu-berlin.de	Koelsch, Stefan/AAV-1556-2020; bradt, joke/C-5930-2014	bradt, joke/0000-0001-7313-9829; Hohmann, Louisa/0000-0002-1055-4467				Abdollahnejad MR, 2006, THERAPEUTIC COMMUNIT, V27, P147; Albornoz Y, 2011, NORD J MUSIC THER, V20, P208, DOI 10.1080/08098131.2010.522717; Aletraris L, 2014, J ADDICT NURS, V25, P190, DOI 10.1097/JAN.0000000000000048; American Music Therapy Association, 2008, MUS THERP INT TRAUM; American Music Therapy Association, 2006, MUS THER MENT HLTH; Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; Auerbach SM, 2008, INT J CLIN HLTH PSYC, V8, P617; Baker FA, 2007, ART PSYCHOTHER, V34, P321, DOI 10.1016/j.aip.2007.04.005; Baker FA, 2012, THERAPEUTIC USES OF RAP AND HIP-HOP, P321; Barber JP, 2001, J CONSULT CLIN PSYCH, V69, P119, DOI 10.1037/0022-006X.69.1.119; Bradt J, 2016, J MUSIC THER, V53, P178, DOI 10.1093/jmt/thw004; Bradt J, 2015, SUPPORT CARE CANCER, V23, P1261, DOI 10.1007/s00520-014-2478-7; Buehringer G, 2011, KLIN PSYCHOL PSYCHOT, P697; C A Malchiodi, 2005, EXPRESSIVE THERAPIES, P1; Cassileth BR, 2003, CANCER, V98, P2723, DOI 10.1002/cncr.11842; Center for Behavioral Health Statistics and Quality, 2015, RES 2014 NAT SURV DR; Cevasco AM, 2005, J MUSIC THER, V42, P64, DOI 10.1093/jmt/42.1.64; Chanda ML, 2013, TRENDS COGN SCI, V17, P179, DOI 10.1016/j.tics.2013.02.007; Conners GJ, 1997, J CONSULT CLIN PSYCH, V65, P588, DOI 10.1037/0022-006X.65.4.588; Cook S, 2015, PSYCHOL ADDICT BEHAV, V29, P371, DOI 10.1037/adb0000058; DELEON G, 1994, AM J DRUG ALCOHOL AB, V20, P495; Dickerson DL, 2014, AM INDIAN ALASKA NAT, V21, P35, DOI 10.5820/aian.2101.2014.35; Dingle GA, 2008, DRUG ALCOHOL REV, V27, P190, DOI 10.1080/09595230701829371; Dougherty KM, 1984, MUSIC THER, V4, P47, DOI DOI 10.1093/MT/4.1.47]; Dundon WD, 2008, DRUG ALCOHOL DEPEN, V95, P230, DOI 10.1016/j.drugalcdep.2008.01.010; Eagle Charles T., 1972, J MUSIC THER, V9, P23, DOI DOI 10.1093/JMT/9.1.23; Eid M, 2015, STAT FORSCHUNGSMETHO; Fisher CG, 2007, SPINE, V32, pS66, DOI 10.1097/BRS.0b013e318145308d; Fritz TH, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00300; GALLAGHER L. M., 2002, MUSIC THERAPY PERSPE, V20, P117, DOI [10.1093/mtp/20.2.117, DOI 10.1093/MTP/20.2.117]; Gallant W. A., 1997, GROUPWORK, V10, P155; Gardstrom SC, 2013, VOICES WORLD FORUM M, P13; Gardstrom SC, 2010, MUSIC THER PERSPECT, V28, P147, DOI 10.1093/mtp/28.2.147; Gardstrom SC, 2013, MUSIC THER PERSPECT, V31, P116, DOI 10.1093/mtp/31.2.116; Gaston E.T., 1970, J MUSIC THER, V7, P3, DOI [DOI 10.1093/JMT/7.1.3, 10.1093/jmt/7.1.3]; Ghetti CM, 2004, MUSIC THER PERSPECT, V22, P84, DOI DOI 10.1093/MTP/22.2.84; Gold C, 2013, PSYCHOTHER PSYCHOSOM, V82, P319, DOI 10.1159/000348452; Gooding LF, 2011, J MUSIC THER, V48, P440, DOI 10.1093/jmt/48.4.440; GOTTHEIL E, 1977, AM J DRUG ALCOHOL AB, V4, P31, DOI 10.3109/00952997709002745; Groshkova T, 2010, ADDICT RES THEORY, V18, P494, DOI 10.3109/16066350903362875; Hammer SE, 1996, J MUSIC THER, V33, P47, DOI 10.1093/jmt/33.1.47; Howard A.A., 1997, J POETRY THER, V11, P81, DOI [DOI 10.1023/B:J0PT.0000010860.98970.16, https://doi.org/10.1023/B:JOPT.0000010860.98970.16]; Hwang EY., 2013, MUSIC MED, V5, P136, DOI [10.1177/1943862113495894, DOI 10.1177/1943862113495894]; Ilgen MA, 2006, J SUBST ABUSE TREAT, V31, P157, DOI 10.1016/j.jsat.2006.04.001; JAMES MR, 1988, J MUSIC THER, V25, P206, DOI 10.1093/jmt/25.4.206; James MR, 1987, MUSIC THERAPY PERSPE, V4, P29; Jansma A, 2000, ADDICT BEHAV, V25, P619, DOI 10.1016/S0306-4603(99)00037-4; Jhanjee Sonali, 2014, Indian J Psychol Med, V36, P112, DOI 10.4103/0253-7176.130960; Jones JD, 2005, J MUSIC THER, V42, P94, DOI 10.1093/jmt/42.2.94; Knuuttila V, 2012, CLIN PSYCHOL-UK, V16, P123, DOI 10.1111/j.1742-9552.2012.00049.x; KOELSCH S., 2012, MUSIC HLTH WELLBEING, P436, DOI DOI 10.1016/J.PLREV.2011.04.003; Koelsch S, 2009, ANN NY ACAD SCI, V1169, P374, DOI 10.1111/j.1749-6632.2009.04592.x; Kotarba J A, 1991, AIDS Educ Prev, V3, P47; Liebowitz M, 2015, ARTS HEALTH, V7, P137, DOI 10.1080/17533015.2014.999246; Lin ST, 2011, HARVARD REV PSYCHIAT, V19, P34, DOI 10.3109/10673229.2011.549769; Long CG, 2000, ADDICT BEHAV, V25, P573, DOI 10.1016/S0306-4603(99)00018-0; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Magee WL, 2002, J MUSIC THER, V39, P20, DOI 10.1093/jmt/39.1.20; Maratos AS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004517.pub2; Mays KL, 2008, SUBST ABUS, V29, P51, DOI 10.1080/08897070802418485; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Meier PS, 2006, DRUG ALCOHOL DEPEN, V83, P57, DOI 10.1016/j.drugalcdep.2005.10.010; Melnyk BM, 2005, EVIDENCE BASED PRACT; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Murphy KM, 2008, EFFECTS GROUP GUIDED; Murphy M., 1983, MUSIC THERAPY, V3, P52, DOI DOI 10.1093/MT/3.1.52; NERAD J, 1989, INT J PSYCHOPHYSIOL, V7, P334, DOI 10.1016/0167-8760(89)90270-5; Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6; Oklan A.M., 2014, PSYCHOMUSICOLOGY, V24, P231, DOI [DOI 10.1037/, 10.1037/pmu0000058, DOI 10.1037/PMU0000058]; Pelletier CL, 2004, J MUSIC THER, V41, P192, DOI 10.1093/jmt/41.3.192; Porter S, 2017, J CHILD PSYCHOL PSYC, V58, P586, DOI 10.1111/jcpp.12656; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; Puffer S, 2005, J EVAL CLIN PRACT, V11, P479, DOI 10.1111/j.1365-2753.2005.00568.x; Rio R., 2005, NORD J MUSIC THER, V14, P107, DOI DOI 10.1080/08098130509478133; Rosenthal R., 1968, URBAN REV, P16, DOI [10.1007/BF02322211, DOI 10.1007/BF02322211]; Ross S, 2008, J ADDICT DIS, V27, P41, DOI 10.1300/J069v27n01_05; ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976; SELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965; Sharma M., 2011, PAKISTAN J PSYCHOL R, V27, P53; Short AD, 2015, PSYCHOL MUSIC, P559; Shuman J, 2016, ART PSYCHOTHER, V49, P50, DOI 10.1016/j.aip.2016.05.014; Silverman MJ, 2016, SUBST USE MISUSE, V51, P241, DOI 10.3109/10826084.2015.1092990; Silverman Michael J., 2015, [Korean Journal of Music Therapy, 한국음악치료학회지], V17, P81, DOI 10.21330/kjmt.2015.17.2.81; Silverman MJ, 2015, J MUSIC THER, V52, P117, DOI 10.1093/jmt/thu057; Silverman MJ, 2014, J ADDICT NURS, V25, P172, DOI 10.1097/JAN.0000000000000047; Silverman MJ, 2012, J MUSIC THER, V49, P414, DOI 10.1093/jmt/49.4.414; Silverman MJ, 2011, J ADDICT NURS, V22, P185, DOI 10.3109/10884602.2011.616606; Silverman MJ, 2011, J MUSIC THER, V48, P509, DOI 10.1093/jmt/48.4.509; Silverman MJ, 2009, MUSIC THER PERSPECT, V27, P115, DOI 10.1093/mtp/27.2.115; Silverman MJ, 2010, ART PSYCHOTHER, V37, P197, DOI 10.1016/j.aip.2010.04.001; Silverman MJ, 2010, ART PSYCHOTHER, V37, P1, DOI 10.1016/j.aip.2009.11.005; Silverman MJ, 2009, ART PSYCHOTHER, V36, P123, DOI 10.1016/j.aip.2008.10.005; Silverman MJ, 2003, ART PSYCHOTHER, V30, P273, DOI 10.1016/j.aip.2003.08.004; Stevens JR, 2009, J EDUC BEHAV STAT, V34, P46, DOI 10.3102/1076998607309080; Substance Abuse and Mental Health Services Administration, 2014, HHS PUBLICATION SMA, VSMA, P14; Substance Abuse and Mental Health Services Administration, 2009, DAS SER S, VS-46; United Nations Office on Drugs and Crime, 2016, INT STAND TREATM DRU; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Winkelman M, 2003, AM J PUBLIC HEALTH, V93, P647, DOI 10.2105/AJPH.93.4.647; Yun SH, 2010, J EVID-INFORM SOC WO, V7, P361, DOI 10.1080/15433710903323870; ZANKER A, 1956, Monatsschr Psychiatr Neurol, V131, P215; Zatorre RJ, 2015, ANN NY ACAD SCI, V1337, P202, DOI 10.1111/nyas.12677	102	46	46	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2017	12	11							e0187363	10.1371/journal.pone.0187363	http://dx.doi.org/10.1371/journal.pone.0187363			36	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM7MC	29141012	Green Published, gold, Green Submitted			2023-01-03	WOS:000415260400022
J	Le Reste, JY; Nabbe, P; Grasset, AB; Le Floch, B; Grall, P; Derriennic, J; Odorico, M; Lalande, S; le Goff, D; Barais, M; Chiron, B; Lingner, H; Guillou, M; Barraine, P				Le Reste, Jean Yves; Nabbe, Patrice; Grasset, Alice Billot; Le Floch, Bernard; Grall, Pauline; Derriennic, Jeremy; Odorico, Michele; Lalande, Sophie; le Goff, Delphine; Barais, Marie; Chiron, Benoit; Lingner, Heidrun; Guillou, Morgane; Barraine, Pierre			Multimorbid outpatients: A high frequency of FP appointments and/or family difficulties, should alert FPs to the possibility of death or acute hospitalization occurring within six months; A primary care feasibility study	PLOS ONE			English	Article							LONG-TERM-CARE; CHRONIC DISEASES; HEALTH; DEFINITION; PREVALENCE; MEDICINE; LIFE	Background The European General Practitioners Research Network (EGPRN) designed and validated a comprehensive definition of multimorbidity using a systematic literature review and qualitative research throughout Europe. This definition was tested as a model to assess death or acute hospitalization in multimorbid outpatients. ObjectiveTo assess which criteria in the EGPRN concept of multimorbidity could detect outpatients at risk of death or acute hospitalization in a primary care cohort at a 6-month follow-up and to assess whether a large scale cohort with FPs would be feasible. Method Family Physicians included a random sample of multimorbid patients who attended appointments in their offices from July to December 2014. Inclusion criteria were those of the EGPRN definition of Multimorbidity. Exclusion criteria were patients under legal protection and those unable to complete the 2-year follow-up. Statistical analysis was undertaken with uni-and multivariate analysis at a 6-month follow-up using a combination of approaches including both automatic classification and expert decision making. A Multiple Correspondence Analysis (MCA) completed the process with a projection of illustrative variables. A logistic regression was finally performed in order to identify and quantify risk factors for decompensation. Results 19 FPs participated in the study. 96 patients were analyzed. 3 different clusters were identified. MCA showed the central function of psychosocial factors and peaceful versus conflictual relationships with relatives in all clusters. While taking into account the limit of a small cohort, age, frequency of family physician visits and extent of family difficulties were the factors which predicted death or acute hospitalization. Conclusion A large scale cohort seems feasible in primary care. A sense of alarm should be triggered to prevent death or acute hospitalization in multimorbid older outpatients who have frequent family physician visits and who experience family difficulties.	[Le Reste, Jean Yves; Nabbe, Patrice; Grasset, Alice Billot; Le Floch, Bernard; Grall, Pauline; Derriennic, Jeremy; Odorico, Michele; Lalande, Sophie; le Goff, Delphine; Barais, Marie; Chiron, Benoit; Guillou, Morgane; Barraine, Pierre] Univ Bretagne Occidentale, SPURBO, Dept Gen Practice, EA 7479, Brest, France; [Lingner, Heidrun] Allgemein Med Hsch Hannover, Hannover, Germany	Universite de Bretagne Occidentale	Le Reste, JY; Nabbe, P (corresponding author), Univ Bretagne Occidentale, SPURBO, Dept Gen Practice, EA 7479, Brest, France.	lereste@univ-brest.fr; nabbep@univ-brest.fr	barais, marie/H-2888-2018	le reste, jean yves/0000-0003-0883-3595				Almirall Jose, 2013, J Comorb, V3, P4; Bongue Bienvenu, 2016, Soins Gerontol, V21, P24, DOI 10.1016/j.sger.2016.05.006; Brandlmeier P, 1976, ZFA (Stuttgart), V52, P1269; Diederichs C, 2011, J GERONTOL A-BIOL, V66, P301, DOI 10.1093/gerona/glq208; DRESS, 2016, COMP INT DEP HOSP; European Academy of Teachers in General Practice (Network within Wonca Europe), 2002, EUR DEF GEN PRACT ME; Fortin M, 2006, QUAL LIFE RES, V15, P83, DOI 10.1007/s11136-005-8661-z; Fortin M, 2012, ANN FAM MED, V10, P142, DOI 10.1370/afm.1337; Galvin R, 2016, AGE AGEING; Garrido-Elustondo S, 2016, ATEN PRIMARIA; Huber Machteld, 2011, BMJ, V343, pd4163, DOI 10.1136/bmj.d4163; Hummers-Pradier E, 2010, EUR J GEN PRACT, V16, P174, DOI 10.3109/13814788.2010.504982; Kaufman L, 2005, FINDING GROUPS ORDIN; Le Reste JY, 2016, EUR J GEN PRACT, V22, P159, DOI 10.3109/13814788.2015.1136619; Le Reste JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115796; Le Reste JY, 2013, J AM MED DIR ASSOC, V14, P319, DOI 10.1016/j.jamda.2013.01.001; Le Reste JY, 2013, J AM MED DIR ASSOC, V14, P132, DOI 10.1016/j.jamda.2012.07.017; Le Reste J, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0337-3; Lee L, 2015, CAN FAM PHYSICIAN, V61, pE148; Lussier MT, 2016, PATIENT EDUC COUNS, V99, P530, DOI 10.1016/j.pec.2015.11.007; Muth C, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0223-1; Muth C, 2014, EUR J GEN PRACT, V20, P139, DOI 10.3109/13814788.2013.839651; Onder G, 2015, EUR J INTERN MED, V26, P157, DOI 10.1016/j.ejim.2015.02.020; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; van den Bussche H, 2013, J CLIN EPIDEMIOL, V66, P209, DOI 10.1016/j.jclinepi.2012.07.019; van den Bussche H, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-101; Van der Akker M, 1996, EUR J GEN PRACT, V2, P65, DOI 10.3109/13814789609162146; Violan C, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-251; WHO, 2008, PHARMAFORUM 0121; Wicke FS, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-62; WINOGRAD C H, 1991, Journal of the American Geriatrics Society, V39, p25S	32	0	0	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2017	12	11							e0186931	10.1371/journal.pone.0186931	http://dx.doi.org/10.1371/journal.pone.0186931			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL6FI	29095849	Green Submitted, Green Published, gold			2023-01-03	WOS:000414340200033
J	von Schaper, E				von Schaper, Eva			Allergan's Mohawk evergreening patent deal draws criticism, but ultimately may flop	NATURE BIOTECHNOLOGY			English	News Item																			0	0	0	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2017	35	11					1002	1002		10.1038/nbt1117-1002	http://dx.doi.org/10.1038/nbt1117-1002			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FM2UM	29121010	Bronze			2023-01-03	WOS:000414856200006
J	Wang, MQ; Lee, RJ; Bi, Y; Li, LL; Yan, GD; Lu, JH; Meng, QF; Teng, LS; Xie, J				Wang, Mengqiao; Lee, Robert J.; Bi, Ye; Li, Lianlian; Yan, Guodong; Lu, Jiahui; Meng, Qingfan; Teng, Lesheng; Xie, Jing			Transferrin-conjugated liposomes loaded with novel dihydroquinoline derivatives as potential anticancer agents	PLOS ONE			English	Article							CELLS; DELIVERY; TUMOR	A series of 1,2-dihydroquinoline derivatives were synthesized and evaluated for cytotoxicity in HeLa, Hep G2 and 6HEK-293T cell lines. EEDQ2 was identified as a promising anti-cancer agent with low IC50 in HeLa (18.55 mu g/ml) and Hep G2 (14.53 mu g/ml) cells. For improving the antitumor activity and tumor selectivity of EEDQ2, we prepared transferrin (Tf)-modified liposomes (LPs) to deliver EEDQ2. When HeLa and Hep G2 cells were treated with LP-delivered EEDQ2, the ROS level was significantly enhanced, and mitochondrial membrane potential was reversed. Tf-LPs improved cell uptake of EEDQ2 by about 3.7 times compared with non-targeted LPs. These data suggest that Tf-LPs delivering EEDQ2 is a promising strategy to treat cancer.	[Wang, Mengqiao; Lee, Robert J.; Bi, Ye; Li, Lianlian; Yan, Guodong; Lu, Jiahui; Meng, Qingfan; Teng, Lesheng; Xie, Jing] Jilin Univ, Coll Life Sci, Changchun, Jilin, Peoples R China; [Lee, Robert J.] Ohio State Univ, Coll Pharm, Div Pharmaceut, 500 W 12Th Ave, Columbus, OH 43210 USA	Jilin University; University System of Ohio; Ohio State University	Teng, LS; Xie, J (corresponding author), Jilin Univ, Coll Life Sci, Changchun, Jilin, Peoples R China.	tenglesheng@jlu.edu.cn; xiejing@jlu.edu.cn		Teng, Lesheng/0000-0003-1623-5384	National Natural Science Foundation of China [81502999]; Jilin Province Science and Technology Development Program [20170414039GH]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin Province Science and Technology Development Program	This research was supported by the National Natural Science Foundation of China (grant no. 81502999) and Jilin Province Science and Technology Development Program (grant no. 20170414039GH).; The work was funded by National Natural Science Foundation of China (No. 81502999) and Jilin Province Science and Technology Development Program (No. 20170414039GH).	Bekhit AA, 2010, EUR J MED CHEM, V45, P6027, DOI 10.1016/j.ejmech.2010.10.001; Bi Y, 2016, CURR DRUG METAB, V17, P763, DOI 10.2174/1389200217666160619191853; Bondock S, 2007, EUR J MED CHEM, V42, P948, DOI 10.1016/j.ejmech.2006.12.025; Chiu SJ, 2006, J CONTROL RELEASE, V112, P199, DOI 10.1016/j.jconrel.2006.02.011; Ding YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122128; Dressler C, 2006, J FLUORESC, V16, P689, DOI 10.1007/s10895-006-0110-z; Engel A, 2003, PHARM RES-DORDR, V20, P51, DOI 10.1023/A:1022294624256; Eswaran R, 2016, J INORG BIOCHEM, V155, P1, DOI 10.1016/j.jinorgbio.2015.11.007; Gomes CRB, 2010, LETT DRUG DES DISCOV, V7, P353; Hossen MN, 2010, J CONTROL RELEASE, V147, P261, DOI 10.1016/j.jconrel.2010.07.100; Lee HH, 2013, INT J ONCOL, V42, P1036, DOI 10.3892/ijo.2013.1762; Li Z, 2014, COLLOID SURFACE B, V122, P630, DOI 10.1016/j.colsurfb.2014.07.042; Ma XY, 2016, CHEM RES CHINESE U, V32, P634, DOI 10.1007/s40242-016-5481-3; Ma XY, 2016, ANTICANCER RES, V36, P2105; Maitani Y, 2001, J LIPOSOME RES, V11, P115, DOI 10.1081/LPR-100103174; Omar K, 2010, BIOORGAN MED CHEM, V18, P426, DOI 10.1016/j.bmc.2009.10.041; Ottana R, 2005, BIOORG MED CHEM LETT, V15, P3930, DOI 10.1016/j.bmcl.2005.05.093; Panwar P, 2010, INT J NANOMED, V5, P101; Przybylo M, 2016, EUR J PHARM SCI, V85, P39, DOI 10.1016/j.ejps.2016.01.028; Raja DS, 2013, EUR J MED CHEM, V64, P148, DOI 10.1016/j.ejmech.2013.03.040; Rekhert JM, 2008, DRUG DISCOV TODAY, V13, P30, DOI 10.1016/j.drudis.2007.09.003; Szilagyi G, 2006, NEUROSCI LETT, V399, P206, DOI 10.1016/j.neulet.2006.01.071; Ulrich AS, 2002, BIOSCIENCE REP, V22, P129, DOI 10.1023/A:1020178304031; Xu M, 2014, CHROMATOGRAPHIA, V77, P223, DOI 10.1007/s10337-013-2591-7; Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349; Zhao CK, 2015, LIFE SCI, V137, P37, DOI 10.1016/j.lfs.2015.07.019; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	27	6	6	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0186821	10.1371/journal.pone.0186821	http://dx.doi.org/10.1371/journal.pone.0186821			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL2ZD	29088257	Green Published, gold, Green Submitted			2023-01-03	WOS:000414088900023
J	Kinoshita, T; Nishimura, Y; Nakamura, T; Hashizaki, T; Kojima, D; Kawanishi, M; Uenishi, H; Arakawa, H; Ogawa, T; Kamijo, Y; Kawasaki, T; Tajima, F				Kinoshita, Tokio; Nishimura, Yukihide; Nakamura, Takeshi; Hashizaki, Takamasa; Kojima, Daisuke; Kawanishi, Makoto; Uenishi, Hiroyasu; Arakawa, Hideki; Ogawa, Takahiro; Kamijo, Yoshi-ichiro; Kawasaki, Takashi; Tajima, Fumihiro			Effects of physiatrist and registered therapist operating acute rehabilitation (PROr) in patients with stroke	PLOS ONE			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; RANDOMIZED CONTROLLED-TRIAL; EARLY MOBILIZATION; PHASE-II; AVERT; SCALE; DISABILITY; HANDICAP; OUTCOMES; SAFETY	Objective Clinical evidence suggests that early mobilization of patients with acute stroke improves activity of daily living (ADL). The purpose of this study was to compare the utility of the physiatrist and registered therapist operating acute rehabilitation (PROr) applied early or late after acute stroke. Subjects and methods This study was prospective cohort study, assessment design. Patients with acute stroke (n = 227) admitted between June 2014 and April 2015 were divided into three groups based on the time of start of PROr: within 24 hours (VEM, n = 47), 24-48 hours (EM, n = 77), and more than 48 hours (OM, n = 103) from stroke onset. All groups were assessed for the number of deaths during hospitalization, and changes in the Glasgow Coma Scale (GCS), National Institute of Health Stroke Scale (NIHSS), and Functional Independence Measure (FIM) at hospital discharge. Interventions All patients were assessed by physiatrists, who evaluated the specific needs for rehabilitation, and then referred them to registered physical therapists and occupational therapists to provide early mobilization (longer than one hour per day per patient). Results The number of deaths encountered during the PROr period was 13 (out of 227, 5.7%), including 2 (4.3%) in the VEM group. GCS improved significantly during the hospital stay in all three groups, but the improvement on discharge was significantly better in the VEM group compared with the EM and OM groups. FIM improved significantly in the three groups, and the gains in total FIM and motor subscale were significantly greater in the VEM than the other groups. Conclusions PROr seems safe and beneficial rehabilitation to improve ADL in patients with acute stroke.	[Kinoshita, Tokio; Hashizaki, Takamasa; Kojima, Daisuke; Kawanishi, Makoto; Uenishi, Hiroyasu; Arakawa, Hideki; Ogawa, Takahiro; Kamijo, Yoshi-ichiro; Kawasaki, Takashi; Tajima, Fumihiro] Wakayama Med Univ, Dept Rehabil Med, Wakayama, Japan; [Nishimura, Yukihide] Iwate Med Univ, Dept Rehabil Med, Morioka, Iwate, Japan; [Nakamura, Takeshi] Yokohama City Univ, Sch Med, Dept Rehabil Med, Yokohama, Kanagawa, Japan	Wakayama Medical University; Iwate Medical University; Yokohama City University	Tajima, F (corresponding author), Wakayama Med Univ, Dept Rehabil Med, Wakayama, Japan.	tajibun@gmail.com	Kamijo, Yoshi-ichiro/AAH-2810-2020	Nishimura, Yukihide/0000-0002-5365-1347	JSPS KAKENHI [15K01384]; Japan Society for the Promotion Science (JSPS) [15K01384]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Society for the Promotion Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported in part by JSPS KAKENHI Grant Number 15K01384. The URL of Japan Society for the Promotion Science (JSPS) is https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K01384/. The author who received funding is FT.	Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Chumney D, 2010, J REHABIL RES DEV, V47, P17, DOI 10.1682/JRRD.2009.08.0140; Cumming TB, 2008, J REHABIL MED, V40, P609, DOI 10.2340/16501977-0226; Cumming TB, 2011, STROKE, V42, P153, DOI 10.1161/STROKEAHA.110.594598; DEHAAN R, 1995, STROKE, V26, P2027, DOI 10.1161/01.STR.26.11.2027; Dromerick AW, 2003, J REHABIL RES DEV, V40, P1, DOI 10.1682/JRRD.2003.01.0001; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Greening NJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4315; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Intercollegiat e Stroke Working Party, 2012, NAT CFLIN GUID STROK; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MAHONEY F I, 1965, Md State Med J, V14, P61; Management of Stroke Rehabilitation Working Group, 2010, VA DOD CLIN PRACT GU; Momosaki R, 2016, GERIATR GERONTOL INT, V16, P963, DOI 10.1111/ggi.12582; Moriki T, 2013, OPEN J THER REHABIL, V01, P1; National Stroke Foundation, 2010, CLIN GUID STROK MAN; Roberts L, 1998, STROKE, V29, P986, DOI 10.1161/01.STR.29.5.986; Sorbello D, 2009, CEREBROVASC DIS, V28, P378, DOI 10.1159/000230712; Tay-Teo K, 2008, CEREBROVASC DIS, V26, P475, DOI 10.1159/000155984; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; The Japan Stoke Society, 2015, JAP GUID MAN STROK; Tyedin K, 2010, DISABIL REHABIL, V32, P875, DOI 10.3109/09638280903349552; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604	29	9	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0187099	10.1371/journal.pone.0187099	http://dx.doi.org/10.1371/journal.pone.0187099			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK9QH	29073250	gold, Green Published, Green Submitted			2023-01-03	WOS:000413845400114
J	Patino, AM; Marsh, RH; Nilles, EJ; Baugh, CW; Rouhani, SA; Kayden, S				Patino, Andres M.; Marsh, Regan H.; Nilles, Eric J.; Baugh, Christopher W.; Rouhani, Shada A.; Kayden, Stephanie			Facing the Shortage of IV Fluids - A Hospital-Based Oral Rehydration Strategy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Patino, Andres M.; Marsh, Regan H.; Nilles, Eric J.; Baugh, Christopher W.; Rouhani, Shada A.; Kayden, Stephanie] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA; [Patino, Andres M.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Marsh, Regan H.; Rouhani, Shada A.] Partners Hlth, Boston, MA USA; [Nilles, Eric J.; Kayden, Stephanie] Harvard Humanitarian Initiat, Cambridge, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Partners Healthcare System; Harvard University	Patino, AM (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.; Patino, AM (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.		Nilles, Eric/ABA-4757-2021; Baugh, Christopher William/AAJ-3688-2021	Nilles, Eric/0000-0001-7044-5257; Baugh, Christopher William/0000-0002-2360-1891; Patino, Andres/0000-0002-4599-4016; Rouhani, Shada/0000-0002-2801-192X				[Anonymous], 2014, DRUG SHORT PUBL HLTH; Harting L, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004390.pub2; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; Munos MK, 2010, INT J EPIDEMIOL, V39, P75, DOI 10.1093/ije/dyq025; Saker A, 2018, USA TODAY NETWO 0114	5	13	14	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2018	378	16					1475	1477		10.1056/NEJMp1801772	http://dx.doi.org/10.1056/NEJMp1801772			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD2EI	29561701	Bronze			2023-01-03	WOS:000430312500003
J	Oryan, A; Alidadi, S; Bigham-Sadegh, A; Moshiri, A				Oryan, Ahmad; Alidadi, Soodeh; Bigham-Sadegh, Amin; Moshiri, Ali			Healing potentials of polymethylmethacrylate bone cement combined with platelet gel in the critical-sized radial bone defect of rats	PLOS ONE			English	Article							RICH PLASMA; POLYMETHYL METHACRYLATE; COMPOSITE SCAFFOLD; CANCELLOUS BONE; IN-VIVO; REGENERATION; MODEL; AUGMENTATION; RABBIT; PHOSPHATE	Polymethylmethacrylate (PMMA) is the most commonly used filler material that lacks biological properties and osteoconductivity or osteoinductivity. Platelet gel (PG) is a typical source of growth factors, cytokines and molecules efficient for bone formation and remodeling. The aim of this study was to evaluate bone healing and regeneration of bone defect in rat model by combining PMMA with PG. A total of 50 defects were created in the diaphysis of the radii of 25 male Sprague-Dawley rats. These defects were randomly divided into five groups (n = 10 defects for each group) and treated by autograft, plain PMMA, PG and PMMA-PG or left untreated. The rats were examined clinically and radiologically during the experiment and also after euthanasia at the 8th post-operative week, the healed defects were evaluated by gross morphology, histopathology, histomorphometry, computed tomography, scanning electron microscopy and biomechanical testing. PG could function as efficiently as autograft in promoting bone healing of the radial bones. Additionally, bone formation, and densities of cartilaginous and osseous tissues in the defects treated with autograft, PG and PMMA-PG were more satisfactory than the untreated and PMMA treated defects. Compared with the PMMA-PG implant, more PMMA residuals remained in the defect area and induced more intense inflammatory reaction. In conclusion, addition of PG could improve the bone regenerative properties of PMMA bone cement compared with PMMA alone in vivo. Therefore, the PG-PMMA can be proposed as a promising option to increase regenerative potential of PMMA, particularly when it is used as fixator, filler or adhesive in the dentistry, neurosurgery and bone tissue engineering applications.	[Oryan, Ahmad; Alidadi, Soodeh] Shiraz Univ, Sch Vet Med, Dept Pathol, Shiraz, Iran; [Bigham-Sadegh, Amin] Shahrekord Univ, Sch Vet Med, Dept Clin Sci, Shahrekord, Iran; [Moshiri, Ali] AJA Univ Med Sci, Dept Orthoped Surg, Fac Med, Tehran, Iran	Shiraz University; Shahrekord University	Bigham-Sadegh, A (corresponding author), Shahrekord Univ, Sch Vet Med, Dept Clin Sci, Shahrekord, Iran.	dr.bigham@gmail.com	Alidadi, Soodeh/M-4690-2017; Moshiri, Ali/H-1851-2013; Oryan, Ahmad/J-6539-2014	Alidadi, Soodeh/0000-0003-2341-8533; Moshiri, Ali/0000-0003-3967-7468; Oryan, Ahmad/0000-0003-1697-2376				Aghyarian S, 2014, J BIOMATER APPL, V29, P688, DOI 10.1177/0885328214544770; Arabmotlagh M, 2014, J BIOMED MATER RES B, V102, P1613, DOI 10.1002/jbm.b.33140; Arora M, 2013, WORLD J ORTHOP, V4, P67, DOI 10.5312/wjo.v4.i2.67; Betoni W, 2013, J ORAL IMPLANTOL, V39, P14, DOI 10.1563/AAID-JOI-D-10-00043; Dalby MJ, 2002, BIOMATERIALS, V23, P569, DOI 10.1016/S0142-9612(01)00139-9; Fini M, 2002, BIOMATERIALS, V23, P4523, DOI 10.1016/S0142-9612(02)00196-5; Hatten HP, 2012, INTERV NEURORADIOL, V18, P105, DOI 10.1177/159101991201800114; Hautaamaki MP, 2008, ACTA ORTHOP, V79, P555, DOI 10.1080/17453670710015571; He FP, 2015, J BIOMED MATER RES A, V103, P1312, DOI 10.1002/jbm.a.35248; Jager M, 2003, J BIOMAT SCI-POLYM E, V14, P1283, DOI 10.1163/156856203322553491; Khairy NM, 2013, INT J ORAL MAX SURG, V42, P249, DOI 10.1016/j.ijom.2012.09.009; Kim SB, 2004, BIOMATERIALS, V25, P5715, DOI 10.1016/j.biomaterials.2004.01.022; LANE JM, 1987, ORTHOP CLIN N AM, V18, P213; Lv Q, 2006, J MATER SCI-MATER M, V17, P1349, DOI 10.1007/s10856-006-0610-z; Lye KW, 2013, CLIN ORAL IMPLAN RES, V24, P100, DOI 10.1111/j.1600-0501.2011.02388.x; Magnan B, 2013, Musculoskelet Surg, V97, P93, DOI 10.1007/s12306-013-0293-9; Marx RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079-2104(98)90029-4; Mooren RECM, 2010, INT J ORAL MAX SURG, V39, P371, DOI 10.1016/j.ijom.2009.12.019; Moshiri A, 2015, J CELL MOL MED, V19, P1308, DOI 10.1111/jcmm.12511; Moshiri A, 2014, EXPERT OPIN BIOL TH, V14, P1065, DOI 10.1517/14712598.2014.915305; Mousa WF, 2000, BIOMATERIALS, V21, P2137, DOI 10.1016/S0142-9612(00)00097-1; Niemeyer P, 2010, BIOMATERIALS, V31, P3572, DOI 10.1016/j.biomaterials.2010.01.085; Ogundipe OK, 2011, J ORAL MAXIL SURG, V69, P2305, DOI 10.1016/j.joms.2011.02.014; Oryan A, 2012, CELL TISSUE BANK, V13, P639, DOI 10.1007/s10561-011-9285-x; Oryan A, 2017, CALCIFIED TISSUE INT; Oryan A, 2017, J CONTROL RELEASE, V254, P65, DOI 10.1016/j.jconrel.2017.03.040; Oryan A, 2016, EXPERT OPIN BIOL TH, V16, P213, DOI 10.1517/14712598.2016.1118458; Oryan A, 2015, EXP BIOL MED, V240, P194, DOI 10.1177/1535370214554532; Oryan A, 2014, BIODRUGS, V28, P537, DOI 10.1007/s40259-014-0107-0; Parizi AM, 2012, J MATER SCI-MATER M, V23, P473, DOI 10.1007/s10856-011-4478-1; Peng W, 2016, MAXILLOFAC PLAST REC, V38, P1; Plachokova AS, 2009, INT J ORAL MAX SURG, V38, P861, DOI 10.1016/j.ijom.2009.04.009; Rodriguez IA, 2014, BIOMED RES INT, V2014; Tajima S, 2015, TISSUE ENG PT A, V21, P895, DOI [10.1089/ten.tea.2014.0336, 10.1089/ten.TEA.2014.0336]; van Bergen CJA, 2013, OSTEOARTHR CARTILAGE, V21, P1746, DOI 10.1016/j.joca.2013.07.014; Weibrich G, 2004, BONE, V34, P665, DOI 10.1016/j.bone.2003.12.010; Wildemann B, 2005, BIOMATERIALS, V26, P4035, DOI 10.1016/j.biomaterials.2004.10.004; Wolf-Brandstetter C, 2013, J BIOMED MATER RES B, V101B, P599, DOI 10.1002/jbm.b.32862; Xing ZC, 2013, J BIOMAT SCI-POLYM E, V24, P61, DOI 10.1163/156856212X623526; Yang J, 2015, MED SCI MONITOR, V21, P1162, DOI 10.12659/MSM.893845; Zhang ZY, 2013, CELL TRANSPLANT, V22, P175, DOI 10.3727/096368912X653183; Zhu TJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03207-9	42	10	11	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2018	13	4							e0194751	10.1371/journal.pone.0194751	http://dx.doi.org/10.1371/journal.pone.0194751			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB3VV	29608574	Green Published, gold, Green Submitted			2023-01-03	WOS:000428988800017
J	Tam, CS; Anderson, MA; Pott, C; Agarwal, R; Handunnetti, S; Hicks, RJ; Burbury, K; Turner, G; Di Iulio, J; Bressel, M; Westerman, D; Lade, S; Dreyling, M; Dawson, SJ; Dawson, MA; Seymour, JF; Roberts, AW				Tam, Constantine S.; Anderson, Mary Ann; Pott, Christiane; Agarwal, Rishu; Handunnetti, Sasanka; Hicks, Rodney J.; Burbury, Kate; Turner, Gillian; Di Iulio, Juliana; Bressel, Mathias; Westerman, David; Lade, Stephen; Dreyling, Martin; Dawson, Sarah-Jane; Dawson, Mark A.; Seymour, John F.; Roberts, Andrew W.			Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; PROGRESSION-FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; NON-HODGKIN-LYMPHOMA; RESPONSE ASSESSMENT; WORKING GROUP; OPEN-LABEL; PHASE; INHIBITOR	BACKGROUND Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy. Preclinical models predict synergy in combination. METHODS We conducted a single-group, phase 2 study of daily oral ibrutinib and venetoclax in patients, as compared with historical controls. Patients commenced ibrutinib monotherapy at a dose of 560 mg per day. After 4 weeks, venetoclax was added in stepwise, weekly increasing doses to 400 mg per day. Both drugs were continued until progression or an unacceptable level of adverse events. The primary end point was the rate of complete response at week 16. Minimal residual disease (MRD) was assessed by flow cytometry in bone marrow and by allele-specific oligonucleotide-polymerase chain reaction (ASO-PCR) in blood. RESULTS The study included 24 patients with relapsed or refractory mantle-cell lymphoma (23 patients) or previously untreated mantle-cell lymphoma (1 patient). Patients were 47 to 81 years of age, and the number of previous treatments ranged from none to six. Half the patients had aberrations of TP53, and 75% had a high-risk prognostic score. The complete response rate according to computed tomography at week 16 was 42%, which was higher than the historical result of 9% at this time point with ibrutinib monotherapy (P<0.001). The rate of complete response as assessed by positron-emission tomography was 62% at week 16 and 71% overall. MRD clearance was confirmed by flow cytometry in 67% of the patients and by ASO-PCR in 38%. In a time-to-event analysis, 78% of the patients with a response were estimated to have an ongoing response at 15 months. The tumor lysis syndrome occurred in 2 patients. Common side effects were generally low grade and included diarrhea (in 83% of the patients), fatigue (in 75%), and nausea or vomiting (in 71%). CONCLUSIONS In this study involving historical controls, dual targeting of BTK and BCL2 with ibrutinib and venetoclax was consistent with improved outcomes in patients with mantle-cell lymphoma who had been predicted to have poor outcomes with current therapy. (Funded by Janssen and others; AIM ClinicalTrials.gov number, NCT02471391.)	[Tam, Constantine S.; Anderson, Mary Ann; Handunnetti, Sasanka; Hicks, Rodney J.; Burbury, Kate; Turner, Gillian; Di Iulio, Juliana; Bressel, Mathias; Westerman, David; Lade, Stephen; Dawson, Sarah-Jane; Dawson, Mark A.; Seymour, John F.; Roberts, Andrew W.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Tam, Constantine S.; Anderson, Mary Ann; Agarwal, Rishu; Handunnetti, Sasanka; Hicks, Rodney J.; Burbury, Kate; Westerman, David; Dawson, Sarah-Jane; Dawson, Mark A.; Seymour, John F.; Roberts, Andrew W.] Univ Melbourne, Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia; [Tam, Constantine S.; Hicks, Rodney J.; Dawson, Sarah-Jane; Dawson, Mark A.; Seymour, John F.; Roberts, Andrew W.] Univ Melbourne, Fac Med, Melbourne, Vic, Australia; [Dawson, Sarah-Jane; Dawson, Mark A.] Univ Melbourne, Ctr Canc Res, Melbourne, Vic, Australia; [Tam, Constantine S.; Anderson, Mary Ann; Burbury, Kate; Seymour, John F.; Roberts, Andrew W.] Royal Melbourne Hosp, Dept Clin Haematol & Bone Marrow Transplantat, Parkville, Vic, Australia; [Anderson, Mary Ann; Roberts, Andrew W.] Walter & Eliza Hall Inst Med Res, Div Canc & Haematol, Parkville, Vic, Australia; [Pott, Christiane] Univ Hosp Schleswig Holstein, Kiel, Germany; [Dreyling, Martin] Ludwig Maximilian Univ Munich, Klinikum Univ, Munich, Germany	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Kiel; Schleswig Holstein University Hospital; University of Munich	Tam, CS (corresponding author), Peter MacCallum Canc Ctr, Dept Haematol, 305 Grattan St, Melbourne, Vic 3000, Australia.	constantine.tam@petermac.org	Roberts, Andrew W./C-6736-2012; Dawson, Mark A/B-9317-2017; Seymour, John/K-7326-2019	Roberts, Andrew W./0000-0002-7341-5720; Dawson, Mark A/0000-0002-5464-5029; Seymour, John/0000-0003-2188-6835; Tam, Constantine/0000-0002-9759-5017; Anderson, Mary Ann/0000-0002-3515-0215; Dawson, Sarah-Jane/0000-0002-8276-0374	Janssen	Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	Funded by Janssen and others	Axelrod M, 2014, LEUKEMIA, V28, P407, DOI 10.1038/leu.2013.249; Balasubramanian S, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.78.78; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Cheminant M, 2016, HAEMATOLOGICA, V101, P336, DOI 10.3324/haematol.2015.134957; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Davids MS, 2017, J CLIN ONCOL, V35, P826, DOI 10.1200/JCO.2016.70.4320; Delfau-Larue MH, 2015, BLOOD, V126, P604, DOI 10.1182/blood-2015-02-628792; Department of Health and Human Services, 2010, COMMON TERMINOLOGY C; Dreyling M, 2005, BLOOD, V105, P2677, DOI 10.1182/blood-2004-10-3883; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Eskelund CW, 2017, BLOOD, V130, P1903, DOI 10.1182/blood-2017-04-779736; Geisler CH, 2008, BLOOD, V112, P2687, DOI 10.1182/blood-2008-03-147025; Habermann TM, 2009, BRIT J HAEMATOL, V145, P344, DOI 10.1111/j.1365-2141.2009.07626.x; Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Jayappa KD, 2017, BLOOD ADV, V1, P933, DOI 10.1182/bloodadvances.2016004176; Kamel S, 2015, LEUKEMIA, V29, P783, DOI 10.1038/leu.2014.247; Kluin-Nelemans HC, 2012, NEW ENGL J MED, V367, P520, DOI 10.1056/NEJMoa1200920; Li Y, 2016, ONCOGENE, V35, P6223, DOI 10.1038/onc.2016.155; Martin P, 2017, BLOOD, V130, P1881, DOI 10.1182/blood-2017-05-737510; Muller-Hermelink, 2001, PATHOLOGY GENETICS T, P168; O'Connor OA, 2005, J CLIN ONCOL, V23, P676, DOI 10.1200/JCO.2005.02.050; Ponader S, 2014, J CLIN ONCOL, V32, P1830, DOI 10.1200/JCO.2013.53.1046; Pott C, 2006, BLOOD, V107, P2271, DOI 10.1182/blood-2005-07-2845; Pulte D, 2017, EUR J CANCER, V84, P81, DOI 10.1016/j.ejca.2017.07.014; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Romaguera JE, 2005, J CLIN ONCOL, V23, P7013, DOI 10.1200/JCO.2005.01.1825; Rule S, 2013, HAEMATOLOGICA, V98, P489; Seymour JF, 2017, LANCET ONCOL, V18, P230, DOI 10.1016/S1470-2045(17)30012-8; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Stilgenbauer S, 2016, LANCET ONCOL, V17, P768, DOI 10.1016/S1470-2045(16)30019-5; van der Velden VHJ, 2007, LEUKEMIA, V21, P604, DOI 10.1038/sj.leu.2404586; Velders GA, 1996, J CLIN ONCOL, V14, P1269, DOI 10.1200/JCO.1996.14.4.1269; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Wu CL, 2016, ONCOTARGET, V7, P38180, DOI 10.18632/oncotarget.9500; Younes A, 2017, ANN ONCOL, V28, P1436, DOI 10.1093/annonc/mdx097; Zhao XX, 2015, BRIT J HAEMATOL, V168, P765, DOI 10.1111/bjh.13149	41	251	257	3	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 29	2018	378	13					1211	1223		10.1056/NEJMoa1715519	http://dx.doi.org/10.1056/NEJMoa1715519			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA8HN	29590547	Bronze			2023-01-03	WOS:000428580500007
J	Browne, S; Jha, AK; Ameri, K; Marcus, SG; Yeghiazarians, Y; Healy, KE				Browne, Shane; Jha, Amit K.; Ameri, Kurosh; Marcus, Sivan G.; Yeghiazarians, Yerem; Healy, Kevin E.			TGF-beta 1/CD105 signaling controls vascular network formation within growth factor sequestering hyaluronic acid hydrogels	PLOS ONE			English	Article							CARDIOSPHERE-DERIVED CELLS; MESENCHYMAL STEM-CELLS; TGF-BETA RECEPTOR; ENDOTHELIAL-CELL; MOLECULAR-WEIGHT; PROGENITOR CELLS; DELIVERY-SYSTEM; ANGIOGENESIS; ENDOGLIN; PROLIFERATION	Cell-based strategies for the treatment of ischemic diseases are at the forefront of tissue engineering and regenerative medicine. Cell therapies purportedly can play a key role in the neovascularization of ischemic tissue; however, low survival and poor cell engraftment with the host vasculature following implantation limits their potential to treat ischemic diseases. To overcome these limitations, we previously developed a growth factor sequestering hyaluronic acid (HyA)-based hydrogel that enhanced transplanted mouse cardiosphere-derived cell survival and formation of vasculature that anastomosed with host vessels. In this work, we examined the mechanism by which HyA hydrogels presenting transforming growth factor beta-1 (TGF-beta 1) promoted proliferation of more clinically relevant human cardiospherederived cells (hCDC), and their formation of vascular-like networks in vitro. We observed hCDC proliferation and enhanced formation of vascular-like networks occurred in the presence of TGF-beta 1. Furthermore, production of nitric oxide (NO), VEGF, and a host of angiogenic factors were increased in the presence of TGF-beta 1. This response was dependent on the co-activity of CD105 (Endoglin) with the TGF-beta R2 receptor, demonstrating its role in the process of angiogenic differentiation and vascular organization of hCDC. These results demonstrated that hCDC form vascular-like networks in vitro, and that the induction of vascular networks by hCDC within growth factor sequestering HyA hydrogels was mediated by TGF-beta 1/CD105 signaling.	[Browne, Shane; Jha, Amit K.; Marcus, Sivan G.; Healy, Kevin E.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Browne, Shane; Jha, Amit K.; Marcus, Sivan G.; Healy, Kevin E.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA; [Browne, Shane] Natl Univ Ireland Galway, Ctr Res Med Devices CURAM, Galway, Ireland; [Ameri, Kurosh; Yeghiazarians, Yerem] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Yeghiazarians, Yerem] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA; [Yeghiazarians, Yerem] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Ollscoil na Gaillimhe-University of Galway; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Healy, KE (corresponding author), Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA.; Healy, KE (corresponding author), Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA.	kehealy@berkeley.edu		Browne, Shane/0000-0002-1005-1712	National Heart Lung and Blood Institute of the National Institutes of Health [R01HL096525]; Jan Fandrianto and Selfia Halim Chair; Irish Research Council ELEVATE fellowship [ELEVATEPD/2014/33]; UCSF Translational Cardiac Stem Cell Program; Leone-Perkins Foundation; Torian Foundation; Vadasz Foundation	National Heart Lung and Blood Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Jan Fandrianto and Selfia Halim Chair; Irish Research Council ELEVATE fellowship(Irish Research Council for Science, Engineering and Technology); UCSF Translational Cardiac Stem Cell Program; Leone-Perkins Foundation; Torian Foundation; Vadasz Foundation	This work was supported in part by National Heart Lung and Blood Institute of the National Institutes of Health R01HL096525 (KEH), the Jan Fandrianto and Selfia Halim Chair (KEH), an Irish Research Council ELEVATE fellowship to SB (ELEVATEPD/2014/33), the UCSF Translational Cardiac Stem Cell Program (YY), the Leone-Perkins Foundation (YY), and by the Torian Foundation and the Vadasz Foundation (YY).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed TAE, 2011, TISSUE ENG PT A, V17, P323, DOI 10.1089/ten.TEA.2009.0773; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Bartunek J, 2010, HEART, V96, P792, DOI 10.1136/hrt.2007.139394; Bir SC, 2012, CARDIOVASC RES, V95, P7, DOI 10.1093/cvr/cvs143; Briquez PS, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2015.6; Browne S, 2017, CURR OPIN PHARMACOL, V36, P34, DOI 10.1016/j.coph.2017.07.002; Browne S, 2015, BIOMATERIALS, V69, P133, DOI 10.1016/j.biomaterials.2015.08.012; Browne S, 2013, TISSUE ENG PT A, V19, P1491, DOI [10.1089/ten.tea.2012.0721, 10.1089/ten.TEA.2012.0721]; Chang CY, 2012, BIOMATERIALS, V33, P8026, DOI 10.1016/j.biomaterials.2012.07.058; Cheng K, 2014, JACC-HEART FAIL, V2, P49, DOI 10.1016/j.jchf.2013.08.008; Cheng K, 2012, BIOMATERIALS, V33, P5317, DOI 10.1016/j.biomaterials.2012.04.006; Cheng K, 2012, BIOMATERIALS, V33, P2872, DOI 10.1016/j.biomaterials.2011.12.040; Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682; Dudzinski DM, 2007, CARDIOVASC RES, V75, P247, DOI 10.1016/j.cardiores.2007.03.023; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; Gaffey AC, 2015, J THORAC CARDIOV SUR, V150, P1268, DOI 10.1016/j.jtcvs.2015.07.035; Gao JS, 2012, BIOMATERIALS, V33, P3673, DOI 10.1016/j.biomaterials.2012.01.061; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7; Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424; Gurski LA, 2009, BIOMATERIALS, V30, P6076, DOI 10.1016/j.biomaterials.2009.07.054; Harbers GM, 2005, J BIOMED MATER RES A, V75A, P855, DOI 10.1002/jbm.a.30482; Highley CB, 2016, CURR OPIN BIOTECH, V40, P35, DOI 10.1016/j.copbio.2016.02.008; Hoban DB, 2013, BIOMATERIALS, V34, P9420, DOI 10.1016/j.biomaterials.2013.08.073; Holladay CA, 2012, BIOMATERIALS, V33, P1303, DOI 10.1016/j.biomaterials.2011.10.019; Huang NF, 2009, REGEN MED, V4, P527, DOI 10.2217/RME.09.32; Jha AK, 2016, BIOMATERIALS, V89, P136, DOI 10.1016/j.biomaterials.2016.02.023; Jha AK, 2015, J CONTROL RELEASE, V209, P308, DOI 10.1016/j.jconrel.2015.04.034; Jha AK, 2015, BIOMATERIALS, V47, P1, DOI 10.1016/j.biomaterials.2014.12.043; Khademhosseini A, 2006, J BIOMED MATER RES A, V79A, P522, DOI 10.1002/jbm.a.30821; Khetan S, 2013, NAT MATER, V12, P458, DOI [10.1038/NMAT3586, 10.1038/nmat3586]; Kim S, 2005, DEGRADATION CELL MIG, P13; Kogan G, 2007, BIOTECHNOL LETT, V29, P17, DOI 10.1007/s10529-006-9219-z; Kusuma S, 2013, SELF ORG VASCULAR NE, P110; Lam J, 2014, ADV FUNCT MATER, V24, P7053, DOI 10.1002/adfm.201401483; Lam J, 2013, BIOMATERIALS, V34, P3938, DOI 10.1016/j.biomaterials.2013.01.091; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Lee ST, 2011, J AM COLL CARDIOL, V57, P455, DOI 10.1016/j.jacc.2010.07.049; Lei YG, 2011, BIOMATERIALS, V32, P39, DOI 10.1016/j.biomaterials.2010.08.103; Li RX, 2017, J CONTROL RELEASE, V261, P234, DOI 10.1016/j.jconrel.2017.07.008; Li TS, 2012, J AM COLL CARDIOL, V59, P942, DOI 10.1016/j.jacc.2011.11.029; Martino MM, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00045; Mayfield AE, 2014, BIOMATERIALS, V35, P133, DOI 10.1016/j.biomaterials.2013.09.085; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Namba T, 2003, CIRCULATION, V108, P2250, DOI 10.1161/01.CIR.0000093190.53478.78; Nelson TJ, 2010, STEM CELLS CLONING, V3, P29; Nikitovic D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00169; Park HJ, 2016, BIOMACROMOLECULES, V17, P1939, DOI 10.1021/acs.biomac.5b01670; Popa ER, 2006, J MOL CELL CARDIOL, V41, P86, DOI 10.1016/j.yjmcc.2006.04.021; Poynter JA, 2011, J AM COLL SURGEONS, V213, P253, DOI 10.1016/j.jamcollsurg.2011.04.005; Prestwich GD, 2011, J CONTROL RELEASE, V155, P193, DOI 10.1016/j.jconrel.2011.04.007; Rayahin JE, 2015, ACS BIOMATER SCI ENG, V1, P481, DOI 10.1021/acsbiomaterials.5b00181; Redgrave RE, 2017, STEM CELL REP, V8, P1287, DOI 10.1016/j.stemcr.2017.04.015; Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b; Robinson ST, 2016, ACTA BIOMATER, V36, P86, DOI 10.1016/j.actbio.2016.03.002; Segers VFM, 2011, CIRC RES, V109, P910, DOI 10.1161/CIRCRESAHA.111.249052; She XW, 2004, INT J CANCER, V108, P251, DOI 10.1002/ijc.11551; Shen DL, 2012, J CELL MOL MED, V16, P2112, DOI 10.1111/j.1582-4934.2011.01512.x; Shen YI, 2016, BIOMATERIALS, V102, P107, DOI 10.1016/j.biomaterials.2016.06.009; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Song H, 2010, STEM CELLS, V28, P555, DOI 10.1002/stem.302; Tang JM, 2009, EXP CELL RES, V315, P3521, DOI 10.1016/j.yexcr.2009.09.026; Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013; Tian HY, 2012, EMBO J, V31, P3885, DOI 10.1038/emboj.2012.246; Valluru M, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00089; van Meeteren LA, 2012, CELL TISSUE RES, V347, P177, DOI 10.1007/s00441-011-1222-6; Wall ST, 2010, J BIOMED MATER RES A, V95A, P1055, DOI 10.1002/jbm.a.32904; Wang JL, 2012, J BIOMED MATER RES A, V100A, P1438, DOI 10.1002/jbm.a.34081; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Xu X, 2012, SOFT MATTER, V8, P3280, DOI 10.1039/c2sm06463d; Xu YY, 2016, ACTA BIOMATER, V31, P99, DOI 10.1016/j.actbio.2015.12.021; Yu JS, 2010, BIOMATERIALS, V31, P7012, DOI 10.1016/j.biomaterials.2010.05.078; Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044	74	22	23	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194679	10.1371/journal.pone.0194679	http://dx.doi.org/10.1371/journal.pone.0194679			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA1RF	29566045	Green Submitted, Green Published, gold			2023-01-03	WOS:000428093900092
J	Ebonwu, J; Mumbauer, A; Uys, M; Wainberg, ML; Medina-Marino, A				Ebonwu, Joy; Mumbauer, Alexandra; Uys, Margot; Wainberg, Milton L.; Medina-Marino, Andrew			Determinants of late antenatal care presentation in rural and pen-urban communities in South Africa: A cross-sectional study	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; JOHANNESBURG; BOOKING; WOMEN; HIV	Objective To investigate and compare determinates for delayed first presentation to antenatal care (ANC) services. Methods A cross-sectional study was conducted amongst pregnant women attending their first ANC visit in rural Capricorn District and pen-urban Tlokwe sub-district communities in South Africa. Data collection included questionnaires and medical record abstraction. Bivariate and multivariate analyses assessed factors associated with late ANC presentation. Results We recruited 807 pregnant women. Of these, 51% of rural women and 28% of pen-urban women presented late for first ANC. Rural women were more likely to present late for first ANC (AOR = 2.65; 95% Cl 1.98-3.55) and report barriers to accessing ANC services (P<0.0001). Late ANC presentation in rural communities was associated with being married (AOR = 2.36; 95 % CI 1.33-4.19), employed (AOR = 1.90; 95% CI 1.03-3.50), <20 years of age (AOR = 2.19; 95% CI 1.10-4.37), and reporting an unplanned pregnancy (AOR = 2.21; 95% Cl 1.40-3.50). Late presentation in pen-urban communities was associated with unplanned pregnancy (AOR = 1.67; 95% Cl 1.01-2.74), being told to come back later to initiate ANC after presenting early (AOR 0.51; 95% Cl 0.30-0.89) and being pregnant for the first time (AOR = 0.56; 95% Cl 0.34-0.94) Conclusion Both rural and pen-urban women had high rates of late presentation for first ANC. However, women in the rural communities were more likely to present late. Unplanned pregnancy was an independent risk factor in both rural and pen-urban communities. Interventions around family planning, especially for adolescent girls and young women, are needed to improve early presentation for ANC.	[Ebonwu, Joy; Mumbauer, Alexandra; Medina-Marino, Andrew] Fdn Profess Dev, Res Unit, Pretoria, South Africa; [Uys, Margot] Fdn Profess Dev, Integrated Hlth Syst Strengthening Dept, Pretoria, South Africa; [Wainberg, Milton L.] Columbia Univ, New York State Psychiat Inst, New York, NY USA	Columbia University; New York State Psychiatry Institute	Medina-Marino, A (corresponding author), Fdn Profess Dev, Res Unit, Pretoria, South Africa.	andrewmedinamarino@gmail.com		Wainberg, Milton/0000-0002-9390-4652; , Andrew/0000-0002-0095-4141	United States President's Emergency Plan for AIDS Relief (PEPFAR) [AID-674-A-12-00017, U2GPS001137-03]	United States President's Emergency Plan for AIDS Relief (PEPFAR)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Funding was provided by the United States President's Emergency Plan for AIDS Relief (PEPFAR) Cooperative agreements AID-674-A-12-00017 and U2GPS001137-03. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript,	Banda I, 2014, MED J ZAMBIA, V39; Black V, 2008, JAIDS-J ACQ IMM DEF, V49, P276, DOI 10.1097/QAI.0b013e318189a769; Exavery A, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-35; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Gudayu TW, 2015, AFR J REPROD HEALTH, V19, P94; Gudayu TW, BMC PREGNANCY CHILDB; Haddad DN, 2016, INT J GYNECOL OBSTET, V132, P64, DOI 10.1016/j.ijgo.2015.06.041; Hoffman RM, 2010, JAIDS-J ACQ IMM DEF, V54, P35, DOI 10.1097/QAI.0b013e3181cf9979; Kisuule I, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-121; Kost K, 1998, FAM PLANN PERSPECT, V30, P79, DOI 10.2307/2991664; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS5, DOI 10.1016/j.ijgo.2009.07.016; Manzi A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-290; Massyn N, 2016, DURB HLTH SYST TRUST; Mcintyre P., 2006, PREGNANT ADOLESCENTS; Myer L, 2003, J MIDWIFERY WOM HEAL, V48, P268, DOI 10.1016/S1526-9523(02)00421-X; National Department of Health, 2013 NAT ANT SENT HI; National Department of Health Republic of South Africa, 2015, GUID MAT CAR S AFR M; Ndidi E, 2011, GHANA MED J, V44; Pattinson R.C., 2007, BASIC ANTENATAL CARE; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Sibeko S, 2006, S AFR FAM PRACT, V48, P17, DOI 10.1080/20786204.2006.10873478; Simkhada B, 2008, J ADV NURS, V61, P244, DOI 10.1111/j.1365-2648.2007.04532.x; Solarin I, 2013, MATERN CHILD HLTH J, V17, P359, DOI 10.1007/s10995-012-1019-6; Statistics South Africa, 2016, S AFR DEM HLTH SURV; *WHO, WHO REC ANT CAR POS; Zegeye Amtatachew M, 2013, Afr J Reprod Health, V17, P130	27	42	44	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2018	13	3							e0191903	10.1371/journal.pone.0191903	http://dx.doi.org/10.1371/journal.pone.0191903			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5UV	29518082	Green Published, Green Submitted, gold			2023-01-03	WOS:000426902900004
J	Kadle, RL; Abdou, SA; Villarreal-Ponce, AP; Soares, MA; Sultan, DL; David, JA; Massie, J; Rifkin, WJ; Rabbani, P; Ceradini, DJ				Kadle, Rohini L.; Abdou, Salma A.; Villarreal-Ponce, Alvaro P.; Soares, Marc A.; Sultan, Darren L.; David, Joshua A.; Massie, Jonathan; Rifkin, William J.; Rabbani, Piul; Ceradini, Daniel J.			Microenvironmental cues enhance mesenchymal stem cell-mediated immunomodulation and regulatory T-cell expansion	PLOS ONE			English	Article							MARROW STROMAL CELLS; TISSUE ALLOTRANSPLANT SURVIVAL; REDUCED OXYGEN-TENSION; BONE-MARROW; ALLOGRAFT SURVIVAL; INDOLEAMINE 2,3-DIOXYGENASE; LYMPHOCYTE PROLIFERATION; DIFFERENTIATION CAPACITY; IN-VITRO; SUPPRESSION	Mesenchymal stem cells (MSCs) are known to both have powerful immunosuppressive properties and promote allograft tolerance. Determining the environmental oxygen tension and inflammatory conditions under which MSCs are optimally primed for this immunosuppressive function is essential to their utilization in promoting graft tolerance. Of particular interest is the mechanisms governing the interaction between MSCs and regulatory T cells (Tregs), which is relatively unknown. We performed our experiments utilizing rat bone marrow derived MSCs. We observed that priming MSCs in hypoxia promotes maintenance of stem-like characteristics, with greater expression of typical MSC cell-surface markers, increased proliferation, and maintenance of differentiation potential. Addition of autologous MSCs to CD4+/allogeneic endothelial cell (EC) co-culture increases regulatory T cell (Treg) proliferation, which is further enhanced when MSCs are primed in hypoxia. Furthermore, MSC-mediated Treg expansion does not require direct cell-cell contact. The expression of indolamine 2,3-dioxygenase, a mediator of MSC immunomodulation, increases when MSCs are primed in hypoxia, and inhibition of IDO significantly decreases the expansion of Tregs. Priming with inflammatory cytokines IFN gamma and TNF alpha increases also expression of markers associated with MSC immunomodulatory function, but decreases MSC proliferation. The expression of IDO also increases when MSCs are primed with inflammatory cytokines. However, there is no increase in Treg expansion when MSCs are primed with IFN gamma, suggesting an alternate mechanism for inflammatory-stimulated MSC immunomodulation. Overall, these results suggest that MSCs primed in hypoxia or inflammatory conditions are optimally primed for immunosuppressive function. These results provide a clearer picture of how to enhance MSC immunomodulation for clinical use.	[Kadle, Rohini L.; Abdou, Salma A.; Villarreal-Ponce, Alvaro P.; Soares, Marc A.; Sultan, Darren L.; David, Joshua A.; Massie, Jonathan; Rifkin, William J.; Rabbani, Piul; Ceradini, Daniel J.] NYU, Langone Med Ctr, Dept Plast Surg, New York, NY 10016 USA	New York University; NYU Langone Medical Center	Ceradini, DJ (corresponding author), NYU, Langone Med Ctr, Dept Plast Surg, New York, NY 10016 USA.	Daniel.Ceradini@nyumc.org	Rifkin, William/AAG-1533-2020; /ABE-5226-2021	Rabbani, Piul/0000-0001-8302-8225; Villarreal-Ponce, Alvaro/0000-0003-2398-165X; Rifkin, William/0000-0002-2314-4125	Department of defense, AFIRM II [WFUHS 441038]; American Association of Plastic Surgery Academic Scholar Award; Howard Hughes Medical Institute [57008244]; NIH NCI [T32CA160002]; National Institutes of Health/National Cancer Institute [P30CA016087]	Department of defense, AFIRM II(United States Department of Defense); American Association of Plastic Surgery Academic Scholar Award; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Department of defense, AFIRM II (WFUHS 441038 DJC; D. Ceradini); American Association of Plastic Surgery Academic Scholar Award (D. Ceradini); Howard Hughes Medical Institute Medical Research Fellow (Grant Number 57008244, J. Massie); NIH NCI Institutional Training Grant (T32CA160002; D. Ceradini).; We are grateful to NYU Langone's Cytometry and Cell Sorting Laboratory, and Microscopy Core, which are supported in part by grant P30CA016087 from the National Institutes of Health/National Cancer Institute.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Aksu AE, 2008, CLIN IMMUNOL, V127, P348, DOI 10.1016/j.clim.2008.02.003; Beane OS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115963; Benvenuto F, 2007, STEM CELLS, V25, P1753, DOI 10.1634/stemcells.2007-0068; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007-0197; Del Fattore A, 2015, CELL TRANSPLANT, P1; Di Lanni M, 2008, EXP HEMATOL, V36, P309, DOI 10.1016/j.exphem.2007.11.007; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Doorn J, 2012, TISSUE ENG PART B-RE, V18, P101, DOI [10.1089/ten.TEB.2011.0488, 10.1089/ten.teb.2011.0488]; Dos Santos F, 2010, J CELL PHYSIOL, V223, P27, DOI 10.1002/jcp.21987; Eom YW, 2014, BIOCHEM BIOPH RES CO, V445, P16, DOI 10.1016/j.bbrc.2014.01.084; Fehrer C, 2007, AGING CELL, V6, P745, DOI 10.1111/j.1474-9726.2007.00336.x; Ge W, 2010, TRANSPLANTATION, V90, P1312, DOI 10.1097/TP.0b013e3181fed001; Grayson WL, 2007, BIOCHEM BIOPH RES CO, V358, P948, DOI 10.1016/j.bbrc.2007.05.054; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hemeda H, 2010, STEM CELLS DEV, V19, P693, DOI 10.1089/scd.2009.0365; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008; Kuo YR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035459; Kuo YR, 2011, PLAST RECONSTR SURG, V127, P569, DOI 10.1097/PRS.0b013e318200a92c; Kuo YR, 2009, TRANSPLANTATION, V87, P1769, DOI 10.1097/TP.0b013e3181a664f1; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Le Blanc K, 2015, IMMUNOL LETT, V168, P140, DOI 10.1016/j.imlet.2015.05.004; Lennon DP, 2001, J CELL PHYSIOL, V187, P345, DOI 10.1002/jcp.1081; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Maccario R, 2005, HAEMATOLOGICA, V90, P516; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Obermajer N, 2014, J IMMUNOL, V193, P4988, DOI 10.4049/jimmunol.1401776; Paquet J, 2015, STEM CELL TRANSL MED, V4, P1; Plumas J, 2005, LEUKEMIA, V19, P1597, DOI 10.1038/sj.leu.2403871; Popp FC, 2008, TRANSPL IMMUNOL, V20, P55, DOI 10.1016/j.trim.2008.08.004; Potier E, 2007, BONE, V40, P1078, DOI 10.1016/j.bone.2006.11.024; Prado-Lopez S, 2014, IMMUNOL CELL BIOL, P1; Pricola KL, 2009, J CELL BIOCHEM, V108, P577, DOI 10.1002/jcb.22289; Raemer PC, 2009, TRANSPLANTATION, V87, P340, DOI 10.1097/TP.0b013e3181957308; Rasmusson I, 2006, EXP CELL RES, V312, P2169, DOI 10.1016/j.yexcr.2006.03.019; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Roemeling-Van Rhijn M, 2013, FRONT IMMUNOL, V4, P8; Sato K, 2007, BLOOD, V109, P228, DOI 10.1182/blood-2006-02-002246; Solari MG, 2009, J AUTOIMMUN, V32, P116, DOI 10.1016/j.jaut.2009.01.003; Spaggiari GM, 2006, BLOOD, V107, P1484, DOI 10.1182/blood-2005-07-2775; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Spencer JA, 2014, NATURE, V508, P269, DOI 10.1038/nature13034; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Whiting D, 2004, J IMMUNOL, V172, P7417, DOI 10.4049/jimmunol.172.12.7417; Xu GW, 2007, CELL RES, V17, P240, DOI 10.1038/cr.2007.4; Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479; Zhang Linxia, 2010, J Vis Exp, DOI 10.3791/1852; Zhou HP, 2006, TRANSPL P, V38, P3046, DOI 10.1016/j.transproceed.2006.10.002; Zhou SH, 2005, J BIOL CHEM, V280, P22688, DOI 10.1074/jbc.M412953200; Zhuang JW, 2014, EXP THER MED, V8, P237, DOI 10.3892/etm.2014.1714	54	41	43	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0193178	10.1371/journal.pone.0193178	http://dx.doi.org/10.1371/journal.pone.0193178			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513756	Green Published, Green Submitted, gold			2023-01-03	WOS:000426896800043
J	Pahlavan, S; Tousi, MS; Ayyari, M; Alirezalu, A; Ansari, H; Saric, T; Baharvand, H				Pahlavan, Sara; Tousi, Marziyeh Shalchi; Ayyari, Mahdi; Alirezalu, Abolfazl; Ansari, Hassan; Saric, Tomo; Baharvand, Hossein			Effects of hawthorn (Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia-specific induced pluripotent stem cells	FASEB JOURNAL			English	Article						nutraceuticals; in vitro drug testing; CPVT1; LQTS2	POLYMORPHIC VENTRICULAR-TACHYCARDIA; HEART-FAILURE; RAT MODEL; OXYACANTHA; PATIENT; DIFFERENTIATION; COMPLEMENTARY; PHARMACOLOGY; PROGRESSION; GENERATION	Cardiac arrhythmias are major life-threatening conditions. The landmark discovery of induced pluripotent stem cells has provided a promising in vitro system for modeling hereditary cardiac arrhythmias as well as drug development and toxicity testing. Nowadays, nutraceuticals are frequently used as supplements for cardiovascular therapy. Here we studied the cardiac effects of hawthorn (Crataegus pentagyna) leaf extract using cardiomyocytes (CMs) differentiated from healthy human embryonic stem cells, long QT syndrome type 2 (LQTS2), and catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1) patient-specific induced pluripotent stem cells. The hydroalcoholic extract resulted in a dose-dependent negative chronotropic effect in all CM preparations leading to a significant reduction at 1000 mu g/ml. This was accompanied by prolongation of field potential durations, although with different magnitudes in CMs from different human embryonic stem cell and iPSC lines. Hawthorn further prolonged field potential durations in LQTS2 CMs but reduced the beating frequencies and occurrence of immature field potentials triggered by beta(1)-adrenergic stimulation in CPVT1 CMs at 300 and 1000 mu g/ml. Furthermore, isoquercetin and vitexin flavonoids significantly slowed down isoproterenol (5 mu M)-induced beating frequencies at 3 and 10 mu g/ml. Therefore, C. pentagyna leaf extract and its isoquercetin and vitexin flavonoids may be introduced as a novel nutraceutical with antiarrhythmic potential for CPVT1 patients.	[Pahlavan, Sara; Tousi, Marziyeh Shalchi; Ayyari, Mahdi; Ansari, Hassan; Baharvand, Hossein] Acad Ctr Educ Culture & Res, Royan Inst Stem Cell Biol & Technol, Dept Stem Cells & Dev Biol, Cell Sci Res Ctr, Tehran, Iran; [Ayyari, Mahdi] TMU, Dept Hort Sci, Tehran, Iran; [Alirezalu, Abolfazl] Urmia Univ, Dept Hort Sci, Fac Agr, Orumiyeh, Iran; [Saric, Tomo] Univ Cologne, Inst Neurophysiol, Med Fac, Ctr Physiol & Pathophysiol, Cologne, Germany; [Baharvand, Hossein] Univ Sci & Culture, Dept Dev Biol, Tehran, Iran	Academic Center for Education, Culture & Research (ACECR); Urmia University; University of Cologne	Baharvand, H (corresponding author), Royan Inst, Banihashem Sq,Banihashem St,POB 16635-148, Tehran 1665659911, Iran.	baharvand@royaninstitute.org	Alirezalu, Abolfazl/U-7964-2019	Alirezalu, Abolfazl/0000-0002-5882-8981; Pahlavan, Sara/0000-0002-8854-2626	Royan Institute; Iranian Council of Herbal Medicine; Iran National Science Foundation (INSF) [96001316]; Iran Science Elites Federation; EBiSC project; European Commission	Royan Institute; Iranian Council of Herbal Medicine; Iran National Science Foundation (INSF)(Iran National Science Foundation (INSF)); Iran Science Elites Federation; EBiSC project; European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by grants from the Royan Institute, the Iranian Council of Herbal Medicine, the Iran National Science Foundation (INSF; Grant 96001316), and the Iran Science Elites Federation to H.B. The banking of CPVT1 and LQTS2 iPSC lines was supported by the EBiSC project (to T.S. and J.H.). EBiSC is supported as a multinational public-private Innovative Medicines Initiative (http://www.imi.europa.eu/) funded by the European Commission and in-kind contributions from Pfizer Ltd., H. Lundbeck A/S, Janssen Pharmaceutica NV, Novo Nordisk A/S, AstraZeneca A/B, UCB Pharma SA, and Bayer Pharma AG and Lilly (joining after the Hot Start). The authors declare no conflicts of interest.	Al Makdessi S, 1999, BASIC RES CARDIOL, V94, P71, DOI 10.1007/s003950050128; Alp H, 2015, ANATOL J CARDIOL, V15, P970, DOI 10.5152/akd.2014.5869; AMMON HPT, 1981, PLANTA MED, V43, P209, DOI 10.1055/s-2007-971502; Baharvand H, 2006, DEV GROWTH DIFFER, V48, P117, DOI 10.1111/j.1440-169x.2006.00851.x; Brenyo A, 2014, AM J CARDIOL, V113, P897, DOI 10.1016/j.amjcard.2013.11.044; Burridge PW, 2012, CELL STEM CELL, V10, P16, DOI 10.1016/j.stem.2011.12.013; Chang WT, 2005, AM J CHINESE MED, V33, P1, DOI 10.1142/S0192415X05002606; Chen ZY, 1998, LIFE SCI, V63, P1983, DOI 10.1016/S0024-3205(98)00476-7; Dahmer S, 2010, AM FAM PHYSICIAN, V81, P465; Diane A, 2016, FOOD FUNCT, V7, P3943, DOI [10.1039/c6fo01023g, 10.1039/C6FO01023G]; Dong LY, 2008, AM J CHINESE MED, V36, P385, DOI 10.1142/S0192415X08005849; Edwards JE, 2012, PHYTOCHEMISTRY, V79, P5, DOI 10.1016/j.phytochem.2012.04.006; Fatima A, 2016, STEM CELL RES, V16, P304, DOI 10.1016/j.scr.2015.12.039; Fatima A, 2011, CELL PHYSIOL BIOCHEM, V28, P579, DOI 10.1159/000335753; Flattery Maureen, 2008, Prog Cardiovasc Nurs, V23, P187, DOI 10.1111/j.1751-7117.2008.00014.x; Fonoudi H, 2016, JOVE-J VIS EXP, DOI 10.3791/54276; Fonoudi H, 2015, STEM CELL TRANSL MED, V4, P1482, DOI 10.5966/sctm.2014-0275; Ganji F, 2015, CELL J, V16, P426; Garjani A, 2000, PHYTOTHER RES, V14, P428, DOI 10.1002/1099-1573(200009)14:6&lt;428::AID-PTR618&gt;3.0.CO;2-L; Halbach MD, 2003, CELL PHYSIOL BIOCHEM, V13, P271, DOI 10.1159/000074542; Harris K, 2015, CURR PROTOC PHARM, V71, P11181; Harvey RD, 2003, BRIT J PHARMACOL, V139, P1074, DOI 10.1038/sj.bjp.0705338; Herron TJ, 2016, CIRC-ARRHYTHMIA ELEC, V9, DOI 10.1161/CIRCEP.113.003638; Holubarsch CJF, 2008, EUR J HEART FAIL, V10, P1255, DOI 10.1016/j.ejheart.2008.10.004; Hwang HS, 2009, PHARMACOTHERAPY, V29, P639, DOI 10.1592/phco.29.6.639; Itzhaki I, 2012, J AM COLL CARDIOL, V60, P990, DOI 10.1016/j.jacc.2012.02.066; Jung CB, 2012, EMBO MOL MED, V4, P180, DOI 10.1002/emmm.201100194; Koch E, 2011, PLANTA MED, V77, P1123, DOI 10.1055/s-0030-1270849; Larijani MR, 2011, STEM CELLS DEV, V20, P1911, DOI 10.1089/scd.2010.0517; Li XM, 2015, MOL MED REP, V12, P5423, DOI 10.3892/mmr.2015.4080; Long SR, 2006, PHYTOMEDICINE, V13, P643, DOI 10.1016/j.phymed.2006.01.005; Lu CC, 2013, N-S ARCH PHARMACOL, V386, P747, DOI 10.1007/s00210-013-0873-0; Muller A, 1996, PHYTOMEDICINE, V3, P257, DOI 10.1016/S0944-7113(96)80063-8; Muller A, 1999, PLANTA MED, V65, P335, DOI 10.1055/s-1999-13997; Nishizawa H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007069; Novak A, 2012, J CELL MOL MED, V16, P468, DOI 10.1111/j.1582-4934.2011.01476.x; Pittler MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005312.pub2; Rigelsky JM, 2002, AM J HEALTH-SYST PH, V59, P417, DOI 10.1093/ajhp/59.5.417; Salehi S, 2009, J NAT MED-TOKYO, V63, P1, DOI 10.1007/s11418-008-0278-4; SCHUSSLER M, 1995, ARZNEIMITTEL-FORSCH, V45-2, P842; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Veveris M, 2004, LIFE SCI, V74, P1945, DOI 10.1016/j.lfs.2003.09.050; Vijayan NA, 2012, MOL CELL BIOCHEM, V367, P1, DOI 10.1007/s11010-012-1251-9; Vitale AM, 2011, INT J BIOCHEM CELL B, V43, P843, DOI 10.1016/j.biocel.2011.03.013; Zhang XH, 2013, CELL CALCIUM, V54, P57, DOI 10.1016/j.ceca.2013.04.004; Zick SM, 2005, J CARD FAIL, V11, P586, DOI 10.1016/j.cardfail.2005.06.427; Zick SM, 2008, EUR J HEART FAIL, V10, P587, DOI 10.1016/j.ejheart.2008.04.008; Zick SM, 2009, EUR J HEART FAIL, V11, P990, DOI 10.1093/eurjhf/hfp116; Zwi L, 2009, CIRCULATION, V120, P1513, DOI 10.1161/CIRCULATIONAHA.109.868885	49	13	14	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2018	32	3					1440	1451		10.1096/fj.201700494RR	http://dx.doi.org/10.1096/fj.201700494RR			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FZ0GN	29133340				2023-01-03	WOS:000427246000026
J	Dona, D; Zingarella, S; Gastaldi, A; Lundin, R; Perilongo, G; Frigo, AC; Hamdy, RF; Zaoutis, T; Da Dalt, L; Giaquinto, C				Dona, Daniele; Zingarella, Silvia; Gastaldi, Andrea; Lundin, Rebecca; Perilongo, Giorgio; Frigo, Anna Chiara; Hamdy, Rana F.; Zaoutis, Theoklis; Da Dalt, Liviana; Giaquinto, Carlo			Effects of clinical pathway implementation on antibiotic prescriptions for pediatric community-acquired pneumonia	PLOS ONE			English	Article							ANTIBACTERIAL DRUG-USE; KLEBSIELLA-PNEUMONIAE; CHILDREN; RESISTANCE; EPIDEMIOLOGY; INFECTIONS; MANAGEMENT; RISK	Background Italian pediatric antimicrobial prescription rates are among the highest in Europe. As a first step in an Antimicrobial Stewardship Program, we implemented a Clinical Pathway (CP) for Community Acquired Pneumonia with the aim of decreasing overall prescription of antibiotics, especially broad-spectrum. Materials and methods The CP was implemented on 10/01/2015. We collected antibiotic prescribing and outcomes data from children aged 3 months-15 years diagnosed with CAP from 10/15/2014 to 04/15/2015 (pre-intervention period) and from 10/15/2015 to 04/15/2016 (post-intervention period). We assessed antibiotic prescription differences pre-and post-CP, including rates, breadth of spectrum, and duration of therapy. We also compared length of hospital stay for inpatients and treatment failure for inpatients and outpatients. Chi-square and Fisher's exact test were used to compare categorical variables and Wilcoxon rank sum test was used to compare quantitative outcomes. Results 120 pre-and 86 post-intervention clinic visits were identified with a diagnosis of CAP. In outpatients, we observed a decrease in broad-spectrum regimens (50% pre-CP vs. 26.8% post-CP, p = 0.02), in particular macrolides, and an increase in narrow-spectrum (amoxicillin) post-CP. Post-CP children received fewer antibiotic courses (median DOT from 10 pre-CP to 8 post-CP, p<0.0001) for fewer days (median LOT from 10 pre-CP to 8 post-CP, p<0.0001) than their pre-CP counterparts. Physicians prescribed narrow-spectrum mono-therapy more frequently than broad-spectrum combination therapy (DOT/LOT ratio 1.157 pre-CP vs. 1.065 post-CP). No difference in treatment failure was reported before and after implementation (2.3% pre-CP vs. 11.8% post-CP, p = 0.29). Among inpatients we also noted a decrease in broad-spectrum regimens (100% pre-CP vs. 66.7% post-CP, p = 0.02) and the introduction of narrow-spectrum regimens (0% pre-CP vs. 33.3% post-CP, p = 0.02) post-CP. Hospitalized patients received fewer antibiotic courses post-CP (median DOT from 18.5 pre-CP to 10 post-CP, p = 0.004), while there was no statistical difference in length of therapy (median LOT from 11 pre-CP to 10 post-CP, p = 0.06). Days of broad spectrum therapy were notably lower post-CP (median bsDOT from 17 pre-CP to 4.5 postCP, p<0.0001). No difference in treatment failure was reported before and after CP implementation (16.7% pre-CP vs. 15.4% post-CP, p = 1). Conclusions Introduction of a CP for CAP in a Pediatric Emergency Department led to reduction of broad-spectrum antibiotic prescriptions, of combination therapy and of duration of treatment both for outpatients and inpatients.	[Dona, Daniele; Zaoutis, Theoklis] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA; [Dona, Daniele; Zaoutis, Theoklis] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA; [Dona, Daniele; Gastaldi, Andrea; Giaquinto, Carlo] Univ Padua, Div Pediat Infect Dis, Dept Woman & Child Hlth, Padua, Italy; [Dona, Daniele; Lundin, Rebecca; Giaquinto, Carlo] PENTA Fdn, Padua, Italy; [Zingarella, Silvia] Univ Padua, Dept Woman & Child Hlth, Pediat Emergency Dept, Padua, Italy; [Perilongo, Giorgio] Univ Padua, Dept Woman & Child Hlth, Padua, Italy; [Frigo, Anna Chiara] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Biostat Epidemiol & Publ Hlth Unit, Padua, Italy; [Hamdy, Rana F.] Childrens Natl Hlth Syst, Dept Pediat, Washington, DC USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Padua; University of Padua; University of Padua; University of Padua; Children's National Health System	Dona, D (corresponding author), Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA.; Dona, D (corresponding author), Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA.; Dona, D (corresponding author), Univ Padua, Div Pediat Infect Dis, Dept Woman & Child Hlth, Padua, Italy.; Dona, D (corresponding author), PENTA Fdn, Padua, Italy.	daniele.dona@phd.unipd.it	Giaquinto, Carlo/AAB-5016-2020; Donà, Daniele/W-7088-2019	Donà, Daniele/0000-0001-7105-2105; Lundin, Rebecca/0000-0002-8380-4834; GIAQUINTO, CARLO/0000-0001-9365-0413; PERILONGO, GIORGIO/0000-0002-3712-0386; Gastaldi, Andrea/0000-0002-8110-210X				Ambroggio L, 2013, PEDIATRICS, V131, pE1623, DOI 10.1542/peds.2012-2635; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI [10.1093/cid/cir531, 10.1093/cid/cir625]; Bradley JS, 2010, PEDIATR INFECT DIS J, V29, P1043, DOI 10.1097/INF.0b013e3181f42a53; Bratu S, 2005, ANTIMICROB AGENTS CH, V49, P3018, DOI 10.1128/AAC.49.7.3018-3020.2005; Center for Disease Control and Prevention, 2015, AMB HLTH CAR DAT; Clavenna A, 2011, ARCH DIS CHILD, V96, P590, DOI 10.1136/adc.2010.183541; De Luca M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154662; Don M, 2010, ACTA PAEDIATR, V99, P1602, DOI 10.1111/j.1651-2227.2010.01924.x; Frei CR, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-188; Gagliotti C, 2014, USO ANTIBIOTICI RESI; Harris M, 2011, THORAX, V66, pII1, DOI 10.1136/thoraxjnl-2011-200598; Hasegawa J, 2015, PEDIATR INT, V57, P582, DOI 10.1111/ped.12587; Hidron AI, 2008, INFECT CONT HOSP EP, V29, P996, DOI 10.1086/591861; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Jenkins TC, 2013, AM J MED, V126, P327, DOI 10.1016/j.amjmed.2012.10.027; Juven T, 2000, PEDIATR INFECT DIS J, V19, P293, DOI 10.1097/00006454-200004000-00006; Launay E, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0661-3; Leyenaar JK, 2014, J PEDIATR-US, V165, P585, DOI 10.1016/j.jpeds.2014.04.062; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701; Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751; Pakyz AL, 2008, ARCH INTERN MED, V168, P2254, DOI 10.1001/archinte.168.20.2254; Patel G, 2008, INFECT CONT HOSP EP, V29, P1099, DOI 10.1086/592412; Polk RE, 2011, CLIN INFECT DIS, V53, P1100, DOI 10.1093/cid/cir672; Polk RE, 2007, CLIN INFECT DIS, V44, P664, DOI 10.1086/511640; Rosenblut A, 2006, ANN OTO RHINOL LARYN, V115, P186, DOI 10.1177/000348940611500305; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; Samore MH, 2005, JAMA-J AM MED ASSOC, V294, P2305, DOI 10.1001/jama.294.18.2305; Schwaber MJ, 2008, ANTIMICROB AGENTS CH, V52, P1028, DOI 10.1128/AAC.01020-07; Simbalista R, 2011, CLINICS, V66, P95, DOI 10.1590/S1807-59322011000100017; Smith J, 2012, PEDIATRICS, V129, pE1326, DOI 10.1542/peds.2011-2412; South M, 2003, MED J AUSTRALIA, V178, P207, DOI 10.5694/j.1326-5377.2003.tb05163.x; Stein RT, 2007, PEDIATR PULM, V42, P1095, DOI 10.1002/ppul.20652; Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3; WATANABE M, 1991, ANTIMICROB AGENTS CH, V35, P147, DOI 10.1128/AAC.35.1.147; Yigit H, 2001, ANTIMICROB AGENTS CH, V45, P1151, DOI 10.1128/AAC.45.4.1151-1161.2001	36	19	20	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2018	13	2							e0193581	10.1371/journal.pone.0193581	http://dx.doi.org/10.1371/journal.pone.0193581			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX7ND	29489898	Green Published, gold			2023-01-03	WOS:000426276000092
J	Laiteerapong, N; Cooper, JM; Skandari, MR; Clarke, PM; Winn, AN; Naylor, RN; Huang, ES				Laiteerapong, N.; Cooper, J. M.; Skandari, M. R.; Clarke, P. M.; Winn, A. N.; Naylor, R. N.; Huang, E. S.			Cost-Effectiveness of Individualized Management of Diabetes Among US Adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material													Laiteerapong, Neda/ABC-5566-2021; Laiteerapong, Neda/AAO-2596-2020	Laiteerapong, Neda/0000-0003-0124-4325; 					0	0	0	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2018	168	3					I22	I22		10.7326/P17-9050	http://dx.doi.org/10.7326/P17-9050			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV0CU	29230474				2023-01-03	WOS:000424224300002
J	Abdel-Wahab, N; Shah, M; Lopez-Olivo, MA; Suarez-Almazor, ME				Abdel-Wahab, Noha; Shah, Mohsin; Lopez-Olivo, Maria A.; Suarez-Almazor, Maria E.			Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							ADVANCED MELANOMA; METASTATIC MELANOMA; ADVERSE EVENTS; RHEUMATOID-ARTHRITIS; MUSCULAR SARCOIDOSIS; LUPUS-ERYTHEMATOSUS; MALIGNANT-MELANOMA; MYASTHENIA-GRAVIS; IPILIMUMAB; NIVOLUMAB	Background: Cancer immunotherapy with checkpoint inhibitors (CPIs) is associated with frequent immune-related adverse events (irAEs) and is often not recommended for patients with concomitant autoimmune disease. Purpose: To summarize the evidence on adverse events associated with CPIs in patients with cancer and preexisting autoimmune disease. Data Sources: MEDLINE, EMBASE, Web of Science, PubMed ePubs, and the Cochrane Central Register of Controlled Trials through September 2017 with no language restrictions. Study Selection: Original case reports, case series, and observational studies describing patients with cancer and autoimmune disease who were receiving CPIs. Data Extraction: 2 reviewers independently extracted data and assessed the quality of reporting. Data Synthesis: 123 patients in 49 publications were identified; 92 (75%) had exacerbation of preexisting autoimmune disease, irAEs, or both. No differences in adverse events were observed in patients with active versus inactive disease. Patients receiving immunosuppressive therapy at initiation of CPI therapy seemed to have fewer adverse events than those not receiving treatment. Most flares and irAEs were managed with corticosteroids; 16% required other immunosuppressive therapies. Adverse events improved in more than half of patients without discontinuation of CPI therapy. Three patients died of adverse events. Limitations: The quality and quantity of data were limited. Case reports typically describe unique manifestations and are not generalizable to the population at large. Because there were no prospective observational studies, incidence could not be determined. Conclusion: Flares and irAEs in patients with autoimmune disease who are receiving CPIs can often be managed without discontinuing therapy, although some events may be severe and fatal. Prospective longitudinal studies are needed to establish incidence of adverse events and evaluate risk-benefit ratios and patient preferences in this population.	[Abdel-Wahab, Noha; Shah, Mohsin; Lopez-Olivo, Maria A.; Suarez-Almazor, Maria E.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Sect Rheumatol & Clin Immunol, Unit 1465, 1515 Holcombe Blvd, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Suarez-Almazor, ME (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med, Sect Rheumatol & Clin Immunol, Unit 1465, 1515 Holcombe Blvd, Houston, TX 77030 USA.	msalmazor@mdanderson.org	Lopez-Olivo, Maria/AAD-6510-2019; Shah, Mohsin/H-3025-2019	Lopez-Olivo, Maria/0000-0002-5165-8393; Shah, Mohsin/0000-0002-3450-4843	National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR053593]	National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Dr. Suarez-Almazor had a K24 career award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases while the study was conducted (grant AR053593).	Abdel-Wahab N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160221; Audemard A, 2013, DERMATOLOGY, V227, P146, DOI 10.1159/000353408; Aya F, 2017, ANN ONCOL, V28, P433, DOI 10.1093/annonc/mdw613; Bagley SJ., 2016, CANC TREAT COMMUN, V6, P20, DOI [10.1016/j.ctrc.2016.02.009, DOI 10.1016/J.CTRC.2016.02.009]; Barreto M, 2004, EUR J HUM GENET, V12, P620, DOI 10.1038/sj.ejhg.5201214; Batacchi Z, 2015, THYROID, V25, pA215; Benn Bryan S, 2017, J Thorac Oncol, V12, pe100, DOI 10.1016/j.jtho.2017.03.006; Bergqvist V, 2017, CANCER IMMUNOL IMMUN, V66, P581, DOI 10.1007/s00262-017-1962-6; Bertrand A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0455-8; Bonigen J, 2017, J EUR ACAD DERMATOL, V31, pe254, DOI 10.1111/jdv.14011; Bostwick A Doran, 2015, J Immunother Cancer, V3, P19, DOI 10.1186/s40425-015-0064-2; Boutros C, 2016, NAT REV CLIN ONCOL, V13, P473, DOI 10.1038/nrclinonc.2016.58; Calabrese C, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2016-000412; Calabrese L, 2017, ANN RHEUM DIS, V76, P1, DOI 10.1136/annrheumdis-2016-209782; Cappelli LC, 2017, ARTHRIT CARE RES, V69, P1751, DOI 10.1002/acr.23177; Chia PL, 2016, J IMMUNOTHER, V39, P202, DOI 10.1097/CJI.0000000000000121; Chou S, 2017, J CUTAN PATHOL, V44, P851, DOI 10.1111/cup.13013; Cusnir I, 2017, J RHEUMATOL, V44, P950; Dulos J, 2012, J IMMUNOTHER, V35, P169, DOI 10.1097/CJI.0b013e318247a4e7; Esfahani K, 2017, NEW ENGL J MED, V376, P1989, DOI 10.1056/NEJMc1703047; Gerdes LA, 2016, ANN NEUROL, V80, P294, DOI 10.1002/ana.24715; Gettings EJ, 2015, MULT SCLER J, V21, P670, DOI 10.1177/1352458514549403; Gielisse EAR, 2014, J CROHNS COLITIS, V8, P1742, DOI 10.1016/j.crohns.2014.08.002; Gutzmer R, 2017, EUR J CANCER, V75, P24, DOI 10.1016/j.ejca.2016.12.038; Hegde U, 2017, NEUROLOGY SP6, V88, P1526; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hughes J, 2015, DIABETES CARE, V38, pe55, DOI 10.2337/dc14-2349; Izzedine H, 2014, INVEST NEW DRUG, V32, P769, DOI 10.1007/s10637-014-0092-7; Johnson DB, 2016, JAMA ONCOL, V2, P234, DOI 10.1001/jamaoncol.2015.4368; Johnson DB, 2015, CANCER IMMUNOL RES, V3, P464, DOI 10.1158/2326-6066.CIR-14-0217; Kageyama SI, 2016, INT CANCER CONF J, V5, P192, DOI 10.1007/s13691-016-0256-8; Kamil F, 2013, AM J GASTROENTEROL, V108, pS404, DOI 10.14309/00000434-201310001-01361; Kato Y, 2016, J EUR ACAD DERMATOL, V30, pE89, DOI 10.1111/jdv.13336; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Kelly WN, 2007, DRUG SAFETY, V30, P367, DOI 10.2165/00002018-200730050-00001; Kwatra Vineet, 2017, J Med Case Rep, V11, P73, DOI 10.1186/s13256-017-1229-z; Kyi C, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0035-z; Lau KHV, 2016, MUSCLE NERVE, V54, P157, DOI 10.1002/mus.25141; Lau KHV, 2016, NEUROLOGY SP3, V86; Le Burel S, 2018, ANN RHEUM DIS, V77, P468, DOI 10.1136/annrheumdis-2016-210820; Le Burel S, 2017, EUR J CANCER, V82, P34, DOI 10.1016/j.ejca.2017.05.032; Lee B, 2016, ANN ONCOL, V27, P1174, DOI 10.1093/annonc/mdw056; Lee YH, 2015, Z RHEUMATOL, V74, P230, DOI 10.1007/s00393-014-1415-y; Lee YH, 2009, LUPUS, V18, P9, DOI 10.1177/0961203308093923; Lee YH, 2014, HUM IMMUNOL, V75, P414, DOI 10.1016/j.humimm.2014.02.020; Li G, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0157-0; Liu JL, 2009, J EUR ACAD DERMATOL, V23, P425, DOI 10.1111/j.1468-3083.2009.03087.x; Maeda O, 2016, NAGOYA J MED SCI, V78, P119; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Matsumura N, 2016, ACTA DERM-VENEREOL, V96, P259, DOI 10.2340/00015555-2212; Maul LV, 2016, J IMMUNOTHER, V39, P188, DOI 10.1097/CJI.0000000000000118; Menzies AM, 2017, ANN ONCOL, V28, P368, DOI 10.1093/annonc/mdw443; Narita T, 2016, J DERMATOL, V43, P210, DOI 10.1111/1346-8138.13028; Ong M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0171-8; Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807; Pedersen M, 2014, CANCER IMMUNOL IMMUN, V63, P1341, DOI 10.1007/s00262-014-1607-y; Phadke Sneha D, 2016, J Investig Med High Impact Case Rep, V4, p2324709616674316; Plachouri KM, 2012, J DTSCH DERMATOL GES, V10, P861; Puri A, 2017, MELANOMA RES, V27, P519, DOI 10.1097/CMR.0000000000000387; Ribas A, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.18_suppl.lba9000; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Roberts P, 2016, JAMA OPHTHALMOL, V134, P1184, DOI 10.1001/jamaophthalmol.2016.2944; Roche L, 2017, BRIT J DERMATOL, V177, P143; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sahuquillo-Torralba A, 2016, ACTAS DERMO-SIFILOGR, V107, P264, DOI 10.1016/j.ad.2015.07.012; Scalapino KJ, 2008, IMMUNOL REV, V223, P143, DOI 10.1111/j.1600-065X.2008.00639.x; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shreders A, 2015, J CLIN ONCOL, V33; Spain L, 2016, ANN ONCOL, V27, P1135, DOI 10.1093/annonc/mdw130; Uemura M, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0309-7; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; von Euw E, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-35; Weber JS, 2013, J CLIN ONCOL, V31, P4311, DOI 10.1200/JCO.2013.51.4802; Weishaupt C, 2012, J DTSCH DERMATOL GES, V10, P683; Wu J, 2016, INT J RHEUM DIS, V19, P1237, DOI 10.1111/1756-185X.12705; Zhu J, 2016, MUSCLE NERVE, V54, P506, DOI 10.1002/mus.25055; Zmeili O, 2013, ENDOCR REV, P1	78	237	245	7	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2018	168	2					121	+		10.7326/M17-2073	http://dx.doi.org/10.7326/M17-2073			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU8IN	29297009				2023-01-03	WOS:000424096600016
J	Voldby, C; Green, K; Rosthoj, S; Kongstad, T; Philipsen, L; Buchvald, F; Skov, M; Pressler, T; Gustafsson, P; Nielsen, KG				Voldby, Christian; Green, Kent; Rosthoj, Susanne; Kongstad, Thomas; Philipsen, Lue; Buchvald, Frederik; Skov, Marianne; Pressler, Tania; Gustafsson, Per; Nielsen, Kim G.			The effect of time-of-day and chest physiotherapy on multiple breath washout measures in children with clinically stable cystic fibrosis	PLOS ONE			English	Article							POSITIVE EXPIRATORY PRESSURE; INERT-GAS WASHOUT; LUNG CLEARANCE INDEX; PULMONARY-FUNCTION; DISEASE; SPIROMETRY; STANDARDIZATION; EXACERBATIONS; DRAINAGE; VOLUMES	Background In this pilot study we investigated daytime variation of multiple breath nitrogen washout (N2MBW) measures in children with clinically stable cystic fibrosis. To our knowledge the effect of time-of-day on multiple breath washout measures in patients with cystic fibrosis has not previously been reported. Furthermore, we assessed the influence of chest physiotherapy on N2MBW measures. Methods Ten school children with cystic fibrosis performed N2MBW followed by spirometry and plethysmography in the morning and afternoon at three visits that were one month apart. Chest physiotherapy was performed immediately before the afternoon measurements at visit 2 and immediately before morning and afternoon measurements at visit 3. The influence of time-of-day and chest physiotherapy on the measures was evaluated using linear mixed models. Results There were adequate quality data from 8 children with median age (range) 9.6 (6.0; 15.1) years. Baseline lung clearance index (LCI) (range) was 9.0 (7.1; 13.0) and baseline FEV1% predicted was 97.5 (78.5; 117.9). No N2MBW measures were significantly influenced by time-of-day or chest physiotherapy. LCI (95% confidence interval) decreased non-significantly 0.05 (-0.32; 0.22) during the day and increased non-significantly 0.08 (-0.26; 0.42) after chest physiotherapy. All spirometric measures were unaffected by time-of-day and chest physiotherapy. For plethysmographic measures FRCpleth decreased significantly (p<0.01) 110 mL during the day, whereas a borderline significant (p = 0.046) decrease in Delta FRCpleth-MBW during the day and a borderline significant (p = 0.03) increase in TLC after CPT were observed. Conclusion This study demonstrated that the time-of-day as well as chest physiotherapy performed immediately prior to N2MBW had no consistent or significant influence on N2MBW measures. However, we emphasize that further studies of the effect of both daytime variation and the effect of chest physiotherapy on multiple breath washout measures are warranted.	[Voldby, Christian; Green, Kent; Kongstad, Thomas; Philipsen, Lue; Buchvald, Frederik; Skov, Marianne; Pressler, Tania; Nielsen, Kim G.] Univ Copenhagen, Paediat Pulm Serv, CF Ctr Copenhagen, Copenhagen, Denmark; [Green, Kent; Kongstad, Thomas] Univ Copenhagen, Womens & Childrens Hlth, Res Unit, Copenhagen, Denmark; [Rosthoj, Susanne] Univ Copenhagen, Fac Hlth Sci, Dept Biostat, Inst Publ Hlth, Copenhagen, Denmark; [Gustafsson, Per] Cent Hosp Skovde, Dept Paediat, Skovde, Sweden	University of Copenhagen; University of Copenhagen; University of Copenhagen	Voldby, C (corresponding author), Univ Copenhagen, Paediat Pulm Serv, CF Ctr Copenhagen, Copenhagen, Denmark.	christian_voldby@hotmail.com	Nielsen, KG/AAE-6575-2020	Nielsen, KG/0000-0001-5906-9449; Rosthoj, Susanne/0000-0002-3619-413X	John & Birthe Meyer Foundation; Aase & Einar Danielsen Foundation	John & Birthe Meyer Foundation; Aase & Einar Danielsen Foundation	This study was funded by the John & Birthe Meyer Foundation (no available URL) and Aase & Einar Danielsen Foundation (URL: http://www.danielsensfond.dk/Default.aspx). There are no available grant numbers. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin R, 2016, RESP MED, V112, P59, DOI 10.1016/j.rmed.2016.01.020; BATEMAN JRM, 1978, CLIN SCI MOL MED, V55, P523, DOI 10.1042/cs0550523; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BRAGGION C, 1995, PEDIATR PULM, V19, P16, DOI 10.1002/ppul.1950190104; Fainardi Valentina, 2011, J Clin Med Res, V3, P279, DOI 10.4021/jocmr697w; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Fuchs SI, 2010, PEDIATR PULM, V45, P301, DOI 10.1002/ppul.21180; Grosse-Onnebrink J, 2017, CHEST PHYSIOTHERAPY, P1; Gustafsson PM, 2008, THORAX, V63, P129, DOI 10.1136/thx.2007.077784; Gustafsson PM, 2003, EUR RESPIR J, V22, P972, DOI 10.1183/09031936.03.00049502; HASANI A, 1993, THORAX, V48, P287, DOI 10.1136/thx.48.3.287; HOFMEYR JL, 1986, THORAX, V41, P951, DOI 10.1136/thx.41.12.951; Hortal MCR, 2014, RESP CARE, V59, P1537, DOI 10.4187/respcare.02823; Houltz B, 2012, EUR RESP J S56, V40, pP3797; Lannefors L, 2004, J ROY SOC MED, V97, P8; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MORTENSEN J, 1991, CHEST, V100, P1350, DOI 10.1378/chest.100.5.1350; Pfleger A, 2015, J CYST FIBROS, V14, P627, DOI 10.1016/j.jcf.2014.12.017; PFLEGER A, 1992, LUNG, V170, P323; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Robinson PD, 2013, EUR RESPIR J, V41, P507, DOI 10.1183/09031936.00069712; Robinson PD, 2009, RESPIRATION, V78, P339, DOI 10.1159/000225373; Ruppel GL, 2012, RESP CARE, V57, P26, DOI 10.4187/respcare.01374; Singer F, 2013, PEDIATR PULM, V48, P739, DOI 10.1002/ppul.22651; VANDERSCHANS CP, 1991, THORAX, V46, P252, DOI 10.1136/thx.46.4.252; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; WELLER PH, 1980, RESPIRATION, V40, P53, DOI 10.1159/000194251	27	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2018	13	1							e0190894	10.1371/journal.pone.0190894	http://dx.doi.org/10.1371/journal.pone.0190894			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FS3NS	29320566	gold, Green Published, Green Submitted			2023-01-03	WOS:000419689600072
J	Gopalakrishnan, V; Spencer, CN; Nezi, L; Reuben, A; Andrews, MC; Karpinets, TV; Prieto, PA; Vicente, D; Hoffman, K; Wei, SC; Cogdill, AP; Zhao, L; Hudgens, CW; Hutchinson, DS; Manzo, T; de Macedo, MP; Cotechini, T; Kumar, T; Chen, WS; Reddy, SM; Sloane, RS; Galloway-Pena, J; Jiang, H; Chen, PL; Shpall, EJ; Rezvani, K; Alousi, AM; Chemaly, RF; Shelburne, S; Vence, LM; Okhuysen, PC; Jensen, VB; Swennes, AG; McAllister, F; Sanchez, EMR; Zhang, Y; Le Chatelier, E; Zitvogel, L; Pons, N; Austin-Breneman, JL; Haydu, LE; Burton, EM; Gardner, JM; Sirmans, E; Hu, J; Lazar, AJ; Tsujikawa, T; Diab, A; Tawbi, H; Glitza, IC; Hwu, WJ; Patel, SP; Woodman, SE; Amaria, RN; Davies, MA; Gershenwald, JE; Hwu, P; Lee, JE; Zhang, J; Coussens, LM; Cooper, ZA; Futreal, PA; Daniel, CR; Ajami, NJ; Petrosino, JF; Tetzlaff, MT; Sharma, P; Allison, JP; Jenq, RR; Wargo, JA				Gopalakrishnan, V.; Spencer, C. N.; Nezi, L.; Reuben, A.; Andrews, M. C.; Karpinets, T. V.; Prieto, P. A.; Vicente, D.; Hoffman, K.; Wei, S. C.; Cogdill, A. P.; Zhao, L.; Hudgens, C. W.; Hutchinson, D. S.; Manzo, T.; de Macedo, M. Petaccia; Cotechini, T.; Kumar, T.; Chen, W. S.; Reddy, S. M.; Sloane, R. Szczepaniak; Galloway-Pena, J.; Jiang, H.; Chen, P. L.; Shpall, E. J.; Rezvani, K.; Alousi, A. M.; Chemaly, R. F.; Shelburne, S.; Vence, L. M.; Okhuysen, P. C.; Jensen, V. B.; Swennes, A. G.; McAllister, F.; Sanchez, E. Marcelo Riquelme; Zhang, Y.; Le Chatelier, E.; Zitvogel, L.; Pons, N.; Austin-Breneman, J. L.; Haydu, L. E.; Burton, E. M.; Gardner, J. M.; Sirmans, E.; Hu, J.; Lazar, A. J.; Tsujikawa, T.; Diab, A.; Tawbi, H.; Glitza, I. C.; Hwu, W. J.; Patel, S. P.; Woodman, S. E.; Amaria, R. N.; Davies, M. A.; Gershenwald, J. E.; Hwu, P.; Lee, J. E.; Zhang, J.; Coussens, L. M.; Cooper, Z. A.; Futreal, P. A.; Daniel, C. R.; Ajami, N. J.; Petrosino, J. F.; Tetzlaff, M. T.; Sharma, P.; Allison, J. P.; Jenq, R. R.; Wargo, J. A.			Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients	SCIENCE			English	Article							INTESTINAL MICROBIOTA; CTLA-4 BLOCKADE; PD-1 BLOCKADE; CANCER; THERAPY; SENSITIVITY; MECHANISMS; IPILIMUMAB; DIVERSITY; NIVOLUMAB	Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested enhanced systemic and antitumor immunity in responding patients with a favorable gut microbiome as well as in germ-free mice receiving fecal transplants from responding patients. Together, these data have important implications for the treatment of melanoma patients with immune checkpoint inhibitors.	[Gopalakrishnan, V.; Reuben, A.; Andrews, M. C.; Prieto, P. A.; Vicente, D.; Cogdill, A. P.; Sloane, R. Szczepaniak; Jiang, H.; Austin-Breneman, J. L.; Haydu, L. E.; Burton, E. M.; Gardner, J. M.; Gershenwald, J. E.; Lee, J. E.; Cooper, Z. A.; Wargo, J. A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Gopalakrishnan, V.; Spencer, C. N.; Daniel, C. R.] Univ Texas Houston, Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA; [Spencer, C. N.; Nezi, L.; Karpinets, T. V.; Zhao, L.; Manzo, T.; Kumar, T.; Shelburne, S.; Zhang, J.; Cooper, Z. A.; Futreal, P. A.; Jenq, R. R.; Wargo, J. A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Hoffman, K.; Daniel, C. R.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; [Wei, S. C.; Cogdill, A. P.; Vence, L. M.; Sharma, P.; Allison, J. P.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Hudgens, C. W.; de Macedo, M. Petaccia; Lazar, A. J.; Tetzlaff, M. T.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Hutchinson, D. S.; Swennes, A. G.; Ajami, N. J.; Petrosino, J. F.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Cotechini, T.; Tsujikawa, T.; Coussens, L. M.] Oregon Hlth & Sci Univ, Dept Cell Dev & Cell Biol, Portland, OR 97239 USA; [Chen, W. S.; Chen, P. L.; Lazar, A. J.; Tetzlaff, M. T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Reddy, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Galloway-Pena, J.; Chemaly, R. F.; Shelburne, S.; Okhuysen, P. C.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA; [Shpall, E. J.; Rezvani, K.; Alousi, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Houston, TX 77030 USA; [Jensen, V. B.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [McAllister, F.; Sanchez, E. Marcelo Riquelme; Zhang, Y.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Le Chatelier, E.; Pons, N.] Inst Natl Rech Agronom, Ctr Rech Jouy En Josas, F-78352 Jouy En Josas, France; [Zitvogel, L.] Inst Gustave Roussy, Ctr Invest Clin Biotherapie, F-94805 Villejuif, France; [Sirmans, E.; Diab, A.; Tawbi, H.; Glitza, I. C.; Hwu, W. J.; Patel, S. P.; Woodman, S. E.; Amaria, R. N.; Davies, M. A.; Hwu, P.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA; [Hu, J.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Prieto, P. A.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14642 USA; [de Macedo, M. Petaccia] AC Camargo Canc Ctr, Sao Paulo, Brazil; [Chen, P. L.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Austin-Breneman, J. L.] Harvard Univ, Cambridge, MA 02138 USA; [Cooper, Z. A.] MedImmune, Gaithersburg, MD 20878 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Oregon Health & Science University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Rochester; A.C.Camargo Cancer Center; H Lee Moffitt Cancer Center & Research Institute; Harvard University; AstraZeneca; Medimmune	Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.; Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	jwargo@mdanderson.org	Burton, Elizabeth/AAB-9393-2021; Macedo, Mariana/AAD-6151-2022; Manzo, Teresa/AAC-3398-2019; RIQUELME, ERICK/AAA-6191-2022; Nezi, Luigi/AAB-1957-2019; Tsujikawa, Takahiro/AAK-6499-2020; LE CHATELIER, Emmanuelle/O-1243-2017; Petrosino, Joseph F./AAF-1621-2019; Gopalakrishnan, Vancheswaran/S-9550-2019; Davies, Michael/GWV-2527-2022; Galloway-Pena, Jessica/J-5496-2019; Coussens, Lisa/ABH-9834-2020; Reddy, Sangeetha/GNZ-8658-2022; Cotechini, Tiziana/AAH-2161-2021; Zhang, Yu/AAA-6997-2020; Lazar, Alexander J/A-3416-2008; Gershenwald, Jeff/AAX-4367-2020	Burton, Elizabeth/0000-0002-3424-4922; Macedo, Mariana/0000-0002-0434-7605; Manzo, Teresa/0000-0001-8552-3625; Nezi, Luigi/0000-0002-4670-7656; Tsujikawa, Takahiro/0000-0003-1647-342X; LE CHATELIER, Emmanuelle/0000-0002-2724-0536; Gopalakrishnan, Vancheswaran/0000-0002-8704-035X; Galloway-Pena, Jessica/0000-0003-1081-254X; Cotechini, Tiziana/0000-0001-6762-3649; Lazar, Alexander J/0000-0002-6395-4499; Gershenwald, Jeff/0000-0003-4519-5369; Szczepaniak Sloane, Robert/0000-0002-4106-8330; Andrews, Miles/0000-0003-1231-8641; Allison, James/0000-0001-8980-5697; Reddy, Sangeetha/0000-0002-8401-1481; Hudgens, Courtney/0000-0001-8312-7485; ZITVOGEL, laurence/0000-0003-1596-0998; Cooper, Zachary/0000-0003-1059-0940; Cogdill, Alexandria/0000-0001-8917-9462; Reuben, Alexandre/0000-0003-4510-0382; Kumar, Tapsi/0000-0003-2825-3387; Wei, Spencer/0000-0001-9673-9683	Binational Science Foundation; Melanoma Research Alliance; Stand Up To Cancer; MD Anderson Cancer Center Multidisciplinary Research Program Grant; MD Anderson Cancer Center's Melanoma Moon Shots Program; philanthropic; Kimberley Clarke Foundation Award for Scientific Achievement by Odyssey Fellowship program at The University of Texas MD Anderson Cancer Center; National Cancer Institute (NCI) of NIH [CA016672, R25CA057730]; University of Texas MD Anderson Cancer Center's Various Donors Melanoma and Skin Cancers Priority Program Fund; Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant; NCI of NIH; Brenden-Colson Center for Pancreatic Health; Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the NIH (NIH) [UL1TR000128]; GlaxoSmithKline; Roche/Genentech; Merck; AstraZeneca; Sanofi-Aventis; AstraZeneca/MedImmune; Novartis; Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [K08CA160692, K12CA088084, P30CA016672, R25CA057730, R25CA056452] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000128] Funding Source: NIH RePORTER	Binational Science Foundation(US-Israel Binational Science Foundation); Melanoma Research Alliance; Stand Up To Cancer; MD Anderson Cancer Center Multidisciplinary Research Program Grant; MD Anderson Cancer Center's Melanoma Moon Shots Program; philanthropic; Kimberley Clarke Foundation Award for Scientific Achievement by Odyssey Fellowship program at The University of Texas MD Anderson Cancer Center; National Cancer Institute (NCI) of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Texas MD Anderson Cancer Center's Various Donors Melanoma and Skin Cancers Priority Program Fund; Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant; NCI of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Brenden-Colson Center for Pancreatic Health; Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the NIH (NIH); GlaxoSmithKline(GlaxoSmithKline); Roche/Genentech(Roche HoldingGenentech); Merck(Merck & Company); AstraZeneca(AstraZeneca); Sanofi-Aventis(Sanofi-Aventis); AstraZeneca/MedImmune(AstraZeneca); Novartis(Novartis); Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The data reported in this paper are tabulated in the main text and supplementary materials. The authors wish to acknowledge all patients and families affected by melanoma. J.A.W. is supported by the Binational Science Foundation, the Melanoma Research Alliance, Stand Up To Cancer, an MD Anderson Cancer Center Multidisciplinary Research Program Grant, and MD Anderson Cancer Center's Melanoma Moon Shots Program. This project was supported by the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center's Melanoma Moon Shots program. J.A.W., P.S., and J.P.A. are members of the Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center. A.R. is supported by the Kimberley Clarke Foundation Award for Scientific Achievement provided by the Odyssey Fellowship program at The University of Texas MD Anderson Cancer Center. K.H. is supported by the National Cancer Institute (NCI) of NIH under award numbers CA016672 (principal investigator R. DePinho) and R25CA057730 (principal investigator S. Chang). J.E.L. is supported by philanthropic contributions to the University of Texas MD Anderson Cancer Center's Melanoma Moon Shots Program, The University of Texas MD Anderson Cancer Center's Various Donors Melanoma and Skin Cancers Priority Program Fund, the Miriam and Jim Mulva Research Fund, the McCarthy Skin Cancer Research Fund, and the Marit Peterson Fund for Melanoma Research. The authors acknowledge the Miriam and Sheldon G. Adelson Medical Research Foundation for their support of MD Anderson Cancer Center's Biospecimen Collection team. L.M.C. acknowledges a Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant, support from the NCI of NIH, and the Brenden-Colson Center for Pancreatic Health. T.T. acknowledges the Oregon Clinical and Translational Research Institute from the National Center for Advancing Translational Sciences at the NIH (NIH #UL1TR000128). J.A.W. acknowledges C. Diaz for administrative support. Fecal, oral and murine 16S, and fecal WGS sequencing data are available from the European Nucelotide Archive under accession numbers PRJEB22894, PRJEB22874, PRJEB22895, and PRJEB22893, respectively. Human WGS sequencing data are available from the European Genomephenome Archive under accession number EGAS00001002698. J.A.W. and V.G. are inventors on a U.S. patent application (PCT/US17/53717) submitted by The University of Texas MD Anderson Cancer Center that covers methods to enhance checkpoint blockade therapy by the microbiome. T.T. and L.M.C. are inventors on a World Intellectual Property Organization patent (WO 2017/087847) held by Oregon Health and Science University that covers the multiplex technology. M.A.D. is an advisory board member for Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Roche/Genentech, Sanofi-Aventis, and Vaccinex and has received funding from GlaxoSmithKline, Roche/Genentech, Merck, AstraZeneca, and Sanofi-Aventis. A. J. L. is a consultant for MedImmune, Bristol-Myers Squibb, Novartis, and Merck and has received research support from AstraZeneca/MedImmune. Z.A.C. is an employee of MedImmune and owns stock or options in AstraZeneca. J.E.G. is on the advisory board of Merck and receives royalties from Mercator Therapeutics. S.P.P. has honoraria from Speaker's bureau of Dava Oncology, Merck, and Bristol-Myers Squibb and is an advisory board member for Amgen and Roche/Genentech. P.H. serves on the advisory board of Lion Biotechnologies and Immatics US. R.N.A.; r has received research support from Merck, Novartis, and Bristol-Myers Squibb. P.S. is a consultant for Bristol-Myers Squibb, Jounce Therapeutics, Helsinn, and GlaxoSmithKline and is also a stockholder from Jounce Therapeutics. J.P.A. is a consultant and stockholder for Jounce Therapeutics, receives royalties from Bristol-Myers Squibb, and has intellectual property with Bristol-Myers Squibb and Merck. J.A.W. has received honoraria from Speakers' bureau of Dava Oncology, Bristol-Myers Squibb, and Illumina and is an advisory board member for GlaxoSmithKline, Novartis, and Roche/Genentech. The other authors declare no competing interests.	Bachireddy P, 2015, NAT REV CANCER, V15, P201, DOI 10.1038/nrc3907; Blacher E, 2017, J IMMUNOL, V198, P572, DOI 10.4049/jimmunol.1601247; Caspi R, 2008, NUCLEIC ACIDS RES, V36, pD623, DOI [10.1093/nar/gkt1103, 10.1093/nar/gkm900]; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Drewes JL, 2016, BRIT J CANCER, V115, P273, DOI 10.1038/bjc.2016.189; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Johnson DB, 2016, CANCER IMMUNOL RES, V4, P959, DOI 10.1158/2326-6066.CIR-16-0143; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Lozupone C, 2011, ISME J, V5, P169, DOI 10.1038/ismej.2010.133; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Muegge BD, 2011, SCIENCE, V332, P970, DOI 10.1126/science.1198719; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Peled JU, 2017, J CLIN ONCOL, V35, P1650, DOI 10.1200/JCO.2016.70.3348; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schwartz LH, 2016, EUR J CANCER, V62, P132, DOI 10.1016/j.ejca.2016.03.081; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Segre JA, 2015, SCIENCE, V349, P1058, DOI 10.1126/science.aad0781; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Taur Y, 2014, BLOOD, V124, P1174, DOI 10.1182/blood-2014-02-554725; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Vesely MD, 2013, ANN NY ACAD SCI, V1284, P1, DOI 10.1111/nyas.12105; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537	38	2071	2179	76	768	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2018	359	6371					97	103		10.1126/science.aan4236	http://dx.doi.org/10.1126/science.aan4236			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR8KW	29097493	Green Accepted			2023-01-03	WOS:000419324700075
J	Jobin, C				Jobin, Christian			Precision medicine using microbiota	SCIENCE			English	Editorial Material							BACTERIA		[Jobin, Christian] Univ Florida, Dept Med, Dept Infect Dis & Immunol, Gainesville, FL 32611 USA; [Jobin, Christian] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Jobin, C (corresponding author), Univ Florida, Dept Med, Dept Infect Dis & Immunol, Gainesville, FL 32611 USA.; Jobin, C (corresponding author), Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32611 USA.	christian.jobin@medicine.ufl.edu			National Institutes of Health [R01 DK73338]; University of Florida, Department of Medicine Gatorade Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073338] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Florida, Department of Medicine Gatorade Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	C.J. is supported by National Institutes of Health grant R01 DK73338 and by the University of Florida, Department of Medicine Gatorade Fund.	Cani PD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01765; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Kelly CR, 2015, GASTROENTEROLOGY, V149, P223, DOI 10.1053/j.gastro.2015.05.008; Koppel N, 2017, SCIENCE, V356, DOI 10.1126/science.aag2770; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Miquel S, 2015, MBIO, V6, DOI 10.1128/mBio.00300-15; Pasolli E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004977; Plovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537	15	66	70	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2018	359	6371					32	34		10.1126/science.aar2946	http://dx.doi.org/10.1126/science.aar2946			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FR8KW	29302001				2023-01-03	WOS:000419324700055
J	Courtright, KR; Cassel, JB; Halpern, SD				Courtright, Katherine R.; Cassel, J. Brian; Halpern, Scott D.			A Research Agenda for High-Value Palliative Care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL		Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Richmond, VA USA; [Courtright, Katherine R.] Hosp Univ Penn, 5048 Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA; [Cassel, J. Brian] 1101 East Marshall St,Sanger Hall Suite 6030, Richmond, VA 23298 USA; [Halpern, Scott D.] 726 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Virginia Commonwealth University; University of Pennsylvania; Pennsylvania Medicine	Courtright, KR (corresponding author), Hosp Univ Penn, 5048 Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	katherine.courtright@uphs.upenn.edu			NHLBI NIH HHS [T32 HL098054] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL098054] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Carson SS, 2016, JAMA-J AM MED ASSOC, V316, P51, DOI 10.1001/jama.2016.8474; Emanuel EJ, 2016, ANN INTERN MED, V164, P114, DOI 10.7326/M15-1330; Gardiner C, 2017, PALLIATIVE MED, V31, P323, DOI 10.1177/0269216316670287; Hayward Rodney A, 2006, BMC Med Res Methodol, V6, P18, DOI 10.1186/1471-2288-6-18; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Kozlov E, 2015, AM J HOSP PALLIAT ME, V32, P772, DOI 10.1177/1049909114543322; Kreimeyer K, 2017, J BIOMED INFORM, V73, P14, DOI 10.1016/j.jbi.2017.07.012; Lupu D, 2010, J PAIN SYMPTOM MANAG, V40, P899, DOI 10.1016/j.jpainsymman.2010.07.004; Meeker D, 2016, JAMA-J AM MED ASSOC, V315, P562, DOI 10.1001/jama.2016.0275; Meier DE, 2017, HEALTH AFFAIR, V36, P1265, DOI 10.1377/hlthaff.2017.0164	10	19	18	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 2	2018	168	1					71	+		10.7326/M17-2164	http://dx.doi.org/10.7326/M17-2164			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR5SO	29132161	Green Accepted			2023-01-03	WOS:000419126700010
J	Pons, ED; Knauth, DR; Vigo, A; Mengue, SS				Pons, Emilia da Silva; Knauth, Daniela Riva; Vigo, Alvaro; Mengue, Sotero Serrate		PNAUM Res Grp	Predisposing factors to the practice of self-medication in Brazil: Results from the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM)	PLOS ONE			English	Article							HEALTH	Objective To understand the predisposing factors that lead to the practice of self-medication and the factors associated with the use of medicines via self-medication in the adult population of Brazil. Methods The analyzed data are part of the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM), a survey whose population consisted of individual residents permanently domiciled in urban areas in Brazil. In this work, the data references the 31 573 respondents aged 20 or higher (76.2% of the final PNAUM sample). Poisson regression models with robust variance were used for estimating the independent effect of each variable with medicine use via self-medication. Results Of the interviewees, 73.6% stated they had used some medication without medical recommendation if they had previously used the same product; 73.8% stated they had used non-prescribed medicine when the medicine was already present at home; and 35.5% stated they had used some non-prescribed medication when they knew someone who had already taken the same medication. The prevalence of self-medication was 18.3%. The variables associated with the highest probability of using medicine via self-medication were: geographic region within Brazil, gender, age group, per capita income, self-assessment of health, self-reported use of previously used non-prescribed medication, and self-reported use of non-prescribed medication when that medication was already present at home. Conclusions The use of medicines via self-medication in Brazil is relatively frequent and influenced by previous experience and familiarity with the medications, and is more common among women and individuals with low self-assessment of health.	[Pons, Emilia da Silva; Knauth, Daniela Riva; Vigo, Alvaro; Mengue, Sotero Serrate; PNAUM Res Grp] Univ Fed Rio Grande do Sul, Grad Program Epidemiol, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul	Pons, ED (corresponding author), Univ Fed Rio Grande do Sul, Grad Program Epidemiol, Porto Alegre, RS, Brazil.	emiliapons@yahoo.com.br	Vigo, Alvaro/S-2243-2019	Vigo, Alvaro/0000-0002-5797-9470; GADELHA, CARLOS A. G./0000-0002-9148-8819; Mengue, Sotero/0000-0002-3349-8541	Ministerio da Saude, Secretaria de Ciencia e Tecnologia Insumos Estrategicos, Departamento de Assistencia Farmaceutica e Insumos Estrategicos e Departamento de Ciencia e Tecnologia [25000.111834/2]; CNPq Phd scholarship	Ministerio da Saude, Secretaria de Ciencia e Tecnologia Insumos Estrategicos, Departamento de Assistencia Farmaceutica e Insumos Estrategicos e Departamento de Ciencia e Tecnologia; CNPq Phd scholarship	This study was supported by Ministerio da Saude, Secretaria de Ciencia e Tecnologia Insumos Estrategicos, Departamento de Assistencia Farmaceutica e Insumos Estrategicos e Departamento de Ciencia e Tecnologia (Processo 25000.111834/2) to SSM PNAUM; and a CNPq Phd scholarship to ESP.	Arrais PSD, 1997, REV SAUDE PUBL, V31, P71, DOI 10.1590/S0034-89101997000100010; Bolanos H, 2005, DRUG INF J, V39, P99, DOI 10.1177/009286150503900113; BOLTANSKI Luc, 2004, CLASSES SOCIAIS CORP; Britten N., 1996, MODERN MED PERSPECTI; BUSH PJ, 1976, MED CARE, V14, P1014; BUSH PJ, 1978, J HEALTH SOC BEHAV, V19, P179, DOI 10.2307/2136533; Carrasco-Garrido P, 2008, PHARMACOEPIDEM DR S, V17, P193, DOI 10.1002/pds.1455; Carrera-Lasfuentes P, 2013, ATEN PRIM, V45, P528, DOI 10.1016/j.aprim.2013.05.006; Carvalho MF, 2005, CAD SAUDE PUBLICA S, V21, P100; de Loyola AI, 2002, REV SAUDE PUBL, V36, P55, DOI 10.1590/S0034-89102002000100009; Fainzang S, 2014, DRUG SAFETY, V37, P333, DOI 10.1007/s40264-014-0153-z; Figueiras A, 2000, EUR J EPIDEMIOL, V16, P19, DOI 10.1023/A:1007608702063; HAAK H, 1989, REV SAUDE PUBL, V23, P143, DOI 10.1590/S0034-89101989000200008; JOHNSON RE, 1983, MED CARE, V21, P225, DOI 10.1097/00005650-198302000-00009; Kaufert P, 2000, LIVING WORKING NEW M; Knopf H, 2013, BUNDESGESUNDHEITSBLA, V56, P868, DOI 10.1007/s00103-013-1667-8; LAM CLK, 1994, SOC SCI MED, V39, P1641, DOI 10.1016/0277-9536(94)90078-7; Laure P, 1998, THERAPIE, V53, P127; LEVIN LS, 1983, ANNU REV PUBL HEALTH, V4, P181, DOI 10.1146/annurev.pu.04.050183.001145; Lowy I, 2010, HIST CIENC SAUDE-MAN, V17, P53, DOI 10.1590/S0104-59702010000500004; Lopes N, 2003, THESIS; Lopes NM, 2009, RCCS ANN REV, P1; Martin E, 1996, GENDER SCI AUTHORITY; Mengue SS, 2016, REV SAUDE PUBL, V50, DOI [10.1590/S1518-8787.2016050006156, 10.1590/s1518-8787.2016050006156]; Montastruc JL, 1997, THERAPIE, V52, P105; Nielsen MW, 2003, EUR J CLIN PHARMACOL, V59, P677, DOI 10.1007/s00228-003-0678-z; SEGALL A, 1990, MED CARE, V28, P301, DOI 10.1097/00005650-199004000-00002; Vilarino JF, 1998, REV SAUDE PUBL, V32, P43, DOI 10.1590/S0034-89101998000100006; World Health Organization, 2000, REG GUID TEL PROD; World Health Organization, 1986, GUID ASS MED PROD US; World Health Organization, 1998, ROL PHARM SELF CAR S	31	8	10	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2017	12	12							e0189098	10.1371/journal.pone.0189098	http://dx.doi.org/10.1371/journal.pone.0189098			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FP2SV	29220378	gold, Green Published, Green Submitted			2023-01-03	WOS:000417469900032
J	Lopez, G; Braggio, D; Zewdu, A; Casadei, L; Batte, K; Bid, HK; Koller, D; Yu, P; Iwenofu, OH; Strohecker, A; Choy, E; Lev, D; Pollock, R				Lopez, Gonzalo; Braggio, Danielle; Zewdu, Abeba; Casadei, Lucia; Batte, Kara; Bid, Hemant Kumar; Koller, David; Yu, Peter; Iwenofu, Obiajulu Hans; Strohecker, Anne; Choy, Edwin; Lev, Dina; Pollock, Raphael			Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITOR; ACTIVITY IN-VITRO; PANCREATIC-CANCER; HDAC INHIBITOR; TRICHOSTATIN-A; CELL-GROWTH; CHEMOTHERAPY; RESISTANT; MGCD0103; VORINOSTAT	Leiomyosarcoma (LMS) is a malignant soft tissue sarcoma (STS) with a dismal prognosis following metastatic disease. Chemotherapeutic intervention has demonstrated to have modest clinical efficacy with no curative potential in LMS patients. Previously, we demonstrated pan-HDAC inhibition to have a superior effect in various complex karyotypic sarcomas. In this study, our goal is to evaluate the therapeutic efficacy of mocetinostat alone and in combination with gemcitabine in LMS. Human leiomyosarcoma (LMS) cell lines were used for in vitro and in vivo studies. Compounds tested included the class I HDAC inhibitor, mocetinostat, and nucleoside analog, gemcitabine. MTS and clonogenic assays were used to evaluate the effect of mocetinostat on LMS cell growth. Cleaved caspase 3/7 analysis was used to determine the effects of mocetinostat on apoptosis. Compusyn software was used to determine in vitro synergy studies for the combination of mocetinostat plus gemcitabine. A LMS xenograft model in SCID mice was used to test the impact of mocetinostat alone, gemcitabine alone and the combination of mocetinostat plus gemcitabine. Mocetinostat abrogated LMS cell growth and clonogenic potential, and enhanced apoptosis in LMS cell lines. The combination of mocetinostat plus gemcitabine exhibited a synergistic effect in LMS cells in vitro. Similarly, mocetinostat combined with gemcitabine resulted in superior anti-LMS effects in vivo. Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells. LMS are aggressive, metastatic tumors with poor prognosis where effective therapeutic interventions are wanting. Our studies demonstrate the potential utility of mocetinostat combined with gemcitabine for the treatment of LMS.	[Lopez, Gonzalo; Braggio, Danielle; Zewdu, Abeba; Casadei, Lucia; Batte, Kara; Koller, David; Yu, Peter; Strohecker, Anne] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Bid, Hemant Kumar] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; [Iwenofu, Obiajulu Hans] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; [Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; [Lev, Dina] Sheba Med Ctr, Surg B, Tel Aviv, Israel; [Pollock, Raphael] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Michigan System; University of Michigan; University System of Ohio; Ohio State University; Harvard University; Massachusetts General Hospital; Chaim Sheba Medical Center; University System of Ohio; Ohio State University	Pollock, R (corresponding author), Ohio State Univ, Dept Surg, Columbus, OH 43210 USA.	raphael.pollock@osumc.edu		CASADEI, Lucia/0000-0002-5731-8197; Pollock, Raphael/0000-0002-0443-1583	NIH SARC SPORE grant [U54CA168512]; National Leiomyosarcoma Foundation grant [GRT00041181/60052311]	NIH SARC SPORE grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Leiomyosarcoma Foundation grant	This work was supported by NIH SARC SPORE grant (U54CA168512), funding recipient RP; and National Leiomyosarcoma Foundation grant (GRT00041181/60052311), funding recipient GL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammerpohl O, 2007, BRIT J CANCER, V96, P73, DOI 10.1038/sj.bjc.6603511; Ansari D, 2014, ANTICANCER RES, V34, P5269; Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Boumber Y, 2011, EXPERT OPIN INV DRUG, V20, P823, DOI 10.1517/13543784.2011.577737; Buggy JJ, 2006, MOL CANCER THER, V5, P1309, DOI 10.1158/1535-7163.MCT-05-0442; Candelaria M, 2010, MED ONCOL, V27, P1133, DOI 10.1007/s12032-009-9349-y; Candelaria M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029181; Cen Y, 2011, CURR MED CHEM, V18, P1919, DOI 10.2174/092986711795590084; Chatterjee S, 2016, GYNECOL ONCOL, V141, P51; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002; Dovzhanskiy DI, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-226; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; HEINEMANN V, 1988, CANCER RES, V48, P4024; Henderson SE, 2016, NEOPLASIA, V18, P765, DOI 10.1016/j.neo.2016.10.003; Hensley ML, 2008, GYNECOL ONCOL, V109, P329, DOI 10.1016/j.ygyno.2008.03.010; Hensley ML, 2002, J CLIN ONCOL, V20, P2824, DOI 10.1200/JCO.2002.11.050; Hosokawa M, 2015, ONCOL LETT, V10, P761, DOI 10.3892/ol.2015.3253; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Iwahashi S, 2011, INT J CLIN ONCOL, V16, P671, DOI 10.1007/s10147-011-0246-y; Iwahashi S, 2011, ONCOL REP, V26, P1057, DOI 10.3892/or.2011.1407; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Klein JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079502; Lee HS, 2017, SCI REP-UK, V7, DOI 10.1038/srep41615; Lee J, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S7194; Look KY, 2004, GYNECOL ONCOL, V92, P644, DOI 10.1016/j.ygyno.2003.11.023; Lopez G, 2011, CANCER RES, V71, P185, DOI 10.1158/0008-5472.CAN-10-2799; Lopez G, 2009, CLIN CANCER RES, V15, P3472, DOI 10.1158/1078-0432.CCR-08-2714; Merimsky O, 1998, EUR J CANCER, V34, P1296; Pastor-Anglada M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00013; Piacentini P, 2006, VIRCHOWS ARCH, V448, P797, DOI 10.1007/s00428-006-0173-x; Rundall BK, 2005, SURGERY, V138, P360, DOI 10.1016/j.surg.2005.06.016; Sakamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145985; Sampson ER, 2011, J ORTHOP RES, V29, P623, DOI 10.1002/jor.21274; Samulitis BK, 2015, CANCER BIOL THER, V16, P43, DOI 10.4161/15384047.2014.986967; Schniewind Bodo, 2006, J Carcinog, V5, P25, DOI 10.1186/1477-3163-5-25; Seddon B, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0029-8; Shang MJ, 2015, TUMOR BIOL, V36, P9015, DOI 10.1007/s13277-015-3537-5; Siu LL, 2008, J CLIN ONCOL, V26, P1940, DOI 10.1200/JCO.2007.14.5730; Sung V, 2011, CANCER SCI, V102, P1201, DOI 10.1111/j.1349-7006.2011.01921.x; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang R, 2001, GENE CHROMOSOME CANC, V31, P54, DOI 10.1002/gcc.1118; Wang ZJ, 2016, CANCER MED-US, V5, P3437, DOI 10.1002/cam4.956; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Xue K, 2016, J CANCER RES CLIN, V142, P379, DOI 10.1007/s00432-015-2026-y	47	8	9	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2017	12	11							e0188859	10.1371/journal.pone.0188859	http://dx.doi.org/10.1371/journal.pone.0188859			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO0ZL	29186204	Green Submitted, Green Published, gold			2023-01-03	WOS:000416484900067
J	Valdes, L; Perez, I; de Menorval, LC; Altshuler, E; Fossum, JO; Rivera, A				Valdes, Leslie; Perez, Irela; de Menorval, Louis Charles; Altshuler, Ernesto; Fossum, Jon Otto; Rivera, Aramis			A simple way for targeted delivery of an antibiotic: In vitro evaluation of a nanoclay-based composite	PLOS ONE			English	Article							CLAY-MINERALS; DRUG; CIPROFLOXACIN; ADSORPTION; SYSTEMS; DISSOLUTION; RESISTANCE; MECHANISMS; SMECTITE; HYBRID	The sodium-modified form of fluorohectorite nanoclay (NaFh) is introduced as a potential drug carrier, demonstrating its ability for the controlled release of the broad-spectrum antibiotic Ciprofloxacin through in vitro tests. The new clay-drug composite is designed to target the local infections in the large intestine, where it delivers most of the incorporated drug thanks to its pH-sensitive behavior. The composite has been conceived to avoid the use of coating technology and to decrease the side-effects commonly associated to the burst-release of the ciprofloxacin at the stomach level. NaFh was obtained from lithium-fluorohectorite by ion exchange, and its lack of toxicity was demonstrated by in vivo studies. Ciprofloxacin hydrochloride (Cipro) was encapsulated into the clay at different values of the pH, drug initial concentration, temperature and time. Systematic studies by X-ray diffraction (XRD), infrared and visible spectrophotometry (FT-IR and UV-vis), and thermal analysis (TGA) indicated that the NaFh host exhibits a high encapsulation efficiency for Cipro, which reaches a 90% of the initial Cipro in solution at 65 degrees C, with initial concentration of drug in solution of 1.36 x 10(-2) mol L-1 at acid pH. XRD revealed that a true intercalation of Cipro takes place between clay layers. TG showed an increased thermal stability of the drug when intercalated into the clay, as compared to the "free" Cipro. IR suggested a strong clay-Cipro interaction via ketone group, as well as the establishment of hydrogen bonds between the two materials. In vitro drug release tests revealed that NaFh is a potentially efficient carrier to deliver Cipro in the large intestine, where the release process is mediated by more than just one mechanism.	[Valdes, Leslie; Perez, Irela] Univ Havana, Dept Pharm, Inst Pharm & Food IFAL, Havana, Cuba; [de Menorval, Louis Charles] Univ Montpellier 2, Equipe Agregats Interface & Mat Energie AIME, Inst Charles Gerhardt Montpellier, Montpellier, France; [Altshuler, Ernesto] Univ Havana, Phys Fac, Grp Complex Syst & Stat Phys, Havana, Cuba; [Fossum, Jon Otto] Norwegian Univ Sci & Technol NTNU, Dept Phys, Trondheim, Norway; [Rivera, Aramis] Univ Havana, Inst Mat Sci & Technol IMRE, Zeolites Engn Lab, Havana, Cuba	Universidad de la Habana; Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; Universidad de la Habana; Norwegian University of Science & Technology (NTNU); Universidad de la Habana	Rivera, A (corresponding author), Univ Havana, Inst Mat Sci & Technol IMRE, Zeolites Engn Lab, Havana, Cuba.	aramis@imre.uh.cu	Fossum, Jon Otto/AAL-8903-2021; Fossum, Jon O/L-1510-2016	Fossum, Jon Otto/0000-0002-8952-303X; Fossum, Jon O/0000-0002-8952-303X; Rivera, Aramis/0000-0002-8579-7850; Altshuler, Ernesto/0000-0003-4192-5635	Ministerio de Educacion Superior	Ministerio de Educacion Superior	A. Rivera, L. Valdes, I. Perez and E. Altshuler acknowledge the Ministerio de Educacion Superior for partially funding this investigation, through providing salaries, laboratory area with standard working conditions, as well as basic expendables and reagents. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguzzi C, 2007, APPL CLAY SCI, V36, P22, DOI 10.1016/j.clay.2006.06.015; Babic S, 2007, TRAC-TREND ANAL CHEM, V26, P1043, DOI 10.1016/j.trac.2007.09.004; Bergaya F, 2006, DEV CLAY SCI, V1, P1, DOI 10.1016/S1572-4352(05)01001-9; BERKHEISER V, 1975, CLAY CLAY MINER, V23, P404, DOI 10.1346/CCMN.1975.0230514; Blandon LM, 2016, COLLOID SURFACE B, V145, P706, DOI 10.1016/j.colsurfb.2016.05.078; Boehling P, 2017, EUR J PHARM SCI, V104, P72, DOI 10.1016/j.ejps.2017.03.031; Calabrese I, 2013, INT J PHARMACEUT, V457, P224, DOI 10.1016/j.ijpharm.2013.09.017; CAMPOLIRICHARDS DM, 1988, DRUGS, V35, P373, DOI 10.2165/00003495-198835040-00003; Carlson L, 2004, BENTONITE MINERALO 1; Carretero MI, 2002, APPL CLAY SCI, V21, P155, DOI 10.1016/S0169-1317(01)00085-0; Droy-Lefaix MT, 2006, DEV CLAY SCI, V1, P743, DOI 10.1016/S1572-4352(05)01025-1; Dubinin M., 1947, PHYS CHEM SECT USSR, V55, P331, DOI DOI 10.4236/OJS.2014.41001; El-Gamel NEA, 2012, J THERM ANAL CALORIM, V108, P253, DOI 10.1007/s10973-011-1584-8; Ezealisiji K., 2016, INT J DRUG DELIVERY, V8, P99; Farias T, 2009, COLLOID SURFACE A, V345, P51, DOI 10.1016/j.colsurfa.2009.04.022; FRANCES C, 1991, INT J PHARM, V77, P193, DOI 10.1016/0378-5173(91)90317-H; Freundlich H, 1906, Z PHYS CHEM-STOCH VE, V57, P385; Gu C, 2005, ENVIRON SCI TECHNOL, V39, P9166, DOI 10.1021/es051109f; Hamilton AR, 2014, APPL CLAY SCI, V87, P129, DOI 10.1016/j.clay.2013.10.020; Hansen EL, 2012, SCI REP-UK, V2, DOI 10.1038/srep00618; Hayes AW, 2014, HAYES' PRINCIPLES AND METHODS OF TOXICOLOGY, 6TH EDITION, P1, DOI 10.1201/b17359; Hemmen H, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.036315; HoogkampKorstanje JAA, 1997, J ANTIMICROB CHEMOTH, V40, P427, DOI 10.1093/jac/40.3.427; Janicijevic J, 2015, INT J PHARMACEUT, V496, P466, DOI 10.1016/j.ijpharm.2015.10.047; JAYNES WF, 1992, CLAY CLAY MINER, V40, P397, DOI 10.1346/CCMN.1992.0400404; Joshi GV, 2011, MICROPOR MESOPOR MAT, V142, P542, DOI 10.1016/j.micromeso.2010.12.040; Kaviratna PD, 1996, J PHYS CHEM SOLIDS, V57, P1897, DOI 10.1016/S0022-3697(96)00076-5; Kevadiya BD, 2012, EUR J PHARM SCI, V47, P265, DOI 10.1016/j.ejps.2012.04.009; Komadel P, 1996, CLAY CLAY MINER, V44, P228, DOI 10.1346/CCMN.1996.0440208; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; LaRock DL, 2015, NAT REV MICROBIOL, V13, P191, DOI 10.1038/nrmicro3420; LEBEL M, 1988, PHARMACOTHERAPY, V8, P3; Lopez-Galindo A, 2007, APPL CLAY SCI, V36, P51, DOI 10.1016/j.clay.2006.06.016; Lopez-Galindo A., 2004, INTERFACE SCI TECHNO, V1, P267, DOI DOI 10.1016/S1573-4285(04)80044-9; Molu ZB, 2010, MICROPOR MESOPOR MAT, V127, P50, DOI 10.1016/j.micromeso.2009.06.027; Mura P, 2016, INT J PHARMACEUT, V509, P8, DOI 10.1016/j.ijpharm.2016.05.028; Neugebauer U, 2005, SPECTROCHIM ACTA A, V61, P1505, DOI 10.1016/j.saa.2004.11.014; OECD-OCDE, 2001, GUIDELINE 425 ACUTE, P1; Organization for Economic Co-operation and Development (OECD), 2008, GUID DOC AC OR TOX T; Rivera A, 2005, MICROPOR MESOPOR MAT, V80, P337, DOI 10.1016/j.micromeso.2005.01.011; Rivera A, 2016, APPL CLAY SCI, P124; Rozynek Z, 2012, EUR PHYS J E, V35, DOI 10.1140/epje/i2012-12009-x; Schou M, 2001, J AFFECT DISORDERS, V67, P21, DOI 10.1016/S0165-0327(01)00380-9; Stuart B.H, 2004, INFRARED SPECTROSCOP, DOI [DOI 10.1111/j.1750-3841.2008.00799.x, 10.1002/0470011149]; Stucki JW, 2006, DEV CLAY SCI, V1, P423, DOI 10.1016/S1572-4352(05)01013-5; Sun J, 2002, EUR J PHARM BIOPHARM, V54, P51, DOI 10.1016/S0939-6411(02)00018-8; Takahashi T, 2005, J CONTROL RELEASE, V107, P408, DOI 10.1016/j.jconrel.2005.03.031; Tenorio RP, 2010, LANGMUIR, V26, P9703, DOI 10.1021/la100377s; Thiebault T, 2015, J COLLOID INTERF SCI, V453, P1, DOI 10.1016/j.jcis.2015.04.029; Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230-973X.96920; Trivedi P, 2007, ENVIRON SCI TECHNOL, V41, P3153, DOI 10.1021/es061921y; USDPI, 1993, DRUG INF HLTH CAR PR; Viseras C, 2008, MATER SCI TECH-LOND, V24, P1020, DOI 10.1179/174328408X341708; Viseras C, 2007, APPL CLAY SCI, V36, P37, DOI 10.1016/j.clay.2006.07.006; Viseras C, 2010, APPL CLAY SCI, V48, P291, DOI 10.1016/j.clay.2010.01.007; WOLFSON JS, 1985, ANTIMICROB AGENTS CH, V28, P581, DOI 10.1128/AAC.28.4.581	56	10	10	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2017	12	11							e0187879	10.1371/journal.pone.0187879	http://dx.doi.org/10.1371/journal.pone.0187879			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN0DI	29149176	Green Published, gold, Green Submitted			2023-01-03	WOS:000415646100016
J	Gulland, A				Gulland, Anne			Five minutes with . . . Charlie Auld	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Department of Health, 2017, REG MED ASS PROF UK	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	2017	359								j5220	10.1136/bmj.j5220	http://dx.doi.org/10.1136/bmj.j5220			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN4DL	29138146				2023-01-03	WOS:000415953500006
J	Kaplan, LI				Kaplan, Lawrence I.			The Greatest Gift How a Patient's Death Taught Me to Be a Physician	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Kaplan, Lawrence I.] Temple Univ, Internal Med, Lewis Katz Sch Med, 3500 N Broad St,Ste 325, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kaplan, LI (corresponding author), Temple Univ, Internal Med, Lewis Katz Sch Med, 3500 N Broad St,Ste 325, Philadelphia, PA 19140 USA.	kaplanli@tuhs.temple.edu							0	1	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 14	2017	318	18					1761	1762		10.1001/jama.2017.15158	http://dx.doi.org/10.1001/jama.2017.15158			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN0IE	29136448				2023-01-03	WOS:000415660700012
J	Butala, NM; Kramer, DB; Shen, CY; Strom, JB; Kennedy, KF; Wang, Y; Valsdottir, LR; Wasfy, JH; Yeh, RW				Butala, Neel M.; Kramer, Daniel B.; Shen, Changyu; Strom, Jordan B.; Kennedy, Kevin F.; Wang, Yun; Valsdottir, Linda R.; Wasfy, Jason H.; Yeh, Robert W.			Applicability of Publicly Reported Hospital Readmission Measures to Unreported Conditions and Other Patient Populations A Cross-sectional All-Payer Study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ADMINISTRATIVE CLAIMS MEASURE; HEART-FAILURE; 30-DAY READMISSIONS; REDUCTION PROGRAM; MEDICARE PATIENTS; OLDER-ADULTS; RATES; RISK; PERFORMANCE	Background: Readmission rates after hospitalizations for heart failure (HF), acute myocardial infarction (AMI), and pneumonia among Medicare beneficiaries are used to assess quality and determine reimbursement. Whether these measures reflect readmission rates for other conditions or insurance groups is unknown. Objective: To investigate whether hospital-level 30-day readmission measures for publicly reported conditions (HF, AMI, and pneumonia) among Medicare patients reflect those for Medicare patients hospitalized for unreported conditions or non-Medicare patients hospitalized with HF, AMI, or pneumonia. Design: Cross-sectional. Setting: Population-based. Participants: Hospitals in the all-payer Nationwide Readmissions Database in 2013 and 2014. Measurements: Hospital-level 30-day all-cause risk-standardized excess readmission ratios (ERRs) were compared for 3 groups of patients: Medicare beneficiaries admitted for HF, AMI, or pneumonia (Medicare reported group); Medicare beneficiaries admitted for other conditions (Medicare unreported group); and non-Medicare beneficiaries admitted for HF, AMI, or pneumonia (non-Medicare group). Results: Within-hospital differences in ERRs varied widely among groups. Medicare reported ratios differed from Medicare unreported ratios by more than 0.1 for 29% of hospitals and from non-Medicare ratios by more than 0.1 for 46% of hospitals. Among hospitals with higher readmission ratios, ERRs for the Medicare reported group tended to overestimate ERRs for the non-Medicare group but underestimate those for the Medicare unreported group. Limitation: Medicare groups and risk adjustment differed slightly from those used by the Centers for Medicare & Medicaid Services. Conclusion: Hospital ERRs, as estimated by Medicare to determine financial penalties, have poor agreement with corresponding measures for populations and conditions not tied to financial penalties. Current publicly reported measures may not be good surrogates for overall hospital quality related to 30-day readmissions.	[Butala, Neel M.; Wasfy, Jason H.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Butala, Neel M.; Kramer, Daniel B.; Shen, Changyu; Strom, Jordan B.; Wasfy, Jason H.; Yeh, Robert W.] Harvard Med Sch, Boston, MA USA; [Kramer, Daniel B.; Shen, Changyu; Strom, Jordan B.; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Kennedy, Kevin F.] Univ Missouri, St Lukes Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA; [Wang, Yun] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Kramer, Daniel B.; Shen, Changyu; Strom, Jordan B.; Valsdottir, Linda R.; Yeh, Robert W.] Beth Israel Dea coness Med Ctr, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave,Suite 440, Boston, MA 02215 USA; [Butala, Neel M.; Wasfy, Jason H.] Div Cardiol, GRB 7,55 Fruit St, Boston, MA 02114 USA; [Wang, Yun] 655 Huntington Ave,Bldg 1,Room 451, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; Harvard University; Harvard T.H. Chan School of Public Health	Yeh, RW (corresponding author), Beth Israel Dea coness Med Ctr, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave,Suite 440, Boston, MA 02215 USA.	ryeh@bidmc.harvard.edu	Yeh, Robert/AAJ-3463-2020	Strom, Jordan/0000-0002-6592-6141	Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology	Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology	Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology.	[Anonymous], 2018, HOSP COMP; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boccuti C, 2017, ISSUE BRIEF; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; Campione JR, 2017, AM J MED QUAL, V32, P48, DOI 10.1177/1062860615612158; CDC/ National Center for Health Statistics, 2010, NUMB RAT DISCH SHORT; Center for Health Information and Analysis, 2016, HOSP WID AD ALL PAYE; Centers for Medicare & Medicaid Services, 2013, 2013 MEAS UPD SPEC R; Centers for Medicare & Medicaid Services, 2016, HOSP WID ALL COND 30; Chappidi MR, 2017, J UROLOGY, V197, P296, DOI 10.1016/j.juro.2016.08.082; Dharmarajan K, 2017, J AM GERIATR SOC, V65, P421, DOI 10.1111/jgs.14583; Dharmarajan K, 2014, CURR GERIATR REP, V3, P306, DOI 10.1007/s13670-014-0103-8; Dharmarajan K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h411; Dharmarajan K, 2013, JAMA-J AM MED ASSOC, V309, P355, DOI 10.1001/jama.2012.216476; Freedman JD, 2016, NEW ENGL J MED, V375, P2215, DOI 10.1056/NEJMp1613276; Hansen LO, 2011, HEALTH SERV RES, V46, P596, DOI 10.1111/j.1475-6773.2010.01204.x; Horwitz LI, 2017, MED CARE, V55, P528, DOI 10.1097/MLR.0000000000000713; Horwitz LI, 2014, ANN INTERN MED, V161, pS66, DOI 10.7326/M13-3000; Horwitz LI, 2012, J HOSP MED, V7, P690, DOI 10.1002/jhm.1965; James J., 2013, HEALTH AFFAIR, V34, P1, DOI [10.1377/hpb20131112.646839, DOI 10.1377/HPB20131112.646839]; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2013, JAMA-J AM MED ASSOC, V309, P342, DOI 10.1001/jama.2012.94856; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Koehler BE, 2009, J HOSP MED, V4, P211, DOI 10.1002/jhm.427; Kolte D, 2017, CIRC-CARDIOVASC INTE, V10, DOI 10.1161/CIRCINTERVENTIONS.116.004472; Krumholz HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160492; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Lindenauer PK, 2011, J HOSP MED, V6, P142, DOI 10.1002/jhm.890; Lindenauer Peter K, 2010, J Hosp Med, V5, pE12, DOI 10.1002/jhm.822; Linertova R, 2011, J EVAL CLIN PRACT, V17, P1167, DOI 10.1111/j.1365-2753.2010.01493.x; Mayr FB, 2017, JAMA-J AM MED ASSOC, V317, P530, DOI 10.1001/jama.2016.20468; McHugh MD, 2013, MED CARE, V51, P52, DOI [10.1097/MLR.0b013e3182763284, 10.1097/01.NNA.0000435146.46961.d1]; Mellor J, 2017, HEALTH ECON, V26, P1037, DOI 10.1002/hec.3382; Rosen AK, 2016, MED CARE, V54, P155, DOI 10.1097/MLR.0000000000000455; Ross JS, 2010, HEALTH AFFAIR, V29, P2317, DOI 10.1377/hlthaff.2010.0564; Salerno AM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016149; Stranges PM, 2015, AM J MANAG CARE, V21, P106; Strom JB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180767; Thygesen LC, 2015, SCAND J PRIM HEALTH, V33, P65, DOI 10.3109/02813432.2015.1041831; Wasfy JH, 2017, ANN INTERN MED, V166, P324, DOI 10.7326/M16-0185; Zuckerman RB, 2016, NEW ENGL J MED, V374, P1543, DOI 10.1056/NEJMsa1513024	42	7	7	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	2018	168	9					631	+		10.7326/M17-1492	http://dx.doi.org/10.7326/M17-1492			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GI3BZ	29582086				2023-01-03	WOS:000434247300005
J	Wedell-Neergaard, AS; Krogh-Madsen, R; Petersen, GL; Hansen, AM; Pedersen, BK; Lund, R; Bruunsgaard, H				Wedell-Neergaard, Anne-Sophie; Krogh-Madsen, Rikke; Petersen, Gitte Lindved; Hansen, Ase Marie; Pedersen, Bente Klarlund; Lund, Rikke; Bruunsgaard, Helle			Cardiorespiratory fitness and the metabolic syndrome: Roles of inflammation and abdominal obesity	PLOS ONE			English	Article							C-REACTIVE PROTEIN; BODY-MASS INDEX; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; ADIPOSE-TISSUE; RISK-FACTORS; EXERCISE; MARKERS; FAT; ATHEROSCLEROSIS	Objective Individuals with metabolic syndrome have increased risk of type 2 diabetes and cardiovascular disease. We aimed to test the hypothesis that a high level of cardiorespiratory fitness (CR-fitness), counteracts accumulation of visceral fat, decreases inflammation and lowers risk factors of the metabolic syndrome. Method The study sample included 1,293 Danes (age 49-52 years) who from 2009 to 2011 participated in the Copenhagen Aging and Midlife Biobank, including a questionnaire, physical tests, and blood samples. Multiple linear regression models were performed with CR-fitness as exposure and plasma levels of cytokines and high sensitive C-reactive protein as outcomes and measures of abdominal obesity were added to test if they explained the potential association. Similarly, multiple linear regression models were performed with CR-fitness as exposure and factors of the metabolic syndrome as outcomes and the potential explanation by inflammatory biomarkers were tested. All models were adjusted for the effect of age, sex, smoking, alcohol consumption, socio-economic status, and acute inflammatory events within the preceding two weeks. Results CR-fitness was inversely associated with high sensitive C-reactive protein, Interleukin (IL) 6, and IL-18, and directly associated with the anti-inflammatory cytokine IL-10, but not associated with tumor necrosis factor alpha, interferon gamma or IL-113. Abdominal obesity could partly explain the significant associations. Moreover, CR-fitness was inversely associated with an overall metabolic syndrome score, as well as triglycerides, glycated haemoglobin Alc, systolic blood pressure, diastolic blood pressure and directly associated with high-density lipoprotein. Single inflammatory biomarkers and a combined inflammatory score partly explained these associations. Conclusion Data suggest that CR-fitness has anti-inflammatory effects that are partly explained by a reduction in abdominal obesity and a decrease in the metabolic syndrome risk profile. The overall inflammatory load was mainly driven by high sensitive C-reactive protein and IL-6.	[Wedell-Neergaard, Anne-Sophie; Krogh-Madsen, Rikke; Pedersen, Bente Klarlund; Bruunsgaard, Helle] Univ Copenhagen, Rigshosp, Ctr Inflammat & Metab, Ctr Phys Act Res, Copenhagen, Denmark; [Petersen, Gitte Lindved; Hansen, Ase Marie; Lund, Rikke] Univ Copenhagen, Dept Publ Hlth, Sect Social Med, Copenhagen, Denmark; [Petersen, Gitte Lindved; Lund, Rikke] Univ Copenhagen, Ctr Hlth Ageing, Copenhagen, Denmark; [Hansen, Ase Marie] Natl Res Ctr Working Environm, Copenhagen, Denmark; [Bruunsgaard, Helle] Univ Copenhagen Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; National Research Centre for the Working Environment; Rigshospitalet; University of Copenhagen	Bruunsgaard, H (corresponding author), Univ Copenhagen, Rigshosp, Ctr Inflammat & Metab, Ctr Phys Act Res, Copenhagen, Denmark.; Bruunsgaard, H (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.	helle.bruunsgaard@regionh.dk	Hansen, Åse/AAJ-1043-2020; Bruunsgaard, Helle/AAY-3293-2020; Petersen, Gitte Lindved/AAQ-1190-2020; Pedersen, Bente Klarlund/AGR-3217-2022	Hansen, Åse/0000-0002-4075-3918; Bruunsgaard, Helle/0000-0003-2330-0834; Petersen, Gitte Lindved/0000-0001-8920-4015; Pedersen, Bente Klarlund/0000-0001-6508-6288; Krogh-Madsen, Rikke/0000-0003-4914-2715; Lund, Rikke/0000-0002-0381-4291	VELUX FOUNDATION [VELUX 26145, 31539]; TrygFonden; Danish Council for Strategic Research [09067009, 09-075724]	VELUX FOUNDATION(Velux Fonden); TrygFonden; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF))	The Copenhagen Aging and Midlife Biobank has been supported by a generous grant from the VELUX FOUNDATION (VELUX 26145 and 31539). The Centre for Physical Activity Research (CFAS) is supported by a grant from TrygFonden. CFAS is a member of DD2 - the Danish Center for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grant no. 09067009 and 09-075724). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abramson JL, 2002, ARCH INTERN MED, V162, P1286, DOI 10.1001/archinte.162.11.1286; Albert MA, 2004, AM J CARDIOL, V93, P221, DOI 10.1016/j.amjcard.2003.09.046; Aronson D, 2004, ATHEROSCLEROSIS, V176, P173, DOI 10.1016/j.atherosclerosis.2004.04.025; Asghar A, 2017, CELL IMMUNOL, V315, P18, DOI 10.1016/j.cellimm.2017.03.001; ASHWELL M, 1985, BRIT MED J, V290, P1692, DOI 10.1136/bmj.290.6483.1692; ASTRAND PO, 1954, J APPL PHYSIOL, V7, P218, DOI 10.1152/jappl.1954.7.2.218; Avlund K, 2014, J AGING HEALTH, V26, P5, DOI 10.1177/0898264313509277; Benatti FB, 2015, NAT REV RHEUMATOL, V11, P86, DOI 10.1038/nrrheum.2014.193; Blake GJ, 2001, CIRC RES, V89, P763, DOI 10.1161/hh2101.099270; Booth F, 2014, COMPR PHYSL, V2, P1143; Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001; C Reactive Protein Coronary Heart Disease Genetics Collaboration, 2011, BMJ-BRIT MED J, V342, P1; Carnethon MR, 2009, AM J LIFESTYLE MED, V3, p44S, DOI 10.1177/1559827609332737; Chan CS, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.348599; Christensen U, 2014, J AGING HEALTH, V26, P106, DOI 10.1177/0898264314522894; Church TS, 2002, ARTERIOSCL THROM VAS, V22, P1869, DOI 10.1161/01.ATV.0000036611.77940.F8; Cottam DR, 2004, OBES SURG, V14, P589, DOI 10.1381/096089204323093345; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; El Said HW, 2017, INT UROL NEPHROL, V49, P1251, DOI 10.1007/s11255-017-1568-0; Eng JJ, 2004, ARCH PHYS MED REHAB, V85, P113, DOI 10.1016/S0003-9993(03)00436-2; Garnett SP, 2008, INT J OBESITY, V32, P1028, DOI 10.1038/ijo.2008.51; Goh LGH, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004138; Hansen AM, 2014, J AGING HEALTH, V26, P72, DOI 10.1177/0898264313508187; Hayashino Y, 2014, METABOLISM, V63, P431, DOI 10.1016/j.metabol.2013.08.018; Ibrahim MM, 2010, OBES REV, V11, P11, DOI 10.1111/j.1467-789X.2009.00623.x; Ilhan F, 2015, WORLD J CLIN CASES, V3, P345, DOI 10.12998/wjcc.v3.i4.345; Janssen I, 2002, AM J CLIN NUTR, V75, P683, DOI 10.1093/ajcn/75.4.683; Karstoft K, 2016, IMMUNOL CELL BIOL, V94, P146, DOI 10.1038/icb.2015.101; Kim HY, 2013, CLIN CHEM LAB MED, V51, P2195, DOI 10.1515/cclm-2013-0045; Knudsen SH, 2012, J APPL PHYSIOL, V113, P7, DOI 10.1152/japplphysiol.00189.2011; Koene RJ, 2016, CIRCULATION, V133, P1104, DOI 10.1161/CIRCULATIONAHA.115.020406; Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009; Krogh-Madsen R, 2014, J APPL PHYSIOL, V116, P231, DOI 10.1152/japplphysiol.00155.2013; Landi F, 1999, J AM GERIATR SOC, V47, P1072, DOI 10.1111/j.1532-5415.1999.tb05229.x; Lee CMY, 2008, J CLIN EPIDEMIOL, V61, P646, DOI 10.1016/j.jclinepi.2007.08.012; Lee WY, 2004, INT J CARDIOL, V97, P101, DOI 10.1016/j.ijcard.2003.08.016; Leon MLA, 2005, INFLAMM RES, V54, P395, DOI 10.1007/s00011-005-1377-2; Mally K, 2011, EUR J APPL PHYSIOL, V111, P1879, DOI 10.1007/s00421-010-1795-x; Mathers C, 2009, GLOB HLTH RISKS MORT; McKellar GE, 2009, NAT REV CARDIOL, V6, P410, DOI 10.1038/nrcardio.2009.57; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Nakanishi K, 2001, CYTOKINE GROWTH F R, V12, P53, DOI 10.1016/S1359-6101(00)00015-0; Oliveros E, 2014, PROG CARDIOVASC DIS, V56, P426, DOI 10.1016/j.pcad.2013.10.003; Olsen RH, 2008, JAMA-J AM MED ASSOC, V299, P1261, DOI 10.1001/jama.299.11.1259; Onat A, 2004, INT J OBESITY, V28, P1018, DOI 10.1038/sj.ijo.0802695; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581; Pedersen BK, 2017, EUR J CLIN INVEST, V47, P600, DOI 10.1111/eci.12781; Peter I, 2014, MED SCI SPORT EXER, V46, P302, DOI 10.1249/MSS.0b013e3182a66155; Rana JS, 2006, INT J CARDIOL, V110, P224, DOI 10.1016/j.ijcard.2005.08.040; Reuben DB, 2003, J AM GERIATR SOC, V51, P1125, DOI 10.1046/j.1532-5415.2003.51380.x; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Ridker PM, 2017, LANCET, V6736, P1; Shoji K, 2008, OBES RES CLIN PRACT, V2, P269, DOI 10.1016/j.orcp.2008.09.001; Sigal RJ, 2010, DIABETES CARE, V33, P147, DOI DOI 10.2337/DC10-9990; Slaats J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005973; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Tilg H, 2008, MOL MED, V14, P222, DOI 10.2119/2007-00119.Tilg; Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697; Wensveen FM, 2015, EUR J IMMUNOL, V45, P2446, DOI 10.1002/eji.201545502; Williams MJA, 2005, EUR J CARDIOV PREV R, V12, P216, DOI 10.1097/00149831-200506000-00005; Wu ZJ, 2017, CLIN CHEM, V63, P663, DOI 10.1373/clinchem.2016.260828; Zacho J, 2008, NEW ENGL J MED, V359, P1897, DOI 10.1056/NEJMoa0707402	69	55	57	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2018	13	3							e0194991	10.1371/journal.pone.0194991	http://dx.doi.org/10.1371/journal.pone.0194991			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA8PV	29590212	Green Submitted, Green Published, gold			2023-01-03	WOS:000428603100095
J	Kuo, IT; Chang, KY; Juan, DF; Hsu, SJ; Chan, CT; Tsou, MY				Kuo, I-Ting; Chang, Kuang-Yi; Juan, De -Fong; Hsu, Steen J.; Chan, Chia-Tai; Tsou, Mei-Yung			Time-dependent analysis of dosage delivery information for patient-controlled analgesia services	PLOS ONE			English	Article							CLINICAL-PRACTICE GUIDELINE; POSTOPERATIVE PAIN; MANAGEMENT	Pain relief always plays the essential part of perioperative care and an important role of medical quality improvement. Patient-controlled analgesia (PCA) is a method that allows a patient to self-administer small boluses of analgesic to relieve the subjective pain. PCA logs from the infusion pump consisted of a lot of text messages which record all events during the therapies. The dosage information can be extracted from PCA logs to provide easily understanding features. The analysis of dosage information with time has great help to figure out the variance of a patient's pain relief condition. To explore the trend of pain relief requirement, we developed a PCA dosage information generator (PCA DIG) to extract meaningful messages from PCA logs during the first 48 hours of therapies. PCA dosage information including consumption, delivery, infusion rate, and the ratio between demand and delivery is presented with corresponding values in 4 successive time frames. Time dependent statistical analysis demonstrated the trends of analgesia requirements decreased gradually along with time. These findings are compatible with clinical observations and further provide valuable information about the strategy to customize postoperative pain management.	[Kuo, I-Ting; Juan, De -Fong; Chan, Chia-Tai] Natl Yang Ming Univ, Dept Biomed Engn, Taipei, Taiwan; [Chang, Kuang-Yi; Tsou, Mei-Yung] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Hsu, Steen J.] Minghsin Univ Sci & Technol, Dept Informat Management, Hsinchu, Taiwan; [Tsou, Mei-Yung] Natl Yang Ming Univ, Fac Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University	Chan, CT (corresponding author), Natl Yang Ming Univ, Dept Biomed Engn, Taipei, Taiwan.; Tsou, MY (corresponding author), Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.; Tsou, MY (corresponding author), Natl Yang Ming Univ, Fac Med, Taipei, Taiwan.	ctchan@ym.edu.tw; mytsou@vghtpe.gov.tw			National Science Council, Taiwan [NSC 99-2221-E-010-010, NSC 100-2221-E-010-001]; Taipei Veterans General Hospital, Taiwan [V102C-188]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital, Taiwan(Taipei Veterans General Hospital)	This work was supported by National Science Council, Taiwan (https.//www.most.gov.tw/), Grant numbers: NSC 99-2221-E-010-010 and NSC 100-2221-E-010-001; Taipei Veterans General Hospital, Taiwan (https://www.vghtpe.gov.tw/), Grant number: V102C-188. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ab Rahman NHN, 2012, EUR J EMERG MED, V19, P241, DOI 10.1097/MEJ.0b013e32834bfc17; [Anonymous], 1979, Pain, V6, P249; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; BENNETT RL, 1982, ANN SURG, V195, P700, DOI 10.1097/00000658-198206000-00004; Buvanendran A, 2007, BEST PRACT RES-CLIN, V21, P31, DOI 10.1016/j.bpa.2006.12.003; Chang AM, 2004, J ADV NURS, V46, P531, DOI 10.1111/j.1365-2648.2004.03027.x; Chang KY, 2006, J FORMOS MED ASSOC, V105, P918, DOI 10.1016/S0929-6646(09)60177-7; Chang KY, 2006, CLIN J PAIN, V22, P751, DOI 10.1097/01.ajp.0000210924.56654.03; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; DeGood DE., 2001, HDB PAIN ASSESSMENT, P320; Devine EC, 1999, RES NURS HEALTH, V22, P119, DOI 10.1002/(SICI)1098-240X(199904)22:2<119::AID-NUR4>3.0.CO;2-W; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; GU X, 1993, J PAIN SYMPTOM MANAG, V8, P17, DOI 10.1016/0885-3924(93)90115-C; Ho Chun-Ning, 2008, Acta Anaesthesiol Taiwan, V46, P112, DOI 10.1016/S1875-4597(08)60004-1; Kuo IT, 2010, J CLIN MONIT COMPUT, V24, P20; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Rahman NHNA, 2012, J EMERG MED, V43, P951, DOI 10.1016/j.jemermed.2012.02.069; Rugyte Danguole, 2002, Medicina (Kaunas), V38, P1078; SECHZER PH, 1971, ANESTH ANAL CURR RES, V50, P1; Wells N., 2008, PATIENT SAFETY QUALI; Yen CR, 2010, ANESTHESIOLOGY, V112, P688, DOI 10.1097/ALN.0b013e3181cbd1f3	23	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2018	13	3							e0194140	10.1371/journal.pone.0194140	http://dx.doi.org/10.1371/journal.pone.0194140			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ3GA	29543837	Green Submitted, gold, Green Published			2023-01-03	WOS:000427473500049
J	La Torre, G; Saulle, R; Di Murro, F; Siliquini, R; Firenze, A; Maurici, M; Mannocci, A; Colamesta, V; Barilla, F; Ferrante, F; Agati, L				La Torre, Giuseppe; Saulle, Roselle; Di Murro, Francesca; Siliquini, Roberta; Firenze, Alberto; Maurici, Massimo; Mannocci, Alice; Colamesta, Vittoria; Barilla, Francesco; Ferrante, Fabio; Agati, Luciano		Collaborative Grp	Mediterranean diet adherence and synergy with acute myocardial infarction and its determinants: A multicenter case-control study in Italy	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; BLOOD-LIPIDS; RISK-FACTORS; URIC-ACID; SURVIVAL; HEALTH	Background Cardiovascular diseases are the leading causes of mortality and morbidity in Western countries. The possible synergistic effect of poor adherence to a Mediterranean diet (MD) and other risk factors for acute myocardial infarction (AMI) such as hypertension, cholesterol, ever smoker, BMI> 25, diabetes, has not been deeply studied. Design Case-control study. Methods Patients with first AMI and controls from four tertiary referral Italian centers were screened for enrolment. Dietary information was collected through a questionnaire and a MD adherence score was calculated. Physical activity and smoking habits were also registered. The Synergy Index was calculated according to Rothman. Results 127 cases and 173 controls were enrolled. The analysis was conducted using a dichotomous variable for the MD score with values >= 7 representing good adherence. Multivariate analysis showed the following variables associated to AMI: ever smoker (OR = 2.08), diabetes (OR = 1.42), hypertension (OR = 2.08), hypercholesterolemia (OR = 2.47), BMI> 25 (OR = 1.99), while a protective effect emerged both in subjects scoring > 7 on the MD score interests: The authors have declared that no competing interests exist. (OR = 0.55) and in subjects resident of Southern Italy (OR = 0.38). A synergistic effect does exist between poor adherence to the MD and the following risk factors: hypertension, hypercholesterolemia, BMI >25, diabetes and being a resident in central and northern Italy. Conclusion Synergy between heart disease risk factors and MD underlines the need to enlarge the list of known modifiable cardiovascular risk factors to include and promote adherence to Mediterranean dietary habits.	[La Torre, Giuseppe; Saulle, Roselle; Di Murro, Francesca; Mannocci, Alice; Colamesta, Vittoria] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy; [Siliquini, Roberta] Torino Univ, Dept Publ Hlth Sci & Pediat, Turin, Italy; [Firenze, Alberto] Univ Palermo, Dept Sci Hlth Promot & Mother Child Care G DAless, Palermo, Italy; [Maurici, Massimo] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy; [Barilla, Francesco] Sapienza Univ Rome, Dept Cardiovasc Resp Nephrol Anesthesiol & Geriat, Rome, Italy; [Ferrante, Fabio; Agati, Luciano] Sapienza Univ Rome, Dept Cardiol, Policlin Umberto I, Rome, Italy	Sapienza University Rome; University of Turin; University of Palermo; University of Rome Tor Vergata; Sapienza University Rome; Sapienza University Rome; University Hospital Sapienza Rome	La Torre, G (corresponding author), Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy.	giuseppe.latorre@uniroma1.1t	La Torre, Giuseppe/AAI-6866-2020; Agati, Luciano/AFQ-4559-2022; Stefanadis, Christodoulos/ABH-2232-2020; Firenze, Alberto/ADK-8482-2022; Maurici, Massimo/F-5083-2013	La Torre, Giuseppe/0000-0002-1233-2040; Agati, Luciano/0000-0003-3186-1797; Stefanadis, Christodoulos/0000-0001-5974-6454; Maurici, Massimo/0000-0001-5884-161X; CIMINO, SARA/0000-0002-8948-4122; Provenzano, Sandro/0000-0001-7179-7246				Ambring A, 2004, CLIN SCI, V106, P519, DOI 10.1042/CS20030315; [Anonymous], 2013, WHO GLOB REP MORT AT; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Edwards NL, 2009, CURR OPIN RHEUMATOL, V21, P132, DOI 10.1097/BOR.0b013e3283257b96; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857; Gagliardi ACM, 2009, ATHEROSCLEROSIS, V202, P11, DOI 10.1016/j.atherosclerosis.2008.05.022; Garcia-Fernandez E, 2014, NUTRIENTS, V6, P3474, DOI 10.3390/nu6093474; Harrison TR, 2005, PRINCIPLES INTERNAL, V2; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Hlebowicz J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071095; Jacobs DR, 2009, AM J CLIN NUTR, V89, pS1543, DOI 10.3945/ajcn.2009.26736B; Kastorini CM, 2016, NUTR METAB CARDIOVAS, V26, P223, DOI 10.1016/j.numecd.2015.12.010; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; Keys A, 1980, MULTIVARIATE ANAL DE, P1; Kleber ME, 2015, J AM SOC NEPHROL, V26, P2831, DOI 10.1681/ASN.2014070660; La Torre G, 2017, ANN IG MED PREV COMU, V29, P584, DOI 10.7416/ai.2017.2187; La Torre G., 2013, SMOKING PREVENTION C; La Torre G, 2013, SMOKING PREVENTION C, P1, DOI [DOI 10.1007/978-1-4614-7046-5_1, 10.1007/978-1-4614-7046-5_1]; Liu SM, 1999, AM J CLIN NUTR, V70, P412; Mahmood Sajid, 2014, Indian J Community Med, V39, P87, DOI 10.4103/0970-0218.132724; Mannocci A, 2010, EPIDEMIOL BIOSTAT PU, V7, P369; Martinez-Gonzalez MA, 2011, NUTR METAB CARDIOVAS, V21, P237, DOI 10.1016/j.numecd.2009.10.005; Martinez-Gonzalez MA, 2004, EUR J EPIDEMIOL, V19, P9, DOI 10.1023/B:EJEP.0000013351.60227.7b; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Masia R, 1998, J EPIDEMIOL COMMUN H, V52, P707, DOI 10.1136/jech.52.11.707; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Mura Gioia, 2015, Clin Pract Epidemiol Ment Health, V11, P77, DOI 10.2174/1745017901511010077; Pancallo MT, 2015, CLIN TER, V166, pE306, DOI 10.7417/T.2015.1883; Pitsavos C, 2002, CORONARY ARTERY DIS, V13, P295, DOI 10.1097/00019501-200208000-00008; Ramallal R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135221; Ricco A, 2007, EPIDEMIOL BIOSTAT PU, V4, P119; Rosato V, 2019, EUR J NUTR, V58, P173, DOI 10.1007/s00394-017-1582-0; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V103, P506, DOI 10.1093/oxfordjournals.aje.a112252; Ryan M, 2000, QJM-MON J ASSOC PHYS, V93, P85, DOI 10.1093/qjmed/93.2.85; Sacks FM, 2002, AM J MED, V113, P13, DOI 10.1016/S0002-9343(01)00987-1; Saulle R, 2016, ANN IG MED PREV COMU, V28, P349, DOI 10.7416/ai.2016.2115; Stamler J, 1969, BOERHAAVE COURSE ISC; Tande DL, 2004, PREV MED, V38, P452, DOI 10.1016/j.ypmed.2003.11.018; Thygesen K, 2008, G ITAL CARDIOL, V9, P209, DOI 10.1714/653.7629; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Turati F, 2015, PUBLIC HEALTH NUTR, V18, P713, DOI 10.1017/S1368980014000858; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WHO, 2003, WHO TECH REP SER, V916, P1; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	46	12	12	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2018	13	3							e0193360	10.1371/journal.pone.0193360	http://dx.doi.org/10.1371/journal.pone.0193360			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ3GA	29543823	Green Published, gold			2023-01-03	WOS:000427473500013
J	Egger, S; Hughes, S; Smith, DP; Chambers, S; Kahn, C; Moxey, A; O'Connell, DL				Egger, Sam; Hughes, Suzanne; Smith, David P.; Chambers, Suzanne; Kahn, Clare; Moxey, Annette; O'Connell, Dianne L.			Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors	PLOS ONE			English	Article							QUALITY-OF-LIFE; UNPROVED METHODS; MEN; HEALTH; INDEX; RELIABILITY; VALIDATION; THERAPIES; WOMEN; CAM	Objective To assess whether the use of complementary and alternative medicines therapies (CAMs) for prostate cancer and/or its treatment side effects by long-term survivors is associated with selected socio-demographic, clinical, health-related quality-of-life (HRQOL) and/or psychological factors. Design, setting and participants The Prostate Cancer Care and Outcomes Study (PCOS) is a population-based cohort study of men with prostate cancer who were aged less than 70 years at diagnosis in New South Wales, Australia. Included in these analyses were men who returned a 10-year follow-up questionnaire, which included questions about CAM use. Methods Validated instruments assessed patient's HRQOL and psychological well-being. Poisson regression with robust variance estimation was used to estimate the adjusted relative risks of current CAM use for prostate cancer according to socio-demographic, clinical, HRQOL and psychological factors. Results 996 of 1634 (61%) living PCOS participants completed the 10-year questionnaire. Of these 996 men, 168 (17%) were using CAMs for prostate cancer and 525 (53%) were using CAMs for any reason (including prostate cancer). Those using CAM for prostate cancer were more likely to be regular or occasional support group participants (vs. no participation RR = 2.02; 95%Cl 1.41-2.88), born in another country (vs. Australian born RR = 1.59; 95%Cl 1.17-2.16), have received androgen deprivation treatment (ADT) since diagnosis (RR = 1.60; 95%Cl 1.12-2.28) or in the past two years (RR = 2.34; 95%Cl 1.56-3.52). CAM use was associated with greater fear of recurrence (RR =1.29; 95%Cl 1.12-1.48), cancer-specific distress (RR = 1.15; 95%Cl 1.01-1.30), cancer -specific hyperarousal (RR = 1.17; 95%Cl 1.04-1.31), cancer locus of control (RR = 1.16; 95%Cl 1.01-1.34) and less satisfaction with medical treatments (RR = 0.86; 95%Cl 0.76-0.97), but not with intrusive thinking, cognitive avoidance, depression, anxiety or any HRQOL domains. Conclusions In this study, about one in six long term prostate cancer survivors used CAMs for their prostate cancer with use centred around ADT, country of birth, distress, cancer control, fear of recurrence and active help seeking.	[Egger, Sam; Hughes, Suzanne; Smith, David P.; Kahn, Clare; O'Connell, Dianne L.] Canc Council New South Wales, Canc Res Div, Sydney, NSW, Australia; [Smith, David P.; O'Connell, Dianne L.] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia; [Smith, David P.; Chambers, Suzanne] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [Chambers, Suzanne] Canc Council Queensland, Canc Res Ctr, Brisbane, Qld, Australia; [Chambers, Suzanne] Prostate Canc Fdn Australia, Sydney, NSW, Australia; [Chambers, Suzanne] Edith Cowan Univ, Exercise Med Res Inst, Perth, WA, Australia; [Chambers, Suzanne] Univ Southern Queensland, Inst Resilient Reg, Toowoomba, Qld, Australia; [Moxey, Annette; O'Connell, Dianne L.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia	Cancer Council New South Wales; University of Sydney; Griffith University; Menzies Health Institute Queensland; Cancer Council Queensland; Edith Cowan University; University of Southern Queensland; University of Newcastle	Egger, S (corresponding author), Canc Council New South Wales, Canc Res Div, Sydney, NSW, Australia.	same@nswcc.org.au	Chambers, Suzanne K/H-5957-2012	Chambers, Suzanne K/0000-0003-2369-6111; Smith, David/0000-0002-1474-3214; Egger, Sam/0000-0003-1808-6909	Prostate Cancer Foundation of Australia [PG40]; Career Development Fellowship from the Cancer Institute NSW [15/CDF/1-10]	Prostate Cancer Foundation of Australia; Career Development Fellowship from the Cancer Institute NSW	This work was supported by the Prostate Cancer Foundation of Australia (PG40) (to Dianne O'Connell). David Smith was supported by a Career Development Fellowship from the Cancer Institute NSW (#15/CDF/1-10).	Agresti A., 2012, CATEGORICAL DATA ANA; Australian Bureau of Statistics, 2001, CENS POP HOUS SOC EC; Australian Institute of Health and Welfare, 2017, CANC SERIES, V101; Bishop FL, 2011, PROSTATE CANCER P D, V14, P1, DOI 10.1038/pcan.2010.38; Boon H, 2003, UROLOGY, V62, P849, DOI 10.1016/S0090-4295(03)00668-X; Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; Chambers SK, 2016, PSYCHOL MEN MASCULIN, V17, P228, DOI 10.1037/men0000018; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Diefenbach MA, 2003, J UROLOGY, V170, P166, DOI 10.1097/01.ju.0000070963.12496.cc; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; Glover J, 2002, REMOTE AREAS STAT GE; Goldsbury DE, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-253; Greenberg DB, 1997, CANCER-AM CANCER SOC, V80, P1936, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1936::AID-CNCR10>3.0.CO;2-Z; Hall JD, 2003, BJU INT, V91, P603, DOI 10.1046/j.1464-410X.2003.04181.x; Henderson JW, 2003, PSYCHO-ONCOL, V12, P59, DOI 10.1002/pon.636; Hyde MK, 2016, SEX MED-UK, V4, pE7, DOI 10.1016/j.esxm.2015.12.004; Jagtenberg T, 2006, J ALTERN COMPLEM MED, V12, P323, DOI 10.1089/acm.2006.12.323; Lee MM, 2002, AM J PUBLIC HEALTH, V92, P1606, DOI 10.2105/AJPH.92.10.1606; Lippert MC, 1999, CANCER, V86, P2642, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2642::AID-CNCR8>3.3.CO;2-W; Litwin MS, 1998, MED CARE, V36, P1002, DOI 10.1097/00005650-199807000-00007; Miller M, 1998, SUPPORT CARE CANCER, V6, P337, DOI 10.1007/s005200050175; Quandt SA, 2009, J ALTERN COMPLEM MED, V15, P331, DOI 10.1089/acm.2008.0521; Schraub S, 2000, SUPPORT CARE CANCER, V8, P10; Smith DP, 2007, J CLIN ONCOL, V25, P2560, DOI 10.1200/JCO.2006.09.8046; Smith DP, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4817; Steginga SK, 2004, PATIENT EDUC COUNS, V55, P70, DOI 10.1016/j.pec.2003.07.007; Szymanski KM, 2010, UROLOGY, V76, P1245, DOI 10.1016/j.urology.2010.01.027; Tascilar M, 2006, ONCOLOGIST, V11, P732, DOI 10.1634/theoncologist.11-7-732; Taylor KL, 2012, J CLIN ONCOL, V30, P2768, DOI 10.1200/JCO.2011.41.2767; Walach H, 2009, J ALTERN COMPLEM MED, V15, P1139, DOI 10.1089/acm.2009.0423; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wei JT, 2000, UROLOGY, V56, P899, DOI 10.1016/S0090-4295(00)00858-X; Weiss Daniel S., 1997, P399; Wilkinson S, 2008, EUR J CANCER CARE, V17, P492, DOI 10.1111/j.1365-2354.2007.00904.x; Yu XQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-460; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	37	11	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0193686	10.1371/journal.pone.0193686	http://dx.doi.org/10.1371/journal.pone.0193686			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513724	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000426896800068
J	Chem, ED; Anong, DN; Akoachere, JFKT				Chem, Elvis Dzelamonyuy; Anong, Damian Nota; Akoachere, Jane-Francis K. T.			Prescribing patterns and associated factors of antibiotic prescription in primary health care facilities of Kumbo East and Kumbo West Health Districts, North West Cameroon	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; RESISTANCE; CHILDREN; PREDICTORS; PHYSICIANS; CENTERS; EUROPE; DRUGS	Background Inappropriate use of antibiotics is a global public health challenge and has been associated with antibiotic resistance. WHO reports show that efforts to promote rational antibiotic use in developing countries are poor. With the growing number of infections with antibiotic resistant bacteria, rational drug use becomes imperative and studies that promote rational drug use are highly necessary. Considering this, we investigated prescribing patterns and predictors of antibiotic prescription in primary health care facilities in Kumbo East (KE) and Kumbo West (KW) health districts in North West Cameroon, to contribute data which could influence policy on antibiotic use. Methods and findings A cross sectional retrospective study was conducted from April 2014 to April 2015 in 26 randomly selected primary care facilities. Questionnaires were administered to 59 antibiotic prescribers to determine factors that predict antibiotic prescribing. Data on antibiotic prescription were collected by review of consultation registers. Prescription rates and demographics, prescriber and institution factors were analyzed using ANOVA. The best predictor of prescription was determined using multiple linear regression analysis. Results A total of 30,096 prescriptions were reviewed. Overall antibiotic prescription rate was 36.71%, with a mean of 1.14 antibiotics prescribed per patient. Amoxicillin was the most prescribed (29.9%). The most prevalent indications for prescribing were respiratory tract infections (21.27%). All antibiotics prescribed were broad- spectrum. Antibiotics were prescribed for patients with malaria and also in situations where diagnosis was uncertain. Prescribing by generic name was 98.36% while 99.87% was from Essential Drug List. Use of laboratory results, patient turnout and Performance Based Financing (PBF) were significantly associated with antibiotic prescribing rates (p < 0.05). PBF moderated prescribing. Conclusion There was misuse of antibiotics in primary care facilities in study area. We recommend all primary care health facilities in study area to be included in the PBF scheme and that prescribing should only be done by physicians as the have adequate training.	[Chem, Elvis Dzelamonyuy; Anong, Damian Nota; Akoachere, Jane-Francis K. T.] Univ Buea, Fac Sci, Dept Microbiol & Parasitol, Buea, Cameroon		Akoachere, JFKT (corresponding author), Univ Buea, Fac Sci, Dept Microbiol & Parasitol, Buea, Cameroon.	jakoachere@yahoo.com		Dzelamonyuy, Chem Elvis/0000-0002-1346-8871				Akkerman AE, 2005, BRIT J GEN PRACT, V55, P114; Akoachere Jane-Francis Tatah Kihla, 2012, BMC Res Notes, V5, P219, DOI 10.1186/1756-0500-5-219; [Anonymous], 2015, NAT MAL CONTR PROGR, P22; [Anonymous], EDM RES SER; Apisarnthanarak A, 2007, AM J INFECT CONTROL, V35, P606, DOI 10.1016/j.ajic.2007.05.008; Bharathiraja R, 2005, INDIAN J PEDIATR, V72, P1; Bilal AI, BMC HLTH SERV RES, V16, P144; Cadieux G, 2007, CAN MED ASSOC J, V177, P877, DOI 10.1503/cmaj.070151; Carneiro M, 2011, REV ASSOC MED BRAS, V57, P421, DOI 10.1590/S0104-42302011000400016; Charan N, 2013, J BIOMEDICAL PHARM R, V2, P71; Chareonkul Chanin, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P418; Chung A, 2007, BMJ-BRIT MED J, V335, P429, DOI 10.1136/bmj.39274.647465.BE; Consortium AEDES/IRESCO, PERF BAS FIN IMPL MA; Costelloe Ceire, 2010, BMJ, V340, pc2096, DOI 10.1136/bmj.c2096; Davey P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003543.pub3; Dekker ARJ, 2015, FAM PRACT, V32, P401, DOI 10.1093/fampra/cmv019; Department of human resources, 2009, REV EQ OPP WOM WORKP, P3; Dong LF, 2008, J ANTIMICROB CHEMOTH, V62, P410, DOI 10.1093/jac/dkn153; Donkor ES, INT J ENV RES PUBLIC, V9, P3519; Dyar OJ, 2016, EXPERT REV ANTI-INFE, V14, P403, DOI 10.1586/14787210.2016.1151353; Erah P. O., 2003, Tropical Journal of Pharmaceutical Research, V2, P175; Fadare JO, 2016, EXPERT REV PHARM OUT, V16, P639, DOI 10.1586/14737167.2016.1120673; Finch R, 2007, J ANTIMICROB CHEMOTH, V60, pI79, DOI 10.1093/jac/dkm165; Fitchett JR, 2016, LANCET INFECT DIS, V16, P388, DOI 10.1016/S1473-3099(15)00410-7; Gandra S, 2014, CLIN MICROBIOL INFEC, V20, P973, DOI 10.1111/1469-0691.12798; Gebeyehu E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138179; Gjelstad S, 2011, J ANTIMICROB CHEMOTH, V66, P2425, DOI 10.1093/jac/dkr295; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; HOGERZEIL HV, 1993, LANCET, V342, P1408, DOI 10.1016/0140-6736(93)92760-Q; Holloway K., 2011, WHO WORLD MED SITUAT, V3rd; Holloway KA, 2013, TROP MED INT HEALTH, V18, P656, DOI 10.1111/tmi.12123; Horwood J, 2016, BRIT J GEN PRACT, V66, pE207, DOI 10.3399/bjgp16X683821; Huang AM, 2005, CLIN INFECT DIS, V57, P1237; Jubulis J, 2015, INT J TUBERC LUNG D, V19, P823, DOI 10.5588/ijtld.14.0527; Kesah FNC, 2013, ANN TROP MED PUBLIC, V6, P446, DOI 10.4103/1755-6783.127797; Kotwani A, 2010, FAM PRACT, V27, P684, DOI 10.1093/fampra/cmq059; Laing R., 2001, W AFR J PHARM DRUG R, V18, P6, DOI [10.4314/wajpdr.v18i1.14718, DOI 10.4314/WAJPDR.V18I1.14718]; Lim Y.-P., 2012, EVID BASED COMPLEMEN, V2012, P1; Llor C, 2014, THER ADV DRUG SAF, V5, P229, DOI 10.1177/2042098614554919; Lloyd W, 2013, ANTIBIOTIC PRESCRIBI, P2; Mahmoud R., 2014, SUDAN MED MONIT, V9, P61, DOI [10.4103/1858-5000.146575, DOI 10.4103/1858-5000.146575]; Mainous AG, 2009, ANN FAM MED, V7, P431, DOI 10.1370/afm.999; Mashalla Y, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.13042; Mbam LA, 2015, J HLTH SCI DIS, V6, P1; Mbonye AK, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010632; Naseeb TA, 2005, SAUDI MED J, V26, P1436; National Institute for Health and Clinical Excellence (UK), 2008, RESP TRACT INF ANT S; Ndhlovu M, 2015, TROP MED INT HEALTH, V20, P1696, DOI 10.1111/tmi.12591; Ofori-Asenso R, BMC PUBLIC HLTH, V16, P724; Otoom S., 2010, Eastern Mediterranean Health Journal, V16, P511; Pavin M, 2003, TROP MED INT HEALTH, V8, P182, DOI 10.1046/j.1365-3156.2003.00992.x; Petersen I, 2007, J ANTIMICROB CHEMOTH, V60, pI43, DOI 10.1093/jac/dkm156; Piovani D, 2015, PHARMACOEPIDEM DR S, V24, P121, DOI 10.1002/pds.3654; Rezal RSM, 2015, EXPERT REV ANTI-INFE, V13, P665, DOI 10.1586/14787210.2015.1025057; Rudasingwa M, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1327241; Shankar Ravi Pathiyil, 2003, Ann Clin Microbiol Antimicrob, V2, P7; Smith RD, 2012, TECHNICAL REPORT; Steinman MA, 2003, JAMA-J AM MED ASSOC, V289, P719, DOI 10.1001/jama.289.6.719; van den Broek d'Obrenan J, 2014, J ANTIMICROB CHEMOTH, V69, P1701, DOI 10.1093/jac/dku005; van der Velden AW, 2013, INT J CLIN PRACT, V67, P10, DOI 10.1111/ijcp.12336; Veronin MA, 2011, J PHARM HEALTH SERV, V2, P135, DOI 10.1111/j.1759-8893.2011.00059.x; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; World Bank, 2014, PERF BAS FIN CAM INN; Wu YQ, 2016, EUR J CLIN PHARMACOL, V72, P359, DOI 10.1007/s00228-015-1997-6	64	46	46	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2018	13	3							e0193353	10.1371/journal.pone.0193353	http://dx.doi.org/10.1371/journal.pone.0193353			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY1CC	29505584	Green Published, Green Submitted, gold			2023-01-03	WOS:000426548200011
J	Fu, CF; Huang, JD; Wang, JT; Lin, SW; Wu, CC				Fu, Chien-Fang; Huang, Jiun-Da; Wang, Jann-Tay; Lin, Shu-Wen; Wu, Chien-Chih			The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia	PLOS ONE			English	Article							CONCENTRATION-TIME CURVE; HIGH-FLUX HEMODIALYSIS; INFECTIONS; MORTALITY; BIOFILMS; AREA	Background Vancomycin is a standard treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and its efficacy is closely linked to the recommended serum trough concentration of 15 +/- 20 mg/L. However, it is unknown how the pre-dialysis trough serum concentration (Cpre-HD) correlates with MRSA eradication in renal failure patients undergoing intermittent hemodialysis (HD). Objective To evaluate the relationship between Cpre-HD and the treatment outcomes in this population. Materials and methods A retrospective study was conducted to enroll renal failure patients undergoing HD who had received vancomycin treatment for MRSA bacteremia during January 2013 to June 2016. Treatment failure was defined as persistent bacteremia after >= 7 days of vancomycin therapy or recurrent MRSA infection within 30 days. Patient characteristics, vancomycin dosing regimen, Cpre-HD, vancomycin minimum inhibitory concentration (MIC), and subsequent culture data were reviewed. The receiver operating characteristic (ROC) curve was used to find the optimal cut-off point of Cpre-HD. Results 42 patients were enrolled and 64% had treatment failure. Although there were no significant differences in demographics or Cpre-HD between the two groups, Cpre-HD/MIC was significantly higher in the success group than that in the failure group (22.80 +/- 10.90 vs. 14.94 +/- 6.11, p = 0.019). The area under the ROC curve was 0.74, while the sensitivity, specificity, positive predictive value, and negative predictive value were 67%, 78%, 62.5%, and 81%, respectively, at the optimal Cpre-HD/MIC of. 18.6. Conclusions Cpre-HD/MIC was associated with vancomycin treatment outcome in MRSA bacteremia, and targeting to achieve a Cpre-HD/MIC of. 18.6 may improve treatment outcomes in renal failure patients who are on intermittent HD.	[Fu, Chien-Fang; Huang, Jiun-Da; Lin, Shu-Wen; Wu, Chien-Chih] Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan; [Wang, Jann-Tay] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Lin, Shu-Wen; Wu, Chien-Chih] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan; [Lin, Shu-Wen] Natl Taiwan Univ, Coll Med, Grad Inst Clin Pharm, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Wu, CC (corresponding author), Natl Taiwan Univ, Coll Med, Sch Pharm, Taipei, Taiwan.; Wu, CC (corresponding author), Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan.	101440@ntuh.gov.tw		LIN, SHU-WEN/0000-0002-9940-0850; WANG, JANN-TAY/0000-0002-0924-3469; Wu, Chien Chih/0000-0002-9517-2176				Ariano RE, 2005, AM J KIDNEY DIS, V46, P681, DOI 10.1053/j.ajkd.2005.07.018; Barth RH, 1996, KIDNEY INT, V50, P929, DOI 10.1038/ki.1996.393; Brown J, 2012, ANTIMICROB AGENTS CH, V56, P634, DOI 10.1128/AAC.05609-11; Brown M, 2011, CLIN INFECT DIS, V53, P164, DOI 10.1093/cid/cir322; Centers for Disease C, 2005, MMWR-MORBID MORTAL W, V56, P197; CLSI, 2018, CLSI PUBL, Veleventh; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; Crew P, 2015, AM J HEALTH-SYST PH, V72, P1856, DOI 10.2146/ajhp150051; DASGUPTA MK, 1991, ADV PERIT D, V7, P165; DASGUPTA MK, 1989, BLOOD PURIFICAT, V7, P144, DOI 10.1159/000169586; Holmes NE, 2013, ANTIMICROB AGENTS CH, V57, P1654, DOI 10.1128/AAC.01485-12; Jung Y, 2014, INT J ANTIMICROB AG, V43, P179, DOI 10.1016/j.ijantimicag.2013.10.017; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Lin SY, 2014, INT J ANTIMICROB AG, V43, P384, DOI 10.1016/j.ijantimicag.2014.01.002; Liu C, 2011, CLIN INFECT DIS, V53, P319, DOI [10.1093/cid/ciq146, 10.1093/cid/cir353]; Lodise TP, 2014, CLIN INFECT DIS, V59, P666, DOI 10.1093/cid/ciu398; Marr KA, 1997, ANN INTERN MED, V127, P275, DOI 10.7326/0003-4819-127-4-199708150-00003; Moise-Broder PA, 2004, CLIN PHARMACOKINET, V43, P925, DOI 10.2165/00003088-200443130-00005; Pai AB, 2004, AM J HEALTH-SYST PH, V61, P1812, DOI 10.1093/ajhp/61.17.1812; Raad Issam I., 1994, Middle East Journal of Anesthesiology, V12, P381; Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI 10.2146/ajhp080434; Siala W, 2014, ANTIMICROB AGENTS CH, V58, P6385, DOI 10.1128/AAC.03482-14; Song KH, 2015, INT J ANTIMICROB AG, V46, P689, DOI 10.1016/j.ijantimicag.2015.09.010; Steinkraus G, 2007, J ANTIMICROB CHEMOTH, V60, P788, DOI 10.1093/jac/dkm258; van Hal SJ, 2012, CLIN INFECT DIS, V54, P755, DOI 10.1093/cid/cir935; Vandecasteele SJ, 2011, CLIN INFECT DIS, V53, P124, DOI 10.1093/cid/cir337	26	11	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2018	13	3							e0193585	10.1371/journal.pone.0193585	http://dx.doi.org/10.1371/journal.pone.0193585			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY1CC	29505620	Green Submitted, Green Published, gold			2023-01-03	WOS:000426548200022
J	Autilio, C; Echaide, M; De Luca, D; Perez-Gil, J				Autilio, Chiara; Echaide, Mercedes; De Luca, Daniele; Perez-Gil, Jesus			Controlled hypothermia may improve surfactant function in asphyxiated neonates with or without meconium aspiration syndrome	PLOS ONE			English	Article							INDUCED LUNG INJURY; PULMONARY SURFACTANT; PRETERM INFANTS; FILM FORMATION; MEMBRANES; CHOLESTEROL; VENTILATION; ADSORPTION; ENCEPHALOPATHY; TEMPERATURE	Background Whole-body hypothermia (WBH) is used to improve neurological outcomes in perinatal asphyxia. Recent studies suggested a beneficial effect of hypothermia for some types of acute respiratory failure. However, no data are available about the biophysical function of human surfactant during WBH. We investigated whether WBH improves surfactant biophysical properties in asphyxiated neonates with or without meconium aspiration syndrome (MAS). Methods Non-bronchoscopic bronchoalveolar lavage (BAL) has been collected from 10 asphyxiated neonates (2 with MAS, 8 with no lung disease (NLD)) at different time-points (pre-WBH, 24h, 48h, 72h of WBH and post-WBH). Surfactant was extracted and tested by captive bubble surfactometry (CBS) in triplicate, at 37 degrees C and 33.5 degrees C,through initial adsorption and dynamic compression-expansion cycling. Phosphatidylcholine and cholesterol were assayed using enzymatic methods. Clinical data were recorded in real-time. Results Minimum surface tension under dynamic testing was significantly improved as assessed at 33.5 degrees C compared with its behavior at 37 degrees C in NLD neonates: the difference was evident after at least 72h of WBH and remained significant at 6h after rewarming (72h: p = 0.009; rewarming: p = 0.040). Similar results were obtained in MAS patients whose surfactant activity improved already at 48h of hypothermia. Total cholesterol showed a trend to increase at the first 24-48h of hypothermia in NLD patients. Conversely, hypothermia seemed to reduce the excess of exogenous cholesterol in MAS surfactant. Conclusions Surfactant biophysical properties may improve after 48-72h of WBH in asphyxiated neonates and the improvement is maintained shortly after rewarming. Due to study limitations, further studies are warranted to better clarify the effects of hypothermia on surfactant activity.	[Autilio, Chiara; Echaide, Mercedes; Perez-Gil, Jesus] Univ Complutense Madrid, Fac Biol, Dept Biochem, Madrid, Spain; [Autilio, Chiara; Echaide, Mercedes; Perez-Gil, Jesus] Univ Complutense Madrid, Hosp Octubre 12, Res Inst, Madrid, Spain; [Autilio, Chiara] Univ Cattolica Sacro Cuore, A Gemelli Univ Hosp, Dept Lab Med, Lab Clin Mol Biol, Rome, Italy; [De Luca, Daniele] South Paris Univ Hosp, AP HP, A Beclere Med Ctr, Div Pediat & Neonatal Crit Care, Paris, France	Complutense University of Madrid; Complutense University of Madrid; Hospital Universitario 12 de Octubre; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Perez-Gil, J (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Biochem, Madrid, Spain.; Perez-Gil, J (corresponding author), Univ Complutense Madrid, Hosp Octubre 12, Res Inst, Madrid, Spain.	jperezgil@bio.ucm.es	Perez-Gil, Jesus/H-3102-2019; ECHAIDE, MERCEDES/I-1649-2015; Autilio, Chiara/A-6613-2018	Perez-Gil, Jesus/0000-0003-3587-7147; ECHAIDE, MERCEDES/0000-0002-0836-0858; Autilio, Chiara/0000-0003-3446-1692; De Luca, Daniele/0000-0002-3846-4834	Laerdal Foundation Grant; ADRN (Association pour le Developpement et la Recherche en Neonatologie) non-profit foundation; Spanish Ministry of Economy and Competitiveness [BIO2015-67930-R]; Regional Government of Madrid [P2013/MIT-2807]	Laerdal Foundation Grant; ADRN (Association pour le Developpement et la Recherche en Neonatologie) non-profit foundation; Spanish Ministry of Economy and Competitiveness(Spanish Government); Regional Government of Madrid	The study has been funded by the Laerdal Foundation Grant 2014 (received by DLD), by a travel grant from ADRN (Association pour le Developpement et la Recherche en Neonatologie) non-profit foundation, and by grants from Spanish Ministry of Economy and Competitiveness (BIO2015-67930-R) and the Regional Government of Madrid (P2013/MIT-2807). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altinsoy C, 2014, J MATERN-FETAL NEO M, V27, P421, DOI 10.3109/14767058.2013.818115; Aslami H, 2012, TRANSL RES, V159, P110, DOI 10.1016/j.trsl.2011.10.005; Aslami H, 2010, RESUSCITATION, V81, P1723, DOI 10.1016/j.resuscitation.2010.09.006; Autilio C, 2017, THER HYPOTH IN PRESS; Autilio C, 2017, J PEDIATR-US, V182, P66, DOI 10.1016/j.jpeds.2016.11.057; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Ball MK, 2010, RESUSCITATION, V81, P749, DOI 10.1016/j.resuscitation.2009.12.007; de la Serna JB, 2013, FARADAY DISCUSS, V161, P535, DOI 10.1039/c2fd20096a; de la Serna JB, 2009, BIOPHYS J, V97, P1381, DOI 10.1016/j.bpj.2009.06.040; Bernhard W, 2016, ANN ANAT, V208, P146, DOI 10.1016/j.aanat.2016.08.003; Bernhard W, 2011, J APPL PHYSIOL, V111, P449, DOI 10.1152/japplphysiol.00766.2010; Boet A, 2014, MINERVA ANESTESIOL, V80, P1345; BOYNTON BR, 1989, J APPL PHYSIOL, V66, P1343, DOI 10.1152/jappl.1989.66.3.1343; Casals O, 2012, BIOCHIM BIOPHYS ACTA, V1818, P2550; Dargaville PA, 1999, AM J RESP CRIT CARE, V160, P771, DOI 10.1164/ajrccm.160.3.9811048; Dargaville PA, 2011, J PEDIATR-US, V158, P383, DOI 10.1016/j.jpeds.2010.08.044; de Blic J, 2000, EUR RESPIR J, V15, P217; De Jaegere A, 2006, AM J RESP CRIT CARE, V174, P639, DOI 10.1164/rccm.200603-351OC; de la Serna JB, 2004, J BIOL CHEM, V279, P40715, DOI 10.1074/jbc.M404648200; De Luca D, 2016, AM J RESP CRIT CARE, V194, P381, DOI 10.1164/rccm.201602-0422LE; De Luca D, 2014, EUR RESPIR J, V44, P1708, DOI 10.1183/09031936.00117714; De Luca D, 2013, CRIT CARE, V17, DOI 10.1186/cc12842; De Luca D, 2011, INTENS CARE MED, V37, P1158, DOI 10.1007/s00134-011-2243-z; Dhillon G, 2015, INDIAN J CRIT CARE M, V19, P353, DOI 10.4103/0972-5229.158278; DOYLE R, 1994, AM J RESP CRIT CARE, V149, P1619, DOI 10.1164/ajrccm.149.6.8004321; Duan M, 2011, RESP CARE, V56, P1956, DOI 10.4187/respcare.01211; Echaide M, 2017, BBA-BIOMEMBRANES, V1859, P1725, DOI 10.1016/j.bbamem.2017.03.015; Gille C, 2007, J LIPID RES, V48, P307, DOI 10.1194/jlr.M600451-JLR200; Griese M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117985; Gunasekara L, 2005, BBA-MOL CELL BIOL L, V1737, P27, DOI 10.1016/j.bbalip.2005.09.002; Hall NJ, 2010, PEDIATRICS, V125, pE300, DOI 10.1542/peds.2008-3211; HAWCO MW, 1981, J APPL PHYSIOL, V51, P509, DOI 10.1152/jappl.1981.51.2.509; Hobi N, 2014, BBA-BIOMEMBRANES, V1838, P1842, DOI 10.1016/j.bbamem.2014.02.015; Hong SB, 2005, CRIT CARE MED, V33, P2049, DOI 10.1097/01.CCM.0000178186.37167.53; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Keating E, 2007, BIOPHYS J, V93, P1391, DOI 10.1529/biophysj.106.099762; LEMPERT J, 1971, J APPL PHYSIOL, V31, P380, DOI 10.1152/jappl.1971.31.3.380; Lopez-Rodriguez E, 2014, BBA-BIOMEMBRANES, V1838, P1568, DOI 10.1016/j.bbamem.2014.01.028; Lopez-Rodriguez E, 2011, BIOPHYS J, V100, P646, DOI 10.1016/j.bpj.2010.12.3715; Naito H K, 1984, Lab Res Methods Biol Med, V10, P1; NANJEE MN, 1991, CLIN CHEM, V37, P868; Nespeca M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153328; NOTTER RH, 1980, J LIPID RES, V21, P10; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Parra E, 2015, CHEM PHYS LIPIDS, V185, P153, DOI 10.1016/j.chemphyslip.2014.09.002; Perez-Gil J, 2008, BBA-BIOMEMBRANES, V1778, P1676, DOI 10.1016/j.bbamem.2008.05.003; Piastra M, 2014, EARLY HUM DEV, V90, pS41, DOI 10.1016/S0378-3782(14)50011-4; Pietrini D, 2012, EUR J PEDIATR, V171, P1855, DOI 10.1007/s00431-012-1769-6; Pietrini D, 2012, CURR DRUG TARGETS, V13, P925, DOI 10.2174/138945012800675641; Ravasio A, 2008, J LIPID RES, V49, P2479, DOI 10.1194/jlr.D800029-JLR200; SCHOEL WM, 1994, BBA-GEN SUBJECTS, V1200, P281, DOI 10.1016/0304-4165(94)90169-4; Schurch S, 1998, BBA-MOL BASIS DIS, V1408, P180, DOI 10.1016/S0925-4439(98)00067-2; Serrano AG, 2006, CHEM PHYS LIPIDS, V141, P105, DOI 10.1016/j.chemphyslip.2006.02.017; Suri LNM, 2013, BBA-BIOMEMBRANES, V1828, P1707, DOI 10.1016/j.bbamem.2013.03.005; Suri LNM, 2012, BBA-BIOMEMBRANES, V1818, P1581, DOI 10.1016/j.bbamem.2012.02.021; YU SH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P264, DOI 10.1016/0005-2760(93)90228-2	56	24	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2018	13	2							e0192295	10.1371/journal.pone.0192295	http://dx.doi.org/10.1371/journal.pone.0192295			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV4BG	29420583	Green Published, gold, Green Submitted			2023-01-03	WOS:000424517900062
J	Mihaylov, IB; Mellon, EA; Yechieli, R; Portelance, L				Mihaylov, Ivaylo B.; Mellon, Eric A.; Yechieli, Raphael; Portelance, Lorraine			Automated inverse optimization facilitates lower doses to normal tissue in pancreatic stereotactic body radiotherapy	PLOS ONE			English	Article							ORDER CONSTRAINED OPTIMIZATION; MODULATED RADIATION-THERAPY; PROSTATE-CANCER; LUNG IMRT; QUALITY; PLANS	Purpose Inverse planning is trial-and-error iterative process. This work introduces a fully automated inverse optimization approach, where the treatment plan is closely tailored to the unique patient anatomy. The auto-optimization is applied to pancreatic stereotactic body radiotherapy (SBRT). Materials and methods The automation is based on stepwise reduction of dose-volume histograms (DVHs). Five uniformly spaced points, from 1% to 70% of the organ at risk (OAR) volumes, are used. Doses to those DVH points are iteratively decreased through multiple optimization runs. With each optimization run the doses to the OARs are decreased, while the dose homogeneity over the target is increased. The iterative process is terminated when a pre-specified dose heterogeneity over the target is reached. Twelve pancreatic cases were retrospectively studied. Doses to the target, maximum doses to duodenum, bowel, stomach, and spinal cord were evaluated. In addition, mean doses to liver and kidneys were tallied. The auto-optimized plans were compared to the actual treatment plans, which are based on national protocols. Results The prescription dose to 95% of the planning target volume (PTV) is the same for the treatment and the auto-optimized plans. The average difference for maximum doses to duodenum, bowel, stomach, and spinal cord are -4.6 Gy, -1.8 Gy, -1.6 Gy, and -2.4 Gy respectively. The negative sign indicates lower doses with the auto-optimization. The average differences in the mean doses to liver and kidneys are -0.6 Gy, and -1.1 Gy to -1.5 Gy respectively. Conclusions Automated inverse optimization holds great potential for personalization and tailoring of radiotherapy to particular patient anatomies. It can be utilized for normal tissue sparing or for an isotoxic dose escalation.	[Mihaylov, Ivaylo B.; Mellon, Eric A.; Yechieli, Raphael; Portelance, Lorraine] Univ Miami, Dept Radiat Oncol, Miami, FL 33152 USA	University of Miami	Mihaylov, IB (corresponding author), Univ Miami, Dept Radiat Oncol, Miami, FL 33152 USA.	i.mihaylov@med.miami.edu		Mihaylov, Ivaylo/0000-0003-4518-5902	NIH [R01 CA163370]; Philips Radiation Oncology Systems; NATIONAL CANCER INSTITUTE [R01CA163370] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Philips Radiation Oncology Systems; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH grant R01 CA163370 and in part by Philips Radiation Oncology Systems to IBM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaltonen P, 1997, ACTA ONCOL, V36, P1, DOI 10.1080/0284186X.1997.11835454; American Cancer Society, 2016, CANC FACTS FIGURES 2; Appenzoller LM, 2012, MED PHYS, V39, P7446, DOI 10.1118/1.4761864; Brown JM, 1998, CANCER RES, V58, P1408; Butler Laura E, 2004, J Appl Clin Med Phys, V5, P16, DOI 10.1120/jacmp.26.146; Chanyavanich V, 2011, MED PHYS, V38, P2515, DOI 10.1118/1.3574874; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Forster J, 2001, MED PHYS, V28, P28, DOI 10.1118/1.1333413; Fredriksson A, 2012, PHYS MED BIOL, V57, P7799, DOI 10.1088/0031-9155/57/23/7799; Good D, 2013, INT J RADIAT ONCOL, V87, P176, DOI 10.1016/j.ijrobp.2013.03.015; Hodapp N, 2012, STRAHLENTHER ONKOL, V188, P97, DOI 10.1007/s00066-011-0015-x; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Li TR, 2013, MED PHYS, V40, DOI 10.1118/1.4823473; Lu RZ, 2008, PHYS MED BIOL, V53, P6749, DOI 10.1088/0031-9155/53/23/007; Mihaylov IB, 2008, MED PHYS, V35, P3722, DOI 10.1118/1.2956710; Mihaylov IB, 2007, MED PHYS, V34, P1244, DOI 10.1118/1.2712413; Mihaylov IB, 2015, PHYS MED BIOL, V60, P3927, DOI 10.1088/0031-9155/60/10/3927; MIHAYLOV IB, 2014, FRONT ONCOL, V4, P22467; Mihaylov IB, 2012, INT J RADIAT ONCOL, V82, P1292, DOI 10.1016/j.ijrobp.2010.06.020; Mihaylov IB, 2010, INT J RADIAT ONCOL, V77, P285, DOI 10.1016/j.ijrobp.2009.08.021; Mihaylov IB, 2009, RADIOTHER ONCOL, V93, P147, DOI 10.1016/j.radonc.2009.05.008; Moore KL, 2011, INT J RADIAT ONCOL, V81, P545, DOI 10.1016/j.ijrobp.2010.11.030; Niemierko A, 1997, MED PHYS, V24, P103, DOI 10.1118/1.598063; Niemierko A, 1999, MED PHYS, V26, P1100, DOI DOI 10.1118/1.598063; Petit SF, 2012, RADIOTHER ONCOL, V102, P38, DOI 10.1016/j.radonc.2011.05.025; Purdie TG, 2011, INT J RADIAT ONCOL, V81, P575, DOI 10.1016/j.ijrobp.2010.11.016; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rivera L, 2013, MED PHYS, V40, DOI 10.1118/1.4788653; Song Y, 2016, RADIOTHER ONCOL, V119, P531, DOI 10.1016/j.radonc.2016.04.010; Stabenau H, 2011, MED PHYS, V38, P2731, DOI 10.1118/1.3575416; Wu BB, 2011, INT J RADIAT ONCOL, V79, P1241, DOI 10.1016/j.ijrobp.2010.05.026; Wu QW, 2000, MED PHYS, V27, P701, DOI 10.1118/1.598932; Xhaferllari I, 2013, J APPL CLIN MED PHYS, V14, P176, DOI 10.1120/jacmp.v14i1.4052; Yuan LL, 2015, PHYS MED BIOL, V60, P1831, DOI 10.1088/0031-9155/60/5/1831; Zhang XD, 2011, PHYS MED BIOL, V56, P3873, DOI 10.1088/0031-9155/56/13/009; Zhu XF, 2011, MED PHYS, V38, P719, DOI 10.1118/1.3539749	36	4	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2018	13	1							e0191036	10.1371/journal.pone.0191036	http://dx.doi.org/10.1371/journal.pone.0191036			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT1QM	29351303	Green Published, gold, Green Submitted			2023-01-03	WOS:000422911300040
J	Chen, F; Yang, M; Li, Q; Pan, J; Li, XS; Meng, Q				Chen, Fei; Yang, Min; Li, Qian; Pan, Jay; Li, Xiaosong; Meng, Qun			Does providing more services increase the primary hospitals' revenue? An assessment of national essential medicine policy based on 2,675 counties in China	PLOS ONE			English	Article							MULTILEVEL ANALYSIS; SOCIAL EPIDEMIOLOGY; CARE FACILITIES; PROVINCE; IMPACT	Objective To understand whether the increased outpatient service provision (OSP) brings in enough additional income (excluding income from essential medicine) for primary hospitals (INCOME) to compensate for reduced costs of medicine. Methods The two outcomes, annual OSP and INCOME for the period of 2008-2012, were collected from 34,506 primary hospitals in 2,675 counties in 31 provinces in China by the national surveillance system. The data had a four-level hierarchical structure; time points were nested within primary hospital, hospitals within county, and counties within province. We fitted bivariate five-level random effects regression models to examine correlations between OSP and INCOME in terms of their mean values and dose-response effects of the essential medicine policy (EMP). We adjusted for the effects of time period and selected hospital resources. Findings The estimated correlation coefficients between the two outcomes' mean values were strongly positive among provinces (r = 0.910), moderately positive among counties (r = 0.380), and none among hospitals (r = 0.002) and time (r = 0.007). The correlation between their policy effects was weakly positive among provinces (r = 0.234), but none at the county and hospital levels. However, there were markedly negative correlation coefficients between the mean and policy effects at -0.328 for OSP and -0.541 for INCOME at the hospital level. Conclusion There was no evidence to suggest an association between the two outcomes in terms of their mean values and dose-response effects of EMP at the hospital level. This indicated that increased OSP did not bring enough additional INCOME. Sustainable mechanisms to for this work.	[Chen, Fei; Pan, Jay; Li, Xiaosong] Sichuan Univ, West China Sch Publ Hlth, Chengdu, Sichuan, Peoples R China; [Yang, Min; Li, Qian; Pan, Jay] Sichuan Univ, West China Res Ctr Rural Hlth Dev, Chengdu, Sichuan, Peoples R China; [Meng, Qun] Natl Hlth & Family Planning Commiss China, Ctr Hlth Informat & Stat, Beijing, Peoples R China	Sichuan University; Sichuan University	Li, XS (corresponding author), Sichuan Univ, West China Sch Publ Hlth, Chengdu, Sichuan, Peoples R China.; Yang, M (corresponding author), Sichuan Univ, West China Res Ctr Rural Hlth Dev, Chengdu, Sichuan, Peoples R China.	yangmin2013@scu.edu.cn; lixiaosong1101@126.com	Pan, Jay/Z-4492-2019	Pan, Jay/0000-0001-9501-1535				Ai-tian Y, 2011, CHINESE HLTH EC, V04, P20; Chen L, 2012, CHINESE J HLTH POLIC, V4, P7; China Central Government, 2009, IMPL PLAN REC PRIOR; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Du N, 2015, CHINA EC STUDIES, V1, P8; Fang Y, 2013, LANCET GLOB HEALTH, V1, pE227, DOI 10.1016/S2214-109X(13)70072-X; Gai X, 2005, PSYCHOL SCI, V28, P429; Goldstein H., 2011, MULTILEVEL STAT MODE; Goldstein H, 2009, STAT MODEL, V9, P173, DOI 10.1177/1471082X0800900301; Hipgrave D, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001337; Huang Donghong, 2015, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V40, P222, DOI 10.11817/j.issn.1672-7347.2015.02.018; [金芳 Jin Fang], 2004, [中国卫生统计, Chinese Journal of Health Statistics], V21, P204; [金有豫 Jin Youyu], 2011, [中国药房, China Pharmacy], V22, P293; Laing R, 2003, LANCET, V361, P1723, DOI 10.1016/S0140-6736(03)13375-2; Liu H, 2012, CHINESE J DRUG EVALU, V29, P270; Liu Z, 2014, CHINESE HLTH EC, V33, P8; Merlo J, 2003, J EPIDEMIOL COMMUN H, V57, P550, DOI 10.1136/jech.57.8.550; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P443, DOI 10.1136/jech.2004.023473; Ministry of Health of China, 2011, EST NAT ESS MED SYST; National Bureau of Statistics of China, 2013, CHIN CIT STAT YB 201; National Health and Family Planning Commission, 2013, NAT HLTH FAM PLAN CO; Rasbash J., 2012, USERS GUIDE MLWIN VE; Rasbash J., 2009, MLWIN VERSION 2 1; Roux AVD, 2002, J EPIDEMIOL COMMUN H, V56, P588, DOI 10.1136/jech.56.8.588; Singer J., 2003, APPL LONGITUDINAL DA; Song Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0507-3; Song Yan, 2014, J Pharm Policy Pract, V7, P12, DOI 10.1186/2052-3211-7-12; Tang YQ, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-183; Wang S, 2011, CHINESE J HLTH POLIC, V4, P30; Wang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090365; Xu SM, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1073-z; Yang C, 2012, CHIN J HLTH POLICY, V05, P35; Yang H, 2014, PRACTICAL PREVENTIVE, V21, P1405; Yang L, 2013, B WORLD HEALTH ORGAN, V91, P184, DOI 10.2471/BLT.11.097998; Yang LP, 2013, HEALTH POLICY PLANN, V28, P750, DOI 10.1093/heapol/czs116; Yang M, 2015, LANCET, V386, P28, DOI 10.1016/S0140-6736(15)00606-6; Yu F, 2011, CHINESE HLTH EC, V1, P18; Yu W, 2015, SHANGHAI MED PHARM J, V3, P16; [曾丽 Zeng Li], 2011, [中国药房, China Pharmacy], V22, P3758; Zhou L, 2013, CHONGQING MED, V5, P20; Zhou Z, 2015, PLOS ONE, V10	41	0	1	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2018	13	1							e0190855	10.1371/journal.pone.0190855	http://dx.doi.org/10.1371/journal.pone.0190855			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FS8HZ	29338028	gold, Green Published, Green Submitted			2023-01-03	WOS:000422652700021
J	Chessman, AW				Chessman, Alexander W.			Guideline: Experts recommend a single dose of oral steroids for pain relief in acute sore throat	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Chessman, Alexander W.] Med Univ South Carolina, Charleston, SC 29401 USA	Medical University of South Carolina	Chessman, AW (corresponding author), Med Univ South Carolina, Charleston, SC 29401 USA.							Gehanno P, 2003, CLIN DRUG INVEST, V23, P263, DOI 10.2165/00044011-200323040-00006; Pierce CA, 2010, ANN PHARMACOTHER, V44, P489, DOI 10.1345/aph.1M332; Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715; Spinks A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000023.pub4; WALJEE AK, 2017, BMJ-BRIT MED J, V357, DOI DOI 10.1136/BMJ.J1415	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 16	2018	168	2					JC2	JC2		10.7326/ACPJC-2018-168-2-002	http://dx.doi.org/10.7326/ACPJC-2018-168-2-002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU8IN	29335714				2023-01-03	WOS:000424096600002
J	Reignier, J; Boisrame-Helms, J; Brisard, L; Lascarrou, JB; Hssain, AA; Anguel, N; Argaud, L; Asehnoune, K; Asfar, P; Bellec, F; Botoc, V; Bretagnol, A; Bui, HN; Canet, E; Da Silva, D; Darmon, M; Das, V; Devaquet, J; Djibre, M; Ganster, F; Garrouste-Orgeas, M; Gaudry, S; Gontier, O; Guerin, C; Guidet, B; Guitton, C; Herbrecht, JE; Lacherade, JC; Letocart, P; Martino, F; Maxime, V; Mercier, E; Mira, JP; Nseir, S; Piton, G; Quenot, JP; Richecoeur, J; Rigaud, JP; Robert, R; Rolin, N; Schwebel, C; Sirodot, M; Tinturier, F; Thevenin, D; Giraudeau, B; Le Gouge, A				Reignier, Jean; Boisrame-Helms, Julie; Brisard, Laurent; Lascarrou, Jean-Baptiste; Hssain, Ali Ait; Anguel, Nadia; Argaud, Laurent; Asehnoune, Karim; Asfar, Pierre; Bellec, Frederic; Botoc, Vlad; Bretagnol, Anne; Bui, Hoang-Nam; Canet, Emmanuel; Da Silva, Daniel; Darmon, Michael; Das, Vincent; Devaquet, Jerome; Djibre, Michel; Ganster, Frederique; Garrouste-Orgeas, Maite; Gaudry, Stephane; Gontier, Olivier; Guerin, Claude; Guidet, Bertrand; Guitton, Christophe; Herbrecht, Jean-Etienne; Lacherade, Jean-Claude; Letocart, Philippe; Martino, Frederic; Maxime, Virginie; Mercier, Emmanuelle; Mira, Jean-Paul; Nseir, Saad; Piton, Gael; Quenot, Jean-Pierre; Richecoeur, Jack; Rigaud, Jean-Philippe; Robert, Rene; Rolin, Nathalie; Schwebel, Carole; Sirodot, Michel; Tinturier, Francois; Thevenin, Didier; Giraudeau, Bruno; Le Gouge, Amelie		NUTRIREA-2 Trial Investigators	Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)	LANCET			English	Article							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; METAANALYSIS; SUPPORT; PATIENT; INTOLERANCE; GUIDELINES; MORTALITY; FAILURE; SEPSIS	Background Whether the route of early feeding affects outcomes of patients with severe critical illnesses is controversial. We hypothesised that outcomes were better with early first-line enteral nutrition than with early first-line parenteral nutrition. Methods In this randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2 trial) done at 44 French intensive-care units (ICUs), adults (18 years or older) receiving invasive mechanical ventilation and vasopressor support for shock were randomly assigned (1: 1) to either parenteral nutrition or enteral nutrition, both targeting normocaloric goals (20-25 kcal/kg per day), within 24 h after intubation. Randomisation was stratified by centre using permutation blocks of variable sizes. Given that route of nutrition cannot be masked, blinding of the physicians and nurses was not feasible. Patients receiving parenteral nutrition could be switched to enteral nutrition after at least 72 h in the event of shock resolution (no vasopressor support for 24 consecutive hours and arterial lactate <2 mmol/L). The primary endpoint was mortality on day 28 after randomisation in the intention-to-treat-population. This study is registered with ClinicalTrials. gov, number NCT01802099. Findings After the second interim analysis, the independent Data Safety and Monitoring Board deemed that completing patient enrolment was unlikely to significantly change the results of the trial and recommended stopping patient recruitment. Between March 22, 2013, and June 30, 2015, 2410 patients were enrolled and randomly assigned; 1202 to the enteral group and 1208 to the parenteral group. By day 28, 443 (37%) of 1202 patients in the enteral group and 422 (35%) of 1208 patients in the parenteral group had died (absolute difference estimate 2.0%; [95% CI -1.9 to 5.8]; p=0.33). Cumulative incidence of patients with ICU-acquired infections did not differ between the enteral group (173 [14%]) and the parenteral group (194 [16%]; hazard ratio [HR] 0.89 [95% CI 0.72-1.09]; p=0.25). Compared with the parenteral group, the enteral group had higher cumulative incidences of patients with vomiting (406 [34%] vs 246 [20%]; HR 1.89 [1.62-2.20]; p<0.0001), diarrhoea (432 [36%] vs 393 [33%]; 1.0 [1.05-1.37]; p=0.009), bowel ischaemia (19 [2%] vs five [<1%]; 3.84 [1.43-10.3]; p=0.007), and acute colonic pseudo-obstruction (11 [1%] vs three [<1%]; 3.7 [1.03-13.2; p=0.04). Interpretation In critically ill adults with shock, early isocaloric enteral nutrition did not reduce mortality or the risk of secondary infections but was associated with a greater risk of digestive complications compared with early isocaloric parenteral nutrition.	[Reignier, Jean; Lascarrou, Jean-Baptiste] CHU Nantes, Med Intens Reanimat, Nantes, France; [Reignier, Jean; Lascarrou, Jean-Baptiste] Univ Nantes, Nantes, France; [Boisrame-Helms, Julie] Univ Strasbourg, Fac Med, EA 7293, FMTS, Strasbourg, France; [Boisrame-Helms, Julie] Hop Univ Strasbourg, Nouvel Hop Civil, Med Intens Care Unit, Strasbourg, France; [Brisard, Laurent] Hop Laennec, CHU Nantes, Dept Anesthesie & Reanimat, Nantes, France; [Hssain, Ali Ait] CHU Clermont Ferrand, Hop Gabriel Montpied, Med Intens Care Unit, Clermont Ferrand, France; [Anguel, Nadia] CHU Bicetre, AP HP, Med Intens Care Unit, Le Kremlin Bicetre, France; [Argaud, Laurent] Hop Edouard Herriot, Hosp Civils Lyon, Med Intens Care Unit, Lyon, France; [Asehnoune, Karim] CHU Nantes, Hotel Dieu, Surg Intens Care Unit, Nantes, France; [Asehnoune, Karim] Univ Nantes, Nantes, France; [Asfar, Pierre] Ctr Hosp Univ Angers, Med Intens Care & Hyperbar Oxygen Therapy Unit, Angers, France; [Asfar, Pierre] Univ Angers, UBL, Lab Biol Neurovasc & Mitochondriale Integree, CNRS,UMR 6214,INSERM,U1083, Angers, France; [Bellec, Frederic] Ctr Hosp Montauban, Med Surg Intens Care Unit, Montauban, France; [Botoc, Vlad] Ctr Hosp St Malo, Med Surg Intens Care Unit, St Malo, France; [Bretagnol, Anne] CHR Orleans, Med Intens Care Unit, Orleans, France; [Bui, Hoang-Nam] CHU Bordeaux, Hop Pellegrin, Med Intens Care Unit, Bordeaux, France; [Canet, Emmanuel] St Louis Univ Hosp, AP HP, Med Intens Care Unit, Paris, France; [Da Silva, Daniel] Ctr Hosp St Denis, Med Surg Intens Care Unit, St Denis, France; [Darmon, Michael] Univ Hosp, Med Surg Intens Care Unit, St Etienne, France; [Das, Vincent] Ctr Hosp Intercommunal Andre Gregoire, Med Surg Intens Care Unit, Montreuil, France; [Devaquet, Jerome] Hop Foch, Med Surg Intens Care Unit, Suresnes, France; [Djibre, Michel] Tenon Univ Hosp, AP HP, Med Surg Intens Care Unit, Paris, France; [Ganster, Frederique] Hop Emile Muller, Med Intens Care Unit, Mulhouse, France; [Garrouste-Orgeas, Maite] Paris Diderot Univ, INSERM, UMR 1137,Sorbonne Paris Cite, IAME Team 5,Decis Sci Infect Dis DeSCID,Contro, Paris, France; [Garrouste-Orgeas, Maite] Hop St Joseph, Med Surg Unit, Paris, France; [Garrouste-Orgeas, Maite] French & British Inst, Med Unit, Levallois Perret, France; [Garrouste-Orgeas, Maite] French & British Inst, Palliat Res Grp, Levallois Perret, France; [Garrouste-Orgeas, Maite] OUTCOMEREA Res Grp, Drancy, France; [Gaudry, Stephane] Hop Louis Mourier, AP HP, Med Surg Intens Care Unit, Colombes, France; [Gaudry, Stephane] Univ Paris Diderot, ECEVE, UMR 1123, Sorbonne Paris Cite, Paris, France; [Gontier, Olivier] Hop Chartres, Med Surg Intens Care Unit, Chartres, France; [Guerin, Claude] Hosp Civils Lyon, Grp Hosp Nord, Med Intens Care Unit, Lyon, France; [Guerin, Claude] Univ Lyon, IMRB, INSERM 955, Lyon, France; [Guidet, Bertrand] Hop St Antoine, AP HP, Med Intens Care Unit, Paris, France; [Guidet, Bertrand] UPMC Univ Paris 06, Sorbonne Univ, INSERM,Equipe Epidemiol Hosp Qualite & Org Soins, UMR S 1136,Inst Pierre Louis Epidemiol & Sante Pu, Paris, France; [Guitton, Christophe] Hop Mans, Med Surg Intens Care Unit, Le Mans, France; [Herbrecht, Jean-Etienne] Hop Univ Strasbourg, Hop Hautepierre, Med Intens Care Unit, Strasbourg, France; [Herbrecht, Jean-Etienne] Univ Strasbourg, FMTS, Fac Med, U1121, Strasbourg, France; [Lacherade, Jean-Claude] Ctr Hosp Dept Vendee, Med Intens Reanimat, La Roche Sur Yon, France; [Letocart, Philippe] Hop Jacques Puel, Med Surg Intens Care Unit, Rodez, France; [Martino, Frederic] CHU Pointe A Pitre, Med Surg Intens Care Unit, Pointe a Pitre, Guadeloupe, France; [Maxime, Virginie] Hop Raymond Poincare, AP HP, Med Surg Intens Care Unit, Garches, France; [Mercier, Emmanuelle] CHU Tours, Hop Bretonneau, Med Intens Reanimat, Tours, France; [Mira, Jean-Paul] Cochin Univ Hosp, AP HP, Med Intens Care Unit, Paris, France; [Nseir, Saad] CHU Lille, Med Intens Care Unit, Lille, France; [Nseir, Saad] Univ Lille, Sch Med, Lille, France; [Piton, Gael] CHRU Besancon, Med Intens Care Unit, Besancon, France; [Piton, Gael] Univ Franche Comte, EA3920, Besancon, France; [Quenot, Jean-Pierre] Francois Mitterrand Univ Hosp, Med Surg Intens Care Unit, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne, INSERM, UMR 866, Lipness Team, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne, LabExLipSTIC, Dijon, France; [Richecoeur, Jack] Hop Beauvais, Med Surg Intens Care Unit, Beauvais, France; [Rigaud, Jean-Philippe] Hop Dieppe, Med Surg Intens Care Unit, Dieppe, France; [Robert, Rene] CHU Poitiers, Med Intens Care Unit, Poitiers, France; [Robert, Rene] Univ Poitiers, INSERM, CIC1402, Poitiers, France; [Rolin, Nathalie] Ctr Hosp Melun, Med Surg Intens Care Unit, Melun, France; [Schwebel, Carole] CHU Albert Michallon Grenoble, Med Intens Care Unit, Grenoble, France; [Schwebel, Carole] Univ Grenoble Alpes, INSERM, U1039, Radiopharmaceut Bioclin, La Tronche, France; [Sirodot, Michel] Ctr Hosp Annecy Genevois, Med Surg Intens Care Unit, Metz Tessy, Pringy, France; [Tinturier, Francois] CHU Amiens Picardie, Surg Intens Care Unit, Amiens, France; [Thevenin, Didier] Ctr Hosp Docteur Schaffner, Med Surg Intens Care Unit, Lens, France; [Giraudeau, Bruno; Le Gouge, Amelie] INSERM, CIC 1415, Tours, France; [Giraudeau, Bruno; Le Gouge, Amelie] Univ Tours, Tours, France; [Giraudeau, Bruno; Le Gouge, Amelie] CHU Tours, Tours, France; [Giraudeau, Bruno] Univ Francois Rabelais Tours, PRES Ctr, Val de Loire Univ, Tours, France	Nantes Universite; CHU de Nantes; Nantes Universite; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Nantes Universite; CHU de Nantes; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; CHU Lyon; Nantes Universite; CHU de Nantes; Nantes Universite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Regional d'Orleans; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de St Etienne; Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier Le Mans; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHD Vendee; CHU Guadeloupe; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Universite de Franche-Comte; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Franche-Comte; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre Hospitalier Annecy Genevois; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours	Reignier, J (corresponding author), Ctr Hosp Univ Hotel Dieu, Serv Med Intens Reanimat, F-44093 Nantes 1, France.	jean.reignier@chu-nantes.fr	Lascarrou, Jean Baptiste/I-4079-2014; Giraudeau, Bruno/L-9003-2015; guerin, claude/H-5692-2014; Carmen, Team3/Y-7384-2019; Misset, Benoit/P-7817-2018	Lascarrou, Jean Baptiste/0000-0003-3706-078X; Giraudeau, Bruno/0000-0003-3031-8258; guerin, claude/0000-0003-4700-6672; Carmen, Team3/0000-0002-3614-0924; Garrouste-Orgeas, Maite/0000-0003-4250-1666; Lab, Carmen/0000-0002-5935-3236; Richard, Christian/0000-0002-4153-301X; gruson, didier/0000-0002-1199-5125; AIT HSSAIN, Ali/0000-0002-7764-5793; Parmentier-Decrucq, Erika/0000-0002-5836-5956; Favory, raphael/0000-0001-7772-2608; Coudroy, Remi/0000-0002-0036-1899; QUENOT, Jean-Pierre/0000-0003-2351-682X; Misset, Benoit/0000-0001-6466-0065; Helms, Julie/0000-0003-0895-6800	La Roche-sur-Yon Departmental Hospital; French Ministry of Health	La Roche-sur-Yon Departmental Hospital; French Ministry of Health	La Roche-sur-Yon Departmental Hospital and French Ministry of Health.	Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; Berger MM, 2005, CLIN NUTR, V24, P124, DOI 10.1016/j.clnu.2004.08.005; Binnekade JM, 2005, CRIT CARE, V9, pR218, DOI 10.1186/cc3504; Blaser AR, 2014, ACTA ANAESTH SCAND, V58, P914, DOI 10.1111/aas.12302; Blaser AR, 2017, INTENS CARE MED, V43, P380, DOI 10.1007/s00134-016-4665-0; Braga M, 2001, CRIT CARE MED, V29, P242, DOI 10.1097/00003246-200102000-00003; Brisard L, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-507; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Elke G, 2008, CRIT CARE MED, V36, P1762, DOI 10.1097/CCM.0b013e318174dcf0; Elke G, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1298-1; Gatt M, 2009, CRIT CARE MED, V37, P171, DOI 10.1097/CCM.0b013e318192fb44; GIANOTTI L, 1994, CRIT CARE MED, V22, P265, DOI 10.1097/00003246-199402000-00018; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; Harvey SE, 2014, NEW ENGL J MED, V371, P1673, DOI 10.1056/NEJMoa1409860; HEYLAND D, 1995, CRIT CARE MED, V23, P1055, DOI 10.1097/00003246-199506000-00010; Kang W, 2007, JPEN-PARENTER ENTER, V31, P246, DOI 10.1177/0148607107031003246; Khalid I, 2010, AM J CRIT CARE, V19, P261, DOI 10.4037/ajcc2010197; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Kudsk KA, 2002, AM J SURG, V183, P390, DOI 10.1016/S0002-9610(02)00821-8; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Mancl EE, 2013, JPEN-PARENTER ENTER, V37, P641, DOI 10.1177/0148607112470460; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Marik PE, 2004, BMJ-BRIT MED J, V328, P1407, DOI 10.1136/bmj.38118.593900.55; McClave SA, 1999, CRIT CARE MED, V27, P1252, DOI 10.1097/00003246-199907000-00003; McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI [10.1177/0148607115621863, 10.1097/CCM.0000000000001525]; McClave Stephen A, 2003, Nutr Clin Pract, V18, P279, DOI 10.1177/0115426503018004279; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; Oldenburg WA, 2004, ARCH INTERN MED, V164, P1054, DOI 10.1001/archinte.164.10.1054; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Preiser JC, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0737-8; Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rokyta R, 2003, PHYSIOL RES, V52, P31; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Thibault R, 2011, INTENS CARE MED, V37, P35, DOI 10.1007/s00134-010-2061-8; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431	41	250	278	12	101	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 13	2018	391	10116					133	143		10.1016/S0140-6736(17)32146-3	http://dx.doi.org/10.1016/S0140-6736(17)32146-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT0EG	29128300				2023-01-03	WOS:000422793400028
J	Bonaudo, M; Martorana, M; Dimonte, V; D'Alfonso, A; Fornero, G; Politano, G; Gianino, MM				Bonaudo, Marco; Martorana, Maria; Dimonte, Valerio; D'Alfonso, Alessandra; Fornero, Giulio; Politano, Gianfranco; Gianino, Maria Michela			Medication discrepancies across multiple care transitions: A retrospective longitudinal cohort study in Italy	PLOS ONE			English	Article							PATIENTS AFTER-DISCHARGE; PATIENT SAFETY; HOSPITAL DISCHARGE; ADVERSE EVENTS; RECONCILIATION; ADMISSION; INPATIENT; ERRORS; IMPLEMENTATION; INFORMATION	Purpose Medication discrepancies are defined as unexplained differences among regimens across different sites of care. The problem of medication discrepancies that occur during the entire care pathway from hospital admission to a local care setting discharge (namely all types of settings dedicated to formal care other than hospitals) has received little attention in the medical literature. The present study aims to (1) determine the prevalence of medication discrepancies that occur during the entire care pathway from hospital admission to local care setting discharge, (2) describe the discrepancy and medication type, and (3) identify potential risk factors for experiencing medication discrepancies in patient care transitions. Evidence from an integrated health care system, such as the Italian one, may explain results from other studies in different healthcare systems. Methods A retrospective longitudinal cohort study of patients admitted from July 2015 to July 2016 to the Giovanni Bosco Hospital serving Turin, Italy and its surrounding territory was performed. Discrepancies were recorded at the following four care transitions: T1: Hospital admission; T2: Hospital discharge; T3: Admission into local care settings; T4: Discharge from local care settings. All evaluations were based on documented regimens and were performed by a team (doctor, nurse and pharmacists). Results Of 366 included patients, 25.68% had at least one discrepancy. The most frequent type of discrepancy was from medication omission (N =74; 71.15%). Only discharge from a long-stay care setting (T4) was significantly associated with the onset of discrepancies (p = 0.045). When considering a lack of adequate documentation, not as missing data but as a discrepancy, 43.72% of patients had at least one discrepancy. Conclusions This study suggests that an integrated health care system, such as Italian system, may influence the prevalence of discrepancies, thus highlighting the need for structured multidisciplinary and, if possible, computerized medication reconciliation to prevent medication discrepancies and improve the quality of medical documentation.	[Bonaudo, Marco; Martorana, Maria; Dimonte, Valerio; Gianino, Maria Michela] Univ Torino, Dept Publ Hlth Sci & Pediat, Turin, Italy; [D'Alfonso, Alessandra] ASLTO2, Publ Hlth Author, Turin, Italy; [Fornero, Giulio] Teaching Hosp, AOU Citta Salute & Sci, Turin, Italy; [Politano, Gianfranco] Politecn Torino, Dept Control & Comp Engn, Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; Polytechnic University of Turin	Bonaudo, M (corresponding author), Univ Torino, Dept Publ Hlth Sci & Pediat, Turin, Italy.	marco.bonaudo@unito.it		Bonaudo, Marco/0000-0001-9278-8998; DIMONTE, Valerio/0000-0002-0003-3481				ASL TO2, 2015, ATT AZ ASL TO2; Bayoumi I, 2009, ANN PHARMACOTHER, V43, P1667, DOI 10.1345/aph.1M059; Belda-Rustarazo S, 2015, INT J CLIN PRACT, V69, P1268, DOI 10.1111/ijcp.12701; Blank LJ, 2012, GERIATR NURS, V33, P401, DOI 10.1016/j.gerinurse.2012.07.007; Bruce Bayley K, 2007, Ther Clin Risk Manag, V3, P695; Huynh C, 2016, INT J PHARM PRACT, V24, P196, DOI 10.1111/ijpp.12229; Climente-Marti M, 2010, ANN PHARMACOTHER, V44, P1747, DOI 10.1345/aph.1P184; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Cornish PL, 2005, ARCH INTERN MED, V165, P424, DOI 10.1001/archinte.165.4.424; Cua YM, 2008, ANN ACAD MED SINGAP, V37, P136; Delate T, 2008, PHARMACOTHERAPY, V28, P444, DOI 10.1592/phco.28.4.444; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gonzalez-Garcia L, J EVAL CLIN PRACT; Hellstrom Lina M, 2012, BMC Clin Pharmacol, V12, P9, DOI 10.1186/1472-6904-12-9; Kramer JS, 2007, AM J HEALTH-SYST PH, V64, P404, DOI 10.2146/ajhp060506; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kwan JL, 2013, ANN INTERN MED, V158, P397, DOI 10.7326/0003-4819-158-5-201303051-00006; Lau HS, 2000, BRIT J CLIN PHARMACO, V49, P597, DOI 10.1046/j.1365-2125.2000.00204.x; Laugaland K, 2012, WORK, V41, P2915, DOI 10.3233/WOR-2012-0544-2915; Maresca ER, 2012, BOLL SIFO, V58, P17; Ministero della Salute-D.G. Programmazione sanitaria, 2015, RIC TER FARM; Monfort AS, 2016, INT J CLIN PHARM-NET, V38, P838, DOI 10.1007/s11096-016-0292-7; Monte AA, 2015, J EMERG MED, V49, P78, DOI 10.1016/j.jemermed.2014.12.052; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Agud MM, 2016, INT J CLIN PHARM-NET, V38, P996, DOI 10.1007/s11096-016-0331-4; Mueller SK, 2012, ARCH INTERN MED, V172, P1057, DOI 10.1001/archinternmed.2012.2246; Nemeth Lynne S, 2010, J Patient Saf, V6, P238, DOI 10.1097/PTS.0b013e3181fe401f; Pherson EC, 2014, AM J HEALTH-SYST PH, V71, P1576, DOI 10.2146/ajhp130764; Pippins JR, 2008, J GEN INTERN MED, V23, P1414, DOI 10.1007/s11606-008-0687-9; R-Core-Team, 2016, LANG ENV STAT COMP; Redmond P, 2016, FAM PRACT, V33, P172, DOI 10.1093/fampra/cmw006; Smith Jodi D, 2004, Am J Geriatr Pharmacother, V2, P141, DOI 10.1016/S1543-5946(04)90019-0; Stewart AL, 2014, PHARM PRACT, V12; Tam VC, 2005, CAN MED ASSOC J, V173, P510, DOI 10.1503/cmaj.045311; Tjia J, 2009, J GEN INTERN MED, V24, P630, DOI 10.1007/s11606-009-0948-2; Unroe KT, 2010, AM J GERIATR PHARMAC, V8, P115, DOI 10.1016/j.amjopharm.2010.04.002; van Sluisveld N, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-170; Varadarajan RR, 2016, RES SOC ADM PHARM, V12; Whittington John, 2004, Qual Manag Health Care, V13, P53; Wong JD, 2008, ANN PHARMACOTHER, V42, P1373, DOI 10.1345/aph.1L190; World Health Organization (WHO), 2013, ACT PAT SAF HIGH 5S	42	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2018	13	1							e0191028	10.1371/journal.pone.0191028	http://dx.doi.org/10.1371/journal.pone.0191028			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FS7BY	29329310	Green Published, gold, Green Submitted			2023-01-03	WOS:000419954100032
J	Matson, V; Fessler, J; Bao, R; Chongsuwat, T; Zha, YY; Alegre, ML; Luke, JJ; Gajewski, TF				Matson, Vyara; Fessler, Jessica; Bao, Riyue; Chongsuwat, Tara; Zha, Yuanyuan; Alegre, Maria-Luisa; Luke, Jason J.; Gajewski, Thomas F.			The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients	SCIENCE			English	Article								Anti-PD-1-based immunotherapy has had a major impact on cancer treatment but has only benefited a subset of patients. Among the variables that could contribute to interpatient heterogeneity is differential composition of the patients' microbiome, which has been shown to affect antitumor immunity and immunotherapy efficacy in preclinical mouse models. We analyzed baseline stool samples from metastatic melanoma patients before immunotherapy treatment, through an integration of 16S ribosomal RNA gene sequencing, metagenomic shotgun sequencing, and quantitative polymerase chain reaction for selected bacteria. A significant association was observed between commensal microbial composition and clinical response. Bacterial species more abundant in responders included Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium. Reconstitution of germ-free mice with fecal material from responding patients could lead to improved tumor control, augmented T cell responses, and greater efficacy of anti-PD-L1 therapy. Our results suggest that the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients.	[Matson, Vyara; Fessler, Jessica; Gajewski, Thomas F.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Bao, Riyue] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA; [Bao, Riyue] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Chongsuwat, Tara; Zha, Yuanyuan; Alegre, Maria-Luisa; Luke, Jason J.; Gajewski, Thomas F.] Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Gajewski, TF (corresponding author), Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.; Gajewski, TF (corresponding author), Univ Chicago, Dept Med, Chicago, IL 60637 USA.	tgajewsk@medicine.bsd.uchicago.edu	Zha, Yuanyuan/I-2890-2015; Luke, Jason John/AAB-9724-2022	Zha, Yuanyuan/0000-0003-4323-0730; Luke, Jason John/0000-0002-1182-4908; Gajewski, Thomas/0000-0001-5727-3972	NIH grant [R35 CA210098]; Team Science Award from the Melanoma Research Alliance; American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy; University of Chicago Medicine Comprehensive Cancer Center; University of Chicago Cancer Biology Training program [T32 CA009594]; Center for Research Informatics of The University of Chicago Biological Science Division; Roche-Genentech; BMS; Merck; Incyte; Seattle Genetics; Ono; Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [R35CA210098, T32CA009594, F99CA234946] Funding Source: NIH RePORTER	NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Team Science Award from the Melanoma Research Alliance; American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy; University of Chicago Medicine Comprehensive Cancer Center; University of Chicago Cancer Biology Training program; Center for Research Informatics of The University of Chicago Biological Science Division; Roche-Genentech(Roche HoldingGenentech); BMS(Bristol-Myers Squibb); Merck(Merck & Company); Incyte; Seattle Genetics; Ono; Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank E. Chang, A. Sivan, C. Nagler, L. Huang, P. Bleda-Ferre, N. Hubert, Z. Early, and B. Theriault for helpful discussions and M. Jarsulic, B. Choy, N. Martinec, S. Owens, S. Greenwald, H. Morrison, and J. Polinski for technical assistance. This work was supported by NIH grant R35 CA210098, a Team Science Award from the Melanoma Research Alliance, the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy, funds from the University of Chicago Medicine Comprehensive Cancer Center, the University of Chicago Cancer Biology Training program (T32 CA009594), and The Center for Research Informatics of The University of Chicago Biological Science Division. The bioinformatics analysis was performed on Gardner High-Performance Computing clusters at Center for Research Informatics, Biological Sciences Division. Data reported in this study are tabulated in the main text and supplementary materials. The 16S and shotgun sequencing were performed at the Argonne National Laboratory and the University of Chicago-affiliated Marine Biological Laboratory, respectively; data files were deposited into The NCBI Sequence Read Archive (SRA) and are available under the accession no. SRP116709. Custom code and additional processed data used in this study are publicly available on GitHub at https://github.com/cribioinfo/sci2017_analysis. T.F.G. is an advisory board member for Roche-Genentech, Merck, Abbvie, Bayer, Aduro, and Fog Pharma. T.F.G. receives research support from Roche-Genentech, BMS, Merck, Incyte, Seattle Genetics, and Ono. T.F.G. is a shareholder/cofounder of Jounce Therapeutics. The University of Chicago holds a licensing arrangement with Evelo. T.F.G is an inventor on U.S. patent US20160354416 A1 submitted by the University of Chicago that covers the use the microbiota to improve cancer immunotherapy. J.J.L. is a consultant to and receives research funding from Bristol-Myers Squibb and Merck.	Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Corrales L, 2017, CELL RES, V27, P96, DOI 10.1038/cr.2016.149; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Gopalakrishnan V., 2017, SCIENCE; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ugurel S, 2008, CANCER IMMUNOL IMMUN, V57, P685, DOI 10.1007/s00262-007-0407-z; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329	17	1337	1412	28	327	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 5	2018	359	6371					104	+		10.1126/science.aao3290	http://dx.doi.org/10.1126/science.aao3290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR8KW	29302014	Green Accepted			2023-01-03	WOS:000419324700076
J	Serrano-Munoz, D; Gomez-Soriano, J; Bravo-Esteban, E; Vazquez-Farinas, M; Taylor, J; Avendano-Coy, J				Serrano-Munoz, Diego; Gomez-Soriano, Julio; Bravo-Esteban, Elisabeth; Vazquez-Farinas, Maria; Taylor, Julian; Avendano-Coy, Juan			Intensity matters: Therapist-dependent dose of spinal transcutaneous electrical nerve stimulation	PLOS ONE			English	Article							HEALTHY-HUMAN SUBJECTS; EXPERIMENTAL PAIN; H-REFLEX; PARAMETER MANIPULATION; HEMIPARETIC SUBJECTS; CORD-INJURY; TENS; SPASTICITY; THRESHOLDS; HUMANS	The intensity used during transcutaneous electrical nerve stimulation (TENS) in both, clinical practice and research studies, is often based on subjective commands such as strong but comfortable sensation. There is no consensus regarding the effectiveness dose of TENS. The objective was to determine the difference in the effect of spinal TENS on soleus H-reflex modulation when applied by two therapists instructed to apply the stimulation at a strong but comfortable intensity. Twenty healthy volunteers divided into two groups: Therapist 1 (n = 10) and Therapist 2 (n = 10). Both therapist applied spinal TENS and sham stimulation at the T1012 spinal level for 40min in random order to each subject, at an intensity designed to produce a strong but comfortable sensation. To avoid habituation, the intensity was adjusted every 2min. Soleus H-reflex was recorded before, during, and 10min after TENS by an observer blinded to the stimulus applied. Despite the instruction to apply TENS at a strong comfortable level, a significant difference in current density was identified: Therapist 1 (0.67mA/cm(2), SD 0.54) applied more than Therapist 2 (0.53mA/cm(2), SD 0.57; p<0.001) at the onset of the intervention. Maximal peak-to-peak H-reflex amplitude was inhibited significantly more 10min following TENS applied by Therapist 1 (-0.15mV, SD 0.16) compared with Therapist 2 (0.04mV, SD 0.16; p = 0.03). Furthermore, current density significantly correlated with the inhibitory effect on peak-to-peak Soleus H-reflex amplitude 10 min after stimulation (Rho = -0.38; p = 0.04). TENS intensity dosage by the therapist based on the subjective perception of the participants alone is unreliable and requires objective standardization. In addition, higher current density TENS produced greater inhibition of the Soleus H-reflex	[Serrano-Munoz, Diego; Taylor, Julian] Hosp Nacl Paraplej, Sensorimotor Funct Grp, Toledo, Spain; [Gomez-Soriano, Julio; Bravo-Esteban, Elisabeth; Avendano-Coy, Juan] Castilla Mancha Univ, Nursing & Physiotherapy Sch, Toledo Physiotherapy Res Grp GIFTO, Toledo, Spain; [Vazquez-Farinas, Maria] Hosp Nacl Paraplej, SESCAM, Toledo, Spain; [Taylor, Julian] NHS, Buckinghamshire Healthcare Trust, Natl Spinal Injuries Ctr, Stoke Mandeville Spinal Res, Aylesbury, Bucks, England; [Taylor, Julian] Univ Oxford, Harris Manchester Coll, Oxford, England	Hospital Nacional de Paraplejicos; Hospital Nacional de Paraplejicos; University of Oxford	Gomez-Soriano, J (corresponding author), Castilla Mancha Univ, Nursing & Physiotherapy Sch, Toledo Physiotherapy Res Grp GIFTO, Toledo, Spain.	julio.soriano@uclm.es	Gómez-Soriano, Julio/AAE-2990-2019; Serrano-Muñoz, Diego/AAD-2803-2019; Taylor, Julian/AAC-2802-2021; Avendaño Coy, Juan/Q-3631-2019	Gómez-Soriano, Julio/0000-0002-5542-4105; Serrano-Muñoz, Diego/0000-0002-7521-5087; Taylor, Julian/0000-0003-2553-2348; Avendaño Coy, Juan/0000-0002-8760-3490	Foundation Mutua Madrilena-Adeslas	Foundation Mutua Madrilena-Adeslas	Diego Serrano-Munoz was supported by Foundation Mutua Madrilena-Adeslas (2015).	Aarskog R, 2007, PHYSIOTHER RES INT, V12, P251, DOI 10.1002/pri.384; Avendano-Coy J, 2017, ARCH PHYS MED REHAB, V98, P888, DOI 10.1016/j.apmr.2016.11.020; Aydin G, 2005, AM J PHYS MED REHAB, V84, P584, DOI 10.1097/01.phm.0000171173.86312.69; Bjordal JM, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-51; Buonocore M, 2007, Eura Medicophys, V43, P155; Chen CC, 2010, J PAIN, V11, P53, DOI 10.1016/j.jpain.2009.05.008; Chesterton LS, 2003, PAIN, V106, P73, DOI 10.1016/S0304-3959(03)00292-6; Chesterton LS, 2002, PAIN, V99, P253, DOI 10.1016/S0304-3959(02)00118-5; Claydon LS, 2008, EUR J PAIN, V12, P696, DOI 10.1016/j.ejpain.2007.10.014; Claydon LS, 2013, CLIN J PAIN, V29, P533, DOI 10.1097/AJP.0b013e318262330f; Claydon LS, 2011, CLIN J PAIN, V27, P635, DOI 10.1097/AJP.0b013e31821962b4; Cramp FL, 2000, ARCH PHYS MED REHAB, V81, P324, DOI 10.1016/S0003-9993(00)90079-0; CRONE C, 1990, EXP BRAIN RES, V81, P35; Dean J, 2006, CLIN PHYSIOL FUNCT I, V26, P314, DOI 10.1111/j.1475-097X.2006.00689.x; DEYO RA, 1990, AM J PHYS MED REHAB, V69, P6, DOI 10.1097/00002060-199002000-00003; Ellrich J, 2005, NEUROMODULATION, V8, P225, DOI 10.1111/j.1525-1403.2005.00029.x; Fernandez-Tenorio E, 2016, NEUROLOGIA; Gomez-Soriano J, 2012, REV NEUROLOGIA, V55, P217, DOI 10.33588/rn.5504.2012229; GOULET C, 1994, ARCH PHYS MED REHAB, V75, P1132, DOI 10.1016/0003-9993(94)90090-6; Hardy SG, 2002, PHYS THER, V82, P354, DOI 10.1093/ptj/82.4.354; Hofstoetter US, 2014, J SPINAL CORD MED, V37, P202, DOI 10.1179/2045772313Y.0000000149; HUICHAN CWY, 1993, CAN J NEUROL SCI, V20, P97, DOI 10.1017/S0317167100047636; Joodaki M R, 2001, Electromyogr Clin Neurophysiol, V41, P23; Kim EJ, 2003, CLIN NEUROPHYSIOL, V114, P1189, DOI 10.1016/S1388-2457(03)00106-8; Lazarou L, 2009, CLIN J PAIN, V25, P773, DOI 10.1097/AJP.0b013e3181a7ece3; LEVIN MF, 1992, ELECTROEN CLIN NEURO, V85, P131, DOI 10.1016/0168-5597(92)90079-Q; LITTLE JW, 1985, ARCH PHYS MED REHAB, V66, P19; Martins FL, 2012, BRAZ J PHYS THER, V16, P337, DOI 10.1590/S1413-35552012005000032; Moran F, 2011, J PAIN, V12, P929, DOI 10.1016/j.jpain.2011.02.352; Ng SSM, 2007, STROKE, V38, P2953, DOI 10.1161/STROKEAHA.107.490318; Pantaleao MA, 2011, J PAIN, V12, P581, DOI 10.1016/j.jpain.2010.11.001; PETRIE J, 1985, CLIN EXP RHEUMATOL, V3, P151; Pinheiro GT, 2008, FISIOTER PESQUI, V15, P118; Ristic D, 2008, EUR J PAIN, V12, P480, DOI 10.1016/j.ejpain.2007.07.013; Rutjes AWS, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002823.pub2; Schunke M, 2011, PROMETHEUS TEXTO ATL, V1, P66; Simorgh L, 2008, Electromyogr Clin Neurophysiol, V48, P301; Turi Z, 2014, BRAIN STIMUL, V7, P460, DOI 10.1016/j.brs.2014.01.059; Vassal F, 2013, CLIN NEUROPHYSIOL, V124, P1861, DOI 10.1016/j.clinph.2013.04.001; Walsh DM, 2000, CLIN PHYSIOL, V20, P191; Watson T, 2020, ELECTROPHYSICAL AGEN	41	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2017	12	12							e0189734	10.1371/journal.pone.0189734	http://dx.doi.org/10.1371/journal.pone.0189734			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ2KG	29244850	Green Submitted, gold, Green Published			2023-01-03	WOS:000418184700056
J	Okamoto, C; Hayakawa, Y; Aoyama, T; Komaki, H; Minatoguchi, S; Iwasa, M; Yamada, Y; Kanamori, H; Kawasaki, M; Nishigaki, K; Mikami, A; Minatoguchi, S				Okamoto, Chihiro; Hayakawa, Yuka; Aoyama, Takuma; Komaki, Hisaaki; Minatoguchi, Shingo; Iwasa, Masamitsu; Yamada, Yoshihisa; Kanamori, Hiromitsu; Kawasaki, Masanori; Nishigaki, Kazuhiko; Mikami, Atsushi; Minatoguchi, Shinya			Excessively low salt diet damages the heart through activation of cardiac (pro) renin receptor, renin-angiotensin-aldosterone, and sympatho-adrenal systems in spontaneously hypertensive rats	PLOS ONE			English	Article							BLOOD-PRESSURE; URINARY SODIUM; EXCRETION; RISK	Objective A high salt intake causes hypertension and leads to cardiovascular disease. Therefore, a low salt diet is now recommended to prevent hypertension and cardiovascular disease. However, it is still unknown whether an excessively low salt diet is beneficial or harmful for the heart. Methods Wistar Kyoto rats (WKYs) and spontaneously hypertensive rats (SHRs) received normal salt chow (0.9% salt diet) and excessively low salt chow (0.01% salt diet referred to as saltless diet) for 8 weeks from 8 to 16 weeks of age. The effects of the excessively low salt diet on the cardiac (pro) renin receptor, renin-angiotensin-aldosterone, and sympatho-adrenal systems were investigated. Results The excessively low salt diet did not affect the systolic blood pressure but significantly increased the heart rate both in WKYs and SHRs. The excessively low salt diet significantly elevated plasma renin activity, plasma angiotensin I, II and aldosterone concentrations, and plasma noradrenaline and adrenaline concentrations both in WKYs and SHRs. Cardiac expressions of renin, prorenin, (P)RR, angiotensinogen, and angiotensin II AT1 receptor and phosphorylated (p)-ERK1/2, p-HSP27, p-38MAPK, and TGF-beta 1 were significantly enhanced by the excessively low salt diet in both WKYs and SHRs. The excessively low salt diet accelerated cardiac interstitial and perivascular fibrosis and increased the cardiomyocyte size and interventricular septum thickness in WKYs and SHRs but the extent was greater in SHRs. Conclusion An excessively low salt diet damages the heart through activation of plasma renin-angiotensin-aldosterone and sympatho-adrenal systems and activation of cardiac (P) RR and angiotensin II AT1 receptor and their downstream signals both in WKYs and SHRs.	[Okamoto, Chihiro; Hayakawa, Yuka; Aoyama, Takuma; Komaki, Hisaaki; Minatoguchi, Shingo; Iwasa, Masamitsu; Yamada, Yoshihisa; Kanamori, Hiromitsu; Kawasaki, Masanori; Nishigaki, Kazuhiko; Mikami, Atsushi; Minatoguchi, Shinya] Gifu Univ, Grad Sch Med, Dept Cardiol, Gifu, Japan	Gifu University	Minatoguchi, S (corresponding author), Gifu Univ, Grad Sch Med, Dept Cardiol, Gifu, Japan.	minatos@gifu-u.ac.jp			Gifu University Graduate School of Medicine; Salt Science Research Foundation; Suzuken Memorial Foundation	Gifu University Graduate School of Medicine; Salt Science Research Foundation; Suzuken Memorial Foundation	This work was supported by a grant from the Gifu University Graduate School of Medicine (to Shinya. Minatoguchi) and from Salt Science Research Foundation (to Shinya. Minatoguchi) and from Suzuken Memorial Foundation (to Y Yamada, C Okamoto and Shinya Minatoguchi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; Carillo BA, 2007, REGUL PEPTIDES, V140, P5, DOI 10.1016/j.regpep.2006.11.007; COHN JN, 1995, CLIN CARDIOL, V18, P4; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; Cook NR, 2014, CIRCULATION, V129, P981, DOI 10.1161/CIRCULATIONAHA.113.006032; Crowley SD, 2006, P NATL ACAD SCI USA, V103, P17985, DOI 10.1073/pnas.0605545103; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; ELLIOTT P, 1988, BRIT MED J, V297, P319; Freel EM, 2004, J AM SOC NEPHROL, V15, P1993, DOI 10.1097/01.ASN.0000132473.50966.14; Morales MG, 2012, INT J BIOCHEM CELL B, V44, P1993, DOI 10.1016/j.biocel.2012.07.028; Hayakawa Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120453; Hodge G, 2002, ACTA PHYSIOL SCAND, V174, P209, DOI 10.1046/j.1365-201x.2002.00937.x; Huang Y, 2007, KIDNEY INT, V72, P45052; Ichihara A, 2006, HYPERTENSION, V47, P894, DOI 10.1161/01.HYP.0000215838.48170.0b; LEENEN FHH, 1989, J HYPERTENS, V7, P57, DOI 10.1097/00004872-198901000-00009; Manger WM., 1982, ADV CARDIOL, V30, P17; Muhlestein JB, 2010, AM J CARDIOL, V106, P764, DOI 10.1016/j.amjcard.2010.04.040; O'Donnell MJ, 2011, JAMA-J AM MED ASSOC, V306, P2229, DOI 10.1001/jama.2011.1729; REID JL, 1986, AM J CARDIOL, V57, pE6, DOI 10.1016/0002-9149(86)90716-2; Sakoda M, 2007, HYPERTENS RES, V30, P1139, DOI 10.1291/hypres.30.1139; Saris JJ, 2006, HYPERTENSION, V48, P564, DOI 10.1161/01.HYP.0000240064.19301.1b; Schroten NF, 2012, HEART FAIL REV, V17, P191, DOI 10.1007/s10741-011-9262-2; Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567; WARREN S E, 1980, Clinical Cardiology, V3, P348	24	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2017	12	12							e0189099	10.1371/journal.pone.0189099	http://dx.doi.org/10.1371/journal.pone.0189099			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP2SV	29220406	Green Published, gold, Green Submitted			2023-01-03	WOS:000417469900033
J	Chaisri, U; Tungtrongchitr, A; Indrawattana, N; Meechan, P; Phurttikul, W; Tasaniyananda, N; Saelim, N; Chaicumpa, W; Sookrung, N				Chaisri, Urai; Tungtrongchitr, Anchalee; Indrawattana, Nitaya; Meechan, Panisara; Phurttikul, Watchara; Tasaniyananda, Natt; Saelim, Nawannaporn; Chaicumpa, Wanpen; Sookrung, Nitat			Immunotherapeutic efficacy of liposome-encapsulated refined allergen vaccines against Dermatophagoides pteronyssinus allergy	PLOS ONE			English	Article							HOUSE-DUST MITE; REGULATORY B-CELLS; DENDRITIC CELLS; AIRWAY INFLAMMATION; IMMUNOGLOBULIN-E; T-CELLS; ASTHMATIC-CHILDREN; TERTIARY STRUCTURE; PROTEASE ALLERGEN; MOLECULAR-BASIS	Allergen specific immunotherapy (AIT) can modulate the allergic response causing a long-term symptom subsidence/abolishment which leads to reduced drug use and prevention of new sensitization. AIT of house dust mite allergy (HDM) using the mite crude extract (CE) as the therapeutic agent is not only less effective than the AIT for many other allergens, but also frequently causes adverse effects during the treatment course. In this study, mouse model of Dermatophagoides pteronyssinus (Dp) allergy was invented for testing therapeutic efficacies of intranasally administered liposome (L) encapsulated vaccines made of single Dp major allergens (L-Der p 1, L-Der p 2), combined allergens (L-Der p 1 and Der p 2), and crude Dp extract (L-CE). The allergen sparing intranasal route was chosen as it is known that the effective cells induced at the nasal-associated lymphoid tissue can exert their activities at the lower respiratory tissue due to the common mucosal traffic. Liposome was chosen as the vaccine delivery vehicle and adjuvant as the micelles could reduce toxicity of the entrapped cargo. The Dp-CE allergic mice received eight doses of individual vaccines/placebo on alternate days. All vaccine formulations caused reduction of the Th2 response of the Dp allergic mice. However, only the vaccines made of single refined allergens induced expressions of immunosuppressive cytokines (TGF-beta, IL-35 and/or IL-10) which are the imperative signatures of successful AIT. The data emphasize the superior therapeutic efficacy of single refined major allergen vaccines than the crude allergenic extract vaccine.	[Chaisri, Urai] Fac Trop Med, Dept Trop Pathol, Bangkok, Thailand; [Tungtrongchitr, Anchalee; Saelim, Nawannaporn; Chaicumpa, Wanpen] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Parasitol, Bangkok, Thailand; [Tungtrongchitr, Anchalee; Meechan, Panisara; Phurttikul, Watchara; Tasaniyananda, Natt; Saelim, Nawannaporn; Chaicumpa, Wanpen; Sookrung, Nitat] Mahidol Univ, Siriraj Hosp, Fac Med, Ctr Res Excellence Therapeut Prot & Antibody Engn, Bangkok, Thailand; [Indrawattana, Nitaya] Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand; [Sookrung, Nitat] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Res & Dev, Bangkok, Thailand	Mahidol University; Mahidol University; Mahidol University	Sookrung, N (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Ctr Res Excellence Therapeut Prot & Antibody Engn, Bangkok, Thailand.; Sookrung, N (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Dept Res & Dev, Bangkok, Thailand.	nitat.soo@mahidol.ac.th			NSTDA Chair Professor Grant - Crown Property Bureau of Thailand [P-1450624]; Thailand Research Fund [TRF RSA 5780025]; Faculty of Medicine Siriraj Hospital, Mahidol University [TRF RSA 5780025]	NSTDA Chair Professor Grant - Crown Property Bureau of Thailand; Thailand Research Fund(Thailand Research Fund (TRF)); Faculty of Medicine Siriraj Hospital, Mahidol University	The work was supported by the NSTDA Chair Professor Grant (P-1450624) funded by the Crown Property Bureau of Thailand to WC. NSR is supported by the TRF RSA 5780025 grant of the Thailand Research Fund and Faculty of Medicine Siriraj Hospital, Mahidol University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0063-2; ALVING CR, 1994, AIDS RES HUM RETROV, V10, pS91; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Batard T, 2006, INT ARCH ALLERGY IMM, V140, P295, DOI 10.1159/000093707; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bukantz Samuel C, 2008, Clin Allergy Immunol, V21, P455; Bussmann C, 2007, CLIN EXP ALLERGY, V37, P1277, DOI 10.1111/j.1365-2222.2007.02783.x; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chauhan AK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00215; Chen KW, 2008, MOL IMMUNOL, V45, P2486, DOI 10.1016/j.molimm.2008.01.006; Chen KW, 2012, J ALLERGY CLIN IMMUN, V130, P435, DOI 10.1016/j.jaci.2012.05.035; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Foged C, 2004, VACCINE, V22, P1903, DOI 10.1016/j.vaccine.2003.11.008; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; GONDAL JA, 1993, EUR J CANCER, V29A, P1536, DOI 10.1016/0959-8049(93)90290-V; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Gutowska-Owsiak D, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0014-8; Hasan AA, 2009, IMMUNOBIOLOGY, V214, P2, DOI 10.1016/j.imbio.2008.04.006; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Ichikawa S, 2005, J BIOCHEM, V137, P255, DOI 10.1093/jb/mvi039; Ichikawa S, 2009, GENES CELLS, V14, P1055, DOI 10.1111/j.1365-2443.2009.01334.x; Johannessen BR, 2005, FEBS LETT, V579, P1208, DOI 10.1016/j.febslet.2004.11.115; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; King C, 1998, J IMMUNOL, V161, P3645; Korematsu S, 2000, J IMMUNOL, V165, P2895, DOI 10.4049/jimmunol.165.5.2895; Le Texier L, 2011, AM J TRANSPLANT, V11, P429, DOI 10.1111/j.1600-6143.2010.03336.x; Li XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033628; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; Lu YP, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8415094; Ludewig B, 2000, VACCINE, V19, P23, DOI 10.1016/S0264-410X(00)00163-8; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Matsumoto M, 2014, IMMUNITY, V41, P1040, DOI 10.1016/j.immuni.2014.10.016; McGhee JR, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001397; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Meechan P, 2013, INT ARCH ALLERGY IMM, V161, P351, DOI 10.1159/000348314; Moingeon P, 2011, IMMUNOL ALLERGY CLIN, V31, P407, DOI 10.1016/j.iac.2011.03.001; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609; Nakazawa T, 2005, FEBS LETT, V579, P1988, DOI 10.1016/j.febslet.2005.01.088; Natarajan P, 2014, METHODS MOL BIOL, V1190, P207, DOI 10.1007/978-1-4939-1161-5_15; Neveu WA, 2009, J IMMUNOL, V183, P1732, DOI 10.4049/jimmunol.0802923; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Parekh VV, 2003, J IMMUNOL, V170, P5897, DOI 10.4049/jimmunol.170.12.5897; Passalacqua G, 2011, CLIN EXP ALLERGY, V41, P1247, DOI 10.1111/j.1365-2222.2010.03688.x; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Piyadasa H, 2016, BIOL OPEN, V5, P112, DOI 10.1242/bio.014464; PLATTSMILLS TAE, 1995, ALLERGY, V50, P5, DOI 10.1111/j.1398-9995.1995.tb02729.x; RAO M, 1995, INFECT IMMUN, V63, P2396, DOI 10.1128/IAI.63.7.2396-2402.1995; Ray A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010012; Ray A, 2015, INT IMMUNOL, V27, P531, DOI 10.1093/intimm/dxv033; Rincon-Arevalo H, 2016, INT REV IMMUNOL, V35, P156, DOI 10.3109/08830185.2015.1015719; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Schaut RG, 2016, J IMMUNOL, V196, P4100, DOI 10.4049/jimmunol.1502678; Schmidt A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00051; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Senna G, 2011, CURR OPIN ALLERGY CL, V11, P375, DOI 10.1097/ACI.0b013e328348a7cd; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Singh B, 2013, INDIAN J MED RES, V138, P591; Sookrung N, 2003, ASIAN PAC J ALLERGY, V21, P1; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; Sun CM, 2005, IMMUNITY, V22, P467, DOI 10.1016/j.immuni.2005.02.008; Takahashi Toshiya, 2000, Allergology International, V49, P55, DOI 10.1046/j.1440-1592.2000.00159.x; Takai T, 2000, EUR J BIOCHEM, V267, P6650, DOI 10.1046/j.1432-1327.2000.01760.x; Takai T, 1999, MOL IMMUNOL, V36, P1055, DOI 10.1016/S0161-5890(99)00098-X; Taube C, 2003, J IMMUNOL, V170, P4301, DOI 10.4049/jimmunol.170.8.4301; Thomas WR, 2015, ALLERGOL INT, V64, P304, DOI 10.1016/j.alit.2015.05.004; Thomas WR, 2012, HUM VACC IMMUNOTHER, V8, P1469, DOI 10.4161/hv.20812; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Tian J, 2001, J IMMUNOL, V167, P1081, DOI 10.4049/jimmunol.167.2.1081; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Williams Jesse W, 2012, J Allergy (Cairo), V2012, P236075, DOI 10.1155/2012/236075; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Zhao J, 2013, MUCOSAL IMMUNOL, V6, P335, DOI 10.1038/mi.2012.76	95	10	10	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2017	12	11							e0188627	10.1371/journal.pone.0188627	http://dx.doi.org/10.1371/journal.pone.0188627			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN9ZL	29182623	Green Submitted, Green Published, gold			2023-01-03	WOS:000416402000044
J	Wick, W; Gorlia, T; Bendszus, M; Taphoorn, M; Sahm, F; Harting, I; Brandes, AA; Taal, W; Domont, J; Idbaih, A; Campone, M; Clement, PM; Stupp, R; Fabbro, M; Le Rhun, E; Dubois, F; Weller, M; von Deimling, A; Golfinopoulos, V; Bromberg, JC; Platten, M; Klein, M; van den Bent, MJ				Wick, Wolfgang; Gorlia, Thierry; Bendszus, Martin; Taphoorn, Martin; Sahm, Felix; Harting, Inga; Brandes, Alba A.; Taal, Walter; Domont, Julien; Idbaih, Ahmed; Campone, Mario; Clement, Paul M.; Stupp, Roger; Fabbro, Michel; Le Rhun, Emilie; Dubois, Francois; Weller, Michael; von Deimling, Andreas; Golfinopoulos, Vassilis; Bromberg, Jacoline C.; Platten, Michael; Klein, Martin; van den Bent, Martin J.			Lomustine and Bevacizumab in Progressive Glioblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; SINGLE-AGENT BEVACIZUMAB; RESPONSE ASSESSMENT; PROGNOSTIC-FACTORS; PLUS IRINOTECAN; CLINICAL-TRIALS; TEMOZOLOMIDE; RADIOTHERAPY; PHASE-2; METHYLATION	BACKGROUND Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. METHODS We randomly assigned patients with progression after chemoradiation in a 2: 1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients). The methylation status of the promoter of O-6-methylguanine-DNA methyltransferase (MGMT) was assessed. Health-related quality of life and neurocognitive function were evaluated at baseline and every 12 weeks. The primary end point of the trial was overall survival. RESULTS A total of 437 patients underwent randomization. The median number of 6-week treatment cycles was three in the combination group and one in the monotherapy group. With 329 overall survival events (75.3%), the combination therapy did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence interval [CI], 8.1 to 10.1) in the combination group and 8.6 months (95% CI, 7.6 to 10.4) in the monotherapy group (hazard ratio for death, 0.95; 95% CI, 0.74 to 1.21; P = 0.65). Locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group: 4.2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61; P<0.001). Grade 3 to 5 adverse events occurred in 63.6% of the patients in the combination group and 38.1% of the patients in the monotherapy group. The addition of bevacizumab to lomustine affected neither health-related quality of life nor neurocognitive function. The MGMT status was prognostic. CONCLUSIONS Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma.	[Wick, Wolfgang; Bendszus, Martin; Sahm, Felix; Harting, Inga; von Deimling, Andreas; Platten, Michael] Univ Med Ctr, Heidelberg, Germany; [Gorlia, Thierry; Golfinopoulos, Vassilis] European Org Res Treatment Canc, Brussels, Belgium; [Clement, Paul M.] Katholieke Univ Leuven, Leuven Canc Inst, Leuven, Belgium; [Taphoorn, Martin] Haaglanden Med Ctr, The Hague, Netherlands; [Taal, Walter; Bromberg, Jacoline C.; van den Bent, Martin J.] Erasmus MC Canc Inst, Rotterdam, Netherlands; [Klein, Martin] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Brandes, Alba A.] IRCCS Ist Sci Neurol, Azienda Unita Sanitaria Locale Bologna, Med Oncol Dept, Bologna, Italy; [Domont, Julien] Inst Gustave Roussy, Villejuif, France; [Idbaih, Ahmed] Univ Pierre & Marie Curie 06, Hop Univ Pitie Salpetriere Charles Foix,UMR S1127, AP HP,Unite Mixte Rech UMR 7225,Sorbonne Univ, Serv Neurol 2 Mazarin,INSERM,Unite 1127,CNRS, Paris, France; [Idbaih, Ahmed] Inst Cerveau & Moelle Epiniere, Paris, France; [Campone, Mario] Inst Cancerol Ouest, Ctr Rene Gauducheau, St Herblain, France; [Fabbro, Michel] Inst Reg Canc Montpellier, Montpellier, France; [Le Rhun, Emilie; Dubois, Francois] CHRU Lille, Lille, France; [Stupp, Roger; Weller, Michael] Univ Hosp Zurich, Dept Oncol, Zurich, Switzerland; [Stupp, Roger; Weller, Michael] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland; [Stupp, Roger; Weller, Michael] Univ Zurich, Zurich, Switzerland	Ruprecht Karls University Heidelberg; European Organisation for Research & Treatment of Cancer; KU Leuven; Haaglanden Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Vrije Universiteit Amsterdam; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Lille - ISITE; CHU Lille; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich	Wick, W (corresponding author), Heidelberg Univ, Neurol Clin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.; Wick, W (corresponding author), Heidelberg Univ, Natl Ctr Tumor Dis, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.; Wick, W (corresponding author), German Canc Res Ctr, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	wolfgang.wick@med.uni-heidelberg.de	Clement, Paul/HGC-8376-2022; Stupp, Roger/L-3303-2019; Sahm, Felix/GQY-8202-2022; Wick, Wolfgang/AAA-2545-2020; Platten, Michael/F-2902-2013; von Deimling, Andreas/F-7774-2013; Klein, Martin/C-4192-2012; Idbaih, Ahmed/N-8746-2017	Sahm, Felix/0000-0001-5441-1962; Wick, Wolfgang/0000-0002-6171-634X; Platten, Michael/0000-0002-4746-887X; von Deimling, Andreas/0000-0002-5863-540X; Klein, Martin/0000-0003-4160-5746; Gkolfinopoulos, Vasileios/0000-0002-8667-9477; Weller, Michael/0000-0002-1748-174X; van den Bent, Martin/0000-0001-5710-5127; Idbaih, Ahmed/0000-0001-5290-1204; Taal, Walter/0000-0002-5530-7259; Klein, Martin/0000-0001-5553-7911	F. Hoffmann-La Roche; EORTC Cancer Research Fund; Eudra-CT [2010-023218-30]	F. Hoffmann-La Roche(Hoffmann-La Roche); EORTC Cancer Research Fund; Eudra-CT	Funded by an unrestricted educational grant from F. Hoffmann-La Roche and by the EORTC Cancer Research Fund; EORTC 26101 ClinicalTrials.gov number, NCT01290939; Eudra-CT number, 2010-023218-30.	Bady P, 2012, ACTA NEUROPATHOL, V124, P547, DOI 10.1007/s00401-012-1016-2; Benton A.L., 1989, MULTILINGUAL APHASIA, V3rd ed.; Brandes AA, 2016, NEURO-ONCOLOGY, V18, P1304, DOI 10.1093/neuonc/now035; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Dirven L, 2015, EUR J CANCER, V51, P1321, DOI 10.1016/j.ejca.2015.03.025; Efficace F, 2003, J CLIN ONCOL, V21, P3502, DOI 10.1200/JCO.2003.12.121; Ellingson BM, 2015, NEURO-ONCOLOGY, V17, P1188, DOI 10.1093/neuonc/nov095; Fayers PM, 1997, EUR J CANCER, V33, P20, DOI 10.1016/S0959-8049(96)00412-1; FREEDMAN LS, 1976, BIOMETRICS, V32, P691, DOI 10.2307/2529759; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Herrlinger U, 2016, J CLIN ONCOL, V34, P1611, DOI 10.1200/JCO.2015.63.4691; Kickingereder P, 2016, CLIN CANCER RES, V22, P5765, DOI 10.1158/1078-0432.CCR-16-0702; Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Radbruch A, 2012, NEURO-ONCOLOGY, V14, P222, DOI 10.1093/neuonc/nor200; Sandmann T, 2015, J CLIN ONCOL, V33, P2735, DOI 10.1200/JCO.2015.61.5005; Schwarzenberg J, 2014, CLIN CANCER RES, V20, P3550, DOI 10.1158/1078-0432.CCR-13-1440; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Taal W, 2014, LANCET ONCOL, V15, P943, DOI 10.1016/S1470-2045(14)70314-6; Taphoorn MJB, 2010, EUR J CANCER, V46, P1033, DOI 10.1016/j.ejca.2010.01.012; Wen PY, 2010, J CLIN ONCOL, V28, P1963, DOI 10.1200/JCO.2009.26.3541; Wick W, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.2019; Wick W, 2014, NAT REV NEUROL, V10, P372, DOI 10.1038/nrneurol.2014.100; Wiestler B, 2014, NEURO-ONCOLOGY, V16, P1630, DOI 10.1093/neuonc/nou138	27	421	431	3	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2017	377	20					1954	1963		10.1056/NEJMoa1707358	http://dx.doi.org/10.1056/NEJMoa1707358			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM7CU	29141164	Green Published, Bronze			2023-01-03	WOS:000415228800008
J	Shiferaw, S; Spigt, M; Seme, A; Amogne, A; Skrovseth, S; Desta, S; Radloff, S; Tsui, A; GeertJan, D				Shiferaw, Solomon; Spigt, Mark; Seme, Assefa; Amogne, Ayanaw; Skrovseth, Stein; Desta, Selamawit; Radloff, Scott; Tsui, Amy; GeertJan, Dinant			Does proximity of women to facilities with better choice of contraceptives affect their contraceptive utilization in rural Ethiopia?	PLOS ONE			English	Article							SERVICES; QUALITY; IMPACT; CARE	Background There is limited evidence of the linkage between contraceptive use, the range of methods available and level of contraceptive stocks at health facilities and distance to facility in developing countries. The present analysis aims at examining the influence of contraceptive method availability and distance to the nearby facilities on modern contraceptive utilization among married women in rural areas in Ethiopia using geo-referenced data. Methods We used data from the first round of surveys of the Performance Monitoring & Accountability 2020 project in Ethiopia (PMA2020/Ethiopia-2014). The survey was conducted in a sample of 200 enumeration areas (EAs) where for each EA, 35 households and up to 3 public or private health service delivery points (SDPs) were selected. The main outcome variable was individual use of a contraceptive method for married women in rural Ethiopia. Correlates of interest include distance to nearby health facilities, range of contraceptives available in facilities, household wealth index, and the woman's educational status, age, and parity and whether she recently visited a health facility. This analysis primarily focuses on stock provision at public SDPs. Results Overall complete information was collected from 1763 married rural women ages 15-49 years and 198 SDPs in rural areas (97.1% public). Most rural women (93.9%) live within 5 kilometers of their nearest health post while a much lower proportion (52.2%) live within the same distance to the nearest health centers and hospital (0.8%), respectively. The main sources of modern contraceptive methods for married rural women were health posts (48.8%) and health centers (39.0%). The mean number of the types of contraceptive methods offered by hospitals, health centers and health posts was 6.2, 5.4 and 3.7 respectively. Modern contraceptive use (mCPR) among rural married women was 27.3% (95% CI: 25.3, 29.5). The percentage of rural married women who use modern contraceptives decreased as distance from the nearest SDP increased; 41.2%, 27.5%, 22.0%, and 22.6% of women living less than 2 kilometers, 2 to 3.9 kilometers, 4 to 5.9 kilometers and 6 or more kilometers, respectively (p-value<0.01). Additionally, women who live close to facilities that offer a wider range of contraceptive methods were significantly more likely to use modern contraceptives. The mCPR ranged from 42.3% among women who live within 2 kilometers of facilities offering 3 or more methods to 22.5% among women living more than 6 kilometers away from the nearest facility with the same number (3 or more methods) available after adjusting for observed covariates. Conclusions Although the majority of the Ethiopian population lives within a relatively close distance to lower level facilities (health posts), the number and range of methods available (method choice) and proximity are independently associated with contraceptive utilization. By demonstrating the extent to which objective measures of distance (of relatively small magnitude) explain variation in contraceptive use among rural women, the study fills an important planning gap for family planning programs operating in resource limited settings.	[Shiferaw, Solomon; Seme, Assefa] Addis Ababa Univ, Sch Publ Hlth, Dept Reprod Hlth & Hlth Serv Management, Coll Hlth Sci, Addis Ababa, Ethiopia; [Spigt, Mark] Maastricht Univ Netherlands, Dept Family Med, Fac Hlth Med & Life Sci, Maastricht, Netherlands; [Amogne, Ayanaw] Mela Res Plc, Addis Ababa, Ethiopia; [Skrovseth, Stein; GeertJan, Dinant] UiT Arctic Univ Norway, Dept Math & Stat, Tromso, Norway; [Skrovseth, Stein; GeertJan, Dinant] Univ Hosp North Norway, Norwegian Ctr Hlth Res E, Tromso, Norway; [Desta, Selamawit; Radloff, Scott; Tsui, Amy] Johns Hopkins Univ, Bill & Melinda Gates Inst Populat & Reprod Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Addis Ababa University; Maastricht University; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway; Bill & Melinda Gates Foundation; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Shiferaw, S (corresponding author), Addis Ababa Univ, Sch Publ Hlth, Dept Reprod Hlth & Hlth Serv Management, Coll Hlth Sci, Addis Ababa, Ethiopia.	solomonshiferaw@gmail.com	Dangal, Ganesh/O-1989-2017	Dangal, Ganesh/0000-0002-5834-5525	Bill and Melinda Gates Foundation through Bill and Melinda Gates Institute at the Bloomberg School of Public Health, Johns Hopkins University	Bill and Melinda Gates Foundation through Bill and Melinda Gates Institute at the Bloomberg School of Public Health, Johns Hopkins University	The project was made possible by generous support from the Bill and Melinda Gates Foundation through the Bill and Melinda Gates Institute at the Bloomberg School of Public Health, Johns Hopkins University. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ayanaw Amogne is affiliated to Mela Research Plc. Mela Research did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of author salaries.; The authors would like to thank survey respondents and the field staff, including the regional coordinators, field supervisors, resident enumerators, and other personnel of Addis AbabaUniversity for their dedicated effort. The project was made possible by generous support from the Bill and Melinda Gates Foundation through the Bill and Melinda Gates Institute for Population and Reproductive Health at the Bloomberg School of Public Health, Johns Hopkins University. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Local support was provided by the Ethiopia Federal Ministry of Health and the respective Regional Health Bureaus and the Central Statistics Agency.	Agadjanian Victor, 2015, Int J Gynaecol Obstet, V130 Suppl 3, pE47, DOI 10.1016/j.ijgo.2015.03.019; [Anonymous], 2017, CENTRAL STAT AGENCY; Ayele HI Wondimu, TRENDS DETERMINANTS; Blanc AK, 2002, STUD FAMILY PLANN, V33, P127, DOI 10.1111/j.1728-4465.2002.00127.x; Chen S, 2003, STUD FAMILY PLANN, V34, P263, DOI 10.1111/j.1728-4465.2003.00263.x; Entwisle B, 1997, DEMOGRAPHY, V34, P171, DOI 10.2307/2061697; Ettarh Remare R, 2012, Afr J Reprod Health, V16, P48; Federal Democratic Republic of Ethiopia Ministry of Health, 2010, HLTH SECT DEV PROGR; Federal democratic republic of Ethiopia Ministry of Health, 2015, HLTH SECT TRANSF PLA; Federal Ministry of Health, 2010, IMPL HLTH CAR FIN RE; Gabrysch S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000394; Guilkey SCaDK, 2002, EFFECT FACILITY CHAR; Jones SG, 2010, HEALTH SERV RES, V45, P316, DOI 10.1111/j.1475-6773.2009.01044.x; Karim AM, 2005, SESS 102 ACC F UNPUB; KEY FAMILY PLANNING INDICATORS, 2016, KEY FAMILY PLANNING; Lewis T, B WHO, V90, P332; Magnani RJ, 1999, STUD FAMILY PLANN, V30, P120, DOI 10.1111/j.1728-4465.1999.00120.x; [MEASURE DHS IGF Macro CSA], 2016, ETH DEM HLTH SURV 20; Mensch B, 1996, STUD FAMILY PLANN, V27, P59, DOI 10.2307/2138134; Skiles MP, 2015, INT PERSPECT SEX R H, V41, P20, DOI 10.1363/4102015; Skiles MP, 2013, POPUL HEALTH METR, V11, DOI 10.1186/1478-7954-11-14; Stephenson R, 2008, INT FAM PLAN PERSPEC, V34, P62, DOI 10.1363/ifpp.34.062.08; Tsui AO, 2002, WORKING PAPER SERIES, V60	23	28	28	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 13	2017	12	11							e0187311	10.1371/journal.pone.0187311	http://dx.doi.org/10.1371/journal.pone.0187311			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM4OL	29131860	Green Submitted, Green Published, gold			2023-01-03	WOS:000414997800009
J	Gu, H; You, H; Yana, ZW; Yang, NC; Kou, Y; Sun, J; Yu, T; Zhang, N				Gu, Hai; You, Hua; Yana, Zhiwen; Yang, Nichao; Kou, Yun; Sun, Jun; Yu, Ting; Zhang, Ning			Determinants of the utilization of postpartum family visits: Evidence from rural areas of Eastern China	PLOS ONE			English	Article							MEDICAL-CARE; POSTNATAL CARE; PREDICTORS; WOMEN	Background Postpartum Family Visits (PFVs) have been advocated as a way to improve health outcomes for puerperal women and their newborns. This study aimed to identify individual factors associated with the utilization of PFVs in rural Jiangsu Province, China. Methods We employed responses of the household survey in Jiangsu province, part of the National Health Service Survey (NHSS), a nationally representative survey in China. The data analysis framework was designed based on Andersen's behavioral model. The outcome variables included nonuse and deficient use of PFVs, and the explanatory variables were organized into three hierarchical levels: predisposing, enabling and need factors. Univariate analysis and multivariate logistic regression analysis were conducted to examine the impact of the three hierarchical levels on PFVs utilization. Results A total of 884 rural women who had a childbearing history in the prior five years answered PFVs questions. About 23.4% of them had never received any PFVs, and 40.4% received <3 visits. In the results of multivariate logistic regression, educational level (OR = 0.43, 95% CI: 0.24-0.77), income (OR = 0.62, 95% CI: 0.43-0.88), the distance from the nearest hospital (OR = 1.49, 95% CI: 1.07-2.07) and parity (OR = 2.17, 95% CI: 1.54-3.05) had significant relationship with nonuse. Factors significantly associated with deficient use of PFVs included employment (OR = 0.62, 95% CI: 0.39-0.98), the distance from the nearest hospital (OR = 1.73, 95% CI: 1.26-2.36), level of delivery institution (OR = 1.57, 95% CI: 1.14-2.17), and parity (OR = 1.45, 95% CI: 1.03-2.05). Conclusion The study found lower Social Economic Status (SES), long distance with primary health institutions, and the increased need for services stemming from multi-parity reduced the likelihood of nonuse or deficient use of PFVs in rural areas. Multiparous, low SES women and those living far away from primary health institutions should be paid more attention to assure the coverage of postpartum care.	[Gu, Hai; Yang, Nichao; Kou, Yun; Sun, Jun; Yu, Ting] Nanjing Univ, Ctr Hlth Policy & Management Studies, Nanjing, Jiangsu, Peoples R China; [You, Hua] Nanjing Med Univ, Sch Publ Hlth, Dept Social Med & Hlth Educ, Nanjing, Jiangsu, Peoples R China; [Yana, Zhiwen] Nanjing Med Univ, Clin Med Sch 1, Nanjing, Jiangsu, Peoples R China; [Yu, Ting] Yangzhou City Peoples Govt, Mayors Off, Yangzhou, Jiangsu, Peoples R China; [Zhang, Ning] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Policy & Promot, Amherst, MA 01003 USA	Nanjing University; Nanjing Medical University; Nanjing Medical University; University of Massachusetts System; University of Massachusetts Amherst	You, H (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Social Med & Hlth Educ, Nanjing, Jiangsu, Peoples R China.; Zhang, N (corresponding author), Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Policy & Promot, Amherst, MA 01003 USA.	youhua98@163.com; ningzhang@schoolph.umass.edu	Dangal, Ganesh/O-1989-2017	Dangal, Ganesh/0000-0002-5834-5525; you, hua/0000-0002-0004-0470	National Natural Science Foundation of China [71603131]; Jiangsu Provincial Natural Science Foundation of China [BK20161030]; Top-notch Academic Programs Project of Jiangsu Higher Education Institutions, TAPP [PPZY2015A067]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Natural Science Foundation of China(Natural Science Foundation of Jiangsu Province); Top-notch Academic Programs Project of Jiangsu Higher Education Institutions, TAPP	This study was supported by National Natural Science Foundation of China (71603131), https://isisn.nsfc.gov.cn/egrantweb/; Jiangsu Provincial Natural Science Foundation of China (BK20161030), http://210.73.128.81/13kjskj2/; Top-notch Academic Programs Project of Jiangsu Higher Education Institutions, TAPP (PPZY2015A067), http://180.209.64.40/.	Aday L A, 1974, Health Serv Res, V9, P208; Albers LL, 2000, J MIDWIFERY WOM HEAL, V45, P55, DOI 10.1016/S1526-9523(99)00003-3; American College of Obstetricians and Gynecologists, 2002, GUID PER CAR; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Andersen R, 1968, BEHAV MODEL FAMILIES BEHAV MODEL FAMILIES; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Bryant AS, 2006, MATERN CHILD HLTH J, V10, P511, DOI 10.1007/s10995-006-0128-5; Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Chakraborty N, 2002, HEALTH SOC CARE COMM, V10, P492, DOI 10.1046/j.1365-2524.2002.00389.x; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Dijkstra-Kersten SMA, 2015, J EPIDEMIOL COMMUN H, V69, P660, DOI 10.1136/jech-2014-205088; Fahey JO, 2013, J MIDWIFERY WOM HEAL, V58, P613, DOI 10.1111/jmwh.12139; GARFIELD SR, 1976, NEW ENGL J MED, V294, P426, DOI 10.1056/NEJM197602192940806; Henderson V, 2016, MATERN CHILD HLTH J, V20, pS132, DOI 10.1007/s10995-016-2044-7; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jean Yeung WJ, 2013, CHINESE SOCIOLOGICAL, V45, P54; Jiang L, 2005, MATERN CHILD HLTH J, V20, P2626; Kim Yangho, 2013, J Prev Med Public Health, V46, P96, DOI 10.3961/jpmph.2013.46.2.96; LEVKOFF SE, 1987, MED CARE, V25, P1148, DOI 10.1097/00005650-198712000-00004; Li XM, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-319; Lu MC, 2002, AM J OBSTET GYNECOL, V187, P1329, DOI 10.1067/mob.2002.126848; Midhet F, 1998, SOC SCI MED, V46, P1587, DOI 10.1016/S0277-9536(97)10137-X; Mirkovic KR, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-016-1202-7; Moran AC, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001415; National Health and Family Planning Commission of People's Republic of China, MAN MEAS SYST MAT HE; National Health and Family Planning Commission of People's Republic of China, 2009, NOT MIN HLTH ISS NAT; National Health and Family Planning Commission of People's Republic of China, REP 3 NAT HLTH SERV; National Health and Family Planning Commission of People's Republic of China, 2013, 5 NAT HLTH SERV SURV; Pan Y, 2001, MATERN CHILD HLTH J, V16, P89; Sword WA, 2006, CAN J PUBLIC HEALTH, V97, P191, DOI 10.1007/BF03405582; Tao FB, 2011, MIDWIFERY, V27, P707, DOI 10.1016/j.midw.2009.10.001; Wang XL, 2000, CHINESE J BEHAV MED, V9, P175; WHO Department of Reproductive Health and Research, 1998, POSTP CAR MOTH NEWB; WHO Technical working group, 1996, POSTP CAR MOTH NEWB, V26, P255; WOLINSKY FD, 1978, J HEALTH SOC BEHAV, V19, P384, DOI 10.2307/2136586; Wu J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161683; Xu D, 2016, CHINESE PRIMARY HLTH, V30, P35; You H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055955; [于贞杰 Yu Zhenjie], 2013, [中国全科医学, Chinese General Practice], V16, P4037; Zhang T, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0543-9; Zhang Wei, 2016, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V41, P1220; [赵光斌 Zhao Guangbin], 2013, [中国全科医学, Chinese General Practice], V16, P2930; Zou M, 2015, SOCIOLOGY, V49, P1133, DOI 10.1177/0038038514562853	43	8	8	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194061	10.1371/journal.pone.0194061	http://dx.doi.org/10.1371/journal.pone.0194061			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA1RF	29566028	Green Published, gold, Green Submitted			2023-01-03	WOS:000428093900031
J	Higgins, GS; Boulton, SJ				Higgins, Geoff S.; Boulton, Simon J.			Beyond PARP-POL theta as an anticancer target	SCIENCE			English	Editorial Material							POLYMERASE-THETA; REPAIR; RECOMBINATION; CANCER; OLAPARIB; THERAPY; TUMORS; TRIAL; CELLS; NHEJ		[Higgins, Geoff S.] Univ Oxford, Inst Radiat Oncol, Canc Res UK Med Res Council Oxford, Old Rd,Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England; [Boulton, Simon J.] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England; [Boulton, Simon J.] Artios Pharma Ltd, Babraham Res Campus, Cambridge CB22 3AT, England	University of Oxford; Francis Crick Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Higgins, GS (corresponding author), Univ Oxford, Inst Radiat Oncol, Canc Res UK Med Res Council Oxford, Old Rd,Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.	geoffrey.higgins@oncology.ox.ac.uk; simon.boulton@crick.ac.uk						Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; de Rugy TG, 2016, BIOL OPEN, V5, P1485, DOI 10.1242/bio.018028; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Higgins GS, 2010, CANCER RES, V70, P2984, DOI 10.1158/0008-5472.CAN-09-4040; Kass EM, 2016, MOL CELL, V62, P777, DOI 10.1016/j.molcel.2016.05.021; Kawamura K, 2004, INT J CANCER, V109, P9, DOI 10.1002/ijc.11666; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Mateos-Gomez PA, 2017, NAT STRUCT MOL BIOL, V24, P1116, DOI 10.1038/nsmb.3494; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Pommier Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9246; Wyatt DW, 2016, MOL CELL, V63, P662, DOI 10.1016/j.molcel.2016.06.020	14	38	40	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 16	2018	359	6381					1217	+		10.1126/science.aar5149	http://dx.doi.org/10.1126/science.aar5149			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FZ3QN	29590065	Green Submitted			2023-01-03	WOS:000427504900027
J	Self, WH; Semler, MW; Wanderer, JP; Wang, L; Byrne, DW; Collins, SP; Slovis, CM; Lindsell, CJ; Ehrenfeld, JM; Siew, ED; Shaw, AD; Bernard, GR; Rice, TW				Self, Wesley H.; Semler, Matthew W.; Wanderer, Jonathan P.; Wang, Li; Byrne, Daniel W.; Collins, Sean P.; Slovis, Corey M.; Lindsell, Christopher J.; Ehrenfeld, Jesse M.; Siew, Edward D.; Shaw, Andrew D.; Bernard, Gordon R.; Rice, Todd W.		SALT-ED Investigators	Balanced Crystalloids versus Saline in Noncritically Ill Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE KIDNEY INJURY; IN-HOSPITAL MORTALITY; INTENSIVE-CARE; FLUID RESUSCITATION; 0.9-PERCENT SALINE; CLINICAL-TRIALS; ASSOCIATION; PROTOCOL; STATISTICS; MEDICINE	BACKGROUND Comparative clinical effects of balanced crystalloids and saline are uncertain, particularly in noncritically ill patients cared for outside an intensive care unit (ICU). METHODS We conducted a single-center, pragmatic, multiple-crossover trial comparing balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) with saline among adults who were treated with intravenous crystalloids in the emergency department and were subsequently hospitalized outside an ICU. The type of crystalloid that was administered in the emergency department was assigned to each patient on the basis of calendar month, with the entire emergency department crossing over between balanced crystalloids and saline monthly during the 16-month trial. The primary outcome was hospital-free days (days alive after discharge before day 28). Secondary outcomes included major adverse kidney events within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to >= 200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first. RESULTS A total of 13,347 patients were enrolled, with a median crystalloid volume administered in the emergency department of 1079 ml and 88.3% of the patients exclusively receiving the assigned crystalloid. The number of hospital-free days did not differ between the balanced-crystalloids and saline groups (median, 25 days in each group; adjusted odds ratio with balanced crystalloids, 0.98; 95% confidence interval [CI], 0.92 to 1.04; P = 0.41). Balanced crystalloids resulted in a lower incidence of major adverse kidney events within 30 days than saline (4.7% vs. 5.6%; adjusted odds ratio, 0.82; 95% CI, 0.70 to 0.95; P = 0.01). CONCLUSIONS Among noncritically ill adults treated with intravenous fluids in the emergency department, there was no difference in hospital-free days between treatment with balanced crystalloids and treatment with saline.	[Self, Wesley H.; Collins, Sean P.; Slovis, Corey M.] Vanderbilt Univ, Med Ctr, Dept Emergency Med, Nashville, TN 37232 USA; [Wanderer, Jonathan P.; Ehrenfeld, Jesse M.; Shaw, Andrew D.] Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN 37232 USA; [Wanderer, Jonathan P.; Ehrenfeld, Jesse M.] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37232 USA; [Wang, Li; Byrne, Daniel W.; Lindsell, Christopher J.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Semler, Matthew W.; Bernard, Gordon R.; Rice, Todd W.] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Siew, Edward D.] Vanderbilt Univ, Med Ctr, Div Nephrol & Hypertens, Dept Med,Vanderbilt Ctr Kidney Dis, Nashville, TN 37232 USA; [Siew, Edward D.] Vanderbilt Univ, Med Ctr, Integrated Program Acute Kidney Injury Res, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Rice, TW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, T-1218 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	todd.rice@vanderbilt.edu	Ehrenfeld, Jesse/AAI-2951-2020; Rice, Todd/X-7853-2019; Byrne, Daniel/GRE-6302-2022	Self, Wesley/0000-0002-9300-3045; Siew, Edward/0000-0003-1343-8784; Collins, Sean/0000-0002-2305-9836; Wanderer, Jonathan/0000-0002-3119-6873; Rice, Todd/0000-0002-7136-5408	Vanderbilt Institute for Clinical and Translational Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445, UL1TR002243] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL087738, R34HL105869, K12HL133117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM110469] Funding Source: NIH RePORTER	Vanderbilt Institute for Clinical and Translational Research; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funded by the Vanderbilt Institute for Clinical and Translational Research and others	BULLIVANT EMA, 1989, AM J PHYSIOL, V256, pF152, DOI 10.1152/ajprenal.1989.256.1.F152; Califf RM, 2016, NEW ENGL J MED, V375, P2395, DOI 10.1056/NEJMsb1610128; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Hammond NE, 2017, CRIT CARE RESUSC, V19, P239; Kellum JA, 1998, SHOCK, V9, P364, DOI 10.1097/00024382-199805000-00009; Laplante S, 2017, PHARMACOECONOMI 0904; Moritz ML, 2015, NEW ENGL J MED, V373, P1350, DOI 10.1056/NEJMra1412877; Myburgh JA, 2013, NEW ENGL J MED, V369, P1243, DOI 10.1056/NEJMra1208627; Palevsky PM, 2012, CLIN J AM SOC NEPHRO, V7, P844, DOI 10.2215/CJN.12791211; Raghunathan K, 2014, CRIT CARE MED, V42, P1585, DOI 10.1097/CCM.0000000000000305; Rochwerg B, 2014, ANN INTERN MED, V161, P347, DOI 10.7326/M14-0178; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Self WH, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1923-6; Semler MW, 2018, NEW ENGL J MED, V378, P829, DOI 10.1056/NEJMoa1711584; Semler MW, 2017, AM J RESP CRIT CARE, V195, P1362, DOI 10.1164/rccm.201607-1345OC; Semler MW, 2016, CRIT CARE MED, V44, P1541, DOI 10.1097/CCM.0000000000001941; Semler MW, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0528-z; Shaw AD, 2014, INTENS CARE MED, V40, P1897, DOI 10.1007/s00134-014-3505-3; Shaw AD, 2012, ANN SURG, V255, P821, DOI 10.1097/SLA.0b013e31825074f5; Upchurch CP, 2017, ANN EMERG MED, V69, P24, DOI 10.1016/j.annemergmed.2016.08.009; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Ware JH, 2011, NEW ENGL J MED, V364, P1685, DOI 10.1056/NEJMp1103502; WILCOX CS, 1983, J CLIN INVEST, V71, P726, DOI 10.1172/JCI110820; Young P, 2016, CRIT CARE MED, V44, P1538, DOI 10.1097/CCM.0000000000001844; Young P, 2015, JAMA-J AM MED ASSOC, V314, P1701, DOI 10.1001/jama.2015.12334; Yunos NM, 2015, INTENS CARE MED, V41, P257, DOI 10.1007/s00134-014-3593-0; Yunos NM, 2012, JAMA-J AM MED ASSOC, V308, P1566, DOI 10.1001/jama.2012.13356; Yunos NM, 2011, CRIT CARE MED, V39, P2419, DOI 10.1097/CCM.0b013e31822571e5; Zampieri FG, 2017, CRIT CARE RESUSC, V19, P175; Zavada J, 2010, NEPHROL DIAL TRANSPL, V25, P3911, DOI 10.1093/ndt/gfp766; Zhou F, 2014, CRIT CARE MED, V42, pE270, DOI 10.1097/CCM.0000000000000145	32	309	320	2	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 1	2018	378	9					819	828		10.1056/NEJMoa1711586	http://dx.doi.org/10.1056/NEJMoa1711586			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX7GP	29485926	Green Accepted, Bronze			2023-01-03	WOS:000426256300007
J	Li, Y; Wang, SP; Pan, CX; Xue, FS; Xian, JF; Huang, YQ; Wang, XY; Li, TZ; He, HG				Li, Yun; Wang, Shengpei; Pan, Chuxiong; Xue, Fushan; Xian, Junfang; Huang, Yaqi; Wang, Xiaoyi; Li, Tianzuo; He, Huiguang			Comparison of NREM sleep and intravenous sedation through local information processing and whole brain network to explore the mechanism of general anesthesia	PLOS ONE			English	Article							CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; PROPOFOL ANESTHESIA; HUMANS; CONNECTIVITY; PRECUNEUS; CINGULATE; NEURONS; INDEX; RAT	Background The mechanism of general anesthesia (GA) has been explored for hundreds of years, but unclear. Previous studies indicated a possible correlation between NREM sleep and GA. The purpose of this study is to compare them by in vivo human brain function to probe the neuromechanism of consciousness, so as to find out a clue to GA mechanism. Methods 24 healthy participants were equally assigned to sleep or propofol sedation group by sleeping ability. EEG and Ramsay Sedation Scale were applied to determine sleep stage and sedation depth respectively. Resting-state functional magnetic resonance imaging (RS-fMRI) was acquired at each status. Regional homogeneity (ReHo) and seed-based whole brain functional connectivity maps (WB-FC maps) were compared. Results During sleep, ReHo primarily weakened on frontal lobe (especially preoptic area), but strengthened on brainstem. While during sedation, ReHo changed in various brain areas, including cingulate, precuneus, thalamus and cerebellum. Cingulate, fusiform and insula were concomitance of sleep and sedation. Comparing to sleep, FCs between the cortex and subcortical centers (centralized in cerebellum) were significantly attenuated under sedation. As sedation deepening, cerebellum-based FC maps were diminished, while thalamus-and brainstem-based FC maps were increased. Conclusion There're huge distinctions in human brain function between sleep and GA. Sleep mainly rely on brainstem and frontal lobe function, while sedation is prone to affect widespread functional network. The most significant differences exist in the precuneus and cingulate, which may play important roles in mechanisms of inducing unconciousness by anesthetics.	[Li, Yun; Pan, Chuxiong; Li, Tianzuo] Capital Med Univ, Beijing Tongren Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Wang, Shengpei; He, Huiguang] Chinese Acad Sci, Inst Automat, Res Ctr Brain Inspired Intelligence, Beijing, Peoples R China; [Wang, Shengpei] Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, Beijing, Peoples R China; [Xue, Fushan] Chinese Acad Med Sci, Plast Surg Hosp, Dept Anesthesiol, Beijing, Peoples R China; [Xue, Fushan] Peking Union Med Coll, Beijing, Peoples R China; [Xian, Junfang] Beijing Tongren Hosp, Dept Radiol, Beijing, Peoples R China; [Huang, Yaqi] Capital Med Univ, Sch Biomed Engn, Beijing, Peoples R China; [Wang, Xiaoyi] Beijing Tongren Hosp, Dept Laryngol, Sleep Med Ctr, Beijing, Peoples R China; [Li, Tianzuo] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China	Capital Medical University; Chinese Academy of Sciences; Institute of Automation, CAS; Chinese Academy of Sciences; Institute of Automation, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Plastic Surgery Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Capital Medical University; Capital Medical University; Capital Medical University; Capital Medical University	Li, TZ (corresponding author), Capital Med Univ, Beijing Tongren Hosp, Dept Anesthesiol, Beijing, Peoples R China.; He, HG (corresponding author), Chinese Acad Sci, Inst Automat, Res Ctr Brain Inspired Intelligence, Beijing, Peoples R China.; Li, TZ (corresponding author), Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China.	trmzltz@outlook.com; huiguang.he@ia.ac.cn	He, Huiguang/AAD-7643-2020; Xue, Fu-Shan/ADO-0664-2022	He, Huiguang/0000-0002-0684-1711; Li, Yun/0000-0002-2869-1451	National Science and Technology Pillar Program of China [2012BAI05B03]; National Natural Science Foundation of China [81171422, 61271151, 91520202]; Youth Innovation Promotion Association CAS	National Science and Technology Pillar Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association CAS	This study was supported by the National Science and Technology Pillar Program of China (2012BAI05B03), the National Natural Science Foundation of China (81171422, 61271151, 91520202), Youth Innovation Promotion Association CAS. All the funders were used for compensation to subjects. This study was supported by the National Science and Technology Pillar Program of China (2012BAI05B03), the National Natural Science Foundation of China (81171422, 61271151, and 91520202), Youth Innovation Promotion Association CAS.	Adapa RM, 2012, ANAESTHESIA, V67, P33, DOI 10.1111/j.1365-2044.2011.06917.x; Allen PJ, 2000, NEUROIMAGE, V12, P230, DOI 10.1006/nimg.2000.0599; Bonhomme V, 2001, J NEUROPHYSIOL, V85, P1299, DOI 10.1152/jn.2001.85.3.1299; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; CAVAZZUTI M, 1991, BRIT J ANAESTH, V66, P490, DOI 10.1093/bja/66.4.490; Chisholm CJ, 2006, MAYO CLIN PROC, V81, P46, DOI 10.4065/81.1.46; Engbers FH, 2010, BRIT J ANAESTH, V104, P261, DOI 10.1093/bja/aep385; Fiset P, 1999, J NEUROSCI, V19, P5506; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Gaus SE, 2002, NEUROSCIENCE, V115, P285, DOI 10.1016/S0306-4522(02)00308-1; Gili T, 2013, J NEUROSCI, V33, P4024, DOI 10.1523/JNEUROSCI.3480-12.2013; Jones EG, 2002, PHILOS T R SOC B, V357, P1659, DOI 10.1098/rstb.2002.1168; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Liu XP, 2013, NEUROIMAGE, V83, P581, DOI 10.1016/j.neuroimage.2013.07.003; Luo T, 2011, ANESTHESIOLOGY, V115, P36, DOI 10.1097/ALN.0b013e3182207655; Maquet P, 2000, J SLEEP RES, V9, P207; Margulies DS, 2009, P NATL ACAD SCI USA, V106, P20069, DOI 10.1073/pnas.0905314106; Martuzzi R, 2011, NEUROIMAGE, V58, P1044, DOI 10.1016/j.neuroimage.2011.06.075; Meuret P, 2000, ANESTHESIOLOGY, V93, P708, DOI 10.1097/00000542-200009000-00020; Mulert C, 2005, INT J PSYCHOPHYSIOL, V56, P65, DOI 10.1016/j.ijpsycho.2004.10.002; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; Novelli L, 2010, J SLEEP RES, V19, P238, DOI 10.1111/j.1365-2869.2009.00785.x; Pal D, 2016, ANESTHESIOLOGY, V125, P929, DOI 10.1097/ALN.0000000000001342; Picchioni Dante, 2014, Sleep, V37, P387, DOI 10.5665/sleep.3422; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rosenorn-Lanng D, 2010, J NEUROSCIENCE, P1529; Solt K, 2007, CURR OPIN ANESTHESIO, V20, P300, DOI 10.1097/ACO.0b013e32816678a5; Upadhyay J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027839; Vargo J, 2009, CLIN GASTROENTEROL H, V7, P156, DOI 10.1016/j.cgh.2008.09.004; Veselis RA, 2005, ANESTHESIOLOGY, V102, P26, DOI 10.1097/00000542-200501000-00008; Yamada M, 2006, ACTA ANAESTH SCAND, V50, P875, DOI 10.1111/j.1399-6576.2006.01033.x; Zang YF, 2004, NEUROIMAGE, V22, P394, DOI 10.1016/j.neuroimage.2003.12.030	33	11	12	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2018	13	2							e0192358	10.1371/journal.pone.0192358	http://dx.doi.org/10.1371/journal.pone.0192358			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX7BV	29486001	Green Published, gold, Green Submitted			2023-01-03	WOS:000426242400008
J	Maude, SL; Laetsch, TW; Buechner, J; Rives, S; Boyer, M; Bittencourt, H; Bader, P; Verneris, MR; Stefanski, HE; Myers, GD; Qayed, M; De Moerloose, B; Hiramatsu, H; Schlis, K; Davis, KL; Martin, PL; Nemecek, ER; Yanik, GA; Peters, C; Baruchel, A; Boissel, N; Mechinaud, F; Balduzzi, A; Krueger, J; June, CH; Levine, BL; Wood, P; Taran, T; Leung, M; Mueller, KT; Zhang, Y; Sen, K; Lebwohl, D; Pulsipher, MA; Grupp, SA				Maude, S. L.; Laetsch, T. W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M. R.; Stefanski, H. E.; Myers, G. D.; Qayed, M.; De Moerloose, B.; Hiramatsu, H.; Schlis, K.; Davis, K. L.; Martin, P. L.; Nemecek, E. R.; Yanik, G. A.; Peters, C.; Baruchel, A.; Boissel, N.; Mechinaud, F.; Balduzzi, A.; Krueger, J.; June, C. H.; Levine, B. L.; Wood, P.; Taran, T.; Leung, M.; Mueller, K. T.; Zhang, Y.; Sen, K.; Lebwohl, D.; Pulsipher, M. A.; Grupp, S. A.			Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAR-T-CELLS; PEDIATRIC-PATIENTS	BACKGROUND In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849.)	[Maude, S. L.; Grupp, S. A.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [June, C. H.; Levine, B. L.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [June, C. H.; Levine, B. L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Maude, S. L.; Grupp, S. A.] Childrens Hosp Philadelphia, Div Oncol, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Maude, S. L.; Grupp, S. A.] Childrens Hosp Philadelphia, Canc Immunotherapy Program, Philadelphia, PA 19104 USA; [Laetsch, T. W.] Univ Texas Dallas, Southwestern Med Ctr, Dept Pediat, Dallas, TX USA; Pauline Allen Gill Ctr Canc & Blood Disorders, Childrens Hlth, Dallas, TX USA; [Buechner, J.] Oslo Univ Hosp, Dept Pediat Hematol & Oncol, Oslo, Norway; [Rives, S.] Hosp St Joan Deu Barcelona, Dept Pediat Hematol & Oncol, Barcelona, Spain; [Boyer, M.] Univ Utah, Dept Pediat & Internal Med, Salt Lake City, UT USA; [Bittencourt, H.] Univ Montreal, Dept Pediat, Fac Med, Montreal, PQ, Canada; [Bittencourt, H.] CHU Sainte Justine, Res Ctr, Hematol Oncol Div, Montreal, PQ, Canada; [Bittencourt, H.] CHU Sainte Justine, Res Ctr, Charles Bruneau Canc Ctr, Montreal, PQ, Canada; [Krueger, J.] Hosp Sick Children, Div Haematol Oncol Bone Marrow Transplantat, Toronto, ON, Canada; [Bader, P.] Univ Hosp Frankfurt, Hosp Children & Adolescents, Div Stem Cell Transplantat & Immunol, Frankfurt, Germany; [Verneris, M. R.; Stefanski, H. E.] Univ Minnesota, Div Pediat Blood & Marrow Transplant, Minneapolis, MN USA; [Myers, G. D.] Childrens Mercy Hosp & Clin, Kansas City, MO USA; [Qayed, M.] Emory Univ, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA; [De Moerloose, B.] Ghent Univ Hosp, Dept Pediat Hematol Oncol & Stem Cell Transplanta, Ghent, Belgium; [De Moerloose, B.] CRIG, Ghent, Belgium; [Hiramatsu, H.] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Schlis, K.; Davis, K. L.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Pulsipher, M. A.] USC Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol Blood & Marrow Transplant, Los Angeles, CA USA; [Martin, P. L.] Duke Univ, Med Ctr, Div Pediat Blood & Marrow Transplant, Durham, NC USA; [Nemecek, E. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Yanik, G. A.] CS Mott Childrens Hosp, Ann Arbor, MI USA; [Peters, C.] St Anna Childrens Hosp, Stem Cell Transplantat Unit, Vienna, Austria; [Baruchel, A.] Univ Hosp Robert Debre, Paris, France; [Baruchel, A.; Boissel, N.] Univ Paris Diderot, Paris, France; [Boissel, N.] St Louis Hop, Paris, France; [Mechinaud, F.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Balduzzi, A.] Univ Milano Bicocca, Clin Pediat, Monza, Italy; [Wood, P.; Taran, T.; Leung, M.; Zhang, Y.; Sen, K.; Lebwohl, D.] Novartis Pharmaceut, E Hanover, NJ USA; [Mueller, K. T.] Novartis Inst Biomed Res, E Hanover, NJ USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oslo; Utah System of Higher Education; University of Utah; Universite de Montreal; Universite de Montreal; Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Minnesota System; University of Minnesota Twin Cities; Children's Mercy Hospital; Emory University; Ghent University; Ghent University Hospital; Ghent University; Kyoto University; Stanford University; Children's Hospital Los Angeles; University of Southern California; Duke University; Oregon Health & Science University; Saint Anna Children's Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Royal Children's Hospital Melbourne; University of Milano-Bicocca; Novartis; Novartis	Maude, SL (corresponding author), 3012 Colket Translat Res Bldg,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	maude@email.chop.edu	BALDUZZI, Adriana/AAC-1033-2019; Grupp, Stephan A/D-1145-2009; Rives, Susana/AHA-6765-2022; Boissel, Nicolas/P-2190-2018; De+Moerloose, Barbara/AAN-3298-2020	Rives, Susana/0000-0002-5658-1831; Boissel, Nicolas/0000-0003-2091-7927; Peters, Christina/0000-0003-0369-8515; De Moerloose, Barbara/0000-0002-2449-539X; Buechner, Jochen/0000-0001-5848-4501; Balduzzi, Adriana Cristina/0000-0002-5879-0610	Novartis Pharmaceuticals; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002378, KL2TR002381] Funding Source: NIH RePORTER	Novartis Pharmaceuticals(Novartis); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849.	Abramson JS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.7513; Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; GARDNER R, 2016, BLOOD, V128; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; GRUPP SA, 2016, BLOOD, V128; Grupp SA, 2015, BLOOD, V126, P681, DOI DOI 10.1158/1078-0432.CCR-08-0144; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Janetzki S, 2009, IMMUNITY, V31, P527, DOI 10.1016/j.immuni.2009.09.007; Jeha S, 2006, J CLIN ONCOL, V24, P1917, DOI 10.1200/JCO.2005.03.8554; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2015, BLOOD, V126, P684; Lee S, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.5500.5500; Liu ZG, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.255.255; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Maude SL, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3011; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; SHAH B, 2016, BLOOD, V128; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; von Stackelberg A, 2016, J CLIN ONCOL, V34, P4381, DOI 10.1200/JCO.2016.67.3301	20	2434	2512	31	275	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 1	2018	378	5					439	448		10.1056/NEJMoa1709866	http://dx.doi.org/10.1056/NEJMoa1709866			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU3WP	29385370	Green Accepted, Bronze			2023-01-03	WOS:000423783200008
J	Noyes, N; Cho, KC; Ravel, J; Forney, LJ; Abdo, Z				Noyes, Noelle; Cho, Kyu-Chul; Ravel, Jacques; Forney, Larry J.; Abdo, Zaid			Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis	PLOS ONE			English	Article							NUTRITION EXAMINATION SURVEY; BACTERIAL VAGINOSIS; RISK-FACTORS; MULTIVARIATE ANALYSES; NATIONAL-HEALTH; BREAST-CANCER; US GIRLS; WOMEN; FLORA; MENARCHE	The vaginal microbiome plays an influential role in several disease states in reproductive age women, including bacterial vaginosis (BV). While demographic characteristics are associated with differences in vaginal microbiome community structure, little is known about the influence of sexual and hygiene habits. Furthermore, associations between the vaginal microbiome and risk symptoms of bacterial vaginosis have not been fully elucidated. Using Bayesian network (BN) analysis of 16S rRNA gene sequence results, demographic and extensive questionnaire data, we describe both novel and previously documented associations between habits of women and their vaginal microbiome. The BN analysis approach shows promise in uncovering complex associations between disparate data types. Our findings based on this approach support published associations between specific microbiome members (e.g., Eggerthella, Gardnerella, Dialister, Sneathia and Ruminococcaceae), the Nugent score (a BV diagnostic) and vaginal pH (a risk symptom of BV). Additionally, we found that several microbiome members were directly connected to other risk symptoms of BV (such as vaginal discharge, odor, itch, irritation, and yeast infection) including L. jensenii, Corynebacteria, and Proteobacteria. No direct connections were found between the Nugent Score and risk symptoms of BV other than pH, indicating that the Nugent Score may not be the most useful criteria for assessment of clinical BV. We also found that demographics (i.e., age, ethnicity, previous pregnancy) were associated with the presence/absence of specific vaginal microbes. The resulting BN revealed several as-yet undocumented associations between birth control usage, menstrual hygiene practices and specific microbiome members. Many of these complex relationships were not identified using common analytical methods, i.e., ordination and PERMANOVA. While these associations require confirmatory follow-up study, our findings strongly suggest that future studies of the vaginal microbiome and vaginal pathologies should include detailed surveys of participants' sanitary, sexual and birth control habits, as these can act as confounders in the relationship between the microbiome and disease. Although the BN approach is powerful in revealing complex associations within multidimensional datasets, the need in some cases to discretize the data for use in BN analysis can result in loss of information. Future research is required to alleviate such limitations in constructing BN networks. Large sample sizes are also required in order to allow for the incorporation of a large number of variables (nodes) into the BN, particularly when studying associations between metadata and the microbiome. We believe that this approach is of great value, complementing other methods, to further our understanding of complex associations characteristic of microbiome research.	[Noyes, Noelle; Abdo, Zaid] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; [Cho, Kyu-Chul] Univ Idaho, Dept Stat, Moscow, ID 83843 USA; [Ravel, Jacques] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA; [Forney, Larry J.] Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA; [Cho, Kyu-Chul] Naver Corp, Seongnam Si, Gyeonggi Do, South Korea	Colorado State University; Idaho; University of Idaho; University System of Maryland; University of Maryland Baltimore; Idaho; University of Idaho	Abdo, Z (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	zaid.abdo@colostate.edu	Ravel, Jacques/D-2530-2009		Colorado State University Vice President for Research; United States Department of Agriculture-National Institute of Food and Agriculture [2016-67012-24679]; National Institute of Allergies and Infectious Diseases, National Institutes of Health [U19 AI084044, U01 AI070921, UH2AI083264]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI084044] Funding Source: NIH RePORTER	Colorado State University Vice President for Research; United States Department of Agriculture-National Institute of Food and Agriculture(United States Department of Agriculture (USDA)); National Institute of Allergies and Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was partially funded by startup funding to ZA from Colorado State University Vice President for Research, United States Department of Agriculture-National Institute of Food and Agriculture 2016-67012-24679 postdoctoral training grant to ZA and NN https://nifa.usda.gov/ and National Institute of Allergies and Infectious Diseases, National Institutes of Health https://www.niaid.nih.gov/ (grant number U19 AI084044 to RJ, U01 AI070921 to RJ and UH2AI083264 to RJ and LJF).	Allsworth JE, 2007, OBSTET GYNECOL, V109, P114, DOI 10.1097/01.AOG.0000247627.84791.91; AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; Anderson SE, 2003, PEDIATRICS, V111, P844, DOI 10.1542/peds.111.4.844; Bastian M., 2009, ICWSM, V8, P361; Bautista CT, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0074-5; Beigi RH, 2005, J INFECT DIS, V191, P924, DOI 10.1086/428288; Bernstein MN, 2016, BIORXIV; Bhadra A, 2016, ARXIV160400376STAT; Bharwani A, 2017, BMC MED, V15, DOI 10.1186/s12916-016-0771-7; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; Brotman RM, 2008, AM J EPIDEMIOL, V168, P188, DOI 10.1093/aje/kwn103; CAREY JC, 1991, AM J OBSTET GYNECOL, V164, P728; Chumlea WC, 2003, PEDIATRICS, V111, P110, DOI 10.1542/peds.111.1.110; CLARKE KR, 1993, AUST J ECOL, V18, P117, DOI 10.1111/j.1442-9993.1993.tb00438.x; Cruz-Ramirez N, 2007, COMPUT BIOL MED, V37, P1553, DOI 10.1016/j.compbiomed.2007.02.003; Donders G, 2017, EUR J CLIN MICROBIOL, V36, P43, DOI 10.1007/s10096-016-2768-8; Donders GGG, 2000, AM J OBSTET GYNECOL, V182, P872, DOI 10.1016/S0002-9378(00)70338-3; Erol O, 2014, EUR J CONTRACEP REPR, V19, P187, DOI 10.3109/13625187.2014.900532; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; Farage MA, 2013, REV RECENT CLIN TRIA, V8, P29, DOI 10.2174/1574887111308010005; Ferris MJ, 2007, J CLIN MICROBIOL, V45, P1016, DOI 10.1128/JCM.02085-06; Fischer C, 2017, ELIFE, V6, DOI 10.7554/eLife.18855; Fredricks DN, 2005, NEW ENGL J MED, V353, P1899, DOI 10.1056/NEJMoa043802; Freedman DS, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.4.e43; Gajer P, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003605; Gamez JA, 2011, DATA MIN KNOWL DISC, V22, P106, DOI 10.1007/s10618-010-0178-6; Gelman A., 2007, DATA ANAL USING REGR; Gevaert O, 2006, BIOINFORMATICS, V22, pE184, DOI 10.1093/bioinformatics/btl230; Gloor GB, 2016, CAN J MICROBIOL, V62, P692, DOI 10.1139/cjm-2015-0821; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; Gondo F, 2011, GYNECOL OBSTET INVES, V71, P158, DOI 10.1159/000316051; Haggerty CL, 2016, SEX TRANSM INFECT, V92, P441, DOI 10.1136/sextrans-2015-052285; Hay PE, 1997, INT J STD AIDS, V8, P603, DOI 10.1258/0956462971918850; Hellberg D, 2000, INT J STD AIDS, V11, P603, DOI 10.1258/0956462001916461; Hickey RJ, 2013, BJOG-INT J OBSTET GY, V120, P695, DOI 10.1111/1471-0528.12151; Hoffman MK, 2017, INFECT DIS OBSTET GY, V2017; Hojsgaard S, 2012, J STAT SOFTW, V46, P1; Horstman AM, 2012, J GERONTOL A-BIOL, V67, P1140, DOI 10.1093/gerona/gls068; Jacobson JC, 2014, CONTRACEPTION, V90, P130, DOI 10.1016/j.contraception.2014.04.006; Klebanoff MA, 2010, SEX TRANSM DIS, V37, P94, DOI 10.1097/OLQ.0b013e3181bc063c; Kline R. B, 2011, PRINCIPLES PRACTICE; Lamont RF, 2011, BJOG-INT J OBSTET GY, V118, P533, DOI 10.1111/j.1471-0528.2010.02840.x; Legendre P, 2001, OECOLOGIA, V129, P271, DOI 10.1007/s004420100716; Li XD, 2014, EUR J CLIN MICROBIOL, V33, P1525, DOI 10.1007/s10096-014-2103-1; Livengood Charles H, 2009, Rev Obstet Gynecol, V2, P28; Ma B, 2012, ANNU REV MICROBIOL, V66, P371, DOI 10.1146/annurev-micro-092611-150157; Machado D, 2016, FRONT MICROBIOL, V6, DOI [10.3389/fmicb.2015.00330, 10.3389/fmicb.2015.01528]; MacKay AP, 2001, FAM PLANN PERSPECT, V33, P161, DOI 10.2307/2673719; Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127; MCCORMACK WM, 1977, J INFECT DIS, V136, P740, DOI 10.1093/infdis/136.6.740; Monnat SM, 2014, J HEALTH CARE POOR U, V25, P332, DOI 10.1353/hpu.2014.0050; Nayfach S, 2016, CELL, V166, P1103, DOI 10.1016/j.cell.2016.08.007; Neapolitan RE, 2004, P 13 ACM SIGKDD INT; Ness RB, 2003, J NATL MED ASSOC, V95, P201; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; Nunn Kenetta L., 2016, Yale Journal of Biology and Medicine, V89, P331; Nwankwo TO, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0558-9; Paulson JN, 2013, NAT METHODS, V10, P1200, DOI [10.1038/NMETH.2658, 10.1038/nmeth.2658]; Pearce MM, 2014, MBIO, V5, DOI 10.1128/mBio.01283-14; Petrova MI, 2017, TRENDS MICROBIOL, V25, P182, DOI 10.1016/j.tim.2016.11.007; Pires CVG, 2016, OBSTET GYNECOL, V127, P273, DOI 10.1097/AOG.0000000000001257; Powell AM, 2015, CLIN OBSTET GYNECOL, V58, P453, DOI 10.1097/GRF.0000000000000124; Pybus V, 1999, MICROBES INFECT, V1, P285, DOI 10.1016/S1286-4579(99)80024-0; R Core Team, 2016, R LANG ENV STAT COMP; Ramoni RB, 2009, STROKE, V40, pS67, DOI 10.1161/STROKEAHA.108.533273; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Roehrig S. F., 1993, Proceeding of the Twenty-Sixth Hawaii International Conference on System Sciences (Cat. No.93TH0501-7), P523, DOI 10.1109/HICSS.1993.284352; Romero R, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-4; Romo LF, 2012, J PEDIATR ADOL GYNEC, V25, P328, DOI 10.1016/j.jpag.2012.06.001; Sauer AG, 2015, CANCER EPIDEMIOL, V39, P650, DOI 10.1016/j.canep.2015.05.002; Scutari M, 2010, J STAT SOFTW, V35, P1, DOI 10.18637/jss.v035.i03; Shankar J, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.01.13; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Srinivasan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037818; Steck H., 2008, P 24 C UNC ART INT U, P511; Sweeney EL, 2016, J INFECT DIS, V213, P1340, DOI 10.1093/infdis/jiv587; Tibaldi C, 2016, INT J GYNECOL OBSTET, V133, P89, DOI 10.1016/j.ijgo.2015.07.035; Tierney L, 2016, SIMPLE NETWORK WORKS; Uusitalo L, 2007, ECOL MODEL, V203, P312, DOI 10.1016/j.ecolmodel.2006.11.033; Verhelst R, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-16; Wang B, 2014, EUR J CLIN MICROBIOL, V33, P1749, DOI 10.1007/s10096-014-2128-5; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Warton DI, 2012, METHODS ECOL EVOL, V3, P89, DOI 10.1111/j.2041-210X.2011.00127.x; Wu TJ, 2002, PEDIATRICS, V110, P752, DOI 10.1542/peds.110.4.752; Xia YL, 2017, GENES DIS, V4, P138, DOI 10.1016/j.gendis.2017.06.001; Yang NJ, 2017, J MOL BIOL, V429, P587, DOI 10.1016/j.jmb.2016.12.023; Zhou Xia, 2010, Infect Dis Obstet Gynecol, V2010, P737425, DOI 10.1155/2010/737425; Zhou X, 2010, FEMS IMMUNOL MED MIC, V58, P169, DOI 10.1111/j.1574-695X.2009.00618.x; Zinaman MJ, 2006, PAEDIATR PERINAT EP, V20, P26, DOI 10.1111/j.1365-3016.2006.00767.x	90	60	61	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2018	13	1							e0191625	10.1371/journal.pone.0191625	http://dx.doi.org/10.1371/journal.pone.0191625			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT8OQ	29364944	gold, Green Published, Green Submitted			2023-01-03	WOS:000423412500062
J	Maddox, KEJ; Orav, EJ; Zheng, J; Epstein, AM				Maddox, Karen E. Joynt; Orav, E. John; Zheng, Jie; Epstein, Arnold M.			Participation and Dropout in the Bundled Payments for Care Improvement Initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Maddox, Karen E. Joynt] Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA; [Orav, E. John] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Zheng, Jie; Epstein, Arnold M.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Maddox, KEJ (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	kjoyntmaddox@wustl.edu			Commonwealth Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL109177] Funding Source: NIH RePORTER	Commonwealth Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the Commonwealth Fund.	[Anonymous], FED REG; Centers for Medicare and Medicaid Services, 2016, QUAL PAYM PROGR DEL; Centers for Medicare and Medicaid Services, BUNDL PAYM CAR IMPR; Centers for Medicare & Medicaid Services, EP PAYM MOD; Dummit L, CMS BUNDLED PAYMENTS, P2; PRICE T, COMMUNICATION	6	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	2018	319	2					191	193		10.1001/jama.2017.14771	http://dx.doi.org/10.1001/jama.2017.14771			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FS4PR	29318267	Bronze, Green Published			2023-01-03	WOS:000419775500019
J	Drew, AJ; Izykowski, MT; Bachus, KN; Henninger, HB; Foreman, KB				Drew, Alex J.; Izykowski, Morgan T.; Bachus, Kent N.; Henninger, Heath B.; Foreman, K. Bo			Transhumeral loading during advanced upper extremity activities of daily living	PLOS ONE			English	Article							UPPER-LIMB; ELBOW; PROSTHETICS; SHOULDER	Percutaneous osseointegrated (OI) implants for direct skeletal attachment of upper extremity prosthetics represent an alternative to traditional socket suspension that may yield improved patient function and satisfaction. This is especially true in high-level, transhumeral amputees where prosthetic fitting is challenging and abandonment rates remain high. However, maintaining mechanical integrity of the bone-implant interface is crucial for safe clinical introduction of this technology. The collection of population data on the transhumeral loading environment will aid in the design of compliance and overload protection devices that mitigate the risk of periprosthetic fracture. We collected marker-based upper extremity kinematic data from non-amputee volunteers during advanced activities of daily living (AADLs) that applied dynamic loading to the humerus. Inverse dynamic analysis was applied to calculate the axial force, bending and torsional moments at three virtual amputation levels representing 25, 50, and 75% residual humeral length. The influences of amputation level, elbow flexion constraint, gender and anthropometric scaling were assessed. Results indicate that the proximal (25%) amputation level experienced significantly higher axial forces and bending moments across all subjects when compared to distal amputation levels (p <= 0.030). Constraining elbow flexion had a limited influence on peak transhumeral loads. Male subjects experienced higher axial forces during all evaluated activities (p <= 0.023). Peak axial force for all activities occurred during jumping jacks (174.5N). Peak bending (57.6Nm) and torsional (57.2Nm) moments occurred during jumping jacks and rapid internal humeral rotation, respectively. Calculated loads fall within the range of implant fixation failure loads reported in cadaveric investigations of humeral stem fixation; indicating that periprosthetic fracture may occur during non-contact AADLs. These kinematic data, collected over a range of AADLs, will aid in the development of overload protection devices and appropriate post-operative rehabilitation protocols that balance return to an active lifestyle with patient safety.	[Drew, Alex J.; Izykowski, Morgan T.; Bachus, Kent N.; Henninger, Heath B.; Foreman, K. Bo] Univ Utah, Dept Orthopaed, Salt Lake City, UT 84112 USA; [Drew, Alex J.; Izykowski, Morgan T.; Bachus, Kent N.; Henninger, Heath B.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [Bachus, Kent N.; Foreman, K. Bo] Dept Vet Affairs, Salt Lake City, UT USA; [Foreman, K. Bo] Univ Utah, Dept Phys Therapy & Athlet Training, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Utah System of Higher Education; University of Utah	Henninger, HB (corresponding author), Univ Utah, Dept Orthopaed, Salt Lake City, UT 84112 USA.; Henninger, HB (corresponding author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.; Foreman, KB (corresponding author), Dept Vet Affairs, Salt Lake City, UT USA.; Foreman, KB (corresponding author), Univ Utah, Dept Phys Therapy & Athlet Training, Salt Lake City, UT USA.	heath.henninger@utah.edu; bo.foreman@hsc.utah.edu	Henninger, Heath B/I-1488-2019	Henninger, Heath B/0000-0002-3635-1289	Medical Research and Materiel Command [W81XWH-15-C-0058]; National Institutes of Health [R01 AR067196]; United States Department of Veterans Affairs Rehabilitation Research and Development Service: Merit Review Award [I01RX001246]; University of Utah Undergraduate Research Opportunity Program; US Army Medical Research and Materiel Command [W81XWH-15-C-0058]; United States Department of Veterans Affairs Rehabilitation Research and Development Service [I01RX001246]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067196] Funding Source: NIH RePORTER; Veterans Affairs [I01RX001246] Funding Source: NIH RePORTER	Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Department of Veterans Affairs Rehabilitation Research and Development Service: Merit Review Award; University of Utah Undergraduate Research Opportunity Program; US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); United States Department of Veterans Affairs Rehabilitation Research and Development Service; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs)	This study was supported by the Medical Research and Materiel Command, award number: #W81XWH-15-C-0058, recipient: KNB; National Institutes of Health, award number: R01 AR067196, recipient: HBH; United States Department of Veterans Affairs Rehabilitation Research and Development Service: Merit Review Award, award number: #I01RX001246, recipient: KNB; and University of Utah Undergraduate Research Opportunity Program, award number: None, recipient: MTI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work is supported by the US Army Medical Research and Materiel Command under Contract #W81XWH-15-C-0058, the National Institutes of Health (R01 AR067196), a Merit Review Award #I01RX001246 from the United States Department of Veterans Affairs Rehabilitation Research and Development Service, and the University of Utah Undergraduate Research Opportunity Program. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army or National Institutes of Health position, policy or decision unless so designated by other documentation. Furthermore, the contents do not represent the views of either the U.S. Department of Veterans Affairs, or the United States Government.	Aguinaldo AL, 2009, AM J SPORT MED, V37, P2043, DOI 10.1177/0363546509336721; Barker TM, 1997, P I MECH ENG H, V211, P483, DOI 10.1243/0954411981534619; Biddiss E, 2007, AM J PHYS MED REHAB, V86, P977, DOI 10.1097/PHM.0b013e3181587f6c; de Leva P, 1996, J BIOMECH, V29, P1223, DOI 10.1016/0021-9290(95)00178-6; DEQUEKER J, 1971, INVEST RADIOL, V6, P260, DOI 10.1097/00004424-197107000-00005; Flury MP, 2011, ARCH ORTHOP TRAUM SU, V131, P267, DOI 10.1007/s00402-010-1170-8; Hansen RL, 2015, 6TH INTERNATIONAL CO; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Jonsson S, 2011, PROSTHET ORTHOT INT, V35, P190, DOI 10.1177/0309364611409003; Kang NV, 2010, J HAND SURG-AM, V35A, P1130, DOI 10.1016/j.jhsa.2010.03.037; Keyak JH, 2009, BONE, V44, P449, DOI 10.1016/j.bone.2008.11.014; Masjedi M, 2013, P I MECH ENG H, V227, P1275, DOI 10.1177/0954411913502330; Matsen FA, 1993, PRACTICAL TOOL EVALU; McCarthy ID, 2012, SPINAL CORD, V50, P333, DOI 10.1038/sc.2011.143; McFarland LV, 2010, J REHABIL RES DEV, V47, P299, DOI 10.1682/JRRD.2009.03.0027; Murray IA, 2004, CLIN BIOMECH, V19, P586, DOI 10.1016/j.clinbiomech.2004.03.004; Rab G, 2002, GAIT POSTURE, V15, P113, DOI 10.1016/S0966-6362(01)00155-2; Richards R R, 1994, J Shoulder Elbow Surg, V3, P347, DOI 10.1016/S1058-2746(09)80019-0; van der Lugt JCT, 2010, INT ORTHOP, V34, P1213, DOI 10.1007/s00264-009-0910-2; Welke B, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475-925X-12-70; WERNER SL, 1993, J ORTHOP SPORT PHYS, V17, P274, DOI 10.2519/jospt.1993.17.6.274; Winter DA, 1990, BIOMECHANICS MOTOR C, V2nd; Zatsiorsky V, 1983, MASS INERTIA CHARACT	23	10	10	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2017	12	12							e0189418	10.1371/journal.pone.0189418	http://dx.doi.org/10.1371/journal.pone.0189418			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7PP	29261703	Green Published, gold, Green Submitted			2023-01-03	WOS:000418554900018
J	Gartlehner, G; Patel, SV; Feltner, C; Weber, RP; Long, R; Mullican, K; Boland, E; Lux, L; Viswanathan, M				Gartlehner, Gerald; Patel, Sheila V.; Feltner, Cynthia; Weber, Rachel Palmieri; Long, Rachel; Mullican, Kelly; Boland, Erin; Lux, Linda; Viswanathan, Meera			Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women Evidence Report and Systematic Review for the US Preventive Services Task Force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; DOSE TRANSDERMAL ESTRADIOL; CORONARY-HEART-DISEASE; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; BREAST-CANCER INCIDENCE; BONE-MINERAL DENSITY; REPLACEMENT THERAPY; ESTROGEN/PROGESTIN REPLACEMENT	IMPORTANCE Postmenopausal status coincides with increased risks for chronic conditions such as heart disease, osteoporosis, cognitive impairment, or some types of cancers. Previously, hormone therapy was used for the primary prevention of these chronic conditions. OBJECTIVE To update evidence for the US Preventive Services Task Force on the benefits and harms of hormone therapy in reducing risks for chronic conditions. DATA SOURCES MEDLINE, Cochrane Library, EMBASE, and trial registries from June 1, 2011, through August 1, 2016. Surveillance for new evidence in targeted publications was conducted through July 1, 2017. STUDY SELECTION English-language randomized clinical trials reporting health outcomes. DATA EXTRACTION AND SYNTHESIS Dual review of abstracts, full-text articles, and study quality; meta-analyses when at least 3 similar studies were available. MAIN OUTCOMES AND MEASURES Beneficial or harmful changes in risks for various chronic conditions. RESULTS Eighteen trials (n = 40058; range, 142-16 608; mean age, 53-79 years) were included. Women using estrogen-only therapy compared with placebo had significantly lower risks, per 10000 person-years, for diabetes (-19 cases [95% CI, -34 to -3]) and fractures (-53 cases [95% CI, -69 to -39]). Risks were statistically significantly increased, per 10000 person-years, for gallbladder disease (30 more cases [95% CI, 16 to 48]), stroke (11 more cases [95% CI, 2 to 23]), venous thromboembolism (11 more cases [95% CI, 3 to 22]), and urinary incontinence (1261 more cases [95% CI, 880 to 1689]). Women using estrogen plus progestin compared with placebo experienced significantly lower risks, per 10000 person-years, for colorectal cancer (-6 cases [95% CI, -9 to -1]), diabetes (-14 cases [95% CI, -24 to -3), and fractures (-44 cases [95% CI, -71 to -13). Risks, per 10000 person-years, were significantly increased for invasive breast cancer (9 more cases [95% CI, 1 to 19]), probable dementia (22 more cases [95% CI, 4 to 53]), gallbladder disease (21 more cases [95% CI, 10 to 34]), stroke (9 more cases [95% CI, 2 to 19]), urinary incontinence (876 more cases [95% CI, 606 to 1168]), and venous thromboembolism (21 more cases [95% CI, 12 to 33]). CONCLUSIONS AND RELEVANCE Hormone therapy for the primary prevention of chronic conditions in menopausal women is associated with some beneficial effects but also with a substantial increase of risks for harms. The available evidence regarding benefits and harms of early initiation of hormone therapy is inconclusive.	[Gartlehner, Gerald; Patel, Sheila V.; Feltner, Cynthia; Weber, Rachel Palmieri; Long, Rachel; Mullican, Kelly; Boland, Erin; Lux, Linda; Viswanathan, Meera] Univ North Carolina Chapel Hill, RTI Int, Evidence Based Practice Ctr, Chapel Hill, NC USA; [Gartlehner, Gerald] Danube Univ Krems, Dept Evidence Based Med & Clin Epidemiol, Krems, Austria; [Patel, Sheila V.; Boland, Erin; Lux, Linda; Viswanathan, Meera] RTI Int, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA; [Feltner, Cynthia; Weber, Rachel Palmieri] Univ North Carolina Chapel Hill, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA; [Feltner, Cynthia] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA; [Long, Rachel; Mullican, Kelly] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Chapel Hill, NC USA	Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Danube University Krems; Research Triangle Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Gartlehner, G (corresponding author), RTI Int, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA.	ggartlehner@rti.org	Lux, Linda/GPX-3639-2022; Gartlehner, Gerald/AAY-2801-2021	Gartlehner, Gerald/0000-0001-5531-3678; Weber, Rachel/0000-0001-7119-7734; Patel, Sheila/0000-0002-6508-8803	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA-290-2012-00015-I]	Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services	This research was funded under contract HHSA-290-2012-00015-I, Task Order 6, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, under a contract to support the US Preventive Services Task Force (USPSTF).	Anderson GL, 2012, LANCET ONCOL, V13, P476, DOI 10.1016/S1470-2045(12)70075-X; Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2015, HUMAN DEV REPORT 201; Berkman ND, 2015, J CLIN EPIDEMIOL, V68, P1312, DOI 10.1016/j.jclinepi.2014.11.023; Boardman HMP, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002229.pub4; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; Canonico M, 2014, MENOPAUSE, V21, P214, DOI 10.1097/GME.0b013e31829752e0; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cherry N, 2014, BJOG-INT J OBSTET GY, V121, P700, DOI 10.1111/1471-0528.12598; Cherry N, 2002, LANCET, V360, P2001; Chlebowski RT, 2015, JAMA ONCOL, V1, P296, DOI 10.1001/jamaoncol.2015.0494; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; Culhane NS, 2003, J FAM PRACTICE, V52, P754; Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Espeland MA, 2013, JAMA INTERN MED, V173, P1429, DOI 10.1001/jamainternmed.2013.7727; Espeland MA, 2010, J AM GERIATR SOC, V58, P1263, DOI 10.1111/j.1532-5415.2010.02953.x; Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79; Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P3618, DOI 10.1210/jc.86.8.3618; Gleason CE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001833; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Gramling R, 2009, EPIDEMIOLOGY, V20, P752, DOI 10.1097/EDE.0b013e3181a71279; Greenspan SL, 2005, AM J MED, V118, P1232, DOI 10.1016/j.amjmed.2005.03.004; Harlow SD, 2012, MENOPAUSE, V19, P387, DOI 10.1097/gme.0b013e31824d8f40; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; Hendrix Susan L, 2003, J Am Osteopath Assoc, V103, pS3; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hodis HN, 2001, ANN INTERN MED, V135, P939, DOI 10.7326/0003-4819-135-11-200112040-00005; Hodis HN, 2016, NEW ENGL J MED, V374, P1221, DOI 10.1056/NEJMoa1505241; Hsia J, 2004, CIRCULATION, V109, P620, DOI 10.1161/01.CIR.0000115309.63979.92; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Johnson SR, 2005, OBSTET GYNECOL, V105, P779, DOI 10.1097/01.AOG.0000157116.23249.52; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; LaCroix AZ, 2011, JAMA-J AM MED ASSOC, V305, P1305, DOI 10.1001/jama.2011.382; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217; Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; McEvoy G.K., 2016, AHFS DRUG INFORM 201; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Nelson HD, 2012, AHRQ PUBLICATION, V12-05167-EF-1; Prentice RL, 2009, AM J EPIDEMIOL, V170, P12, DOI 10.1093/aje/kwp115; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Resnick SM, 2006, J CLIN ENDOCR METAB, V91, P1802, DOI 10.1210/jc.2005-2097; Resnick Susan M, 2004, Clin Trials, V1, P440, DOI 10.1191/1740774504cn040oa; Resnick SM, 2009, J CLIN ENDOCR METAB, V94, P4152, DOI 10.1210/jc.2009-1340; Ritenbaugh C, 2008, CANCER EPIDEM BIOMAR, V17, P2609, DOI 10.1158/1055-9965.EPI-08-0385; Rocca WA, 2014, MOL CELL ENDOCRINOL, V389, P7, DOI 10.1016/j.mce.2014.01.020; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter SR, 2009, AM J MED, V122, P1016, DOI 10.1016/j.amjmed.2009.05.021; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Steinauer JE, 2005, OBSTET GYNECOL, V106, P940, DOI 10.1097/01.AOG.0000180394.08406.15; Tang JY, 2011, J NATL CANCER I, V103, P1469, DOI 10.1093/jnci/djr333; Tierney MC, 2009, PSYCHONEUROENDOCRINO, V34, P1065, DOI 10.1016/j.psyneuen.2009.02.009; Toh S, 2010, ANN INTERN MED, V152, P211, DOI 10.7326/0003-4819-152-4-201002160-00005; U.S. Food & Drug Administration, MEN MED HELP YOU; US Preventive Services Task Force, 2016, METH PROC; Veerus P, 2006, MATURITAS, V55, P162, DOI 10.1016/j.maturitas.2006.01.012; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD; Waetjen LE, 2005, OBSTET GYNECOL, V106, P946, DOI 10.1097/01.AOG.0000182576.48290.6d; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; West SL., 2010, AHRQ PUBLICATION; Whitmer RA, 2011, ANN NEUROL, V69, P163, DOI 10.1002/ana.22239; Yaffe K, 2006, ARCH NEUROL-CHICAGO, V63, P945, DOI 10.1001/archneur.63.7.945	83	81	84	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 12	2017	318	22					2234	2249		10.1001/jama.2017.16952	http://dx.doi.org/10.1001/jama.2017.16952			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP7NR	29234813	Bronze			2023-01-03	WOS:000417822700021
J	O'Donoghue, FJ; McDonald, CF				O'Donoghue, Fergal J.; McDonald, Christine F.			Review: In adults with sleep apnea, positive airway pressure does not reduce cardiovascular events or death	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[O'Donoghue, Fergal J.; McDonald, Christine F.] Univ Melbourne, Inst Breathing & Sleep, Melbourne, Vic, Australia	Institute for Breathing & Sleep (IBAS); University of Melbourne	O'Donoghue, FJ (corresponding author), Univ Melbourne, Inst Breathing & Sleep, Melbourne, Vic, Australia.		McDonald, Christine Faye/AAU-9083-2021					Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263; Jordan AS, 2014, LANCET, V383, P736, DOI 10.1016/S0140-6736(13)60734-5; McEvoy RD, 2016, NEW ENGL J MED, V375, P2302, DOI 10.1056/NEJMc1613219; SULLIVAN CE, 1981, LANCET, V1, P862; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2017	167	10					JC54	JC55		10.7326/ACPJC-2017-167-10-054	http://dx.doi.org/10.7326/ACPJC-2017-167-10-054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO2DP	29159380				2023-01-03	WOS:000416584200006
J	Plazy, M; Perriat, D; Gumede, D; Boyer, S; Pillay, D; Dabis, F; Seeley, J; Orne-Gliemann, J				Plazy, Melanie; Perriat, Delphine; Gumede, Dumile; Boyer, Sylvie; Pillay, Deenan; Dabis, Francois; Seeley, Janet; Orne-Gliemann, Joanna			Implementing universal HIV treatment in a high HIV prevalence and rural South African setting - Field experiences and recommendations of health care providers	PLOS ONE			English	Article							EARLY ANTIRETROVIRAL THERAPY; DIFFERENTIATED CARE; INCOME COUNTRIES; PREVENTION; INITIATION; TRIAL; ART; INFECTION; PERSPECTIVES; ADHERENCE	Background We aimed to describe the field experiences and recommendations of clinic-based health care providers (HCP) regarding the implementation of universal antiretroviral therapy (ART) in rural KwaZulu-Natal, South Africa. Methods In Hlabisa sub-district, the local HIV programme of the Department of Health (DoH) is decentralized in 18 clinics, where ART was offered at a CD4 count <= 500 cells/mu L from January 2015 to September 2016. Within the ANRS 12249 TasP trial, implemented in part of the sub-district, universal ART (no eligibility criteria) was offered in 11 mobile clinics between March 2012 and June 2016. A cross-sectional qualitative survey was conducted in April-July 2016 among clinic-based nurses and counsellors providing HIV care in the DoH and TasP trial clinics. In total, 13 individual interviews and two focus groups discussions (including 6 and 7 participants) were conducted, audio-recorded, transcribed, and thematically analyzed. Results All HCPs reported an overall good experience of delivering ART early in the course of HIV infection, with most patients willing to initiate ART before being symptomatic. Yet, HCPs underlined that not feeling sick could challenge early ART initiation and adherence, and thus highlighted the need to take time for counselling as an important component to achieve universal ART. HCPs also foresaw logistical challenges of universal ART, and were especially concerned about increasing workload and ART shortage. HCPs finally recommended the need to strengthen the existing model of care to facilitate access to ART, e.g., community-based and integrated HIV services. Conclusions The provision of universal ART is feasible and acceptable according to HCPs in this rural South-African area. However their experiences suggest that universal ART, and more generally the 90-90-90 UNAIDS targets, will be difficult to achieve without the implementation of new models of health service delivery.	[Plazy, Melanie; Perriat, Delphine; Dabis, Francois; Orne-Gliemann, Joanna] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, UMR 1219, Bordeaux, France; [Plazy, Melanie; Perriat, Delphine; Dabis, Francois; Orne-Gliemann, Joanna] INSERM, Bordeaux Populat Hlth Res Ctr, ISPED, UMR 1219, Bordeaux, France; [Gumede, Dumile; Pillay, Deenan; Seeley, Janet] Africa Hlth Res Inst, Somkhele, South Africa; [Boyer, Sylvie] Aix Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France; [Pillay, Deenan] UCL, Div Infect & Immun, London, England; [Seeley, Janet] London Sch Hyg & Trop Med, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Africa Health Research Institute; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Plazy, M (corresponding author), Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, UMR 1219, Bordeaux, France.; Plazy, M (corresponding author), INSERM, Bordeaux Populat Hlth Res Ctr, ISPED, UMR 1219, Bordeaux, France.	melanie.plazy@u-bordeaux.fr	DABIS, FRANCOIS/S-9298-2019; Plazy, Melanie/T-9707-2019; Gumede, Dumile/GXZ-5278-2022; Orne-Gliemann, Joanna/T-2787-2019	DABIS, FRANCOIS/0000-0002-1614-8857; Gumede, Dumile/0000-0002-8628-5726; Perriat, Delphine/0000-0001-7498-1700; Seeley, Janet/0000-0002-0583-5272; PLAZY, Melanie/0000-0002-8971-6878	French National Agency for AIDS and Viral Hepatitis Research (ANRS); ANRS; International Initiative for Impact Evaluation, Inc. (3ie); Bill & Melinda Gates Foundation; Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ); Wellcome Trust; French Charity Sidaction; French Ecole des Hautes Etudes en Sante Publique (EHESP)	French National Agency for AIDS and Viral Hepatitis Research (ANRS)(ANRSFrench National Research Agency (ANR)); ANRS(ANRSFrench National Research Agency (ANR)); International Initiative for Impact Evaluation, Inc. (3ie); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ); Wellcome Trust(Wellcome TrustEuropean Commission); French Charity Sidaction; French Ecole des Hautes Etudes en Sante Publique (EHESP)	The French National Agency for AIDS and Viral Hepatitis Research (ANRS) is the sponsor and co-funder of the TasP trial within which this study was conducted. Research discussed in this publication has been co-funded by ANRS together with the International Initiative for Impact Evaluation, Inc. (3ie) with support from the Bill & Melinda Gates Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of 3ie or the Bill & Melinda Gates Foundation. The Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ) co-funded the first part of the trial. Merck & Co. Inc. and Gilead Sciences provided the Atriplat drug supply. The Africa Health Research Institute (AHRI) receives core funding from the Wellcome Trust, which provides the platform for the population- and clinic-based research at Somkhele. Melanie Plazy is supported by the French Charity Sidaction and Delphine Perriat by the French Ecole des Hautes Etudes en Sante Publique (EHESP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, CONS GUID PERS CTR H; Barnighausen T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163960; Bor J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178249; Boyer S, 2016, AIDS CARE, V28, P39, DOI 10.1080/09540121.2016.1164808; Celletti F, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21185; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Dussault G, 2008, SOC SCI MED, V66, P2088, DOI 10.1016/j.socscimed.2008.01.035; Dutta A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001907; Evans C, 2015, AIDS CARE, V27, P753, DOI 10.1080/09540121.2014.1002826; Grimsrud A, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.21484; Haberer JE, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21371; Hayes R, 2011, CURR HIV RES, V9, P429, DOI 10.2174/157016211798038515; Houlihan CF, 2011, INT J EPIDEMIOL, V40, P318, DOI 10.1093/ije/dyp402; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Inzaule SC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167492; Iwuji C, 2016, AIDS C 18 22 JUL DUR; Iwuji CC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002107; Iwuji CC, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-230; Kurth AE, 2012, JAIDS-J ACQ IMM DEF, V61, pE65, DOI [10.1097/QAI.0b013e31826a184c., 10.1097/QAI.0b013e31826a184c]; Lebouche Bertrand, 2014, J Int Assoc Provid AIDS Care, V13, P160, DOI 10.1177/2325957413488196; Lebouche B, 2013, AIDS CARE, V25, P1284, DOI 10.1080/09540121.2013.764394; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; MacPherson P, 2014, JAMA-J AM MED ASSOC, V312, P372, DOI 10.1001/jama.2014.6493; Mao LM, 2013, AIDS CARE, V25, P1375, DOI 10.1080/09540121.2013.766304; Mbonye M, 2016, AIDS CARE, V28, P33, DOI 10.1080/09540121.2016.1164804; Mukherjee JS, 2016, CURR HIV-AIDS REP, V13, P359, DOI 10.1007/s11904-016-0335-7; Nachega JB, 2016, CURR HIV-AIDS REP, V13, P241, DOI 10.1007/s11904-016-0325-9; Orne-Gliemann J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1344-y; Perriat D, J INT AIDS IN PRESS; Peter T, 2017, LANCET INFECT DIS, V17, pE26, DOI 10.1016/S1473-3099(16)30212-2; Phillips A, 2015, NATURE, V528, pS68, DOI 10.1038/nature16046; Plazy M, 2017, 9 IAS C HIV SCI 23 2; Plazy M, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20913; South African Department of Health, 2017, ID CLIN MAN; Treves-Kagan S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2753-2; UNAIDS, 2014, 90 90 90 AMB TREATM; Van Damme W, 2008, SOC SCI MED, V66, P2108, DOI 10.1016/j.socscimed.2008.01.043; Vernooij E, 2016, AIDS CARE, V28, P7, DOI 10.1080/09540121.2016.1178954; WHO, 2010, ANT THER HIV INF AD; WHO (World Health Organization), 2016, PROGR REP 2016 PREV; World Health Organization, 2015, GUID START ANT THER; World Health Organization, 2016, CONS GUID US ANT DRU	44	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2017	12	11							e0186883	10.1371/journal.pone.0186883	http://dx.doi.org/10.1371/journal.pone.0186883			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN1NI	29155832	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000415756700006
J	Brini, I; Guerrero, A; Hannachi, N; Bouguila, J; Orth-Holler, D; Bouhlel, A; Boughamoura, L; Hetzer, B; Borena, W; Schiela, B; Von Laer, D; Boukadida, J; Stoiber, H				Brini, Ines; Guerrero, Aida; Hannachi, Naila; Bouguila, Jihene; Orth-Hoeller, Dorothea; Bouhlel, Amira; Boughamoura, Lamia; Hetzer, Benjamin; Borena, Wegene; Schiela, Britta; Von Laer, Dorothee; Boukadida, Jalel; Stoiber, Heribert			Epidemiology and clinical profile of pathogens responsible for the hospitalization of children in Sousse area, Tunisia	PLOS ONE			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; HUMAN METAPNEUMOVIRUS; PCR; ETIOLOGY; FEATURES; INFANTS; ASSAYS; UNIT	This study aimed to identify a broad spectrum of respiratory pathogens from hospitalized and not-preselected children with acute respiratory tract infections in the Farhat Hached University-hospital of Sousse, Tunisia. Between September 2013 and December 2014, samples from 372 children aged between 1 month and 5 years were collected, and tested using multiplex real-time RT-PCR by a commercial assay for 21 respiratory pathogens. In addition, samples were screened for the presence of Streptococcus pneumoniae 16S rDNA using real-time PCR. The viral distribution and its association with clinical symptoms were statistically analyzed. Viral pathogens were detected in 342 (91.93%) of the samples of which 28.76% were single positive and 63.17% had multiple infections. The most frequent detected viruses were rhinovirus (55.64%), respiratory syncytial virus A/B (33.06%), adenovirus (25.00%), coronavirus NL63, HKU1, OC43, and 229E (21.50%), and metapneumovirus A/B (16.12%). Children in the youngest age group (1-3 months) exhibited the highest frequencies of infection. Related to their frequency of detection, RSV A/B was the most associated pathogen with patient's demographic situation and clinical manifestations (p<0.05). Parainfluenza virus 1-4 and parechovirus were found to increase the risk of death (p<0.05). Adenovirus was statistically associated to the manifestation of gastroenteritis (p = 0.004). Rhinovirus infection increases the duration of oxygen support (p = 0.042). Coronavirus group was statistically associated with the manifestation of bronchiolitis (p = 0.009) and laryngitis (p = 0.017). Streptococcus pneumoniae DNA was detected in 143 (38.44%) of tested samples. However, only 53 samples had a concentration of C-reactive protein from equal to higher than 20 milligrams per liter, and 6 of them were single positive for Streptocuccus pneumoniae. This study confirms the high incidence of respiratory viruses in children hospitalized for acute respiratory tract infections in the Sousse area, Tunisia.	[Brini, Ines; Hannachi, Naila; Boukadida, Jalel] Univ Sousse, Fac Med Sousse, Lab Microbiol & Immunol, Sousse, Tunisia; [Brini, Ines; Hannachi, Naila; Boukadida, Jalel] Univ Hosp Farhat Hached Sousse, Res Unit Genom Characterizat Infect Agents UR12SP, Sousse, Tunisia; [Brini, Ines] Univ Monastir, Fac Pharm Monastir, Monastir, Tunisia; [Brini, Ines; Hetzer, Benjamin] Innsbruck Med Univ, Innsbruck, Austria; [Guerrero, Aida; Borena, Wegene; Schiela, Britta; Von Laer, Dorothee; Stoiber, Heribert] Innsbruck Med Univ, Div Virol, Innsbruck, Austria; [Bouhlel, Amira; Boughamoura, Lamia] Univ Hosp Farhat Hached Sousse Sousse, Pediat Serv, Sousse, Tunisia; [Orth-Hoeller, Dorothea] Innsbruck Med Univ, Div Hyg & Med Microbiol, Innsbruck, Austria	Universite de Sousse; Universite de Sousse; Hopital Farhat Hached; Universite de Monastir; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Brini, I (corresponding author), Univ Sousse, Fac Med Sousse, Lab Microbiol & Immunol, Sousse, Tunisia.; Brini, I (corresponding author), Univ Hosp Farhat Hached Sousse, Res Unit Genom Characterizat Infect Agents UR12SP, Sousse, Tunisia.; Brini, I (corresponding author), Univ Monastir, Fac Pharm Monastir, Monastir, Tunisia.; Brini, I (corresponding author), Innsbruck Med Univ, Innsbruck, Austria.; Stoiber, H (corresponding author), Innsbruck Med Univ, Div Virol, Innsbruck, Austria.	ines.brini@hotmail.com; Heribert.stoiber@i-med.ac.at		von Laer, Dorothee/0000-0001-5825-7237; Orth-Holler, Dorothea/0000-0003-2904-5192	FWF (Horos doctoral Program) [W1253-B24]; Innsbruck Medical University, Innsbruck, Austria; Unit Research for Genomic Characterization of Infectious Agents at Farhat Hached University-hospital of Sousse, Tunisia [UR12SP34]; Ministry of Higher Education and Scientific Research in Tunisia	FWF (Horos doctoral Program); Innsbruck Medical University, Innsbruck, Austria; Unit Research for Genomic Characterization of Infectious Agents at Farhat Hached University-hospital of Sousse, Tunisia; Ministry of Higher Education and Scientific Research in Tunisia	The FWF (Horos doctoral Program, W1253-B24) and Innsbruck Medical University, Innsbruck, Austria (HS): methodology of study. The Unit Research for Genomic Characterization of Infectious Agents UR12SP34 in Farhat Hached university-hospital of Sousse area in Tunisia and the Ministry of Higher Education and Scientific Research in Tunisia (J Boukadida): study design, data collection. The funders had no role in data analysis, decision to publish, or preparation of the manuscript.; This study was in part supported by the FWF (Horos doctoral Program, W1253-B24), the Unit Research for Genomic Characterization of Infectious Agents UR12SP34 at Farhat Hached University-hospital of Sousse, Tunisia, and the Ministry of Higher Education and Scientific Research in Tunisia. The excellent technical assistance of Vicky Staudinger with the S. pneumoniae-qPCR is greatly appreciated. We thank statisticians from the Epidemiology ward at Farhat Hached University-hospital of Sousse, Tunisia, for providing additional instructions about the statistical calculations. We are also indebted to Pr. Khaled Ben Khadim Allah from the Medical English Department at Sousse Medical University, Tunisia, for improving the manuscript's spelling, vocabulary, and grammar.	Abroug F, 2014, EMERG INFECT DIS, V20, P1527, DOI 10.3201/eid2009.140378; Al-Ayed MS, 2014, SAUDI MED J, V35, P1348; Baccala GP, 2008, J CLIN VIROL, V43, P407, DOI 10.1016/j.jcv.2008.08.010; Ben M'hadheb M, 2015, CURR MICROBIOL, V70, P324, DOI 10.1007/s00284-014-0719-0; Bicer S, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-22; Brittain-Long R, 2008, J CLIN VIROL, V41, P53, DOI 10.1016/j.jcv.2007.10.029; Cebey-Lopez M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136526; Chochua S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167725; Corless CE, 2001, J CLIN MICROBIOL, V39, P1553, DOI 10.1128/JCM.39.4.1553-1558.2001; Damak H, 2011, INFLUENZA OTHER RESP, V5, P230, DOI 10.1111/j.1750-2659.2011.00196.x; Do Anh Ha Lien, 2011, PLoS One, V6, pe18176, DOI 10.1371/journal.pone.0018176; Dominguez O, 2005, PEDIATR INFECT DIS J, V24, P733, DOI 10.1097/01.inf.0000172942.96436.2d; El Moussi A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074064; Fodha I, 2004, ANN TROP PAEDIATR, V24, P275, DOI 10.1179/027249304225019055; Fodha I, 2004, ANN TROP PAEDIATR, V24, P219, DOI 10.1179/027249304225018966; Fodha I, 2004, J MED VIROL, V72, P683, DOI 10.1002/jmv.20038; Fodha I, 2007, J MED VIROL, V79, P1951, DOI 10.1002/jmv.21026; Freymuth F, 2006, J MED VIROL, V78, P1498, DOI 10.1002/jmv.20725; Harada Y, 2013, PEDIATR INFECT DIS J, V32, P441, DOI 10.1097/INF.0b013e31828ba08c; Hinman AR, 1998, VACCINE, V16, P1116, DOI 10.1016/S0264-410X(98)80107-2; Huijskens EG, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-276; Jacques J, 2008, J CLIN MICROBIOL, V46, P206, DOI 10.1128/JCM.01414-07; Jroundi I, 2016, EPIDEMIOL INFECT, V144, P516, DOI 10.1017/S095026881500151X; Jroundi I, 2014, J TROP PEDIATRICS, V60, P270, DOI 10.1093/tropej/fmu010; KADI Z, 1990, Revue Roumaine de Virologie, V41, P197; Khadadah M, 2010, J MED VIROL, V82, P1462, DOI 10.1002/jmv.21823; Liu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087818; Louie JK, 2009, PEDIATR INFECT DIS J, V28, P337, DOI 10.1097/INF.0b013e31818ffc1b; Mahony JB, 2008, CLIN MICROBIOL REV, V21, P716, DOI 10.1128/CMR.00037-07; Marzouk M, 2015, MICROB DRUG RESIST, V21, P85, DOI 10.1089/mdr.2014.0084; McIntosh K, 2002, NEW ENGL J MED, V346, P429, DOI 10.1056/NEJMra011994; Mertz D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5061; Muhlemann K, 2006, CLIN MICROBIOL INFEC, V12, P873, DOI [10.1111/j.1469-0691.2006.1472_1.x, 10.1111/j.1469-0691.2006.01472.x]; Nair H, 2013, LANCET, V381, P1380, DOI 10.1016/S0140-6736(12)61901-1; Navne JE, 2016, EPIDEMIOL INFECT, V144, P3226, DOI 10.1017/S0950268816001461; Nemerow GR, 2012, CURR OPIN VIROL, V2, P115, DOI 10.1016/j.coviro.2011.12.008; Pavia AT, 2011, CLIN INFECT DIS, V52, pS284, DOI 10.1093/cid/cir043; Puzelli S, 2009, J MED VIROL, V81, P2066, DOI 10.1002/jmv.21610; Richard N, 2008, PEDIATR INFECT DIS J, V27, P213, DOI 10.1097/INF.0b013e31815b4935; Richter J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147041; Saikku Pekka, 1997, Clin Microbiol Infect, V3, P599, DOI 10.1111/j.1469-0691.1997.tb00464.x; Vandini S, 2016, PAEDIAT RESP REV; Vongphrachanh P, 2010, INFLUENZA OTHER RESP, V4, P47, DOI 10.1111/j.1750-2659.2009.00120.x; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997; Zhang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072606	46	14	16	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2017	12	11							e0188325	10.1371/journal.pone.0188325	http://dx.doi.org/10.1371/journal.pone.0188325			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN0DI	29149199	Green Submitted, Green Published, gold			2023-01-03	WOS:000415646100038
J	Kruse, KE; Batten, J; Constantine, ML; Kache, S; Magnus, D				Kruse, Katherine E.; Batten, Jason; Constantine, Melissa L.; Kache, Saraswati; Magnus, David			Challenges to code status discussions for pediatric patients	PLOS ONE			English	Article							OF-LIFE CARE; PALLIATIVE CARE; FAMILY PERSPECTIVES; RESUSCITATE ORDERS; INTENSIVE-CARE; ATTITUDES; CHILDREN; COMMUNICATION; PHYSICIANS; QUALITY	Objectives In the context of serious or life-limiting illness, pediatric patients and their families are faced with difficult decisions surrounding appropriate resuscitation efforts in the event of a cardiopulmonary arrest. Code status orders are one way to inform end-of-life medical decision making. The objectives of this study are to evaluate the extent to which pediatric providers have knowledge of code status options and explore the association of provider role with (1) knowledge of code status options, (2) perception of timing of code status discussions, (3) perception of family receptivity to code status discussions, and (4) comfort carrying out code status discussions. Design Nurses, trainees (residents and fellows), and attending physicians from pediatric units where code status discussions typically occur completed a short survey questionnaire regarding their knowledge of code status options and perceptions surrounding code status discussions. Setting Single center, quaternary care children's hospital. Measurements and main results 203 nurses, 31 trainees, and 29 attending physicians in 4 high-acuity pediatric units responded to the survey (N = 263, 90% response rate). Based on an objective knowledge measure, providers demonstrate poor understanding of available code status options, with only 22% of providers able to enumerate more than two of four available code status options. In contrast, provider groups self-report high levels of familiarity with available code status options, with attending physicians reporting significantly higher levels than nurses and trainees (p = 0.0125). Nurses and attending physicians show significantly different perception of code status discussion timing, with majority of nurses (63.4%) perceiving discussions as occurring "too late" or "much too late" and majority of attending physicians (55.6%) perceiving the timing as "about right" (p<0.0001). Attending physicians report significantly higher comfort having code status discussions with families than do nurses or trainees (p<0.0001). Attending physicians and trainees perceive families as more receptive to code status discussions than nurses (p<0.0001 and p = 0.0018, respectively). Conclusions Providers have poor understanding of code status options and differ significantly in their comfort having code status discussions and their perceptions of these discussions. These findings may reflect inherent differences among providers, but may also reflect discordant visions of appropriate care and function as a potential source of moral distress. Lack of knowledge of code status options and differences in provider perceptions are likely barriers to quality communication surrounding end-of-life options.	[Kruse, Katherine E.; Batten, Jason; Magnus, David] Stanford Univ, Sch Med, Stanford Ctr Biomed Eth, Stanford, CA 94305 USA; [Kruse, Katherine E.; Kache, Saraswati] Stanford Univ, Dept Pediat, Sch Med, Div Pediat Crit Care Med, Stanford, CA 94305 USA; [Constantine, Melissa L.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA	Stanford University; Stanford University; University of Minnesota System; University of Minnesota Twin Cities	Kruse, KE (corresponding author), Stanford Univ, Sch Med, Stanford Ctr Biomed Eth, Stanford, CA 94305 USA.; Kruse, KE (corresponding author), Stanford Univ, Dept Pediat, Sch Med, Div Pediat Crit Care Med, Stanford, CA 94305 USA.	kruse575@gmail.com			Jackson Vaughan Critical Care Research Award	Jackson Vaughan Critical Care Research Award	Dr. Kruse received grant support from the Jackson Vaughan Critical Care Research Award. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Anderson WG, 2011, J GEN INTERN MED, V26, P359, DOI 10.1007/s11606-010-1568-6; Auerbach AD, 2008, J HOSP MED, V3, P437, DOI 10.1002/jhm.369; Austin W, 2005, HEC FORUM, V17, P33, DOI 10.1007/s10730-005-4949-1; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Contro NA, 2004, PEDIATRICS, V114, P1248, DOI 10.1542/peds.2003-0857-L; Dellon EP, 2010, J PAIN SYMPTOM MANAG, V40, P821, DOI 10.1016/j.jpainsymman.2010.03.021; Dillman DA, 2009, TAILORED DESIGN METH, Vthird; Dube CE, 2003, AMBUL PEDIATR, V3, P137, DOI 10.1367/1539-4409(2003)003<0137:SOCSPA>2.0.CO;2; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamric AB, 2012, AJOB PRIM RES, V3, P1, DOI [10.1080/21507716.2011.652337, DOI 10.1080/21507716.2011.652337]; Henrich NJ, 2016, J CRIT CARE, V35, P57, DOI 10.1016/j.jcrc.2016.04.033; Heyland DK, 2006, CHEST, V130, P419, DOI 10.1378/chest.130.2.419; Hilden JM, 2001, J CLIN ONCOL, V19, P205, DOI 10.1200/JCO.2001.19.1.205; Hinds Pamela S, 2005, J Palliat Med, V8 Suppl 1, pS70, DOI 10.1089/jpm.2005.8.s-70; JARRETT N, 1995, J ADV NURS, V22, P72, DOI 10.1046/j.1365-2648.1995.22010072.x; Khaneja S, 1998, ARCH PEDIAT ADOL MED, V152, P909; Kolarik RC, 2006, PEDIATRICS, V117, P1949, DOI 10.1542/peds.2005-1111; Kraemer H.C., 1987, MANY SUBJECTS STAT P, V1st ed.; Mack JW, 2007, J CLIN ONCOL, V25, P5636, DOI 10.1200/JCO.2007.12.6110; McCallum DE, 2000, J PAIN SYMPTOM MANAG, V20, P417, DOI 10.1016/S0885-3924(00)00212-8; Michelson KN, 2013, PEDIATR CRIT CARE ME, V14, pE34, DOI 10.1097/PCC.0b013e31826e7408; Mirza Ayoub, 2005, Am J Hosp Palliat Care, V22, P20, DOI 10.1177/104990910502200107; Sanderson A, 2013, JAMA PEDIATR, V167, P954, DOI 10.1001/jamapediatrics.2013.2204; Serwint JR, 2004, J PEDIATR-US, V145, P229, DOI 10.1016/j.jpeds.2004.04.055; Solomon MZ, 2005, PEDIATRICS, V116, P872, DOI 10.1542/peds.2004-0905; Sulmasy DP, 2008, CRIT CARE MED, V36, P1817, DOI 10.1097/CCM.0b013e31817c79fe; Vazirani RM, 2000, CRIT CARE MED, V28, P3740, DOI 10.1097/00003246-200011000-00036; WEBSTER GC, 1991, CAN J ANAESTH, V38, P553, DOI 10.1007/BF03008184; Wolfe J, 2000, JAMA-J AM MED ASSOC, V284, P2469, DOI 10.1001/jama.284.19.2469	29	12	12	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2017	12	11							e0187375	10.1371/journal.pone.0187375	http://dx.doi.org/10.1371/journal.pone.0187375			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL6FI	29095938	Green Published, Green Submitted, gold			2023-01-03	WOS:000414340200079
J	Holmes, D				Holmes, David			NON-UNION BONE FRACTURE: A QUICKER FIX	NATURE			English	Editorial Material															Translational Research Informatics Center (TRI); Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine	Translational Research Informatics Center (TRI); Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine	Nature is pleased to acknowledge the financial support of the Translational Research Informatics Center (TRI) and the Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine. As always, Nature retains sole responsibility for all editorial content.		0	31	31	4	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2017	550	7677					S193	S193		10.1038/550S193a	http://dx.doi.org/10.1038/550S193a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK7OW	29069072	Bronze			2023-01-03	WOS:000413697800001
J	Atinga, RA; Yarney, L; Gavu, NM				Atinga, Roger A.; Yarney, Lily; Gavu, Narissa Minta			Factors influencing long-term medication non-adherence among diabetes and hypertensive patients in Ghana: A qualitative investigation	PLOS ONE			English	Article							HEALTH-CARE; ADHERENCE; PREVALENCE; MEDICINES; AWARENESS; THERAPY; HEALERS; ADULTS	Background Evidence remains limited on why diabetes and hypertensive patients admitted to long-term drug therapy miss doses or discontinue medication taking. We examined this phenomenon from the perspective of diabetes and hypertension patients at a Ghanaian teaching hospital. Methods Between July and December 2015, we conducted a qualitative study targeting caregivers and their patients with chronic diabetes and hypertensive on re-admission at the Korle Bu Teaching Hospital due to non-adherence to prescribed medication. Participants were sampled purposefully and taking through in-depth interviews using an interview guide. Notes and audio recordings of interviews were transcribed, managed and coded for themes guided by the thematic network analysis recommended by Attride-Stirling. Results Non-adherence was the result of perceptions that the medications are not effective for managing the conditions. Patients with these perceptions rejected the medications and turned to herbal medicines and spiritual healing as therapeutic alternatives, because of their easy accessibility, perceived efficacy and affordability. Other factors identified to influence non-adherence included polypharmacy practice; tight work schedules; social norms; poor prescription instruction by health providers; and knowledge and experience of medication. Conclusion Findings suggests the need for health providers to adopt therapeutic approaches that take into account patients' beliefs, values and norms in administering medications. Sensitisation of patients and caregivers during admission on the implication of non-adherence, as well as interventions that monitor and provide feedback mechanisms on patients' medication taking behaviour holds promise for maximising diabetes and hypertensive medication adherence.	[Atinga, Roger A.; Yarney, Lily] Univ Ghana, Business Sch, Dept Publ Adm & Hlth Serv Management, Legon, Accra, Ghana; [Gavu, Narissa Minta] Korle Bu Teaching Hosp, Med Dept, Accra, Ghana	University of Ghana	Atinga, RA (corresponding author), Univ Ghana, Business Sch, Dept Publ Adm & Hlth Serv Management, Legon, Accra, Ghana.	ayimbillah@yahoo.com		Yarney, Lily/0000-0003-3423-326X	University of Ghana Business School Faculty support	University of Ghana Business School Faculty support	This research received support from the University of Ghana Business School Faculty support.	Ae-Ngibise K, 2010, INT REV PSYCHIATR, V22, P558, DOI 10.3109/09540261.2010.536149; Aikins Ad-G, 2005, BMJ, V33; Akter S, 2014, B WORLD HEALTH ORGAN, V92, P204, DOI 10.2471/BLT.13.128371; [Anonymous], 2013, ANN REP KORL BU TEAC; Attride-Stirling J., 2001, QUAL RES, V1, P385; Atun R, 2013, LANCET, V381, P690, DOI 10.1016/S0140-6736(13)60063-X; Berkowitz AD, 2002, SOCIAL NORMS APPROAC; Beune EJAJ, 2008, J HYPERTENS, V26, P648, DOI 10.1097/HJH.0b013e3282f4d20b; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Bruce Suliasnaia P, 2015, Pharm Pract (Granada), V13, P533; Calys-Tagoe Benedict N L, 2014, BMC Res Notes, V7, P577, DOI 10.1186/1756-0500-7-577; Chatio S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116856; Cramer JA, 2004, DIABETES CARE, V27, P1218, DOI 10.2337/diacare.27.5.1218; Dako-Gyeke P, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-211; Dakubo J, 2014, POSTGRADUATE MED J G, V3, P15; Dodor EA, 2005, T ROY SOC TROP MED H, V99, P827, DOI 10.1016/j.trstmh.2005.06.011; Farnes C, 2011, INT NURS REV, V58, P491, DOI 10.1111/j.1466-7657.2011.00917.x; Ghana Health Service, 2015, ANN REP GHAN HLTH SE; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Ho SC, 2016, J AFFECT DISORDERS, V193, P1, DOI 10.1016/j.jad.2015.12.029; Hogerzeil HV, 2013, LANCET, V381, P680, DOI 10.1016/S0140-6736(12)62128-X; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; Ibrahim MM, 2012, LANCET, V380, P611, DOI 10.1016/S0140-6736(12)60861-7; Laryeh JG, 2013, FACTORS INFLUENCING; Lehane E, 2007, INT J NURS STUD, V44, P1468, DOI 10.1016/j.ijnurstu.2006.07.010; Lloyd-Sherlock P, 2014, INT J EPIDEMIOL, V43, P116, DOI 10.1093/ije/dyt215; Luppa M, 2007, J AFFECT DISORDERS, V98, P29, DOI 10.1016/j.jad.2006.07.017; Mattke S., 2011, IMPROVING ACCESS MED; McMullen CK, 2015, PATIENT EDUC COUNS, V98, P102, DOI 10.1016/j.pec.2014.09.015; Mills E, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-19; Mohan V, 2013, INT J HYPERTENS, V2013, DOI 10.1155/2013/409083; Munro S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-104; Ofosu-Amaah S., 1996, HOSP AUTONOMY GHANA; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Pereira M, 2009, J HYPERTENS, V27, P963, DOI 10.1097/HJH.0b013e3283282f65; Read UM, 2009, GLOBALIZATION HEALTH, V5, DOI 10.1186/1744-8603-5-13; Sabate AL, 2003, ADHERENCE LONG TERM; Sackey MB., 2002, I AFRICAN STUDIES RE, V18, P5; Saha S, 2008, J NATL MED ASSOC, V100, P1275, DOI 10.1016/S0027-9684(15)31505-4; Sarki AM, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001959; Sato A, 2012, HLTH POLICY PLANNING, V2013, P1; Schiffrin EL, 2012, LANCET, V380, P539, DOI 10.1016/S0140-6736(12)61219-7; Skinner M, 2015, GERIATR NURS, V36, P367, DOI 10.1016/j.gerinurse.2015.05.003; Tabi MM, 2006, INT NURS REV, V53, P52, DOI 10.1111/j.1466-7657.2006.00444.x; Ventana Systems Inc., 2014, VENS PLE SOFTW; Vervoort SCJM, 2007, AIDS, V21, P271, DOI 10.1097/QAD.0b013e328011cb20; Vlasnik Jon J, 2005, Case Manager, V16, P47; Voorham J, 2011, CLIN THER, V33, P121, DOI 10.1016/j.clinthera.2011.01.024; Wolf MS, 2011, MED CARE, V49, P96, DOI 10.1097/MLR.0b013e3181f38174; World Health Organization, 2014, FACT SHEET; Zarowitz BJ, 2005, PHARMACOTHERAPY, V25, P1636, DOI 10.1592/phco.2005.25.11.1636	51	26	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2018	13	3							e0193995	10.1371/journal.pone.0193995	http://dx.doi.org/10.1371/journal.pone.0193995			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA8PV	29590156	Green Published, gold, Green Submitted			2023-01-03	WOS:000428603100044
J	Bose, C; Awasthi, S; Sharma, R; Benes, H; Hauer-Jensen, M; Boerma, M; Singh, SP				Bose, Chhanda; Awasthi, Sanjay; Sharma, Rajendra; Benes, Helen; Hauer-Jensen, Martin; Boerma, Marjan; Singh, Sharda P.			Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model	PLOS ONE			English	Article							OXIDATIVE STRESS; INDUCED CACHEXIA; CYTOCHROME-C; DUAL ROLES; CELL-DEATH; NRF2; EXPRESSION; METABOLISM; FACTOR-2; TARGET	Breast cancer is the most common malignancy in women of the Western world. Doxorubicin (DOX) continues to be used extensively to treat early-stage or node-positive breast cancer, human epidermal growth factor receptor-2 (HER2)-positive breast cancer, and metastatic disease. We have previously demonstrated in a mouse model that sulforaphane (SFN), an isothiocyanate isolated from cruciferous vegetables, protects the heart from DOX-induced toxicity and damage. However, the effects of SFN on the chemotherapeutic efficacy of DOX in breast cancer are not known. Present studies were designed to investigate whether SFN alters the effects of DOX on breast cancer regression while also acting as a cardioprotective agent. Studies on rat neonatal cardiomyocytes and multiple rat and human breast cancer cell lines revealed that SFN protects cardiac cells but not cancer cells from DOX toxicity. Results of studies in a rat orthotopic breast cancer model indicated that SFN enhanced the efficacy of DOX in regression of tumor growth, and that the DOX dosage required to treat the tumor could be reduced when SFN was administered concomitantly. Additionally, SFN enhanced mitochondria! respiration in the hearts of DOX-treated rats and reduced cardiac oxidative stress caused by DOX, as evidenced by the inhibition of lipid peroxidation, the activation of NF-E2 related factor 2 (Nrf2) and associated antioxidant enzymes. These studies indicate that SFN not only acts synergistically with DOX in cancer regression, but also protects the heart from DOX toxicity through Nrf2 activation and protection of mitochondrial integrity and functions.	[Bose, Chhanda] Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; [Awasthi, Sanjay; Singh, Sharda P.] Texas Tech Hlth Sci Ctr, Dept Internal Med, Div Hematol & Oncol, Lubbock, TX 79409 USA; [Sharma, Rajendra; Singh, Sharda P.] Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; [Benes, Helen] Univ Arkansas Med Sci, Dept Neurobiol & Dev Sci, Little Rock, AR 72205 USA; [Hauer-Jensen, Martin; Boerma, Marjan] Univ Arkansas Med Sci, Div Radiat Hlth, Little Rock, AR 72205 USA; [Singh, Sharda P.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Texas Tech University System; Texas Tech University Health Science Center; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Singh, SP (corresponding author), Texas Tech Hlth Sci Ctr, Dept Internal Med, Div Hematol & Oncol, Lubbock, TX 79409 USA.; Singh, SP (corresponding author), Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA.; Singh, SP (corresponding author), Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.	sharda.singh@ttuhsc.edu	Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717; singh, sharda/0000-0003-4361-4558	National Institutes of Health [R01 AG032643]; American Heart Association [14GRNT18890084]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20 GM109005]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM109005] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health(General Electric); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by a grant from the National Institutes of Health (R01 AG032643 to SPS), a grant from the American Heart Association (14GRNT18890084 to SPS), and through an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (www.nigms.nih.gov) under grant number P20 GM109005 to MHJ.; This work was supported in part by a grant from the National Institutes of Health (R01 AG032643), a grant from the American Heart Association (14GRNT18890084), and through an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (www.nigms.nih.gov) under grant number P20 GM109005. The authors thank Dr. Lee Ann MacMillan-Crow for her advice and experimental protocol for the high resolution respirometry assays. The authors also thank Vetriselvan Malavan and Mecit Kaplan for their technical help in experiments.	Ali Khan M, 2015, EVID-BASED COMPL ALT, V2015; Alumkal JJ, 2015, INVEST NEW DRUG, V33, P480, DOI 10.1007/s10637-014-0189-z; Amjad Ali I, 2015, Curr Pharmacol Rep, V1, P382; Annibaldi A, 2010, CURR OPIN CLIN NUTR, V13, P466, DOI 10.1097/MCO.0b013e32833a5577; Awasthi S, 2010, DIABETES, V59, P714, DOI 10.2337/db09-0911; Bai Y, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/407580; Benes H, 2013, CARDIOVASC TOXICOL, V13, P347, DOI 10.1007/s12012-013-9215-1; Caram MEV, 2015, BREAST CANCER RES TR, V152, P163, DOI 10.1007/s10549-015-3454-8; Carvalho FS, 2014, MED RES REV, V34, P106, DOI 10.1002/med.21280; Chandra D, 2011, BBA-BIOENERGETICS, V1807, P620, DOI 10.1016/j.bbabio.2010.10.023; Chen L, 2016, CAN RESPIR J, V2016, DOI 10.1155/2016/9092871; Clementi ME, 2003, ANTICANCER RES, V23, P2445; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; De Angelis Antonella, 2016, Cardiooncology, V2, P2, DOI 10.1186/s40959-016-0012-4; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dirks-Naylor AJ, 2013, LIFE SCI, V93, P913, DOI 10.1016/j.lfs.2013.10.013; Durham WJ, 2009, CURR OPIN CLIN NUTR, V12, P72, DOI 10.1097/MCO.0b013e32831cef61; El-Agamy DS, 2016, EXP BIOL MED, V241, P1577, DOI 10.1177/1535370216643418; Fan HT, 2012, EPIGENETICS-US, V7, P1379, DOI 10.4161/epi.22609; Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254; Force T, 2013, CIRCULATION; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Furtado CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030462; Geisberg Carrie, 2012, Curr Heart Fail Rep, V9, P211, DOI 10.1007/s11897-012-0098-4; Geismann C, 2014, ONCOTARGETS THER, V7, P1497, DOI 10.2147/OTT.S36624; Gholamin M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-261; Hinch ECA, 2013, J CACHEXIA SARCOPENI, V4, P287, DOI 10.1007/s13539-013-0116-8; Hu LG, 2010, CANCER CHEMOTH PHARM, V66, P467, DOI 10.1007/s00280-009-1182-7; Hughey CC, 2011, J VISUALIZED EXPT JO; Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Jensen BC, 2013, PHARMACOGENOMICS, V14, P205, DOI [10.2217/PGS.12.205, 10.2217/pgs.12.205]; Jirkovsky E, 2012, J PHARMACOL EXP THER, V343, P468, DOI 10.1124/jpet.112.198358; Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339; Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c; Klement GL, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00113; Kombairaju Ponvijay, 2012, J Carcinog, V11, P8, DOI 10.4103/1477-3163.98459; Kuznetsov AV, 2004, AM J PHYSIOL-HEART C, V286, pH1633, DOI 10.1152/ajpheart.00701.2003; Kwatra M, 2016, PHARM BIOL, V54, P637, DOI 10.3109/13880209.2015.1070879; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937; Maki T, 1996, J CLIN INVEST, V97, P656, DOI 10.1172/JCI118462; Mantovani G, 2012, CURR PHARM DESIGN, V18, P4813, DOI 10.2174/138161212803216889; Marsh JD, 1998, CIRCULATION, V98, P256, DOI 10.1161/01.CIR.98.3.256; McElhanon K.E., 2013, OPEN J APOPTOSIS, V2, P11; Mein J, 2014, FASEB J S, V28; Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002; Menna P, 2012, EXPERT OPIN DRUG SAF, V11, pS21, DOI 10.1517/14740338.2011.589834; Mitry MA, 2016, IJC HEART VASC, V10, P17, DOI 10.1016/j.ijcha.2015.11.004; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Montaigne D, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/951539; Montaigne D, 2010, TOXICOL APPL PHARM, V244, P300, DOI 10.1016/j.taap.2010.01.006; Octavia Y, 2012, J MOL CELL CARDIOL, V52, P1213, DOI 10.1016/j.yjmcc.2012.03.006; Ohkoshi A, 2013, CANCER PREV RES, V6, P149, DOI 10.1158/1940-6207.CAPR-12-0401-T; Parajuli N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048590; Patel AG, 2012, ELIFE, V1, DOI 10.7554/eLife.00387; Pawlik A, 2013, EUR J NUTR, V52, P1949, DOI 10.1007/s00394-013-0499-5; Pereira GC, 2011, CURR PHARM DESIGN, V17, P2113; Piquereau J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00102; Rahman AM, 2007, INT J NANOMED, V2, P567; Rajendran P, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-68; Schimmel KJM, 2004, CANCER TREAT REV, V30, P181, DOI 10.1016/j.ctrv.2003.07.003; Shelton P, 2013, FASEB J, V27, P414, DOI 10.1096/fj.12-217257; Sin TK, 2015, J GERONTOLOGY A; Singh P, 2015, FREE RADICAL BIO MED, V86, P90, DOI 10.1016/j.freeradbiomed.2015.05.028; Singh SV, 2009, CANCER RES, V69, P2117, DOI 10.1158/0008-5472.CAN-08-3502; Smith TAD, 2016, ANTICANCER RES, V36, P87; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Strom J, 2016, FASEB J, V30, P66, DOI 10.1096/fj.14-268904; Sun CC, 2015, J BIOL CHEM, V290, P17784, DOI 10.1074/jbc.M115.655019; Suzuki T, 2013, TRENDS PHARMACOL SCI, V34, P340, DOI 10.1016/j.tips.2013.04.005; Tian M, 2011, INT J ONCOL, V39, P1321, DOI 10.3892/ijo.2011.1150; Tian M, 2010, INT J ONCOL, V37, P347, DOI 10.3892/ijo_00000683; Tien CC, 2016, REGUL TOXICOL PHARM, V81, P69, DOI 10.1016/j.yrtph.2016.08.002; Todorova VK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048398; Todorova VK, 2011, ANTICANCER RES, V31, P215; van Dalen EC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003917.pub2; van den Hurk C, 2015, ANTI-CANCER DRUG, V26, P687, DOI 10.1097/CAD.0000000000000239; Veeranki OL, 2013, BRIT J NUTR, V109, P25, DOI 10.1017/S0007114512000657; Volkova M, 2011, CURR CARDIOL REV, V7, P214, DOI 10.2174/157340311799960645; Wang LF, 2015, AM J TRANSL RES, V7, P1724; Xu Y, 2013, CANCER RES, V73, P4406, DOI 10.1158/0008-5472.CAN-12-4297; Yoon DS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.3; Zhang CY, 2013, BIOCHEM PHARMACOL, V85, P1398, DOI 10.1016/j.bcp.2013.02.010; Zhang YY, 2015, J PHARMACOL EXP THER, V352, P166, DOI 10.1124/jpet.114.219261	85	43	44	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2018	13	3							e0193918	10.1371/journal.pone.0193918	http://dx.doi.org/10.1371/journal.pone.0193918			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5UV	29518137	Green Submitted, Green Published, gold			2023-01-03	WOS:000426902900048
J	Dell'Arti, L; Barteselli, G; Riva, L; Carini, E; Graziadei, G; Benatti, E; Invernizzi, A; Cappellini, MD; Viola, F				Dell'Arti, Laura; Barteselli, Giulio; Riva, Lorenzo; Carini, Elisa; Graziadei, Giovanna; Benatti, Eleonora; Invernizzi, Alessandro; Cappellini, Maria D.; Viola, Francesco			Sickle cell maculopathy: Identification of systemic risk factors, and microstructural analysis of individual retinal layers of the macula	PLOS ONE			English	Article							OPTICAL COHERENCE TOMOGRAPHY; RETINOPATHY; DISEASE; PATHOGENESIS; ISCHEMIA; AGE	Purpose To identify systemic risk factors for sickle cell maculopathy, and to analyze the microstructure of the macula of Sickle Cell Disease ( SCD) patients by using automated segmentation of individual retinal layers. Methods Thirty consecutive patients with SCD and 30 matched controls underwent spectral-domain optical coherence tomography ( SD-OCT) and automated thickness measurement for each retinal layer; thicknesses for SCD patients were then compared to normal controls. Demographic data, systemic data, and lab results were collected for each SCD patient; multivariate logistic regression analysis was used to identify potential risk factors for sickle cell maculopathy. Results Ongoing chelation treatment ( p = 0.0187) was the most predictive factor for the presence of sickle cell maculopathy; the odds were 94.2% lower when chelation was present. HbF level tended to influence sickle cell maculopathy ( p = 0.0775); the odds decreased by 12.9% when HbF increased by 1%. Sickle cell maculopathy was detected in 43% of SCD patients as patchy areas of retinal thinning on SD-OCT thickness map, mostly located temporally to the macula, especially in eyes with more advanced forms of sickle cell retinopathy ( p = 0.003). In comparison to controls, SCD patients had a subtle thinning of the overall macula and temporal retina compared to controls ( most p<0.0001), involving inner and outer retinal layers. Thickening of the retinal pigment epithelium was also detected in SCD eyes ( p<0.0001). Conclusions Chronic chelation therapy and, potentially, high levels of HbF are possible protective factors for the presence of sickle cell maculopathy, especially for patients with more advanced forms of sickle cell retinopathy. A subtle thinning of the overall macula occurs in SCD patients and involves multiple retinal layers, suggesting that ischemic vasculopathy may happen in both superficial and deep capillary plexi. Thinning of the outer retinal layers suggests that an ischemic insult of the choriocapillaris may also occur in SCD patients.	[Dell'Arti, Laura; Cappellini, Maria D.; Viola, Francesco] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy; [Dell'Arti, Laura; Riva, Lorenzo; Carini, Elisa; Benatti, Eleonora; Viola, Francesco] Osped Maggiore Policlin, IRCCS, Ca Granda Fdn, Ophthalmol Unit, Milan, Italy; [Barteselli, Giulio] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA; [Graziadei, Giovanna] Osped Maggiore Policlin, IRCCS, Ca Granda Fdn, Rare Dis Ctr,Dept Med & Med Specialties, Milan, Italy; [Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci L Sacco, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Roche Holding; Genentech; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Luigi Sacco Hospital	Viola, F (corresponding author), Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.; Viola, F (corresponding author), Osped Maggiore Policlin, IRCCS, Ca Granda Fdn, Ophthalmol Unit, Milan, Italy.	francesco.viola@unimi.it	viola, francesco/AAK-5583-2020; Dell'Arti, Laura/AAB-9520-2019; CAPPELLINI, MARIA DOMENICA/B-4475-2017	viola, francesco/0000-0003-1208-913X; Dell'Arti, Laura/0000-0001-7710-7867; Graziadei, Giovanna/0000-0002-6801-5730; Barteselli, Giulio/0000-0003-0533-1135; CAPPELLINI, MARIA DOMENICA/0000-0001-8676-6864				Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065; Brasileiro F, 2015, RETINA-J RET VIT DIS, V35, P257, DOI 10.1097/IAE.0000000000000309; BUNN HF, 1982, P NATL ACAD SCI-BIOL, V79, P7527, DOI 10.1073/pnas.79.23.7527; Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850; Chhablani J, 2012, INVEST OPHTH VIS SCI, V53, P2274, DOI 10.1167/iovs.12-9435; Cruz PRS, 2015, BLOOD CELL MOL DIS, V54, P33, DOI 10.1016/j.bcmd.2014.08.003; Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622; DIZON RV, 1979, SURV OPHTHALMOL, V23, P297, DOI 10.1016/0039-6257(79)90159-0; Elagouz M, 2010, SURV OPHTHALMOL, V55, P359, DOI 10.1016/j.survophthal.2009.11.004; Estepp JH, 2013, BRIT J HAEMATOL, V161, P402, DOI 10.1111/bjh.12238; FOX PD, 1990, BRIT J OPHTHALMOL, V74, P172, DOI 10.1136/bjo.74.3.172; Ghasemi Falavarjani K, 2016, RETINA; Gnana-Prakasam JP, 2009, BIOCHEM J, V424, P243, DOI 10.1042/BJ20090424; GOLDBAUM MH, 1978, AM J OPHTHALMOL, V86, P45, DOI 10.1016/0002-9394(78)90013-2; GOLDBERG MF, 1971, AM J OPHTHALMOL, V71, P649, DOI 10.1016/0002-9394(71)90429-6; Han IC, 2017, AM J OPHTHALMOL; Hoang QV, 2011, AM J OPHTHALMOL, V151, P990, DOI 10.1016/j.ajo.2010.12.010; Jung JJ, 2016, RETIN CASES BRIEF RE; LEE CM, 1987, BRIT J OPHTHALMOL, V71, P540, DOI 10.1136/bjo.71.7.540; Lee MT, 2006, BLOOD, V108, P847, DOI 10.1182/blood-2005-10-009506; Martin GC, 2017, JAMA OPHTHALMOL, V135, P1100, DOI 10.1001/jamaophthalmol.2017.3008; Mathew R, 2015, BRIT J OPHTHALMOL, V99, P967, DOI 10.1136/bjophthalmol-2014-305532; Minvielle W, 2016, AM J OPHTHALMOL, V164, P137, DOI 10.1016/j.ajo.2015.12.023; Oberwahrenbrock T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137316; Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X; Romayanada N, 1973, T AM ACAD OPHTHALMOL, V77; Sanfilippo Christian J, 2015, Retin Cases Brief Rep, V9, P360, DOI 10.1097/ICB.0000000000000210; STEIN MR, 1970, ARCH OPHTHALMOL-CHIC, V84, P485, DOI 10.1001/archopht.1970.00990040487017; Tan CS, 2016, BRIT J OPHTHALMOL, V100, P235, DOI 10.1136/bjophthalmol-2015-306652; Tan CSH, 2012, INVEST OPHTH VIS SCI, V53, P1639, DOI 10.1167/iovs.12-9566; Yu SQ, 2015, AM J OPHTHALMOL, V159, P53, DOI 10.1016/j.ajo.2014.09.027	31	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2018	13	3							e0193582	10.1371/journal.pone.0193582	http://dx.doi.org/10.1371/journal.pone.0193582			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX8RR	29494697	gold, Green Published			2023-01-03	WOS:000426363200069
J	Tainio, K; Athanasiou, A; Tikkinen, KAO; Aaltonen, R; Hernandes, JC; Glazer-Livson, S; Jakobsson, M; Joronen, K; Kiviharju, M; Louvanto, K; Oksjoki, S; Tahtinen, R; Virtanen, S; Nieminen, P; Kyrgiou, M; Kalliala, I				Tainio, Karoliina; Athanasiou, Antonios; Tikkinen, Kari A. O.; Aaltonen, Riikka; Cardenas Hernandes, Jovita; Glazer-Livson, Sivan; Jakobsson, Maija; Joronen, Kirsi; Kiviharju, Mari; Louvanto, Karolina; Oksjoki, Sanna; Tahtinen, Riikka; Virtanen, Seppo; Nieminen, Pekka; Kyrgiou, Maria; Kalliala, Ilkka			Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HUMAN-PAPILLOMAVIRUS INFECTION; DISEASE PROGRESSION; OBSTETRIC OUTCOMES; PROGNOSTIC-FACTORS; NATURAL-HISTORY; BETA-CAROTENE; DOUBLE-BLIND; EARLY CIN; LOW-RISK; REGRESSION	OBJECTIVE To estimate the regression, persistence, and progression of untreated cervical intraepithelial neoplasia grade 2 (CIN2) lesions managed conservatively as well as compliance with follow-up protocols. DESIGN Systematic review and meta-analysis. DATA SOURCES Medline, Embase, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) from 1 January 1973 to 20 August 2016. ELIGIBILITY CRITERIA Studies reporting on outcomes of histologically confirmed CIN2 in non-pregnant women, managed conservatively for three or more months. DATA SYNTHESIS Two reviewers extracted data and assessed risk of bias. Random effects model was used to calculate pooled proportions for each outcome, and heterogeneity was assessed using I-2 statistics. MAIN OUTCOME MEASURES Rates of regression, persistence, or progression of CIN2 and default rates at different follow-up time points (3, 6, 12, 24, 36, and 60 months). RESULTS 36 studies that included 3160 women were identified (seven randomised trials, 16 prospective cohorts, and 13 retrospective cohorts; 50% of the studies were at low risk of bias). At 24 months, the pooled rates were 50% (11 studies, 819/1470 women, 95% confidence interval 43% to 57%; I-2= 77%) for regression, 32% (eight studies, 334/1257 women, 23% to 42%; I-2= 82%) for persistence, and 18% (nine studies, 282/1445 women, 11% to 27%; I-2= 90%) for progression. In a subgroup analysis including 1069 women aged less than 30 years, the rates were 60% (four studies, 638/1069 women, 57% to 63%; I-2= 0%), 23% (two studies, 226/938 women, 20% to 26%; I-2= 97%), and 11% (three studies, 163/1033 women, 5% to 19%; I-2= 67%), respectively. The rate of non-compliance (at six to 24 months of follow-up) in prospective studies was around 10%. CONCLUSIONS Most CIN2 lesions, particularly in young women (< 30 years), regress spontaneously. Active surveillance, rather than immediate intervention, is therefore justified, especially among young women who are likely to adhere to monitoring.	[Tainio, Karoliina; Glazer-Livson, Sivan; Jakobsson, Maija; Kiviharju, Mari; Louvanto, Karolina; Virtanen, Seppo; Nieminen, Pekka; Kalliala, Ilkka] Univ Helsinki, Dept Obstet & Gynaecol, Helsinki, Finland; [Tainio, Karoliina; Tikkinen, Kari A. O.; Glazer-Livson, Sivan; Jakobsson, Maija; Kiviharju, Mari; Louvanto, Karolina; Virtanen, Seppo; Nieminen, Pekka; Kalliala, Ilkka] Helsinki Univ Hosp, Helsinki, Finland; [Athanasiou, Antonios] Univ Hosp Ioannina, Dept Obstet & Gynaecol, Ioannina, Greece; [Tikkinen, Kari A. O.] Univ Helsinki, Dept Urol, Helsinki, Finland; [Tikkinen, Kari A. O.] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Aaltonen, Riikka; Joronen, Kirsi; Oksjoki, Sanna] Turku Univ Hosp, Dept Obstet & Gynaecol, Turku, Finland; [Aaltonen, Riikka; Joronen, Kirsi; Oksjoki, Sanna] Univ Turku, Turku, Finland; [Cardenas Hernandes, Jovita] Natl Ctr Hlth Technol Excellence CENETEC, Direct Hlth Technol Assessment, Mexico City, DF, Mexico; [Louvanto, Karolina] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England; [Tahtinen, Riikka] Kuopio Univ Hosp, Dept Obstet & Gynaecol, Kuopio, Finland; [Kyrgiou, Maria; Kalliala, Ilkka] Imperial Coll, Dept Surg & Canc, Inst Reprod & Dev Biol, London W12 0NN, England; [Kyrgiou, Maria] Imperial Healthcare NHS Trust, Queen Charlottes & Chelsea Hammersmith Hosp, West London Gynaecol Canc Ctr, London, England	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University Hospital Ioannina; University of Helsinki; University of Helsinki; University of Turku; University of Turku; University of London; Queen Mary University London; Kuopio University Hospital; University of Eastern Finland; Imperial College London	Kyrgiou, M (corresponding author), Imperial Coll, Dept Surg & Canc, Inst Reprod & Dev Biol, London W12 0NN, England.; Kyrgiou, M (corresponding author), Imperial Healthcare NHS Trust, Queen Charlottes & Chelsea Hammersmith Hosp, West London Gynaecol Canc Ctr, London, England.	m.kyrgiou@imperial.ac.uk	Kalliala, Ilkka/ABC-9253-2021; Nieminen, Pekka/W-8570-2019; Aro, Karoliina/J-8379-2019; Athanasiou, Antonios/GZM-3553-2022; Louvanto, Karolina/GXG-3296-2022; Tikkinen, Kari/L-3632-2018	Kalliala, Ilkka/0000-0002-7664-0587; Aro, Karoliina/0000-0003-3467-7194; Louvanto, Karolina/0000-0002-1172-363X; Athanasiou, Antonios/0000-0002-9442-3703; Tikkinen, Kari/0000-0002-1389-8214	Sigrid Juselius Fellowship [P52483]; British Society of Colposcopy Cervical Pathology Jordan/Singer Award [P47773]; Imperial College Healthcare Charity [P47907]; Genesis Research Trust [P55549]; Imperial Healthcare NHS Trust National Institute for Health Research Biomedical Research Centre [P45272]; Academy of Finland [276046, 309387]; Competitive Research Funding of the Helsinki and Uusimaa Hospital District [TYH2016135, TYH2017114, TYH2014310, TYH 2013338]; Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation	Sigrid Juselius Fellowship(Sigrid Juselius Foundation); British Society of Colposcopy Cervical Pathology Jordan/Singer Award; Imperial College Healthcare Charity; Genesis Research Trust; Imperial Healthcare NHS Trust National Institute for Health Research Biomedical Research Centre; Academy of Finland(Academy of Finland); Competitive Research Funding of the Helsinki and Uusimaa Hospital District; Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	Sigrid Juselius Fellowship (P52483: to IK and MK); British Society of Colposcopy Cervical Pathology Jordan/Singer Award (P47773: to MK); the Imperial College Healthcare Charity (P47907: to MK); Genesis Research Trust (P55549: to MK); and the Imperial Healthcare NHS Trust National Institute for Health Research Biomedical Research Centre (P45272: to MK). Academy of Finland (276046, 309387: to KAOT), Competitive Research Funding of the Helsinki and Uusimaa Hospital District (TYH2016135, TYH2017114: to KAOT), Jane and Aatos Erkko Foundation (to KAOT), and Sigrid Juselius Foundation (to KAOT). Competitive Research Funding of the Helsinki and Uusimaa Hospital District (TYH2014310, TYH 2013338 to PN). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The guarantor had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Alvarez RD, 2003, CANCER EPIDEM BIOMAR, V12, P114; [Anonymous], 2016, CYTOLOGICAL CHANGES; Arbyn M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1284; BIBBO M, 1989, AM J CLIN PATHOL, V92, P261, DOI 10.1093/ajcp/92.3.261; Bleecker E, 2014, J LOW GENIT TRACT DI, V18, P46, DOI 10.1097/LGT.0b013e3182901ef3; Brentnall AR, 2014, INT J CANCER, V135, P1425, DOI 10.1002/ijc.28790; Carreon JD, 2007, INT J GYNECOL PATHOL, V26, P441, DOI 10.1097/pgp.0b013e31805152ab; Castle PE, 2009, OBSTET GYNECOL, V113, P18, DOI 10.1097/AOG.0b013e31818f5008; DEVET HCW, 1991, J CLIN EPIDEMIOL, V44, P273, DOI 10.1016/0895-4356(91)90039-C; Discacciati MG, 2014, BIOMARK INSIGHTS, V9, P15, DOI [10.4137/BMIMI.S14296, 10.4137/BMI.S14296]; Discacciati MG, 2011, EUR J OBSTET GYN R B, V155, P204, DOI 10.1016/j.ejogrb.2010.12.002; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fuchs K, 2007, J PEDIATR ADOL GYNEC, V20, P269, DOI 10.1016/j.jpag.2007.04.012; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Garzetti GG, 1996, GYNECOL ONCOL, V61, P197, DOI 10.1006/gyno.1996.0124; Guedes AC, 2007, INT J GYNECOL CANCER, V17, P1099, DOI 10.1111/j.1525-1438.2007.00899.x; Guedes AC, 2010, ANTICANCER RES, V30, P2319; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hillemanns P, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.10.1107; Ho GYF, 2011, J LOW GENIT TRACT DI, V15, P268, DOI 10.1097/LGT.0b013e3182216fef; HORDING U, 1991, EUR J OBSTET GYN R B, V40, P43, DOI 10.1016/0028-2243(91)90043-K; Hosaka M, 2013, INT J CANCER, V132, P327, DOI 10.1002/ijc.27680; IARC, 2005, IARC HDB CANC PREV C, V10, P302; Insinga RP, 2004, AM J OBSTET GYNECOL, V191, P105, DOI 10.1016/j.ajog.2004.01.043; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; Iwasaka T, 1998, INT J GYNECOL OBSTET, V62, P269, DOI 10.1016/S0020-7292(98)00072-1; Kalliala I, 2005, BRIT MED J, V331, P1183, DOI 10.1136/bmj.38663.459039.7C; KATAJA V, 1992, SEX TRANSM DIS, V19, P154, DOI 10.1097/00007435-199205000-00009; Keefe KA, 2001, CANCER EPIDEM BIOMAR, V10, P1029; Kottaridi C, 2017, J INFECT DIS, V215, P764, DOI 10.1093/infdis/jiw645; Kruse AJ, 2004, CELL ONCOL, V26, P13; Kruse AJ, 2004, INT J GYNECOL PATHOL, V23, P100, DOI 10.1097/00004347-200404000-00003; Kyrgiou M, 2006, LANCET, V367, P489, DOI 10.1016/S0140-6736(06)68181-6; Kyrgiou M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012847; Kyrgiou M, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3633; Kyrgiou M, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6192; Kyrgiou M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008478.pub2; Landy R, 2016, BRIT J CANCER, V115, P1140, DOI 10.1038/bjc.2016.290; D'Ottaviano MGL, 2013, OBSTET GYNECOL INT, V2013, DOI 10.1155/2013/328909; Loopik DL, 2016, J LOW GENIT TRACT DI, V20, P213, DOI 10.1097/LGT.0000000000000215; Louvanto K, 2015, INT J CANCER, V136, pE638, DOI 10.1002/ijc.29196; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Matsumoto K, 2011, INT J CANCER, V128, P2898, DOI 10.1002/ijc.25630; McAllum B, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.069; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; Mirabello L, 2013, INT J CANCER, V132, P1412, DOI 10.1002/ijc.27750; Mitra A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16865; Miyamoto S, 2016, INT J GYNECOL OBSTET, V134, P45, DOI 10.1016/j.ijgo.2015.12.005; Mizushima T, 2016, INT J GYNECOL PATHOL, V35, P106, DOI 10.1097/PGP.0000000000000228; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Monteiro DLM, 2010, J PEDIATR ADOL GYNEC, V23, P230, DOI 10.1016/j.jpag.2010.01.002; Moore K, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.03.029; Moscicki AB, 2010, OBSTET GYNECOL, V116, P1373, DOI 10.1097/AOG.0b013e3181fe777f; Munk AC, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-30; Munk AC, 2012, GYNECOL ONCOL, V127, P489, DOI 10.1016/j.ygyno.2012.09.010; Munk AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045114; Munro A, 2016, ACTA OBSTET GYN SCAN, V95, P291, DOI 10.1111/aogs.12835; Nogawa T, 2013, J OBSTET GYNAECOL RE, V39, P1347, DOI 10.1111/jog.12068; Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39; Okadome M, 2014, J OBSTET GYNAECOL RE, V40, P561, DOI 10.1111/jog.12202; Omori M, 2007, AM J CLIN PATHOL, V128, P208, DOI 10.1309/0UP5PJK9RYF7BPHM; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Rahangdale L, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.12.042; Richart R M, 1973, Pathol Annu, V8, P301; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Tsoumpou I, 2009, CANCER TREAT REV, V35, P210, DOI 10.1016/j.ctrv.2008.10.005; Ueda Y, 2003, LAB INVEST, V83, P1517, DOI 10.1097/01.LAB.0000092234.68751.83; Van Delft KWM, 2011, ONCOL LETT, V2, P575, DOI 10.3892/ol.2011.289; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350; Vink MA, 2013, AM J EPIDEMIOL, V178, P1161, DOI 10.1093/aje/kwt077; Wang SM, 2013, INT J GYNECOL CANCER, V23, P716, DOI 10.1097/IGC.0b013e318286a95d; Waxman AG, 2012, OBSTET GYNECOL, V120, P1465, DOI [10.1097/AOG.0b013e31827001d5, http://10.1097/AOG.0b013e31827001d5]; WEAVER MG, 1990, MODERN PATHOL, V3, P679; WHO, 2014, CLASS TUM FAM REPR O; Wilkinson TM, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2015.01.010; WOODMAN CBJ, 1993, J PUBLIC HEALTH MED, V15, P327, DOI 10.1093/oxfordjournals.pubmed.a042884; Yokoyama M, 2003, CANCER LETT, V192, P171, DOI 10.1016/S0304-3835(02)00715-2	78	146	158	9	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2018	360								k499	10.1136/bmj.k499	http://dx.doi.org/10.1136/bmj.k499			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FY4IH	29487049	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000426785400002
J	Franceschini, M; Goffredo, M; Pournajaf, S; Paravati, S; Agosti, M; De Pisi, F; Galafate, D; Posteraro, F				Franceschini, Marco; Goffredo, Michela; Pournajaf, Sanaz; Paravati, Stefano; Agosti, Maurizio; De Pisi, Francesco; Galafate, Daniele; Posteraro, Federico			Predictors of activities of daily living outcomes after upper limb robot-assisted therapy in subacute stroke patients	PLOS ONE			English	Article							QUALITY-OF-LIFE; FRAGILITY INDEX; RECOVERY; REHABILITATION; MOTOR; TRIALS; IMPAIRMENTS; INTERVENTIONS; METAANALYSIS; ASSOCIATION	Background Upper limb recovery is one of the main goals of post-stroke rehabilitation due to its importance for autonomy in Activities of Daily Living (ADL). Although the efficacy of upper limb Robot-assisted Therapy (RT) is well established in literature, the impact of the initial status of the patient on the effects of RT is still understudied. This paper aims to identify whether demographic, clinical and motor characteristics of stroke patients may influence the ability to independently perform ADL after RT. Methods A retrospective study was conducted on sixty stroke patients who conducted planar upper limb goal-directed tasks with the InMotion 2.0 robot. The RT was administered 5 days/week for 4 weeks and each session lasted 45 minutes. The primary outcome measure was the Modified Barthel Index (BI), dichotomized into favourable (BI >= 75) and unfavourable (BI< 75) outcomes. The potential predictors were the demographic and clinical records, and the following clinical assessment scores: Modified Ashworth Scale-Shoulder (MAS-S); Modified Ashworth Scale-Elbow (MAS-E); Fugl-Meyer Assessment Upper Extremity (FMA-UE); upper limb section of the Motricity Index (MIul); total passive Range Of Motion (pROM); and Box and Block Test (BBT). Results Statistical analysis showed that the BBT, FMA-UE and MIul scores were significant predictors of a favourable outcome in ADL. The cut-off scores of the independent variables were calculated (FMA-UE = 32; MIul = 48; BBT = 3) with respect to the dichotomic BI outcome. Their robustness was assessed with the Fragility Index (FMA-UE = 2; MIul = 3; BBT = 7), showing that BBT is the most robust predictor of favourable BI outcome. Moreover, subjects with all predictors higher than the cut-off scores had higher probability to increase their independence in ADL at the end of the therapy. Demographic records, spasticity and pROM were not identified as predictors. Conclusion Stroke patients with greater manual dexterity and less impairment appear to have a higher probability of achieving clinically significant ADL outcomes after upper limb RT. The obtained results can help to optimise the management of RT treatment planning. Further studies on a larger number of patients with a long-term follow up are recommended in order to evaluate other potential predictors and to validate the results.	[Franceschini, Marco; Goffredo, Michela; Pournajaf, Sanaz; Paravati, Stefano; De Pisi, Francesco; Galafate, Daniele] IRCCS San Raffaele Pisana, Dept Neurorehabil, Rome, Italy; [Franceschini, Marco] San Raffaele Univ, Rome, Italy; [Agosti, Maurizio] NHS Univ Hosp Parma, Rehabil Geriatr Dept, Rehabil Med Serv, Parma, Italy; [Posteraro, Federico] Dept Neurorehabil Hlth Area West Tuscany, Viareggio, Italy	IRCCS San Raffaele Pisana; Vita-Salute San Raffaele University; University of Parma; University Hospital of Parma	Goffredo, M (corresponding author), IRCCS San Raffaele Pisana, Dept Neurorehabil, Rome, Italy.	michela.goffredo@sanraffaele.it	Pournajaf, Sanaz/K-3924-2018; Goffredo, Michela/K-8805-2016	Pournajaf, Sanaz/0000-0001-8749-2236; Goffredo, Michela/0000-0002-2651-8479; Agosti, Maurizio/0000-0003-2365-3488; Posteraro, Federico/0000-0002-7643-6834				[Anonymous], 2012, GAZZETTA UFFICIALE R, V72, P47; Aparicio HJ, 2016, NEUROLOGY, V86, pI2; Bejot Y, 2016, RISING STROKE INCIDE; Bovolenta F, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-18; Bovolenta F, 2009, J REHABIL MED, V41, P971, DOI 10.2340/16501977-0402; Brewer BR, 2007, TOP STROKE REHABIL, V14, P22, DOI 10.1310/tsr1406-22; Buchner A., 2013, CANCER, V3; Collin C, 1988, Int Disabil Stud, V10, P61; Coupar F, 2012, CLIN REHABIL, V26, P291, DOI 10.1177/0269215511420305; Dobkin BH, 2009, NEUROREHAB NEURAL RE, V23, P197, DOI 10.1177/1545968309331863; Drubach DA., 1994, J NEURAL REHABIL, V8, P881; Duret C, 2015, RESTOR NEUROL NEUROS, V33, P57, DOI 10.3233/RNN-140418; Evaniew N, 2015, SPINE J, V15, P2188, DOI 10.1016/j.spinee.2015.06.004; Fang MC, 2014, AM J MED, V127, P608, DOI 10.1016/j.amjmed.2014.03.017; Fritz SL, 2005, STROKE, V36, P1172, DOI 10.1161/01.STR.0000165922.96430.d0; Hsieh YW, 2014, ARCH PHYS MED REHAB, V95, P316, DOI 10.1016/j.apmr.2013.09.018; Huang PC, 2014, AM J OCCUP THER, V68, P325, DOI 10.5014/ajot.2014.010546; Khellaf M, 2010, STROKE, V41, P2762, DOI 10.1161/STROKEAHA.110.592147; Krebs HI, 2014, STROKE, V45, P200, DOI 10.1161/STROKEAHA.113.002296; Kutner NG, 2010, PHYS THER, V90, P493, DOI 10.2522/ptj.20090160; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; Kwakkel G, 2007, RESTOR NEUROL NEUROS, V25, P453; Lipsey MW., 1990, DESIGN SENSITIVITY; Mehrholz J, 2012, COCHRANE DATABASE SY, V6; Mirelman A, 2009, STROKE, V40, P169, DOI 10.1161/STROKEAHA.108.516328; Morone G, 2011, NEUROREHAB NEURAL RE, V25, P636, DOI 10.1177/1545968311401034; Musicco M, 2003, ARCH PHYS MED REHAB, V84, P551, DOI 10.1053/apmr.2003.50084; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Norouzi-Gheidari N, 2012, J REHABIL RES DEV, V49, P479, DOI 10.1682/JRRD.2010.10.0210; Pedersen PM, 1997, ARCH PHYS MED REHAB, V78, P161, DOI 10.1016/S0003-9993(97)90258-6; Ridgeon EE, 2016, CRIT CARE MED, V44, P1278, DOI 10.1097/CCM.0000000000001670; Sale P, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-104; Smania N, 2009, EUR J PHYS REHAB MED, V45, P349; Sommerfeld DK, 2004, STROKE, V35, P134, DOI 10.1161/01.STR.0000105386.05173.5E; Sveen U, 1999, DISABIL REHABIL, V21, P372, DOI 10.1080/096382899297477; Tibaek M, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003158; Uyttenboogaart M, 2005, STROKE, V36, P1984, DOI 10.1161/01.STR.0000177872.87960.61; Wade D T, 1989, Int Disabil Stud, V11, P89; Wagner JM, 2007, PHYS THER, V87, P751, DOI 10.2522/ptj.20060135; Walsh M, 2014, J CLIN EPIDEMIOL, V67, P622, DOI 10.1016/j.jclinepi.2013.10.019	40	25	27	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2018	13	2							e0193235	10.1371/journal.pone.0193235	http://dx.doi.org/10.1371/journal.pone.0193235			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FW8RO	29466440	gold, Green Submitted, Green Published			2023-01-03	WOS:000425604300100
J	Hill, ZB; Martinko, AJ; Nguyen, DP; Wells, JA				Hill, Zachary B.; Martinko, Alexander J.; Nguyen, Duy P.; Wells, James A.			Human antibody-based chemically induced dimerizers for cell therapeutic applications	NATURE CHEMICAL BIOLOGY			English	Article							T-CELLS; INDUCED DIMERIZATION; SAFETY SWITCH; ACTIVATION; PLATFORM; CRISPR; MECHANISMS; SELECTION; PROTEINS; BIOLOGY	Chemically induced dimerizers (CIDs) have emerged as one of the most powerful tools for artificially regulating signaling pathways in cells; however, currently available CID systems lack the properties desired for use in regulating cellular therapies. Here, we report the development of human antibody-based chemically induced dimerizers (AbCIDs) from known small-molecule-protein complexes by selecting for synthetic antibodies that recognize the chemical epitope created by the bound small molecule. We demonstrate this concept by generating three antibodies that are highly selective for the BCL-xL-ABT-737 complex compared to BCL-xL alone. We show the potential of AbCIDs for application in regulating human cell therapies by using them to induce CRISPRa-mediated gene expression and to regulate CAR T-cell activation. We believe that the AbCIDs generated in this study will find application in regulating cell therapies and that the general method of AbCID development may lead to the creation of many new and orthogonal CIDs.	[Hill, Zachary B.; Martinko, Alexander J.; Nguyen, Duy P.; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; [Martinko, Alexander J.] Univ Calif San Francisco, Chem & Chem Biol Grad Program, San Francisco, CA 94143 USA; [Wells, James A.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wells, JA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.; Wells, JA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	jim.wells@ucsf.edu	Martinko, Alexander/X-3040-2019	Hill, Zachary/0000-0003-4890-2233	NIH [CA191018, GM097316]; NCI [P41 CA196276]; Helen Hay Whitney Foundation; HHMI; NIH-NCI [K99CA203002]; NSF GRFP; Damon Runyon Cancer Research Foundation [DRG-2204-14]; NATIONAL CANCER INSTITUTE [K99CA203002, R01CA191018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM097316] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Helen Hay Whitney Foundation; HHMI(Howard Hughes Medical Institute); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF GRFP(National Science Foundation (NSF)NSF - Office of the Director (OD)); Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank S. Sidhu (University of Toronto) for providing the phage-displayed Fab library. We thank A. Weiss (UCSF) and T. Kadlecek (UCSF) for kindly providing the NFAT-dependent GFP reporter Jurkat cell line. Funding was provided by R01 grants from the NIH (CA191018 and GM097316) and a P41 grant from the NCI (P41 CA196276). Z.B.H. was supported by a postdoctoral fellowship from the Helen Hay Whitney Foundation and HHMI, as well as a Pathway to Independence Award from the NIH-NCI (K99CA203002). A.J.M. was supported by a predoctoral fellowship from the NSF GRFP. D.P.N. is the Connie and Bob Lurie Fellow of the Damon Runyon Cancer Research Foundation (DRG-2204-14).	Barlow AD, 2012, DIABETOLOGIA, V55, P1355, DOI 10.1007/s00125-012-2475-7; Besbes S, 2015, ONCOTARGET, V6, P12862, DOI 10.18632/oncotarget.3868; Cao Y, 2016, ANGEW CHEM INT EDIT, V55, P7520, DOI 10.1002/anie.201601902; Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Czlapinski JL, 2008, J AM CHEM SOC, V130, P13186, DOI 10.1021/ja8037728; DeFrancesco L, 2017, NAT BIOTECHNOL, V35, P6, DOI 10.1038/nbt0117-6b; DeRose R, 2013, PFLUG ARCH EUR J PHY, V465, P409, DOI 10.1007/s00424-012-1208-6; Di Stasi A, 2011, NEW ENGL J MED, V365, P1673, DOI 10.1056/NEJMoa1106152; Erhart D, 2013, CHEM BIOL, V20, P549, DOI 10.1016/j.chembiol.2013.03.010; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Fegan A, 2010, CHEM REV, V110, P3315, DOI 10.1021/cr8002888; Fesnak AD, 2016, NAT REV CANCER, V16, P566, DOI 10.1038/nrc.2016.97; Fiedler M., 2014, HDB THERAPEUTIC ANTI, V1, P435; Gao JJ, 2009, P NATL ACAD SCI USA, V106, P3071, DOI 10.1073/pnas.0812952106; Gao YC, 2016, NAT METHODS, V13, P1043, DOI [10.1038/NMETH.4042, 10.1038/nmeth.4042]; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Goreshnik I, 2010, J AM CHEM SOC, V132, P938, DOI 10.1021/ja907886v; Hornsby M, 2015, MOL CELL PROTEOMICS, V14, P2833, DOI 10.1074/mcp.O115.052209; Issa F, 2015, TRANSPLANTATION, V99, P2434, DOI 10.1097/TP.0000000000001016; June C. H., 2017, US Patent, Patent No. [9,540,445, 9540445]; Kelly PN, 2013, CELL DEATH DIFFER, V20, P57, DOI 10.1038/cdd.2012.92; Koerber JT, 2015, J MOL BIOL, V427, P576, DOI 10.1016/j.jmb.2014.11.017; Kong HY, 2013, BIOMOL THER, V21, P423, DOI 10.4062/biomolther.2013.085; Kopytek SJ, 2000, CHEM BIOL, V7, P313, DOI 10.1016/S1074-5521(00)00109-5; Lee EF, 2007, CELL DEATH DIFFER, V14, P1711, DOI 10.1038/sj.cdd.4402178; Liang FS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001449; Lienert F, 2014, NAT REV MOL CELL BIO, V15, P95, DOI 10.1038/nrm3738; Ma JSY, 2016, P NATL ACAD SCI USA, V113, pE450, DOI 10.1073/pnas.1524193113; Miyamoto T, 2012, NAT CHEM BIOL, V8, P465, DOI [10.1038/NCHEMBIO.922, 10.1038/nchembio.922]; Nguyen DP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12009; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022; Rajan S, 2015, SCI REP-UK, V5, DOI 10.1038/srep10609; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; Rizk SS, 2011, NAT STRUCT MOL BIOL, V18, P437, DOI 10.1038/nsmb.2002; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schellekens H, 2005, NEPHROL DIAL TRANSPL, V20, P3, DOI 10.1093/ndt/gfh1092; Seiler CY, 2014, NUCLEIC ACIDS RES, V42, pD1253, DOI 10.1093/nar/gkt1060; Shah NB, 2014, JOVE-J VIS EXP, DOI 10.3791/51383; Shekhawat SS, 2011, CURR OPIN CHEM BIOL, V15, P789, DOI 10.1016/j.cbpa.2011.10.014; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Staus DP, 2016, NATURE, V535, P448, DOI 10.1038/nature18636; Straathof KC, 2005, BLOOD, V105, P4247, DOI 10.1182/blood-2004-11-4564; Thomsen ND, 2013, P NATL ACAD SCI USA, V110, P8477, DOI 10.1073/pnas.1306759110; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wang BB, 2012, TRANSPL IMMUNOL, V26, P50, DOI 10.1016/j.trim.2011.10.004; Wei P, 2012, NATURE, V488, P384, DOI 10.1038/nature11259; Wiemann S, 2016, NAT METHODS, V13, P191, DOI 10.1038/nmeth.3776; Zhang H, 2007, CELL DEATH DIFFER, V14, P943, DOI 10.1038/sj.cdd.4402081; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	54	29	33	2	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2018	14	2					112	+		10.1038/nchembio.2529	http://dx.doi.org/10.1038/nchembio.2529			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FS7GS	29200207	Green Accepted, Green Submitted			2023-01-03	WOS:000419966500005
J	Ohman, EM				Ohman, E. Magnus			Secondary prevention shifts into second gear	LANCET			English	Editorial Material							ACUTE CORONARY SYNDROMES; EVENT RATES; CLOPIDOGREL; ASPIRIN; OUTPATIENTS; RIVAROXABAN; TICAGRELOR; RISK		[Ohman, E. Magnus] Duke Univ, Sch Med, Durham, NC 27710 USA; [Ohman, E. Magnus] Duke Clin Res Inst, Durham, NC 27710 USA	Duke University; Duke University	Ohman, EM (corresponding author), Duke Univ, Sch Med, Durham, NC 27710 USA.; Ohman, EM (corresponding author), Duke Clin Res Inst, Durham, NC 27710 USA.	ohman001@mc.duke.edu			Janssen; Bayer	Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Bayer(Bayer AG)	I have received research grants from Janssen and Bayer for my role as Co-Chairman on the GEMINI-ACS; the study was completed in 2016 and the paper was published in The Lancet in 2017, and the contract was ended after publication with no further research going forward. I declare no other competing interests.	Bhatt DL, 2010, JAMA-J AM MED ASSOC, V304, P1350, DOI 10.1001/jama.2010.1322; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Bittl JA, 2017, J AM COLL CARDIOL, V70, P1376, DOI 10.1016/j.jacc.2017.07.764; Bonaca MP, 2015, NEW ENGL J MED, V372, P1791, DOI 10.1056/NEJMoa1500857; Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1; Connolly SJ, 2017, LANCET; Eikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118; Fanaroff AC, 2017, INT J CARDIOL, V241, P87, DOI 10.1016/j.ijcard.2017.03.046; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Kumbhani DJ, 2013, AM J MED, V126, P693, DOI 10.1016/j.amjmed.2013.01.033; Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277; Roe MT, 2012, NEW ENGL J MED, V366, P85, DOI 10.1056/NEJMe1112770; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327	13	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 20	2018	391	10117					181	182		10.1016/S0140-6736(17)32816-7	http://dx.doi.org/10.1016/S0140-6736(17)32816-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU5BI	29132878				2023-01-03	WOS:000423867000004
J	Liu, JM; Liu, J; Wang, GA; Liu, GY; Zhou, HJ; Fan, Y; Liang, FX; Wang, H				Liu, Jianmin; Liu, Jing; Wang, Guang'an; Liu, Guangya; Zhou, Huanjiao; Fan, Yun; Liang, Fengxia; Wang, Hua			Electroacupuncture at Guanyuan (CV 4), Zusanli (ST 36) and Baihui (DU 20) regulate the aging-related changes in gene expression profile of the hippocampus in sub-acutely aging rats	PLOS ONE			English	Article							BRAIN; DISEASE; MODEL	To investigate the molecular mechanisms of sub-acutely aging and demonstrate the effect of electroacupuncture (EA) at the Guanyuan (CV 4), Zusanli (ST 36) and Baihui (DU 20) acupoint on the sub-acutely aging brain, cDNA microarrays and bioinformatics analyses were carried out. Thirty Sprague-Dawley (SD) male rats were selected and randomly divided into three groups: the control group (C), the sub-acutely aging model group (M) and the electroacupuncture group (M+EA). Sub-acutely aging model rats were obtained by D-galactose s.c. injection continuously for 40 days. Total RNA was extracted from the hippocampus area of brains in three groups for cDNA microarrays. The data of different groups were compared and analyzed by differential expression analysis, Gene ontology (GO) term enrichment, Kyoto Encyclopedia of Genes Genomes (KEGG) pathway enrichment and quantitative real-time PCR. According to the results, 4052 DE genes were identified in our study. Among them, there were 3079 differentially expressed (DE) genes between group M and group C, and these genes are associated with the aging of rats. Moreover, 983 genes were expressed differently in group M+EA compared with group M, revealing that points stimuli could regulate gene expression in brain with aging. Gene ontology (GO) term enrichment and KEGG enrichment were performed to further classify the differential expression genes. Important GO terms and KEGG pathways connected with sub-acutely aging EA effects were identified. At last, 3 significant differentially expressed genes were selected for real-time quantitative PCR to clarify the cDNA microarray results. In conclusion, the cDNA microarray data first compared and analyzed the differences of gene expression profile in the hippocampus of rats in different groups, which contribute to our knowledge on the molecular mechanisms of EA towards sub-acutely aging.	[Liu, Jianmin; Liu, Jing; Liu, Guangya; Zhou, Huanjiao; Fan, Yun; Liang, Fengxia; Wang, Hua] Hubei Univ Chinese Med, Acupuncture Moxibust & Orthoped Coll, Wuhan, Hubei, Peoples R China; [Liu, Jianmin; Liu, Jing; Liu, Guangya; Liang, Fengxia; Wang, Hua] Hubei Prov Collaborat Innovat Ctr Prevent Treatme, Wuhan, Hubei, Peoples R China; [Wang, Guang'an] Henan Univ Chinese Med, Clin Med Coll 3, Zhengzhou, Henan, Peoples R China	Hubei University of Chinese Medicine; Henan University of Traditional Chinese Medicine	Wang, H (corresponding author), Hubei Univ Chinese Med, Acupuncture Moxibust & Orthoped Coll, Wuhan, Hubei, Peoples R China.; Wang, H (corresponding author), Hubei Prov Collaborat Innovat Ctr Prevent Treatme, Wuhan, Hubei, Peoples R China.	huang.edu@hotmail.com	Liang, Feng/GZK-4305-2022; Liang, Fenghua/HHM-3798-2022		scientific research guidance projects of Hubei province [B2016111]	scientific research guidance projects of Hubei province	This work was supported by 2016 scientific research guidance projects of Hubei province (No. B2016111). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by 2016 scientific research guidance projects of Hubei province (NO. B2016111).	AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Arnold CR, 2014, EXP GERONTOL, V54, P75, DOI 10.1016/j.exger.2014.01.018; Brasnjevic I, 2006, ALZHEIMERS DEMENTI S, V2, pS619; Cheng HY, 2008, NEUROSCI LETT, V432, P111, DOI 10.1016/j.neulet.2007.12.009; Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988; Ding XR, 2006, NEUROSCI LETT, V399, P11, DOI 10.1016/j.neulet.2006.01.067; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Hai F, 2005, BEHAV BRAIN RES, V157, P245; Homeier D, 2014, CLIN GERIATR MED, V30, P671, DOI 10.1016/j.cger.2014.08.001; Jiang QQ, 2000, MODERN REHABILITATIO, V4, P1690; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Liang F, 2015, EVID-BASED COMPL ALT, V2015, P530; Liu Jian-Min, 2009, Zhen Ci Yan Jiu, V34, P242; [刘静 Liu Jing], 2014, [电子显微学报, Journal of Chinese Electronic Microscopy Society], V33, P69; Liu JM, 2014, SHANGHAI J ACUPUNCTU, V33, P66; Marioni JC, 2008, GENOME RES, V18, P1509, DOI 10.1101/gr.079558.108; Mcdonald J L, 2015, EVIDENCE BASED COMPL, V2015; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Oliveros J.C., 2007, VENNY INTERACTIVE TO; Pawelec G, 2008, EXP GERONTOL, V43, P34, DOI 10.1016/j.exger.2007.09.609; Roberts SB, 2001, J GERONTOL A-BIOL, V56, P66, DOI 10.1093/gerona/56.suppl_1.66; Sarkar S, 2006, MECH AGEING DEV, V127, P391, DOI 10.1016/j.mad.2005.12.010; Sidler Corinne, 2013, Frontiers in Genetics, V4, P211, DOI 10.3389/fgene.2013.00211; Stahl EC, 2015, ORGANOGENESIS, V11, P159, DOI 10.1080/15476278.2015.1120046; Tang HT, 2010, SHANGHAI J ACU MOX, V29, P573; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Wang Hua, 2012, Zhen Ci Yan Jiu, V37, P266; Wang Jia-you, 2011, Zhen Ci Yan Jiu, V36, P36; Weng L, 2006, BIOINFORMATICS, V22, P1111, DOI 10.1093/bioinformatics/btl045; World Health Organization, 2002, AC REV AN REP CONTR; [吴焕林 WU Huanlin], 2008, [中医杂志, Journal of Traditional Chinese Medicine], V49, P622; Xiao Ling, 2012, Zhongguo Zhen Jiu, V32, P435; Yang Hua-Yuan, 2008, Zhen Ci Yan Jiu, V33, P186; Yankner BA, 2008, ANNU REV PATHOL-MECH, V3, P41, DOI 10.1146/annurev.pathmechdis.2.010506.092044; Yu JC, 2005, PHYSIOL BEHAV, V86, P434, DOI 10.1016/j.physbeh.2005.07.015; Zhang XH, 2005, CHINESE J GERONTOLOG, V8, P933; Zhu MF, 2015, EVIDENCE BASED COMPL, V2015; Zhu Ya-zhen, 2007, Fudan Xuebao (Yixueban), V34, P617	39	2	2	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2018	13	1							e0191623	10.1371/journal.pone.0191623	http://dx.doi.org/10.1371/journal.pone.0191623			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT1QM	29352289	Green Published, gold, Green Submitted			2023-01-03	WOS:000422911300121
J	Kuo, CH; Lin, YL; Lee, CJ; Wang, CH; Lai, YH; Liou, HH; Hsu, BG				Kuo, Chiu-Huang; Lin, Yu-Li; Lee, Chung-Jen; Wang, Chih-Hsien; Lai, Yu-Hsien; Liou, Hung-Hsiang; Hsu, Bang-Gee			Hyperleptinemia positively associated with central arterial stiffness in hemodialysis patients	PLOS ONE			English	Article							PULSE-WAVE VELOCITY; SERUM OSTEOPROTEGERIN; LEPTIN; KIDNEY; PHYSIOLOGY	Objective Leptin plays a role in stimulating vascular inflammation, vascular smooth muscle hypertrophy, and augmenting blood pressure, which contributes to the pathogenesis of atherosclerosis and leads to arterial stiffness. This vascular damage, measured by carotid-femoral pulse wave velocity (cfPWV), is recognized as an independent predictor of cardiovascular mortality in hemodialysis (HD) patients. The aim of this study was to evaluate the relationship between serum leptin and arterial stiffness in HD patients. Patients and methods In 112 of the 126 HD patients were eligible and their biochemical data were collected for analysis. Serum leptin level was measured using a commercial enzyme-linked immunosor-bent assay kit. Carotid-femoral pulse wave velocity was measured by a validated tonometry system (SphygmoCor). Those have cfPWV values above 10 m/s are defined as the high arterial stiffness group. Results Among the participants, thirty-eight of them who were in the high arterial stiffness group, had a higher prevalence of diabetes mellitus (p = 0.002), age (p = 0.029), body mass index (BMI, p = 0.018), body fat mass (p = 0.001), hemoglobin (p = 0.040), and serum leptin levels (P < 0.001). Multivariable logistic regression analysis showed that leptin (odds ratio [OR] 1.09; 95% confidence interval [CI] 1.04 +/- 1.14; p < 0.001), diabetes (OR 7.17; CI 1.39 +/- 37.00; p = 0.019), body fat mass (OR 1.16; CI 1.02 +/- 1.33; p = 0.027); and hemoglobin (OR 2.11; CI 1.15 +/- 3.87; p = 0.015) were independently associated with arterial stiffness in HD patients. Conclusion In our study, hyperleptinemia was positively correlated to the high cfPWV and thus was related to high arterial stiffness in HD patients.	[Kuo, Chiu-Huang; Lin, Yu-Li; Wang, Chih-Hsien; Lai, Yu-Hsien; Hsu, Bang-Gee] Buddhist Tzu Chi Gen Hosp, Div Nephrol, Hualien, Taiwan; [Lee, Chung-Jen] Tzu Chi Univ Sci & Technol, Dept Nursing, Hualien, Taiwan; [Wang, Chih-Hsien; Hsu, Bang-Gee] Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Liou, Hung-Hsiang] Hsin Jen Hosp, Dept Med, Div Nephrol, New Taipei, Taiwan; [Hsu, Bang-Gee] Buddhist Tzu Chi Gen Hosp, Hualien, Taiwan	Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University of Science & Technology; Tzu Chi University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital	Hsu, BG (corresponding author), Buddhist Tzu Chi Gen Hosp, Div Nephrol, Hualien, Taiwan.; Hsu, BG (corresponding author), Tzu Chi Univ, Sch Med, Hualien, Taiwan.; Liou, HH (corresponding author), Hsin Jen Hosp, Dept Med, Div Nephrol, New Taipei, Taiwan.; Hsu, BG (corresponding author), Buddhist Tzu Chi Gen Hosp, Hualien, Taiwan.	hh258527@ms23.hinet.net; gee.lily@msa.hinet.net	Hsu, Bang-Gee/AAV-5287-2020	Lai, Yu-Hsien/0000-0002-6687-1058; Kuo, Chiu huang/0000-0002-9239-6932	Ministry of Science and Technology, Taiwan [MOST-104-2314-B-303-010]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by a grant from Ministry of Science and Technology, Taiwan, MOST-104-2314-B-303-010 (https://www.most.gov.tw/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, J HYPERTENS, V31, P1497; Beotowski J., 2012, CLIN EXP PHARM PHYSL, V39, p168 , DOI [10.1111/j.1440-1681.2011.05623, DOI 10.1111/J.1440-1681.2011.05623.X]; Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434; Blacher J, 1998, HYPERTENSION, V32, P570, DOI 10.1161/01.HYP.32.3.570; Briet M, 2012, KIDNEY INT, V82, P388, DOI 10.1038/ki.2012.131; Chen K, 2016, POSTGRAD MED, V128, P783, DOI 10.1080/00325481.2016.1214060; Cheng KH, 2008, INT J OBESITY, V32, P268, DOI 10.1038/sj.ijo.0803726; Coppari R, 2012, NAT REV DRUG DISCOV, V11, P692, DOI 10.1038/nrd3757; Dagogo-Jack S, 1998, PERITON DIALYSIS INT, V18, P34; Hsu BG, 2015, TOHOKU J EXP MED, V236, P247, DOI 10.1620/tjem.236.247; Kim-Shapiro DB, 2006, ARTERIOSCL THROM VAS, V26, P697, DOI 10.1161/01.ATV.0000204350.44226.9a; Lee C, 2014, BIOMED RES INT, V2014, P1; Lee MC, 2014, TRANSPL P, V46, P353, DOI 10.1016/j.transproceed.2013.11.145; Moreno PR, 2006, CIRCULATION, V113, P2245, DOI 10.1161/CIRCULATIONAHA.105.578955; Muhsen Hasan K., 2015, CARDIOVASCULAR PHARM, V04; Nasrallah MP, 2013, SEMIN NEPHROL, V33, P54, DOI 10.1016/j.semnephrol.2012.12.005; Nasri H, 2006, SAUDI J KIDNEY DIS T, V17, P521; Qasim A, 2008, J AM COLL CARDIOL, V52, P231, DOI 10.1016/j.jacc.2008.04.016; Rahmouni K, 2010, CURR HYPERTENS REV, V6, P104, DOI 10.2174/157340210791170994; Raikou V, 2014, J MOLECULAR PATHOPHY, V3, P6; Rider OJ, 2010, OBESITY, V18, P2311, DOI 10.1038/oby.2010.64; Robles NR, 1998, NEPHRON, V78, P118, DOI 10.1159/000044895; Schram MT, 2004, HYPERTENSION, V43, P176, DOI 10.1161/01.HYP.0000111829.46090.92; Sharma K, 1997, KIDNEY INT, V51, P1980, DOI 10.1038/ki.1997.269; Shimizu Y, 2014, GERIATR GERONTOL INT, V14, P811, DOI 10.1111/ggi.12171; Sweeney G, 2010, NAT REV CARDIOL, V7, P22, DOI 10.1038/nrcardio.2009.224; Tsai JP, 2015, TRANSPL P, V47, P1825, DOI 10.1016/j.transproceed.2015.06.002; Tsai JP, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872-016-0268-5; Tziakas DN, 2010, INT J CARDIOL, V142, P2, DOI 10.1016/j.ijcard.2009.10.031; Wang JH, 2014, J CLIN HYPERTENS, V16, P301, DOI 10.1111/jch.12288; Windham BG, 2010, AM J HYPERTENS, V23, P501, DOI 10.1038/ajh.2010.8	31	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2018	13	1							e0190694	10.1371/journal.pone.0190694	http://dx.doi.org/10.1371/journal.pone.0190694			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR9OU	29304064	Green Published, Green Submitted, gold			2023-01-03	WOS:000419403800100
J	Morales-Rios, O; Jasso-Gutierrez, L; Reyes-Lopez, A; Garduno-Espinosa, J; Munoz-Hernandez, O				Morales-Rios, Olga; Jasso-Gutierrez, Luis; Reyes-Lopez, Alfonso; Garduno-Espinosa, Juan; Munoz-Hernandez, Onofre			Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico	PLOS ONE			English	Article							CHILDRENS HOSPITALS; POLYPHARMACY; INPATIENTS; DATABASE; INFANTS; US	Background Drug-drug interactions (DDIs) detected in a patient may not be clinically apparent (potential DDIs), and when they occur, they produce adverse drug reactions (ADRs), toxicity or loss of treatment efficacy. In pediatrics, there are only few publications assessing potential DDIs and their risk factors. There are no studies in children admitted to emergency departments (ED). The present study estimates the prevalence and describes the characteristics of potential DDIs in patients admitted to an ED from a tertiary care hospital in Mexico; in addition, potential DDI-associated risk factors are investigated. Methods A secondary analysis of data from 915 patients admitted to the ED of the Hospital Infantil de Mexico "Federico Gomez" was conducted. The Medscape Drug Interaction Checker software was used to identify potential DDIs. The results are expressed as number of cases (%), means (95% CI) and medians (25-75th percentiles). Count data regressions for number of total and severity-stratified potential DDIs were performed adjusting for patient characteristics, number of administered drugs, days of stay, presence of ADRs and diagnoses. Results The prevalence of potential DDIs was 61%, with a median of 4 (2-8). A proportion of 0.2% of potential DDIs was "Contraindicated", 7.5% were classified as "Serious", 62.8% as "Significant" and 29.5% as "Minor". Female gender, age, days of stay, number of administered drugs and diagnoses of Neoplasms (C00-D48), Congenital malformations (Q00-Q99), Diseases of the Blood, Blood-forming Organs and Immunity (D50-D89) and Diseases of the nervous system (G00-G99) were significantly associated with potential DDIs. Conclusion The prevalence of potential DDIs in the ED is high, and strategies should therefore be established to monitor patients' safety during their stay, in addition to conducting investigations to estimate the real harm potential DDIs inflict on patients.	[Morales-Rios, Olga; Jasso-Gutierrez, Luis] Hosp Infantil Mexico Dr Federico Gomez, Dept Evaluac & Anal Med, Ciudad De Mexico, Mexico; [Reyes-Lopez, Alfonso] Hosp Infantil Mexico Dr Federico Gomez, Ctr Estudios Econ & Sociales Salud, Ciudad De Mexico, Mexico; [Garduno-Espinosa, Juan] Hosp Infantil Mexico Dr Federico Gomez, Direcc Invest, Ciudad De Mexico, Mexico; [Munoz-Hernandez, Onofre] Comis Nacl Arbitraje Med, Ciudad De Mexico, Mexico; [Morales-Rios, Olga; Jasso-Gutierrez, Luis; Reyes-Lopez, Alfonso; Garduno-Espinosa, Juan] Dr Marquez 162, Ciudad De Mexico, Mexico; [Munoz-Hernandez, Onofre] Mitla 250 10 Piso, Ciudad De Mexico, Mexico	Hospital Infantil de Mexico Federico Gomez; Hospital Infantil de Mexico Federico Gomez; Hospital Infantil de Mexico Federico Gomez	Morales-Rios, O (corresponding author), Hosp Infantil Mexico Dr Federico Gomez, Dept Evaluac & Anal Med, Ciudad De Mexico, Mexico.	magdalaqfb@yahoo.com.mx	Espinosa, Juan Garduño/B-9867-2014	Espinosa, Juan Garduño/0000-0002-3000-4948	Fondos Federales [HIM 2017-008 SSA 1303]	Fondos Federales	The author OMR received "Fondos Federales" for this work. Grant Number: HIM 2017-008 SSA 1303. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvim Mariana Macedo, 2015, Rev. bras. ter. intensiva, V27, P353, DOI 10.5935/0103-507X.20150060; Bjerrum Lars, 2008, Eur J Gen Pract, V14, P23, DOI 10.1080/13814780701815116; Cruciol-Souza Joice Mara, 2006, Clinics, V61, P515, DOI 10.1590/S1807-59322006000600005; Dai DW, 2016, PEDIATR CRIT CARE ME, V17, pE218, DOI 10.1097/PCC.0000000000000684; Espinosa MAFD, 2014, INT J CLIN PHARM-NET, V36, P1160, DOI 10.1007/s11096-014-0011-1; Dechanont S, 2014, PHARMACOEPIDEM DR S, V23, P489, DOI 10.1002/pds.3592; Doubova SV, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-147; Easton KL, 2004, BRIT J CLIN PHARMACO, V57, P611, DOI 10.1111/j.1365-2125.2003.02052.x; Easton-Carter KL, 2003, J PAEDIATR CHILD H, V39, P124, DOI 10.1046/j.1440-1754.2003.00103.x; European Medicines Agency, ICH TOP E 11 CLIN IN; Feinstein J, 2015, PEDIATRICS, V135, pE99, DOI 10.1542/peds.2014-2015; Feudtner C, 2012, ARCH PEDIAT ADOL MED, V166, P9, DOI 10.1001/archpediatrics.2011.161; FORD DR, 1977, J AM PHARM ASSOC, V17, P354, DOI 10.1016/S0003-0465(16)34215-X; Frechen S, 2012, DRUG SAFETY, V35, P745, DOI 10.2165/11631280-000000000-00000; Ganeva M, 2013, ADV CLIN EXP MED, V22, P555; Hospital Infantil de Mexico Federico Gomez, AN EST HIMFG; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Kwan T C, 1979, Can J Hosp Pharm, V32, P12; Langerova P, 2013, EUR J PEDIATR, V172, P631, DOI 10.1007/s00431-013-1933-7; Lebowitz Mollie Blazar, 2016, Hosp Pediatr, V6, P282, DOI 10.1542/hpeds.2015-0249; Leone R, 2010, DRUG SAFETY, V33, P667, DOI 10.2165/11534400-000000000-00000; Lindell-Osuagwu L, 2009, J CLIN PHARM THER, V34, P277, DOI 10.1111/j.1365-2710.2008.01005.x; Long S., 2001, REGRESSION MODELS CA; Mino-Leon D, 2011, REV INVEST CLIN, V63, P170; Miranda V, 2011, J PAIN SYMPTOM MANAG, V42, P342, DOI 10.1016/j.jpainsymman.2010.11.014; Rios OM, 2016, INT J CLIN PHARM-NET, V38, P80, DOI 10.1007/s11096-015-0209-x; Moura C, 2011, CLIN DRUG INVEST, V31, P309, DOI 10.2165/11586200-000000000-00000; Moura C, 2009, J PHARM PHARM SCI, V12, P266, DOI 10.18433/J35C7Z; Oshikoya KA, 2013, THER CLIN RISK MANAG, V9, P215, DOI 10.2147/TCRM.S44205; PUCKETT WH, 1971, AM J HOSP PHARM, V28, P247, DOI 10.1093/ajhp/28.4.247; Roblek T, 2015, EUR J CLIN PHARMACOL, V71, P131, DOI 10.1007/s00228-014-1786-7; Rodriguez-Terol A, 2009, Farm Hosp, V33, P134; Vitry AI, 2007, BRIT J CLIN PHARMACO, V63, P709, DOI 10.1111/j.1365-2125.2006.02809.x; Womer J, 2014, J PAIN SYMPTOM MANAG, V48, P903, DOI 10.1016/j.jpainsymman.2013.12.241; Yeh ML, 2014, COMPUT METH PROG BIO, V113, P15, DOI 10.1016/j.cmpb.2013.07.016	35	14	14	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2018	13	1							e0190882	10.1371/journal.pone.0190882	http://dx.doi.org/10.1371/journal.pone.0190882			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR9OU	29304072	Green Submitted, Green Published, gold			2023-01-03	WOS:000419403800133
J	Liu, CY; Lau, KY; Hsu, CC; Chen, JL; Lee, CH; Huang, TT; Chen, YT; Huang, CT; Lin, PH; Tseng, LM				Liu, Chun-Yu; Lau, Ka-Yi; Hsu, Chia-Chi; Chen, Ji-Lin; Lee, Chia-Han; Huang, Tzu-Ting; Chen, Yi-Ting; Huang, Chun-Teng; Lin, Po-Han; Tseng, Ling-Ming			Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells	PLOS ONE			English	Article							RESISTANT PROSTATE-CANCER; DEPENDENT KINASE 4/6; ANTITUMOR-ACTIVITY; SELECTIVE INHIBITOR; TUMOR-SUPPRESSOR; BASAL-LIKE; SUBTYPES; RETINOBLASTOMA; IDENTIFICATION; PD-0332991	Objectives Triple negative breast cancer (TNBC) lacks specific drug targets and remains challenging. Palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is approved for metastatic estrogen receptor (ER)-positive and human epithermal growth factor 2 (HER2)-negative breast cancer. The nature of cell cycle inhibition by palbociclib suggests its potential in TNBC cells. Retinoblastoma (RB, a known substrate of CDK4/6) pathway deregulation is a frequent occurrence in TNBC and studies have revealed that pharmacological CDK4/6 inhibition induces a cooperative cytostatic effect with doxorubicin in RB-proficient TNBC models. In addition, recent studies reported that anti-androgen therapy shows preclinical efficacy in androgen-receptor (AR)-positive TNBC cells. Here we examined the effect of palbociclib in combination with an anti-androgen enzalutamide in TNBC cells. Method MDA-MB-453, BT-549, MDA-MB-231 and MDA-MB-468 TNBC cell lines were used for in vitro studies. Protein expressions were assessed by Western blot analysis. Cytostatic effect was examined by MTT assay. Cell cycle and apoptosis were examined by flow cytometry. Results Palbociclib showed inhibitory effect in RB-proficient TNBC cells, and enzalutamide inhibited cell viability in AR-positive TNBC cells. Enzalutamide treatment could enhance the palbociclib-induced cytostatic effect in AR-positive/RB-proficient TNBC cells. In addition, palbociclib-mediated G1 arrest in AR-positive/RB-proficient TNBC cells was attenuated by RB knockdown. Conclusion Our study provided a preclinical rationale in selecting patients who might have therapeutic benefit from combining CDK4/6 inhibitors with AR antagonists.	[Liu, Chun-Yu; Hsu, Chia-Chi; Chen, Ji-Lin; Huang, Tzu-Ting; Tseng, Ling-Ming] Taipei Vet Gen Hosp, Comprehens Breast Hlth Ctr, Taipei, Taiwan; [Liu, Chun-Yu; Huang, Chun-Teng; Tseng, Ling-Ming] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Liu, Chun-Yu; Lau, Ka-Yi; Hsu, Chia-Chi; Chen, Ji-Lin; Lee, Chia-Han; Huang, Tzu-Ting; Chen, Yi-Ting] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan; [Huang, Chun-Teng] Taipei City Hosp, Div Hematol Oncol, Dept Med, Yang Ming Branch, Taipei, Taiwan; [Lin, Po-Han] Natl Taiwan Univ Hosp, Dept Med Genet, Taipei, Taiwan; [Tseng, Ling-Ming] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei City Hospital; National Taiwan University; National Taiwan University Hospital; Taipei Veterans General Hospital	Tseng, LM (corresponding author), Taipei Vet Gen Hosp, Comprehens Breast Hlth Ctr, Taipei, Taiwan.; Tseng, LM (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Tseng, LM (corresponding author), Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan.	lmtseng@vghtpe.gov.tw	Huang, Tzu-Ting/S-9455-2019; Lin, Po-Han/AEU-8550-2022; Chen, Yi/HIR-2608-2022	Lin, Po-Han/0000-0001-6066-398X; Huang, Tzu-Ting/0000-0002-3675-2760; Hsu, Chia-Chi/0000-0003-1532-7017	Taiwan Clinical Oncology Research Foundation-the Yen Tjing Ling Medical Foundation [CI-104-07]; Ministry of Science and Technology, Taiwan [MOST 104-2628-B-075-001-MY3]; Yang Ming Branch of Taipei City Hospital [10601-62-020]; Taipei Veterans General Hospital [V104C-151, V105C-067, V106C-101]; TVGH-NTUH Joint Research Program from Taipei Veterans General Hospital [VN105-09, VN106-07]; TVGH-NTUH Joint Research Program from National Taiwan-University Hospital [VN105-09, VN106-07]; Ministry of Health and Welfare, Executive Yuan, Taiwan [MOHW105-TDU-B-211-134003, MOHW106-TDU-B-211-144-003]	Taiwan Clinical Oncology Research Foundation-the Yen Tjing Ling Medical Foundation; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Yang Ming Branch of Taipei City Hospital; Taipei Veterans General Hospital(Taipei Veterans General Hospital); TVGH-NTUH Joint Research Program from Taipei Veterans General Hospital; TVGH-NTUH Joint Research Program from National Taiwan-University Hospital; Ministry of Health and Welfare, Executive Yuan, Taiwan	This work was funded by the Taiwan Clinical Oncology Research Foundation-the Yen Tjing Ling Medical Foundation (CI-104-07); Ministry of Science and Technology, Taiwan (MOST 104-2628-B-075-001-MY3) to C-YL; Yang Ming Branch of Taipei City Hospital (10601-62-020) to C-YL; Taipei Veterans General Hospital (V104C-151, V105C-067, V106C-101) to C-YL; TVGH-NTUH Joint Research Program (VN105-09, VN106-07) from Taipei Veterans General Hospital and National Taiwan-University Hospital to C-YL; Ministry of Health and Welfare, Executive Yuan, Taiwan (MOHW105-TDU-B-211-134003; MOHW106-TDU-B-211-144-003 for the Center of Excellence for Cancer Research at Taipei Veterans General) to C-YL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASGHAR U, 2015, J CLIN ONC 15 SUPPL, V33; Asghar US, 2017, CLIN CANCER RES, V23, P5561, DOI 10.1158/1078-0432.CCR-17-0369; Barton VN, 2015, MOL CANCER THER, V14, P769, DOI 10.1158/1535-7163.MCT-14-0926; Beer TM, 2014, NEW ENGL J MED, V371, P1755, DOI 10.1056/NEJMc1410239; Caiazza F, 2016, ENDOCR-RELAT CANCER, V23, P323, DOI 10.1530/ERC-16-0068; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gelmon K, 2012, ANN ONCOL, V23, P2223, DOI 10.1093/annonc/mds067; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Kalimutho M, 2015, TRENDS PHARMACOL SCI, V36, P822, DOI 10.1016/j.tips.2015.08.009; Kobayashi K, 2016, SURG TODAY, V46, P821, DOI 10.1007/s00595-015-1252-x; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Lehmann BD, 2014, J PATHOL, V232, P142, DOI 10.1002/path.4280; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Logan JE, 2013, ANTICANCER RES, V33, P2997; Loriot Y, 2013, ANN ONCOL, V24, P1807, DOI 10.1093/annonc/mdt136; Loriot Y, 2015, LANCET ONCOL, V16, P509, DOI 10.1016/S1470-2045(15)70113-0; Malorni L, 2012, BREAST CANCER RES TR, V136, P795, DOI 10.1007/s10549-012-2315-y; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Robinson TJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078641; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Schrader AJ, 2014, EUR UROL, V65, P30, DOI 10.1016/j.eururo.2013.06.042; Subhawong AP, 2009, AM J SURG PATHOL, V33, P163, DOI 10.1097/PAS.0b013e31817f9790; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Witkiewicz AK, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3652; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974	37	31	36	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2017	12	12							e0189007	10.1371/journal.pone.0189007	http://dx.doi.org/10.1371/journal.pone.0189007			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ7SY	29261702	gold, Green Published, Green Submitted			2023-01-03	WOS:000418564200021
J	Kowalska, K; Olejnik, A; Szwajgier, D; Olkowicz, M				Kowalska, Katarzyna; Olejnik, Anna; Szwajgier, Dominik; Olkowicz, Mariola			Inhibitory activity of chokeberry, bilberry, raspberry and cranberry polyphenol-rich extract towards adipogenesis and oxidative stress in differentiated 3T3-L1 adipose cells	PLOS ONE			English	Article							GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; BERRY FRUITS; LEPTIN; HYPERGLYCEMIA; ANTHOCYANINS; PREVENTION; SECRETION; HEALTH; GAMMA	Berries are a rich source of antioxidants and phytochemicals that have received considerable interest for their possible relations to human health. In this study, the anti-adipogenic effect of polyphenol-rich extract obtained from chokeberry Aronia melanocarpa (Michx.) Elliot, raspberry Rubus idaeus L., bilberry Vaccinium myrtillus L. and cranberry Vaccinium macrocarpon Aiton fruits and its underlying molecular mechanisms were investigated in differentiated 3T3-L1 adipose cells. Treatment with the extract (25-100 mu g/mL) significantly decreased lipid accumulation and reactive oxygen species generation in adipocytes without showing cytotoxicity. Real-time PCR analysis revealed that the extract at a concentration of 100 mu g/mL suppressed adipogenesis and lipogenesis via the down-regulation of PPAR. (67%), C/EBPa (72%), SREBP1 (62%), aP2 (24%), FAS (32%), LPL (40%), HSL (39%), and PLIN1 (32%) gene expression. Moreover, the extract significantly increased the expression of adiponectin (4.4-fold) and decreased leptin expression (90%) and respectively regulated the production of these adipokines in 3T3-L1 adipocytes. The obtained results suggest that the analyzed extract may be a promising source of bioactive compounds that support long-term weight maintenance and promote the effective management of obesity.	[Kowalska, Katarzyna; Olejnik, Anna; Olkowicz, Mariola] Poznan Univ Life Sci, Dept Biotechnol & Food Microbiol, Poznan, Poland; [Szwajgier, Dominik] Univ Life Sci, Dept Biotechnol Human Nutr & Sci Food Commod, Lublin, Poland	Poznan University of Life Sciences	Olejnik, A (corresponding author), Poznan Univ Life Sci, Dept Biotechnol & Food Microbiol, Poznan, Poland.	anna.olejnik@up.poznan.pl	Kowalska, Katarzyna/AAC-7968-2021; Olkowicz, Mariola/ABF-1182-2020; Szwajgier, Dominik/ABD-6715-2021	Kowalska, Katarzyna/0000-0001-7706-4035; Szwajgier, Dominik/0000-0002-2285-0669; Olejnik, Anna/0000-0002-4385-0051	National Science Centre, Poland [2015/19/B/NZ9/01054]	National Science Centre, Poland(National Science Centre, Poland)	This work was supported by the National Science Centre, Poland (grant number 2015/19/B/NZ9/01054 to AO). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MA, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0080-3; Choi HS, 2006, J IMMUNOASS IMMUNOCH, V27, P31, DOI 10.1080/15321810500403722; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Efferth T, 2011, CURR DRUG TARGETS, V12, P122, DOI 10.2174/138945011793591626; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Herranz-Lopez M, 2012, PHYTOMEDICINE, V19, P253, DOI 10.1016/j.phymed.2011.12.001; HOSSAIN MK, 2016, INT J MOL SCI, V17; Jeong MY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/475386; Kellogg J, 2010, J AGR FOOD CHEM, V58, P3884, DOI 10.1021/jf902693r; Kim HK, 2012, NUTR RES, V32, P770, DOI 10.1016/j.nutres.2012.06.008; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Koskinen-Kolasa A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1112-0; Kowalska K, 2016, CURR OPIN CLIN NUTR, V19, P446, DOI 10.1097/MCO.0000000000000322; Kowalska K, 2015, FOOD CHEM, V185, P383, DOI 10.1016/j.foodchem.2015.03.152; Kowalska K, 2014, FOOD CHEM, V148, P246, DOI 10.1016/j.foodchem.2013.10.032; Liu RH, 2013, ADV NUTR, V4, p384S, DOI 10.3945/an.112.003517; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Montagnese C, 2015, NUTRITION, V31, P908, DOI 10.1016/j.nut.2015.01.002; Sahagun DO, 2012, PPAR RES, V2012, DOI 10.1155/2012/318613; Qin BL, 2012, BRIT J NUTR, V108, P581, DOI 10.1017/S000711451100599X; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Seeram NP, 2008, J AGR FOOD CHEM, V56, P630, DOI 10.1021/jf072504n; Skrovankova S, 2015, INT J MOL SCI, V16, P24673, DOI 10.3390/ijms161024673; Suzuki R, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-14; Takahashi A, 2015, J OLEO SCI, V64, P1243, DOI 10.5650/jos.ess15181; Tamori Y, 2002, DIABETES, V51, P2045, DOI 10.2337/diabetes.51.7.2045; Tsuda T, 2003, J NUTR, V133, P2125, DOI 10.1093/jn/133.7.2125; Tsuda T, 2006, BIOCHEM PHARMACOL, V71, P1184, DOI 10.1016/j.bcp.2005.12.042; Tsuda T, 2004, BIOCHEM BIOPH RES CO, V316, P149, DOI 10.1016/j.bbrc.2004.02.031; Turer AT, 2012, DIABETOLOGIA, V55, P2319, DOI 10.1007/s00125-012-2598-x; Wang Q, 2015, NUTR RES, V35, P317, DOI 10.1016/j.nutres.2014.12.009; Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003	32	31	31	2	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2017	12	11							e0188583	10.1371/journal.pone.0188583	http://dx.doi.org/10.1371/journal.pone.0188583			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN9ZL	29182628	Green Submitted, Green Published, gold			2023-01-03	WOS:000416402000039
J	Sanda, B; Vistad, I; Sagedal, LR; Haakstad, LAH; Lohne-Seiler, H; Torstveit, MK				Sanda, Birgitte; Vistad, Ingvild; Sagedal, Linda Reme; Haakstad, Lene Annette Hagen; Lohne-Seiler, Hilde; Torstveit, Monica Klungland			Effect of a prenatal lifestyle intervention on physical activity level in late pregnancy and the first year postpartum	PLOS ONE			English	Article							GESTATIONAL WEIGHT-GAIN; ACTIVITY QUESTIONNAIRE; EXERCISE INTERVENTION; NORWEGIAN FIT; OBESE WOMEN; DIETARY; RISK; RELIABILITY; OVERWEIGHT; RETENTION	Background Despite documented health benefits for mother and baby, physical activity (PA)-level tends to decline in pregnancy. Overweight/obese and physically inactive women are two selected groups at increased risk of pregnancy complications. Thus, efficient strategies to maintain or increase PA-level in pregnancy and the postpartum period, especially among these women, are warranted. This secondary analysis examined the effect of a prenatal lifestyleintervention on PA-level in late pregnancy and the first year postpartum, with subanalysis on initially physically active versus inactive and normal-weight versus overweight/obese women. Method The Norwegian Fit for Delivery (NFFD) randomized controlled trial included healthy primiparous women with singleton pregnancies and body mass index (BMI) >= 19 kg/m(2) assigned to an intervention group, n = 303 (twice weekly group-exercises and dietary counseling) or a control group, n = 303 (standard prenatal care). The International Physical Activity Questionnaire short-form was used to assess PA-levels at inclusion (mean gestational week (GW) 16), GW 36, and six and 12 months postpartum. Results AtGW 36, a positive intervention-effect with a significant between-group difference in total PA-level compared to time of inclusion was found for the total group (530 MET-min/week, p = 0.001) and the subgroups of normal-weight (533 MET-min/week, p = 0.003) and initially active women (717 MET-min/week, p<0.001). Intervention-effect was dependent on exercise-adherence among overweight/obese and inactive women. Compared to time of inclusion, the intervention groups maintained total PA-level at GW 36, while total PA-level decreased in the control groups. The PA-levels increased postpartum, but with no significant differences between the randomization groups. Conclusion The NFFD prenatal combined lifestyle intervention had a significant effect on TPA-level in late pregnancy among women entering pregnancy normal-weight or physically active, thereby preventing the downward trend typically seen during pregnancy. Intervention-effect among overweight/obese and physically inactive women was, however, dependent on exercise-adherence. Long-term intervention-effect was not observed in the postpartum period.	[Sanda, Birgitte; Lohne-Seiler, Hilde; Torstveit, Monica Klungland] Univ Agder, Fac Hlth & Sport Sci, Kristiansand, Norway; [Sanda, Birgitte; Vistad, Ingvild; Sagedal, Linda Reme] Southern Norway Hosp Trust, Dept Obstet & Gynecol, Kristiansand, Norway; [Haakstad, Lene Annette Hagen] Norwegian Sch Sports Sci, Oslo, Norway	University of Agder; Norwegian School of Sport Sciences	Sanda, B (corresponding author), Univ Agder, Fac Hlth & Sport Sci, Kristiansand, Norway.; Sanda, B (corresponding author), Southern Norway Hosp Trust, Dept Obstet & Gynecol, Kristiansand, Norway.	birgitte.sanda@uia.no			Norwegian South-Eastern Regional Health Authority; municipality of Aust Agder in Norway; municipality of Vest Agder in Norway; University of Agder, Norway	Norwegian South-Eastern Regional Health Authority; municipality of Aust Agder in Norway; municipality of Vest Agder in Norway; University of Agder, Norway	The NFFD trial was funded by the Norwegian South-Eastern Regional Health Authority (https://www.heise-sorost.no/south-eastern-noway-regional-health-authority), with additional funding from the municipalities of Aust Agder and Vest Agder in Norway. The first author is a PhD fellow funded by the University of Agder, Norway (https://www.uia.no/en). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACOG Committee Obstetric Practice, 2002, Obstet Gynecol, V99, P171; Andersen LK, 2015, SEX REPROD HEALTHC, V6, P198, DOI 10.1016/j.srhc.2015.04.004; Aune D, 2014, EPIDEMIOLOGY, V25, P331, DOI 10.1097/EDE.0000000000000036; Bacchi E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166254; Borg E, 2006, SCAND J MED SCI SPOR, V16, P57, DOI 10.1111/j.1600-0838.2005.00448.x; Borodulin Katja, 2009, BMC Womens Health, V9, P32, DOI 10.1186/1472-6874-9-32; Comm Obstet Practice, 2015, OBSTET GYNECOL, V126, pe135, DOI 10.1097/AOG.0000000000001214; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Di Mascio D, 2016, AM J OBSTET GYNECOL; Dodd JM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0161-y; Eime RM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1796-0; Evenson KR, 2012, PAEDIATR PERINAT EP, V26, P479, DOI 10.1111/j.1365-3016.2012.01311.x; Garnas Kirsti Krohn, 2016, PLoS Med, V13, pe1002079, DOI 10.1371/journal.pmed.1002079; Gaston A, 2011, J SCI MED SPORT, V14, P299, DOI 10.1016/j.jsams.2011.02.006; Haakstad LAH, 2017, MIDWIFERY, V46, P45, DOI 10.1016/j.midw.2017.01.010; Halvorsen S, 2013, PHYSIOTHERAPY, V99, P42, DOI 10.1016/j.physio.2011.11.002; Hawkins M, 2014, AM J PUBLIC HEALTH, V104, pE74, DOI 10.2105/AJPH.2014.302072; Hayes L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0479-2; Health NDo, 2014, PHYS ACT GUID PREGN; Health NDo, 2015, FYS AKT SED BLANT VO; Hillesund ER, 2016, J DEV ORIG HLTH DIS, V7, P538, DOI 10.1017/S2040174416000258; Hui A, 2012, BJOG-INT J OBSTET GY, V119, P70, DOI 10.1111/j.1471-0528.2011.03184.x; Hui AL, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-331; Hui HL., 2006, CAN J DIABETES, V30, P169, DOI DOI 10.1016/S1499-2671(06)02010-7; Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-115; Nascimento SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133564; Nascimento SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128953; Nelson SM, 2010, HUM REPROD UPDATE, V16, P255, DOI 10.1093/humupd/dmp050; Overby NC, 2015, MATERN CHILD NUTR, V11, P20, DOI 10.1111/mcn.12026; Owe KM, 2009, SCAND J MED SCI SPOR, V19, P637, DOI 10.1111/j.1600-0838.2008.00840.x; Perales M, 2015, EVAL HEALTH PROF, V38, P59, DOI 10.1177/0163278714533566; Perales M, 2016, EARLY HUM DEV, V94, P43, DOI 10.1016/j.earlhumdev.2016.01.004; Poobalan AS, 2009, OBES REV, V10, P28, DOI 10.1111/j.1467-789X.2008.00537.x; Poston L, 2015, LANCET DIABETES ENDO, V3, P767, DOI 10.1016/S2213-8587(15)00227-2; Price BB, 2012, MED SCI SPORT EXER, V44, P2263, DOI 10.1249/MSS.0b013e318267ad67; Prince SA, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-56; Rasmussen, 2009, WEIGHT GAIN PREGN RE; Richardsen KR, 2016, INT J BEHAV NUTR PHY, V13, DOI 10.1186/s12966-016-0401-y; Ruchat SM, 2012, MED SCI SPORT EXER, V44, P1419, DOI 10.1249/MSS.0b013e31825365f1; Sagedal LR, 2017, BJOG-INT J OBSTET GY, V124, P97, DOI 10.1111/1471-0528.13862; Sagedal LR, 2017, BJOG-INT J OBSTET GY, V124, P111, DOI 10.1111/1471-0528.13863; Sagedal LR, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-132; Sanabria-Martinez G, 2015, BJOG-INT J OBSTET GY, V122, P1167, DOI 10.1111/1471-0528.13429; Sanda B, 2017, BMC SPORTS SCI MED R, V9, DOI 10.1186/s13102-017-0070-4; Santos IA, 2005, OBSTET GYNECOL, V106, P243, DOI 10.1097/01.AOG.0000171113.36624.86; Sebire NJ, 2001, INT J OBESITY, V25, P1175, DOI 10.1038/sj.ijo.0801670; Torloni MR, 2009, OBES REV, V10, P194, DOI 10.1111/j.1467-789X.2008.00541.x; US Department of Health and Human Services, PHYS ACT GUID ADV CO; Vinter CA, 2014, ACTA OBSTET GYN SCAN, V93, P794, DOI 10.1111/aogs.12429; WHO, 2010, GLOB REC PHYS ACT HL, V2010; YaB WJ Miller, 2005, LEISURE SCI	51	9	9	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2017	12	11							e0188102	10.1371/journal.pone.0188102	http://dx.doi.org/10.1371/journal.pone.0188102			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN8QZ	29176762	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000416291900038
J	Stewart, D; Gibson-Smith, K; MacLure, K; Mair, A; Alonso, A; Codina, C; Cittadini, A; Fernandez-Llimos, F; Fleming, G; Gennimata, D; Gillespie, U; Harrison, C; Junius-Walker, U; Kardas, P; Kempen, T; Kinnear, M; Lewek, P; Malva, J; McIntosh, J; Scullin, C; Wiese, B				Stewart, Derek; Gibson-Smith, Kathrine; MacLure, Katie; Mair, Alpana; Alonso, Albert; Codina, Carles; Cittadini, Antonio; Fernandez-Llimos, Fernando; Fleming, Glenda; Gennimata, Dimitra; Gillespie, Ulrika; Harrison, Cathy; Junius-Walker, Ulrike; Kardas, Przemyslaw; Kempen, Thomas; Kinnear, Moira; Lewek, Pawel; Malva, Joao; McIntosh, Jennifer; Scullin, Claire; Wiese, Birgitt			A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people	PLOS ONE			English	Article							NURSING-RESEARCH; CARE; MULTIMORBIDITY; POPULATION; PREVALENCE; GUIDELINES; SAFETY; IMPACT	Background Inappropriate use of multiple medicines (inappropriate polypharmacy) is a major challenge in older people with consequences of increased prevalence and severity of adverse drug reactions and interactions, and reduced medicines adherence. The aim of this study was to determine the levels of consensus amongst key stakeholders in the European Union (EU) in relation to aspects of the management of polypharmacy in older people. Methods Forty-six statements were developed on aspects of healthcare structures, processes and desired outcomes, with consensus defined at >= 80% agreement. Panel members were strategists (e.g. directors, leading clinicians and commissioners) from each of the 28 EU member states, with a target recruitment of five per member state. Three Delphi rounds were conducted via email, with panel members being provided with summative results and collated, anonymised comments at the commencement of Rounds 2 and 3. Results Ninety panel members were recruited (64.3% of target), with high participation levels throughout the three Delphi rounds (91.1%, 83.3%, 72.2%). During Round 1, consensus was obtained for 27/46 statements (58.7%), with an additional two statements in Round 2 and none in Round 3. Consensus was obtained for statements relating to: potential gain arising from polypharmacy management (3/4 statements); strategic development (7/7); change management (5/7) indicator measures (4/6); legislation (0/3); awareness raising (5/5); polypharmacy reviews (5/7); and EU vision (0/7). Analysis of free text comments indicated that the vision statements were too ambitious and not achievable by the specified timeframe of 2025. Conclusion Consensus was obtained amongst key EU strategists around many aspects of polypharmacy management in older people. Notably, no consensus was achieved in relation to statements relating to the need to alter legislation in areas of healthcare delivery, remuneration and practitioner scope of practice. While the vision for the EU by 2025 was considered rather ambitious, there is great potential and clear opportunity to advance polypharmacy management throughout the EU and beyond.	[Stewart, Derek; Gibson-Smith, Kathrine; MacLure, Katie] Robert Gordon Univ, Sch Pharm & Life Sci, Aberdeen, Scotland; [Mair, Alpana] Scottish Govt, Effect Prescribing & Therapeut Hlth & Social Care, Edinburgh, Midlothian, Scotland; [Alonso, Albert; McIntosh, Jennifer] FCRB, Directorate Res & Innovat, Barcelona, Spain; [Codina, Carles] Hosp Clin Barcelona, Pharm Dept, Barcelona, Spain; [Cittadini, Antonio] Univ Federico II, Dept Translat Med Sci, Naples, Italy; [Fernandez-Llimos, Fernando] Univ Lisbon, Fac Pharm, Dept Social Pharm, Inst Med Res iMed Ulisboa, Lisbon, Portugal; [Fleming, Glenda] Northern Hlth & Social Care Trust, Med Optimisat Innovat Ctr, Belfast, Antrim, North Ireland; [Gennimata, Dimitra] Univ Peloponnese, Dept Social & Educ Policy, Corinthos, Greece; [Gillespie, Ulrika; Kempen, Thomas] Uppsala Univ Hosp, Pharm Dept, Uppsala, Sweden; [Harrison, Cathy] Dept Hlth Social Serv & Publ Safety, Belfast, Antrim, North Ireland; [Junius-Walker, Ulrike; Wiese, Birgitt] Hannover Med Sch, Inst Gen Med, Hannover, Germany; [Kardas, Przemyslaw; Lewek, Pawel] Med Univ Lodz, Dept Family Med, Lodz, Poland; [Kinnear, Moira] Western Gen Hosp, NHS Lothian Pharm Serv, Edinburgh, Midlothian, Scotland; [Malva, Joao] Univ Coimbra, Fac Med, Coimbra, Portugal; [Scullin, Claire] Queens Univ, Sch Pharm, Belfast, Antrim, North Ireland	Robert Gordon University; University of Barcelona; Hospital Clinic de Barcelona; University of Naples Federico II; Universidade de Lisboa; Uppsala University; Uppsala University Hospital; Hannover Medical School; Medical University Lodz; University of Edinburgh; Universidade de Coimbra; Queens University Belfast	Stewart, D (corresponding author), Robert Gordon Univ, Sch Pharm & Life Sci, Aberdeen, Scotland.	d.stewart@rgu.ac.uk	iMed.ULisboa, PEPSocPh/B-4101-2014; MacLure, Katie/GRJ-8912-2022; Fernandez-Llimos, Fernando/B-8931-2008; Malva, Joao/L-3557-2014	Fernandez-Llimos, Fernando/0000-0002-8529-9595; fleming, glenda/0000-0001-7321-8092; Stewart, Derek/0000-0001-7360-8592; Lewek, Pawel/0000-0003-3690-7096; Malva, Joao/0000-0002-5438-4447; Kempen, Thomas/0000-0001-5173-5005; Alonso, Albert/0000-0003-0921-8033; Kardas, Przemyslaw/0000-0002-6078-2628; MacLure, Katie/0000-0003-0686-948X	SIMPATHY project [663082]; European Commission CHAFEA Health Program; Public Health Agency [SPI/5309/16] Funding Source: researchfish	SIMPATHY project; European Commission CHAFEA Health Program; Public Health Agency	This work has been supported by the SIMPATHY project, grant agreement number 663082, co-funded by the European Commission CHAFEA Health Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Beuscart JB, 2017, BRIT J CLIN PHARMACO, V83, P942, DOI 10.1111/bcp.13197; Cadogan CA, 2016, DRUG SAFETY, V39, P109, DOI 10.1007/s40264-015-0378-5; Campbell SM, 2001, J CLIN PHARM THER, V26, P5, DOI 10.1046/j.1365-2710.2001.00331.x; Clayton M.J., 1997, EDUC PSYCHOL-UK, V17, P373, DOI [10.1080/0144341970170401, DOI 10.1080/0144341970170401]; Cohen JE, 2003, SCIENCE, V302, P1172, DOI 10.1126/science.1088665; Craig P, 2008, BMJ-BRIT MED J, V337, pa1665; Dwyer LL, 2010, AM J GERIATR PHARMAC, V8, P63, DOI 10.1016/j.amjopharm.2010.01.001; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Guthrie B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6341; Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x; Hazen AC, 2017, RES SOCIAOL IN PRESS; Hutchings Andrew, 2006, J Health Serv Res Policy, V11, P218, DOI 10.1258/135581906778476553; Johansson T, 2016, BRIT J CLIN PHARMACO, V82, P532, DOI 10.1111/bcp.12959; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kaufmann CP, 2014, EUR J CLIN PHARMACOL, V70, P1, DOI 10.1007/s00228-013-1575-8; Keeney S, 2006, J ADV NURS, V53, P205, DOI 10.1111/j.1365-2648.2006.03716.x; Kenz HE, 2014, HEART CHANGE, V31, P345; Kirkpatrick SA, 2016, ACAD MANAGEMENT P, P10225; Koberlein J, 2013, GRUYTER, V25, P243; Millar AN, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1915-6; Ornstein SM, 2013, J AM BOARD FAM MED, V26, P518, DOI 10.3122/jabfm.2013.05.130012; Paparella G., 2016, PERSON CTR CARE EURO; Patterson SM, 2014, COCHRANE DB SYST REV, P10, DOI DOI 10.1002/14651858.CD008165.PUB3/FULL; Payne RA, 2014, EUR J CLIN PHARMACOL, V70, P575, DOI 10.1007/s00228-013-1639-9; Payne RA, 2011, BRIT J GEN PRACT, V61, P83, DOI 10.3399/bjgp11X556146; Schien E, 1995, ORG CULTURE LEADERSH; Smith M, 2013, HEALTH AFFAIR, V32, P1963, DOI 10.1377/hlthaff.2013.0542; Stewart D, 2017, EXPERT OPIN DRUG SAF, V16, P203, DOI 10.1080/14740338.2017.1265503; Stewart D, 2012, BRIT J CLIN PHARMACO, V74, P662, DOI 10.1111/j.1365-2125.2012.04204.x; Valentijn PP, 2013, INT J INTEGR CARE, V13; van den Bussche H, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-54; von der Gracht HA, 2012, TECHNOL FORECAST SOC, V79, P1525, DOI 10.1016/j.techfore.2012.04.013; Walsh EK, 2017, PHARMACOEPIDEM DR S, V26, P481, DOI 10.1002/pds.4188; Weaver SJ, 2013, ANN INTERN MED, V158, P369, DOI 10.7326/0003-4819-158-5-201303051-00002; World Health Organization, 2015, WHO GLOB STRAT PEOPL; World Health Organization, 2015, AG HLTH	39	39	39	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 20	2017	12	11							e0188348	10.1371/journal.pone.0188348	http://dx.doi.org/10.1371/journal.pone.0188348			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN1NI	29155870	Green Published, gold, Green Submitted			2023-01-03	WOS:000415756700050
J	Kabore, FN; Eymard-Duvernay, S; Zoungrana, J; Badiou, S; Bado, G; Hema, A; Diouf, A; Delaporte, E; Koulla-Shiro, S; Ciaffi, L; Cournil, A				Kabore, Firmin Nongodo; Eymard-Duvernay, Sabrina; Zoungrana, Jacques; Badiou, Stephanie; Bado, Guillaume; Hema, Arsene; Diouf, Assane; Delaporte, Eric; Koulla-Shiro, Sinata; Ciaffi, Laura; Cournil, Amandine			TDF and quantitative ultrasound bone quality in African patients on second line ART, ANRS 12169 2LADY sub-study	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; TENOFOVIR DISOPROXIL FUMARATE; X-RAY ABSORPTIOMETRY; MINERAL DENSITY; ANTIRETROVIRAL-NAIVE; RISK-FACTORS; ABACAVIR-LAMIVUDINE; VITAMIN-D; OSTEOPOROSIS; PREVALENCE	Background Bone demineralization, which leads to osteoporosis and increased fracture risk, is a common metabolic disorder in HIV-infected individuals. In this study, we aimed to assess the change in bone quality using quantitative ultrasound (QUS) over 96 weeks of follow-up after initiation of second-line treatment, and to identify factors associated with change in bone quality. Methods and findings In a randomized trial (ANRS 12169), TDF and PI-na ve participants failing standard first-line treatment, from Burkina Faso, Cameroon, and Senegal were randomized to receive either TDF/FTC/LPVr, ABC/ddl/LPVr or TDF/FTC/DRVr. Their bone quality was assessed using calcaneal QUS at baseline and every 24 weeks until week 96. Stiffness index (SI) was used to measure bone quality. Out of 228 participants, 168 (74%) were women. At baseline, median age was 37 years (IQR: 33-46 years) and median T-CD4 count was 199 cells/mu l (IQR: 113-319 cells/mu l). The median duration of first-line antiretroviral treatment (ART) was 52 months (IQR: 36-72 months) and the median baseline SI was 101 (IQR: 87-116). In multivariable analysis, factors associated with baseline SI were sex ([beta = -10.8 [-18.1,-3.5] for women), age ([beta = -8.7 [-12.4,-5.1] per 10 years), body mass index (BMI) ((beta = +0.8 [0.1,1.5] per unit of BMI), and study site ((beta = +12.8 [6.5,19.1] for Cameroon). After 96 weeks of second-line therapy, a reduction of 7.1% in mean SI was observed, as compared with baseline. Factors associated with SI during the follow-up were similar to those found at baseline. Exposure to TDF was not associated with a greater loss of bone quality over time. Conclusion Bone quality decreased after second-line ART initiation in African patients independently of TDF exposure. Factors associated with bone quality include age, sex, baseline BMI, study site, and duration of follow-up.	[Kabore, Firmin Nongodo] Ctr MURAZ, Dept Clin Res, Bobo Dioulasso, Burkina Faso; [Eymard-Duvernay, Sabrina; Badiou, Stephanie; Delaporte, Eric; Ciaffi, Laura; Cournil, Amandine] Univ Montpellier, Inst Rech Dev, INSERM, Unite Mixte Int 233,U1175, Montpellier, France; [Zoungrana, Jacques; Bado, Guillaume] Univ Hosp Souro Sanou, Dept Infect Dis, Bobo Dioulasso, Burkina Faso; [Badiou, Stephanie] Univ Hosp, Biochem Dept, Montpellier, France; [Hema, Arsene] Univ Hosp Souro Sanou, Dept Hosp Hyg, Bobo Dioulasso, Burkina Faso; [Diouf, Assane] Ctr Reg Rech & Format CRCF, Dakar, Senegal; [Delaporte, Eric] Univ Hosp, Dept Infect Dis, Montpellier, France; [Koulla-Shiro, Sinata] Yaounde Cent Hosp, Serv Malad Infect, Yaounde, Cameroon; [Koulla-Shiro, Sinata] Univ Yaounde I, Fac Med & Sci Biomed, Yaounde, Cameroon	Centre Muraz; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; University of Yaounde I	Kabore, FN (corresponding author), Ctr MURAZ, Dept Clin Res, Bobo Dioulasso, Burkina Faso.	nongodo@yahoo.fr	Delaporte, Eric/J-5397-2018; KABORE, Firmin/GLR-5359-2022	Delaporte, Eric/0000-0002-1822-9853; KABORE, Firmin/0000-0002-3462-6568; HEMA, Arsene/0000-0002-5279-643X				Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb; Calmy A, 2009, J INFECT DIS, V200, P1746, DOI 10.1086/644785; Carr A, 2015, HIV MED, V16, P137, DOI 10.1111/hiv.12242; Castronuovo D, 2013, EUR REV MED PHARMACO, V17, P2413; Christodoulou S, 2012, BIOMED RES INT BIOME, V2013, P2013; Ciaffi L, 2015, AIDS, V29, P1473, DOI 10.1097/QAD.0000000000000709; Clo A, 2015, NEW MICROBIOL, V38, P345; Conesa-Botella A, 2012, INT J TUBERC LUNG D, V16, P1517, DOI 10.5588/ijtld.11.0146; Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198-014-2794-2; Cotter AG, 2013, J CLIN ENDOCR METAB, V98, P1659, DOI 10.1210/jc.2012-3686; Cournil A., 2015, Journal of AIDS and Clinical Research, V6, P443; Cournil A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031726; Dao CN, 2011, CLIN INFECT DIS, V52, P396, DOI 10.1093/cid/ciq158; Das Satyajit, 2014, Recent Pat Antiinfect Drug Discov, V9, P6; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Dravid A, 2014, J INT AIDS SOC, V17, P53, DOI 10.7448/IAS.17.4.19567; Fantauzzi A, 2016, HIV AIDS-RES PALLIAT, V8, P109, DOI 10.2147/HIV.S99904; Fausto A, 2006, BONE, V38, P893, DOI 10.1016/j.bone.2005.11.001; Graubard B I, 1996, Stat Methods Med Res, V5, P263, DOI 10.1177/096228029600500304; Gudmundsdottir SL, 2005, J CLIN DENSITOM, V8, P80, DOI 10.1385/JCD:8:1:080; Guilbert ER, 2009, CONTRACEPTION, V79, P167, DOI 10.1016/j.contraception.2008.10.016; Hans D, 2003, OSTEOPOROSIS INT, V14, P251, DOI 10.1007/s00198-002-1358-z; Harris VW, 2012, J INFECT DIS, V205, pS391, DOI 10.1093/infdis/jis199; Haskelberg H, 2014, JAIDS-J ACQ IMM DEF, V67, P161, DOI 10.1097/QAI.0000000000000288; Isley MM, 2011, REV ENDOCR METAB DIS, V12, P93, DOI 10.1007/s11154-011-9180-6; Jacobson DL, 2008, JAIDS-J ACQ IMM DEF, V49, P298, DOI 10.1097/QAI.0b013e3181893e8e; Javier Rose-Marie, 2011, REV RHUM MONOGR, V78, P101; Kanis JA, 2007, ASSESSMENT OSTEOPORO; Kim HS, 2013, J KOREAN MED SCI, V28, P827, DOI 10.3346/jkms.2013.28.6.827; Krieg MA, 2008, J CLIN DENSITOM, V11, P163, DOI 10.1016/j.jocd.2007.12.011; Mansueto P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/735615; Matovu FK, 2016, CURR OPIN HIV AIDS, V11, P306, DOI 10.1097/COH.0000000000000274; McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188; McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412; Mikhail MB, 1999, OSTEOPOROSIS INT, V9, P24, DOI 10.1007/s001980050112; Moayyeri A, 2012, OSTEOPOROSIS INT, V23, P143, DOI 10.1007/s00198-011-1817-5; Moyle GJ, 2013, ANTIVIR THER, V18, P905, DOI 10.3851/IMP2667; Nayak S, 2006, ANN INTERN MED, V144, P832, DOI 10.7326/0003-4819-144-11-200606060-00009; Pines A, 2013, CLIMACTERIC, V16, P199; Pinzone MR, 2016, INFECTION, V44, P197, DOI 10.1007/s15010-015-0842-2; Reynes J, 2013, AIDS RES HUM RETROV, V29, P256, DOI [10.1089/aid.2011.0275, 10.1089/AID.2011.0275]; Samarawickrama A, 2014, J INT AIDS SOC, V17, P54, DOI 10.7448/IAS.17.4.19568; Schafer JJ, 2013, PHARMACOTHERAPY, V33, P665, DOI 10.1002/phar.1257; Schtscherbyna A, 2012, INT J INFECT DIS, V16, pE872, DOI 10.1016/j.ijid.2012.07.019; Steenhoff AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117123; Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417; Tabor E, 2017, J ULTRAS MED, DOI [10.1016/j.ejrad.2008.11.024, DOI 10.1016/J.EJRAD.2008.11.024PMID:19135327]; Thomsen K, 2015, OSTEOPOROSIS INT, V26, P1459, DOI 10.1007/s00198-014-3012-y; Trimpou P, 2010, EUR J RADIOL, V73, P360, DOI 10.1016/j.ejrad.2008.11.024; UNAIDS, 2014, UNAIDS REP 2014 GAP; Vanderjagt DJ, 2004, BONE, V35, P387, DOI 10.1016/j.bone.2004.04.001; Wejse C, 2007, AM J CLIN NUTR, V86, P1376, DOI 10.1093/ajcn/86.5.1376; Zanovec M, 2011, J CLIN DENSITOM, V14, P116, DOI 10.1016/j.jocd.2011.02.002	53	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2017	12	11								10.1371/journal.pone.0186686	http://dx.doi.org/10.1371/journal.pone.0186686			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM0ME	29117238	Green Submitted, Green Published, gold			2023-01-03	WOS:000414659600012
J	Pedersen, MO; Gang, AO; Brown, P; Pedersen, M; Knudsen, H; Nielsen, SL; Poulsen, T; Klausen, TW; Hogdall, E; Norgaard, P				Pedersen, Mette Olgod; Gang, Anne Ortved; Brown, Peter; Pedersen, Michael; Knudsen, Helle; Nielsen, Signe Ledou; Poulsen, Tim; Klausen, Tobias Wirenfeldt; Hogdall, Estrid; Norgaard, Peter			Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers	PLOS ONE			English	Article							RITUXIMAB PLUS CYCLOPHOSPHAMIDE; SINGLE CENTERS EXPERIENCE; NON-HODGKINS-LYMPHOMA; POOR-PROGNOSIS; CLINICAL-FEATURES; GERMINAL CENTER; PHASE-II; TRANSLOCATIONS; REARRANGEMENTS; EXPRESSION	Background Double expression of MYC and BCL2 proteins (DE) and double-hit MYC+BCL2/BCL6 translocations (DH) were established as important biomarkers in patients with diffuse large B-cell lymphoma (DLBCL) by the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Whether this applies to the subgroup of young patients with high risk DLBCL is not known. We previously found that in a uniform retrospective population-based cohort of patients aged 18-60 years with high-risk DLBCL, the addition of etoposide to R-CHOP chemotherapy (R-CHOEP) resulted in improved survival mainly in patients with germinal center B-cell like (GCB) immunophenotype. The aim of this study was to investigate the prognostic and predictive value of DE and DH in this patient cohort. Methods Data on all young Danish patients diagnosed with de novo high-risk DLBCL 2004-2008 and treated with R-CHOP or R-CHOEP were obtained from the Danish Lymphoma database (n = 159). Tumor samples were available from 103 patients. MYC and BCL2 proteins were analyzed with quantitative immunohistochemistry (IHC) using different cut off values. MYC-, BCL2-and BCL6-translocations were examined with fluorescent in situ hybridization (FISH). Results DE with MYC > 75% and BCL2 > 85% was an independent negative prognostic marker of progression free survival (PFS) in patients treated with R-CHOP but not R-CHOEP (p < 0.001), also after exclusion of patients with DH. A predictive effect of DE for response (PFS) to R-CHOEP vs. R-CHOP was almost significant (p = 0.07). DH was not prognostic in this patient cohort. Conclusion In young patients with high-risk DLBCL, treatment with R-CHOEP may overcome the negative prognostic impact of DE observed in patients treated with R-CHOP.	[Pedersen, Mette Olgod; Knudsen, Helle; Nielsen, Signe Ledou; Poulsen, Tim; Hogdall, Estrid; Norgaard, Peter] Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark; [Gang, Anne Ortved; Klausen, Tobias Wirenfeldt] Herlev & Gentofte Hosp, Dept Hematol, Herlev, Denmark; [Brown, Peter; Pedersen, Michael] Rigshosp, Dept Hematol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Pedersen, MO (corresponding author), Herlev & Gentofte Hosp, Dept Pathol, Herlev, Denmark.	Mette-pedersen@dadlnet.dk		Hogdall, Estrid/0000-0003-4689-5658; Brown, Peter de Nully/0000-0002-6522-4086; Poulsen, Tim/0000-0001-9781-0541	Department of Pathology, Herlev Hospital; Dansk Kraeftforsknings Fond and Roche NS	Department of Pathology, Herlev Hospital; Dansk Kraeftforsknings Fond and Roche NS	This work was supported by the Department of Pathology, Herlev Hospital; Dansk Kraeftforsknings Fond and Roche NS (unrestricted grant).	Akyurek N, 2012, CANCER-AM CANCER SOC, V118, P4173, DOI 10.1002/cncr.27396; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Arboe B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157999; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Ballman KV, 2015, J CLIN ONCOL, V33, P3968, DOI 10.1200/JCO.2015.63.3651; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Dunleavy K, 2014, BLOOD, V124, P395; Foot NJ, 2011, J CLIN PATHOL, V64, P802, DOI 10.1136/jclinpath-2011-200015; Gang AO, 2012, ANN ONCOL, V23, P147, DOI 10.1093/annonc/mdr058; Gang AO, 2014, LEUKEMIA LYMPHOMA, P1; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Holte H, 2013, ANN ONCOL, V24, P1385, DOI 10.1093/annonc/mds621; Horn H, 2015, LEUKEMIA, V29, P1564, DOI 10.1038/leu.2015.43; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kanungo A, 2006, MODERN PATHOL, V19, P25, DOI 10.1038/modpathol.3800500; Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230; Kluk MJ, 2016, AM J CLIN PATHOL, V145, P166, DOI 10.1093/ajcp/aqv028; Kramer MH, 1998, BLOOD, P92; Kuhnl A, 2017, ANN ONCOL; Le Gouill S, 2007, HAEMATOLOGICA, V92, P1335, DOI 10.3324/haematol.11305; Li S., 2011, MODERN PATHOL, V25, P145; Li SY, 2012, MODERN PATHOL, V25, P145, DOI 10.1038/modpathol.2011.147; Lin P, 2007, HAEMATOLOGICA, V92, P1297, DOI 10.3324/haematol.11263; Mahmoud AZ, 2015, MODERN PATHOL, V28, P545, DOI 10.1038/modpathol.2014.140; Melen CM, 2016, BRIT J HAEMATOL, V175, P614, DOI 10.1111/bjh.14399; Niitsu N, 2009, LEUKEMIA, V23, P777, DOI 10.1038/leu.2008.344; Pedersen MO, 2014, EUR J HAEMATOL, V92, P42, DOI 10.1111/ejh.12212; Pedersen MO, 2012, EUR J HAEMATOL, V89, P63, DOI 10.1111/j.1600-0609.2012.01787.x; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Schmitz N, 2012, LANCET ONCOL, V13, P1250, DOI 10.1016/S1470-2045(12)70481-3; Slack GW, 2011, ADV ANAT PATHOL, V18, P219, DOI 10.1097/PAP.0b013e3182169948; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Swerdlow S.H., 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Tibiletti MG, 2009, HUM PATHOL, V40, P645, DOI 10.1016/j.humpath.2008.06.032; Tomita N, 2009, HAEMATOL-HEMATOL J, V94, P935, DOI 10.3324/haematol.2008.005355; Vyberg M, 2016, VIRCHOWS ARCH, V468, P19, DOI 10.1007/s00428-015-1829-1; Wasterlid T, 2017, HEMATOL ONCOL, V35, P151, DOI 10.1002/hon.2256; Wilson WH, 2008, J CLIN ONCOL, V26, P2717, DOI 10.1200/JCO.2007.13.1391; Wilson WH, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.469.469; Wilson WH, 2012, HAEMATOL-HEMATOL J, V97, P758, DOI 10.3324/haematol.2011.056531; Xu-Monette ZY, 2015, MODERN PATHOL, V28, P1555, DOI 10.1038/modpathol.2015.118	47	13	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0186983	10.1371/journal.pone.0186983	http://dx.doi.org/10.1371/journal.pone.0186983			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL2ZD	29088292	gold, Green Published, Green Submitted			2023-01-03	WOS:000414088900034
J	Zitvogel, L; Ma, YT; Raoult, D; Kroemer, G; Gajewski, TF				Zitvogel, Laurence; Ma, Yuting; Raoult, Didier; Kroemer, Guido; Gajewski, Thomas F.			The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies	SCIENCE			English	Review							FUSOBACTERIUM-NUCLEATUM; COLORECTAL-CANCER; GUT MICROBIOTA; INTESTINAL MICROBIOTA; ENTEROCOCCUS-HIRAE; RESISTANCE; ANTITUMOR; IMMUNITY; BACTERIA; DISEASE	The fine line between human health and disease can be driven by the interplay between host and microbial factors. This "metagenome" regulates cancer initiation, progression, and response to therapies. Besides the capacity of distinct microbial species to modulate the pharmacodynamics of chemotherapeutic drugs, symbiosis between epithelial barriers and their microbial ecosystems has a major impact on the local and distant immune system, markedly influencing clinical outcome in cancer patients. Efficacy of cancer immunotherapy with immune checkpoint antibodies can be diminished with administration of antibiotics, and superior efficacy is observed with the presence of specific gut microbes. Future strategies of precision medicine will likely rely on novel diagnostic and therapeutic tools with which to identify and correct defects in the microbiome that compromise therapeutic efficacy.	[Zitvogel, Laurence] GRCC, Equipe Labellisee Ligue Natl Canc, Villejuif, France; [Zitvogel, Laurence] INSERM, U1015, Villejuif, France; [Zitvogel, Laurence] Univ Paris Sud, Univ Paris Saclay, Gustave Roussy, Villejuif, France; [Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France; [Ma, Yuting] Chinese Acad Med Sci, Inst Basic Med Sci, Ctr Syst Med, Beijing 100005, Peoples R China; [Ma, Yuting] Peking Union Med Coll, Beijing 100005, Peoples R China; [Ma, Yuting] Suzhou Inst Syst Med, Suzhou 215123, Jiangsu, Peoples R China; [Raoult, Didier] Aix Marseille Univ, Unite Rech Malad Infect & Trop Emergentes, Inst Hosp Univ IHU Mediterranee Infect, UM63,CNRS 7278,IRD 198,INSERM 1095, 19-21 Blvd Jean Moulin, F-13005 Marseille, France; [Kroemer, Guido] Univ Paris 05, Univ Pierre & Marie Curie, Ctr Rech Cordeliers, Sorbonne Paris Cite, Paris, France; [Kroemer, Guido] GRCC, Metabol & Cell Biol Platforms, Villejuif, France; [Kroemer, Guido] Equipe 11 Labellisee Ligue Natl Canc, UMRS 1138, Paris, France; [Gajewski, Thomas F.] Univ Chicago, Dept Med, Dept Pathol, Chicago, IL 60615 USA; [Gajewski, Thomas F.] Univ Chicago, Ben May Dept Canc, Chicago, IL 60615 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Chicago; University of Chicago	Zitvogel, L (corresponding author), GRCC, Equipe Labellisee Ligue Natl Canc, Villejuif, France.; Zitvogel, L (corresponding author), INSERM, U1015, Villejuif, France.; Zitvogel, L (corresponding author), Univ Paris Sud, Univ Paris Saclay, Gustave Roussy, Villejuif, France.; Zitvogel, L (corresponding author), Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France.; Gajewski, TF (corresponding author), Univ Chicago, Dept Med, Dept Pathol, Chicago, IL 60615 USA.; Gajewski, TF (corresponding author), Univ Chicago, Ben May Dept Canc, Chicago, IL 60615 USA.	laurence.zitvogel@gustaveroussy.fr; tgajewsk@medicine.bsd.uchicago.edu	RAOULT, Didier/A-8434-2008; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	RAOULT, Didier/0000-0002-0633-5974; KROEMER, Guido/0000-0002-9334-4405; Gajewski, Thomas/0000-0001-5727-3972; ZITVOGEL, laurence/0000-0003-1596-0998	Ligue Contre le Cancer (Equipe Labelisee); Agence Nationale de la Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LeDucq Foundation; LabEx Immuno-Oncology; Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Recherche Hospitalo-Universitaire-LUMIERE; Seerave Foundation; Institut Suisse de Recherche Experimentale sur le Cancer (ISREC) Foundation; Swiss Foundation; Paris Alliance of Cancer Research Institutes (PACRI); Natural Science Foundation of China (NSFC) [81722037, 81671630]; China Ministry of Science and Technology (National key research and development program) [2017YFA0506200]; Natural Science Foundation of Jiangsu Province [BK20170006, BK20160379]; Chinese National Thousand Talents Program; Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine [CAMS-I2M, 2016-I2M-1-005]; Non-profit Central Research Institute Fund of CAMS [2016ZX310194, 2017NL31004, 2017RC31008]; French Ministery/IHU Mediterranee Infections; Team Science Award from the Melanoma Research Alliance [R35 CA210098]; American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy; University of Chicago Medicine Comprehensive Cancer Center; Institutional Training Grant [T32 CA009594]; Center for Research Informatics of The University of Chicago Biological Science Division; Roche-Genentech; BMS; Merck; Incyte; Seattle Genetics; Ono	Ligue Contre le Cancer (Equipe Labelisee)(Ligue nationale contre le cancer); Agence Nationale de la Recherche (ANR)-Projets blancs(French National Research Agency (ANR)); ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)); LeDucq Foundation(Leducq Foundation); LabEx Immuno-Oncology; Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Recherche Hospitalo-Universitaire-LUMIERE; Seerave Foundation; Institut Suisse de Recherche Experimentale sur le Cancer (ISREC) Foundation; Swiss Foundation(Swiss National Science Foundation (SNSF)); Paris Alliance of Cancer Research Institutes (PACRI); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China Ministry of Science and Technology (National key research and development program); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Chinese National Thousand Talents Program; Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine; Non-profit Central Research Institute Fund of CAMS; French Ministery/IHU Mediterranee Infections; Team Science Award from the Melanoma Research Alliance; American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy; University of Chicago Medicine Comprehensive Cancer Center; Institutional Training Grant; Center for Research Informatics of The University of Chicago Biological Science Division; Roche-Genentech(Roche HoldingGenentech); BMS(Bristol-Myers Squibb); Merck(Merck & Company); Incyte; Seattle Genetics; Ono	L.Z. and G.K. were supported by the Ligue Contre le Cancer (Equipe Labelisee); Agence Nationale de la Recherche (ANR)-Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Institut Universitaire de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LeDucq Foundation; the LabEx Immuno-Oncology; the Site de Recherche Integree sur le Cancer (SIRIC) Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); Recherche Hospitalo-Universitaire-LUMIERE; the Seerave Foundation; Institut Suisse de Recherche Experimentale sur le Cancer (ISREC) Foundation; Swiss Foundation; the Paris Alliance of Cancer Research Institutes (PACRI); and philanthropy (from E. Badinter and N. Meyer). L.Z. is inventor on patent EP17305206 and European license 16306779.6 held by Institut Gustave Roussy that covers use of microbial modulators for anti-PD1/PD-L1/PD-L2 antibody-based treatments. Y.M. is supported by the Natural Science Foundation of China (NSFC, grants 81722037 and 81671630), China Ministry of Science and Technology (National key research and development program, grant 2017YFA0506200), Natural Science Foundation of Jiangsu Province (grants BK20170006 and BK20160379), Chinese National Thousand Talents Program, Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (grants CAMS-I2M and 2016-I2M-1-005), and the Non-profit Central Research Institute Fund of CAMS (grants 2016ZX310194, 2017NL31004, and 2017RC31008). D.R. is supported by the French Ministery/IHU Mediterranee Infections. T.G. was supported by Team Science Award R35 CA210098 from the Melanoma Research Alliance, the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy, and funds from the University of Chicago Medicine Comprehensive Cancer Center; by Institutional Training Grant T32 CA009594, and from The Center for Research Informatics of The University of Chicago Biological Science Division. T.F.G. is an advisory board member for Roche-Genentech, Merck, Abbvie, Bayer, Aduro, and Fog Pharma. T.F.G. receives research support from Roche-Genentech, BMS, Merck, Incyte, Seattle Genetics, and Ono. T.F.G. is a shareholder/cofounder of Jounce Therapeutics. L.Z., D.R., and G.K. are shareholders/founders of everImmune. The University of Chicago holds a licensing arrangement with Evelo. T.F.G. is an inventor on patent 15/170,284 submitted by the University of Chicago that covers the use of microbiota to improve cancer immunotherapy.	Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Arthur JC, 2013, SCI REP-UK, V3, DOI 10.1038/srep02868; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Banna GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00603; Belkaid Y, 2013, NAT IMMUNOL, V14, P646, DOI 10.1038/ni.2604; Bindels LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131009; Blanton LV, 2016, SCIENCE, V351, DOI 10.1126/science.aad3311; Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240; Bultman SJ, 2016, SEMIN ONCOL, V43, P97, DOI 10.1053/j.seminoncol.2015.09.001; Caballero S, 2017, CELL HOST MICROBE, V21, P592, DOI 10.1016/j.chom.2017.04.002; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; de Vos WM, 2012, NUTR REV, V70, pS45, DOI 10.1111/j.1753-4887.2012.00505.x; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Dzutsev A, 2017, ANNU REV IMMUNOL, V35, P199, DOI 10.1146/annurev-immunol-051116-052133; Enache-Angoulvant A, 2005, CLIN INFECT DIS, V41, P1559, DOI 10.1086/497832; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Gopalakrishnan V., 2017, SCIENCE, V358; Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010; Hanninen A, 2018, GUT, V67, P1445, DOI 10.1136/gutjnl-2017-314508; Huang HC, 2011, ARCH DERMATOL RES, V303, P527, DOI 10.1007/s00403-011-1135-y; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Joglekar P, 2017, CELL, V169, P378, DOI 10.1016/j.cell.2017.04.009; Kang CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076520; Lagier JC, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.203, 10.1038/nmicrobiol.2016.203]; Lee SM, 2013, NATURE, V501, P426, DOI 10.1038/nature12447; LI J, 2016, P NATL ACAD SCI USA, V1306, pE130; Liang XJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04985; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Moayyedi P, 2017, MED J AUSTRALIA, V207, P166, DOI 10.5694/mja17.00295; Nanjundappa RH, 2017, CELL, V171, P655, DOI 10.1016/j.cell.2017.09.022; Odamaki T, 2015, INT J GENOMICS, V2015, DOI 10.1155/2015/567809; Ottman N, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.01014-17; Pahle J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3123-x; Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205; Peled JU, 2017, J CLIN ONCOL, V35, P1650, DOI 10.1200/JCO.2016.70.3348; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; PLOVIER H, 2017, NAT MED, V107, pU113; Pluzanska A, 1985, Pol Arch Med Wewn, V73, P351; Pustelny C, 2015, INFECT IMMUN, V83, P417, DOI 10.1128/IAI.02234-14; Roberts NJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008982; Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016; ROSZKOWSKI K, 1985, J CANCER RES CLIN, V109, P72, DOI 10.1007/BF01884258; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sato J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12535-9; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Stappenbeck TS, 2016, NATURE, V534, P191, DOI 10.1038/nature18285; Steed AL, 2017, SCIENCE, V357, P498, DOI 10.1126/science.aam5336; TAKADA H, 1995, INFECT IMMUN, V63, P57, DOI 10.1128/IAI.63.1.57-65.1995; Takagi A, 2001, CARCINOGENESIS, V22, P599, DOI 10.1093/carcin/22.4.599; Takahashi T, 2001, J UROLOGY, V166, P2506, DOI 10.1016/S0022-5347(05)65625-X; Thaiss CA, 2016, CELL, V167, P1495, DOI 10.1016/j.cell.2016.11.003; Thiemann S, 2017, CELL HOST MICROBE, V21, P682, DOI 10.1016/j.chom.2017.05.005; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Venugopalan V, 2010, EMERG INFECT DIS, V16, P1661, DOI 10.3201/eid1611.100574; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Wang Y, 2014, GUT MICROBES, V5, P552, DOI 10.4161/gmic.29797; Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022; Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018; Yissachar N, 2017, CELL, V168, P1135, DOI 10.1016/j.cell.2017.02.009; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zhang JY, 2014, GENOME ANNOUNCEMENTS, V2, DOI 10.1128/genomeA.00521-14; Zitvogel L, 2017, NAT REV MICROBIOL, V15, P465, DOI 10.1038/nrmicro.2017.44	73	345	365	9	275	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2018	359	6382			SI		1366	1370		10.1126/science.aar6918	http://dx.doi.org/10.1126/science.aar6918			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA0ZG	29567708	Green Submitted			2023-01-03	WOS:000428043600039
J	Wang, CC; Schmid, CH; Fielding, RA; Harvey, WF; Reid, KF; Price, LL; Driban, JB; Kalish, R; Rones, R; McAlindon, T				Wang, Chenchen; Schmid, Christopher H.; Fielding, Roger A.; Harvey, William F.; Reid, Kieran F.; Price, Lori Lyn; Driban, Jeffrey B.; Kalish, Robert; Rones, Ramel; McAlindon, Timothy			Effect of tai chi versus aerobic exercise for fibromyalgia: comparative effectiveness randomized controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC OPIOID USE; SELF-EFFICACY; IMPACT QUESTIONNAIRE; LIMITED ELDERS; 6-MINUTE WALK; MUSCLE POWER; PAIN; MANAGEMENT; ARTHRITIS; SYMPTOMS	OBJECTIVES To determine the effectiveness of tai chi interventions compared with aerobic exercise, a current core standard treatment in patients with fibromyalgia, and to test whether the effectiveness of tai chi depends on its dosage or duration. DESIGN Prospective, randomized, 52 week, single blind comparative effectiveness trial. SETTING Urban tertiary care academic hospital in the United States between March 2012 and September 2016. PARTICIPANTS 226 adults with fibromyalgia (as defined by the American College of Rheumatology 1990 and 2010 criteria) were included in the intention to treat analyses: 151 were assigned to one of four tai chi groups and 75 to an aerobic exercise group. INTERVENTIONS Participants were randomly assigned to either supervised aerobic exercise (24 weeks, twice weekly) or one of four classic Yang style supervised tai chi interventions (12 or 24 weeks, once or twice weekly). Participants were followed for 52 weeks. Adherence was rigorously encouraged in person and by telephone. MAIN OUTCOME MEASURES The primary outcome was change in the revised fibromyalgia impact questionnaire (FIQR) scores at 24 weeks compared with baseline. Secondary outcomes included changes of scores in patient's global assessment, anxiety, depression, self efficacy, coping strategies, physical functional performance, functional limitation, sleep, and health related quality of life. RESULTS FIQR scores improved in all five treatment groups, but the combined tai chi groups improved statistically significantly more than the aerobic exercise group in FIQR scores at 24 weeks (difference between groups=5.5 points, 95% confidence interval 0.6 to 10.4,P=0.03) and several secondary outcomes (patient's global assessment=0.9 points, 0.3 to 1.4, P=0.005; anxiety=1.2 points, 0.3 to 2.1, P=0.006; self efficacy=1.0 points, 0.5 to 1.6, P=0.0004; and coping strategies, 2.6 points, 0.8 to 4.3, P=0.005). Tai chi treatment compared with aerobic exercise administered with the same intensity and duration (24 weeks, twice weekly) had greater benefit (between group difference in FIQR scores=16.2 points, 8.7 to 23.6, P<0.001). The groups who received tai chi for 24 weeks showed greater improvements than those who received it for 12 weeks (difference in FIQR scores=9.6 points, 2.6 to 16.6,P=0.007). There was no significant increase in benefit for groups who received tai chi twice weekly compared with once weekly. Participants attended the tai chi training sessions more often than participants attended aerobic exercise. The effects of tai chi were consistent across all instructors. No serious adverse events related to the interventions were reported. CONCLUSION Tai chi mind-body treatment results in similar or greater improvement in symptoms than aerobic exercise, the current most commonly prescribed non-drug treatment, for a variety of outcomes for patients with fibromyalgia. Longer duration of tai chi showed greater improvement. This mind-body approach may be considered a therapeutic option in the multidisciplinary management of fibromyalgia.	[Wang, Chenchen; Harvey, William F.; Driban, Jeffrey B.; McAlindon, Timothy] Tufts Univ, Sch Med, Tufts Med Ctr, Ctr Complementary & Integrat Med, Boston, MA 02111 USA; [Wang, Chenchen; Harvey, William F.; Driban, Jeffrey B.; McAlindon, Timothy] Tufts Univ, Sch Med, Tufts Med Ctr, Div Rheumatol, Boston, MA 02111 USA; [Schmid, Christopher H.] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA; [Schmid, Christopher H.] Brown Univ, Sch Publ Hlth, Ctr Evidence Synth Hlth, Providence, RI 02912 USA; [Fielding, Roger A.; Reid, Kieran F.] Tufts Univ, Sch Med, Nutr Exercise Physiol & Sarcopenia Lab, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Price, Lori Lyn] Tufts Univ, Inst Clin Res & Hlth Policy Studies, Tufts Med Ctr, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA; [Kalish, Robert] Tufts Univ, Sch Med, Div Rheumatol, Tufts Med Ctr, Boston, MA 02111 USA; [Rones, Ramel] Ctr Mind Body Therapies, Boston, MA USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Brown University; Brown University; Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; Tufts Medical Center; Tufts University	Wang, CC (corresponding author), Tufts Univ, Sch Med, Tufts Med Ctr, Ctr Complementary & Integrat Med, Boston, MA 02111 USA.; Wang, CC (corresponding author), Tufts Univ, Sch Med, Tufts Med Ctr, Div Rheumatol, Boston, MA 02111 USA.	cwang2@tuftsmedicalcenter.org	Schmid, Christopher H./J-2398-2014; Driban, Jeffrey/H-3486-2019	Schmid, Christopher H./0000-0002-0855-5313; Driban, Jeffrey/0000-0001-6098-4273	National Center for Complementary and Integrative Health of the National Institutes of Health (NIH) [R01AT006367, K24AT007323]; National Center for Research Resources, NIH [UL1 RR025752]; National Center for Advancing Translational Sciences, NIH [UL1TR000073, UL1TR001064]; US Department of Agriculture [58-1950-4-003]; Boston Claude D Pepper Older Americans Independence Center [1P30AG031679]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000073, UL1TR001064] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT006367] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT007323] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG031679] Funding Source: NIH RePORTER	National Center for Complementary and Integrative Health of the National Institutes of Health (NIH); National Center for Research Resources, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences, NIH; US Department of Agriculture(United States Department of Agriculture (USDA)); Boston Claude D Pepper Older Americans Independence Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by the National Center for Complementary and Integrative Health of the National Institutes of Health (NIH, R01AT006367 and K24AT007323), the National Center for Research Resources, NIH (UL1 RR025752) and the National Center for Advancing Translational Sciences, NIH (UL1TR000073 and UL1TR001064). RAF and KRF are supported in part by supported by the US Department of Agriculture, under agreement No 58-1950-4-003 and the Boston Claude D Pepper Older Americans Independence Center (1P30AG031679). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Complementary and Integrative Health of the National Institutes of Health. The organizations mentioned here did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Bean JF, 2002, J GERONTOL A-BIOL, V57, pM751, DOI 10.1093/gerona/57.11.M751; Beck A.T., 1996, MANUAL BECK DEPRESSI; Bennett RM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2783; Bennett RM, 2009, J RHEUMATOL, V36, P1304, DOI 10.3899/jrheum.081090; Bidonde J, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012700; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS163; Bruce B, 2005, CLIN EXP RHEUMATOL, V23, pS14; Buckhardt C, 2005, GUIDELINE MANAGEMENT; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Busch AJ, 2008, J RHEUMATOL, V35, P1130; Busch AJ, 2011, CURR PAIN HEADACHE R, V15, P358, DOI 10.1007/s11916-011-0214-2; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Callahan D, 2007, AGING CLIN EXP RES, V19, P194, DOI 10.1007/bf03324689; Carson JW, 2010, PAIN, V151, P530, DOI 10.1016/j.pain.2010.08.020; Carville SF, 2008, ANN RHEUM DIS, V67, P536, DOI 10.1136/ard.2007.071522; Clark M, 2008, NASM ESSENTIALS PERS; Cohen S, NATO ASI SERIES D, V24; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; Fitzcharles MA, 2011, AM J MED, V124, P955, DOI 10.1016/j.amjmed.2011.05.031; Fitzmaurice G.M., 2011, APPL LONGITUDINAL AN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fries JF, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3461; Fries JF, 2009, J RHEUMATOL, V36, P2061, DOI 10.3899/jrheum.090358; Fries JF, 2009, J CLIN EPIDEMIOL, V62, P779, DOI 10.1016/j.jclinepi.2008.12.001; George SZ, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0509-2; Goldenberg D., 2009, CLIN MANAGEMENT FIBR; Goldenberg D., 2016, CHRONIC WIDESPREAD P; Goldenberg DL, 2004, JAMA-J AM MED ASSOC, V292, P2388, DOI 10.1001/jama.292.19.2388; Goldenberg DL, 2016, MAYO CLIN PROC, V91, P640, DOI 10.1016/j.mayocp.2016.02.002; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Hauser W, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3002; Jones KD, 2012, CLIN RHEUMATOL, V31, P1205, DOI 10.1007/s10067-012-1996-2; Jones KD, 2009, RHEUM DIS CLIN N AM, V35, P373, DOI 10.1016/j.rdc.2009.05.004; Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005; King S, 1999, J RHEUMATOL, V26, P2233; Lauche R, 2013, COMPLEMENT THER MED, V21, P396, DOI 10.1016/j.ctim.2013.06.001; Lauche R, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/610615; Lee MS, 2008, CLIN RHEUMATOL, V27, P211, DOI 10.1007/s10067-007-0700-4; Lindell L, 2000, SCAND J PRIM HEALTH, V18, P149; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; NIAMS, 1999, FIBR RES CHALL OPP N; Painter JT, 2013, CLIN THER, V35, P303, DOI 10.1016/j.clinthera.2013.02.003; Painter JT, 2013, JCR-J CLIN RHEUMATOL, V19, P72, DOI 10.1097/RHU.0b013e3182863447; Peng XM, 2015, CLIN J PAIN, V31, P7, DOI 10.1097/AJP.0000000000000079; Phillips K, 2011, BEST PRACT RES CL RH, V25, P141, DOI 10.1016/j.berh.2011.02.005; Porter LS, 2002, PAIN, V98, P169, DOI 10.1016/S0304-3959(02)00042-8; Ramel J, 2009, CURR RHEUMATOL REV, V5, P188, DOI 10.2174/157339709790192459; Resnick B, 2000, J GERONTOL B-PSYCHOL, V55, pS352, DOI 10.1093/geronb/55.6.S352; Rooks DS, 2007, ARCH INTERN MED, V167, P2192, DOI 10.1001/archinte.167.20.2192; ROSENSTIEL AK, 1983, PAIN, V17, P33, DOI 10.1016/0304-3959(83)90125-2; Shelby RA, 2014, SUPPORT CARE CANCER, V22, P2851, DOI 10.1007/s00520-014-2269-1; Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010; Suzuki T, 2001, J AM GERIATR SOC, V49, P1161, DOI 10.1046/j.1532-5415.2001.49232.x; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wang CC, 2016, ANN INTERN MED, V165, P77, DOI 10.7326/M15-2143; Wang CC, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0548-x; Wang CC, 2010, NEW ENGL J MED, V363, P743, DOI 10.1056/NEJMoa0912611; Wang Chenchen, 2008, V52, P218, DOI 10.1159/000134302; Ware JE, 2009, SF 36 PHYS MENTAL HL; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1560, DOI 10.1002/art.1780400904; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	66	86	90	5	56	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	2018	360								k851	10.1136/bmj.k851	http://dx.doi.org/10.1136/bmj.k851			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB1LG	29563100	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000428811700027
J	McCaskey, MA; Wirth, B; Schuster-Amft, C; de Bruin, ED				McCaskey, Michael A.; Wirth, Brigitte; Schuster-Amft, Corina; de Bruin, Eling D.			Postural sensorimotor training versus sham exercise in physiotherapy of patients with chronic non-specific low back pain: An exploratory randomised controlled trial	PLOS ONE			English	Article							OSWESTRY DISABILITY INDEX; MOVEMENT VARIABILITY; MUSCLE-SPINDLES; GERMAN VERSION; QUIET STANCE; SAMPLE-SIZE; PROPRIOCEPTION; INDIVIDUALS; MANAGEMENT; BALANCE	Sensorimotor training (SMT) is popularly applied as exercise in rehabilitation settings, particularly for musculoskeletal pain. With insufficient evidence on its effect on pain and function, this exploratory randomised controlled trial investigated the potential effects of SMT in rehabilitation of chronic non-specific low back pain. Two arms received 9x30 minutes physiotherapy with added interventions: The experimental arm received 15 minutes of postural SMT while the comparator arm performed 15 minutes of added sub-effective low-intensity training. A treatment blinded tester assessed outcomes at baseline 2-4 days prior to intervention, pre- and post-intervention, and at 4-week follow-up. Main outcomes were pain and functional status assessed with a 0-100mm visual analogue scale and the Oswestry Disability Questionnaire. Additionally, postural control was analysed using a video-based tracking system and a pressure plate during perturbed stance. Robust, nonparametric multi-variate hypothesis testing was performed. 22 patients (11 females, aged 32 to 75 years) with mild to moderate chronic pain and functional limitations were included for analysis (11 per arm). At post-intervention, average values of primary outcomes improved slightly, but not to a clinically relevant or statistically significant extent. At 4-week follow-up, there was a significant improvement by 12 percentage points (pp) on the functional status questionnaire in the SMT-group (95% confidence intervall (CI) = 5.3pp to 17.7pp, p < 0.001) but not in the control group (4 pp improvement, CI = 11.8pp to 19.2pp). However, group-by-time interaction effects for functional status (Q = 3.3, 19 p = 0.07) and pain (Q = 0.84, p = 0.51) were non-significant. Secondary kinematic outcomes did not change over time in either of the groups. Despite significant improvement of functional status after SMT, overall findings of this exploratory study suggest that SMT provides no added benefit for pain reduction or functional improvement in patients with moderate chronic non-specific low back pain.	[McCaskey, Michael A.; de Bruin, Eling D.] ETH, Inst Human Movement Sci, Dept Hlth Sci & Technol, Zurich, Switzerland; [McCaskey, Michael A.; Schuster-Amft, Corina] Reha Rheinfelden, Res Dept, Rheinfelden, Switzerland; [Schuster-Amft, Corina] Bern Univ Appl Sci, Inst Rehabil & Performance Technol, Bern, Switzerland; [Wirth, Brigitte] Univ Zurich, Balgrist Univ Hosp, Dept Chiropract Med, Zurich, Switzerland; [de Bruin, Eling D.] Karolinska Inst, Div Physiotherapy, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Karolinska Institutet	McCaskey, MA (corresponding author), ETH, Inst Human Movement Sci, Dept Hlth Sci & Technol, Zurich, Switzerland.; McCaskey, MA (corresponding author), Reha Rheinfelden, Res Dept, Rheinfelden, Switzerland.	michael.mccaskey@hest.ethz.ch	de Bruin, Eling D./A-4751-2011; McCaskey, Michael Alexander/Q-8055-2019; Schuster, Corina/B-6939-2008	de Bruin, Eling D./0000-0002-6542-7385; McCaskey, Michael Alexander/0000-0002-6152-8816; Schuster-Amft, Corina/0000-0003-1120-4423; Wirth, Brigitte/0000-0001-6935-1800	cantonal department of health and social services of the Canton of Argovia, Switzerland; MM and CS' employer Reha Rheinfelden, Switzerland	cantonal department of health and social services of the Canton of Argovia, Switzerland; MM and CS' employer Reha Rheinfelden, Switzerland	MM and CS were partially funded by a grant from the cantonal department of health and social services of the Canton of Argovia (www.ag.ch/dgs), Switzerland. Internal funding was provided by MM and CS' employer Reha Rheinfelden, Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and the authors had unrestricted access to the data. There was no additional external funding received for this study.	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; Alfieri FM, 2012, CLIN INTERV AGING, V7, P119, DOI 10.2147/CIA.S27747; Aman JE, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01075; AMONOOKUOFI HS, 1983, J ANAT, V136, P509; Ashton-Miller JA, 2001, KNEE SURG SPORT TR A, V9, P128, DOI 10.1007/s001670100208; BEARD DJ, 1994, J BONE JOINT SURG BR, V76B, P654, DOI 10.1302/0301-620X.76B4.8027158; Behm DG, 2010, APPL PHYSIOL NUTR ME, V35, P91, DOI 10.1139/H09-127; Beinert K, 2013, J MOTOR BEHAV, V45, P271, DOI 10.1080/00222895.2013.785928; Bize R., 2012, BEWEGUNGSFORDERUNG A; Black DP, 2007, EXP BRAIN RES, V183, P511, DOI 10.1007/s00221-007-1066-1; Bombardier C, 2000, SPINE, V25, P3100, DOI 10.1097/00007632-200012150-00003; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; Brumagne S, 2000, SPINE, V25, P989, DOI 10.1097/00007632-200004150-00015; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cavanaugh JT, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-42; Cavanaugh JT, 2007, J AM GERIATR SOC, V55, P120, DOI 10.1111/j.1532-5415.2006.00997.x; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cholewicki J, 2000, J BIOMECH, V33, P1733, DOI 10.1016/S0021-9290(00)00126-3; Claeys K, 2012, J ELECTROMYOGR KINES, P1; Claeys K, 2015, J ELECTROMYOGR KINES, V25, P329, DOI 10.1016/j.jelekin.2014.10.013; Costa LOP, 2009, PHYS THER, V89, P1275, DOI 10.2522/ptj.20090218; Costa LDM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3829; DIWAN FH, 1986, J EMBRYOL EXP MORPH, V92, P223; Fairbank J C, 1980, Physiotherapy, V66, P271; Freeman M A, 1965, J Bone Joint Surg Br, V47, P678; Garber C. E., 2011, MED SCI SPORTS EXERC; Giesecke T, 2004, ARTHRITIS RHEUM-US, V50, P613, DOI 10.1002/art.20063; Granacher U, 2009, DTSCH Z SPORTMEDIZIN, P60; Harbourne RT, 2009, PHYS THER, V89, P284, DOI 10.2522/ptj.20080130.ar; Henry SM, 2014, SPINE J, V14, P2799, DOI 10.1016/j.spinee.2014.03.024; Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247; HIDES JA, 1994, SPINE, V19, P165, DOI 10.1097/00007632-199401001-00009; Hodges PW, 1996, SPINE, V21, P2640, DOI 10.1097/00007632-199611150-00014; Hodges PW, 2001, EXP BRAIN RES, V141, P261, DOI 10.1007/s002210100873; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; HOLM S, 1979, SCAND J STAT, V6, P65; Holm Sten, 2002, J Electromyogr Kinesiol, V12, P219, DOI 10.1016/S1050-6411(02)00028-7; Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428; Hsu WL, 2007, J NEUROPHYSIOL, V97, P3024, DOI 10.1152/jn.01142.2006; Hsu WL, 2013, AGE, V35, P1299, DOI 10.1007/s11357-012-9422-x; Hwang JA, 2013, J PHYS THER SCI, V25, P1189, DOI 10.1589/jpts.25.1189; IHARA H, 1986, AM J SPORT MED, V14, P309, DOI 10.1177/036354658601400412; Janda V, 2006, REHABILITATION SPINE, P203; Kiers H, 2012, EUR J APPL PHYSIOL, V112, P1577, DOI 10.1007/s00421-011-2124-8; Kim D, 2011, CLIN KINESIOL, V65, P18; Koes BW, 2010, EUR SPINE J, V19, P2075, DOI 10.1007/s00586-010-1502-y; Krishnamoorthy V, 2005, EXP BRAIN RES, V164, P1, DOI 10.1007/s00221-004-2205-6; Langevin HM, 2007, MED HYPOTHESES, V68, P74, DOI 10.1016/j.mehy.2006.06.033; Latash M., 2008, NEUROPHYSIOLOGICAL B, V2nd; Latash ML, 2010, MOTOR CONTROL, V14, P294; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Lederman E., 2010, NEUROMUSCULAR REHABI, P48; Lederman E, 2010, J BODYW MOV THER, V14, P84, DOI 10.1016/j.jbmt.2009.08.001; Leeuw M, 2007, J BEHAV MED, V30, P77, DOI 10.1007/s10865-006-9085-0; Lilford R, 2002, BRIT J SURG, V89, P129; Loeser JD, 1999, ACTA ANAESTH SCAND, V43, P957, DOI 10.1034/j.1399-6576.1999.430914.x; Lomond KV, 2014, MANUAL THER, V19, P425, DOI 10.1016/j.math.2014.04.007; Maki BE, 1996, CLIN GERIATR MED, V12, P635; Mannion AF, 2006, EUR SPINE J, V15, P66, DOI 10.1007/s00586-004-0816-z; Mannion AF, 2006, EUR SPINE J, V15, P55, DOI 10.1007/s00586-004-0815-0; Mazaheri M, 2013, GAIT POSTURE, V37, P12, DOI 10.1016/j.gaitpost.2012.06.013; McCaskey M., 2016, THESIS; McCaskey MA, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1104-4; McCaskey MA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-382; Moseley GL, 2004, EUR J PAIN, V8, P39, DOI 10.1016/S1090-3801(03)00063-6; Moseley GL, 2003, MANUAL THER, V8, P130, DOI 10.1016/S1356-689X(03)00051-1; O'Sullivan P, 2005, MANUAL THER, V10, P242, DOI 10.1016/j.math.2005.07.001; Oddsson LIE, 2003, J APPL PHYSIOL, V94, P1410, DOI 10.1152/japplphysiol.01183.2001; Oesch P., 2007, ASSESSMENTS MUSKULOS; Osthoff AKR, 2015, SPINE, V40, pE97, DOI 10.1097/BRS.0000000000000677; Otte C, 2010, MAN MED, V48, P267, DOI 10.1007/s00337-010-0770-2; Page P, 2006, J BODYW MOV THER, V10, P77, DOI 10.1016/j.jbmt.2005.04.006; PARKHURST TM, 1994, J ORTHOP SPORT PHYS, V19, P282, DOI 10.2519/jospt.1994.19.5.282; Peterka R J, 1990, J Vestib Res, V1, P87; Pijnenburg M, 2015, BRAIN CONNECT, V5, P303, DOI 10.1089/brain.2014.0309; Rasev E., 2010, INSTRUCTION POSTURAL; Rasev E., 2011, THESIS; Rolli Salathe Cornelia, 2013, ISRN Pain, V2013, P640690, DOI 10.1155/2013/640690; Ruhe A, 2011, EUR SPINE J, V20, P358, DOI 10.1007/s00586-010-1543-2; Runge CF, 1999, GAIT POSTURE, V10, P161, DOI 10.1016/S0966-6362(99)00032-6; Saragiotto BT, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012004; Scholz JP, 2007, EXP BRAIN RES, V180, P163, DOI 10.1007/s00221-006-0848-1; Scholz JP, 1999, EXP BRAIN RES, V126, P289, DOI 10.1007/s002210050738; Schulz KF, 2002, LANCET, V359, P966, DOI 10.1016/S0140-6736(02)08029-7; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stergiou N, 2011, HUM MOVEMENT SCI, V30, P869, DOI 10.1016/j.humov.2011.06.002; Tajali S, 2013, BIOMED ENG-APP BAS C, V25, DOI 10.4015/S1016237213500105; Tsao H, 2008, J ELECTROMYOGR KINES, V18, P559, DOI 10.1016/j.jelekin.2006.10.012; Ulrik Roijezon PP, 2015, MAN THER, P1; Vogt L, 2003, MANUAL THER, V8, P21, DOI 10.1054/math.2002.0476; Von Korff M, 2000, SPINE, V25, P3140, DOI 10.1097/00007632-200012150-00009; Waddell G, 2004, BACK PAIN REVOLUTION, P71; Wilcox R.R., 2012, STAT MODELING DECISI, Vthird; Winter D. A, 1995, GAIT POSTURE, V3, P193; Zusman M, 2013, J MULTIDISCIP HEALTH, V6, P197, DOI 10.2147/JMDH.S44117	96	11	11	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2018	13	3							e0193358	10.1371/journal.pone.0193358	http://dx.doi.org/10.1371/journal.pone.0193358			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FY7GW	29522571	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000427030800017
J	Ding, N; Jiang, J; Qin, PP; Wang, QX; Hu, JT; Li, ZG				Ding, Ning; Jiang, Jing; Qin, Pingping; Wang, Qiaoxia; Hu, Jiatong; Li, Zhigang			Mast cells are important regulator of acupoint sensitization via the secretion of tryptase, 5-hydroxytryptamine, and histamine	PLOS ONE			English	Article							OSTEOARTHRITIS; ACUPUNCTURE; KNEE; PAIN; ELECTROACUPUNCTURE; ACTIVATION; RECEPTORS; SEROTONIN; MECHANISM; RESPONSES	Mast cells (MCs) play a crucial role in mediating the establishment of networks among the circulatory, nervous and immune system at acupoints. However, the changes which occur in MCs during acupoint sensitization, i.e. the dynamic transformation of an acupoint from a "silenced" to an "activated" status, remain uncharacterized. To investigate the morphological and functional changes of MCs as an aid to understanding the cellular mechanism underlying acupoint sensitization, a rat model of knee osteoarthritis (OA) was induced by an injection of mono-iodoacetate (MIA) on day 0. On day 14, toluidine blue and immunofluorescence staining were used to observe the recruitment and degranulation of MCs and the release of mast cell co-expressed mediators: tryptase, 5-hydroxytryptamine (5-HT) and histamine (HA) at the acupoints Yanglingquan (GB34), Heding (EX-LE2) and Weizhong (BL40). Results showed that the number of MCs as well as the percentages of degranulated and extensively degranulated MCs at the acupoints GB34 and EX-LE2 in the light (A), mild (B), heavy (C) osteoarthritis groups were larger than those in the normal control (N) and normal saline (NS) groups (p < 0.01). Comparisons among the A, B and C groups suggested that the number and the degranulation extent of the MCs at the acupoints GB34 and EXLE2 were positively correlated with the severity of the disease. Some MCs in the A, B and C group showed the release of 5-HT, HA, and tryptase in degranulation at the acupoints GB34 and EX-LE2. Such changes in MCs were not observed at the acupoint BL40. In conclusion, this study confirmed that acupoint sensitization is associated with the increase in recruitment and degranulation levels of MCs on a acupoint-specific and disease severity-dependent manner. The release of tryptase, 5-HT, and HA during MC degranulation is likely to be one of the cellular mechanisms occurring during acupoint sensitization.	[Ding, Ning; Qin, Pingping; Wang, Qiaoxia; Hu, Jiatong; Li, Zhigang] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China; [Jiang, Jing] Beijing Univ Chinese Med, Sch Nursing, Beijing, Peoples R China	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Li, ZG (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.	lizhigang620@126.com			National Natural Science Foundation of China [81590952]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by the National Natural Science Foundation of China (No. 81590952).	Ahsin S, 2009, PAIN, V147, P60, DOI 10.1016/j.pain.2009.08.004; Bhaskaran S, 2014, AM J PHYSIOL-CELL PH, V306, pC143, DOI 10.1152/ajpcell.00247.2013; Chen B, 2017, CHIN J INTEGR MED, V23, P878, DOI 10.1007/s11655-016-2269-8; Chen S, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/158012; Chen XY, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0071-9; Corbett MS, 2013, OSTEOARTHR CARTILAGE, V21, P1290, DOI 10.1016/j.joca.2013.05.007; de Souza DA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/142359; Dudeck A, 2010, EXP DERMATOL, V19, P424, DOI 10.1111/j.1600-0625.2010.01073.x; Galli SJ, 2008, J DERMATOL SCI, V49, P7, DOI 10.1016/j.jdermsci.2007.09.009; Glatzer F, 2013, J ALLERGY CLIN IMMUN, V132, P1358, DOI 10.1016/j.jaci.2013.06.023; GRUBER BL, 1995, BLOOD, V86, P2488; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660; Hough LB, 2011, J PHARMACOL EXP THER, V336, P30, DOI 10.1124/jpet.110.171264; Islam MZ, 2014, J VET MED SCI, V76, P1339, DOI 10.1292/jvms.14-0223; Karner M, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/427265; Keles N, 2012, EXP TOXICOL PATHOL, V64, P713, DOI 10.1016/j.etp.2011.01.005; Kushnir-Sukhov NM, 2006, J IMMUNOL, V177, P6422, DOI 10.4049/jimmunol.177.9.6422; Li L, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/931283; Liu X, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6431574; Ma XP, 2009, WORLD J GASTROENTERO, V15, P5211, DOI 10.3748/wjg.15.5211; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005; Mei ZG, 2011, J TRADIT CHIN MED, V31, P311, DOI 10.1016/S0254-6272(12)60010-7; Mingfu L., 2013, EVID-BASED COMPL ALT, V2013; Nilsson G, 2000, IMMUNOLOGY, V99, P314, DOI 10.1046/j.1365-2567.2000.00972.x; Ohtsu H, 2012, INT ARCH ALLERGY IMM, V158, P2, DOI 10.1159/000337735; Oliveira MCG, 2007, NEUROSCIENCE, V145, P708, DOI 10.1016/j.neuroscience.2006.12.021; Payne V, 2004, ANAESTHESIA, V59, P695, DOI 10.1111/j.1365-2044.2004.03757.x; Pomonis JD, 2005, PAIN, V114, P339, DOI 10.1016/j.pain.2004.11.008; Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014; Purepong N, 2012, ACUPUNCT MED, V30, P187, DOI 10.1136/acupmed-2012-010140; Rong PJ, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/516851; Rong PJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/742195; Rosa AC, 2013, BRIT J PHARMACOL, V170, P38, DOI 10.1111/bph.12266; Shajib MS, 2015, ACTA PHYSIOL, V213, P561, DOI 10.1111/apha.12430; Shi Y, 2011, WORLD J GASTROENTERO, V17, P3733, DOI 10.3748/wjg.v17.i32.3733; Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225; Tsujii K, 2009, J PHARMACOL SCI, V109, P388, DOI 10.1254/jphs.08332FP; Wang Guangjun, 2014, Medicines (Basel), V1, P56, DOI 10.3390/medicines1010056; Wetterberg J, 2011, J EUR ACAD DERMATOL, V25, P1200, DOI 10.1111/j.1468-3083.2010.03952.x; Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7; Wu HG, 2008, DIGEST DIS SCI, V53, P1644, DOI 10.1007/s10620-007-0062-4; Wu J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0916-4; Wu ML, 2015, J CHEM NEUROANAT, V68, P14, DOI 10.1016/j.jchemneu.2015.06.002; Xie DX, 2013, ACUPUNCT MED, V31, P422, DOI 10.1136/acupmed-2013-010409; Yang W., 2014, EVID-BASED COMPL ALT, V2014; Yao W, 2014, INT J BIOL SCI, V10, P511, DOI 10.7150/ijbs.8631; Yu L.-L., 2014, EVID-BASED COMPL ALT, V2014; Yu YX, 2016, EUR J PHARMACOL, V778, P33, DOI 10.1016/j.ejphar.2015.07.017; Zhu HN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08855-5	52	22	25	3	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0194022	10.1371/journal.pone.0194022	http://dx.doi.org/10.1371/journal.pone.0194022			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513755	Green Published, gold, Green Submitted			2023-01-03	WOS:000426896800097
J	Everink, IHJ; van Haastregt, JCM; Evers, SMAA; Kempen, GIJM; Schols, JMGA				Everink, Irma H. J.; van Haastregt, Jolanda C. M.; Evers, Silvia M. A. A.; Kempen, Gertrudis I. J. M.; Schols, Jos M. G. A.			An economic evaluation of an integrated care pathway in geriatric rehabilitation for older patients with complex health problems	PLOS ONE			English	Article							TRANSITIONS INTERVENTION; HOSPITAL DISCHARGE; COST-EFFECTIVENESS; LIFE	Background Integrated care pathways which cover multiple care settings are increasingly used as a tool to structure care, enhance coordination and improve transitions between care settings. However, little is known about their economic impact. The objective of this study is to determine the cost-effectiveness and cost-utility of an integrated care pathway designed for patients with complex health problems transferring from the hospital, a geriatric rehabilitation facility and primary care. Methods This economic evaluation was performed from a societal perspective alongside a prospective cohort study with two cohorts of patients. The care as usual cohort was included before implementation of the pathway and the care pathway cohort after implementation of the pathway. Both cohorts were measured over nine months, during which intervention costs, healthcare costs, patient and family costs were identified. The outcome measures were dependence in activities of daily living (measured with the KATZ-15) and quality adjusted life years (EQ-5D-3L). Costs and effects were bootstrapped and various sensitivity analyses were performed to assess robustness of the results. Results After nine months, the average societal costs were significantly lower for patients in the care pathway cohort ( 50,791) versus patients in the care as usual cohort ( 62,170; CI = -22,090, -988). Patients in the care pathway cohort had better scores on the KATZ-15 (1.04), indicating cost-effectiveness. No significant differences were found between the two groups on QALY scores (0.01). Conclusions The results of this study indicate that the integrated care pathway is a cost-effective intervention. Therefore, dissemination of the integrated care pathway on a wider scale could be considered. This would provide us the opportunity to confirm the findings of our study in larger economic evaluations. When looking at QALYs, no effects were found. Therefore, it is also recommended to explore if therapy in geriatric rehabilitation could also pay attention to other quality of life-related domains, such as mood and social participation.	[Everink, Irma H. J.; van Haastregt, Jolanda C. M.; Evers, Silvia M. A. A.; Kempen, Gertrudis I. J. M.; Schols, Jos M. G. A.] Maastricht Univ, Fac Hlth Med & Life Sci, Dept Hlth Serv Res, Maastricht, Netherlands; [Everink, Irma H. J.; van Haastregt, Jolanda C. M.; Evers, Silvia M. A. A.; Kempen, Gertrudis I. J. M.; Schols, Jos M. G. A.] Maastricht Univ, Fac Hlth Med & Life Sci, CAPHRI, Maastricht, Netherlands; [Evers, Silvia M. A. A.] Ctr Econ Evaluat, Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Utrecht, Netherlands; [Schols, Jos M. G. A.] Maastricht Univ, Fac Hlth Med & Life Sci, Dept Family Med, Maastricht, Netherlands	Maastricht University; Maastricht University; Trimbos Institute; Maastricht University	Everink, IHJ (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Dept Hlth Serv Res, Maastricht, Netherlands.; Everink, IHJ (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, CAPHRI, Maastricht, Netherlands.	i.everink@maastrichtuniversity.nl	Kempen, Gertrudis/Y-8796-2019; Evers, Silvia/ABG-2128-2020; Kempen, Gertrudis I/H-5978-2016; Evers, Silvia MAA/K-9720-2015	Kempen, Gertrudis/0000-0002-7053-2198; Evers, Silvia/0000-0003-1026-570X; Kempen, Gertrudis I/0000-0002-7053-2198; Evers, Silvia MAA/0000-0003-1026-570X	Dutch National Care for the Elderly Program; Dutch Organization for Health Research and Development (ZonMw) [314070401]	Dutch National Care for the Elderly Program; Dutch Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This study was funded by The Dutch National Care for the Elderly Program and sponsored by The Dutch Organization for Health Research and Development (ZonMw #314070401) to J.M.G.A.S. The funding source had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen D, 2009, INT J EVID-BASED HEA, V7, P61, DOI 10.1111/j.1744-1609.2009.00127.x; [Anonymous], 2015, KOST METH KOST REF E; [Anonymous], 2012, INT J INTEGR CARE; BACHMANN S, 2010, BRIT MED J, V340, pC1718, DOI DOI 10.1136/BMJ.C1718; Boltz M., 2012, EVIDENCE BASED GERIA; Broughton EI, 2011, INT J CARE COORD, V15, P76, DOI 10.1258/jicp.2011.011004; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Courtney M, 2009, J AM GERIATR SOC, V57, P395, DOI 10.1111/j.1532-5415.2009.02138.x; Dautremont JF, 2013, J OTOLARYNGOL-HEAD N, V42, DOI 10.1186/1916-0216-42-59; De Bleser Leentje, 2006, J Nurs Manag, V14, P553, DOI 10.1111/j.1365-2934.2006.00702.x; Deneckere S, 2012, SOC SCI MED, V75, P264, DOI 10.1016/j.socscimed.2012.02.060; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Everink IHJ, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-016-1974-5; Everink Irma Helga Johanna, 2015, Tijdschr Gerontol Geriatr, V46, P104, DOI 10.1007/s12439-015-0125-5; Fields Jane, 2013, Health Manag Technol, V34, P10; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Hendriks MRC, 2013, MED DECIS MAKING, V33, P998, DOI 10.1177/0272989X13482045; Holtzer-Goor KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138225; Husereau D, 2013, INT J TECHNOL ASSESS, V29, P117, DOI 10.1017/S0266462313000160; Institute of Medicine of the National Academies, 2007, PREVENTING MEDICATIO; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Kane RL, 1997, MED CARE, V35, pJS4; Kim S, 2003, J ARTHROPLASTY, V18, P69, DOI 10.1054/arth.2003.50030; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Krummenauer F, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-338; Lamers LM, 2006, HEALTH ECON, V15, P1121, DOI 10.1002/hec.1124; Lin YK, 2011, J MED SYST, V35, P203, DOI 10.1007/s10916-009-9357-7; Lutomski JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081673; McCloskey R, 2004, J ADV NURS, V46, P186, DOI 10.1111/j.1365-2648.2003.02978.x; Mesteig M, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-1; Nolte E, 2014, WHAT IS EVIDENCE EC; Olsson LE, 2009, J ADV NURS, V65, P1626, DOI 10.1111/j.1365-2648.2009.05017.x; Patrick L, 2001, J AM GERIATR SOC, V49, P1471, DOI 10.1046/j.1532-5415.2001.4911239.x; Richardson G, 2004, HEALTH ECON, V13, P1203, DOI 10.1002/hec.901; Rosstad T, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-121; Stange KC, 2009, ANN FAM MED, V7, P100, DOI 10.1370/afm.971; van Asselt ADI, 2009, PHARMACOECONOMICS, V27, P519, DOI 10.2165/00019053-200927060-00007; Van Herck P, 2004, J INTEGRATED CARE PA, V8, P95, DOI DOI 10.1177/147322970400800302; Van Houdt S, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-296; Voss R, 2011, ARCH INTERN MED, V171, P1232, DOI 10.1001/archinternmed.2011.278; Wells JL, 2003, ARCH PHYS MED REHAB, V84, P898, DOI 10.1016/S0003-9993(02)04930-4; Zwaap J, 2015, KOSTENEFFECTIVITEIT	43	16	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2018	13	2							e0191851	10.1371/journal.pone.0191851	http://dx.doi.org/10.1371/journal.pone.0191851			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FX7ND	29489820	Green Published, gold, Green Submitted			2023-01-03	WOS:000426276000010
J	Davis, J				Davis, Jacky			PERSONAL VIEW Most UK doctors support assisted dying, a new poll shows: the BMA's opposition does not represent members	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Davis, Jacky] Whittington Hosp, London, England; [Davis, Jacky] BMA Council, London, England; [Davis, Jacky] Healthcare Profess Assisted Dying, London, England	University of London; University College London	Davis, J (corresponding author), Whittington Hosp, London, England.; Davis, J (corresponding author), BMA Council, London, England.; Davis, J (corresponding author), Healthcare Profess Assisted Dying, London, England.	drjcdavis@hotmail.com						[Anonymous], 2017, IS IT TIME LEGALISE; British Medical Association, 2017, PHYS ASS DYING BMA P; British Medical Association, 2014, ASS DYING BILL PARL; Campaign for Dignity in Dying, 2015, LARG EV POLL ASS DYI; Campaign for Dignity in Dying, 2015, PAT WOULD TRUST DOCT; Davis J., 2016, BMA SHOULD MOVE NEUT; Hartropp P, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3274; Nicholl D, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3566; Oregon Hospice and Palliative Care Association, HOSP OR DEATH DIGN A; RCGP, 2014, ASS DYING CONS AN; Royal College of Physicians of London, RCP REAFF POS ASS DY	11	8	8	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	2018	360								k301	10.1136/bmj.k301	http://dx.doi.org/10.1136/bmj.k301			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW0HY	29437652				2023-01-03	WOS:000424975900003
J	Watts, G				Watts, Geoff			Prospects for dementia research	LANCET			English	Editorial Material																			0	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 3	2018	391	10119					416	416		10.1016/S0140-6736(18)30190-9	http://dx.doi.org/10.1016/S0140-6736(18)30190-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FV1OL	29407021				2023-01-03	WOS:000424333600013
J	Connors, JM; Jurczak, W; Straus, DJ; Ansell, SM; Kim, WS; Gallamini, A; Younes, A; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Oki, Y; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Chen, R; Ramchandren, R; Zinzani, PL; Cunningham, D; Rosta, A; Josephson, NC; Song, E; Sachs, J; Liu, R; Jolin, HA; Huebner, D; Radford, J				Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illes, A.; Picardi, M.; Lech-Maranda, E.; Oki, Y.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; Walewski, J.; Chen, R.; Ramchandren, R.; Zinzani, P. L.; Cunningham, D.; Rosta, A.; Josephson, N. C.; Song, E.; Sachs, J.; Liu, R.; Jolin, H. A.; Huebner, D.; Radford, J.		ECHELON-1Study Grp	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; COOPERATIVE-ONCOLOGY-GROUP; RESPONSE CRITERIA; PROGNOSTIC SCORE; OPEN-LABEL; ABVD; DISEASE; TOXICITY; TRIAL; INTERGROUP	BACKGROUND Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. METHODS We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival. RESULTS At a median follow-up of 24.9 months, 2-year modified progression-free survival rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.7 to 85.0) and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points (hazard ratio for an event of progression, death, or modified progression, 0.77; 95% CI, 0.60 to 0.98; P = 0.03). There were 28 deaths with A+AVD and 39 with ABVD (hazard ratio for interim overall survival, 0.72 [95% CI, 0.44 to 1.17]; P = 0.19). All secondary efficacy end points trended in favor of A+AVD. Neutropenia occurred in 58% of the patients receiving A+AVD and in 45% of those receiving ABVD; in the A+AVD group, the rate of febrile neutropenia was lower among the 83 patients who received primary prophylaxis with granulocyte colony-stimulating factor than among those who did not (11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A+AVD group and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group who had peripheral neuropathy had resolution or improvement at the last follow-up visit. Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD and in 3% of those receiving ABVD. Among the deaths that occurred during treatment, 7 of 9 in the A+AVD group were associated with neutropenia and 11 of 13 in the ABVD group were associated with pulmonary-related toxicity. CONCLUSIONS A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and use of subsequent anticancer therapy at 2 years.	[Connors, J. M.; Savage, K. J.] Univ British Columbia, Vancouver, BC, Canada; [Connors, J. M.; Savage, K. J.] British Columbia Canc Agcy Ctr Lymphoid Canc, Dept Med Oncol, Vancouver, BC, Canada; [Jurczak, W.] Jagiellonian Univ, Dept Hematol, Krakow, Poland; [Lech-Maranda, E.] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland; [Lech-Maranda, E.] Ctr Postgrad Med Educ, Dept Hematol & Transfus Med, Warsaw, Poland; [Smolewski, P.] Med Univ Lodz, Dept Expt Hematol, Lodz, Poland; [Walewski, J.] Maria Sklodowska Curie Memorial Inst, Dept Lymphoid Malignancy, Warsaw, Poland; [Walewski, J.] Oncol Ctr, Warsaw, Poland; [Straus, D. J.; Younes, A.] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA; [Ansell, S. M.] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA; [Kim, W. S.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea; [Gallamini, A.] Antoine Lacassagne Canc Ctr, Res Innovat & Stat, Nice, France; [Alekseev, S.] Petrov Res Inst Oncol, St Petersburg, Russia; [Illes, A.] Univ Debrecen, Fac Med, Dept Hematol, Debrecen, Hungary; [Rosta, A.] Natl Inst Oncol, Dept Hematol, Budapest, Hungary; [Picardi, M.] Federico II Univ Hosp, Dept Adv Biomed Sci, Naples, Italy; [Zinzani, P. L.] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy; [Oki, Y.] MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA; [Feldman, T.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA; [Bartlett, N. L.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA; [Chen, R.] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA; [Ramchandren, R.] Barbara Ann Karmanos Canc Ctr, Dept Hematol & Oncol, Detroit, MI USA; [Cunningham, D.] Royal Marsden NHS Fdn Trust, Gastrointestinal & Lymphoma Unit, Sutton, Surrey, England; [Radford, J.] Univ Manchester & Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Dept Med Oncol, Manchester, Lancs, England; [Josephson, N. C.; Song, E.] Seattle Genet, Dept Clin Dev, Bothell, WA USA; [Sachs, J.; Jolin, H. A.; Huebner, D.] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA; [Liu, R.] Millennium Pharmaceut Inc, Global Biostat, Cambridge, MA USA	University of British Columbia; Jagiellonian University; Collegium Medicum Jagiellonian University; Centre of Postgraduate Medical Education - Poland; Medical University Lodz; Maria Sklodowska-Curie National Research Institute of Oncology; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Sungkyunkwan University (SKKU); Samsung Medical Center; UNICANCER; Centre Antoine Lacassagne; N.N. Petrov Research Institute of Oncology; University of Debrecen; National Institute of Oncology Hungary; University of Naples Federico II; University of Bologna; University of Texas System; UTMD Anderson Cancer Center; Hackensack University Medical Center; Washington University (WUSTL); City of Hope; Barbara Ann Karmanos Cancer Institute; Royal Marsden NHS Foundation Trust; Christie NHS Foundation Trust; University of Manchester; Seattle Genetics; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Connors, JM (corresponding author), British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada.	jconnors@bccancer.bc.ca	Jurczak, Wojciech/L-7645-2019; Jurczak, Wojciech/AAV-7973-2020; Luminari, Stefano/J-5916-2014; Walewski, Jan/ABC-9523-2020; Santoro, Armando/J-9594-2018; Radford, John A/N-1331-2015; Jurczak, Wojciech/ABB-2136-2020; Specht, Lena/J-6422-2019; Savage, Kerry/HCH-5539-2022; Connors, Joseph/AAF-5284-2019; Jurczak, Wojciech/M-1625-2019; Lech-Maranda, Ewa/AAH-5474-2020; Garcia-Sanz, Ramon/B-7986-2017; ZINZANI, PIER LUIGI/J-9182-2016	Jurczak, Wojciech/0000-0003-1879-8084; Luminari, Stefano/0000-0001-8446-2285; Santoro, Armando/0000-0003-1709-9492; Radford, John A/0000-0001-7898-2786; Jurczak, Wojciech/0000-0003-1879-8084; Specht, Lena/0000-0002-6902-2190; Connors, Joseph/0000-0002-1361-7531; Lech-Maranda, Ewa/0000-0001-9592-0851; Kuliczkowski, Kazimierz/0000-0001-6812-1421; Walewski, Jan/0000-0003-4247-2674; Garcia-Sanz, Ramon/0000-0003-4120-2787; Warzocha, Krzysztof/0000-0002-2396-3905; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Robak, Tadeusz/0000-0002-3411-6357; Bartlett, Nancy/0000-0001-8470-394X; Briones Meijide, Javier/0000-0003-2750-3735; Smolewski, Piotr/0000-0003-2700-3343; Stroyakovskiy, Daniil/0000-0003-1973-1092; Greenwood, Matthew/0000-0002-3667-2613; Cunningham, David/0000-0001-5158-1069	Millennium Pharmaceuticals; Seattle Genetics; Amgen; Bayer Healthcare; Bristol-Myers Squibb; Cephalon; F. Hoffmann-La Roche; Genentech; Janssen; Lilly; Merck; NanoString Technologies; Takeda; Pharmacyclics; Acerta; Pfizer; Celtrion; Gilead; TG Therapeutics; MorphoSys; Sandoz Novartis; Servier; Nordic Nanovector; Spectrum; LAM Therapeutics; Celldex; Affimed; Regeneron; Novartis; Celgene; Johnson Johnson; Kyowa Hakko Kirin; Mundipharma; Roche; Celltrion; Eisa; Janssen-Cilag; AbbVie; Teva Pharmaceuticals; Immune Design; Forty Seven; AstraZeneca; Kite; GSK/Novartis; Teva; Boehringer Ingelheim; Karyopham; Ariad; Sanofi; Bayer; TG Pharmaceuticals; Merrimack; Medimmune; Merck Serono; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Seattle Genetics; Amgen(Amgen); Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); Bristol-Myers Squibb(Bristol-Myers Squibb); Cephalon; F. Hoffmann-La Roche(Hoffmann-La Roche); Genentech(Roche HoldingGenentech); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Lilly(Eli Lilly); Merck(Merck & Company); NanoString Technologies; Takeda(Takeda Pharmaceutical Company Ltd); Pharmacyclics; Acerta; Pfizer(Pfizer); Celtrion; Gilead(Gilead Sciences); TG Therapeutics; MorphoSys; Sandoz Novartis; Servier(Servier); Nordic Nanovector; Spectrum; LAM Therapeutics; Celldex; Affimed; Regeneron(Regeneron); Novartis(Novartis); Celgene(Bristol-Myers SquibbCelgene Corporation); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Kyowa Hakko Kirin(Kyowa Kirin Ltd); Mundipharma; Roche(Roche Holding); Celltrion; Eisa; Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); AbbVie(AbbVie); Teva Pharmaceuticals(Teva Pharmaceutical Industries); Immune Design; Forty Seven; AstraZeneca(AstraZeneca); Kite; GSK/Novartis; Teva(Teva Pharmaceutical Industries); Boehringer Ingelheim(Boehringer Ingelheim); Karyopham; Ariad; Sanofi; Bayer(Bayer AG); TG Pharmaceuticals; Merrimack; Medimmune(AstraZenecaMedimmune); Merck Serono(Merck & Company); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, and Seattle Genetics.; Dr. Connors reports receiving grant support from Amgen, Bayer Healthcare, Bristol-Myers Squibb, Cephalon, F. Hoffmann-La Roche, Genentech, Janssen, Lilly, Merck, NanoString Technologies, Seattle Genetics, and Takeda; Dr. Jurczak, receiving grant support from Janssen, Pharmacyclics, Acerta, Pfizer, Celtrion, Gilead, TG Therapeutics, and Merck, grant support and consulting fees from MorphoSys and Sandoz Novartis, and consulting fees from Servier, Nordic Nanovector, and Spectrum; Dr. Straus, receiving honoraria from DAVA Oncology; Dr. Ansell, receiving grant support from Millennium Pharmaceuticals, Bristol-Myers Squibb, Seattle Genetics, LAM Therapeutics, Celldex, Affimed, Merck, and Regeneron; Dr. Kim, receiving grant support from Millennium Pharmaceuticals, Novartis, Merck, Celgene, Johnson & Johnson, Kyowa Hakko Kirin, and Mundipharma, and grant support and honoraria from Roche, Celltrion, and Eisa; Dr. Gallamini, receiving grant support and consulting fees from Millennium Pharmaceuticals; Dr. Younes, receiving honoraria from Millennium Pharmaceuticals, Seattle Genetics, Merck, and Bristol-Myers Squibb; Dr. Illes, receiving advisory board fees from Millennium Pharmaceuticals, Novartis, Janssen, Roche, and Celgene; Dr. Lech-Maranda, receiving lecture fees from Roche, Novartis, Gilead, and Bristol-Myers Squibb, advisory board fee from Janssen-Cilag, AbbVie, and Teva Pharmaceuticals, and lecture fees and advisory board fees from Amgen; Dr. Feldman, receiving honoraria from Seattle Genetics, Celgene, AbbVie, Pharmacyclics, Janssen, and Kite Pharma, and consulting fees from Bristol-Myers Squibb; Dr. Smolewski, receiving fees for participating in a clinical study as an investigator from Roche; Dr. Savage, receiving consulting fees and honoraria from Seattle Genetics, Merck, Bristol-Myers Squibb, Servier, Gilead, and Novartis, honoraria from Millennium Pharmaceuticals, and grant support from Roche; Dr. Bartlett, receiving grant support from Millennium Pharmaceuticals, Celgene, Genentech, Merck, Bristol-Myers Squibb, Immune Design, Forty Seven, Affimed, Janssen, Pharmacyclics, AstraZeneca, Novartis, and Gilead, and grant support and advisory board fees from Seattle Genetics, Pfizer, and Kite; Dr. Walewski, receiving grant support, lecture fees, consulting fees, and travel support from Roche, Celgene, and Janssen-Cilag, grant support, consulting fees, and lecture fees from Mundipharma, grant support from GSK/Novartis, lecture fees, consulting fees, and travel support from Takeda, consulting fees and lecture fees from Teva and Servier, consulting fees from Boehringer Ingelheim, Karyopham, and Ariad, lecture fees and travel support from Gilead, and grant support, lecture fees and travel support from Sanofi; Dr. Chen, grant support, consulting fees, and honoraria from Seattle Genetics, grant support and consulting fees from Bristol-Myers Squibb and Pharmacyclics, honoraria from Genentech, and consulting fees and honoraria from Merck; Dr. Zinzani, receiving advisory board fees from Millennium Pharmaceuticals, Roche, Celgene, Janssen, Gilead, Bayer, Merck, Servier, and TG Pharmaceuticals; Dr. Cunningham, receiving grant support, paid to his institution, from AstraZeneca, Amgen, Bayer, Celgene, Merrimack, Medimmune, Merck Serono, and Sanofi; Dr. Josephson, being employed by and owning stock in Seattle Genetics; Dr. Song, being employed by Seattle Genetics; Dr. Sachs, being employed by Unum Therapeutics, and being previously employed by Millennium Pharmaceuticals; Dr. Liu, being employed by Millennium Pharmaceuticals; Dr.; Jolin, being employed by Millennium Pharmaceuticals; Dr. Huebner, being previously employed by Millennium Pharmaceuticals; and Dr. Radford, receiving grant support from Takeda, Bristol-Myers Squibb, Seattle Genetics, and Novartis, and holding shares in GSK and AstraZeneca. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2016, ADCETRIS BRENTUXIMA; Barnes JA, 2011, ANN ONCOL, V22, P910, DOI 10.1093/annonc/mdq549; Borchmann P, 2017, HAEMATOLOGICA, V102, P24; Borchmann P, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.580.580; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; Canellos GP, 2004, J CLIN ONCOL, V22, P1532, DOI 10.1200/JCO.2004.99.010; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Carde P, 2016, J CLIN ONCOL, V34, P2028, DOI 10.1200/JCO.2015.64.5648; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Connors JM, 2017, BLOOD, V130, P1375, DOI 10.1182/blood-2017-05-784678; Engert A, 2005, J CLIN ONCOL, V23, P5052, DOI 10.1200/JCO.2005.11.080; Engert A, 2016, J CLIN ONCOL, V34, P1167, DOI 10.1200/JCO.2015.64.8683; Engert A, 2012, LANCET, V379, P1791, DOI 10.1016/S0140-6736(11)61940-5; Gordon LI, 2013, J CLIN ONCOL, V31, P684, DOI 10.1200/JCO.2012.43.4803; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Johnson P, 2016, NEW ENGL J MED, V374, P2419, DOI 10.1056/NEJMoa1510093; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Martin WG, 2005, J CLIN ONCOL, V23, P7614, DOI 10.1200/JCO.2005.02.7243; Matasar MJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv018; Meignan M, 2010, LEUKEMIA LYMPHOMA, V51, P2171, DOI 10.3109/10428194.2010.529208; Ng AK, 2016, SEMIN HEMATOL, V53, P209, DOI 10.1053/j.seminhematol.2016.05.008; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; Shenoy P, 2011, ADV HEMATOL, V2011, DOI DOI 10.1155/2011/725219; Spaepen K, 2001, BRIT J HAEMATOL, V115, P272, DOI 10.1046/j.1365-2141.2001.03169.x; Younes A, 2013, LANCET ONCOL, V14, P1348, DOI 10.1016/S1470-2045(13)70501-1	26	401	418	5	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2018	378	4					331	344		10.1056/NEJMoa1708984	http://dx.doi.org/10.1056/NEJMoa1708984			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT5ZX	29224502	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000423233400006
J	Pagan, JD; Kitaoka, M; Anthony, RM				Pagan, Jose D.; Kitaoka, Maya; Anthony, Robert M.			Engineered Sialylation of Pathogenic Antibodies In Vivo Attenuates Autoimmune Disease	CELL			English	Article							FC-GAMMA-RIII; ANTIINFLAMMATORY ACTIVITY; INTRAVENOUS IMMUNOGLOBULIN; HUMAN IGG1; THROMBOCYTOPENIC PURPURA; SIALIC-ACID; GLYCOSYLATION; IVIG; RECEPTOR; PROTECTION	Self-reactive IgGs contribute to the pathology of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Paradoxically, IgGs are used to treat inflammatory diseases in the form of high-dose intravenous immunoglobulin (IVIG). Distinct glycoforms on the IgG crystallizable fragment (Fc) dictate these divergent functions. IgG anti-inflammatory activity is attributed to sialylation of the Fc glycan. We therefore sought to convert endogenous IgG to anti-inflammatory mediators in vivo by engineering solubilized glycosyltransferases that attach galactose or sialic acid. When both enzymes were administered in a prophylactic or therapeutic fashion, autoimmune inflammation was markedly attenuated in vivo. The enzymes worked through a similar pathway to IVIG, requiring DC-SIGN, STAT6 signaling, and Fc gamma RIIB. Importantly, sialylation was highly specific to pathogenic IgG at the site of inflammation, driven by local platelet release of nucleotide-sugar donors. These results underscore the therapeutic potential of glycoengineering in vivo.	[Pagan, Jose D.; Kitaoka, Maya; Anthony, Robert M.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA; [Pagan, Jose D.; Kitaoka, Maya; Anthony, Robert M.] Harvard Med Sch, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Anthony, RM (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA.; Anthony, RM (corresponding author), Harvard Med Sch, Boston, MA 02129 USA.	robert.anthony@mgh.harvard.edu			NIAMS/NIH [DP2AR068272]; Lupus Research Alliance; MGH H.M. Goodman Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI091684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [DP2AR068272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351] Funding Source: NIH RePORTER	NIAMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Lupus Research Alliance; MGH H.M. Goodman Fellowship; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from NIAMS/NIH (DP2AR068272), the Lupus Research Alliance, and the MGH H.M. Goodman Fellowship to R.M.A. The authors are grateful to J. Paulson for providing anti-ST6GAL1 anti-sera; J. Ravetch for providing K/BxN sera; H. Meade for providing ST6GAL1; M.E. Conroy; J.W. Griffith; R. Rahimi; C. Sokol for clinical expertise; and K. Jeffrey, F. Wermeling, T. Mayadas, M. Pittet, K.T. Shade, E.E. Martinez, M.E. Conroy, T. Means, and A. Luster for constructive comments and careful reading of this manuscript.	Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Aigouy B, 2013, NAT METHODS, V10, P1048, DOI 10.1038/nmeth.2692; Albert H, 2008, P NATL ACAD SCI USA, V105, P15005, DOI 10.1073/pnas.0808248105; Allhorn M, 2010, BLOOD, V115, P5080, DOI 10.1182/blood-2009-08-239020; [Anonymous], EXP IMMUNOL S1, V178, P97; Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Bayry J, 2009, P NATL ACAD SCI USA, V106, pE24, DOI 10.1073/pnas.0900016106; Benkhoucha M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-209; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; Brown DG, 2015, J AM ACAD DERMATOL, V72, P524, DOI 10.1016/j.jaad.2014.10.027; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Campbell IK, 2014, J IMMUNOL, V192, P5031, DOI 10.4049/jimmunol.1301611; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Clynes R, 2007, CURR OPIN IMMUNOL, V19, P646, DOI 10.1016/j.coi.2007.09.004; Collin M, 2001, EMBO J, V20, P3046, DOI 10.1093/emboj/20.12.3046; Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119.abs; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Devi S, 2010, AM J PATHOL, V177, P1131, DOI 10.2353/ajpath.2010.091143; Ferrara C, 2011, P NATL ACAD SCI USA, V108, P12669, DOI 10.1073/pnas.1108455108; Fiebiger BM, 2015, P NATL ACAD SCI USA, V112, pE2385, DOI 10.1073/pnas.1505292112; Hansen RJ, 2002, THROMB HAEMOSTASIS, V88, P898, DOI 10.1055/s-0037-1613331; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; IMBACH P, 1981, LANCET, V1, P1228; Ishitsuka Y, 2009, J PHARMACOL SCI, V111, P211, DOI 10.1254/jphs.09128SC; Jefferis R, 2005, BIOTECHNOL PROGR, V21, P11, DOI 10.1021/bp040016j; Jefferis R, 2009, NAT REV DRUG DISCOV, V8, P226, DOI 10.1038/nrd2804; Jefferis Roy, 2009, V483, P223, DOI 10.1007/978-1-59745-407-0_13; Jones MB, 2016, P NATL ACAD SCI USA, V113, P7207, DOI 10.1073/pnas.1523968113; Jones MB, 2012, J BIOL CHEM, V287, P15365, DOI 10.1074/jbc.M112.345710; Kalcheva I, 1997, MAMM GENOME, V8, P619, DOI 10.1007/s003359900518; Kaneko Y, 2006, J EXP MED, V203, P789, DOI 10.1084/jem.20051900; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Lanoue A, 2004, J EXP MED, V200, P1383, DOI 10.1084/jem.20040795; Lee MM, 2014, J BIOL CHEM, V289, P8742, DOI 10.1074/jbc.C113.546713; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Li N, 2005, J CLIN INVEST, V115, P3440, DOI 10.1172/JCI24394; Li TZ, 2017, P NATL ACAD SCI USA, V114, P3485, DOI 10.1073/pnas.1702173114; LOO MH, 1987, J UROLOGY, V137, P571, DOI 10.1016/S0022-5347(17)44108-5; Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072; Meng L, 2013, J BIOL CHEM, V288, P34680, DOI 10.1074/jbc.M113.519041; Natsume A, 2005, J IMMUNOL METHODS, V306, P93, DOI 10.1016/j.jim.2005.07.025; Nimmerjahn F, 2008, ANNU REV IMMUNOL, V26, P513, DOI 10.1146/annurev.immunol.26.021607.090232; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2015, TRENDS IMMUNOL, V36, P325, DOI 10.1016/j.it.2015.04.005; Ohmi Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11205; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Pfeifle R, 2017, NAT IMMUNOL, V18, P104, DOI 10.1038/ni.3579; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Pucci F, 2016, CELL REP, V17, P1764, DOI 10.1016/j.celrep.2016.10.031; RAEDER EA, 1982, AM J CARDIOL, V50, P271, DOI 10.1016/0002-9149(82)90176-X; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Scallon BJ, 2007, MOL IMMUNOL, V44, P1524, DOI 10.1016/j.molimm.2006.09.005; Schlothauer T, 2016, PROTEIN ENG DES SEL, V29, P457, DOI 10.1093/protein/gzw040; SCHRIJVER G, 1990, KIDNEY INT, V38, P86, DOI 10.1038/ki.1990.171; Schwab I, 2014, EUR J IMMUNOL, V44, P1444, DOI 10.1002/eji.201344230; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Schwab I, 2012, EUR J IMMUNOL, V42, P826, DOI 10.1002/eji.201142260; Schwarzenberger C, 2015, AM J PHYSIOL-RENAL, V308, pF1238, DOI 10.1152/ajprenal.00535.2014; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Stadlmann J, 2009, PROTEOMICS, V9, P4143, DOI 10.1002/pmic.200800931; Sugimoto I, 2007, J BIOL CHEM, V282, P34896, DOI 10.1074/jbc.M704766200; Tackenberg B, 2010, J CLIN IMMUNOL, V30, pS65, DOI 10.1007/s10875-010-9398-1; Tackenberg B, 2009, P NATL ACAD SCI USA, V106, P4788, DOI 10.1073/pnas.0807319106; Tan M, 2016, CELL PHYSIOL BIOCHEM, V38, P2348, DOI 10.1159/000445588; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Underwood M, 2006, BMJ-BRIT MED J, V332, P1315, DOI 10.1136/bmj.332.7553.1315; Wang TT, 2017, SCIENCE, V355, P395, DOI 10.1126/science.aai8128; Wang TT, 2015, CELL, V162, P160, DOI 10.1016/j.cell.2015.06.026; WANG XC, 1993, J BIOL CHEM, V268, P4355; Washburn N, 2015, P NATL ACAD SCI USA, V112, pE1297, DOI 10.1073/pnas.1422481112; Woodard-Grice AV, 2008, J BIOL CHEM, V283, P26364, DOI 10.1074/jbc.M800836200; Yang R, 2010, NEPHROL DIAL TRANSPL, V25, P2479, DOI 10.1093/ndt/gfq115; Youings A, 1996, BIOCHEM J, V314, P621, DOI 10.1042/bj3140621; Zhang G, 2016, EXP NEUROL, V282, P49, DOI 10.1016/j.expneurol.2016.05.020	79	107	113	3	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 25	2018	172	3					564	+		10.1016/j.cell.2017.11.041	http://dx.doi.org/10.1016/j.cell.2017.11.041			27	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FT9BS	29275858	Green Accepted, Bronze			2023-01-03	WOS:000423447600015
J	Veerbeek, JM; Winters, C; van Wegen, EEH; Kwakkel, G				Veerbeek, Janne M.; Winters, Caroline; van Wegen, Erwin E. H.; Kwakkel, Gert			Is the proportional recovery rule applicable to the lower limb after a first-ever ischemic stroke?	PLOS ONE			English	Article							FUGL-MEYER ASSESSMENT; MOTOR RECOVERY; CORTICOSPINAL TRACT; IMPROVEMENT; IMPAIRMENT; POSTSTROKE; PREDICTION; REHABILITATION; VARIABILITY; PLASTICITY	Objective To investigate (a) the applicability of the proportional recovery rule of spontaneous neurobiological recovery to motor function of the paretic lower extremity (LE); and (b) the presence of fitters and non-fitters of this prognostic rule poststroke. When present, the clinical threshold for fitting nor non-fitting would be determined, as well as within-subject generalizability to the paretic upper extremity (UE). Methods Prospective cohort study in which the Fugl-Meyer Assessment (FMA)-LE and FMA-UE were measured <72 hours and 6 months poststroke. Predicted maximum potential recovery was defined as [FMA-LEmax-FMA-LEinitial = 34-FMA-LEinitial]. Hierarchical clustering in 202 first-ever ischemic stroke patients distinguished between fitting and not fitting the rule. Descriptive statistics determined whether fitters and non-fitters for LE were the same persons as for UE. Results 175 (87%) patients fitted the FMA-LE recovery rule. The observed average improvement of the fitters was similar to 64% of the predicted maximum potential recovery. In the non-fitter group, the maximum initial FMA-LE score was 13 points. Fifty-one out of 78 patients (similar to 65%) who scored below the identified 14-point threshold at baseline fitted the FMA-LE rule. Non-fitters were more severely affected than fitters. All non-fitters of the FMA-LE rule did also not fit the proportional recovery rule for FMA-UE. Conclusions Proportional recovery seems to be consistent within subjects across LE and UE motor impairment at the hemiplegic side in first-ever ischemic hemispheric stroke subjects. Future studies should investigate prospectively distinguishing between fitters and not-fitters within the subgroup of patients who have initial low FMA-LE scores. Subsequently, patients could be stratified based on fitting or not fitting the recovery rule as this would impact rehabilitation management and trial design.	[Veerbeek, Janne M.; Winters, Caroline; van Wegen, Erwin E. H.; Kwakkel, Gert] Vrije Univ Amsterdam, Dept Rehabil Med, Med Ctr, Amsterdam, Netherlands; [Veerbeek, Janne M.; Winters, Caroline; van Wegen, Erwin E. H.; Kwakkel, Gert] Amsterdam Movement Sci, Amsterdam, Netherlands; [Veerbeek, Janne M.; Winters, Caroline; van Wegen, Erwin E. H.; Kwakkel, Gert] Amsterdam Neurosci, Amsterdam, Netherlands; [Veerbeek, Janne M.] Univ Zurich, Div Vasc Neurol & Neu rorehabil, Zurich, Switzerland; [Veerbeek, Janne M.] Ctr Neurol & Rehabil, Cereneo, Vitznau, Switzerland; [Kwakkel, Gert] Rehabil Res Ctr, Amsterdam, Netherlands; [Kwakkel, Gert] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Zurich; Northwestern University	Kwakkel, G (corresponding author), Vrije Univ Amsterdam, Dept Rehabil Med, Med Ctr, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Amsterdam Movement Sci, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Amsterdam Neurosci, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Rehabil Res Ctr, Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Chicago, IL 60611 USA.	g.kwakkel@vumc.nl	Veerbeek, Janne/W-7424-2019	Veerbeek, Janne/0000-0002-6337-6780; van Wegen, Erwin/0000-0002-7920-9995; Kwakkel, Gert/0000-0002-4041-4043	"Wetenschappelijk College Fysiotherapie" of the Royal Dutch Society for Physical Therapy (KNGF), the Netherlands [33368]; Dutch National Institute of Health (ZonMw), EXPLICIT-stroke programme [89000001]	"Wetenschappelijk College Fysiotherapie" of the Royal Dutch Society for Physical Therapy (KNGF), the Netherlands; Dutch National Institute of Health (ZonMw), EXPLICIT-stroke programme	The present work was part of the EPOS research project funded by the ''Wetenschappelijk College Fysiotherapie'' (grant number 33368) of the Royal Dutch Society for Physical Therapy (KNGF), the Netherlands. This part of the EPOS project was co-financed by the Dutch National Institute of Health (ZonMw) (grant number 89000001) as a part of the EXPLICIT-stroke programme (www.explicit-stroke.nl).	Berkhemer OA, 2016, STROKE, V47, P768, DOI 10.1161/STROKEAHA.115.011788; Bernhardt J, 2017, NEUROREHAB NEURAL RE, V31, P694, DOI 10.1177/1545968317724290; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Bigourdan A, 2016, STROKE, V47, P1053, DOI 10.1161/STROKEAHA.115.011576; Buch ER, 2016, NEUROLOGY, V86, P1924, DOI 10.1212/WNL.0000000000002675; Buma F, 2013, RESTOR NEUROL NEUROS, V31, P707, DOI 10.3233/RNN-130332; Byblow WD, 2015, ANN NEUROL; Carrera E, 2014, BRAIN, V137, P2408, DOI 10.1093/brain/awu101; Corbetta M, 2005, NAT NEUROSCI, V8, P1603, DOI 10.1038/nn1574; Cramer SC, 2012, EUR J NEUROL, V19, P718, DOI 10.1111/j.1468-1331.2011.03615.x; Di Pino G, 2014, NAT REV NEUROL, V10, P597, DOI 10.1038/nrneurol.2014.162; Dunn LE, 2016, CEREBROVASC DIS EXTR, V6, P12, DOI 10.1159/000444149; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Feng WW, 2015, ANN NEUROL, V78, P860, DOI 10.1002/ana.24510; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; Grefkes C, 2008, ANN NEUROL, V63, P236, DOI 10.1002/ana.21228; Hiu T, 2016, BRAIN, V139, P468, DOI 10.1093/brain/awv360; Hunter AJ, 2011, PHYS THER, V91, P1503, DOI 10.2522/ptj.20100271; Khatri R, 2012, NEUROLOGY, V79, pS52, DOI 10.1212/WNL.0b013e3182697e70; Kim B, 2017, NEUROREHAB NEURAL RE, V31, P3, DOI 10.1177/1545968316662708; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; Kwakkel G, 2016, NEUROREHAB NEURAL RE, V30, P804, DOI 10.1177/1545968315624784; Lazar RM, 2010, STROKE, V41, P1485, DOI 10.1161/STROKEAHA.109.577338; Lindau NT, 2014, BRAIN, V137, P739, DOI 10.1093/brain/awt336; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Ng YS, 2016, AM J PHYS MED REHAB, V95, P709, DOI 10.1097/PHM.0000000000000502; Nijboer TCW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100584; Prabhakaran S, 2008, NEUROREHAB NEURAL RE, V22, P64, DOI 10.1177/1545968307305302; SANFORD J, 1993, PHYS THER, V73, P447, DOI 10.1093/ptj/73.7.447; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Smith MC, 2017, STROKE, V48, P1400, DOI 10.1161/STROKEAHA.116.016478; Stanne TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114156; Stinear C, 2010, LANCET NEUROL, V9, P1228, DOI 10.1016/S1474-4422(10)70247-7; Stinear CM, 2017, STROKE, V48, P795, DOI 10.1161/STROKEAHA.116.016020; Turhan N, 2009, NEUROREHABILITATION, V24, P321, DOI 10.3233/NRE-2009-0485; Veerbeek JM, 2011, NEUROREHAB NEURAL RE, V25, P268, DOI 10.1177/1545968310384271; Veerbeek JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087987; Wahl AS, 2014, SCIENCE, V344, P1250, DOI 10.1126/science.1253050; Winters C, 2016, NEUROREHABIL NEURAL; Winters C, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1592-x; Winters C, 2015, NEUROREHAB NEURAL RE, V29, P614, DOI 10.1177/1545968314562115; Zarahn E, 2011, CEREB CORTEX, V21, P2712, DOI 10.1093/cercor/bhr047	42	27	28	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2018	13	1							e0189279	10.1371/journal.pone.0189279	http://dx.doi.org/10.1371/journal.pone.0189279			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FS7BY	29329286	Green Published, Green Submitted, gold			2023-01-03	WOS:000419954100006
J	Nehme, H; Saulnier, P; Ramadan, AA; Cassisa, V; Guillet, C; Eveillards, M; Umerska, A				Nehme, Hassan; Saulnier, Patrick; Ramadan, Alyaa A.; Cassisa, Viviane; Guillet, Catherine; Eveillards, Matthieu; Umerska, Anita			Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity	PLOS ONE			English	Article							GRAM-NEGATIVE BACTERIA; OUTER-MEMBRANE PERMEABILITY; SYNERGISTIC INTERACTIONS; IN-VITRO; DELIVERY; PHENOTHIAZINES; ANTIBIOTICS; NANOPLEXES; RESISTANCE; STABILITY	Bacterial antibiotic resistance is an emerging public health problem worldwide; therefore, new therapeutic strategies are needed. Many studies have described antipsychotic compounds that present antibacterial activity. Hence, the aims of this study were to evaluate the in vitro antibacterial activity of antipsychotics belonging to different chemical families, to assess the influence of their association with lipid nanocapsules (LNCs) on their antimicrobial activity as well as drug release and to study the uptake of LNCs by bacterial cells. Antibacterial activity was evaluated against Gram-positive Staphylococcus aureus and Gram negative Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acineto-bacter baumanni by minimum inhibitory concentration (MIC) assay, and the capability of killing tested microorganisms was evaluated by time kill assay. LNCs were prepared by phase inversion method, and the antipsychotic agents were incorporated using pre-loading and post-loading strategies. Only phenothiazines and thioxanthenes showed antibacterial activity, which was independent of antibiotic-resistance patterns. Loading the nanocarriers with the drugs affected the properties of the former, particularly their zeta potential. The release rate depended on the drug and its concentration-a maximum of released drug of less than 40% over 24 hours was observed for promazine. The influence of the drug associations on the antibacterial properties was concentration-dependent since, at low concentrations (high nanocarrier/drug ratio), the activity was lost, probably due to the high affinity of the drug to nanocarriers and slow release rate, whereas at higher concentrations, the activity was well maintained for the majority of the drugs. Chlorpromazine and thioridazine increased the uptake of the LNCs by bacteria compared with blank LNCs, even below the minimum inhibitory concentration.	[Nehme, Hassan; Saulnier, Patrick; Ramadan, Alyaa A.; Umerska, Anita] Univ Bretagne Loire, Univ Angers, CNRS 6021, INSERM 1066,MINT, Angers, France; [Ramadan, Alyaa A.] Alexandria Univ, Fac Pharm, Dept Pharmaceut, Alexandria, Egypt; [Cassisa, Viviane] CHU Angers, Lab Bacteriol, Angers, France; [Guillet, Catherine] CHU, IBS, IFR 132, SCCAN, Angers, France; [Eveillards, Matthieu] Univ Angers, Univ Nantes, INSERM, CRCINA,Equipe ATIP AVENIR, Angers, France; [Umerska, Anita] Univ Lorraine, CITHEFOR, EA, Nancy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Egyptian Knowledge Bank (EKB); Alexandria University; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Universite de Lorraine	Umerska, A (corresponding author), Univ Bretagne Loire, Univ Angers, CNRS 6021, INSERM 1066,MINT, Angers, France.; Umerska, A (corresponding author), Univ Lorraine, CITHEFOR, EA, Nancy, France.	anitaumerska@yahoo.fr	Ramadan, Alyaa/AAL-5073-2021	Ramadan, Alyaa/0000-0003-2143-7909; Umerska, Anita/0000-0002-4981-8247; Saulnier, Patrick/0000-0002-6408-3533; Eveillard, Matthieu/0000-0002-5916-3627				Annadurai S., 1998, Indian Journal of Experimental Biology, V36, P86; Boge L, 2017, INT J PHARMACEUT, V526, P400, DOI 10.1016/j.ijpharm.2017.04.082; Boge L, 2016, LANGMUIR, V32, P4217, DOI 10.1021/acs.langmuir.6b00338; Bunjes H, 2010, J PHARM PHARMACOL, V62, P1637, DOI 10.1111/j.2042-7158.2010.01024.x; Dasgupta A, 2008, TOP HETEROCYCL CHEM, V15, P67, DOI 10.1007/7081_2007_108; DASTIDAR SG, 1995, J CHEMOTHERAPY, V7, P201, DOI 10.1179/joc.1995.7.3.201; Dastidar Sujata G., 2004, Acta Microbiologica et Immunologica Hungarica, V51, P75; Dastidar SG, 2013, ANTIBIOTICS-BASEL, V2, P58, DOI 10.3390/antibiotics2010058; Delcour AH, 2009, BBA-PROTEINS PROTEOM, V1794, P808, DOI 10.1016/j.bbapap.2008.11.005; Dutta NK, 2005, IN VIVO, V19, P539; EI-Nakeeb MA, 2011, BRAZ J MICROBIOL, V42, P980; Galani I, 2012, J CHEMOTHERAPY, V24, P191, DOI 10.1179/1973947812Y.0000000015; Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668; Hidalgo AA, 2004, BIOPHYS CHEM, V109, P85, DOI 10.1016/j.bpc.2003.10.020; Huynh NT, 2009, INT J PHARMACEUT, V379, P201, DOI 10.1016/j.ijpharm.2009.04.026; Koeck R., 2016, New Microbes and New Infections, V9, P24, DOI 10.1016/j.nmni.2015.11.004; Kruszewska Hanna, 2002, Acta Pol Pharm, V59, P436; Livermore DM, 2011, J ANTIMICROB CHEMOTH, V66, P48, DOI 10.1093/jac/dkq408; Mazumder R, 2001, INT J ANTIMICROB AG, V18, P403, DOI 10.1016/S0924-8579(01)00324-7; MOLNAR J, 1976, ACTA MICROBIOL HUNG, V23, P45; Mouzouvi CRA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179211; MUHLRADT PF, 1973, EUR J BIOCHEM, V35, P471, DOI 10.1111/j.1432-1033.1973.tb02861.x; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; PLESIAT P, 1992, MOL MICROBIOL, V6, P1323, DOI 10.1111/j.1365-2958.1992.tb00853.x; Salem II, 2005, METHOD ENZYMOL, V391, P261, DOI 10.1016/S0076-6879(05)91015-X; Scher MS, 2010, SCI TRANSL MED, V120, P1812; Spellberg B, 2014, CLIN INFECT DIS, V59, pS71, DOI 10.1093/cid/ciu392; Umerska A, 2017, INT J NANOMED, V12, P5687, DOI 10.2147/IJN.S139625; Umerska A, 2016, EUR J PHARM BIOPHARM, V108, P100, DOI 10.1016/j.ejpb.2016.09.001; Umerska A, 2016, INT J PHARMACEUT, V506, P191, DOI 10.1016/j.ijpharm.2016.04.028; Umerska A, 2015, INT J PHARMACEUT, V493, P224, DOI 10.1016/j.ijpharm.2015.07.008; Umerska A, 2015, EUR J PHARM BIOPHARM, V93, P242, DOI 10.1016/j.ejpb.2015.04.006; Umerska A, 2014, J BIOMED NANOTECHNOL, V10, P3658, DOI 10.1166/jbn.2014.1878; Valcourt C, 2016, INT J PHARMACEUT, V498, P23, DOI 10.1016/j.ijpharm.2015.11.042; Woolverton CJ, 2001, J ANTIMICROB CHEMOTH, V48, P861, DOI 10.1093/jac/48.6.861; Zgurskaya HI, 2009, FUTURE MICROBIOL, V4, P919, DOI 10.2217/FMB.09.62; Zilberman M, 2008, J CONTROL RELEASE, V130, P202, DOI 10.1016/j.jconrel.2008.05.020	38	43	44	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2018	13	1							e0189950	10.1371/journal.pone.0189950	http://dx.doi.org/10.1371/journal.pone.0189950			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR6OK	29298353	gold, Green Published, Green Submitted			2023-01-03	WOS:000419185200033
J	Mota, GS; Sartori, CJ; Miranda, I; Quilho, T; Mori, FA; Pereira, H				Mota, Graciene S.; Sartori, Caroline J.; Miranda, Isabel; Quilho, Teresa; Mori, Fabio Akira; Pereira, Helena			Bark anatomy, chemical composition and ethanol-water extract composition of Anadenanthera peregrina and Anadenanthera colubrina	PLOS ONE			English	Article							ANTIOXIDANT ACTIVITY; TANNINS; CORK; VARIABILITY; GRANDIS; PHLOEM; BRAZIL; VIEW	The bark of Anadenanthera peregrina (L.) Speg and Anadenanthera colubrina (Vell.) Brenan were characterized in relation to anatomical and chemical features. The barks were similar and included a thin conducting phloem, a largely dilated and sclerified non-conducting phloem, and a rhyridome with periderms with thin phellem interspersed by cortical tissues. Only small differences between species were observed that cannot be used alone for taxonomic purposes. The summative chemical composition of A. peregrina and A. colubrina was respectively: 8.2% and 7.7% ash; 28.8% and 29.3% extractives; 2.4% and 2.6% suberin; and 18.9% lignin. The monosaccharide composition showed the predominance of glucose (on average 82% of total neutral sugars) and of xylose (9%). The ethanol-water extracts of A. peregrina and A. colubrina barks included a high content of phenolics, respectively: total phenolics 583 and 682 mg GAE/g extract; 148 and 445 mg CE/g extract; tannins 587 and 98 mg CE/g extract. The antioxidant activity was 238 and 269 mg Trolox/g extract. The barks of the Anadenanthera species are a potential source of polar extractives that will represent an important valorization and therefore contribute to improve the overall economic potential and sustainability of A. peregrina and A. colubrina	[Mota, Graciene S.] Univ Fed Lavras, Dept Ciencias Biol, Lavras, MG, Brazil; [Sartori, Caroline J.; Mori, Fabio Akira] Univ Fed Lavras, Dept Ciencias Florestais, Lavras, MG, Brazil; [Miranda, Isabel; Quilho, Teresa; Pereira, Helena] Univ Lisbon, Inst Super Agron, Ctr Estudos Florestais, Lisbon, Portugal	Universidade Federal de Lavras; Universidade Federal de Lavras; Universidade de Lisboa	Mota, GS (corresponding author), Univ Fed Lavras, Dept Ciencias Biol, Lavras, MG, Brazil.	motagraciene7@gmail.com	Pereira, Helena/V-5236-2019; Mori, Fabio/AAP-8571-2021; Quilhó, Teresa/AAM-7149-2021	Pereira, Helena/0000-0002-5393-4443; Mori, Fabio/0000-0002-7468-018X; Quilhó, Teresa/0000-0001-8353-3459; Mota, Graciene/0000-0002-6977-4149; Miranda, Isabel/0000-0003-0280-5219	Individual PhD Sandwich Scholarships of CAPES (Coordenacao de Apoio ao Pessoal de Nivel Superior, Brazil); FAPEMIG (Fundacao de Apoio a Pesquisa do Estado de Minas Gerais, Brazil); CNPq (Conselho Nacional de Pesquisa Cientifica, Brazil); FCT - Fundacao para a Ciencia e a Tecnologia, Portugal [UID/AGR/00239/2013]	Individual PhD Sandwich Scholarships of CAPES (Coordenacao de Apoio ao Pessoal de Nivel Superior, Brazil); FAPEMIG (Fundacao de Apoio a Pesquisa do Estado de Minas Gerais, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); CNPq (Conselho Nacional de Pesquisa Cientifica, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FCT - Fundacao para a Ciencia e a Tecnologia, Portugal(Portuguese Foundation for Science and Technology)	Graciene S. Mota and Caroline J. Sartori were supported by Individual PhD Sandwich Scholarships of CAPES (Coordenacao de Apoio ao Pessoal de Nivel Superior, Brazil), and this work was financially supported by FAPEMIG (Fundacao de Apoio a Pesquisa do Estado de Minas Gerais, Brazil) and CNPq (Conselho Nacional de Pesquisa Cientifica, Brazil). This work is part of the research activities of Centro de Estudos Florestais (CEF), a research unit supported by FCT - Fundacao para a Ciencia e a Tecnologia, Portugal, under UID/AGR/00239/2013.	Abdalla S, 2014, BIORESOURCES, V9, P3396; Altschul SVR, 1964, CONTRIBUTIONS GRAY H, V193, P3; Angyalossy V, 2016, IAWA J, V37, P517, DOI 10.1163/22941932-20160151; ARCHER RH, 1993, IAWA J, V14, P35, DOI 10.1163/22941932-90000574; Baitelo JB, 1997, SEMENTES MUDAS ARVOR; Baptista I, 2013, IND CROP PROD, V50, P166, DOI 10.1016/j.indcrop.2013.07.004; Boatwright JS, 2009, S AFR J BOT, V75, P546, DOI 10.1016/j.sajb.2009.06.001; Carvalho PER, 2003, EMBRAPA INFORMACA GI; CHATTAWAY MARGARET M., 1953, AUSTRALIAN JOUR BOT, V1, P402, DOI 10.1071/BT9530402; Costa CG, 1997, IAWA J, V18, P385, DOI 10.1163/22941932-90001504; Damascena NP, 2014, NAT PROD RES, V28, P753, DOI 10.1080/14786419.2013.877902; de Souza Sales Rocha Eveline Angelica Lira, 2013, Revista de Ciencias Farmaceuticas Basica e Aplicada, V34, P351; Valente BMDT, 2013, SCI FOR, V41, P485; Esau K, 1969, PHLOEM ENCY PLANT AN; Ferreira JPA, 2015, IND CROP PROD, V74, P998, DOI 10.1016/j.indcrop.2015.05.065; Foelkel C, 2006, CASCA ARVORE EUCALIP; Francisco TM, 2017, AM J PRIMATOL, V79, DOI 10.1002/ajp.22615; FURUNO T, 1990, IAWA BULL, V11, P239, DOI 10.1163/22941932-90001181; Janceva S, 2011, ENVIRONMENT, TECHNOLOGY, RESOURCES, PROCEEDINGS OF THE 8TH INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE, 2011, VOL I, P265; Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2; Kenicer G, 2005, ENDINB J BOT, V62, P195; Krishnappa P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/507851; Lima MA, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-75; Lorenzi H, 2002, MAN ID CULT PLANT AR; Lorenzi H, 2009, ARVORES BRASILEIRAS; Maia, 2012, CAATINGA ARVORES ARB; Metcalfe C.R., 1950, ANATOMY DICOTYLEDONS; Miranda I, 2016, IND CROP PROD, V82, P81, DOI 10.1016/j.indcrop.2015.12.003; Miranda I, 2013, IND CROP PROD, V41, P299, DOI 10.1016/j.indcrop.2012.04.024; Miranda I, 2012, IND CROP PROD, V36, P395, DOI 10.1016/j.indcrop.2011.10.035; Monteiro JM, 2006, J ETHNOPHARMACOL, V105, P173, DOI 10.1016/j.jep.2005.10.016; Mori CLSO, 2003, BRASIL FLORESTAL BRA, V77, P29; Outer RW, 1976, ACTA BOT NEERL, V25, P481; Paes JB, 2013, REV CAATINGA, V26, P22; PATEL RN, 1985, NEW ZEAL J BOT, V23, P511, DOI 10.1080/0028825X.1985.10434225; PEREIRA H, 1988, WOOD SCI TECHNOL, V22, P211, DOI 10.1007/BF00386015; Pereira H., 2007, CORK BIOL PRODUCTION; Pereira H, 2015, BIORESOURCES, V10, P6207; POTGIETER MJ, 1994, IAWA J, V15, P161, DOI 10.1163/22941932-90001358; Queiroz L. P. de, 2009, LEGUMINOSAS CAATINGA; Quilho T, 1999, IAWA J, V20, P171, DOI 10.1163/22941932-90000677; Quilho T, 2000, IAWA J, V21, P31, DOI 10.1163/22941932-90000234; ROTH I, 1981, ENCY PLANT ANATOMY 3, V9; Santos JS, 2013, J ETHNOPHARMACOL, V148, P218, DOI 10.1016/j.jep.2013.04.012; Santos SAO, 2012, IND CROP PROD, V39, P120, DOI 10.1016/j.indcrop.2012.02.003; Sartori C, 2016, HOLZFORSCHUNG, P1; Sartori CJ, 2014, FLORESTA AMBIENTE, V21, P394, DOI 10.1590/2179-8087.061113; Sartori CJ, 2014, CERNE, V20, P239, DOI 10.1590/01047760.201420021512; Sen A, 2010, IND CROP PROD, V31, P417, DOI 10.1016/j.indcrop.2010.01.002; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Suckow I. M. S., 2009, IF SERIE REGISTROS, V40, P131; Sulaiman CT, 2012, INDIAN J PHARM SCI, V74, P258, DOI 10.4103/0250-474X.106069; Sultana B, 2007, FOOD CHEM, V104, P1106, DOI 10.1016/j.foodchem.2007.01.019; Trentin DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066257; TROCKENBRODT M, 1995, ANN BOT-LONDON, V75, P281, DOI 10.1006/anbo.1995.1022; TROCKENBRODT M, 1986, IAWA BULL, V7, P62, DOI 10.1163/22941932-90000442	57	21	22	3	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2017	12	12							e0189263	10.1371/journal.pone.0189263	http://dx.doi.org/10.1371/journal.pone.0189263			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR3ZV	29281656	gold, Green Published, Green Submitted			2023-01-03	WOS:000419006200018
J	Stupp, R; Taillibert, S; Kanner, A; Read, W; Steinberg, DM; Lhermitte, B; Toms, S; Idbaih, A; Ahluwalia, MS; Fink, K; Di Meco, F; Lieberman, F; Zhu, JJ; Stragliotto, G; Tran, DD; Brem, S; Hottinger, AF; Kirson, ED; Lavy-Shahaf, G; Weinberg, U; Kim, CY; Paek, SH; Nicholas, G; Burna, J; Hirte, H; Weller, M; Palti, Y; Hegi, M; Ram, Z				Stupp, Roger; Taillibert, Sophie; Kanner, Andrew; Read, William; Steinberg, David M.; Lhermitte, Benoit; Toms, Steven; Idbaih, Ahmed; Ahluwalia, Manmeet S.; Fink, Karen; Di Meco, Francesco; Lieberman, Frank; Zhu, Jay-Jiguang; Stragliotto, Giuseppe; Tran, David D.; Brem, Steven; Hottinger, Andreas F.; Kirson, Eilon D.; Lavy-Shahaf, Gitit; Weinberg, Uri; Kim, Chae-Yong; Paek, Sun-Ha; Nicholas, Garth; Burna, Jordi; Hirte, Hal; Weller, Michael; Palti, Yoram; Hegi, Monika; Ram, Zvi			Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEWLY-DIAGNOSED GLIOBLASTOMA; CENTRAL-NERVOUS-SYSTEM; QUALITY-OF-LIFE; PHASE-III TRIAL; ADJUVANT TEMOZOLOMIDE; MALIGNANT GLIOMA; OPEN-LABEL; BRAIN; RADIOTHERAPY; BEVACIZUMAB	IMPORTANCE Tumor-treating fields (TTFields) is an antimitotic treatment modality that interferes with glioblastoma cell division and organelle assembly by delivering low-intensity alternating electric fields to the tumor. OBJECTIVE To investigate whether TTFields improves progression-free and overall survival of patients with glioblastoma, a fatal disease that commonly recurs at the initial tumor site or in the central nervous system. DESIGN, SETTING, AND PARTICIPANTS In this randomized, open-label trial, 695 patients with glioblastoma whose tumor was resected or biopsied and had completed concomitant radiochemotherapy (median time from diagnosis to randomization, 3.8 months) were enrolled at 83 centers (July 2009-2014) and followed up through December 2016. A preliminary report from this trial was published in 2015; this report describes the final analysis. INTERVENTIONS Patients were randomized 2: 1 to TTFields plus maintenance temozolomide chemotherapy (n = 466) or temozolomide alone (n = 229). The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (>= 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device. Temozolomide was administered to both groups (150-200mg/m(2)) for 5 days per 28-day cycle (6-12 cycles). MAIN OUTCOMES AND MEASURES Progression-free survival (tested at a = .046). The secondary end point was overall survival (tested hierarchically at a = .048). Analyses were performed for the intent-to-treat population. Adverse events were compared by group. RESULTS Of the 695 randomized patients (median age, 56 years; IQR, 48-63; 473 men [68%]), 637 (92%) completed the trial. Median progression-free survival from randomization was 6.7 months in the TTFields-temozolomide group and 4.0 months in the temozolomide-alone group (HR, 0.63; 95% CI, 0.52-0.76; P < .001). Median overall survival was 20.9 months in the TTFields-temozolomide group vs 16.0 months in the temozolomide-alone group (HR, 0.63; 95% CI, 0.53-0.76; P < .001). Systemic adverse event frequency was 48% in the TTFields-temozolomide group and 44% in the temozolomide-alone group. Mild to moderate skin toxicity underneath the transducer arrays occurred in 52% of patients who received TTFields-temozolomide vs no patients who received temozolomide alone. CONCLUSIONS AND RELEVANCE In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance temozolomide alone, resulted in statistically significant improvement in progression-free survival and overall survival. These results are consistent with the previous interim analysis.	[Stupp, Roger] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Lou & Jean Malnati Brain Tumor Inst, Chicago, IL 60611 USA; [Stupp, Roger; Lhermitte, Benoit; Hottinger, Andreas F.; Hegi, Monika] CHU Vaudois, Lausanne, Switzerland; [Stupp, Roger; Lhermitte, Benoit; Hottinger, Andreas F.; Hegi, Monika] Univ Lausanne, Lausanne, Switzerland; [Stupp, Roger; Weller, Michael] Univ Zurich Hosp, Zurich, Switzerland; [Stupp, Roger; Weller, Michael] Univ Zurich, Zurich, Switzerland; [Taillibert, Sophie; Idbaih, Ahmed] Univ Paris 06, Sorbonne Univ, Inst Cerveau & Moelle Epiniere, CNRS,INSERM,UMR S 1127,U1127,UMR7225,UPMC,ICM, F-75013 Paris, France; [Kanner, Andrew; Ram, Zvi] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel; [Read, William] Univ Calif San Diego, San Diego, CA 92103 USA; [Read, William] Emory Univ, Atlanta, GA 30322 USA; [Steinberg, David M.] Tel Aviv Univ, Tel Aviv, Israel; [Toms, Steven] Geisinger Hlth Syst, Danville, PA USA; [Ahluwalia, Manmeet S.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Fink, Karen] Baylor Univ, Med Ctr, Houston, TX 77030 USA; [Di Meco, Francesco] Ist Nazl Neurol Carlo Besta, Milan, Italy; [Lieberman, Frank] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Zhu, Jay-Jiguang] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Zhu, Jay-Jiguang] Tufts Med Ctr, Boston, MA USA; [Stragliotto, Giuseppe] Karolinska Hosp, Stockholm, Sweden; [Tran, David D.] Washington Univ, Barnes Jewish Hosp, St Louis, MO USA; [Brem, Steven] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Brem, Steven] Univ Penn, Philadelphia, PA 19104 USA; [Kirson, Eilon D.; Lavy-Shahaf, Gitit; Weinberg, Uri; Palti, Yoram] Novocure Ltd, Haifa, Israel; [Kim, Chae-Yong] Seoul Natl Univ, Bundang Hosp, Coll Med, Bundang, South Korea; [Paek, Sun-Ha] Seoul Natl Univ, Seoul, South Korea; [Nicholas, Garth] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Burna, Jordi] Hosp Univ Bellvitge, Barcelona, Spain; [Hirte, Hal] Juravinski Canc Ctr, Hamilton, ON, Canada	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Zurich; University Zurich Hospital; University of Zurich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Tel Aviv University; Sackler Faculty of Medicine; University of California System; University of California San Diego; Emory University; Tel Aviv University; Geisinger Health System; Cleveland Clinic Foundation; Baylor University; IRCCS Istituto Neurologico Besta; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Health Science Center Houston; Tufts Medical Center; Karolinska Institutet; Karolinska University Hospital; Barnes-Jewish Hospital; Washington University (WUSTL); H Lee Moffitt Cancer Center & Research Institute; University of Pennsylvania; Novocure Limited; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); University of Ottawa; Ottawa Hospital Research Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; McMaster University	Stupp, R (corresponding author), Northwestern Univ, Lou & Jean Malnati Brain Tumor Inst, Robert H Lurie Comprehens Canc Ctr, 676 N St Clair St,Ste 2210, Chicago, IL 60611 USA.	roger.stupp@northwestern.edu	Stupp, Roger/L-3303-2019; Brem, Steven/HIK-3353-2022; DiMeco, Francesco/Z-5431-2019; Hegi, Monika/O-4796-2015; Toms, Steven/HJA-7831-2022; DiMeco, Francesco/Q-3785-2016; Idbaih, Ahmed/N-8746-2017	Hegi, Monika/0000-0003-0855-6495; Kanner, Andrew Ariye/0000-0002-0812-8573; KIM, CHAE-YONG/0000-0001-9773-5553; DiMeco, Francesco/0000-0001-6213-5793; Le Rhun, Emilie/0000-0002-9408-3278; Weller, Michael/0000-0002-1748-174X; Idbaih, Ahmed/0000-0001-5290-1204	Novocure Ltd.	Novocure Ltd.	The study was funded by Novocure Ltd.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Coulibaly B, 2010, HUM PATHOL, V41, P815, DOI 10.1016/j.humpath.2009.09.020; DeMets D L, 1995, Cancer Treat Res, V75, P1; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Ganiere V, 2006, NAT CLIN PRACT ONCOL, V3, P339, DOI 10.1038/ncponc0514; Giladi M, 2015, SCI REP-UK, V5, DOI 10.1038/srep18046; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hegi ME, 2012, ACTA NEUROPATHOL, V123, P841, DOI 10.1007/s00401-011-0938-4; Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104; Kirson Eilon D, 2009, BMC Med Phys, V9, P1, DOI 10.1186/1756-6649-9-1; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277; Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Stupp R, 2015, JAMA-J AM MED ASSOC, V314, P2535, DOI 10.1001/jama.2015.16669; Stupp R, 2014, LANCET ONCOL, V15, P1100, DOI 10.1016/S1470-2045(14)70379-1; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Taphoorn MJB, 2010, EUR J CANCER, V46, P1033, DOI 10.1016/j.ejca.2010.01.012; Vlassenbroeck I, 2008, J MOL DIAGN, V10, P332, DOI 10.2353/jmoldx.2008.070169; Weller M, 2017, LANCET ONCOL, V18, P1373, DOI 10.1016/S1470-2045(17)30517-X; Westphal M, 2015, EUR J CANCER, V51, P522, DOI 10.1016/j.ejca.2014.12.019	26	964	987	13	107	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2017	318	23					2306	2316		10.1001/jama.2017.18718	http://dx.doi.org/10.1001/jama.2017.18718			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ3RJ	29260225	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000418274000018
J	Nam, K; Maruyama, CL; Wang, CS; Trump, BG; Lei, P; Andreadis, ST; Baker, OJ				Nam, Kihoon; Maruyama, Christina L.; Wang, Ching-Shuen; Trump, Bryan G.; Lei, Pedro; Andreadis, Stelios T.; Baker, Olga J.			Laminin-111-derived peptide conjugated fibrin hydrogel restores salivary gland function	PLOS ONE			English	Article							GENE DELIVERY; INTEGRIN; CHANNEL; CANCER; TUMORIGENESIS; AQUAPORIN-5; XEROSTOMIA; COLLAGEN; BINDING	Hyposalivation reduces the patient quality of life, as saliva is important for maintaining oral health. Current treatments for hyposalivation are limited to medications such as the muscarinic receptor agonists, pilocarpine and cevimeline. However, these therapies only provide temporary relief. Therefore, alternative therapies are essential to restore salivary gland function. An option is to use bioengineered scaffolds to promote functional salivary gland regeneration. Previous studies demonstrated that the laminin-111 protein is critical for intact salivary gland cell cluster formation and organization. However, laminin-111 protein as a whole is not suitable for clinical applications as some protein domains may contribute to unwanted side effects such as degradation, tumorigenesis and immune responses. Conversely, the use of synthetic laminin-111 peptides makes it possible to minimize the immune reactivity or pathogen transfer. In addition, it is relatively simple and inexpensive as compared to animal-derived proteins. Therefore, the goal of this study was to demonstrate whether a 20 day treatment with laminin-111-derived peptide conjugated fibrin hydrogel promotes tissue regeneration in submandibular glands of a wound healing mouse model. In this study, laminin-111-derived peptide conjugated fibrin hydrogel significantly accelerated formation of salivary gland tissue. The regenerated gland tissues displayed not only structural but also functional restoration.	[Nam, Kihoon; Maruyama, Christina L.; Wang, Ching-Shuen; Trump, Bryan G.; Baker, Olga J.] Univ Utah, Sch Dent, Salt Lake City, UT 84112 USA; [Lei, Pedro; Andreadis, Stelios T.] Univ Buffalo State Univ New York, Dept Chem & Biol Engn, Buffalo, NY USA; [Andreadis, Stelios T.] Univ Buffalo State Univ New York, Sch Engn & Appl Sci, Dept Biomed Engn, Buffalo, NY USA; [Andreadis, Stelios T.] Univ Buffalo State Univ New York, Ctr Bioinformat & Life Sci, Buffalo, NY USA	Utah System of Higher Education; University of Utah; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Baker, OJ (corresponding author), Univ Utah, Sch Dent, Salt Lake City, UT 84112 USA.	olga.baker@hsc.utah.edu	Lei, Pedro/U-1027-2019		National Institutes of Health-National Institute of Dental and Craniofacial Research [R01DE022971, R01DE021697]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022971, R56DE021697] Funding Source: NIH RePORTER	National Institutes of Health-National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study is supported by the National Institutes of Health-National Institute of Dental and Craniofacial Research Grants R01DE022971 (to 0.B. and S.A.) and R01DE021697 (to O.B.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnold KM, 2015, CANCER GROWTH METAST, V8, P1, DOI 10.4137/CGM.S11286; Asakura S, 1997, J BIOL CHEM, V272, P8824, DOI 10.1074/jbc.272.13.8824; Brett D, 2008, WOUNDS, V20, P347; Carlson E. R., 2015, TRAUMA INJURIES SALI, P409; Del Bufalo F, 2016, BIOMATERIALS, V84, P76, DOI 10.1016/j.biomaterials.2016.01.030; des Rieux A, 2009, J CONTROL RELEASE, V136, P148, DOI 10.1016/j.jconrel.2009.02.004; Dijkema T, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-91; Ehrlich HP, 2012, ADV WOUND CARE, V1, P3, DOI 10.1089/wound.2011.0311; Frith JE, 2012, STEM CELLS DEV, V21, P2442, DOI 10.1089/scd.2011.0615; Geiger B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005033; Ghajar CM, 2008, HISTOCHEM CELL BIOL, V130, P1105, DOI 10.1007/s00418-008-0537-1; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jeong J, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.121; Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7; Kesimer M, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-163; Kidd ME, 2012, J CONTROL RELEASE, V157, P80, DOI 10.1016/j.jconrel.2011.08.036; Kruegel J, 2010, CELL MOL LIFE SCI, V67, P2879, DOI 10.1007/s00018-010-0367-x; Lei P, 2009, BIOMATERIALS, V30, P3790, DOI 10.1016/j.biomaterials.2009.03.049; Liang MS, 2013, BIOMATERIALS, V34, P7281, DOI 10.1016/j.biomaterials.2013.05.073; Liang MS, 2011, BIOMATERIALS, V32, P8684, DOI 10.1016/j.biomaterials.2011.07.079; Litvinov RI, 2005, BIOPHYS J, V89, P2824, DOI 10.1529/biophysj.105.061887; Maruyama CL, 2015, J DENT RES; Matsuzaki T, 1999, CELL TISSUE RES, V295, P513, DOI 10.1007/s004410051257; Matsuzaki T, 2012, ACTA HISTOCHEM CYTOC, V45, P251, DOI 10.1267/ahc.12018; Nam K, 2017, J DENT RES, V96, P798, DOI 10.1177/0022034517695496; Nam K, 2016, BIOMACROMOLECULES, V17, P2293, DOI 10.1021/acs.biomac.6b00588; O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369-7021(11)70058-X; Ogawa M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3498; Padmashali RM, 2011, BIOMATERIALS, V32, P3330, DOI 10.1016/j.biomaterials.2011.01.035; Parveen S, 2006, J STEM CELLS REGEN, V1, P8; Patel VN, 2014, SEMIN CELL DEV BIOL, V25, P52, DOI 10.1016/j.semcdb.2013.12.001; Pinna R, 2015, THER CLIN RISK MANAG, V11, P171, DOI 10.2147/TCRM.S70652; Pook M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138346; Rajasekaran SA, 2008, BBA-BIOMEMBRANES, V1778, P757, DOI 10.1016/j.bbamem.2007.11.007; RAO CN, 1991, CONNECT TISSUE RES, V25, P321, DOI 10.3109/03008209109029167; Rasmussen CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145389; Romanenko VG, 2010, J BIOL CHEM, V285, P12990, DOI 10.1074/jbc.M109.068544; Sonesson M, 2008, ARCH ORAL BIOL, V53, P523, DOI 10.1016/j.archoralbio.2008.01.002; Soon ASC, 2011, BIOMATERIALS, V32, P4406, DOI 10.1016/j.biomaterials.2011.02.050; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Suehiro K, 2000, J BIOCHEM, V128, P705, DOI 10.1093/oxfordjournals.jbchem.a022804; Villa A, 2015, THER CLIN RISK MANAG, V11, P45, DOI 10.2147/TCRM.S76282; Vissink A, 2010, INT J RADIAT ONCOL, V78, P983, DOI 10.1016/j.ijrobp.2010.06.052; WEISFOGH US, 1988, EUR SURG RES, V20, P381, DOI 10.1159/000128789; Wiener RC, 2010, J AM DENT ASSOC, V141, P279, DOI 10.14219/jada.archive.2010.0161; Wilson M, 2015, MACROMOLECULES, V48, P6313, DOI 10.1021/acs.macromol.5b00885; Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005; Yuan X, 2016, TISSUE ENG PT A, V22, P928, DOI [10.1089/ten.tea.2016.0052, 10.1089/ten.TEA.2016.0052]	48	20	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2017	12	11							e0187069	10.1371/journal.pone.0187069	http://dx.doi.org/10.1371/journal.pone.0187069			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL6FI	29095857	Green Published, Green Submitted, gold			2023-01-03	WOS:000414340200043
J	Ireland, L; Santos, A; Campbell, F; Figueiredo, C; Hammond, D; Ellies, LG; Weyer-Czernilofsky, U; Bogenrieder, T; Schmid, M; Mielgo, A				Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Hammond, Dean; Ellies, Lesley G.; Weyer-Czernilofsky, Ulrike; Bogenrieder, Thomas; Schmid, Michael; Mielgo, Ainhoa			Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer	ONCOGENE			English	Article							MOUSE MAMMARY-TUMOR; PANCREATIC-CANCER; ANTICANCER THERAPIES; FACTOR-I; PHASE-I; RESISTANCE; PROGRESSION; MICROENVIRONMENT; MACROPHAGES; DISEASE	Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and support cancer progression. Thus, gaining a better understanding of how macrophages support cancer could lead to the development of more effective therapies. In this study, we find that breast cancer-associated macrophages express high levels of insulin-like growth factors 1 and 2 (IGFs) and are the main source of IGFs within both primary and metastatic tumors. In total, 75% of breast cancer patients show activation of insulin/IGF-1 receptor signaling and this correlates with increased macrophage infiltration and advanced tumor stage. In patients with invasive breast cancer, activation of Insulin/IGF-1 receptors increased to 87%. Blocking IGF in combination with paclitaxel, a chemotherapeutic agent commonly used to treat breast cancer, showed a significant reduction in tumor cell proliferation and lung metastasis in pre-clinical breast cancer models compared to paclitaxel monotherapy. Our findings provide the rationale for further developing the combination of paclitaxel with IGF blockers for the treatment of invasive breast cancer, and Insulin/IGF1R activation and IGF+ stroma cells as potential biomarker candidates for further evaluation.	[Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Schmid, Michael; Mielgo, Ainhoa] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England; [Hammond, Dean] Univ Liverpool, Dept Physiol, Liverpool, Merseyside, England; [Ellies, Lesley G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Weyer-Czernilofsky, Ulrike] Boehringer Ingelheim RCV GmbH & Co KG, Pharmacol & Translat Res, Vienna, Austria; [Bogenrieder, Thomas] Boehringer Ingelheim RCV GmbH & Co KG Med & Trans, Vienna, Austria; [Bogenrieder, Thomas] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadem, Dept Urol, Munich, Germany	University of Liverpool; University of Liverpool; University of California System; University of California San Diego; Boehringer Ingelheim; University of Munich	Mielgo, A (corresponding author), Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England.	amielgo@liverpool.ac.uk	Figueiredo, Carlos Rogerio de/H-1236-2014	Figueiredo, Carlos Rogerio de/0000-0003-3680-4070; Schmid, Michael/0000-0002-3445-0013	Sir Henry Dale research fellowship - Wellcome Trust [102521/Z/13/Z]; Sir Henry Dale research fellowship - Royal Society [102521/Z/13/Z]; Medical Research Council [MR/L000512/1]; North West Cancer Research fund;  [K22CA118182]; MRC [MR/P018920/1, MR/L000512/1] Funding Source: UKRI; Medical Research Council [MR/P018920/1] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [K22CA118182] Funding Source: NIH RePORTER	Sir Henry Dale research fellowship - Wellcome Trust; Sir Henry Dale research fellowship - Royal Society; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); North West Cancer Research fund; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by a Sir Henry Dale research fellowship to Dr. Ainhoa Mielgo, jointly funded by the Wellcome Trust and the Royal Society (grant number 102521/Z/13/Z), a New Investigator research grant from the Medical Research Council to Dr. Michael Schmid (grant number MR/L000512/1) and North West Cancer Research funding. Generation of primary breast cancer cells was supported by funding provided to Dr. Lesley Ellies (K22CA118182).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bronte V, 2015, NAT MED, V21, P117, DOI 10.1038/nm.3794; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004; DEXTER DL, 1978, CANCER RES, V38, P3174; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Farabaugh SM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00059; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Gibby K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3174; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gradishar WJ, 2016, CLIN CANCER RES, V22, P301, DOI 10.1158/1078-0432.CCR-15-0588; Guha M, 2013, NAT REV DRUG DISCOV, V12, P250, DOI 10.1038/nrd3992; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006; Leek RD, 1996, CANCER RES, V56, P4625; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lodhia KA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00142; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma CX, 2013, BREAST CANCER RES TR, V139, P145, DOI 10.1007/s10549-013-2528-8; Maglione JE, 2001, CANCER RES, V61, P8298; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Marquette C, 2012, CURR TREAT OPTION ON, V13, P263, DOI 10.1007/s11864-012-0184-6; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Mills CD, 2016, CANCER RES, V76, P513, DOI 10.1158/0008-5472.CAN-15-1737; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olson OC, 2013, CELL RES, V23, P179, DOI 10.1038/cr.2012.123; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pulaski BA, 1998, CANCER RES, V58, P1486; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Robertson JFR, 2013, LANCET ONCOL, V14, P228, DOI 10.1016/S1470-2045(13)70026-3; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Schmid MC, 2011, CANCER CELL, V19, P715, DOI 10.1016/j.ccr.2011.04.016; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wan YW, 2016, BIOINFORMATICS, V32, P952, DOI 10.1093/bioinformatics/btv677; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883	59	38	38	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2022	2036		10.1038/s41388-017-0115-x	http://dx.doi.org/10.1038/s41388-017-0115-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367764	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000429899400006
J	Dobkin, C; Finkelstein, A; Kluender, R; Notowidigdo, MJ				Dobkin, Carlos; Finkelstein, Amy; Kluender, Raymond; Notowidigdo, Matthew J.			Myth and Measurement - The Case of Medical Bankruptcies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Dobkin, Carlos] Univ Calif Santa Cruz, Dept Econ, Santa Cruz, CA 95064 USA; [Finkelstein, Amy; Kluender, Raymond] MIT, Dept Econ, Cambridge, MA 02139 USA; [Notowidigdo, Matthew J.] Northwestern Univ, Dept Econ, Evanston, IL USA	University of California System; University of California Santa Cruz; Massachusetts Institute of Technology (MIT); Northwestern University	Dobkin, C (corresponding author), Univ Calif Santa Cruz, Dept Econ, Santa Cruz, CA 95064 USA.			Dobkin, Carlos/0000-0002-5171-8325	NIA NIH HHS [R37 AG032449, R01 AG032449, P01 AG005842] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG032449, P01AG005842] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Dobkin C, 2018, AM ECON REV, V108, P308, DOI 10.1257/aer.20161038; Dranove D, 2006, HEALTH AFFAIR, V25, pW74, DOI 10.1377/hlthaff.25.w74; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; Himmelstein DU, 2009, AM J MED, V122, P741, DOI 10.1016/j.amjmed.2009.04.012; HIMMELSTEIN DU, 2005, HEALTH AFFAIR, V24, P63, DOI DOI 10.1377/HLTHAFF.W5.63	5	22	23	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2018	378	12					1076	1078		10.1056/NEJMp1716604	http://dx.doi.org/10.1056/NEJMp1716604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ9OV	29562153	Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000427942300002
J	Franklin, D; Babl, FE; Schlapbach, LJ; Oakley, E; Craig, S; Neutze, J; Furyk, J; Fraser, JF; Jones, M; Whitty, JA; Dalziel, SR; Schibler, A				Franklin, Donna; Babl, Franz E.; Schlapbach, Luregn J.; Oakley, Ed; Craig, Simon; Neutze, Jocelyn; Furyk, Jeremy; Fraser, John F.; Jones, Mark; Whitty, Jennifer A.; Dalziel, Stuart R.; Schibler, Andreas			A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NASAL CANNULA THERAPY; NONINVASIVE VENTILATION; VIRAL BRONCHIOLITIS; CHILDREN; MANAGEMENT; DIAGNOSIS; TRENDS	BACKGROUND High-flow oxygen therapy through a nasal cannula has been increasingly used in infants with bronchiolitis, despite limited high-quality evidence of its efficacy. The efficacy of high-flow oxygen therapy through a nasal cannula in settings other than intensive care units (ICUs) is unclear. METHODS In this multicenter, randomized, controlled trial, we assigned infants younger than 12 months of age who had bronchiolitis and a need for supplemental oxygen therapy to receive either high-flow oxygen therapy (high-flow group) or standard oxygen therapy (standard-therapy group). Infants in the standard-therapy group could receive rescue high-flow oxygen therapy if their condition met criteria for treatment failure. The primary outcome was escalation of care due to treatment failure (defined as meeting >= 3 of 4 clinical criteria: persistent tachycardia, tachypnea, hypoxemia, and medical review triggered by a hospital early-warning tool). Secondary outcomes included duration of hospital stay, duration of oxygen therapy, and rates of transfer to a tertiary hospital, ICU admission, intubation, and adverse events. RESULTS The analyses included 1472 patients. The percentage of infants receiving escalation of care was 12% (87 of 739 infants) in the high-flow group, as compared with 23% (167 of 733) in the standard-therapy group (risk difference, -11 percentage points; 95% confidence interval, -15 to -7; P<0.001). No significant differences were observed in the duration of hospital stay or the duration of oxygen therapy. In each group, one case of pneumothorax (<1% of infants) occurred. Among the 167 infants in the standard-therapy group who had treatment failure, 102 (61%) had a response to high-flow rescue therapy. CONCLUSIONS Among infants with bronchiolitis who were treated outside an ICU, those who received high-flow oxygen therapy had significantly lower rates of escalation of care due to treatment failure than those in the group that received standard oxygen therapy.	[Franklin, Donna; Schlapbach, Luregn J.; Schibler, Andreas] Univ Queensland, Lady Cilento Childrens Hosp, Ctr Childrens Hlth Res, Pediat Crit Care Res Grp, Brisbane, Qld, Australia; [Franklin, Donna; Schlapbach, Luregn J.; Schibler, Andreas] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia; [Franklin, Donna; Schlapbach, Luregn J.; Fraser, John F.; Schibler, Andreas] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Jones, Mark] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia; [Franklin, Donna; Fraser, John F.] Prince Charles Hosp, Adult Intens Care Serv, Crit Care Res Grp, Brisbane, Qld, Australia; [Franklin, Donna; Babl, Franz E.; Oakley, Ed; Craig, Simon; Neutze, Jocelyn; Furyk, Jeremy; Dalziel, Stuart R.; Schibler, Andreas] Paediat Res Emergency Dept Int Collaborat PREDICT, Parkville, Vic, Australia; [Babl, Franz E.; Oakley, Ed] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Emergency Dept, Melbourne, Vic, Australia; [Babl, Franz E.; Oakley, Ed] Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Paediat, Melbourne, Vic, Australia; [Craig, Simon] Monash Univ, Sch Clin Sci, Dept Med, Clayton, Vic, Australia; [Craig, Simon] Monash Hlth, Monash Med Ctr, Paediat Emergency Dept, Clayton, Vic, Australia; [Furyk, Jeremy] James Cook Univ, Coll Med & Dent, Townsville, Qld, Australia; [Furyk, Jeremy] Townsville Hosp, Emergency Dept, Townsville, Qld, Australia; [Schlapbach, Luregn J.] Univ Bern, Bern Univ Hosp, Inselspital, Dept Pediat, Bern, Switzerland; [Neutze, Jocelyn] KidzFirst Middlemore Hosp, Auckland, New Zealand; [Neutze, Jocelyn] Univ Auckland, Auckland, New Zealand; [Dalziel, Stuart R.] Univ Auckland, Starship Childrens Hosp, Childrens Emergency Dept, Auckland, New Zealand; [Dalziel, Stuart R.] Univ Auckland, Liggins Inst, Auckland, New Zealand; [Whitty, Jennifer A.] Univ East Anglia, Norwich Med Sch, Hlth Econ Grp, Norwich, Norfolk, England	University of Queensland; Mater Research; University of Queensland; University of Queensland; University of Queensland; Prince Charles Hospital; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Melbourne; Monash University; Monash University; James Cook University; University of Bern; University Hospital of Bern; University of Auckland; Starship Children's Hospital; University of Auckland; University of Auckland; University of East Anglia	Schibler, A (corresponding author), Univ Queensland, Lady Cilento Childrens Hosp, Ctr Childrens Hlth Res, Precinct & Mater Res Inst, Level 7,62 Graham St, S Bank, Qld 4101, Australia.	a.schibler@uq.edu.au	Schlapbach, Luregn J/F-7465-2017; Craig, Simon/H-9410-2019; Whitty, Jennifer/N-6434-2013	Schlapbach, Luregn J/0000-0003-2281-2598; Fraser, John/0000-0002-7012-2519; Schibler, Andreas/0000-0002-0791-5938; Whitty, Jennifer/0000-0002-5886-1933	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Funded by the National Health and Medical Research Council and others. Australian and New Zealand Clinical Trials Registry number, ACTRN12613000388718.	[Anonymous], 2013, LANCET RESP MED, V1, P113, DOI 10.1016/S2213-2600(12)70053-X; Bressan S, 2013, EUR J PEDIATR, V172, P1649, DOI 10.1007/s00431-013-2094-4; Essouri S, 2006, PEDIATR CRIT CARE ME, V7, P329, DOI 10.1097/01.PCC.0000225089.21176.0B; Fernandes RM, 2014, JAMA-J AM MED ASSOC, V311, P87, DOI 10.1001/jama.2013.284921; Franklin D, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0501-x; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Green CA, 2016, ARCH DIS CHILD, V101, P140, DOI 10.1136/archdischild-2015-308723; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Javouhey E, 2008, INTENS CARE MED, V34, P1608, DOI 10.1007/s00134-008-1150-4; Kepreotes E, 2017, LANCET, V389, P930, DOI 10.1016/S0140-6736(17)30061-2; Lazner MR, 2012, PEDIATR PULM, V47, P909, DOI 10.1002/ppul.22513; Lee JH, 2013, INTENS CARE MED, V39, P247, DOI 10.1007/s00134-012-2743-5; Long E, 2016, EMERG MED J, V33, P386, DOI 10.1136/emermed-2015-204914; Manley BJ, 2013, NEW ENGL J MED, V369, P1425, DOI 10.1056/NEJMoa1300071; Mayfield S, 2014, J PAEDIATR CHILD H, V50, P373, DOI 10.1111/jpc.12509; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; Pham TMT, 2015, PEDIATR PULM, V50, P713, DOI 10.1002/ppul.23060; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Schibler A, 2011, INTENS CARE MED, V37, P847, DOI 10.1007/s00134-011-2177-5; Schlapbach LJ, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01648-2016; Zorc JJ, 2010, PEDIATRICS, V125, P342, DOI 10.1542/peds.2009-2092	21	189	195	2	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2018	378	12					1121	1131		10.1056/NEJMoa1714855	http://dx.doi.org/10.1056/NEJMoa1714855			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ9OV	29562151	Green Published, Bronze			2023-01-03	WOS:000427942300008
J	Zettermark, S; Vicente, RP; Merlo, J				Zettermark, Sofia; Vicente, Raquel Perez; Merlo, Juan			Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: A pharmacoepidemiological study on 800 000 Swedish women	PLOS ONE			English	Article							COMBINED ORAL-CONTRACEPTIVES; NATIONAL COMORBIDITY SURVEY; DEPRESSIVE SYMPTOMS; ADVERSE MOOD; DOUBLE-BLIND; POPULATION; DISCONTINUATION; ASSOCIATION; EXPERIENCE; DISORDERS	The burden of depression and anxiety disorders is greater in women, and female sex hormones have been shown to affect mood. Psychological side effects of hormonal contraception (HC) are also a common complaint in the clinic, but few previous studies have investigated this subject. We therefore wanted to investigate whether use of HC was associated with adverse psychological health outcomes, and whether this association was modified by age. All women aged 12-30 years on 31 December 2010, residing in Sweden for at least four years and with no previous psychiatric morbidity (n = 815 662), were included. We followed the women from their first HC use (or 31 December 2010, if they were non-users) at baseline, until a prescription fill of psychotropic drugs or the end of the one-year follow-up. We performed age -stratified logistic regression models and estimated odds ratios (OR) to measure the association between different HC methods and psychotropic drug use, as well as the area under the receiver operating curve to estimate discriminatory accuracy of HC in relation to psychotropic drugs. Overall, we found an association between HC and psychotropic drugs (adjusted OR 1.34, 95% confidence interval [CI] 1.30-1.37). In the age -stratified analysis, the strongest association was found in adolescent girls (adjusted OR 3.46, 95% CI 3.04-4.94 for age 12 to 14 years), while it was non-existent for adult women. We conclude that hormonal contraception is associated with psychotropic drug use among adolescent girls, suggesting an adverse effect of HC on psychological health in this population.	[Zettermark, Sofia; Vicente, Raquel Perez; Merlo, Juan] Lund Univ, Clin Res Ctr, Dept Clin Sci, Unit Social Epidemiol, Malmo, Sweden	Lund University	Zettermark, S (corresponding author), Lund Univ, Clin Res Ctr, Dept Clin Sci, Unit Social Epidemiol, Malmo, Sweden.	sofia.zettermark@med.lu.se	Merlo, Juan/E-2136-2011; Zettermark, Sofia/AAD-1920-2021	Merlo, Juan/0000-0001-8379-9708; Zettermark, Sofia/0000-0003-3181-8609	Swedish Scientific Council [2013-2484]; Faculty of Medicine, Lund University; Region Skane County Council	Swedish Scientific Council; Faculty of Medicine, Lund University; Region Skane County Council	This work was supported by the Swedish Scientific Council (# 2013-2484, PI: Juan Merlo) and research funds from the Faculty of Medicine, Lund University, and Region Skane County Council.	Andreen L, 2009, PSYCHONEUROENDOCRINO, V34, P1121, DOI 10.1016/j.psyneuen.2009.02.003; Berenson AB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.048; Berlin M, 2017, DEV MENTAL HLTH ISSU; Bottcher B, 2012, ARCH GYNECOL OBSTET, V286, P231, DOI 10.1007/s00404-012-2298-2; Borgstom A, 2008, EUR J OBSTET GYN R B, V141, P127, DOI 10.1016/j.ejogrb.2008.07.018; Duke JM, 2007, CONTRACEPTION, V75, P27, DOI 10.1016/j.contraception.2006.08.002; Francis J, 2015, CONTRACEPTION, V91, P336, DOI 10.1016/j.contraception.2014.12.010; Gardarsdottir H, 2007, J AFFECT DISORDERS, V98, P109, DOI 10.1016/j.jad.2006.07.003; Graham CA, 1995, CONTRACEPTION, V52, P363, DOI 10.1016/0010-7824(95)00226-X; Joffe H, 1998, BIOL PSYCHIAT, V44, P798, DOI 10.1016/S0006-3223(98)00169-3; KESSLER RC, 1994, J AFFECT DISORDERS, V30, P15, DOI 10.1016/0165-0327(94)90147-3; Kessler RC, 2006, ARCH GEN PSYCHIAT, V63, P415, DOI 10.1001/archpsyc.63.4.415; Keyes KM, 2013, AM J EPIDEMIOL, V178, P1378, DOI 10.1093/aje/kwt188; Kulkarni J, 2007, EXPERT OPIN DRUG SAF, V6, P371, DOI 10.1517/14740338.6.4.371; Kurshan N, 2005, ARCH WOMEN MENT HLTH, V9, P1, DOI 10.1007/s00737-005-0102-z; Lara LAS, 2016, J PEDIATR ADOL GYNEC, V29, P417, DOI 10.1016/j.jpag.2015.11.012; Lindberg M, 2012, EUR J CONTRACEP REPR, V17, P106, DOI 10.3109/13625187.2012.658925; Longitudinal integration database for health insurance and labour market studies (LISA), 2016, STAT SWED GUID RES U; Lopez Laureen M, 2013, COCHRANE DB SYST REV, V30; Ludvigsson JF, 2016, EUR J EPIDEMIOL, V31, P125, DOI 10.1007/s10654-016-0117-y; Ludvigsson JF, 2009, EUR J EPIDEMIOL, V24, P659, DOI 10.1007/s10654-009-9350-y; Merlo J, 2017, SSM-POPUL HLTH, V3, P684, DOI 10.1016/j.ssmph.2017.08.005; O'Connell K, 2007, CONTRACEPTION, V75, P299, DOI 10.1016/j.contraception.2006.09.008; Oinonen KA, 2002, J AFFECT DISORDERS, V70, P229, DOI 10.1016/S0165-0327(01)00356-1; Ott MA, 2008, ARCH SEX BEHAV, V37, P605, DOI 10.1007/s10508-007-9302-0; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486; Rogines-Velo MP, 2012, MENOPAUSE, V19, P471, DOI 10.1097/gme.0b013e3182333847; Rosenberg MJ, 1998, AM J OBSTET GYNECOL, V179, P577, DOI 10.1016/S0002-9378(98)70047-X; Sanders SA, 2001, CONTRACEPTION, V64, P51, DOI 10.1016/S0010-7824(01)00218-9; Segebladh B, 2009, CONTRACEPTION, V79, P50, DOI 10.1016/j.contraception.2008.08.001; Shen H, 2007, NAT NEUROSCI, V10, P469, DOI 10.1038/nn1868; Sivin I, 2003, DRUG SAFETY, V26, P303, DOI 10.2165/00002018-200326050-00002; Skovlund C, 2016, JAMA PSYCHIAT, V73, P1154, DOI 10.1001/jamapsychiatry.2016.2387; Sundstrom I, 1998, NEUROENDOCRINOLOGY, V67, P126, DOI 10.1159/000054307; Svendal G, 2012, J AFFECT DISORDERS, V140, P92, DOI 10.1016/j.jad.2012.03.030; Toffol E, 2011, HUM REPROD, V26, P3085, DOI 10.1093/humrep/der269; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294; Wiebe ER, 2013, AM J EPIDEMIOL, V178, P1389, DOI 10.1093/aje/kwt186; Wirehn AB, 2010, EUR J CONTRACEP REPR, V15, P41, DOI 10.3109/13625181003587004; Yonkers KA, 2003, J CLIN PSYCHIAT, V64, P8; Zethraeus N, 2016, J CLIN ENDOCR METAB, V101, P4046, DOI 10.1210/jc.2016-2032	42	44	44	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194773	10.1371/journal.pone.0194773	http://dx.doi.org/10.1371/journal.pone.0194773			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA1RF	29566064	gold, Green Published, Green Submitted			2023-01-03	WOS:000428093900103
J	Hassager, C; Nagao, K; Hildick-Smith, D				Hassager, Christian; Nagao, Ken; Hildick-Smith, David			Out-of-hospital cardiac arrest: in-hospital intervention strategies	LANCET			English	Review							PERCUTANEOUS CORONARY INTERVENTION; TARGETED TEMPERATURE MANAGEMENT; ELEVATION MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; MILD THERAPEUTIC HYPOTHERMIA; CEREBRAL OXYGEN-SATURATION; 33 DEGREES-C; VENTRICULAR-FIBRILLATION; COMATOSE SURVIVORS; NEUROLOGICAL PROGNOSTICATION	The prognosis after out-of-hospital cardiac arrest (OHCA) has improved in the past few decades because of advances in interventions used outside and in hospital. About half of patients who have OHCA with initial ventricular tachycardia or ventricular fibrillation and who are admitted to hospital in coma after return of spontaneous circulation will survive to discharge with a reasonable neurological status. In this Series paper we discuss in-hospital management of patients with post-cardiac-arrest syndrome. In most patients, the most important in-hospital interventions other than routine intensive care are continuous active treatment (in non-comatose and comatose patients and including circulatory support in selected patients), cooling of core temperature to 32-36 degrees C by targeted temperature management for at least 24 h, immediate coronary angiography with or without percutaneous coronary intervention, and delay of final prognosis until at least 72 h after OHCA. Prognosis should be based on clinical observations and multimodal testing, with focus on no residual sedation.	[Hassager, Christian] Rigshosp, Dept Cardiol, Copenhagen, Denmark; [Hassager, Christian] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark; [Nagao, Ken] Nihon Univ Hosp, Cardiovasc Ctr, Tokyo, Japan; [Hildick-Smith, David] Brighton & Sussex Univ Hosp, Sussex Cardiac Ctr, Dept Cardiol, Brighton Hove, England	Rigshospitalet; University of Copenhagen; University of Copenhagen; Nihon University	Hassager, C (corresponding author), Univ Copenhagen, Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark.	hassager@dadlnet.dk		Hassager, Christian/0000-0002-1199-0981				ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; Argaud L, 2016, JAMA CARDIOL, V1, P557, DOI 10.1001/jamacardio.2016.1701; Batista LM, 2010, RESUSCITATION, V81, P398, DOI 10.1016/j.resuscitation.2009.12.016; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 2016, CIRCULATION, V134, P797, DOI 10.1161/CIRCULATIONAHA.116.021989; Bernard SA, 2012, CRIT CARE MED, V40, P747, DOI 10.1097/CCM.0b013e3182377038; Bernard SA, 2010, CIRCULATION, V122, P737, DOI 10.1161/CIRCULATIONAHA.109.906859; Bjelland TW, 2010, RESUSCITATION, V81, P1627, DOI 10.1016/j.resuscitation.2010.07.002; Brain Resuscitation Clinical Trial II Study Group, 1991, NEW ENGL J MED, V325, P1046; Bro-Jeppesen J, 2014, RESUSCITATION, V85, P1480, DOI 10.1016/j.resuscitation.2014.08.007; Bro-Jeppesen J, 2013, RESUSCITATION, V84, P1734, DOI 10.1016/j.resuscitation.2013.07.023; Bro-Jeppesen J, 2009, RESUSCITATION, V80, P171, DOI 10.1016/j.resuscitation.2008.09.009; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Camuglia AC, 2014, RESUSCITATION, V85, P1533, DOI 10.1016/j.resuscitation.2014.08.025; Cariou A, 2016, J AM COLL CARDIOL, V68, P40, DOI 10.1016/j.jacc.2016.04.040; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; Cronberg T, 2015, JAMA NEUROL, V72, P634, DOI 10.1001/jamaneurol.2015.0169; Dae MW, 2002, AM J PHYSIOL-HEART C, V282, pH1584, DOI 10.1152/ajpheart.00980.2001; Debaty G, 2014, INTENS CARE MED, V40, P1832, DOI 10.1007/s00134-014-3519-x; Deye N, 2015, CIRCULATION, V132, P182, DOI 10.1161/CIRCULATIONAHA.114.012805; Dragancea I, 2017, RESUSCITATION, V117, P50, DOI 10.1016/j.resuscitation.2017.05.014; Dumas F, 2010, CIRC-CARDIOVASC INTE, V3, P200, DOI 10.1161/CIRCINTERVENTIONS.109.913665; Erlinge D, 2014, J AM COLL CARDIOL, V63, P1857, DOI 10.1016/j.jacc.2013.12.027; Garot P, 2007, CIRCULATION, V115, P1354, DOI 10.1161/CIRCULATIONAHA.106.657619; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hosmane VR, 2009, J AM COLL CARDIOL, V53, P409, DOI 10.1016/j.jacc.2008.08.076; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Ibrahim K, 2014, RESUSCITATION, V85, P649, DOI 10.1016/j.resuscitation.2014.02.004; Ito N, 2014, RESUSCITATION, V85, P778, DOI 10.1016/j.resuscitation.2014.02.012; Joffre J, 2014, RESUSCITATION, V85, P769, DOI 10.1016/j.resuscitation.2014.02.013; Kim F, 2014, JAMA-J AM MED ASSOC, V311, P45, DOI 10.1001/jama.2013.282173; Kirkegaard H, 2017, JAMA-J AM MED ASSOC, V318, P341, DOI 10.1001/jama.2017.8978; Knafelj R, 2007, RESUSCITATION, V74, P227, DOI 10.1016/j.resuscitation.2007.01.016; Laitio R, 2016, JAMA-J AM MED ASSOC, V315, P1120, DOI 10.1001/jama.2016.1933; Langkjaer S, 2015, RESUSCITATION, V92, P141, DOI 10.1016/j.resuscitation.2015.03.023; Larsen JM, 2012, RESUSCITATION, V83, P1427, DOI 10.1016/j.resuscitation.2012.08.337; Lettieri C, 2009, AM HEART J, V157, P569, DOI 10.1016/j.ahj.2008.10.018; Lilja G, 2015, CIRCULATION, V131, P1340, DOI 10.1161/CIRCULATIONAHA.114.014414; Longstreth WT, 2002, NEUROLOGY, V59, P506, DOI 10.1212/WNL.59.4.506; Lybeck A, 2018, RESUSCITATION, V126, P166, DOI 10.1016/j.resuscitation.2018.01.027; Mattsson N, 2017, ANN NEUROL, V82, P665, DOI 10.1002/ana.25067; Metter RB, 2011, RESUSCITATION, V82, P1180, DOI 10.1016/j.resuscitation.2011.04.001; Millin MG, 2016, RESUSCITATION, V108, P54, DOI 10.1016/j.resuscitation.2016.09.004; Mylotte D, 2013, JACC-CARDIOVASC INTE, V6, P115, DOI 10.1016/j.jcin.2012.10.006; Nagao K, 2016, CIRCULATION, V133, P1386, DOI 10.1161/CIRCULATIONAHA.115.018788; Nagao K, 2010, CIRC J, V74, P77, DOI 10.1253/circj.CJ-09-0502; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nishiyama K, 2015, RESUSCITATION, V96, P135, DOI 10.1016/j.resuscitation.2015.07.049; Noc M, INVASIVE CORONARY TR; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI [10.1016/j.jacc.2012.11.019, 10.1161/CIR.0b013e3182742cf6]; Ortega-Deballon I, 2016, RESUSCITATION, V101, P12, DOI 10.1016/j.resuscitation.2016.01.018; Ouweneel DM, 2017, J AM COLL CARDIOL, V69, P278, DOI 10.1016/j.jacc.2016.10.022; Patel N, 2016, JAMA CARDIOL, V1, P890, DOI 10.1001/jamacardio.2016.2860; Peels HO, 2008, CATHETER CARDIO INTE, V71, P147, DOI 10.1002/ccd.21265; Penela D, 2013, J AM COLL CARDIOL, V61, P686, DOI 10.1016/j.jacc.2012.10.029; Rab T, 2015, J AM COLL CARDIOL, V66, P62, DOI 10.1016/j.jacc.2015.05.009; Radsel P, 2011, AM J CARDIOL, V108, P634, DOI 10.1016/j.amjcard.2011.04.008; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Salam I, 2016, EUR HEART J-ACUTE CA, V5, P317, DOI 10.1177/2048872615585519; Shavelle DM, 2017, AM J CARDIOL, V120, P729, DOI 10.1016/j.amjcard.2017.06.010; Shinozaki K, 2017, CIRC J, V81, P1839, DOI 10.1253/circj.CJ-17-0335; Silva S, 2017, CRIT CARE MED, V45, pE763, DOI 10.1097/CCM.0000000000002379; Soholm H, 2013, RESUSCITATION, V84, P162, DOI 10.1016/j.resuscitation.2012.06.029; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Stammet P, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1729-7; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; Stub D, 2011, CIRCULATION, V123, P1428, DOI 10.1161/CIRCULATIONAHA.110.988725; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Thiele H, 2012, NEW ENGL J MED, V367, P1287, DOI 10.1056/NEJMoa1208410; Tranberg T, 2017, EUR HEART J, V38, P1645, DOI 10.1093/eurheartj/ehx104; Wanscher M, 2012, RESUSCITATION, V83, P1078, DOI 10.1016/j.resuscitation.2012.05.009; Westhall E, 2016, NEUROLOGY, V86, P1482, DOI 10.1212/WNL.0000000000002462; Wiberg S, 2016, CIRCULATION; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Wolfrum S, 2008, CRIT CARE MED, V36, P1780, DOI 10.1097/CCM.0b013e31817437ca; Wu O, 2009, RADIOLOGY, V252, P173, DOI 10.1148/radiol.2521081232; Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667; Yokoyama H, 2011, CIRC J, V75, P1063, DOI 10.1253/circj.CJ-11-0137; Youn CS, 2015, RESUSCITATION, V96, P1, DOI 10.1016/j.resuscitation.2015.06.029; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	84	66	73	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 10	2018	391	10124					989	998		10.1016/S0140-6736(18)30315-5	http://dx.doi.org/10.1016/S0140-6736(18)30315-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ1UN	29536863				2023-01-03	WOS:000427363100032
J	Sanghvi, MM; Aung, N; Cooper, JA; Paiva, JM; Lee, AM; Zemrak, F; Fung, K; Thomson, RJ; Lukaschuk, E; Carapella, V; Kim, YJ; Harvey, NC; Piechnik, SK; Neubauer, S; Petersen, SE				Sanghvi, Mihir M.; Aung, Nay; Cooper, Jackie A.; Paiva, Jose Miguel; Lee, Aaron M.; Zemrak, Filip; Fung, Kenneth; Thomson, Ross J.; Lukaschuk, Elena; Carapella, Valentina; Kim, Young Jin; Harvey, Nicholas C.; Piechnik, Stefan K.; Neubauer, Stefan; Petersen, Steffen E.			The impact of menopausal hormone therapy (MHT) on cardiac structure and function: Insights from the UK Biobank imaging enhancement study	PLOS ONE			English	Article							ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; CLINICAL-IMPLICATIONS; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; OUTCOMES; FAILURE; RISK	Background The effect of menopausal hormone therapy (MHT) previously known as hormone replacement therapy on cardiovascular health remains unclear and controversial. This cross-sectional study examined the impact of MHT on left ventricular (LV) and left atrial (LA) structure and function, alterations in which are markers of subclinical cardiovascular disease, in a population-based cohort. Methods Post-menopausal women who had never used MHT and those who had used MHT >= 3 years participating in the UK Biobank who had undergone cardiovascular magnetic resonance (CMR) imaging and free of known cardiovascular disease were included. Multivariable linear regression was performed to examine the relationship between cardiac parameters and MHT use >= 3 years. To explore whether MHT use on each of the cardiac outcomes differed by age, multivariable regression models were constructed with a cross product of age and MHT fitted as an interaction term. Results Of 1604 post-menopausal women, 513 (32%) had used MHT >= 3 years. In the MHT cohort, median age at menopause was 50 (IQR: 45-52) and median duration of MHT was 8 years. In the non-MHT cohort, median age at menopause was 51 (IQR: 48-53). MHT use was associated with significantly lower LV end-diastolic volume (122.8 ml vs 119.8 ml, effect size = -2.4%, 95% Cl: -4.2% to -0.5%; p = 0.013) and LA maximal volume (60.2 ml vs 57.5 ml, effect size = -4.5%, 95% Cl: -7.8% to -1.0%; p = 0.012). There was no significant difference in LV mass. MHT use significantly modified the effect between age and CMR parameters; MHT users had greater decrements in LV end-diastolic volume, LV end-systolic volume and LA maximal volume with advancing age. Conclusions MHT use was not associated with adverse, subclinical changes in cardiac structure and function. Indeed, significantly smaller LV and LA chamber volumes were observed which have been linked to favourable cardiovascular outcomes. These findings represent a nave approach to examining MHT's effect on the cardiovascular system.	[Sanghvi, Mihir M.; Aung, Nay; Cooper, Jackie A.; Paiva, Jose Miguel; Lee, Aaron M.; Zemrak, Filip; Fung, Kenneth; Thomson, Ross J.; Petersen, Steffen E.] Queen Mary Univ London, William Harvey Res Inst, NIHR Biomed Res Ctr Barts, Charterhouse Sq, London, England; [Lukaschuk, Elena; Carapella, Valentina; Kim, Young Jin; Piechnik, Stefan K.; Neubauer, Stefan] Univ Oxford, Div Cardiovasc Med, Radcliffe Dept Med, Oxford, England; [Kim, Young Jin] Yonsei Univ, Severance Hosp, Dept Radiol, Coll Med, Seoul, South Korea; [Harvey, Nicholas C.] Univ Southampton, Southampton Gen Hosp, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England; [Harvey, Nicholas C.] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England; [Harvey, Nicholas C.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England	University of London; Queen Mary University London; University of Oxford; Yonsei University; Yonsei University Health System; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust	Petersen, SE (corresponding author), Queen Mary Univ London, William Harvey Res Inst, NIHR Biomed Res Ctr Barts, Charterhouse Sq, London, England.	s.e.petersen@qmul.ac.uk	Petersen, Steffen E/A-8389-2011; Thomson, Ross/AAU-6636-2020; Thomson, Ross/GXV-0334-2022	Petersen, Steffen E/0000-0003-4622-5160; Thomson, Ross/0000-0002-8229-8060; Harvey, Nicholas/0000-0002-8194-2512; Carapella, Valentina/0000-0001-9750-9425; Aung, Nay/0000-0001-5095-1611; Sanghvi, Mihir/0000-0002-1914-4149; Neubauer, Stefan/0000-0001-9017-5645; Zemrak, Filip/0000-0001-6730-4955	Medical College of Saint Bartholomews Hospital Trust; NIHR Cardiovascular Biomedical Research Centre at Barts; SmartHeart Engineering and Physical Sciences Research Council [EP/P001009/1]; Oxford NIHR Biomedical Research Centre; Oxford British Heart Foundation Centre of Research Excellence; Medical Research Council [MR/L016311/1]; Wellcome Trust Research Training Fellowship [203553/Z/Z]; British Heart Foundation [PG/14/89/31194]; EPSRC [EP/P001009/1] Funding Source: UKRI; MRC [G0400491, MC_U147585819, MC_U147585827] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/P001009/1] Funding Source: researchfish	Medical College of Saint Bartholomews Hospital Trust; NIHR Cardiovascular Biomedical Research Centre at Barts; SmartHeart Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Oxford NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Oxford British Heart Foundation Centre of Research Excellence; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust Research Training Fellowship(Wellcome Trust); British Heart Foundation(British Heart Foundation); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the following institutions: KF is supported by The Medical College of Saint Bartholomews Hospital Trust (www.barts-londonschooltrust.org.uk), an independent registered charity that promotes and advances medical and dental education and research at Barts and The London School of Medicine and Dentistry. AL and SEP acknowledge support from the NIHR Cardiovascular Biomedical Research Centre at Barts (www.whri.qmul.ac.uk) and from the SmartHeart Engineering and Physical Sciences Research Council (www.epsrc.ac.uk) program grant (EP/P001009/1). SN and SKP are supported by the Oxford NIHR Biomedical Research Centre (www.oxfordbrc.nihr.ac.uk) and the Oxford British Heart Foundation Centre of Research Excellence (http://www.cardioscience.ox.ac.uk/bhf-centre-of-research-excellence). This project was enabled through access to the MRC eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council (grant number MR/L016311/1) (www.emedlab.ac.uk). NA is supported by a Wellcome Trust Research Training Fellowship (203553/Z/Z) (www.wellcome.ac.uk). The authors SEP, SN and SKP acknowledge the British Heart Foundation (www.bhf.org.uk) for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging resource in 5000 CMR scans (PG/14/89/31194). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American College of Obstetricians and Gynecologists, ACOG COMM OP; [Anonymous], R LANG ENV STAT COMP; Barrett-Connor E, 2007, AM J EPIDEMIOL, V166, P506, DOI 10.1093/aje/kwm214; Boardman HMP, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002229.pub4; Clarkson TB, 2013, MENOPAUSE, V20, P342, DOI [10.1097/gme.0b013e3182843aad, 10.1097/GME.0b013e3182843aad]; Cohen J, 1988, BEHAV SCI; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Harvey RE, 2015, WOMENS HEALTH, V11, P239, DOI [10.2217/whe.14.64, 10.2217/WHE.14.64]; Hodis HN, 2016, NEW ENGL J MED, V374, P1221, DOI 10.1056/NEJMoa1505241; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kerkhof PLM, 2015, CLIN MED INSIGHTS-CA, V9, P11, DOI [10.4137/CMC.s18744, 10.4137/CMC.S18744]; Kizer JR, 2006, AM HEART J, V151, P412, DOI 10.1016/j.ahj.2005.04.031; KRONMAL RA, 1993, J ROY STAT SOC A STA, V156, P379, DOI 10.2307/2983064; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; Manson JE, 2017, JAMA-J AM MED ASSOC, V318, P927, DOI 10.1001/jama.2017.11217; Marjoribanks J, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e8141; Mathias A, 2016, J AM COLL CARDIOL, V68, P1268, DOI 10.1016/j.jacc.2016.06.051; Petersen SE, 2017, J CARDIOVASC MAGN R, V19, DOI 10.1186/s12968-017-0327-9; Petersen SE, 2016, J CARDIOVASC MAGN R, V18, DOI 10.1186/s12968-016-0227-4; Petersen SE, 2013, J CARDIOVASC MAGN R, V15, DOI 10.1186/1532-429X-15-46; Pines Amos, 2010, J Midlife Health, V1, P41, DOI 10.4103/0976-7800.66990; POSTHUMA WFM, 1994, BRIT MED J, V308, P1268; Rodstrom K, 1999, BMJ, V319; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schierbeck LL, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6409; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Tsang TSM, 2006, J AM COLL CARDIOL, V47, P1018, DOI 10.1016/j.jacc.2005.08.077; Tu YK, 2004, J DENT, V32, P143, DOI 10.1016/j.jdent.2003.09.004; Vasan RS, 1997, NEW ENGL J MED, V336, P1350, DOI 10.1056/NEJM199705083361903	34	13	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2018	13	3							e0194015	10.1371/journal.pone.0194015	http://dx.doi.org/10.1371/journal.pone.0194015			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5UV	29518141	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000426902900060
J	Jarchum, I				Jarchum, Irene			All MiNDS on the brain	NATURE BIOTECHNOLOGY			English	Editorial Material																		Dagdeviren C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan2742	1	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	2018	36	3					238	238		10.1038/nbt.4094	http://dx.doi.org/10.1038/nbt.4094			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FY3DS	29509742	Bronze			2023-01-03	WOS:000426698700016
J	Owens, B				Owens, Brian			Gut bacteria link to immunotherapy sparks interest	NATURE BIOTECHNOLOGY			English	News Item																			0	7	7	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	2018	36	2					121	123		10.1038/nbt0218-121	http://dx.doi.org/10.1038/nbt0218-121			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FV0ZQ	29406499				2023-01-03	WOS:000424291200004
J	Kwong, JC; Schwartz, KL; Campitelli, MA; Chung, H; Crowcroft, NS; Karnauchow, T; Katz, K; Ko, DT; McGeer, AJ; McNally, D; Richardson, DC; Rosella, LC; Simor, A; Smieja, M; Zahariadis, G; Gubbay, JB				Kwong, Jeffrey C.; Schwartz, Kevin L.; Campitelli, Michael A.; Chung, Hannah; Crowcroft, Natasha S.; Karnauchow, Timothy; Katz, Kevin; Ko, Dennis T.; McGeer, Allison J.; McNally, Dayre; Richardson, David C.; Rosella, Laura C.; Simor, Andrew; Smieja, Marek; Zahariadis, George; Gubbay, Jonathan B.			Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; CONTROLLED CASE SERIES; UNITED-STATES; SEASONAL INFLUENZA; EXCESS MORTALITY; RISK-FACTORS; VACCINATION; ENGLAND; VIRUS; DEATH	BACKGROUND Acute myocardial infarction can be triggered by acute respiratory infections. Previous studies have suggested an association between influenza and acute myocardial infarction, but those studies used nonspecific measures of influenza infection or study designs that were susceptible to bias. We evaluated the association between laboratory-confirmed influenza infection and acute myocardial infarction. METHODS We used the self-controlled case-series design to evaluate the association between laboratory-confirmed influenza infection and hospitalization for acute myocardial infarction. We used various high-specificity laboratory methods to confirm influenza infection in respiratory specimens, and we ascertained hospitalization for acute myocardial infarction from administrative data. We defined the "risk interval" as the first 7 days after respiratory specimen collection and the "control interval" as 1 year before and 1 year after the risk interval. RESULTS We identified 364 hospitalizations for acute myocardial infarction that occurred within 1 year before and 1 year after a positive test result for influenza. Of these, 20 (20.0 admissions per week) occurred during the risk interval and 344 (3.3 admissions per week) occurred during the control interval. The incidence ratio of an admission for acute myocardial infarction during the risk interval as compared with the control interval was 6.05 (95% confidence interval [CI], 3.86 to 9.50). No increased incidence was observed after day 7. Incidence ratios for acute myocardial infarction within 7 days after detection of influenza B, influenza A, respiratory syncytial virus, and other viruses were 10.11 (95% CI, 4.37 to 23.38), 5.17 (95% CI, 3.02 to 8.84), 3.51 (95% CI, 1.11 to 11.12), and 2.77 (95% CI, 1.23 to 6.24), respectively. CONCLUSIONS We found a significant association between respiratory infections, especially influenza, and acute myocardial infarction.	[Kwong, Jeffrey C.; Schwartz, Kevin L.; Campitelli, Michael A.; Chung, Hannah; Ko, Dennis T.; Rosella, Laura C.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Kwong, Jeffrey C.; Schwartz, Kevin L.; Crowcroft, Natasha S.; Rosella, Laura C.; Gubbay, Jonathan B.] Univ Toronto, Publ Hlth Ontario, Toronto, ON, Canada; [Kwong, Jeffrey C.; Schwartz, Kevin L.; Crowcroft, Natasha S.; McGeer, Allison J.; Rosella, Laura C.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Kwong, Jeffrey C.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Crowcroft, Natasha S.; Katz, Kevin; McGeer, Allison J.; Simor, Andrew; Gubbay, Jonathan B.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kwong, Jeffrey C.] Univ Hlth Network, Toronto, ON, Canada; [Katz, Kevin] North York Gen Hosp, Toronto, ON, Canada; [Ko, Dennis T.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [McGeer, Allison J.] Sinai Hlth Syst, Toronto, ON, Canada; [Gubbay, Jonathan B.] Hosp Sick Children, Toronto, ON, Canada; [Karnauchow, Timothy; McNally, Dayre] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada; [Karnauchow, Timothy] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Richardson, David C.] William Osler Hlth Syst, Brampton, ON, Canada; [Smieja, Marek] McMaster Univ, Hamilton, ON, Canada; [Zahariadis, George] London Hlth Sci Ctr, London, ON, Canada; [Zahariadis, George] Newfoundland & Labrador Publ Hlth Lab, St John, NF, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; North York General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; McMaster University; London Health Sciences Centre	Kwong, JC (corresponding author), Inst Clin Evaluat Sci, G1 06,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	jeff.kwong@utoronto.ca	ortiz, alberto/Y-7582-2018; Cuervo, Guillermo/B-1883-2012; Gubbay, Jonathan/Q-8580-2019; McGeer, Allison/AAB-6885-2020	ortiz, alberto/0000-0002-9805-9523; Cuervo, Guillermo/0000-0002-7075-943X; Gubbay, Jonathan/0000-0003-0026-3786; McGeer, Allison/0000-0001-5647-6137; Ko, Dennis/0000-0001-6840-8051	Canadian Institutes of Health Research [CIHR MOP 130568]; Public Health Ontario; Institute for Clinical Evaluative Sciences - Ontario Ministry of Health and Long-Term Care	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Public Health Ontario; Institute for Clinical Evaluative Sciences - Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario)	Supported by an operating grant (CIHR MOP 130568) from the Canadian Institutes of Health Research, by Public Health Ontario, and by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care.	ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; Aull L, 2007, SOUTH MED J, V100, P873, DOI 10.1097/SMJ.0b013e31813c6b34; Austin PC, 2002, AM HEART J, V144, P290, DOI 10.1067/mhj.2002.123839; Buchan Sarah A, 2016, CMAJ Open, V4, pE455; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; COLLINS S. D., 1932, Public Health Reports, V47, P2159, DOI 10.2307/4580606; Corrales-Medina VF, 2012, CIRCULATION, V125, P773, DOI 10.1161/CIRCULATIONAHA.111.040766; Corrales-Medina VF, 2010, LANCET INFECT DIS, V10, P83, DOI 10.1016/S1473-3099(09)70331-7; Darvishian M, 2014, LANCET INFECT DIS, V14, P1228, DOI 10.1016/S1473-3099(14)70960-0; Foster ED, 2013, EPIDEMIOL INFECT, V141, P735, DOI 10.1017/S0950268812002890; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Guan XR, 2012, INFLAMM RES, V61, P591, DOI 10.1007/s00011-012-0449-3; HOUSWORTH J, 1974, AM J EPIDEMIOL, V100, P40, DOI 10.1093/oxfordjournals.aje.a112007; Ip DKM, 2016, CLIN INFECT DIS, V62, P431, DOI 10.1093/cid/civ909; Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; MacIntyre CR, 2013, HEART, V99, P1843, DOI 10.1136/heartjnl-2013-304320; Madjid M, 2007, EUR HEART J, V28, P1205, DOI 10.1093/eurheartj/ehm035; MANTON KG, 1982, DEMOGRAPHY, V19, P527, DOI 10.2307/2061017; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; PONKA A, 1981, ANN CLIN RES, V13, P429; Redelmeier DA, 2013, J CLIN EPIDEMIOL, V66, P955, DOI 10.1016/j.jclinepi.2013.05.003; Rees K, 2015, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD005050.PUB3; Reichert TA, 2004, AM J EPIDEMIOL, V160, P492, DOI 10.1093/aje/kwh227; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747; STERN MP, 1978, CIRCULATION, V58, P537, DOI 10.1161/01.CIR.58.3.537; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; Warren-Gash C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002604; Warren-Gash C, 2012, J INFECT DIS, V206, P1652, DOI 10.1093/infdis/jis597; Warren-Gash C, 2011, J INFECT DIS, V203, P1710, DOI 10.1093/infdis/jir171; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1	32	567	590	3	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 25	2018	378	4					345	353		10.1056/NEJMoa1702090	http://dx.doi.org/10.1056/NEJMoa1702090			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT5ZX	29365305	Bronze			2023-01-03	WOS:000423233400007
J	Zulu, T; Heap, M; Sinanovic, E				Zulu, Tryphine; Heap, Marion; Sinanovic, Edina			The cost and utilisation patterns of a pilot sign language interpreter service for primary health care services in South Africa	PLOS ONE			English	Article							DEAF PEOPLE	Background The World Health Organisation estimates disabling hearing loss to be around 5.3%, while a study of hearing impairment and auditory pathology in Limpopo, South Africa found a prevalence of nearly 9%. Although Sign Language Interpreters (SLIs) improve the communication challenges in health care, they are unaffordable for many signing Deaf people and people with disabling hearing loss. On the other hand, there are no legal provisions in place to ensure the provision of SLIs in the health sector in most countries including South Africa. To advocate for funding of such initiatives, reliable cost estimates are essential and such data is scarce. To bridge this gap, this study estimated the costs of providing such a service within a South African District health service based on estimates obtained from a pilot-project that initiated the first South African Sign Language Interpreter (SASLI) service in healthcare. Methods The ingredients method was used to calculate the unit cost per SASLI-assisted visit from a provider perspective. The unit costs per SASLI-assisted visit were then used in estimating the costs of scaling up this service to the District Health Services. The average annual SASLI utilisation rate per person was calculated on Stata v. 12 using the projects' registry from 2008 +/- 2013. Sensitivity analyses were carried out to determine the effect of changing the discount rate and personnel costs. Results Average Sign Language Interpreter services' utilisation rates increased from 1.66 to 3.58 per person per year, with a median of 2 visits, from 2008 +/- 2013. The cost per visit was US $189.38 in 2013 whilst the estimated costs of scaling up this service ranged from US $14.2million to US$76.5million in the Cape Metropole District. These cost estimates represented 2.3%-12.2% of the budget for the Western Cape District Health Services for 2013. Conclusions In the presence of Sign Language Interpreters, Deaf Sign language users utilise health care service to a similar extent as the hearing population. However, this service requires significant capital investment by government to enable access to healthcare for the Deaf.	[Zulu, Tryphine; Sinanovic, Edina] Univ Cape Town, Sch Publ Hlth & Family Med, Fac Hlth Sci, Hlth Econ Unit, Cape Town, South Africa; [Heap, Marion] Univ Cape Town, Sch Publ Hlth & Family Med, Fac Hlth Sci, Hlth & Human Rights Programme, Cape Town, South Africa	University of Cape Town; University of Cape Town	Zulu, T (corresponding author), Univ Cape Town, Sch Publ Hlth & Family Med, Fac Hlth Sci, Hlth Econ Unit, Cape Town, South Africa.	tryphinen@gmail.com	Sinanovic, Edina/AAR-2590-2020		South African medical Research Council	South African medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	TZ received a bursary for her MPH degree from the South African medical Research Council, http://www.mrc.ac.za/ researchdevelopment/opportunity.htm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the South African Medical Research Council for funding TZ as part of the National Health Scholars Program and Prof Lesley London, head of the Health and Human Rights programme that runs the SASLI service for providing access to the dataset.	Aarons Debra, 1998, STELLENBOSCH PAPERS, V31, P1, DOI DOI 10.5774/31-0-55; Abraham D, 2006, MAKING CASE COMMUNIT, P189; Ahmad W, 1998, DEAF PEOPLE MINORITY; Bartlett G, 2008, CAN MED ASSOC J, V178, P5; Comhairle, 2006, REV SIGN LANG INT SE; Council SANA, 2012, NAT STRAT PLAN HIV S; Deaf Federation of South Africa, 2011, POL PROV REG S AFR S; Drennan G., 1999, INTERPRETING, V4, P169, DOI [10.1075/intp.4.2.03dre, DOI 10.1075/intp.4.2.03dre]; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Emond A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006668; Gie J, 2007, PLANNING DISTRICT PR; Gilson L, 2012, HLTH POLICY SYSTEMS; Glaser M, 2006, DISABILITY SOCIAL CH, P192; Hanass-Hancock J, 2009, J INT AIDS SOC, V12, P1; Haricharan HJ, 2012, DISABIL SOC, P37; Harmer L, 1999, J Deaf Stud Deaf Educ, V4, P73, DOI 10.1093/deafed/4.2.73; Heap M, 2006, DISABILITY SOCIAL CH, P134; Jokinen M, 2010, SUBMISSION WORLD FED; Kritzinger J, 2014, PATIENT EDUC COUNS, V94, P379, DOI 10.1016/j.pec.2013.12.006; MacLachlan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035864; McKee MM, 2011, AM J PREV MED, V41, P75, DOI 10.1016/j.amepre.2011.03.004; Newton, 2002, ACCESS PRIMARY CARE; Nilsson A, 2013, MEDISIGNS PRESCRIPTI; Pullen DL., 2015, PREVALENCE HEARING I; Rodda M, 2002, AM ANN DEAF, V147, P45, DOI 10.1353/aad.2012.0243; Scheier Donna B, 2009, J N Y State Nurses Assoc, V40, P4; Steinberg AG, 2006, J GEN INTERN MED, V21, P260, DOI 10.1111/j.1525-1497.2006.00340.x; World Health Organization, 2012, WHO GLOB EST PREV HE	28	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2017	12	12							e0189983	10.1371/journal.pone.0189983	http://dx.doi.org/10.1371/journal.pone.0189983			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FQ8ZJ	29272272	Green Published, gold, Green Submitted			2023-01-03	WOS:000418651500021
J	Sobral-Leite, M; Lips, EH; Vieira-Monteiro, HD; Giacomin, LC; Freitas-Alves, DR; Cornelissen, S; Mulder, L; Wesseling, J; Schmidt, MK; Vianna-Jorge, R				Sobral-Leite, Marcelo; Lips, Esther H.; Vieira-Monteiro, Hayra de Andrade; Giacomin, Leticia Carlos; Freitas-Alves, Daniely Regina; Cornelissen, Sten; Mulder, Lennart; Wesseling, Jelle; Schmidt, Marjanka K.; Vianna-Jorge, Rosane			Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients	PLOS ONE			English	Article							GROWTH-FACTOR-RECEPTOR; FAVORABLE PROGNOSTIC-FACTOR; HISTOLOGICAL GRADE; GENE POLYMORPHISMS; CHEMOTHERAPY; THERAPY; PREDICTORS; RECURRENCE; EXPRESSION; CARCINOMA	Pathological response of breast cancer to neoadjuvant chemotherapy (NAC) presents great variability, and new prognostic biomarkers are needed. Our aim was to evaluate the association of the epidermal growth factor receptor gene (EGFR) polymorphism R497K (rs2227983) with prognostic features and clinical outcomes of breast cancer, including the pathological response to NAC and the recurrence-free survival (RFS). Tumoral complete response (tCR) was defined by no remaining invasive cancer in the excised breast, whereas pathological complete response (pCR) was defined by no remaining invasive cancer both in the excised breast and lymph nodes. Two independent cohorts were analyzed: one from Brazil (INCA, n = 288) and one from The Netherlands (NKI-AVL, n = 255). In the INCA cohort, the variant (Lys-containing) genotypes were significantly associated with lower proportion of tCR (ORadj = 0.92; 95% CI = 0.85 +/- 0.99), whereas in the NKI-AVL cohort they were associated with tumor grade 3 (p = 0.035) and with triple-negative subtype (p = 0.032), but not with clinical outcomes. Such distinct prognostic associations may have arisen due to different neoadjuvant protocols (p < 0.001), or to lower age at diagnosis (p < 0.001) and higher proportion of tumor grade 3 (p = 0.018) at the NKI-AVL cohort. Moreover, NKI-AVL patients achieved better proportion of pCR (21.2% vs 8.3%, p < 0.001) and better RFS (HRadj = 0.48; 95% adjCI = 0.26 +/- 0.86) than patients from INCA. In conclusion, large scale studies comprehending different populations are needed to evaluate the impact of genome variants on breast cancer outcomes.	[Sobral-Leite, Marcelo; Lips, Esther H.; Cornelissen, Sten; Mulder, Lennart; Wesseling, Jelle; Schmidt, Marjanka K.] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [Sobral-Leite, Marcelo; Vieira-Monteiro, Hayra de Andrade; Giacomin, Leticia Carlos; Freitas-Alves, Daniely Regina; Vianna-Jorge, Rosane] Inst Nacl Canc, Coordenacao Pesquisa, Rio De Janeiro, RJ, Brazil; [Vieira-Monteiro, Hayra de Andrade; Freitas-Alves, Daniely Regina; Vianna-Jorge, Rosane] Fiocruz MS, Programa Posgrad Sau Publ & Meio Ambiente, Escola Nacl Saude Publ, Rio De Janeiro, RJ, Brazil; [Wesseling, Jelle] Netherlands Canc Inst, Div Pathol, Amsterdam, Netherlands; [Vianna-Jorge, Rosane] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Programa Farmacol & Inflamacao, Rio De Janeiro, RJ, Brazil	Netherlands Cancer Institute; National Cancer Institute (Inca); Fundacao Oswaldo Cruz; Netherlands Cancer Institute; Universidade Federal do Rio de Janeiro	Vianna-Jorge, R (corresponding author), Inst Nacl Canc, Coordenacao Pesquisa, Rio De Janeiro, RJ, Brazil.; Vianna-Jorge, R (corresponding author), Fiocruz MS, Programa Posgrad Sau Publ & Meio Ambiente, Escola Nacl Saude Publ, Rio De Janeiro, RJ, Brazil.; Vianna-Jorge, R (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Programa Farmacol & Inflamacao, Rio De Janeiro, RJ, Brazil.	rosanevj@gmail.com	Schmidt, Marjanka K/G-9058-2011; Vianna-Jorge, Rosane/AAC-7301-2020; Vianna-Jorge, Rosane/A-1230-2013	Schmidt, Marjanka K/0000-0002-2228-429X; Vianna-Jorge, Rosane/0000-0001-5407-4695; Vianna-Jorge, Rosane/0000-0001-5407-4695; Mulder, Lennart/0000-0001-8844-1481; Sobral-Leite, Marcelo/0000-0002-4275-8050; Freitas-Alves, Daniely/0000-0002-3304-9922; Giacomin, Leticia/0000-0001-6422-6795	KWF Kankerbestrijding; Center for Translational Molecular Medicine [030104]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [474522/2010-5, 573806/2008-0]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro [E-26/110356/2010, E26/170.026/2008]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior [1321-13-7]	KWF Kankerbestrijding(KWF Kankerbestrijding); Center for Translational Molecular Medicine; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by KWF Kankerbestrijding (MKS): https://www.kwf.nl/pages/default.aspx; Center for Translational Molecular Medicine (030104; EL and JW); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (474522/2010-5 and 573806/2008-0): http://cnpq.br/; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (E-26/110356/2010 and E26/170.026/2008): http://www.faperj.br/; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (1321-13-7; MSL): http://www.capes.gov.br/; The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akay CL, 2012, ANN SURG ONCOL, V19, P901, DOI 10.1245/s10434-011-2006-7; Alaoui-Jamali M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00017; Altman DG, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001216; Amir E, 2010, CANCER TREAT REV, V36, P410, DOI 10.1016/j.ctrv.2009.12.012; Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767; Bandres E, 2007, ORAL ONCOL, V43, P713, DOI 10.1016/j.oraloncology.2006.09.002; Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438; Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Davis NM, 2014, ONCOTARGET, V5, P4603, DOI 10.18632/oncotarget.2209; de Souza JA, 2016, J CLIN ONCOL, V34, P6, DOI 10.1200/JCO.2015.62.2860; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fitzal F, 2011, BREAST CANCER RES TR, V127, P121, DOI 10.1007/s10549-010-1164-9; Goncalves A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-169; Hammond ME, 2010, J CLIN ONCOLOGY OFFI, V28; Hsieh YY, 2012, CANCER SCI, V103, P791, DOI 10.1111/j.1349-7006.2012.02225.x; Jaka A, 2014, EXP DERMATOL, V23, P751, DOI 10.1111/exd.12510; Kallel I, 2009, J BIOMED BIOTECHNOL, V2009; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; Lai CY, 2013, ANN SURG ONCOL, V20, pS599, DOI 10.1245/s10434-013-3069-4; Leite MS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-190; Lester SC, 2009, ARCH PATHOL LAB MED, V133, P1515, DOI 10.1043/1543-2165-133.10.1515; Li CI, 2005, BRIT J CANCER, V93, P1046, DOI 10.1038/sj.bjc.6602787; Li Q, 2013, ELECTRON J DIFFER EQ; Li XR, 2011, MED ONCOL, V28, pS129, DOI 10.1007/s12032-010-9742-6; Lips EH, 2013, BREAST CANCER RES TR, V140, P63, DOI 10.1007/s10549-013-2620-0; Lips EH, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0642-8; Lluch A, 2014, EXPERT OPIN EMERG DR, V19, P165, DOI 10.1517/14728214.2014.903919; Lurje G, 2008, CLIN CANCER RES, V14, P7884, DOI 10.1158/1078-0432.CCR-07-5165; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; Masuda H, 2011, CANCER CHEMOTH PHARM, V67, P911, DOI 10.1007/s00280-010-1371-4; MORIAI T, 1994, P NATL ACAD SCI USA, V91, P10217, DOI 10.1073/pnas.91.21.10217; Rigter LS, 2013, BRIT J CANCER, V109, P2965, DOI 10.1038/bjc.2013.661; Rodenhuis S, 2010, ANN ONCOL, V21, P481, DOI 10.1093/annonc/mdp348; Santa-Maria CA, 2015, ONCOLOGY-NY, V29, P828; Sasaki H, 2009, J CANCER RES CLIN, V135, P313, DOI 10.1007/s00432-008-0464-5; Saxena N, 2012, WORLD J SURG, V36, P2838, DOI 10.1007/s00268-012-1746-2; Schmidt M, 2014, BREAST CARE, V9, P154, DOI 10.1159/000363755; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tang YQ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-S1-S4; Vieira-Monteiro HD, 2016, CANCER BIOL THER, V17, P674, DOI 10.1080/15384047.2016.1190486; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Wang WS, 2007, CLIN CANCER RES, V13, P3597, DOI 10.1158/1078-0432.CCR-06-2601; Wang YR, 2014, SHOCK VIB, V2014, DOI 10.1155/2014/397584; Zhang W, 2005, CLIN CANCER RES, V11, P600	47	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2017	12	12							e0189750	10.1371/journal.pone.0189750	http://dx.doi.org/10.1371/journal.pone.0189750			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ8BI	29267323	Green Published, Green Submitted, gold			2023-01-03	WOS:000418587400044
J	Lugoboni, F; Zamboni, L; Federico, A; Tamburin, S				Lugoboni, Fabio; Zamboni, Lorenzo; Federico, Angela; Tamburin, Stefano		GICS	Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study	PLOS ONE			English	Article							SEXUAL DYSFUNCTION; RISK-FACTORS; HEROIN-ADDICTS; THERAPY; ASSOCIATION; PREVALENCE; QUESTIONNAIRE; TESTOSTERONE; METAANALYSIS; INFECTION	Background Erectile dysfunction (ED) is common among men on opioid replacement therapy (ORT), but most previous studies exploring its prevalence and determinants yielded contrasting findings. Moreover, the impact of ED on patients' quality of life (QoL) has been seldom explored. Objective To explore the prevalence and determinants of ED in men on ORT, and the impact on QoL. Methods In a multicentre cross-sectional study, we recruited 797 consecutive male patients on methadone and buprenorphine treatment, collected data on demographic, clinical, and psychopathological factors, and explored their role as predictors of ED and QoL through univariate and multivariate analysis. ED severity was assessed with a self-assessment questionnaire. Results Nearly half of patients in our sample were sexually inactive or reported some degree of ED. Some demographic, clinical and psychopathological variables significantly differed according to the presence or absence of ED. Multivariate regression analysis indicated that age, employment, smoke, psychoactive drugs, opioid maintenance dosage, and severity of psychopathological factors significantly influenced the risk and severity of ED. QoL was worse in patients with ED and significantly correlated with ED severity. Age, education, employment, opioid maintenance dosage, ED score, and severity of psychopathology significantly influenced QoL in the multivariate analysis. Conclusions ED complaints can be explored in male opioid users on ORT through a simple and quick self-assessment tool. ED may have important effects on emotional and social well-being, and may affect outcome.	[Lugoboni, Fabio; Zamboni, Lorenzo; Federico, Angela] Verona Univ Hosp, Dept Med, Addict Med Unit, Verona, Italy; [Federico, Angela; Tamburin, Stefano] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona	Tamburin, S (corresponding author), Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy.	stefano.tamburin@univr.it	Tamburin, Stefano/AAB-9500-2019	Tamburin, Stefano/0000-0002-1561-2187				Aghighi A, 2015, INT J IMPOT RES, V27, P63, DOI 10.1038/ijir.2014.34; Bacon CG, 2006, J UROLOGY, V176, P217, DOI 10.1016/S0022-5347(06)00589-1; Baldwin David S, 2004, Expert Opin Drug Saf, V3, P457, DOI 10.1517/14740338.3.5.457; Bang-Ping J, 2009, J SEX MED, V6, P1072, DOI 10.1111/j.1743-6109.2007.00707.x; Bliesener N, 2005, J CLIN ENDOCR METAB, V90, P203, DOI 10.1210/jc.2004-0929; Brown R, 2005, J ADDICT DIS, V24, P91, DOI 10.1300/J069v24n02_08; Chen W, 2012, J ADDICT MED, V6, P212, DOI 10.1097/ADM.0b013e318259b2c4; Cioe PA, 2013, J SUBST ABUSE TREAT, V45, P451, DOI 10.1016/j.jsat.2013.06.004; Cioe PA, 2010, J ADDICT DIS, V29, P455, DOI 10.1080/10550887.2010.509279; CROWLEY TJ, 1978, INT J ADDICT, V13, P285, DOI 10.3109/10826087809039281; Derogatis LR., 1994, SCL 90 R SYMPTOM CHE; Deyo RA, 2013, SPINE, V38, P909, DOI 10.1097/BRS.0b013e3182830482; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), ANN REP 2016 STAT DR; Frederick LR, 2014, J SEX MED, V11, P2546, DOI 10.1111/jsm.12647; Gerra G, 2016, EUR ADDICT RES, V22, P163, DOI 10.1159/000441470; Hallinan R, 2009, INT J ANDROL, V32, P131, DOI 10.1111/j.1365-2605.2007.00824.x; Hallinan R, 2008, J SEX MED, V5, P684, DOI 10.1111/j.1743-6109.2007.00702.x; Heidari Z, 2012, INT J HIGH RISK BEHA, V1, P12; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Johnson SD, 2004, ARCH SEX BEHAV, V33, P55, DOI 10.1023/B:ASEB.0000007462.97961.5a; Meldrum DR, 2012, INT J IMPOT RES, V24, P61, DOI 10.1038/ijir.2011.51; National Institutes of Health, 1993, IMP NIH CONS STAT; Nguyen HV, 2006, INTERN MED J, V36, P362, DOI 10.1111/j.1445-5994.2006.01093.x; Nielsen S, 2014, 329 1 NEW S WAL; Pajusco B, 2012, INT J ENV RES PUB HE, V9, P932, DOI 10.3390/ijerph9030932; PICCINELLI M, 1993, COMPR PSYCHIAT, V34, P198, DOI 10.1016/0010-440X(93)90048-9; Ponholzer A, 2005, EUR UROL, V47, P80, DOI 10.1016/j.eururo.2004.08.017; Prunas A, 2012, EUR PSYCHIAT, V27, P591, DOI 10.1016/j.eurpsy.2010.12.006; Quaglio G, 2008, DRUG ALCOHOL DEPEN, V94, P12, DOI 10.1016/j.drugalcdep.2007.09.025; Rao J, 2009, J CLIN GASTROENTEROL, V43, P94, DOI 10.1097/MCG.0b013e3180cabc14; Resnick MJ, 2015, EUR UROL, V67, P1019, DOI 10.1016/j.eururo.2014.08.035; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Selvin E, 2007, AM J MED, V120, P151, DOI 10.1016/j.amjmed.2006.06.010; Smith HS, 2012, PAIN PHYSICIAN, V15, pES145; Teoh JBF, 2017, J ADDICT MED, V11, P40, DOI 10.1097/ADM.0000000000000267; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009; Xia YH, 2013, PSYCHOL HEALTH MED, V18, P321, DOI 10.1080/13548506.2012.729845; Yee A, 2014, INT J IMPOT RES, V26, P161, DOI 10.1038/ijir.2014.18; Yee A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147852; Yee A, 2014, J SEX MED, V11, P22, DOI 10.1111/jsm.12352; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088289	41	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188994	10.1371/journal.pone.0188994	http://dx.doi.org/10.1371/journal.pone.0188994			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FO4UI	29190831	Green Submitted, Green Published, gold			2023-01-03	WOS:000416841900185
J	Kalantar-Zadeh, K; Fouque, D				Kalantar-Zadeh, Kamyar; Fouque, Denis			Nutritional Management of Chronic Kidney Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIETARY-PROTEIN RESTRICTION; GLOMERULAR-FILTRATION-RATE; POTASSIUM EXCRETION; ATHEROSCLEROSIS RISK; SODIUM RESTRICTION; URINARY SODIUM; RENAL-DISEASE; P-CRESOL; PROGRESSION; ASSOCIATION		[Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens, Harold Simmons Ctr Kidney Dis Res & Epidemiol, Orange, CA 92868 USA; [Kalantar-Zadeh, Kamyar] Long Beach Vet Affairs Healthcare Syst, Long Beach, CA USA; [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90024 USA; [Kalantar-Zadeh, Kamyar] Harbor UCLA, Los Angeles Biomed Res Inst, Torrance, CA USA; [Fouque, Denis] Univ Claude Bernard Lyon, Dept Nephrol, Ctr Hosp Lyon Sud, Cardiometab & Nutr CarMeN, Lyon, France	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Kalantar-Zadeh, K (corresponding author), Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens, Orange, CA 92868 USA.	kkz@uci.edu	Carmen, Team1/Y-7382-2019; Kalantar-Zadeh, Kamyar/Q-4734-2018; Hoorn, Ewout/S-4135-2019	Carmen, Team1/0000-0003-4234-1746; Kalantar-Zadeh, Kamyar/0000-0002-8666-0725; Hoorn, Ewout/0000-0002-8738-3571; Lab, Carmen/0000-0002-5935-3236				[Anonymous], 2005, PROT AND AM AC; [Anonymous], 2004, WAT POT SOD CHLOR SU; Araki S, 2015, CLIN J AM SOC NEPHRO, V10, P2152, DOI 10.2215/CJN.00980115; Armstrong JE, 2010, PEDIATR NEPHROL, V25, P1497, DOI 10.1007/s00467-010-1529-7; Bello AK, 2017, JAMA-J AM MED ASSOC, V317, P1864, DOI 10.1001/jama.2017.4046; Berg AH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005218; BRENNER BM, 1981, ACTA ENDOCRINOL-COP, V97, P7; Brunori G, 2007, AM J KIDNEY DIS, V49, P569, DOI 10.1053/j.ajkd.2007.02.278; Bushinsky DA, 2012, NEPHROL DIAL TRANSPL, V27, P10, DOI 10.1093/ndt/gfr406; Chen XR, 2016, AM J KIDNEY DIS, V67, P423, DOI 10.1053/j.ajkd.2015.10.018; Chen Y, 2017, AM J KIDNEY DIS, V70, P244, DOI 10.1053/j.ajkd.2017.01.044; Chiavaroli L, 2015, EUR J CLIN NUTR, V69, P761, DOI 10.1038/ejcn.2014.237; Cirillo M, 2014, NEPHROL DIAL TRANSPL, V29, P1733, DOI 10.1093/ndt/gfu056; Clase CM, 2013, SEMIN DIALYSIS, V26, P546, DOI 10.1111/sdi.12099; DAMICO G, 1992, LANCET, V339, P1131, DOI 10.1016/0140-6736(92)90731-H; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; de Brito-Ashurst I, 2009, J AM SOC NEPHROL, V20, P2075, DOI 10.1681/ASN.2008111205; de Zeeuw D, 2010, LANCET, V376, P1543, DOI 10.1016/S0140-6736(10)61032-X; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Garneata L, 2016, J AM SOC NEPHROL, V27, P2164, DOI 10.1681/ASN.2015040369; Goraya N, 2012, KIDNEY INT, V81, P86, DOI 10.1038/ki.2011.313; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Han E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154683; Haring B, 2017, J RENAL NUTR, V27, P233, DOI 10.1053/j.jrn.2016.11.004; He FJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004937.pub2; He J, 2016, J AM SOC NEPHROL, V27, P1202, DOI [10.1681/ASN.2015010022, 10.1049/joe.2015.0102]; Hill KM, 2013, KIDNEY INT, V83, P959, DOI 10.1038/ki.2012.403; Hood VL, 1998, NEW ENGL J MED, V339, P819, DOI 10.1056/NEJM199809173391207; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; Ishigami J, 2016, CLIN J AM SOC NEPHRO, V11, P1735, DOI 10.2215/CJN.02170216; Kalantar-Zadeh K, 2010, CLIN J AM SOC NEPHRO, V5, P519, DOI 10.2215/CJN.06080809; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; KAYSEN GA, 1986, KIDNEY INT, V29, P572, DOI 10.1038/ki.1986.36; Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006; Khoueiry G, 2011, J RENAL NUTR, V21, P438, DOI 10.1053/j.jrn.2010.09.001; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Ko GJ, 2017, CURR OPIN CLIN NUTR, V20, P77, DOI [10.1097/MCO.0000000000000342, 10.1097/mco.0000000000000342]; Koppe L, 2015, KIDNEY INT, V88, P958, DOI 10.1038/ki.2015.255; Kovesdy CP, 2013, AM J CLIN NUTR, V97, P1163, DOI 10.3945/ajcn.112.036418; Kovesdy CP, 2012, CIRCULATION, V125, P677, DOI 10.1161/CIRCULATIONAHA.111.065391; KRAPF R, 1992, J CLIN INVEST, V90, P2456, DOI 10.1172/JCI116137; Kwakernaak AJ, 2014, LANCET DIABETES ENDO, V2, P385, DOI 10.1016/S2213-8587(14)70030-0; Levey AS, 2011, KIDNEY INT, V80, P17, DOI 10.1038/ki.2010.483; Levey AS, 1999, J AM SOC NEPHROL, V10, P2426; Lynch KE, 2011, CLIN J AM SOC NEPHRO, V6, P620, DOI 10.2215/CJN.04620510; Maroni BJ, 1997, J CLIN INVEST, V99, P2479, DOI 10.1172/JCI119432; McCabe KM, 2013, KIDNEY INT, V83, P835, DOI 10.1038/ki.2012.477; McMahon EJ, 2013, J AM SOC NEPHROL, V24, P2096, DOI 10.1681/ASN.2013030285; Mente A, 2014, NEW ENGL J MED, V371, P601, DOI 10.1056/NEJMoa1311989; Mills KT, 2016, JAMA-J AM MED ASSOC, V315, P2200, DOI 10.1001/jama.2016.4447; Moorthi RN, 2014, AM J NEPHROL, V40, P582, DOI 10.1159/000371498; Noori N, 2010, AM J KIDNEY DIS, V56, P338, DOI 10.1053/j.ajkd.2010.03.022; O'Donnell M, 2015, CIRC RES, V116, P1046, DOI 10.1161/CIRCRESAHA.116.303771; Paes-Barreto JG, 2013, J RENAL NUTR, V23, P164, DOI 10.1053/j.jrn.2012.10.004; Palmer BF, 2016, MAYO CLIN PROC, V91, P496, DOI 10.1016/j.mayocp.2016.01.012; Patel KP, 2012, CLIN J AM SOC NEPHRO, V7, P982, DOI 10.2215/CJN.12491211; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; Rossi M, 2015, NUTR METAB CARDIOVAS, V25, P860, DOI 10.1016/j.numecd.2015.03.015; RUILOPE LM, 1992, J AM SOC NEPHROL, V3, P1307; Sallstrom J, 2010, AM J PHYSIOL-REG I, V299, pR1263, DOI 10.1152/ajpregu.00649.2009; Salmean YA, 2015, J RENAL NUTR, V25, P316, DOI 10.1053/j.jrn.2014.09.002; Schulman G, 2015, J AM SOC NEPHROL, V26, P1732, DOI 10.1681/ASN.2014010042; Sim JJ, 2013, AM J MED, V126, P311, DOI 10.1016/j.amjmed.2012.08.018; Smyth A, 2014, KIDNEY INT, V86, P1205, DOI 10.1038/ki.2014.214; So R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166495; Sontrop JM, 2013, AM J NEPHROL, V37, P434, DOI 10.1159/000350377; Spiegel DM, 2012, KIDNEY INT, V81, P1116, DOI 10.1038/ki.2011.490; St-Jules DE, 2016, J RENAL NUTR, V26, P282, DOI 10.1053/j.jrn.2016.02.005; Stolarz-Skrzypek K, 2011, JAMA-J AM MED ASSOC, V305, P1777, DOI 10.1001/jama.2011.574; Sullivan C, 2009, JAMA-J AM MED ASSOC, V301, P629, DOI 10.1001/jama.2009.96; Sumida K, 2017, J AM SOC NEPHROL, V28, P1248, DOI 10.1681/ASN.2016060656; Swaminathan S., 2013, NUTR MANAGEMENT RENA, P339; Tonelli M, 2010, NEW ENGL J MED, V362, P1312, DOI 10.1056/NEJMra0912522; Tovar-Palacio C, 2011, AM J PHYSIOL-RENAL, V300, pF263, DOI 10.1152/ajprenal.00171.2010; Vaziri ND, 2013, AM J NEPHROL, V37, P1, DOI 10.1159/000345969; Walser M, 1999, J AM SOC NEPHROL, V10, P110; Weiner ID, 2015, CLIN J AM SOC NEPHRO, V10, P1444, DOI 10.2215/CJN.10311013; Wrone EM, 2003, AM J KIDNEY DIS, V41, P580, DOI 10.1053/ajkd.2003.50119; Wu HL, 2013, J RENAL NUTR, V23, P271, DOI 10.1053/j.jrn.2012.09.003; Xu X, 2016, JAMA INTERN MED, V176, P1443, DOI 10.1001/jamainternmed.2016.4687; YOUNG VR, 1994, AM J CLIN NUTR, V59, p1203S, DOI 10.1093/ajcn/59.5.1203S	82	279	298	8	63	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 2	2017	377	18					1765	1776		10.1056/NEJMra1700312	http://dx.doi.org/10.1056/NEJMra1700312			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FL4ZB	29091561	Green Published			2023-01-03	WOS:000414239100009
J	Hung, YY; Chan, HY; Pan, YJ				Hung, Yu-Yuan; Chan, Hung-Yu; Pan, Yi-Ju			Risk factors for readmission in schizophrenia patients following involuntary admission	PLOS ONE			English	Article							INFLUENCING COMPULSORY ADMISSION; PSYCHIATRIC-PATIENTS; HOSPITAL ADMISSION; MENTALLY-ILL; EUROPEAN-UNION; PATIENTS VIEWS; 1ST ADMISSION; LEGAL STATUS; ETHNICITY; OUTCOMES	Background Individuals with schizophrenia who are involuntarily admitted may have poorer prognosis, including higher readmission rates, than those voluntarily admitted. However, little is known about the risk factors for readmission in those schizophrenia patients who are involuntarily admitted. Aims We aim to explore the risk factors for readmission in this population. Method We enrolled 138 schizophrenia patients with involuntary admission from July 2008 to June 2013 and followed those patients for readmission outcomes at 3 months and at 1 year. Results The one-year and 3-months readmission rates were 33.3% and 15.2%, respectively. Unmarried status (adjusted odds ratio (aOR) = 6.28, 95% CI: 1.48-26.62), previous history of involuntary admission (aOR = 4.08, 95% CI: 1.19-14.02), longer involuntary admission days (aOR = 1.04, 95% CI: 1.01-1.07) and shorter total admission days (aOR = 1.03, 95% CI: 1.01-1.05) were associated with increased risk for 1-year readmission. Younger age (aOR = 1.10, 95% CI 1.02-1.18) was associated with increased risk for 3-months readmission. Conclusions Unmarried status, prior history of involuntary admission, longer involuntary admission days and shorter total admission days were associated with increased risk for 1-year readmission. Healthcare providers may need to focus on patients with these risk factors to reduce subsequent readmissions.	[Hung, Yu-Yuan; Chan, Hung-Yu] Minist Hlth & Welf, Taoyuan Psychiat Ctr, Taoyuan, Taiwan; [Chan, Hung-Yu] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan; [Chan, Hung-Yu] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Pan, Yi-Ju] Far Eastern Mem Hosp, Dept Psychiat, New Taipei, Taiwan; [Pan, Yi-Ju] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; Far Eastern Memorial Hospital; National Yang Ming Chiao Tung University	Pan, YJ (corresponding author), Far Eastern Mem Hosp, Dept Psychiat, New Taipei, Taiwan.; Pan, YJ (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.	panyiju0211@gmail.com			Taoyuan Psychiatric Center, Ministry of Health and Welfare of Taiwan [TYPC-2015-01]	Taoyuan Psychiatric Center, Ministry of Health and Welfare of Taiwan	This study was supported by a grant from the Taoyuan Psychiatric Center, Ministry of Health and Welfare of Taiwan (TYPC-2015-01) to Dr. YY Hung, (http://www.typc.mohw.gov.tw/englsh/). The funding body had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anand VS, 2002, J FORENSIC SCI, V47, P1365; APPLEBY L, 1993, AM J PSYCHIAT, V150, P72; BEBBINGTON PE, 1994, BRIT J PSYCHIAT, V165, P743, DOI 10.1192/bjp.165.6.743; Bola JR, 2011, COMMUNITY MENT HLT J, V47, P603, DOI 10.1007/s10597-011-9396-7; Chang HC, 2009, J CLIN PSYCHIAT, V70, P141, DOI 10.4088/JCP.08l04447; Cougnard A, 2004, SOC PSYCH PSYCH EPID, V39, P804, DOI 10.1007/s00127-004-0826-5; CUFFEL BJ, 1992, COMMUNITY MENT HLT J, V28, P471, DOI 10.1007/BF00754192; Donoghue BO, 2011, J MENT HEALTH, V20, P249, DOI 10.3109/09638237.2011.562263; Dressing H, 2004, SOC PSYCH PSYCH EPID, V39, P797, DOI 10.1007/s00127-004-0814-9; Feigon S, 2003, PSYCHOL REP, V93, P816, DOI 10.2466/PR0.93.7.816-818; Fennig S, 1999, PSYCHIAT SERV, V50, P1049, DOI 10.1176/ps.50.8.1049; Haddad PM, 2009, BRIT J PSYCHIAT, V195, pS20, DOI 10.1192/bjp.195.52.s20; HAFNER H, 1989, BRIT J PSYCHIAT, V155, P12, DOI 10.1192/bjp.155.1.12; Hansson L, 1999, SOC PSYCH PSYCH EPID, V34, P99, DOI 10.1007/s001270050118; Houston KG, 2001, PSYCHOL REP, V88, P1012, DOI 10.2466/PR0.88.3.1012-1014; Kallert TW, 2008, EUR ARCH PSY CLIN N, V258, P195, DOI 10.1007/s00406-007-0777-4; Katsakou C, 2006, ACTA PSYCHIAT SCAND, V114, P232, DOI 10.1111/j.1600-0447.2006.00823.x; Krivoy A, 2012, COMPR PSYCHIAT, V53, P995, DOI 10.1016/j.comppsych.2012.03.006; Lin CH, 2010, CLINICS, V65, P481, DOI 10.1590/S1807-59322010000500005; Lin HC, 2006, SCHIZOPHR RES, V83, P211, DOI 10.1016/j.schres.2006.01.012; MCEVOY JP, 1989, COMPR PSYCHIAT, V30, P13, DOI 10.1016/0010-440X(89)90113-2; Myklebust LH, 2012, NORD J PSYCHIAT, V66, P178, DOI 10.3109/08039488.2011.611252; Preti A, 2009, PSYCHOL MED, V39, P485, DOI 10.1017/S0033291708003607; Priebe S, 2010, BRIT J PSYCHIAT, V196, P179, DOI 10.1192/bjp.bp.109.068916; Priebe S, 2009, BRIT J PSYCHIAT, V194, P49, DOI 10.1192/bjp.bp.108.052266; RIECHER A, 1991, PSYCHOL MED, V21, P197, DOI 10.1017/S0033291700014781; Salize HJ, 2004, BRIT J PSYCHIAT, V184, P163, DOI 10.1192/bjp.184.2.163; Silva NC, 2009, PSYCHIAT SERV, V60, P786, DOI 10.1176/ps.2009.60.6.786; Singh SP, 1998, SOC PSYCH PSYCH EPID, V33, P39; Thieda P, 2003, PSYCHIAT SERV, V54, P508, DOI 10.1176/appi.ps.54.4.508; Valevski A, 2007, SOC PSYCH PSYCH EPID, V42, P916, DOI 10.1007/s00127-007-0243-7; van der Post L, 2012, INT J SOC PSYCHIATR, V58, P374, DOI 10.1177/0020764011399970; van der Post LFM, 2014, SOC PSYCH PSYCH EPID, V49, P283, DOI 10.1007/s00127-013-0742-7; Wang JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129204; Woo BKP, 2006, J GERIATR PSYCH NEUR, V19, P226, DOI 10.1177/0891988706292754; Zinkler M, 2002, ACTA PSYCHIAT SCAND, V106, P3, DOI 10.1034/j.1600-0447.2002.02268.x	36	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0186768	10.1371/journal.pone.0186768	http://dx.doi.org/10.1371/journal.pone.0186768			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FK9QH	29073180	gold, Green Submitted, Green Published			2023-01-03	WOS:000413845400051
J	Marston, HD; Paules, CI; Fauci, AS				Marston, Hilary D.; Paules, Catharine I.; Fauci, Anthony S.			Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Marston, Hilary D.; Paules, Catharine I.; Fauci, Anthony S.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Marston, HD (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.			Paules, Catharine/0000-0002-9064-6678				Davey RT, 2016, NEW ENGL J MED, V375, P1448, DOI 10.1056/NEJMoa1604330; Mire CE, 2017, TRENDS MOL MED, V23, P669, DOI 10.1016/j.molmed.2017.06.008; Paules CI, 2017, J INFECT DIS, V216, P356, DOI 10.1093/infdis/jix292; Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564; Walker L.M., 2018, NAT REV IMMUNOL	5	76	80	3	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2018	378	16					1469	1472		10.1056/NEJMp1802256	http://dx.doi.org/10.1056/NEJMp1802256			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD2EI	29513615				2023-01-03	WOS:000430312500001
J	Mazer-Amirshahi, M; Fox, ER				Mazer-Amirshahi, Maryann; Fox, Erin R.			Saline Shortages - Many Causes, No Simple Solution	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Mazer-Amirshahi, Maryann] MedStar Washington Hosp Ctr, Dept Emergency Med, Washington, DC 20010 USA; [Mazer-Amirshahi, Maryann] Georgetown Univ, Sch Med, Washington, DC 20057 USA; [Fox, Erin R.] Univ Utah Hlth, Dept Pharm, Salt Lake City, UT USA	MedStar Washington Hospital Center; Georgetown University; Utah System of Higher Education; University of Utah	Mazer-Amirshahi, M (corresponding author), MedStar Washington Hosp Ctr, Dept Emergency Med, Washington, DC 20010 USA.; Mazer-Amirshahi, M (corresponding author), Georgetown Univ, Sch Med, Washington, DC 20057 USA.							American Society of Health-System Pharmacists, 2017, SMALL VOL PAR SOL SH; Hick JL, 2014, NEW ENGL J MED, V370, P1573, DOI 10.1056/NEJMp1401833; Langreth R, 2017, BLOOMBERG BUSINESSWE; Scott Gottlieb M. D., 2018, NEWS RELEASE FOOD DR; Woodcock J, 2013, CLIN PHARMACOL THER, V93, P170, DOI 10.1038/clpt.2012.220	5	41	41	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 19	2018	378	16					1472	1475		10.1056/NEJMp1800347	http://dx.doi.org/10.1056/NEJMp1800347			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD2EI	29561694	Bronze			2023-01-03	WOS:000430312500002
J	Abbasi, J				Abbasi, Jennifer			Robert Kerns, PhD: Researching Nondrug Approaches to Pain Management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item															National Center for Complementary & Integrative Health [U24AT009769] Funding Source: NIH RePORTER	National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2018	319	15					1535	1537		10.1001/jama.2018.0247	http://dx.doi.org/10.1001/jama.2018.0247			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD0UT	29590287				2023-01-03	WOS:000430217100002
J	Adachi, K; Kano, Y; Nagai, T; Okuyama, N; Sakoda, Y; Tamada, K				Adachi, Keishi; Kano, Yosuke; Nagai, Tomohiko; Okuyama, Namiko; Sakoda, Yukimi; Tamada, Koji			IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor	NATURE BIOTECHNOLOGY			English	Article							CHIMERIC ANTIGEN RECEPTOR; FIBROBLASTIC RETICULAR CELLS; OF-FUNCTION MUTATIONS; ADOPTIVE IMMUNOTHERAPY; THERAPY; GENE; INTERLEUKIN-7; HOMEOSTASIS; LYMPHOCYTE; INHIBITION	Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance. We engineered CAR-T cells to express interleukin (IL)-7 and CCL19 (7 x 19 CAR-T cells), as these factors are essential for the maintenance of T-cell zones in lymphoid organs. In mice, 7 x 19 CAR-T cells achieved complete regression of pre-established solid tumors and prolonged mouse survival, with superior anti-tumor activity compared to conventional CAR-T cells. Histopathological analyses showed increased infiltration of dendritic cells (DC) and T cells into tumor tissues following 7 x 19 CAR-T cell therapy. Depletion of recipient T cells before 7 x 19 CAR-T cell administration dampened the therapeutic effects of 7 x 19 CAR-T cell treatment, suggesting that CAR-T cells and recipient immune cells collaborated to exert anti-tumor activity. Following treatment of mice with 7 x 19 CAR-T cells, both recipient conventional T cells and administered CAR-T cells generated memory responses against tumors.	[Adachi, Keishi; Kano, Yosuke; Nagai, Tomohiko; Okuyama, Namiko; Sakoda, Yukimi; Tamada, Koji] Yamaguchi Univ, Grad Sch Med, Dept Immunol, Ube, Yamaguchi, Japan	Yamaguchi University	Tamada, K (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Immunol, Ube, Yamaguchi, Japan.	ktamada@yamaguchi-u.ac.jp	adachi, keishi/AAT-7471-2020		Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) [14532963]; Practical Research for Innovative Cancer Control; Project for Cancer Research and Therapeutic Evolution (P-CREATE) [16770206]; Japan Agency for Medical Research and Development (AMED); Noile-Immune Biotech Inc.; Grants-in-Aid for Scientific Research [16H02474] Funding Source: KAKEN	Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT); Practical Research for Innovative Cancer Control; Project for Cancer Research and Therapeutic Evolution (P-CREATE); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Noile-Immune Biotech Inc.; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study is supported by research funds from Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) 14532963 (to K.T.), Practical Research for Innovative Cancer Control, and Project for Cancer Research and Therapeutic Evolution (P-CREATE) 16770206 (to K.T.), by Japan Agency for Medical Research and Development (AMED), and Noile-Immune Biotech Inc.	Adachi K, 2015, CANCER SCI, V106, P945, DOI 10.1111/cas.12695; Bracci L, 2007, CLIN CANCER RES, V13, P644, DOI 10.1158/1078-0432.CCR-06-1209; Bradley LM, 2005, TRENDS IMMUNOL, V26, P172, DOI 10.1016/j.it.2005.01.004; Brown FD, 2015, J IMMUNOL, V194, P1389, DOI 10.4049/jimmunol.1402520; Deng W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019986; Duong CPM, 2015, MOL IMMUNOL, V67, P46, DOI 10.1016/j.molimm.2014.12.009; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Geng DG, 2010, CANCER RES, V70, P7442, DOI 10.1158/0008-5472.CAN-10-0247; Greco R, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00095; Heninger AK, 2012, J IMMUNOL, V189, P5649, DOI 10.4049/jimmunol.1201286; Hou LF, 2015, CELL MOL IMMUNOL, V12, P213, DOI 10.1038/cmi.2014.49; Jiang Q, 2005, CYTOKINE GROWTH F R, V16, P513, DOI 10.1016/j.cytogfr.2005.05.004; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kakarla S, 2014, CANCER J, V20, P151, DOI 10.1097/PPO.0000000000000032; Kang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029800; Kellermann SA, 1999, J IMMUNOL, V162, P3859; Lal S, 2000, IMMUNOL TODAY, V21, P48, DOI 10.1016/S0167-5699(99)01550-9; Link A, 2007, NAT IMMUNOL, V8, P1255, DOI 10.1038/ni1513; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; Luther SA, 2002, J IMMUNOL, V169, P424, DOI 10.4049/jimmunol.169.1.424; Maude SL, 2015, BLOOD, V125, P4017, DOI 10.1182/blood-2014-12-580068; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Pellegrini M, 2011, CELL, V144, P601, DOI 10.1016/j.cell.2011.01.011; Pellegrini M, 2009, NAT MED, V15, P528, DOI 10.1038/nm.1953; Penaranda C, 2012, P NATL ACAD SCI USA, V109, P12668, DOI 10.1073/pnas.1203692109; Proietti E, 1998, J CLIN INVEST, V101, P429, DOI 10.1172/JCI1348; Ramos CA, 2014, CANCER J, V20, P112, DOI 10.1097/PPO.0000000000000031; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Shi M, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0268-9; Shochat C, 2014, BLOOD, V124, P106, DOI 10.1182/blood-2013-10-529685; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Srivastava S, 2015, TRENDS IMMUNOL, V36, P494, DOI 10.1016/j.it.2015.06.004; Tamada K, 2012, CLIN CANCER RES, V18, P6436, DOI 10.1158/1078-0432.CCR-12-1449; Till BG, 2012, BLOOD, V119, P3940, DOI 10.1182/blood-2011-10-387969; Yang Jiahui, 2012, Methods Mol Biol, V901, P209, DOI 10.1007/978-1-61779-931-0_14; Yoshida R, 1998, INT IMMUNOL, V10, P901, DOI 10.1093/intimm/10.7.901; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924; Zervos E, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0314-2; Zhang LR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158529; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004; Zheng ZL, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-29; Zhong XS, 2010, MOL THER, V18, P413, DOI 10.1038/mt.2009.210	44	319	365	43	221	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2018	36	4					346	+		10.1038/nbt.4086	http://dx.doi.org/10.1038/nbt.4086			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	GB8RG	29505028				2023-01-03	WOS:000429342400019
J	Pieniazek, A; Gwozdzinski, L; Zbrog, Z; Gwozdzinski, K				Pieniazek, Anna; Gwozdzinski, Lukasz; Zbrog, Zbigniew; Gwozdzinski, Krzysztof			Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients	PLOS ONE			English	Article							HUMAN-SERUM-ALBUMIN; CHRONIC-RENAL-FAILURE; ACID-BINDING SITES; OXIDATIVE STRESS; FATTY-ACID; NITRIC-OXIDE; MITOCHONDRIAL DYSFUNCTION; ANTIOXIDANT PROPERTIES; SULFENIC ACID; SPIN-LABEL	Objective In chronic hemodialyzed (CH) patients the balance between production of reactive oxygen species and antioxidant defense system is disturbed and shifted towards oxidative conditions. The properties of albumin in CH patients were studied before hemodialysis (HD) and post-HD. Methods Two oxidants were applied, organic t-butyl hydroperoxide (t-BOOH) and inorganic hydroperoxide (H2O2), for oxidation of albumin molecules. By comparison, albumin from healthy donors was also modified by both oxidants. The thiol content in albumin was determined by the Ellman method. Albumin properties were evaluated with the spin labelling technique using two covalently bound spin labels, maleimide (MSL) and iodoacetamide (ISL), and fatty acid spin probe, 16-doxylstearic acid (16-DS). Results A decrease in thiols level in HD albumin was greater than in control albumin. The t-BOOH modified the microenvironment at the binding site of MSL and ISL in control albumin molecules to a greater extent than hydrogen peroxide. Control albumin treated with t-BOOH and H2O2 showed an increase in the mobility of 16-DS. However, no changes were observed in albumin from CH patients treated with either of the oxidizing agents. Conclusion Both oxidants induced strong conformational changes in albumin from healthy volunteers, but were less effective or ineffective in modification of albumin derived from CH patients. These results show that albumin from CH patients is highly modified in vivo and is not vulnerable to oxidation in the same way as normal albumin.	[Pieniazek, Anna; Gwozdzinski, Krzysztof] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Biophys, Lodz, Poland; [Gwozdzinski, Lukasz] Med Univ Lodz, Dept Pharmacol & Toxicol, Lodz, Poland; [Zbrog, Zbigniew] Nicolas Copern Dist Hosp, Nephrol & Transplantat Ctr, Lodz, Poland	University of Lodz; Medical University Lodz	Gwozdzinski, K (corresponding author), Univ Lodz, Fac Biol & Environm Protect, Dept Mol Biophys, Lodz, Poland.	krzysztof.gwozdzinski@biol.uni.lodz.pl		Pieniazek, Anna/0000-0001-5061-1596; Gwozdzinski, Lukasz/0000-0003-3702-1238; Gwozdzinski, Krzysztof/0000-0003-2590-7496				Bar-Or D, 2001, BIOCHEM BIOPH RES CO, V284, P856, DOI 10.1006/bbrc.2001.5042; BERLINER LJ, 1983, ANN NY ACAD SCI, V414, P153, DOI 10.1111/j.1749-6632.1983.tb31681.x; Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158; Bourdon E, 2001, ANTIOXID REDOX SIGN, V3, P293, DOI 10.1089/152308601300185241; Carballal S, 2007, AMINO ACIDS, V32, P543, DOI 10.1007/s00726-006-0430-y; Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m; CHEVION M, 1993, P NATL ACAD SCI USA, V90, P1102, DOI 10.1073/pnas.90.3.1102; Chintagari NR, 2016, AM J RESP CELL MOL, V55, P288, DOI 10.1165/rcmb.2015-0197OC; Clermont G, 2000, CARDIOVASC RES, V47, P618, DOI 10.1016/S0008-6363(00)00117-6; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERA S, 1988, INT J PEPT PROT RES, V31, P435; Fujiwara SI, 2008, BIOPHYS J, V94, P95, DOI 10.1529/biophysj.107.111377; FUNG LWM, 1981, BIOPHYS J, V33, P253, DOI 10.1016/S0006-3495(81)84886-2; Gatto MT, 2002, BIOMED CHROMATOGR, V16, P404, DOI 10.1002/bmc.174; Gwozdzinski K, 1995, BIOCHEM SOC T, V23, pS635, DOI 10.1042/bst023635s; Gwozdzinski K, 1997, ACTA BIOCHIM POL, V44, P99; Himmelfarb J, 2001, KIDNEY INT, V60, P358, DOI 10.1046/j.1523-1755.2001.00807.x; Ikeda Y, 2011, J BIOCHEM, V149, P443, DOI 10.1093/jb/mvq156; Jaisson S, 2011, CLIN CHEM, V57, P1499, DOI 10.1373/clinchem.2011.163188; Jakubowski H, 2013, HOMOCYSTEINE PROTEIN, P121; Jourd'heuil D, 2000, FREE RADICAL BIO MED, V28, P409, DOI 10.1016/S0891-5849(99)00257-9; Kassa T, 2015, J BIOL CHEM, V290, P27939, DOI 10.1074/jbc.M115.651257; Kawakami A, 2006, FEBS J, V273, P3346, DOI 10.1111/j.1742-4658.2006.05341.x; Kazmierczak SC, 2006, CLIN CHEM, V52, P2129, DOI 10.1373/clinchem.2006.073148; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; Liakopoulos V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3081856; Libetta C, 2011, CLIN BIOCHEM, V44, P1189, DOI 10.1016/j.clinbiochem.2011.06.988; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madore F, 1997, AM J KIDNEY DIS, V30, P665, DOI 10.1016/S0272-6386(97)90491-1; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Mera K, 2005, BIOCHEM BIOPH RES CO, V334, P1322, DOI 10.1016/j.bbrc.2005.07.035; Mitrogianni Z, 2004, AM J KIDNEY DIS, V44, P286, DOI 10.1053/j.ajkd.2004.04.034; MORRISETT JD, 1975, J BIOL CHEM, V250, P2487; Oettl K, 2007, BRIT J PHARMACOL, V151, P580, DOI 10.1038/sj.bjp.0707251; Ogasawara Y, 2006, BIOCHEM BIOPH RES CO, V340, P353, DOI 10.1016/j.bbrc.2005.11.183; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pavicevic AA, 2014, J PHYS CHEM B, V118, P10898, DOI 10.1021/jp5068928; Pawlak K, 2013, LIFE SCI, V92, P253, DOI 10.1016/j.lfs.2012.12.002; Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208; Pieniazek A, 2009, FREE RADICAL RES, V43, P1008, DOI 10.1080/10715760903165003; Polaschegg HD, 2009, SEMIN DIALYSIS, V22, P524, DOI 10.1111/j.1525-139X.2009.00616.x; Quinlan GJ, 2005, HEPATOLOGY, V41, P1211, DOI 10.1002/hep.20720; Reeder BJ, 2010, ANTIOXID REDOX SIGN, V13, P1087, DOI 10.1089/ars.2009.2974; Roche M, 2008, FEBS LETT, V582, P1783, DOI 10.1016/j.febslet.2008.04.057; Roehrs M, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-59; Ruskovska T, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/843157; Sakota D, 2008, ARTIF ORGANS, V32, P785, DOI 10.1111/j.1525-1594.2008.00631.x; Simard JR, 2005, P NATL ACAD SCI USA, V102, P17958, DOI 10.1073/pnas.0506440102; Stefanska A, 2005, JIFCC, V16, P1; Taverna M, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-4; Turell L, 2013, FREE RADICAL BIO MED, V65, P244, DOI 10.1016/j.freeradbiomed.2013.05.050; van der Vusse GJ, 2009, DRUG METAB PHARMACOK, V24, P300, DOI 10.2133/dmpk.24.300; Varan HI, 2010, INT J NEPHROL RENOV, V3, P39; WEISS SJ, 1989, NEW ENGL J MED, V320, P365	55	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2018	13	3							e0192268	10.1371/journal.pone.0192268	http://dx.doi.org/10.1371/journal.pone.0192268			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ7QU	29554100	Green Published, gold, Green Submitted			2023-01-03	WOS:000427796800004
J	Romanelli, A; Affinito, A; Avitabile, C; Catuogno, S; Ceriotti, P; Laboni, M; Modica, J; Condorelli, G; Catalucci, D				Romanelli, Alessandra; Affinito, Alessandra; Avitabile, Concetta; Catuogno, Silvia; Ceriotti, Paola; Laboni, Margherita; Modica, Jessica; Condorelli, Geroloma; Catalucci, Daniele			An anti-PDGFR ss aptamer for selective delivery of small therapeutic peptide to cardiac cells	PLOS ONE			English	Article							CALCIUM-CHANNEL; GROWTH-FACTOR; CA2+ CHANNEL; LIGANDS; PROTEIN; HEART	Small therapeutic peptides represent a promising field for the treatment of pathologies such as cardiac diseases. However, the lack of proper target-selective carriers hampers their translation towards a potential clinical application. Aptamers are cell-specific carriers that bind with high affinity to their specific target. However, some limitations on their conjugation to small peptides and the functionality of the resulting aptamer-peptide chimera exist. Here, we generated a novel aptamer-peptide chimera through conjugation of the PDGFR ss-targeting Gint4. T aptamer to MP, a small mimetic peptide that via targeting of the Ca-v ss 2 subunit of the L-type calcium channel (LTCC) can recover myocardial function in pathological heart conditions associated with defective LTCC function. The conjugation reaction was performed by click chemistry in the presence of N,N,N', N',N"-pentamethyldiethylenetriamine as a Cu (I) stabilizing agent in a DMSO-free aqueous buffer. When administered to cardiac cells, the Gint4. T-MP aptamer-peptide chimera was successfully internalized in cells, allowing the functional targeting of MP to LTCC. This approach represents the first example of the use of an internalizing aptamer for selective delivery of a small therapeutic peptide to cardiac cells.	[Romanelli, Alessandra] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Affinito, Alessandra; Laboni, Margherita; Condorelli, Geroloma] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy; [Avitabile, Concetta] CNR, Inst Biostruct & Bioimaging, Naples, Italy; [Catuogno, Silvia; Condorelli, Geroloma] CNR, Inst Expt Endocrinol & Oncol G Salvatore, IEOS, Naples, Italy; [Ceriotti, Paola; Modica, Jessica; Catalucci, Daniele] Humanitas Clin & Res Ctr, Milan, Italy; [Catalucci, Daniele] CNR, Inst Genet & Biomed Res, Milan Unit, Milan, Italy; [Laboni, Margherita] Bracco Imaging SpA, Turin, Italy	University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); Bracco	Condorelli, G (corresponding author), Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy.; Condorelli, G (corresponding author), CNR, Inst Expt Endocrinol & Oncol G Salvatore, IEOS, Naples, Italy.; Catalucci, D (corresponding author), Humanitas Clin & Res Ctr, Milan, Italy.; Catalucci, D (corresponding author), CNR, Inst Genet & Biomed Res, Milan Unit, Milan, Italy.	gecondor@unina.it; daniele.catalucci@cnr.it	Catuogno, Silvia/AAB-9969-2019; Catalucci, Daniele/B-6745-2015; Affinito, Alessandra/Q-7859-2018	Catuogno, Silvia/0000-0002-1653-4205; Catalucci, Daniele/0000-0001-7041-6114; Modica, Jessica/0000-0002-4986-8009; Avitabile, Concetta/0000-0001-5542-6920; Affinito, Alessandra/0000-0002-3887-6513	Italian Ministry of Health [GR-2011-02352546]; AIRC - IG [18473]; Federazione Italiana Ricerca sul Cancro (FIRC); Italian Ministry of Health [GR-2011-02352546]; AIRC - IG [18473]; Federazione Italiana Ricerca sul Cancro (FIRC)	Italian Ministry of Health(Ministry of Health, Italy); AIRC - IG(Fondazione AIRC per la ricerca sul cancro); Federazione Italiana Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); AIRC - IG(Fondazione AIRC per la ricerca sul cancro); Federazione Italiana Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Italian Ministry of Health (http://www.salute.gov.it/portale/ home html; GR-2011-02352546) to DC and by Associazione Italiana Ricerca sul Cancro (http://www.airc.it/aiutare-la-ricerca/bomboniere-solidali.aps?ets_cmmk=3123&ets_sgmt=16923&gclid=cjwKEAjwvYPKBRCYr5GLgNCJ_isSJABqwfw7 DMtnt2m8pISbXCI0XMmSHgRPg495q6IIUt4jeXObjhoCIrrw_wcB; AIRC - IG 2016 Id. 18473) to GC. MI was supported by the Federazione Italiana Ricerca sul Cancro (FIRC, http://www.fondazionefirc.it) Post-Doctoral Research Fellowship.	Alvarez RH, 2006, MAYO CLIN PROC, V81, P1241, DOI 10.4065/81.9.1241; Avitabile C, 2013, BBA-GEN SUBJECTS, V1830, P3767, DOI 10.1016/j.bbagen.2013.01.026; Blaich A, 2012, J BIOL CHEM, V287, P22616, DOI 10.1074/jbc.M112.357921; Bodi I, 2005, J CLIN INVEST, V115, P3306, DOI 10.1172/JCI27167; Brugada P, 2013, EUR HEART J, V34, P3610, DOI 10.1093/eurheartj/eht113; Camorani S, 2014, MOL THER, V22, P828, DOI 10.1038/mt.2013.300; Catuogno S, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9040069; Catuogno S, 2015, J CONTROL RELEASE, V210, P147, DOI 10.1016/j.jconrel.2015.05.276; Chan TR, 2004, ORG LETT, V6, P2853, DOI 10.1021/ol0493094; Chintalgattu V, 2010, J CLIN INVEST, V120, P472, DOI 10.1172/JCI39434; Christ T, 2004, CIRCULATION, V110, P2651, DOI 10.1161/01.CIR.0000145659.80212.6A; El-Sagheer AH, 2010, P NATL ACAD SCI USA, V107, P15329, DOI 10.1073/pnas.1006447107; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Esposito CL, 2016, J CONTROL RELEASE, V238, P43, DOI 10.1016/j.jconrel.2016.07.032; Goonasekera SA, 2012, J CLIN INVEST, V122, P280, DOI 10.1172/JCI58227; Hacker DE, 2017, ACS CHEM BIOL, V12, P795, DOI 10.1021/acschembio.6b01006; Kaspar AA, 2013, DRUG DISCOV TODAY, V18, P807, DOI 10.1016/j.drudis.2013.05.011; Lee J, 2013, ANAL CHEM, V85, P9692, DOI 10.1021/ac402038t; Miragoli M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan6205; Paredes E, 2011, CHEMBIOCHEM, V12, P125, DOI 10.1002/cbic.201000466; Patel A, 2014, THER DELIV, V5, P337, DOI [10.4155/TDE.14.5, 10.4155/tde.14.5]; Ramesh S, 2016, BIOMATER SCI-UK, V4, P1713, DOI 10.1039/c6bm00688d; Rusconi F, 2016, CIRCULATION, V134, P534, DOI 10.1161/CIRCULATIONAHA.116.021347; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; Thiel WH, 2016, MOL THERAPY J AM SOC; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Weiss N, 2014, PATHOLOGIES CALCIUM, Vxviii; Zahid M, 2015, MOLECULES, V20, P13055, DOI 10.3390/molecules200713055; Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199	30	10	10	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2018	13	3							e0193392	10.1371/journal.pone.0193392	http://dx.doi.org/10.1371/journal.pone.0193392			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY5TA	29513717	Green Published, Green Submitted, gold			2023-01-03	WOS:000426896800057
J	Gittler, M; Davis, AM				Gittler, Michelle; Davis, Andrew M.			Guidelines for Adult Stroke Rehabilitation and Recovery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FUNCTIONAL RECOVERY; POSTACUTE CARE		[Gittler, Michelle] Schwab Rehabil Hosp, Chicago, IL USA; [Davis, Andrew M.] Univ Chicago, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago	Davis, AM (corresponding author), Univ Chicago, 5841 S Maryland Ave, Chicago, IL 60637 USA.	amd@uchicago.edu						Adams HP, 2015, J STROKE CEREBROVASC, V24, P2429, DOI 10.1016/j.jstrokecerebrovasdis.2015.08.017; Chan L, 2013, ARCH PHYS MED REHAB, V94, P622, DOI 10.1016/j.apmr.2012.09.033; Gadidi V, 2011, ARCH PHYS MED REHAB, V92, P1802, DOI 10.1016/j.apmr.2011.06.014; Skolarus LE, 2012, NEUROLOGY, V78, P1590, DOI 10.1212/WNL.0b013e3182563bf5; Towfighi A, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0792-7; Veerbeek JM, 2017, NEUROREHAB NEURAL RE, V31, P107, DOI 10.1177/1545968316666957; Willey JZ, 2010, STROKE, V41, P1896, DOI 10.1161/STROKEAHA.110.583997; Winstein CJ, 2016, STROKE, V47, pE98, DOI 10.1161/STR.0000000000000098	8	80	96	7	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	2018	319	8					820	821		10.1001/jama.2017.22036	http://dx.doi.org/10.1001/jama.2017.22036			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX6GK	29486016				2023-01-03	WOS:000426181300025
J	Getz, KD; Miller, TP; Seif, AE; Li, YM; Huang, YSV; Fisher, BT; Aplenc, R				Getz, Kelly D.; Miller, Tamara P.; Seif, Alix E.; Li, Yimei; Huang, Yuan-Shung V.; Fisher, Brian T.; Aplenc, Richard			Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia	PLOS ONE			English	Article							CANCER PAIN MANAGEMENT; UNITED-STATES; EMERGENCY-DEPARTMENT; CHILDRENS HOSPITALS; SEX-DIFFERENCES; ANALGESIA USE; CARE; QUALITY; METAANALYSIS; DISPARITY	Purpose A cohort of pediatric patients with AML treated at hospitals contributing to the Pediatric Health Information System was used to evaluate differences in opioid utilization by sex, age, race, and insurance. Methods Billing data were used to compute the prevalence of opioid exposure and to quantify rates of utilization among those exposed to opioids as days of use per 1000 inpatient days. Multivariable regressions were used to compare opioid prevalence, and rates of utilization among those exposed. Results On average across courses, 95.2% of patients were exposed to analgesics, 84.7% were exposed to non-opioid analgesics and 77.7% were exposed to opioids. The proportion of opioid-exposed patients increased with age, but did not differ by gender, race, or insurance status. Analyses limited to patients exposed to opioids revealed modest differences in days of opioid use among female patients (adjusted rate ratio (aRR) = 1.19, 95% CI: 1.11, 1.28), patients <1 year (aRR = 1.37, 95% CI: 1.21, 1.55) or >= 10 years of age (aRR = 1.63, 95% CI: 1.46, 1.82), whereas Asian patients received fewer days of opioids compared with white patients (aRR = 0.76, 95% CI: 0.61, 0.95). There was moderate hospital-level variability in both the prevalence of opioid utilization overall and preference for specific opioid medications. There was greater inconsistency in practice concerning choices for supplemental and alternative opioids than in first-line opioid utilization. Conclusion Additional work is needed to discern whether observed differences in opioid utilization by age and race reflect a difference in treatment or a difference in the experience of pain. Future studies should also explore the factors which guide decisions on opioid selections in an attempt to explain the variability across institutions.	[Getz, Kelly D.; Miller, Tamara P.; Seif, Alix E.; Li, Yimei; Aplenc, Richard] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Getz, Kelly D.; Huang, Yuan-Shung V.; Fisher, Brian T.; Aplenc, Richard] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA; [Seif, Alix E.; Fisher, Brian T.; Aplenc, Richard] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA USA; [Li, Yimei; Fisher, Brian T.; Aplenc, Richard] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Fisher, Brian T.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Getz, KD (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.; Getz, KD (corresponding author), Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA.	getzk@email.chop.edu	Miller, Tamara P./AAB-2282-2020; Getz, Kelly/W-8190-2018; Seif, Alix/B-9918-2013	Getz, Kelly/0000-0003-2020-5153; Fisher, Brian/0000-0002-8224-4281; Seif, Alix/0000-0002-1799-2582	Alex's Lemonade Stand Foundation; NIH [R01CM 65277-01]; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grants from Alex's Lemonade Stand Foundation (https://www.alexslemonade.org/grants/search; PI: Aplenc) and NIH (R01CM 65277-01, PI: Aplenc). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ameringer S, 2010, PAIN MANAG NURS, V11, P224, DOI 10.1016/j.pmn.2009.05.006; Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1093/bja/aet127; Boerner KE, 2014, PAIN, V155, P983, DOI 10.1016/j.pain.2014.01.031; Chen CH, 2012, PALLIATIVE MED, V26, P206, DOI 10.1177/0269216311402711; Child Health Corporation of America, 2014, CHILD HLTH CORP AM A; Cintron A, 2006, J PALLIAT MED, V9, P1454, DOI 10.1089/jpm.2006.9.1454; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Collins JJ, 2001, MED J AUSTRALIA, V175, P453, DOI 10.5694/j.1326-5377.2001.tb143673.x; Dahl June L, 2004, J Natl Cancer Inst Monogr, P124; Dickason RM, 2015, WEST J EMERG MED, V16, P372, DOI 10.5811/westjem.2015.3.23893; Elder K, 2014, J PEDIATR-US, V165, P434, DOI 10.1016/j.jpeds.2014.06.046; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761; Hechler T, 2014, PAIN, V155, P118, DOI 10.1016/j.pain.2013.09.015; Heden L, 2013, J PAIN SYMPTOM MANAG, V46, P366, DOI 10.1016/j.jpainsymman.2012.09.012; Hewitt M, 2008, J PEDIATR, V152, P39, DOI 10.1016/j.jpeds.2007.07.005; Kavcic M, 2013, PEDIATR BLOOD CANCER, V60, P508, DOI 10.1002/pbc.24402; Kozlowski LJ, 2014, PAIN MANAG NURS, V15, P22, DOI 10.1016/j.pmn.2012.04.003; Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827; Ljungman G, 2000, PEDIATR HEMAT ONCOL, V17, P211, DOI 10.1080/088800100276389; Marinangeli F, 2004, J PAIN SYMPTOM MANAG, V27, P409, DOI 10.1016/j.jpainsymman.2003.10.006; Maude SL, 2014, PEDIATR CRIT CARE ME, V15, P112, DOI 10.1097/PCC.0000000000000042; McNeill JA, 2007, ONCOL NURS FORUM, V34, P1121, DOI 10.1188/07.ONF.1121-1128; Meghani SH, 2014, J CLIN ONCOL, V32, P2773, DOI 10.1200/JCO.2013.54.7992; Mercadante S, 2014, CRIT REV ONCOL HEMAT, V91, P93, DOI 10.1016/j.critrevonc.2014.01.005; Miller Elizabeth, 2011, Oncol Nurs Forum, V38, pE382, DOI 10.1188/11.ONF.E382-E393; Mills AM, 2011, AM J EMERG MED, V29, P752, DOI 10.1016/j.ajem.2010.02.023; Narayan MC, 2010, AM J NURS, V110, P38, DOI 10.1097/01.NAJ.0000370157.33223.6d; Orsey AD, 2009, PEDIATR BLOOD CANCER, V52, P761, DOI 10.1002/pbc.21824; Rasooly IR, 2014, J PEDIATR-US, V165, P618, DOI 10.1016/j.jpeds.2014.04.059; Sadhasivam S, 2015, PAIN MED, V16, P985, DOI 10.1111/pme.12660; Smith AW, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00075; Stevens BJ, 2012, J PAIN, V13, P857, DOI 10.1016/j.jpain.2012.05.010; Sung L, 2009, BRIT J CANCER, V100, P82, DOI 10.1038/sj.bjc.6604826; van de Wetering MD, 2011, SEMIN ONCOL, V38, P374, DOI 10.1053/j.seminoncol.2011.03.006; Varni JW, 2004, J DEV BEHAV PEDIATR, V25, P239, DOI 10.1097/00004703-200408000-00003; Womer J, 2014, J PAIN SYMPTOM MANAG, V48, P903, DOI 10.1016/j.jpainsymman.2013.12.241; World Health Organization, 2012, WHO GUID PHARM TREAT	38	14	15	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2018	13	2							e0192529	10.1371/journal.pone.0192529	http://dx.doi.org/10.1371/journal.pone.0192529			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FV4BG	29420604	Green Submitted, Green Published, gold			2023-01-03	WOS:000424517900089
J	Williams, JG; Bachman, MW; Lyons, MD; Currie, BB; Brown, LH; Jones, AW; Cabanas, JG; Kronhaus, AK; Myers, JB				Williams, Jefferson G.; Bachman, Michael W.; Lyons, Michael D.; Currie, Benjamin B.; Brown, Lawrence H.; Jones, A. Wooten; Cabanas, Jose G.; Kronhaus, Alan K.; Myers, J. Brent			Improving Decisions About Transport to the Emergency Department for Assisted Living Residents Who Fall	ANNALS OF INTERNAL MEDICINE			English	Article							OLDER-PEOPLE; CARE; RADIOGRAPHY; VALIDATION; POLICY	Background: Residents of assisted living facilities who fall may not be seriously ill or injured, but policies often require immediate transport to an emergency department regardless of the patient's condition. Objective: To determine whether unnecessary transport can be avoided. Design: Prospective cohort study. Setting: One large county with a single system of emergency medical services. Participants: Convenience sample of residents in 22 assisted living facilities served by 1 group of primary care physicians. Intervention: Paramedics providing emergency medical services followed a protocol that included consulting with a physician by telephone. Measurements: The number of transports after a fall and the number of time-sensitive conditions in nontransported patients. Results: Of the 1473 eligible residents, 953 consented to participate in the study (mean age, 86 years; 76% female) and 359 had 840 falls in 43 months. The protocol recommended non-transport after 553 falls. Eleven of these patients had a timesensitive condition. At least 7 of them received appropriate care: 4 requested and received transport despite the protocol recommendation, and 3 had minor injuries that were successfully managed on site. Three additional patients had fractures that were diagnosed by outpatient radiography. The final patient developed vomiting and diarrhea, started palliative care, and died 60 hours after the fall. At least 549 of the 553 patients (99.3% [95% CI, 98.2% to 99.8%]) with a protocol recommendation for non-transport received appropriate care. Limitation: The resources required for this program will preclude use in some locations. Conclusion: Shared decision making between paramedics and primary care physicians can prevent transport to the emergency department for many residents of assisted living facilities who fall.	[Williams, Jefferson G.; Bachman, Michael W.; Lyons, Michael D.; Currie, Benjamin B.; Cabanas, Jose G.; Myers, J. Brent] Wake Cty Emergency Med Serv, 331 South McDowell St, Raleigh, NC 27601 USA; Univ North Carolina Chapel Hill, Chapel Hill, NC USA; [Brown, Lawrence H.] Univ Texas Austin, Emergency Med Program, Dept Surg & Perioperat Care, Dell Med Sch, 1400 North I-35,Suite 2-230, Austin, TX 78754 USA; James Cook Univ, Mt Isa Ctr Rural & Remote Hlth, Townsville, Qld, Australia; East Carolina Univ, Brody Sch Med, Greenville, NC USA; Doctors Making Housecalls, Durham, NC USA; [Jones, A. Wooten] 406 Lancelot Dr, Greenville, NC 27858 USA; [Kronhaus, Alan K.] 2511 Old Cornwallis Rd,Suite 200, Durham, NC 27713 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Texas System; University of Texas Austin; James Cook University; University of North Carolina; East Carolina University	Williams, JG (corresponding author), Wake Cty Emergency Med Serv, 331 South McDowell St, Raleigh, NC 27601 USA.	jeff.williams@wakegov.com		Brown, Lawrence/0000-0002-5940-1840				Abualenain J, 2013, ANN EMERG MED, V61, P638, DOI 10.1016/j.annemergmed.2013.01.016; Bergeron E, 2006, J TRAUMA, V60, P268, DOI 10.1097/01.ta.0000197651.00482.c5; Brown LH, 2009, PREHOSP EMERG CARE, V13, P516, DOI 10.1080/10903120903144809; Buderer NMF, 1996, ACAD EMERG MED, V3, P895, DOI 10.1111/j.1553-2712.1996.tb03538.x; Centers for Disease Control and Prevention, 2011, WISQARS LEAD CAUS NO; Centers for Disease Control and Prevention, NONF INJ DAT; Centers for Medicare & Medicaid Services, OV MED PHYS FEE SCHE; Cone DC, 2013, PREHOSP EMERG CARE, V17, P51, DOI 10.3109/10903127.2012.717168; Halter M, 2011, EMERG MED J, V28, P44, DOI 10.1136/emj.2009.079566; Hastings SN, 2007, J GEN INTERN MED, V22, P1527, DOI 10.1007/s11606-007-0343-9; Helling TS, 1999, J TRAUMA, V46, P453, DOI 10.1097/00005373-199903000-00019; Institute for Healthcare Improvement, 2017, IHI TRIPL AIM IN; Kellermann AL, 2011, NEW ENGL J MED, V364, P2278, DOI 10.1056/NEJMp1101544; Martinez R, 2010, ACAD EMERG MED, V17, P1346, DOI 10.1111/j.1553-2712.2010.00945.x; Morganti KG, 2014, ANN EMERG MED, V63, P615, DOI 10.1016/j.annemergmed.2013.09.025; Munjal K, 2013, JAMA-J AM MED ASSOC, V309, P667, DOI 10.1001/jama.2012.211273; Myers JB, 2013, MOB INT HEALTHC SUMM; Ojo Peter, 2009, Conn Med, V73, P139; Simpson PM, 2014, PREHOSP EMERG CARE, V18, P342, DOI 10.3109/10903127.2013.864355; Simpson PM, 2014, PREHOSP EMERG CARE, V18, P185, DOI 10.3109/10903127.2013.856504; SINGAL BM, 1992, ANN EMERG MED, V21, P802, DOI 10.1016/S0196-0644(05)81025-X; Siracuse JJ, 2012, AM J SURG, V203, P335, DOI 10.1016/j.amjsurg.2011.09.018; Snooks HA, 2004, EMERG MED J, V21, P212, DOI 10.1136/emj.2003.005199; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; Weiss Steven J, 2003, Prehosp Emerg Care, V7, P79, DOI 10.1080/10903120390937148; Williams JG, 2015, PREHOSP EMERG CARE, V19, P68, DOI 10.3109/10903127.2014.936631	27	17	17	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 6	2018	168	3					179	+		10.7326/M17-0969	http://dx.doi.org/10.7326/M17-0969			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV0CU	29230475				2023-01-03	WOS:000424224300006
J	Pinto, N; Duarte, M; Goncalves, H; Silva, R; Gama, J; Pato, MV				Pinto, Nuno; Duarte, Marta; Goncalves, Helena; Silva, Ricardo; Gama, Jorge; Pato, Maria Vaz			Bilateral theta-burst magnetic stimulation influence on event-related brain potentials	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; STRIATAL DOPAMINE RELEASE; HUMAN MOTOR CORTEX; CORTICAL PLASTICITY; RESPONSE-INHIBITION; P300; DEPRESSION; RTMS; IMPACT; TASK	Theta-burst stimulation (TBS) can be a non-invasive technique to modulate cognitive functions, with promising therapeutic potential, but with some contradictory results. Event related potentials are used as a marker of brain deterioration and can be used to evaluate TBS-related cognitive performance, but its use remains scant. This study aimed to study bilateral inhibitory and excitatory TBS effects upon neurocognitive performance of young healthy volunteers, using the auditory P300' results. Using a double-blind sham-controlled study, 51 healthy volunteers were randomly assigned to five different groups, two submitted to either excitatory (iTBS) or inhibitory (cTBS) stimulation over the left dorsolateral pre-frontal cortex (DLPFC), two other actively stimulated the right DLPFC and finally a sham stimulation group. An oddball based auditory P300 was performed just before a single session of iTBS, cTBS or sham stimulation and repeated immediately after. P300 mean latency comparison between the pre- and post-TBS stimulation stages revealed significantly faster post stimulation latencies only when iTBS was performed on the left hemisphere (p = 0.003). Right and left hemisphere cTBS significantly delayed P300 latency (right p = 0.026; left p = 0.000). Multiple comparisons for N200 showed slower latencies after iTBS over the right hemisphere. No significant difference was found in amplitude variation. TBS appears to effectively influence neural networking involved in P300 formation, but effects seem distinct for iTBS vs cTBS and for the right or the left hemisphere. P300 evoked potentials can be an effective and practical tool to evaluate transcranial magnetic stimulation related outcomes.	[Pinto, Nuno; Duarte, Marta; Goncalves, Helena; Silva, Ricardo; Gama, Jorge; Pato, Maria Vaz] Univ Beira Interior, CICS Hlth Sci Res Ctr, Fac Hlth Sci, Covilha, Portugal; [Pinto, Nuno] Polytech Inst Castelo Branco, Dr Lopes Dias Sch Hlth, Castelo Branco, Portugal; [Gama, Jorge] Univ Beira Interior, Dept Math, Covilha, Portugal; [Pato, Maria Vaz] Sousa Martins Hosp, Guarda Local Hlth Unit, Guarda, Portugal	Universidade da Beira Interior; Polytechnic Institute of Castelo Branco; Universidade da Beira Interior	Pinto, N (corresponding author), Univ Beira Interior, CICS Hlth Sci Res Ctr, Fac Hlth Sci, Covilha, Portugal.; Pinto, N (corresponding author), Polytech Inst Castelo Branco, Dr Lopes Dias Sch Hlth, Castelo Branco, Portugal.	nfcpinto@gmail.com	da Assunção AMC Vaz Patto, Maria/A-1091-2017; Pinto, Nuno Filipe Cardoso/T-9700-2018	da Assunção AMC Vaz Patto, Maria/0000-0002-0653-3428; Pinto, Nuno Filipe Cardoso/0000-0002-6605-2407; Gama, Jorge/0000-0003-3926-580X; Oliveira e Silva, Ricardo Pinho de Oliveira/0000-0002-7476-0980				Anderkova L, 2014, J NEUROL SCI, V339, P15, DOI 10.1016/j.jns.2014.01.037; Balaz M, 2010, EXP BRAIN RES, V203, P317, DOI 10.1007/s00221-010-2232-4; Bloom JS, 2005, NEUROPSYCHOL REV, V15, P59, DOI 10.1007/s11065-005-6252-y; Chen KC, 2014, PSYCHOL MED, V44, P2151, DOI 10.1017/S0033291713002808; Chung SW, 2015, DEPRESS ANXIETY, V32, P182, DOI 10.1002/da.22335; Cooper NR, 2008, CLIN EEG NEUROSCI, V39, P139, DOI 10.1177/155005940803900308; Croarkin PE, 2016, PSYCHIAT RES-NEUROIM, V247, P25, DOI 10.1016/j.pscychresns.2015.11.005; Deuschl G, 1999, RECOMMENDATIONS PRAC, Vxv; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288; Dlabac-de Lange JJ, 2017, BRAIN STIMUL, V10, P59, DOI 10.1016/j.brs.2016.08.002; Duncan CC, 2009, CLIN NEUROPHYSIOL, V120, P1883, DOI 10.1016/j.clinph.2009.07.045; Evers S, 2001, NEUROREPORT, V12, P2915, DOI 10.1097/00001756-200109170-00032; FAUX SF, 1990, ELECTROEN CLIN NEURO, V75, P378, DOI 10.1016/0013-4694(90)90083-V; Frodl-Bauch T, 1999, NEUROPSYCHOBIOLOGY, V40, P86, DOI 10.1159/000026603; Guse B, 2010, J NEURAL TRANSM, V117, P105, DOI 10.1007/s00702-009-0333-7; Hansenne M, 2004, BIOL PSYCHOL, V67, P331, DOI 10.1016/j.biopsycho.2004.01.004; Huang X, 2017, MOL PSYCHIATR, V22, P1274, DOI 10.1038/mp.2017.143; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Huster RJ, 2010, HUM BRAIN MAPP, V31, P1260, DOI 10.1002/hbm.20933; Jing H, 2001, J NEUROL, V248, P184, DOI 10.1007/s004150170224; JOHNSON R, 1993, PSYCHOPHYSIOLOGY, V30, P90; Kaller CP, 2013, HUM BRAIN MAPP, V34, P36, DOI 10.1002/hbm.21423; Karton I, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.656; Ko JH, 2008, EUR J NEUROSCI, V28, P2147, DOI 10.1111/j.1460-9568.2008.06501.x; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Linden DEJ, 2005, NEUROSCIENTIST, V11, P563, DOI 10.1177/1073858405280524; Magnano I, 2006, J NEUROL SCI, V245, P117, DOI 10.1016/j.jns.2005.08.027; Michael N, 2003, EUR J NEUROSCI, V17, P2462, DOI 10.1046/j.1460-9568.2003.02683.x; Miller AR, 2001, J EXP PSYCHOL LEARN, V27, P354, DOI 10.1037/0278-7393.27.2.354; NAGAMOTO HT, 1991, SCHIZOPHR RES, V4, P31, DOI 10.1016/0920-9964(91)90007-E; Noda Y, 2015, PSYCHOL MED, V45, P3411, DOI 10.1017/S0033291715001609; Noguchi K, 2012, J STAT SOFTW, V50, P1, DOI 10.18637/jss.v050.i12; Oberman L, 2011, J CLIN NEUROPHYSIOL, V28, P67, DOI 10.1097/WNP.0b013e318205135f; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Patel Salil H, 2005, Int J Med Sci, V2, P147; Pogarell O, 2006, J PSYCHIATR RES, V40, P307, DOI 10.1016/j.jpsychires.2005.09.001; Pogarell O, 2011, PSYCHIAT RES-NEUROIM, V194, P212, DOI 10.1016/j.pscychresns.2011.02.002; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; Polich J, 2007, CLIN NEUROPHYSIOL, V118, P2128, DOI 10.1016/j.clinph.2007.04.019; Rego SRM, 2012, CLIN EEG NEUROSCI, V43, P285, DOI 10.1177/1550059412445657; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sandrini M, 2011, NEUROSCI BIOBEHAV R, V35, P516, DOI 10.1016/j.neubiorev.2010.06.005; Shen Y, 2017, BIOL PSYCHIAT, V81, pE49, DOI 10.1016/j.biopsych.2016.06.013; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Sohn YH, 1998, J NEUROL SCI, V158, P83, DOI 10.1016/S0022-510X(98)00102-6; STANZIONE P, 1991, ELECTROEN CLIN NEURO, V80, P446, DOI 10.1016/0168-5597(91)90093-D; Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001; Upton DJ, 2010, CLIN EEG NEUROSCI, V41, P127, DOI 10.1177/155005941004100304; Wasserman E, 2008, OXFORD HDB TRANSCRAN, Vxiv; Yang XR, 2014, J ECT, V30, P242, DOI 10.1097/YCT.0000000000000094	50	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2018	13	1							e0190693	10.1371/journal.pone.0190693	http://dx.doi.org/10.1371/journal.pone.0190693			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR9OU	29304065	Green Published, Green Submitted, gold			2023-01-03	WOS:000419403800099
J	Kawakami, H; Mihara, T; Nakamura, N; Ka, K; Goto, T				Kawakami, Hiromasa; Mihara, Takahiro; Nakamura, Nobuhito; Ka, Koui; Goto, Takahisa			Effect of magnesium added to local anesthetics for caudal anesthesia on postoperative pain in pediatric surgical patients: A systematic review and meta-analysis with Trial Sequential Analysis	PLOS ONE			English	Review							INTRATHECAL MAGNESIUM; REGIONAL ANESTHESIA; ANALGESIC EFFICACY; SULFATE; KETAMINE; ADJUVANT; CHILDREN	Background Magnesium has been investigated as an adjuvant for neuraxial anesthesia, but the effect of caudal magnesium on postoperative pain is inconsistent. The aim of this systematic review and meta-analysis was to evaluate the analgesic effect of caudal magnesium. Methods We searched six databases, including trial registration sites. Randomized clinical trials reporting the effect of caudal magnesium on postoperative pain after general anesthesia were eligible. The risk ratio for use of rescue analgesics after surgery was combined using a random-effects model. We also assessed adverse events. The I-2 statistic was used to assess heterogeneity. We assessed risk of bias with Cochrane domains. We controlled type I and II errors due to sparse data and repetitive testing with Trial Sequential Analysis. We assessed the quality of evidence with GRADE. Results Four randomized controlled trials (247 patients) evaluated the need for rescue analgesics. In all four trials, 50 mg of magnesium was administered with caudal ropivacaine. The results suggested that the need for rescue analgesia was reduced significantly by caudal magnesium administration (risk ratio 0.45; 95% confidence interval 0.24-0.86). There was considerable heterogeneity as indicated by an I-2 value of 62.5%. The Trial Sequential Analysis-adjusted confidence interval was 0.04-5.55, indicating that further trials are required. The quality of evidence was very low. The rate of adverse events was comparable between treatment groups. Conclusion Caudal magnesium may reduce the need for rescue analgesia after surgery, but further randomized clinical trials with a low risk of bias and a low risk of random errors are necessary to assess the effect of caudal magnesium on postoperative pain and adverse events.	[Kawakami, Hiromasa; Mihara, Takahiro; Nakamura, Nobuhito; Ka, Koui] Kanagawa Childrens Med Ctr, Dept Anesthesiol, Yokohama, Kanagawa, Japan; [Mihara, Takahiro; Goto, Takahisa] Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Yokohama, Kanagawa, Japan; [Kawakami, Hiromasa] Yokohama City Univ, Med Ctr, Dept Anesthesiol, Yokohama, Kanagawa, Japan	Yokohama City University; Yokohama City University	Mihara, T (corresponding author), Kanagawa Childrens Med Ctr, Dept Anesthesiol, Yokohama, Kanagawa, Japan.; Mihara, T (corresponding author), Yokohama City Univ, Grad Sch Med, Dept Anesthesiol & Crit Care Med, Yokohama, Kanagawa, Japan.	miharaxxxtotoro@yahoo.co.jp	Mihara, Takahiro/AAH-8487-2020	Mihara, Takahiro/0000-0003-0613-511X	Yokohama City University Graduate School of Medicine	Yokohama City University Graduate School of Medicine	We received only the departmental funding from Yokohama City University Graduate School of Medicine. The funding source had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Albrecht E, 2013, ANAESTHESIA, V68, P190, DOI 10.1111/j.1365-2044.2012.07337.x; Askar F, 2017, INT ANN MED, V1; Birbicer H, 2007, PEDIATR SURG INT, V23, P195, DOI 10.1007/s00383-006-1779-4; Bujalska-Zadrozny M, 2017, EUR J PHARM SCI, V99, P113, DOI 10.1016/j.ejps.2016.11.020; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Chanimov M, 1997, ANAESTHESIA, V52, P223, DOI 10.1111/j.1365-2044.1997.034-az0057.x; Chertin Boris, 2016, Curr Urol, V9, P132; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ecoffey C, 2010, PEDIATR ANESTH, V20, P1061, DOI 10.1111/j.1460-9592.2010.03448.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elshal S., 2009, MED J CAIRO U, V77, P11; Engelman E, 2012, ACTA ANAESTH SCAND, V56, P817, DOI 10.1111/j.1399-6576.2012.02651.x; Guo BL, 2015, PAIN PHYSICIAN, V18, P405; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Inturrisi C E, 2005, Minerva Anestesiol, V71, P401; Karl HW, 1996, CAN J ANAESTH, V43, P1065, DOI 10.1007/BF03011911; Kim EM, 2014, PEDIATR ANESTH, V24, P1231, DOI 10.1111/pan.12559; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; McMaster University, GRADEPRO GUID DEV TO; Mohammad Wasim, 2015, Anesth Essays Res, V9, P15, DOI 10.4103/0259-1162.150141; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Morrison AP, 2013, BRIT J ANAESTH, V110, P702, DOI 10.1093/bja/aet064; Najafi Atabak, 2013, Saudi J Anaesth, V7, P464, DOI 10.4103/1658-354X.121049; Ozdogan L, 2013, REV BRAS ANESTESIOL, V63, P139, DOI [10.1016/j.bjane.2012.02.002, 10.1016/S0034-7094(13)70205-8]; Schnabel A, 2011, BRIT J ANAESTH, V107, P601, DOI 10.1093/bja/aer258; Shahi Vaibhav, 2014, J Anaesthesiol Clin Pharmacol, V30, P538, DOI 10.4103/0970-9185.142852; Shruthi A H, 2016, Middle East J Anaesthesiol, V23, P449; Sridhar Raghavendra Biligiri, 2017, Anesth Essays Res, V11, P636, DOI 10.4103/0259-1162.206853; Suresh S, 2015, ANESTH ANALG, V120, P151, DOI 10.1213/ANE.0000000000000446; THURNAU GR, 1987, AM J OBSTET GYNECOL, V157, P1435, DOI 10.1016/S0002-9378(87)80239-9; Tong Y, 2014, PEDIATR ANESTH, V24, P1224, DOI 10.1111/pan.12519; Walker SM, 2010, ANESTHESIOLOGY, V113, P147, DOI 10.1097/ALN.0b013e3181dcd71c; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; Xie Min, 2017, J Evid Based Med, V10, P16, DOI 10.1111/jebm.12230; Yousef Gamal T, 2014, Anesth Essays Res, V8, P13, DOI 10.4103/0259-1162.128895	38	6	6	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2018	13	1							e0190354	10.1371/journal.pone.0190354	http://dx.doi.org/10.1371/journal.pone.0190354			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR5JA	29293586	Green Submitted, Green Published, gold			2023-01-03	WOS:000419101600098
J	Jacobsen, AR; Eriksen, F; Hansen, RW; Erlandsen, M; Thorup, L; Damgard, MB; Kirkegaard, MG; Hansen, KW				Jacobsen, Anne Roed; Eriksen, Freja; Hansen, Rasmus Wurgler; Erlandsen, Mogens; Thorup, Line; Damgard, Mette Bjerre; Kirkegaard, Martin Glumer; Hansen, Klavs Wurgler			Determinants for adherence to continuous positive airway pressure therapy in obstructive sleep apnea	PLOS ONE			English	Article							LONG-TERM COMPLIANCE; CPAP ADHERENCE; CARDIOVASCULAR OUTCOMES; OSA	Background Continuous positive airway pressure (CPAP) therapy is an efficacious treatment for patients diagnosed with obstructive sleep apnea (OSA). However, there are only few data on long-term adherence. The aim of this study is to quantify the extent of non-adherence and describe the clinical characteristics. Methods A retrospective study including 695 patients with newly diagnosed OSA and prescribed CPAP therapy within an inclusion period of 14 months. All patients were offered free of charge individually adjusted CPAP therapy. Data on comorbidity, medication, BMI and Epworth Sleepiness Score (ESS) were obtained by questionnaires and consultation with an otorhinolaryngeal specialist. Results The median follow-up time after initiating CPAP therapy was 3.0 (range 2.4-3.6) years. An adherence rate of 89% was found for severe OSA, 71% for moderate OSA and 55% for mild OSA. 18% initiated humidification. Patients adherent to CPAP had a significantly higher Body Mass Index (BMI), Apnea Hypopnea Index (AHI), Oxygen Desaturation Index (ODI) and ESS compared to non-adherent patients. Furthermore, adherence was associated with a higher frequency of observed interrupted breathing, a less frequent use of hypnotic drugs, fewer smokers, and they were more often offered humidification. Age, gender and comorbidity were not significantly associated with adherence. In a Cox model only AHI (Hazard Ratio (HR) 0.963, p < 0.001), ESS (HR 0.939, p = 0.001) and smoking (HR 1.576, p = 0.022) were independently associated with CPAP non-adherence. Conclusions The severity of OSA, subjective daytime sleepiness and smoking status are independently related to adherence to CPAP therapy.	[Jacobsen, Anne Roed; Eriksen, Freja; Hansen, Rasmus Wurgler; Hansen, Klavs Wurgler] Reg Hosp Silkeborg, Ctr Diagnost, Silkeborg, Denmark; [Erlandsen, Mogens] Aarhus Univ, Dept Publ Hlth, Sect Biostat, Aarhus, Denmark; [Thorup, Line] Reg Hosp Silkeborg, Interdisciplinary Res Unit, Elective Surg Ctr, Silkeborg, Denmark; [Damgard, Mette Bjerre; Kirkegaard, Martin Glumer] Reg Hosp Silkeborg, Elective Surg Ctr, Sleep Disorders Clin, Silkeborg, Denmark	Aarhus University	Jacobsen, AR (corresponding author), Reg Hosp Silkeborg, Ctr Diagnost, Silkeborg, Denmark.	aroedjacobsen@gmail.com	Hansen, Klavs Würgler/AAW-1679-2021	Hansen, Klavs Würgler/0000-0002-7452-2747; Hansen, Rasmus Wurgler/0000-0001-8012-3307; Jacobsen, Anne Roed/0000-0002-9204-0864	Central Region Denmark Research Fund	Central Region Denmark Research Fund	The study has been funded by Central Region Denmark Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avlonitou E, 2012, SLEEP BREATH, V16, P563, DOI 10.1007/s11325-011-0543-8; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Galetke W, 2011, RESPIRATION, V82, P155, DOI 10.1159/000322838; Ghosh D, 2013, RESP MED, V107, P936, DOI 10.1016/j.rmed.2012.10.008; Greenstone M, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3745; Guralnick AS, 2012, J CLIN SLEEP MED, V8, P501, DOI 10.5664/jcsm.2140; Joo MJ, 2007, J CLIN SLEEP MED, V3, P285; Jordan AS, 2014, LANCET, V383, P736, DOI 10.1016/S0140-6736(13)60734-5; Kohler M, 2010, THORAX, V65, P829, DOI 10.1136/thx.2010.135848; Kreivi H-K, 2016, RESP CARE; Krieger J, 1996, SLEEP, V19, pS136, DOI 10.1093/sleep/19.suppl_9.S136; Kryger MH, 2011, J CLIN SLEEP MED, V7, P449, DOI 10.5664/JCSM.1304; Mador MJ, 2005, CHEST, V128, P2151, DOI 10.1378/chest.128.4.2151; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Milleron O, 2004, EUR HEART J, V25, P728, DOI 10.1016/j.ehj.2004.02.008; Richard W, 2007, EUR ARCH OTO-RHINO-L, V264, P1081, DOI 10.1007/s00405-007-0311-3; Salepci B, 2013, RESP CARE, V58, P1467, DOI 10.4187/respcare.02139; Sawyer AM, 2011, SLEEP MED REV, V15, P343, DOI 10.1016/j.smrv.2011.01.003; Shapiro GK, 2010, SLEEP BREATH, V14, P323, DOI 10.1007/s11325-010-0391-y; Thomas JJ, 2012, CLIN EXP PHARMACOL P, V39, P995, DOI 10.1111/1440-1681.12024; van Zeller M, 2013, RESP MED, V107, P2046, DOI 10.1016/j.rmed.2013.10.011; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Woehrle H, 2011, SLEEP MED, V12, P1034, DOI 10.1016/j.sleep.2011.05.008; Wolkove N, 2008, CAN RESPIR J, V15, P365, DOI 10.1155/2008/534372; Yetkin O, 2008, SLEEP BREATH, V12, P365, DOI 10.1007/s11325-008-0188-4	27	47	51	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2017	12	12							e0189614	10.1371/journal.pone.0189614	http://dx.doi.org/10.1371/journal.pone.0189614			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FQ5HM	29253872	gold, Green Submitted, Green Published			2023-01-03	WOS:000418389500043
J	Hoffmann, D; Palumbo, F; Ravel, J; Roghmann, MC; Rowthorn, V; von Rosenvinge, E				Hoffmann, Diane; Palumbo, Francis; Ravel, Jacques; Roghmann, Mary-Claire; Rowthorn, Virginia; von Rosenvinge, Erik			Improving regulation of microbiota transplants	SCIENCE			English	Editorial Material									[Hoffmann, Diane; Palumbo, Francis; Ravel, Jacques; Roghmann, Mary-Claire; Rowthorn, Virginia; von Rosenvinge, Erik] Univ Maryland, Baltimore, MD 21201 USA; [Roghmann, Mary-Claire; von Rosenvinge, Erik] Vet Affairs Maryland Hlth Care Syst, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Hoffmann, D (corresponding author), Univ Maryland, Baltimore, MD 21201 USA.	dhoffmann@law.umaryland.edu	Ravel, Jacques/D-2530-2009	von Rosenvinge, Erik C./0000-0002-1862-7288	National Institute of Allergy and Infectious Diseases [R21AI119633]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI119633] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institute of Allergy and Infectious Diseases (R21AI119633). The opinions expressed are solely those of the aut hors. The authors acknowledge the valuable contributions of the members of the working group (4).	American College of Obstetricians and Gynecologists, PRACT ADV VAG SEED; Barbut F., CLOSTRIDIUM DIFFICIL; Cammarota G, 2015, ALIMENT PHARM THER, V41, P835, DOI 10.1111/apt.13144; Food U.S., 2016, ENF POL REG IN PRESS; Kelly CR, 2016, ANN INTERN MED, V165, P609, DOI 10.7326/M16-0271; Khonits A., 2016, FDA2013D0811; Laakmann Anna B., 2015, CARDOZO L REV, V36, P913; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Petrof EO, 2014, GASTROENTEROLOGY, V146, P1573, DOI 10.1053/j.gastro.2014.01.004; Przychodzki Anna, 2016, COMMENT DOCKET NO FD; Riley MF, 2015, J LAW BIOSCI, V2, P742, DOI 10.1093/jlb/lsv046; Sachs RE, 2015, J LAW BIOSCI, V2, P396, DOI 10.1093/jlb/lsv032; Shin H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075729, 10.1371/journal.pone.0081330]; Smith MB, 2014, NATURE, V506, P290, DOI 10.1038/506290a; U.S. Food and Drug Administration, 2012, TISS REF GROUP FY201; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037	16	38	39	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 15	2017	358	6369					1390	1391		10.1126/science.aaq0034	http://dx.doi.org/10.1126/science.aaq0034			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FP8TH	29242336	Green Accepted			2023-01-03	WOS:000417918500024
J	Heckel, M; Geissdorfer, W; Herbst, FA; Stiel, S; Ostgathe, C; Bogdan, C				Heckel, Maria; Geissdoerfer, Walter; Herbst, Franziska A.; Stiel, Stephanie; Ostgathe, Christoph; Bogdan, Christian			Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) at a palliative care unit: A prospective single service analysis	PLOS ONE			English	Article							GRAM-NEGATIVE BACTERIA; INFECTION; PREVALENCE; EPIDEMIOLOGY; SURVEILLANCE; GERMANY; IMPACT	Background The emergence of multidrug-resistant bacterial microorganisms is a particular challenge for the health care systems. Little is known about the occurrence of methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Gram-negative bacteria (MDRGNB) in patients of palliative care units (PCU). Aim The primary aim of this study was to determine the carriage of MRSA among patients of a PCU at a German University Hospital and to assess whether the positive cases would have been detected by a risk-factor-based screening-approach. Design Between February 2014 and January 2015 patients from our PCU were tested for MRSA carriage within 48 hours following admission irrespective of pre-existing risk factors. In addition, risk factors for MRSA colonization were assessed. Samples from the nostrils and, if applicable, from pre-existing wounds were analysed by standardized culture-based laboratory techniques for the presence of MRSA and of other bacteria and fungi. Results from swabs taken prior to admission were also recorded if available. Results 297 out of 317 patients (93.7%) fulfilled one or more MRSA screening criteria. Swabs from 299 patients were tested. The detection rate was 2.1% for MRSA. All MRSA cases would have been detected by a risk-factor-based screening-approach. Considering the detected cases and the results from swabs taken prior to admission, 4.1% of the patients (n = 13) were diagnosed with MRSA and 4.1% with MDRGNB (n = 13), including two patients with MRSA and MDRGNB (0.6%). The rate of MRSA carriage in PCU patients (4.1%) was elevated compared to the rate seen in the general cohort of patients admitted to our University Hospital (2.7%). Conclusions PCU patients have an increased risk to carry MRSA compared to other hospitalized patients. Although a risk factor-based screening is likely to detect all MRSA carriers amongst PCU patients, we rather recommend a universal screening to avoid the extra effort to identify the few risk factor-negative patients (< 7%). As we did not perform a systematic MDRGNB screening, further studies are needed to determine the true prevalence of MDRGNB amongst PCU patients.	[Heckel, Maria; Ostgathe, Christoph] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Palliat Med, Comprehens Canc Ctr CCC Erlangen EMN, Univ Klinikum Erlangen, Erlangen, Germany; [Geissdoerfer, Walter; Bogdan, Christian] Univ Klinikum Erlangen, Mikrobiol Inst Klin Mikrobiol Immunol & Hyg, Erlangen, Germany; [Geissdoerfer, Walter; Bogdan, Christian] Friedrich Alexander Univ FAU Erlangen Nurnberg, Erlangen, Germany; [Herbst, Franziska A.; Stiel, Stephanie] Hannover Med Sch, Inst Gen Practice, Hannover, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Hannover Medical School	Heckel, M (corresponding author), Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Palliat Med, Comprehens Canc Ctr CCC Erlangen EMN, Univ Klinikum Erlangen, Erlangen, Germany.; Geissdorfer, W (corresponding author), Univ Klinikum Erlangen, Mikrobiol Inst Klin Mikrobiol Immunol & Hyg, Erlangen, Germany.; Geissdorfer, W (corresponding author), Friedrich Alexander Univ FAU Erlangen Nurnberg, Erlangen, Germany.	maria.heckel@uk-erlangen.de; walter.geissdoerfer@uk-erlangen.de	Herbst, Franziska A./AAP-5067-2021; Ostgathe, Christoph/I-4385-2019	Herbst, Franziska A./0000-0003-2602-9277; Ostgathe, Christoph/0000-0003-4449-5036; Heckel, Maria/0000-0001-6212-2562; Stiel, Stephanie/0000-0002-5963-2526	German Federal Ministry of Education and Research (BMBF) [01GY1314]; Deutsche Forschungsgemeinschaft; Friedrich-Alexander Universitat Erlangen-Nurnberg (FAU)	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Friedrich-Alexander Universitat Erlangen-Nurnberg (FAU)	The presented study was part of the project M-EndoL-MRSA in end-of-life care which was financed by the German Federal Ministry of Education and Research (BMBF) (https://www.bmbf.de/en/index.html) and administratively monitored by the project management agency-part of the German Aerospace Center (Deutsches Zentrum fur Luft- und Raumfahrt) (http://www.dlr.de/dlr/en/desktopdefault.aspx/tabid-10002/) Grant Number: 01GY1314. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We acknowledge support by Deutsche Forschungsgemeinschaft and Friedrich-Alexander Universitat Erlangen-Nurnberg (FAU) within the funding programme Open Access Publishing.	Ali S, 2005, PALLIATIVE MED, V19, P188, DOI 10.1191/0269216305pm1011oa; [Anonymous], 2014, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V57, P696; [Anonymous], 2012, BUNDESGESUNDHEITSBLA, V55, P1311, DOI 10.1007/s00103-012-1549-5; [Anonymous], 2008, EPID B, V42, P363; Arias CA, 2009, NEW ENGL J MED, V360, P439, DOI 10.1056/NEJMp0804651; Bukki J, 2011, PALLIATIVE MED, V27, P84; Dand P, 2005, PALLIATIVE MED, V19, P185, DOI 10.1191/0269216305pm997oa; Davies H, 2000, Nurs Stand, V14, P35; Diederen B, 2005, J CLIN MICROBIOL, V43, P1925, DOI 10.1128/JCM.43.4.1925-1927.2005; Diekema DJ, 2007, CLIN INFECT DIS, V44, P1101, DOI 10.1086/512820; ECDC, 2014, ANT RES INT DAT EARS; European Centre for Disease Prevention and Control (ECDC), 2015, ANN REPORT EUROPEAN; Gammon J, 1998, Int J Nurs Pract, V4, P84; Ghanem HM, 2013, AM J HOSP PALLIAT ME, V30, P377, DOI 10.1177/1049909112452335; Gleeson A, 2016, PALLIATIVE MED, V30, P374, DOI 10.1177/0269216315595158; Gurieva T, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002874; Heckel Maria, 2017, J Palliat Med, V20, P273, DOI 10.1089/jpm.2016.0301; Herrmann M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073876; Hospiz- und Palliativ-Erfassung (HOPE), 2015, CLARA KLIN FORSCH CL; Hubner C, 2015, ANTIMICROB RESIST IN, V4, DOI 10.1186/s13756-015-0093-0; Jazmati N, 2017, EUR J CLIN MICROBIOL, V36, P1847, DOI 10.1007/s10096-017-3000-1; Jorgensen JH, 2015, MANUAL CLIN MICROBIO; Kaye KS, 2015, PHARMACOTHERAPY, V35, P949, DOI 10.1002/phar.1636; Kock R, 2013, EPIDEMIOL B, V5, P41; Loulergue J, 2006, EUR J CLIN MICROBIOL, V25, P407, DOI 10.1007/s10096-006-0144-9; McAllister SK, 2011, J CLIN MICROBIOL, V49, P4126, DOI 10.1128/JCM.05323-11; Meyer E, 2014, DTSCH ARZTEBL INT, V111, P331, DOI 10.3238/arztebl.2014.0331; Mitteilung der Kommission fur Krankenhaushygiene und Infektionspravention am RKI, 1999, BUNDESGESUNDHEITSBLA, V42, P954; Newton JT, 2001, J HOSP INFECT, V48, P275, DOI 10.1053/jhin.2001.1019; O'Riordan MT, 2015, INFECT CONT HOSP EP, V36, P856, DOI 10.1017/ice.2015.111; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Otter JA, 2015, CLIN MICROBIOL INFEC, V21, P1057, DOI 10.1016/j.cmi.2015.09.021; Peleg AY, 2010, NEW ENGL J MED, V362, P1804, DOI 10.1056/NEJMra0904124; Pogue JM, 2015, CLIN MICROBIOL INFEC, V21, P302, DOI 10.1016/j.cmi.2014.12.025; Prentice W, 1998, PALLIATIVE MED, V12, P443, DOI 10.1191/026921698673226380; Rees J, 2000, Nurs Stand, V14, P32; Robotham JV, 2016, LANCET INFECT DIS, V16, P348, DOI 10.1016/S1473-3099(15)00417-X; Schmalz O, 2016, PALLIATIVE MED, V30, P703, DOI 10.1177/0269216316637772; Schroder C, 2015, INT J MED MICROBIOL, V305, P799, DOI 10.1016/j.ijmm.2015.08.034; Sipahi OR, 2008, EXPERT REV ANTI-INFE, V6, P523, DOI 10.1586/14787210.6.4.523; Skyman E, 2010, SCAND J CARING SCI, V24, P101, DOI 10.1111/j.1471-6712.2009.00692.x; Stiel S, 2015, BMC PALLIAT CARE; Tarzi S, 2001, J HOSP INFECT, V49, P250, DOI 10.1053/jhin.2001.1098; Tubbicke A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-438; Verhoeven P, 2010, J CLIN MICROBIOL, V48, P4242, DOI 10.1128/JCM.01425-10; Warnke P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111627; Wassenberg MWM, 2011, CLIN MICROBIOL INFEC, V17, P1704, DOI 10.1111/j.1469-0691.2011.03502.x	47	10	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 11	2017	12	12							e0188940	10.1371/journal.pone.0188940	http://dx.doi.org/10.1371/journal.pone.0188940			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP5GS	29228010	Green Published, gold, Green Submitted			2023-01-03	WOS:000417648600020
J	Charara, M; Tovmasyan, A; Batinic-Haberle, I; Craik, J; Benov, L				Charara, Malak; Tovmasyan, Artak; Batinic-Haberle, Ines; Craik, James; Benov, Ludmil			Post-illumination cellular effects of photodynamic treatment	PLOS ONE			English	Article							LIPID-PEROXIDATION; PHOTO-TREATMENT; PROTEIN; APOPTOSIS; CELLS; OXIDATION; PATHWAYS; SURVIVAL; THERAPY; DAMAGE	Increased interest in clinical application of photodynamic therapy (PDT) in various medical fields poses a demand for better understanding of processes triggered by photo-treatment. Most of the work on PDT performed so far has focused on the immediate effects of photo-treatment. It is generally accepted that cellular damage occurs during light exposure and within a short period thereafter. If cells are not killed during the PDT, they might recover, depending on the extent of the photo-induced damage. Little is known, however, about the relationship between the properties of photosensitizers (PSs) and the delayed consequences of PDT. The aim of this work was to investigate cellular responses to sub-lethal photodynamic treatment and how toxicogenic potency may be affected by molecular features of the PS. Results demonstrated that for cationic porphyrin-based PSs, lipophilicity is the main factor determining the fate of the cells in the 24-hour post-illumination period. PSs with amphiphilic properties initiated oxidative reactions that continued in the dark, long after light exposure, and caused suppression of metabolism and loss of cell viability with concomitant changes in electrophoretic mobility of proteins, including caspases. Apoptotic activity was not stimulated in the post-illumination period. This study demonstrated that in PDT mediated by amphiphilic cationic metalloporphyrin PSs, even when immediate photo-damage is relatively mild, destructive oxidative processes initiated during PDT continue in the absence of light to substantially impair metabolism, and that post-illumination protein modification may modify utilization of cell death pathways.	[Charara, Malak; Craik, James; Benov, Ludmil] Kuwait Univ, Dept Biochem, Fac Med, Kuwait, Kuwait; [Tovmasyan, Artak; Batinic-Haberle, Ines] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA	Kuwait University; Duke University	Benov, L (corresponding author), Kuwait Univ, Dept Biochem, Fac Med, Kuwait, Kuwait.	lbenov@hsc.edu.kw	Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146	College of Graduate Studies; Kuwait University [YM09/13]; General Research Funds; HSC Omics [SRUL02/13]	College of Graduate Studies; Kuwait University; General Research Funds; HSC Omics	LB MC JC were supported by College of Graduate Studies and grants YM09/13 from Kuwait University. IBH was supported by General Research Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This study is based on a M. Sc. Thesis submitted by Malak Charara to the College of Graduate Studies, Kuwait University. The authors thank Professor Yunus Luqmani, Faculty of Pharmacy, Kuwait University for providing the cell line used in this study. We are grateful to Ms. Milini Thomas, Ms. F. Sequeira, and the staff of HSC Omics (grant SRUL02/13), for excellent technical assistance.	Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Al Saleh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020610; Al-Mutairi DA, 2007, BBA-GEN SUBJECTS, V1770, P1520, DOI 10.1016/j.bbagen.2007.06.006; Al-Mutairi DA, 2007, FREE RADICAL RES, V41, P89, DOI 10.1080/10715760600952869; Awad MM, 2016, APPL MICROBIOL BIOT, V100, P7679, DOI 10.1007/s00253-016-7632-3; Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438; BACHOWSKI GJ, 1991, J PHOTOCH PHOTOBIO B, V9, P307, DOI 10.1016/1011-1344(91)80168-H; Benov L, 2001, PROTOPLASMA, V217, P33, DOI 10.1007/BF01289410; Benov Ludmil, 2015, Med Princ Pract, V24 Suppl 1, P14, DOI 10.1159/000362416; Benov L, 2012, AMINO ACIDS, V42, P117, DOI 10.1007/s00726-010-0640-1; Benov L, 2011, ANTI-CANCER AGENT ME, V11, P233, DOI 10.2174/187152011795255975; Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Broekgaarden M, 2015, CANCER METAST REV, V34, P643, DOI 10.1007/s10555-015-9588-7; Chatterjee SR, 1997, CHEM-BIOL INTERACT, V108, P27, DOI 10.1016/S0009-2797(97)00092-6; Chatterjee SR, 1997, MOL CELL BIOCHEM, V166, P25, DOI 10.1023/A:1006840714583; Davies MJ, 2016, BIOCHEM J, V473, P805, DOI 10.1042/BJ20151227; Davies MJ, 2003, BIOCHEM BIOPH RES CO, V305, P761, DOI 10.1016/S0006-291X(03)00817-9; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007; Dean RT, 1997, BIOCHEM J, V324, P1; Ezzeddine R, 2013, J BIOL CHEM, V288, P36579, DOI 10.1074/jbc.M113.511642; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Geiger PG, 1997, FREE RADICAL BIO MED, V23, P57, DOI 10.1016/S0891-5849(96)00587-4; Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X; Girotti AW, 2004, ANTIOXID REDOX SIGN, V6, P301, DOI 10.1089/152308604322899369; Grebenova D, 2000, PHOTOCHEM PHOTOBIOL, V72, P16, DOI 10.1562/0031-8655(2000)072<0016:PCIHLC>2.0.CO;2; Ishii T, 2007, FREE RADICAL RES, V41, P1253, DOI 10.1080/10715760701678652; Kessel D, 1996, PHOTOCHEM PHOTOBIOL, V64, P601, DOI 10.1111/j.1751-1097.1996.tb03111.x; Lavie G, 1999, BRIT J CANCER, V79, P423, DOI 10.1038/sj.bjc.6690066; Lin D, 2008, ADV BIOACTIVATION RE; MacKenzie SH, 2012, ADV EXP MED BIOL, V747, P55, DOI 10.1007/978-1-4614-3229-6_4; Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516; Munshi A, 2005, METH MOLEC MED, V110, P21; Noodt BB, 1996, BRIT J CANCER, V74, P22, DOI 10.1038/bjc.1996.310; Odeh AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108238; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; Pizzimenti S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00242; Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611; Sakharov DV, 2005, FEBS LETT, V579, P1255, DOI 10.1016/j.febslet.2005.01.024; Sakharov DV, 2003, EUR J BIOCHEM, V270, P4859, DOI 10.1046/j.1432-1033.2003.03885.x; Sayre LM, 2006, DRUG METAB REV, V38, P651, DOI 10.1080/03602530600959508; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; THOMAS JP, 1989, CANCER RES, V49, P1682; Thomas M, 2015, FUTURE MICROBIOL, V10, P709, DOI [10.2217/FMB.14.148, 10.2217/fmb.14.148]; Tsaytler PA, 2008, J PROTEOME RES, V7, P3868, DOI 10.1021/pr800189q; VERWEIJ H, 1981, BIOCHIM BIOPHYS ACTA, V647, P87, DOI 10.1016/0005-2736(81)90297-2; Weijer R, 2017, CELL MOL LIFE SCI, V74, P1133, DOI 10.1007/s00018-016-2401-0; WILKINSON F, 1995, J PHYS CHEM REF DATA, V24, P663, DOI 10.1063/1.555965; ZELENIN AV, 1984, CYTOMETRY, V5, P348, DOI 10.1002/cyto.990050410	51	5	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 4	2017	12	12							e0188535	10.1371/journal.pone.0188535	http://dx.doi.org/10.1371/journal.pone.0188535			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO7EC	29200431	Green Published, gold, Green Submitted			2023-01-03	WOS:000417033200009
J	Lopez, J; Fernandez, SN; Gonzalez, R; Solana, MAJ; Urbano, J; Toledo, B; Lopez-Herce, J				Lopez, Jorge; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria A. J.; Urbano, Javier; Toledo, Blanca; Lopez-Herce, Jesus			Comparison between manual and mechanical chest compressions during resuscitation in a pediatric animal model of asphyxial cardiac arrest	PLOS ONE			English	Article							CARDIOPULMONARY-RESUSCITATION; QUALITY; DEVICE	Aims Chest compressions (CC) during cardiopulmonary resuscitation are not sufficiently effective in many circumstances. Mechanical CC could be more effective than manual CC, but there are no studies comparing both techniques in children. The objective of this study was to compare the effectiveness of manual and mechanical chest compressions with Thumper device in a pediatric cardiac arrest animal model. Material and methods An experimental model of asphyxial cardiac arrest (CA) in 50 piglets (mean weight 9.6 kg) was used. Animals were randomized to receive either manual CC or mechanical CC using a pediatric piston chest compressions device (Life-Stat (R), Michigan Instruments). Mean arterial pressure (MAP), arterial blood gases and end-tidal CO2 (etCO2) values were measured at 3, 9, 18 and 24 minutes after the beginning of resuscitation. Results There were no significant differences in MAP, DAP, arterial blood gases and etCO2 between chest compression techniques during CPR. Survival rate was higher in the manual CC (15 of 30 = 50%) than in the mechanical CC group (3 of 20 = 15%) p = 0.016. In the mechanical CC group there was a non significant higher incidence of haemorrhage through the endotracheal tube (45% vs 20%, p = 0.114). Conclusions In a pediatric animal model of cardiac arrest, mechanical piston chest compressions produced lower survival rates than manual chest compressions, without any differences in hemodynamic and respiratory parameters.	[Lopez, Jorge; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria A. J.; Urbano, Javier; Toledo, Blanca; Lopez-Herce, Jesus] Gregorio Maranon Gen Univ Hosp, Pediat Intens Care Dept, Madrid, Spain; [Lopez, Jorge; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria A. J.; Urbano, Javier; Toledo, Blanca; Lopez-Herce, Jesus] Univ Complutense Madrid, Sch Med, Pediat Dept, Madrid, Spain; [Lopez, Jorge; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria A. J.; Urbano, Javier; Toledo, Blanca; Lopez-Herce, Jesus] Gregorio Maranon Hosp, Hlth Res Inst, Madrid, Spain; [Lopez, Jorge; Fernandez, Sarah N.; Gonzalez, Rafael; Solana, Maria A. J.; Urbano, Javier; Toledo, Blanca; Lopez-Herce, Jesus] Red Salud Maternoinfantil & Desarrollo Red SAMID, Madrid, Spain	General University Gregorio Maranon Hospital; Complutense University of Madrid; General University Gregorio Maranon Hospital	Lopez-Herce, J (corresponding author), Gregorio Maranon Gen Univ Hosp, Pediat Intens Care Dept, Madrid, Spain.; Lopez-Herce, J (corresponding author), Univ Complutense Madrid, Sch Med, Pediat Dept, Madrid, Spain.; Lopez-Herce, J (corresponding author), Gregorio Maranon Hosp, Hlth Res Inst, Madrid, Spain.; Lopez-Herce, J (corresponding author), Red Salud Maternoinfantil & Desarrollo Red SAMID, Madrid, Spain.	pielvi@hotmail.com	Fernandez Lafever, Sarah Nicole/AAE-4978-2022; López, Jorge Eduardo/HJA-7565-2022; Cortes, Rafael Gonzalez/ABB-4855-2020; Lopez, Jorge/AAD-4109-2022; Lopez-Herce, Jesus/A-1602-2019	Fernandez Lafever, Sarah Nicole/0000-0003-4859-5966; Cortes, Rafael Gonzalez/0000-0002-3259-7898; Lopez, Jorge/0000-0002-9942-6399; Lopez-Herce, Jesus/0000-0001-6105-9178; Urbano, Javier/0000-0002-3511-2905	Carlos III Health Institute: Mother-Child Health and Development Network (Red SAMID) - RETICS - PN I+D+I [PI15/00743]; ISCIIISub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF) [RD16/0022/0007]	Carlos III Health Institute: Mother-Child Health and Development Network (Red SAMID) - RETICS - PN I+D+I; ISCIIISub-Directorate General for Research Assessment and Promotion; European Regional Development Fund (ERDF)(European Commission)	This work was supported by Carlos III Health Institute (PI15/00743): Mother-Child Health and Development Network (Red SAMID) - RETICS funded by the PN I+D+I 2008-2011 (Spain), ISCIIISub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF), ref. RD16/0022/0007. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badaki-Makun O, 2013, PEDIATRICS, V131, pE797, DOI 10.1542/peds.2012-1892; Blomberg H, 2011, RESUSCITATION, V82, P1332, DOI 10.1016/j.resuscitation.2011.06.002; Botran M, 2011, INTENS CARE MED, V37, P1873, DOI 10.1007/s00134-011-2338-6; Brooks SC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007260.pub3; Cheng A, 2015, RESUSCITATION, V97, P13, DOI 10.1016/j.resuscitation.2015.08.024; Couper K, 2016, RESUSCITATION, V103, P24, DOI 10.1016/j.resuscitation.2016.03.004; Gates S, 2015, RESUSCITATION, V94, P91, DOI 10.1016/j.resuscitation.2015.07.002; Gates S, 2012, HEART, V98, P908, DOI 10.1136/heartjnl-2011-301571; Giraud R, 2015, ANN EMERG MED, V65, P23, DOI 10.1016/j.annemergmed.2014.01.020; Gonzalez R, 2014, PEDIATR CRIT CARE ME, V15, pE280, DOI 10.1097/PCC.0000000000000127; HALPERIN HR, 1993, NEW ENGL J MED, V329, P762, DOI 10.1056/NEJM199309093291104; Jin SY, 2016, CLIN EXP EMERG MED, V3, P27, DOI 10.15441/ceem.16.119; Kim MJ, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0118-y; Koga Y, 2015, RESUSCITATION, V96, P226, DOI 10.1016/j.resuscitation.2015.08.013; Li H, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0202-y; Liao QM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-53; Lopez J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162185; Lopez-Herce J, 2011, INTENS CARE MED, V37, P147, DOI 10.1007/s00134-010-2006-2; Lu Xiao-guang, 2010, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V22, P496; Maconochie IK, 2015, RESUSCITATION, V95, pE147, DOI 10.1016/j.resuscitation.2015.07.044; Maconochie IK, 2015, RESUSCITATION, V95, P223, DOI 10.1016/j.resuscitation.2015.07.028; Perkins GD, 2015, LANCET, V385, P947, DOI 10.1016/S0140-6736(14)61886-9; Putzer G, 2016, J EMERG MED, V50, P594, DOI 10.1016/j.jemermed.2015.10.002; Putzer G, 2013, AM J EMERG MED, V31, P384, DOI 10.1016/j.ajem.2012.07.018; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Rudinska LI, 2016, RESUSCITATION, V103, P66, DOI 10.1016/j.resuscitation.2016.04.002; Sanchez B, 2015, J CRIT CARE, V30, P711, DOI 10.1016/j.jcrc.2015.03.001; Smekal D, 2014, RESUSCITATION, V85, P1708, DOI 10.1016/j.resuscitation.2014.09.017; Sutton RM, 2015, RESUSCITATION, V93, P150, DOI 10.1016/j.resuscitation.2015.04.010; TAYLOR GJ, 1978, JAMA-J AM MED ASSOC, V240, P644, DOI 10.1001/jama.240.7.644; Tranberg T, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0114-2; Xanthos T, 2011, EUR J EMERG MED, V18, P108, DOI 10.1097/MEJ.0b013e32833e79cf	32	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188846	10.1371/journal.pone.0188846	http://dx.doi.org/10.1371/journal.pone.0188846			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190801	gold, Green Submitted, Green Published			2023-01-03	WOS:000416841900141
J	Bonsante, F; Gouyon, JB; Robillard, PY; Gouyon, B; Iacobelli, S				Bonsante, Francesco; Gouyon, Jean-Bernard; Robillard, Pierre-Yves; Gouyon, Beatrice; Iacobelli, Silvia			Early optimal parenteral nutrition and metabolic acidosis in very preterm infants	PLOS ONE			English	Article							AMINO-ACID; GROWTH; GUIDELINES	Background It is currently recognized that an optimized nutritional approach, consisting of an early and substantial supply of protein and energy by parenteral route, may be beneficial for very low birth weight infants and recent guidelines endorse this strategy. However, the impact of the enhanced parenteral nutrition (PN) on acid-basic balance has never been investigated. The aim of the present study is to assess the effect of nutrient intake on acid-base homeostasis in a large population of preterm infants on PN. Methods This observational study described the acid-base profile of very preterm infants (<= 29 week's gestation) receiving PN during the first week of life. For this purpose three different cohorts of infants who received increasing (group 1 to group 3) nutritional intakes were considered. Nutrition data were recorded daily and correlated to acid-base data (pH, base excess, and lactate). The outcome measure to assess metabolic acidosis was the base excess (BE). Results 161 infants were included. 1127 daily nutritional records and 795 blood gas data were analyzed. The three groups were different with regard to nutritional intravenous intakes. Group 3 in particular had a higher mean intake of both amino acids (3.3 +/- 0.8 g/kg/d) and lipids (2.8 +/- 1.4 g/kg/d) during the first week of life. Metabolic acidosis was more severe in the group with the highest parenteral intake of amino acids and lipids: mean BE =-8.7 +/- 3.4 (group 3);-6.4 +/- 3.4 (group 2);-5.1 +/- 3.0 (group 1)]. At the multivariate analysis the significant risk factors for metabolic acidosis were: gestational age, initial base excess, amino acid and lipid intravenous intakes. Discussion Acid-base homeostasis was influenced by the nutritional intake. Earlier and higher intravenous amino acid and lipid intakes particularly increased the risk of metabolic acidosis. The nutritional tolerance was different depending on gestational age, and the smaller infants (24-26 week's gestation) displayed greater acidotic disequilibrium and a higher need of bicarbonate.	[Bonsante, Francesco; Robillard, Pierre-Yves; Iacobelli, Silvia] CHU Reunion, Reanimat Neonatale & Pediat Neonatol, Site Sud, St Pierre, Reunion, France; [Bonsante, Francesco; Gouyon, Jean-Bernard; Robillard, Pierre-Yves; Gouyon, Beatrice; Iacobelli, Silvia] CHU Reunion, CEPOI, EA 7388, Site Sud, St Pierre, Reunion, France	CHU Reunion; CHU Reunion	Bonsante, F (corresponding author), CHU Reunion, Reanimat Neonatale & Pediat Neonatol, Site Sud, St Pierre, Reunion, France.; Bonsante, F (corresponding author), CHU Reunion, CEPOI, EA 7388, Site Sud, St Pierre, Reunion, France.	fbonsante@yahoo.com	Robillard, Pierre-Yves/AAD-9774-2021					[Anonymous], 1995, CMAJ, V152, P1765; BENYAJATI S, 1975, AM J PHYSIOL, V228, P693, DOI 10.1152/ajplegacy.1975.228.3.693; Bonsante F, 2011, EUR J CLIN NUTR, V65, P1088, DOI 10.1038/ejcn.2011.79; Bonsante F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072880; Braake FWJT, 2005, J PEDIATR-US, V147, P457, DOI 10.1016/j.jpeds.2005.05.038; Christmann V, 2013, ACTA PAEDIATR, V102, pE530, DOI 10.1111/apa.12302; Gouyon B, 2017, J CLIN PHARM THER, V42, P64, DOI 10.1111/jcpt.12474; GREENE HL, 1988, AM J CLIN NUTR, V48, P1324; Guellec I, 2015, J PEDIATR GASTR NUTR, V61, P605, DOI 10.1097/MPG.0000000000000898; Heird W C, 1972, N Engl J Med, V287, P943, DOI 10.1056/NEJM197211092871901; Iacobelli S, 2010, Minerva Pediatr, V62, P203; Iacobelli S, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/931597; Iacona SL, 2015, E HLTH BIOENG C IEEE, P1, DOI [10.1109/EHB.2015.7391370, DOI 10.1109/EHB.2015.7391370]; Ibrahim Hassan M, 2004, J Perinatol, V24, P482, DOI 10.1038/sj.jp.7211114; Jadhav P, 2007, JPEN-PARENTER ENTER, V31, P278, DOI 10.1177/0148607107031004278; Kermorvant-Duchemin E, 2012, J PEDIATR GASTR NUTR, V54, P613, DOI 10.1097/MPG.0b013e318245b428; Koletzko Berthold, 2005, J Pediatr Gastroenterol Nutr, V41 Suppl 2, pS1, DOI 10.1097/01.mpg.0000181841.07090.f4; Maggio L, 2007, J PEDIATR GASTR NUTR, V44, P124, DOI 10.1097/01.mpg.0000237927.00105.f7; Moltu SJ, 2014, J PEDIATR GASTR NUTR, V58, P344, DOI 10.1097/MPG.0000000000000220; Moltu SJ, 2013, CLIN NUTR, V32, P207, DOI 10.1016/j.clnu.2012.09.004; Sato T, 2002, EARLY HUM DEV, V70, P15, DOI 10.1016/S0378-3782(02)00042-7; Senterre T, 2012, ACTA PAEDIATR, V101, pE64, DOI 10.1111/j.1651-2227.2011.02443.x; Senterre T, 2011, J PEDIATR GASTR NUTR, V53, P536, DOI 10.1097/MPG.0b013e31822a009d	23	16	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 27	2017	12	11							e0186936	10.1371/journal.pone.0186936	http://dx.doi.org/10.1371/journal.pone.0186936			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN8QZ	29176758	Green Published, gold, Green Submitted			2023-01-03	WOS:000416291900003
J	Ashry, A				Ashry, Al			Review: In obstructive sleep apnea, continuous positive airway pressure does not reduce cardiovascular outcomes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Ashry, Al] Med Univ South Carolina, Charleston, SC 29425 USA	Medical University of South Carolina	Ashry, A (corresponding author), Med Univ South Carolina, Charleston, SC 29425 USA.	alaashry@musc.edu							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2017	167	10					JC55	JC55		10.7326/ACPJC-2017-167-10-055	http://dx.doi.org/10.7326/ACPJC-2017-167-10-055			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO2DP	29159381				2023-01-03	WOS:000416584200007
J	Vigil, JM; Stith, SS; Adams, IM; Reeve, AP				Vigil, Jacob M.; Stith, Sarah S.; Adams, Ian M.; Reeve, Anthony P.			Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study	PLOS ONE			English	Article							MARIJUANA LAWS; BACK-PAIN; PREVALENCE; SUBSTANCES; RISK	Background Current levels and dangers of opioid use in the U.S. warrant the investigation of harm-reducing treatment alternatives. Purpose A preliminary, historical, cohort study was used to examine the association between enroll-ment in the New Mexico Medical Cannabis Program (MCP) and opioid prescription use. \ Methods Thirty-seven habitual opioid using, chronic pain patients (mean age = 54 years; 54% male; 86% chronic back pain) enrolled in the MCP between 4/1/2010 and 10/3/2015 were compared to 29 non-enrolled patients (mean age = 60 years; 69% male; 100% chronic back pain). We used Prescription Monitoring Program opioid records over a 21 month period (first three months prior to enrollment for the MCP patients) to measure cessation (defined as the absence of opioid prescriptions activity during the last three months of observation) and reduction (calculated in average daily intravenous [IV] morphine dosages). MCP patient-reported benefits and side effects of using cannabis one year after enrollment were also collected. Results By the end of the 21 month observation period, MCP enrollment was associated with 17.27 higher age-and gender-adjusted odds of ceasing opioid prescriptions (CI 1.89 to 157.36, p = 0.012), 5.12 higher odds of reducing daily prescription opioid dosages (CI 1.56 to 16.88, p = 0.007), and a 47 percentage point reduction in daily opioid dosages relative to a mean change of positive 10.4 percentage points in the comparison group (CI -90.68 to -3.59, p = 0.034). The monthly trend in opioid prescriptions over time was negative among MCP patients (-0.64mg IV morphine, CI -1.10 to -0.18, p = 0.008), but not statistically different from zero in the comparison group (0.18mg IV morphine, CI -0.02 to 0.39, p = 0.081). Survey responses indicated improvements in pain reduction, quality of life, social life, activity levels, and concentration, and few side effects from using cannabis one year after enrollment in the MCP (ps<0.001). Conclusions The clinically and statistically significant evidence of an association between MCP enrollment and opioid prescription cessation and reductions and improved quality of life warrants further investigations on cannabis as a potential alternative to prescription opioids for treating chronic pain.	[Vigil, Jacob M.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Stith, Sarah S.] Univ New Mexico, Dept Econ, Albuquerque, NM 87131 USA; [Adams, Ian M.; Reeve, Anthony P.] Ind Rehabil Clin, Albuquerque, NM USA	University of New Mexico; University of New Mexico	Vigil, JM (corresponding author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.	vigilj@unm.edu	Adams, Ian Marshall/GQB-5002-2022		University of New Mexico Medical Cannabis Research Fund	University of New Mexico Medical Cannabis Research Fund	This research was funded in part by the University of New Mexico Medical Cannabis Research Fund.; This research was funded in part by the University of New Mexico Medical Cannabis Research Fund. All authors had access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses. We thank J. Alcock for comments on an earlier draft.	Abrams DI, 2016, CURR ONCOL, V23, pS8, DOI 10.3747/co.23.3099; Ashton CH, 2001, BRIT J PSYCHIAT, V178, P101, DOI 10.1192/bjp.178.2.101; Bachhuber MA, 2014, JAMA INTERN MED, V174, P1668, DOI 10.1001/jamainternmed.2014.4005; Bonn-Miller MO, 2011, PSYCHOL ADDICT BEHAV, V25, P485, DOI 10.1037/a0021945; Bradford AC, 2016, HEALTH AFFAIR, V35, P1230, DOI 10.1377/hlthaff.2015.1661; Calabria B, 2010, DRUG ALCOHOL REV, V29, P318, DOI 10.1111/j.1465-3362.2009.00149.x; CDC, 2016, WID RANG ONL DAT EP; Chey WD, 2014, NEW ENGL J MED, V370, P2387, DOI 10.1056/NEJMoa1310246; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Crane EH, EMERGENCY DEP VISITS; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Deyo RA, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g6380; Friedman D, 2015, NEW ENGL J MED, V373, P1048, DOI 10.1056/NEJMra1407304; Fuster D, J ADDICTION MED; Garcia-Portilla M. P., 2012, BRIT J CLIN PHARMACO, V77, P272; Globalrph. com, 2016, OP NARC AN CONV; Haroutounian S, 2016, CLIN J PAIN, V32, P1036, DOI 10.1097/AJP.0000000000000364; Hill KP, 2016, JAMA-J AM MED ASSOC, V315, P2338, DOI 10.1001/jama.2016.5181; Hurd YL, TRENDS IN NEUROSCIEN; Kim JH, 2016, AM J PUBLIC HEALTH, V106, P2032, DOI 10.2105/AJPH.2016.303426; Lucas P, 2017, INT J DRUG POLICY, V42, P30, DOI 10.1016/j.drugpo.2017.01.011; Lucas P, 2016, DRUG ALCOHOL REV, V35, P326, DOI 10.1111/dar.12323; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN C; Reiman A, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-35; Rubin R., 2017, JAMA; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339; Shaheed CA, 2016, JAMA INTERN MED, V176, P958, DOI 10.1001/jamainternmed.2016.1251; Stith SS, 2016, SCIENCE, V352, P1182, DOI 10.1126/science.aaf7450; Tashkin Donald P, 2013, Ann Am Thorac Soc, V10, P239, DOI 10.1513/AnnalsATS.201212-127FR; Trescot A, 2008, PAIN PHYSICIAN, V11, pS181; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Wang T, 2008, CAN MED ASSOC J, V178, P1669, DOI 10.1503/cmaj.071178; Ware MA, 2015, J PAIN, V16, P1233, DOI 10.1016/j.jpain.2015.07.014; Whiting PF, 2016, JAMA-J AM MED ASSOC, V3913, P2456; Wilkie G, 2016, JAMA ONCOL, V2, P670, DOI 10.1001/jamaoncol.2016.0155	37	74	73	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2017	12	11							e0187795	10.1371/journal.pone.0187795	http://dx.doi.org/10.1371/journal.pone.0187795			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FM8YO	29145417	Green Submitted, gold, Green Published			2023-01-03	WOS:000415378800030
J	Bennett, SD; Lowther, SA; Chingoli, F; Chilima, B; Kabuluzi, S; Ayers, TL; Warne, TA; Mintz, E				Bennett, Sarah D.; Lowther, Sara A.; Chingoli, Felix; Chilima, Benson; Kabuluzi, Storn; Ayers, Tracy L.; Warne, Thomas A.; Mintz, Eric			Assessment of water, sanitation and hygiene interventions in response to an outbreak of typhoid fever in Neno District, Malawi	PLOS ONE			English	Article							DIARRHEA PREVENTION; BACTEREMIA; CHILDREN; BURDEN; ADULTS	On May 2, 2009 an outbreak of typhoid fever began in rural villages along the Malawi Mozambique border resulting in 748 illnesses and 44 deaths by September 2010. Despite numerous interventions, including distribution of WaterGuard (WG) for in-home water treatment and education on its use, cases of typhoid fever continued. To inform response activities during the ongoing Typhoid outbreak information on knowledge, attitudes, and practices surrounding typhoid fever, safe water, and hygiene were necessary to plan future outbreak interventions. In September 2010, a survey was administered to female heads in randomly selected households in 17 villages in Neno District, Malawi. Stored household drinking water was tested for free chlorine residual (FCR) levels using the N,N diethyl-p-phenylene diamine colorimetric method (HACH Company, Loveland, CO, USA). Attendance at community-wide educational meetings was reported by 56% of household respondents. Respondents reported that typhoid fever is caused by poor hygiene (77%), drinking unsafe water (49%), and consuming unsafe food (25%), and that treating drinking water can prevent it (68%). WaterGuard, a chlorination solution for drinking water treatment, was observed in 112 (56%) households, among which 34% reported treating drinking water. FCR levels were adequate (FCR >= 0.2 mg/L) in 29 (76%) of the 38 households who reported treatment of stored water and had stored water available for testing and an observed bottle of WaterGuard in the home. Soap was observed in 154 (77%) households, among which 51% reported using soap for hand washing. Educational interventions did not reach almost one-half of target households and knowledge remains low. Despite distribution and promotion of WaterGuard and soap during the outbreak response, usage was low. Future interventions should focus on improving water, sanitation and hygiene knowledge, practices, and infrastructure. Typhoid vaccination should be considered.	[Bennett, Sarah D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA; [Bennett, Sarah D.; Ayers, Tracy L.; Mintz, Eric] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA; [Lowther, Sara A.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA; [Chingoli, Felix] Neno Dist Hlth Off, Neno, Malawi; [Chilima, Benson; Kabuluzi, Storn] Minist Hlth, Community Hlth Serv Unit, Lilongwe, Malawi; [Warne, Thomas A.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Lilongwe, Malawi	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Bennett, SD (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Bennett, SD (corresponding author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA.	iyk3@cdc.gov		Ayers, Tracy/0000-0003-4140-3263	Division of Global Disease Detection and Emergency Response, CGH; Division of Global Disease Detection and Emergency Response, CDC	Division of Global Disease Detection and Emergency Response, CGH; Division of Global Disease Detection and Emergency Response, CDC	The investigation was funded by the Division of Global Disease Detection and Emergency Response, CGH, CDC.	Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367; Blum LS, 2014, AM J TROP MED HYG, V91, P729, DOI 10.4269/ajtmh.14-0067; Breiman RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029119; Buckle Geoffrey C, 2012, J Glob Health, V2, P010401, DOI 10.7189/jogh.02.010401; Clarke K, 2012, AM SOC TROP MED HYG; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Crump JA, 2010, CLIN INFECT DIS, V50, P241, DOI 10.1086/649541; Fiebelkorn AP, 2012, SOC SCI MED, V75, P622, DOI 10.1016/j.socscimed.2012.02.011; Figueroa ME, 2010, CTR PUBLICATION HCI; Gordon MA, 2002, AIDS, V16, P1633, DOI 10.1097/00002030-200208160-00009; Gordon MA, 2008, CLIN INFECT DIS, V46, P963, DOI 10.1086/529146; Imanishi M, 2014, AM J TROP MED HYG, V90, P945, DOI 10.4269/ajtmh.13-0497; Luby SP, 2006, TROP MED INT HEALTH, V11, P479, DOI 10.1111/j.1365-3156.2006.01592.x; Luby SP, 2004, AM J TROP MED HYG, V71, P420, DOI 10.4269/ajtmh.2004.71.420; Luby SP, 2008, AM J TROP MED HYG, V78, P382, DOI 10.4269/ajtmh.2008.78.382; Lutterloh E, 2012, CLIN INFECT DIS, V54, P1100, DOI 10.1093/cid/cis012; Makutsa P, 2001, AM J PUBLIC HEALTH, V91, P1571, DOI 10.2105/AJPH.91.10.1571; Mintz E, 2008, CONTROL COMMUNICABLE, P664; Mogasale V, 2014, LANCET GLOB HEALTH, V2, pE570, DOI 10.1016/S2214-109X(14)70301-8; Muyembe-Tamfum JJ, 2009, TRAVEL MED INFECT DI, V7, P40, DOI 10.1016/j.tmaid.2008.12.006; Neil KP, 2012, CLIN INFECT DIS, V54, P1091, DOI 10.1093/cid/cis025; Nelson C., 2012, CONTROLLING TYPHOID; Neno District Health Officer, 2010, TYPH FEV OUTBR REP; Parry CM, 2002, NEW ENGL J MED, V347, P1770, DOI 10.1056/NEJMra020201; Reller ME, 2003, AM J TROP MED HYG, V69, P411, DOI 10.4269/ajtmh.2003.69.411; Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d; Slayton RB, 2013, HUM VACC IMMUNOTHER, V9, P903, DOI 10.4161/hv.23007; Thevos A K, 2000, Educ Health (Abingdon), V13, P366; Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010; Walters MS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002726; Were V., 2012, INT J POPUL RES, V2012, P1, DOI [10.1155/2012/470598, DOI 10.1155/2012/470598]; WHO Regional Office for Africa, 2012, OUTBREAK B, V2, P12; WHO/UNICEF Joint Monitoring Programme, 2012, PROGR DRINK WAT SAN; WHO-WORLD HEALTH ORGANIZATION, 2012, REP AD HOC CONS TYPH; World Health Organization, 2003, BACKGR DOC DIAGN TRE; World Health Organization (WHO), 2008, GUID DRINK WAT QUAL	36	13	14	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2018	13	2							e0193348	10.1371/journal.pone.0193348	http://dx.doi.org/10.1371/journal.pone.0193348			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX4LV	29474394	Green Published, Green Submitted, gold			2023-01-03	WOS:000426049500091
J	von Babo, M; Chmiel, C; Muggler, SA; Rakusa, J; Schuppli, C; Meier, P; Fischler, M; Urner, M				von Babo, Michelle; Chmiel, Corinne; Muggler, Simon Andreas; Rakusa, Julia; Schuppli, Caroline; Meier, Philipp; Fischler, Manuel; Urner, Martin			Transfusion practice in anemic, non-bleeding patients: Cross-sectional survey of physicians working in general internal medicine teaching hospitals in Switzerland	PLOS ONE			English	Article							BLOOD-CELL TRANSFUSION; CLINICAL-PRACTICE GUIDELINE; ACUTE LUNG INJURY; CRITICAL-CARE; RECOMMENDATIONS; STRATEGIES; MANAGEMENT; MULTICENTER; DEFINE; PLASMA	Background Transfusion practice might significantly influence patient morbidity and mortality. Between European countries, transfusion practice of red blood cells (RBC) greatly differs. Only sparse data are available on transfusion practice of general internal medicine physicians in Switzerland. Methods In this cross-sectional survey, physicians working in general medicine teaching hospitals in Switzerland were investigated regarding their self-reported transfusion practice in anemic patients without acute bleeding. The definition of anemia, transfusion triggers, knowledge on RBC transfusion, and implementation of guidelines were assessed. Results 560 physicians of 71 hospitals (64%) responded to the survey. Anemia was defined at very diverging hemoglobin values (by 38% at a hemoglobin <130 g/L for men and by 57% at <120 g/L in non-pregnant women). 62% and 43% respectively, did not define anemia in men and in women according to the World Health Organization. Fifty percent reported not to transfuse RBC according to international guidelines. Following factors were indicated to influence the decision to transfuse: educational background of the physicians, geographical region of employment, severity of anemia, and presence of known coronary artery disease. 60% indicated that their knowledge on Transfusion-related Acute Lung Injury (TRALI) did not influence transfusion practice. 50% of physicians stated that no local transfusion guidelines exist and 84% supported the development of national recommendations on transfusion in non-acutely bleeding, anemic patients. Conclusion This study highlights the lack of adherence to current transfusion guidelines in Switzerland. Identifying and subsequently correcting this deficit in knowledge translation may have a significant impact on patient care.	[von Babo, Michelle; Chmiel, Corinne; Muggler, Simon Andreas; Rakusa, Julia; Fischler, Manuel; Urner, Martin] Waid City Hosp, Dept Internal Med, Zurich, Switzerland; [Chmiel, Corinne] Univ Zurich, Inst Primary Care, Zurich, Switzerland; [Schuppli, Caroline] Univ Zurich, Anthropol Inst & Museum, Zurich, Switzerland; [Meier, Philipp] Swiss Fed Inst Environm Sci & Technol EAWAG, Appl Aquat Ecol, Dubendorf, Switzerland; [Urner, Martin] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada	University of Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); University of Toronto	Urner, M (corresponding author), Waid City Hosp, Dept Internal Med, Zurich, Switzerland.; Urner, M (corresponding author), Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.	martin.urner@gmail.com	Urner, Martin/AAK-5701-2020	Urner, Martin/0000-0003-1133-4885; Chmiel, Corinne/0000-0002-5249-6592				Achermann R, 2011, CLIN MICROBIOL INFEC, V17, P855, DOI 10.1111/j.1469-0691.2010.03348.x; Agresti A., 2010, ANAL ORDINAL CATEGOR, DOI [DOI 10.1002/9780470594001, 10.1002/9780470594001]; Amer Soc Anesthesiologists, 2015, ANESTHESIOLOGY, V122, P241, DOI 10.1097/ALN.0000000000000463; Ansari S, 2012, BLOOD TRANSFUS-ITALY, V10, P28, DOI 10.2450/2011.0108-10; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Baruch Y, 2008, HUM RELAT, V61, P1139, DOI 10.1177/0018726708094863; Bates D, 2007, IME4 PACKAGE R PACKA, V2; Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; Bivand RS, 2008, USE R, P1; Blajchman MA, 2001, TRANSFUS CLIN BIOL, V8, P207, DOI 10.1016/S1246-7820(01)00136-7; Bundesarztekammer B, 2013, QUERSCHN LEITL BAK T; Calder L, 1997, CAN MED ASSOC J, V156, pS1; Carson JL, 2014, HEMATOL-AM SOC HEMAT, P548, DOI 10.1182/asheducation-2014.1.548; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub3; Christensen RHB, 2014, TUTORIAL FITTING CUM; Christensen RHB, 2010, ORDINAL REGRESSION M, P22; Corwin HL, 2004, CRIT CARE, V8, pS42, DOI 10.1186/cc2411; Souza Diego Agra de, 2013, Rev. Bras. Hematol. Hemoter., V35, P263, DOI 10.5581/1516-8484.20130070; Ferraris VA, 2007, ANN THORAC SURG, V83, P27, DOI 10.1016/j.athoracsur.2007.02.099; Fontana S, 2014, TRANSFUS MED HEMOTH, V41, P182, DOI 10.1159/000363540; Gajic O, 2006, CRIT CARE MED, V34, pS109, DOI 10.1097/01.CCM.0000214311.56231.23; Giangrande PLF, 2000, BRIT J HAEMATOL, V110, P758, DOI 10.1046/j.1365-2141.2000.02139.x; Gombotz H, 2007, TRANSFUSION, V47, P1468, DOI 10.1111/j.1537-2995.2007.01286.x; Goodnough LT, 2013, LANCET, V381, P1845, DOI 10.1016/S0140-6736(13)60650-9; Goodnough LT, 2015, AM J HEMATOL, V90, P927, DOI 10.1002/ajh.24101; Halekoh U, 2014, J STAT SOFTW, V59, P1; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 2005, CRIT CARE MED, V33, P7, DOI 10.1097/01.CCM.0000151047.33912.A3; Hebert PC, 2003, JAMA-J AM MED ASSOC, V289, P1941, DOI 10.1001/jama.289.15.1941; HILL SR, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002042.PUB2; Hovaguimian F, 2016, ANESTHESIOLOGY, V125, P46, DOI 10.1097/ALN.0000000000001162; Janssen M, 2014, COLLECTION TESTING U; Janssen MP, 2013, COLLECTION TESTING U; Kian H, 2007, CHEST, V131, P1308, DOI 10.1378/chest.06-3048; Klein HG, 2007, LANCET, V370, P415, DOI 10.1016/S0140-6736(07)61197-0; Kraft E, 2013, SCHWEIZERISCHE ARZTE, V94, P453; Lee JS, 2010, NAT MED, V16, P381, DOI 10.1038/nm0410-381; Lewin-Koh N.J., 2011, MAPTOOLS TOOLS READI; Liumbruno G, 2009, BLOOD TRANSFUS-ITALY, V7, P49, DOI 10.2450/2008.0020-08; Liumbruno GM, 2011, BLOOD TRANSFUS-ITALY, V9, P189, DOI 10.2450/2011.0075-10; Liumbruno GM, 2011, BLOOD TRANSFUS-ITALY, V9, P19, DOI 10.2450/2010.0074-10; Madjdpour C, 2006, MINERVA ANESTESIOL, V72, P283; McAvoy BR, 1996, BRIT MED J, V313, P732; Murphy MF, 2001, BRIT J HAEMATOL, V113, P24; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Politsmakher A, 2013, AM J MED, V126, P894, DOI 10.1016/j.amjmed.2013.06.013; Shander A, 2013, BLOOD TRANSFUS-ITALY, V11, P193, DOI 10.2450/2012.0195-12; Simon TL, 1998, ARCH PATHOL LAB MED, V122, P130; Spahn Donat R, 2004, Best Pract Res Clin Anaesthesiol, V18, P661, DOI 10.1016/j.bpa.2004.05.002; Steensma DP, 2007, MAYO CLIN PROC, V82, P958, DOI 10.4065/82.8.958; Sullivan KM, 2008, TROP MED INT HEALTH, V13, P1267, DOI 10.1111/j.1365-3156.2008.02143.x; Vamvakas EC, 2010, TRANSFUS MED REV, V24, P77, DOI 10.1016/j.tmrv.2009.11.001; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	54	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2018	13	1							e0191752	10.1371/journal.pone.0191752	http://dx.doi.org/10.1371/journal.pone.0191752			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU1NX	29381721	Green Published, Green Accepted, gold			2023-01-03	WOS:000423617800033
J	Pitman, B				Pitman, Bonnie			Pharma Art-Abstract Medication in the Work of Beverly Fishman	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Pitman, Bonnie] Edith ODonnell Inst Art Hist, Residence, Dallas, TX USA; [Pitman, Bonnie] Univ Texas Dallas, Ctr Brain Hlth, Art Brain Initiat, Richardson, TX 75080 USA	University of Texas System; University of Texas Dallas	Pitman, B (corresponding author), Univ Texas Dallas, 800 W Campbell Rd,ATC 11,Off ATC 3-602, Richardson, TX 75080 USA.	bpitman@utdallas.edu							0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 23	2018	319	4					326	328		10.1001/jama.2017.18675	http://dx.doi.org/10.1001/jama.2017.18675			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT8LW	29362772				2023-01-03	WOS:000423405300001
J	Tran, BX; Nguyen, LH; Tran, TT; Latkin, CA				Bach Xuan Tran; Long Hoang Nguyen; Tung Thanh Tran; Latkin, Carl A.			Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients	PLOS ONE			English	Article							ADMINISTERED ANTIRETROVIRAL THERAPY; INJECTION-DRUG USERS; QUALITY-OF-LIFE; MEDICATION ADHERENCE; COST-EFFECTIVENESS; GLOBAL BURDEN; SYSTEMATIC ANALYSIS; SERVICE UTILIZATION; INTERNET ADDICTION; RISK BEHAVIORS	Introduction Methadone maintenance treatment (MMT) services may reduce the risk of HIV transmission if patients completely adhere to the treatment. Identifying adherence patterns and potential related factors is vital for the sustainability of MMT program in Vietnam. This study examined social and structural factors associated with adherence to MMT among patients in different service delivery models. Materials and methods A total of 510 patients at three MMT clinics in Hanoi were interviewed. Measures of self-reported adherence included the number of missed doses in the past 7 days and the level of adherence in the past 30 days using a visual analog scale (VAS) scoring from 0 (non-adherence) to 100 (perfect adherence). Multivariate regressions were employed to identify factors associated with non-adherence to MMT. Results A total of 17.7% of participants reported incomplete MMT adherence in the last 30 days and 8.3% reported missing a dose in the last seven days, respectively. Living with HIV/AIDS, poor self-care and usual activities, and disclosure of health issues to spouses or intimate partners were associated with non-adherence. Those patients with pain or depression were more likely to report better adherence. Disclosing health status to spouse/partner increased the risk of incomplete adherence, while disclosing to friends reduced the number of missed dose in the last seven days. Patients attending clinics with comprehensive services had a lower VAS score of adherence compared to those enrolling in clinics with only MMT and general health care. Conclusions Sustaining the compliance of patients to MMT is principal in the rapid expansion of this service in Vietnam. It is necessary to address the complexity of health care demands of drug users, their difficulties to be rehabilitated into workforce and society, and the stigmatization to maximize the outcomes of MMT program.	[Bach Xuan Tran] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam; [Bach Xuan Tran; Latkin, Carl A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Long Hoang Nguyen] Vietnam Natl Univ, Sch Med & Pharm, Hanoi, Vietnam; [Tung Thanh Tran] Duy Tan Univ, Inst Global Hlth Innovat, Da Nang, Vietnam	Hanoi Medical University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Vietnam National University Hanoi; Duy Tan University	Tran, BX (corresponding author), Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam.; Tran, BX (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.	bach.jhu@gmail.com						Tran BX, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2405-y; Tran BX, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-016-3983-z; Tran BX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168687; Tran BX, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0485-8; Tran BX, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0091-4; Tran BX, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-132; Tran BX, 2012, GLOB PUBLIC HEALTH, V7, P1080, DOI 10.1080/17441692.2012.736259; Tran BX, 2012, AIDS CARE, V24, P283, DOI 10.1080/09540121.2011.608420; Barclay TR, 2007, HEALTH PSYCHOL, V26, P40, DOI 10.1037/0278-6133.26.1.40; Boyd J, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0159-9; Control VAoHA, 2015, ANN REV HIV AIDS CON; Control VAoHA, 2016, ANN REV HIV AIDS CON; Dima AL, 2014, SOC SCI MED, V108, P166, DOI 10.1016/j.socscimed.2014.02.045; Fekete EM, 2009, BRAIN BEHAV IMMUN, V23, P693, DOI 10.1016/j.bbi.2009.01.007; Forouzanfar MH, 2016, LANCET, V388, P1659, DOI 10.1016/S0140-6736(16)31679-8; Greenwald MK, 2002, EXP CLIN PSYCHOPHARM, V10, P39, DOI 10.1037//1064-1297.10.1.39; Haskew M, 2008, J SUBST ABUSE TREAT, V35, P109, DOI 10.1016/j.jsat.2007.08.013; Havens JR, J SUBSTANCE ABUSE TR, V36, P306; Herget Greg, 2005, HIV AIDS Policy Law Rev, V10, P23; Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31470-2; Kermode M, 2011, B WORLD HEALTH ORGAN, V89, P243, DOI 10.2471/BLT.11.086850; Khalsa JH, 2010, AM J ADDICTION, V19, P96, DOI 10.1111/j.1521-0391.2009.00010.x; Larance B, 2012, NONADHERENCE OPIOID; Latkin CA, 1999, AM J DRUG ALCOHOL AB, V25, P463, DOI 10.1081/ADA-100101873; Latkin CA, 2016, AIDS EDUC PREV, V28, P417, DOI 10.1521/aeap.2016.28.5.417; Lin CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132589; Nguyen LH, 2017, SUBST ABUSE TREAT PR, V12, DOI 10.1186/s13011-017-0115-4; Nguyen LH, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0633-9; Lucas GM, 2004, CLIN INFECT DIS, V38, pS409, DOI 10.1086/421405; Lucas GM, 2007, AIDS PATIENT CARE ST, V21, P564, DOI 10.1089/apc.2006.0192; McCance-Katz EF, 1998, J ACQ IMMUN DEF SYND, V18, P435, DOI 10.1097/00042560-199808150-00004; Milloy MJS, 2012, AIDS, V26, P1049, DOI 10.1097/QAD.0b013e32835221cc; Musa R, 2012, ASIA-PAC J PUBLIC HE, V24, P826, DOI 10.1177/1010539511404396; National Committee for AIDS DaPPaC, 2012, NAT STRAT HIV AIDS P; Nguyen LH, 2015, AIDS BEHAV; Nguyen LH, 2017, AIDS BEHAV; Obermeyer CM, 2011, AM J PUBLIC HEALTH, V101, P1011, DOI 10.2105/AJPH.2010.300102; Pharmacists OCo, 2014, METH MAINT TREATM MM; Raffa JD, DRUG ALCOHOL DEPENDE, V89, P306; Rao D, 2007, AIDS CARE, V19, P28, DOI 10.1080/09540120600652303; Rao R, 2013, B WORLD HEALTH ORGAN, V91, P150, DOI 10.2471/BLT.12.111815; Riegel B, 2009, EUR J CARDIOVASC NUR, V8, P337, DOI 10.1016/j.ejcnurse.2009.06.003; Rotzinger A, PATIENT ED COUNSELIN, V99, P1413; Roux P, 2014, CURR PHARM DESIGN, V20, P4097, DOI 10.2174/13816128113199990623; Serovich JM, 2008, AIDS BEHAV, V12, P227, DOI 10.1007/s10461-007-9295-7; Shen JC, 2016, J ADDICT MED, V10, P40, DOI 10.1097/ADM.0000000000000180; Tran BX, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2897-0; Tran Bach Xuan, 2013, Int J Drug Policy, V24, pe105, DOI 10.1016/j.drugpo.2013.07.007; Tran BX, 2012, DRUG ALCOHOL DEPEN, V125, P260, DOI 10.1016/j.drugalcdep.2012.02.021; Tran BX, 2016, PLOS ONE, V11; Tran BX, 2015, PLOS ONE, V10; Tran BX, 2012, PLOS ONE, V7; Hoang TV, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0075-9; Ushie BA, 2012, AIDS PATIENT CARE ST, V26, P674, DOI 10.1089/apc.2011.0304; Van Nguyen H, 2017, HARM REDUCT J, V14; Wang HD, 2016, LANCET HIV, V3, pE361, DOI 10.1016/S2352-3018(16)30087-X; WHO Office for Europe, 2012, PRACT GUID TOOLK IMP; Wolff K, 2002, THER DRUG MONIT, V24, P457, DOI 10.1097/00007691-200208000-00001; Wong KH, 2003, J SUBST ABUSE TREAT, V24, P233, DOI 10.1016/S0740-5472(03)00029-1; Yang F, 2013, HARM REDUCT J, V10, DOI 10.1186/1477-7517-10-3; Zhang MWB, 2017, ASIAN J PSYCHIATR, V28, P15, DOI 10.1016/j.ajp.2017.03.025; Zhang MWB, 2017, HEALTHC INFORM RES, V23, P109, DOI 10.4258/hir.2017.23.2.109; Zhao M, 2015, TXB ADDICTION TREATM, P531; Zhou KN, 2017, J ADDICT MED, V11, P28, DOI 10.1097/ADM.0000000000000263; Zhou KN, 2014, ADDICT BEHAV, V39, P22, DOI 10.1016/j.addbeh.2013.09.001	65	23	23	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2018	13	1							e0190941	10.1371/journal.pone.0190941	http://dx.doi.org/10.1371/journal.pone.0190941			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FS9PC	29346444	Green Published, Green Submitted, gold			2023-01-03	WOS:000422749500022
J	Yanovski, SZ; Yanovski, JA				Yanovski, Susan Z.; Yanovski, Jack A.			Toward Precision Approaches for the Prevention and Treatment of Obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Yanovski, Susan Z.] NIDDK, NIH, Bethesda, MD 20892 USA; [Yanovski, Jack A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Res, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Yanovski, SZ (corresponding author), NIDDK, Off Obes Res, NIH, 6707 Democracy Blvd,Room 6025, Bethesda, MD 20892 USA.	sy29f@nih.gov		Yanovski, Jack/0000-0001-8542-1637	Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the United States National Institutes of Health; Zafgen; Rhythm Pharmaceuticals; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000641] Funding Source: NIH RePORTER	Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the United States National Institutes of Health; Zafgen; Rhythm Pharmaceuticals; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Both authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr J. A. Yanovski reports receiving grant funding from the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the United States National Institutes of Health, Zafgen, and Rhythm Pharmaceuticals. No other disclosures were reported.	Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Hales CM, 2017, PREVALENCE OBESITY A, V288, P1; Kuhnen P, 2016, NEW ENGL J MED, V375, P240, DOI 10.1056/NEJMoa1512693; Nicoletti CF, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090974; Rask-Andersen M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006977; Schulz LO, 2006, DIABETES CARE, V29, P1866, DOI 10.2337/dc06-0138; Stubbs J, 2011, OBES REV, V12, P688, DOI 10.1111/j.1467-789X.2011.00883.x; Unick JL, 2015, OBESITY, V23, P1353, DOI 10.1002/oby.21112; Yanovski SZ, 2014, JAMA-J AM MED ASSOC, V311, P74, DOI 10.1001/jama.2013.281361	10	52	54	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	2018	319	3					223	224		10.1001/jama.2017.20051	http://dx.doi.org/10.1001/jama.2017.20051			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT3BY	29340687	Green Accepted			2023-01-03	WOS:000423022300009
J	Chen, WC; Su, VYF; Yu, WK; Chen, YW; Yang, KY				Chen, Wei-Chih; Su, Vincent Yi-Fong; Yu, Wen-Kuang; Chen, Yen-Wen; Yang, Kuang-Yao			Prognostic factors of noninvasive mechanical ventilation in lung cancer patients with acute respiratory failure	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; RISK; EXTUBATION	Introduction Few studies have reported outcomes of lung cancer patients with acute respiratory failure (RF) using noninvasive positive pressure ventilation (NIPPV). The aim of this study was to investigate the prognostic factors in these patients. Materials and methods This retrospective observational study included all hospitalized lung cancer patients who received NIPPV for acute RF. It was conducted at a tertiary medical center in Taiwan from 2005 to 2010. The primary outcome was all cause mortality at 28 days after the initiation of NIPPV. Secondary outcomes included all-cause in-hospital mortality, weaning from NIPPV, intubation rate, tracheostomy rate, duration of NIPPV, hospital stay and intensive care unit stay. Results The all-cause mortality rate at day 28 of the enrolled 58 patients was 39.66%.The 90-day and 1-year mortality rates were 63.79% and 86.21%, respectively. NIPPV as the first line therapy for RF had higher 28-day mortality rate than it used for post-extubation RF (57.6% versus 16.0%, p<0.05). Independent predictors of mortality at 28 days were progressive disease or newly diagnosed lung cancer (OR 14.02 95% Cl 1.03-191.59, p = 0.048), combined with other organ failure (OR 18.07 95% Cl 1.87-172.7, p = 0.012), and NIPPV as the first line therapy for RF (OR 35.37 95% Cl 3.30-378.68, p = 0.003). Conclusion Lung cancer patients using NIPPV with progressive or newly diagnosed cancer disease, combined with other organ failure, or NIPPV as the first line therapy for respiratory failure have a poor outcome.	[Chen, Wei-Chih; Su, Vincent Yi-Fong; Yu, Wen-Kuang; Chen, Yen-Wen; Yang, Kuang-Yao] Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan; [Chen, Wei-Chih; Yu, Wen-Kuang; Chen, Yen-Wen; Yang, Kuang-Yao] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan; [Su, Vincent Yi-Fong] Taipei City Hosp, Dept Internal Med, Yangming Branch, Taipei, Taiwan; [Yang, Kuang-Yao] Natl Yang Ming Univ, Sch Med, Inst Emergency & Crit Care Med, Taipei, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Taipei City Hospital; National Yang Ming Chiao Tung University	Yang, KY (corresponding author), Taipei Vet Gen Hosp, Dept Chest Med, Taipei, Taiwan.; Yang, KY (corresponding author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Yang, KY (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Emergency & Crit Care Med, Taipei, Taiwan.	kyyang@vghtpe.gov.tw			Taiwan National Science Council Research Grant [MOST 103-2314-B-075-049-MY2]; Taipei Veterans General Hospital [V102C-025, V103C-078, V104C-038, V106C-072, V107C-077]	Taiwan National Science Council Research Grant; Taipei Veterans General Hospital(Taipei Veterans General Hospital)	This work was supported by a Taiwan National Science Council Research Grant MOST 103-2314-B-075-049-MY2 and Taipei Veterans General Hospital Grants V102C-025, V103C-078, V104C-038, V106C-072, and V107C-077. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam AK, 2008, EUR RESPIR J, V31, P47, DOI 10.1183/09031936.00031607; Adda M, 2008, CRIT CARE MED, V36, P2766, DOI 10.1097/CCM.0b013e31818699f6; Andrejak C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-159; [Anonymous], 2013, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD004127; Azoulay E, 2001, CRIT CARE MED, V29, P519, DOI 10.1097/00003246-200103000-00009; Conti G, 1998, INTENS CARE MED, V24, P1283, DOI 10.1007/s001340050763; El Solh AA, 2006, EUR RESPIR J, V28, P588, DOI 10.1183/09031936.06.00150705; EWER MS, 1986, JAMA-J AM MED ASSOC, V256, P3364, DOI 10.1001/jama.256.24.3364; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferreira JC, 2015, J CRIT CARE, V30, P1003, DOI 10.1016/j.jcrc.2015.04.121; Ferrer M, 2006, AM J RESP CRIT CARE, V173, P164, DOI 10.1164/rccm.200505-718OC; Ferrer M, 2009, LANCET, V374, P1082, DOI 10.1016/S0140-6736(09)61038-2; Gristina GR, 2011, CRIT CARE MED, V39, P2232, DOI 10.1097/CCM.0b013e3182227a27; Meert AP, 2003, SUPPORT CARE CANCER, V11, P56, DOI 10.1007/s00520-002-0373-0; Nava S, 2005, CRIT CARE MED, V33, P2465, DOI 10.1097/01.CCM.0000186416.44752.72; Neuschwander A, 2017, J CRIT CARE, V38, P295, DOI 10.1016/j.jcrc.2016.11.042; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Organized jointly by the American Thoracic Society the European Respiratory Society the European Society of Intensive Care Medicine and the Societe de Reanimation de Langue Francaise and approved by ATS Board of Directors December 2000, 2001, Am J Respir Crit Care Med, V163, P283; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; Rabbat A, 2005, BRIT J HAEMATOL, V129, P350, DOI 10.1111/j.1365-2141.2005.05459.x; Rathi NK, 2017, J CRIT CARE, V39, P56, DOI 10.1016/j.jcrc.2017.01.007; Roques S, 2009, INTENS CARE MED, V35, P2044, DOI 10.1007/s00134-009-1625-y; Slatore CG, 2012, J CLIN ONCOL, V30, P1686, DOI 10.1200/JCO.2011.40.0846; Soares M, 2014, ANN ONCOL, V25, P1829, DOI 10.1093/annonc/mdu234; Soares M, 2007, CHEST, V131, P840, DOI 10.1378/chest.06-2244; Toffart AC, 2011, CHEST, V139, P101, DOI 10.1378/chest.09-2863; Torres VBL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164537; Vallieres E, 2009, J THORAC ONCOL, V4, P1049, DOI 10.1097/JTO.0b013e3181b27799	28	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2018	13	1							e0191204	10.1371/journal.pone.0191204	http://dx.doi.org/10.1371/journal.pone.0191204			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FS7BY	29329356	Green Published, gold, Green Submitted			2023-01-03	WOS:000419954100049
J	Murff, HJ				Murff, Harvey J.			Review: Weak evidence of benefits of cannabis for chronic neuropathic pain; moderate to weak evidence of adverse effects	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Murff, Harvey J.] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA	Vanderbilt University	Murff, HJ (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.							Dzau VJ, 2014, JAMA-J AM MED ASSOC, V312, P1507, DOI 10.1001/jama.2014.12986; Park JY, 2017, DRUG ALCOHOL DEPEN, V177, P1, DOI 10.1016/j.drugalcdep.2017.03.009; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309	4	0	0	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 19	2017	167	12					JC62	JC62		10.7326/ACPJC-2017-167-12-062	http://dx.doi.org/10.7326/ACPJC-2017-167-12-062			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ3SD	29255852				2023-01-03	WOS:000418276000002
J	El Alaoui, C; Chemin, J; Fechtall, T; Lory, P				El Alaoui, Chaymae; Chemin, Jean; Fechtall, Taoufiq; Lory, Philippe			Modulation of T-type Ca2+ channels by Lavender and Rosemary extracts	PLOS ONE			English	Article							GATED CALCIUM-CHANNELS; ROSMARINIC ACID; NEUROPATHIC PAIN; SENSORY NEURONS; ESSENTIAL OIL; THALAMIC NEURONS; RAT MODEL; OFFICINALIS; INHIBITION; BLOCK	Medicinal plants represent a significant reservoir of unexplored substances for early-stage drug discovery. Of interest, two flowering Mediterranean plants have been used for thousands of years for their beneficial effects on nervous disorders, including anxiety and mood. However, the therapeutic potential of these plants regarding their ability to target ion channels and neuronal excitability remains largely unknown. Towards this goal, we have investigated the ability of Lavender and Rosemary to modulate T-type calcium channels (TTCCs). TTCCs play important roles in neuronal excitability, neuroprotection, sensory processes and sleep. These channels are also involved in epilepsy and pain. Using the whole-cell patch-clamp technique, we have characterized how Lavender and Rosemary extracts, as well as their major active compounds Linalool and Rosmarinic acid, modulate the electro-physiological properties of recombinant TTCCs (Ca(V)3.2) expressed in HEK-293T cells. Both the methanolic and essential oil extracts as well as the active compounds of these plants inhibit Ca(v)3.2 current in a concentration-dependent manner. In addition, these products also induce a negative shift of the steady-state inactivation of Ca(V)3.2 current with no change in the activation properties. Taken together, our findings reveal that TTCCs are a molecular target of the Lavender and Rosemary compounds, suggesting that inhibition of TTCCs could contribute to the anxiolytic and the neuroprotective effects of these plants.	[El Alaoui, Chaymae; Chemin, Jean; Lory, Philippe] Univ Montpellier, NSERM, CNRS, Inst Genom Fonct, Montpellier, France; [El Alaoui, Chaymae; Chemin, Jean; Lory, Philippe] LabEx Ion Channel Sci & Therapeut, Montpellier, France; [El Alaoui, Chaymae; Fechtall, Taoufiq] Univ Hassan 2, Lab Neurosci Physiopathol Integrees & Subst Nat, Fac Sci & Tech Mohammedia, Casablanca, Morocco	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Hassan II University of Casablanca	Lory, P (corresponding author), Univ Montpellier, NSERM, CNRS, Inst Genom Fonct, Montpellier, France.; Lory, P (corresponding author), LabEx Ion Channel Sci & Therapeut, Montpellier, France.	phippe.lory@igf.cnrs.fr		LORY, philippe/0000-0002-1638-7604	LabEx 'Ion Channel Science and Therapeutics'; 'Bourse du Ministere de l'Enseignement Superieur et de la Recherche Scientifique' Maroc; Erasmus Mundus Averroes; L'Oreal-UNESCO for Women in Science Programs	LabEx 'Ion Channel Science and Therapeutics'; 'Bourse du Ministere de l'Enseignement Superieur et de la Recherche Scientifique' Maroc; Erasmus Mundus Averroes; L'Oreal-UNESCO for Women in Science Programs	This work was supported by LabEx 'Ion Channel Science and Therapeutics' to PL. CEA was supported by 'Bourse du Ministere de l'Enseignement Superieur et de la Recherche Scientifique' Maroc, Erasmus Mundus Averroes and L'Oreal-UNESCO for Women in Science Programs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.r This work was supported by LabEx 'Ion Channel Science and Therapeutics' to PL. CEA was supported by 'Bourse du Ministere de l'Enseignement Superieur et de la Recherche Scientifique' Maroc, Erasmus Mundus Averroes and L'Oreal-UNESCO for Women in Science Programs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Authors are grateful to Dr. Isabelle Bidaud for critical help with cell culture. Special thanks to Dr. R. Bouharroud (INRA, Agadir) for plant extraction protocols.	Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Berger ND, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-77; Bialer M, 2015, EPILEPSY RES, V111, P85, DOI 10.1016/j.eplepsyres.2015.01.001; Bourinet E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515; Cain SM, 2013, BBA-BIOMEMBRANES, V1828, P1572, DOI 10.1016/j.bbamem.2012.07.028; Carabelli V, 2007, J PHYSIOL-LONDON, V584, P149, DOI 10.1113/jphysiol.2007.132274; Catterall WA, 2005, PHARMACOL REV, V57, P397, DOI 10.1124/pr.57.4.4; Cavanagh HMA, 2002, PHYTOTHER RES, V16, P301, DOI 10.1002/ptr.1103; Cazade M, 2014, MOL PHARMACOL, V85, P218, DOI 10.1124/mol.113.089581; Chemin J, 2002, J NEUROSCI, V22, P6856; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chemin J, 2001, EMBO J, V20, P7033, DOI 10.1093/emboj/20.24.7033; Chemin J, 2000, FEBS LETT, V478, P166, DOI 10.1016/S0014-5793(00)01832-9; Chioca LR, 2013, J ETHNOPHARMACOL, V147, P412, DOI 10.1016/j.jep.2013.03.028; Chuang RSI, 1998, NAT NEUROSCI, V1, P668, DOI 10.1038/3669; Elisabetsky E, 1999, PHYTOMEDICINE, V6, P107, DOI 10.1016/S0944-7113(99)80044-0; Enyeart JA, 2009, J NAT PROD, V72, P1533, DOI 10.1021/np900227x; Fallarini S, 2009, BRIT J PHARMACOL, V157, P1072, DOI 10.1111/j.1476-5381.2009.00213.x; Gamaro Giovana Duzzo, 2011, ISRN Pharmacol, V2011, P451682, DOI 10.5402/2011/451682; Gilani AH, 2000, J ETHNOPHARMACOL, V71, P161, DOI 10.1016/S0378-8741(99)00198-1; Gomora JC, 2001, MOL PHARMACOL, V60, P1121, DOI 10.1124/mol.60.5.1121; Gonzalez-Rodriguez P, 2015, J PHYSIOL-LONDON, V593, P4729, DOI 10.1113/JP271053; Gonzalez-Trujano ME, 2007, J ETHNOPHARMACOL, V111, P476, DOI 10.1016/j.jep.2006.12.011; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Herrero M, 2010, J CHROMATOGR A, V1217, P2512, DOI 10.1016/j.chroma.2009.11.032; Hill TDM, 2013, BRIT J PHARMACOL, V170, P679, DOI 10.1111/bph.12321; Hosking RD, 2008, BRIT J ANAESTH, V101, P59, DOI 10.1093/bja/aen119; Huang LP, 2008, J PHARM PHARMACOL, V60, P1515, DOI 10.1211/jpp/60.11.0013; Huang LP, 2004, J PHARMACOL EXP THER, V309, P193, DOI 10.1124/jpet.103.060814; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Jagodic MM, 2008, J NEUROPHYSIOL, V99, P3151, DOI 10.1152/jn.01031.2007; Jarvis MF, 2014, BIOCHEM PHARMACOL, V89, P536, DOI 10.1016/j.bcp.2014.03.015; Jin X, 2013, NEUROCHEM RES, V38, P1828, DOI 10.1007/s11064-013-1088-y; Kawai F, 1996, J GEN PHYSIOL, V108, P525, DOI 10.1085/jgp.108.6.525; Kelm MA, 2000, PHYTOMEDICINE, V7, P7, DOI 10.1016/S0944-7113(00)80015-X; KIMURA Y, 1987, J NAT PROD, V50, P392, DOI 10.1021/np50051a009; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Koulivand PH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/681304; Lee M, 2014, J PERIPHER NERV SYST, V19, pS11, DOI 10.1111/jns.12080_2; Lehrner J, 2005, PHYSIOL BEHAV, V86, P92, DOI 10.1016/j.physbeh.2005.06.031; Linck VM, 2010, PHYTOMEDICINE, V17, P679, DOI 10.1016/j.phymed.2009.10.002; Linck VD, 2009, PHYTOMEDICINE, V16, P303, DOI 10.1016/j.phymed.2008.08.001; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Llinas RR, 1999, P NATL ACAD SCI USA, V96, P15222, DOI 10.1073/pnas.96.26.15222; Lory P, 2007, EXPERT OPIN THER TAR, V11, P717, DOI 10.1517/14728222.11.5.717; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; Martin RL, 2000, J PHARMACOL EXP THER, V295, P302; Narusuye K, 2005, J NEURAL TRANSM, V112, P193, DOI 10.1007/s00702-004-0187-y; Ngo SNT, 2011, CRIT REV FOOD SCI, V51, P946, DOI 10.1080/10408398.2010.490883; Ozarowski M, 2013, FITOTERAPIA, V91, P261, DOI 10.1016/j.fitote.2013.09.012; Park SE, 2010, CELL MOL NEUROBIOL, V30, P759, DOI 10.1007/s10571-010-9502-3; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Petrovska Biljana Bauer, 2012, Pharmacogn Rev, V6, P1, DOI 10.4103/0973-7847.95849; Powell KL, 2014, BRIT J CLIN PHARMACO, V77, P729, DOI 10.1111/bcp.12205; Re L, 2000, PHARMACOL RES, V42, P177, DOI 10.1006/phrs.2000.0671; Rocha J, 2015, BASIC CLIN PHARMACOL, V116, P398, DOI 10.1111/bcpt.12335; Ross HR, 2008, J BIOL CHEM, V283, P16124, DOI 10.1074/jbc.M707104200; Sahu A, 1999, BIOCHEM PHARMACOL, V57, P1439, DOI 10.1016/S0006-2952(99)00044-1; Sakkaki S, 2016, NEUROPHARMACOLOGY, V101, P320, DOI 10.1016/j.neuropharm.2015.09.032; Schuwald AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059998; Sen T, 2015, ADV BIOCHEM ENG BIOT, V147, P59, DOI 10.1007/10_2014_273; Seo H, 2013, J PHARMACOL EXP THER, V347, P310, DOI 10.1124/jpet.113.207936; Serra J, 2015, PAIN, V156, P2175, DOI 10.1097/j.pain.0000000000000249; Shen FY, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0008-3; Sucher NJ, 2015, EPILEPSY BEHAV, V52, P308, DOI 10.1016/j.yebeh.2015.05.012; Takaki I, 2008, J MED FOOD, V11, P741, DOI 10.1089/jmf.2007.0524; Talley EM, 1999, J NEUROSCI, V19, P1895; Todorovic SM, 2011, BRIT J PHARMACOL, V163, P484, DOI 10.1111/j.1476-5381.2011.01256.x; Traboulsie A, 2006, MOL PHARMACOL, V69, P1963, DOI 10.1124/mol.105.020842; Tringham E, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003120; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; Won J, 2003, EUR J IMMUNOL, V33, P870, DOI 10.1002/eji.200323010; Woronuk G, 2011, PLANTA MED, V77, P7, DOI 10.1055/s-0030-1250136; Xiao CN, 2008, J AGR FOOD CHEM, V56, P10142, DOI 10.1021/jf8016833; Zamponi GW, 2015, PHARMACOL REV, V67, P821, DOI 10.1124/pr.114.009654; Ziegler D, 2015, PAIN, V156, P2013, DOI 10.1097/j.pain.0000000000000263	77	23	23	3	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0186864	10.1371/journal.pone.0186864	http://dx.doi.org/10.1371/journal.pone.0186864			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9QH	29073181	gold, Green Published, Green Submitted			2023-01-03	WOS:000413845400065
J	Rachas, A; Tuppin, P; Meyer, L; Falissard, B; Faye, A; Mahlaoui, N; de la Rochebrochard, E; Frank, M; Durieux, P; Warszawski, J				Rachas, Antoine; Tuppin, Philippe; Meyer, Laurence; Falissard, Bruno; Faye, Albert; Mahlaoui, Nizar; de la Rochebrochard, Elise; Frank, Marie; Durieux, Pierre; Warszawski, Josiane			Excess mortality and hospitalizations in transitional-age youths with a long-term disease: A national population-based cohort study	PLOS ONE			English	Article							SICKLE-CELL-DISEASE; EMERGENCY-ROOM VISITS; YOUNG-ADULTS; TRANSPLANT RECIPIENTS; SOUTH-CAROLINA; CARE; ADOLESCENTS; CHILDREN; HEALTH; MANAGEMENT	Introduction The number of adolescents with a severe chronic disease has increased in high-income countries due to improvements in the prognosis of childhood-onset chronic conditions. The transition from childhood to adulthood is a critical period that may be associated with increased mortality and morbidity. We aimed to estimate the prevalence of adolescents with a long-term disease (LTD) in France and assess their mortality and hospitalization risks relative to the general population. Materials and methods We extracted a population-based cohort from the French national health insurance database that included 61,119 subjects who reached 14 years of age between 2005 and 2014. LTDs are diagnosed by patients' physicians and then confirmed and registered by a physician of the national health insurance system. We assessed mortality and hospitalizations using data of patients who were between 14 and 21 years-old. Results Among 14-year-old adolescents, 3.30% (95% confidence interval: 3.16-3.44) had a LTD. Their mortality rate between the ages of 14 and 21 years was 20.9/10,000 person-years (13.7-32.1) versus 1.9 (1.5-2.5) for adolescents without a LTD. Mortality was higher in males than females in youths without a LTD, but not in those with a LTD. We found a similar pattern for the risk of hospitalization for an external cause. The five-year probability of hospitalization was 61.8% among youths with a LTD versus 42.7% for those without. The rate of planned hospitalizations sharply fell at 19 years-of-age among youths with a LTD, whereas the rate of unplanned hospitalizations remained stable. Conclusion The 3% of youths with a LTD have ten-fold higher mortality than those without and a high risk of hospitalization. The decrease in the rate of planned hospitalizations at age 19 among youths with a LTD may indicate differences in medical practice after transfer to adult care or a break in medical care.	[Rachas, Antoine; Meyer, Laurence; Falissard, Bruno; de la Rochebrochard, Elise; Warszawski, Josiane] Versailles St Quentin En Yvelines Univ, Paris Sud Univ, INSERM, Ctr Res Epidemiol & Populat Hlth,UMR 1018, Villejuif, France; [Rachas, Antoine; Meyer, Laurence; Falissard, Bruno; Warszawski, Josiane] Paris Sud Univ Hosp, AP HP, Dept Epidemiol & Publ Hlth, Paris, France; [Rachas, Antoine; Meyer, Laurence; Falissard, Bruno; Warszawski, Josiane] Paris Sud Univ, Le Kremlin Bicetre, France; [Tuppin, Philippe] Caisse Natl Assurance Malad Travailleurs Salaries, Paris, France; [Faye, Albert] Paris 7 Denis Diderot Univ, Sorbonne Paris Cite, Paris, France; [Faye, Albert] Robert Debre Hosp, AP HP, Gen Pediat Unit, Paris, France; [Faye, Albert] INSERM, U1123, Paris, France; [Mahlaoui, Nizar] Necker Enfants Malad Univ Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Mahlaoui, Nizar] Necker Enfants Malad Univ Hosp, AP HP, Pediat Immunohematol & Rheumatol Unit, Paris, France; [Mahlaoui, Nizar] INSERM, Lab Human Genet Infect Dis, Necker Branch, UMR 1163, Paris, France; [Mahlaoui, Nizar; Durieux, Pierre] Paris Descartes Univ, Sorbonne Paris Cite, Paris, France; [de la Rochebrochard, Elise] INED, Paris, France; [Frank, Marie] Paris Sud Univ Hosp, AP HP, Dept Med Informat, Paris, France; [Durieux, Pierre] Georges Pompidou European Hosp, Dept Informat & Publ Hlth, Paris, France; [Durieux, Pierre] Paris Descartes Univ, INSERM, Cordeliers Res Ctr, UMRS 872, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Rachas, A (corresponding author), Versailles St Quentin En Yvelines Univ, Paris Sud Univ, INSERM, Ctr Res Epidemiol & Populat Hlth,UMR 1018, Villejuif, France.; Rachas, A (corresponding author), Paris Sud Univ Hosp, AP HP, Dept Epidemiol & Publ Hlth, Paris, France.; Rachas, A (corresponding author), Paris Sud Univ, Le Kremlin Bicetre, France.	antoine.rachas@gmail.com	de La Rochebrochard, Elise/O-5802-2015; MAHLAOUI, Nizar/AAH-6103-2020	de La Rochebrochard, Elise/0000-0002-1639-7335; MAHLAOUI, Nizar/0000-0002-0030-8094				Akchurin OM, 2014, PEDIATR TRANSPLANT, V18, P538, DOI 10.1111/petr.12289; Annunziato RA, 2007, PEDIATR TRANSPLANT, V11, P608, DOI 10.1111/j.1399-3046.2007.00689.x; [Anonymous], MORT RAT SEX AG 2014; Bauman ME, 2016, THROMB RES, V141, P183, DOI 10.1016/j.thromres.2016.03.019; Berry JG, 2017, J PEDIATR-US, V182, P267, DOI 10.1016/j.jpeds.2016.11.054; Blin P, 2015, EUR J NEUROL, V22, P464, DOI 10.1111/ene.12592; Bollegala N, 2013, J CROHNS COLITIS, V7; Bouee S, 2016, THROMB J, V14, DOI 10.1186/s12959-016-0078-0; Burgel PR, 2015, EUR RESPIR J, V46, P133, DOI 10.1183/09031936.00196314; Busse FP, 2007, HORM RES, V67, P132, DOI 10.1159/000096583; Cohen E, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2734; Duflos CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163268; Gleeson H, 2013, CLIN ENDOCRINOL, V78, P23, DOI 10.1111/cen.12053; Hazra R, 2010, ANNU REV MED, V61, P169, DOI 10.1146/annurev.med.050108.151127; Hemker BG, 2011, AM J HEMATOL, V86, P863, DOI 10.1002/ajh.22106; Horton R, 2016, LANCET, V387, P2174, DOI 10.1016/S0140-6736(16)30243-4; Javalkar K, 2016, J ADOLESCENT HEALTH, V58, P40, DOI 10.1016/j.jadohealth.2015.09.013; Mann JR, 2015, MUSCLE NERVE, V52, P714, DOI 10.1002/mus.24599; Mann JR, 2015, PM&R, V7, P499, DOI 10.1016/j.pmrj.2014.11.011; McPheeters M, 2014, TRANSITION CARE CHIL; Michaud P-A., 2007, ADOLESCENT CHRONIC C; Moons P, 2010, CIRCULATION, V122, P2264, DOI 10.1161/CIRCULATIONAHA.110.946343; Okumura MJ, 2013, J ADOLESCENT HEALTH, V52, P413, DOI 10.1016/j.jadohealth.2012.08.005; Quinn CT, 2010, BLOOD, V115, P3447, DOI 10.1182/blood-2009-07-233700; Rachas A, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0256; Samuel SM, 2014, PEDIATRICS, V133, pE993, DOI 10.1542/peds.2013-2345; Shankar SM, 2005, AM J HEMATOL, V80, P262, DOI 10.1002/ajh.20485; Tuppin P, 2017, REV EPIDEMIOL SANTE; U. S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics, 2015, SUMM HLTH STAT NAT H; UK CF Registry, 2009, ANN DAT REP 2008; van Staa A, 2011, J ADOLESC HLTH OFF P, V48; Weill A, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2002; Zhang LF, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-4	33	9	9	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2018	13	3							e0193729	10.1371/journal.pone.0193729	http://dx.doi.org/10.1371/journal.pone.0193729			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ0JA	29534076	Green Published, gold, Green Submitted			2023-01-03	WOS:000427253500010
J	Chowell, D; Morris, LGT; Grigg, CM; Weber, JK; Samstein, RM; Makarov, V; Kuo, FS; Kendall, SM; Requena, D; Riaz, N; Greenbaum, B; Carroll, J; Garon, E; Hyman, DM; Zehir, A; Solit, D; Berger, M; Zhou, RH; Rizvi, NA; Chan, TA				Chowell, Diego; Morris, Luc G. T.; Grigg, Claud M.; Weber, Jeffrey K.; Samstein, Robert M.; Makarov, Vladimir; Kuo, Fengshen; Kendall, Sviatoslav M.; Requena, David; Riaz, Nadeem; Greenbaum, Benjamin; Carroll, James; Garon, Edward; Hyman, David M.; Zehir, Ahmet; Solit, David; Berger, Michael; Zhou, Ruhong; Rizvi, Naiyer A.; Chan, Timothy A.			Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy	SCIENCE			English	Article							PD-1 BLOCKADE; HISTOCOMPATIBILITY ANTIGENS; MUTATIONAL LANDSCAPE; METASTATIC MELANOMA; CTLA-4 BLOCKADE; RESISTANCE; THERAPY; MOLECULES; HIV-1; IDENTIFICATION	CD8(+) T cell-dependent killing of cancer cells requires efficient presentation of tumor antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to which patient-specific HLA-I genotype influences response to anti-programmed cell death protein 1 or anti-cytotoxic T lymphocyte-associated protein 4 is currently unknown. We determined the HLA-I genotype of 1535 advanced cancer patients treated with immune checkpoint blockade (ICB). Maximal heterozygosity at HLA-I loci ("A," "B," and "C") improved overall survival after ICB compared with patients who were homozygous for at least one HLA locus. In two independent melanoma cohorts, patients with the HLA-B44 supertype had extended survival, whereas the HLA-B62 supertype (including HLA-B*15:01) or somatic loss of heterozygosity at HLA-I was associated with poor outcome. Molecular dynamics simulations of HLA-B*15:01 revealed different elements that may impair CD8(+) T cell recognition of neoantigens. Our results have important implications for predicting response to ICB and for the design of neoantigen-based therapeutic vaccines.	[Chowell, Diego; Samstein, Robert M.; Makarov, Vladimir; Kuo, Fengshen; Kendall, Sviatoslav M.; Riaz, Nadeem; Solit, David; Berger, Michael; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Chowell, Diego; Morris, Luc G. T.; Samstein, Robert M.; Makarov, Vladimir; Kuo, Fengshen; Kendall, Sviatoslav M.; Riaz, Nadeem; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA; [Morris, Luc G. T.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Grigg, Claud M.; Rizvi, Naiyer A.] NewYork Presbyterian Columbia Univ, Med Ctr, 177 Ft Washington Ave, New York, NY 10032 USA; [Weber, Jeffrey K.; Zhou, Ruhong] IBM Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; [Requena, David] Rockefeller Univ, Lab Cellular Biophys, New York, NY 10065 USA; [Riaz, Nadeem; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Greenbaum, Benjamin] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, New York, NY 10029 USA; [Greenbaum, Benjamin] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Greenbaum, Benjamin] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pathol, New York, NY 10029 USA; [Carroll, James; Garon, Edward] Univ Calif Los Angeles, David Geffen Sch Med, 2825 Santa Monica Blvd,Suite 200, Santa Monica, CA 90404 USA; [Hyman, David M.; Solit, David] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Hyman, David M.; Chan, Timothy A.] Weill Cornell Sch Med, New York, NY 10065 USA; [Zehir, Ahmet; Berger, Michael] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Solit, David; Berger, Michael] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, New York, NY 10065 USA; [Zhou, Ruhong] Columbia Univ, Dept Chem, New York, NY 10027 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; NewYork-Presbyterian Hospital; International Business Machines (IBM); Rockefeller University; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY 10065 USA.; Rizvi, NA (corresponding author), NewYork Presbyterian Columbia Univ, Med Ctr, 177 Ft Washington Ave, New York, NY 10032 USA.; Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA.; Chan, TA (corresponding author), Weill Cornell Sch Med, New York, NY 10065 USA.	nar2144@cumc.columbia.edu; chant@mskcc.org	Chan, Timothy A/ABD-5850-2021; Zehir, Ahmet/ABE-7155-2020; Solit, David B./AAC-5309-2019; Requena, David/AAF-4255-2019	Zehir, Ahmet/0000-0001-5406-4104; Solit, David/0000-0002-6614-802X; Riaz, Nadeem/0000-0001-9873-5862; Zhou, Ruhong/0000-0001-8624-5591; Samstein, Robert/0000-0001-6860-2401; Kuo, Fengshen/0000-0003-1797-2896; Requena, David/0000-0002-5968-1133; Morris, Luc/0000-0002-4417-2280	NIH/National Cancer Institute Cancer Center Support Grant [P30 CA008748]; NIH [K08 DE024774, 1R01CA205426]; Damon Runyon Cancer Research Foundation; Pershing Square Sohn Cancer Research Alliance; STARR Cancer Consortium; Stand Up 2 Cancer; BMS; NATIONAL CANCER INSTITUTE [R35CA232097, R01CA205426, R01CA208403, P30CA016042, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE024774] Funding Source: NIH RePORTER	NIH/National Cancer Institute Cancer Center Support Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Damon Runyon Cancer Research Foundation; Pershing Square Sohn Cancer Research Alliance(Pershing Square Sohn Cancer Research Alliance); STARR Cancer Consortium; Stand Up 2 Cancer; BMS(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Data reported in this study are tabulated in the main text and supplementary materials. This work was supported by NIH/National Cancer Institute Cancer Center Support Grant P30 CA008748, NIH grant K08 DE024774 (L.G.T.M), Damon Runyon Cancer Research Foundation (L.G.T.M), Pershing Square Sohn Cancer Research Alliance (T.A.C), STARR Cancer Consortium (T.A.C), Stand Up 2 Cancer (T.A.C), and NIH grant 1R01CA205426 (N.A.R and T.A.C). T.A.C. is a cofounder of Gritstone Oncology. We thank the Chan laboratory and members of the Bristol-Myers Squibb (BMS) biomarker team for helpful and stimulating discussions. We thank all the patients for their participation in the clinical trials, which is critical to improving care. We thank members of the melanoma service at MSK, including J. Wolchok, A. Shoushtari, M. Postow, and M. Callahan for their care of clinical trial patients. We thank members of the Columbia University oncology team for their excellent care of trial patients. We thank J. Sims, J. Havel, Y. Shen, and R. Srivastava for very stimulating discussions and helpful suggestions. We thank the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, the Cycle for Survival, and members of the Molecular Pathology and Diagnostics for their help with MSK-IMPACT sequencing. The data are available at the following accession numbers: dbGAP, phs001041.v1.p1; dbGAP, phs000452.v2.p1; SRA, SRP067938 and SRP090294; dbGAP, phs000980.v1.p1; SRA, PRJNA419415, PRJNA419422, and PRJNA419530; cBioPortal for Cancer Genomics, http://cbioportal.org/msk-impact (37). The results published here are in part based on data generated by a TCGA pilot project established by the National Cancer Institute and National Human Genome Research Institute. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov. T.A.C. receives research funding from BMS. N.A.R. is a consultant/advisory board member for AstraZeneca, BMS, Roche, Merck, Novartis, Lilly, and Pfizer. T.A.C. and N.A.R are cofounders of Gritstone Oncology.	Aptsiauri N, 2007, INT REV CYTOL, V256, P139, DOI 10.1016/S0074-7696(07)56005-5; Carlson CS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3680; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chowell D, 2015, P NATL ACAD SCI USA, V112, pE1754, DOI 10.1073/pnas.1500973112; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; DIBRINO M, 1995, BIOCHEMISTRY-US, V34, P10130, DOI 10.1021/bi00032a005; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Gao JJ, 2016, CELL, V167, P397, DOI 10.1016/j.cell.2016.08.069; Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203; Gopalakrishnan V., 2017, SCIENCE; Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Hillen N, 2008, EUR J IMMUNOL, V38, P2993, DOI 10.1002/eji.200838632; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le D. T., 2017, SCIENCE, V356; Li B, 2016, NAT GENET, V48, P725, DOI 10.1038/ng.3581; Liu P, 2005, NATURE, V437, P159, DOI 10.1038/nature03926; Marsh S. G., 1999, THE HLA FACTSBOOK; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Petersdorf EW, 2015, NEW ENGL J MED, V373, P599, DOI 10.1056/NEJMoa1500140; PI T. J. T., 2012, HLA DIS ASS; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Riaz N, 2016, NAT GENET, V48, P1327, DOI 10.1038/ng.3677; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robins HS, 2009, BLOOD, V114, P4099, DOI 10.1182/blood-2009-04-217604; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Routy B., 2017, SCIENCE; Schaefer MR, 2008, J IMMUNOL, V180, P7804, DOI 10.4049/jimmunol.180.12.7804; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Sims JS, 2016, P NATL ACAD SCI USA, V113, pE3529, DOI 10.1073/pnas.1601012113; SNARY D, 1977, EUR J IMMUNOL, V7, P580, DOI 10.1002/eji.1830070816; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tu YS, 2013, NAT NANOTECHNOL, V8, P594, DOI [10.1038/nnano.2013.125, 10.1038/NNANO.2013.125]; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhao F, 2016, CANCER RES, V76, P4347, DOI 10.1158/0008-5472.CAN-16-0008; Zhou RH, 2004, SCIENCE, V305, P1605, DOI 10.1126/science.1101176	60	544	578	10	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2018	359	6375					582	+		10.1126/science.aao4572	http://dx.doi.org/10.1126/science.aao4572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU4AS	29217585	Green Accepted			2023-01-03	WOS:000423795800044
J	Vedantham, S; Goldhaber, SZ; Julian, JA; Kahn, SR; Jaff, MR; Cohen, DJ; Magnuson, E; Razavi, MK; Comerota, AJ; Gornik, HL; Murphy, TP; Lewis, L; Duncan, JR; Nieters, P; Derfler, MC; Filion, M; Gu, CS; Kee, S; Schneider, J; Saad, N; Blinder, M; Moll, S; Sacks, D; Lin, J; Rundback, J; Garcia, M; Razdan, R; VanderWoude, E; Marques, V; Kearon, C				Vedantham, S.; Goldhaber, S. Z.; Julian, J. A.; Kahn, S. R.; Jaff, M. R.; Cohen, D. J.; Magnuson, E.; Razavi, M. K.; Comerota, A. J.; Gornik, H. L.; Murphy, T. P.; Lewis, L.; Duncan, J. R.; Nieters, P.; Derfler, M. C.; Filion, M.; Gu, C. -S.; Kee, S.; Schneider, J.; Saad, N.; Blinder, M.; Moll, S.; Sacks, D.; Lin, J.; Rundback, J.; Garcia, M.; Razdan, R.; VanderWoude, E.; Marques, V.; Kearon, C.		ATTRACT Trial Investigators	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY IMPROVEMENT GUIDELINES; POSTTHROMBOTIC SYNDROME; COMPRESSION STOCKINGS; VENOUS THROMBOSIS; RANDOMIZED-TRIAL; CLINICAL INVESTIGATIONS; ANTITHROMBOTIC THERAPY; HEPARIN; STREPTOKINASE; OUTCOMES	BACKGROUND The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome. METHODS We randomly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation plus pharmaco-mechanical thrombolysis (catheter-mediated or device-mediated intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or maceration, with or without stenting). The primary outcome was development of the post-thrombotic syndrome between 6 and 24 months of follow-up. RESULTS Between 6 and 24 months, there was no significant between-group difference in the percentage of patients with the post-thrombotic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.11; P = 0.56). Pharmacomechanical thrombolysis led to more major bleeding events within 10 days (1.7% vs. 0.3% of patients, P = 0.049), but no significant difference in recurrent venous thromboembolism was seen over the 24-month follow-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P = 0.09). Moderate-to-severe post-thrombotic syndrome occurred in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P = 0.04). Severity scores for the post-thrombotic syndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 18, and 24 months of follow-up (P<0.01 for the comparison of the Villalta scores at each time point), but the improvement in quality of life from baseline to 24 months did not differ significantly between the treatment groups. CONCLUSIONS Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding.	[Vedantham, S.; Lewis, L.; Duncan, J. R.; Nieters, P.; Derfler, M. C.; Saad, N.; Blinder, M.] Washington Univ, Sch Med, St Louis, MO USA; [Goldhaber, S. Z.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Jaff, M. R.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA; [Julian, J. A.; Filion, M.; Gu, C. -S.; Kearon, C.] McMaster Univ, Hamilton, ON, Canada; [Kahn, S. R.] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada; [Cohen, D. J.; Magnuson, E.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, KS USA; [Razavi, M. K.] St Josephs Vasc Inst, Orange, CA USA; [Kee, S.] Univ Calif Los Angeles, Los Angeles, CA USA; [Comerota, A. J.] Univ Michigan, Ann Arbor, MI 48109 USA; [Gornik, H. L.] Cleveland Clin, Heart & Vasc Inst, Cleveland, OH 44106 USA; [Murphy, T. P.] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA; [Schneider, J.] Cent DuPage Hosp, Winfield, IL USA; [Moll, S.] Univ N Carolina, Chapel Hill, NC USA; [Sacks, D.] Reading Hosp, Reading, PA USA; [Lin, J.] Henry Ford Hosp, Detroit, MI 48202 USA; [Rundback, J.] Holy Name Hosp, Teaneck, NJ USA; [Garcia, M.] Christiana Care Hosp, Newark, DE USA; [Razdan, R.; VanderWoude, E.] St Elizabeths Reg Med Ctr, Lincoln, NE USA; [Marques, V.] Pepin Heart Ctr, Tampa, FL USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; McMaster University; McGill University; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; Cleveland Clinic Foundation; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of North Carolina; University of North Carolina Chapel Hill; Henry Ford Health System; Henry Ford Hospital; Christiana Care Health System	Vedantham, S (corresponding author), Washington Univ St Louis, Mallinckrodt Inst Radiol, 510 S Kingshighway Blvd, St Louis, MO 63110 USA.	vedanthams@wustl.edu	Lazo-Langner, Alejandro/E-6993-2011	Lazo-Langner, Alejandro/0000-0001-6869-8431; Infeld, Margaret/0000-0002-1923-6166; Yu, Hyeon/0000-0002-4318-2575	National Heart, Lung, and Blood Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002345, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL088476, U54HL112303, U01HL088118] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by the National Heart, Lung, and Blood Institute and others;	AbuRahma AF, 2001, ANN SURG, V233, P752, DOI 10.1097/00000658-200106000-00004; ARNESEN H, 1982, ACTA MED SCAND, V211, P65; Bashir R, 2014, JAMA INTERN MED, V174, P1494, DOI 10.1001/jamainternmed.2014.3415; Bernstein SL, 2006, AM J EMERG MED, V24, P162, DOI 10.1016/j.ajem.2005.08.007; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; Cynamon J, 2006, J VASC INTERV RADIOL, V17, P1043, DOI 10.1097/01.RVI.0000221085.25333.40; Delis KT, 2004, ANN SURG, V239, P118, DOI 10.1097/01.sla.0000103067.10695.74; ELLIOT MS, 1979, BRIT J SURG, V66, P838, DOI 10.1002/bjs.1800661203; Enden T, 2012, LANCET, V379, P31, DOI 10.1016/S0140-6736(11)61753-4; Haig Y, 2016, LANCET HAEMATOL, V3, pE64, DOI 10.1016/S2352-3026(15)00248-3; Hilleman DE, 2008, J VASC INTERV RADIOL, V19, P377, DOI 10.1016/j.jvir.2007.10.027; Kahn SR, 2008, J THROMB HAEMOST, V6, P1105, DOI 10.1111/j.1538-7836.2008.03002.x; Kahn SR, 2009, J THROMB HAEMOST, V7, P884, DOI 10.1111/j.1538-7836.2009.03339.x; Kahn SR, 2009, J THROMB HAEMOST, V7, P879, DOI 10.1111/j.1538-7836.2009.03294.x; Kahn SR, 2008, ANN INTERN MED, V149, P698, DOI 10.7326/0003-4819-149-10-200811180-00004; Kahn SR, 2014, LANCET, V383, P880, DOI 10.1016/S0140-6736(13)61902-9; Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026; Kearon C, 2012, CHEST, V141, pE419S, DOI 10.1378/chest.11-2301; Lamping DL, 2003, J VASC SURG, V37, P410, DOI 10.1067/mva.2003.152; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; Mewissen MW, 1999, RADIOLOGY, V211, P39, DOI 10.1148/radiology.211.1.r99ap4739; Plate G, 1990, Eur J Vasc Surg, V4, P483, DOI 10.1016/S0950-821X(05)80788-1; Prandoni P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Robertson L, 2015, COCHRANE DB SYST REV, V30; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; SEMBA CP, 1994, RADIOLOGY, V191, P487, DOI 10.1148/radiology.191.2.8153327; TURPIE AGG, 1990, CHEST, V97, pS172, DOI 10.1378/chest.97.4_Supplement.172S; Van Dongen CJJ, 2005, J THROMB HAEMOST, V3, P939; Vasquez MA, 2010, J VASC SURG, V52, P1387, DOI 10.1016/j.jvs.2010.06.161; Vedantham S, 2006, J VASC INTERV RADIOL, V17, P435, DOI 10.1097/01.RVI.0000197348.57762.15; Vedantham S, 2006, J VASC INTERV RADIOL, V17, P417, DOI 10.1097/01.RVI.0000197359.26571.C2; Vedantham S, 2004, J VASC INTERV RADIOL, V15, P565, DOI 10.1097/01.RVI.0000127894.00553.02; Vedantham S, 2014, J VASC INTERV RADIOL, V25, P1317, DOI 10.1016/j.jvir.2014.04.019; Vedantham S, 2013, AM HEART J, V165, P523, DOI 10.1016/j.ahj.2013.01.024; Ware J, 1994, SF 36 PHYS MENTAL SU; Watson L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002783.pub4	37	351	381	1	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 7	2017	377	23					2240	2252		10.1056/NEJMoa1615066	http://dx.doi.org/10.1056/NEJMoa1615066			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FO9IL	29211671	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000417201100007
J	Shen, LH; Sun, Z; Chu, SC; Cai, ZH; Nie, P; Wu, CZ; Yuan, RS; Hu, LH; He, B				Shen, Linghong; Sun, Zhe; Chu, Shichun; Cai, Zhaohua; Nie, Peng; Wu, Caizhe; Yuan, Ruosen; Hu, Liuhua; He, Ben			Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation	PLOS ONE			English	Article							ER STRESS; ACCELERATED ATHEROSCLEROSIS; OXIDATIVE STRESS; APOE-DEFICIENT; PROTEIN; DYSLIPIDEMIA; INTEGRATION; MECHANISMS; CHOLESTIN; PATHWAYS	Xuezhikang (XZK), an extract of red yeast rice, is a traditional Chinese medicine widely used for the treatment of cardiovascular diseases in China and other countries. However, whether XZK treatment can improve atherosclerotic plaque stability is not fully understood. Based on our previously developed mouse model of spontaneous vulnerable plaque formation and rupture in carotid arteries in ApoE(-/-) mice. We showed that low-dose (600 mg/kg/d) XZK improved plaque stability without decreasing plaque area, whereas high-dose (1200 mg/kg/d) XZK dramatically inhibited vulnerable plaque progression accompanied by decreased plaque area. Mechanistically, XZK significantly suppressed lesional endoplasmic reticulum (ER) stress in mouse carotid arteries. In vitro, XZK inhibited 7-KC-induced activation of ER stress in RAW264.7 macrophages, as assessed by the reduced levels of p-PERK, p-IRE1 alpha, p-eIF2 alpha, c-ATF6, s-XBP1, and CHOP. Compared to controls, the XZK-treated group displayed dramatically decreased apoptotic cell numbers (shown by decreased TUNEL-and cleaved caspase3-positive cells), lower necrotic core area and ratio, and reduced expression of NF-kappa B target gene. In RAW264.7 cells, XZK inhibited 7-KC-induced upregulation of apoptosis, protein expression of apoptotic markers (cleaved caspase-3 and cleaved PARP), and NF-kappa B activation (shown by target gene transcription and I kappa Ba reduction). Collectively, our results suggest that XZK effectively suppresses vulnerable plaque progression and rupture by mitigating macrophage ER stress and consequently inhibiting apoptosis and the NF-kappa B pro-inflammatory pathway, thereby providing an alternative therapeutic strategy for stabilizing atherosclerotic plaques.	[Shen, Linghong; He, Ben] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China; [Sun, Zhe; Chu, Shichun; Cai, Zhaohua; Nie, Peng; Wu, Caizhe; Yuan, Ruosen; Hu, Liuhua] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Shen, LH; He, B (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China.	rjshenlinghong@126.com; rjheben@126.com	Nie, Peng/GQI-1872-2022; Cai, Zhaohua/CAH-8221-2022		National Natural Science Foundation of China [91539106, 81770428, 2017YFC0909301, 81330006, 81370399, 81600337, 81500266]; Shanghai Municipal Natural Science Foundation [15ZR1425800]; Shanghai Municipal Commission of Health and Family Planning [20154Y0036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Natural Science Foundation; Shanghai Municipal Commission of Health and Family Planning	This work was supported by grants numbers 91539106, 81770428, 2017YFC0909301, 81330006, 81370399, 81600337, and 81500266 from the National Natural Science Foundation of China; grants numbers 15ZR1425800 from the Shanghai Municipal Natural Science Foundation; and grant number 20154Y0036 from the Shanghai Municipal Commission of Health and Family Planning. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Bowes AJ, 2009, AM J PATHOL, V174, P330, DOI 10.2353/ajpath.2009.080385; Bromati CR, 2011, AM J PHYSIOL-REG I, V300, pR92, DOI 10.1152/ajpregu.00169.2010; Burleigh ME, 2005, J MOL CELL CARDIOL, V39, P443, DOI 10.1016/j.yjmcc.2005.06.011; Cao RH, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/781780; Childress L, 2013, J CLIN LIPIDOL, V7, P117, DOI 10.1016/j.jacl.2012.09.003; Cominacini L, 2015, CURR MED CHEM, V22, P1565, DOI 10.2174/0929867322666150311150829; Cui ML, 2016, HYPERTENSION, V67, P153, DOI 10.1161/HYPERTENSIONAHA.115.06114; Dandekar A, 2015, METHODS MOL BIOL, V1292, P205, DOI 10.1007/978-1-4939-2522-3_15; Dickhout JG, 2005, ARTERIOSCL THROM VAS, V25, P2623, DOI 10.1161/01.ATV.0000189159.96900.d9; Dong YZ, 2010, CIRCULATION, V121, P792, DOI 10.1161/CIRCULATIONAHA.109.900928; Erbay E, 2009, NAT MED, V15, P1383, DOI 10.1038/nm.2067; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Finn AV, 2010, ARTERIOSCL THROM VAS, V30, P1282, DOI 10.1161/ATVBAHA.108.179739; Funk CD, 2006, ARTERIOSCL THROM VAS, V26, P1204, DOI 10.1161/01.ATV.0000222960.43792.ff; Garbin U, 2014, ANTIOXID REDOX SIGN, V21, P850, DOI 10.1089/ars.2014.5870; Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010; Gorlach A, 2015, REDOX BIOL, V6, P260, DOI 10.1016/j.redox.2015.08.010; Hansson GK, 2015, J INTERN MED, V278, P483, DOI 10.1111/joim.12406; Heber D, 1999, AM J CLIN NUTR, V69, P231; Hotamisligil GS, 2010, NAT MED, V16, P396, DOI 10.1038/nm0410-396; Jin SX, 2012, ARTERIOSCL THROM VAS, V32, P2372, DOI 10.1161/ATVBAHA.111.236158; Kataoka Y, 2015, CARDIOVASC DIAGN THE, V5, P280, DOI 10.3978/j.issn.2223-3652.2015.05.06; Li JJ, 2005, CLIN CHIM ACTA, V352, P217, DOI 10.1016/j.cccn.2004.09.026; Linton MF, 2016, CIRC J, V80, P2259, DOI 10.1253/circj.CJ-16-0924; Liu J, 2008, CANCER RES, V68, P8871, DOI 10.1158/0008-5472.CAN-08-1972; Lu ZL, 2008, AM J CARDIOL, V101, P1689, DOI 10.1016/j.amjcard.2008.02.056; Moriarty PM, 2014, J CLIN LIPIDOL, V8, P568, DOI 10.1016/j.jacl.2014.09.002; Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054; Nicholls SJ, 2005, ARTERIOSCL THROM VAS, V25, P1102, DOI 10.1161/01.ATV.0000163262.83456.6d; Nie P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097009; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Schoenhagen P, 2002, CIRCULATION, V106, P760, DOI 10.1161/01.CIR.0000025708.36290.05; Seimon T, 2009, J LIPID RES, V50, pS382, DOI 10.1194/jlr.R800032-JLR200; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; Shang QH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/636547; Song YF, 2016, AQUAT TOXICOL, V175, P20, DOI 10.1016/j.aquatox.2016.03.003; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766; Tam AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045078; Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003; Tsukano H, 2010, ARTERIOSCL THROM VAS, V30, P1925, DOI 10.1161/ATVBAHA.110.206094; Werstruck GH, 2006, DIABETES, V55, P93, DOI 10.2337/diabetes.55.01.06.db05-0633; Yang CW, 2012, COMPLEMENT THER MED, V20, P466, DOI 10.1016/j.ctim.2012.07.004; Zhang KZ, 2010, INT J CLIN EXP MED, V3, P33; Zhao SP, 2004, CIRCULATION, V110, P915, DOI 10.1161/01.CIR.0000139985.81163.CE; Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97; Zhu XY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0062731, 10.1371/journal.pone.0060146, 10.1371/journal.pone.0070631, 10.1371/journal.pone.0070686, 10.1371/journal.pone.0081900, 10.3389/fnsyn.2013.00008]	49	16	20	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2017	12	11							e0188841	10.1371/journal.pone.0188841	http://dx.doi.org/10.1371/journal.pone.0188841			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FO4UI	29190732	Green Submitted, gold, Green Published			2023-01-03	WOS:000416841900140
J	Kaiser, M; Pohl, L; Ketelhut, S; Kastl, L; Gorzelanny, C; Gotte, M; Schnekenburger, J; Goycoolea, FM; Kemper, B				Kaiser, Mathias; Pohl, Luisa; Ketelhut, Steffi; Kastl, Lena; Gorzelanny, Christian; Goette, Martin; Schnekenburger, Juergen; Goycoolea, Francisco M.; Kemper, Bjoern			Nanoencapsulated capsaicin changes migration behavior and morphology of madin darby canine kidney cell monolayers	PLOS ONE			English	Article							DIGITAL HOLOGRAPHIC MICROSCOPY; POORLY ABSORBABLE DRUGS; IN-VITRO; CHITOSAN NANOCAPSULES; MOLECULAR-WEIGHT; TRANSMUCOSAL DELIVERY; ABSORPTION ENHANCERS; ION CHANNELS; TUMOR-CELLS; NANOPARTICLES	We have developed a drug delivery nanosystem based on chitosan and capsaicin. Both substances have a wide range of biological activities. We investigated the nanosystem's influence on migration and morphology of Madin Darby canine kidney (MDCK-C7) epithelial cells in comparison to the capsaicin-free nanoformulation, free capsaicin, and control cells. For minimally-invasive quantification of cell migration, we applied label-free digital holographic microscopy (DHM) and single-cell tracking. Moreover, quantitative DHM phase images were used as novel stain-free assay to quantify the temporal course of global cellular morphology changes in confluent cell layers. Cytoskeleton alterations and tight junction protein redistributions were complementary analyzed by fluorescence microscopy. Calcium influx measurements were conducted to characterize the influence of the nanoformulations and capsaicin on ion channel activities. We found that both, capsaicin-loaded and unloaded chitosan nanocapsules, and also free capsaicin, have a significant impact on directed cell migration and cellular motility. Increase of velocity and directionality of cell migration correlates with changes in the cell layer surface roughness, tight junction integrity and cytoskeleton alterations. Calcium influx into cells occurred only after nanoformulation treatment but not upon addition of free capsaicin. Our results pave the way for further studies on the biological significance of these findings and potential biomedical applications, e.g. as drug and gene carriers.	[Kaiser, Mathias; Goycoolea, Francisco M.] Westfalische Wilhelms Univ Munster, Inst Plant Biol & Biotechnol IBBP, Schlossgarten 3, Munster, Germany; [Pohl, Luisa; Ketelhut, Steffi; Kastl, Lena; Schnekenburger, Juergen; Kemper, Bjoern] Westfalische Wilhelms Univ Munster, Med Fac, Biomed Technol Ctr, Mendelstr 17, Munster, Germany; [Gorzelanny, Christian] Heidelberg Univ, Med Fac Mannheim, Dept Derimatol, Expt Dermatol, Theodor Kutzer Ufer 1-3, Mannheim, Germany; [Goette, Martin] Westfalische Wilhelms Univ Munster, Dept Gynecol & Obstet, Albert Schweitzer Campus 1, Munster, Germany; [Goycoolea, Francisco M.] Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England	University of Munster; University of Munster; Ruprecht Karls University Heidelberg; University of Munster; University of Leeds	Goycoolea, FM (corresponding author), Westfalische Wilhelms Univ Munster, Inst Plant Biol & Biotechnol IBBP, Schlossgarten 3, Munster, Germany.; Kemper, B (corresponding author), Westfalische Wilhelms Univ Munster, Med Fac, Biomed Technol Ctr, Mendelstr 17, Munster, Germany.; Goycoolea, FM (corresponding author), Univ Leeds, Sch Food Sci & Nutr, Leeds, W Yorkshire, England.	goycoole@uni-muenster.de; bkemper@uni-muenster.de	Gotte, M/Z-5878-2019; Götte, Martin/G-2254-2018; Goycoolea, Francisco M./Q-5841-2017	Gotte, M/0000-0003-2360-2496; Götte, Martin/0000-0003-2360-2496; Goycoolea, Francisco M./0000-0001-7949-5429; Kemper, Bjorn/0000-0003-3693-9397; Schnekenburger, Juergen/0000-0002-0199-2908	DFG [GRK 1549]; European Union's Seventh Framework Programme for research, technological development and demonstration [613931]; Open Access Publication Fund of the University of Muenster; DFG, Germany [GRK 1549]; Danish Agency for Science, Technology and Innovation, Denmark (FENAMI project) [10-093456]	DFG(German Research Foundation (DFG)); European Union's Seventh Framework Programme for research, technological development and demonstration; Open Access Publication Fund of the University of Muenster; DFG, Germany(German Research Foundation (DFG)); Danish Agency for Science, Technology and Innovation, Denmark (FENAMI project)	This study was founded by the German Research foundation (DFG: (Project GRK 1549 International Research Training Group 'Molecular and Cellular GlycoSciences'), from The Danish Agency for Science, Technology and Innovation, 440 Denmark (FENAMI project 10-093456); the research leading to these results has also received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 613931 (Nano3Bio). We further acknowledge support by the Open Access Publication Fund of the University of Muenster.; We acknowledge support from DFG, Germany (Project GRK 1549 International Research Training Group 'Molecular and Cellular GlycoSciences'), from The Danish Agency for Science, Technology and Innovation, Denmark (FENAMI project 10-093456); the research leading to these results has also received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 613931 (Nano3Bio). We acknowledge support by Open Access Publication Fund of the University of Minster.	Ahmad MZ, 2010, EXPERT OPIN DRUG DEL, V7, P927, DOI 10.1517/17425247.2010.498473; ARTURSSON P, 1994, PHARMACEUT RES, V11, P1358, DOI 10.1023/A:1018967116988; Bauwens A, 2013, CELL MOL LIFE SCI, V70, P425, DOI 10.1007/s00018-012-1060-z; Beck-Broichsitter M, 2012, J CONTROL RELEASE, V161, P214, DOI 10.1016/j.jconrel.2011.12.004; Calvo P, 1997, INT J PHARM, V153, P41, DOI 10.1016/S0378-5173(97)00083-5; Carl D, 2004, APPL OPTICS, V43, P6536, DOI 10.1364/AO.43.006536; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chae SY, 2005, J CONTROL RELEASE, V102, P383, DOI 10.1016/j.jconrel.2004.10.012; Chen CH, 2015, AM J PHYSIOL-CELL PH, V309, pC600, DOI 10.1152/ajpcell.00155.2015; Chen Y, 2012, ADV DRUG DELIVER REV, V64, P640, DOI 10.1016/j.addr.2011.11.010; De Campos AM, 2001, INT J PHARM, V224, P159, DOI 10.1016/S0378-5173(01)00760-8; de la Fuente M, 2008, MACROMOL BIOSCI, V8, P441, DOI 10.1002/mabi.200700190; Dodane V, 1999, INT J PHARM, V182, P21, DOI 10.1016/S0378-5173(99)00030-7; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Felice F, 2015, INT J BIOL MACROMOL, V76, P236, DOI 10.1016/j.ijbiomac.2015.02.041; Fernandez-Urrusuno R, 1999, PHARMACEUT RES, V16, P1576, DOI 10.1023/A:1018908705446; Foster HE, 2014, PROG DRUG RES, V68, P307, DOI 10.1007/978-3-0348-0828-6_13; Frohlich E, 2012, INT J NANOMED, V7, P5577, DOI 10.2147/IJN.S36111; Goldberg M, 2007, J BIOMAT SCI-POLYM E, V18, P241, DOI 10.1163/156856207779996931; Goycoolea FM, 2012, COLLOID POLYM SCI, V290, P1423, DOI 10.1007/s00396-012-2669-z; Goycoolea FM, 2009, BIOMACROMOLECULES, V10, P1736, DOI 10.1021/bm9001377; Haeger A, 2015, TRENDS CELL BIOL, V25, P556, DOI 10.1016/j.tcb.2015.06.003; Han JK, 2005, CYTOTECHNOLOGY, V47, P89, DOI 10.1007/s10616-005-3756-5; Han J, 2009, J AGR FOOD CHEM, V57, P11148, DOI 10.1021/jf901943q; Han JY, 2002, CYTOTECHNOLOGY, V40, P93, DOI 10.1023/A:1023922306968; He B, 2011, EUR J PHARMACOL, V667, P195, DOI 10.1016/j.ejphar.2011.06.001; Isoda H, 2001, CYTOTECHNOLOGY, V36, P155, DOI 10.1023/A:1014053306343; Kaiser A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140994; Kaiser M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10048; Kean T, 2010, ADV DRUG DELIVER REV, V62, P3, DOI 10.1016/j.addr.2009.09.004; Kemper B, 2006, P SOC PHOTO-OPT INS, P6191; Kemper B, 2008, APPL OPTICS, V47, pA52, DOI 10.1364/AO.47.000A52; Kemper B, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2204609; Kim M. K., 2010, SPIE REV, V1; Korel F, 2002, J AGR FOOD CHEM, V50, P3257, DOI 10.1021/jf010537b; Kotze AF, 1997, INT J PHARM, V159, P243, DOI 10.1016/S0378-5173(97)00287-1; Kunsmann L, 2015, SCI REP-UK, V5, DOI 10.1038/srep13252; Lichtman JW, 2005, NAT METHODS, V2, P910, DOI 10.1038/NMETH817; Lozano MV, 2008, BIOMACROMOLECULES, V9, P2186, DOI 10.1021/bm800298u; Marquet P, 2005, OPT LETT, V30, P468, DOI 10.1364/OL.30.000468; Matthews BD, 2010, INTEGR BIOL-UK, V2, P435, DOI 10.1039/c0ib00034e; Meghvansi MK, 2010, J ETHNOPHARMACOL, V132, P1, DOI 10.1016/j.jep.2010.08.034; Menchicchi B, 2014, BIOMACROMOLECULES, V15, P3550, DOI 10.1021/bm5007954; Miyazaki A, 2015, BIOCHEM BIOPH RES CO, V458, P161, DOI 10.1016/j.bbrc.2015.01.086; Nagumo Y, 2007, BIOCHEM BIOPH RES CO, V355, P520, DOI 10.1016/j.bbrc.2007.02.002; Nagumo Y, 2008, BIOCHEM BIOPH RES CO, V377, P921, DOI 10.1016/j.bbrc.2008.10.071; Nitta SK, 2013, INT J MOL SCI, V14, P1629, DOI 10.3390/ijms14011629; Nomarski G., 1955, J PHYSIQUE RADIUM, V16, P9; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Pla AF, 2012, ONCOGENE, V31, P200, DOI 10.1038/onc.2011.231; Popescu G., 2011, QUANTITATIVE PHASE I; Prego C, 2006, J DRUG DELIV SCI TEC, V16, P331, DOI 10.1016/S1773-2247(06)50061-9; Prego C, 2006, J NANOSCI NANOTECHNO, V6, P2921, DOI 10.1166/jnn.2006.429; Prego C, 2006, PHARM RES-DORDR, V23, P549, DOI 10.1007/s11095-006-9570-8; Prego C, 2005, J CONTROL RELEASE, V101, P151, DOI 10.1016/j.jconrel.2004.07.030; Schipper NGM, 1996, PHARMACEUT RES, V13, P1686, DOI 10.1023/A:1016444808000; Schipper NGM, 1997, PHARMACEUT RES, V14, P923, DOI 10.1023/A:1012160102740; Schwab A, 2012, PHYSIOL REV, V92, P1865, DOI 10.1152/physrev.00018.2011; Shiobara T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079954; Shotton D. M., 1997, CONFOCAL LASER SCANN; Sonaje K, 2012, MOL PHARMACEUT, V9, P1271, DOI 10.1021/mp200572t; Teijeiro-Osorio D, 2009, BIOMACROMOLECULES, V10, P243, DOI 10.1021/bm800975j; Valeur B., 2012, MOL FLUORESCENCE PRI, V2nd; Vicente S, 2013, J CONTROL RELEASE, V172, P773, DOI 10.1016/j.jconrel.2013.09.012; Vicente S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062500; Vllasaliu D, 2010, INT J PHARMACEUT, V400, P183, DOI 10.1016/j.ijpharm.2010.08.020; Waning J, 2007, CELL CALCIUM, V42, P17, DOI 10.1016/j.ceca.2006.11.005; Wilson T., 1984, THEORY PRACTICE SCAN; Yeh TH, 2011, BIOMATERIALS, V32, P6164, DOI 10.1016/j.biomaterials.2011.03.056; ZERNIKE F, 1955, SCIENCE, V121, P345, DOI 10.1126/science.121.3141.345; Zhang LL, 2007, CIRC RES, V100, P1063, DOI 10.1161/01.RES.0000262653.84850.8b	71	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2017	12	11							e0187497	10.1371/journal.pone.0187497	http://dx.doi.org/10.1371/journal.pone.0187497			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL7JU	29107993	Green Published, gold			2023-01-03	WOS:000414424600035
J	Pluangnooch, P; Timalsena, S; Wongkajornsilp, A; Soontrapa, K				Pluangnooch, Panwadee; Timalsena, Sunita; Wongkajornsilp, Adisak; Soontrapa, Kitipong			Cytokine-induced killer cells: A novel treatment for allergic airway inflammation	PLOS ONE			English	Article							ADOPTIVE IMMUNOTHERAPY; CIK CELLS; T-CELLS; ASTHMA; INTERLEUKIN-13; THERAPIES; PHENOTYPE; LYMPHOMA; DISEASE; MODEL	The effectiveness of cytokine-induced killer (CIK) cells for treatment of cancers has long been appreciated. Here, we report for the first time that CIK cells can be applied to treat allergic airway inflammation. Adopting from an established protocol with some modifications, we generated CIK cells ex vivo from mouse T cells, and examined their effectiveness in treatment of allergic airway inflammation using the ovalbumin-induced model of allergic airway inflammation. Based upon evaluation of bronchoalveolar lavage cellularity,T helper type2 cytokine levels and lung histology, all of which are important parameters for determining the severity of allergic airway inflammation, diseased mice treated with CIK cells showed significant reductions in all the parameters without any obvious adverse effects. Interestingly, the observed effects were comparable to those treated with dexamethasone. Thus, our study provides a novel application of CIK cells in treatment of allergic airway inflammation.	[Pluangnooch, Panwadee; Timalsena, Sunita; Wongkajornsilp, Adisak; Soontrapa, Kitipong] Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pharmacol, Bangkok, Thailand	Mahidol University	Soontrapa, K (corresponding author), Mahidol Univ, Fac Med, Siriraj Hosp, Dept Pharmacol, Bangkok, Thailand.	kitipong.soo@mahidol.ac.th	Wongkajornsilp, Adisak/AAH-7668-2019	Wongkajornsilp, Adisak/0000-0002-3965-0997; Soontrapa, Kitipong/0000-0002-1704-3301	Thailand Research Fund [MRG-5580129]; Siriraj Foundation [D-003658]	Thailand Research Fund(Thailand Research Fund (TRF)); Siriraj Foundation	This study was supported by Thailand Research Fund (MRG-5580129) and the Siriraj Foundation (D-003658) to KS.; The authors wish to thank Dr. Toru Oga at Kyoto University and Dr. Wanpen Chaicumpa, Dr. Nitat Sookrung and Dr. Kittipong. Maneechotesuwan at Mahidol Univerity and for helpful advice. This work was supported by the Thailand Research Fund (MRG-5580129) and the Siriraj Foundation (D-003658).	Ayars AG, 2016, MED CLIN N AM, V100, P851, DOI 10.1016/j.mcna.2016.03.010; Baker J, 2001, BLOOD, V97, P2923, DOI 10.1182/blood.V97.10.2923; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Fulkerson PC, 2006, AM J PATHOL, V169, P2117, DOI 10.2353/ajpath.2006.060617; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Haworth O, 2011, J IMMUNOL, V186, P6129, DOI 10.4049/jimmunol.1004007; Irifune K, 2005, EUR RESPIR J, V25, P653, DOI 10.1183/09031936.05.00021304; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Jakel CE, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/473245; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kouro T, 2009, INT IMMUNOL, V21, P1303, DOI 10.1093/intimm/dxp102; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Leemhuis T, 2005, BIOL BLOOD MARROW TR, V11, P181, DOI 10.1016/j.bbmt.2004.11.019; Linn YC, 2010, J BIOMED BIOTECHNOL, V2010, P8; Liu YF, 2016, ONCOL LETT, V12, P5205, DOI 10.3892/ol.2016.5337; McDonald VM, 2017, RESPIROLOGY, V22, P53, DOI 10.1111/resp.12957; Mesiano G, 2012, EXPERT OPIN BIOL TH, V12, P673, DOI 10.1517/14712598.2012.675323; Niu Q, 2011, INT IMMUNOPHARMACOL, V11, P449, DOI 10.1016/j.intimp.2010.12.014; Randolph DA, 1999, J IMMUNOL, V162, P2375; Schmeel FC, 2014, INT J MOL SCI, V15, P14632, DOI 10.3390/ijms150814632; Schmidt TL, 2014, IMMUNOL RES, V58, P300, DOI 10.1007/s12026-014-8507-2; SCHMIDTWOLF IGH, 1991, J EXP MED, V174, P139, DOI 10.1084/jem.174.1.139; Timalsena S, 2016, ASIAN PAC J ALLERGY; Wang C, 2015, SCI REP-UK, V5, DOI 10.1038/srep14124; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x	26	3	6	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0186971	10.1371/journal.pone.0186971	http://dx.doi.org/10.1371/journal.pone.0186971			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9QH	29073213	Green Submitted, gold, Green Published			2023-01-03	WOS:000413845400083
J	Voigt, J; Carpenter, L; Leuchter, A				Voigt, Jeffrey; Carpenter, Linda; Leuchter, Andrew			Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients - A lifetime analysis	PLOS ONE			English	Article							TREATMENT-RESISTANT; ELECTROCONVULSIVE-THERAPY; CLINICAL-RESPONSE; DOUBLE-BLIND; EFFICACY; SAFETY; METAANALYSIS; MORTALITY; RTMS	Objective Repetitive Transcranial Magnetic Stimulation (rTMS) commonly is used for the treatment of Major Depressive Disorder (MDD) after patients have failed to benefit from trials of multiple antidepressant medications. No analysis to date has examined the cost-effectiveness of rTMS used earlier in the course of treatment and over a patients' lifetime. Methods We used lifetime Markov simulation modeling to compare the direct costs and quality adjusted life years (QALYs) of rTMS and medication therapy in patients with newly diagnosed MDD (ages 20-59) who had failed to benefit from one pharmacotherapy trial. Patients' life expectancies, rates of response and remission, and quality of life outcomes were derived from the literature, and treatment costs were based upon published Medicare reimbursement data. Baseline costs, aggregate per year quality of life assessments (QALYs), Monte Carlo simulation, tornado analysis, assessment of dominance, and one way sensitivity analysis were also performed. The discount rate applied was 3%. Results Lifetime direct treatment costs, and QALYs identified rTMS as the dominant therapy compared to antidepressant medications (i. e., lower costs with better outcomes) in all age ranges, with costs/improved QALYs ranging from $2,952/0.32 (older patients) to $11,140/ 0.43 (younger patients). One-way sensitivity analysis demonstrated that the model was most sensitive to the input variables of cost per rTMS session, monthly prescription drug cost, and the number of rTMS sessions per year. Conclusion rTMS was identified as the dominant therapy compared to antidepressant medication trials over the life of the patient across the lifespan of adults with MDD, given current costs of treatment. These models support the use of rTMS after a single failed antidepressant medication trial versus further attempts at medication treatment in adults with MDD.	[Voigt, Jeffrey] Med Device Consultants Ridgewood LLC, Ridgewood, NJ 07450 USA; [Carpenter, Linda] Brown Univ, Dept Psychiat & Human Behav, Brown Inst Brain Sci, Providence, RI 02912 USA; [Leuchter, Andrew] Univ Calif Los Angeles, Neuromodulat Div, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA	Brown University; University of California System; University of California Los Angeles	Voigt, J (corresponding author), Med Device Consultants Ridgewood LLC, Ridgewood, NJ 07450 USA.	meddevconsultant@aol.com		Voigt, Jeffrey/0000-0002-1755-8612	Magstim; Neuronetics; NeoSync; Jannssen	Magstim; Neuronetics; NeoSync; Jannssen	The funder (Magstim) provided an unrestricted grant to Medical Device Consultants of Ridgewood (commercial company) for the research, analysis, and preparation of the manuscript. The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Linda Carpenter, MD, has received consulting income from Magstim, Inc (<$5,000/year). Additionally, Dr. Carpenter has received clinical trial research support from Neuronetics, NeoSync, and Jannssen; and equipment support from NeoSync and Neuronetics.	Berlim MT, 2013, PSYCHOL MED, V43, P2245, DOI 10.1017/S0033291712002802; Brakemeier EL, 2007, J PSYCHIATR RES, V41, P395, DOI 10.1016/j.jpsychires.2006.01.013; Buikema A, 2015, AM J PHARM BENEFIST, V7, P135; Dunner DL, 2014, J CLIN PSYCHIAT, V75, P1394, DOI 10.4088/JCP.13m08977; Gallo JJ, 2013, BMJ BRIT MED J, V346, DOI 10.1136/bmj.f2570; George MS, 2010, ARCH GEN PSYCHIAT, V67, P507, DOI 10.1001/archgenpsychiatry.2010.46; Gold MR, 1996, COST EFFECTIVENESS H, P285; Greenberg PE, 2015, J CLIN PSYCHIAT, P76; Health Quality Ontario, 2016, Ont Health Technol Assess Ser, V16, P1; Huang X, 2017, MOL PSYCHIATR, V22, P1274, DOI 10.1038/mp.2017.143; Janicak PG, 2008, J CLIN PSYCHIAT, V69, P222, DOI 10.4088/JCP.v69n0208; Kedzior KK, 2015, DEPRESS ANXIETY, V32, P193, DOI 10.1002/da.22339; Kozel FA, 2004, CNS SPECTRUMS, V9, P476; Leuchter AF, 2015, BRAIN STIMUL, V8, P787, DOI 10.1016/j.brs.2015.05.005; Levkovitz Y, 2015, WORLD PSYCHIATRY, V14, P64, DOI 10.1002/wps.20199; Liu BS, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0342-4; MedPAC, 2017, HOSP INP OUTP SERV A; Miller LW, 2013, CIRCULATION, V127, P743, DOI 10.1161/CIRCULATIONAHA.112.139824; Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158; Nguyen KH, 2015, VALUE HEALTH, V18, P597, DOI 10.1016/j.jval.2015.04.004; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Perera T, 2016, BRAIN STIMUL, V9, P336, DOI 10.1016/j.brs.2016.03.010; Philip NS, 2016, BRAIN STIMUL, V9, P251, DOI 10.1016/j.brs.2015.11.007; Piatt EE, 2010, PSYCHIAT SERV, V61, P663, DOI 10.1176/ps.2010.61.7.663; PRUDIC J, 1990, PSYCHIAT RES, V31, P287, DOI 10.1016/0165-1781(90)90098-P; Prudic J, 1996, AM J PSYCHIAT, V153, P985; Rasanen P, 1999, J AFFECT DISORDERS, V55, P67, DOI 10.1016/S0165-0327(99)00002-6; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; SACKEIM HA, 1990, J CLIN PSYCHOPHARM, V10, P96, DOI 10.1097/00004714-199004000-00004; Sanders GD, 2005, NEW ENGL J MED, V353, P1471, DOI 10.1056/NEJMsa051989; Schousboe JT, 2007, JAMA-J AM MED ASSOC, V298, P629, DOI 10.1001/jama.298.6.629; Shen Y, 2017, BIOL PSYCHIAT, V81, pE49, DOI 10.1016/j.biopsych.2016.06.013; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Simpson KN, 2009, ADV THER, V26, P346, DOI 10.1007/s12325-009-0013-x; Sinyor M, 2010, CAN J PSYCHIAT, V55, P126, DOI 10.1177/070674371005500303; Tosteson ANA, 2008, ANN INTERN MED, V149, P845, DOI 10.7326/0003-4819-149-12-200812160-00003; Udupa K, 2007, J AFFECT DISORDERS, V104, P231, DOI 10.1016/j.jad.2007.04.002; Vallejo-Torres L, 2015, PSYCHOL MED, V45, P1459, DOI 10.1017/S0033291714002554; Zivin K, 2012, PSYCHIAT SERV, V63, P823, DOI 10.1176/appi.ps.201100317	40	30	30	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0186950	10.1371/journal.pone.0186950	http://dx.doi.org/10.1371/journal.pone.0186950			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9QH	29073256	Green Published, gold, Green Submitted			2023-01-03	WOS:000413845400079
J	Fuller-Jackson, JP; Clarke, IJ; Rao, A; Henry, BA				Fuller-Jackson, John-Paul; Clarke, Iain J.; Rao, Alexandra; Henry, Belinda A.			Exercise counteracts the homeostatic decrease in thermogenesis caused by caloric restriction in sheep	FASEB JOURNAL			English	Article						brown adipose tissue; diet; physical activity; hypothalamic appetite-regulating peptides	BROWN ADIPOSE-TISSUE; REDUCED BODY-WEIGHT; ENERGY-EXPENDITURE; ADAPTIVE THERMOGENESIS; SKELETAL-MUSCLE; MELANOCORTIN-4 RECEPTOR; UNCOUPLING PROTEIN-3; OVARIECTOMIZED EWES; PHYSICAL-ACTIVITY; OREXIN-A	Caloric restriction causes a homeostatic reduction in thermogenesis. We aimed to determine whether exercise could counteract this. We studied four groups of normal-weight ewes (n = 5), including control sedentary fed ad libitum, exercise fed ad libitum (30 min/d, 5 d/wk), diet-restricted (70% of ad libitum food intake), and combined diet and exercise. Temperature probes implanted in sternal and retroperitoneal adipose tissue and skeletal muscle measured thermogenesis. After the 4-wk intervention, hypothalami were collected for in situ hybridization, and fat and muscle biopsies were collected for real-time PCR and Western blotting. Combined diet and exercise reduced adiposity (P < 0.05). Caloric restriction alone reduced overnight temperatures in sternal and retroperitoneal fat (P < 0.05), which was counteracted by exercise (P < 0.05). Exercise did not induce expression of cellular markers of browning in adipose tissue. There was no effect of diet or exercise on skeletal muscle thermogenesis. Combined diet and exercise increased the expression of neuropeptide Y and agouti-related protein in the hypothalamic arcuate nucleus (P < 0.05), consistent with reduced adiposity. Gene expressions of key hypothalamic appetite-regulating peptides were not associated with altered thermogenesis. We demonstrate that exercise counteracts the inhibitory effect of caloric restriction to restore thermogenesis in adipose tissue of sheep.Fuller-Jackson, J.-P., Clarke, I. J., Rao, A., Henry, B. A. Exercise counteracts the homeostatic decrease in thermogenesis caused by caloric restriction in sheep.	[Fuller-Jackson, John-Paul; Clarke, Iain J.; Rao, Alexandra; Henry, Belinda A.] Monash Univ, Dept Physiol, Monash Biomed Discovery Inst, Clayton, Vic, Australia	Monash University	Henry, BA (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Metab Diabet & Obes Program, Dept Physiol, 26 Innovat Walk,Bldg 13 F,Wellington Rd, Clayton, Vic 3800, Australia.	belinda.henry@monash.edu		Clarke, Iain/0000-0002-6613-2757; Fuller-Jackson, John-Paul/0000-0002-2997-1340				Anderson EJP, 2016, J MOL ENDOCRINOL, V56, pT157, DOI 10.1530/JME-16-0014; Arruda AP, 2007, BBA-BIOMEMBRANES, V1768, P1498, DOI 10.1016/j.bbamem.2007.03.016; Backholer K, 2010, NEUROENDOCRINOLOGY, V91, P27, DOI 10.1159/000260060; BALLOR DL, 1988, AM J CLIN NUTR, V47, P19, DOI 10.1093/ajcn/47.1.19; Balthasar N, 2005, CELL, V123, P493, DOI 10.1016/j.cell.2005.08.035; Bamshad M, 1999, AM J PHYSIOL-REG I, V276, pR1569, DOI 10.1152/ajpregu.1999.276.6.R1569; BOCKING AD, 1986, J DEV PHYSIOL, V8, P237; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Cakir I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008322; Calbet JAL, 2015, SCAND J MED SCI SPOR, V25, P223, DOI 10.1111/sms.12194; Camps SGJA, 2015, METABOLISM, V64, P1284, DOI 10.1016/j.metabol.2015.06.016; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111; Germano CMR, 2008, HORM METAB RES, V40, P842, DOI 10.1055/s-0028-1086024; Goele K, 2009, OBESITY FACTS, V2, P105, DOI 10.1159/000210369; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Hara J, 2001, NEURON, V30, P345, DOI 10.1016/S0896-6273(01)00293-8; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; Henry BA, 2015, J ANIM SCI, V93, P2083, DOI 10.2527/jas.2014-8764; Henry BA, 2001, BRAIN RES, V918, P40, DOI 10.1016/S0006-8993(01)02918-3; Henry BA, 2000, ENDOCRINOLOGY, V141, P1506, DOI 10.1210/en.141.4.1506; Henry BA, 2017, ENDOCRINOLOGY, V158, P2212, DOI 10.1210/en.2017-00081; Henry BA, 2011, ENDOCRINOLOGY, V152, P2609, DOI 10.1210/en.2011-0143; Hewagalamulage SD, 2015, J NEUROENDOCRINOL, V27, P44, DOI 10.1111/jne.12233; Hewagalamulage SD, 2016, ENDOCRINOLOGY, V157, P3540, DOI 10.1210/en.2016-1287; HIRATA K, 1981, JPN J PHYSIOL, V31, P657; Johns DJ, 2014, J ACAD NUTR DIET, V114, P1557, DOI 10.1016/j.jand.2014.07.005; KAHN CR, 1976, J CELL BIOL, V70, P261, DOI 10.1083/jcb.70.2.261; KEKOW J, 1988, DIABETES, V37, P321, DOI 10.2337/diabetes.37.3.321; Kissileff HR, 2012, AM J CLIN NUTR, V95, P309, DOI 10.3945/ajcn.111.012385; Kiwaki K, 2004, AM J PHYSIOL-ENDOC M, V286, pE551, DOI 10.1152/ajpendo.00126.2003; Kotz CM, 2006, NEUROSCIENCE, V142, P29, DOI 10.1016/j.neuroscience.2006.05.028; Kotz CM, 2002, REGUL PEPTIDES, V104, P27, DOI 10.1016/S0167-0115(01)00346-9; LEHMAN MN, 1986, J COMP NEUROL, V244, P19, DOI 10.1002/cne.902440103; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEWIS DE, 1993, AM J PHYSIOL, V264, pE279, DOI 10.1152/ajpendo.1993.264.2.E279; Loh K, 2015, TRENDS ENDOCRIN MET, V26, P125, DOI 10.1016/j.tem.2015.01.003; MacLean PS, 2009, AM J PHYSIOL-REG I, V297, pR793, DOI 10.1152/ajpregu.00192.2009; Motiani P, 2017, DIABETES OBES METAB, V19, P1379, DOI 10.1111/dom.12947; Muller MJ, 2015, AM J CLIN NUTR, V102, P807, DOI 10.3945/ajcn.115.109173; Nixon Joshua P, 2012, Handb Exp Pharmacol, P77, DOI 10.1007/978-3-642-24716-3_4; Norheim F, 2014, FEBS J, V281, P739, DOI 10.1111/febs.12619; Novak CM, 2006, AM J PHYSIOL-ENDOC M, V290, pE396, DOI 10.1152/ajpendo.00293.2005; Oldfield BJ, 2002, NEUROSCIENCE, V110, P515, DOI 10.1016/S0306-4522(01)00555-3; Overton JM, 2004, PHYSIOL BEHAV, V81, P749, DOI 10.1016/j.physbeh.2004.04.025; Rogers NH, 2016, ENDOCRINOLOGY, V157, P1430, DOI 10.1210/en.2015-1745; Rosenbaum M, 2008, AM J CLIN NUTR, V88, P906, DOI 10.1093/ajcn/88.4.906; Rosenbaum M, 2016, OBESITY, V24, P1620, DOI 10.1002/oby.21559; ROTHWELL NJ, 1984, BIOSCIENCE REP, V4, P351, DOI 10.1007/BF01140499; Scharhag-Rosenberger F, 2014, MED SCI SPORT EXER, V46, P1736, DOI 10.1249/MSS.0000000000000286; Song CK, 2008, AM J PHYSIOL-REG I, V295, pR417, DOI 10.1152/ajpregu.00174.2008; THOMAS GB, 1991, ENDOCRINOLOGY, V128, P1151, DOI 10.1210/endo-128-2-1151; Trexler E. T., 2017, J NAT SCI, V3, pe335; Tupone D, 2011, J NEUROSCI, V31, P15944, DOI 10.1523/JNEUROSCI.3909-11.2011; Valle A, 2005, AM J PHYSIOL-ENDOC M, V289, pE15, DOI 10.1152/ajpendo.00553.2004; Verty ANA, 2010, ENDOCRINOLOGY, V151, P4236, DOI 10.1210/en.2009-1235; Vosselman MJ, 2015, INT J OBESITY, V39, P1696, DOI 10.1038/ijo.2015.130; Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016; Wu MV, 2014, J BIOL CHEM, V289, P34129, DOI 10.1074/jbc.M114.591008; YOSHIOKA K, 1989, ENDOCRINOL JAPON, V36, P403; Yu YH, 2009, BEHAV BRAIN RES, V205, P50, DOI 10.1016/j.bbr.2009.07.003	61	2	2	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2018	32	7					3859	3869		10.1096/fj.201701504R	http://dx.doi.org/10.1096/fj.201701504R			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ2MI	29455575				2023-01-03	WOS:000435104500031
J	Gostin, LO; Hodge, JG; Wetter, SA				Gostin, Lawrence O.; Hodge, James G., Jr.; Wetter, Sarah A.			Enforcing Federal Drug Laws in States Where Medical Marijuana Is Lawful	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Gostin, Lawrence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA; [Hodge, James G., Jr.; Wetter, Sarah A.] Arizona State Univ, Sandra Day OConnor Coll Law, Phoenix, AZ USA	Georgetown University; Arizona State University; Arizona State University-Downtown Phoenix	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				[Anonymous], 2015, BEH HLTH TRENDS US R; [Anonymous], 2011, MEM US ATT GUID REG; [Anonymous], 2018, MEM ALL US ATT MAR E; De Pinto J, 2017, MARIJUANA LEGALIZATI; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CANN CANN C; ProCon, 2016, NUMB LEG MED MAR PAT; Wang GS, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0971; Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358	8	5	5	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2018	319	14					1435	1436		10.1001/jama.2018.1083	http://dx.doi.org/10.1001/jama.2018.1083			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC2CR	29582074	Green Published			2023-01-03	WOS:000429590200011
J	Romey-Glusing, R; Li, Y; Hoffmann, J; von Frieling, J; Knop, M; Pfefferkorn, R; Bruchhaus, I; Fink, C; Roeder, T				Romey-Gluesing, Renja; Li, Yang; Hoffmann, Julia; von Frieling, Jakob; Knop, Mirjam; Pfefferkorn, Roxana; Bruchhaus, Iris; Fink, Christine; Roeder, Thomas			Nutritional regimens with periodically recurring phases of dietary restriction extend lifespan in Drosophila	FASEB JOURNAL			English	Article						lifespan extension; sex differences; insulin; metabolic rate; impl2	INSULIN-PRODUCING NEURONS; CALORIC RESTRICTION; METABOLIC-RATE; CAENORHABDITIS-ELEGANS; VOLUNTARY EXERCISE; FEMALE DROSOPHILA; GENE-EXPRESSION; BLOOD-PRESSURE; BODY-WEIGHT; PROTEIN	Nutritional interventions such as caloric and dietary restriction increase lifespan in various animal models. To identify alternative and less demanding nutritional interventions that extend lifespan, we subjected fruit flies (Drosophila melanogaster) to weekly nutritional regimens that involved alternating a conventional diet with dietary restriction. Short periods of dietary restriction (up to 2 d) followed by longer periods of a conventional diet yielded minimal increases in lifespan. We found that 3 or more days of contiguous dietary restriction (DR) was necessary to yield a lifespan extension similar to that observed with persistent DR. Female flies were more responsive to these interventions than males. Physiologic changes known to be associated with prolonged DR, such as reduced metabolic rates, showed the same time course as lifespan extension. Moreover, concurrent transcriptional changes indicative of reduced insulin signaling were identified with DR. These physiologic and transcriptional changes were sustained, as they were detectable several days after switching to conventional diets. Taken together, diets with longer periods of DR extended lifespan concurrently with physiologic and transcriptional changes that may underlie this increase in lifespan.	[Romey-Gluesing, Renja; Li, Yang; Hoffmann, Julia; von Frieling, Jakob; Knop, Mirjam; Pfefferkorn, Roxana; Fink, Christine; Roeder, Thomas] Univ Kiel, Inst Zool, Dept Mol Physiol, Botanischen Garten 1-9, D-24118 Kiel, Germany; [Bruchhaus, Iris] Bernhard Nocht Inst Trop Med, Hamburg, Germany; [Fink, Christine; Roeder, Thomas] ARCN, German Ctr Lung Res DZL, Grosshansdorf, Germany; [Romey-Gluesing, Renja] Univ Hamburg, Dept Biol, Hamburg, Germany; [Li, Yang] Ocean Univ China, Dept Marine Geosci, Qingdao, Peoples R China; [Hoffmann, Julia] Amedon GmbH, Lubeck, Germany	University of Kiel; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg; Ocean University of China	Roeder, T (corresponding author), Univ Kiel, Inst Zool, Dept Mol Physiol, Botanischen Garten 1-9, D-24118 Kiel, Germany.	troeder@zoologie.uni-kiel.de	Fink, Christine/ABF-7102-2021; Roeder, Thomas/B-9016-2011	Roeder, Thomas/0000-0002-3489-3834; Fink, Christine/0000-0003-0083-2168	Deutsche Forschungsgemeinschaft [CRC1182]; BMB+F (Vision Epifood)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMB+F (Vision Epifood)	The authors thank Britta Laubenstein and Christiane Sandberg (Kiel University) for excellent technical help; the Bloomington Drosophila Stock Center for fly stocks, and Sangbin Park and Seung Kim (Stanford University, CA, USA) for the dILP2-tagged flies and the reagents to perform the initial experiments. This work was supported by the Deutsche Forschungsgemeinschaft (CRC1182, Project C2) and the BMB+F (Vision Epifood). The authors declare no conflicts of interest.	Alic N, 2011, AGING CELL, V10, P137, DOI 10.1111/j.1474-9726.2010.00653.x; ANDERSSON B, 1988, ACTA MED SCAND, V223, P485; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012; Bruce KD, 2013, EXP GERONTOL, V48, P1129, DOI [10.1016/j.exger.2013.02.003, 10.1016/j.exge]; Brzek P, 2012, J EXP BIOL, V215, P3191, DOI 10.1242/jeb.065318; Colman RJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4557; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Deshpande SA, 2014, NAT METHODS, V11, P535, DOI [10.1038/nmeth.2899, 10.1038/NMETH.2899]; El-Kholy S, 2015, CELL TISSUE RES, V361, P669, DOI 10.1007/s00441-015-2137-4; Fink C, 2013, APPL ENVIRON MICROB, V79, P6984, DOI 10.1128/AEM.01903-13; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Franz O, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.11.e3; GARABEDIAN MJ, 1985, P NATL ACAD SCI USA, V82, P1396, DOI 10.1073/pnas.82.5.1396; Geminard C, 2009, CELL METAB, V10, P199, DOI 10.1016/j.cmet.2009.08.002; Gill S, 2015, SCIENCE, V347, P1265, DOI 10.1126/science.1256682; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; GOODRICK CL, 1983, EXP AGING RES, V9, P203, DOI 10.1080/03610738308258453; GOODRICK CL, 1983, J GERONTOL, V38, P36, DOI 10.1093/geronj/38.1.36; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Gronke S, 2005, CELL METAB, V1, P323, DOI 10.1016/j.cmet.2005.04.003; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Haselton A, 2010, CELL CYCLE, V9, P3063, DOI 10.4161/cc.9.15.12458; Haselton Aaron T, 2011, J Vis Exp, DOI 10.3791/2722; Heck MJ, 2017, J GERONTOL A-BIOL, V72, P616, DOI 10.1093/gerona/glw094; Hildebrandt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023796; Hoffmann J, 2013, AGING-US, V5, P315, DOI 10.18632/aging.100553; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hulbert AJ, 2004, EXP GERONTOL, V39, P1137, DOI 10.1016/j.exger.2004.04.006; Ja WW, 2009, P NATL ACAD SCI USA, V106, P18633, DOI 10.1073/pnas.0908016106; Jiang JC, 2000, FASEB J, V14, P2135; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; Lee C, 2016, F1000RES, V5, pF1000, DOI DOI 10.12688/F1000RESEARCH.7136.1; Lee D, 2015, AGING CELL, V14, P8, DOI 10.1111/acel.12277; Lee KP, 2008, P NATL ACAD SCI USA, V105, P2498, DOI 10.1073/pnas.0710787105; Levine ME, 2014, CELL METAB, V19, P407, DOI 10.1016/j.cmet.2014.02.006; Li Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35359; Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008; Luo JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108185; Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391; Mager DE, 2006, FASEB J, V20, P631, DOI 10.1096/fj.05-5263com; Mair W, 2004, EXP GERONTOL, V39, P1011, DOI 10.1016/j.exger.2004.03.018; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; MCCARTER RJ, 1989, AM J PHYSIOL, V257, pE175, DOI 10.1152/ajpendo.1989.257.2.E175; Mirzaei H, 2016, CURR OPIN CLIN NUTR, V19, P74, DOI 10.1097/MCO.0000000000000239; Mirzaei H, 2014, TRENDS ENDOCRIN MET, V25, P558, DOI 10.1016/j.tem.2014.07.002; Nassel DR, 2015, GEN COMP ENDOCR, V221, P255, DOI 10.1016/j.ygcen.2014.11.021; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Park S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004555; Partridge L, 2011, EXP GERONTOL, V46, P376, DOI 10.1016/j.exger.2010.09.003; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Rajan A, 2012, CELL, V151, P123, DOI 10.1016/j.cell.2012.08.019; Roeder T, 1999, PROG NEUROBIOL, V59, P533, DOI 10.1016/S0301-0082(99)00016-7; Roeder T, 2005, ANNU REV ENTOMOL, V50, P447, DOI 10.1146/annurev.ento.50.071803.130404; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Sarraf-Zadeh L, 2013, DEV BIOL, V381, P97, DOI 10.1016/j.ydbio.2013.06.008; Schramm G, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e96; Sharma N, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-90; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Wagner C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-446; Wei M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8700; Whitaker R, 2014, AGING-US, V6, P355, DOI 10.18632/aging.100662; Yatsenko A. S., 2014, JOVE-J VIS EXP, V88; Zheng SQ, 2017, J GERONTOL A-BIOL, V72, P464, DOI 10.1093/gerona/glw105	67	10	10	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2018	32	4					1993	2003		10.1096/fj.201700934R	http://dx.doi.org/10.1096/fj.201700934R			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB4SP	29196499				2023-01-03	WOS:000429051400021
J	Albuquerque, PL; Campelo, M; Mendonca, T; Augusto, L; Fontes, M; Brito, RD; Monte-Silva, K				Albuquerque, Plinio Luna; Campelo, Mayara; Mendonca, Thyciane; Augusto, Luis; Fontes, Mendes; Brito, Rodrigo de Mattos; Monte-Silva, Katia			Effects of repetitive transcranial magnetic stimulation and trans-spinal direct current stimulation associated with treadmill exercise in spinal cord and cortical excitability of healthy subjects: A triple-blind, randomized and sham-controlled study	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; TRAINING-INDUCED PLASTICITY; NOCICEPTIVE FLEXION REFLEX; HIGH-FREQUENCY RTMS; SOLEUS H-REFLEX; OF-THE-ART; RECIPROCAL INHIBITION; CONTROLLED-TRIAL; RECOVERY CURVE; HUMANS	Repetitive transcranial magnetic stimulation (rTMS) over motor cortex and trans-spinal direct current stimulation (tsDCS) modulate corticospinal circuits in healthy and injured subjects. However, their associated effects with physical exercise is still not defined. This study aimed to investigate the effect of three different settings of rTMS and tsDCS combined with treadmill exercise on spinal cord and cortical excitability of healthy subjects. We performed a triple blind, randomized, sham-controlled crossover study with 12 healthy volunteers who underwent single sessions of rTMS (1Hz, 20Hz and Sham) and tsDCS (anodal, cathodal and Sham) associated with 20 minutes of treadmill walking. Cortical excitability was assessed by motor evoked potential (MEP) and spinal cord excitability by the Hoffmann reflex (Hr), nociceptive flexion reflex (NFR) and homosynaptic depression (HD). All measures were assessed before, immediately, 30 and 60 minutes after the experimental procedures. Our results demonstrated that anodal tsDCS/treadmill exercise reduced MEP's amplitude and NFR's area compared to sham condition, conversely, cathodal tsDCS/treadmill exercise increased NFR's area. High-frequency rTMS increased MEP's amplitude and NFR's area compared to sham condition. Anodal tsDCS/treadmill exercise and 20Hz rTMS/treadmill exercise reduced Hr amplitude up to 30 minutes after stimulation offset and no changes were observed in HD measures. We demonstrated that tsDCS and rTMS combined with treadmill exercise modulated cortical and spinal cord excitability through different mechanisms. tsDCS modulated spinal reflexes in a polarity-dependent way acting at local spinal circuits while rTMS probably promoted changes in the presynaptic inhibition of spinal motoneurons. In addition, the association of two neuromodulatory techniques induced long-lasting changes.	[Albuquerque, Plinio Luna; Campelo, Mayara; Mendonca, Thyciane; Augusto, Luis; Fontes, Mendes; Brito, Rodrigo de Mattos; Monte-Silva, Katia] Univ Fed Pernambuco, Dept Phys Therapy, Appl Neurosci Lab, Recife, PE, Brazil; [Albuquerque, Plinio Luna] Ctr Univ Tabosa Almeida, Dept Phys Therapy, Caruaru, PE, Brazil; [Albuquerque, Plinio Luna; Campelo, Mayara; Monte-Silva, Katia] Univ Fed Pernambuco, Postgrad Program Neuropsychiat & Behav Sci, Recife, PE, Brazil	Universidade Federal de Pernambuco; Universidade Federal de Pernambuco	Monte-Silva, K (corresponding author), Univ Fed Pernambuco, Dept Phys Therapy, Appl Neurosci Lab, Recife, PE, Brazil.; Monte-Silva, K (corresponding author), Univ Fed Pernambuco, Postgrad Program Neuropsychiat & Behav Sci, Recife, PE, Brazil.	monte.silvakk@gmail.com	Silva, Katia Monte/V-4004-2019; Monte-Silva, Katia KMS/A-2444-2014	Silva, Katia Monte/0000-0001-7301-2553; Monte-Silva, Katia KMS/0000-0001-7301-2553				Aguilar J, 2011, J PHYSIOL-LONDON, V589, P4981, DOI 10.1113/jphysiol.2011.214189; Ahmed Z, 2013, J NEUROSCI, V33, P14949, DOI 10.1523/JNEUROSCI.2793-13.2013; Ahmed Z, 2012, J APPL PHYSIOL, V112, P1576, DOI 10.1152/japplphysiol.00967.2011; Arai N, 2007, CLIN NEUROPHYSIOL, V118, P2227, DOI 10.1016/j.clinph.2007.07.006; Galvao SCB, 2014, ARCH PHYS MED REHAB, V95, P222, DOI 10.1016/j.apmr.2013.10.023; Berardelli A, 1998, EXP BRAIN RES, V122, P79, DOI 10.1007/s002210050493; Bhatia BD, 2011, NEUROSCI LETT, V488, P107, DOI 10.1016/j.neulet.2010.08.087; Bocci T, 2014, NEUROSCI LETT, V578, P75, DOI 10.1016/j.neulet.2014.06.037; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Cogiamanian F, PAIN; Cogiamanian F, 2008, CLIN NEUROPHYSIOL, V119, P2636, DOI 10.1016/j.clinph.2008.07.249; Cosentino G, 2012, EUR J NEUROSCI, V35, P119, DOI 10.1111/j.1460-9568.2011.07939.x; CRONE C, 1994, ACTA PHYSIOL SCAND, V152, P351, DOI 10.1111/j.1748-1716.1994.tb09817.x; Donges SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172333; Fitzgerald PB, 2006, CLIN NEUROPHYSIOL, V117, P2584, DOI 10.1016/j.clinph.2006.06.712; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Grecco LH, 2015, J NEURORESTORATOLOGY, V3, P73, DOI 10.2147/JN.S77813; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Harel NY, 2015, J ELECTROMYOGR KINES, V25, P438, DOI 10.1016/j.jelekin.2015.02.009; Heide AC, 2014, BRAIN STIMUL, V7, P636, DOI 10.1016/j.brs.2014.06.008; Hosseinzadeh M, 2013, EUR J APPL PHYSIOL, V113, P2595, DOI 10.1007/s00421-013-2701-0; Hubli M, 2013, CLIN NEUROPHYSIOL, V124, P1187, DOI 10.1016/j.clinph.2012.11.021; Inghilleri M, 2004, CLIN NEUROPHYSIOL, V115, P1063, DOI 10.1016/j.clinph.2003.12.003; Johnson S, 2006, PAIN, V123, P187, DOI 10.1016/j.pain.2006.02.030; Jubeau M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089157; Knikou M, 2010, CLIN NEUROPHYSIOL, V121, P1655, DOI 10.1016/j.clinph.2010.01.039; Kumru H, 2015, MUSCLE NERVE, V52, P616, DOI 10.1002/mus.24579; Kumru H, 2010, NEUROREHAB NEURAL RE, V24, P435, DOI 10.1177/1545968309356095; Lamy JC, 2012, J NEUROPHYSIOL, V108, P906, DOI 10.1152/jn.10898.2011; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Matsudo S., 2001, REV BRAS ATIV F S SA, V6, P5; Mazzocchio R, 2006, CLIN NEUROPHYSIOL, V117, P1682, DOI 10.1016/j.clinph.2006.04.019; McDonnell MN, 2013, J APPL PHYSIOL, V114, P1174, DOI 10.1152/japplphysiol.01378.2012; Meunier S, 2007, J PHYSIOL-LONDON, V579, P375, DOI 10.1113/jphysiol.2006.122911; Motl RW, 2003, NEUROSCI LETT, V347, P69, DOI 10.1016/S0304-3940(03)00652-9; Muller-Dahlhaus F, 2015, NEUROSCIENTIST, V21, P185, DOI 10.1177/1073858414526645; Mylius V, 2007, NEUROSCI LETT, V415, P49, DOI 10.1016/j.neulet.2006.12.042; Nahmias F, 2009, PAIN, V147, P224, DOI 10.1016/j.pain.2009.09.016; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PANIZZA M, 1995, AM J PHYS MED REHAB, V74, P357; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Perez MA, 2005, J PHYSIOL-LONDON, V568, P343, DOI 10.1113/jphysiol.2005.089904; Perez MA, 2005, EXP BRAIN RES, V162, P202, DOI 10.1007/s00221-004-2144-2; Perrotta A, 2016, CLIN NEUROPHYSIOL, V127, P755, DOI 10.1016/j.clinph.2015.01.031; Price DD, 2003, PAIN, V106, P215, DOI 10.1016/j.pain.2003.10.016; Priori A, 2014, J PHYSIOL-LONDON, V592, P3345, DOI 10.1113/jphysiol.2013.270280; Quartarone A, 2005, EXP BRAIN RES, V161, P114, DOI 10.1007/s00221-004-2052-5; Rastgoo M, 2016, DISABIL REHABIL, V38, P1918, DOI 10.3109/09638288.2015.1107780; Rhudy JL, 2007, PAIN, V128, P244, DOI 10.1016/j.pain.2006.09.024; Rocha S, 2016, DISABIL REHABIL, V38, P653, DOI 10.3109/09638288.2015.1055382; Rossini PM, 2015, CLIN NEUROPHYSIOL, V126, P1071, DOI 10.1016/j.clinph.2015.02.001; Sadowski B, 2008, J HUM KINET, V20, P5, DOI 10.2478/v10078-008-0014-x; SCHOMBURG ED, 1990, NEUROSURG REV, V13, P179, DOI 10.1007/BF00313016; Shen Y, 2016, BIOL PSYCHIAT, V80, pE13, DOI 10.1016/j.biopsych.2016.02.006; Singh AM, 2014, BMC SPORTS SCI MED R, V6, DOI 10.1186/2052-1847-6-23; Summers J, 2004, NEUROSCI LETT, V368, P197, DOI 10.1016/j.neulet.2004.07.008; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Terraneo A, 2016, EUR NEUROPSYCHOPHARM, V26, P37, DOI 10.1016/j.euroneuro.2015.11.011; Truini A, 2011, EUR J PAIN, V15, P1023, DOI 10.1016/j.ejpain.2011.04.009; Valero-Cabre A, 2001, NEUROREPORT, V12, P3845, DOI 10.1097/00001756-200112040-00048; Winkler T, 2010, CLIN NEUROPHYSIOL, V121, P957, DOI 10.1016/j.clinph.2010.01.014; [No title captured], DOI DOI 10.1016/J.EJPAIN.2009.04.010	64	14	16	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2018	13	3							e0195276	10.1371/journal.pone.0195276	http://dx.doi.org/10.1371/journal.pone.0195276			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8ZI	29596524	Green Published, gold			2023-01-03	WOS:000428630000101
J	Welty, SE; Rusin, CG; Stanberry, LI; Mandy, GT; Gest, AL; Ford, JM; Backes, CH; Richardson, CP; Howard, CR; Hansen, TN; Smith, CV				Welty, Stephen E.; Rusin, Craig G.; Stanberry, Larissa I.; Mandy, George T.; Gest, Alfred L.; Ford, Jeremy M.; Backes, Carl H., Jr.; Richardson, C. Peter; Howard, Christopher R.; Hansen, Thomas N.; Smith, Charles V.			Short term evaluation of respiratory effort by premature infants supported with bubble nasal continuous airway pressure using Seattle-PAP and a standard bubble device	PLOS ONE			English	Article							PRETERM INFANTS; OXYGEN COST; CPAP; STRATEGIES; EFFICACY; MOTHERS; SAFETY	Background Almost one million prematurely born infants die annually from respiratory insufficiency, pre-dominantly in countries with limited access to respiratory support for neonates. The primary hypothesis tested in the present study was that a modified device for bubble nasal continuous positive airway pressure (Bn-CPAP) would provide lower work of spontaneous breathing, estimated by esophageal pressure-rate products. Methods Infants born <32 weeks gestation and stable on Bn-CPAP with FiO(2) <0.30 were studied within 72 h following delivery. Esophageal pressures during spontaneous breathing were measured during 2 h on standard Bn-CPAP, then 2 h with Bn-CPAP using a modified bubble device presently termed Seattle-PAP, which produces a different pattern of pressure fluctuations and which provided greater respiratory support in preclinical studies, then 2 h on standard Bn-CPAP. Results All 40 infants enrolled completed the study and follow-up through 36 wks post menstrual age or hospital discharge, whichever came first. No infants were on supplemental oxygen at completion of follow-up. No infants developed pneumothoraces or nasal trauma, and no adverse events attributed to the study were observed. Pressure-rate products on the two devices were not different, but effort of breathing, assessed by areas under esophageal pressure-time curves, was lower with Seattle-PAP than with standard Bn-CPAP. Conclusion Use of Seattle-PAP to implement Bn-CPAP lowers the effort of breathing exerted even by relatively healthy spontaneously breathing premature neonates. Whether the lower effort of breathing observed with Seattle-PAP translates to improvements in neonatal mortality or morbidity will need to be determined by studies in appropriate patient populations.	[Welty, Stephen E.; Smith, Charles V.] Univ Washington, Dept Pediat, Coll Med, Seattle, WA 98195 USA; [Rusin, Craig G.; Mandy, George T.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Stanberry, Larissa I.; Ford, Jeremy M.; Richardson, C. Peter; Howard, Christopher R.; Hansen, Thomas N.] Seattle Childrens Res Inst, Dept Pediat, Ctr Dev Therapeut, Seattle, WA USA; [Gest, Alfred L.] West Virginia Univ, Sch Med, Dept Pediat, Morgantown, WV USA; [Backes, Carl H., Jr.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Backes, Carl H., Jr.] Ohio State Univ, Coll Med, Ctr Perinatal Res, Columbus, OH 43210 USA; [Backes, Carl H., Jr.] Sch Publ Hlth, Columbus, OH USA	University of Washington; University of Washington Seattle; Baylor College of Medicine; Seattle Children's Hospital; West Virginia University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	Smith, CV (corresponding author), Univ Washington, Dept Pediat, Coll Med, Seattle, WA 98195 USA.	charles.smith@seattlechildrens.org	Hansen, Thomas/GWZ-2858-2022; Welty, Stephen/AAZ-4307-2021; Welty, Stephen/AGS-7454-2022	Welty, Stephen/0000-0002-6321-8440	The Bill & Melinda Gates Foundation [OPP1094124]	The Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation)	The work described was supported by OPP1094124 (TNH, CVS) from The Bill & Melinda Gates Foundation (www.gatesfoundation.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammari A, 2005, J PEDIATR-US, V147, P341, DOI 10.1016/j.jpeds.2005.04.062; Auguie B., 2017, GRIDEXTRA MISCELLANE; Bahman-Bijari B, 2011, IRAN J PEDIATR, V21, P151; BELLEMARE F, 1982, J APPL PHYSIOL, V53, P1196, DOI 10.1152/jappl.1982.53.5.1196; BELLEMARE F, 1982, J APPL PHYSIOL, V53, P1190, DOI 10.1152/jappl.1982.53.5.1190; Bhutta ZA, 2004, BRIT MED J, V329, P1151, DOI 10.1136/bmj.329.7475.1151; Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3; Carlo WA, 2014, PEDIATRICS, V133, P171, DOI 10.1542/peds.2013-3442; Courtney SE, 2011, J PERINATOL, V31, P44, DOI 10.1038/jp.2010.55; Dargaville PA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3985; Diblasi RM, 2010, PEDIATR RES, V67, P624, DOI 10.1203/PDR.0b013e3181dcd580; FIELD S, 1982, AM REV RESPIR DIS, V126, P9; Glantz S. A., 2005, PRIMER BIOSTATISTICS; GOTANDA K, 1988, JPN J PHARMACOL, V47, P217, DOI 10.1254/jjp.47.217; HANSEN TN, 1979, PEDIATR RES, V13, P1167, DOI 10.1203/00006450-197910000-00018; Jadcherla SR, 2007, J PEDIATR-US, V151, P597, DOI 10.1016/j.jpeds.2007.04.042; Jensen EA, 2016, SEMIN FETAL NEONAT M, V21, P133, DOI 10.1016/j.siny.2016.02.010; Jensen EA, 2016, SEMIN FETAL NEONAT M, V21, P181, DOI 10.1016/j.siny.2016.02.003; Jobe A H, 2001, Semin Neonatol, V6, P331, DOI 10.1053/siny.2001.0068; LANDERS S, 1986, PEDIATR RES, V20, P884, DOI 10.1203/00006450-198609000-00016; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6; Martin S, 2014, ARCH DIS CHILD-FETAL, V99, pF495, DOI 10.1136/archdischild-2013-305519; McKenzie DK, 1995, ADV EXP MED BIOL, V384, P401; Munar W, 2015, SEMIN PERINATOL, V39, P416, DOI 10.1053/j.semperi.2015.06.003; Otis AB, 1976, HDB PHYSL 3, P463; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Pillow JJ, 2007, AM J RESP CRIT CARE, V176, P63, DOI 10.1164/rccm.200609-1368OC; Roussos C, 2003, EUR RESPIR J, V22, p3S, DOI 10.1183/09031936.03.00038503; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; Sahni R, 2016, SEMIN FETAL NEONAT M, V21, P196, DOI 10.1016/j.siny.2016.02.008; SAUNDERS RA, 1976, BIOL NEONATE, V29, P178; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Subramaniam P, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001243.pub3; Tagare A, 2013, J TROP PEDIATRICS, V59, P113, DOI 10.1093/tropej/fms061; Tapia JL, 2012, J PEDIATR-US, V161, P75, DOI 10.1016/j.jpeds.2011.12.054; THIBEAULT DW, 1966, PEDIATRICS, V37, P954; Thukral A, 2016, J PERINATOL, V36, pS21, DOI 10.1038/jp.2016.29; Vucovich MM, 2014, AM J PHYSIOL-HEART C, V307, pH732, DOI 10.1152/ajpheart.00838.2013; Welty SE, 2016, CLIN PERINATOL, V43, P661, DOI 10.1016/j.clp.2016.07.004	41	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2018	13	3							e0193807	10.1371/journal.pone.0193807	http://dx.doi.org/10.1371/journal.pone.0193807			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8PV	29590143	Green Published, gold			2023-01-03	WOS:000428603100033
J	Sahin, U; Tureci, O				Sahin, Ugur; Tureci, Ozlem			Personalized vaccines for cancer immunotherapy	SCIENCE			English	Review							CYTOLYTIC T-LYMPHOCYTES; EXOME ANALYSIS REVEALS; MASS-SPECTROMETRY; CTLA-4 BLOCKADE; PD-1 BLOCKADE; CELLS; IMMUNITY; MUTATIONS; VECTORS; TOOLS	Cancer is characterized by an accumulation of genetic alterations. Somatic mutations can generate cancer-specific neoepitopes that are recognized by autologous T cells as foreign and constitute ideal cancer vaccine targets. Every tumor has its own unique composition of mutations, with only a small fraction shared between patients. Technological advances in genomics, data science, and cancer immunotherapy now enable the rapid mapping of the mutations within a genome, rational selection of vaccine targets, and on-demand production of a therapy customized to a patient's individual tumor. First-in-human clinical trials of personalized cancer vaccines have shown the feasibility, safety, and immunotherapeutic activity of targeting individual tumor mutation signatures. With vaccination development being promoted by emerging innovations of the digital age, vaccinating a patient with individual tumor mutations may become the first truly personalized treatment for cancer.	[Sahin, Ugur] Biopharmaceut New Technol BioNTech Corp, D-55131 Mainz, Germany; [Sahin, Ugur] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, D-55131 Mainz, Germany; [Sahin, Ugur] Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55131 Mainz, Germany; [Tureci, Ozlem] CI3 Cluster Individualized Immunointervent eV, D-55131 Mainz, Germany	BioNTech SE; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Sahin, U (corresponding author), Biopharmaceut New Technol BioNTech Corp, D-55131 Mainz, Germany.; Sahin, U (corresponding author), Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, D-55131 Mainz, Germany.; Sahin, U (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, D-55131 Mainz, Germany.	sahin@uni-mainz.de						Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; Bassani-Sternberg M, 2015, MOL CELL PROTEOMICS, V14, P658, DOI 10.1074/mcp.M114.042812; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Ehrlich P., 1909, NED TIJDSCHR GENEES, V5, P273; Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014; FOLEY EJ, 1953, CANCER RES, V13, P835; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Laumont CM, 2018, CELL MOL LIFE SCI, V75, P607, DOI 10.1007/s00018-017-2628-4; Lin IYC, 2015, VACCINES-BASEL, V3, P940, DOI 10.3390/vaccines3040940; Liu XS, 2017, CELL, V168, P600, DOI 10.1016/j.cell.2017.01.014; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Melief C. J. M., 2018, ONCOIMMUNOLOGY PRACT, P249; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Rice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tureci O, 2016, CLIN CANCER RES, V22, P1885, DOI 10.1158/1078-0432.CCR-15-1509; TYZZER EE, 1916, J CANCER RES, V1, P125; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	50	456	479	39	346	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 23	2018	359	6382			SI		1355	1360		10.1126/science.aar7112	http://dx.doi.org/10.1126/science.aar7112			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA0ZG	29567706				2023-01-03	WOS:000428043600037
J	Lhermie, G; Tauer, LW; Grohn, YT				Lhermie, Guillaume; Tauer, Loren William; Grohn, Yrjo Tapio			The farm cost of decreasing antimicrobial use in dairy production	PLOS ONE			English	Article							DRY COW MANAGEMENT; CLINICAL MASTITIS; MILK-PRODUCTION; REPRODUCTIVE-PERFORMANCE; UDDER HEALTH; LAMENESS; DISEASE; ASSOCIATIONS; METAANALYSIS; REPLACEMENT	Antimicrobials are used in animal agriculture to cure bacterial infectious diseases. However, antimicrobial use (AMU) inevitably leads to the selection of resistant bacteria, potentially infecting humans. As a global public threat, antimicrobial resistance has led policy makers to implement regulations supervising AMU. The objective of our research was to investigate the farm impact of several potential policies aimed at decreasing AMU. We modeled a dairy herd of 1000 cows with an average level of disease prevalence for the nine most frequent bacterial dairy diseases found in western countries. We calculated the farm net costs of AMU prohibition, as well as cost increases in antimicrobial treatments prices, and an increase in the milk withdrawal period after AMU. Sensitivity analyses were conducted to assess the impact of output and input prices, and disease prevalence. At a mean disease prevalence, the average net costs of not using antimicrobials were $61 per cow per year greater compared to a scenario modeling current farm AMU. The model predicted that the minimum and maximum increased costs associated with AMU prohibition were $46 and $73 per cow per year compared to current AMU. In each scenario, the cost difference increased with disease prevalence. Sensitivity analysis showed that the three stochastic variables which most significantly influenced the cost difference were respectively, cow replacement prices, cow slaughter price, and the milk price. Antimicrobial price increases of a factor of five, or extending the milk withdrawal period by 15 days, resulted in increasing the costs of diseases to a level where the farmer was better off not using antimicrobials. Our results suggest that the farm level costs of AMU prohibition in many cases might be minor, although the consequences of any policy instrument should be carefully evaluated to reach the ultimate goal of decreasing AMU without threatening the sustainability of milk production.	[Lhermie, Guillaume; Grohn, Yrjo Tapio] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY 14853 USA; [Tauer, Loren William] Cornell Univ, Dyson Sch Appl Econ & Management, Cornell SC Johnson Coll Business, Ithaca, NY USA	Cornell University; Cornell University	Lhermie, G (corresponding author), Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY 14853 USA.	gl467@cornell.edu	Tauer, Loren/AAD-6301-2020; Lhermie, Guillaume/F-6396-2019	Lhermie, Guillaume/0000-0003-2538-1586	Cornell University, Academic Venture fund, Atkinson Center [555]	Cornell University, Academic Venture fund, Atkinson Center	This work was supported by Cornell University Grant number 555, Academic Venture fund 2017, Atkinson Center (http://www.atkinson.cornell.edu/grants/). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AE, 2017, J DAIRY SCI, V100, P2119, DOI 10.3168/jds.2016-11517; Almasian M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14115-3; Bar D, 2008, J DAIRY SCI, V91, P2205, DOI 10.3168/jds.2007-0573; Bar D, 2008, J DAIRY SCI, V91, P2196, DOI 10.3168/jds.2007-0460; Bar D, 2007, J DAIRY SCI, V90, P4643, DOI 10.3168/jds.2007-0145; BARKEMA HW, 1994, PREV VET MED, V20, P249, DOI 10.1016/0167-5877(94)90058-2; Bewley JM, 2010, AGRIC FINANCE REV, V70, P97, DOI 10.1108/00021461011042666; Booth CJ, 2004, J DAIRY SCI, V87, P4115, DOI 10.3168/jds.S0022-0302(04)73554-7; Cazer CL, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01753; CDC, 2013, ANTIBIOTIC RESISTANC; Cha E, 2011, J DAIRY SCI, V94, P4476, DOI 10.3168/jds.2010-4123; Cha E, 2010, PREV VET MED, V97, P1, DOI 10.1016/j.prevetmed.2010.07.011; De Vliegher S, 2012, J DAIRY SCI, V95, P1025, DOI 10.3168/jds.2010-4074; De Vries A, 2006, P 11 INT S VET EP EC, P19; Dohoo I., 2010, VET EPIDEMIOLOGIC RE; Dubuc J, 2011, J DAIRY SCI, V94, P1339, DOI 10.3168/jds.2010-3758; ECDC, 2017, PROP EU GUID PRUD US; Evans NJ, 2016, VET J, V211, P3, DOI 10.1016/j.tvjl.2015.10.028; Fourichon C, 2000, THERIOGENOLOGY, V53, P1729, DOI 10.1016/S0093-691X(00)00311-3; Fourichon C, 1999, PREV VET MED, V41, P1, DOI 10.1016/S0167-5877(99)00035-5; Francoz D, 2017, J DAIRY SCI, P1; Francoz D, 2016, ANIM HEALTH RES REV, V17, P169, DOI 10.1017/S1466252316000177; Gaddis KLP, 2012, J DAIRY SCI, V95, P5422, DOI 10.3168/jds.2012-5572; Gorden PJ, 2010, VET CLIN N AM-FOOD A, V26, P243, DOI 10.1016/j.cvfa.2010.03.004; Groenendaal H, 2004, J DAIRY SCI, V87, P2146, DOI 10.3168/jds.S0022-0302(04)70034-X; Grohn YT, 2003, PREV VET MED, V61, P27, DOI 10.1016/S0167-5877(03)00158-2; Grohn YT, 1998, J DAIRY SCI, V81, P966, DOI 10.3168/jds.S0022-0302(98)75657-7; Haimerl P, 2017, J DAIRY SCI, V100, P3783, DOI 10.3168/jds.2016-11834; Halasa T, 2007, VET QUART, V29, P18, DOI 10.1080/01652176.2007.9695224; Halasa T, 2009, J DAIRY SCI, V92, P3150, DOI 10.3168/jds.2008-1741; Halasa T, 2009, J DAIRY SCI, V92, P3134, DOI 10.3168/jds.2008-1740; Heikkila AM, 2012, J DAIRY SCI, V95, P139, DOI 10.3168/jds.2011-4321; Hill AE, 2009, PREV VET MED, V88, P264, DOI 10.1016/j.prevetmed.2008.12.001; Huxley JN, 2013, LIVEST SCI, V156, P64, DOI 10.1016/j.livsci.2013.06.012; Kausche FM, 2003, VET THER, V4, P83; LeBlanc SJ, 2008, VET J, V176, P102, DOI 10.1016/j.tvjl.2007.12.019; Lhermie G, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02114; Liang D, 2017, J DAIRY SCI, V100, P1472, DOI 10.3168/jds.2016-11565; Liang D, 2013, ESTIMATING EC LOSSES; McDougall S, 2007, ANIM REPROD SCI, V99, P9, DOI 10.1016/j.anireprosci.2006.03.017; National Research Council, 2001, NUTR REQ DAIR CATTL, V7th; Oliveira L, 2013, J DAIRY SCI, V96, P7538, DOI 10.3168/jds.2012-6078; Pinedo PJ, 2010, J DAIRY SCI, V93, P2250, DOI 10.3168/jds.2009-2572; Rabiee AR, 2013, J DAIRY SCI, V96, P6915, DOI 10.3168/jds.2013-6544; Raboisson D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164200; Rajala-Schultz PJ, 1999, J DAIRY SCI, V82, P1213, DOI 10.3168/jds.S0022-0302(99)75344-0; Richert RM, 2013, J DAIRY SCI, V96, P5018, DOI 10.3168/jds.2012-6257; Rollin E, 2015, PREV VET MED, V122, P257, DOI 10.1016/j.prevetmed.2015.11.006; Rowbotham RF, 2016, J DAIRY SCI, V99, P4707, DOI 10.3168/jds.2015-10675; Scherpenzeel CGM, 2016, J DAIRY SCI, V99, P3753, DOI 10.3168/jds.2015-9963; Schukken YH, 2009, J DAIRY SCI, V92, P3091, DOI 10.3168/jds.2008-1557; Seegers H, 2003, VET RES, V34, P475, DOI 10.1051/vetres:2003027; Stevens M, 2016, J DAIRY SCI, V99, P2118, DOI 10.3168/jds.2015-10199; Swinkels JM, 2005, J DAIRY SCI, V88, P4273, DOI 10.3168/jds.S0022-0302(05)73113-1; Tang KL, 2017, LANCET PLANET HEALTH, V1, pE316, DOI 10.1016/S2542-5196(17)30141-9; US Department of Agriculture, 2012, 2012 CENS AGR; USDA, 2017, EC RES SERV DAT PROD; USDA, MILK PROD PER COW US; USDA, 2015, USDA AGR PROJ 2025; USDA NAHMS, 2008, ANT US US DAIR OP 20; Van Boeckel TP, 2017, SCIENCE, V357, P1350, DOI 10.1126/science.aao1495; WHO/ FAO/ OIE, 2016, ANT RES MAN DEV NAT; Wisconsin University, UND DAIR MARK	63	15	15	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0194832	10.1371/journal.pone.0194832	http://dx.doi.org/10.1371/journal.pone.0194832			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA1RF	29566103	Green Published, gold, Green Submitted			2023-01-03	WOS:000428093900111
J	Cummings, M; Hrobjartsson, A; Ernst, E				Cummings, Mike; Hrobjartsson, Asbjorn; Ernst, Edzard			Should doctors recommend acupuncture for pain?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INDIVIDUAL-PATIENT-DATA; MIGRAINE PROPHYLAXIS		[Cummings, Mike] British Med Acupuncture Soc, London, England; [Hrobjartsson, Asbjorn] Univ Southern Denmark, Ctr Evidence Based Med, Odense, Denmark; [Ernst, Edzard] Univ Exeter, Exeter, Devon, England	University of Southern Denmark; University of Exeter	Cummings, M (corresponding author), British Med Acupuncture Soc, London, England.; Hrobjartsson, A (corresponding author), Univ Southern Denmark, Ctr Evidence Based Med, Odense, Denmark.	cummings@btinternet.com; asbjorn.hrobjartsson@rsyd.dk	Cummings, Mike/J-7108-2019	Cummings, Mike/0000-0003-2224-8835				[Anonymous], 2017, WE MUST WARN RISKS N; Cochrane Library, ACUPUNCTURE; Cummings M., 2017, BMJ; Derbyshire D, 2013, GUARDIAN; Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004; Filshie J, 2016, MED ACUPUNCTURE W SC; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; Hrobjartsson A, 2014, INT J EPIDEMIOL, V43, P1272, DOI 10.1093/ije/dyu115; Linde K, 2016, COCHRANE DB SYST REV, V2; Madsen MV, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3115; Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391; Miller FG, 2010, NEW ENGL J MED, V363, P1776, DOI 10.1056/NEJMc1009789; NICE, 2016, LOW BACK PAIN SCIA S; More AOO, 2016, ACUPUNCT MED, V34, P476, DOI 10.1136/acupmed-2016-011097; Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367; Saramago P, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0224-1; Scottish Intercollegiate Guidelines Network, 2013, SIGN 136 MAN CHRON P; Vickers AJ, 2017, J PAIN, V30, DOI [10.1016/j.jpain.2017.11.005.29198932, DOI 10.1016/J.JPAIN.2017.11.005.29198932]; Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654; Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467; White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005; Yang CP, 2011, CEPHALALGIA, V31, P1510, DOI 10.1177/0333102411420585	22	7	7	2	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2018	360								k970	10.1136/bmj.k970	http://dx.doi.org/10.1136/bmj.k970			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ1ZG	29514785				2023-01-03	WOS:000427375500006
J	Wang, MA; Yao, LC; Cheng, MS; Cai, DY; Martinek, J; Pan, CX; Shi, W; Ma, AH; White, RWD; Airhart, S; Liu, ET; Banchereau, J; Brehm, MA; Greiner, DL; Shultz, LD; Palucka, K; Keck, JG				Wang, Minan; Yao, Li-Chin; Cheng, Mingshan; Cai, Danying; Martinek, Jan; Pan, Chong-Xian; Shi, Wei; Ma, Ai-Hong; White, Ralph W. De Vere; Airhart, Susan; Liu, Edison T.; Banchereau, Jacques; Brehm, Michael A.; Greiner, Dale L.; Shultz, Leonard D.; Palucka, Karolina; Keck, James G.			Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy	FASEB JOURNAL			English	Article						checkpoint inhibitor; mouse model; patient-derived xenograft; pembrolizumab	T-CELL RESPONSES; PD-1 BLOCKADE; IMMUNE CELLS; ANTI-PD-1 ANTIBODY; HUMAN-BLOOD; B7 FAMILY; RECEPTOR; MOUSE; SUBSETS; TUMORS	Establishment of an in vivo small animal model of human tumor and human immune system interaction would enable preclinical investigations into the mechanisms underlying cancer immunotherapy. To this end, nonobese diabetic (NOD). Cg-Prkdc(scid)IL2rg(tm1Wjl)/Sz (null; NSG) mice were transplanted with human (h) CD34(+) hematopoietic progenitor and stem cells, which leads to the development of human hematopoietic and immune systems [humanized NSG (HuNSG)]. HuNSG mice received human leukocyte antigen partially matched tumor implants from patient-derived xenografts [PDX; non-small cell lungcancer (NSCLC), sarcoma, bladder cancer, andtriple-negative breast cancer (TNBC)] or from a TNBC cell line-derived xenograft (CDX). Tumor growth curves were similar in HuNSG compared with nonhuman immune-engrafted NSG mice. Treatment with pembrolizumab, which targets programmed cell death protein 1, produced significant growth inhibition in both CDX and PDX tumors in HuNSG but not in NSG mice. Finally, inhibition of tumor growth was dependent on hCD8(+) T cells, as demonstrated by antibody-mediated depletion. Thus, tumor-bearing HuNSG mice may represent an important, new model for preclinical immunotherapy research.	[Wang, Minan; Yao, Li-Chin; Cheng, Mingshan; Cai, Danying; Keck, James G.] Jackson Lab, Dept In Vivo Pharmacol Serv, 1650 Santa Ana Ave, Sacramento, CA 95838 USA; [Martinek, Jan; Airhart, Susan; Liu, Edison T.; Banchereau, Jacques; Palucka, Karolina] Jackson Lab, Dept Immunol, Farmington, CT USA; [Pan, Chong-Xian; Shi, Wei; White, Ralph W. De Vere] Univ Calif Davis, Davis Comprehens Canc Ctr, Dept Urol, Davis, CA USA; [Ma, Ai-Hong] Univ Calif Davis, Davis Comprehens Canc Ctr, Dept Biochem & Mol Med, Davis, CA USA; [Brehm, Michael A.; Greiner, Dale L.] Univ Massachusetts, Med Sch, Dept Mol Med, Worcester, MA 01605 USA; [Brehm, Michael A.; Greiner, Dale L.] Univ Massachusetts, Med Sch, Diabet Ctr Excellence, Worcester, MA 01605 USA; [Shultz, Leonard D.] Jackson Lab, Dept Immunol, Bar Harbor, ME USA	Jackson Laboratory; Jackson Laboratory; University of California System; University of California Davis; University of California System; University of California Davis; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Jackson Laboratory	Wang, MA (corresponding author), Jackson Lab, Dept In Vivo Pharmacol Serv, 1650 Santa Ana Ave, Sacramento, CA 95838 USA.	minan.wang@jax.org		Brehm, Michael/0000-0001-6813-3262	Jackson Laboratory; NATIONAL CANCER INSTITUTE [R01CA176803, P30CA093373, P30CA034196] Funding Source: NIH RePORTER	Jackson Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank the Flow Contract Site Laboratory (Bothell, WA, USA) for processing and staining samples for flow cytometry, and Pure Transplant Solutions (Oklahoma City, OK, USA) for HLA typing. This study was funded by The Jackson Laboratory. The authors declare no conflicts of interest.	Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792; Ashizawa T, 2017, CLIN CANCER RES, V23, P149, DOI 10.1158/1078-0432.CCR-16-0122; Brehm MA, 2010, DIABETES, V59, P2265, DOI 10.2337/db10-0323; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Chen QF, 2009, P NATL ACAD SCI USA, V106, P21783, DOI 10.1073/pnas.0912274106; Dong HD, 1999, NAT MED, V5, P1365; Felix NJ, 2007, NAT REV IMMUNOL, V7, P942, DOI 10.1038/nri2200; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P394, DOI 10.1038/nrclinonc.2016.65; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee J, 2017, J CLIN INVEST, V127, P2433, DOI 10.1172/JCI92030; Li Y, 2016, EUR J IMMUNOL, V46, P1291, DOI 10.1002/eji.201546132; McGee HS, 2010, AM J RESP CELL MOL, V43, P432, DOI 10.1165/rcmb.2009-0258OC; Merryman RW, 2017, BLOOD, V129, P1380, DOI 10.1182/blood-2016-09-738385; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mullard A, 2013, NAT REV DRUG DISCOV, V12, P489, DOI 10.1038/nrd4066; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Palucka AK, 2003, BLOOD, V102, P3302, DOI 10.1182/blood-2003-02-0384; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Rosenblatt J, 2011, J IMMUNOTHER, V34, P409, DOI 10.1097/CJI.0b013e31821ca6ce; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Shultz LD, 2012, NAT REV IMMUNOL, V12, P786, DOI 10.1038/nri3311; Shultz LD, 2010, P NATL ACAD SCI USA, V107, P13022, DOI 10.1073/pnas.1000475107; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Strowig T, 2009, J EXP MED, V206, P1423, DOI 10.1084/jem.20081720; Tanaka S, 2012, J IMMUNOL, V188, P6145, DOI 10.4049/jimmunol.1103660; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Theocharides APA, 2016, HAEMATOLOGICA, V101, P5, DOI 10.3324/haematol.2014.115212; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Waldron-Lynch F, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003401; Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Zilberberg J, 2015, BIOL BLOOD MARROW TR, V21, P1000, DOI 10.1016/j.bbmt.2014.11.001; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	51	159	164	9	58	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2018	32	3					1537	1549		10.1096/fj.201700740R	http://dx.doi.org/10.1096/fj.201700740R			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FZ0GN	29146734	Green Published, hybrid			2023-01-03	WOS:000427246000033
J	Kvistborg, P; Yewdell, JW				Kvistborg, Pia; Yewdell, Jonathan W.			Enhancing responses to cancer immunotherapy	SCIENCE			English	Editorial Material									[Kvistborg, Pia] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands; [Yewdell, Jonathan W.] NIAID, Lab Viral Dis, Cellular Biol Sect, 9000 Rockville Pike, Bethesda, MD 20892 USA	Netherlands Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kvistborg, P (corresponding author), Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.	p.kvistborg@nki.nl	yewdell, jyewdell@nih.gov jonathan/A-1702-2012		Division of Intramural Research, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001210] Funding Source: NIH RePORTER	Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J.W.Y. is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases.	Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; McGranahan N, 2017, CELL, V170, P825, DOI 10.1016/j.cell.2017.08.012; Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064; Robinson J, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006862; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Starck SR, 2016, IMMUNOL REV, V272, P8, DOI 10.1111/imr.12434; WILLIAMS DB, 1985, J CELL BIOL, V101, P725, DOI 10.1083/jcb.101.3.725; Wolchok JD, 2017, NEW ENGL J MED, V377, P2503; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	10	25	28	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 2	2018	359	6375					516	517		10.1126/science.aar6574	http://dx.doi.org/10.1126/science.aar6574			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU4AS	29420276				2023-01-03	WOS:000423795800021
J	Dias, JG; de Oliveira, IT				Dias, Jose G.; de Oliveira, Isabel Tiago			Exploring unobserved household living conditions in multilevel choice modeling: An application to contraceptive adoption by Indian women	PLOS ONE			English	Article							ITEM RESPONSE THEORY; PRINCIPAL-COMPONENTS; SOCIOECONOMIC-STATUS; HEALTH; WEALTH; POVERTY; INDEXES; FERTILITY; COUNTRIES; COUNTDOWN	This research analyzes the effect of the poverty-wealth dimension on contraceptive adoption by Indian women when no direct measures of income/expenditures are available to use as covariates. The index-Household Living Conditions (HLC)-is based on household assets and dwelling characteristics and is computed by an item response model simultaneously with the choice model in a new single-step approach. That is, the HLC indicator is treated as a latent covariate measured by a set of items, it depends on a set of concomitant variables, and explains contraceptive choices in a probit regression. Additionally, the model accounts for complex survey design and sample weights in a multilevel framework. Regarding our case study on contraceptive adoption by Indian women, results show that women with better household living conditions tend to adopt contraception more often than their counterparts. This effect is significant after controlling other factors such as education, caste, and religion. The external validation of the indicator shows that it can also be used at aggregate levels of analysis (e.g., county or state) whenever no other indicators of household living conditions are available.	[Dias, Jose G.] IUL, BRU, ISCTE, Lisbon, Portugal; [de Oliveira, Isabel Tiago] IUL, CIES, ISCTE, Lisbon, Portugal	Instituto Universitario de Lisboa; Instituto Universitario de Lisboa	Dias, JG (corresponding author), IUL, BRU, ISCTE, Lisbon, Portugal.	jose.dias@iscte-iul.pt	Dias, José G./N-6217-2015; Oliveira, Isabel/AAE-4688-2022	Oliveira, Isabel/0000-0002-9350-4130; Dias, Jose G./0000-0003-4732-7230	Fundacao para a Ciencia e Tecnologia (Portugal) [PTDC/CS-DEM/108033/2008, UID/GES/00315/2013, UID/SOC/03126/2013]; Fundação para a Ciência e a Tecnologia [PTDC/CS-DEM/108033/2008] Funding Source: FCT	Fundacao para a Ciencia e Tecnologia (Portugal)(Portuguese Foundation for Science and Technology); Fundação para a Ciência e a Tecnologia	This research was supported by the Fundacao para a Ciencia e Tecnologia (Portugal), Grant PTDC/CS-DEM/108033/2008, UID/GES/00315/2013, and UID/SOC/03126/2013.	Afifi M, 2009, NURS HEALTH SCI, V11, P29, DOI 10.1111/j.1442-2018.2009.00419.x; Aguilera AM, 2006, COMPUT STAT DATA AN, V50, P1905, DOI 10.1016/j.csda.2005.03.011; Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; [Anonymous], 2017, ESAPWP248 UN POP DIV; [Anonymous], 2008, ANAL HLTH EQUITY USI; Asparouhov T, 2005, STRUCT EQU MODELING, V12, P411, DOI 10.1207/s15328007sem1203_4; Bamiwuye SO, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-45; Barros AJD, 2012, LANCET, V379, P1225, DOI 10.1016/S0140-6736(12)60113-5; Batana YM, 2013, SOC INDIC RES, V112, P337, DOI 10.1007/s11205-013-0251-9; Bleeker SE, 2003, J CLIN EPIDEMIOL, V56, P826, DOI 10.1016/S0895-4356(03)00207-5; Boerma JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; Bollen KA, 2001, ANNU REV SOCIOL, V27, P153, DOI 10.1146/annurev.soc.27.1.153; Booysen F, 2008, WORLD DEV, V36, P1113, DOI 10.1016/j.worlddev.2007.10.008; Cai L, 2016, ANNU REV STAT APPL, V3, P297, DOI 10.1146/annurev-statistics-041715-033702; Char A, 2001, REPROD HEALTH MATTER, V18, P154; Clark S, 2000, DEMOGRAPHY, V37, P95, DOI 10.2307/2648099; de Oliveira IT, 2014, QUAL QUANT, V48, P1001, DOI 10.1007/s11135-012-9820-2; Deaton A., 1997, The analysis of household surveys: a microeconometric approach to development policy.; DeMars C., 2010, ITEM RESPONSE THEORY; Dokubo EK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106760; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Filmer D, 2012, DEMOGRAPHY, V49, P359, DOI 10.1007/s13524-011-0077-5; Gaudin S, 2011, DEMOGRAPHY, V48, P343, DOI 10.1007/s13524-010-0006-z; Grosh M., 2000, DESIGNING HOUSEHOLD; Gwatkin D., 2005, SOCIOECONOMIC DIFFER, V2nd ed.; Harkavy O., 2007, GLOBAL FAMILY PLANNI, P301; Hays RD, 2000, MED CARE, V38, P28; Hong R, 2006, INT J EQUITY HLTH, V5; Hox J.J., 2018, MULTILEVEL ANAL; IIPS and Macro International, 2007, NATL FAMILY HLTH SUR, V1; Imai KS, 2010, DP201017 KOB U; Iyer S, 2002, J SCI STUD RELIG, V41, P711, DOI 10.1111/1468-5906.00156; Janowitz B, 2010, WEALTH STATUS FAMILY; Jayaraman A, 2009, INT PERSPECT SEX R H, V35, P29, DOI 10.1363/ifpp.35.029.09; Jejeebhoy S., 1995, WOMENS AUTONOMY REPR; Kaiser BN, 2017, AM J HUM BIOL, V29, DOI 10.1002/ajhb.22987; Kamata A, 2008, STRUCT EQU MODELING, V15, P136, DOI 10.1080/10705510701758406; Kreft I.G., 1998, INTRO MULTILEVEL MOD, DOI DOI 10.4135/9781849209366; Magadi M, 2011, HEALTH PLACE, V17, P1067, DOI 10.1016/j.healthplace.2011.06.004; Ministry of Statistics and Programme Implementation, 2015, STAT DOM PROD OTH AG; Mishra V, 2007, AIDS, V21, pS17, DOI 10.1097/01.aids.0000300532.51860.2a; Mohanty Sanjay K., 2009, Genus, V65, P113; Montgomery MR, 2000, DEMOGRAPHY, V37, P155, DOI 10.2307/2648118; Montgomery MR, 2005, DEMOGRAPHY, V42, P397, DOI 10.1353/dem.2005.0020; Morris SS, 2000, J EPIDEMIOL COMMUN H, V54, P381, DOI 10.1136/jech.54.5.381; Moursund A, 2003, POP STUD-J DEMOG, V57, P285, DOI 10.1080/0032472032000137817; Muthen L. K., 2010, MPLUS USERS GUIDE, V6th; Navarro C, 2008, APPL ECON, V40, P597, DOI 10.1080/00036840600722323; Oliveira ITD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100050; Prusty RK, 2014, J HEALTH POPUL NUTR, V32, P342; Rama Baru, 2010, Economic and Political Weekly, V45, P49; Reise SP, 2009, ANNU REV CLIN PSYCHO, V5, P27, DOI 10.1146/annurev.clinpsy.032408.153553; Roy S., 2015, J STAT APPL PROLETT, V2, P149; Rutstein SO, 2004, DHS COMP REPORTS NO; Sahn DE, 2000, WORLD DEV, V28, P2123, DOI 10.1016/S0305-750X(00)00075-9; Scott M.A., 2013, SAGE HDB MULTILEVEL; Srinivasan K., 2006, MEMORIAL LECT SERIES; Suresh Sharma, 2011, Journal of Public Health and Epidemiology, V3, P632; Tasciotti L, 2017, EUR J DEV RES; Ucar B, 2015, SOC INDIC RES, V121, P745, DOI 10.1007/s11205-014-0670-2; United Nations, 2017, WORLD CONTR US 2017; Van der Linden W.J., 1997, HDB MODERN ITEM RESP; Vandemoortele M, 2014, SOC INDIC RES, V118, P877, DOI 10.1007/s11205-013-0447-z; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029	65	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2018	13	1							e0191784	10.1371/journal.pone.0191784	http://dx.doi.org/10.1371/journal.pone.0191784			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU2GT	29385187	Green Published, gold			2023-01-03	WOS:000423668400054
J	Mintz, M; Khair, S; Grewal, S; LaComb, JF; Park, J; Channer, B; Rajapakse, R; Bucobo, JC; Buscaglia, JM; Monzur, F; Chawla, A; Yang, J; Robertson, CE; Frank, DN; Li, E				Mintz, Michael; Khair, Shanawaj; Grewal, Suman; LaComb, Joseph F.; Park, Jiyhe; Channer, Breana; Rajapakse, Ramona; Bucobo, Juan Carlos; Buscaglia, Jonathan M.; Monzur, Farah; Chawla, Anupama; Yang, Jie; Robertson, Charlie E.; Frank, Daniel N.; Li, Ellen			Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; COLONOSCOPY; MANAGEMENT; SIGNATURES; DIVERSITY; ALIGNMENT	Background Studies of colonoscopic fecal microbiota transplant (FMT) in patients with recurrent CDI, indicate that this is a very effective treatment for preventing further relapses. In order to provide this service at Stony Brook University Hospital, we initiated an open-label prospective study of single colonoscopic FMT among patients with >= 2 recurrences of CDI, with the intention of monitoring microbial composition in the recipient before and after FMT, as compared with their respective donor. We also initiated a concurrent open label prospective trial of single colonoscopic FMT of patients with ulcerative colitis (UC) not responsive to therapy, after obtaining an IND permit (IND 15642). To characterize how FMT alters the fecal microbiota in patients with recurrent Clostridia difficile infections (CDI) and/or UC, we report the results of a pilot microbiome analysis of 11 recipients with a history of 2 or more recurrences of C. difficile infections without inflammatory bowel disease (CDI-only), 3 UC recipients with recurrent C. difficile infections (CDI + UC), and 5 UC recipients without a history of C. difficile infections (UC-only). Method V3V4 Illumina 16S ribosomal RNA (rRNA) gene sequencing was performed on the pre-FMT, 1-week post-FMT, and 3-months post-FMT recipient fecal samples along with those collected from the healthy donors. Fitted linear mixed models were used to examine the effects of Group (CDI-only, CDI + UC, UC-only), timing of FMT (Donor, pre-FMT, 1-week post-FMT, 3-months post-FMT) and first order Group*FMT interactions on the diversity and composition of fecal microbiota. Pairwise comparisons were then carried out on the recipient vs. donor and between the pre-FMT, 1-week post-FMT, and 3-months post-FMT recipient samples within each group. Results Significant effects of FMT on overall microbiota composition (e.g., beta diversity) were observed for the CDI-only and CDI + UC groups. Marked decreases in the relative abundances of the strictly anaerobic Bacteroidetes phylum, and two Firmicutes sub-phyla associated with butyrate production (Ruminococcaceae and Lachnospiraceae) were observed between the CDI-only and CDI + UC recipient groups. There were corresponding increases in the microaerophilic Proteobacteria phylum and the Firmicutes/Bacilli group in the CDI-only and CDI + UC recipient groups. At a more granular level, significant effects of FMT were observed for 81 genus-level operational taxonomic units (OTUs) in at least one of the three recipient groups (p<0.00016 with Bonferroni correction). Pairwise comparisons of the estimated pre-FMT recipient/donor relative abundance ratios identified 6 Gammaproteobacteria OTUs, including the Escherichia-Shigella genus, and 2 Fusobacteria OTUs with significantly increased relative abundance in the pre-FMT samples of all three recipient groups (FDR < 0.05), however the magnitude of the fold change was much larger in the CDI-only and CDI + UC recipients than in the UC-only recipients. Depletion of butyrate producing OTUs, such as Faecalibacterium, in the CDI-only and CDI + UC recipients, were restored after FMT. Conclusion The results from this pilot study suggest that the microbial imbalances in the CDI + UC recipients more closely resemble those of the CDI-only recipients than the UC-only recipients.	[Mintz, Michael; Khair, Shanawaj; Grewal, Suman; LaComb, Joseph F.; Channer, Breana; Rajapakse, Ramona; Bucobo, Juan Carlos; Buscaglia, Jonathan M.; Monzur, Farah; Li, Ellen] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Park, Jiyhe] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA; [Chawla, Anupama] SUNY Stony Brook, Dept Pediat, Stony Brook, NY 11794 USA; [Yang, Jie] SUNY Stony Brook, Dept Family Populat & Prevent Med, Stony Brook, NY 11794 USA; [Robertson, Charlie E.; Frank, Daniel N.] Univ Colorado Denver, Dept Med, Aurora, CO USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Li, E (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.	ellen.li@stonybrookmedicine.edu		Yang, Jie/0000-0003-3469-5931; Khair, shanawaj/0000-0001-7902-5689; LaComb, Joseph/0000-0002-2981-1072	Simons Foundation [1130410 1 7408]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	Simons Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the Simons Foundation (1130410 1 7408) to EL (https://www.simonsfoundation.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albenberg L, 2014, GASTROENTEROLOGY, V147, P1055, DOI 10.1053/j.gastro.2014.07.020; Anderson MJ, 2011, ECOL LETT, V14, P19, DOI 10.1111/j.1461-0248.2010.01552.x; Bakken JS, 2011, CLIN GASTROENTEROL H, V9, P1044, DOI 10.1016/j.cgh.2011.08.014; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Frank DN, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-362; Fuentes S, 2017, ISME J, V11, P1877, DOI 10.1038/ismej.2017.44; Garey KW, 2008, J HOSP INFECT, V70, P298, DOI 10.1016/j.jhin.2008.08.012; Garrett WS, 2010, CELL HOST MICROBE, V8, P292, DOI 10.1016/j.chom.2010.08.004; Hourigan SK, 2015, ALIMENT PHARM THER, V42, P741, DOI 10.1111/apt.13326; Hughes ER, 2017, CELL HOST MICROBE, V21, P208, DOI 10.1016/j.chom.2017.01.005; Johnson S, 2009, J INFECTION, V58, P403, DOI 10.1016/j.jinf.2009.03.010; Kelly Ciaran P, 2008, N Engl J Med, V359, P1932, DOI 10.1056/NEJMra0707500; Khanna S, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0269-3; Koroleva EP, 2015, J IMMUNOL METHODS, V421, P61, DOI 10.1016/j.jim.2015.02.003; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Lessa FC, 2015, NEW ENGL J MED, V372, P2369, DOI [10.1056/NEJMc1505190, 10.1056/NEJMoa1408913]; Li E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026284; Lopez-Siles M, 2017, ISME J, V11, P841, DOI 10.1038/ismej.2016.176; Mattila E, 2012, GASTROENTEROLOGY, V142, P490, DOI 10.1053/j.gastro.2011.11.037; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; Nelson RL, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004610.pub5; Olsen MA, 2015, CLIN MICROBIOL INFEC, V21, P164, DOI 10.1016/j.cmi.2014.08.017; Paine ER, 2014, GASTROENTEROL REP, V2, P161, DOI 10.1093/gastro/gou028; Petersen AM, 2015, SCAND J GASTROENTERO, V50, P1199, DOI 10.3109/00365521.2015.1028993; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Rao K, 2016, INFLAMM BOWEL DIS, V22, P1744, DOI 10.1097/MIB.0000000000000793; Robertson CE, 2013, BIOINFORMATICS, V29, P3100, DOI 10.1093/bioinformatics/btt526; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Schloss PD, 2011, APPL ENVIRON MICROB, V77, P3219, DOI 10.1128/AEM.02810-10; Shin H, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075729, 10.1371/journal.pone.0081330]; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Son JS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137725; Staley C, 2016, MBIO, V7, DOI 10.1128/mBio.01965-16; Weingarden AR, 2014, AM J PHYSIOL-GASTR L, V306, pG310, DOI 10.1152/ajpgi.00282.2013; Willing BP, 2010, GASTROENTEROLOGY, V139, P1844, DOI 10.1053/j.gastro.2010.08.049; Yoon SS, 2010, J CLIN GASTROENTEROL, V44, P562, DOI 10.1097/MCG.0b013e3181dac035	39	18	21	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2018	13	1							e0190997	10.1371/journal.pone.0190997	http://dx.doi.org/10.1371/journal.pone.0190997			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU2GT	29385143	Green Submitted, Green Published, gold			2023-01-03	WOS:000423668400029
J	Dudley, L; Mukinda, F; Dyers, R; Marais, F; Sissolak, D				Dudley, Lilian; Mukinda, Fidele; Dyers, Robin; Marais, Frederick; Sissolak, Dagmar			Mind the gap! Risk factors for poor continuity of care of TB patients discharged from a hospital in the Western Cape, South Africa	PLOS ONE			English	Article							TUBERCULOSIS-CONTROL; HEALTH; ACCURACY; QUALITY; LINKAGE; RECORD; MODEL	Background TB patients discharged from hospitals in South Africa experience poor continuity of care, failing to continue TB treatment at other levels of care. Factors contributing to poor continuity of TB care are insufficiently described to inform interventions. Objective To describe continuity of care and risk factors in TB patients discharged from a referral hospital in the Western Cape, South Africa. Design This retrospective observational study used routine information to describe continuity of care and risk factors in TB patients discharged from hospital. Results 788 hospitalized TB patients were identified in 6 months. Their median age was 32 years, 400 (51%) were male, and 653 (83%) were urban. A bacteriological TB test was performed for 74%, 25% were tested for HIV in hospital, and 32% of all TB patients had documented evidence of HIV co-infection. Few (13%) were notified for TB; 375 (48%) received TB medication; 284 (36%) continued TB treatment after discharge; 91 (24%) had a successful TB treatment outcome, and 166 (21%) died. Better continuity of care was associated with adults, urban residence, bacteriological TB tests in hospital and TB medication on discharge. Fragmented hospital TB data systems did not provide continuity with primary health care information systems. Conclusions Discharged TB patients experienced poor continuity of care, with children, rural patients, those not tested for TB in hospital or discharged without TB medication at greatest risk. Suboptimal quality of hospital TB care and a fragmented hospital information system without linkages to other levels underpinned poor continuity of care.	[Dudley, Lilian; Mukinda, Fidele; Dyers, Robin; Marais, Frederick] Stellenbosch Univ, Fac Med & Hlth Sci, Div Hlth Syst & Publ Hlth, Cape Town, South Africa; [Dudley, Lilian] Harvard Chan Sch Publ Hlth, Dept Global Hlth, Boston, MA 02115 USA; [Dyers, Robin; Marais, Frederick] Western Cape Prov Govt, Dept Hlth, Cape Town, South Africa; [Sissolak, Dagmar] Berlin Cent, Dept Publ Hlth, Dept Infect Control Med Disaster Control & Enviro, Berlin, Germany	Stellenbosch University; Harvard University; Harvard T.H. Chan School of Public Health	Dudley, L (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Div Hlth Syst & Publ Hlth, Cape Town, South Africa.; Dudley, L (corresponding author), Harvard Chan Sch Publ Hlth, Dept Global Hlth, Boston, MA 02115 USA.	ldudley@sun.ac.za	Mukinda, Fidele K./AAD-6258-2019	Mukinda, Fidele K./0000-0002-0764-6213	Medical Research Council of South Africa; Stellenbosch University	Medical Research Council of South Africa(South African Medical Research Council); Stellenbosch University	The study was funded by the Medical Research Council of South Africa and Stellenbosch University (LD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, NAT TB MAN GUID; Boehme CC, 2011, LANCET, V377, P1495, DOI 10.1016/S0140-6736(11)60438-8; Day C, 2011, S AFRICAN HLTH REV 2; Department of Health, 2012, NAT HIV SYPH SER PRE; du Preez K, 2011, PUBLIC HEALTH ACTION, V1, P19, DOI 10.5588/pha.11.0010; Dunbar R, 2011, INT J TUBERC LUNG D, V15, P337; Dyers RE, 2016, SAMJ S AFR MED J, V106, P181, DOI [10.7196/SAMJ.2016.v106i2.10079, 10.7196/SAMJ.2016.V106I2.10079]; Edginton ME, 2005, INT J TUBERC LUNG D, V9, P398; Ford N, 2016, J INT AIDS SOC, V19; Hongoro C, 2005, INT J QUAL HEALTH C, V17, P287, DOI 10.1093/intqhc/mzi040; Irawati SR, 2007, INT J TUBERC LUNG D, V11, P33; Janson J, 2012, PUBLIC HEALTH ACTION, V2, P61, DOI 10.5588/pha.12.0003; Karim SSA, 2009, LANCET, V374, P921, DOI 10.1016/S0140-6736(09)60916-8; Loveday M, 2008, INT J TUBERC LUNG D, V12, P1042; Lurie MN, 2014, HEALTH PSYCHOL BEHAV, V2, P34, DOI 10.1080/21642850.2013.866898; Reid A, 2005, JAIDS-J ACQ IMM DEF, V40, P53, DOI 10.1097/01.qai.0000174251.35398.72; ROOS LL, 1991, METHOD INFORM MED, V30, P117; Sinanovic E, 2003, INT J TUBERCULOSI S9, V7, P56; Sissolak D, 2010, INT J INFECT DIS, V14, pE423, DOI 10.1016/j.ijid.2009.06.030; StataCorp, 2013, STAT REL 13 STAT SOF; Uplekar M, 2008, INT J TUBERC LUNG D, V12, P986; Van Walraven C, 2011, CANADIAN MED ASS J; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wang L, 2009, INT J TUBERC LUNG D, V13, P1486; Wang LX, 2010, B WORLD HEALTH ORGAN, V88, P937, DOI 10.2471/BLT.09.071753; World Health Organization, GLOB TUB REP 2016; YACH D, 1988, SOC SCI MED, V27, P683, DOI 10.1016/0277-9536(87)90328-5	27	13	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2018	13	1							e0190258	10.1371/journal.pone.0190258	http://dx.doi.org/10.1371/journal.pone.0190258			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FT8QE	29370162	Green Published, Green Submitted, gold			2023-01-03	WOS:000423416600008
J	Mack, SC; Pajtler, KW; Chavez, L; Okonechnikov, K; Bertrand, KC; Wang, XX; Erkek, S; Federation, A; Song, A; Lee, C; Wang, X; McDonald, L; Morrow, JJ; Saiakhova, A; Sin-Chan, P; Wu, QL; Michaelraj, KA; Miller, TE; Hubert, CG; Ryzhova, M; Garzia, L; Donovan, L; Dombrowski, S; Factor, DC; Luu, B; Valentim, CLL; Gimple, RC; Morton, A; Kim, L; Prager, BC; Lee, JJY; Wu, XC; Zuccaro, J; Thompson, Y; Holgado, BL; Reimand, J; Ke, SQ; Tropper, A; Lai, SS; Vijayarajah, S; Doan, S; Mahadev, V; Minan, AF; Grobner, SN; Lienhard, M; Zapatka, M; Huang, ZQ; Aldape, KD; Carcaboso, AM; Houghton, PJ; Keir, ST; Milde, T; Witt, H; Li, Y; Li, CJ; Bian, XW; Jones, DTW; Scott, I; Singh, SK; Huang, A; Dirks, PB; Bouffet, E; Bradner, JE; Amaswamy, VR; Jabado, N; Rutka, JT; Northcott, PA; Lupien, M; Lichter, P; Korshunov, A; Scacheri, PC; Pfister, SM; Kool, M; Taylor, MD; Rich, JN				Mack, Stephen C.; Pajtler, Kristian W.; Chavez, Lukas; Okonechnikov, Konstantin; Bertrand, Kelsey C.; Wang, Xiuxing; Erkek, Serap; Federation, Alexander; Song, Anne; Lee, Christine; Wang, Xin; McDonald, Laura; Morrow, James J.; Saiakhova, Alina; Sin-Chan, Patrick; Wu, Qiulian; Michaelraj, Kulandaimanuvel Antony; Miller, Tyler E.; Hubert, Christopher G.; Ryzhova, Marina; Garzia, Livia; Donovan, Laura; Dombrowski, Stephen; Factor, Daniel C.; Luu, Betty; Valentim, Claudia L. L.; Gimple, Ryan C.; Morton, Andrew; Kim, Leo; Prager, Briana C.; Lee, John J. Y.; Wu, Xiaochong; Zuccaro, Jennifer; Thompson, Yuan; Holgado, Borja L.; Reimand, Juri; Ke, Susan Q.; Tropper, Adam; Lai, Sisi; Vijayarajah, Senthuran; Doan, Sylvia; Mahadev, Vaidehi; Fernandez Minan, Ana; Groebner, Susanne N.; Lienhard, Matthias; Zapatka, Marc; Huang, Zhiqin; Aldape, Kenneth D.; Carcaboso, Angel M.; Houghton, Peter J.; Keir, Stephen T.; Milde, Till; Witt, Hendrik; Li, Yan; Li, Chao-Jun; Bian, Xiu-Wu; Jones, David T. W.; Scott, Ian; Singh, Sheila K.; Huang, Annie; Dirks, Peter B.; Bouffet, Eric; Bradner, James E.; Amaswamy, Vijay R.; Jabado, Nada; Rutka, James T.; Northcott, Paul A.; Lupien, Mathieu; Lichter, Peter; Korshunov, Andrey; Scacheri, Peter C.; Pfister, Stefan M.; Kool, Marcel; Taylor, Michael D.; Rich, Jeremy N.			Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling	NATURE			English	Article							SUPER-ENHANCERS; COMPARTMENTS; EXPRESSION; SUBGROUPS; TUMORS	Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Intracranial ependymomas are segregated on the basis of anatomical location (supratentorial region or posterior fossa) and further divided into distinct molecular subgroups that reflect differences in the age of onset, gender predominance and response to therapy(1-3). The most common and aggressive subgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack recurrent somatic mutations(2). Conversely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy number gains and losses but have favourable clinical outcomes(1,3). More than 70% of supratentorial ependymomas are defined by highly recurrent gene fusions in the NF-kappa B subunit gene RELA (ST-EPN-RELA), and a smaller number involve fusion of the gene encoding the transcriptional activator YAP1 (ST-EPN-YAP1)(1,3,4). Subependymomas, a distinct histologic variant, can also be found within the supratetorial and posterior fossa compartments, and account for the majority of tumours in the molecular subgroups ST-EPN-SE and PF-EPN-SE. Here we describe mapping of active chromatin landscapes in 42 primary ependymomas in two non-overlapping primary ependymoma cohorts, with the goal of identifying essential super-enhancer-associated genes on which tumour cells depend. Enhancer regions revealed putative oncogenes, molecular targets and pathways; inhibition of these targets with small molecule inhibitors or short hairpin RNA diminished the proliferation of patient-derived neurospheres and increased survival in mouse models of ependymomas. Through profiling of transcriptional enhancers, our study provides a framework for target and drug discovery in other cancers that lack known genetic drivers and are therefore difficult to treat.	[Mack, Stephen C.; Bertrand, Kelsey C.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Mack, Stephen C.; Bertrand, Kelsey C.] Texas Childrens Canc Ctr, Dept Pediat Hematolgy & Oncol, Houston, TX USA; [Mack, Stephen C.; Wang, Xiuxing; Song, Anne; Lee, Christine; Wu, Qiulian; Miller, Tyler E.; Hubert, Christopher G.; Dombrowski, Stephen; Valentim, Claudia L. L.; Gimple, Ryan C.; Morton, Andrew; Kim, Leo; Prager, Briana C.; Ke, Susan Q.; Tropper, Adam; Lai, Sisi; Mahadev, Vaidehi; Rich, Jeremy N.] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA; [Mack, Stephen C.; Wang, Xiuxing; Song, Anne; Lee, Christine; Wu, Qiulian; Miller, Tyler E.; Hubert, Christopher G.; Dombrowski, Stephen; Valentim, Claudia L. L.; Gimple, Ryan C.; Morton, Andrew; Kim, Leo; Prager, Briana C.; Ke, Susan Q.; Tropper, Adam; Lai, Sisi; Mahadev, Vaidehi; Rich, Jeremy N.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Mol Med, Cleveland, OH 44195 USA; [Pajtler, Kristian W.; Chavez, Lukas; Okonechnikov, Konstantin; Erkek, Serap; Groebner, Susanne N.; Witt, Hendrik; Jones, David T. W.; Pfister, Stefan M.; Kool, Marcel] NCT Heidelberg KiTZ, Hopp Childrens Canc Ctr, D-69120 Heidelberg, Germany; [Pajtler, Kristian W.; Chavez, Lukas; Okonechnikov, Konstantin; Erkek, Serap; Groebner, Susanne N.; Witt, Hendrik; Jones, David T. W.; Pfister, Stefan M.; Kool, Marcel] German Canc Res Ctr, Div Pediat Neurooncol, D-69120 Heidelberg, Germany; [Pajtler, Kristian W.; Chavez, Lukas; Okonechnikov, Konstantin; Erkek, Serap; Groebner, Susanne N.; Witt, Hendrik; Jones, David T. W.; Pfister, Stefan M.; Kool, Marcel] German Canc Consortium DKTK, D-69120 Heidelberg, Germany; [Pajtler, Kristian W.; Milde, Till; Witt, Hendrik; Pfister, Stefan M.] Heidelberg Univ Hosp, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany; [Chavez, Lukas] Univ Calif San Diego, Sch Med, Dept Med, Div Med Genet, La Jolla, CA 92093 USA; [Bertrand, Kelsey C.; Vijayarajah, Senthuran] Cleveland Clin, Dept Pediat, Cleveland, OH 44195 USA; [Wang, Xiuxing; Wu, Qiulian; Gimple, Ryan C.; Kim, Leo; Prager, Briana C.; Rich, Jeremy N.] Univ Calif San Diego, Sch Med, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA; [Erkek, Serap] European Mol Biol Lab, Genome Biol Unit, Heidelberg, Germany; [Federation, Alexander] Univ Washington, Dept Genom Sci, Seattle, WA 98195 USA; [Wang, Xin; McDonald, Laura; Sin-Chan, Patrick; Michaelraj, Kulandaimanuvel Antony; Garzia, Livia; Donovan, Laura; Luu, Betty; Lee, John J. Y.; Wu, Xiaochong; Zuccaro, Jennifer; Thompson, Yuan; Holgado, Borja L.; Scott, Ian; Huang, Annie; Dirks, Peter B.; Bouffet, Eric; Amaswamy, Vijay R.; Rutka, James T.; Taylor, Michael D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Program Dev & Stem Cell Biol, Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Morrow, James J.; Saiakhova, Alina; Factor, Daniel C.; Morton, Andrew; Li, Yan; Scacheri, Peter C.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Miller, Tyler E.; Gimple, Ryan C.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Ryzhova, Marina] NN Burdenko Inst Neurosurg, Dept Neuropathol, 4th Tverskaya Yamskaya 16, Moscow 125047, Russia; [Dombrowski, Stephen; Rich, Jeremy N.] Rose Ella Burkhardt Brain Tumor & Neurooncol Ctr, Neurol Inst, Dept Neurosurg, Cleveland Clin, Cleveland, OH 44195 USA; [Reimand, Juri] Ontario Inst Canc Res, Computat Biol Program, Toronto, ON M5G 0A3, Canada; [Reimand, Juri; Lupien, Mathieu] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada; [Vijayarajah, Senthuran] Univ Utah, Sch Med, Dept Pediat, Div Crit Care, Salt Lake City, UT USA; [Doan, Sylvia] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Fernandez Minan, Ana] Ctr Andaluz Biol Desarrollo, Consejo Super Invest Cient, Seville, Spain; [Fernandez Minan, Ana] Univ Pablo Olavide, Seville, Spain; [Lienhard, Matthias] Max Planck Inst Mol Genet, Dept Computat Mol Biol, D-14195 Berlin, Germany; [Zapatka, Marc; Huang, Zhiqin; Lichter, Peter] German Canc Res Ctr, Div Mol Genet, D-69121 Heidelberg, Germany; [Aldape, Kenneth D.] Univ Hlth Network, Dept Pathol, Toronto, ON M5G 1L7, Canada; [Carcaboso, Angel M.] Fundacio Sant Joan Deu, Preclin Therapeut & Drug Delivery Res Program, Barcelona 08950, Spain; [Houghton, Peter J.] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Columbus, OH USA; [Keir, Stephen T.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Milde, Till] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol, INF 280, D-69120 Heidelberg, Germany; [Li, Chao-Jun] Nanjing Univ, Natl Resource Ctr Mutant Mice, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Bian, Xiu-Wu] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing, Peoples R China; [Bian, Xiu-Wu] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China; [Bian, Xiu-Wu] Minist Educ China, Key Lab Tumor Immunopathol, Chongqing, Peoples R China; [Singh, Sheila K.] McMaster Univ, Dept Surg, Fac Hlth Sci, Div Neurosurg, Hamilton, ON, Canada; [Huang, Annie; Bouffet, Eric; Bradner, James E.] Novartis Inst Biomed Res, Cambridge, MA 02139 USA; [Amaswamy, Vijay R.] Hosp Sick Children, Div Hematol & Oncol, Toronto, ON M5G 1X8, Canada; [Jabado, Nada] McGill Univ, Dept Pediat, Montreal, PQ H3Z 2Z3, Canada; [Jabado, Nada] McGill Univ, Dept Human Genet, Montreal, PQ H3Z 2Z3, Canada; [Jabado, Nada] McGill Univ Hlth Ctr, Res Inst, Montreal, PQ H3Z 2Z3, Canada; [Northcott, Paul A.] St Jude Childrens Res Hosp, Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Korshunov, Andrey] Heidelberg Univ, Dept Neuropathol, D-69120 Heidelberg, Germany; [Korshunov, Andrey] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, D-69121 Heidelberg, Germany	Baylor College of Medicine; Texas Children's Cancer Center; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of California System; University of California San Diego; Cleveland Clinic Foundation; University of California System; University of California San Diego; European Molecular Biology Laboratory (EMBL); University of Washington; University of Washington Seattle; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Case Western Reserve University; Case Western Reserve University; Russian Academy of Medical Sciences; N.N.Burdenko National Medical Research Center of Neurosurgery; Cleveland Clinic Foundation; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); Universidad Pablo de Olavide; Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Duke University; Helmholtz Association; German Cancer Research Center (DKFZ); Nanjing University; Army Medical University; Army Medical University; Ministry of Education, China; McMaster University; Novartis; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; McGill University; McGill University; St Jude Children's Research Hospital; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Rich, JN (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA.; Rich, JN (corresponding author), Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Mol Med, Cleveland, OH 44195 USA.; Kool, M (corresponding author), NCT Heidelberg KiTZ, Hopp Childrens Canc Ctr, D-69120 Heidelberg, Germany.; Kool, M (corresponding author), German Canc Res Ctr, Div Pediat Neurooncol, D-69120 Heidelberg, Germany.; Rich, JN (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA.; Taylor, MD (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Program Dev & Stem Cell Biol, Div Neurosurg, Toronto, ON M5G 1X8, Canada.; Rich, JN (corresponding author), Rose Ella Burkhardt Brain Tumor & Neurooncol Ctr, Neurol Inst, Dept Neurosurg, Cleveland Clin, Cleveland, OH 44195 USA.	m.kool@dkfz-heidelberg.de; mdtaylor@sickkids.ca; drjeremyrich@gmail.com	Wang, Xiuxing/HGU-0583-2022; Wang, Xiuxing/ABF-8681-2020; Wang, Xiuxing/N-6759-2019; Li, Chao-Jun/G-3522-2019; Singh, Sheila K/W-2799-2018; Gimple, Ryan/AAU-8944-2020; Jones, David T. W./Z-1963-2019; Michealraj, Antony/AAJ-7925-2020; Pajtler, Kristian/AAN-9029-2020; Rich, Jeremy/AAM-1445-2021; Jabado, Nada/AAN-4026-2020; Okonechnikov, Konstantin/AAD-4239-2019; wang, xiuxing/AAY-4068-2021; Pfister, Stefan M/F-6860-2013; Milde, Till/AAR-4528-2021; Bian, Xiu-Wu/D-4736-2017; Erkek, Serap/AAV-5549-2020; Northcott, Paul A/N-4022-2018; Zapatka, Marc/G-9896-2013; Ryzhova, Marina/G-4178-2014; Li, Chao/GSM-8117-2022; Jones, David TW/G-9588-2013; Reimand, Jüri/U-9264-2019; Bouffet, Eric/AAB-8999-2020	Wang, Xiuxing/0000-0001-7115-729X; Wang, Xiuxing/0000-0002-5993-9368; Li, Chao-Jun/0000-0002-3859-8824; Singh, Sheila K/0000-0003-1272-5300; Michealraj, Antony/0000-0002-3967-0816; Pfister, Stefan M/0000-0002-5447-5322; Milde, Till/0000-0002-7267-1052; Bian, Xiu-Wu/0000-0003-4383-0197; Northcott, Paul A/0000-0002-1220-5252; Zapatka, Marc/0000-0001-8287-5967; Ryzhova, Marina/0000-0001-7206-6365; Li, Chao/0000-0001-6110-6210; Jones, David TW/0000-0002-2036-5141; Reimand, Jüri/0000-0002-2299-2309; Song, Anne/0000-0003-4717-3374; Taylor, Michael/0000-0001-7009-3466; Korshunov, Andrey/0000-0002-5257-3623; Lee, Lee-Poturalski, Christine/0000-0002-3383-6360; Carcaboso, Angel/0000-0002-8485-426X; Pajtler, Kristian W./0000-0002-3562-6121; Donovan, Laura/0000-0001-5557-5539; Chavez, Lukas/0000-0002-8718-8848; Miller, Tyler E/0000-0002-1269-1895; Erkek, Serap/0000-0003-4439-5203; Li, Chaojun/0000-0001-9474-7321; Ramaswamy, Vijay/0000-0002-6557-895X; Morton, Andrew/0000-0002-1234-1676	Alex's Lemonade Stand Young Investigator Award; CIHR Banting Fellowship; Cancer Prevention Research Institute of Texas [RR170023]; Sibylle Assmus Award for Neurooncology; DKFZ-MOST (Ministry of Science, Technology & Space, Israel) program in cancer research; James S. McDonnell Foundation; NIH [CA154130, R01 CA169117, R01 CA171652, R01 NS087913, R01 NS089272, T32GM00725, F30CA217065]; Garron Family Chair in Childhood Cancer Research; Pediatric Brain Tumour Foundation; Grand Challenge Award from CureSearch for Children's Cancer; National Institutes of Health [R01CA148699, R01CA159859]; Terry Fox Research Institute; Brainchild; Stand Up To Cancer St. Baldrick's Pediatric Dream Team Translational Research Grant [SU2C-AACR-DT1113]; ICGC DE-Mining grant [01KU1505]; NATIONAL CANCER INSTITUTE [F30CA203101, R01CA154130, R35CA197718, R01CA160356, R01CA204279, F30CA217065, R01CA171652, R01CA193677, R01CA159859, R01CA148699, R01CA169117] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK113185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087913, R01NS089272] Funding Source: NIH RePORTER	Alex's Lemonade Stand Young Investigator Award; CIHR Banting Fellowship; Cancer Prevention Research Institute of Texas; Sibylle Assmus Award for Neurooncology; DKFZ-MOST (Ministry of Science, Technology & Space, Israel) program in cancer research; James S. McDonnell Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Garron Family Chair in Childhood Cancer Research; Pediatric Brain Tumour Foundation; Grand Challenge Award from CureSearch for Children's Cancer; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Terry Fox Research Institute; Brainchild; Stand Up To Cancer St. Baldrick's Pediatric Dream Team Translational Research Grant; ICGC DE-Mining grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by an Alex's Lemonade Stand Young Investigator Award (S. C. M.), The CIHR Banting Fellowship (S. C. M.), The Cancer Prevention Research Institute of Texas (S. C. M., RR170023), Sibylle Assmus Award for Neurooncology (K. W. P.), the DKFZ-MOST (Ministry of Science, Technology & Space, Israel) program in cancer research (H. W.), James S. McDonnell Foundation (J. N. R.) and NIH grants: CA154130 (J. N. R.), R01 CA169117 (J. N. R.), R01 CA171652 (J. N. R.), R01 NS087913 (J. N. R.) and R01 NS089272 (J. N. R.). R. C. G. is supported by NIH grants T32GM00725 and F30CA217065. M. D. T. is supported by The Garron Family Chair in Childhood Cancer Research, and grants from the Pediatric Brain Tumour Foundation, Grand Challenge Award from CureSearch for Children's Cancer, the National Institutes of Health (R01CA148699, R01CA159859), The Terry Fox Research Institute and Brainchild. M. D. T. is also supported by a Stand Up To Cancer St. Baldrick's Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT1113). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. We thank S. Archer for technical writing and editing expertise. In addition, we thank the High-Throughput Sequencing Unit of the DKFZ Genomics and Proteomics Core Facility for technical support and acknowledge technical assistance by M. Mauermann, T. Wedig, A. Wittmann and L. Siebert. Additional support came from the ICGC DE-Mining grant (#01KU1505). We thank The Children's Hospital at Westmead (CHW) Tumour Bank for support of tumour samples (H. W.). We thank D. Schumick (Cleveland Clinic Art Department) and G. Hsu (https://www.hsubiomedicalvisual.com) for their assistance with creative artwork.	Abedalthagafi MS, 2016, J PATHOL, V238, P584, DOI 10.1002/path.4682; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/nmeth.2689, 10.1038/NMETH.2689]; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hnisz D, 2015, MOL CELL, V58, P362, DOI 10.1016/j.molcel.2015.02.014; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268; Johann PD, 2016, CANCER CELL, V29, P379, DOI 10.1016/j.ccell.2016.02.001; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Lienhard M, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw1193; Lin CY, 2016, NATURE, V530, P57, DOI 10.1038/nature16546; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Mohankumar KM, 2015, NAT GENET, V47, P878, DOI 10.1038/ng.3323; Okonechnikov K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167417; Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002; Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109; Pope BD, 2014, NATURE, V515, P402, DOI 10.1038/nature13986; Ramsey SA, 2010, BIOINFORMATICS, V26, P2071, DOI 10.1093/bioinformatics/btq405; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Stein LD, 2015, NATURE, V523, P149, DOI 10.1038/523149a; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Witt H, 2011, CANCER CELL, V20, P143, DOI 10.1016/j.ccr.2011.07.007; Zhang XY, 2016, NAT GENET, V48, P176, DOI 10.1038/ng.3470	30	123	123	3	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 4	2018	553	7686					101	+		10.1038/nature25169	http://dx.doi.org/10.1038/nature25169			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FS4NI	29258295	Green Accepted			2023-01-03	WOS:000419769300038
J	Nimmo, S				Nimmo, Stephanie			Letting my daughter go	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material														Nimmo, Stephanie/0000-0003-2041-2443					0	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	2018	360								j5771	10.1136/bmj.j5771	http://dx.doi.org/10.1136/bmj.j5771			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FS3UP	29298767	Bronze, Green Published			2023-01-03	WOS:000419709400006
J	Li, Q; Wang, QF; Wang, O; Shao, KF; Lin, HS; Lei, YG				Li, Qiang; Wang, Qiaofeng; Wang, Ou; Shao, Kaifeng; Lin, Haishuang; Lei, Yuguo			A simple and scalable hydrogel-based system for culturing protein-producing cells	PLOS ONE			English	Article							PLURIPOTENT STEM-CELLS; MAMMALIAN-CELLS; CHO-CELLS; DIFFERENTIATION; THERAPEUTICS; EXPRESSION; STRATEGIES; EXPANSION; DISEASE; GROWTH	Recombinant protein therapeutics have become important components of the modern medicine. Majority of them are produced with mammalian cells that are cultured either through adherent culturing, in which cells are cultured on substrates, or suspension culturing, in which cells are suspended and cultured in agitated cell culture medium in a culture vessel. The adherent cell culturing method is limited by its low yield. In suspension culturing, cells need extensive genetic manipulation to grow as single cells at high density, which is time- and labor-consuming. Here, we report a new method, which utilizes a thermoreversible hydrogel as the scaffold for culturing protein-expressing cells. The hydrogel scaffolds not only provide 3D spaces for the cells, but also act as physical barriers to prevent excessive cellular agglomeration and protect cells from the hydrodynamic stresses. As a result, cells can grow at high viability, high growth rate, and extremely high yield even without genetic manipulations. The cell yield in the hydrogels is around 20 times of the suspension culturing. In addition, the protein productivity per cell per day in the hydrogel is higher than the adherent culturing method. This new method is simple, scalable and defined. It will be of great value for both the research laboratories and pharmaceutical industry for producing proteins.	[Li, Qiang; Wang, Ou; Lin, Haishuang; Lei, Yuguo] Univ Nebraska, Dept Chem & Biomol Engn, Lincoln, NE 68588 USA; [Li, Qiang; Wang, Ou; Lei, Yuguo] Univ Nebraska, Biomed Engn Program, Lincoln, NE 68588 USA; [Wang, Qiaofeng] Tongji Univ, Sch Med, Shanghai East Hosp, Shanghai, Peoples R China; [Shao, Kaifeng] Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai, Peoples R China; [Lei, Yuguo] Univ Nebraska Med Ctr, Mary & Dick Holland Regenerat Med Program, Omaha, NE 68198 USA; [Lei, Yuguo] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Tongji University; Chinese Academy of Sciences; Shanghai Advanced Research Institute, CAS; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lei, YG (corresponding author), Univ Nebraska, Dept Chem & Biomol Engn, Lincoln, NE 68588 USA.; Lei, YG (corresponding author), Univ Nebraska, Biomed Engn Program, Lincoln, NE 68588 USA.; Lei, YG (corresponding author), Univ Nebraska Med Ctr, Mary & Dick Holland Regenerat Med Program, Omaha, NE 68198 USA.; Lei, YG (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	ylei14@unl.edu	Li, Qiang/AAX-4719-2021; Shao, Kaifeng/T-3547-2018	Li, Qiang/0000-0001-6716-4630; Shao, Kaifeng/0000-0003-2066-9054; Lei, Yuguo/0000-0002-7682-6912	Shanghai Bureau of Science and technology [ZJ2014-ZD-002]; Zhangjiang National Innovation; Nebraska DHHS Stem Cell Research Project	Shanghai Bureau of Science and technology; Zhangjiang National Innovation; Nebraska DHHS Stem Cell Research Project	This work was funded by Nebraska DHHS Stem Cell Research Project (to Y.L.) and a special grant from the Zhangjiang National Innovation and Shanghai Bureau of Science and technology (grant no. ZJ2014-ZD-002, to K.S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.& para;& para;This work was funded by Nebraska DHHS Stem Cell Research Project (to Y.L.) and a special grant from the Zhangjiang National Innovation and Shanghai Bureau of Science and technology (grant no. ZJ2014-ZD-002, to K.S.)	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bandaranayake AD, 2014, FEBS LETT, V588, P253, DOI 10.1016/j.febslet.2013.11.035; Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074; Chen KG, 2014, STEM CELL RES, V12, P610, DOI 10.1016/j.scr.2014.02.002; Chen KG, 2014, CELL STEM CELL, V14, P13, DOI 10.1016/j.stem.2013.12.005; Chu L, 2001, CURR OPIN BIOTECH, V12, P180, DOI 10.1016/S0958-1669(00)00197-X; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clincke M, 2013, BMC P, V7, P6; De Jesus M, 2011, EUR J PHARM BIOPHARM, V78, P184, DOI 10.1016/j.ejpb.2011.01.005; Durrschmid M, 2003, BIOTECHNOL BIOENG, V83, P681, DOI 10.1002/bit.10700; Fridley KM, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt136; Fuerer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009370; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hajdu Z, 2010, J TISSUE ENG REGEN M, V4, P659, DOI 10.1002/term.291; Ismadi MZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106493; Jadhav V, 2013, BIOTECHNOL ADV, V31, P1501, DOI 10.1016/j.biotechadv.2013.07.007; Jenkins MJ, 2015, BIOTECHNOL J, V10, P83, DOI 10.1002/biot.201400348; Jones D, 2003, BIOTECHNOL PROGR, V19, P163, DOI 10.1021/bp025574h; Kim JY, 2012, APPL MICROBIOL BIOT, V93, P917, DOI 10.1007/s00253-011-3758-5; Kinney MA, 2011, TISSUE ENG PART B-RE, V17, P249, DOI [10.1089/ten.teb.2011.0040, 10.1089/ten.TEB.2011.0040]; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Kong D, 1998, CYTOTECHNOLOGY, V26, P131, DOI 10.1023/A:1007997412002; Kropp C, 2017, PROCESS BIOCHEM, V59, P244, DOI 10.1016/j.procbio.2016.09.032; Lai TF, 2013, PHARMACEUTICALS, V6, P579, DOI 10.3390/ph6050579; Landauer K, 2003, BIOTECHNOL PROGR, V19, P21, DOI 10.1021/bp025568l; Lei YG, 2014, CELL MOL BIOENG, V7, P172, DOI 10.1007/s12195-014-0333-z; Lei YG, 2013, P NATL ACAD SCI USA, V110, pE5039, DOI 10.1073/pnas.1309408110; Li Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep31915; Medina RJ, 2006, J CELL BIOCHEM, V98, P174, DOI 10.1002/jcb.20757; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Serra M, 2012, TRENDS BIOTECHNOL, V30, P350, DOI 10.1016/j.tibtech.2012.03.003; Steiner D, 2010, NAT BIOTECHNOL, V28, P361, DOI 10.1038/nbt.1616; Unger DR, 2000, BIOTECHNOL BIOENG, V70, P117, DOI 10.1002/1097-0290(20001020)70:2<117::AID-BIT1>3.0.CO;2-8; Wiberg FC, 2006, BIOTECHNOL BIOENG, V94, P396, DOI 10.1002/bit.20865; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026; Zhu JW, 2012, BIOTECHNOL ADV, V30, P1158, DOI 10.1016/j.biotechadv.2011.08.022	38	9	9	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2018	13	1							e0190364	10.1371/journal.pone.0190364	http://dx.doi.org/10.1371/journal.pone.0190364			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR5JA	29293594	gold, Green Published			2023-01-03	WOS:000419101600101
J	Pincus, D; Ravi, B; Wasserstein, D; Huang, A; Paterson, JM; Nathens, AB; Kreder, HJ; Jenkinson, RJ; Wodchis, WP				Pincus, Daniel; Ravi, Bheeshma; Wasserstein, David; Huang, Anjie; Paterson, J. Michael; Nathens, Avery B.; Kreder, Hans J.; Jenkinson, Richard J.; Wodchis, Walter P.			Association BetweenWait Time and 30-Day Mortality in Adults Undergoing Hip Fracture Surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; PATIENT; EMERGENCY; DATABASE; OUTCOMES; DELAY	IMPORTANCE Although wait times for hip fracture surgery have been linked to mortality and are being used as quality-of-care indicators worldwide, controversy exists about the duration of the wait that leads to complications. OBJECTIVE To use population-based wait-time data to identify the optimal time window in which to conduct hip fracture surgery before the risk of complications increases. DESIGN, SETTING, AND PARTICIPANTS Population-based, retrospective cohort study of adults undergoing hip fracture surgery between April 1, 2009, and March 31, 2014, at 72 hospitals in Ontario, Canada. Risk-adjusted restricted cubic splines modeled the probability of each complication according to wait-time. The inflection point (in hours) when complications began to increase was used to define early and delayed surgery. To evaluate the robustness of this definition, outcomes among propensity-score matched early and delayed surgical patients were compared using percent absolute risk differences (RDs, with 95% CIs). EXPOSURE Time elapsed from hospital arrival to surgery (in hours). MAIN OUTCOMES AND MEASURES Mortality within 30 days. Secondary outcomes included a composite of mortality or other medical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia). RESULTS Among 42 230 patients with hip fracture (mean [SD] age, 80.1 years [10.7], 70.5% women) who met study entry criteria, overall mortality at 30 days was 7.0%. The risk of complications increased when wait times were greater than 24 hours, irrespective of the complication considered. Compared with 13 731 propensity-score matched patients who received surgery earlier, 13 731 patients who received surgery after 24 hours had a significantly higher risk of 30-day mortality (898 [6.5%] vs 790 [5.8%];% absolute RD, 0.79; 95% CI, 0.23-1.35) and the composite outcome (1680 [12.2%]) vs 1383 [10.1%];% absolute RD, 2.16; 95% CI, 1.43-2.89). CONCLUSIONS AND RELEVANCE Among adults undergoing hip fracture surgery, increased wait time was associated with a greater risk of 30-day mortality and other complications. A wait time of 24 hours may represent a threshold defining higher risk.	[Pincus, Daniel; Ravi, Bheeshma; Wasserstein, David; Nathens, Avery B.; Kreder, Hans J.; Jenkinson, Richard J.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Pincus, Daniel; Ravi, Bheeshma; Paterson, J. Michael; Nathens, Avery B.; Kreder, Hans J.; Wodchis, Walter P.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Pincus, Daniel; Huang, Anjie; Paterson, J. Michael; Nathens, Avery B.; Kreder, Hans J.; Jenkinson, Richard J.; Wodchis, Walter P.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Ravi, Bheeshma; Wasserstein, David; Nathens, Avery B.; Kreder, Hans J.; Jenkinson, Richard J.] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON, Canada; [Wodchis, Walter P.] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute	Pincus, D (corresponding author), Univ Toronto, Div Orthopaed Surg, Dept Surg, 149 Coll St,Room 508-A, Toronto, ON M5T 1P5, Canada.	d.pincus@utoronto.ca	Pincus, Daniel/K-6113-2017; Pincus, Daniel/M-3033-2019	Pincus, Daniel/0000-0003-3783-8205; Pincus, Daniel/0000-0003-3783-8205; wodchis, walter/0000-0003-2494-7031	Marvin Tile Chair in Orthopaedic Surgery at Sunnybrook Health Sciences Centre, Toronto; Institute for Clinical Evaluative Sciences, an independent research institute - Ontario Ministry of Health and Long-Term Care	Marvin Tile Chair in Orthopaedic Surgery at Sunnybrook Health Sciences Centre, Toronto; Institute for Clinical Evaluative Sciences, an independent research institute - Ontario Ministry of Health and Long-Term Care	This study was supported by the Marvin Tile Chair in Orthopaedic Surgery at Sunnybrook Health Sciences Centre, Toronto, and by the Institute for Clinical Evaluative Sciences, an independent research institute funded by the Ontario Ministry of Health and Long-Term Care.	Agabiti N, 2007, INT J QUAL HEALTH C, V19, P37, DOI 10.1093/intqhc/mzl065; Aggarwal A, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0454-2; Austin PC, 2011, STAT MED, V30, P1292, DOI 10.1002/sim.4200; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bretherton CP, 2015, BONE JOINT J, V97B, P104, DOI 10.1302/0301-620X.97B1.35041; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Buse GL, 2014, CAN MED ASSOC J, V186, pE52, DOI 10.1503/cmaj.130901; Canadian Institute for Health Information, 2017, WAIT TIM PRIOR PROC; Dawson NV, 2012, MED DECIS MAKING, V32, P225, DOI 10.1177/0272989X12437605; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Dy CJ, 2011, J BONE JOINT SURG AM, V93A, P1326, DOI [10.2106/JBJS.I.01132, 10.2106/JBJSJ.01132]; Frood Jennifer, 2010, Healthc Q, V13, P16; Fu MC, 2017, BONE JOINT J, V99B, P1216, DOI 10.1302/0301-620X.99B9.BJJ-2017-0101.R1; Juurlink D, 2006, CANADIAN I HLTH INFO; Kralj B., 2005, MEASURING RURALITY P; Leslie WD, 2010, OSTEOPOROSIS INT, V21, P1317, DOI 10.1007/s00198-009-1080-1; Marrie RA, 2009, J CLIN EPIDEMIOL, V62, P511, DOI 10.1016/j.jclinepi.2008.05.015; McIsaac DI, 2017, CAN MED ASSOC J, V189, pE905, DOI 10.1503/cmaj.160576; Moja L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046175; Nyholm AM, 2015, J BONE JOINT SURG AM, V97A, P1333, DOI 10.2106/JBJS.O.00029; Pincus D, 2012, CLIN PHARMACOL THER, V92, P766, DOI 10.1038/clpt.2012.171; Pincus D, 2017, J BONE JOINT SURG AM, V99, P914, DOI 10.2106/JBJS.16.00788; Prasad V, 2013, JAMA-J AM MED ASSOC, V309, P241, DOI 10.1001/jama.2012.96867; Ravi B, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3284; Royal College of Physicians, 2015, NAT HIP FRACT DAT AN; Ryan DJ, 2015, J ORTHOP TRAUMA, V29, P343, DOI 10.1097/BOT.0000000000000313; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Sayers A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0825-5; Schilling PL, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.N.01330; Sheehan KJ, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1018-7; Sheehan KJ, 2016, CAN MED ASSOC J, V188, P1219, DOI 10.1503/cmaj.160522; Sheehan KJ, 2016, J ORTHOP RES, V34, P197, DOI 10.1002/jor.22997; Simunovic N, 2010, CAN MED ASSOC J, V182, P1609, DOI 10.1503/cmaj.092220; Uzoigwe CE, 2013, INJURY, V44, P726, DOI 10.1016/j.injury.2012.08.025; Weiner J., 2011, J HOPKINS ACG SYSTEM	36	284	295	4	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 28	2017	318	20					1994	2003		10.1001/jama.2017.17606	http://dx.doi.org/10.1001/jama.2017.17606			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FN8ZR	29183076	Green Published, Bronze			2023-01-03	WOS:000416317600020
J	Sauter, TC; Iten, N; Schwab, PR; Hautz, WE; Ricklin, ME; Exadaktylos, AK				Sauter, Thomas C.; Iten, Nora; Schwab, Patrik R.; Hautz, Wolf E.; Ricklin, Meret E.; Exadaktylos, Aristomenis K.			Out-of-hospital cardiac arrests in Switzerland: Predictors for emergency department mortality in patients with ROSC or on-going CPR on admission to the emergency department	PLOS ONE			English	Article							RESUSCITATION OUTCOMES CONSORTIUM; INTERNATIONAL LIAISON COMMITTEE; AMERICAN-HEART-ASSOCIATION; EURECA ONE-27 NATIONS; STROKE FOUNDATION; SOUTHERN AFRICA; ONE REGISTRY; ONE EUROPE; SURVIVAL; GENDER	Background One of the leading causes of death is out-of-hospital cardiac arrest (OHCA) with an in-hospital mortality of about 70%. To identify predictors for the high mortality of OHCA patients and especially for women, that are considered at high risk for in-hospital mortality, we evaluated one specific setting of in-hospital treatment after OHCA: the emergency department (ED). Methods Retrospective analysis of consecutive ED admissions with OHCA at the Inselspital Bern, Switzerland from 1st June 2012 to 31th Mai 2015. Demographic, preclinical and ED medical data were compared for patient groups with return of circulation (ROSC) and on-going resuscitation (CPR) on admission, as well as for subgroups with and without ED mortality. Predictors for ED mortality were investigated using univariate analysis with logistic regression. Results In 354 patients (228 (64.4%) with ROSC; 126 (35.6%) with on-going CPR) we found an overall ED mortality of 28.5% (5.7% ROSC group; 69.8% on-going CPR group). Female gender (OR 7.053 (CI 95% 2.085; 24.853), p = 0.002) and greater age (OR 1.052 (95% CI 1.006-1.101), p = 0.029) were associated with ED mortality in the ROSC but not in the ongoing CPR group. Ventricular fibrillation as initially monitored rhythm (OR 0.126 (95% CI 0.027-0.582), p = 0.008) and shorter CPR duration (OR 1.055 (95% CI 1.024; 1.088), p = 0.001) were associated with ED survival in patients with ROSC but not in patients with ongoing CPR on admission. In ROSC patients a higher lactate and lower pH were associated with mortality (pH: OR 0.009 (CI95% 0.000; 0.420), p = 0.016; lactate: OR 1.183 (95% CI 1.037; 1.349), p = 0.013); similar in on-going CPR patients (pH 0.061 (95% CI 0.007, 0.558), p = 0.013, lactate: 1.146 (95% CI 1.041; 1.261), p = 0.005). Conclusion Patients with ROSC who died during ED care were predominantly women and older patients, as well as patients with non-shockable initial heart rhythm and long CPR durations. In patients with on-going CPR on admission, no clinical or demographic predictors for ED mortality were found. Higher lactate and lower pH were predictors in both OHCA groups.	[Sauter, Thomas C.; Iten, Nora; Schwab, Patrik R.; Hautz, Wolf E.; Ricklin, Meret E.; Exadaktylos, Aristomenis K.] Univ Hosp Bern, Inselspital, Dept Emergency Med, Bern, Switzerland; [Schwab, Patrik R.] Sanitaetspolizei Bern, Emergency Med Serv, Bern, Switzerland	University of Bern; University Hospital of Bern	Sauter, TC (corresponding author), Univ Hosp Bern, Inselspital, Dept Emergency Med, Bern, Switzerland.	thomas.sauter@insel.ch	Ricklin, Meret Elisabeth/AAY-7948-2021	Ricklin, Meret Elisabeth/0000-0003-3047-9350; Sauter, Thomas C/0000-0002-6646-5789; Hautz, Wolf/0000-0002-2445-984X				Bougouin W, 2015, RESUSCITATION, V94, P55, DOI 10.1016/j.resuscitation.2015.06.018; Daya MR, 2015, RESUSCITATION, V91, P108, DOI 10.1016/j.resuscitation.2015.02.003; Exadaktylos A, 2015, ICU MANAG 2015, V15, P160; Grasner JT, 2016, RESUSCITATION, V105, P188, DOI 10.1016/j.resuscitation.2016.06.004; Hasan OF, 2014, CURR MED RES OPIN, V30, P2169, DOI 10.1185/03007995.2014.936552; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Morrison LJ, 2007, RESUSCITATION, V74, P266, DOI 10.1016/j.resuscitation.2007.01.009; Morrison LJ, 2016, RESUSCITATION, V100, P76, DOI 10.1016/j.resuscitation.2015.12.002; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nolan JP, 2007, ANAESTHESIA, V62, P1207, DOI 10.1111/j.1365-2044.2007.05232.x; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Verbeek PR, 2002, ACAD EMERG MED, V9, P671, DOI 10.1197/aemj.9.7.671; Whittaker A, 2016, POSTGRAD MED J, V92, P250, DOI 10.1136/postgradmedj-2015-133575; Wnent J, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0093-3	16	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2017	12	11							e0188180	10.1371/journal.pone.0188180	http://dx.doi.org/10.1371/journal.pone.0188180			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM8YO	29145510	Green Published, gold, Green Submitted			2023-01-03	WOS:000415378800081
J	Fernandes, JR; Berthoud, TK; Kornai, A; Angel, JB				Fernandes, Jason R.; Berthoud, Tamara K.; Kornai, Ashok; Angel, Jonathan B.			IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERIC IG RECEPTOR; T-CELLS; PERIPHERAL-BLOOD; ROR-ALPHA; DIFFERENTIATION; EXPRESSION; INTERLEUKIN-17; RESPONSES; INDUCTION	Objectives HIV infection causes a profound depletion of gut derived Th17 cells, contributing to loss of mucosal barrier function and an increase in microbial translocation, thus driving systemic immune activation. Despite normalization of circulating CD4+ T cell counts with highly active antiretroviral therapy (HAART), Th17 frequency and function often remain impaired. Given the importance of interleukin (IL)-23 in the generation and stabilization of Th17 cells we hypothesized that impaired IL-23 signaling causes persistent Th17 dysfunction in HIV infection. Methods The effects of in vitro HIV infection on responses to IL-23 in Th17 cells were examined. These included the production of IL-17, phosphorylated STAT3 (pSTAT3) and the transcription of retinoic acid orphan receptor C (RORC) gene. Blood derived Th17 cells from untreated and HAART-treated HIV-infected individuals were also examined for the IL-23 induced production of phosphorylated STAT3 (pSTAT3) and the expression of the IL-23 receptors. Results In vitro HIV infection significantly inhibited IL-17 production and IL-23 induced pSTAT3 while expression of RORC RNA was unaffected. Th17 cells isolated from untreated and HAARTtreated HIV-infected individuals showed complete loss of IL-23 induced pSTAT3 without a decrease in the expression of the IL-23 receptors. Conclusions This study is the first to demonstrate an effect of HIV on the IL-23 signaling pathway in Th17 cells. We show that in vitro and in vivo HIV infection results in impaired IL-23 signaling which is not reversed by HAART nor is it a result of reduced receptor expression, suggesting that HIV interferes with IL-23-activated signaling pathways. These findings may explain the inability of HAART to restore Th17 frequency and function and the resulting persistent chronic immune activation observed in HIV infected individuals.	[Fernandes, Jason R.; Berthoud, Tamara K.; Angel, Jonathan B.] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Fernandes, Jason R.; Berthoud, Tamara K.; Kornai, Ashok; Angel, Jonathan B.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Kornai, Ashok] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada; [Angel, Jonathan B.] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute	Angel, JB (corresponding author), Ottawa Hosp Res Inst, Ottawa, ON, Canada.; Angel, JB (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada.; Angel, JB (corresponding author), Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada.	jangel@ohri.ca		Angel, Jonathan B/0000-0003-3102-4462	Canadian Institutes of Health Research Grant [HOP-98830]	Canadian Institutes of Health Research Grant(Canadian Institutes of Health Research (CIHR))	This work was supported by Canadian Institutes of Health Research Grant HOP-98830 to JBA and AK, http://wm.cihr-irsc.gc.cate/193.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200; Alvarez Y, 2013, J VIROL, V87, P10843, DOI 10.1128/JVI.01838-13; Basu R, 2013, IMMUNOL REV, V252, P89, DOI 10.1111/imr.12035; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Cao AT, 2012, J IMMUNOL, V189, P4666, DOI 10.4049/jimmunol.1200955; Caruso R, 2008, EUR J IMMUNOL, V38, P470, DOI 10.1002/eji.200737635; Cecchinato V, 2008, MUCOSAL IMMUNOL, V1, P279, DOI 10.1038/mi.2008.14; Chaudhuri A, 2008, BLOOD, V111, P2062, DOI 10.1182/blood-2007-05-091207; Chege D, 2011, AIDS, V25, P741, DOI 10.1097/QAD.0b013e328344cefb; Chen Z, 2007, ARTHRITIS RHEUM-US, V56, P2936, DOI 10.1002/art.22866; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Cheng SM, 2009, BLOOD, V113, P5192, DOI 10.1182/blood-2008-10-183525; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Crome SQ, 1950, J IMMUNOL BALTIM MD, V185; Dandekar S, 2010, CURR OPIN HIV AIDS, V5, P173, DOI 10.1097/COH.0b013e328335eda3; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Diveu C, 2009, J IMMUNOL, V182, P5748, DOI 10.4049/jimmunol.0801162; Du JG, 2008, J IMMUNOL, V180, P4785, DOI 10.4049/jimmunol.180.7.4785; Duan MC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/898053; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752; Goodman WA, 2011, J IMMUNOL, V186, P3336, DOI 10.4049/jimmunol.1001455; Gordon SN, 2010, J IMMUNOL, V185, P5169, DOI 10.4049/jimmunol.1001801; Haller C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001212; He Y, 2012, AIDS RES HUM RETROV, V28, P339, DOI [10.1089/aid.2011.0140, 10.1089/AID.2011.0140]; Hernandez-Santos N, 2013, MUCOSAL IMMUNOL, V6, P900, DOI 10.1038/mi.2012.128; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Honda M, 1950, J IMMUNOL BALTIM MD, V148; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jaffar Z, 2009, J IMMUNOL, V182, P4507, DOI 10.4049/jimmunol.0900237; Kim CJ, 2013, J IMMUNOL, V191, P2164, DOI 10.4049/jimmunol.1300829; Klatt NR, 2012, MUCOSAL IMMUNOL, V5, P646, DOI 10.1038/mi.2012.38; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Le Saout C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003976; Lee YK, 2009, CURR OPIN IMMUNOL, V21, P274, DOI 10.1016/j.coi.2009.05.021; Lurati A, 2015, OPEN ACCESS RHEUMATO, V7, P63, DOI 10.2147/OARRR.S81905; Macal M, 2008, MUCOSAL IMMUNOL, V1, P475, DOI 10.1038/mi.2008.35; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Marchetti G, 2008, AIDS, V22, P2035, DOI 10.1097/QAD.0b013e3283112d29; Mat NFC, 2011, J INTERF CYTOK RES, V31, P363, DOI 10.1089/jir.2010.0083; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Miller RC, 2011, EUR J IMMUNOL, V41, P1058, DOI 10.1002/eji.201041198; Monteleone I, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/297645; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Morrison PJ, 2011, IMMUNOLOGY, V133, P397, DOI 10.1111/j.1365-2567.2011.03454.x; Nakayama K, 2012, AIDS RES HUM RETROV, V28, P702, DOI [10.1089/aid.2011.0073, 10.1089/AID.2011.0073]; Ndhlovu LC, 2008, AIDS, V22, P990, DOI 10.1097/QAD.0b013e3282ff884e; Neri F, 2011, VIROLOGY, V410, P316, DOI 10.1016/j.virol.2010.11.018; Ness-Schwickerath KJ, 2011, CELL MOL LIFE SCI, V68, P2371, DOI 10.1007/s00018-011-0700-z; Pallikkuth S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003471; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Peck A, 2010, IMMUNOLOGY, V129, P147, DOI 10.1111/j.1365-2567.2009.03189.x; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743; Rozmyslowicz T, 2010, EXP HEMATOL, V38, P1157, DOI 10.1016/j.exphem.2010.08.009; Rudolph JM, 2009, J VIROL, V83, P11528, DOI 10.1128/JVI.01423-09; Singh A, 2012, CYTOKINE, V60, P55, DOI 10.1016/j.cyto.2012.06.288; Sohn SJ, 2013, J IMMUNOL, V191, P2205, DOI 10.4049/jimmunol.1202859; Stritesky GL, 2008, J IMMUNOL, V181, P5948, DOI 10.4049/jimmunol.181.9.5948; Xu H, 2012, MUCOSAL IMMUNOL, V5, P658, DOI 10.1038/mi.2012.39; Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	68	19	21	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 1	2017	12	11								10.1371/journal.pone.0186823	http://dx.doi.org/10.1371/journal.pone.0186823			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL4VN	29091911	gold, Green Submitted, Green Published			2023-01-03	WOS:000414229700031
J	Xu, Y; Zhao, WL; Li, T; Zhao, Y; Bu, HE; Song, SL				Xu, Yang; Zhao, Wenli; Li, Te; Zhao, Ye; Bu, Huaien; Song, Shilin			Effects of acupuncture for the treatment of endometriosis-related pain: A systematic review and meta-analysis	PLOS ONE			English	Review							PELVIC PAIN; CA-125; WOMEN; SURGERY; QUALITY; CANCER; LIFE	Background Endometriosis is a multifactorial, oestrogen-dependent, inflammatory, gynaecological condition that can result in long-lasting visceral pelvic pain and infertility. Acupuncture could be an effective treatment for endometriosis and may relieve pain. Our aim in the present study was to determine the effectiveness of acupuncture as a treatment for endometriosis-related pain. Methods In December 2016, six databases were searched for randomised controlled trials that determined the effectiveness of acupuncture in the treatment of endometriosis-related pain. Ultimately, 10 studies involving 589 patients were included. The main outcomes assessed were variation in pain level, variation in peripheral blood CA-125 level, and clinical effective rate. All analyses were performed using comprehensive meta-analysis statistical software. Results Of the 10 studies included, only one pilot study used a placebo control and assessed blinding; the rest used various controls (medications and herbs), which were impossible to blind. The sample sizes were small in all studies, ranging from 8 to 36 patients per arm. The mean difference (MD) in pain reduction (pre-minus post-interventional pain level D measured on a 0-10-point scale) between the acupuncture and control groups was 1.36 (95% confidence intervals [ CI] = 1.01-1.72, P<0.0001). Acupuncture had a positive effect on peripheral blood CA-125 levels, as compared with the control groups (MD = 5.9, 95% CI = 1.56-10.25, P = 0.008). Similarly, the effect of acupuncture on clinical effective rate was positive, as compared with the control groups (odds ratio = 2.07; 95% CI = 1.24-3.44, P = 0.005). Conclusions Few randomised, blinded clinical trials have addressed the efficacy of acupuncture in treating endometriosis-related pain. Nonetheless, the current literature suggests that acupuncture reduces pain and serum CA-125 levels, regardless of the control intervention used. To confirm these findings, additional, blinded studies with proper controls and adequate sample sizes are needed.	[Xu, Yang] Tianjin Acad Integrat Med, Nankai Hosp, Dept Gynecol & Obstet, Tianjin, Peoples R China; [Zhao, Wenli] Tianjin Univ Tradit Chinese Med, Grad Sch, Tianjin, Peoples R China; [Zhao, Wenli] Tianjin Acad Integrat Med, Nankai Hosp, Dept Neurol, Tianjin, Peoples R China; [Li, Te] Tianjin Hearing Impairment Specialist Hosp, Dept Chinese Med, Tianjin, Peoples R China; [Zhao, Ye] Univ Florida, Dept Chem Engn, Gainesville, FL 32611 USA; [Bu, Huaien] Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Dept Publ Hlth, Tianjin, Peoples R China; [Song, Shilin] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Lab Anat, Tianjin, Peoples R China	Tianjin University of Traditional Chinese Medicine; State University System of Florida; University of Florida; Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine	Bu, HE (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Dept Publ Hlth, Tianjin, Peoples R China.; Song, SL (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Lab Anat, Tianjin, Peoples R China.	buhuaien@163.com; haiguagua@163.com						Abbott JA, 2003, HUM REPROD, V18, P1922, DOI 10.1093/humrep/deg275; Ahn SH, 2016, FERTIL STERIL, V106, P1420, DOI 10.1016/j.fertnstert.2016.07.005; Amaral Vivian Ferreira do, 2006, Sao Paulo Med. J., V124, P223; Amer Saad, 2008, OBSTET GYNECOL REPRO, V18, P126; ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; BARBIERI RL, 1986, FERTIL STERIL, V45, P630; Brawn J, 2014, HUM REPROD UPDATE, V20, P737, DOI 10.1093/humupd/dmu025; Chen GX., 2014, THESIS, P16; Chen Ming, 2010, Zhongguo Zhen Jiu, V30, P725; Chen QX, 2015, THESIS, P16; Chen S, 2014, EVID-BASED COMPL ALT, V2014; Cheng YM, 2002, OBSTET GYNECOL, V99, P375, DOI 10.1016/S0029-7844(01)01731-8; DIZEREGA GS, 1980, FERTIL STERIL, V33, P649; EISERMANN J, 1988, FERTIL STERIL, V50, P573; Fedele L, 2004, AM J OBSTET GYNECOL, V190, P1020, DOI 10.1016/j.ajog.2003.10.698; Ferrero S, 2005, FERTIL STERIL, V83, P573, DOI 10.1016/j.fertnstert.2004.07.973; Gao CY., 2015, THESIS, P16; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hui KK, 2006, INTEGR CANCER THER, V5, P56, DOI 10.1177/1534735405286109; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; JACOBS I, 1988, LANCET, V1, P889; Jin YB, 2009, ACUPUNCTURE RES, V26, P188; Johnston MF, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep236; Kaludjerovic J, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/837901; Kennedy S, 2005, HUM REPROD, V20, P2698, DOI 10.1093/humrep/dei135; Liu YX, 2003, XIN ZHONG YI, V35, P55; Liu YY, 2009, HU BEI ZHONG YI ZA Z, V31, P53; Lund I, 2016, J PAIN RES, V9, P157, DOI 10.2147/JPR.S55580; Ma Jie, 2008, Zhen Ci Yan Jiu, V33, P235; Miller JD, 2000, AM J OBSTET GYNECOL, V182, P1483, DOI 10.1067/mob.2000.106846; Scheerer C, 2016, ARCH GYNECOL OBSTET, V294, P657, DOI 10.1007/s00404-016-4142-6; Staud R, 2006, EXPERT REV NEUROTHER, V6, P661, DOI 10.1586/14737175.6.5.661; Sun Yuan-Zheng, 2006, Zhongguo Zhen Jiu, V26, P863; Tian LY, 2016, CLIN J TRAD CHIN MED, P670; Tian X, 2014, ALTERN THER HEALTH M, V20, P33; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Vercellini P, 2009, HUM REPROD UPDATE, V15, P177, DOI 10.1093/humupd/dmn062; Wang M, 1991, ZHONGGUO ZHONG XI YI, V11; Wayne PM, 2008, J PEDIATR ADOL GYNEC, V21, P247, DOI 10.1016/j.jpag.2007.07.008; Wieser F, 2007, HUM REPROD UPDATE, V13, P487, DOI 10.1093/humupd/dmm015; Wu JX, 2013, J EMERG TRADIT CHIN, P1947; Xiang Dong-Fang, 2011, Zhongguo Zhen Jiu, V31, P113; Yan Hong, 2008, Zhongguo Zhen Jiu, V28, P579; Zhang Xinxin, 2015, Zhongguo Zhen Jiu, V35, P323; Zhen R, 2009, YI XUE LI LUN YU SHI, V22, P571; Zhu XS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007864.pub2	46	29	30	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2017	12	10							e0186616	10.1371/journal.pone.0186616	http://dx.doi.org/10.1371/journal.pone.0186616			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9WD	29077705	Green Published, gold, Green Submitted			2023-01-03	WOS:000413861200014
J	Hallek, M; Shanafelt, TD; Eichhorst, B				Hallek, Michael; Shanafelt, Tait D.; Eichhorst, Barbara			Chronic lymphocytic leukaemia	LANCET			English	Review							PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PROGRESSION-FREE SURVIVAL; PHASE-II TRIAL; BIWEEKLY CHLORAMBUCIL TREATMENT; INTERNATIONAL PROGNOSTIC INDEX; STEM-CELL TRANSPLANTATION; SERUM THYMIDINE KINASE; OPEN-LABEL; HIGH-RISK	Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care. The impressive efficacy of kinase inhibitors ibrutinib and idelalisib and the BCL-2 antagonist venetoclax have changed the standard of care in specific subsets of patients. In this Seminar, we review the recent progress in the management of chronic lymphocytic leukaemia and highlight new questions surrounding the optimal disease management.	[Hallek, Michael; Eichhorst, Barbara] Univ Hosp Cologne, Dept Internal Med, Ctr Integrated Oncol Koln Bonn, D-50937 Cologne, Germany; [Shanafelt, Tait D.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	University of Cologne; Stanford University	Hallek, M (corresponding author), Univ Hosp Cologne, Dept Internal Med, Ctr Integrated Oncol Koln Bonn, D-50937 Cologne, Germany.	michael.hallek@uni-koeln.de	Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455	Roche; Abbvie; Janssen; Celgene; Mundipharma; GlaxoSmithKline; Gilead; Genentech; Pharmacyclics; Hospira; Cephalon	Roche(Roche Holding); Abbvie(AbbVie); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Celgene(Bristol-Myers SquibbCelgene Corporation); Mundipharma; GlaxoSmithKline(GlaxoSmithKline); Gilead(Gilead Sciences); Genentech(Roche HoldingGenentech); Pharmacyclics; Hospira; Cephalon	MH has received research funding, speaker's honoraria, and consulting fees from Roche, Abbvie, Janssen, Celgene, Mundipharma, GlaxoSmithKline, and Gilead. TDS has received research funding from Genentech, Pharmacyclics, Janssen, Abbvie, GlaxoSmithKline, Celgene, Hospira, and Cephalon to support clinical trials and laboratory research. BE has received research grants from Roche, Abbvie, Janssen, and Gilead, attending advisory boards for Roche, Abbvie, Janssen, and Gilead, and received honoraria for presentations from Roche, Abbvie, Janssen, Gilead, Novartis, and Celgene.	[Anonymous], 1999, J Natl Cancer Inst, V91, P861; Benjamini O, 2015, LEUKEMIA LYMPHOMA, V56, P1643, DOI 10.3109/10428194.2014.957203; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Bottcher S, 2013, HEMATOL ONCOL CLIN N, V27, P267, DOI 10.1016/j.hoc.2013.01.005; Bottcher S, 2012, J CLIN ONCOL, V30, P980, DOI 10.1200/JCO.2011.36.9348; Brander D, 2016, HAEMATOLOGICA, V101, P58; Brewer JD, 2015, INT J DERMATOL, V54, pE287, DOI 10.1111/ijd.12564; Brunvand M, 2015, BLOOD, V126, P494, DOI DOI 10.1182/BL00D.V126.23.494; Bulian P, 2014, J CLIN ONCOL, V32, P897, DOI 10.1200/JCO.2013.50.8515; Bullrich F, 1999, CANCER RES, V59, P24; Burger JA, 2015, NEW ENGL J MED, V373, P2425, DOI 10.1056/NEJMoa1509388; Burger JA, 2014, LANCET ONCOL, V15, P1090, DOI 10.1016/S1470-2045(14)70335-3; Burger JA, 2014, SEMIN CANCER BIOL, V24, P71, DOI 10.1016/j.semcancer.2013.08.011; Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376; Byrd JC, 2015, BLOOD, V125, P2497, DOI 10.1182/blood-2014-10-606038; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Cerhan JR, 2015, BLOOD, V126, P2265, DOI 10.1182/blood-2015-04-537498; Chanan-Khan A, 2016, LANCET ONCOL, V17, P200, DOI 10.1016/S1470-2045(15)00465-9; Chigrinova E, 2013, BLOOD, V122, P2673, DOI 10.1182/blood-2013-03-489518; Cortese D, 2014, LEUKEMIA, V28, P710, DOI 10.1038/leu.2013.333; Cramer P, 2016, ONCOL RES TREAT, V39, P25, DOI 10.1159/000443903; Cramer P, 2015, HAEMATOLOGICA, V100, P1451, DOI 10.3324/haematol.2015.124693; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; da Cunha-Bang C, 2016, BLOOD, V128, P2181, DOI 10.1182/blood-2016-07-724740; Dabaja BS, 2001, LEUKEMIA LYMPHOMA, V42, P329, DOI 10.3109/10428190109064589; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dighiero G, 1998, NEW ENGL J MED, V338, P1506, DOI 10.1056/NEJM199805213382104; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dreger P, 2007, LEUKEMIA, V21, P12, DOI 10.1038/sj.leu.2404441; Dreger P, 2014, BLOOD, V124, P3841, DOI 10.1182/blood-2014-07-586826; Eichhorst B, 2016, Ann Oncol, V27, pv143; Eichhorst B, 2016, LANCET ONCOL, V17, P928, DOI 10.1016/S1470-2045(16)30051-1; Eichhorst BF, 2009, BLOOD, V114, P3382, DOI 10.1182/blood-2009-02-206185; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; EMA, 2014, GUID US MIN RES DIS; Fink AM, 2013, LEUKEMIA, V27, P1949, DOI 10.1038/leu.2013.190; Fink AM, 2017, LANCET HAEMATOL, V4, pE475, DOI 10.1016/S2352-3026(17)30171-0; Fischer K, 2016, BLOOD, V127, P208, DOI 10.1182/blood-2015-06-651125; Fischer K, 2012, J CLIN ONCOL, V30, P3209, DOI 10.1200/JCO.2011.39.2688; Fischer K, 2011, J CLIN ONCOL, V29, P3559, DOI 10.1200/JCO.2010.33.8061; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Foon KA, 2012, BLOOD, V119, P3184, DOI 10.1182/blood-2012-01-408047; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gentile M, 2016, BLOOD, V128, P2093, DOI 10.1182/blood-2016-07-728261; Ginaldi L, 1998, J CLIN PATHOL, V51, P364, DOI 10.1136/jcp.51.5.364; Goede V, 2015, LEUKEMIA, V29, P1602, DOI 10.1038/leu.2015.14; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Greil R, 2016, LANCET HAEMATOL, V3, pE317, DOI 10.1016/S2352-3026(16)30045-X; Gribben JG, 2013, HEMATOL-AM SOC HEMAT, P151, DOI 10.1182/asheducation-2013.1.151; Hallek M, 1999, BLOOD, V93, P1732; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 1996, LEUKEMIA LYMPHOMA, V22, P439, DOI 10.3109/10428199609054782; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2016, LANCET ONCOL, V17, P779, DOI 10.1016/S1470-2045(16)30029-8; Hallek M, 2013, BLOOD, V122, P3723, DOI 10.1182/blood-2013-05-498287; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HAN T, 1973, CANCER-AM CANCER SOC, V31, P502, DOI 10.1002/1097-0142(197303)31:3<502::AID-CNCR2820310303>3.0.CO;2-7; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Hillmen P, 2007, J CLIN ONCOL, V25, P5616, DOI 10.1200/JCO.2007.12.9098; Hillmen P, 2015, LANCET, V385, P1873, DOI 10.1016/S0140-6736(15)60027-7; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jones JA, 2015, J CLIN ONCOL, V33; Kay NE, 2007, BLOOD, V109, P405, DOI 10.1182/blood-2006-07-033274; Kay NE, 2010, CANCER-AM CANCER SOC, V116, P2180, DOI 10.1002/cncr.25028; Keating M. J., 1995, Blood, V86, p606A; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Kikushige Y, 2011, CANCER CELL, V20, P246, DOI 10.1016/j.ccr.2011.06.029; Kjellander C, 2016, ANN HEMATOL, V95, P871, DOI 10.1007/s00277-016-2643-9; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Knauf WU, 2009, J CLIN ONCOL, V27, P4378, DOI 10.1200/JCO.2008.20.8389; KNOSPE WH, 1974, CANCER, V33, P555, DOI 10.1002/1097-0142(197402)33:2<555::AID-CNCR2820330234>3.0.CO;2-I; KNOSPE WH, 1980, CANCER CLIN TRIALS, V3, P329; Kovacs G, 2016, J CLIN ONCOL, V34, P3758, DOI 10.1200/JCO.2016.67.1305; Lampson BL, 2016, BLOOD, V128, P195, DOI 10.1182/blood-2016-03-707133; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Landgren O, 2007, BLOOD, V109, P2198, DOI 10.1182/blood-2006-08-044008; Langerbeins P, 2014, AM J HEMATOL, V89, pE239, DOI 10.1002/ajh.23841; Leong DP, 2016, BLOOD, V128, P138, DOI 10.1182/blood-2016-05-712828; Maddocks-Christianson K, 2007, BRIT J HAEMATOL, V139, P398, DOI 10.1111/j.1365-2141.2007.06801.x; Malcikova J, 2015, LEUKEMIA, V29, P877, DOI 10.1038/leu.2014.297; Malcikova J, 2009, BLOOD, V114, P5307, DOI 10.1182/blood-2009-07-234708; Marti GE, 2005, BRIT J HAEMATOL, V130, P325, DOI 10.1111/j.1365-2141.2005.05550.x; Maurer C, 2016, LEUKEMIA, V30, P2019, DOI 10.1038/leu.2016.113; Melchardt T, 2013, LEUKEMIA LYMPHOMA, V54, P1602, DOI 10.3109/10428194.2012.755178; Molica S, 2016, AM J HEMATOL, V91, P1090, DOI 10.1002/ajh.24493; Montillo M, 2002, HAEMATOLOGICA, V87, P695; MONTSERRAT E, 1991, LEUKEMIA LYMPHOMA, V5, P89, DOI 10.3109/10428199109103385; Moreau EJ, 1997, AM J CLIN PATHOL, V108, P378; Moreira J, 2013, LEUKEMIA, V27, P136, DOI 10.1038/leu.2012.187; Morice WG, 2008, MAYO CLIN PROC, V83, P776, DOI 10.4065/83.7.776; O'Brien S, 2016, LANCET ONCOL, V17, P1409, DOI 10.1016/S1470-2045(16)30212-1; O'Brien SM, 2015, BLOOD, V126, P2686, DOI 10.1182/blood-2015-03-630947; Osterborg A, 2015, BRIT J HAEMATOL, V170, P40, DOI 10.1111/bjh.13380; Palumbo GA, 2009, LEUKEMIA RES, V33, P1212, DOI 10.1016/j.leukres.2009.01.017; Parikh SA, 2015, AM J HEMATOL, V90, P334, DOI 10.1002/ajh.23939; Pflug N, 2014, BLOOD, V124, P49, DOI 10.1182/blood-2014-02-556399; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Puente XS, 2013, NAT GENET, V45, P229, DOI 10.1038/ng.2556; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Rassenti LZ, 2008, BLOOD, V112, P1923, DOI 10.1182/blood-2007-05-092882; Rawstron AC, 2007, LEUKEMIA, V21, P956, DOI 10.1038/sj.leu.2404584; Rawstron AC, 2008, NEW ENGL J MED, V359, P575, DOI 10.1056/NEJMoa075290; Reynolds C, 2012, INVEST NEW DRUG, V30, P1232, DOI 10.1007/s10637-011-9737-y; Robak T, 2007, EUR J HAEMATOL, V79, P107, DOI 10.1111/j.1600-0609.2007.00889.x; Robak T, 2010, J CLIN ONCOL, V28, P1756, DOI 10.1200/JCO.2009.26.4556; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Rossi D, 2008, BRIT J HAEMATOL, V142, P202, DOI 10.1111/j.1365-2141.2008.07166.x; Rossi D, 2015, BLOOD, V126, P1921, DOI 10.1182/blood-2015-05-647925; Rossi D, 2012, BRIT J HAEMATOL, V158, P426, DOI 10.1111/j.1365-2141.2012.09155.x; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schollkopf C, 2007, INT J CANCER, V121, P151, DOI 10.1002/ijc.22672; Schweighofer CD, 2009, BRIT J HAEMATOL, V144, P95, DOI 10.1111/j.1365-2141.2008.07394.x; Seymour JF, N ENGL J ME IN PRESS; Shanafelt TD, 2013, BLOOD, V121, P4137, DOI 10.1182/blood-2012-12-470005; Shanafelt TD, 2009, CANCER-AM CANCER SOC, V115, P363, DOI 10.1002/cncr.24004; Sharman J. P., 2014, BLOOD, V124, P330; SHUSTIK C, 1988, HEMATOL ONCOL, V6, P7, DOI 10.1002/hon.2900060103; Slager Susan L., 2014, Journal of the National Cancer Institute Monographs, P41, DOI 10.1093/jncimonographs/lgu001; Solomon BM, 2016, LEUKEMIA, V30, P331, DOI 10.1038/leu.2015.235; Solomon BM, 2013, J CLIN ONCOL, V31, P930, DOI 10.1200/JCO.2012.43.4449; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Stilgenbauer S, 2007, HAEMATOLOGICA, V92, P1242, DOI 10.3324/haematol.10720; Stilgenbauer S, 2016, LANCET ONCOL, V17, P768, DOI 10.1016/S1470-2045(16)30019-5; Strati P, 2016, LANCET HAEMATOL, V3, pE407, DOI 10.1016/S2352-3026(16)30064-3; Sylvan SE, 2014, LEUKEMIA LYMPHOMA, V55, P1774, DOI 10.3109/10428194.2013.827786; Thompson PA, 2016, BLOOD, V127, P303, DOI 10.1182/blood-2015-09-667675; Tsimberidou AM, 2008, J CLIN ONCOL, V26, P196, DOI 10.1200/JCO.2007.11.8513; Tsimberidou AM, 2006, J CLIN ONCOL, V24, P2343, DOI 10.1200/JCO.2005.05.0187; van Oers MHJ, 2015, LANCET ONCOL, V16, P1370, DOI 10.1016/S1470-2045(15)00143-6; Vigano M, 2014, EXPERT OPIN BIOL TH, V14, P1019, DOI 10.1517/14712598.2014.912273; VONTRESCKOW J, 2016, BLOOD, V128; Whitaker Jennifer A, 2014, Clin Adv Hematol Oncol, V12, P440; Wierda WG, 2007, BLOOD, V109, P4679, DOI 10.1182/blood-2005-12-051458; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245; Zhou Y, 2012, MODERN PATHOL, V25, P237, DOI 10.1038/modpathol.2011.158	146	151	156	5	62	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 14	2018	391	10129					1524	1537		10.1016/S0140-6736(18)30422-7	http://dx.doi.org/10.1016/S0140-6736(18)30422-7			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC6TS	29477250				2023-01-03	WOS:000429926000028
J	Krishnamurthi, N; Francis, J; Fihn, SD; Meyer, CS; Whooley, MA				Krishnamurthi, Nirupama; Francis, Joseph; Fihn, Stephan D.; Meyer, Craig S.; Whooley, Mary A.			Leading causes of cardiovascular hospitalization in 8.45 million US veterans	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ELECTRONIC HEALTH RECORDS; ADMINISTRATIVE DATA; RACIAL-DIFFERENCES; VALIDATED METHODS; CLINICAL-TRIALS; UNITED-STATES; BIG DATA; HEART; AFFAIRS	Background We sought to determine the leading causes of cardiovascular (CV) hospitalization, and to describe and compare national rates of CV hospitalization by age, gender, race, ethnicity, region, and year, among U.S. veterans. Methods We evaluated the electronic health records of all veterans aged >18 years who had accessed any healthcare services at either a VA healthcare facility or a non-VA healthcare facility that was reimbursed by the VA, between January 1 2010 and December 31 2014. Among these 8,452,912 patients, we identified the 5 leading causes of CV hospitalization and compared rates of hospitalization by age, gender, race, ethnicity, region, year and type of VA healthcare user. Results The top 5 causes of CV hospitalization were: coronary atherosclerosis, heart failure, acute myocardial infarction, stroke and atrial fibrillation. Overall, 297,373 (3.5%) veterans were hospitalized for one or more of these cardiovascular conditions. The percentage of veterans hospitalized for one or more of these CV conditions decreased over time, from 1.23% in 2010 to 1.18% in 2013, followed by a slight increase to 1.20% in 2014. There was significant variation in rates of CV hospitalization by gender, race, ethnicity, geographic region, and urban vs. rural zip code. In particular, older, male, Black, non-Hispanic, urban and Continental region veterans experienced the highest rates of CV hospitalizations. Conclusions Among 8.5 million patients enrolled in the VA healthcare system from 2010 to 2014, there was substantial variation in rates of CV hospitalization by age, gender, race, geographical distribution, year, and use of non-VA (vs. VA only) healthcare care facilities.	[Krishnamurthi, Nirupama; Meyer, Craig S.; Whooley, Mary A.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Krishnamurthi, Nirupama; Meyer, Craig S.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Francis, Joseph] Vet Hlth Adm, Off Reporting Analyt Performance Improvement & De, Washington, DC USA; [Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA; [Fihn, Stephan D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Whooley, MA (corresponding author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA.; Whooley, MA (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.	mary.whooley@ucsf.edu	PAN, ZEQIANG/X-6341-2018; Fihn, Stephan/ABA-1040-2020; Krishnamurthi, Nirupama/Q-2925-2019	Krishnamurthi, Nirupama/0000-0001-5096-5888; Whooley, Mary/0000-0002-5943-0078	Veterans Affairs Health Services Research & Development Service Quality Enhancement Research Initiative (QUERI)	Veterans Affairs Health Services Research & Development Service Quality Enhancement Research Initiative (QUERI)	This study was funded by the Veterans Affairs Health Services Research & Development Service Quality Enhancement Research Initiative (QUERI). https://www.queri.research.va.gov/.	[Anonymous], RUR VET OUTR TOOLK; [Anonymous], LOC MAP; [Anonymous], CHRON COND DAT WAR; Antman EM, 2016, CIRCULATION, V133, P823, DOI 10.1161/CIRCULATIONAHA.116.020976; Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; Benjamin E.J., 2017, CIRCULATION, V135, P146; Bufalino V, 2014, CIRC-CARDIOVASC QUAL, V7, P493, DOI 10.1161/HCQ.0000000000000003; Casper M, 2003, ATLAS STROKE MORTALI; Casper M, 2010, J AM COLL CARDIOL, V55, P294, DOI 10.1016/j.jacc.2009.10.021; Centers for Disease Control and Prevention National Center for Health Statistics, 2017, UND CAUS DEATH 1999; Corley DA, 2015, J ONCOL PRACT, V11, P204, DOI 10.1200/JOP.2014.003194; Fihn SD, 2014, HEALTH AFFAIR, V33, P1203, DOI 10.1377/hlthaff.2014.0054; Fleurence RL, 2014, J AM MED INFORM ASSN, V21, P578, DOI 10.1136/amiajnl-2014-002747; Goldstein KM, 2014, WOMEN HEALTH ISS, V24, P477, DOI 10.1016/j.whi.2014.05.005; Hripcsak G, 2015, STUD HEALTH TECHNOL, V216, P574, DOI 10.3233/978-1-61499-564-7-574; Jensen PN, 2012, PHARMACOEPIDEM DR S, V21, P141, DOI 10.1002/pds.2317; Kim J, 2017, J AM COLL CARDIOL, V69, P899, DOI 10.1016/j.jacc.2017.01.006; Lau E, 2016, CIRCULATION, V134, P362, DOI 10.1161/CIRCULATIONAHA.116.021892; Li B, 2011, AM J EPIDEMIOL, V174, P761, DOI 10.1093/aje/kwr154; Liu LJ, 2011, INT J CARDIOL, V149, P39, DOI 10.1016/j.ijcard.2009.11.037; Maynard C, 2004, DIABETES CARE, V27, pB22, DOI 10.2337/diacare.27.suppl_2.B22; McCormick N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135834; Mensah GA, 2005, CIRCULATION, V111, P1233, DOI 10.1161/01.CIR.0000158136.76824.04; Mentz RJ, 2016, CIRCULATION, V133, P872, DOI 10.1161/CIRCULATIONAHA.115.019902; Newby LK, 2015, CIRCULATION, V132, P1303, DOI 10.1161/CIRCULATIONAHA.115.018750; Niesner K, 2013, EPIDEMIOLOGY, V24, P334, DOI 10.1097/EDE.0b013e3182821e75; Noel PH, 2010, J REHABIL RES DEV, V47, P739, DOI 10.1682/JRRD.2009.08.0110; Office of Research and Development, VA RES CARD DIS; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Price Lauren E, 2015, Nurs Adm Q, V39, P311, DOI 10.1097/NAQ.0000000000000118; ROGOT E, 1989, J CLIN EPIDEMIOL, V42, P245, DOI 10.1016/0895-4356(89)90060-7; Saczynski JS, 2012, PHARMACOEPIDEM DR S, V21, P129, DOI 10.1002/pds.2313; Solomon SD, 2016, CIRCULATION, V133, P2662, DOI 10.1161/CIRCULATIONAHA.115.020723; Subramanian U, 2002, J GEN INTERN MED, V17, P604, DOI 10.1046/j.1525-1497.2002.11048.x; Vasan RS, 2016, CIRCULATION, V133, P2626, DOI 10.1161/CIRCULATIONAHA.116.023528; Weintraub WS, 2011, CIRCULATION, V124, P103, DOI 10.1161/CIR.0b013e31821ccf71; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wright SM, 1997, HEALTH SERV RES, V31, P739; Young BA, 2003, DIABETES CARE, V26, P2392, DOI 10.2337/diacare.26.8.2392	39	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2018	13	3							e0193996	10.1371/journal.pone.0193996	http://dx.doi.org/10.1371/journal.pone.0193996			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GA1RF	29566396	Green Submitted, Green Published, gold			2023-01-03	WOS:000428093900026
J	Brussoni, M; George, MA; Jin, A; Amram, O; McCormick, R; Lalonde, CE				Brussoni, Mariana; George, M. Anne; Jin, Andrew; Amram, Ofer; McCormick, Rod; Lalonde, Christopher E.			Hospitalizations due to unintentional transport injuries among Aboriginal population of British Columbia, Canada: Incidence, changes over time and ecological analysis of risk markers	PLOS ONE			English	Article							MOTOR-VEHICLE CRASHES; OFF-RESERVE; ROAD; DEATHS; TRAUMA; INTERVENTIONS; EXPOSURE; RATES	Background Worldwide, Indigenous people have disproportionately higher rates of transport injuries. We examined disparities in injury-related hospitalizations resulting from transport incidents for three population groups in British Columbia (BC): total population, Aboriginal off-reserve, and Aboriginal on-reserve populations. We also examined sociodemographic, geographic and ethnic risk markers for disparities. Methods We identified Aboriginal people through BC's universal health care insurance plan insurance premium group and birth and death record notations. We calculated crude incidence rate and Standardized Relative Risk (SRR) of hospitalization for unintentional transport injury, standardized for age, gender and Health Service Delivery Area (HSDA), relative to the total population of BC. We tested hypothesized associations of geographic, socio-economic, and employment-related characteristics of Aboriginal communities with SRR of transport injury by multivariable linear regression. Results During the period 1991-2010, the SRR for the off-reserve Aboriginal population was 1.77 (95% CI: 1.71 to 1.83); and 2.00 (95% CI: 1.93 to 2.07) among those living on-reserve. Decline in crude rate and SRRs was observed over this period among both the Aboriginal and total populations of BC, but was proportionally greater among the Aboriginal population. The best-fitting multivariable risk marker model was an excellent fit (R-2 = 0.912, p<0.001), predicted SRRs very close to observed values, and retained the following terms: urban residence, population per room, proportion of the population with a high school certificate, proportion of the population employed; and multiplicative interactions of Aboriginal ethnicity with population per room and proportion of the population employed. Conclusions Disparities in risk of hospitalization due to unintentional transport injury have narrowed. Aboriginal ethnicity modifies the effects of socioeconomic risk factors. Continued improvement of socioeconomic conditions and implementation of culturally relevant injury prevention interventions are needed.	[Brussoni, Mariana; George, M. Anne] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Brussoni, Mariana; George, M. Anne] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Brussoni, Mariana; George, M. Anne] British Columbia Childrens Hosp, Res Inst, Vancouver, BC, Canada; [Brussoni, Mariana] British Columbia Injury Res & Prevent Unit, Vancouver, BC, Canada; [Amram, Ofer] Washington State Univ, Dept Nutr & Exercise Physiol, Elson S Floyd Coll Med, Vancouver, BC, Canada; [McCormick, Rod] Thompson Rivers Univ, Fac Human Social & Educ Dev, Kamloops, BC, Canada; [Lalonde, Christopher E.] Univ Victoria, Dept Psychol, Victoria, BC, Canada	University of British Columbia; University of British Columbia; BC Childrens Hospital; University of British Columbia; Washington State University; University of Victoria	Brussoni, M (corresponding author), Univ British Columbia, Dept Pediat, Vancouver, BC, Canada.; Brussoni, M (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.; Brussoni, M (corresponding author), British Columbia Childrens Hosp, Res Inst, Vancouver, BC, Canada.; Brussoni, M (corresponding author), British Columbia Injury Res & Prevent Unit, Vancouver, BC, Canada.	mbrussoni@bcchr.ubc.ca	Brussoni, Mariana/U-9404-2018; Jin, Andrew/H-5725-2019	Brussoni, Mariana/0000-0002-1495-816X; Jin, Andrew/0000-0002-8708-2381; George, M. Anne/0000-0001-7129-2117; Lalonde, Christopher/0000-0002-0446-0464	Canadian Institutes of Health Research, Institute of Aboriginal People's Health [81043]; British Columbia Children's Hospital Research Institute; British Columbia Region, First Nations; Inuit Health Program, Health Canada	Canadian Institutes of Health Research, Institute of Aboriginal People's Health(Canadian Institutes of Health Research (CIHR)); British Columbia Children's Hospital Research Institute; British Columbia Region, First Nations; Inuit Health Program, Health Canada	This research was funded by the Canadian Institutes of Health Research, Institute of Aboriginal People's Health (http://www.cihr.irsc.gc ca/e/8668.html), funding reference: AHR #81043. Salary support for authors was provided by the British Columbia Children's Hospital Research Institute (MB and MAG) and by the British Columbia Region, First Nations and Inuit Health Program, Health Canada (AJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Salary support for authors was provided by the British Columbia Children's Hospital Research Institute (MB and MAG) and by the British Columbia Region, First Nations and Inuit Health Program, Health Canada (AJ). The authors thank Anna Low, Sherylyn Arabsky and Kelly Sanderson of Population Data BC for assistance with data access and linkage, and Stewart Deyell of Statistics Canada for assistance in obtaining custom tabulations of Census data.	Ahlm K, 2010, INT J CIRCUMPOL HEAL, V69, P129, DOI 10.3402/ijch.v69i2.17432; [Anonymous], 2015, PARACHUTE COST INJUR; BC Vital Statistics Agency, 2011, VIT STAT BIRTHS POP; BC Vital Statistics Agency, 2011, VIT STAT DEATHS POP; Braver ER, 2003, ACCIDENT ANAL PREV, V35, P295, DOI 10.1016/S0001-4575(01)00106-3; *BRIT COL VIT STAT, 2004, REG AN HLTH STAT STA; Brussoni M, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3078-x; Brussoni M, 2015, PREV SCI, V16, P560, DOI 10.1007/s11121-014-0503-1; Canadian Institute for Health Information, 2011, DISCH ABSTR DAT HOSP; CHIPMAN ML, 1993, ACCIDENT ANAL PREV, V25, P207, DOI 10.1016/0001-4575(93)90061-Z; Clapham K, 2008, INJURY, V39, pS19, DOI 10.1016/S0020-1383(08)70025-1; Desapriya E, 2011, ASIA-PAC J PUBLIC HE, V23, P1005, DOI 10.1177/1010539510361787; DesMeules M, 2006, HLTH ARE RURAL CANAD; Ellis BH, 2003, J PSYCHOACTIVE DRUGS, V35, P89, DOI 10.1080/02791072.2003.10399999; Falster MO, 2013, ACCIDENT ANAL PREV, V54, P32, DOI 10.1016/j.aap.2013.01.015; George MA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2262-x; George MA, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0629-4; George M Anne, 2015, Inj Epidemiol, V2, P7; George MA, 2015, HEALTH REP, V26, P3; George MA, 2013, INT J CIRCUMPOL HEAL, V72, P441, DOI 10.3402/ijch.v72i0.21182; Ghani Y, 2014, PROCD SOC BEHV, V155, P63, DOI 10.1016/j.sbspro.2014.10.257; Gomez D, 2010, J TRAUMA, V69, P633, DOI 10.1097/TA.0b013e3181b8ef81; Hosking J, 2013, AUST NZ J PUBL HEAL, V37, P162, DOI 10.1111/1753-6405.12034; Insurance Corporation of British Columbia, 2015, CORP ACT ADV AN REP; Ishikawa T, 2014, AM J PUBLIC HEALTH, V104, pE1, DOI 10.2105/AJPH.2013.301683; Jin A, 2016, J RACIAL ETHN HLTH D, P1; Jin A, J HLTH CARE POOR UND, V28, P952; Jin A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121694; Jin A, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-710; Kahn HA, 1989, ADJUSTMENT DATA USE, P95; Kim K, 2012, INJURY PREV, V18, P264, DOI 10.1136/injuryprev-2011-040306; Pan SW, 2015, J TRANSP HEALTH, V2, P595, DOI 10.1016/j.jth.2015.09.003; Peden M., 2004, WORLD REPORT ROAD TR; Provincial Health Officer, 2016, RUBB MEETS ROAD RED; Public Health Agency of Canada, 2012, INJ IN REV; Rajabali F., 2015, EC BURDEN INJURY BRI, DOI [10.14288/1.0397291, DOI 10.14288/1.0397291]; Rakauskas ME, 2009, ACCIDENT ANAL PREV, V41, P931, DOI 10.1016/j.aap.2009.05.008; Short MM, 2013, CAN J RURAL MED, V18, P86; Short MM, 2014, CAN J PUBLIC HEALTH, V105, pE296, DOI 10.17269/cjph.105.4176; Simons R, 2010, J TRAUMA, V69, P11, DOI 10.1097/TA.0b013e3181e17b39; Spoerri A, 2011, ACCIDENT ANAL PREV, V43, P40, DOI 10.1016/j.aap.2010.06.009; Stephan K, 2011, ACCIDENT ANAL PREV, V43, P1062, DOI 10.1016/j.aap.2010.12.011; Truth and Reconciliation Commission of Canada, 2015, HON TRUTH REC FUT SU; Truth & Reconciliation Commission of Canada, 2015, TRUTH REC COMM CAN C; Turner Cathy, 2003, Inj Control Saf Promot, V10, P123, DOI 10.1076/icsp.10.3.123.14560; U.S. Department of Transportation National Highway Traffic Safety Administration, 1996, RURAL AND URBAN CRAS; Wood DS, 2006, ADDICTION, V101, P393, DOI 10.1111/j.1360-0443.2006.01347.x; World Health Organization, 2018, NONCOMMUNICABLE DIS	48	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2018	13	1							e0191384	10.1371/journal.pone.0191384	http://dx.doi.org/10.1371/journal.pone.0191384			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FT8TF	29373595	Green Published, gold, Green Submitted			2023-01-03	WOS:000423425400010
J	Fernandez-Navarro, P; Aragones, MT; Ley, V				Fernandez-Navarro, Pablo; Aragones, Maria Teresa; Ley, Victoria			Leisure-time physical activity and prevalence of non-communicable pathologies and prescription medication in Spain	PLOS ONE			English	Article							AEROBIC EXERCISE; MORTALITY; ADULTS; HEALTH; CHOLESTEROL; FITNESS; OBESITY; CANCER; WOMEN; RISK	Our aims were to describe physical activity (PA) behaviour in Spain and to examine its association with the prevalence of some of the major non-communicable diseases and with the use of prescription medication. Individualized secondary data retrieved from the 2014 European Health Interview Survey (EHIS) for Spain were used to conduct a cross-sectional epidemiological study (n = 18926). PA was assessed by two different measures: a specific designed variable for EHIS and a leisure time PA frequency-based query of the national survey. Diseases analyzed were hypertension, diabetes, hypercholesterolemia, depression and anxiety. The use of prescription medication was also included in the study. Weighted percentages were computed and contingency tables were calculated to describe PA by levels of the traits and sociodemographic characteristics. Chi-square test was used to compare percentages between groups and weighted logistic regression models were used to assess the relationship between PA and the prevalence of the disease. About 73% of the Spanish population performs no PA at all or only occasionally during their leisure time, and only one third meets minimum PA international guidelines (>= 150min/week). Men are considerably more active than women and less PA is observed as the education level decreases and as age increases. The risk of the diseases evaluated was up to three times higher among inactive individuals. This study provides national population-based estimations highlighting the impact of PA in Spain, not only in the prevalence of some of the major non-communicable diseases but also in reducing prescription medication, and the potential sex and socioeconomic influence.	[Fernandez-Navarro, Pablo] Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain; [Fernandez-Navarro, Pablo] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain; [Aragones, Maria Teresa; Ley, Victoria] Spanish Agcy Hlth Protect Sports, Natl Sports Council, Dept Sports & Hlth, Madrid, Spain	Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP	Fernandez-Navarro, P (corresponding author), Carlos III Inst Hlth, Canc & Environm Epidemiol Unit, Natl Ctr Epidemiol, Madrid, Spain.; Fernandez-Navarro, P (corresponding author), Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain.; Ley, V (corresponding author), Spanish Agcy Hlth Protect Sports, Natl Sports Council, Dept Sports & Hlth, Madrid, Spain.	pfernandezn@isciii.es; victoria.ley@aei.gob.es	Ley, Victoria/I-8862-2017; Navarro, Pablo Fernandez/E-8893-2018	Ley, Victoria/0000-0003-2740-1560; Navarro, Pablo Fernandez/0000-0001-9427-2581; Gonzalez Palacios, Javier/0000-0002-8099-8469; Gonzalez Sanchez, Mario/0000-0003-0229-3559	Spain's Health Research Fund, Institute de Salud Carlos III [EPY 1271/15]	Spain's Health Research Fund, Institute de Salud Carlos III	This work was supported by EPY 1271/15 from Spain's Health Research Fund, Institute de Salud Carlos III; https://portalfis.isciii.es/es/Paginas/inicio.aspx. PFN is the PI of the project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2004, J STAT SOFTW, DOI DOI 10.18637/JSS.V009.I05; Arem H, 2015, JAMA INTERN MED, V175, P959, DOI 10.1001/jamainternmed.2015.0533; Becofsky KM, 2015, AM J EPIDEMIOL, V181, P311, DOI 10.1093/aje/kwu330; Booth FW, 2015, DIABETOLOGIA, V58, P1730, DOI 10.1007/s00125-015-3617-5; Bull F, 2015, BRIT J SPORT MED, V49, P749, DOI 10.1136/bjsports-2013-093200; Craft Lynette L., 2004, Prim Care Companion J Clin Psychiatry, V6, P104; Devaux M, 2013, EUR J PUBLIC HEALTH, V23, P464, DOI 10.1093/eurpub/ckr058; Ekelund U, 2015, AM J CLIN NUTR, V101, P613, DOI 10.3945/ajcn.114.100065; Eurostat, 2015, EUR HLTH INT SURV ME; Finger JD, 2015, ARCH PUBLIC HEALTH, V73, P1; Fishman EI, 2016, MED SCI SPORT EXER, V48, P1303, DOI 10.1249/MSS.0000000000000885; Fiuza-Luces C, 2013, PHYSIOLOGY, V28, P330, DOI 10.1152/physiol.00019.2013; Gordon B, 2014, CURR SPORT MED REP, V13, P253, DOI 10.1249/JSR.0000000000000073; Hupin D, 2015, BRIT J SPORT MED, V49, DOI 10.1136/bjsports-2014-094306; ISCA (International Sport and Culture Association) & CEBR (Centre for Economics and Business Research), 2015, EC COST PHYS IN EUR; Katzmarzyk PT, 2016, ANN INTERN MED, V164, P620, DOI 10.7326/M16-0269; Kodama S, 2007, ARCH INTERN MED, V167, P999, DOI 10.1001/archinte.167.10.999; Ladabaum U, 2014, AM J MED, V127, P717, DOI 10.1016/j.amjmed.2014.02.026; Laske C, 2010, INT J NEUROPSYCHOPH, V13, P595, DOI 10.1017/S1461145709991234; Lee DC, 2015, J AM COLL CARDIOL, V65, P420, DOI 10.1016/j.jacc.2014.11.022; Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9; Mann S, 2014, SPORTS MED, V44, P211, DOI 10.1007/s40279-013-0110-5; Marques A, 2015, PREV MED, V81, P333, DOI 10.1016/j.ypmed.2015.09.018; Moore SC, 2016, JAMA INTERN MED, V176, P816, DOI 10.1001/jamainternmed.2016.1548; Neufer PD, 2015, CELL METAB, V22, P4, DOI 10.1016/j.cmet.2015.05.011; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Prince SA, 2014, OBES REV, V15, P905, DOI 10.1111/obr.12215; Romero V, 2007, PSYCHOSOMATICS, V54, P525; Schnohr P, 2015, J AM COLL CARDIOL, V65, P411, DOI 10.1016/j.jacc.2014.11.023; Smith AD, 2016, DIABETOLOGIA, V59, P2527, DOI 10.1007/s00125-016-4079-0; Smith Mark A, 2011, Front Psychiatry, V2, P82, DOI 10.3389/fpsyt.2011.00082; Therneau TM, 2016, SURVIVAL SURVIVAL AN, P128; Tomiyama AJ, 2016, INT J OBESITY, V40, P883, DOI 10.1038/ijo.2016.17; Wahid A, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002495; WHO, 2015, GLOB REC PHYS ACT HL; WHO, 2015, WHO GLOBAL HEALTH OB; World Health Organization, GLOB DAT BOD MASS IN	38	20	20	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2018	13	1							e0191542	10.1371/journal.pone.0191542	http://dx.doi.org/10.1371/journal.pone.0191542			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT1QM	29352280	gold, Green Published, Green Submitted			2023-01-03	WOS:000422911300110
J	Vaidya, J; Massarut, S; Vaidya, HJ; Alexander, EC; Richards, T; Caris, JA; Sirohi, B; Tobias, JS				Vaidya, Jayant; Massarut, Samuele; Vaidya, Hrisheekesh J.; Alexander, Emma C.; Richards, Thomas; Caris, Jochem A.; Sirohi, Bhawna; Tobias, Jeffrey S.			Rethinking neoadjuvant chemotherapy for breast cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DOSE-INTENSIFIED CHEMOTHERAPY; III RANDOMIZED GEPARTRIO; OPEN-LABEL; PHASE-3 TRIAL; PREOPERATIVE CHEMOTHERAPY; ADJUVANT TRASTUZUMAB; DARBEPOETIN ALPHA; PREPARE TRIAL; CYCLOPHOSPHAMIDE; METAANALYSIS		[Vaidya, Jayant] UCL, Div Surg & Intervent Sci, London, England; [Vaidya, Jayant] Royal Free Hosp, Whittington Hosp, Dept Surg, London, England; [Vaidya, Jayant] Univ Coll London Hosp, London, England; [Massarut, Samuele] Ctr Riferimento Oncol Aviano, Aviano, Italy; [Vaidya, Hrisheekesh J.] Imperial Coll London, Imperial Coll Sch Med, London, England; [Alexander, Emma C.] Kings Coll London, GKT Sch Med Educ, London, England; [Richards, Thomas; Tobias, Jeffrey S.] Univ Coll London Hosp, Dept Clin Oncol, London, England; [Caris, Jochem A.] Whittington Hosp, Dept Surg, London, England; [Sirohi, Bhawna] Barts Hlth NHS Trust, Dept Med Oncol, London, England	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; IRCCS Aviano (CRO); Imperial College London; University of London; King's College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London; Barts Health NHS Trust	Vaidya, J (corresponding author), UCL, Div Surg & Intervent Sci, London, England.; Vaidya, J (corresponding author), Royal Free Hosp, Whittington Hosp, Dept Surg, London, England.	jayant.vaidya@ucl.ac.uk	Massarut, Samuele/J-2995-2018; Vaidya, Jayant S/A-7218-2008	Massarut, Samuele/0000-0003-4717-0544; Vaidya, Jayant S/0000-0003-1760-1278; Vaidya, Hrisheekesh/0000-0003-0885-9859; Alexander, Emma/0000-0001-7063-6846				Alberro JA, 2018, LANCET ONCOL, V19, P27, DOI 10.1016/S1470-2045(17)30777-5; Badwe R, 2015, LANCET ONCOL, V16, P1380, DOI 10.1016/S1470-2045(15)00135-7; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Cancer Research UK, 2017, CANC STAT; Cify A S, 2015, ENDING MED REVERSALS; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gianni L, 2016, LANCET ONCOL, V17, P791, DOI 10.1016/S1470-2045(16)00163-7; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Gianni L, 2009, J CLIN ONCOL, V27, P2474, DOI 10.1200/JCO.2008.19.2567; Kim C, 2016, MAYO CLIN P, DOI [10.1016/j.mayocp.2016.02.012.27236424, DOI 10.1016/J.MAYOCP.2016.02.012.27236424]; Mauri D, 2005, JNCI-J NATL CANCER I, V97, P188, DOI 10.1093/jnci/dji021; Mieog JSD, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005002.pub2; Miller KD, 2017, NEW ENGL J MED, V377, P186, DOI 10.1056/NEJMe1706150; Moja L, 2012, COCHRANE DB SYST REV; O'Sullivan CC, 2015, J CLIN ONCOL, V33, P2600, DOI 10.1200/JCO.2015.60.8620; Piccart-Gebhart M, 2016, J CLIN ONCOL, V34, P1034, DOI 10.1200/JCO.2015.62.1797; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Spring LM, 2016, JAMA ONCOL, V2, P1477, DOI 10.1001/jamaoncol.2016.1897; Untch M, 2011, ANN ONCOL, V22, P1988, DOI 10.1093/annonc/mdq709; Untch M, 2011, ANN ONCOL, V22, P1999, DOI 10.1093/annonc/mdq713; Untch M, 2010, J CLIN ONCOL, V28, P2024, DOI 10.1200/JCO.2009.23.8451; Untch M, 2009, J CLIN ONCOL, V27, P2938, DOI 10.1200/JCO.2008.20.3133; Valachis A, 2011, BREAST, V20, P485, DOI 10.1016/j.breast.2011.06.009; von Minckwitz G, 2005, J CLIN ONCOL, V23, P2676, DOI 10.1200/JCO.2005.05.078; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P552, DOI 10.1093/jnci/djn089; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; von Minckwitz G, 2017, NEW ENGL J MED, V377, P122, DOI 10.1056/NEJMoa1703643; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065	34	60	65	3	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 11	2018	360								j5913	10.1136/bmj.j5913	http://dx.doi.org/10.1136/bmj.j5913			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FS9NC	29326104	Green Published			2023-01-03	WOS:000422743900014
J	Bagian, JP; Paull, DE				Bagian, James P.; Paull, Douglas E.			Handovers During Anesthesia Care Patient Safety Risk or Opportunity for Improvement?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMPLEMENTATION		[Bagian, James P.] Univ Michigan, Ctr Healthcare Engn & Patient Safety, 1205 Beal Ave,2753 IOE Bldg, Ann Arbor, MI 48109 USA; [Paull, Douglas E.] Natl Ctr Patient Safety, Dept Vet Affairs, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Bagian, JP (corresponding author), Univ Michigan, Ctr Healthcare Engn & Patient Safety, 1205 Beal Ave,2753 IOE Bldg, Ann Arbor, MI 48109 USA.	jbagian@umich.edu		Bagian, James/0000-0003-1792-6099; Paull, Douglas/0000-0001-8876-2824				[Anonymous], 2017, Sentinel Event Alert, P1; Cohen MD, HANDOFFS HOSP REV LI; Gross TK, 2016, AM PEDIAT NEWS; Jones PM, 2018, JAMA-J AM MED ASSOC, V319, P143, DOI 10.1001/jama.2017.20040; Manser T, 2012, P HUM FACT ERG SOC 2, V862; National Patient Safety Foundation, 2015, RCA2 IMPR ROOT CAUS; Neily J, 2010, JAMA-J AM MED ASSOC, V304, P1693, DOI 10.1001/jama.2010.1506; Sathishkumar S, 2015, ANESTHESIOLOGY, V123, P29, DOI 10.1097/ALN.0000000000000699; Starmer AJ, 2013, JAMA-J AM MED ASSOC, V310, P2262, DOI 10.1001/jama.2013.281961; The Accreditation Council for Graduate Medical Education, 2014, CLIN LEARN ENV REV C; The Joint Commission, TRANS CAR NEED MOR E; Weiss KB, 2013, JAMA-J AM MED ASSOC, V309, P1687, DOI 10.1001/jama.2013.1931	12	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 9	2018	319	2					125	127		10.1001/jama.2017.20602	http://dx.doi.org/10.1001/jama.2017.20602			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FS4PR	29318263				2023-01-03	WOS:000419775500011
J	McMinn, D; Fergusson, SJ; Daly, M				McMinn, D.; Fergusson, S. J.; Daly, M.			Does pride really come before a fall? Longitudinal analysis of older English adults	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; AGED 65; STRATEGIES; COMMUNITY; PROFILE; BALANCE; FEAR	OBJECTIVE To test whether high levels of reported pride are associated with subsequent falls. DESIGN Secondary analysis of the English Longitudinal Study of Ageing (ELSA) dataset. SETTING Multi-wave longitudinal sample of non-institutionalised older English adults. PARTICIPANTS ELSA cohort of 6415 participants at wave 5 (baseline, 2010/11), of whom 4964 were available for follow-up at wave 7 (follow-up, 2014/15). MAIN OUTCOME MEASURES Self reported pride at baseline (low/moderate/high) and whether the participant had reported having fallen during the two years before follow-up. RESULTS The findings did not support the contention that "pride comes before a fall." Unadjusted estimates indicate that the odds of reported falls were significantly lower for people with high pride levels compared with those who had low pride (odds ratio 0.69, 95% confidence interval 0.58 to 0.81, P<0.001). This association remained after adjustment for age, sex, household wealth, and history of falls (odds ratio 0.81, 0.68 to 0.97, P<0.05). It was partially attenuated after further adjustment for mobility problems, eyesight problems, the presence of a limiting long term illness, a diagnosis of arthritis or osteoporosis, medication use, cognitive function, and pain and depression (odds ratio 0.86, 0.72 to 1.03, P<0.1). Because the confidence interval exceeded 1 in the final model, it remains possible that pride may not be an independent predictor of falls when known risk factors are considered. People with moderate pride did not have lower odds of having fallen than those with low pride in adjusted models. Participants lost to follow-up did not differ from those retained in terms of key variables, and weighting the analyses to account for selective attrition did not produce different results. CONCLUSIONS Contrary to the well known saying " pride comes before a fall," these findings suggest that pride may actually be a protective factor against falling in older adults. Future studies may seek to investigate the mechanisms underpinning this relation.	[McMinn, D.] Univ Aberdeen, Rowett Inst Nutr & Hlth, Aberdeen AB25 2ZD, Scotland; [Fergusson, S. J.] Royal Alexandra Hosp, Paisley PA2 9PN, Renfrew, Scotland; [Daly, M.] Univ Stirling, Dept Management Work & Org, Stirling, Scotland	University of Aberdeen; University of Stirling	Daly, M (corresponding author), Univ Stirling, Dept Management Work & Org, Stirling, Scotland.	michael.daly@stir.ac.uk	Daly, Michael/AAD-7703-2019	Daly, Michael/0000-0003-1557-8326				Ambrose AF, 2013, MATURITAS, V75, P51, DOI 10.1016/j.maturitas.2013.02.009; Ayoung-Chee P, 2014, J TRAUMA ACUTE CARE, V76, P498, DOI 10.1097/TA.0000000000000102; Bandeen-Roche K, 2015, J GERONTOL A-BIOL, V70, P1427, DOI 10.1093/gerona/glv133; Davis JC, 2010, OSTEOPOROSIS INT, V21, P1295, DOI 10.1007/s00198-009-1162-0; Delbaere Kim, 2010, BMJ, V341, pc4165, DOI 10.1136/bmj.; Fortinsky RH, 2009, HEALTH RISK SOC, V11, P341, DOI 10.1080/13698570903015735; Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x; Gale CR, 2016, AGE AGEING, V45, P789, DOI 10.1093/ageing/afw129; Hadjistavropoulos T, 2011, J AGING HEALTH, V23, P3, DOI 10.1177/0898264310378039; Hawk Cheryl, 2006, Chiropr Osteopat, V14, P3, DOI 10.1186/1746-1340-14-3; Karlsson MK, 2013, OSTEOPOROSIS INT, V24, P747, DOI 10.1007/s00198-012-2256-7; Mansournia MA, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i189; NICE,, 2013, FALLS OLD PEOPL ASS; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rubenstein LZ, 2006, AGE AGEING, V35, P37, DOI 10.1093/ageing/afl084; Sekaran NK, 2013, J AM GERIATR SOC, V61, P96, DOI 10.1111/jgs.12071; Steptoe A, 2015, LANCET, V385, P640, DOI 10.1016/S0140-6736(13)61489-0; Steptoe A, 2013, INT J EPIDEMIOL, V42, P1640, DOI 10.1093/ije/dys168; Visschedijk JHM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0158-1; Wang YC, 2012, AGING MENT HEALTH, V16, P763, DOI 10.1080/13607863.2012.678479	20	1	1	2	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2017	359								j5451	10.1136/bmj.j5451	http://dx.doi.org/10.1136/bmj.j5451			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ4KT	29229614	Green Published, Green Submitted, hybrid, Green Accepted			2023-01-03	WOS:000418327000005
J	Raja, A; Miller, ES; Flores, EJ; Wakeman, SE; Eng, G				Raja, Ali; Miller, Emily S.; Flores, Efren J.; Wakeman, Sarah E.; Eng, George			Case 37-2017: A 36-Year-Old Man with Unintentional Opioid Overdose	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONCARDIOGENIC PULMONARY-EDEMA; RANDOMIZED CLINICAL-TRIAL; HEROIN OVERDOSE; USE DISORDER; DEPENDENCE; DETOXIFICATION; INCARCERATION; MAINTENANCE; WITHDRAWAL; METHADONE		[Raja, Ali; Miller, Emily S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Flores, Efren J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Eng, George] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Raja, Ali; Miller, Emily S.] Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA; [Raja, Ali; Flores, Efren J.] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA; [Wakeman, Sarah E.] Harvard Med Sch, Dept Med, Boston, MA USA; [Eng, George] Harvard Med Sch, Dept Pathol, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Raja, A (corresponding author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.; Raja, A (corresponding author), Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA.; Raja, A (corresponding author), Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA.		Raja, Ali S./AAE-5103-2019	Flores, Efren/0000-0003-1398-0426				[Anonymous], 2017, OP REL INP STAYS EM; Center for Behavioral Health Statistics and Quality, 2014, TREATM EP DAT SET TE; Centers for Disease Control and Prevention, 2016, OP OV DRUG OV DEATH; Chutuape MA, 2001, AM J DRUG ALCOHOL AB, V27, P19, DOI 10.1081/ADA-100103117; Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI 10.1056/NEJMc1505541; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Day E, 2011, J SUBST ABUSE TREAT, V40, P56, DOI 10.1016/j.jsat.2010.08.007; Department of Justice Drug Enforcement Administration, 2016, 2016 NAT DRUG THREAT; Fiellin DA, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.07.005; HIND CRK, 1990, THORAX, V45, P957, DOI 10.1136/thx.45.12.957; Kakko J, 2003, LANCET, V361, P662, DOI 10.1016/S0140-6736(03)12600-1; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Ling W, 2016, J NEUROIMMUNE PHARM, V11, P394, DOI 10.1007/s11481-016-9663-z; Ling W, 2013, ADDICTION, V108, P1788, DOI 10.1111/add.12266; Maradiaga JA, 2016, J SUBST ABUSE TREAT, V62, P49, DOI 10.1016/j.jsat.2015.11.004; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Massachusetts Department of Public Health, 2017, DAT BRIEF OP REL OV; McGovern B., 2017, BOSTON HERALD; Mell HK, 2006, CLIN TOXICOL, V44, P399, DOI 10.1080/15563650600671803; Nosyk B, 2014, DRUG ALCOHOL DEPEN, V143, P149, DOI 10.1016/j.drugalcdep.2014.07.020; Osler W., 1880, OEDEMA LEFT LUNG MOR, P291; Rich JD, 2015, LANCET, V386, P350, DOI 10.1016/S0140-6736(14)62338-2; Rosenblatt RA, 2015, ANN FAM MED, V13, P23, DOI 10.1370/afm.1735; Sedy J, 2008, PHYSIOL RES, V57, P499, DOI 10.33549/physiolres.931432; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Shanahan CW, 2010, J GEN INTERN MED, V25, P803, DOI 10.1007/s11606-010-1311-3; Sigmon SC, 2016, NEW ENGL J MED, V375, P2504, DOI 10.1056/NEJMc1610047; Sporer KA, 2001, CHEST, V120, P1628, DOI 10.1378/chest.120.5.1628; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; Sterrett C, 2003, AM J EMERG MED, V21, P32, DOI 10.1053/ajem.2003.50006; US Food and Drug Administration. National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions, 2015, FED REG; Wakeman SE, 2017, J GEN INTERN MED, V32, P909, DOI 10.1007/s11606-017-4077-z; Wakeman SE, 2016, SUBST ABUS, V37, P635, DOI 10.1080/08897077.2016.1187240; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103	34	3	3	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2017	377	22					2181	2188		10.1056/NEJMcpc1710563	http://dx.doi.org/10.1056/NEJMcpc1710563			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FO1VI	29171813	Bronze			2023-01-03	WOS:000416555000012
J	Yang, XY; Liu, Y; Liu, B; He, L; Liu, ZS; Yan, YS; Liu, J; Liu, BY				Yang, Xingyue; Liu, Yan; Liu, Bing; He, Liyun; Liu, Zhishun; Yan, Yanshi; Liu, Jia; Liu, Baoyan			Factors related to acupuncture response in patients with chronic severe functional constipation: Secondary analysis of a randomized controlled trial	PLOS ONE			English	Article							ELECTROACUPUNCTURE; PRUCALOPRIDE; MANAGEMENT	Background Acupuncture has been demonstrated to be effective and safe for chronic severe functional constipation (CSFC). However, which patients with CSFC will have a better response to acupuncture remains unclear. Objective To explore factors related to acupuncture response in patients with CSFC. Methods We performed a secondary analysis of a previous multicenter randomized controlled trial consisting of a 2-week run-in period, 8-week treatment, and 12-week follow-up without treatment in which patients with CSFC were randomly allocated to an electroacupuncture group or a sham electroacupuncture group. Responders were defined as participants with an increase of at least one complete spontaneous bowel movement (CSBM) in week 20 compared with the baseline period. The CSBM responder rate in both groups was described, and the baseline characteristics of participants potentially related to acupuncture response were mainly analyzed using logistic regression analysis with bootstrapping techniques. Results A total of 1021 participants were analyzed in this study, of whom 516 (50.5%) were classified as responders. The CSBM responder rate in week 20 was significantly greater in the electroacupuncture group than in the sham electroacupuncture group (62.9% vs. 37.9%, respectively; P<0.001). Both age and comorbidity were negatively associated with clinical response: with every one-year increase in age, the likelihood of clinical response was reduced by 1.2% (OR 0.988, 95% Cl 0.980 to 0.996; P = 0.005), and patients with comorbidities were approximately 42% less likely to respond to treatment (OR 0.581, 95% Cl 0.248 to 0.914; P = 0.001). Conclusion CSFC patients with increasing age and comorbidity may be less likely to respond to acupuncture. These findings contribute to guiding clinical practice in terms of pretreatment patient selection. Further research is needed to confirm the association.	[Yang, Xingyue] Beijing Univ Chinese Med, Beijing, Peoples R China; [Liu, Yan; He, Liyun; Yan, Yanshi; Liu, Jia; Liu, Baoyan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China; [Liu, Bing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China; [Liu, Zhishun] China Acad Chinese Med Sci, Guangan Men Hosp, Beijing, Peoples R China	Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; China Academy of Chinese Medical Sciences	Liu, BY (corresponding author), China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing, Peoples R China.	baoyanjournal@163.com			Fundamental Research Funds for the Central public welfare research institutes [Z0474]; National Natural Science Foundation of China [81503679]; Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program [2012BAI241301]	Fundamental Research Funds for the Central public welfare research institutes; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program	This study is supported by Fundamental Research Funds for the Central public welfare research institutes (Z0474) and National Natural Science Foundation of China (NO. 81503679) received by Yan Liu; also supported by the Ministry of Science and Technology of the People's Republic of China through the Twelfth Five-Year National Science and Technology Pillar Program (2012BAI241301) received by Baoyan Liu. Yan Liu contributes to study design, data analysis, decision to publish and preparation of the manuscript. Baoyan Liu contributes to study design and decision to publish.	Camilleri M, 2008, NEW ENGL J MED, V358, P2344, DOI 10.1056/NEJMoa0800670; Camilleri M, 2016, DIGEST DIS SCI, V61, P2357, DOI 10.1007/s10620-016-4147-9; Chen ZX, 2017, SCI REP-UK, V7, DOI 10.1038/srep40837; Ee C, 2016, ANN INTERN MED, V164, P146, DOI 10.7326/M15-1380; Harrell Frank E., 2001, REGRESSION MODELING; Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660; Johanson JF, 2004, CLIN GASTROENTEROL H, V2, P796, DOI 10.1016/S1542-3565(04)00356-8; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75; Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118; Liu ZS, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-176; Madsen JL, 2004, AGE AGEING, V33, P154, DOI 10.1093/ageing/afh040; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Mugie SM, 2011, BEST PRACT RES CL GA, V25, P3, DOI 10.1016/j.bpg.2010.12.010; Naslund J, 2002, J REHABIL MED, V34, P231, DOI 10.1080/165019702760279233; Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050; Paquette IM, 2016, DIS COLON RECTUM, V59, P479, DOI 10.1097/DCR.0000000000000599; Patel BA, 2017, SCI REP-UK, V7, DOI 10.1038/srep42754; Patel BA, 2014, EXP GERONTOL, V53, P24, DOI 10.1016/j.exger.2014.02.007; Rao SSC, 2010, CLIN INTERV AGING, V5, P163; Rong Peijing, 2011, Front Med, V5, P151, DOI 10.1007/s11684-011-0129-7; Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755; Sherman KJ, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-114; Shi GX, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-42; Wald A, 2016, JAMA-J AM MED ASSOC, V315, P185, DOI 10.1001/jama.2015.16994; Witt CM, 2011, CLIN J PAIN, V27, P550, DOI 10.1097/AJP.0b013e31820dfbf5; Yang Xiaolin, 2013, Evid Based Complement Alternat Med, V2013, P926928, DOI 10.1155/2013/926928; Yeung WF, 2017, ACUPUNCT MED, V35, DOI 10.1136/acupmed-2016-011058; Zhang M, 2015, WORLD J GASTROENTERO, V21, P13368, DOI 10.3748/wjg.v21.i47.13368	29	10	10	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2017	12	11							e0187723	10.1371/journal.pone.0187723	http://dx.doi.org/10.1371/journal.pone.0187723			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FN5GQ	29166673	Green Submitted, Green Published, gold			2023-01-03	WOS:000416035300017
J	Jackson, T; Shields, MD; Heaney, LG; Kendall, M; Pearce, CJ; Hui, CY; Pinnock, H				Jackson, Tracy; Shields, Michael D.; Heaney, Liam G.; Kendall, Marilyn; Pearce, Christina J.; Hui, Chi Yan; Pinnock, Hilary			The impact of financial incentives on the implementation of asthma or diabetes self-management: A systematic review	PLOS ONE			English	Review							PAY-FOR-PERFORMANCE; PRIMARY-CARE; GLYCEMIC CONTROL; HEALTH-CARE; QUALITY; PROGRAM; INTERVENTIONS; PHYSICIANS; ENGLAND	Introduction Financial incentives are utilised in healthcare systems in a number of countries to improve quality of care delivered to patients by rewarding practices or practitioners for achieving set targets. Objectives To systematically review the evidence investigating the impact of financial incentives for implementation of supported self-management on quality of care including: organisational process outcomes, individual behavioural outcomes, and health outcomes for individuals with asthma or diabetes; both conditions with an extensive evidence base for self-management. Methods We followed Cochrane methodology, using a PICOS search strategy to search eight databases in November 2015 (updated May 2017) including a broad range of implementation methodologies. Studies were weighted by robustness of methodology, number of participants and the quality score. We used narrative synthesis due to heterogeneity of studies. Results We identified 2,541 articles; 12 met our inclusion criteria. The articles were from the US (n = 7), UK (n = 4) and Canada (n = 1). Measured outcomes were HbA1c tests undertaken and/or the level achieved (n = 10), written action plans for asthma (n = 1) and hospital/emergency department visits (n = 1). Three of the studies were part of a larger incentive scheme including many conditions; one focused on asthma; eight focussed on diabetes. In asthma, the proportion receiving 'perfect care' (including providing a written action plan) increased from 4% to 88% in one study, and there were fewer hospitalisations/emergency department visits in another study. Across the diabetes studies, quality-of-care/GP performance scores improved in three, were unchanged in six and deteriorated in one. Conclusions Results for the impact of financial incentives for the implementation of self-management were mixed. The evidence in diabetes suggests no consistent impact on diabetic control. There was evidence from a single study of improved process and health outcomes in asthma. Further research is needed to confirm these findings and understand the process by which financial incentives may impact (or not) on care.	[Jackson, Tracy; Hui, Chi Yan; Pinnock, Hilary] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Edinburgh, Midlothian, Scotland; [Shields, Michael D.; Heaney, Liam G.] Queens Univ Belfast, Asthma UK Ctr Appl Res, Ctr Expt Med, Belfast, Antrim, North Ireland; [Kendall, Marilyn] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Pearce, Christina J.] UCL Sch Pharm, Ctr Behav Med, BMA House, London, England	University of Edinburgh; Queens University Belfast; University of Edinburgh; University of London; University College London; University of London School of Pharmacy	Shields, MD (corresponding author), Queens Univ Belfast, Asthma UK Ctr Appl Res, Ctr Expt Med, Belfast, Antrim, North Ireland.	rn.shields@qub.ac.uk	Pearce, Christina J/B-4745-2017	Pearce, Christina J/0000-0002-7393-191X; Jackson, Tracy/0000-0002-6188-3607	University of Edinburgh CMVM PhD Studentship [Asthma UK Centre for Applied Research] [PHD/14/16]; National Institute for Health Research [RP-DG-1213-10008] Funding Source: researchfish; Asthma UK [AUK-AC-2012-01] Funding Source: researchfish	University of Edinburgh CMVM PhD Studentship [Asthma UK Centre for Applied Research]; National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	TJ is funded by The University of Edinburgh CMVM PhD Studentship [Asthma UK Centre for Applied Research PHD/14/16]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams J, 2014, HEALTH PSYCHOL REV, V8, P286, DOI 10.1080/17437199.2013.848410; [Anonymous], 2014, GLOB ASTHM REP; Armour BS, 2001, ARCH INTERN MED, V161, P1261, DOI 10.1001/archinte.161.10.1261; Asthma UK, 2013, COMP YOUR CAR REP; Beck JK, 2004, PEDIATRICS, V113, pE47, DOI 10.1542/peds.113.1.e47; British Medical Association NHS Employers, 2016, 2016 17 GEN MED SERV; British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2014, BRIT GUID MAN ASTHM; Chien AT, 2012, PREV MED, V55, pS80, DOI 10.1016/j.ypmed.2012.05.004; Conrad DA, 2013, HEALTHCARE-J DEL SCI, V1, P108, DOI 10.1016/j.hjdsi.2013.04.012; Corrigan J. M., 2004, 1 ANN CROSSING QUALI; Coulter A, 2013, DELIVERING BETTER SE; Department of Health, 2016, PRIM MED SERV DIR EN; Diabetes UK, 2015, 42 PEOPL TYP 2 DIAB; Diabetes UK, 2016, DIAB FACTS STATS; Doran T, 2008, LANCET, V372, P728, DOI 10.1016/S0140-6736(08)61123-X; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Dudley RA, 1998, MILBANK Q, V76, P649, DOI 10.1111/1468-0009.00109; @ective Practice and Organisation of Care (EPOC), 2013, DAT EXTR MAN EPOC RE; Eijkenaar F, 2013, EUR J HEALTH ECON, V14, P117, DOI 10.1007/s10198-011-0347-6; Fagan PJ, 2010, HEALTH SERV RES, V45, P1763, DOI 10.1111/j.1475-6773.2010.01166.x; Flodgren G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009255; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; Glasziou PP, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5047; Gulliford MC, 2007, DIABETIC MED, V24, P505, DOI 10.1111/j.1464-5491.2007.02090.x; Health and Social Care Information Centre, 2017, 1 HLTH SOC CAR INF C; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Kontopantelis E, 2013, BMJ QUAL SAF, V22, P53, DOI 10.1136/bmjqs-2012-001033; LeBlanc E, 2017, CAN J DIABETES, V41, P190, DOI 10.1016/j.jcjd.2016.09.008; Mandel KE, 2007, ARCH PEDIAT ADOL MED, V161, P650, DOI 10.1001/archpedi.161.7.650; McDonald R., 2010, IMPACT INCENTIVES BE; Mukherjee M, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0657-8; Ogilvie D, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-8; Pape UJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119185; Pearce G, 2016, J HEALTH SERV RES PO, V21, P73, DOI 10.1177/1355819615602725; Peinemann F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085035; Pinnock H, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0823-7; Pinnock H, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6795; Pinnock H, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0361-0; Pinnock H, 2015, IMPLEMENT SCI, V10, DOI 10.1186/s13012-015-0235-z; Powell H, 2002, COCHRANE DATABASE SY; Roland M, 2006, PRIM HEALTH CARE RES, V7, P18, DOI DOI 10.1191/1463423606PC2720A; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Scott A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008451.pub2; Song F, 2013, OPEN ACCESS J CLIN T, V5, P71, DOI 10.2147/OAJCT.S34419; Taylor S, 2014, HLTH SERVICES DELIVE, V2; Vamos EP, 2011, CANADIAN MED ASS J; Woerle HJ, 2007, DIABETES RES CLIN PR, V77, P280, DOI 10.1016/j.diabres.2006.11.011; Young GJ, 2007, J GEN INTERN MED, V22, P872, DOI 10.1007/s11606-007-0185-5	48	11	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 6	2017	12	11							e0187478	10.1371/journal.pone.0187478	http://dx.doi.org/10.1371/journal.pone.0187478			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FL7JU	29107955	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000414424600033
J	Moon, SJ; Lee, WY; Hwang, JS; Hong, YP; Morisky, DE				Moon, Sun Jae; Lee, Weon-Young; Hwang, Jin Seub; Hong, Yeon Pyo; Morisky, Donald E.			Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8	PLOS ONE			English	Review							TYPE-2 DIABETES PATIENTS; PREDICTIVE-VALIDITY; NONADHERENCE; INTERVENTION; VALIDATION; QUADAS-2; VERSION	Background This systematic review examined the reliability and validity of the Morisky Medication Adherence Scale-8 (MMAS-8), which has been widely used to assess patient medication adherence in clinical research and medical practice. Methods Of 418 studies identified through searching 4 electronic databases, we finally analyzed 28 studies meeting the selection criteria of this study regarding the reliability and validity of MMAS-8 including sensitivity and specificity. Meta-analysis for Cronbach's alpha, intraclass correlation coefficient (ICC), sensitivity and specificity to detect a patient with nonadherence to medication were performed. The pooled estimates for Cronbach's a and ICC were calculated using the random-effects weighted T transformation. A bivariate random-effects model was used to estimate pooled sensitivity and specificity. Findings The pooled Cronbach's a estimate for type 2 diabetes group in 7 studies and osteoporosis group in 3 studies were 0.67 (95% Confidence Interval(CI), 0.65 to 0.69) and 0.77 (95% CI, 0.72 to 0.83), respectively. With regard to test-retest, the pooled ICC for type 2 diabetes group in 3 studies and osteoporosis group in 2 studies were 0.81 (95% CI, 0.75 to 0.85) and 0.80 (95% CI, 0.74 to 0.85). For a cut-off value of 6, the pooled sensitivity and specificity in 12 studies were 0.43 (95% CI, 0.33 to 0.53) and 0.73 (95% CI, 0.68 to 0.78), respectively. Conclusions The MMAS-8 had acceptable internal consistency and reproducibility in a few diseases like type 2 diabetes. Using the cut-off value of 6, criterion validity was not enough good to validly screen a patient with nonadherence to medication. However, this study did not calculated a pooled estimate for criterion validity using the higher values than 6 as a cut-off value since most of included individual studies did not report criterion validity based on those values.	[Moon, Sun Jae; Lee, Weon-Young; Hong, Yeon Pyo] Chung Ang Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Hwang, Jin Seub] Daegu Univ, Dept Comp Sci & Stat, Gyongsan, Gyeongsangbuk D, South Korea; [Morisky, Donald E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA	Chung Ang University; Chung Ang University Hospital; Daegu University; University of California System; University of California Los Angeles	Lee, WY (corresponding author), Chung Ang Univ, Coll Med, Dept Prevent Med, Seoul, South Korea.	wylee@cau.ac.kr	Morisky, Donald/AAU-4679-2021	Moon, Sun Jae/0000-0003-3786-6935				Alcoba M, 2003, JAIDS-J ACQ IMM DEF, V33, P253, DOI 10.1097/00126334-200306010-00022; AlGhurair SA, 2012, J CLIN HYPERTENS, V14, P877, DOI 10.1111/j.1751-7176.2012.00699.x; [Anonymous], 2013, ADV COMM PHARM PRACT; [Anonymous], 2013, PRIM CAR PHYS FEEL R, P20; Arora S, 2014, ANN EMERG MED, V63, P745, DOI 10.1016/j.annemergmed.2013.10.012; Ashur ST, 2015, E MEDITERR HEALTH J, V21, P722, DOI 10.26719/2015.21.10.722; Berry DL, 2015, PATIENT PREFER ADHER, V9, P1587, DOI 10.2147/PPA.S91534; Bramlage P, 2014, CLIN DRUG INVEST, V34, P403, DOI 10.1007/s40261-014-0188-z; Brown MT, 2011, MAYO CLIN PROC, V86, P304, DOI 10.4065/mcp.2010.0575; Chan HK, 2014, INT J CLIN PHARM-NET, V36, P904, DOI 10.1007/s11096-014-0003-1; Cohen Robin A, 2013, NCHS Data Brief, P1; Crutzen R, 2017, HEALTH PSYCHOL REV, V11, P242, DOI 10.1080/17437199.2015.1124240; Cummings DM, 2014, ANN PHARMACOTHER, V48, P970, DOI 10.1177/1060028014536532; DiBonaventura M, 2014, PATIENT PREFER ADHER, V8, P873, DOI 10.2147/PPA.S55550; Garfield S, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-149; Goodhand JR, 2013, ALIMENT PHARM THER, V38, P1097, DOI 10.1111/apt.12476; Granger BB, 2015, AM HEART J, V169, P539, DOI 10.1016/j.ahj.2015.01.006; Guo XH, 2014, J DIABETES, V6, P290, DOI 10.1111/1753-0407.12100; Jones CM, 2005, ANN THORAC SURG, V79, P16, DOI 10.1016/j.athoracsur.2004.09.040; Kamran A, 2014, ANN MED HEALTH SCI R, V4, P922, DOI 10.4103/2141-9248.144914; Kassab Y, 2013, INT J CLIN PHARM-NET, V35, P275, DOI 10.1007/s11096-012-9735-y; Katalenich B, 2015, CLIN THER, V37, P1216, DOI 10.1016/j.clinthera.2015.03.022; MACASKILL P, 2010, ANAL PRESENTING RESU; Marcum ZA, 2013, JAMA-J AM MED ASSOC, V309, P2105, DOI 10.1001/jama.2013.4638; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Park LG, 2014, PATIENT EDUC COUNS, V94, P261, DOI 10.1016/j.pec.2013.10.027; Parthan Anju, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P325, DOI 10.1586/14737167.6.3.325; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; Rodriguez MC, 2006, PSYCHOL METHODS, V11, P306, DOI 10.1037/1082-989X.11.3.306; Schueler S, 2012, ANN INTERN MED, V156, P323, DOI 10.7326/0003-4819-156-4-201202210-00018; Sijtsma K, 2009, PSYCHOMETRIKA, V74, P107, DOI 10.1007/s11336-008-9101-0; Tabasi HK, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/s40200-014-0113-2; Tandon S, 2015, DIABETES RES CLIN PR, V110, P129, DOI 10.1016/j.diabres.2015.10.001; Tepie MF, 2013, VALUE HEALTH, V16, pA568; Trikalinos TA, 2012, METHODS GUIDE MED TE; Vinluan CM, 2015, J PHARM HEALTH SERV, V6, P103, DOI 10.1111/jphs.12093; Viswanathan Meera, 2012, Evid Rep Technol Assess (Full Rep), P1; Wagner JH, 2001, J CLIN EPIDEMIOL, V54, pS91, DOI 10.1016/S0895-4356(01)00450-4; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009	42	46	50	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2017	12	11							e0187139	10.1371/journal.pone.0187139	http://dx.doi.org/10.1371/journal.pone.0187139			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FL6FI	29095870	Green Published, gold			2023-01-03	WOS:000414340200049
J	Good, MM; Montoya, TI; Shi, HL; Zhou, J; Huang, YH; Tang, LP; Acevedo, JF; Word, RA				Good, Meadow M.; Montoya, T. Ignacio; Shi, Haolin; Zhou, Jun; Huang, YiHui; Tang, Liping; Acevedo, Jesus F.; Word, R. Ann			Thermosensitive hydrogels deliver bioactive protein to the vaginal wall	PLOS ONE			English	Article							PELVIC ORGAN PROLAPSE; DRUG-DELIVERY; URINARY-INCONTINENCE; EXTRACELLULAR-MATRIX; IN-VIVO; FIBULIN-5; TISSUE; RELEASE; MICE; NANOPARTICLES	The pathophysiology and natural history of pelvic organ prolapse (POP) are poorly understood. Consequently, our approaches to treatment of POP are limited. Alterations in the extracellular matrix components of pelvic support ligaments and vaginal tissue, including collagen and elastin, have been associated with the development of POP in animals and women. Prior studies have shown the protease MMP-9, a key player of ECM degradation, is upregulated in vaginal tissues from both mice and women with POP. On the other hand, fibulin-5, an elastogenic organizer, has been found to inhibit MMP-9 in the vaginal wall. Hence, we hypothesized that prolonged release of fibulin-5 may delay progression of POP. To test the hypothesis, oligo (ethylene glycol)-based thermosensitive hydrogels were fabricated, characterized and then used to deliver fibulin-5 to the vaginal wall and inhibit MMP-9 activity. The results indicate that hydrogels are cell and tissue compatible. The hydrogels also prolong the 1/2 life of fibulin-5 in cultured vaginal fibroblasts and in the vaginal wall in vivo. Finally, fibulin-5-containing hydrogels resulted in incorporation of fibulin-5 into the vaginal matrix and inhibition of MMP-9 for several weeks after injection. These results support the idea of fibulin-5 releasing hydrogel being developed as a new treatment for POP.	[Good, Meadow M.; Montoya, T. Ignacio; Shi, Haolin; Acevedo, Jesus F.; Word, R. Ann] Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Div Female Pelv Med & Reconstruct Surg, Dallas, TX 75390 USA; [Zhou, Jun; Huang, YiHui; Tang, Liping] Univ Texas Arlington, Dept Bioengn, Arlington, TX 76019 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington	Word, RA (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Obstet & Gynecol, Div Female Pelv Med & Reconstruct Surg, Dallas, TX 75390 USA.; Tang, LP (corresponding author), Univ Texas Arlington, Dept Bioengn, Arlington, TX 76019 USA.	ltang@uta.edu; Ruth.word@UTSouthwestern.edu	Huang, Yihui/Q-2909-2019	Huang, Yihui/0000-0001-6994-8180	NIH [AG028048]; NATIONAL INSTITUTE ON AGING [R01AG028048] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH AG028048. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by a grant from NIH (AG028048).	Ankareddi I, 2008, BIRTH DEFECTS RES B, V83, P112, DOI 10.1002/bdrb.20150; Bae YH, 1998, J CONTROL RELEASE, V53, P249, DOI 10.1016/S0168-3659(97)00258-7; Bekerecioglu M, 2008, ARCH GYNECOL OBSTET, V277, P551, DOI 10.1007/s00404-007-0403-8; Bromberg LE, 1998, ADV DRUG DELIVER REV, V31, P197, DOI 10.1016/S0169-409X(97)00121-X; Budatha M, 2011, J CLIN INVEST, V121, P2048, DOI 10.1172/JCI45636; Cai T, 2012, NANOMED-NANOTECHNOL, V8, P1301, DOI 10.1016/j.nano.2012.02.002; Choi B., 2015, IN SITU GELLING POLY, P5; Clark AL, 2003, AM J OBSTET GYNECOL, V189, P1261, DOI 10.1067/S0002-9378(03)00829-9; Drewes PG, 2007, AM J PATHOL, V170, P578, DOI 10.2353/ajpath.2007.060662; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1; Gyhagen M, 2013, BJOG-INT J OBSTET GY, V120, P152, DOI 10.1111/1471-0528.12020; Han CK, 1998, POLYMER, V39, P2809, DOI 10.1016/S0032-3861(97)00612-5; Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168-3659(01)00248-6; Jelovsek JE, 2007, LANCET, V369, P1027, DOI 10.1016/S0140-6736(07)60462-0; Lutz JF, 2006, J AM CHEM SOC, V128, P13046, DOI 10.1021/ja065324n; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Moalli PA, 2005, OBSTET GYNECOL, V106, P953, DOI 10.1097/01.AOG.0000182584.15087.dd; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Northington GM, 2011, J CLIN INVEST, V121, P1688, DOI 10.1172/JCI57438; Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6; PEPPAS NA, 1994, SCIENCE, V263, P1715, DOI 10.1126/science.8134835; Phillips CH, 2006, BJOG-INT J OBSTET GY, V113, P39, DOI 10.1111/j.1471-0528.2005.00773.x; Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153; Shu XZ, 2004, BIOMATERIALS, V25, P1339, DOI 10.1016/j.biomaterials.2003.08.014; Stile RA, 2002, BIOMACROMOLECULES, V3, P591, DOI 10.1021/bm0101466; Tehrani SM, 2016, MACROMOLECULES, V49, P8711, DOI 10.1021/acs.macromol.6b01270; Vihola H, 2005, BIOMATERIALS, V26, P3055, DOI 10.1016/j.biomaterials.2004.09.008; Weng H, 2004, J BIOMAT SCI-POLYM E, V15, P1167, DOI 10.1163/1568562041753106; Word RA, 2009, OBSTET GYN CLIN N AM, V36, P521, DOI 10.1016/j.ogc.2009.09.001; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; Yang JA, 2014, PROG POLYM SCI, V39, P1973, DOI 10.1016/j.progpolymsci.2014.07.006; Yang J, 2013, CARBOHYD POLYM, V92, P719, DOI 10.1016/j.carbpol.2012.09.036; Zheng Q, 2007, MOL CELL BIOL, V27, P1083, DOI 10.1128/MCB.01330-06; Zhou J, 2011, BIOMATERIALS, V32, P9383, DOI 10.1016/j.biomaterials.2011.08.064	35	9	10	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2017	12	10							e0186268	10.1371/journal.pone.0186268	http://dx.doi.org/10.1371/journal.pone.0186268			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FK9QH	29073153	gold, Green Published, Green Submitted			2023-01-03	WOS:000413845400019
J	Gentile, A; Lucion, MF; Juarez, MD; Martinez, AC; Romanin, V; Bakir, J; Viegas, M; Mistchenko, A				Gentile, Angela; Florencia Lucion, Maria; del Valle Juarez, Maria; Clara Martinez, Ana; Romanin, Viviana; Bakir, Julia; Viegas, Mariana; Mistchenko, Alicia			Influenza virus: 16 years' experience of clinical epidemiologic patterns and associated infection factors in hospitalized children in Argentina	PLOS ONE			English	Article							SEASONALITY; OUTPATIENT; BRAZIL	Background Influenza is an important cause of acute lower respiratory tract infection (aLRTI), hospitalization, and mortality in children. This study aimed to describe the clinical and epidemiologic patterns and infection factors associated with influenza, and compare case features of influenza A and B. Methods In a prospective, cross-sectional study, patients admitted for aLRTI, between 2000 and 2015, were tested for respiratory syncytial virus, adenovirus, influenza, or parainfluenza, and confirmed by fluorescent antibody (FA) or real-time polymerase chain reaction (RT-PCR) assay of nasopharyngeal aspirates. Results Of 14,044 patients, 37.7% (5290) had FA-or RT-PCR-confirmed samples that identified influenza in 2.8% (394/14,044; 91.4% [360] influenza A, 8.6% [34] influenza B) of cases. Influenza frequency followed a seasonal epidemic pattern (May-July, the lowest average temperature months). The median age of cases was 12 months (interquartile range: 6-21 months); 56.1% (221/394) of cases were male. Consolidated pneumonia was the most frequent clinical presentation (56.9%; 224/394). Roughly half (49.7%; 196/394) of all cases had previous respiratory admissions; 9.4% (37/394) were re-admissions; 61.5% (241/392) had comorbidities; 26.2% (102/389) had complications; 7.8% (30/384) had nosocomial infections. The average case fatality rate was 2.1% (8/389). Chronic neurologic disease was significantly higher in influenza B cases compared to influenza A cases (p = 0.030). The independent predictors for influenza were: age >= 6 months, odds ratio (OR): 1.88 (95% confidence interval [CI]: 1.44-2.45); p< 0.001; presence of chronic neurologic disease, OR: 1.48 (95% CI: 1.01-2.17); p = 0.041; previous respiratory admissions, OR: 1.71 (95% CI: 1.36-2.14); p<0.001; re-admissions, OR: 1.71 (95% CI: 1.17-2.51); p = 0.006; clinical pneumonia, OR: 1.50 (95% CI: 1.21-1.87); p<0.001; immunodeficiency, OR: 1.87 (95% CI: 1.15-3.05); p = 0.011; cystic fibrosis, OR: 4.42 (95% CI: 1.29-15.14); p = 0.018. Conclusion Influenza showed an epidemic seasonal pattern (May-July), with higher risk in children >= 6 months, or with pneumonia, previous respiratory admissions, or certain comorbidities.	[Gentile, Angela; Florencia Lucion, Maria; del Valle Juarez, Maria; Clara Martinez, Ana; Romanin, Viviana; Bakir, Julia] Ricardo Gutierrez Childrens Hosp, Dept Epidemiol, Buenos Aires, DF, Argentina; [Viegas, Mariana; Mistchenko, Alicia] Ricardo Gutierrez Childrens Hosp, Dept Virol, Buenos Aires, DF, Argentina	Hospital de Ninos Doctor Ricardo Gutierrez; University of Buenos Aires; Hospital de Ninos Doctor Ricardo Gutierrez; University of Buenos Aires	Gentile, A (corresponding author), Ricardo Gutierrez Childrens Hosp, Dept Epidemiol, Buenos Aires, DF, Argentina.	angelagentile21@gmail.com		Gentile, Angela/0000-0002-1072-7700				Alonso WJ, 2007, AM J EPIDEMIOL, V165, P1434, DOI 10.1093/aje/kwm012; Comite Nacional de Neumonologoia Comite Nacional de Infectologoia Comite de Medicina Interna, REC MAN INF RESP AG; Daley AJ, 2000, J PAEDIATR CHILD H, V36, P332, DOI 10.1046/j.1440-1754.2000.00533.x; Dapat C, 2009, INTERVIROLOGY, V52, P310, DOI 10.1159/000237738; De Kirchner CEF, ABORDAJE INTERGAL IN; Arango AE, 2015, INFLUENZA OTHER RESP, V9, P1, DOI 10.1111/irv.12271; Finkelman BS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001296; Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137; Huai Y, 2017, INFLUENZA OTHER RESP, V11, P148, DOI 10.1111/irv.12419; Lucion MF, 2014, ARCH ARGENT PEDIATR, V112, P397, DOI [10.5546/aap.2014.397, 10.5546/aap.2014.eng.397]; Marcone DN, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1213-4; McMorrow ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138272; Mosnier A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136186; Moura FEA, 2009, AM J TROP MED HYG, V81, P180, DOI 10.4269/ajtmh.2009.81.180; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369; Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036; Tamerius J, 2011, ENVIRON HEALTH PERSP, V119, P439, DOI 10.1289/ehp.1002383	18	5	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2018	13	3							e0195135	10.1371/journal.pone.0195135	http://dx.doi.org/10.1371/journal.pone.0195135			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA8ZI	29596527	Green Published, gold, Green Submitted			2023-01-03	WOS:000428630000082
J	Ganfure, G; Ameya, G; Tamirat, A; Lencha, B; Bikila, D				Ganfure, Gemechu; Ameya, Gemechu; Tamirat, Ababe; Lencha, Bikila; Bikila, Dereje			First aid knowledge, attitude, practice, and associated factors among kindergarten teachers of Lideta sub-city Addis Ababa, Ethiopia	PLOS ONE			English	Article							PRIMARY-SCHOOL TEACHERS; UNINTENTIONAL INJURIES; CHILDREN; EPILEPSY; SAMPLE; HEALTH	Background Injuries are very common and can occur at any point of time in a day. Unintended injuries in kindergarten children are the most common and need immediate life saving care which is known as first aid. This study aimed to investigate knowledge, attitude, practice, and associated factors of first aid among kindergarten teachers of Lideta sub-city Addis Ababa, Ethiopia. Method A cross-sectional study was conducted among kindergarten teachers. Data was collected using pretested, structured and self-administered questionnaire S1 File. The collected data was entered in to Epi Data version 3.1 software and analyzed using SPSS version 20. Logistic regression analysis was used to identify association between kindergarten teachers' knowledge and attitudes towards first aid and different variables. Odds ratios with 95% CI and p<0.05 were computed to determine the presence of the association. Result One hundred and ninety-four teachers participated in the study with a response rate of 95%. Only 40% of the teachers were knowledgeable and 75% of them had positive attitude for first aid. Eighty percent of teachers encountered with children in need of first aid. Kindergarten teachers older than 35 years [AOR = 4.2, 95%Cl: (1.02, 16.9)], five years' experience [AOR = 3.1, 95%Cl: (1.2, 7.6)], having previous first aid training [AOR = 3.1, 95%Cl: (1.2, 7.7)], source of first aid information and teachers serving in private kindergarten are associated with having knowledge of first aid. Long time experience, type of kindergarten, previous training, and exposure to children in need of first aid were positive association with attitude towards first aid. Conclusion Low first aid knowledge and high positive attitude among kindergarten teachers. Having long time experience, being older age, previous first aid training, and serving in private kindergarten were positively associated with first aid knowledge and positive attitude. Creating awareness and including first aid courses in the kindergarten teachers' curriculum need to be considered.	[Ganfure, Gemechu] Madda Walabu Univ, Goba Referral Hosp, Dept Midwifery, Goba, Ethiopia; [Ameya, Gemechu] Arba Minch Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, Arba Minch, Ethiopia; [Tamirat, Ababe] Hawassa Univ, Coll Med & Hlth Sci, Dept Nursing, Hawassa, Ethiopia; [Lencha, Bikila] Madda Walabu Univ, Goba Referral Hosp, Dept Publ Hlth, Goba, Ethiopia; [Bikila, Dereje] Arsi Univ, Coll Med & Hlth Sci, Dept Nursing, Asella, Ethiopia	Arba Minch University; Hawassa University	Ameya, G (corresponding author), Arba Minch Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, Arba Minch, Ethiopia.	gemechuameya@gmail.com		Ameya, Gemechu/0000-0002-2408-3045	Madda Walabu University	Madda Walabu University	The authors thank Madda Walabu University for its unreserved support, follow-up, and sponsorship for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdella NHA., 2015, AM J RES COMMUN, V3, P178; Ablewhite J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1547-2; Abulhamail AS, 2014, SEIZURE-EUR J EPILEP, V23, P280, DOI 10.1016/j.seizure.2013.12.010; Al-Samghan AS, 2015, MED J CAIRO U, V83, P541; American Academy of Pediatrics, 2007, PED 1 AID CAR TEACH, V1st ed; Baser M, 2007, J EMERG NURS, V33, P428, DOI 10.1016/j.jen.2006.11.003; Black C., 1997, 1 AID INT FEDERATION; Bruce B, 2005, INJURY PREV, V11, P143, DOI 10.1136/ip.2004.007971; Chirongoma F, 2017, MALAWI MED J, V29, P151, DOI 10.4314/mmj.v29i2.14; CSA ICF, 2016, ETH DEM HLTH SURV; Eze CN, 2015, SEIZURE-EUR J EPILEP, V33, P46, DOI 10.1016/j.seizure.2015.10.014; Gagliardi M, 1994, Prehosp Disaster Med, V9, P222; Guptha LC, 2002, MANUAL OF 1 AID, P147; Health and safety team, 2011, GUID HEAD TEACH MAN; Khanom A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-806; Kumar D. S., 2013, National Journal of Community Medicine, V4, P349; Lam NN., 2017, BURNS OPEN, V1, P29, DOI DOI 10.1016/j.burnso.2017.04.001; Li F, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-121; Michaels D., 2011, OSHA FIELD SAFETY HL, P117; Muneeswari B., 2014, GLOBAL J MED PUBLIC, V3, P2277; Olympia RP, 2010, PEDIATR EMERG CARE, V26, P239, DOI 10.1097/PEC.0b013e3181d6d9c8; Polit DF, 2006, RES NURS HEALTH, V29, P489, DOI 10.1002/nur.20147; Priyangika KGG, 2015, JETERAPS, V6, P404; Santagati G, 2016, J PEDIATR-US, V177, P267, DOI 10.1016/j.jpeds.2016.06.083; Setien MA, 2014, J COMMUN HEALTH, V39, P167, DOI 10.1007/s10900-013-9755-0; Sonmez Y, 2014, TURK PEDIATR ARSIVI, V49, P238, DOI 10.5152/tpa.2014.1581; Waibel R, 2003, J SCHOOL HEALTH, V73, P167, DOI 10.1111/j.1746-1561.2003.tb03597.x; Yang Gong-huan, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P193; Zhou WeiGuo, 2008, Journal of Environmental & Occupational Medicine, V25, P586	29	22	22	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2018	13	3							e0194263	10.1371/journal.pone.0194263	http://dx.doi.org/10.1371/journal.pone.0194263			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ0JA	29534091	Green Published, Green Submitted, gold			2023-01-03	WOS:000427253500039
J	da Silva, FC; Iop, RD; de Oliveira, LC; Boll, AM; de Alvarenga, JGS; Gutierres, PJ; de Melo, LMAB; Xavier, A; da Silva, R				da Silva, Franciele Cascaes; Iop, Rodrigo da Rosa; de Oliveira, Laiana Candido; Boll, Alice Mathea; Souza de Alvarenga, Jose Gustavo; Barbosa Gutierres Filho, Paulo Jose; Aguiar Bezerra de Melo, Lidia Mara; Xavier, Andre Junqueira; da Silva, Rudney			Effects of physical exercise programs on cognitive function in Parkinson's disease patients: A systematic review of randomized controlled trials of the last 10 years	PLOS ONE			English	Review							MINI-MENTAL-STATE; NONMOTOR SYMPTOMS; AEROBIC EXERCISE; EXECUTIVE FUNCTION; ARGENTINE TANGO; SCREENING TOOL; OLDER-ADULTS; DEMENTIA; IMPAIRMENT; MOTOR	Background Given the relative importance of cognitive impairment, there was considerable interest in identifying the cognitive profile of PD patients, in order to ensure specific and appropriate therapeutic interventions. Purpose To determine the effects of physical exercise programs on cognitive function in PD patients, compared with the control group. Data sources Medline, Cochrane, Scopus, PEDro and Web of Science (last searched in September 2016). Study selection Randomized clinical trials examining the effects of physical exercise programs and cognitive function in PD patients. Nine studies fulfilled the selection criteria and were included in this review. Data extraction Characteristics of the publication, characteristics of the participants, test used for cognitive screening, cognitive domain assessed, tools used to assess cognitive function, characteristics of the experimental intervention, characteristics of the control group, mean results and standard deviation of function cognitive. The PEDro score was used to evaluate methodological quality. Data synthesis Most eligible studies showed good methodological quality based on the PEDro scale. Studies have shown that adapted tango for PD patients, cognitive training combined with motor training, and treadmill training promote the preservation or improvement of cognitive function in PD patients. Limitations The diversity of cognitive tests used to assess cognitive function and the high heterogeneity identified between the physical exercise programs. Conclusions Physical exercise programs promote positive and significant effects on global cognitive function, processing speed, sustained attention and mental flexibility in PD patients, at a mild to moderate stage for patients with a 6-year clinical diagnosis of PD. However, treadmill training performed 3 times a week for about 60 minutes and for a period of 24 weeks produced larger improvements in cognition.	[da Silva, Franciele Cascaes; Iop, Rodrigo da Rosa; de Oliveira, Laiana Candido; Boll, Alice Mathea; da Silva, Rudney] Univ Estado Santa Catarina, Ctr Hlth Sci & Sports, Adapted Phys Act Lab, Florianopolis, SC, Brazil; [Souza de Alvarenga, Jose Gustavo; Barbosa Gutierres Filho, Paulo Jose; Aguiar Bezerra de Melo, Lidia Mara] Univ Brasilia, Fac Phys Educ, Brasilia, DF, Brazil; [Xavier, Andre Junqueira] Univ Southern Santa Catarina, Med Course, Florianopolis, SC, Brazil	Universidade do Estado de Santa Catarina; Universidade de Brasilia; Universidade do Sul de Santa Catarina	da Silva, FC (corresponding author), Univ Estado Santa Catarina, Ctr Hlth Sci & Sports, Adapted Phys Act Lab, Florianopolis, SC, Brazil.	francascaes@yahoo.com.br	Silva, Rudney/C-3189-2017; Filho, Paulo Gutierres/ABG-4019-2021	Silva, Rudney/0000-0002-9386-0039; Filho, Paulo Gutierres/0000-0001-7753-0825; Silva, Franciele Cascaes/0000-0002-4444-9403				Aarsland D, 2005, MOVEMENT DISORD, V20, P1255, DOI 10.1002/mds.20527; Aarsland D, 2001, NEUROLOGY, V56, P730, DOI 10.1212/WNL.56.6.730; Aarsland D, 2017, NAT REV NEUROL; Aarsland D, 2016, PARKINSONISM RELAT D, V22, pS144, DOI 10.1016/j.parkreldis.2015.09.034; Barbosa ER, 2013, ARQ NEURO-PSIQUIAT, V71, P203, DOI 10.1590/0004-282X20130001; Biundo R, 2014, PARKINSONISM RELAT D, V20, P394, DOI 10.1016/j.parkreldis.2014.01.009; Broeders M, 2013, J INT NEUROPSYCH SOC, V19, P695, DOI 10.1017/S1355617713000295; Caballol N, 2007, MOVEMENT DISORD, V22, pS358, DOI 10.1002/mds.21677; Campanholo Kenia Repiso, 2014, Dement. neuropsychol., V8, P26, DOI 10.1590/S1980-57642014DN81000005; Carod-Artal FJ, 2007, MOVEMENT DISORD, V22, P91, DOI 10.1002/mds.21216; Chaudhuri KR, 2009, LANCET NEUROL, V8, P464, DOI 10.1016/S1474-4422(09)70068-7; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; Cruise KE, 2011, ACTA NEUROL SCAND, V123, P13, DOI 10.1111/j.1600-0404.2010.01338.x; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Cusso ME, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00035; de Lau LML, 2005, ARCH NEUROL-CHICAGO, V62, P1265, DOI 10.1001/archneur.62.8.1265; Dubbelink KTEO, 2014, NEUROLOGY, V82, P263, DOI 10.1212/WNL.0000000000000034; Dubois B, 2007, MOVEMENT DISORD, V22, P2314, DOI 10.1002/mds.21844; Duchesne C, 2015, BRAIN COGNITION, V99, P68, DOI 10.1016/j.bandc.2015.07.005; Duncan RP, 2012, NEUROREHAB NEURAL RE, V26, P132, DOI 10.1177/1545968311421614; Ekker MS, 2016, PARKINSONISM RELAT D, V22, pS73, DOI 10.1016/j.parkreldis.2015.08.031; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Foster ER, 2013, ARCH PHYS MED REHAB, V94, P240, DOI 10.1016/j.apmr.2012.07.028; Gallagher DA, 2010, MOVEMENT DISORD, V25, P2493, DOI 10.1002/mds.23394; Gill DJ, 2008, MOVEMENT DISORD, V23, P1043, DOI 10.1002/mds.22017; GOTHAM AM, 1988, BRAIN, V111, P299, DOI 10.1093/brain/111.2.299; Hackney ME, 2009, J REHABIL MED, V41, P475, DOI 10.2340/16501977-0362; Hamdan Amer C., 2009, Psychol. Neurosci., V2, P199, DOI 10.3922/j.psns.2009.2.012; Hanagasi HA, 2017, J NEUROL SCI, V374, P26, DOI 10.1016/j.jns.2017.01.012; Hashimoto H, 2015, COMPLEMENT THER MED, V23, P210, DOI 10.1016/j.ctim.2015.01.010; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Hindle JV, 2013, MOVEMENT DISORD, V28, P1034, DOI 10.1002/mds.25377; Hobson P, 2004, MOVEMENT DISORD, V19, P1043, DOI 10.1002/mds.20216; Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47; Kalron A, 2015, NEUROREHABILITATION, V37, P273, DOI 10.3233/NRE-151260; Kattenstroth JC, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00005; Kulisevsky J, 2009, MOVEMENT DISORD, V24, P1103, DOI 10.1002/mds.22506; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lee A, 2016, NEUROL CLIN, V34, P955, DOI 10.1016/j.ncl.2016.06.012; Lischka AR, 2012, CAN J AGING, V31, P295, DOI 10.1017/S0714980812000220; Litvan I, 2012, MOVEMENT DISORD, V27, P349, DOI 10.1002/mds.24893; Litvan I, 2011, MOVEMENT DISORD, V26, P1814, DOI 10.1002/mds.23823; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Mahieux F, 1998, J NEUROL NEUROSUR PS, V64, P178, DOI 10.1136/jnnp.64.2.178; McKee KE, 2013, J MOTOR BEHAV, V45, P519, DOI 10.1080/00222895.2013.834288; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; McKinlay A, 2010, J INT NEUROPSYCH SOC, V16, P268, DOI 10.1017/S1355617709991299; McNeely ME, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00239; Meireles Joana, 2012, Front Neurol, V3, P88, DOI 10.3389/fneur.2012.00088; Melo LM, 2007, REV PSIQ CLIN, V34, P176; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Murray DK, 2014, TRANSL NEURODEGENER, V3, DOI 10.1186/2047-9158-3-5; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Muslimovic D, 2009, J INT NEUROPSYCH SOC, V15, P426, DOI 10.1017/S1355617709090614; Nadeau A, 2014, MED SCI SPORT EXER, V46, P645, DOI 10.1249/MSS.0000000000000144; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nocera Joe R, 2013, J Yoga Phys Ther, V3, DOI 10.4172/2157-7595.1000137; Nocera JR, 2010, NEUROCASE, V16, P301, DOI 10.1080/13554790903559663; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; Pedersen KF, 2013, JAMA NEUROL, V70, P580, DOI 10.1001/jamaneurol.2013.2110; Petzinger GM, 2013, LANCET NEUROL, V12, P716, DOI 10.1016/S1474-4422(13)70123-6; Picelli A, 2016, FUNCT NEUROL, V31, P25; Pompeu JE, 2012, PHYSIOTHERAPY, V98, P196, DOI 10.1016/j.physio.2012.06.004; Paris AP, 2011, MOVEMENT DISORD, V26, P1251, DOI 10.1002/mds.23688; Reynolds GO, 2016, MOVEMENT DISORD, V31, P23, DOI 10.1002/mds.26484; Riedel O, 2008, J NEUROL, V255, P255, DOI 10.1007/s00415-008-0720-2; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; Romann Aline Juliane, 2012, Dement. neuropsychol., V6, P2, DOI 10.1590/S1980-57642012DN06010002; Romenets SR, 2015, COMPLEMENT THER MED, V23, P175, DOI 10.1016/j.ctim.2015.01.015; Schneider JS, 2010, PARKINSONISM RELAT D, V16, P507, DOI 10.1016/j.parkreldis.2010.06.001; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Souza RG, 2007, ARQ NEURO-PSIQUIAT, V65, P787, DOI 10.1590/S0004-282X2007000500010; Svenningsson P, 2012, LANCET NEUROL, V11, P697, DOI 10.1016/S1474-4422(12)70152-7; Tabak R, 2013, J NEUROL PHYS THER, V37, P58, DOI 10.1097/NPT.0b013e31829219bc; Tanaka K, 2009, BRAIN COGNITION, V69, P435, DOI 10.1016/j.bandc.2008.09.008; Tang YL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152716; Van Uem JMT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151997; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Wind AW, 1997, INT J GERIATR PSYCH, V12, P101, DOI 10.1002/(SICI)1099-1166(199701)12:1<101::AID-GPS469>3.0.CO;2-R; Yarnall AJ, 2014, NEUROLOGY, V82, P308, DOI 10.1212/WNL.0000000000000066; Zadikoff C, 2008, MOVEMENT DISORD, V23, P297, DOI 10.1002/mds.21837	82	75	76	4	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2018	13	2							e0193113	10.1371/journal.pone.0193113	http://dx.doi.org/10.1371/journal.pone.0193113			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FX7BV	29486000	gold, Green Submitted, Green Published			2023-01-03	WOS:000426242400014
J	Etinger, A; Kumar; Ackley, W; Soiefer, L; Chun, J; Singh, P; Grossman, E; Matalon, A; Holzman, RS; Meijers, B; Lowenstein, J				Etinger, Aleksey; Kumar; Ackley, William; Soiefer, Leland; Chun, Jonathan; Singh, Prabjhot; Grossman, Eric; Matalon, Albert; Holzman, Robert S.; Meijers, Bjorn; Lowenstein, Jerome			The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes	PLOS ONE			English	Article							P-CRESYL SULFATE; RESIDUAL RENAL-FUNCTION; INDOXYL SULFATE; PROTEIN-BINDING; CLEARANCE; MORTALITY; DIALYSIS; TOXINS	Background There is growing evidence that the accumulation of protein-bound uremic retention solutes, such as indoxyl sulfate, p-cresyl sulfate and kynurenic acid, play a role in the accelerated cardiovascular disease seen in patients undergoing chronic hemodialysis. Protein-binding, presumably to albumin, renders these solutes poor-dialyzable. We previously observed that the free fraction of indoxyl sulfate was markedly reduced at the end of hemodialysis. We hypothesized that solute binding might be pH-dependent and attributed the changes in free solute concentration to the higher serum pH observed at the end of standard hemodialysis with dialysis buffer bicarbonate concentration greater than 35 mmol/L. We observed that acidification of uremic plasma to pH 6 in vitro greatly increased the proportion of freeIS. Methods We tested our hypothesis by reducing the dialysate bicarbonate buffer concentration to 25 mmol/L for the initial half of the hemodialysis treatment ("isohydric dialysis"). Eight stable hemodialysis patients underwent" isohydric dialysis" for 90 minutes and then were switched to standard buffer (bicarbonate = 37mmol/L). A second dialysis, 2 days later, employed standard buffer throughout. Results We found a clearcut separation of blood pH and bicarbonate concentrations after 90 minutes of "isohydric dialysis" (pH = 7.37, bicarbonate = 22.4 mmol/L) and standard dialysis (pH = 7.49, bicarbonate = 29.0 mmol/L). Binding affinity varied widely among the 10 uremic retention solutes analyzed. Kynurenic acid (0.05 free), p-cresyl sulfate (0.12 free) and indoxyl sulfate (0.13 free) demonstrated the greatest degree of binding. Three solutes (indoxyl glucuronide, p-cresyl glucuronide, and phenyl glucuronide) were virtually unbound. Analysis of free and bound concentrations of uremic retention solutes confirmed our prediction that binding of solute is affected by pH. However, in a mixed models analysis, we found that the reduction in total uremic solute concentration during dialysis accounted for a greater proportion of the variation in free concentration, presumably an effect of saturation binding to albumin, than did the relatively small change in pH produced by isohydric dialysis. The effect of pH on binding appeared to be restricted to those solutes most highly protein-bound. The solutes most tightly bound exhibited the lowest dialyzer clearances. An increase in dialyzer clearance during isohydric and standard dialyses was statistically significant only for kynurenic acid. Conclusion These findings provide evidence that the binding of uremic retention solutes is influenced by pH. The effect of reducing buffer bicarbonate concentration ("isohydric dialysis:"), though significant, was small but may be taken to suggest that further modification of dialysis technique that would expose blood to a greater decrease in pH would lead to a greater increase the free fraction of solute and enhance the efficacy of hemodialysis in the removal of highly protein-bound uremic retention solutes.	[Etinger, Aleksey; Kumar; Ackley, William; Soiefer, Leland; Chun, Jonathan; Singh, Prabjhot; Grossman, Eric; Matalon, Albert; Holzman, Robert S.; Lowenstein, Jerome] NYU, Sch Med, New York, NY 10003 USA; [Meijers, Bjorn] Univ Hosp Leuven, Dept Nephrol, Leuven, Belgium; [Meijers, Bjorn] Dept Immunol & Microbiol, Leuven, Belgium	New York University; KU Leuven; University Hospital Leuven	Lowenstein, J (corresponding author), NYU, Sch Med, New York, NY 10003 USA.	jerome.lowenstein@nyumc.org		Lowenstein, Jerome/0000-0002-2090-2015; Chun, Jonathan/0000-0002-0720-7173; , aleksey/0000-0002-2427-5186	Nephrology Division of NYU Langone Medical Center	Nephrology Division of NYU Langone Medical Center	Supported by discretionary funds in Nephrology Division of NYU Langone Medical Center	Bargman JM, 2001, J AM SOC NEPHROL, V12, P2158, DOI 10.1681/ASN.V12102158; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bohringer F, 2015, ASAIO J, V61, P55, DOI 10.1097/MAT.0000000000000166; Chun J, 2015, CHANGES PH HEMODIALY; de Loor H, 2016, ANAL CHIM ACTA, V936, P149, DOI 10.1016/j.aca.2016.06.057; Eloot S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076838; Evenepoel P, 2017, KIDNEY INT, V92, P1323, DOI 10.1016/j.kint.2017.06.029; Jhawar S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118703; Kochansky CJ, 2008, MOL PHARM, V5, P438, DOI 10.1021/mp800004s; Krieter DH, 2017, ACTA PHYSIOL, V219, P510, DOI 10.1111/apha.12730; Lenth RV, 2016, J STAT SOFTW, V69, P1, DOI 10.18637/jss.v069.i01; Liabeuf S, 2010, NEPHROL DIAL TRANSPL, V25, P1183, DOI 10.1093/ndt/gfp592; Lowenstein J, 2017, KIDNEY INT, V91, P561, DOI 10.1016/j.kint.2016.09.052; Lowenstein J, 2011, FASEB J, V25, P1781, DOI 10.1096/fj.11-0602ufm; Meijers BKI, 2008, AM J KIDNEY DIS, V51, P839, DOI 10.1053/j.ajkd.2007.12.035; Meijers B, 2014, SEMIN NEPHROL, V34, P228, DOI 10.1016/j.semnephrol.2014.02.012; Meijers BKI, 2011, NEPHROL DIAL TRANSPL, V26, P759, DOI 10.1093/ndt/gfq818; Meijers BKI, 2010, CLIN J AM SOC NEPHRO, V5, P1182, DOI 10.2215/CJN.07971109; Melamed ML, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-134; Nakagawa S, 2013, METHODS ECOL EVOL, V4, P133, DOI 10.1111/j.2041-210x.2012.00261.x; Nazzal L, 2017, NEPHROL DIAL TRANSPL, V32, P1809, DOI 10.1093/ndt/gfx029; Poesen R, 2013, CLIN J AM SOC NEPHRO, V8, P1508, DOI 10.2215/CJN.00300113; R Core Team, 2021, R LANG ENV STAT COMP; Rhee EP, 2013, J AM SOC NEPHROL, V24, P1330, DOI 10.1681/ASN.2012101006; Rhee EP, 2010, J AM SOC NEPHROL, V21, P1041, DOI 10.1681/ASN.2009111132; Sam Ramin, 2006, Hemodial Int, V10, P15, DOI 10.1111/j.1542-4758.2006.01170.x; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P114; Shafi T, 2017, KIDNEY INT, V92, P1484, DOI 10.1016/j.kint.2017.05.012; Shafi T, 2016, KIDNEY INT, V89, P1099, DOI 10.1016/j.kint.2015.10.011; Smith WW, 1938, J BIOL CHEM, V124, P107; Sombolos KI, 2005, ARTIF ORGANS, V29, P892, DOI 10.1111/j.1525-1594.2005.00126.x; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Termorshuizen, 2001, AM J KIDNEY DIS, V38, P85; U S Renal Data System, US RENAL DATA SYSTEM; Uwai Y, 2012, PHARMACOL RES, V65, P254, DOI 10.1016/j.phrs.2011.11.003; Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x; Watanabe H, 2012, DRUG METAB DISPOS, V40, P1423, DOI 10.1124/dmd.112.045617; Wu IW, 2012, NEPHROL DIAL TRANSPL, V27, P1169, DOI 10.1093/ndt/gfr453	38	15	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2018	13	2							e0192770	10.1371/journal.pone.0192770	http://dx.doi.org/10.1371/journal.pone.0192770			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX1SB	29470534	Green Published, gold, Green Submitted			2023-01-03	WOS:000425831000018
J	Avelino-Silva, TJ; Campora, F; Curiati, JAE; Jacob-Filho, W				Avelino-Silva, Thiago Junqueira; Campora, Flavia; Esper Curiati, Jose Antonio; Jacob-Filho, Wilson			Prognostic effects of delirium motor subtypes in hospitalized older adults: A prospective cohort study	PLOS ONE			English	Article							MORTALITY; SEVERITY; OUTCOMES; ASSOCIATION; DEMENTIA; AROUSAL; INDEX; RISK	Objectives To investigate the association between delirium motor subtypes and hospital mortality and 12-month mortality in hospitalized older adults. Design Prospective cohort study conducted from 2009 to 2015. Setting Geriatric ward of a university hospital in Sao Paulo, Brazil. Participants We included 1,409 consecutive admissions of acutely ill patients aged 60 years and over. We excluded admissions for end-of-life care, with missing data on the main variables, length of stay shorter than 48 hours, or when consent to participate was not given. Main outcomes and measures Delirium was detected using the Confusion Assessment Method and categorized in hypoactive, hyperactive, or mixed delirium. Primary outcomes were time to death in the hospital, and time to death in 12 months (for the discharged sample). Comprehensive geriatric assessment was performed at admission and included socio-demographic, clinical, functional, cognitive, and laboratory variables. Further clinical data were documented upon death or discharge. Multivariate analyses used Cox proportional hazards models adjusted for possible confounders. Results We included 1,409 admissions, with a mean age of 80 years. The proportion of in-hospital deaths was 19%, with a cumulative mortality of 38% in 12 months. Delirium occurred in 47% of the admissions. Hypoactive delirium was the predominant motor subtype (53%), followed by mixed delirium (30%) and hyperactive delirium (17%). Hospital mortality rates were respectively 33%, 34% and 15%. We verified that hypoactive and mixed delirium were independently associated with hospital mortality, with respective hazard ratios of 2.43 (95%CI = 1.64-3.59) and 2.31 (95%CI = 1.53-3.50). Delirium motor subtypes were not independently predictive of 12-month mortality. Conclusions One in three acutely ill hospitalized older adults who suffered hypoactive or mixed delirium died in the hospital. Clinicians should be aware that hypoactive symptoms of delirium, whether shown exclusively or in alternation with hyperactive symptoms, are indicative of a worse prognosis in this population.	[Avelino-Silva, Thiago Junqueira; Campora, Flavia; Esper Curiati, Jose Antonio; Jacob-Filho, Wilson] Univ Sao Paulo, Med Sch, Dept Internal Med, Div Geriatr, Sao Paulo, SP, Brazil	Universidade de Sao Paulo	Avelino-Silva, TJ (corresponding author), Univ Sao Paulo, Med Sch, Dept Internal Med, Div Geriatr, Sao Paulo, SP, Brazil.	thiago.silva@fm.usp.br	Avelino-Silva, Thiago J/J-8794-2013	Avelino-Silva, Thiago J/0000-0001-9347-0519	CAPES Foundation, Ministry of Education, Brazilian Federal Government	CAPES Foundation, Ministry of Education, Brazilian Federal Government	TJAS developed part of this project as a visiting scholar at the University of California San Francisco, supported by a scholarship from the CAPES Foundation, Ministry of Education, Brazilian Federal Government. None of the authors reported a potential, real, or perceived conflict of interest or additional financial disclosures.	Appelbaum PS, 2007, NEW ENGL J MED, V357, P1834, DOI 10.1056/NEJMcp074045; Avelino-Silva TJ, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-129; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Camus MV, 2000, J GERIATR PSYCH NEUR, V13, P38, DOI 10.1177/089198870001300106; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DeCrane SK, 2011, CLIN NURS RES, V20, P404, DOI 10.1177/1054773811419497; Eubank KJ, 2014, ANN INTERN MED, V160, P574, DOI 10.7326/M14-0553; Guigoz Y, 2006, J NUTR HEALTH AGING, V10, P466; Han JH, 2017, AM J GERIAT PSYCHIAT, V25, P233, DOI 10.1016/j.jagp.2016.05.016; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Inouye S., 2003, SHORT CONFUSION ASSE; Inouye S. K., 2003, CONFUSION ASSESSMENT; Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1; Inouye SK, 1999, DEMENT GERIATR COGN, V10, P393, DOI 10.1159/000017177; Inouye SK, 2001, ARCH INTERN MED, V161, P2467, DOI 10.1001/archinte.161.20.2467; Jackson TA, 2015, INT J GERIATR PSYCHI; Jorm AF, 2004, INT PSYCHOGERIATR, V16, P275, DOI 10.1017/S1041610204000390; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kelly KG, 2001, AM J GERIAT PSYCHIAT, V9, P72, DOI 10.1176/appi.ajgp.9.1.72; Kiely DK, 2007, J GERONTOL A-BIOL, V62, P174, DOI 10.1093/gerona/62.2.174; Kim SY, 2015, PSYCHOSOM MED, V77, P903, DOI 10.1097/PSY.0000000000000239; Leslie DL, 2008, ARCH INTERN MED, V168, P27, DOI 10.1001/archinternmed.2007.4; LIPOWSKI ZJ, 1983, AM J PSYCHIAT, V140, P1426; LIPTZIN B, 1992, BRIT J PSYCHIAT, V161, P843, DOI 10.1192/bjp.161.6.843; Marcantonio E, 2002, J AM GERIATR SOC, V50, P850, DOI 10.1046/j.1532-5415.2002.50210.x; McCusker J, 2004, J AM GERIATR SOC, V52, P1744, DOI 10.1111/j.1532-5415.2004.52471.x; Meagher DJ, 2011, J PSYCHOSOM RES, V71, P395, DOI 10.1016/j.jpsychores.2011.06.001; Morandi A, 2017, AM J GERIAT PSYCHIAT, V25, P1064, DOI 10.1016/j.jagp.2017.05.003; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Peritogiannis V, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/416792; Peterson JF, 2006, J AM GERIATR SOC, V54, P479, DOI 10.1111/j.1532-5415.2005.00621.x; Siddiqi N, 2006, CLIN MED, V6, P540, DOI 10.7861/clinmedicine.6-6-540; Slor CJ, 2013, J PSYCHOSOM RES, V74, P444, DOI 10.1016/j.jpsychores.2012.12.007; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Tieges Z, 2013, AM J GERIAT PSYCHIAT, V21, P1244, DOI 10.1016/j.jagp.2013.05.003; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; Wei LA, 2008, J AM GERIATR SOC, V56, P823, DOI 10.1111/j.1532-5415.2008.01674.x; Witlox J, 2010, JAMA-J AM MED ASSOC, V304, P443, DOI 10.1001/jama.2010.1013; Yang F, 2008, GERONTOLOGIST, V48, P96	39	24	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2018	13	1							e0191092	10.1371/journal.pone.0191092	http://dx.doi.org/10.1371/journal.pone.0191092			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FU1NX	29381733	Green Published, Green Submitted, gold			2023-01-03	WOS:000423617800014
J	Ferrer, M; Travierso, C; Cilloniz, C; Gabarrus, A; Ranzani, OT; Polverino, E; Liapikou, A; Blasi, F; Torres, A				Ferrer, Miquel; Travierso, Chiara; Cilloniz, Catia; Gabarrus, Albert; Ranzani, Otavio T.; Polverino, Eva; Liapikou, Adamantia; Blasi, Francesco; Torres, Antoni			Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; INFECTIOUS-DISEASES-SOCIETY; ACUTE RESPIRATORY-FAILURE; MECHANICAL VENTILATION; NONINVASIVE VENTILATION; GUIDELINES; VALIDATION; PREDICTION; MORTALITY; ADMISSION	Background Patients with severe community-acquired pneumonia (SCAP) and life-threatening acute respiratory failure may require invasive mechanical ventilation (IMV). Since use of IMV is often associated with significant morbidity and mortality, we assessed whether patients invasively ventilated would represent a target population for interventions aimed at reducing mortality of SCAP. Methods We prospectively recruited consecutive patients with SCAP for 12 years. We assessed the characteristics and outcomes of patients invasively ventilated at presentation of pneumonia, compared with those without IMV, and determined the influence of risks factors on mortality with a multivariate weighted logistic regression using a propensity score. Results Among 3,719 patients hospitalized with CAP, 664 (18%) had criteria for SCAP, and 154 (23%) received IMV at presentation of pneumonia; 198 (30%) presented with septic shock. In 370 (56%) cases SCAP was diagnosed based solely on the presence of 3 or more IDSA/ATS minor criteria. Streptococcus pneumoniae was the main pathogen in both groups. The 30-day mortality was higher in the IMV, compared to non-intubated patients (51, 33%, vs. 94, 18% respectively, p< 0.001), and higher than that predicted by APACHE-II score (26%). IMV independently predicted 30-day mortality in multivariate analysis (adjusted odds-ratio 3.54, 95% confidence interval 1.45-8.37, p = 0.006). Other independent predictors of mortality were septic shock, worse hypoxemia and increased serum potassium. Conclusion Invasive mechanical ventilation independently predicted 30-day mortality in patients with SCAP. Patients invasively ventilated should be considered a different population with higher mortality for future clinical trials on new interventions addressed to improve mortality of SCAP.	[Ferrer, Miquel; Travierso, Chiara; Cilloniz, Catia; Gabarrus, Albert; Ranzani, Otavio T.; Polverino, Eva; Liapikou, Adamantia; Torres, Antoni] Univ Barcelona, Dept Pneumol, Resp Inst, Hosp Clin,IDIBAPS, Barcelona, Spain; [Ferrer, Miquel; Cilloniz, Catia; Gabarrus, Albert; Polverino, Eva; Torres, Antoni] Ctr Invest Biomed Red Enfermedades Resp CibeRes C, Barcelona, Spain; [Travierso, Chiara; Blasi, Francesco] Univ Milan, Dipartimento Fisiopatol Med Chirurg & Trapianti, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Ranzani, Otavio T.] Univ Sao Paulo, Pulm Div, Heart Inst, Med Sch, Sao Paulo, Brazil; [Liapikou, Adamantia] Sotiria Chest Dis Hosp, Dept Resp Med 6, Athens, Greece	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universidade de Sao Paulo	Ferrer, M (corresponding author), Univ Barcelona, Dept Pneumol, Resp Inst, Hosp Clin,IDIBAPS, Barcelona, Spain.; Ferrer, M (corresponding author), Ctr Invest Biomed Red Enfermedades Resp CibeRes C, Barcelona, Spain.	miferrer@clinic.ub.es	Ranzani, Otavio T./K-1196-2012; Torres, Antoni/H-6128-2017; Cillóniz, Catia/Y-1898-2018; POLVERINO, eva/AAI-6053-2021; Lliapikou, Adamadia/H-8512-2019; Blasi, Francesco/O-5885-2017	Ranzani, Otavio T./0000-0002-4677-6862; Torres, Antoni/0000-0002-8643-2167; Polverino, Eva/0000-0002-4058-5109; Blasi, Francesco/0000-0002-2285-9970; cilloniz, catia/0000-0002-4646-9838; Gabarrus, Albert/0000-0003-3492-1310; Ferrer, Miguel/0000-0001-8171-6673				Aliberti S, 2008, CHEST, V134, P955, DOI 10.1378/chest.08-0334; Alvarez-Lerma Francisco, 2004, Curr Opin Crit Care, V10, P369; Aydogdu M, 2010, TUBERK TORAK, V58, P25; Bodi M, 2005, CLIN INFECT DIS, V41, P1709, DOI 10.1086/498119; Brookhart MA, 2006, AM J EPIDEMIOL, V163, P1149, DOI 10.1093/aje/kwj149; Carrillo A, 2012, INTENS CARE MED, V38, P458, DOI 10.1007/s00134-012-2475-6; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Cilloniz C, 2011, THORAX, V66, P340, DOI 10.1136/thx.2010.143982; Ewig S, 2011, INTENS CARE MED, V37, P214, DOI 10.1007/s00134-010-2077-0; FAHMEIR L, 1994, MULTIVARIATE STAT MO; Ferrer M, 2003, AM J RESP CRIT CARE, V168, P1438, DOI 10.1164/rccm.200301-072OC; Ferrer M, 2012, EUR J INTERN MED, V23, P420, DOI 10.1016/j.ejim.2012.02.011; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kolditz M, 2015, THORAX, V70, P551, DOI 10.1136/thoraxjnl-2014-206744; Lee Jin Hwa, 2007, Korean Journal of Internal Medicine, V22, P157; LEEPER KV, 1995, CLIN CHEST MED, V16, P155; LEROY O, 1995, INTENS CARE MED, V21, P24, DOI 10.1007/BF02425150; Liapikou A, 2009, CLIN INFECT DIS, V48, P377, DOI 10.1086/596307; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; McCullagh P., 1989, GEN LINEAR MODELS; Mongardon N, 2012, CRIT CARE, V16, DOI 10.1186/cc11471; Oosterheert JJ, 2003, CURR OPIN INFECT DIS, V16, P153, DOI 10.1097/00001432-200304000-00012; Pascual FE, 2000, CHEST, V117, P503, DOI 10.1378/chest.117.2.503; Pierson David J, 2002, Respir Care, V47, P249; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Restrepo MI, 2008, CHEST, V133, P610, DOI 10.1378/chest.07-1456; Restrepo MI, 2010, CHEST, V137, P552, DOI 10.1378/chest.09-1547; Tejerina E, 2005, J CRIT CARE, V20, P230, DOI 10.1016/j.jcrc.2005.05.010; Thoemmes F, 2016, EMERG ADULTHOOD, V4, P40, DOI 10.1177/2167696815621645; Valencia M, 2007, CHEST, V132, P515, DOI 10.1378/chest.07-0306; Welte T, 2015, RESP MED, V109, P758, DOI 10.1016/j.rmed.2015.03.008	34	44	47	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2018	13	1							e0191721	10.1371/journal.pone.0191721	http://dx.doi.org/10.1371/journal.pone.0191721			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT8QE	29370285	gold, Green Published, Green Submitted			2023-01-03	WOS:000423416600087
J	Geroldinger, A; Sauter, SK; Heinze, G; Endel, G; Dorda, W; Duftschmid, G				Geroldinger, Angelika; Sauter, Simone Katja; Heinze, Georg; Endel, Gottfried; Dorda, Wolfgang; Duftschmid, Georg			Mortality and continuity of care - Definitions matter! A cohort study in diabetics	PLOS ONE			English	Article							SYSTEM; HOSPITALIZATION; COSTS	Objective To demonstrate that when investigating the relevance of continuity of care for patient outcomes, different definitions can lead to contradicting results. Methods We used claims data from the regional public health insurer of Lower Austria covering the period from 2008 to 2011. The study sample included subjects with repeated dispensings of anti-diabetic drugs. The continuity of care index was calculated firstly based on a patient's contacts with general practitioners (primary COCl) and secondly based on contacts at all medical disciplines (total COCl). The association of the two continuity of care measures with mortality was assessed in separate univariable and multivariable Cox regression models. Results Our study sample consisted of 51,717 patients with a median observation time of 3.65 years. The data showed that a high total COCI was associated with increased mortality, while there was no association between primary COCI and mortality. Conclusions Measures of continuity of care are highly sensitive to the type of medical disciplines taken into account. The continuity of care index calculated from contacts at all medical disciplines might measure diversity rather than continuity of care.	[Geroldinger, Angelika; Sauter, Simone Katja; Heinze, Georg; Dorda, Wolfgang; Duftschmid, Georg] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria; [Endel, Gottfried] Main Assoc Austrian Social Secur Org, Vienna, Austria	Medical University of Vienna	Geroldinger, A (corresponding author), Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.	angelika.geroldinger@gmx.at	Endel, Gottfried/Y-5456-2019	Endel, Gottfried/0000-0003-2071-4572; Geroldinger, Angelika/0000-0002-4659-4911; Heinze, Georg/0000-0003-1147-8491	Main Association of Austrian Social Security Organizations	Main Association of Austrian Social Security Organizations	This work was supported by the Main Association of Austrian Social Security Organizations, which provided access to a research data base containing administrative data and supported the authors AG, SKS and WD financially.	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; [Anonymous], 2012, WAHL SICH GES BER JE; Bayliss EA, 2015, ANN FAM MED, V13, P123, DOI 10.1370/afm.1739; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; BRESLAU N, 1975, J MED EDUC, V50, P965; Chen CC, 2011, AM J MANAG CARE, V17, P420; Cheng SH, 2011, HEALTH POLICY PLANN, V26, P157, DOI 10.1093/heapol/czq035; Chini F, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-688; Duftschmid G, 2016, C HLTH EXPL COMPL IN; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Jee SH, 2006, MED CARE RES REV, V63, P158, DOI 10.1177/1077558705285294; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Leleu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071669; Lustman A, 2016, PRIM CARE DIABETES, V10, P165, DOI 10.1016/j.pcd.2015.10.001; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; Reid R.J., 2002, DEFUSING CONFUSION C; Rinner C, 2016, INT J MED INFORM, V92, P44, DOI 10.1016/j.ijmedinf.2016.05.001; Shin DW, 2014, ANN FAM MED, V12, P534, DOI 10.1370/afm.1685; STEINWACHS DM, 1979, MED CARE, V17, P551, DOI 10.1097/00005650-197906000-00001; Team RC, 2015, R LANG ENV STAT COMP; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; WHO Collaborating Centre for Drug Statistics Methodology, 2015, GUID ATC CLASS DDD A; Worrall G, 2011, CAN FAM PHYSICIAN, V57, pE16	23	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2018	13	1							e0191386	10.1371/journal.pone.0191386	http://dx.doi.org/10.1371/journal.pone.0191386			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT1QM	29351547	Green Submitted, Green Published, gold			2023-01-03	WOS:000422911300078
J	Eroglu, Z; Zaretsky, JM; Hu-Lieskovan, S; Kim, DW; Algazi, A; Johnson, DB; Liniker, E; Kong, B; Munhoz, R; Rapisuwon, S; Gherardini, PF; Chmielowski, B; Wang, XY; Shintaku, IP; Wei, C; Sosman, JA; Joseph, RW; Postow, MA; Carlino, MS; Hwu, WJ; Scolyer, RA; Messina, J; Cochran, AJ; Long, GV; Ribas, A				Eroglu, Zeynep; Zaretsky, Jesse M.; Hu-Lieskovan, Siwen; Kim, Dae Won; Algazi, Alain; Johnson, Douglas B.; Liniker, Elizabeth; Kong, Ben; Munhoz, Rodrigo; Rapisuwon, Suthee; Gherardini, Pier Federico; Chmielowski, Bartosz; Wang, Xiaoyan; Shintaku, I. Peter; Wei, Cody; Sosman, Jeffrey A.; Joseph, Richard W.; Postow, Michael A.; Carlino, Matteo S.; Hwu, Wen-Jen; Scolyer, Richard A.; Messina, Jane; Cochran, Alistair J.; Long, Georgina V.; Ribas, Antoni			High response rate to PD-1 blockade in desmoplastic melanomas	NATURE			English	Article							CELL LUNG-CANCER; METASTATIC MELANOMA; MUTATIONS; EXPRESSION; PEMBROLIZUMAB; RESISTANCE; IMMUNOTHERAPY; DISRUPTION; ANTI-PD-1; PATHWAY	Desmoplastic melanoma is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, and is highly associated with ultraviolet light-induced DNA damage(1). We analysed sixty patients with advanced desmoplastic melanoma who had been treated with antibodies to block programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1). Objective tumour responses were observed in forty-two of the sixty patients (70%; 95% confidence interval 57-81%), including nineteen patients (32%) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF1 mutations (fourteen out of seventeen cases) in these tumours. Immunohistochemistry analysis from nineteen desmoplastic melanomas and thirteen non-desmoplastic melanomas revealed a higher percentage of PD-L1-positive cells in the tumour parenchyma in desmoplastic melanomas (P = 0.04); these cells were highly associated with increased CD8 density and PD-L1 expression in the tumour invasive margin. Therefore, patients with advanced desmoplastic melanoma derive substantial clinical benefit from PD-1 or PD-L1 immune checkpoint blockade therapy, even though desmoplastic melanoma is defined by its dense desmoplastic fibrous stroma. The benefit is likely to result from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.	[Eroglu, Zeynep; Zaretsky, Jesse M.; Hu-Lieskovan, Siwen; Chmielowski, Bartosz; Wang, Xiaoyan; Shintaku, I. Peter; Wei, Cody; Cochran, Alistair J.; Ribas, Antoni] Univ Calif Los Angeles, Los Angeles, CA 90095 USA; [Eroglu, Zeynep; Kim, Dae Won; Messina, Jane] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Eroglu, Zeynep; Kim, Dae Won; Messina, Jane] Univ S Florida, Tampa, FL USA; [Kim, Dae Won; Hwu, Wen-Jen] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Algazi, Alain] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Johnson, Douglas B.; Sosman, Jeffrey A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Liniker, Elizabeth; Carlino, Matteo S.; Scolyer, Richard A.; Long, Georgina V.] Melanoma Inst Australia, Sydney, NSW, Australia; [Kong, Ben; Carlino, Matteo S.] Westmead Hosp, Sydney, NSW, Australia; [Munhoz, Rodrigo; Postow, Michael A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Munhoz, Rodrigo; Postow, Michael A.] Weill Cornell Med Coll, New York, NY USA; [Rapisuwon, Suthee] Georgetown Lombardi Canc Ctr, Washington, DC USA; [Gherardini, Pier Federico] Parker Inst Canc Immunotherapy, San Francisco, CA USA; [Joseph, Richard W.] Mayo Clin, Jacksonville, FL 32224 USA; [Carlino, Matteo S.; Scolyer, Richard A.; Long, Georgina V.] Univ Sydney, Sydney, NSW, Australia; [Scolyer, Richard A.] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Long, Georgina V.] Royal North Shore Hosp, Sydney, NSW, Australia; [Sosman, Jeffrey A.] Northwestern Univ, Med Ctr, Chicago, IL 60611 USA	University of California System; University of California Los Angeles; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco; Vanderbilt University; Melanoma Institute Australia; University of Sydney; Memorial Sloan Kettering Cancer Center; Cornell University; Mayo Clinic; University of Sydney; University of Sydney; Royal North Shore Hospital; Northwestern University	Hu-Lieskovan, S; Ribas, A (corresponding author), Univ Calif Los Angeles, Los Angeles, CA 90095 USA.	shu-lieskovan@mednet.ucla.edu; aribas@mednet.ucla.edu	Carlino, Matteo/GRS-7198-2022; Long, Georgina V/C-1771-2013; Scolyer, Richard/AAE-8511-2019	Long, Georgina V/0000-0001-8894-3545; Scolyer, Richard/0000-0002-8991-0013; Rapisuwon, Suthee/0000-0002-1389-925X; Carlino, Matteo/0000-0002-7861-4104	Grimaldi Family Fund; Parker Institute for Cancer Immunotherapy; National Institutes of Health (NIH) [R35 CA197633, P01 CA168585]; Ressler Family Fund; Samuels Family Fund; Garcia-Corsini Family Fund; Moffitt Cancer Center NCI Skin SPORE [5P50CA168536]; Moffitt's Total Cancer Care Initiative and Collaborative Data Services [P30-CA076292]; NIH training grant [GM08042]; American Society of Clinical Oncology (ASCO); Tower Cancer Research Foundation Grant; Dr. Charles Coltman Fellowship Award from the Hope Foundation; NHMRC Fellowship; University of Sydney Medical Foundation; NATIONAL CANCER INSTITUTE [P01CA168585, P30CA008748, R35CA197633, P30CA076292, P50CA168536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	Grimaldi Family Fund; Parker Institute for Cancer Immunotherapy; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ressler Family Fund; Samuels Family Fund; Garcia-Corsini Family Fund; Moffitt Cancer Center NCI Skin SPORE; Moffitt's Total Cancer Care Initiative and Collaborative Data Services; NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Clinical Oncology (ASCO); Tower Cancer Research Foundation Grant; Dr. Charles Coltman Fellowship Award from the Hope Foundation; NHMRC Fellowship(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney Medical Foundation(University of Sydney); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was funded in part by the Grimaldi Family Fund, the Parker Institute for Cancer Immunotherapy, National Institutes of Health (NIH) grants R35 CA197633 and P01 CA168585, the Ressler Family Fund, the Samuels Family Fund and the Garcia-Corsini Family Fund (to A.R.). Z.E. was supported in part by the Moffitt Cancer Center NCI Skin SPORE (5P50CA168536) and Moffitt's Total Cancer Care Initiative and Collaborative Data Services (P30-CA076292) for this work. J.M.Z. is part of the UCLA Medical Scientist Training Program supported by NIH training grant GM08042. S.H.-L. was supported by a Young Investigator Award and a Career Development Award from the American Society of Clinical Oncology (ASCO), a Tower Cancer Research Foundation Grant, and a Dr. Charles Coltman Fellowship Award from the Hope Foundation. We acknowledge the Translational Pathology Core Laboratory (TPCL) and R. Guo, W. Li, J. Pang and M. H. Macabali from UCLA for blood and biopsy processing, and X. Li, L. Dong, J. Yoshizawa, and J. Zhou from the UCLA Clinical Microarray Core for sequencing expertise. G.V.L. is supported by an NHMRC Fellowship and The University of Sydney Medical Foundation. R.A.S. is supported by an NHMRC Fellowship.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Busam KJ, 2004, AM J SURG PATHOL, V28, P1518, DOI 10.1097/01.pas.0000141391.91677.a4; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Daud AI, 2016, J CLIN ONCOL, V34, P4102, DOI 10.1200/JCO.2016.67.2477; Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477; Frydenlund N, 2017, MODERN PATHOL, V30, P357, DOI 10.1038/modpathol.2016.210; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Han DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119716; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Nghiem PT, 2016, NEW ENGL J MED, V374, P2542, DOI 10.1056/NEJMoa1603702; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Ribas A, 2016, JAMA-J AM MED ASSOC, V315, P1600, DOI 10.1001/jama.2016.4059; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Wiesner T, 2015, AM J SURG PATHOL, V39, P1357, DOI 10.1097/PAS.0000000000000451; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	30	176	186	4	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 18	2018	553	7688					347	+		10.1038/nature25187	http://dx.doi.org/10.1038/nature25187			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT9MB	29320474	Green Accepted, Green Submitted			2023-01-03	WOS:000423475100053
J	Pai, CW; Lin, HY; Tsai, SH; Chen, PL				Pai, Chih-Wei; Lin, Hsiao-Yu; Tsai, Shin-Han; Chen, Ping-Ling			Comparison of traffic-injury related hospitalisation between bicyclists and motorcyclists in Taiwan	PLOS ONE			English	Article							HELMET LAW; SEVERITY; CRASHES; VEHICLE; RISK; HEAD; ENVIRONMENT; ACCIDENTS; PATTERNS; OUTCOMES	Objectives Bicyclists and motorcyclists contribute substantially to the morbidity and mortality rates of road crash casualties. The objective of the study was to investigate the crash characteristics of bicyclist and motorcyclist casualties presented to hospitals in Taiwan resulting from crashes. Methods By using linked data from The National Traffic Crash Dataset and the National Health Insurance Database between 2003 and 2012, logistic regression models were used to examine the determinants of hospitalisation among motorcyclist and bicyclist casualties. The examined variables include demographic characteristics, road and weather conditions, and vehicle characteristics. Results A total of 1,998,606 two-wheelers were enrolled in the study, of whom 216,600 were hospitalised: 203,623 were motorcyclists and 12,964 were bicyclists. Bicyclists were more likely to be hospitalised than motorcyclists were (14.0% vs. 10.7%). The pooled logistic regression model shows that bicyclists had higher odds of hospitalisation than motorcyclists (adjusted odds ratio [AOR] =1.11, 95% confident interval [CI] = 1.08-1.14). In the motorcyclist and bicyclist models, helmet non-use appears to be a determinant of hospitalisation for motorcyclists (AOR = 1.14, CI = 1.12-1.16), although insignificant for cyclists (AOR = 1.03, CI = 0.94-1.12). Other important determinants of hospitalisation for motorcyclists and cyclists include female riders, elderly riders, rural roadways, unlicensed riding (for motorcyclists only), curved roadways, defective roadways, alcohol consumption (only for motorcyclists), and single-vehicle crashes (for motorcyclists only). Conclusions The result that bicyclists had an increased probability of being hospitalised than motorcyclists is particularly noteworthy, because there have recently been much more users of bikesharing systems in metropolitan cities where cycle helmets are not provided. We further found that helmet non-use was also a risk factor for motorcyclists, but insignificant for cyclists, possibly due to lower helmet utilization rates among bicyclists. Our findings regarding the increased hospitalisation percentage emphasize the importance of helmet use.	[Pai, Chih-Wei; Tsai, Shin-Han; Chen, Ping-Ling] Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth, Taipei, Taiwan; [Lin, Hsiao-Yu] Taipei Med Univ Hosp, Dept Urol, Taipei, Taiwan; [Tsai, Shin-Han] Shuang Ho Hosp, Dept Emergency Med, New Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Shuang Ho Hospital	Tsai, SH; Chen, PL (corresponding author), Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth, Taipei, Taiwan.; Lin, HY (corresponding author), Taipei Med Univ Hosp, Dept Urol, Taipei, Taiwan.; Tsai, SH (corresponding author), Shuang Ho Hosp, Dept Emergency Med, New Taipei, Taiwan.	ablin@tmu.edu.tw; shtsai@tmu.edu.tw; plchen@tmu.edu.tw			Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan [E1030909-104]; Taipei Medical University - Shuang Ho Hospital [102TMU-SHH-12]	Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan; Taipei Medical University - Shuang Ho Hospital	This study was supported by a grant from the Health Promotion Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan (Grant number: E1030909-104) and a grant from Taipei Medical University - Shuang Ho Hospital (Grant number: 102TMU-SHH-12) to PLC.	Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; Attewell RG, 2001, ACCIDENT ANAL PREV, V33, P345, DOI 10.1016/S0001-4575(00)00048-8; Boufous S, 2012, ACCIDENT ANAL PREV, V49, P404, DOI 10.1016/j.aap.2012.03.011; Broughton J, 2005, TRL6292005; Chen P-L, 2015, STAT INJURY SURVEILL; Chen P, 2016, ACCIDENT ANAL PREV, V86, P239, DOI 10.1016/j.aap.2015.11.002; Chiu WT, 2011, JAMA-J AM MED ASSOC, V306, P267, DOI 10.1001/jama.2011.989; Chung CH, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-744; Cunningham G, 2012, ANZ J SURG, V82, P551, DOI 10.1111/j.1445-2197.2012.06127.x; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Gavin AL, 2005, J AUSTRALAS COLL ROA, V16, P25; Haworth N, 1997, CR174 FED OFF ROAD S; Ichikawa M, 2003, ACCIDENT ANAL PREV, V35, P183, DOI 10.1016/S0001-4575(01)00102-6; Islam S, 2017, ACCIDENT ANAL PREV, V108, P163, DOI 10.1016/j.aap.2017.08.016; Jung S, 2013, ACCIDENT ANAL PREV, V59, P357, DOI 10.1016/j.aap.2013.06.030; Kasantikul V, 2005, ACCIDENT ANAL PREV, V37, P357, DOI 10.1016/j.aap.2004.07.006; Keng SH, 2005, ACCIDENT ANAL PREV, V37, P349, DOI 10.1016/j.aap.2004.09.006; Kim JK, 2007, ACCIDENT ANAL PREV, V39, P238, DOI 10.1016/j.aap.2006.07.002; Klop J.R., 1999, TRANSPORT RES REC, V1674, P78; Liu BC, 2008, HELMETS PREVENTING I; Liu C.Y., 2006, J HEALTH MANAG, V4, P1; Mackay M, 1988, SPECIAL REPORT 218 T, V2, P158; Mayrose J, 2008, J SAFETY RES, V39, P429, DOI 10.1016/j.jsr.2008.07.001; Meuleners LB, 2007, ACCIDENT ANAL PREV, V39, P1222, DOI 10.1016/j.aap.2007.03.006; Moore DN, 2011, ACCIDENT ANAL PREV, V43, P621, DOI 10.1016/j.aap.2010.09.015; National Expressway Engineering Bureau Ministry of Transportation and Communications, 2004, 2 HIGHW CONSTR ALB T, P68; Noland RB, 2004, TRANSPORT RES REC, P28; Olivier J, 2017, INT J EPIDEMIOL, V46, P278, DOI [10.1093/ije/dyw153, 10.1093/ije/dyw360]; Ouellet James V, 2006, Traffic Inj Prev, V7, P49, DOI 10.1080/15389580500338652; Pai CW, 2008, ACCIDENT ANAL PREV, V40, P479, DOI 10.1016/j.aap.2007.08.003; Passmore J, 2010, TRAFFIC INJ PREV, V11, P202, DOI 10.1080/15389580903497121; Preusser D. F., 2003, EVALUATION REPEAL MO; Quddus MA, 2002, J SAFETY RES, V33, P445, DOI 10.1016/S0022-4375(02)00051-8; Rifaat SM, 2012, ACCIDENT ANAL PREV, V49, P44, DOI 10.1016/j.aap.2011.02.025; Robartes E, 2017, ACCIDENT ANAL PREV, V104, P165, DOI 10.1016/j.aap.2017.04.020; ROSMAN DL, 1994, ACCIDENT ANAL PREV, V26, P215, DOI 10.1016/0001-4575(94)90091-4; Segui-Gomez M, 2008, INJURY RELATED HOSPI; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Sun Y, 2012, DIABETES CARE, V35, P1047, DOI 10.2337/dc11-1511; SUPRAMANIAM V, 1984, ACCIDENT ANAL PREV, V16, P157, DOI 10.1016/0001-4575(84)90009-5; Wen CH, 2012, ACCIDENT ANAL PREV, V49, P193, DOI 10.1016/j.aap.2011.03.006; Wiznia DH, 2016, TRAFFIC INJ PREV, V17, P633, DOI 10.1080/15389588.2015.1136059; Xiong LL, 2015, AIMS PUBLIC HEALTH, V2, P74, DOI 10.3934/publichealth.2015.1.74; Yan XP, 2011, ACCIDENT ANAL PREV, V43, P1751, DOI 10.1016/j.aap.2011.04.006	44	17	17	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2018	13	1							e0191221	10.1371/journal.pone.0191221	http://dx.doi.org/10.1371/journal.pone.0191221			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FS8II	29342208	Green Submitted, Green Published, gold			2023-01-03	WOS:000422653800052
J	Chowdhury, AI; Haider, R; Abdullah, AM; Christou, A; Ali, NA; Rahman, AE; Iqbal, A; Bari, S; Hoque, DME; El Arifeen, S; Kissoon, N; Larson, CP				Chowdhury, Atique Iqbal; Haider, Rafiqul; Abdullah, Abu Yousuf Md; Christou, Aliki; Ali, Nabeel Ashraf; Rahman, Ahmed Ehsnaur; Iqbal, Afrin; Bari, Sanwarul; Hoque, D. M. Emdadul; El Arifeen, Shams; Kissoon, Niranjan; Larson, Charles P.			Using geospatial techniques to develop an emergency referral transport system for suspected sepsis patients in Bangladesh	PLOS ONE			English	Article							HEALTH-CARE; DEVELOPING-COUNTRIES; INFORMATION-SYSTEMS; SERVICES; ACCESS; ACCESSIBILITY; INTERVENTION; AFRICA; EQUITY; MALAWI	Background A geographic information system (GIS)-based transport network within an emergency referral system can be the key to reducing health system delays and increasing the chances of survival, especially during an emergency. We employed a GIS to design an emergency transport system for the rapid transfer of pregnant or early post-partum women, newborns, and children under 5 years of age with suspected sepsis under the Interrupting Pathways to Sepsis Initiative (IPSI) project. Methods A GIS database was developed by mapping the villages, roads, and relevant physical features of the study area. A travel-time algorithm was developed to incorporate the time taken by different modes of local transport to reach the health complexes. These were used in a network analysis to identify the shortest routes to the hospitals from the villages, which were categorized into green, yellow, and red zones based on their proximity to the nearest hospitals to provide transport facilities. An emergency call-in centre established for the project managed the transport system, and its data was used to assess the uptake of this transport system amongst distant communities. Results Fifteen pre-existing and two new routes were identified as the shortest routes to the health complexes. The call-in centre personnel used this route information to direct both patients and transport drivers to the nearest transport hubs or pick-up points. Adherence with referral advice was high in areas where the IPSI transport operated. Over the study period, the utilisation of the project's transport doubled and referral compliance from distant zones similarly increased. Conclusions The GIS system created for this study facilitated rapid referral of patients in emergency from distant zones, using locally available transport and resources. The methodology described in this study to develop and implement an emergency transport system can be applied in similar, rural, low-income country settings.	[Chowdhury, Atique Iqbal; Haider, Rafiqul; Abdullah, Abu Yousuf Md; Ali, Nabeel Ashraf; Rahman, Ahmed Ehsnaur; Iqbal, Afrin; Bari, Sanwarul; Hoque, D. M. Emdadul; El Arifeen, Shams] Int Ctr Diarrhoeal Dis Res Icddr B, Maternal & Child Hlth Div, Dhaka, Bangladesh; [Christou, Aliki] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia; [Kissoon, Niranjan; Larson, Charles P.] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada	International Centre for Diarrhoeal Disease Research (ICDDR); University of Sydney; University of British Columbia	Chowdhury, AI (corresponding author), Int Ctr Diarrhoeal Dis Res Icddr B, Maternal & Child Hlth Div, Dhaka, Bangladesh.	atiquei@icddrb.org	Christou, Aliki/D-1249-2018; Hoque, Dewan/O-3606-2015; Kissoon, Niranjan/AAC-6140-2021; Hoque, Dewan Md. Emdadul/J-1999-2019; Chowdhury, Atique Iqbal/A-6046-2016; Abdullah, Abu Yousuf Md/AAX-7051-2021; Haider, Rafiqul/A-4236-2016	Christou, Aliki/0000-0001-9525-8255; Hoque, Dewan/0000-0001-8219-9196; Hoque, Dewan Md. Emdadul/0000-0001-8219-9196; Chowdhury, Atique Iqbal/0000-0001-9140-5983; Abdullah, Abu Yousuf Md/0000-0001-8641-990X; Arifeen, Shams/0000-0002-5372-5932; Haider, Rafiqul/0000-0002-7864-3319; Kissoon, Niranjan/0000-0001-8847-9973	Global Affairs Canada Trade and Developments MUSKOKA Initiative on Maternal, Newborn and Child Health (MNCH) [S065353001]	Global Affairs Canada Trade and Developments MUSKOKA Initiative on Maternal, Newborn and Child Health (MNCH)	This study was a component of the project titled "Interrupting Pathways to Maternal, Newborn and Early Childhood Sepsis Initiative" (IPSI) (project number S065353001) that was funded by Global Affairs Canada Trade and Developments MUSKOKA Initiative on Maternal, Newborn and Child Health (MNCH), received by Dr. Charles Larson, url http://www.internatonal.gc.ca/. The funders had no role in study design, data collection, analysis and writing the manuscript.	Abdullah AYM, 2017, TROP MED HEALTH, V45, DOI 10.1186/s41182-017-0054-9; Al-Taiar A, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-38; [Anonymous], 2017, INDEPENDENT; [Anonymous], 2016, DAILY STAR; [Anonymous], 2012, GOOGL EARTH 6 2; Bailey P., 2009, MON EM OBST CAR HDB; Bailey PE, 2011, INT J GYNECOL OBSTET, V115, P300, DOI 10.1016/j.ijgo.2011.09.004; Banu M, 2014, PUBLIC HEALTH, V128, P332, DOI 10.1016/j.puhe.2014.01.009; Banu M, 2010, MANOSHI WORKING PAPE, P1; BBS (Bangladesh Bureau of Statistics), POP HOUS CENS 2011 C; Bishop ID, 2000, CITIES, V17, P85, DOI 10.1016/S0264-2751(00)00004-4; Bossyns P, 2005, TROP MED INT HEALTH, V10, P879, DOI 10.1111/j.1365-3156.2005.01459.x; Brammer H, 1993, GEOGRAPHICAL COMPLEX, P246; Children St, 2013, MAMONI INTEGRATED SA; Dewan A, 2017, TROP MED HEALTH, V45, DOI 10.1186/s41182-017-0069-2; Ensor T, 2004, HEALTH POLICY PLANN, V19, P69, DOI 10.1093/heapol/czh009; Global Health Hub @ UBC, INT PATHW SEPS IN IP; Hofman JJ, 2008, INT J GYNECOL OBSTET, V102, P191, DOI 10.1016/j.ijgo.2008.04.001; Kim D, 2016, J HEALTH POPUL NUTR, V35, DOI 10.1186/s41043-016-0045-1; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Machira K, 2017, AFR HEALTH SCI, V17, P400, DOI 10.4314/ahs.v17i2.14; Makanga PT, 2017, INT J HEALTH GEOGR, V16, DOI 10.1186/s12942-016-0074-4; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1035, DOI 10.1001/jama.289.8.1035; Murray SF, 2006, SOC SCI MED, V62, P2205, DOI 10.1016/j.socscimed.2005.10.025; Neutens T, 2015, J TRANSP GEOGR, V43, P14, DOI 10.1016/j.jtrangeo.2014.12.006; Noor AM, 2006, TROP MED INT HEALTH, V11, P188, DOI 10.1111/j.1365-3156.2005.01555.x; Noor AM, 2003, TROP MED INT HEALTH, V8, P917, DOI 10.1046/j.1365-3156.2003.01112.x; Paul BK, 2009, NAT HAZARDS, V50, P289, DOI 10.1007/s11069-008-9340-5; Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011; Rahman AE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170267; Sabde Y, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-57; Schuurman Nadine, 2006, Int J Health Geogr, V5, P43, DOI 10.1186/1476-072X-5-43; STORY M, 1986, PHOTOGRAMM ENG REM S, V52, P397; Sudhof L, 2013, TROP MED INT HEALTH, V18, P18, DOI 10.1111/tmi.12016; Tanser F, 2006, SOC SCI MED, V63, P691, DOI 10.1016/j.socscimed.2006.01.015; Tayler-Smith K, 2013, TROP MED INT HEALTH, V18, P166, DOI 10.1111/tmi.12022; Terkelsen CJ, 2011, ANN INTERN MED, V155, P361, DOI 10.7326/0003-4819-155-6-201109200-00004; United Nations Children's Fund (UNICEF), 2010, OP PER REF TRANSP SE; Zinszer K, 2014, B WORLD HEALTH ORGAN, V92, P178, DOI 10.2471/BLT.13.125260	39	4	5	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 16	2018	13	1							e0191054	10.1371/journal.pone.0191054	http://dx.doi.org/10.1371/journal.pone.0191054			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FS8HZ	29338012	gold, Green Published, Green Submitted			2023-01-03	WOS:000422652700027
J	Moeller, J; Denisin, AK; Sim, JY; Wilson, RE; Ribeiro, AJS; Pruitt, BL				Moeller, Jens; Denisin, Aleksandra K.; Sim, Joo Yong; Wilson, Robin E.; Ribeiro, Alexandre J. S.; Pruitt, Beth L.			Controlling cell shape on hydrogels using lift-off protein patterning	PLOS ONE			English	Article							GLYCOL) ASSEMBLED MONOLAYERS; EXTRACELLULAR-MATRIX; SPATIAL-ORGANIZATION; MICROPATTERNS; LITHOGRAPHY; ADSORPTION; POLYMERS; FORCE; TOOL	Polyacrylamide gels functionalized with extracellular matrix proteins are commonly used as cell culture platforms to evaluate the combined effects of extracellular matrix composition, cell geometry and substrate rigidity on cell physiology. For this purpose, protein transfer onto the surface of polyacrylamide hydrogels must result in geometrically well-resolved micropatterns with homogeneous protein distribution. Yet the outcomes of micropatterning methods have not been pairwise evaluated against these criteria. We report a high-fidelity photoresist lift-off patterning method to pattern ECM proteins on polyacrylamide hydrogels with elastic moduli ranging from 5 to 25 kPa. We directly compare the protein transfer efficiency and pattern geometrical accuracy of this protocol to the widely used microcontact printing method. Lift-off patterning achieves higher protein transfer efficiency, increases pattern accuracy, increases pattern yield, and reduces variability of these factors within arrays of patterns as it bypasses the drying and transfer steps of microcontact printing. We demonstrate that lift-off patterned hydrogels successfully control cell size and shape and enable long-term imaging of actin intracellular structure and lamellipodia dynamics when we culture epithelial cells on these substrates.	[Moeller, Jens; Denisin, Aleksandra K.; Sim, Joo Yong; Wilson, Robin E.; Ribeiro, Alexandre J. S.; Pruitt, Beth L.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Denisin, Aleksandra K.; Pruitt, Beth L.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Pruitt, Beth L.] Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94305 USA; [Pruitt, Beth L.] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Pruitt, BL (corresponding author), Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA.; Pruitt, BL (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.; Pruitt, BL (corresponding author), Stanford Univ, Stanford Cardiovasc Inst, Stanford, CA 94305 USA.; Pruitt, BL (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.	pruitt@stanford.edu	Moeller, Jens/F-5110-2011; Denisin, Aleksandra/N-4715-2018; Sim, Joo Yong/AAC-8087-2019	Moeller, Jens/0000-0002-7226-0675; Denisin, Aleksandra/0000-0002-4262-9371; Sim, Joo Yong/0000-0003-3779-7589	National Science Foundation [EFRI-MIKS 1136790, CMMI 1662431, ECCS-1542152]; National Institutes of Health [R01EB006745, 1R21HL13099301]; National Science Foundation; ILJU Foundation; Stanford BioX; Stanford Office of the Vice Provost for Graduate Education; American Heart Association; Stanford Graduate Fellowship	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); ILJU Foundation; Stanford BioX; Stanford Office of the Vice Provost for Graduate Education; American Heart Association(American Heart Association); Stanford Graduate Fellowship(Stanford University)	This project was supported in part by the National Science Foundation (EFRI-MIKS 1136790, CMMI 1662431, ECCS-1542152), National Institutes of Health (R01EB006745, 1R21HL13099301). The authors are grateful for graduate and post-doctoral research fellowships from the National Science Foundation, ILJU Foundation, Stanford BioX, Stanford Office of the Vice Provost for Graduate Education, American Heart Association, and Stanford Graduate Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderegg F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028583; Azioune A, 2010, METHOD CELL BIOL, V97, P133, DOI 10.1016/S0091-679X(10)97008-8; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Burnette DT, 2011, NAT CELL BIOL, V13, P371, DOI 10.1038/ncb2205; Cavalcanti-Adam EA, 2007, BIOPHYS J, V92, P2964, DOI 10.1529/biophysj.106.089730; Chen WQ, 2012, LAB CHIP, V12, P391, DOI 10.1039/c1lc20721k; Christman KL, 2006, SOFT MATTER, V2, P928, DOI 10.1039/b611000b; Das T, 2015, NAT CELL BIOL, V17, P276, DOI 10.1038/ncb3115; Delamarche E, 1997, ADV MATER, V9, P741, DOI 10.1002/adma.19970090914; Desai RA, 2014, METHOD CELL BIOL, V119, P3, DOI 10.1016/B978-0-12-416742-1.00001-9; Falconnet D, 2004, NANO LETT, V4, P1909, DOI 10.1021/nl0489438; Falconnet D, 2004, ADV FUNCT MATER, V14, P749, DOI 10.1002/adfm.200305182; Fredericks EC, 1986, United States patent, Patent No. [US 06/567,034, 06567034]; Grevesse T, 2013, LAB CHIP, V13, P777, DOI 10.1039/c2lc41168g; Guo Wei-hui, 2011, Cold Spring Harb Protoc, V2011, pprot5582, DOI 10.1101/pdb.prot5582; Huang YGY, 2005, LANGMUIR, V21, P8058, DOI 10.1021/la0502185; Hui CY, 2002, LANGMUIR, V18, P1394, DOI 10.1021/la0113567; Ihalainen TO, 2015, NAT MATER, V14, P1252, DOI [10.1038/NMAT4389, 10.1038/nmat4389]; Kassianidou E, 2015, BBA-MOL CELL RES, V1853, P3065, DOI 10.1016/j.bbamcr.2015.04.006; Kaufmann T, 2010, POLYM CHEM-UK, V1, P371, DOI 10.1039/b9py00281b; Kollimada SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153471; Lee J, 2013, BIOMATERIALS, V34, P8140, DOI 10.1016/j.biomaterials.2013.07.074; Madou M. J., 2011, MANUFACTURING TECHNI; Madou PM, 2012, PHOTOLITHOGRAPHY, P2051; Masters T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044261; Moller J, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/12/125016; Narui Y, 2012, CHEM SCI, V3, P794, DOI 10.1039/c1sc00475a; Park TH, 2003, BIOTECHNOL PROGR, V19, P243, DOI 10.1021/bp020143k; Pasche S, 2005, J PHYS CHEM B, V109, P17545, DOI 10.1021/jp050431+; Pasche S, 2003, LANGMUIR, V19, P9216, DOI 10.1021/la034111y; Polio SR, 2014, INTEGR BIOL-UK, V6, P357, DOI [10.1039/c3ib40127h, 10.1039/c3b40127h]; Qin D, 2010, NAT PROTOC, V5, P491, DOI 10.1038/nprot.2009.234; Rape AD, 2011, BIOMATERIALS, V32, P2043, DOI 10.1016/j.biomaterials.2010.11.044; Ravasio A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8683; Ribeiro AJS, 2016, METHODS, V94, P51, DOI 10.1016/j.ymeth.2015.08.005; Ribeiro AJS, 2015, P NATL ACAD SCI USA, V112, P12705, DOI 10.1073/pnas.1508073112; Ricoult SG, 2014, LANGMUIR, V30, P12002, DOI 10.1021/la502742r; Ruiz SA, 2007, SOFT MATTER, V3, P168, DOI 10.1039/b613349e; Schulze KD, 2017, J BIOMECH; Sim JY, 2015, MOL BIOL CELL, V26, P2456, DOI 10.1091/mbc.E14-12-1618; Stalder AF, 2006, COLLOID SURFACE A, V286, P92, DOI 10.1016/j.colsurfa.2006.03.008; Strale PO, 2016, ADV MATER, V28, P2024, DOI 10.1002/adma.201504154; Tan JL, 2002, LANGMUIR, V18, P519, DOI 10.1021/la011351+; Tang X, 2012, SOFT MATTER, V8, P7197, DOI 10.1039/c2sm25533b; Tee SY, 2011, BIOPHYS J, V100, pL25, DOI 10.1016/j.bpj.2010.12.3744; Thery M, 2010, J CELL SCI, V123, P4201, DOI 10.1242/jcs.075150; Trappmann B, 2012, NAT MATER, V11, P642, DOI [10.1038/NMAT3339, 10.1038/nmat3339]; Tse J.R., 2010, CURR PROTOC CELL BIO, DOI [10.1002/0471143030.cb1016s47, DOI 10.1002/0471143030.CB1016S47]; Tseng P, 2014, ADV MATER, V26, P1242, DOI 10.1002/adma.201304607; Tseng QZ, 2012, P NATL ACAD SCI USA, V109, P1506, DOI 10.1073/pnas.1106377109; Tseng QZ, 2011, LAB CHIP, V11, P2231, DOI 10.1039/c0lc00641f; Vignaud T, 2014, METHOD CELL BIOL, V120, P93, DOI 10.1016/B978-0-12-417136-7.00006-9; Wagner MS, 2004, ANAL CHEM, V76, P1483, DOI 10.1021/ac034873y; Zhu JM, 2011, EXPERT REV MED DEVIC, V8, P607, DOI [10.1586/ERD.11.27, 10.1586/erd.11.27]	54	17	17	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2018	13	1							e0189901	10.1371/journal.pone.0189901	http://dx.doi.org/10.1371/journal.pone.0189901			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR6OK	29298336	gold, Green Published, Green Submitted			2023-01-03	WOS:000419185200031
J	Fry, TJ; Shah, NN; Orentas, RJ; Stetler-Stevenson, M; Yuan, CM; Ramakrishna, S; Wolters, P; Martin, S; Delbrook, C; Yates, B; Shalabi, H; Fountaine, TJ; Shern, JF; Majzner, RG; Stroncek, DF; Sabatino, M; Feng, Y; Dimitrov, DS; Zhang, L; Nguyen, S; Qin, HY; Dropulic, B; Lee, DW; Mackall, CL				Fry, Terry J.; Shah, Nirali N.; Orentas, Rimas J.; Stetler-Stevenson, Maryalice; Yuan, Constance M.; Ramakrishna, Sneha; Wolters, Pamela; Martin, Staci; Delbrook, Cindy; Yates, Bonnie; Shalabi, Haneen; Fountaine, Thomas J.; Shern, Jack F.; Majzner, Robbie G.; Stroncek, David F.; Sabatino, Marianna; Feng, Yang; Dimitrov, Dimiter S.; Zhang, Ling; Sang Nguyen; Qin, Haiying; Dropulic, Boro; Lee, Daniel W.; Mackall, Crystal L.			CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy	NATURE MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHIMERIC ANTIGEN RECEPTOR; MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOCYTIC-LEUKEMIA; INOTUZUMAB OZOGAMICIN; PHASE-II; CLINICAL-TRIAL; YOUNG-ADULTS; CHILDHOOD; THERAPY	Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent effects in relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL), but antigen loss is a frequent cause of resistance to CD19-targeted immunotherapy. CD22 is also expressed in most cases of B-ALL and is usually retained following CD19 loss. We report results from a phase 1 trial testing a new CD22-targeted CAR (CD22-CAR) in 21 children and adults, including 17 who were previously treated with CD19-directed immunotherapy. Dose-dependent antileukemic activity was observed, with complete remission obtained in 73% (11/15) of patients receiving >= 1 x 10(6) CD22-CAR T cells per kg body weight, including 5 of 5 patients with CD19(dim) or CD19(-) B-ALL. Median remission duration was 6 months. Relapses were associated with diminished CD22 site density that likely permitted CD22(+) cell escape from killing by CD22-CAR T cells. These results are the first to establish the clinical activity of a CD22-CAR in B-ALL, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses. Our results also highlight the critical role played by antigen density in regulating CAR function.	[Fry, Terry J.; Shah, Nirali N.; Orentas, Rimas J.; Ramakrishna, Sneha; Wolters, Pamela; Martin, Staci; Delbrook, Cindy; Yates, Bonnie; Shalabi, Haneen; Fountaine, Thomas J.; Shern, Jack F.; Zhang, Ling; Sang Nguyen; Qin, Haiying; Lee, Daniel W.] NIH, Pediat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA; [Stetler-Stevenson, Maryalice; Yuan, Constance M.] NIH, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Majzner, Robbie G.; Mackall, Crystal L.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Stroncek, David F.; Sabatino, Marianna] NIH, Dept Transfus Med, NIH Clin Ctr, Bethesda, MD 20892 USA; [Feng, Yang; Dimitrov, Dimiter S.] NCI, Canc & Inflammat Program, NIH, Bethesda, MD 20892 USA; [Dropulic, Boro] Lentigen Corp, Gaithersburg, MD USA; [Mackall, Crystal L.] Stanford Univ, Standford Canc Ctr, Stanford, CA 94305 USA; [Orentas, Rimas J.; Dropulic, Boro] Lentigen Technol Inc, Miltenyi Biotec, Gaithersburg, MD USA; [Lee, Daniel W.] Univ Virginia, Dept Pediat, Div Pediat Hematol & Oncol, Charlottesville, VA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; Miltenyi Biotec; University of Virginia	Fry, TJ (corresponding author), NIH, Pediat Oncol Branch, Ctr Canc Res, Bldg 10, Bethesda, MD 20892 USA.	fryt@mail.nih.gov	Stetler-Stevenson, Maryalice/AAV-7393-2020; Shern, Jack/V-4002-2019	Nguyen, Sang/0000-0002-6864-8044; Ramakrishna, Sneha/0000-0001-7445-3190; Lee, Darrall/0000-0002-6990-4441; Fry, Terry/0000-0001-8044-5226	Intramural Research Program National Institute of Health; National Cancer Institute National Institute of Health; NIH Clinical Center National Institute of Health; Stand Up to Cancer-St. Baldrick's Pediatric Dream Team translational [SU2C-AACR-DT113]; St. Baldrick's Foundation; NATIONAL CANCER INSTITUTE [ZIABC011295, ZIABC011565, ZIABC011734] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL002120] Funding Source: NIH RePORTER	Intramural Research Program National Institute of Health; National Cancer Institute National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH Clinical Center National Institute of Health; Stand Up to Cancer-St. Baldrick's Pediatric Dream Team translational; St. Baldrick's Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CLINICAL CENTER	We gratefully acknowledge the study participants and their families, referring medical care teams, the faculty and staff of the NIH and the data managers involved with this work. This work was supported in part by the Intramural Research Program, National Cancer Institute and NIH Clinical Center, National Institutes of Health, by a Stand Up to Cancer-St. Baldrick's Pediatric Dream Team translational research grant (SU2C-AACR-DT113) and by a St. Baldrick's Foundation Scholar Award (D.W.L.). Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. C.L.M. is a member of the Parker Institute for Cancer Immunotherapy, which supports the Stanford University Cancer Immunotherapy Program. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US government.	Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903; Borowitz MJ, 2008, BLOOD, V111, P5477, DOI 10.1182/blood-2008-01-132837; Borowitz MJ, 2015, BLOOD, V126, P964, DOI 10.1182/blood-2015-03-633685; Caruso HG, 2015, CANCER RES, V75, P3505, DOI 10.1158/0008-5472.CAN-15-0139; Chevallier P, 2009, LEUKEMIA, V23, P806, DOI 10.1038/leu.2008.303; Chevallier P, 2015, LANCET HAEMATOL, V2, pE108, DOI 10.1016/S2352-3026(15)00020-4; Chevallier P, 2015, HAEMATOLOGICA, V100, pE128, DOI 10.3324/haematol.2014.120220; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Essig S, 2014, LANCET ONCOL, V15, P841, DOI 10.1016/S1470-2045(14)70265-7; Faderl S, 2010, CANCER-AM CANCER SOC, V116, P1165, DOI 10.1002/cncr.24862; Gardner R, 2016, BLOOD, V127, P2406, DOI 10.1182/blood-2015-08-665547; Grant BW, 2013, CANCER-AM CANCER SOC, V119, P3797, DOI 10.1002/cncr.28299; Grupp SA, 2015, BLOOD, V126, P681, DOI DOI 10.1158/1078-0432.CCR-08-0144; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Guo B., 2016, J CELLULAR IMMUNOTHE, V2, P28; Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002; Jacoby E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12320; Jasper GA, 2011, CYTOM PART B-CLIN CY, V80B, P83, DOI 10.1002/cyto.b.20567; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kantarjian H, 2013, CANCER-AM CANCER SOC, V119, P2728, DOI 10.1002/cncr.28136; Kantarjian H, 2012, LANCET ONCOL, V13, P403, DOI 10.1016/S1470-2045(11)70386-2; Kantarjian HM, 2016, NEW ENGL J MED, V375, P740, DOI 10.1056/NEJMoa1509277; Kawalekar OU, 2016, IMMUNITY, V44, P712, DOI 10.1016/j.immuni.2016.02.023; Kero AE, 2016, CANCER EPIDEMIOL, V41, P42, DOI 10.1016/j.canep.2016.01.009; Kreitman RJ, 2012, J CLIN ONCOL, V30, P1822, DOI 10.1200/JCO.2011.38.1756; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Lucio P, 2001, LEUKEMIA, V15, P1185, DOI 10.1038/sj.leu.2402150; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Olejniczak SH, 2006, IMMUNOL INVEST, V35, P93, DOI 10.1080/08820130500496878; Pui CH, 2015, J CLIN ONCOL, V33, P2938, DOI 10.1200/JCO.2014.59.1636; Pui CH, 2015, LANCET ONCOL, V16, P465, DOI 10.1016/S1470-2045(15)70082-3; Qin H, 2015, BLOOD, V126, P4427, DOI DOI 10.1182/blood.V126.23.4427.4427; Raetz EA, 2015, PEDIATR BLOOD CANCER, V62, P1171, DOI 10.1002/pbc.25454; Ram R, 2012, AM J HEMATOL, V87, P472, DOI 10.1002/ajh.23149; Ramos CA, 2016, J CLIN INVEST, V126, P2588, DOI 10.1172/JCI86000; Raponi S, 2011, LEUKEMIA LYMPHOMA, V52, P1098, DOI 10.3109/10428194.2011.559668; Ritchie DS, 2013, MOL THER, V21, P2122, DOI 10.1038/mt.2013.154; Rytting ME, 2014, CANCER-AM CANCER SOC, V120, P3660, DOI 10.1002/cncr.28930; Shah NN, 2015, PEDIATR BLOOD CANCER, V62, P964, DOI 10.1002/pbc.25410; Smith MA, 2014, CANCER-AM CANCER SOC, V120, P2497, DOI 10.1002/cncr.28748; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Stroncek DF, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1160-5; Stroncek DF, 2016, CYTOTHERAPY, V18, P893, DOI 10.1016/j.jcyt.2016.04.003; Tembhare PR, 2013, AM J CLIN PATHOL, V140, P813, DOI 10.1309/AJCPYFQ4XMGJD6TI; Till BG, 2012, BLOOD, V119, P3940, DOI 10.1182/blood-2011-10-387969; Topp MS, 2015, LANCET ONCOL, V16, P57, DOI 10.1016/S1470-2045(14)71170-2; Topp MS, 2014, J CLIN ONCOL, V32, P4134, DOI 10.1200/JCO.2014.56.3247; Topp MS, 2011, J CLIN ONCOL, V29, P2493, DOI 10.1200/JCO.2010.32.7270; Turatti F, 2007, J IMMUNOTHER, V30, P684, DOI 10.1097/CJI.0b013e3180de5d90; Walker AJ, 2017, MOL THER, V25, P2189, DOI 10.1016/j.ymthe.2017.06.008; Watanabe K, 2015, J IMMUNOL, V194, P911, DOI 10.4049/jimmunol.1402346; Wayne AS, 2010, CLIN CANCER RES, V16, P1894, DOI 10.1158/1078-0432.CCR-09-2980; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Xiao XD, 2009, MABS-AUSTIN, V1, P297, DOI 10.4161/mabs.1.3.8113	58	734	777	8	202	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2018	24	1					20	+		10.1038/nm.4441	http://dx.doi.org/10.1038/nm.4441			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	FT2JB	29155426	Green Accepted			2023-01-03	WOS:000422965900007
J	Kumar-Sinha, C; Chinnaiyan, AM				Kumar-Sinha, Chandan; Chinnaiyan, Arul M.			Precision oncology in the age of integrative genomics	NATURE BIOTECHNOLOGY			English	Review							TERT PROMOTER MUTATIONS; OLAPARIB MAINTENANCE THERAPY; CHROMATIN REMODELING GENES; COPY NUMBER ALTERATIONS; NEGATIVE BREAST-CANCER; CIRCULATING TUMOR DNA; CELL LUNG-CANCER; UNKNOWN PRIMARY; ACQUIRED-RESISTANCE; SOMATIC MUTATIONS	Precision oncology applies genomic and other molecular analyses of tumor biopsies to improve the diagnosis and treatment of cancers. In addition to identifying therapeutic options, precision oncology tracks the response of a tumor to an intervention at the molecular level and detects drug resistance and the mechanisms by which it occurs. Integrative genomics can include sequencing specific panels of genes, exomes, or the entire triad of the patient's germline, tumor exome, and tumor transcriptome. Although the capabilities of sequencing technologies continue to improve, widespread adoption of genomics-driven precision oncology in the clinic has been held back by logistical, regulatory, financial, and ethical considerations. Nevertheless, integrative clinical sequencing programs applied at the point of care have the potential to improve the clinical management of cancer patients.	[Kumar-Sinha, Chandan; Chinnaiyan, Arul M.] Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Kumar-Sinha, Chandan; Chinnaiyan, Arul M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.] Univ Michigan, Med Sch, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kumar-Sinha, C; Chinnaiyan, AM (corresponding author), Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.; Kumar-Sinha, C; Chinnaiyan, AM (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.; Chinnaiyan, AM (corresponding author), Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.; Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.; Chinnaiyan, AM (corresponding author), Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.; Chinnaiyan, AM (corresponding author), Univ Michigan, Med Sch, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA.	chakumar@umich.edu; arul@umich.edu	Kumar, Chandan/HJB-3782-2022	Kumar, Chandan/0000-0002-8696-3400	NIH Early Detection Research Network Award [U01 CA214170]; NIH Clinical Sequencing Exploratory Research (CSER) Award [NIH 1UM1HG006508]; Prostate SPORE Award [P50 CA186786]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [P50CA186786, U01CA214170] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [UM1HG006508] Funding Source: NIH RePORTER	NIH Early Detection Research Network Award; NIH Clinical Sequencing Exploratory Research (CSER) Award; Prostate SPORE Award; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported in part by the NIH Early Detection Research Network Award U01 CA214170, the NIH Clinical Sequencing Exploratory Research (CSER) Award NIH 1UM1HG006508, a Prostate SPORE Award P50 CA186786, and awards from the Prostate Cancer Foundation. A.M.C. is an American Cancer Society Research Professor, a Howard Hughes Medical Institute Investigator, and a Taubman Scholar of the University of Michigan. We thank S. Ellison, scientific writer, for editorial help with the manuscript and R. Kunkel for figure artwork. Helpful discussions with the members of the MI_Oncoseq team including D. Robinson, R. Lonigro, M. Cieslik, Y.-M. Wu, S.M. Dhanasekaran, P. Vats, and X. Cao are gratefully acknowledged.	Abedalthagafi MS, 2015, CANCER GENET-NY, V208, P345, DOI 10.1016/j.cancergen.2015.03.005; Abrams Jeffrey, 2014, Am Soc Clin Oncol Educ Book, P71, DOI 10.14694/EdBook_AM.2014.34.71; ACS Commission on Cancer, 2012, CANC PROGR STAND 201; Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Ahuja N, 2016, ANNU REV MED, V67, P73, DOI 10.1146/annurev-med-111314-035900; Akashi-Tanaka S, 2015, CLIN BREAST CANCER, V15, P80, DOI 10.1016/j.clbc.2014.08.003; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Al-Ahmadie H, 2014, CANCER DISCOV, V4, P1014, DOI 10.1158/2159-8290.CD-14-0380; Alden RS, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.09.03; Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Alexandrov LB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9683; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205; Amendola LM, 2016, AM J HUM GENET, V99, P247, DOI 10.1016/j.ajhg.2016.06.001; Amendola LM, 2015, GENOME RES, V25, P305, DOI 10.1101/gr.183483.114; [Anonymous], 2015, CANCER DISCOV, V5, P685, DOI 10.1158/2159-8290.CD-NB2015-052; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Arango NP, 2017, ONCOTARGET, V8, P41806, DOI 10.18632/oncotarget.16018; Aravanis AM, 2017, CELL, V168, P571, DOI 10.1016/j.cell.2017.01.030; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Auffray C, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0323-y; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Beatson GW, 1896, LANCET, V2, P162, DOI DOI 10.1016/S0140-6736(01)72384-7; Beck TF, 2016, CLIN CHEM, V62, P647, DOI 10.1373/clinchem.2015.249623; Behjati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12605; Bellmunt J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124711; Beltran H, 2015, JAMA ONCOL, V1, P466, DOI 10.1001/jamaoncol.2015.1313; Beltran H, 2013, EUR UROL, V63, P920, DOI 10.1016/j.eururo.2012.08.053; Biegel JA, 1999, CANCER RES, V59, P74; Borah S, 2015, SCIENCE, V347, P1006, DOI 10.1126/science.1260200; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brower V, 2015, NAT BIOTECHNOL, V33, P790, DOI 10.1038/nbt0815-790; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Chang DK, 2014, NAT REV CANCER, V14, P291, DOI 10.1038/nrc3723; Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cieslik M, 2015, GENOME RES, V25, P1372, DOI 10.1101/gr.189621.115; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Colwell J, 2016, CANCER DISCOV, V6, P334, DOI 10.1158/2159-8290.CD-NB2016-018; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; de Bono JS, 2010, NATURE, V467, P543, DOI 10.1038/nature09339; Dhanasekaran SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6893; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678; Engert F, 2017, ONCOTARGET, V8, P48794, DOI 10.18632/oncotarget.10720; Everett JN, 2016, FUTURE ONCOL, V12, P883, DOI 10.2217/fon-2015-0022; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fokkema IFAC, 2005, HUM MUTAT, V26, P63, DOI 10.1002/humu.20201; Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438; Foster MW, 2009, GENET MED, V11, P570, DOI 10.1097/GIM.0b013e3181a2743e; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Fredriksson NJ, 2014, NAT GENET, V46, P1258, DOI 10.1038/ng.3141; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Govindan R, 2015, CLIN CANCER RES, V21, P5439, DOI 10.1158/1078-0432.CCR-15-0354; Gray SW, 2014, GENET MED, V16, P727, DOI 10.1038/gim.2014.26; Green RC, 2016, AM J HUM GENET, V99, P246, DOI 10.1016/j.ajhg.2016.06.002; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Guo NN, 2016, SCI REP-UK, V6, DOI 10.1038/srep33519; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Handorf CR, 2011, J NATL COMPR CANC NE, V9, P1415, DOI 10.6004/jnccn.2011.0120; Heitzer E, 2016, MOL ONCOL, V10, P494, DOI 10.1016/j.molonc.2015.12.004; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Henderson S, 2014, CELL REP, V7, P1833, DOI 10.1016/j.celrep.2014.05.012; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Hong S, 2016, J ONCOL PRACT, V12, P270, DOI 10.1200/JOP.2016.010710; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Hyman DM, 2015, DRUG DISCOV TODAY, V20, P1422, DOI 10.1016/j.drudis.2015.08.005; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jackson EM, 2009, CLIN CANCER RES, V15, P1923, DOI 10.1158/1078-0432.CCR-08-2091; Jarvik GP, 2016, AM J HUM GENET, V98, P1077, DOI 10.1016/j.ajhg.2016.04.003; Karachaliou N, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.16; Keating NL, 2013, JNCI-J NATL CANCER I, V105, P113, DOI 10.1093/jnci/djs502; Khoury JD, 2013, J VIROL, V87, P8916, DOI 10.1128/JVI.00340-13; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Krishnamurthy N, 2017, J CLIN MED, V6, DOI 10.3390/jcm6010003; Kumar-Sinha C, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0252-1; Kuong KJ, 2013, NAT GENET, V45, P964, DOI 10.1038/ng.2736; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lawler M, 2017, NEW ENGL J MED, V376, P2006, DOI 10.1056/NEJMp1612254; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6; Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115; Liu XS, 2017, CELL, V168, P600, DOI 10.1016/j.cell.2017.01.014; Liu YX, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju245; Lonigro RJ, 2011, NEOPLASIA, V13, P1019, DOI 10.1593/neo.111252; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Lorusso D, 2016, ANN ONCOL, V27, P487, DOI 10.1093/annonc/mdv608; LoRusso PM, 2015, MOL CANCER THER, V14, P1962, DOI 10.1158/1535-7163.MCT-15-0153; Lovly CM, 2014, NAT MED, V20, P1027, DOI 10.1038/nm.3667; Lu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10086; Lu Y, 2014, HUM MOL GENET, V23, P6112, DOI 10.1093/hmg/ddu312; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396; Massard C, 2011, NAT REV CLIN ONCOL, V8, P701, DOI 10.1038/nrclinonc.2011.158; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Matthew EM, 2016, ONCOTARGET, V7, P3662, DOI 10.18632/oncotarget.6657; McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i213; McNeil C, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv193; Mehra N, 2015, CURR OPIN ONCOL, V27, P267, DOI 10.1097/CCO.0000000000000182; Meric-Bernstam F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv098; Mody RJ, 2015, JAMA-J AM MED ASSOC, V314, P913, DOI 10.1001/jama.2015.10080; Moreno BH, 2015, BRIT J CANCER, V112, P1421, DOI 10.1038/bjc.2015.124; Mukherjee S., 2010, EMPEROR ALL MALADIES; Mullard A, 2015, NATURE; Mullard A, 2015, NAT REV DRUG DISCOV, V14, P513, DOI 10.1038/nrd4694; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Oien KA, 2012, ANN ONCOL, V23, P271, DOI 10.1093/annonc/mds357; Parsons DW, 2016, JAMA ONCOL, V2, P616, DOI 10.1001/jamaoncol.2015.5699; Pasche B, 2014, JAMA-J AM MED ASSOC, V311, P1975, DOI 10.1001/jama.2014.3742; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Piscuoglio S, 2016, J PATHOL, V238, P508, DOI 10.1002/path.4672; Prasad V, 2016, NATURE, V537, pS63, DOI 10.1038/537S63a; Prasad V, 2016, LANCET ONCOL, V17, pE81, DOI 10.1016/S1470-2045(15)00620-8; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Raymond VM, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv351; Reitman ZJ, 2013, ACTA NEUROPATHOL, V126, P789, DOI 10.1007/s00401-013-1207-5; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rolland T, 2014, CELL, V159, P1212, DOI 10.1016/j.cell.2014.10.050; Ronan JL, 2013, NAT REV GENET, V14, P347, DOI 10.1038/nrg3413; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Rowley JD., 2015, CHROMOSOMAL TRANSLOC; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Schilsky RL, 2014, NAT REV CLIN ONCOL, V11, P432, DOI 10.1038/nrclinonc.2014.54; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Schwaederle M, 2016, MOL CANCER THER, V15, P743, DOI 10.1158/1535-7163.MCT-15-0795; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Seifert BA, 2016, CLIN CANCER RES, V22, P4087, DOI 10.1158/1078-0432.CCR-16-0015; Sekulic A, 2015, MOL GENET GENOM MED, V3, P130, DOI 10.1002/mgg3.121; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shirts BH, 2015, J AM MED INFORM ASSN, V22, P1231, DOI 10.1093/jamia/ocv065; Simonds NI, 2013, JNCI-J NATL CANCER I, V105, P929, DOI 10.1093/jnci/djt108; Sohal DP, 2015, JNCI-J NATL CANCER I, V108; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P132, DOI 10.1038/nrclinonc.2015.19; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Uchida J, 2015, CLIN CHEM, V61, P1191, DOI 10.1373/clinchem.2015.241414; Van Allen EM, 2015, JAMA ONCOL, V1, P238, DOI 10.1001/jamaoncol.2015.34; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; van der Noll R, 2015, BRIT J CANCER, V113, P396, DOI 10.1038/bjc.2015.256; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Varmus H, 2016, SCIENCE, V352, P123, DOI 10.1126/science.aaf7301; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Vincent M, 2014, BIOINFORMATICS, V30, P1417, DOI 10.1093/bioinformatics/btu044; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Wagle N, 2012, CANCER DISCOV, V2, P82, DOI 10.1158/2159-8290.CD-11-0184; Wang A. Z, 2015, SCI TRANSL MED, V7; Wei IH, 2014, NEOPLASIA, V16, P918, DOI 10.1016/j.neo.2014.09.007; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Zanetti M, 2017, SCIENCE, V355, P249, DOI 10.1126/science.aam5331; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054	189	65	66	3	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2018	36	1					46	60		10.1038/nbt.4017	http://dx.doi.org/10.1038/nbt.4017			15	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	FS4MT	29319699	Green Accepted			2023-01-03	WOS:000419767600021
J	Lindelof, N; Lundin-Olsson, L; Skelton, DA; Lundman, B; Rosendahl, E				Lindelof, Nina; Lundin-Olsson, Lillemor; Skelton, Dawn A.; Lundman, Berit; Rosendahl, Erik			Experiences of older people with dementia participating in a high-intensity functional exercise program in nursing homes: "While it's tough, it's useful"	PLOS ONE			English	Article							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; PHYSICAL-ACTIVITY; ALZHEIMERS-DISEASE; CARE FACILITIES; ADULTS; RESIDENTS; ADHERENCE; COMMUNITY; BALANCE	The objective of the study was to describe the views and experiences of participation in a high-intensity functional exercise (HIFE) program among older people with dementia in nursing homes. The study design was a qualitative interview study with 21 participants (15 women), aged 74-96, and with a Mini-Mental State Examination score of 10-23 at study start. The HIFE-program comprises exercises performed in functional weight-bearing positions and including movements used in everyday tasks. The exercise was individually designed, supervised in small groups in the nursing homes and performed during four months. Interviews were performed directly after exercise sessions and field notes about the sessions were recorded. Qualitative content analysis was used for analyses. The analysis revealed four themes: Exercise is challenging but achievable; Exercise gives pleasure and strength; Exercise evokes body memories; and Togetherness gives comfort, joy, and encouragement. The intense and tailored exercise, adapted to each participant, was perceived as challenging but achievable, and gave pleasure and improvements in mental and bodily strength. Memories of previous physical activities aroused and participants rediscovered bodily capabilities. Importance of individualized and supervised exercise in small groups was emphasized and created feelings of encouragement, safety, and coherence. The findings from the interviews reinforces the positive meaning of intense exercise to older people with moderate to severe dementia in nursing homes. The participants were able to safely adhere to and understand the necessity of the exercise. Providers of exercise should consider the aspects valued by participants, e.g. supervision, individualization, small groups, encouragement, and that exercise involved joy and rediscovery of body competencies.	[Lindelof, Nina; Lundin-Olsson, Lillemor; Rosendahl, Erik] Umea Univ, Dept Community Med & Rehabil, Physiotherapy, Umea, Sweden; [Lindelof, Nina; Rosendahl, Erik] Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden; [Skelton, Dawn A.] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland; [Lundman, Berit] Umea Univ, Dept Nursing, Umea, Sweden	Umea University; Umea University; Glasgow Caledonian University; Umea University	Lindelof, N (corresponding author), Umea Univ, Dept Community Med & Rehabil, Physiotherapy, Umea, Sweden.; Lindelof, N (corresponding author), Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden.	nina.lindelof@umu.se	Skelton, Dawn A/B-7552-2013	Skelton, Dawn A/0000-0001-6223-9840; Lindelof, Nina/0000-0002-4449-049X	Swedish Research Council [K2009-69P-21298-01-4, K2009-69X21299-01-1, K2009-69P-21298-04-4, K2014-99X22610-01-6]; Forte-Swedish Research Council for Health; Working Life and Welfare; Vardal Foundation; Promobilia Foundation; Swedish Society of Medicine; Swedish Dementia Association; Swedish Alzheimer Foundation; County Council of Vasterbotten; Ragnhild and Einar Lundstrom's Memorial Foundation; Umea University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Forte-Swedish Research Council for Health; Working Life and Welfare; Vardal Foundation; Promobilia Foundation; Swedish Society of Medicine; Swedish Dementia Association; Swedish Alzheimer Foundation; County Council of Vasterbotten; Ragnhild and Einar Lundstrom's Memorial Foundation; Umea University	The Swedish Research Council, https://www.vr.se/, (K2009-69P-21298-01-4, K2009-69X21299-01-1, K2009-69P-21298-04-4, K2014-99X22610-01-6), to ER, Forte-Swedish Research Council for Health, Working Life and Welfare, http://forte.se/, to ER, The Vardal Foundation, to ER, The Promobilia Foundation, to ER, The Swedish Society of Medicine, to ER, The Swedish Dementia Association, http://www.demensforbundet.se/, to NL, The Swedish Alzheimer Foundation, to ER The County Council of Vasterbotten, http://vll.se, to NL and ER, The Ragnhild and Einar Lundstrom's Memorial Foundation, to NL, and a grant provided by Umea University, http://www.umu.se/, for DS as a visiting Professor, to LLO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allan LM, 2005, J AM GERIATR SOC, V53, P1681, DOI 10.1111/j.1532-5415.2005.53552.x; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2014, HIFE PROGRAM HIGH IN; Atchely R., 1999, CONTINUITY ADAPTATIO; Bandura A, 1997, EFFICACY EXERCISE CO; Barreto PD, 2016, J AM MED DIR ASSOC, V17, P381, DOI 10.1016/j.jamda.2016.01.021; Beer C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015621; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Brassington GS, 2002, AM J PREV MED, V23, P80, DOI 10.1016/S0749-3797(02)00477-4; Caddell LS, 2010, CLIN PSYCHOL REV, V30, P113, DOI 10.1016/j.cpr.2009.10.003; Cahill S, 2011, AGING MENT HEALTH, V15, P562, DOI 10.1080/13607863.2010.551342; Cedervall Y, 2015, AGING MENT HEALTH, V19, P679, DOI 10.1080/13607863.2014.962004; Chong TWH, 2014, ASIA-PAC PSYCHIAT, V6, P179, DOI 10.1111/appy.12015; Fjellman-Wiklundl A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166686; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forbes D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub3; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Harre R., 1998, SINGULAR SELF INTRO; Hawley-Hague H, 2016, J AGING PHYS ACTIV, V24, P119, DOI 10.1123/japa.2014-0108; Hawley-Hague H, 2014, GERONTOLOGIST, V54, P599, DOI 10.1093/geront/gnt075; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kitwood T., 1995, NEW CULTURE DEMENTIA; Kontos P. C., 2005, DEMENTIA, V4, P553, DOI DOI 10.1177/1471301205058311; Krippendorff K., 2012, CONTENT ANAL INTRO I, DOI DOI 10.1111/eff.12318; Lindelof Nina, 2012, Physiotherapy Theory and Practice, V28, P307, DOI 10.3109/09593985.2011.611217; Littbrand H, 2006, PHYS THER, V86, P489, DOI 10.1093/ptj/86.4.489; Littbrand H, 2011, J AM GERIATR SOC, V59, P1274, DOI 10.1111/j.1532-5415.2011.03484.x; Littbrand H, 2011, AM J PHYS MED REHAB, V90, P495, DOI 10.1097/PHM.0b013e318214de26; Littbrand H, 2009, J AM GERIATR SOC, V57, P1741, DOI 10.1111/j.1532-5415.2009.02442.x; MAHONEY F I, 1965, Md State Med J, V14, P61; Malthouse R, 2014, PHYSIOTHERAPY, V100, P169, DOI 10.1016/j.physio.2013.10.002; Mozley CG, 1999, INT J GERIATR PSYCH, V14, P776, DOI 10.1002/(SICI)1099-1166(199909)14:9<776::AID-GPS13>3.0.CO;2-C; Olsen CF, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1041-7; Pitkala KH, 2013, JAMA INTERN MED, V173, P894, DOI 10.1001/jamainternmed.2013.359; Reid N, 2013, INT J ENV RES PUB HE, V10, P6783, DOI 10.3390/ijerph10126783; Rosendahl E, 2006, AUST J PHYSIOTHER, V52, P105, DOI 10.1016/S0004-9514(06)70045-9; Scandol JP, 2013, INJURY, V44, P776, DOI 10.1016/j.injury.2012.11.023; Stathi A., 2003, J ROYAL SOC HLTH, V124, P18; Stathi A, 2007, J AGING PHYS ACTIV, V15, P272, DOI 10.1123/japa.15.3.272; Steeman E, 2006, J ADV NURS, V54, P722, DOI 10.1111/j.1365-2648.2006.03874.x; Suttanon P, 2012, INT PSYCHOGERIATR, V24, P1172, DOI 10.1017/S1041610211002729; Telenius EW, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0151-8; Telenius EW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126102; The National Board och Health Care and Welfare, 2010, NAT GUID CAR CAS DEM; Toots A, 2016, J AM GERIATR SOC, V64, P55, DOI 10.1111/jgs.13880; van Alphen HJM, 2016, ARCH GERONTOL GERIAT, V66, P109, DOI 10.1016/j.archger.2016.05.008; von Kutzleben M, 2012, AGING MENT HEALTH, V16, P378, DOI 10.1080/13607863.2011.614594; Vreugdenhil A, 2012, SCAND J CARING SCI, V26, P12, DOI 10.1111/j.1471-6712.2011.00895.x; Weeks LE, 2008, J GERONTOL NURS, V34, P36, DOI 10.3928/00989134-20080701-11; Westius A, 2009, DEMENTIA, V8, P481, DOI DOI 10.1177/1471301209350287; World Health Organization, 2012, DEM PUBL HLTH PRIOR; Yu F, 2011, RES GERONTOL NURS, V4, P243, DOI 10.3928/19404921-20110303-01	52	25	25	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2017	12	11							e0188225	10.1371/journal.pone.0188225	http://dx.doi.org/10.1371/journal.pone.0188225			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FN0DI	29149198	gold, Green Submitted, Green Published			2023-01-03	WOS:000415646100030
J	Langote, A; Hiremath, S; Ruzicka, M; McCormick, BB				Langote, Amit; Hiremath, Swapnil; Ruzicka, Marcel; McCormick, Brendan B.			Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients	PLOS ONE			English	Article							ANGIOTENSIN-ALDOSTERONE SYSTEM; LOW-DOSE SPIRONOLACTONE; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; SERUM POTASSIUM; BLOOD-PRESSURE; DOUBLE-BLIND; MORTALITY; EFFICACY; SAFETY	Background Hypokalemia is common in peritoneal dialysis (PD) patients and is associated with increased cardiovascular and all-cause mortality. The management approach for such patients routinely includes spironolactone at our centre. We undertook this study to assess the efficacy of spironolactone for the treatment of hypokalemia in PD patients. Methods Retrospective chart review of PD patients at a single centre. Serum potassium was compared prior to initiation of spironolactone and two months afterwards. Indication for spironolactone and changes in blood pressure (BP), weight, and serum creatinine were also recorded. Results The chart review identified 53 patients who fit our selection criteria. The mean age was 64 +/- 15 years and the majority was treated with continuous cyclic peritoneal dialysis. Serum potassium rose from 3.7 +/- 0.5 to 4.2+/- 0.5 mmol/L (P<0.0001) after 2 months with a mean dose of spironolactone of 28.5 +/- 15.2 mg (median dose 25 mg). A significant reduction in systolic BP was observed from 150+/- 18 to 137 +/-24 (P = 0.002); a non-significant reduction in diastolic BP was also observed. The rise in potassium was constant in the range of 0.4 to 0.5 mmol/L regardless of whether spironolactone was initiated for hypokalemia, diuresis, or as an antihypertensive. There was no change in serum creatinine or body weight two months after introduction of spironolactone. Conclusions Spironolactone is safe and effective in treating hypokalemia in PD patients. It is also an effective antihypertensive agent and merits further study in the PD population.	[Langote, Amit] Apollo Hosp Enterprise Ltd, Div Nephrol, Dept Med, Bombay, Maharashtra, India; [Hiremath, Swapnil; Ruzicka, Marcel; McCormick, Brendan B.] Ottawa Hosp, Div Nephrol, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute	McCormick, BB (corresponding author), Ottawa Hosp, Div Nephrol, Dept Med, Ottawa, ON, Canada.	bmccormick@ottawahospital.on.ca	Hiremath, Swapnil/H-3492-2019	Hiremath, Swapnil/0000-0003-0010-3416				Bergstrom J, 1983, Kidney Int Suppl, V16, pS153; BLUMENKRANTZ MJ, 1982, KIDNEY INT, V21, P849, DOI 10.1038/ki.1982.109; Chuang YW, 2009, NEPHROL DIAL TRANSPL, V24, P1603, DOI 10.1093/ndt/gfn709; Dolson GM, 1997, INT J ARTIF ORGANS, V20, P134, DOI 10.1177/039139889702000302; Fulop T, 2017, PERITON DIALYSIS INT, V37, P63, DOI 10.3747/pdi.2016.00022; Gao HB, 1999, AM J NEPHROL, V19, P7, DOI 10.1159/000013418; Gross E, 2005, AM J KIDNEY DIS, V46, P94, DOI 10.1053/j.ajkd.2005.03.005; GUERRANT RL, 1972, GUT, V13, P197, DOI 10.1136/gut.13.3.197; Ito Y, 2014, J AM SOC NEPHROL, V25, P1094, DOI 10.1681/ASN.2013030273; Khan AN, 1996, PERITON DIALYSIS INT, V16, P652; Kwok JS-S, HONG KONG J NEPHROLO, V9, p36 ; Lin CT, 2016, J CLIN HYPERTENS, V18, P121, DOI 10.1111/jch.12628; Mathialahan T, 2005, J PATHOL, V206, P46, DOI 10.1002/path.1750; Matsumoto Y, 2014, J AM COLL CARDIOL, V63, P529, DOI 10.1016/j.jacc.2013.09.056; Matsumoto Y, 2009, CARDIOLOGY, V114, P32, DOI 10.1159/000210553; OREOPOULOS DG, 1982, NEPHRON, V30, P293, DOI 10.1159/000182504; Preston RA, 2009, HYPERTENSION, V53, P754, DOI 10.1161/HYPERTENSIONAHA.108.125252; Quach K, 2016, AM J KIDNEY DIS, V68, P591, DOI 10.1053/j.ajkd.2016.04.011; SANDLE GI, 1987, CLIN SCI, V73, P247, DOI 10.1042/cs0730247; Shavit L, 2011, CLIN NEPHROL, V76, P388, DOI 10.5414/CN106973; SPITAL A, 1985, AM J KIDNEY DIS, V6, P173, DOI 10.1016/S0272-6386(85)80022-6; Szeto CC, 2005, AM J KIDNEY DIS, V46, P128, DOI 10.1053/j.ajkd.2005.03.015; Taheri S, 2012, SAUDI J KIDNEY DIS T, V23, P507; Torlen K, 2012, CLIN J AM SOC NEPHRO, V7, P1272, DOI 10.2215/CJN.00960112; Tziviskou Effie, 2003, International Urology and Nephrology, V35, P429, DOI 10.1023/B:UROL.0000022867.93739.03; Unwin RJ, 2011, NAT REV NEPHROL, V7, P75, DOI 10.1038/nrneph.2010.175; Yongsiri S, 2015, THER APHER DIAL, V19, P81, DOI 10.1111/1744-9987.12219	27	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2017	12	11							e0187269	10.1371/journal.pone.0187269	http://dx.doi.org/10.1371/journal.pone.0187269			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FM2XM	29125879	gold, Green Submitted, Green Published			2023-01-03	WOS:000414866000009
J	Jaramillo-Rocha, V				Jaramillo-Rocha, Valente			Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Jaramillo-Rocha, Valente] Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Jaramillo-Rocha, V (corresponding author), Univ Hlth Network, Toronto, ON, Canada.	valentejaramillo@gmail.com			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD095228] Funding Source: NIH RePORTER; MRC [G0800265] Funding Source: UKRI	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Fan E, 2017, AM J RESP CRIT CARE, V195, P1253, DOI 10.1164/rccm.201703-0548ST; Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103; Murray MJ, 2016, CRIT CARE MED, V44, P2079, DOI 10.1097/CCM.0000000000002027; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI [10.1056/NEJMra1608077, 10.1056/NEJMc1711824]	5	46	50	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2017	377	19					1903	1904		10.1056/NEJMc1711824	http://dx.doi.org/10.1056/NEJMc1711824			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FM2QW	29120141				2023-01-03	WOS:000414845700028
J	Postow, MA; Sidlow, R; Hellmann, MD				Postow, Michael A.; Sidlow, Robert; Hellmann, Matthew D.			Immune-Related Adverse Events Associated with Immune Checkpoint Blockade	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ADVANCED MELANOMA; ALLOGRAFT-REJECTION; TUMOR-REGRESSION; SINGLE-ARM; IPILIMUMAB; IMMUNOTHERAPY; NIVOLUMAB; SAFETY; INHIBITORS; CTLA-4		Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; Weill Cornell Med Coll, New York, NY USA	Memorial Sloan Kettering Cancer Center; Cornell University	Postow, MA (corresponding author), 300 East 66th St, New York, NY 10065 USA.	postowm@mskcc.org		Knaack, Aaron/0000-0001-7712-1415	Bristol-Myers Squibb; Novartis; Ono Pharmaceutical; Array BioPharma; Merck; Incyte; NewLink Genetics; Genentech; AstraZeneca; Janssen; Mirati Therapeutics; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); Novartis(Novartis); Ono Pharmaceutical; Array BioPharma(Pfizer); Merck(Merck & Company); Incyte; NewLink Genetics; Genentech(Roche HoldingGenentech); AstraZeneca(AstraZeneca); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Mirati Therapeutics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr. Postow reports receiving grant support, paid to his institution, and consulting fees from Bristol-Myers Squibb, honoraria from Merck and Bristol-Myers Squibb, and consulting fees and advisory board fees from Novartis, Ono Pharmaceutical, Array BioPharma, Merck, Incyte, and NewLink Genetics; and Dr. Hellmann, receiving consulting fees and advisory board fees from Genentech, Merck, AstraZeneca, Novartis, Janssen, and Mirati Therapeutics and grant support, consulting fees, and advisory board fees from Bristol-Myers Squibb. No other potential conflict of interest relevant to this article was reported.	Abdel-Rahman O, 2016, FUTURE ONCOL, V12, P413, DOI 10.2217/fon.15.222; Arriola E, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1040218; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bashey A, 2009, BLOOD, V113, P1581, DOI 10.1182/blood-2008-07-168468; Bergqvist V, 2017, CANCER IMMUNOL IMMUN, V66, P581, DOI 10.1007/s00262-017-1962-6; Betof AS, 2017, ONCOLOGIST, V22, P963, DOI 10.1634/theoncologist.2016-0450; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Boutros C, 2016, NAT REV CLIN ONCOL, V13, P473, DOI 10.1038/nrclinonc.2016.58; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BURDICK KH, 1964, CANCER, V17, P708, DOI 10.1002/1097-0142(196406)17:6<708::AID-CNCR2820170604>3.0.CO;2-3; Burke MM, 2011, J CLIN ONCOL, V29, pE792, DOI 10.1200/JCO.2011.36.9199; Byrne EH, 2017, CANCER-AM CANCER SOC, V123, P2143, DOI 10.1002/cncr.30444; Callahan MK, 2011, ASCO M, V29, P2505, DOI DOI 10.1200/JC0.2011.29.15_; Carli L, 2013, CLIN RHEUMATOL, V32, P1071, DOI 10.1007/s10067-013-2214-6; Caturegli P, 2016, AM J PATHOL, V186, P3225, DOI 10.1016/j.ajpath.2016.08.020; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Davar D, 2015, CASE REP ONCOL MED, V2015, DOI 10.1155/2015/737389; Del Castillo M, 2016, CLIN INFECT DIS, V63, P1490, DOI 10.1093/cid/ciw539; Ding W, 2017, BLOOD, V129, P3419, DOI 10.1182/blood-2017-02-765685; Dittmar M, 2005, THYROID, V15, P239, DOI 10.1089/thy.2005.15.239; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Downey SG, 2007, CLIN CANCER RES, V13, P6681, DOI 10.1158/1078-0432.CCR-07-0187; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Esfahani K, 2017, NEW ENGL J MED, V376, P1989, DOI 10.1056/NEJMc1703047; Friedman CF, 2016, JAMA ONCOL, V2, P1346, DOI 10.1001/jamaoncol.2016.1051; Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225; Harbour SN, 2015, P NATL ACAD SCI USA, V112, P7061, DOI 10.1073/pnas.1415675112; Horvat TZ, 2015, J CLIN ONCOL, V33, P3193, DOI 10.1200/JCO.2015.60.8448; Hua C, 2016, JAMA DERMATOL, V152, P45, DOI 10.1001/jamadermatol.2015.2707; Huscher D, 2009, ANN RHEUM DIS, V68, P1119, DOI 10.1136/ard.2008.092163; Iwama S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008002; Johnpulle RAN, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1234572; Johnson DB, 2017, CANCER-AM CANCER SOC, V123, P1904, DOI 10.1002/cncr.30642; Johnson DB, 2016, JAMA ONCOL, V2, P234, DOI 10.1001/jamaoncol.2015.4368; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Kanz BA, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0166-5; Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Kyi C, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-19; Langley RG, 2014, NEW ENGL J MED, V371, P326, DOI 10.1056/NEJMoa1314258; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Lipson EJ, 2016, NEW ENGL J MED, V374, P896, DOI 10.1056/NEJMc1509268; Menzies AM, 2017, ANN ONCOL, V28, P368, DOI 10.1093/annonc/mdw443; Morales RE, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0066-0; Morganstein DL, 2017, CLIN ENDOCRINOL, V86, P614, DOI 10.1111/cen.13297; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; National Comprehensive Cancer Network, 2018, PREV TREATM CANC REL; Nishijima TF, 2016, CANCER TREAT REV, V45, P30, DOI 10.1016/j.ctrv.2016.02.006; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Osorio JC, 2017, ANN ONCOL, V28, P583, DOI 10.1093/annonc/mdw640; Owonikoko TK, 2017, CANCER IMMUNOL IMMUN, V66, P45, DOI 10.1007/s00262-016-1918-2; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Renton AE, 2015, JAMA NEUROL, V72, P396, DOI 10.1001/jamaneurol.2014.4103; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Santini F, 2017, J CLIN ONCOL, V35; Schadendorf D, 2017, J CLIN ONCOL, V35, P3807, DOI 10.1200/JCO.2017.73.2289; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Spain L, 2016, ANN ONCOL, V27, P1135, DOI 10.1093/annonc/mdw130; Teulings HE, 2015, J CLIN ONCOL, V33, P773, DOI 10.1200/JCO.2014.57.4756; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Uslu U, 2015, J IMMUNOTHER, V38, P212, DOI 10.1097/CJI.0000000000000081; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weber JS, 2017, J CLIN ONCOL, V35, P785, DOI 10.1200/JCO.2015.66.1389; Weber JS, 2015, J CLIN ONCOL, V33, P2092, DOI 10.1200/JCO.2014.60.0379; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Wightman F, 2015, AIDS, V29, P504, DOI 10.1097/QAD.0000000000000562; Wolchok Jedd D, 2010, Cancer Immun, V10, P9; YANAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P41, DOI 10.1210/jc.80.1.41; Yanai S, 2017, CLIN GASTROENTEROL H, V15, pE80, DOI 10.1016/j.cgh.2016.09.017; Younes A, 2016, LANCET ONCOL, V17, P1283, DOI 10.1016/S1470-2045(16)30167-X	76	2002	2090	31	316	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 11	2018	378	2					158	168		10.1056/NEJMra1703481	http://dx.doi.org/10.1056/NEJMra1703481			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FS7IR	29562154				2023-01-03	WOS:000419971600009
J	Wood, S; Krishnamurthy, N; Santini, T; Raval, S; Farhat, N; Holmes, JA; Ibrahim, TS				Wood, Sossena; Krishnamurthy, Narayanan; Santini, Tales; Raval, Shailesh; Farhat, Nadim; Holmes, John Andy; Ibrahim, Tamer S.			Design and fabrication of a realistic anthropomorphic heterogeneous head phantom for MR purposes	PLOS ONE			English	Article							POWER REQUIREMENTS; QUALITY-ASSURANCE; MULTICENTER FMRI; NOISE-RATIO; FIELD; ABSORPTION; ACTIVATION; DEPOSITION; TISSUE; COILS	Objective The purpose of this study is to design an anthropomorphic heterogeneous head phantom that can be used for MRI and other electromagnetic applications. Materials and methods An eight compartment, physical anthropomorphic head phantom was developed from a 3T MRI dataset of a healthy male. The designed phantom was successfully built and preliminarily evaluated through an application that involves electromagnetic-tissue interactions: MRI (due to it being an available resource). The developed phantom was filled with media possessing electromagnetic constitutive parameters that correspond to biological tissues at similar to 297 MHz. A preliminary comparison between an in-vivo human volunteer (based on whom the anthropomorphic head phantom was created) and various phantoms types, one being the anthropomorphic heterogeneous head phantom, were performed using a 7 Tesla human MRI scanner. Results Echo planar imaging was performed and minimal ghosting and fluctuations were observed using the proposed anthropomorphic phantom. The magnetic field distributions (during MRI experiments at 7 Tesla) and the scattering parameter (measured using a network analyzer) were most comparable between the anthropomorphic heterogeneous head phantom and an in-vivo human volunteer. Conclusion The developed anthropomorphic heterogeneous head phantom can be used as a resource to various researchers in applications that involve electromagnetic-biological tissue interactions such as MRI.	[Wood, Sossena; Krishnamurthy, Narayanan; Santini, Tales; Raval, Shailesh; Farhat, Nadim; Ibrahim, Tamer S.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA; [Holmes, John Andy] Univ Pittsburgh, Swanson Ctr Product Innovat, Pittsburgh, PA USA; [Ibrahim, Tamer S.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ibrahim, TS (corresponding author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA.; Ibrahim, TS (corresponding author), Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA.	tibrahim@pitt.edu	Raval, Shailesh/O-5176-2019	Raval, Shailesh/0000-0001-9202-236X; Wood, Susan/0000-0002-8319-612X; Santini, Tales/0000-0003-4533-9190; Fugh-Berman, Adriane/0000-0002-1717-7617	National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [1F31EB019872-02, 1R01MH111265-01, 1R01EB009848-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB009848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH111265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062065] Funding Source: NIH RePORTER	National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The work reported in this publication is supported by National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under award numbers: 1F31EB019872-02 (https://projectreporter.nih.gov/ project_info_details.cfm?icde=0&aid=8838518), 1R01MH111265-01 (https://projectreporter.nih.gov/proiect_info_details.cfm?aid=9196861&icde= 32699708&daparam=&ddvalue=&ddsub=&cr1&csb=default&cs=ASC&pball=), and 1R01EB009848-01 (https://projectreporter.nih.gov/ project_info_details.cfm?aid=8287175&icde= 32705670). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (https://www.nibib.nih.gov/).	Alon L, 2015, MAGN RESON MED, V74, P1397, DOI 10.1002/mrm.25521; Angelone LM, 2006, MAGN RESON IMAGING, V24, P801, DOI 10.1016/j.mri.2006.01.006; Caon M, 2004, RADIAT ENVIRON BIOPH, V42, P229, DOI 10.1007/s00411-003-0221-8; Chen CC, 2004, J DIGIT IMAGING, V17, P279, DOI 10.1007/s10278-004-1023-5; Chen X, 2013, COMPUTATIONAL ANAL M; CHOU CK, 1984, BIOELECTROMAGNETICS, V5, P435, DOI 10.1002/bem.2250050408; Christ A, 2005, BIOELECTROMAGNETICS, V26, P125, DOI 10.1002/bem.20088; Collins CM, 2011, MAGN RESON MED, V65, P1470, DOI 10.1002/mrm.22845; Friedman L, 2006, J MAGN RESON IMAGING, V23, P827, DOI 10.1002/jmri.20583; Friedman L, 2006, NEUROIMAGE, V33, P471, DOI 10.1016/j.neuroimage.2006.07.012; Fukunaga K, P 11 INT S EL IEEE; Gabriel C, 1998, CHEM SOC REV, V27, P213, DOI 10.1039/a827213z; Gandhi OP, 1996, IEEE T MICROW THEORY, V44, P1884, DOI 10.1109/22.539947; Graedel NN, 2015, MAGN RESON MED, V73, P442, DOI 10.1002/mrm.25123; Hoult DI, 2000, J MAGN RESON IMAGING, V12, P46, DOI 10.1002/1522-2586(200007)12:1<46::AID-JMRI6>3.0.CO;2-D; HOULT DI, 1976, J MAGN RESON, V24, P71, DOI 10.1016/0022-2364(76)90233-X; Hoult DI, 2000, CONCEPT MAGNETIC RES, V12, P173, DOI 10.1002/1099-0534(2000)12:4<173::AID-CMR1>3.0.CO;2-Q; Huber JS, 2009, IEEE T NUCL SCI, V56, P2722, DOI 10.1109/TNS.2009.2028073; Ibrahim TS, 2007, J MAGN RESON IMAGING, V25, P1235, DOI 10.1002/jmri.20919; Ibrahim TS, 2009, NMR BIOMED, V22, P927, DOI 10.1002/nbm.1406; Ibrahim TS, 2004, IEEE T MICROW THEORY, V52, P1999, DOI 10.1109/TMTT.2004.832021; Ibrahim TS, 2005, MAGN RESON MED, V54, P683, DOI 10.1002/mrm.20596; Ikemoto Y, 2011, MED PHYS, V38, P6336, DOI 10.1118/1.3656077; Jurgen K, 2010, HUMAN BRAIN ATLAS HU; Kato H, 2005, MED PHYS, V32, P3199, DOI 10.1118/1.2047807; Kim GB, 2016, KOREAN J RADIOL, V17, P182, DOI 10.3348/kjr.2016.17.2.182; Krishnamurthy N, 2014, J MAGN RESON IMAGING, V39, P475, DOI 10.1002/jmri.24152; Liu YL, 2013, IEEE INT WORKS GENET, P1, DOI 10.1109/GEFS.2013.6601048; Mironov V, 2009, BIOFABRICATION, V1, DOI 10.1088/1758-5082/1/2/022001; Mobashsher AT, 2014, IEEE ANTENN WIREL PR, V13, DOI 10.1109/LAWP.2014.2340409; Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958; Oh S, 2010, MAGN RESON MED, V63, P218, DOI 10.1002/mrm.22174; Pang Y, 2014, QUANT IMAGING MED SU, V4, P50, DOI 10.3978/j.issn.2223-4292.2014.02.07; Pizarro YAA, 2014, SPECIFIC ABSORPTION; Radiology ACo, 2004, RADIOLOGY, P1; Shmueli K, 2007, J MAGN RESON IMAGING, V26, P202, DOI 10.1002/jmri.20993; Simmons A, 1999, MAGNETIC RESONANCE M; Tang L, 2011, CONCEPT MAGN RESON B, V39B, P11, DOI 10.1002/cmr.b.20185; Tofts PS, 2003, QUANTITATIVE MRI OF THE BRAIN: MEASURING CHANGES CAUSED BY DISEASE, P55, DOI 10.1002/0470869526.ch3; Van De Moortele PF, 2005, MAGN RESON MED, V54, P1503, DOI 10.1002/mrm.20708; VAUGHAN JT, 1994, MAGNET RESON MED, V32, P206, DOI 10.1002/mrm.1910320209; Weisskoff RM, 1996, MAGN RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Wood S, ANATOMICALLY DETAILE; Yang QX, 2004, MAGN RESON MED, V52, P1016, DOI 10.1002/mrm.20245; Zhang XT, 2013, IEEE T MED IMAGING, V32, P1058, DOI 10.1109/TMI.2013.2251653	45	33	35	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2017	12	8							e0183168	10.1371/journal.pone.0183168	http://dx.doi.org/10.1371/journal.pone.0183168			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FD5CP	28806768	Green Published, Green Submitted, gold			2023-01-03	WOS:000407548800059
